PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Huai, Q; Liu, YD; Francis, SH; Corbin, JD; Ke, HM				Huai, Q; Liu, YD; Francis, SH; Corbin, JD; Ke, HM			Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CAMP PHOSPHODIESTERASES; CATALYTIC DOMAIN; PDE4; AMP; DIVERSITY; MECHANISM	Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes controlling cellular concentrations of the second messengers cAMP and cGMP. Crystal structures of the catalytic domains of cGMP-specific PDE5A1 and cAMP-specific PDE4D2 in complex with the nonselective inhibitor 3-isobutyl-1-methylxanthine have been determined at medium resolution. The catalytic domain of PDE5A1 has the same topological folding as that of PDE4D2, but three regions show different tertiary structures, including residues 79 - 113, 208 - 224 (H-loop), and 341 - 364 (M-loop) in PDE4D2 or 535 - 566, 661 - 676, and 787 - 812 in PDE5A1, respectively. Because H- and M-loops are involved in binding of the selective inhibitors, the different conformations of the loops, thus the distinct shapes of the active sites, will be a determinant of inhibitor selectivity in PDEs. IBMX binds to a subpocket that comprises key residues Ile-336, Phe-340, Gln-369, and Phe-372 of PDE4D2 or Val-782, Phe-786, Gln-817, and Phe-820 of PDE5A1. This subpocket may be a common site for binding nonselective inhibitors of PDEs.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Vanderbilt University	Ke, HM (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	hke@med.unc.edu	, PEP-MX Core/AGV-4051-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058277, R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059791] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016086] Funding Source: Medline; NIDDK NIH HHS [DK 40029, DK 58277] Funding Source: Medline; NIGMS NIH HHS [GM 59791] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarez R, 1996, PHOSPHODIESTERASE IN, P161; Antoni FA, 2000, FRONT NEUROENDOCRIN, V21, P103, DOI 10.1006/frne.1999.0193; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnard A, 2000, J ROY ANTHROPOL INST, V6, P164; Barnette M S, 1999, Prog Drug Res, V53, P193; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; Chin KV, 2002, ANN NY ACAD SCI, V968, P49, DOI 10.1111/j.1749-6632.2002.tb04326.x; Conti M, 2003, J BIOL CHEM, V278, P5493, DOI 10.1074/jbc.R200029200; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; Corbin JD, 2002, INT J CLIN PRACT, V56, P453; Dal Piaz V, 2000, EUR J MED CHEM, V35, P463, DOI 10.1016/S0223-5234(00)00179-3; Degerman E, 1996, BIOCHEM SOC T, V24, P1010, DOI 10.1042/bst0241010; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Francis SH, 2000, BIOCHEMISTRY-US, V39, P9591, DOI 10.1021/bi000392m; Giembycz M A, 2002, Monaldi Arch Chest Dis, V57, P48; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Huai Q, 2003, BIOCHEMISTRY-US, V42, P13220, DOI 10.1021/bi034653e; Huai Q, 2003, STRUCTURE, V11, P865, DOI 10.1016/S0969-2126(03)00123-0; Huang Z, 2001, CURR OPIN CHEM BIOL, V5, P432, DOI 10.1016/S1367-5931(00)00224-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klein C, 2002, CELL SIGNAL, V14, P493, DOI 10.1016/S0898-6568(01)00283-2; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Liu YG, 2001, CARDIOVASC DRUG REV, V19, P369, DOI 10.1111/j.1527-3466.2001.tb00076.x; Lucas KA, 2000, PHARMACOL REV, V52, P375; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Movsesian MA, 2000, EXPERT OPIN INV DRUG, V9, P963, DOI 10.1517/13543784.9.5.963; Muller T, 1996, TRENDS PHARMACOL SCI, V17, P294, DOI 10.1016/0165-6147(96)10035-3; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelligrino DA, 1998, PROG NEUROBIOL, V56, P1, DOI 10.1016/S0301-0082(98)00009-4; Rotella DP, 2002, NAT REV DRUG DISCOV, V1, P674, DOI 10.1038/nrd893; SEKHAR KR, 1996, PHOSPHODIESTERASE IN, P135; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Souness JE, 2000, IMMUNOPHARMACOLOGY, V47, P127, DOI 10.1016/S0162-3109(00)00185-5; Sturton G, 2002, CHEST, V121, p192S, DOI 10.1378/chest.121.5_suppl.192S; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Truss MC, 2001, WORLD J UROL, V19, P344, DOI 10.1007/s003450100221; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822	46	96	104	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13095	13101		10.1074/jbc.M311556200	http://dx.doi.org/10.1074/jbc.M311556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14668322	hybrid, Green Published			2022-12-27	WOS:000220334900130
J	Cheon, YP; DeMayo, FJ; Bagchi, MK; Bagchi, IC				Cheon, YP; DeMayo, FJ; Bagchi, MK; Bagchi, IC			Induction of cytotoxic T-lymphocyte antigen-2 beta, a cysteine protease inhibitor in decidua - A potential regulator of embryo implantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-L; PLASMINOGEN-ACTIVATOR; CELL SELECTION; EXPRESSION; PURIFICATION; INVASION	During early pregnancy, the steroid hormone progesterone induces differentiation of uterine stroma to decidual cells, which regulate embryo-uterine interactions. The progesterone-induced signaling molecules that participate in the formation and function of decidua remain poorly understood. We recently utilized high-density oligonucleotide microarrays to identify several genes whose expression is markedly altered in pregnant uterus in response to RU486, a well characterized antagonist of the progesterone receptor (PR). Our study revealed that the gene encoding cytotoxic T-lymphocyte antigen-2beta (CTLA-2beta), a cysteine protease inhibitor, is expressed during PR-induced decidualization. The spatio-temporal expression of CTLA-2beta mRNA precisely overlapped with the decidual phase of pregnancy. Interestingly, administration of progesterone to estrogen-primed ovariectomized mice failed to induce CTLA-2beta expression. A concomitant artificial decidual stimulation was necessary to trigger this expression. Uteri of PR knockout mice failed to express this mRNA, even after a combined administration of steroid hormones and artificial stimulation. The uterine expression of CTLA-2beta was, therefore, dependent on PR as well as other unknown factor(s) associated with decidual response. To identify the molecular target( s) of CTLA-2beta, we analyzed its interaction with proteins present in soluble extracts prepared from day 7 pregnant uteri containing implanted embryos. A protein affinity strategy employing recombinant CTLA-2beta helped us to determine that cathepsin L, a cysteine protease, is one of its targets in the pregnant uterus. Consistent with this finding, expression of cathepsin L was detected in the giant trophoblast cells of the ectoplacental cone on day 7 of pregnancy. Collectively, our results support the hypothesis that expression of CTLA-2beta in the decidua may regulate implantation of the embryo by neutralizing the activities of one or more proteases generated by the proliferating trophoblast.	Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA; Univ Illinois, Dept Mol Integrat Physiol, Urbana, IL 61802 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Baylor College of Medicine	Bagchi, IC (corresponding author), Univ Illinois, Dept Vet Biosci, Urbana, IL 61802 USA.	ibagchi@uiuc.edu	DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044611, R01HD043381, R01HD039291, R01HD034527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-44611, R01 HD-39291, R01 HD-34527, R01 HD-43381] Funding Source: Medline; NIDDK NIH HHS [R01-DK-50257] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afonso S, 1997, DEVELOPMENT, V124, P3415; Alexander CM, 1996, DEVELOPMENT, V122, P1723; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BAULIEU EE, 1991, TRENDS ENDOCRIN MET, V2, P233, DOI 10.1016/1043-2760(91)90030-Q; Benavides F, 2001, IMMUNOGENETICS, V53, P233, DOI 10.1007/s002510100320; BEVILACQUA EMAF, 1989, ARCH BIOL MED EXP, V22, P107; BRUNET JF, 1988, IMMUNOL REV, V103, P21, DOI 10.1111/j.1600-065X.1988.tb00747.x; Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767; Cheon YP, 2002, MOL ENDOCRINOL, V16, P2853, DOI 10.1210/me.2002-0270; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; Croy BA, 2002, J REPROD IMMUNOL, V57, P151, DOI 10.1016/S0165-0378(02)00005-0; DEFEO VJ, 1967, CELLULAR BIOL UTERUS, P191; DELARIA K, 1994, J BIOL CHEM, V269, P25172; DENIZOT F, 1989, EUR J IMMUNOL, V19, P631, DOI 10.1002/eji.1830190409; FAZLEABAS AT, 1982, J BIOL CHEM, V257, P6886; FINN CA, 1977, BIOL UTERUS, P246; GU Y, 1999, ENCY REPROD, P836; HAMILTON R T, 1990, Journal of Cell Biology, V111, p357A; Honey K, 2002, J EXP MED, V195, P1349, DOI 10.1084/jem.20011904; Irwin J. C., 1999, ENCY REPROD, V1, P823; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Makrigiannakis A, 2001, NAT IMMUNOL, V2, P1018, DOI 10.1038/ni719; Mellor AL, 2001, NAT IMMUNOL, V2, P64, DOI 10.1038/83183; Moffett-King A, 2002, NAT REV IMMUNOL, V2, P656, DOI 10.1038/nri886; MULLINS DE, 1980, CELL, V20, P865, DOI 10.1016/0092-8674(80)90333-5; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Parr MB., 1989, BIOL UTERUS, P233; Philibert D, 1985, ANTIPROGESTIN STEROI, P49; Psychoyos A, 1976, J Reprod Fertil Suppl, P17; PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x; PSYCHOYOS A, 1973, HDB PHYSL, P187; ROBERTS RM, 1995, MOL CELLULAR ASPECTS, P253; STALLINGSMANN ML, 1994, J BIOL CHEM, V269, P24090; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; Teesalu T, 1996, MECH DEVELOP, V56, P103, DOI 10.1016/0925-4773(96)00515-1; Thellin O, 2003, TOXICOLOGY, V185, P179, DOI 10.1016/S0300-483X(02)00607-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Weitlauf H. M., 1994, P391; YOSHINAGA K, 1988, ANN NY ACAD SCI, V541, P424, DOI 10.1111/j.1749-6632.1988.tb22279.x; Yoshinaga K., 1980, PROGR REPRODUCTIVE B, V7, P189; Zhang X, 1996, BIOL REPROD, V54, P1052, DOI 10.1095/biolreprod54.5.1052	43	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10357	10363		10.1074/jbc.M309434200	http://dx.doi.org/10.1074/jbc.M309434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681235	hybrid			2022-12-27	WOS:000220050400085
J	Koch, J; Guntrum, R; Heintke, S; Kyritsis, C; Tampe, R				Koch, J; Guntrum, R; Heintke, S; Kyritsis, C; Tampe, R			Functional dissection of the transmembrane domains of the transporter associated with antigen processing (TAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; MOLECULAR-MECHANISM; PEPTIDE BINDING; TAPASIN; GLYCOPROTEIN; SUBUNITS; COMPLEX; REGION; IDENTIFICATION; TRANSLOCATION	The transporter associated with antigen processing (TAP1/2) translocates cytosolic peptides of proteasomal degradation into the endoplasmic reticulum ( ER) lumen. A peptide-loading complex of tapasin, major histocompatibility complex class I, and several auxiliary factors is assembled at the transporter to optimize antigen display to cytotoxic T-lymphocytes at the cell surface. The heterodimeric TAP complex has unique N-terminal domains in addition to a 6 + 6-transmembrane segment core common to most ABC transporters. Here we provide direct evidence that this core TAP complex is sufficient for (i) ER targeting, (ii) heterodimeric assembly within the ER membrane, (iii) peptide binding, (iv) peptide transport, and ( v) specific inhibition by the herpes simplex virus protein ICP47 and the human cytomegalovirus protein US6. We show for the first time that the translocation pore of the transporter is composed of the predicted TM-(5 - 10) of TAP1 and TM-( 4 - 9) of TAP2. Moreover, we demonstrate that the N-terminal domains of TAP1 and TAP2 are essential for recruitment of tapasin, consequently mediating assembly of the macromolecular peptide-loading complex.	Goethe Univ Frankfurt, Bioctr, Inst Biochem, D-69439 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Goethe Univ Frankfurt, Bioctr, Inst Biochem, Marie Curie Str 9, D-69439 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9; Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; Babenko AP, 2002, J BIOL CHEM, V277, P43997, DOI 10.1074/jbc.M208085200; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; Brocke P, 2002, CURR OPIN IMMUNOL, V14, P22, DOI 10.1016/S0952-7915(01)00294-1; Chan KW, 2003, EMBO J, V22, P3833, DOI 10.1093/emboj/cdg376; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Garbi N, 2003, EUR J IMMUNOL, V33, P264, DOI 10.1002/immu.200390029; Grandea AG, 1997, IMMUNOGENETICS, V46, P477, DOI 10.1007/s002510050308; Heintke S, 2003, FEBS LETT, V533, P42, DOI 10.1016/S0014-5793(02)03746-8; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; Hewitt EW, 2003, IMMUNOLOGY, V110, P163, DOI 10.1046/j.1365-2567.2003.01738.x; Hewitt EW, 2001, EMBO J, V20, P387, DOI 10.1093/emboj/20.3.387; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; Kyritsis C, 2001, J BIOL CHEM, V276, P48031, DOI 10.1074/jbc.M108528200; Lauvau G, 1999, J BIOL CHEM, V274, P31349, DOI 10.1074/jbc.274.44.31349; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Neumann L, 1997, J MOL BIOL, V272, P484, DOI 10.1006/jmbi.1997.1282; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Park B, 2003, J BIOL CHEM, V278, P14337, DOI 10.1074/jbc.M212882200; Peh CA, 2000, J IMMUNOL, V164, P292, DOI 10.4049/jimmunol.164.1.292; Raghuraman G, 2002, J BIOL CHEM, V277, P41786, DOI 10.1074/jbc.M207128200; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; TAMPE R, 1997, UNUSUAL SECRETORY PA, P115; Tan P, 2002, J IMMUNOL, V168, P1950, DOI 10.4049/jimmunol.168.4.1950; Turnquist HR, 2002, IMMUNOL RES, V25, P261, DOI 10.1385/IR:25:3:261; Turnquist HR, 2001, J IMMUNOL, V167, P4443, DOI 10.4049/jimmunol.167.8.4443; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Vos JC, 1999, J IMMUNOL, V163, P6679; Vos JC, 2000, CURR BIOL, V10, P1, DOI 10.1016/S0960-9822(99)00257-2; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Zarling AL, 2003, J IMMUNOL, V171, P5287, DOI 10.4049/jimmunol.171.10.5287	47	136	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10142	10147		10.1074/jbc.M312816200	http://dx.doi.org/10.1074/jbc.M312816200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679198	hybrid			2022-12-27	WOS:000220050400060
J	Zou, J; Zhu, F; Liu, JJ; Wang, WY; Zhang, RM; Garlisi, CG; Liu, YH; Wang, SH; Shah, H; Wan, YT; Umland, SP				Zou, J; Zhu, F; Liu, JJ; Wang, WY; Zhang, RM; Garlisi, CG; Liu, YH; Wang, SH; Shah, H; Wan, YT; Umland, SP			Catalytic activity of human ADAM33	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ALPHA-CONVERTING-ENZYME; METALLOPROTEINASE INHIBITORS; INTRACELLULAR MATURATION; PROTEOLYTIC ACTIVITY; MEMBRANE-PROTEINS; CYSTEINE SWITCH; CELL-CELL; DISINTEGRIN; CLEAVAGE	ADAM33 ( a disintegrin and metalloproteinase) is an asthma susceptibility gene recently identified through a genetic study of asthmatic families ( van Eerdewegh et al. ( 2002) Nature 418, 426 - 430). In order to characterize the catalytic properties of ADAM33, the metalloproteinase domain of human ADAM33 was expressed in Drosophila S2 cells and purified. The N-terminal sequence of the purified metalloproteinase was exclusively (204)EARR, indicating utilization of one of three furin recognition sites. Of many synthetic peptides tested as potential substrates, four peptides derived from beta-amyloid precursor protein (APP), Kit-ligand-1 (KL-1), tumor necrosis factor-related activation-induced cytokine, and insulin B chain were cleaved by ADAM33; mutation at the catalytic site, E346A, inactivated catalytic activity. Cleavage of APP occurred at His(14)down arrowGln(15), not at the alpha-secretase site and was inefficient (k(cat)/K-m (1.6 +/- 0.3) x 10(2) M-1 s(-1)). Cleavage of a juxtamembrane KL-1 peptide occurred at a site used physiologically with a similar efficiency. Mutagenesis of KL-1 peptide substrate indicated that the P3, P2, P1, and P3' residues were critical for activity. In a transfected cell-based sheddase assay, ADAM33 functioned as a negative regulator of APP shedding and mediated some constitutive shedding of KL-1, which was not regulated by phorbol 12-myristate 13-acetate activation. ADAM33 activity was sensitive to several hydroxamate inhibitors (IK682, K-i = 23 +/- 7 nM) and to tissue inhibitors of metalloproteinase (TIMPs). Activity was inhibited moderately by TIMP-3 and TIMP-4 and weakly inhibited by TIMP-2 but not by TIMP-1, a profile distinct from other ADAMs. The identification of ADAM33 peptide substrates, cellular activity, and a distinct inhibitor profile provide the basis for further functional studies of ADAM33.	Schering Plough Corp, Res Inst, Dept Allergy, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Dept Struct Chem, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Zou, J (corresponding author), Schering Plough Corp, Res Inst, Dept Allergy, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	jun.zou@spcorp.com		Zhang, Rumin/0000-0002-6590-6036				Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Becherer JD, 2003, CURR TOP DEV BIOL, V54, P101, DOI 10.1016/S0070-2153(03)54006-6; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Chesneau V, 2003, J BIOL CHEM, V278, P22331, DOI 10.1074/jbc.M302781200; Duan JJW, 2002, J MED CHEM, V45, P4954, DOI 10.1021/jm0255670; Fourie AM, 2003, J BIOL CHEM, V278, P30469, DOI 10.1074/jbc.M213157200; Garlisi CG, 2003, BIOCHEM BIOPH RES CO, V301, P35, DOI 10.1016/S0006-291X(02)02976-5; Gong WM, 1998, J MOL BIOL, V283, P657, DOI 10.1006/jmbi.1998.2110; Gunn TM, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-2; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Howard L, 2001, FEBS LETT, V498, P82, DOI 10.1016/S0014-5793(01)02506-6; HOWARD L, 1995, METHOD ENZYMOL, V248, P388; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Kang TB, 2002, J BIOL CHEM, V277, P48514, DOI 10.1074/jbc.M208961200; Kuzmic P, 2000, ANAL BIOCHEM, V286, P45, DOI 10.1006/abio.2000.4685; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P189; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Loechel F, 2001, FEBS LETT, V506, P65, DOI 10.1016/S0014-5793(01)02873-3; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Nagase H, 2002, ARTHRITIS RES THER, V4, pS51, DOI 10.1186/ar573; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlomann U, 2002, J BIOL CHEM, V277, P48210, DOI 10.1074/jbc.M203355200; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; Umland SP, 2003, AM J RESP CELL MOL, V29, P571, DOI 10.1165/rcmb.2003-0028OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Williams J W, 1979, Methods Enzymol, V63, P437; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966; Zhang RM, 1999, ANAL BIOCHEM, V270, P268, DOI 10.1006/abio.1999.4109	63	89	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9818	9830		10.1074/jbc.M309696200	http://dx.doi.org/10.1074/jbc.M309696200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14676211	hybrid			2022-12-27	WOS:000220050400021
J	Cohen, L; Karbat, I; Gilles, N; Froy, O; Corzo, G; Angelovici, R; Gordon, D; Gurevitz, M				Cohen, L; Karbat, I; Gilles, N; Froy, O; Corzo, G; Angelovici, R; Gordon, D; Gurevitz, M			Dissection of the functional surface of an anti-insect excitatory toxin illuminates a putative "hot spot" common to all scorpion beta-toxins affecting Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT SODIUM-CHANNELS; CENTRUROIDES-NOXIUS HOFFMANN; SELECTIVE NEUROTOXINS; ANDROCTONUS-AUSTRALIS; MOLECULAR-MECHANISMS; RECEPTOR-SITES; BACULOVIRUS; EXPRESSION; BINDING; VENOM	Scorpion beta-toxins affect the activation of voltage-sensitive sodium channels (NaChs). Although these toxins have been instrumental in the study of channel gating and architecture, little is known about their active sites. By using an efficient system for the production of recombinant toxins, we analyzed by point mutagenesis the entire surface of the beta-toxin, Bj-xtrIT, an anti-insect selective excitatory toxin from the scorpion Buthotus judaicus. Each toxin mutant was purified and analyzed using toxicity and binding assays, as well as by circular dichroism spectroscopy to discern the differences among mutations that caused structural changes and those that specifically affected bioactivity. This analysis highlighted a functional discontinuous surface of 1405 Angstrom(2), which was composed of a number of non-polar and three charged amino acids clustered around the main alpha-helical motif and the C-tail. Among the charged residues, Glu(30) is a center of a putative "hot spot" in the toxin-receptor binding-interface and is shielded from bulk solvent by a hydrophobic "gasket" (Tyr(26) and Val(34)). Comparison of the Bj-xtrIT structure with that of other beta-toxins that are active on mammals suggests that the hot spot and an adjacent non-polar region are spatially conserved. These results highlight for the first time structural elements that constitute a putative "pharmacophore" involved in the interaction of beta-toxins with receptor site-4 on NaChs. Furthermore, the unique structure of the C-terminal region most likely determines the specificity of excitatory toxins for insect NaChs.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Ctr Etud Saclay, Dept Ingn & Etud Prot, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel	Tel Aviv University; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Hebrew University of Jerusalem	Gordon, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel.	dgordon@post.tau.ac.il; mamgur@post.tau.ac.il	Corzo, Gerardo/B-3778-2014; Froy, Oren/C-3550-2009	Corzo, Gerardo/0000-0002-9513-1622; 				BARHANIN J, 1982, J BIOL CHEM, V257, P2553; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BOUGIS PE, 1989, J BIOL CHEM, V264, P19259; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2000, BIOCHIMIE, V82, P883, DOI 10.1016/S0300-9084(00)01174-3; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Gershburg E, 1998, FEBS LETT, V422, P132, DOI 10.1016/S0014-5793(97)01614-1; Gilles N, 2003, FEBS LETT, V540, P81, DOI 10.1016/S0014-5793(03)00226-6; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; Gordon D, 2003, EUR J BIOCHEM, V270, P2663, DOI 10.1046/j.1432-1033.2003.03643.x; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; Gordon Dalia, 1997, Invertebrate Neuroscience, V3, P103, DOI 10.1007/BF02480365; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; Lee D, 2000, J INSECT PHYSIOL, V46, P499, DOI 10.1016/S0022-1910(99)00136-5; LIMA ME, 1989, INSECT BIOCHEM, V19, P413; LIMA ME, 1986, BIOCHEM BIOPH RES CO, V139, P296; MAEDA S, 1991, VIROLOGY, V184, P777, DOI 10.1016/0042-6822(91)90451-G; Marcotte P, 1997, CIRC RES, V80, P363, DOI 10.1161/01.RES.80.3.363; MARTINEAUCLAIRE MF, 1994, EUR J BIOCHEM, V223, P637, DOI 10.1111/j.1432-1033.1994.tb19036.x; MOSKOWITZ H, 1994, INSECT BIOCHEM MOLEC, V24, P13, DOI 10.1016/0965-1748(94)90118-X; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; PANG SZ, 1992, GENE, V116, P165, DOI 10.1016/0378-1119(92)90512-N; PELHATE M, 1982, J EXP BIOL, V97, P67; Pinheiro CB, 2003, ACTA CRYSTALLOGR D, V59, P405, DOI 10.1107/S090744490202111X; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; REED L. J., 1938, AMER JOUR HYG, V27, P493; Regev A, 2003, FEBS LETT, V537, P106, DOI 10.1016/S0014-5793(03)00104-2; Selisko B, 1996, EUR J BIOCHEM, V242, P235, DOI 10.1111/j.1432-1033.1996.0235r.x; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; STEWART LMD, 1991, NATURE, V352, P85, DOI 10.1038/352085a0; ZLOTKIN E, 1985, ARCH BIOCHEM BIOPHYS, V240, P877, DOI 10.1016/0003-9861(85)90098-0; ZLOTKIN E, 1991, BIOCHEMISTRY-US, V30, P4814, DOI 10.1021/bi00233a025; ZLOTKIN E, 1997, TOXINS SIGNAL TRANSD, P95	40	64	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8206	8211		10.1074/jbc.M307531200	http://dx.doi.org/10.1074/jbc.M307531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672947	hybrid			2022-12-27	WOS:000189103300102
J	de Pereda, JM; Waas, WF; Jan, YW; Ruoslahti, E; Schimmel, P; Pascual, J				de Pereda, JM; Waas, WF; Jan, YW; Ruoslahti, E; Schimmel, P; Pascual, J			Crystal structure of a human peptidyl-tRNA hydrolase reveals a new fold and suggests basis for a bifunctional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HYDROLYSIS; PROTEINS; MUTANT; YEAST; SITE	Peptidyl-tRNA hydrolase (Pth) activity releases tRNA from the premature translation termination product peptidyl-tRNA. Two different enzymes have been reported to encode such activity, Pth present in bacteria and eukaryotes and Pth2 present in archaea and eukaryotes. Here we report the crystallographic structure of the Homo sapiens Pth2 at a 2.0-Angstrom resolution as well as its catalytic properties. In contrast to the structure of Escherichia coli Pth, H. sapiens Pth2 has an alpha/beta fold with a four-stranded antiparallel beta-sheet in its core surrounded by two alpha-helices on each side. This arrangement of secondary structure elements generates a fold not previously reported. Its catalytic efficiency is comparable with that reported for the archaeal Sulfolobus solfataricus Pth2 and higher than that of the bacterial E. coli Pth. Several lines of evidence target the active site to two close loops with highly conserved residues. This active site architecture is unrelated to that of E. coli Pth. In addition, intermolecular contacts in the crystal asymmetric unit cell suggest a likely surface for protein-protein interactions related to the Pth2-mediated apoptosis.	Burnham Inst, Ctr Canc, Program Cell Adhes & Signal Transduct, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem & Mol Biol, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute	Pascual, J (corresponding author), Burnham Inst, Ctr Canc, Program Cell Adhes & Signal Transduct, La Jolla, CA 92037 USA.	pascual@burnham.org	pascual, jaime/D-4566-2009; de Pereda, Jose M/AAE-5226-2022; de Pereda, Jose M/F-1733-2010	de Pereda, Jose M/0000-0002-8912-6739; de Pereda, Jose M/0000-0002-8912-6739; pascual, jaime/0000-0001-8992-7475				ATHERLY AG, 1972, NATURE-NEW BIOL, V240, P245, DOI 10.1038/newbio240245a0; Baxevanis AD, 2003, NUCLEIC ACIDS RES, V31, P1, DOI 10.1093/nar/gkg120; Blomberg N, 1997, FOLD DES, V2, P343, DOI 10.1016/S1359-0278(97)00048-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME, P297; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Fromant M, 2003, NUCLEIC ACIDS RES, V31, P3227, DOI 10.1093/nar/gkg428; Fromant M, 1999, BIOCHEMISTRY-US, V38, P4982, DOI 10.1021/bi982657r; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jeffery CJ, 2003, TRENDS GENET, V19, P415, DOI 10.1016/S0168-9525(03)00167-7; JORGENSEN F, 1990, J MOL BIOL, V215, P511, DOI 10.1016/S0022-2836(05)80164-0; JOST JP, 1969, J BIOL CHEM, V244, P5866; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski RA, 1998, CURR OPIN STRUC BIOL, V8, P631, DOI 10.1016/S0959-440X(98)80156-5; Menez J, 2002, MOL MICROBIOL, V45, P123, DOI 10.1046/j.1365-2958.2002.02992.x; MENNINGER JR, 1976, J BIOL CHEM, V251, P3392; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rosas-Sandoval G, 2002, P NATL ACAD SCI USA, V99, P16707, DOI 10.1073/pnas.222659199; Sanishvili R, 2003, J BIOL CHEM, V278, P26039, DOI 10.1074/jbc.M303867200; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; SCHOFIEL.P, 1968, BIOCHIM BIOPHYS ACTA, V155, P410, DOI 10.1016/0005-2787(68)90185-8; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839	25	52	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8111	8115		10.1074/jbc.M311449200	http://dx.doi.org/10.1074/jbc.M311449200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660562	hybrid			2022-12-27	WOS:000189103300091
J	Givens, RM; Lin, MH; Taylor, DJ; Mechold, U; Berry, JO; Hernandez, VJ				Givens, RM; Lin, MH; Taylor, DJ; Mechold, U; Berry, JO; Hernandez, VJ			Inducible expression, enzymatic activity, and origin of higher plant homologues of bacterial RelA/SpoT stress proteins in Nicotiana tabacum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GENE-EXPRESSION; ESCHERICHIA-COLI; ARABIDOPSIS; RELA; CYANOBACTERIA; CHLOROPLASTS; TRANSLATION; RESPONSES; (P)PPGPP	All living cells possess adaptive responses to environmental stress that are essential to ensuring cell survival. For motile organisms, this can culminate in avoidance or attractile behavior, but for sessile organisms such as plants, stress adaptation is a process of success or failure within the confines of a given environment. Nearly all bacterial species possess a highly evolved system for stress adaptation, known as the "stringent response." This ancient and ubiquitous regulatory response is mediated by production of a second messenger of general stress, the nucleotide guanosine- 3',5'-(bis) pyrophosphate (ppGpp), which mediates reprogramming of the global transcriptional output of the cell. Accumulation of ppGpp is stress-induced through the enzymatic activation of the well known bacterial ppGpp synthetases, RelA and SpoT. We have recently discovered homologues of bacterial relA/spoT genes in the model plant Nicotiana tabacum. We hypothesize that these homologues (designated RSH genes for RelA/SpoT homologues) serve a stress-adaptive function in plants analogous with their function in bacteria. In support of this hypothesis, we find 1) inducibility of tobacco RSH gene expression following treatment with jasmonic acid; 2) bona fide ppGpp synthesis activity of purified recombinant Nt-RSH2 protein, and 3) a wide spread distribution of RSH gene expression in the plant kingdom. Phylogenetic analyses identifies a distinct phylogenetic branch for the plant RSH proteins with two subgroups and supports ancient symbiosis and nuclear gene transfer as a possible origin for these stress response genes in plants. In addition, we find that Nt-RSH2 protein co-purifies with chloroplasts in subcellular fractionation experiments. Taken together, our findings implicate a direct mode of action of these ppGpp synthetases with regard to plant physiology, namely regulation of chloroplast gene expression in response to plant defense signals.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; Inst Andre Lwoff, CNRS, UPR 9079, F-94800 Villejuif, France	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Centre National de la Recherche Scientifique (CNRS)	Hernandez, VJ (corresponding author), 3435 Main St,138 Farber Hall, Buffalo, NY 14214 USA.	vjh@buffalo.edu	Mechold, Undine/GYV-3918-2022	Mechold, Undine/0000-0002-6019-0972	NIGMS NIH HHS [GM57189] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057189] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGSLAND KJ, 1991, J BACTERIOL, V173, P3446, DOI 10.1128/jb.173.11.3446-3455.1991; BERRY JO, 1988, P NATL ACAD SCI USA, V85, P4190, DOI 10.1073/pnas.85.12.4190; BERRY JO, 1985, MOL CELL BIOL, V5, P2238, DOI 10.1128/MCB.5.9.2238; Bray EA, 1997, TRENDS PLANT SCI, V2, P48, DOI 10.1016/S1360-1385(97)82562-9; Cashel M., 1994, METH MOL G, V3, P341; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; DOLFERUS R, 1994, ANN BOT-LONDON, V74, P301, DOI 10.1006/anbo.1994.1121; Eagar SH, 1999, OCEANOL ACTA, V22, P603, DOI 10.1016/S0399-1784(00)88951-3; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FARMER EE, 1990, P NATL ACAD SCI USA, V87, P7713, DOI 10.1073/pnas.87.19.7713; GALLIE DR, 1993, ANNU REV PLANT PHYS, V44, P77, DOI 10.1146/annurev.pp.44.060193.000453; Greenberg JT, 1997, ANNU REV PLANT PHYS, V48, P525, DOI 10.1146/annurev.arplant.48.1.525; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Huelsenbeck JP, 2000, SCIENCE, V288, P2349, DOI 10.1126/science.288.5475.2349; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Kasai K, 2002, NUCLEIC ACIDS RES, V30, P4985, DOI 10.1093/nar/gkf628; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; Mach JM, 2001, P NATL ACAD SCI USA, V98, P771, DOI 10.1073/pnas.021465298; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; McCormac D, 1997, PLANT PHYSIOL, V114, P801, DOI 10.1104/pp.114.3.801; McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P585; Mittler R, 1997, J CELL SCI, V110, P1333; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REINBOTHE S, 1993, EMBO J, V12, P1505, DOI 10.1002/j.1460-2075.1993.tb05794.x; Rujan T, 2001, TRENDS GENET, V17, P113, DOI 10.1016/S0168-9525(00)02209-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schenk PM, 2000, P NATL ACAD SCI USA, V97, P11655, DOI 10.1073/pnas.97.21.11655; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Thomma BPHJ, 1998, P NATL ACAD SCI USA, V95, P15107, DOI 10.1073/pnas.95.25.15107; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toulokhonov II, 2001, J BIOL CHEM, V276, P1220, DOI 10.1074/jbc.M007184200; UZAN M, 1976, BIOCHEM BIOPH RES CO, V69, P751, DOI 10.1016/0006-291X(76)90939-6; van der Biezen EA, 2000, P NATL ACAD SCI USA, V97, P3747, DOI 10.1073/pnas.060392397; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; XIAO H, 1991, J BIOL CHEM, V266, P5980; Xiong LZ, 2001, MOL PLANT MICROBE IN, V14, P685, DOI 10.1094/MPMI.2001.14.5.685; Yamada A, 2003, PLANT CELL PHYSIOL, V44, P3, DOI 10.1093/pcp/pcg001	42	66	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7495	7504		10.1074/jbc.M311573200	http://dx.doi.org/10.1074/jbc.M311573200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660585	hybrid			2022-12-27	WOS:000189103300017
J	Inukai, N; Yamaguchi, Y; Kuraoka, I; Yamada, T; Kamijo, S; Kato, J; Tanaka, K; Handa, H				Inukai, N; Yamaguchi, Y; Kuraoka, I; Yamada, T; Kamijo, S; Kato, J; Tanaka, K; Handa, H			A novel hydrogen peroxide-induced phosphorylation and ubiquitination pathway leading to RNA polymerase II proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; COUPLED DNA-REPAIR; HIPPEL-LINDAU PROTEIN; COCKAYNE-SYNDROME; TRANSCRIPTION ELONGATION; LARGE SUBUNIT; IN-VITRO; DAMAGE; KINASES; COMPLEX	DNA damage-induced ubiquitination of the largest subunit of RNA polymerase II, Rpb1, has been implicated in transcription-coupled repair for years. The studies so far, however, have been limited to the use of bulky helix-distorting DNA damages caused by UV light and cisplatin, which are corrected by the nucleotide excision repair pathway. Non-bulky, non-helix-distorting damages are caused at high frequency by reactive oxygen species in cells and corrected by the base excision repair pathway. Contrary to a classic view, we recently found that the second type of DNA lesions also causes RNA polymerase II stalling in vitro. In this paper, we show that hydrogen peroxide (H2O2) causes significant ubiquitination and proteasomal degradation of Rpb1 by mechanisms that are distinct from those employed after UV irradiation. UV irradiation and H2O2 treatment cause characteristic changes in protein kinases phosphorylating the carboxyl-terminal domain at Ser-2 and -5. The H2O2-induced ubiquitination is likely dependent on unusual Ser-5 phosphorylation by ERK1/2. Moreover, the H2O2-induced ubiquitination occurs on transcriptionally engaged polymerases without the help of Cockayne syndrome A and B proteins and von Hippel-Lindau tumor suppressor proteins, which are all required for the UV-induced ubiquitination. These results suggest that stalled polymerases are recognized and ubiquitinated differentially depending on the types of DNA lesions. Our findings may have general implications in the basic mechanism of transcription-coupled nucleotide excision repair and base excision repair.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; Japan Sci & Technol Agcy, PRESTO, Yokohama, Kanagawa 2268501, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Osaka University	Handa, H (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	hhanda@bio.titech.ac.jp	Yamaguchi, Yuki/B-9390-2015	Yamaguchi, Yuki/0000-0002-0197-614X; Kuraoka, Isao/0000-0001-6391-3411				BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bonnet F, 1999, NUCLEIC ACIDS RES, V27, P4399, DOI 10.1093/nar/27.22.4399; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Hasegawa J, 2003, J BIOCHEM, V133, P133, DOI 10.1093/jb/mvg013; Kamiuchi S, 2002, P NATL ACAD SCI USA, V99, P201, DOI 10.1073/pnas.012473199; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kuraoka I, 2003, J BIOL CHEM, V278, P7294, DOI 10.1074/jbc.M208102200; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Luo ZH, 2001, MUTAT RES-DNA REPAIR, V486, P259, DOI 10.1016/S0921-8777(01)00097-0; MARKOWITZ RB, 1995, BIOCHEM BIOPH RES CO, V207, P1051, DOI 10.1006/bbrc.1995.1291; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Na X, 2003, EMBO J, V22, P4249, DOI 10.1093/emboj/cdg410; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tornaletti S, 2001, J BIOL CHEM, V276, P45367, DOI 10.1074/jbc.M105282200; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Unk I, 2001, MOL CELL BIOL, V21, P1656, DOI 10.1128/MCB.21.5.1656-1661.2001; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang LY, 2003, INT J ONCOL, V22, P683; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	35	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8190	8195		10.1074/jbc.M311412200	http://dx.doi.org/10.1074/jbc.M311412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662762	hybrid			2022-12-27	WOS:000189103300100
J	Iwamoto, T; Kita, S; Uehara, A; Imanaga, I; Matsuda, T; Baba, A; Katsuragi, T				Iwamoto, T; Kita, S; Uehara, A; Imanaga, I; Matsuda, T; Baba, A; Katsuragi, T			Molecular determinants of Na+/Ca2+ exchange (NCX1) inhibition by SEA0400	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; CARDIAC NA+-CA2+ EXCHANGER; REVERSE MODE; DEPENDENT REGULATION; SELECTIVE INHIBITOR; DYNAMIC PROPERTIES; CA2+ OVERLOAD; ISOFORMS NCX1; STEADY-STATE; KB-R7943	SEA0400 is a potent and selective Na+/Ca2+ exchanger (NCX) inhibitor. We evaluated the inhibitory effects of SEA0400 on Na-i(+)-dependent Ca-45(2+) uptake and whole-cell Na+/Ca2(+) exchange currents in NCX-transfected fibroblasts. SEA0400 preferentially inhibited Ca-45(2+) uptake by NCX1 compared with inhibitions by NCX2, NCX3, and NCKX2. SEA0400 also selectively blocked outward exchange currents from NCX1 transfectants. We searched for regions that may form the SEA0400 receptor in the NCX1 molecule by NCX1/NCX3 chimeric analysis. The results suggest that the first intracellular loop and the fifth transmembrane segment are mostly responsible for the differential drug responses between NCX1 and NCX3. Further site-directed mutagenesis revealed that multiple mutations at Phe-213 markedly reduced sensitivity to SEA0400 without affecting that to KB-R7943. We also found that Gly-833-to-Cys mutation (within the alpha-2 repeat) greatly reduced the inhibition by SEA0400, but unexpectedly the NCX1 chimera with an alpha-2 repeat from NCKX2 possessed normal drug sensitivity. In addition, exchangers with mutated exchanger inhibitory peptide regions, which display either undetectable or accelerated Na+-dependent inactivation, had a markedly reduced sensitivity or hypersensitivity to SEA0400, respectively. To verify the efficacy of the NCX inhibitor, we examined the renoprotective effect of SEA0400 in a hypoxic injury model using porcine renal tubular cells. SEA0400 protected against hypoxia/reoxygenation-induced cell damage in tubular cells expressing wild-type NCX1 but not in cells expressing SEA0400-insensitive mutants. These results suggest that Phe-213, Gly-833, and residues that eliminate Na+-dependent inactivation are critical determinants for the inhibition by SEA0400, and their mutants are very useful for checking the pharmacological importance of NCX inhibition by SEA0400.	Fukuoka Univ, Sch Med, Dept Pharmacol, Jonan Ku, Fukuoka 8140180, Japan; Fukuoka Univ, Sch Med, Dept Physiol, Jonan Ku, Fukuoka 8140180, Japan; Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Med Pharmacol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Neuropharmacol Lab, Suita, Osaka 5650871, Japan	Fukuoka University; Fukuoka University; National Cerebral & Cardiovascular Center - Japan; Osaka University; Osaka University	Iwamoto, T (corresponding author), Fukuoka Univ, Sch Med, Dept Pharmacol, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8140180, Japan.	tiwamoto@cis.fukuoka-u.ac.jp						Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Choptiany P, 2003, BIOPHYS J, V84, p518A; Doering AE, 1998, J BIOL CHEM, V273, P778, DOI 10.1074/jbc.273.2.778; Elias CL, 2001, AM J PHYSIOL-HEART C, V281, pH1334, DOI 10.1152/ajpheart.2001.281.3.H1334; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; Hilgemann DW, 1996, ANN NY ACAD SCI, V779, P136, DOI 10.1111/j.1749-6632.1996.tb44783.x; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Hoyt KR, 1998, MOL PHARMACOL, V53, P742, DOI 10.1124/mol.53.4.742; Iwamoto T, 1999, J BIOL CHEM, V274, P23094, DOI 10.1074/jbc.274.33.23094; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Iwamoto T, 2003, BIOPHYS J, V84, p189A; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Iwamoto T, 1998, AM J PHYSIOL-CELL PH, V275, pC423, DOI 10.1152/ajpcell.1998.275.2.C423; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Iwamoto T, 2001, MOL PHARMACOL, V59, P524, DOI 10.1124/mol.59.3.524; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Kimura J, 1999, BRIT J PHARMACOL, V128, P969, DOI 10.1038/sj.bjp.0702869; Ladilov Y, 1999, AM J PHYSIOL-HEART C, V276, pH1868, DOI 10.1152/ajpheart.1999.276.6.H1868; LI ZP, 1994, J BIOL CHEM, V269, P17434; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; Magee WP, 2003, AM J PHYSIOL-HEART C, V284, pH903, DOI 10.1152/ajpheart.00784.2002; Matsuda T, 2001, J PHARMACOL EXP THER, V298, P249; MATSUOKA S, 1994, J PHYSIOL-LONDON, V476, P443, DOI 10.1113/jphysiol.1994.sp020146; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nakamura Aki, 1998, Folia Pharmacologica Japonica, V111, P105, DOI 10.1254/fpj.111.105; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1991, ANN NY ACAD SCI, V639, P181, DOI 10.1111/j.1749-6632.1991.tb17305.x; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Ogata M, 2003, EUR J PHARMACOL, V478, P187, DOI 10.1016/j.ejphar.2003.08.082; Pan Y, 2000, AM J PHYSIOL-CELL PH, V279, pC393, DOI 10.1152/ajpcell.2000.279.2.C393; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Pilitsis JG, 2001, BRAIN RES, V916, P192, DOI 10.1016/S0006-8993(01)02896-7; Pintado AJ, 2000, BRIT J PHARMACOL, V130, P1893, DOI 10.1038/sj.bjp.0703519; Qiu ZY, 2001, J BIOL CHEM, V276, P194, DOI 10.1074/jbc.M005571200; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Reuter H, 2002, CIRC RES, V91, P90, DOI 10.1161/01.RES.0000027529.37429.38; Satoh H, 2000, CIRCULATION, V101, P1441, DOI 10.1161/01.CIR.101.12.1441; Schroder UH, 1999, NEUROPHARMACOLOGY, V38, P319, DOI 10.1016/S0028-3908(98)00198-1; Schulze DH, 2003, J BIOL CHEM, V278, P28849, DOI 10.1074/jbc.M300754200; Seki S, 2002, CIRC J, V66, P390, DOI 10.1253/circj.66.390; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; Sobolevsky AI, 1999, NEUROPHARMACOLOGY, V38, P1235, DOI 10.1016/S0028-3908(99)00040-4; Takahashi K, 2003, EUR J PHARMACOL, V458, P155, DOI 10.1016/S0014-2999(02)02732-2; Tanaka H, 2002, BRIT J PHARMACOL, V135, P1096, DOI 10.1038/sj.bjp.0704574; TANI M, 1990, ANNU REV PHYSIOL, V52, P543; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Watano T, 1996, BRIT J PHARMACOL, V119, P555, DOI 10.1111/j.1476-5381.1996.tb15708.x; Watano T, 1999, BRIT J PHARMACOL, V127, P1846, DOI 10.1038/sj.bjp.0702740; Yamashita J, 2003, J PHARMACOL EXP THER, V304, P284, DOI 10.1124/jpet.102.039024; Yamashita J, 2001, J PHARMACOL EXP THER, V296, P412	57	103	113	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7544	7553		10.1074/jbc.M310491200	http://dx.doi.org/10.1074/jbc.M310491200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660663	hybrid			2022-12-27	WOS:000189103300023
J	Lewis, A; McCrossan, ZA; Abbott, GW				Lewis, A; McCrossan, ZA; Abbott, GW			MinK, MiRP1, and MiRP2 diversify Kv3.1 and Kv3.2 potassium channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; PROTEIN-KINASE-C; FAST-SPIKING; RAT-BRAIN; PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL-CHARACTERIZATION; NEOCORTICAL INTERNEURONS; CARDIAC-ARRHYTHMIA; AUDITORY NEURONS; GLOBUS-PALLIDUS	High frequency firing in mammalian neurons requires ultra-rapid delayed rectifier potassium currents generated by homomeric or heteromeric assemblies of Kv3.1 and Kv3.2 potassium channel alpha subunits. Kv3.1 alpha subunits can also form slower activating channels by coassembling with MinK-related peptide 2 (MiRP2), a single transmembrane domain potassium channel ancillary subunit. Here, using channel subunits cloned from rat and expressed in Chinese hamster ovary cells, we show that modulation by MinK, MiRP1, and MiRP2 is a general mechanism for slowing of Kv3.1 and Kv3.2 channel activation and deactivation and acceleration of inactivation, creating a functionally diverse range of channel complexes. MiRP1 also negatively shifts the voltage dependence of Kv3.1 and Kv3.2 channel activation. Furthermore, MinK, MiRP1, and MiRP2 each form channels with Kv3.1-Kv3.2 heteromers that are kinetically distinct from one another and from MiRP/homomeric Kv3 channels. The findings illustrate a mechanism for dynamic expansion of the functional repertoire of Kv3.1 and Kv3.2 potassium currents and suggest roles for these alpha subunits outside the scope of sustained rapid neuronal firing.	Cornell Univ, Weill Med Coll, Div Cardiol, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University; Cornell University	Abbott, GW (corresponding author), Cornell Univ, Weill Med Coll, Div Cardiol, Dept Med, Starr 463,520 E 70th St, New York, NY 10021 USA.	gwa2001@med.cornell.edu		Abbott, Geoffrey/0000-0003-4552-496X				Abbott GW, 2002, FASEB J, V16, DOI 10.1096/fj.01-0520hyp; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CIRC RES, V88, P981, DOI 10.1161/hh1001.091869; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Baranauskas G, 1999, J NEUROSCI, V19, P6394; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Betancourt L, 2000, J NEUROSCI RES, V61, P646, DOI 10.1002/1097-4547(20000915)61:6<646::AID-JNR8>3.0.CO;2-B; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; Chow A, 1999, J NEUROSCI, V19, P9332; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; CRITZ SD, 1993, J NEUROCHEM, V60, P1175, DOI 10.1111/j.1471-4159.1993.tb03273.x; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Erisir A, 1999, J NEUROPHYSIOL, V82, P2476, DOI 10.1152/jn.1999.82.5.2476; Fernandez FR, 2003, J BIOL CHEM, V278, P40890, DOI 10.1074/jbc.M304235200; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; Gan L, 1998, J NEUROBIOL, V37, P69, DOI 10.1002/(SICI)1097-4695(199810)37:1<69::AID-NEU6>3.0.CO;2-6; GRISSMER S, 1992, J BIOL CHEM, V267, P20971; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hernandez-Pineda R, 1999, J NEUROPHYSIOL, V82, P1512, DOI 10.1152/jn.1999.82.3.1512; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; Kaczmarek LK, 1997, PHYSIOL REV, V77, P627, DOI 10.1152/physrev.1997.77.3.627; KANEMASA T, 1995, J NEUROPHYSIOL, V74, P207, DOI 10.1152/jn.1995.74.1.207; Lau D, 2000, J NEUROSCI, V20, P9071; Lien CC, 2003, J NEUROSCI, V23, P2058; Macica CM, 2003, J NEUROSCI, V23, P1133, DOI 10.1523/JNEUROSCI.23-04-01133.2003; Martina M, 1998, J NEUROSCI, V18, P8111; McCrossan ZA, 2003, J NEUROSCI, V23, P8077; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Melman YF, 2002, J BIOL CHEM, V277, P25187, DOI 10.1074/jbc.M200564200; Melman YF, 2001, J BIOL CHEM, V276, P6439, DOI 10.1074/jbc.M010713200; MORENO H, 1995, J NEUROSCI, V15, P5486; Ohya S, 2002, AM J PHYSIOL-CELL PH, V283, pC866, DOI 10.1152/ajpcell.00099.2002; Ohya S, 2002, AM J PHYSIOL-GASTR L, V282, pG277, DOI 10.1152/ajpgi.00200.2001; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; Rudy B, 2001, TRENDS NEUROSCI, V24, P517, DOI 10.1016/S0166-2236(00)01892-0; Rudy B, 1999, ANN NY ACAD SCI, V868, P304, DOI 10.1111/j.1749-6632.1999.tb11295.x; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tansey EP, 2002, HIPPOCAMPUS, V12, P137, DOI 10.1002/hipo.1104; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Tinel N, 2000, FEBS LETT, V480, P137, DOI 10.1016/S0014-5793(00)01918-9; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; VARNUM MD, 1993, P NATL ACAD SCI USA, V90, P11528, DOI 10.1073/pnas.90.24.11528; Wang LY, 1998, J PHYSIOL-LONDON, V509, P183, DOI 10.1111/j.1469-7793.1998.183bo.x; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Yue L, 2000, J PHYSIOL-LONDON, V527, P467, DOI 10.1111/j.1469-7793.2000.00467.x; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839; ZHANG ZJ, 1994, P NATL ACAD SCI USA, V91, P1766, DOI 10.1073/pnas.91.5.1766	52	61	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7884	7892		10.1074/jbc.M310501200	http://dx.doi.org/10.1074/jbc.M310501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14679187	hybrid			2022-12-27	WOS:000189103300065
J	Madabushi, S; Gross, AK; Philippi, A; Meng, EC; Wensel, TG; Lichtarge, O				Madabushi, S; Gross, AK; Philippi, A; Meng, EC; Wensel, TG; Lichtarge, O			Evolutionary trace of G protein-coupled receptors reveals clusters of residues that determine global and class-specific functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE HELICES; CONSTITUTIVE ACTIVATION; HORMONE RECEPTOR; RHODOPSIN; BINDING; SEQUENCE; SITE; TRANSDUCIN; SURFACES; MUTATION	G protein-coupled receptor (GPCR) activation mediated by ligand-induced structural reorganization of its helices is poorly understood. To determine the universal elements of this conformational switch, we used evolutionary tracing (ET) to identify residue positions commonly important in diverse GPCRs. When mapped onto the rhodopsin structure, these trace residues cluster into a network of contacts from the retinal binding site to the G protein-coupling loops. Their roles in a generic transduction mechanism were verified by 211 of 239 published mutations that caused functional defects. When grouped according to the nature of the defects, these residues subdivided into three striking sub-clusters: a trigger region, where mutations mostly affect ligand binding, a coupling region near the cytoplasmic interface to the G protein, where mutations affect G protein activation, and a linking core in between where mutations cause constitutive activity and other defects. Differential ET analysis of the opsin family revealed an additional set of opsin-specific residues, several of which form part of the retinal binding pocket, and are known to cause functional defects upon mutation. To test the predictive power of ET, we introduced novel mutations in bovine rhodopsin at a globally important position, Leu-79, and at an opsin-specific position, Trp-175. Both were functionally critical, causing constitutive G protein activation of the mutants and rapid loss of regeneration after photobleaching. These results define in GPCRs a canonical signal transduction mechanism where ligand binding induces conformational changes propagated through adjacent trigger, linking core, and coupling regions.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Program Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Francisco	Lichtarge, O (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,T921,BCM 225, Houston, TX 77030 USA.	lichtarge@bcm.tmc.edu	Philippi, Anne/M-9853-2017; Gross, Alecia K./AAJ-1792-2021	Philippi, Anne/0000-0003-2184-6008; Gross, Alecia K./0000-0003-1857-6633; Wensel, Theodore/0000-0003-3518-9352	NATIONAL EYE INSTITUTE [R01EY007981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066099] Funding Source: NIH RePORTER; NEI NIH HHS [R01-EY07981] Funding Source: Medline; NIDDK NIH HHS [DK007696] Funding Source: Medline; NIGMS NIH HHS [R01-GM-66099] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Attwood TK, 2002, PROTEIN ENG, V15, P7, DOI 10.1093/protein/15.1.7; ATTWOOD TK, 1993, PROTEIN ENG, V6, P167, DOI 10.1093/protein/6.2.167; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Bissantz C, 2003, PROTEINS, V50, P5, DOI 10.1002/prot.10237; BROWN BW, 1977, WILEY SERIES PROBABI, P196; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; Fanelli F, 1999, MOL PHARMACOL, V56, P214, DOI 10.1124/mol.56.1.214; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; Flower DR, 1999, BBA-REV BIOMEMBRANES, V1422, P207, DOI 10.1016/S0304-4157(99)00006-4; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2009, DOI 10.1021/bi020613j; Gross AK, 2003, BIOCHEMISTRY-US, V42, P2002, DOI 10.1021/bi020612r; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; Horn F, 1998, RECEPTOR CHANNEL, V5, P305; Innis CA, 2000, PROTEIN ENG, V13, P839, DOI 10.1093/protein/13.12.839; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; Kristiansen K, 1996, PROTEINS, V26, P81, DOI 10.1002/(SICI)1097-0134(199609)26:1<81::AID-PROT8>3.0.CO;2-J; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; Landgraf R, 1999, PROTEIN ENG, V12, P943, DOI 10.1093/protein/12.11.943; Le Gouill C, 1999, J BIOL CHEM, V274, P12548, DOI 10.1074/jbc.274.18.12548; Lichtarge O, 1997, J MOL BIOL, V274, P325, DOI 10.1006/jmbi.1997.1395; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; Madabushi S, 2002, J MOL BIOL, V316, P139, DOI 10.1006/jmbi.2001.5327; Mihalek I, 2003, J MOL BIOL, V331, P263, DOI 10.1016/S0022-2836(03)00663-6; Nestler EJ, 2001, NATURE, V409, P834, DOI 10.1038/35057015; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; NISHIKAWA K, 1994, PROTEIN ENG, V7, P733, DOI 10.1093/protein/7.5.733; Oliveira L, 2002, CHEMBIOCHEM, V3, P1010, DOI 10.1002/1439-7633(20021004)3:10<1010::AID-CBIC1010>3.0.CO;2-T; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pritchard L, 1999, J MOL BIOL, V285, P1589, DOI 10.1006/jmbi.1998.2437; ROBINSON PR, 1994, P NATL ACAD SCI USA, V91, P5411, DOI 10.1073/pnas.91.12.5411; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Sowa ME, 2000, P NATL ACAD SCI USA, V97, P1483, DOI 10.1073/pnas.030409597; Sowa ME, 2001, NAT STRUCT BIOL, V8, P234, DOI 10.1038/84974; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; Yao H, 2003, J MOL BIOL, V326, P255, DOI 10.1016/S0022-2836(02)01336-0; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	52	165	173	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8126	8132		10.1074/jbc.M312671200	http://dx.doi.org/10.1074/jbc.M312671200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660595	hybrid			2022-12-27	WOS:000189103300093
J	Mehle, A; Strack, B; Ancuta, P; Zhang, CS; McPike, M; Gabuzda, D				Mehle, A; Strack, B; Ancuta, P; Zhang, CS; McPike, M; Gabuzda, D			Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 VIF; REVERSE TRANSCRIPTION; ENZYME APOBEC3G; SOR GENE; PROTEIN; DNA; HYPERMUTATION; STABILITY; COMPLEX	Viruses must overcome diverse intracellular defense mechanisms to establish infection. The Vif (virion infectivity factor) protein of human immunodeficiency virus 1 (HIV-1) acts by overcoming the antiviral activity of APOBEC3G (CEM15), a cytidine deaminase that induces G to A hypermutation in newly synthesized viral DNA. In the absence of Vif, APOBEC3G incorporation into virions renders HIV-1 non-infectious. We report here that Vif counteracts the antiviral activity of APOBEC3G by targeting it for destruction by the ubiquitin-proteasome pathway. Vif forms a complex with APOBEC3G and enhances APOBEC3G ubiquitination, resulting in reduced steady-state APOBEC3G levels and a decrease in protein half-life. Furthermore, Vif-dependent degradation of APOBEC3G is blocked by proteasome inhibitors or ubiquitin mutant K48R. A mutation of highly conserved cysteines or the deletion of a conserved SLQ(Y/F)LA motif in Vif results in mutants that fail to induce APOBEC3G degradation and produce non-infectious HIV-1; however, mutations of conserved phosphorylation sites in Vif that impair viral replication do not affect APOBEC3G degradation, suggesting that Vif is important for other functions in addition to inducing proteasomal degradation of APOBEC3G. Vif is mon-oubiquitinated in the absence of APOBEC3G but is poly-ubiquitinated and rapidly degraded when APOBEC3G is coexpressed, suggesting that coexpression accelerates the degradation of both proteins. These results suggest that Vif functions by targeting APOBEC3G for degradation via the ubiquitin-proteasome pathway and implicate the proteasome as a site of dynamic interplay between microbial and cellular defenses.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Gabuzda, D (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, JF816,44 Binney St, Boston, MA 02115 USA.	dana_gabuzda@dfci.harvard.edu		Mehle, Andrew/0000-0001-6060-4330	NIAID NIH HHS [AI28691, AI36186] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028691, R01AI036186] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156; BLANC D, 1993, VIROLOGY, V193, P186, DOI 10.1006/viro.1993.1114; Brown HEV, 1999, J VIROL, V73, P9011, DOI 10.1128/JVI.73.11.9011-9020.1999; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GONCALVES J, 1995, J VIROL, V69, P7196, DOI 10.1128/JVI.69.11.7196-7204.1995; GONCALVES J, 1994, J VIROL, V68, P704, DOI 10.1128/JVI.68.2.704-712.1994; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Harris RS, 2003, NAT IMMUNOL, V4, P641, DOI 10.1038/ni0703-641; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; MA XY, 1994, J VIROL, V68, P1714, DOI 10.1128/JVI.68.3.1714-1720.1994; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Ohagen A, 2000, J VIROL, V74, P11055, DOI 10.1128/JVI.74.23.11055-11066.2000; SAKAI H, 1993, J VIROL, V67, P1663, DOI 10.1128/JVI.67.3.1663-1666.1993; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; Tsirigotis M, 2001, J BIOL CHEM, V276, P46073, DOI 10.1074/jbc.M109023200; Ulrich HD, 2002, CURR TOP MICROBIOL, V268, P137; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yang X, 1996, J BIOL CHEM, V271, P10121, DOI 10.1074/jbc.271.17.10121; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	39	377	397	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7792	7798		10.1074/jbc.M313093200	http://dx.doi.org/10.1074/jbc.M313093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672928	hybrid			2022-12-27	WOS:000189103300053
J	Curtis, AM; Seo, SB; Westgate, EJ; Rudic, RD; Smyth, EM; Chakravarti, D; FitzGerald, GA; McNamara, P				Curtis, AM; Seo, SB; Westgate, EJ; Rudic, RD; Smyth, EM; Chakravarti, D; FitzGerald, GA; McNamara, P			Histone acetyltransferase-dependent chromatin remodeling and the vascular clock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN CIRCADIAN CLOCK; ADENOVIRAL ONCOPROTEIN E1A; SUPRACHIASMATIC NUCLEUS; TRANSCRIPTION FACTORS; ACETYLATION; MECHANISM; CBP/P300; COACTIVATOR; PROTEIN; CELLS	Rhythmic gene expression is central to the circadian control of physiology in mammals. Transcriptional activation of Per and Cry genes by heterodimeric bHLH-PAS proteins is a key event in the feedback loop that drives rhythmicity; however, the mechanism is not clearly understood. Here we show the transcriptional coactivators and histone acetyltransferases, p300/CBP, PCAF, and ACTR associate with the bHLH-PAS proteins, CLOCK and NPAS2, to regulate positively clock gene expression. Furthermore, Cry2 mediated repression of NPAS2:BMAL1 is overcome by overexpression of p300 in transactivation assays. Accordingly, p300 exhibits a circadian time-dependent association with NPAS2 in the vasculature, which precedes peak expression of target genes. In addition, a rhythm in core histone H3 acetylation on the mPer1 promoter in vivo correlates with the cyclical expression of their mRNAs. Temporal coactivator recruitment and HAT-dependent chromatin remodeling on the promoter of clock controlled genes in the vasculature permits the mammalian clock to orchestrate circadian gene expression.	Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Seoul Natl Univ, Coll Dent, Seoul, South Korea; Phenomix Corp, La Jolla, CA 92037 USA	University of Pennsylvania; University of Pennsylvania; Seoul National University (SNU)	FitzGerald, GA (corresponding author), Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.uperm.edu	FitzGerald, Garret A/A-4222-2010; Rudic, Dan/B-3432-2016	Rudic, Dan/0000-0001-9122-3127; Curtis, Annie/0000-0002-9601-9624; Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250, P50HL054500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057079] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-62250, HL-54500] Funding Source: Medline; NIDDK NIH HHS [DK 57079] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; Crosio C, 2000, NAT NEUROSCI, V3, P1241, DOI 10.1038/81767; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Glass CK, 2000, GENE DEV, V14, P121; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hida A, 2000, GENOMICS, V65, P224, DOI 10.1006/geno.2000.6166; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kondratov RV, 2003, GENE DEV, V17, P1921, DOI 10.1101/gad.1099503; Kramer A, 2001, SCIENCE, V294, P2511, DOI 10.1126/science.1067716; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REICK M, 2001, SCIENCE, V5, P5; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108	44	167	184	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7091	7097		10.1074/jbc.M311973200	http://dx.doi.org/10.1074/jbc.M311973200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645221	hybrid			2022-12-27	WOS:000188969200107
J	Forsyth, CM; Lemongello, D; LaCount, DJ; Friesen, PD; Fisher, AJ				Forsyth, CM; Lemongello, D; LaCount, DJ; Friesen, PD; Fisher, AJ			Crystal structure of an invertebrate caspase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH PROTEASE; 3-DIMENSIONAL STRUCTURE; COMBINATORIAL APPROACH; DROSOPHILA CASPASE; BACULOVIRUS P35; GRANZYME-B; ACTIVATION; INHIBITION; APOPTOSIS; ENZYME	Caspases play an essential role in the execution of apoptosis. These cysteine proteases are highly conserved among metazoans and are translated as inactive zymogens, which are activated by proteolytic cleavages to generate the large and small subunits and remove the N-terminal prodomain. The 2.3 Angstrom resolution crystal structure of active Sf-caspase-1, the principal effector caspase of the insect Spodoptera frugiperda, is presented here. The structure represents the first nonhuman caspase to be resolved. The structure of the cleaved and active protease was determined with the tetrapeptide inhibitor N-acetyl-Asp-Glu-Val-Asp-chloromethylketone covalently bonded to the active site cysteine. As expected, the overall fold of Sf-caspase-1 is exceedingly similar to that of the five active caspases from humans solved to date. The overall structure and active site arrangement of Sf-caspase-1 is most comparable with that of the human effector caspases, with which it shares highest sequence homology. The most prominent structural difference with Sf-caspase-1 is the position of the N-terminal region of the large subunit. Unlike the N terminus of human caspases, the N terminus of Sf-caspase-1 originates from the active site side where it interacts with active site loop L2 and then extends to the backside of the heterodimer. This unusual structural arrangement raises the possibility that the N-terminal prodomain plays a regulatory role during effector caspase activation or enzyme activity in insects.	Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fisher, AJ (corresponding author), Univ Calif Davis, Dept Chem, 1 Shields Ave, Davis, CA 95616 USA.	fisher@chem.ucdavis.edu		Fisher, Andrew/0000-0003-3488-6594	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040482, R56AI040482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056774] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40482] Funding Source: Medline; NIGMS NIH HHS [GM56774] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1997, J BIOL CHEM, V272, P1421, DOI 10.1074/jbc.272.3.1421; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayascas JR, 2002, CELL DEATH DIFFER, V9, P1078, DOI 10.1038/sj.cdd.4401075; Blanchard H, 2000, J MOL BIOL, V302, P9, DOI 10.1006/jmbi.2000.4041; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chereau D, 2003, BIOCHEMISTRY-US, V42, P4151, DOI 10.1021/bi020593l; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; dela Cruz WP, 2001, J BIOL CHEM, V276, P32933, DOI 10.1074/jbc.M103930200; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Harvey NL, 2001, J BIOL CHEM, V276, P25342, DOI 10.1074/jbc.M009444200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LaCount DJ, 2000, J BIOL CHEM, V275, P15657, DOI 10.1074/jbc.M000791200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meergans T, 2000, BIOCHEM J, V349, P135, DOI 10.1042/0264-6021:3490135; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; NAVAZA J, 1993, ACTA CRYSTALLOGR D, V49, P588, DOI 10.1107/S0907444993005141; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rossmann M. G., 1972, MOL REPLACEMENT METH; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; Yaoita Y, 2002, BIOCHEM BIOPH RES CO, V291, P79, DOI 10.1006/bbrc.2002.6408; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zoog SJ, 2002, EMBO J, V21, P5130	61	14	14	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7001	7008		10.1074/jbc.M312472200	http://dx.doi.org/10.1074/jbc.M312472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645217	hybrid			2022-12-27	WOS:000188969200096
J	Heathfield, TF; Onnerfjord, P; Dahlberg, L; Heinegard, D				Heathfield, TF; Onnerfjord, P; Dahlberg, L; Heinegard, D			Cleavage of fibromodulin in cartilage explants involves removal of the N-terminal tyrosine sulfate-rich region by proteolysis at a site that is sensitive to matrix metalloproteinase-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOARTHRITIC ARTICULAR-CARTILAGE; ARTHRITIC SYNOVIAL-FLUID; COLLAGEN TYPE-I; EXTRACELLULAR-MATRIX; CONNECTIVE TISSUES; REPEAT PROTEINS; BINDING SITES; PROTEOGLYCAN; DECORIN; IDENTIFICATION	Integrity of cartilage fails in joint disease. The current work aimed to identify candidate active proteinases in joint diseases using an in vitro model for cartilage degradation induced by interleukin-1. A critical event in the process of cartilage destruction in joint disease is the failure of the collagen fiber network to maintain integrity. Proteins binding to the surface of the fibers are likely early points of failure. Fibromodulin, a member of the leucine-rich repeat protein family, is one predominant protein in cartilage and is known for its roles in the formation of collagen fibrils and sustained interaction with these formed fibers. Cleavage removes the tyrosine sulfate-rich region in the N terminus of fibromodulin. Whereas fibromodulin bound to collagen in tissue was digested, purified fibromodulin was not cleaved. In contrast an N-terminal 10-kDa fragment, Gln(19)-Lys(98), of the protein generated by Lys-C digestion contains the cleavage site and was a substrate cleaved by the enzyme in medium from stimulated cultures. In solution, digestion of this substrate with matrix metalloproteinase (MMP)-2, -9, -8, and -13 demonstrated that only NMP-13 was capable to efficiently cleave it. The cleavage product obtained after MMP-13 digestion was identical to that observed in cleaved fibromodulin from cartilage explant cultures stimulated with interleukin-1. NMP-13 treatment of fresh articular cartilage also produced the fragment under study. The elucidation of the enzyme responsible for such cleavage may lead to treatment modalities involving its selective inhibition for patients suffering from arthritis. The known structure of the fragments permits the generation of neo-epitope antibodies to the cleavage site, which can be used to detect ongoing cartilage degradation in patients with arthritic disease, an important adjunct in monitoring disease progression, active disease, and efficacy of treatment.	Lund Univ, BMC, Sect Connect Tissue Biol, Dept Cell & Mol Biol, SE-22184 Lund, Sweden; Lund Univ, Malmo Univ Hosp, Dept Orthopaed, SE-20502 Malmo, Sweden	Lund University; Lund University; Skane University Hospital	Heinegard, D (corresponding author), Lund Univ, BMC, Sect Connect Tissue Biol, Dept Cell & Mol Biol, Plan C12, SE-22184 Lund, Sweden.	dick.heinegard@medkem.lu.se	Onnerfjord, Patrik/R-3131-2019	Onnerfjord, Patrik/0000-0002-2345-2937				ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BAYLISS MT, 1978, BIOCHEM J, V169, P123, DOI 10.1042/bj1690123; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; Billinghurst RC, 2000, ARTHRITIS RHEUM, V43, P664, DOI 10.1002/1529-0131(200003)43:3<664::AID-ANR24>3.0.CO;2-D; Billinghurst RC, 1997, J CLIN INVEST, V99, P1534, DOI 10.1172/JCI119316; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; CSSZABO G, 1995, ARTHRITIS RHEUM, V38, P660, DOI 10.1002/art.1780380514; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; Flannelly J, 2002, OSTEOARTHR CARTILAGE, V10, P722, DOI 10.1053/joca.2002.0818; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Font B, 1998, EUR J BIOCHEM, V254, P580, DOI 10.1046/j.1432-1327.1998.2540580.x; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Ganu V, 1998, ARTHRITIS RHEUM, V41, P2143, DOI 10.1002/1529-0131(199812)41:12<2143::AID-ART9>3.0.CO;2-P; Gill MR, 2002, OSTEOARTHR CARTILAGE, V10, P751, DOI 10.1053/joca.2002.0527; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HOLLANDER AP, 1994, J CLIN INVEST, V93, P1722, DOI 10.1172/JCI117156; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Jepsen KJ, 2002, J BIOL CHEM, V277, P35532, DOI 10.1074/jbc.M205398200; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; LIU J, 1994, J BIOL CHEM, V269, P28366; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; Roughley PJ, 1996, OSTEOARTHR CARTILAGE, V4, P153, DOI 10.1016/S1063-4584(96)80011-2; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; SAXNE T, 1988, COLLAGEN REL RES, V8, P233; SINGER II, 1995, J CLIN INVEST, V95, P2178, DOI 10.1172/JCI117907; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Sommarin Y, 1998, J BIOL CHEM, V273, P16723, DOI 10.1074/jbc.273.27.16723; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Svensson L, 2000, FEBS LETT, V470, P178, DOI 10.1016/S0014-5793(00)01314-4; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Sztrolovics R, 1999, BIOCHEM J, V339, P571, DOI 10.1042/0264-6021:3390571; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	53	81	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6286	6295		10.1074/jbc.M307765200	http://dx.doi.org/10.1074/jbc.M307765200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660626	hybrid			2022-12-27	WOS:000188969200013
J	Marx, PF; Havik, SR; Marquart, JA; Bouma, BN; Meijers, JCM				Marx, PF; Havik, SR; Marquart, JA; Bouma, BN; Meijers, JCM			Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PROCARBOXYPEPTIDASE-B; PROTEOLYTIC CLEAVAGE; THERMAL-STABILITY; INTRINSIC PATHWAY; TAFI LEVELS; FACTOR-XI; COAGULATION; PLASMINOGEN; CARBOXYPEPTIDASE; THROMBOMODULIN	Activated thrombin-activable fibrinolysis inhibitor (TAFIa) is a carboxypeptidase B that can down-regulate fibrinolysis. TAFIa is a labile enzyme that can be inactivated by conformational instability or proteolysis. TAFI is similar to 40% identical to pancreatic carboxypeptidase B (CPB). In contrast to TAFIa, pancreatic CPB is a stable protease. We hypothesized that regions or residues that are not conserved in TAFIa compared with pancreatic CPB play a role in the conformational instability of TAFIa and that replacement of these non-conserved residues with residues of pancreatic CPB would lead to a TAFIa molecule with an increased stability. Therefore, we have expressed, purified, and characterized two TAFI-CPB chimeras: TAFI-CPB-(293-333) and TAFI-CPB-(293-401). TAFI-CPB-(293-333) could be activated by thrombin-thrombomodulin, but not as efficiently as wild-type TAFI. After activation, this mutant was unstable and was hardly able to prolong clot lysis of TAFI-deficient plasma. Binding of TAFI-CPB-(293-333) to both plasminogen and fibrinogen was normal compared with wild-type TAFI. TAFI-CPB-(293-401) could be activated by thrombin-thrombomodulin, although at a lower rate compared with wild-type TAFI. The activated mutant displayed a markedly prolonged half-life of 1.5 h. Plasmin could both activate and inactivate this chimera. Interestingly, this chimera did not bind to plasminogen or fibrinogen. TAFI-CPB-(293-401) could prolong the clot lysis time in TAFI-deficient plasma, although not as efficiently as wild-type TAFI. In conclusion, by replacing a region in TAFI with the corresponding region in pancreatic CPB, we were able to generate a TAFIa form with a highly stable activity.	Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Scripps Research Institute; Utrecht University; Utrecht University Medical Center	Marx, PF (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, G1-113,POB 22660, NL-1100 DD Amsterdam, Netherlands.	P.F.Marx@amc.uva.nl	Meijers, J.C.M./S-5981-2019	Meijers, J.C.M./0000-0002-4198-6780				Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; Bouma BN, 1998, THROMB HAEMOSTASIS, V80, P24; Bouma BN, 2001, THROMB RES, V101, P329, DOI 10.1016/S0049-3848(00)00411-4; Brouwers GJ, 2001, BLOOD, V98, P1992, DOI 10.1182/blood.V98.6.1992; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4082, DOI 10.1021/bi00230a038; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EATON DL, 1991, J BIOL CHEM, V266, P21833; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Marx PF, 2000, THROMB HAEMOSTASIS, V83, P297; Marx PF, 2002, BIOCHEMISTRY-US, V41, P6688, DOI 10.1021/bi015982e; MEIJERS JCM, 1992, BLOOD, V79, P1435; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; Mosnier LO, 2003, BLOOD, V101, P4844, DOI 10.1182/blood-2002-09-2944; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Pereira PJB, 2002, J MOL BIOL, V321, P537, DOI 10.1016/S0022-2836(02)00648-4; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; Reijerkerk A, 2003, MOL CANCER RES, V1, P561; Schatteman KA, 1999, CLIN CHEM, V45, P807; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; WALKER JB, 2003, J THROMB HAEMOSTA S1, V1; WANG W, 1994, J BIOL CHEM, V269, P15937	25	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6620	6628		10.1074/jbc.M307337200	http://dx.doi.org/10.1074/jbc.M307337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660622	hybrid			2022-12-27	WOS:000188969200051
J	Haggie, PM; Stanton, BA; Verkman, AS				Haggie, PM; Stanton, BA; Verkman, AS			Increased diffusional mobility of CFTR at the plasma membrane after deletion of its C-terminal PDZ binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DOMAIN INTERACTION CONTROLS; PROTEIN-KINASE-A; BETA(2)-ADRENERGIC RECEPTOR; FUNCTIONAL EXPRESSION; INTERACTING DOMAIN; LATERAL MOBILITY; EZRIN; CELLS; ORGANIZATION	The cystic fibrosis transmembrane conductance regulator ( CFTR) protein is a cAMP- regulated Cl (-) channel expressed at the apical plasma membrane. It has been proposed that the C- terminal PDZ binding motif of CFTR is required for its apical membrane targeting and that PDZ- domain interactions may tether CFTR to the actin cytoskeleton via soluble proteins including EBP50/ NHERF1 and ezrin. We measured the diffusional mobility of human CFTR in the plasma membrane of Madin-Darby canine kidney cells by photobleaching of green fluorescent protein ( GFP)- CFTR chimeras. After bleaching by a focused laser beam, GFP- CFTR fluorescence in the bleached membrane region recovered to similar to 90% of its initial level, indicating that nearly all of the CFTR was mobile. The GFP- CFTR diffusion coefficient ( D) was 0.99 +/- 0.09 x 10(-10) cm(2)/ s at 37degreesC, similar to that of other membrane proteins. GFP- CFTR diffusion was not altered by protein kinase A or C activators but was blocked by paraformaldehyde and filipin. CFTR mutants lacking functional PDZ- binding domains ( GFP-CFTRDelta TRL and GFP- CFTR- Delta TRA) were also mobile with D significantly increased by similar to 60% compared with GFP- CFTR. However, GFP- CFTR, GFP- CFTR- Delta TRL, and GFP- CFTR- Delta TRA had similar mobilities ( D similar to 12 x 10(-10) cm(2)/ s) at the endoplasmic reticulum in brefeldin A- treated cells. Agents that modulate the actin cytoskeleton ( cytochalasin D and jasplakinolide) altered the plasma membrane mobility of CFTR but not CFTR-Delta TRL. EBP50 ( NHERF1), a PDZ domain- containing protein that interacts with the C terminus of CFTR, diffused freely in the cytoplasm with a diffusion coefficient of 0.9 +/- 0.1 x 10(-7) cm(2)/ s. EBP50 diffusion increased by similar to 2- fold after deletion of its ezrin- binding domain. These results indicate that wild- type CFTR is not tethered statically at the plasma membrane but that its diffusion is dependent on PDZ- domain interactions and an intact actin skeleton. PDZ- domain interactions of CFTR are thus dynamic and occur on a time scale of seconds or faster.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Dartmouth Coll Sch Med, Hanover, NH 03755 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Dartmouth College	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL73856] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK45881, DK35124, DK34533] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R01DK034533, R37DK035124, R01DK045881] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Benharouga M, 2003, J BIOL CHEM, V278, P22079, DOI 10.1074/jbc.M301030200; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; Coscoy S, 2002, P NATL ACAD SCI USA, V99, P12813, DOI 10.1073/pnas.192084599; Dahan D, 2001, PFLUG ARCH EUR J PHY, V443, pS92, DOI 10.1007/s004240100652; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Haggie PM, 2002, J BIOL CHEM, V277, P16419, DOI 10.1074/jbc.M112361200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Kunzelmann K, 1999, J MEMBRANE BIOL, V168, P1, DOI 10.1007/s002329900492; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; Meissner O, 2003, BIOCHEMISTRY-US, V42, P1667, DOI 10.1021/bi0263356; Milewski MI, 2001, J CELL SCI, V114, P719; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; Okabe S, 1999, NAT NEUROSCI, V2, P804, DOI 10.1038/12175; Ostedgaard LS, 2003, P NATL ACAD SCI USA, V100, P1937, DOI 10.1073/pnas.2627982100; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Raghuram V, 2003, P NATL ACAD SCI USA, V100, P9620, DOI 10.1073/pnas.1633250100; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Star EN, 2002, NAT NEUROSCI, V5, P239, DOI 10.1038/nn811; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Tardin C, 2003, EMBO J, V22, P4656, DOI 10.1093/emboj/cdg463; Umenishi F, 2000, BIOPHYS J, V78, P1024, DOI 10.1016/S0006-3495(00)76661-6; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Verkman AS, 2003, METHOD ENZYMOL, V360, P635; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9	51	69	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5494	5500		10.1074/jbc.M312445200	http://dx.doi.org/10.1074/jbc.M312445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660592	hybrid			2022-12-27	WOS:000188776500057
J	Pell, G; Szabo, L; Charnock, SJ; Xie, HF; Gloster, TM; Davies, GJ; Gilbert, HJ				Pell, G; Szabo, L; Charnock, SJ; Xie, HF; Gloster, TM; Davies, GJ; Gilbert, HJ			Structural and biochemical analysis of Cellvibrio japonicus xylanase 10C - How variation in substrate-binding cleft influences the catalytic profile of family GH-10 xylanases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-FLUORESCENS; ALPHA-GLUCURONIDASE; CELLULOSA XYLANASE; LINKER SEQUENCES; ACTIVE-SITE; DOMAINS; SPECIFICITY; COMPLEX; CRYSTALLOGRAPHY; HEMICELLULASES	Microbial degradation of the plant cell wall is the primary mechanism by which carbon is utilized in the biosphere. The hydrolysis of xylan, by endo-beta-1,4-xylanases (xylanases), is one of the key reactions in this process. Although amino acid sequence variations are evident in the substrate binding cleft of "family GH10" xylanases (see afmb.cnrs-mrs.fr/CAZY/), their biochemical significance is unclear. The Cellvibrio japonicus GH10 xylanase CjXyn10C is a bi-modular enzyme comprising a GH10 catalytic module and a family 15 carbohydrate-binding module. The three-dimensional structure at 1.85 Angstrom, presented here, shows that the sequence joining the two modules is disordered, confirming that linker sequences in modular glycoside hydrolases are highly flexible. CjXyn10C hydrolyzes xylan at a rate similar to other previously described GH10 enzymes but displays very low activity against xylooligosaccharides. The poor activity on short substrates reflects weak binding at the -2 subsite of the enzyme. Comparison of CjXyn10C with other family GH10 enzymes reveals "polymorphisms" in the substrate binding cleft including a glutamate/glycine substitution at the -2 subsite and a tyrosine insertion in the -2/-3 glycone region of the substrate binding cleft, both of which contribute to the unusual properties of the enzyme. The CjXyn10C-substrate complex shows that Tyr-340 stacks against the xylose residue located at the -3 subsite, and the properties of Y340A support the view that this tyrosine plays a pivotal role in substrate binding at this location. The generic importance of using CjXyn10C as a template in predicting the biochemical properties of GH10 xylanases is discussed.	Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England	Newcastle University - UK; University of York - UK	Gilbert, HJ (corresponding author), Newcastle Univ, Sch Cell & Mol Biosci, Agr Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; Armand S, 2001, BIOCHEMISTRY-US, V40, P7404, DOI 10.1021/bi002704r; ATKINS EDT, 1992, PROGR BIOTECHNOL, V7, P39; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beylot MH, 2001, BIOCHEM J, V358, P599, DOI 10.1042/0264-6021:3580599; Biely P, 1997, J BIOTECHNOL, V57, P151, DOI 10.1016/S0168-1656(97)00096-5; BIELY P, 1981, EUR J BIOCHEM, V119, P559, DOI 10.1111/j.1432-1033.1981.tb05644.x; Black GW, 1996, BIOCHEM J, V319, P515, DOI 10.1042/bj3190515; Black GW, 1997, J BIOTECHNOL, V57, P59, DOI 10.1016/S0168-1656(97)00089-8; BRETT CT, 1996, PHYSL BIOCH PLANT CE, V1; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Ducros V, 2000, J BIOL CHEM, V275, P23020, DOI 10.1074/jbc.275.30.23020; Emami K, 2002, J BACTERIOL, V184, P4124, DOI 10.1128/JB.184.15.4124-4133.2002; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; KELLETT LE, 1990, BIOCHEM J, V272, P369, DOI 10.1042/bj2720369; Lo Leggio L, 1999, PROTEINS, V36, P295; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MILLWARDSADLER SJ, 1994, MOL MICROBIOL, V11, P375, DOI 10.1111/j.1365-2958.1994.tb00317.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy T, 2002, J BACTERIOL, V184, P4925, DOI 10.1128/JB.184.17.4925-4929.2002; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; Nurizzo D, 2002, STRUCTURE, V10, P547, DOI 10.1016/S0969-2126(02)00742-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pell G, 2004, J BIOL CHEM, V279, P9597, DOI 10.1074/jbc.M312278200; Receveur V, 2002, J BIOL CHEM, V277, P40887, DOI 10.1074/jbc.M205404200; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TULL D, 1994, BIOCHEMISTRY-US, V33, P6363, DOI 10.1021/bi00186a041; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Williams SJ, 2000, J AM CHEM SOC, V122, P4229, DOI 10.1021/ja0002870; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z	44	83	87	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11777	11788		10.1074/jbc.M311947200	http://dx.doi.org/10.1074/jbc.M311947200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14670951	hybrid			2022-12-27	WOS:000220157600115
J	Pettus, BJ; Bielawska, A; Subramanian, P; Wijesinghe, DS; Maceyka, M; Leslie, CC; Evans, JH; Freiberg, J; Roddy, P; Hannun, YA; Chalfant, CE				Pettus, BJ; Bielawska, A; Subramanian, P; Wijesinghe, DS; Maceyka, M; Leslie, CC; Evans, JH; Freiberg, J; Roddy, P; Hannun, YA; Chalfant, CE			Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; BINDING DOMAIN; C2 DOMAIN; TRANSLOCATION; PROTEIN; MEMBRANE; KINASE; CELLS; DIACYLGLYCEROL	Recently, we demonstrated that ceramide kinase, and its product, ceramide 1-phosphate (Cer-1-P), were mediators of arachidonic acid released in cells in response to interleukin-1beta and calcium ionophore (Pettus, B. J., Bielawska, A., Spiegel, S., Roddy, P., Hannun, Y. A., and Chalfant, C. E. (2003) J. Biol. Chem. 278, 38206-38213). In this study, we demonstrate that down-regulation of cytosolic phospholipase A(2) (cPLA(2)) using RNA interference technology abolished the ability of Cer-1-P to induce arachidonic acid release in A549 cells, demonstrating that cPLA(2) is the key phospholipase A(2) downstream of Cer-1-P. Treatment of A549 cells with Cer-1-P (2.5 muM) induced the translocation of full-length cPLA(2) from the cytosol to the Golgi apparatus/perinuclear regions, which are known sites of translocation in response to agonists. Cer-1-P also induced the translocation of the CaLB/C2 domain of cPLA(2) in the same manner, suggesting that this domain is responsive to Cer-1-P either directly or indirectly. In vitro studies were then conducted to distinguish these two possibilities. In vitro binding studies disclosed that Cer-1-P interacts directly with full-length cPLA(2) and with the CaLB domain in a calcium- and lipid-specific manner with a K-Ca of 1.54 muM. Furthermore, Cer-1-P induced a calcium- dependent increase in cPLA(2) enzymatic activity as well as lowering the EC50 of calcium for the enzyme from 191 to 31 nM. This study identifies Cer-1-P as an anionic lipid that translocates and directly activates cPLA(2), demonstrating a role for this bioactive lipid in the mediation of inflammatory responses.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Natl Jewish Med & Res Ctr, Cell Biol Program, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	Virginia Commonwealth University; Medical University of South Carolina; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Hunter Holmes McGuire Veterinary Affairs Medical Center	Chalfant, CE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus,Rm 2-003,Sanger Hall,110, Richmond, VA 23298 USA.	cechalfant@vcu.edu	Maceyka, Michael/B-9277-2008	, Preeti/0000-0002-6062-6158	NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072925, F32HL010507, R01HL061378, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NCI NIH HHS [CA87584] Funding Source: Medline; NHLBI NIH HHS [HL34303, HL10507, HL61378, HL072925] Funding Source: Medline; NIGMS NIH HHS [GM43825, GM08716] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DIEZ E, 1992, J BIOL CHEM, V267, P18342; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; GomezMunoz A, 1997, BIOCHEM J, V325, P435, DOI 10.1042/bj3250435; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Hogback S, 2003, BIOCHEM J, V370, P111, DOI 10.1042/bj20020970; Kawano Y, 2001, AM J REPROD IMMUNOL, V46, P393, DOI 10.1034/j.1600-0897.2001.d01-30.x; Kitatani K, 2000, ARCH BIOCHEM BIOPHYS, V382, P296, DOI 10.1006/abbi.2000.2028; Klapisz E, 2000, J LIPID RES, V41, P1680; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LASSUS P, 2002, SCI STKE; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Luberto C, 2002, J BIOL CHEM, V277, P41128, DOI 10.1074/jbc.M206747200; Maceyka M, 1997, J CELL BIOL, V139, P1411, DOI 10.1083/jcb.139.6.1411; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Rile G, 2003, ACTA HAEMATOL-BASEL, V109, P76, DOI 10.1159/000068491; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SHARP JD, 1991, J BIOL CHEM, V266, P14850; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; TAY A, 1995, GENOMICS, V26, P138, DOI 10.1016/0888-7543(95)80093-2; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	34	280	290	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11320	11326		10.1074/jbc.M309262200	http://dx.doi.org/10.1074/jbc.M309262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14676210	hybrid			2022-12-27	WOS:000220157600060
J	Christinger, HW; Fuh, G; de Vos, AM; Wiesmann, C				Christinger, HW; Fuh, G; de Vos, AM; Wiesmann, C			The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-KINASE; ANGSTROM RESOLUTION; ANGIOGENESIS; VEGF; FLT-1; RECEPTOR; BINDING; PROTEIN; PIGF	Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family and plays an important role in pathological angiogenic events. PlGF exerts its biological activities through binding to VEGFR1, a receptor tyrosine kinase that consists of seven immunoglobulin-like domains in its extracellular portion. Here we report the crystal structure of PlGF bound to the second immunoglobulin-like domain of VEGFR1 at 2.5 Angstrom resolution and compare the complex to the closely related structure of VEGF bound to the same receptor domain. The two growth factors, PlGF and VEGF, share a sequence identity of similar to50%. Despite this moderate sequence conservation, they bind to the same binding interface of VEGFR1 in a very similar fashion, suggesting that both growth factors could induce very similar if not identical signaling events.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA	Roche Holding; Genentech	Wiesmann, C (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	chw@gene.com		Wiesmann, Christian/0000-0002-4092-9880				Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, XPLOR MANUAL VERSION; Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; DeLano W.L, PYMOL MOL GRAPHICS S; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LECOUTER J, 2003, NATURE, V299, P890; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Luttun A, 2002, BIOCHEM BIOPH RES CO, V295, P428, DOI 10.1016/S0006-291X(02)00677-0; MAGLIONE D, 1993, ONCOGENE, V8, P925; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK JE, 1994, J BIOL CHEM, V269, P25646; Starovasnik MA, 1999, J MOL BIOL, V293, P531, DOI 10.1006/jmbi.1999.3134; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0	31	112	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10382	10388		10.1074/jbc.M313237200	http://dx.doi.org/10.1074/jbc.M313237200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684734	hybrid			2022-12-27	WOS:000220050400088
J	Das, TK; Samuni, U; Lin, Y; Goldberg, DE; Rousseau, DL; Friedman, JM				Das, TK; Samuni, U; Lin, Y; Goldberg, DE; Rousseau, DL; Friedman, JM			Distal heme pocket conformers of carbonmonoxy derivatives of Ascaris hemoglobi - Evidence of conformational trapping in porous sol-gel matrices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SCATTERING; MYCOBACTERIUM-TUBERCULOSIS; LIGAND-BINDING; ENCAPSULATED HEMOGLOBIN; OXYGEN AVIDITY; TYROSINE B10; MYOGLOBIN; HISTIDINE; MUTANTS; IRON	We report the ligand dependence of the conformer distribution in the distal heme pocket of Ascaris suum hemoglobin (Hb) studied by resonance Raman spectroscopy. The heme-bound CO is used as a spectroscopic antenna to probe the original distribution of conformers in the dioxygen derivative of Ascaris Hb, by utilizing sol-gel encapsulation. The first step is to encapsulate the dioxygen derivative in the porous sol-gel and let the gel age, thus trapping the equilibrium conformational distribution of Ascaris dioxygen Hb. In the second step, the dioxygen ligand is replaced by CO. The sol-gel environment impedes any large scale movements, drastically slowing down the conformational relaxation triggered by the ligation change, essentially "locking in" the initial quaternary and even tertiary structure of the protein. Studying the Fe-CO frequencies of the latter sample allows evaluation of the distribution of the distal heme pocket conformers that was originally associated with the dioxygen derivative. Extending the study to the Ascaris mutants allows for examination of the effect of specific residues in the distal pocket on the conformational distribution. The choice of mutants was largely based on the anticipated variation in hydrogen bonding patterns. The results show that the sol-gel encapsulation can slow or prevent re-equilibration within the distal heme pocket of Ascaris Hb and that the distribution of distal heme pocket conformers for the CO derivative of Ascaris Hb in the sol-gel is highly dependent on the history of the sample. Additionally, we report a detailed study of the CO complex of the mutants in solution for assignment of the various heme pocket conformers, and we present a comparison of the sol-gel data with solution data. The results support a picture in which the dioxygen derivative biases the population strongly toward a tightly packed configuration that favors the network of strong hydrogen bonding interactions, and suggest that Ascaris Hb is uniquely designed for dioxygen capture.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Pfizer Global Res & Dev, Chesterfield, MO 63017 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Yeshiva University; Albert Einstein College of Medicine; Pfizer; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Friedman, JM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jfriedma@aecom.yu.edu		Das, Tapan/0000-0002-3641-3988	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058890, R01GM054812, R01GM067814] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB00296] Funding Source: Medline; NIGMS NIH HHS [GM54812, GM67814, GM58890] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; Bettati S, 1997, J BIOL CHEM, V272, P32050, DOI 10.1074/jbc.272.51.32050; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Das TK, 2000, BIOCHEMISTRY-US, V39, P837, DOI 10.1021/bi9922087; Das TK, 1998, J AM CHEM SOC, V120, P10268, DOI 10.1021/ja982127i; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 1999, J BIOL CHEM, V274, P4207, DOI 10.1074/jbc.274.7.4207; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Das TK, 1999, BIOSPECTROSCOPY, V5, pS64, DOI 10.1002/(SICI)1520-6343(1999)5:5+<S64::AID-BSPY7>3.0.CO;2-W; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Draghi F, 2002, J BIOL CHEM, V277, P7509, DOI 10.1074/jbc.M109206200; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; Guarrera L, 1998, BIOCHEMISTRY-US, V37, P5608, DOI 10.1021/bi972380f; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; Juszczak LJ, 1999, J BIOL CHEM, V274, P30357, DOI 10.1074/jbc.274.43.30357; Khan I, 2000, BIOCHEMISTRY-US, V39, P16099, DOI 10.1021/bi000536x; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; Kundu S, 2002, PROTEINS, V46, P268, DOI 10.1002/prot.10048; Milani M, 2003, P NATL ACAD SCI USA, V100, P5766, DOI 10.1073/pnas.1037676100; Milani M, 2001, EMBO J, V20, P3902, DOI 10.1093/emboj/20.15.3902; Mukai M, 2002, BIOCHEMISTRY-US, V41, P3897, DOI 10.1021/bi0156409; Navati MS, 2003, P NATL ACAD SCI USA, V100, P3832, DOI 10.1073/pnas.262526399; OKAZAKI T, 1965, BIOCHIM BIOPHYS ACTA, V111, P503, DOI 10.1016/0304-4165(65)90060-7; ONDRIAS MR, 1982, BIOCHEMISTRY-US, V21, P3428, DOI 10.1021/bi00257a028; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P12301, DOI 10.1021/bi980752u; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; ROUSSEAU DG, 1992, J STRUCT BIOL, V109, P13; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; Royer WE, 1996, P NATL ACAD SCI USA, V93, P14526, DOI 10.1073/pnas.93.25.14526; Samuni U, 2002, J BIOL CHEM, V277, P25783, DOI 10.1074/jbc.M200301200; Scherlis DA, 2001, J AM CHEM SOC, V123, P8436, DOI 10.1021/ja015665v; Shibayama N, 1999, J AM CHEM SOC, V121, P444, DOI 10.1021/ja983652k; SHIBAYAMA N, 1995, J MOL BIOL, V251, P203, DOI 10.1006/jmbi.1995.0427; SHIRO Y, 1994, BIOCHEMISTRY-US, V33, P14986, DOI 10.1021/bi00254a006; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; STAVROV SS, 1993, BIOPHYS J, V65, P1942, DOI 10.1016/S0006-3495(93)81265-7; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224	48	13	14	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10433	10441		10.1074/jbc.M309590200	http://dx.doi.org/10.1074/jbc.M309590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688246	hybrid			2022-12-27	WOS:000220050400094
J	O'Brien, PJ; Ellenberger, T				O'Brien, PJ; Ellenberger, T			Dissecting the broad substrate specificity of human 3-methyladenine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYLADENINE DNA GLYCOSYLASE; DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; EXCISION-REPAIR; BASE EXCISION; HYPOXANTHINE; BINDING; PURIFICATION; CATALYSIS; 1,N(6)-ETHENOADENINE	Human alkyladenine-DNA glycosylase (AAG) catalyzes the excision of a broad range of modified bases, protecting the genome from many types of alkylative and oxidative DNA damage. We have investigated how AAG discriminates against normal DNA bases, while accommodating a structurally diverse set of lesioned bases, by measuring the rates of AAG-catalyzed (k(st)) and spontaneous N-glycosidic bond hydrolysis (k(non)) for damaged and undamaged DNA oligonucleotides. The rate enhancements for excision of different bases reveal that AAG is most adept at excising the deaminated lesion hypoxanthine (k(st)/k(non) = 10(8)), suggesting that enzymatic activity may have evolved in response to this lesion. Comparisons of the rate enhancements for excision of normal and modified purine nucleobases provide evidence that AAG excludes the normal purines via steric clashes with the exocyclic amino groups of adenine and guanine. However, methylated purines are more chemically labile, and only modest rate enhancements are required for their efficient excision. Base flipping also contributes to specificity as destabilized mismatched base pairs are better substrates than stable Watson-Crick pairs, and many of the lesions recognized by AAG are compromised in their ability to base pair. These findings suggest that AAG reconciles a broad substrate tolerance with the biological imperative to avoid normal DNA by excluding normal bases from the active site rather than by specifically recognizing each lesion.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	tome@hms.harvard.edu			NIGMS NIH HHS [R01 GM52504, GM65043] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM065043, R01GM052504] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAMODT RM, 2004, IN PRESS J BIOL CHEM; Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; Biswas T, 2002, J MOL BIOL, V320, P503, DOI 10.1016/S0022-2836(02)00519-3; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; Bruskov VI, 2002, NUCLEIC ACIDS RES, V30, P1354, DOI 10.1093/nar/30.6.1354; Connor EE, 2002, CHEM BIOL, V9, P1033, DOI 10.1016/S1074-5521(02)00215-6; DUNCAN BK, 1981, ENZYMES, V14, P565; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; GALLAGHER PE, 1982, BIOCHEMISTRY-US, V21, P6404, DOI 10.1021/bi00268a013; GONZALEZ FJ, 1992, TRENDS PHARMACOL SCI, V13, P346, DOI 10.1016/0165-6147(92)90107-H; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; HENDLER S, 1970, BIOCHEMISTRY-US, V9, P4141, DOI 10.1021/bi00823a017; IKUTA S, 1987, BIOCHEMISTRY-US, V26, P5646, DOI 10.1021/bi00392a010; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; Jiang YL, 2002, BIOCHEMISTRY-US, V41, P11236, DOI 10.1021/bi026226r; KARRAN P, 1980, BIOCHEMISTRY-US, V19, P6005, DOI 10.1021/bi00567a010; Kartalou M, 2000, BIOCHEMISTRY-US, V39, P8032, DOI 10.1021/bi000417h; Lau AY, 2000, P NATL ACAD SCI USA, V97, P13573, DOI 10.1073/pnas.97.25.13573; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LEONARD GA, 1994, BIOCHEMISTRY-US, V33, P4755, DOI 10.1021/bi00182a002; LIENHARD GE, 1973, SCIENCE, V180, P149, DOI 10.1126/science.180.4082.149; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; Miao F, 1998, NUCLEIC ACIDS RES, V26, P4034, DOI 10.1093/nar/26.17.4034; O'Brien PJ, 2003, BIOCHEMISTRY-US, V42, P12418, DOI 10.1021/bi035177v; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; OIVANEN M, 1993, TRENDS ORG CHEM, V4, P397; Osborne MR, 2000, CHEM RES TOXICOL, V13, P257, DOI 10.1021/tx990182e; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; RADIKA K, 1984, BIOCHEMISTRY-US, V23, P5118, DOI 10.1021/bi00317a006; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Salinas AE, 1999, CURR MED CHEM, V6, P279; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SINGER B, 1992, P NATL ACAD SCI USA, V89, P9386, DOI 10.1073/pnas.89.20.9386; Stivers JT, 2001, ARCH BIOCHEM BIOPHYS, V396, P1, DOI 10.1006/abbi.2001.2605; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200; WOOD SG, 1986, NUCLEIC ACIDS RES, V14, P6591, DOI 10.1093/nar/14.16.6591	44	138	141	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9750	9757		10.1074/jbc.M312232200	http://dx.doi.org/10.1074/jbc.M312232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14688248	hybrid			2022-12-27	WOS:000220050400013
J	Schneider, D; Engelman, DM				Schneider, D; Engelman, DM			Involvement of transmembrane domain interactions in signal transduction by alpha/beta integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAINS; BIOLOGICAL MEMBRANE; HELIX ASSOCIATION; ESCHERICHIA-COLI; LIGAND-BINDING; BETA-SUBUNITS; GXXXG MOTIF; ACTIVATION; ALPHA(IIB)BETA(3); ALPHA-IIB-BETA-3	The alpha and beta subunits of alpha/beta heterodimeric integrins function together to bind ligands in the extracellular region and transduce signals across cellular membranes. A possible function for the transmembrane regions in integrin signaling has been proposed from structural and computational data. We have analyzed the capacity of the integrin alpha(2), alpha(IIb), alpha(4), beta(1), beta(3), and beta(7) transmembrane domains to form homodimers and/or heterodimers. Our data suggest that the integrin transmembrane helices can help to stabilize heterodimeric integrins but that the interactions do not specifically associate particular pairs of alpha and beta subunits; rather, the alpha/beta subunit interaction constrains the extramembranous domains, facilitating signal transduction by a promiscuous transmembrane helix-helix association.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Freiburg, Dept Biochem & Mol Biol, D-79104 Freiburg, Germany	Yale University; University of Freiburg	Engelman, DM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114, New Haven, CT 06520 USA.	donald.engelman@yale.edu						Adair BD, 2002, P NATL ACAD SCI USA, V99, P14059, DOI 10.1073/pnas.212498199; Armulik A, 1999, J BIOL CHEM, V274, P37030, DOI 10.1074/jbc.274.52.37030; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; Daines DA, 2000, J BACTERIOL, V182, P5267, DOI 10.1128/JB.182.18.5267-5270.2000; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Dmitrova M, 1998, MOL GEN GENET, V257, P205; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; FRACHET P, 1992, BIOCHEMISTRY-US, V31, P2408, DOI 10.1021/bi00123a028; Gottschalk KE, 2002, PROTEIN SCI, V11, P1800, DOI 10.1110/ps.4120102; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; HEMLER M, 1999, EXTRACELLULAR MATRIX, P196; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kleiger G, 2002, BIOCHEMISTRY-US, V41, P5990, DOI 10.1021/bi0200763; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LEMMON MA, 1994, FEBS LETT, V346, P17, DOI 10.1016/0014-5793(94)00467-6; Li RH, 2003, SCIENCE, V300, P795, DOI 10.1126/science.1079441; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mehta RJ, 1998, BIOCHEM J, V330, P861; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Peterson JA, 1998, BLOOD, V92, P2053, DOI 10.1182/blood.V92.6.2053.418k14_2053_2063; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schneider D, 2003, J BIOL CHEM, V278, P3105, DOI 10.1074/jbc.M206287200; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, P NATL ACAD SCI USA, V98, P11175, DOI 10.1073/pnas.201420198; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Ulmer TS, 2001, BIOCHEMISTRY-US, V40, P7498, DOI 10.1021/bi010338l; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Vinogradova O, 2000, P NATL ACAD SCI USA, V97, P1450, DOI 10.1073/pnas.040548197; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	45	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9840	9846		10.1074/jbc.M312749200	http://dx.doi.org/10.1074/jbc.M312749200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681217	hybrid			2022-12-27	WOS:000220050400023
J	Woodworth, A; Pesheva, P; Fiete, D; Baenziger, JU				Woodworth, A; Pesheva, P; Fiete, D; Baenziger, JU			Neuronal-specific synthesis and glycosylation of tenascin-R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX GLYCOPROTEIN; CELL-ADHESION MOLECULE; LONG-TERM POTENTIATION; CIRCULATORY HALF-LIFE; DEVELOPMENTAL EXPRESSION; HNK-1-REACTIVE ANTIGENS; PERISOMATIC INHIBITION; N-ACETYLGALACTOSAMINE; CHONDROITIN SULFATES; HNK-1 CARBOHYDRATE	Tenascin-R (TN-R) is a member of the tenascin family of multidomain matrix glycoproteins that is expressed exclusively in the central nervous system by oligodendrocytes and small neurons during postnatal development and in the adult. TN-R contributes to the regulation of axon extension and regeneration, neurite formation and synaptogenesis, and neuronal growth and migration. TN-R can be modified with three distinct sulfated oligosaccharide structures: HNK-1 (SO4-3-GlcUAbeta1,3Galbeta1,4,GlcNAc), GalNAc-4-SO4, and chondroitin sulfate. We have determined that TN-R expressed in dendrite-rich regions of the rat cerebellum, hippocampus, and cerebral cortex is one of the major matrix glycoproteins that bears N-linked carbohydrates terminating with beta1,4-linked GalNAc-4-SO4. The syntheses of these unique sulfated structures on TN-R are differentially regulated. Levels of HNK-1 on TN-R rise and fall in parallel to the levels of TN-R during postnatal development of the cerebellum. In contrast, levels of GalNAc-4-SO4 are regulated independently from those of TN-R, rising late in cerebellar development and continuing into adulthood. As a result, the pattern of TN-R modification with distinct sulfated carbohydrate structures changes dramatically over the course of postnatal cerebellar development in the rat. Because TN-R interacts with a number of different matrix components and, depending on the circumstances, can either activate or inhibit neurite outgrowth, the highly regulated addition of these unique sulfated structures may modulate the adhesive properties of TN-R over the course of development and during synapse maintenance. In addition, the 160-kDa form of TN-R is particularly enriched for terminal GalNAc-4-SO4 later in development and in the adult, suggesting additional levels of regulation.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Univ Bonn, Neuro & Tumor Cell Biol Grp, Dept Nucl Med, D-53105 Bonn, Germany	Washington University (WUSTL); University of Bonn	Baenziger, JU (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.	Baenziger@pathology.wustl.edu	Baenziger, Jacques U/E-9430-2012		NCI NIH HHS [R37-CA21923] Funding Source: Medline; NIDDK NIH HHS [R01-DK41738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; Altman J, 1997, DEV CEREBELLAR SYSTE; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; Chou DKH, 2002, J NEUROCHEM, V82, P1239, DOI 10.1046/j.1471-4159.2002.01066.x; Chou DKH, 2000, J NEUROSCI RES, V59, P188, DOI 10.1002/(SICI)1097-4547(20000115)59:2<188::AID-JNR5>3.0.CO;2-M; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; FUSS B, 1991, J NEUROSCI RES, V29, P299, DOI 10.1002/jnr.490290305; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GARY SC, 1998, MICROSC RES TECHNIQ, V43, P576; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kang HG, 2001, J BIOL CHEM, V276, P10861, DOI 10.1074/jbc.M011560200; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; Mi YL, 2002, J CLIN INVEST, V109, P269, DOI 10.1172/JCI13997; NORENBERG U, 1995, J CELL BIOL, V130, P473, DOI 10.1083/jcb.130.2.473; PESHEVA P, 1994, J CELL SCI, V107, P2323; Pesheva P, 2000, PROG NEUROBIOL, V61, P465, DOI 10.1016/S0301-0082(99)00061-1; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; Probstmeier R, 2001, J NEUROSCI RES, V64, P70, DOI 10.1002/jnr.1055; Probstmeier R, 2000, J NEUROSCI RES, V60, P21, DOI 10.1002/(SICI)1097-4547(20000401)60:1<21::AID-JNR3>3.0.CO;2-H; Probstmeier R, 2000, BRAIN RES, V863, P42, DOI 10.1016/S0006-8993(00)02075-8; ROSS RA, 1983, J NATL CANCER I, V71, P741; Saghatelyan AK, 2000, EUR J NEUROSCI, V12, P3331, DOI 10.1046/j.1460-9568.2000.00216.x; Saghatelyan AK, 2001, MOL CELL NEUROSCI, V17, P226, DOI 10.1006/mcne.2000.0922; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; Woodworth A, 2002, J BIOL CHEM, V277, P50941, DOI 10.1074/jbc.M209876200; Xiao ZC, 1997, J NEUROSCI RES, V49, P698, DOI 10.1002/(SICI)1097-4547(19970915)49:6<698::AID-JNR4>3.0.CO;2-2; Zamze S, 1999, GLYCOBIOLOGY, V9, P823, DOI 10.1093/glycob/9.8.823	37	34	35	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10413	10421		10.1074/jbc.M312466200	http://dx.doi.org/10.1074/jbc.M312466200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681222	hybrid			2022-12-27	WOS:000220050400092
J	Eickhoff, J; Hanke, M; Stein-Garlach, M; Kiang, TP; Herzberger, K; Habenberger, P; Muller, S; Klebl, B; Marschall, M; Stamminger, T; Cotten, M				Eickhoff, J; Hanke, M; Stein-Garlach, M; Kiang, TP; Herzberger, K; Habenberger, P; Muller, S; Klebl, B; Marschall, M; Stamminger, T; Cotten, M			RICK activates a NF-kappa B-dependent anti-human cytomegalovirus response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE CYTOMEGALOVIRUS; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; ALPHA PROTEOLYSIS; VIRUS REPLICATION; PROTEIN-KINASE; ADENOVIRUS; INDUCTION; INFECTION; PROMOTER	The adapter kinase receptor interacting protein-like interacting caspase-like apoptosis regulatory protein kinase (RICK, also called RIP2 and CARDIAK) was found to be elevated at both the protein and RNA levels during human cytomegalovirus ( HCMV) replication, suggesting either that the virus may require RICK for replication or that RICK is part of an unsuccessful host attempt to inhibit HCMV replication. It is demonstrated here that forced expression of RICK in either a kinase active or inactive form activates nuclear factor (NF)-kappaB by means of its intermediate domain and potently blocks HCMV replication in human fibroblasts. Importantly, NF-kappaB activation, which exerted a modestly positive effect on the early phase of infection, clearly had a strongly negative impact during later viral steps. A stable inhibitor of NF-kappaB (IkappaB) reverses the RICK inhibitory effect, and activation of NF-kappaB by IkappaB kinase beta expression is inhibitory to HCMV, demonstrating that NF-kappaB activation is part of a potent anti-HCMV response. Supernatant transfer experiments identified interferon-beta as a downstream component of the RICK inhibitory pathway. RICK expression was found to synergize with HCMV infection in the induction of interferon-beta expression. This study identifies an endogenous RICK-activated, NF-kappaB- and interferon-beta-dependent antiviral pathway that is either inhibited or faulty under normal HCMV replication conditions; efforts to bolster this pathway may lead to novel anti-viral approaches.	Axxima Pharmaceut AG, D-81377 Munich, Germany; Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Cotten, M (corresponding author), Axxima Pharmaceut AG, Max Lebsche Pl 32, D-81377 Munich, Germany.	Matt.Cotten@axxima.com		Stamminger, Thomas/0000-0001-9878-3119; Cotten, Matthew/0000-0002-3361-3351				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Benedict CA, 2001, IMMUNITY, V15, P617, DOI 10.1016/S1074-7613(01)00222-9; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Browne EP, 2003, P NATL ACAD SCI USA, V100, P11439, DOI 10.1073/pnas.1534570100; Browne EP, 2001, J VIROL, V75, P12319, DOI 10.1128/JVI.75.24.12319-12330.2001; Carlquist JF, 1999, J INFECT DIS, V179, P1094, DOI 10.1086/314734; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Chiocca S, 1997, J VIROL, V71, P3168, DOI 10.1128/JVI.71.4.3168-3177.1997; Compton T, 2003, J VIROL, V77, P4588, DOI 10.1128/JVI.77.8.4588-4596.2003; COTTEN M, 1996, CURRENT PROTOCOLS HU; Efferth T, 2002, J MOL MED-JMM, V80, P233, DOI 10.1007/s00109-001-0300-8; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; FORBES BA, 1990, J INFECT DIS, V162, P39, DOI 10.1093/infdis/162.1.39; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Jiang HY, 2002, J VIROL, V76, P5737, DOI 10.1128/JVI.76.11.5737-5747.2002; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; JORDAN MC, 1977, J GEN VIROL, V37, P419, DOI 10.1099/0022-1317-37-2-419; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; KOMENT RW, 1989, J MED VIROL, V27, P44, DOI 10.1002/jmv.1890270110; KOMENT RW, 1985, J MED VIROL, V15, P149, DOI 10.1002/jmv.1890150207; LATHEY JL, 1991, J VIROL, V65, P6371, DOI 10.1128/JVI.65.11.6371-6375.1991; LEMAY P, 1980, VIROLOGY, V101, P131, DOI 10.1016/0042-6822(80)90490-0; Marschall M, 2000, ANTIMICROB AGENTS CH, V44, P1588, DOI 10.1128/AAC.44.6.1588-1597.2000; Marschall M, 2002, J GEN VIROL, V83, P1013, DOI 10.1099/0022-1317-83-5-1013; Martin Seamus J., 2001, Trends in Cell Biology, V11, P188, DOI 10.1016/S0962-8924(01)01971-7; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Michou AI, 1999, J VIROL, V73, P1399, DOI 10.1128/JVI.73.2.1399-1410.1999; Miller DM, 1999, J IMMUNOL, V162, P6107; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PROSCH S, 1995, VIROLOGY, V208, P197, DOI 10.1006/viro.1995.1143; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; TANAKA J, 1984, J GEN VIROL, V65, P1759, DOI 10.1099/0022-1317-65-10-1759; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VELASCO N, 1984, J INFECTION, V9, P69, DOI 10.1016/S0163-4453(84)94576-6; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yurochko AD, 1997, J VIROL, V71, P5051, DOI 10.1128/JVI.71.7.5051-5059.1997; YUROCHKO AD, 1995, J VIROL, V69, P5391, DOI 10.1128/JVI.69.9.5391-5400.1995; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997	56	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9642	9652		10.1074/jbc.M312893200	http://dx.doi.org/10.1074/jbc.M312893200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670961	hybrid			2022-12-27	WOS:000189265900132
J	Vadseth, C; Souza, JM; Thomson, L; Seagraves, A; Nagaswami, C; Scheiner, T; Torbet, J; Vilaire, G; Bennett, JS; Murciano, JC; Muzykantov, V; Penn, MS; Hazen, SL; Weisel, JW; Ischiropoulos, H				Vadseth, C; Souza, JM; Thomson, L; Seagraves, A; Nagaswami, C; Scheiner, T; Torbet, J; Vilaire, G; Bennett, JS; Murciano, JC; Muzykantov, V; Penn, MS; Hazen, SL; Weisel, JW; Ischiropoulos, H			Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; MYOCARDIAL-INFARCTION; ATHEROSCLEROTIC LESIONS; TYROSINE NITRATION; IN-VIVO; CARDIOVASCULAR-DISEASE; PLASMA-PROTEINS; CLOT FORMATION; HEART-DISEASE; OXIDATION	Formation of nitric oxide-derived oxidants has been linked to development of atherosclerosis and associated thrombotic complications. Although systemic levels of protein nitrotyrosine predict risk for coronary artery disease, neither specific proteins targeted for modification nor functional consequences that might contribute to disease pathogenesis have been defined. Here we report a selective increase in circulating levels of nitrated fibrinogen in patients with coronary artery disease. Exposure of fibrinogen to nitrating oxidants, including those produced by the myeloperoxidase-hydrogen peroxide-nitrite system, significantly accelerates clot formation and factor XIII cross-linking, whereas exposure of fibrinogen to non-nitrating oxidants decelerates clot formation. Clots formed with fibrinogen exposed to nitrating oxidants are composed of large bundles made from twisted thin fibrin fibers with increased permeation and a decrease in storage modulus G' value, suggesting that these clots could be easily deformed by mechanical stresses. In contrast, clots formed with fibrinogen exposed to non-nitrating oxidants showed decreased permeation with normal architecture. Fibrinogen modified by exposure to physiologic nitration systems demonstrated no difference in the rate of plasmin-induced clot lysis, platelet aggregation, or binding. Thus, increased levels of fibrinogen nitration may lead to a pro-thrombotic state via acceleration in formation of fibrin clots. The present results may account, in part, for the association between nitrative stress and risk for coronary artery disease.	Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr 416D, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cardiovasc Med, Cleveland, OH 44195 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Ischiropoulos, H (corresponding author), Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr 416D, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ischirop@mail.med.upenn.edu	Murciano, Juan Carlos/AAG-6253-2021; Hazen, Stanley L/ABD-5845-2021; Thomson, Leonor/C-4684-2008	Murciano, Juan Carlos/0000-0002-4894-046X; Thomson, Leonor/0000-0002-2574-8520	NCRR NIH HHS [RM01 RR018390] Funding Source: Medline; NHLBI NIH HHS [HL62526, P50 HL70128, HL70621] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, P50HL070128, R01HL070621] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Baldus S, 2001, J CLIN INVEST, V108, P1759; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Belisario MA, 1997, BIOCHIMIE, V79, P449, DOI 10.1016/S0300-9084(97)86155-X; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BINI A, 1987, BLOOD, V69, P1038; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Buttery LDK, 1996, LAB INVEST, V75, P77; Collet JP, 2000, ARTERIOSCL THROM VAS, V20, P1354, DOI 10.1161/01.ATV.20.5.1354; Cromheeke KM, 1999, CARDIOVASC RES, V43, P744, DOI 10.1016/S0008-6363(99)00148-0; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; FATAH K, 1992, THROMB HAEMOSTASIS, V68, P130; Fatah K, 1996, THROMB HAEMOSTASIS, V76, P535; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Gole MD, 2000, AM J PHYSIOL-LUNG C, V278, pL961, DOI 10.1152/ajplung.2000.278.5.L961; INADA Y, 1978, BIOCHIM BIOPHYS ACTA, V532, P161, DOI 10.1016/0005-2795(78)90459-2; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LANGER BG, 1988, J BIOL CHEM, V263, P15056; LASSILA R, 1993, ARTERIOSCLER THROMB, V13, P1738, DOI 10.1161/01.ATV.13.12.1738; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Lupidi G, 1999, FEBS LETT, V462, P236, DOI 10.1016/S0014-5793(99)01500-8; Murciano JC, 2002, AM J PHYSIOL-LUNG C, V282, pL529, DOI 10.1152/ajplung.00112.2001; Murthy SNP, 2000, P NATL ACAD SCI USA, V97, P44, DOI 10.1073/pnas.97.1.44; PHILIPS MH, 1973, BIOCHEMISTRY-US, V12, P3642; Pignatelli B, 2001, CANCER RES, V61, P778; Ryan EA, 1999, BIOPHYS J, V77, P2813, DOI 10.1016/S0006-3495(99)77113-4; SALOMAA V, 1995, CIRCULATION, V91, P284, DOI 10.1161/01.CIR.91.2.284; SCRUTTON MC, 1994, BLOOD COAGUL FIBRIN, V5, P719, DOI 10.1097/00001721-199410000-00007; SHACTER E, 1995, FREE RADICAL BIO MED, V18, P815, DOI 10.1016/0891-5849(95)93872-4; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; SMITH EB, 1990, ARTERIOSCLEROSIS, V10, P263, DOI 10.1161/01.ATV.10.2.263; STIEF TW, 1991, THROMB RES, V61, P191, DOI 10.1016/0049-3848(91)90095-E; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; Veklich Y, 1998, BLOOD, V92, P4721, DOI 10.1182/blood.V92.12.4721.424k13_4721_4729; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804	43	179	190	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8820	8826		10.1074/jbc.M306101200	http://dx.doi.org/10.1074/jbc.M306101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681238	hybrid			2022-12-27	WOS:000189265900037
J	Lim, CC; Zuppinger, C; Guo, XX; Kuster, GM; Helmes, M; Eppenberger, HM; Suter, TM; Liao, RL; Sawyer, DB				Lim, CC; Zuppinger, C; Guo, XX; Kuster, GM; Helmes, M; Eppenberger, HM; Suter, TM; Liao, RL; Sawyer, DB			Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; MUSCLE-SPECIFIC CALPAIN; SKELETAL-MUSCLE; CA2+-DEPENDENT PROTEOLYSIS; DOXORUBICIN ADRIAMYCIN; INTERMEDIATE FILAMENTS; MYOCARDIAL-INFARCTION; MYOFIBRILLAR PROTEINS; STUNNED MYOCARDIUM; ALZHEIMERS-DISEASE	Titin, the largest myofilament protein, serves as a template for sarcomere assembly and acts as a molecular spring to contribute to diastolic function. Titin is known to be extremely susceptible to calcium-dependent protease degradation in vitro. We hypothesized that titin degradation is an early event in doxorubicin-induced cardiac injury and that titin degradation occurs by activation of the calcium-dependent proteases, the calpains. Treatment of cultured adult rat cardiomyocytes with 1 or 3 mumol/liter doxorubicin for 24 h resulted in degradation of titin in myocyte lysates, which was confirmed by a reduction in immunostaining of an antibody to the spring-like (PEVK) domain of titin at the I-band of the sarcomere. The elastic domain of titin appears to be most susceptible to proteolysis because co-immunostaining with an antibody to titin at the M-line was preserved, suggesting targeted proteolysis of the springlike domain of titin. Doxorubicin treatment for 1 h resulted in similar to3-fold increase in calpain activity, which remained elevated at 48 h. Co-treatment with calpain inhibitors resulted in preservation of titin, reduction in myofibrillar disarray, and attenuation of cardiomyocyte necrosis but not apoptosis. Co-treatment with a caspase inhibitor did not prevent the degradation of titin, which precludes caspase-3 as an early mechanism of titin proteolysis. We conclude that calpain activation is an early event after doxorubicin treatment in cardiomyocytes and appears to target the degradation of titin. Proteolysis of the spring-like domain of titin may predispose cardiomyocytes to diastolic dysfunction, myofilament instability, and cell death by necrosis.	Boston Univ, Med Ctr, Dept Med,Sch Med, Div Cardiovasc,Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Univ Bern, Inselspital, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland; Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland	Boston University; University of Bern; University Hospital of Bern; Swiss Federal Institutes of Technology Domain; ETH Zurich	Sawyer, DB (corresponding author), Boston Univ, Med Ctr, Dept Med,Sch Med, Div Cardiovasc,Whitaker Cardiovasc Inst, 650 Albany St, Boston, MA 02118 USA.	douglas.sawyer@bmc.org	Zuppinger, Christian/H-4452-2019; Kuster, Gabriela M/AAB-5478-2022	Zuppinger, Christian/0000-0003-1786-0800; Kuster, Gabriela M/0000-0002-8209-4631	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068144, T32HL007224] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03878-02, R01 HL068144, T32 HL07224-27] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson M, 1998, OPHTHALMIC RES, V30, P157, DOI 10.1159/000055469; Andersson M, 1996, OPHTHALMIC RES, V28, P51, DOI 10.1159/000267944; Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; Averna M, 2001, J BIOL CHEM, V276, P38426, DOI 10.1074/jbc.M101936200; BUGAISKY LB, 1989, CIRC RES, V64, P493, DOI 10.1161/01.RES.64.3.493; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; Cazorla O, 2001, CIRC RES, V88, P1028, DOI 10.1161/hh1001.090876; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Communal C, 2002, P NATL ACAD SCI USA, V99, P6252, DOI 10.1073/pnas.092022999; Costelli P, 2001, BRIT J CANCER, V84, P946, DOI 10.1054/bjoc.2001.1696; DALLEDONNE I, 1992, EXP MOL PATHOL, V56, P229, DOI 10.1016/0014-4800(92)90039-E; de Jonge N, 2002, J AM COLL CARDIOL, V39, P963, DOI 10.1016/S0735-1097(02)01713-8; DOROSHOW JH, 1983, CANCER RES, V43, P460; Enns D., 2002, Molecular and Cellular Biochemistry, V241, P29, DOI 10.1023/A:1020861120368; Fukuda N, 2001, CIRCULATION, V104, P1639, DOI 10.1161/hc3901.095898; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gao WD, 1996, CIRC RES, V78, P455; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gotthardt M, 2003, J BIOL CHEM, V278, P6059, DOI 10.1074/jbc.M211723200; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; HEIN S, 1994, J MOL CELL CARDIOL, V26, P1291, DOI 10.1006/jmcc.1994.1148; Helmes M, 2003, J GEN PHYSIOL, V121, P97, DOI 10.1085/jgp.20028652; Helmes M, 1996, CIRC RES, V79, P619, DOI 10.1161/01.RES.79.3.619; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; HUFFLONERGAN E, 1995, J ANIM SCI, V73, P1064; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; KEUNG EC, 1991, J CLIN INVEST, V87, P2108, DOI 10.1172/JCI115241; KIM DH, 1989, J MOL CELL CARDIOL, V21, P433, DOI 10.1016/0022-2828(89)90782-7; Kinbara K, 1997, ARCH BIOCHEM BIOPHYS, V342, P99, DOI 10.1006/abbi.1997.0108; Kostin S, 2003, CIRC RES, V92, P715, DOI 10.1161/01.RES.0000067471.95890.5C; Kuramochi Y, 2004, AM J PHYSIOL-CELL PH, V286, pC222, DOI 10.1152/ajpcell.00312.2003; Lim CC, 2000, J MOL CELL CARDIOL, V32, P2075, DOI 10.1006/jmcc.2000.1239; Linke WA, 1998, J CELL SCI, V111, P1567; Matsumura Y, 1996, CIRC RES, V79, P447, DOI 10.1161/01.RES.79.3.447; MORANO I, 1994, J MOL CELL CARDIOL, V26, P361, DOI 10.1006/jmcc.1994.1045; PAPOIAN T, 1990, AM J PATHOL, V136, P1201; Papp Z, 2000, CARDIOVASC RES, V45, P981, DOI 10.1016/S0008-6363(99)00374-0; Person V, 2000, J CELL SCI, V113, P3851; Ray SK, 2002, J NEUROSCI RES, V69, P197, DOI 10.1002/jnr.10265; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Saeki K, 2002, LIFE SCI, V70, P2377, DOI 10.1016/S0024-3205(02)01524-2; Sandmann S, 2002, EUR J PHARMACOL, V453, P99, DOI 10.1016/S0014-2999(02)02384-1; Sandmann S, 2001, BRIT J PHARMACOL, V132, P767, DOI 10.1038/sj.bjp.0703860; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Sawyer DB, 1999, CIRC RES, V84, P257, DOI 10.1161/01.RES.84.3.257; Sawyer DB, 2002, CIRCULATION, V105, P1551, DOI 10.1161/01.CIR.0000013839.41224.1C; Shi YX, 2000, AM J PHYSIOL-RENAL, V279, pF509, DOI 10.1152/ajprenal.2000.279.3.F509; SINGAL PK, 1987, J MOL CELL CARDIOL, V19, P817, DOI 10.1016/S0022-2828(87)80392-9; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1995, J BIOL CHEM, V270, P31158, DOI 10.1074/jbc.270.52.31158; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Sussman MA, 1997, CIRC RES, V80, P52, DOI 10.1161/01.RES.80.1.52; Suzuki A, 1996, ADV BIOPHYS, V33, P53; TATSUMI R, 1995, ANAL BIOCHEM, V224, P28, DOI 10.1006/abio.1995.1004; TOKUYASU KT, 1987, J CELL BIOL, V105, P2781, DOI 10.1083/jcb.105.6.2781; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; UYTTERHAEGEN L, 1994, J ANIM SCI, V72, P1209, DOI 10.2527/1994.7251209x; WANG K, 1984, ADV EXP MED BIOL, V170, P285; WANG SM, 1988, J CELL BIOL, V107, P1075, DOI 10.1083/jcb.107.3.1075; WANG SM, 1985, J MUSCLE RES CELL M, V6, P293, DOI 10.1007/BF00713171; Xu XL, 2002, NAT GENET, V30, P205, DOI 10.1038/ng816; YOSHIDA K, 1993, BIOCHIM BIOPHYS ACTA, V1182, P215, DOI 10.1016/0925-4439(93)90143-O; Zima T, 2001, EXP MOL PATHOL, V70, P154, DOI 10.1006/exmp.2000.2353; Zima T, 2001, TOXICOL APPL PHARM, V171, P135, DOI 10.1006/taap.2000.9084	69	208	215	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8290	8299		10.1074/jbc.M308033200	http://dx.doi.org/10.1074/jbc.M308033200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676206	hybrid			2022-12-27	WOS:000189103300111
J	Brill, J; Klocke, R; Paul, D; Boison, D; Gouder, N; Klugbauer, N; Hofmann, F; Becker, CM; Becker, K				Brill, J; Klocke, R; Paul, D; Boison, D; Gouder, N; Klugbauer, N; Hofmann, F; Becker, CM; Becker, K			entla, a novel epileptic and ataxic Cacna2d2 mutant of the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HEMIPLEGIC MIGRAINE; CALCIUM-CHANNEL SUBUNIT; DE-NOVO MUTATION; EPISODIC ATAXIA; GABAPENTIN-BINDING; RECEPTOR SUBUNIT; NMDA RECEPTOR; NEUROLOGICAL MUTATION; MISSENSE MUTATION; GLYCINE RECEPTOR	entla (ent) is a novel recessive phenotype of mice. The underlying mutation was mapped to chromosome 9 (60.1 centimorgans) and identified as an allele of the Cacna2d2 gene encoding the alpha2delta-2 subunit of voltage-gated calcium channels. The Cacna2d2(entla) allele harbors a 38-kb duplication comprising the 117 nucleotides of exon 3. The predicted duplication of 39 amino acid residues near the subunit's N terminus results in the expression of a full-length, membrane-associated protein. Western blot data were consistent with correct cleavage of the alpha2delta-2(entla) precursor into alpha2(entla) and delta2 proteins but indicated loss of the disulfide linkage between the two proteins. ent/ent mice develop ataxia by postnatal day 13-15, followed by paroxysmal dyskinesia a few days later. Two distinct types of cortical and hippocampal epileptic activity at 2 and 4 Hz were recorded, indicative of absence epilepsy. Homozygotes display reduced size and weight, increased mortality before weaning, and female infertility. No overt neuroanatomical abnormalities were detected. Ca2+ current densities recorded from acutely dissociated Purkinje cells of homozygous entla animals were reduced by 50% compared with wild type. Ligand binding assays using the antiepileptic drug [H-3]gabapentin, a specific ligand of the alpha2delta-1 and alpha2delta-2 subunits, revealed a >60% reduced maximum binding to cerebellar membranes of ent/ent compared with unaffected littermates. entla is allelic to ducky and ducky(2J), representing the third murine Cacna2d2 allele identified and so far the only one encoding an untruncated protein that is incorporated into membranes.	Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, D-91054 Erlangen, Germany; Univ Hamburg, Inst Expt & Klin Pharmakol, Zentrum Expt Med, D-20246 Hamburg, Germany; Univ Zurich, Inst Pharmakol & Toxikol, CH-8057 Zurich, Switzerland; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	University of Erlangen Nuremberg; University of Hamburg; University of Zurich; Technical University of Munich	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Fahrstr 17, D-91054 Erlangen, Germany.	cmb@biochem.uni-erlangen.de	Boison, Detlev/ABE-6302-2020	Boison, Detlev/0000-0002-7740-5781				Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; Bazil CW, 2002, NEUROLOGIST, V8, P71, DOI 10.1097/00127893-200203000-00002; Brodbeck J, 2002, J BIOL CHEM, V277, P7684, DOI 10.1074/jbc.M109404200; Brown JP, 1998, J BIOL CHEM, V273, P25458, DOI 10.1074/jbc.273.39.25458; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Burgess DL, 1999, MOL CELL NEUROSCI, V13, P293, DOI 10.1006/mcne.1999.0748; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Dolphin AC, 1999, J PHYSIOL-LONDON, V519, P35, DOI 10.1111/j.1469-7793.1999.0035o.x; Doyle J, 1997, MAMM GENOME, V8, P113, DOI 10.1007/s003359900369; Ducros A, 1999, AM J HUM GENET, V64, P89, DOI 10.1086/302192; Eichler EE, 2001, TRENDS GENET, V17, P661, DOI 10.1016/S0168-9525(01)02492-1; Escayg A, 2000, AM J HUM GENET, V66, P1531, DOI 10.1086/302909; Felix R, 2002, CELL MOL NEUROBIOL, V22, P103, DOI 10.1023/A:1019807719343; Friend KL, 1999, HUM GENET, V105, P261, DOI 10.1007/s004390051099; Gong HC, 2001, J MEMBRANE BIOL, V184, P35, DOI 10.1007/s00232-001-0072-7; Guida S, 2001, AM J HUM GENET, V68, P759, DOI 10.1086/318804; Herkert M, 1998, EUR J NEUROSCI, V10, P1553, DOI 10.1046/j.1460-9568.1998.00164.x; Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Jouvenceau A, 2002, NEUROPHARMACOLOGY, V42, P444, DOI 10.1016/S0028-3908(01)00202-7; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Letunic I, 2002, HUM MOL GENET, V11, P1561, DOI 10.1093/hmg/11.13.1561; Lorenzon NM, 1998, J NEUROSCI, V18, P4482; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; Marais E, 2001, MOL PHARMACOL, V59, P1243, DOI 10.1124/mol.59.5.1243; McCormick DA, 2002, INT REV NEUROBIOL, V49, P99; MEIER H, 1968, ACTA NEUROPATHOL, V11, P15, DOI 10.1007/BF00692792; MEIER H, 1970, EXP MED SURG, V28, P256; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; ORTIZ JG, 1990, NEUROSCI LETT, V114, P231, DOI 10.1016/0304-3940(90)90077-M; Perucca E, 2001, EPILEPSIA, V42, P31, DOI 10.1046/j.1528-1157.2001.042suppl.3031.x; PFEIFFER F, 1981, BRAIN RES, V226, P273, DOI 10.1016/0006-8993(81)91099-4; REHM H, 1988, TRENDS PHARMACOL SCI, V9, P316, DOI 10.1016/0165-6147(88)90099-5; Seeber S, 2000, J NEUROCHEM, V75, P2472, DOI 10.1046/j.1471-4159.2000.0752472.x; SNELL GEORGE D., 1955, JOUR HEREDITY, V46, P27; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; Stefani A, 1998, NEUROPHARMACOLOGY, V37, P83, DOI 10.1016/S0028-3908(97)00189-5; Vahedi K, 2000, NEUROLOGY, V55, P1040, DOI 10.1212/WNL.55.7.1040; Wang MH, 1999, BIOCHEM J, V342, P313, DOI 10.1042/0264-6021:3420313; Yue Q, 1998, AM J MED GENET, V77, P298, DOI 10.1002/(SICI)1096-8628(19980526)77:4<298::AID-AJMG9>3.0.CO;2-J; Zhang Y, 2002, J NEUROSCI, V22, P6362; Zwingman TA, 2001, J NEUROSCI, V21, P1169	47	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7322	7330		10.1074/jbc.M308778200	http://dx.doi.org/10.1074/jbc.M308778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660671	hybrid			2022-12-27	WOS:000188969200134
J	Gorbatyuk, VY; Tsai, CK; Chang, CF; Huang, TH				Gorbatyuk, VY; Tsai, CK; Chang, CF; Huang, TH			Effect of N-terminal and Met(23) mutations on the structure and dynamics of onconase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL-FREE APPROACH; SEQUENCE-SPECIFIC RIBONUCLEASE; MAGNETIC-RESONANCE RELAXATION; AMINO-ACID-SEQUENCE; CYTOTOXIC RIBONUCLEASE; P-30 PROTEIN; COUPLING-CONSTANTS; BACKBONE DYNAMICS; CHEMICAL-SHIFT; OOCYTES	Onconase (rONC), otherwise known as ranpirnase or P-30 protein, which was initially purified from extracts of Rana pipiens oocytes and early embryos, exhibits anticancer activity both in vitro and in vivo and is in phase III clinical trials for tumor therapy. We have determined the solution NMR structure of a recombinant onconase with Met(-1), Gln(1), and Leu(23) residues (M-1, Q1, M23L)rONC. The 20 best solution structures had a backbone root mean square deviation of 0.41 +/- 0.09 degrees with respect to the average structure. The energy-minimized average NMR structure had a backbone root mean square deviation of 0.72 Angstrom from the x-ray crystallographic structure of native onconase; however, the orientation of the N-terminal residue in the two structures was very different. Comparison of the N-15 HSQC spectrum of (M-1, Q1, M23L) rONC with that of a mutant E1S-rONC, which is identical to the nONC except with the N-terminal pyroglutamyl residue replaced by Ser, showed that N-terminal and residue 23 mutations induced structural changes in regions beyond the mutation sites. Model-free analysis of the backbone amide N-15-T-1, N-15-T-2, and N-15-H-1 NOE relaxation data for (M-1, Q1, M23L) rONC and E1S-rONC revealed that the E1S-rONC molecule showed very little flexibility, whereas (M-1, Q1, M23L) rONC exhibited substantial flexibility, which may account for the previously observed reduced stability and increased protease susceptibility. The alpha(1) helix and beta-sheets of (M-1, Q1, M23L) rONC displayed bending motions. These data provided strong evidence for the presence of an N-terminal hydrogen bond network in E1S-rONC, but not in (M-1, Q1, M23L) rONC.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Taiwan Normal Univ, Dept Phys, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Taiwan Normal University	Huang, TH (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	bmthh@ibms.sinica.edu.tw		Chang, Chi-Fon/0000-0002-2961-0748				ARDELT W, 1991, J BIOL CHEM, V266, P245; BENKOVIC SJ, 1988, SCIENCE, V239, P1105, DOI 10.1126/science.3125607; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang CF, 1998, J MOL BIOL, V283, P231, DOI 10.1006/jmbi.1998.2082; Chen CP, 1996, J BIOMOL NMR, V8, P331, DOI 10.1007/BF00410331; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FOLMER RHA, 1995, EMBO J, V14, P4132, DOI 10.1002/j.1460-2075.1995.tb00087.x; Gorbatyuk VY, 1999, J BIOMOL NMR, V15, P343, DOI 10.1023/A:1008312325225; Hsu CH, 2003, J MOL BIOL, V326, P1189, DOI 10.1016/S0022-2836(02)01472-9; Huang YT, 2001, J MOL BIOL, V307, P1075, DOI 10.1006/jmbi.2001.4539; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JE, 2003, BIOCHEMISTRY-US, V42, P11443, DOI 10.1021/bi035147s; Leu YJ, 2003, J BIOL CHEM, V278, P7300, DOI 10.1074/jbc.M206701200; LIAO YD, 1992, NUCLEIC ACIDS RES, V20, P1371, DOI 10.1093/nar/20.6.1371; Liao YD, 2003, NUCLEIC ACIDS RES, V31, P5247, DOI 10.1093/nar/gkg746; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Markley JL, 1998, J MOL BIOL, V280, P933, DOI 10.1006/jmbi.1998.1852; Merlino A, 2003, PROTEINS, V53, P101, DOI 10.1002/prot.10466; MIKULSKI SM, 1990, J NATL CANCER I, V82, P151, DOI 10.1093/jnci/82.2.151-a; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; Newton DL, 1998, BIOCHEMISTRY-US, V37, P5173, DOI 10.1021/bi972147h; NEWTON DL, 1994, J NEUROSCI, V14, P538; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Notomista E, 2000, BIOCHEMISTRY-US, V39, P8711, DOI 10.1021/bi000415x; Notomista E, 1999, FEBS LETT, V463, P211, DOI 10.1016/S0014-5793(99)01623-3; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0; SAKAKIBARA F, 1979, CANCER RES, V39, P1347; Saxena SK, 1996, J BIOL CHEM, V271, P20783, DOI 10.1074/jbc.271.34.20783; TITANI K, 1987, BIOCHEMISTRY-US, V26, P2189, DOI 10.1021/bi00382a018; Vitagliano L, 2002, PROTEINS, V46, P97, DOI 10.1002/prot.10033; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491; YOULE RJ, 1994, P NATL ACAD SCI USA, V91, P6012, DOI 10.1073/pnas.91.13.6012; ZHU GA, 1992, J MAGN RESON, V98, P192, DOI 10.1016/0022-2364(92)90124-P	50	21	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5772	5780		10.1074/jbc.M311233200	http://dx.doi.org/10.1074/jbc.M311233200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645226	hybrid			2022-12-27	WOS:000188776500091
J	Keenan, SM; Lents, NH; Baldassare, JJ				Keenan, SM; Lents, NH; Baldassare, JJ			Expression of cyclin E renders cyclin D-CDK4 dispensable for inactivation of the retinoblastoma tumor suppressor protein, activation of E2F, and G(1)-S phase progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F; CELL-CYCLE; GENE-PRODUCT; S-PHASE; HISTONE DEACETYLASE; ECTOPIC EXPRESSION; DEPENDENT KINASES; ALPHA-THROMBIN; BREAST-CANCER; GROWTH-FACTOR	The activation of CDK2-cyclin E in late G(1) phase has been shown to play a critical role in retinoblastoma protein (pRb) inactivation and G(1)-S phase progression of the cell cycle. The phosphatidylinositol 3-OH-kinase inhibitor LY294002 has been shown to block cyclin D1 accumulation, CDK4 activity and, thus, G(1) progression in alpha-thrombin-stimulated IIC9 cells (Chinese hamster embryonic fibroblasts). Our previous results show that expression of cyclin E rescues S phase progression in alpha-thrombin-stimulated IIC9 cells treated with LY294002, arguing that cyclin E renders CDK4 activity dispensable for G(1) progression. In this work we investigate the ability of alpha-thrombin-induced CDK2-cyclin E activity to inactivate pRb in the absence of prior CDK4-cyclin D1 activity. We report that in the absence of CDK4-cyclin D1 activity, CDK2-cyclin E phosphorylates pRb in vivo on at least one residue and abolishes pRb binding to E2F response elements. We also find that expression of cyclin E rescues E2F activation and cyclin A expression in cyclin D kinase-inhibited, alpha-thrombin-stimulated cells. Furthermore, the rescue of E2F activity, cyclin A expression, and DNA synthesis by expression of E can be blocked by the expression of either CDK2(D145N) or Rb-DeltaCDK, a constitutively active mutant of pRb. However, restoring four known cyclin E-CDK2 phosphorylation sites to Rb-DeltaCDK renders it susceptible to inactivation in late G(1), as assayed by E2F activation, cyclin A expression, and S phase progression. These data indicate that CDK2-cyclin E, without prior CDK4-cyclin D activity, can phosphorylate and inactivate pRb, activate E2F, and induce DNA synthesis.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Saint Louis University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA.	baldasjj@slu.edu						Adams PD, 1999, MOL CELL BIOL, V19, P1068; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Courjal F, 1996, INT J CANCER, V69, P247; Davis ST, 2001, SCIENCE, V291, P134, DOI 10.1126/science.291.5501.134; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dhillon NK, 2002, ONCOGENE, V21, P4626, DOI 10.1038/sj.onc.1205576; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harwell RM, 2000, CANCER RES, V60, P481; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; KATO J, 1993, GENE DEV, V7, P331; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; NEVINS JR, 1992, SCIENCE, V258, P424; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Oswald F, 1996, MOL CELL BIOL, V16, P1889; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schraml P, 2003, J PATHOL, V200, P375, DOI 10.1002/path.1356; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Span PN, 2003, ONCOGENE, V22, P4898, DOI 10.1038/sj.onc.1206818; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P17320, DOI 10.1074/jbc.272.28.17320; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338	83	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5387	5396		10.1074/jbc.M310383200	http://dx.doi.org/10.1074/jbc.M310383200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645251	hybrid			2022-12-27	WOS:000188776500044
J	Leontieva, OV; Black, JD				Leontieva, OV; Black, JD			Identification of two distinct pathways of protein kinase C alpha down-regulation in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE-DEPENDENT KINASE; PHOSPHATASE 2A; BRYOSTATIN 1; PHOSPHORYLATION; DEPHOSPHORYLATION; INHIBITION; ACTIVATION; ISOZYMES; PKC; DEGRADATION	Signal transduction pathways are controlled by desensitization mechanisms, which can affect receptors and/or downstream signal transducers. It has long been recognized that members of the protein kinase C (PKC) family of signal transduction molecules undergo down-regulation in response to activation. Previous reports have indicated that key steps in PKCalpha desensitization include caveolar internalization, priming site dephosphorylation, ubiquitination of the dephosphorylated protein, and degradation by the proteasome. In the current study, comparative analysis of PKCalpha processing induced by the PKC agonists phorbol 12-myristate 13-acetate and bryostatin 1 in IEC-18 rat intestinal epithelial cells demonstrates that: (a) at least two pathways of PKCalpha down-regulation can co-exist within cells, and (b) a single PKC agonist can activate both pathways at the same time. Using a combined biochemical and morphological approach, we identify a novel pathway of PKCalpha desensitization that involves ubiquitination of mature, fully phosphorylated activated enzyme at the plasma membrane and subsequent down-regulation by the proteasome. The phosphatase inhibitors okadaic acid and calyculin A accelerated PKCalpha down-regulation and inhibitors of vesicular trafficking did not prevent degradation of the protein, indicating that neither internalization nor priming site dephosphorylation are requisite intermediate steps in this ubiquitin/proteasome dependent pathway of PKCalpha down-regulation. Instead, caveolar trafficking and dephosphorylation are involved in a second, proteasome-independent mechanism of PKCalpha desensitization in this system. Our findings highlight subcellular distribution and phosphorylation state as critical determinants of PKCalpha desensitization pathways.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Black, JD (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA.	jennifer.black@roswellpark.org			NCI NIH HHS [CA 16056] Funding Source: Medline; NIDDK NIH HHS [DK 54909] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054909] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Black JD, 2001, GASTROENTEROLOGY, V120, P1868, DOI 10.1053/gast.2001.25287; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BORNER C, 1989, J BIOL CHEM, V264, P13902; CHEN J, 1994, J BIOL CHEM, V269, P7957; CLEMENS MJ, 1992, J CELL SCI, V103, P881; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; HUWILER A, 1994, BIOCHEM PHARMACOL, V48, P689, DOI 10.1016/0006-2952(94)90046-9; JALAVA A, 1993, BIOCHEM BIOPH RES CO, V191, P472, DOI 10.1006/bbrc.1993.1242; Junoy B, 2002, ENDOCRINOLOGY, V143, P1386, DOI 10.1210/en.143.4.1386; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mochly-Rosen D, 1998, FASEB J, V12, P35; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; Prevostel C, 2000, J CELL SCI, V113, P2575; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Srivastava J, 2002, BIOCHEM J, V368, P349, DOI 10.1042/BJ20020737; Srivastava J, 2002, FEBS LETT, V516, P265, DOI 10.1016/S0014-5793(02)02500-0; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; XIE HY, 1994, J BIOL CHEM, V269, P1981	39	90	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5788	5801		10.1074/jbc.M308375200	http://dx.doi.org/10.1074/jbc.M308375200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638691	hybrid			2022-12-27	WOS:000188776500093
J	Rozanov, DV; Hahn-Dantona, E; Strickland, DK; Strongin, AY				Rozanov, DV; Hahn-Dantona, E; Strickland, DK; Strongin, AY			The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BREAST-CARCINOMA CELLS; INTEGRIN ALPHA(V) SUBUNIT; ALPHA-2-MACROGLOBULIN RECEPTOR; GELATINASE-A; TUMOR-CELLS; MATRIX-METALLOPROTEINASE-9 MMP-9; CELLULAR INTERNALIZATION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX	We demonstrate that the presentation of LRP and the subsequent uptake of its ligands by malignant cells are both strongly regulated by MT1-MMP. Because LRP is essential for the clearance of multiple ligands, these findings have important implications for many pathophysiological processes including the pericellular proteolysis in neoplastic cells as well as the fate of the soluble matrix-degrading proteases such as MMP-2. MT1-MMP is a key protease in cell invasion and a physiological activator of MMP-2. Cellular LRP consists of a non-covalently associated 515-kDa extracellular alpha-chain (LRP-515) and an 85-kDa membrane-spanning beta-chain, and plays a dual role as a multifunctional endocytic receptor and a signaling molecule. Through the capture and uptake of several soluble proteases, LRP is involved in the regulation of matrix proteolysis. LRP-515 associates with the MT1-MMP catalytic domain and is highly susceptible to MT1-MMP proteolysis in vitro. Similar to MT1-MMP, the metalloproteinases MT2-MMP, MT3-MMP and MT4-MMP also degrade LRP. The N-terminal and C-terminal parts of the LRP-515 subunit are resistant and susceptible, respectively, to MT1-MMP proteolysis. In cells co-expressing LRP and MT1-MMP, the proteolytically competent protease decreases the levels of cellular LRP and releases its N-terminal portion in the extracellular milieu while the catalytically inert protease co-precipitates with LRP. These events implicate MT1-MMP, not only in the activation of MMP-2, but also in the mechanisms that control the subsequent fate of MMP-2 in cells and tissues.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	Sanford Burnham Prebys Medical Discovery Institute; American Red Cross	Strongin, AY (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NHLBI NIH HHS [HL50784, HL54710] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, P01HL054710] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 1998, CANCER RES, V58, P3743; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Higashi S, 2003, BIOCHEMISTRY-US, V42, P6514, DOI 10.1021/bi020643m; Higashi S, 2003, J BIOL CHEM, V278, P14020, DOI 10.1074/jbc.M212264200; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Hussain MM, 2001, FRONT BIOSCI, V6, pD417, DOI 10.2741/Hussain1; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Makarova A, 2003, J BIOL CHEM, V278, P50250, DOI 10.1074/jbc.M309150200; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; Migliorini MM, 2003, J BIOL CHEM, V278, P17986, DOI 10.1074/jbc.M212592200; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Patel M, 2003, J BIOL CHEM, V278, P44799, DOI 10.1074/jbc.M308982200; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Rochette MJ, 2002, MOL NEUROBIOL, V26, P81, DOI 10.1385/MN:26:1:081; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200	52	113	116	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4260	4268		10.1074/jbc.M311569200	http://dx.doi.org/10.1074/jbc.M311569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645246	hybrid			2022-12-27	WOS:000188554300043
J	Kroczynska, B; Evangelista, CM; Samant, SS; Elguindi, EC; Blond, SY				Kroczynska, B; Evangelista, CM; Samant, SS; Elguindi, EC; Blond, SY			The SANT2 domain of the murine tumor cell DnaJ-like protein 1 human homologue interacts with alpha(1)-antichymotrypsin and kinetically interferes with its serpin inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; BINDING DOMAIN; GENETIC INTERACTIONS; MEMBRANE-PROTEINS; ATPASE ACTIVITY; MOUSE CDNA; IN-VITRO; YEAST; ER	The murine tumor cell DnaJ-like protein 1 or MTJ1/ ERdj1 is a membrane J-domain protein enriched in microsomal and nuclear fractions. We previously showed that its lumenal J-domain stimulates the ATPase activity of the molecular chaperone BiP/GRP78 (Chevalier, M., Rhee, H., Elguindi, E. C., and Blond, S. Y. (2000) J. Biol. Chem. 275, 19620-19627). MTJ1/ERdj1 also contains a large carboxyl-terminal cytosolic extension composed of two tryptophan-mediated repeats or SANT domains for which the function(s) is unknown. Here we describe the cloning of the human homologue HTJ1 and its interaction with alpha(1)-antichymotrypsin (ACT), a member of the serine proteinase inhibitor (serpin) family. The interaction was initially identified in a two-hybrid screening and further confirmed in vitro by dot blots, native electrophoresis, and fluorescence studies. The second SANT domain of HTJ1 (SANT2) was found to be sufficient for binding to ACT, both in yeast and in vitro. Single tryptophan-alanine substitutions at two strictly conserved residues significantly (Trp-497) or totally (Trp-520) abolished the interaction with ACT. SANT2 binds to human ACT with an intrinsic affinity equal to 0.5 nM. Preincubation of ACT with nearly stoichiometric concentrations of SANT2 wild-type but not SANT2: W520A results in an apparent loss of ACT inhibitory activity toward chymotrypsin. Kinetic analysis indicates that the formation of the covalent inhibitory complex ACT-chymotrypsin is significantly delayed in the presence of SANT2 with no change on the catalytic efficiency of the enzyme. This work demonstrates for the first time that the SANT2 domain of MTJ1/HTJ1/ERdj1 mediates stable and high affinity protein-protein interactions.	Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Pharmaceut Biotechnol MC 870, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Blond, SY (corresponding author), Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Pharmaceut Biotechnol MC 870, Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.	blond@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058107] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM058107-05, R01 GM058107-04, R01 GM058107-03, GM 58107] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Bies C, 1999, BIOL CHEM, V380, P1175, DOI 10.1515/BC.1999.149; BLACQUE OE, 2002, J BIOL CHEM, V272, P9950; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun EL, 2001, MOL BIOL EVOL, V18, P1401, DOI 10.1093/oxfordjournals.molbev.a003924; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; Brizzio V, 1999, MOL BIOL CELL, V10, P609, DOI 10.1091/mbc.10.3.609; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Chevalier M, 2000, J BIOL CHEM, V275, P19620, DOI 10.1074/jbc.M001333200; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Dudek J, 2002, EMBO J, V21, P2958, DOI 10.1093/emboj/cdf315; Duranton J, 1998, BIOCHEMISTRY-US, V37, P11239, DOI 10.1021/bi980223q; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Haigh NG, 2002, J CELL BIOL, V156, P261, DOI 10.1083/jcb.200110074; Hanaoka S, 2001, J MOL BIOL, V312, P167, DOI 10.1006/jmbi.2001.4924; Hook VYH, 1999, J NEUROCHEM, V73, P59, DOI 10.1046/j.1471-4159.1999.0730059.x; HUGHES R, 1995, GENOMICS, V29, P546, DOI 10.1006/geno.1995.9969; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Hwang SR, 2002, BIOCHEMISTRY-US, V41, P10397, DOI 10.1021/bi020088o; Inoue T, 2000, GENES CELLS, V5, P699, DOI 10.1046/j.1365-2443.2000.00362.x; Irving JA, 2002, J BIOL CHEM, V277, P13192, DOI 10.1074/jbc.M108460200; JEPPSSON JO, 1978, EUR J BIOCHEM, V83, P143, DOI 10.1111/j.1432-1033.1978.tb12078.x; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kalsheker NA, 1996, INT J BIOCHEM CELL B, V28, P961, DOI 10.1016/1357-2725(96)00032-5; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamande SR, 1999, SEMIN CELL DEV BIOL, V10, P455, DOI 10.1006/scdb.1999.0317; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; Luo Y, 1999, J BIOL CHEM, V274, P17733, DOI 10.1074/jbc.274.25.17733; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; NAIDOO N, 1995, J BIOL CHEM, V270, P14548, DOI 10.1074/jbc.270.24.14548; Nishikawa S, 1998, BIOCHEM BIOPH RES CO, V244, P785, DOI 10.1006/bbrc.1998.8342; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Nishikawa S, 1997, J BIOL CHEM, V272, P12889, DOI 10.1074/jbc.272.20.12889; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; SHOJI W, 1995, J BIOL CHEM, V270, P24818, DOI 10.1074/jbc.270.42.24818; Silberstein S, 1998, J CELL BIOL, V143, P921, DOI 10.1083/jcb.143.4.921; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Skowronek MH, 1999, BIOL CHEM, V380, P1133, DOI 10.1515/BC.1999.142; Sterner DE, 2002, J BIOL CHEM, V277, P8178, DOI 10.1074/jbc.M108601200; Stronge VS, 2001, J BIOL CHEM, V276, P39779, DOI 10.1074/jbc.M107091200; TAHARA E, 1984, HUM PATHOL, V15, P957, DOI 10.1016/S0046-8177(84)80125-2; TAKADA S, 1986, CANCER RES, V46, P3688; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Tyedmers J, 2000, P NATL ACAD SCI USA, V97, P7214, DOI 10.1073/pnas.97.13.7214; Vincent MJ, 1998, J BIOL CHEM, V273, P950, DOI 10.1074/jbc.273.2.950; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Yan W, 1998, EMBO J, V17, P4809, DOI 10.1093/emboj/17.16.4809; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Yu M, 2000, J BIOL CHEM, V275, P24984, DOI 10.1074/jbc.M000739200; Zargarian L, 1999, BIOCHEMISTRY-US, V38, P1921, DOI 10.1021/bi981199j; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; ZHANG SG, 1992, EMBO J, V11, P3787, DOI 10.1002/j.1460-2075.1992.tb05464.x; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200; Zupicich J, 2001, GENOME BIOL, V2	72	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11432	11443		10.1074/jbc.M310903200	http://dx.doi.org/10.1074/jbc.M310903200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14668352	hybrid, Green Accepted			2022-12-27	WOS:000220157600074
J	Steckelbroeck, S; Jin, Y; Gopishetty, S; Oyesanmi, B; Penning, TM				Steckelbroeck, S; Jin, Y; Gopishetty, S; Oyesanmi, B; Penning, TM			Human cytosolic 3 alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3 beta-hydroxysteroid dehydrogenase activity - Implications for steroid hormone metabolism and action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE; SITE-DIRECTED MUTAGENESIS; ANDROGEN METABOLISM; NEUROACTIVE STEROIDS; HUMAN PROSTATE; DIHYDRODIOL DEHYDROGENASE; HUMAN BRAIN; MALE RATS; HYDROXYSTEROID DEHYDROGENASES; SUBSTRATE-SPECIFICITY	The source of NADPH-dependent cytosolic 3beta-hydroxysteroid dehydrogenase (3beta-HSD) activity is unknown to date. This important reaction leads e. g. to the reduction of the potent androgen 5alpha-dihydrotestosterone (DHT) into inactive 3beta-androstanediol (3beta-Diol). Four human cytosolic aldo-keto reductases (AKR1C1 AKR1C4) are known to act as non-positional-specific 3alpha- / 17beta- /20alpha-HSDs. We now demonstrate that AKR1Cs catalyze the reduction of DHT into both 3alpha- and 3beta-Diol ( established by H-1 NMR spectroscopy). The rates of 3alpha-versus 3beta-Diol formation varied significantly among the isoforms, but with each enzyme both activities were equally inhibited by the nonsteroidal anti-inflammatory drug flufenamic acid. In vitro, AKR1Cs also expressed substantial 3alpha[17beta]-hydroxysteroid oxidase activity with 3alpha-Diol as the substrate. However, in contrast to the 3-ketosteroid reductase activity of the enzymes, their hydroxysteroid oxidase activity was potently inhibited by low micromolar concentrations of the opposing cofactor ( NADPH). This indicates that in vivo all AKR1Cs will preferentially work as reductases. Human hepatoma (HepG2) cells (which lack 3beta-HSD/Delta(5-4) ketosteroid isomerase mRNA expression, but express AKR1C1 - AKR1C3) were able to convert DHT into 3alpha- and 3beta-Diol. This conversion was inhibited by flufenamic acid establishing the in vivo significance of the 3alpha/ 3beta-HSD activities of the AKR1C enzymes. Molecular docking simulations using available crystal structures of AKR1C1 and AKR1C2 demonstrated how 3alpha/3beta-HSD activities are achieved. The observation that AKR1Cs are a source of 3beta-tetrahydrosteroids is of physiological significance because: (i) the formation of 3beta-Diol ( in contrast to 3alpha-Diol) is virtually irreversible, (ii) 3beta-Diol is a pro-apoptotic ligand for estrogen receptor beta, and (iii) 3beta-tetrahydrosteroids act as gamma-aminobutyric acid type A receptor antagonists.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Penning, TM (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 130C John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	penning@pharm.med.upenn.edu		Penning, Trevor/0000-0002-3937-1066	NCI NIH HHS [CA90744] Funding Source: Medline; NIDDK NIH HHS [DK47015] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047015] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER H, 1973, ACTA ENDOCRINOL-COP, V73, P407, DOI 10.1530/acta.0.0730407; Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burczynski ME, 1998, BIOCHEMISTRY-US, V37, P6781, DOI 10.1021/bi972725u; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Chetyrkin SV, 2001, ARCH BIOCHEM BIOPHYS, V386, P1, DOI 10.1006/abbi.2000.2203; CLAIR P, 1984, J STEROID BIOCHEM, V20, P377, DOI 10.1016/0022-4731(84)90237-1; Couture JF, 2003, J MOL BIOL, V331, P593, DOI 10.1016/S0022-2836(03)00762-9; Dufort I, 1999, ENDOCRINOLOGY, V140, P568, DOI 10.1210/en.140.2.568; GEMZIK B, 1992, ARCH BIOCHEM BIOPHYS, V296, P374, DOI 10.1016/0003-9861(92)90587-M; Gingras S, 1999, ENDOCRINOLOGY, V140, P4573, DOI 10.1210/en.140.10.4573; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; HABRIOUX G, 1978, STEROIDS, V32, P61, DOI 10.1016/0039-128X(78)90100-9; He XY, 2000, BBA-MOL CELL BIOL L, V1484, P267, DOI 10.1016/S1388-1981(00)00014-7; Higaki Y, 2003, CHEM-BIOL INTERACT, V143, P503, DOI 10.1016/S0009-2797(02)00206-5; HORST HJ, 1975, ACTA ENDOCRINOL-COP, V79, P394, DOI 10.1530/acta.0.0790394; Huang XF, 2000, J BIOL CHEM, V275, P29452, DOI 10.1074/jbc.M000562200; JACOBI GH, 1977, J CLIN ENDOCR METAB, V44, P107, DOI 10.1210/jcem-44-1-107; Ji Q, 2003, PROSTATE, V54, P275, DOI 10.1002/pros.10192; Jin Y, 2001, BEST PRACT RES CL EN, V15, P79, DOI 10.1053/beem.2001.0120; Jin Y, 2001, BIOCHEMISTRY-US, V40, P10161, DOI 10.1021/bi010919a; KAO LWL, 1977, J STEROID BIOCHEM, V8, P1109; KINOSHITA Y, 1981, ENDOCRINOL JAPON, V28, P499; Krebs H A, 1973, Symp Soc Exp Biol, V27, P299; KRIEG M, 1975, J ENDOCRINOL, V64, P529, DOI 10.1677/joe.0.0640529; Lambert JJ, 2001, BRAIN RES REV, V37, P68, DOI 10.1016/S0165-0173(01)00124-2; Lin HK, 1997, MOL ENDOCRINOL, V11, P1971, DOI 10.1210/me.11.13.1971; LORENCE MC, 1990, ENDOCRINOLOGY, V126, P2493, DOI 10.1210/endo-126-5-2493; Maitra R, 1998, CAN J PHYSIOL PHARM, V76, P909, DOI 10.1139/cjpp-76-9-909; Matsuura K, 1997, BIOCHEM J, V323, P61, DOI 10.1042/bj3230061; MAUVAISJ.P, 1965, J CLIN ENDOCR METAB, V25, P1167, DOI 10.1210/jcem-25-9-1167; MORFIN RF, 1977, BIOCHIMIE, V59, P637, DOI 10.1016/S0300-9084(77)80173-9; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nahoum V, 2001, J BIOL CHEM, V276, P42091, DOI 10.1074/jbc.M105610200; OFFNER P, 1983, J STEROID BIOCHEM, V18, P415; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; PENNING TM, 1983, P NATL ACAD SCI-BIOL, V80, P4504, DOI 10.1073/pnas.80.14.4504; Pirog EC, 1999, J CLIN ENDOCR METAB, V84, P3217, DOI 10.1210/jc.84.9.3217; PRINCE RJ, 1992, NEUROSCI LETT, V135, P273, DOI 10.1016/0304-3940(92)90454-F; Ratnam K, 1999, BIOCHEMISTRY-US, V38, P7856, DOI 10.1021/bi982838t; REICH JG, 1981, ENERGY METABOLISM CE; RHEAUME E, 1991, MOL ENDOCRINOL, V5, P1147, DOI 10.1210/mend-5-8-1147; Rizner TL, 2003, ENDOCRINOLOGY, V144, P2922, DOI 10.1210/en.2002-0032; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; SAARTOK T, 1984, ENDOCRINOLOGY, V114, P2100, DOI 10.1210/endo-114-6-2100; Shaw G, 2000, P NATL ACAD SCI USA, V97, P12256, DOI 10.1073/pnas.220412297; Simard J, 1996, J ENDOCRINOL, V150, pS189; Steckelbroeck S, 2001, J CLIN ENDOCR METAB, V86, P1324, DOI 10.1210/jc.86.3.1324; Steckelbroeck S, 2001, MOL CELL ENDOCRINOL, V171, P165, DOI 10.1016/S0303-7207(00)00432-9; STENSTAD P, 1981, BIOCHIM BIOPHYS ACTA, V663, P169, DOI 10.1016/0005-2760(81)90203-4; STEWART ME, 1977, J ENDOCRINOL, V72, P385, DOI 10.1677/joe.0.0720385; Stoffel-Wagner B, 2003, EPILEPSY RES, V54, P11, DOI 10.1016/S0920-1211(03)00036-6; TALALAY P, 1959, 2 CIBA FDN STUD GROU, P53; THOMAS JL, 1992, BIOCHEMISTRY-US, V31, P5522, DOI 10.1021/bi00139a014; TRAPP T, 1992, J STEROID BIOCHEM, V42, P321, DOI 10.1016/0960-0760(92)90135-6; Trauger JW, 2002, BIOCHEMISTRY-US, V41, P13451, DOI 10.1021/bi026109w; Usami N, 2002, BIOL PHARM BULL, V25, P441, DOI 10.1248/bpb.25.441; VANDOORN EJ, 1975, J STEROID BIOCHEM, V6, P1549, DOI 10.1016/0022-4731(75)90213-7; WALSH PC, 1976, J CLIN INVEST, V57, P1093, DOI 10.1172/JCI108353; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Wang MD, 2000, ACTA PHYSIOL SCAND, V169, P333, DOI 10.1046/j.1365-201x.2000.00744.x; Wang MD, 2002, J NEUROSCI, V22, P3366; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Weihua Zhang, 2001, Proceedings of the National Academy of Sciences of the United States of America, V98, P6330, DOI 10.1073/pnas.111150898; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WRIGHT F, 1980, J STEROID BIOCHEM, V13, P639, DOI 10.1016/0022-4731(80)90030-8; Zhang Y, 2000, J MOL ENDOCRINOL, V25, P221, DOI 10.1677/jme.0.0250221	70	229	234	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10784	10795		10.1074/jbc.M313308200	http://dx.doi.org/10.1074/jbc.M313308200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14672942	hybrid, Green Submitted			2022-12-27	WOS:000220050400134
J	Kebache, S; Cardin, E; Nguyen, DT; Chevet, E; Larose, L				Kebache, S; Cardin, E; Nguyen, DT; Chevet, E; Larose, L			Nck-1 antagonizes the endoplasmic reticulum stress-induced inhibition of translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; HERPES-SIMPLEX VIRUS-1; KAR2 BIP GENE; ER STRESS; GAMMA(1)34.5 PROTEIN; CELLS; INITIATION; KINASE; ADAPTER; EIF2-ALPHA	Eukaryotic cells have developed specific mechanisms to overcome environmental stress. Here we show that the Src homology 2/3 (SH2/SH3) domain-containing protein Nck-1 prevents the unfolded protein response normally induced by pharmacological endoplasmic reticulum ( ER) stress agents. Overexpression of Nck-1 enhances protein translation, whereas it abrogates eukaryotic initiation factor 2alpha(eIF2alpha) phosphorylation and inhibition of translation in response to tunicamycin or thapsigargin treatment. Nck-1 overexpression also attenuates induction of the ER chaperone, the immunoglobulin heavy chain-binding protein (BiP), and impairs cell survival in response to thapsigargin. We provided evidence that in these conditions, the effects of Nck on the unfolded protein response (UPR) involve its second SH3 domain and a calyculin A-sensitive phosphatase activity. In addition, we demonstrated that protein translation is reduced in mouse embryonic fibroblasts lacking both Nck isoforms and is enhanced in similar cells expressing high levels of Nck-1. In these various mouse embryonic fibroblasts, we also provided evidence that Nck modulates the activation of the ER resident eIF2alpha kinase PERK and consequently the phosphorylation of eIF2alpha on Ser-51 in response to stress. Our study establishes that Nck is required for optimal protein translation and demonstrates that, in addition to its adaptor function in mediating signaling from the plasma membrane, Nck also mediates signaling from the ER membrane compartment.	McGill Univ, Fac Med,Polypeptide Lab, Dept Expt Med, Div Endocrinol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Surg, Organelle Signaling Lab, Montreal, PQ H3A 2B2, Canada	McGill University; McGill University	Larose, L (corresponding author), McGill Univ, Fac Med,Polypeptide Lab, Dept Expt Med, Div Endocrinol, Strathcona Bldg,3640 Univ St,Rm W315, Montreal, PQ H3A 2B2, Canada.	louise.larose@mcgill.ca	chevet, eric/E-4992-2016	chevet, eric/0000-0001-5855-4522				Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bladt F, 2003, MOL CELL BIOL, V23, P4586, DOI 10.1128/MCB.23.13.4586-4597.2003; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Gulow K, 2002, J CELL SCI, V115, P2443; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kebache S, 2002, P NATL ACAD SCI USA, V99, P5406, DOI 10.1073/pnas.082483399; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Huizen R, 2003, J BIOL CHEM, V278, P15558, DOI 10.1074/jbc.M212074200; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200	42	45	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9662	9671		10.1074/jbc.M310535200	http://dx.doi.org/10.1074/jbc.M310535200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676213	hybrid			2022-12-27	WOS:000189265900134
J	Lenoir, G; Picard, M; Gauron, C; Montigny, C; Le Marechal, P; Falson, P; le Maire, M; Moller, JV; Champeil, P				Lenoir, G; Picard, M; Gauron, C; Montigny, C; Le Marechal, P; Falson, P; le Maire, M; Moller, JV; Champeil, P			Functional properties of sarcoplasmic reticulum Ca2+-ATPase after proteolytic cleavage at Leu(119)-Lys(120), close to the A-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY TRANSDUCTION MECHANISM; SITE-DIRECTED MUTAGENESIS; MEMBRANE CALCIUM-PUMP; PHOSPHOENZYME INTERMEDIATE; ADENOSINE-TRIPHOSPHATASE; TRANSMEMBRANE SEGMENTS; LIMITED PROTEOLYSIS; INORGANIC-PHOSPHATE; OXIDATIVE CLEAVAGE; PROTEINASE-K	By measuring the phosphorylation levels of individual proteolytic fragments of SERCA1a separated by electrophoresis after their phosphorylation, we were able to study the catalytic properties of a p95C-p14N complex arising from SERCA1a cleavage by proteinase K between Leu(119) and Lys(120), in the loop linking the A-domain with the second transmembrane segment. ATP hydrolysis by the complex was very strongly inhibited, although ATP-dependent phosphorylation and the conversion of the ADP-sensitive E1P form to E2P still occurred at appreciable rates. However, the rate of subsequent dephosphorylation of E2P was inhibited to a dramatic extent, and this was also the case for the rate of "backdoor" formation of E2P from E2 and P-i. E2P formation from E2 at equilibrium nevertheless indicated little change in the apparent affinity for P-i or Mg2+, while binding of orthovanadate was weaker. The p95C-p14N complex also had a slightly reduced affinity for Ca2+ and exhibited a reduced rate for its Ca2+-dependent transition from E2 to Ca(2)E1. Thus, disruption of the N-terminal link of the A-domain with the transmembrane region seems to shift the conformational equilibria of Ca2+-ATPase from the E1/E1P toward the E2/E2P states and to increase the activation energy for dephosphorylation of Ca2+-ATPase, reviving the old idea of the A-domain being a phosphatase domain as part of the transduction machinery.	CEA, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires,CNRS, Unite Rech Associee 2096,Lab Rech Associe 17V, F-91191 Gif Sur Yvette, France; Univ Paris Sud, CEA Saclay, Inst Federat Rech 46, F-91191 Gif Sur Yvette, France; Univ Paris 11, IFR46, F-91405 Orsay, France; Univ Paris 11, Inst Biochim & Biophys Mol & Cellulaire, Equipe Chim Prot, CNRS,Unite Mixte Rech 8619, F-91405 Orsay, France; Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Aarhus University	Champeil, P (corresponding author), CEA, Dept Biol Joliot Curie, Serv Biophys Fonct Membranaires,CNRS, Unite Rech Associee 2096,Lab Rech Associe 17V, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	Picard, Martin/A-3236-2016; Lenoir, Guillaume/I-4002-2019	Picard, Martin/0000-0002-6518-8900; Lenoir, Guillaume/0000-0002-8759-5179; Falson, Pierre/0000-0002-9760-4577				ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1993, BIOCHEMISTRY-US, V32, P10015, DOI 10.1021/bi00089a017; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Champeil P, 1998, J BIOL CHEM, V273, P6619, DOI 10.1074/jbc.273.12.6619; Champeil P, 2000, J BIOL CHEM, V275, P18623, DOI 10.1074/jbc.M000470200; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Daiho T, 2003, J BIOL CHEM, V278, P39197, DOI 10.1074/jbc.M305200200; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; Echarte MM, 2001, ANAL BIOCHEM, V289, P267, DOI 10.1006/abio.2000.4950; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENAO F, 1991, EUR J BIOCHEM, V202, P559, DOI 10.1111/j.1432-1033.1991.tb16408.x; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MEDDA P, 1983, EUR J BIOCHEM, V137, P7, DOI 10.1111/j.1432-1033.1983.tb07788.x; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Moller JV, 2003, ANN NY ACAD SCI, V986, P82, DOI 10.1111/j.1749-6632.2003.tb07142.x; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PORTILLO F, 1996, BIOMEMBR, V5, P225; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SARKADI B, 1988, BIOCHIM BIOPHYS ACTA, V939, P40, DOI 10.1016/0005-2736(88)90044-2; SCOTT TL, 1982, J MEMBRANE BIOL, V64, P137, DOI 10.1007/BF01870879; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shin JM, 2001, J BIOL CHEM, V276, P48440, DOI 10.1074/jbc.M106864200; SHOSHANBARMATZ V, 1987, J BIOL CHEM, V262, P11559; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; TONG SW, 1977, BIOCHEM BIOPH RES CO, V74, P1242, DOI 10.1016/0006-291X(77)91651-5; TOROK K, 1988, EUR J BIOCHEM, V173, P361, DOI 10.1111/j.1432-1033.1988.tb14006.x; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330; Yamasaki K, 2004, J BIOL CHEM, V279, P2202, DOI 10.1074/jbc.M309398200	51	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9156	9166		10.1074/jbc.M311411200	http://dx.doi.org/10.1074/jbc.M311411200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672956	Green Submitted, hybrid			2022-12-27	WOS:000189265900077
J	Nukaga, M; Kumar, S; Nukaga, K; Pratt, RF; Knox, JR				Nukaga, M; Kumar, S; Nukaga, K; Pratt, RF; Knox, JR			Hydrolysis of third-generation cephalosporins by class C beta-lactamases - Structures of a transition state analog of cefotaxime in wild-type and extended spectrum enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROBACTER-CLOACAE P99; MOLECULAR EVOLUTION; SUBSTRATE; INHIBITION; RESISTANCE; MECHANISM; PROTEIN; CEPHALOTHIN; SPECIFICITY; MUTATIONS	Bacterial resistance to the third-generation cephalosporins is an issue of great concern in current antibiotic therapeutics. An important source of this resistance is from production of extended-spectrum (ES) beta-lactamases by bacteria. The Enterobacter cloacae GC1 enzyme is an example of a class C ES beta-lactamase. Unlike wild-type (WT) forms, such as the E. cloacae P99 and Citrobacter freundii enzymes, the ES GC1 beta-lactamase is able to rapidly hydrolyze third-generation cephalosporins such as cefotaxime and ceftazidime. To understand the basis for this ES activity, m-nitrophenyl 2-(2-aminothiazol-4- yl)-2-[(Z)-methoxyimino] acetylaminomethyl phosphonate has been synthesized and characterized. This phosphonate was designed to generate a transition state analog for turnover of cefotaxime. The crystal structures of complexes of the phosphonate with both ES GC1 and WT C. freundii GN346 beta-lactamases have been determined to high resolution (1.4 - 1.5 Angstrom). The serine-bound analog of the tetrahedral transition state for deacylation exhibits a very different binding geometry in each enzyme. In the WT beta-lactamase the cefotaxime-like side chain is crowded against the Omega loop and must protrude from the binding site with its methyloxime branch exposed. In the ES enzyme, a mutated Omega loop adopts an alternate conformation allowing the side chain to be much more buried. During the binding and turnover of the cefotaxime substrate by this ES enzyme, it is proposed that ligand-protein contacts and intra-ligand contacts are considerably relieved relative to WT, facilitating positioning and activation of the hydrolytic water molecule. The ES beta-lactamase is thus able to efficiently inactivate third-generation cephalosporins.	Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	Wesleyan University; University of Connecticut	Pratt, RF (corresponding author), Wesleyan Univ, Dept Chem, Middletown, CT 06459 USA.	rpratt@wesleyan.edu; james.knox@uconn.edu		Pathak, Sanjai/0000-0003-1799-9730	NCRR NIH HHS [RR-01646] Funding Source: Medline; NIAID NIH HHS [AI-17986] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017986, R56AI017986] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barlow M, 2003, GENETICS, V164, P23; Barnaud G, 2001, FEMS MICROBIOL LETT, V195, P185, DOI 10.1111/j.1574-6968.2001.tb10519.x; Beadle BM, 2002, STRUCTURE, V10, P413, DOI 10.1016/S0969-2126(02)00725-6; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Crichlow GV, 2001, BIOCHEMISTRY-US, V40, P6233, DOI 10.1021/bi010131s; Crichlow GV, 1999, BIOCHEMISTRY-US, V38, P10256, DOI 10.1021/bi9908787; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; Knox JR, 1996, CHEM BIOL, V3, P937, DOI 10.1016/S1074-5521(96)90182-9; KOTRA LP, 2001, BACTERIAL RESISTANCE, P123; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; LOBKOVSKY E, 1994, BIOCHEMISTRY-US, V33, P6762, DOI 10.1021/bi00188a004; Matagne A, 1999, NAT PROD REP, V16, P1, DOI 10.1039/a705983c; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morosini MI, 1998, FEMS MICROBIOL LETT, V165, P85, DOI 10.1111/j.1574-6968.1998.tb13131.x; NUKAGA M, 1995, J BIOL CHEM, V270, P5729, DOI 10.1074/jbc.270.11.5729; Nukaga M, 2003, BIOCHEMISTRY-US, V42, P13152, DOI 10.1021/bi034986b; NUKAGA M, 1994, ANTIMICROB AGENTS CH, V38, P1374, DOI 10.1128/AAC.38.6.1374; Nukaga M, 1998, BIOCHEMISTRY-US, V37, P10461, DOI 10.1021/bi980184i; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petrosino J, 1998, TRENDS MICROBIOL, V6, P323, DOI 10.1016/S0966-842X(98)01317-1; Powers RA, 1999, PROTEIN SCI, V8, P2330; Powers RA, 2001, BIOCHEMISTRY-US, V40, P9207, DOI 10.1021/bi0109358; RAHIL J, 1992, BIOCHEMISTRY-US, V31, P5869, DOI 10.1021/bi00140a024; RAHIL J, 1991, J CHEM SOC PERK T 2, P947, DOI 10.1039/p29910000947; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Siemers NO, 1996, BIOCHEMISTRY-US, V35, P2104, DOI 10.1021/bi9514166; Trepanier S, 1999, ANTIMICROB AGENTS CH, V43, P543, DOI 10.1128/AAC.43.3.543; TSUKAMOTO K, 1992, EUR J BIOCHEM, V207, P1123, DOI 10.1111/j.1432-1033.1992.tb17150.x; Vakulenko SB, 2002, ANTIMICROB AGENTS CH, V46, P1966, DOI 10.1128/AAC.46.6.1966-1970.2002; Xu Y, 1996, BIOCHEMISTRY-US, V35, P3595, DOI 10.1021/bi952106q	34	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9344	9352		10.1074/jbc.M312356200	http://dx.doi.org/10.1074/jbc.M312356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660590	hybrid			2022-12-27	WOS:000189265900098
J	Rump, A; Morikawa, Y; Tanaka, M; Minami, S; Umesaki, N; Takeuchi, M; Miyajima, A				Rump, A; Morikawa, Y; Tanaka, M; Minami, S; Umesaki, N; Takeuchi, M; Miyajima, A			Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GENE-EXPRESSION; TUMOR-MARKER; MONOCLONAL-ANTIBODY; GASTRIC-CANCER; CA 125; EXTRACELLULAR SUPERSTRUCTURE; GYNECOLOGIC-ONCOLOGY; HUMAN CARCINOMAS; CA-125 GENE	Mesothelin is a glycosylphosphatidylinositol-linked cell surface molecule expressed in the mesothelial lining of the body cavities and in many tumor cells. Based on the finding that a soluble form of mesothelin specifically binds to ovarian carcinoma cell line OVCAR-3, we isolated cDNAs encoding a mesothelin-binding protein by expression cloning. The polypeptides encoded by the two cloned cDNA fragments matched to portions of CA125, an ovarian cancer antigen and a giant mucin-like glycoprotein present at the surface of tumor cells. By flow cytometric analysis and immunoprecipitation, we demonstrate that CA125 binds to mesothelin in a specific manner. Binding of CA125 to membrane-bound mesothelin mediates heterotypic cell adhesion as anti-mesothelin antibody blocks binding of OVCAR-3 cells expressing CA125 to an endothelial-like cell line expressing mesothelin. Finally, we show that CA125 and mesothelin are co-expressed in advanced grade ovarian adenocarcinoma. Taken together, our data indicate that mesothelin is a novel CA125-binding protein and that CA125 might contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to mesothelin.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Differentiat, Bunkyo Ku, Tokyo 1130032, Japan; Wakayama Med Univ, Dept Anat & Neurobiol, Wakayama 6410012, Japan; Wakayama Med Univ, Dept Obstet & Gynecol, Wakayama 6410012, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan	University of Tokyo; Wakayama Medical University; Wakayama Medical University; Japan Science & Technology Agency (JST)	Miyajima, A (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Cell Growth & Differentiat, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	miyajima@ims.u-tokyo.ac.jp						Argani P, 2001, CLIN CANCER RES, V7, P3862; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; Bera TK, 2000, MOL CELL BIOL, V20, P2902, DOI 10.1128/MCB.20.8.2902-2906.2000; Bon GG, 1996, AM J OBSTET GYNECOL, V174, P107, DOI 10.1016/S0002-9378(96)70381-2; Boussioutas A, 2003, CANCER RES, V63, P2569; Bresalier RS, 1996, CANCER RES, V56, P4354; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CANNISTRA SA, 1993, CANCER RES, V53, P3830; CHANG K, 1992, INT J CANCER, V50, P373, DOI 10.1002/ijc.2910500308; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; Fernandez-Rodriguez J, 2002, TUMOR BIOL, V23, P193, DOI 10.1159/000067252; FLEUREN GJ, 1987, CANCER, V60, P2437, DOI 10.1002/1097-0142(19871115)60:10<2437::AID-CNCR2820601015>3.0.CO;2-K; Frierson HF, 2003, HUM PATHOL, V34, P605, DOI 10.1016/S0046-8177(03)00177-1; FUKS A, 1975, BIOCHIM BIOPHYS ACTA, V417, P123, DOI 10.1016/0304-419X(75)90002-5; Fukuda M, 2002, BBA-GEN SUBJECTS, V1573, P394, DOI 10.1016/S0304-4165(02)00409-9; FUKUDA MN, 1995, GENE DEV, V9, P1199, DOI 10.1101/gad.9.10.1199; Gaetje R, 2002, Clin Exp Obstet Gynecol, V29, P34; Gaetje R, 1999, J SOC GYNECOL INVEST, V6, P278, DOI 10.1016/S1071-5576(99)00027-1; Gimmi CD, 1996, NAT MED, V2, P1367, DOI 10.1038/nm1296-1367; Ginath S, 2002, INT J GYNECOL CANCER, V12, P372, DOI 10.1046/j.1525-1438.2002.01007.x; Gum JR, 2002, BIOCHEM BIOPH RES CO, V291, P466, DOI 10.1006/bbrc.2002.6475; Hara T, 1999, IMMUNITY, V11, P567, DOI 10.1016/S1074-7613(00)80132-6; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; HARDARDOTTIR H, 1990, AM J OBSTET GYNECOL, V163, P1925, DOI 10.1016/0002-9378(90)90775-3; Heintz A P, 2001, J Epidemiol Biostat, V6, P107; Hellstrom I, 2003, CANCER RES, V63, P3695; Hilkens J, 1995, BIOCHEM SOC T, V23, P822, DOI 10.1042/bst0230822; Hippo Y, 2001, CANCER RES, V61, P889; HOLNESS CL, 1993, BLOOD, V81, P1607; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; KOJIMA T, 1995, J BIOL CHEM, V270, P21984, DOI 10.1074/jbc.270.37.21984; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Menczer J, 1997, INT J GYNECOL CANCER, V7, P304, DOI 10.1046/j.1525-1438.1997.00459.x; Miettinen M, 2003, AM J SURG PATHOL, V27, P150, DOI 10.1097/00000478-200302000-00002; Mills L, 2002, CANCER RES, V62, P5106; Morikawa Y, 1996, ARCH PATHOL LAB MED, V120, P490; O'Brien TJ, 1998, INT J BIOL MARKER, V13, P188, DOI 10.1177/172460089801300403; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; O'Brien TJ, 2001, TUMOR BIOL, V22, P348, DOI 10.1159/000050638; OMURA GA, 1991, J CLIN ONCOL, V9, P1138, DOI 10.1200/JCO.1991.9.7.1138; PARMLEY TH, 1974, AM J OBSTET GYNECOL, V120, P234, DOI 10.1016/0002-9378(74)90370-6; PETERS WA, 1986, CANCER, V58, P2625, DOI 10.1002/1097-0142(19861215)58:12<2625::AID-CNCR2820581213>3.0.CO;2-A; PRIEVE MG, 2003, BMC DEV BIOL; Rodriguez GC, 2001, GYNECOL ONCOL, V80, P245, DOI 10.1006/gyno.2000.6042; Sato N, 2003, CANCER RES, V63, P4158; Satoh S, 2000, INT J CANCER, V88, P507, DOI 10.1002/1097-0215(20001115)88:4<507::AID-IJC1>3.0.CO;2-0; Scholler N, 1999, P NATL ACAD SCI USA, V96, P11531, DOI 10.1073/pnas.96.20.11531; Seelenmeyer C, 2003, J CELL SCI, V116, P1305, DOI 10.1242/jcs.00312; SERS C, 1994, CANCER RES, V54, P5689; Sternberg LR, 1999, GASTROENTEROLOGY, V116, P363, DOI 10.1016/S0016-5085(99)70133-2; Strobel T, 1999, GYNECOL ONCOL, V73, P362, DOI 10.1006/gyno.1999.5388; Suwa T, 1998, INT J CANCER, V76, P377, DOI 10.1002/(SICI)1097-0215(19980504)76:3<377::AID-IJC15>3.0.CO;2-8; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Wong NK, 2003, J BIOL CHEM, V278, P28619, DOI 10.1074/jbc.M302741200; Wreschner DH, 2002, PROTEIN SCI, V11, P698, DOI 10.1110/ps.16502; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200; Zeimet AG, 1996, GYNECOL ONCOL, V62, P384, DOI 10.1006/gyno.1996.0253	60	383	436	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9190	9198		10.1074/jbc.M312372200	http://dx.doi.org/10.1074/jbc.M312372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676194	hybrid			2022-12-27	WOS:000189265900080
J	Liu, YQ; Moibi, JA; Leahy, JL				Liu, YQ; Moibi, JA; Leahy, JL			Chronic high glucose lowers pyruvate dehydrogenase activity in islets through enhanced production of long chain acyl-CoA - Prevention of impaired glucose oxidation by enhanced pyruvate recycling through the malate-pyruvate shuttle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELL; STIMULATED INSULIN-SECRETION; GLYCEROL PHOSPHATE DEHYDROGENASE; CARBOXYLASE GENE-EXPRESSION; FATTY-ACID; LINE INS-1; RAT ISLETS; PHOSPHOFRUCTOKINASE ACTIVITY; REGULATED ANAPLEROSIS; CULTURED ISLETS	In islet beta-cells, the high expression of pyruvate carboxylase and the functional importance of the downstream anaplerosis pathways result in a unique characteristic whereby high glucose and fatty acids both increase production of a key fatty acid metabolite, long chain acyl-CoA, for signaling and enzyme regulation in beta-cells. We showed previously in islets that pyruvate dehydrogenase (PDH) activity is lowered by excess fatty acids (the so-called Randle effect). We have now investigated PDH activity and pyruvate metabolism in islets after 48-h culture at 16.7 mmol/liter glucose. Active PDH V-max was lowered 65% by 48 h of high glucose, and this effect was markedly attenuated by co-culture with triacsin C, which inhibits acyl-CoA synthase. Despite the large reduction in PDH activity, glucose oxidation was twice normal. The reason was continued metabolism of pyruvate through pyruvate carboxylase (V-max, 83% of control) and diversion of flux through the pyruvate-malate shuttle. The result was a 3-fold increase of the pyruvate concentration that overcame the lowered PDH activity by mass action as shown by glucose oxidation measured with [6-C-14] glucose being twice normal. In addition, glucose-induced insulin secretion was 3-fold increased after 48 h of high glucose, and this effect was totally blocked by co-culture with triacsin C. These results show that a unique feature of islet beta-cells is not only fatty acids but also excess glucose that impairs PDH activity. Also, a specialized trait of beta-cells is a long chain acyl-CoA-mediated defense mechanism that prevents a reduction in glucose oxidation and consequently in insulin secretion.	Univ Vermont, Coll Med, Div Endocrinol Diabet & Metab, Burlington, VT 05405 USA	University of Vermont	Leahy, JL (corresponding author), Univ Vermont, Coll Med, Div Endocrinol Diabet & Metab, Given C331, Burlington, VT 05405 USA.	jleahy@zoo.uvm.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056818, R01DK056818] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR/DE17702] Funding Source: Medline; NIDDK NIH HHS [DK56818] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; Black PN, 2000, J NUTR, V130, p305S, DOI 10.1093/jn/130.2.305S; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; BRUN T, 1993, J BIOL CHEM, V268, P18905; Busch AK, 2002, DIABETES, V51, P977, DOI 10.2337/diabetes.51.4.977; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; CHEN C, 1994, J CLIN INVEST, V94, P399, DOI 10.1172/JCI117335; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; FARESE RV, 1986, ENDOCRINOLOGY, V118, P1498, DOI 10.1210/endo-118-4-1498; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9; HARTMAN EJ, 1989, PROSTAGLANDINS, V37, P655, DOI 10.1016/0090-6980(89)90103-2; Hosokawa H, 1997, DIABETOLOGIA, V40, P392, DOI 10.1007/s001250050692; Hoy M, 2002, FEBS LETT, V531, P199, DOI 10.1016/S0014-5793(02)03500-7; Iizuka K, 2002, BBA-MOL BASIS DIS, V1586, P23, DOI 10.1016/S0925-4439(01)00082-5; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LIANG Y, 1990, J BIOL CHEM, V265, P16863; Liu YQ, 1999, DIABETES, V48, P1747, DOI 10.2337/diabetes.48.9.1747; Liu YQ, 1998, J CLIN INVEST, V101, P1870, DOI 10.1172/JCI1211; Liu YQ, 1998, DIABETES, V47, P1889, DOI 10.2337/diabetes.47.12.1889; Liu YQ, 2002, J BIOL CHEM, V277, P39163, DOI 10.1074/jbc.M207157200; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MacDonald MJ, 1996, DIABETES, V45, P1626, DOI 10.2337/diabetes.45.11.1626; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MacDonald MJ, 1996, DIABETES, V45, P886, DOI 10.2337/diabetes.45.7.886; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; Patane G, 2002, DIABETES, V51, P2749, DOI 10.2337/diabetes.51.9.2749; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; Prentki M, 2002, DIABETES, V51, pS405, DOI 10.2337/diabetes.51.2007.S405; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; RANDLE PJ, 1994, DIABETOLOGIA, V37, P155; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; Roche E, 1997, J BIOL CHEM, V272, P3091, DOI 10.1074/jbc.272.5.3091; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; Shrago E, 2000, J NUTR, V130, p290S, DOI 10.1093/jn/130.2.290S; SPEARS G, 1971, BIOCHEM J, V125, P1149, DOI 10.1042/bj1251149; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; Yajima H, 2000, DIABETES, V49, P712, DOI 10.2337/diabetes.49.5.712; Yaney GC, 2003, DIABETOLOGIA, V46, P1297, DOI 10.1007/s00125-003-1207-4; Yaney GC, 2000, ENDOCRINOLOGY, V141, P1989, DOI 10.1210/en.141.6.1989; Zhou YP, 1996, DIABETES, V45, P580, DOI 10.2337/diabetes.45.5.580; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394	48	27	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7470	7475		10.1074/jbc.M307921200	http://dx.doi.org/10.1074/jbc.M307921200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660628	hybrid			2022-12-27	WOS:000189103300014
J	Lubyova, B; Kellum, MJ; Frisancho, AJ; Pitha, PM				Lubyova, B; Kellum, MJ; Frisancho, AJ; Pitha, PM			Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR; DOUBLE-STRANDED-RNA; VIRUS-MEDIATED INDUCTION; ACTIVATED PROTEIN-KINASE; IFN-BETA PROMOTER; GENE-EXPRESSION; I INTERFERON; ALPHA GENES; HISTONE ACETYLTRANSFERASE; FUNCTIONAL-ANALYSIS	Kaposi's sarcoma-associated herpesvirus has been linked to Kaposi's sarcoma, body cavity-based lymphoma, and Castleman's disease. The Kaposi's sarcoma-associated herpesvirus genome contains a cluster of open reading frames encoding proteins (vIRFs) with homology to the cellular transcription factors of the interferon regulatory factor family. vIRF-3, also called LANA2, is a latently expressed nuclear protein. Here we demonstrate that vIRF-3 directly interacts with cellular interferon regulatory factor (IRF) IRF-3, IRF-7, and the transcriptional co-activator CBP/p300. The mapping of the vIRF-3 binding domain revealed that vIRF-3 associates with both IRF-3 and IRF-7 through its C-terminal region. The p300 domain, which interacts with vIRF-3, is distinct from the previously identified IBiD domain, to which both vIRF-1 and IRF-3 bind. Thus, in contrast to vIRF-1, vIRF-3 neither blocks the interaction between IRF-3 and p300 nor inhibits the histone acetylation. Although vIRF-3 is not a DNA-binding protein, it is recruited to the IFNA promoters via its interaction with IRF-3 and IRF-7. The presence of vIRF-3 in the enhanceosome assembled on the IFNA promoters increases binding of IRF-3, IRF-7, and acetylated histone H3 to this promoter region. Consequently, vIRF-3 stimulates the IRF-3- and IRF-7-mediated activation of type I interferon (IFNA and IFNB) genes and the synthesis of biologically active type I interferons in infected B cells. These studies illustrate that vIRF-3 and vIRF-1 have clearly distinct functions. In addition to its co-repressor activity, vIRF-3 can also act as a transcriptional activator on genes controlled by cellular IRF-3 and IRF-7.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 E Orleans St, Baltimore, MD 21231 USA.	parowe@jhmi.edu	Lubyova, Barbora/G-5921-2014	Lubyova, Barbora/0000-0002-8714-0414	NATIONAL CANCER INSTITUTE [R01CA076946, P01CA081400] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA76946, P01CA81400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; AU WC, 1993, J BIOL CHEM, V268, P24032; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 1999, J HUMAN VIROL, V2, P19; Burysek L, 2001, J VIROL, V75, P2345, DOI 10.1128/JVI.75.5.2345-2352.2001; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; Chatterjee M, 2002, SCIENCE, V298, P1432, DOI 10.1126/science.1074883; CHEUNG SC, 1991, J IMMUNOL, V146, P121; Deng HY, 2002, J VIROL, V76, P8252, DOI 10.1128/JVI.76.16.8252-8264.2002; Dent CL, 1996, EUR J BIOCHEM, V236, P895, DOI 10.1111/j.1432-1033.1996.t01-1-00895.x; Dent CL, 1996, J INTERF CYTOK RES, V16, P99, DOI 10.1089/jir.1996.16.99; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Esteban M, 2003, J GEN VIROL, V84, P1463, DOI 10.1099/vir.0.19014-0; Fakhari FD, 2002, J VIROL, V76, P6213, DOI 10.1128/JVI.76.12.6213-6223.2002; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Flowers CC, 1998, MOL MED, V4, P402, DOI 10.1007/BF03401747; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Juang YT, 1999, J BIOL CHEM, V274, P18060, DOI 10.1074/jbc.274.25.18060; Karpova AY, 2001, MOL CELL BIOL, V21, P4169, DOI 10.1128/MCB.21.13.4169-4176.2001; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; Kim TY, 2003, J BIOL CHEM, V278, P15272, DOI 10.1074/jbc.M205792200; Kirchhoff S, 2002, J IMMUNOL, V168, P1226, DOI 10.4049/jimmunol.168.3.1226; Leaman DW, 1998, P NATL ACAD SCI USA, V95, P9442, DOI 10.1073/pnas.95.16.9442; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2001, ONCOGENE, V20, P800, DOI 10.1038/sj.onc.1204163; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Lubyova B, 2000, J VIROL, V74, P8194, DOI 10.1128/JVI.74.17.8194-8201.2000; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Masumi A, 1999, MOL CELL BIOL, V19, P1810; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Nakamura H, 2001, J VIROL, V75, P7572, DOI 10.1128/JVI.75.16.7572-7582.2001; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Paulose-Murphy M, 2001, J VIROL, V75, P4843, DOI 10.1128/JVI.75.10.4843-4853.2001; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Roan F, 1999, J GEN VIROL, V80, P2205, DOI 10.1099/0022-1317-80-8-2205; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Seo T, 2001, J VIROL, V75, P6193, DOI 10.1128/JVI.75.13.6193-6198.2001; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; TAKI S, 1997, IMMUNITY, V6, P1; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1996, NATURE, V382, P555; Taniguchi T, 1999, COLD SPRING HARB SYM, V64, P465, DOI 10.1101/sqb.1999.64.465; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Wang XP, 2003, J GEN VIROL, V84, P329, DOI 10.1099/vir.0.18653-0; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yeow WS, 1998, J IMMUNOL, V160, P2932; Yeow WS, 1997, INT J BIOCHEM CELL B, V29, P513, DOI 10.1016/S1357-2725(96)00105-7; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2002, J INTERF CYTOK RES, V22, P73, DOI 10.1089/107999002753452674; Zhang LQ, 2002, SCIENCE, V298, P995, DOI 10.1126/science.1076185; Zhu FX, 2002, P NATL ACAD SCI USA, V99, P5573, DOI 10.1073/pnas.082420599; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	74	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7643	7654		10.1074/jbc.M309485200	http://dx.doi.org/10.1074/jbc.M309485200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668346	hybrid			2022-12-27	WOS:000189103300035
J	Ge, SJ; Pachter, JS				Ge, SJ; Pachter, JS			Caveolin-1 knockdown by small interfering RNA suppresses responses to the chemokine monocyte chemoattractant protein-1 by human astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; TYROSINE PHOSPHORYLATION; AUTOIMMUNE ENCEPHALOMYELITIS; MEDIATED ENDOCYTOSIS; KINASE ACTIVATION; BETA-CHEMOKINES; MESSENGER-RNA; CELL BIOLOGY; IN-VITRO; EXPRESSION	Astrocytes regulate the integrity of the blood-brain barrier and influence inflammatory processes in the central nervous system. The pro-inflammatory chemokine monocyte chemoattractant protein-1 (MCP-1), which is both released by and stimulates astrocytes, is thought to play a crucial role in both these activities. Because astrocytes have been shown to possess caveolae, vesicular structures that participate in intracellular transport and signal transduction events, we reasoned that expression of the major structural protein of these organelles, caveolin-1, might feature critically in the cellular responses to MCP-1. To test this hypothesis, caveolin-1 level was "knocked down" in human astrocyte cultures by using a small interfering RNA approach. This method resulted in efficient (>90% loss) and specific knockdown of caveolin-1 expression while sparring glial fibrillary acidic protein as well as several other proteins involved in endocytosis. Astrocytes suffering caveolin-1 loss showed diminished ability to down-modulate and internalize the MCP-1 receptor (CCR2) in response to exposure to this chemokine and also demonstrated significantly reduced capacity to undergo chemotaxis and calcium flux when MCP-1-stimulated. The results highlight a potentially prominent role for caveolae and/or caveolin-1 in mediating astrocyte responses to MCP-1, a feature that might significantly dictate the progression of inflammatory events at the blood-brain barrier.	Univ Connecticut, Ctr Hlth, Dept Pharmacol, Blood Brain Barrier Lab, Farmington, CT 06030 USA	University of Connecticut	Pachter, JS (corresponding author), Univ Connecticut, Ctr Hlth, Dept Pharmacol, Blood Brain Barrier Lab, 263 Farmington Ave, Farmington, CT 06030 USA.	pachter@nsol.uchc.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054718] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH54718] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andjelkovic AV, 1999, GLIA, V28, P225, DOI 10.1002/(SICI)1098-1136(199912)28:3<225::AID-GLIA6>3.0.CO;2-6; Andjelkovic AV, 2002, J NEUROSCI RES, V70, P219, DOI 10.1002/jnr.10372; Andjelkovic AV, 2000, J LEUKOCYTE BIOL, V68, P545; ANDJELKOVIC AV, 2002, UNIVERSES DELICATE B, P301; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x; Banisadr G, 2002, J NEUROCHEM, V81, P257, DOI 10.1046/j.1471-4159.2002.00809.x; Berman JW, 1996, J IMMUNOL, V156, P3017; Biber K, 2002, CURR OPIN PHARMACOL, V2, P63, DOI 10.1016/S1471-4892(01)00122-9; BJORKSTEN B, 1976, INFECT IMMUN, V14, P315; Brazer SCW, 2003, J BIOL CHEM, V278, P27208, DOI 10.1074/jbc.M301118200; Carnevale KA, 2003, J BIOL CHEM, V278, P25317, DOI 10.1074/jbc.M304182200; Cheeran MCJ, 2001, J NEUROVIROL, V7, P135; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Croitoru-Lamoury J, 2003, GLIA, V41, P354, DOI 10.1002/glia.10181; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dzenko KA, 2001, J NEUROSCI, V21, P9214, DOI 10.1523/JNEUROSCI.21-23-09214.2001; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; Heesen M, 1996, J NEUROSCI RES, V45, P382; Huang DR, 2002, J NEUROSCI, V22, P10633; Isshiki M, 2002, J CELL SCI, V115, P475; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Jee Y, 2002, J NEUROIMMUNOL, V128, P49, DOI 10.1016/S0165-5728(02)00147-9; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Katayama T, 2002, NEUROSCI LETT, V328, P277, DOI 10.1016/S0304-3940(02)00550-5; KENSWORTHY A, 2002, TRENDS BIOCHEM SCI, V27, P435; KIM JS, 1995, J NEUROIMMUNOL, V56, P127, DOI 10.1016/0165-5728(94)00138-E; Kim YN, 2002, EXP CELL RES, V280, P134, DOI 10.1006/excr.2002.5623; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Kutsch O, 2000, J VIROL, V74, P9214, DOI 10.1128/JVI.74.19.9214-9221.2000; Lafer EM, 2002, TRAFFIC, V3, P513, DOI 10.1034/j.1600-0854.2002.30801.x; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Li CY, 2003, ANESTH ANALG, V97, P205, DOI 10.1213/01.ANE.0000066013.34263.54; Luo Y, 2003, GLIA, V43, P119, DOI 10.1002/glia.10231; Mack M, 2000, METH MOL B, V138, P191; Maggi D, 2002, BIOCHEM BIOPH RES CO, V295, P1085, DOI 10.1016/S0006-291X(02)00809-4; Matveev SV, 2002, AM J PHYSIOL-CELL PH, V282, pC935, DOI 10.1152/ajpcell.00349.2001; Megias L, 2000, INT J DEV BIOL, V44, P209; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Mueller A, 2002, BLOOD, V99, P785, DOI 10.1182/blood.V99.3.785; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pearson H, 2002, NATURE, V415, P8, DOI 10.1038/415008a; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; Razani B, 2001, J BIOL CHEM, V276, P38121; Rezaie P, 2002, GLIA, V37, P64, DOI 10.1002/glia.1128; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Sauder C, 2000, J VIROL, V74, P9267, DOI 10.1128/JVI.74.19.9267-9280.2000; Sharafeldin A, 2000, J NEUROIMMUNOL, V103, P165, DOI 10.1016/S0165-5728(99)00238-6; Smits HA, 2002, J NEUROIMMUNOL, V127, P160, DOI 10.1016/S0165-5728(02)00112-1; Solari R, 1997, J BIOL CHEM, V272, P9617; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; VAN DV, 1999, AM J PATHOL, V154, P45; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhang WD, 1999, J NEUROIMMUNOL, V101, P148, DOI 10.1016/S0165-5728(99)00137-X; Zuurman MW, 2003, GLIA, V41, P327, DOI 10.1002/glia.10156	66	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6688	6695		10.1074/jbc.M311769200	http://dx.doi.org/10.1074/jbc.M311769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660607	hybrid			2022-12-27	WOS:000188969200060
J	Goldoni, S; Owens, RT; McQuillan, DJ; Shriver, Z; Sasisekharan, R; Birk, DE; Campbell, S; Iozzo, RV				Goldoni, S; Owens, RT; McQuillan, DJ; Shriver, Z; Sasisekharan, R; Birk, DE; Campbell, S; Iozzo, RV			Biologically active decorin is a monomer in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH PROTEOGLYCANS; COLLAGEN FIBRILLOGENESIS INVITRO; GROWTH-FACTOR; ENDOTHELIAL-CELLS; SELF-ASSOCIATION; DOWN-REGULATION; EXPRESSION; PROTEIN; SUPPRESSION; MIGRATION	It has been reported that decorin and its protein core can have molecular masses nearly double the size of those previously published, suggesting a dimeric structure. In this study we tested whether biologically active decorin and its glycoprotein core would form dimers in solution. We used homo- and hetero-bifunctional chemical cross-linking reagents, BS3 and sulfo-SMPB, respectively, as well as glutaraldehyde and found no preferential dimer formation, whether chemical cross-linking was performed in the presence or absence of live cells. Under the same experimental conditions, we easily detected dimers of epidermal growth factor receptor and basic fibroblast growth factor, two glycoproteins known to dimerize. Only at very high cross-linker to decorin molar ratios (2000:1) were trimers and multimers observed, but performing the chemical cross-linking in the presence of a reducing agent abolished these. The elution of decorin protein core in Superose 6 gel chromatography gave masses compatible with monomeric proteins, both before and after denaturation with 2.5 m guanidine HCl. Matrix-assisted laser desorption ionization gave a mass of 44,077 Da for decorin protein core, without any evidence of dimers or oligomers. Extensive oligomerization of the decorin protein core was observed only after dialysis against water and freeze-drying. These oligomers were considered artifacts because they were independent of chemical cross-linking and were resistant to heat denaturation and disulfide-bond reduction. Oligomeric preparations showed markedly reduced biological activity in both phosphorylation and collagen fibrillogenesis assays. Thus, biologically active decorin is a monomer in solution and, as such, is a monovalent ligand for various extracellular matrix proteins, growth factors, and cell surface receptors.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; LifeCell Corp, Branchburg, NJ 08876 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; Massachusetts Institute of Technology (MIT); Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@lac.jci.tju.edu	Pranić, Shelly Melissa/E-1974-2017; Birk, David/I-4072-2012; Iozzo, Renato/AAS-1980-2020	Pranić, Shelly Melissa/0000-0001-5524-1723; Birk, David/0000-0002-4865-9088; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline; NEI NIH HHS [R01 EY05129] Funding Source: Medline; NIAMS NIH HHS [R01 AR44745, R01 AR42826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044745, R01AR042826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIRK DE, 1981, BIOCHIM BIOPHYS ACTA, V670, P362, DOI 10.1016/0005-2795(81)90108-2; BIRK DE, 1984, ARCH BIOCHEM BIOPHYS, V235, P178, DOI 10.1016/0003-9861(84)90266-2; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; Davis JC, 1999, BIOCHEM J, V341, P613, DOI 10.1042/0264-6021:3410613; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Funderburgh JL, 1998, INVEST OPHTH VIS SCI, V39, P1957; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; GUO BP, 1995, INFECT IMMUN, V63, P3467, DOI 10.1128/IAI.63.9.3467-3472.1995; Hakkinen L, 2000, LAB INVEST, V80, P1869, DOI 10.1038/labinvest.3780197; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Huttenlocher A, 1996, MATRIX BIOL, V15, P239, DOI 10.1016/S0945-053X(96)90115-8; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; LIU J, 1994, J BIOL CHEM, V269, P28366; Neame P. J., 2000, PROTEOGLYCANS STRUCT, P201; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Reed CC, 2002, GLYCOCONJUGATE J, V19, P249, DOI 10.1023/A:1025383913444; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TOOLE BP, 1969, NATURE, V222, P872, DOI 10.1038/222872a0; TOOLE BP, 1968, BIOCHEM J, V109, P857, DOI 10.1042/bj1090857; Troup S, 2003, CLIN CANCER RES, V9, P207; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Xu GX, 2002, BIOL REPROD, V67, P681, DOI 10.1095/biolreprod67.2.681; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	46	95	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6606	6612		10.1074/jbc.M310342200	http://dx.doi.org/10.1074/jbc.M310342200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660661	hybrid			2022-12-27	WOS:000188969200049
J	Muller, C; Calkhoven, CF; Sha, XJ; Leutz, A				Muller, C; Calkhoven, CF; Sha, XJ; Leutz, A			The CCAAT enhancer-binding protein alpha (C/EBP alpha) requires a SWI/SNF complex for proliferation arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; ACUTE MYELOID-LEUKEMIA; SWI-SNF COMPLEX; GROWTH ARREST; RETINOBLASTOMA PROTEIN; IN-VIVO; EXPRESSION; DIFFERENTIATION; BRG1; TRANSCRIPTION	The transcription factor CCAAT enhancer-binding protein alpha (C/EBPalpha) is a tumor suppressor in myeloid cells and inhibits proliferation in all cell types examined. C/EBPalpha interacts with the SWI/SNF chromatin-remodeling complex during the regulation of differentiation-specific genes. Here we show that C/EBPalpha fails to suppress proliferation in SWI/SNF defective cell lines after knock-down of SWI/SNF core components or after deletion of the SWI/SNF interaction domain in C/EBPalpha, respectively. Reconstitution of SWI/SNF function restores C/EBPalpha-dependent proliferation arrest. Our results show that the anti-proliferation activity of C/EBPalpha critically depends on components of the SWI/SNF core complex and suggest that the functional interaction between SWI/SNF and C/EBPalpha is a prerequisite for proliferation arrest.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Leutz, A (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	aleutz@mdc-berlin.de	Leutz, Achim/K-9643-2013	Leutz, Achim/0000-0001-8259-927X; Calkhoven, Cornelis/0000-0001-6318-7210				BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Geng FQ, 2001, MOL CELL BIOL, V21, P4311, DOI 10.1128/MCB.21.13.4311-4320.2001; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCOTT LM, 1992, BLOOD, V80, P1725; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Snaddon J, 2003, GENE CHROMOSOME CANC, V37, P72, DOI 10.1002/gcc.10185; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Swart GWM, 1997, BIOL CHEM, V378, P373, DOI 10.1515/bchm.1997.378.5.373; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wong AKC, 2000, CANCER RES, V60, P6171; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	60	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7353	7358		10.1074/jbc.M312709200	http://dx.doi.org/10.1074/jbc.M312709200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660596	hybrid			2022-12-27	WOS:000188969200138
J	Wu, WI; Voelker, DR				Wu, WI; Voelker, DR			Reconstitution of phosphatidylserine transport from chemically defined donor membranes to phosphatidylserine decarboxylase 2 implicates specific lipid domains in the process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL 4-KINASE; TRANSFER PROTEIN; PHOSPHOLIPASE-D; NULL ALLELE; YEAST; PHOSPHATIDYLETHANOLAMINE	Phosphatidylserine (PtdSer) is transported from its site of synthesis in the endoplasmic retiuculum to the locus of PtdSer decarboxylase 2 (Psd2p) in the Golgi/vacuole and decarboxylated to form phosphatidylethanolamine. Recent biochemical and genetic evidence has implicated the C2 domain of Psd2p and a membrane-ound form of the phosphatidylinositol binding/transfer protein, PstB2p, as essential for this transport process. We devised a reconstituted system in which chemically defined donor membranes function to transfer PtdSer to the biological acceptor membranes containing Psd2p. The transfer of PtdSer is poor when the donor membranes have a high degree of curvature but markedly enhanced when the membranes are relatively planar (greater than or equal to400-nm diameter). PtdSer transfer is also dependent upon both the bulk and the surface concentrations of the lipid, with pure PtdSer vesicles acting as the most efficient donors at all concentrations. The lipid transfer from donor membranes containing either 100% PtdSer or 50% PtdSer at a fixed concentration (e.g. 250 muM PtdSer) differs by a factor of 20. Surface dilution of PtdSer by choline, ethanolamine, glycerol, and inositol phospholipids markedly inhibits PtdSer transfer, whereas phosphatidic acid (PtdOH) stimulates the transfer. Most importantly, the transfer of PtdSer from liposomes to Psd2p fails to occur in acceptor membranes from strains lacking PstB2p or the C2 domain of Psd2p. These data support a model for PtdSer transport from planar domains highly enriched in PtdSer or in PtdSer plus PtdOH.	Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, Denver, CO 80206 USA	National Jewish Health	Voelker, DR (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	voelkerd@njc.org			NIGMS NIH HHS [R01 GM032453, 2 R37 GM 32453] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, R01GM032453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHLEITNER G, 1995, J BIOL CHEM, V270, P29836; Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; BJERVE KS, 1985, BIOCHIM BIOPHYS ACTA, V833, P396, DOI 10.1016/0005-2760(85)90096-7; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409; GNAMUSCH E, 1992, BIOCHIM BIOPHYS ACTA, V1111, P120, DOI 10.1016/0005-2736(92)90281-P; Kitamura H, 2002, J BIOL CHEM, V277, P33720, DOI 10.1074/jbc.M205672200; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; NICHOLS JW, 1985, BIOCHEMISTRY-US, V24, P6390, DOI 10.1021/bi00344a011; Pichler H, 2001, EUR J BIOCHEM, V268, P2351, DOI 10.1046/j.1432-1327.2001.02116.x; PICKETT CB, 1980, EXP CELL RES, V128, P343, DOI 10.1016/0014-4827(80)90070-1; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Schumacher MM, 2002, J BIOL CHEM, V277, P51033, DOI 10.1074/jbc.M205301200; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SLEIGHT RG, 1983, J BIOL CHEM, V258, P9050; Sweeney DA, 2002, J BIOL CHEM, V277, P3030, DOI 10.1074/jbc.M104639200; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Voelker DR, 2003, J LIPID RES, V44, P441, DOI 10.1194/jlr.R200020-JLR200; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; Wu WI, 2000, J BIOL CHEM, V275, P14446, DOI 10.1074/jbc.275.19.14446; Wu WI, 2002, SEMIN CELL DEV BIOL, V13, P185, DOI 10.1016/S1084-9521(02)00047-2; Wu WI, 2001, J BIOL CHEM, V276, P7114, DOI 10.1074/jbc.M010278200; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	37	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6635	6642		10.1074/jbc.M311570200	http://dx.doi.org/10.1074/jbc.M311570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660568	hybrid			2022-12-27	WOS:000188969200053
J	Xun, LY; Webster, CM				Xun, LY; Webster, CM			A monooxygenase catalyzes sequential dechlorinations of 2,4,6-trichlorophenol by oxidative and hydrolytic reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-CEPACIA AC1100; SPHINGOBIUM-CHLOROPHENOLICUM; IRREVERSIBLE INHIBITION; GLUTATHIONE CONJUGATE; ESCHERICHIA-COLI; BACTERIUM BNC1; PENTACHLOROPHENOL; PURIFICATION; DEGRADATION; SOIL	Ralstonia eutropha JMP134 2,4,6-trichlorophenol (2,4,6-TCP) 4-monooxygenase catalyzes sequential dechlorinations of 2,4,6-TCP to 6-chlorohydroxyquinol. Although 2,6-dichlorohydroxyquinol is a logical metabolic intermediate, the enzyme hardly uses it as a substrate, implying it may not be a true intermediate. Evidence is provided to support the proposition that the monooxygenase oxidized 2,4,6-TCP to 2,6-dichloroquinone that remained with the enzyme and got hydrolyzed to 2-chlorohydroxyquinone, which was chemically reduced by ascorbate and NADH to 6-chlorohydroxyquinol. When the monooxygenase oxidized 2,6-dichlorophenol, the product was 2,6-dichloroquinol, which was not further converted to 6-chlorohydroxyquinol, implying that the enzyme only converts 2,6-dichloroquinone to 6-chlorohydroxyquinol. Stoichiometric analysis indicated the consumption of one O-2 molecule per 2,4,6-TCP converted to 6-chlorohydroxyquinol, ruling out the possibility of two oxidative reactions. Experiments with O-18-labeling gave direct evidence for the incorporation of oxygen from both O-2 and H2O into the produced 6-chlorohydroxyquinol. A monooxygenase that catalyzes hydroxylation by both oxidative and hydrolytic reactions has not been reported to date. The ability of the enzyme to perform two types of reactions is not due to the presence of a second functional domain but rather is due to catalytic promiscuity, as a homologous monooxygenase converts 2,4,6-TCP to only 2,6-dichloroquinol. Employing both conventional catalysis and catalytic promiscuity of a single enzyme in two consecutive steps of a metabolic pathway has been unknown previously.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Xun, LY (corresponding author), Washington State Univ, Sch Mol Biosci, Abelson Hall 301, Pullman, WA 99164 USA.	xun@mail.wsu.edu						Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BIRCHMORE RJ, 1979, PHYTOPATHOLOGY, V69, P1022; Bock C, 1996, APPL MICROBIOL BIOT, V45, P257, DOI 10.1007/s002530050680; Bohuslavek J, 2001, APPL ENVIRON MICROB, V67, P688, DOI 10.1128/AEM.67.2.688-695.2001; Cai M, 2002, J BACTERIOL, V184, P4672, DOI 10.1128/JB.184.17.4672-4680.2002; Chothia C, 2003, SCIENCE, V300, P1701, DOI 10.1126/science.1085371; CRAWFORD RL, 1985, ENZYME MICROB TECH, V7, P617, DOI 10.1016/0141-0229(85)90031-6; Dai MH, 2003, J BACTERIOL, V185, P302, DOI 10.1128/JB.185.1.302-310.2003; FIRESTONE D, 1978, ECOL B STOCKHOLM, V27, P39; Galan B, 2000, J BACTERIOL, V182, P627, DOI 10.1128/JB.182.3.627-636.2000; Gisi MR, 2003, J BACTERIOL, V185, P2786, DOI 10.1128/JB.185.9.2786-2792.2003; Haigler BE, 1996, J BACTERIOL, V178, P6019, DOI 10.1128/jb.178.20.6019-6024.1996; Hoekstra EJ, 1999, ENVIRON SCI TECHNOL, V33, P2543, DOI 10.1021/es9900104; HUSAIN M, 1980, J BIOL CHEM, V255, P4189; Kadiyala V, 1998, APPL ENVIRON MICROB, V64, P2479; Kaiser J, 2000, SCIENCE, V288, P1941; KARNS JS, 1983, APPL ENVIRON MICROB, V46, P1182, DOI 10.1128/AEM.46.5.1182-1186.1983; KITUNEN VH, 1987, ENVIRON SCI TECHNOL, V21, P96, DOI 10.1021/es00155a012; Liu Y, 2001, APPL ENVIRON MICROB, V67, P696, DOI 10.1128/AEM.67.2.696-701.2001; Louie TM, 2002, J BACTERIOL, V184, P3492, DOI 10.1128/JB.184.13.3492-3500.2002; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; MIDDAUGH DP, 1994, ARCH ENVIRON CON TOX, V26, P309; Miethling R, 1996, APPL ENVIRON MICROB, V62, P4361, DOI 10.1128/AEM.62.12.4361-4366.1996; NEWMAN LM, 1995, BIOCHEMISTRY-US, V34, P14066, DOI 10.1021/bi00043a012; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; PLOEMEN JHTM, 1991, BIOCHEM PHARMACOL, V41, P1665, DOI 10.1016/0006-2952(91)90167-4; Seffernick JL, 2001, BIOCHEMISTRY-US, V40, P12747, DOI 10.1021/bi011293r; VANOMMEN B, 1988, J BIOL CHEM, V263, P12939; Ward BA, 2003, J PHARMACOL EXP THER, V306, P287, DOI 10.1124/jpet.103.049601; Witschel M, 1997, J BACTERIOL, V179, P6937, DOI 10.1128/jb.179.22.6937-6943.1997; World Health Organization-International Agency for Research on Cancer, 1986, IARC MONOGR, V41, P319; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000; XUN LY, 1992, J BACTERIOL, V174, P2898, DOI 10.1128/JB.174.9.2898-2902.1992; XUN LY, 1995, APPL ENVIRON MICROB, V61, P3499, DOI 10.1128/AEM.61.9.3499-3502.1995; Zaborina O, 1998, J BACTERIOL, V180, P4667, DOI 10.1128/JB.180.17.4667-4675.1998	35	77	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6696	6700		10.1074/jbc.M312072200	http://dx.doi.org/10.1074/jbc.M312072200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662756	hybrid			2022-12-27	WOS:000188969200061
J	Yamasaki, M; Masgrau, R; Morgan, AJ; Churchill, GC; Patel, S; Ashcroft, SJH; Galione, A				Yamasaki, M; Masgrau, R; Morgan, AJ; Churchill, GC; Patel, S; Ashcroft, SJH; Galione, A			Organelle selection determines agonist-specific Ca2+ signals in pancreatic acinar and beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC ADP-RIBOSE; ENDOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE; CALCIUM; NAADP; RELEASE; GLUCOSE; STORES; PATHWAYS	How different extracellular stimuli can evoke different spatiotemporal Ca2+ signals is uncertain. We have elucidated a novel paradigm whereby different agonists use different Ca2+-storing organelles ("organelle seleetion") to evoke unique responses. Some agonists select the endoplasmic reticulum (ER), and others select lysosome-related (acidic) organelles, evoking spatial Ca2+ responses that mirror the organellar distribution. In pancreatic acinar cells, acetylcholine and bombesin exclusively select the ER Ca2+ store, whereas cholecystokinin additionally recruits a lysosome-related organelle. Similarly, in a pancreatic beta cell line MIN6, acetylcholine selects only the ER, whereas glucose mobilizes Ca2+ from a lysosome-related organelle. We also show that the key to organelle selection is the agonist-specific coupling messenger(s) such that the ER is selected by recruitment of inositol 1,4,5-trisphosphate (or cADP-ribose), whereas lysosome-related organelles are selected by NAADP.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; UCL, Dept Physiol, London WC1E 6BT, England; Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England	University of Oxford; University of London; University College London; University of Oxford	Masgrau, R (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	roser.masgrau-juanola@pharmacology.oxford.ac.uk	Masgrau, Roser/D-3047-2011; Galione, Antony/E-5884-2011; Patel, Sandip/O-9591-2015	Masgrau, Roser/0000-0002-6722-5939; Galione, Antony/0000-0002-4132-7646; Patel, Sandip/0000-0001-7247-2013				Aizawa T, 1998, TRENDS PHARMACOL SCI, V19, P496, DOI 10.1016/S0165-6147(98)01273-5; Arredouani A, 2002, AM J PHYSIOL-ENDOC M, V282, pE982, DOI 10.1152/ajpendo.00347.2001; Ashcroft SJH, 2000, J MEMBRANE BIOL, V176, P187, DOI 10.1007/s002320001095; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Burdakov D, 2000, CURR BIOL, V10, P993, DOI 10.1016/S0960-9822(00)00649-7; Burdakov D, 2001, CELL CALCIUM, V29, P211, DOI 10.1054/ceca.2000.0188; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Christensen KA, 2002, J CELL SCI, V115, P599; Churchill GC, 2000, J BIOL CHEM, V275, P38687, DOI 10.1074/jbc.M005827200; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; DAWSON CM, 1984, Q J EXP PHYSIOL CMS, V69, P819, DOI 10.1113/expphysiol.1984.sp002871; Fogarty KE, 2000, J BIOL CHEM, V275, P22487, DOI 10.1074/jbc.M909402199; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Gerasimenko OV, 2002, CELL CALCIUM, V32, P261, DOI 10.1016/S0143416002001938; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; JADOT M, 1984, BIOCHEM J, V219, P965, DOI 10.1042/bj2190965; Krause E, 2002, J BIOL CHEM, V277, P11696, DOI 10.1074/jbc.M107794200; Larbaud D, 2001, CLIN SCI, V101, P551, DOI 10.1042/CS20010042; Lee HC, 2003, CURR BIOL, V13, pR186, DOI 10.1016/S0960-9822(03)00120-9; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; Martin F, 1997, BIOCHEM BIOPH RES CO, V235, P465, DOI 10.1006/bbrc.1997.6804; Masgrau R, 2003, CURR BIOL, V13, P247, DOI 10.1016/S0960-9822(03)00041-1; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; Renstrom E, 2002, J BIOL CHEM, V277, P26717, DOI 10.1074/jbc.C200314200; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; Sorensen CE, 2001, J BIOL CHEM, V276, P32925, DOI 10.1074/jbc.M103313200; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; Titievsky AV, 1996, PFLUG ARCH EUR J PHY, V432, P938, DOI 10.1007/s004240050218; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5	42	170	174	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7234	7240		10.1074/jbc.M311088200	http://dx.doi.org/10.1074/jbc.M311088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660554	hybrid			2022-12-27	WOS:000188969200124
J	Yoneda, K; Furukawa, T; Zheng, Y; Momoi, T; Izawa, I; Inagaki, M; Manabe, M; Inagaki, N				Yoneda, K; Furukawa, T; Zheng, Y; Momoi, T; Izawa, I; Inagaki, M; Manabe, M; Inagaki, N			An autocrine/paracrine loop linking keratin 14 aggregates to tumor necrosis factor alpha-mediated cytotoxicity in a keratinocyte model of epidermolysis bullosa simplex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; INTERLEUKIN-1-BETA-CONVERTING ENZYME; INTERMEDIATE-FILAMENTS; CYSTEINE PROTEASES; SIGNALING PATHWAY; CELL-DEATH; APOPTOSIS; RECEPTOR; DISEASE	Epidermolysis bullosa simplex (EBS) is a blistering cutaneous disease featuring protein aggregates. Here we investigate the molecular mechanisms linking protein aggregates to cell death in a cellular model of EBS in which HaCaT keratinocytes are transfected with plasmids expressing various mutant forms of keratin 14 (K14). In HaCaT cells, mutant K14 was found to form ubiquitinated protein aggregates that suppressed 20 S proteasome function instead of being degraded by 20 S proteasome. Keratinocytes with mutant K14-induced phosphorylation of the stress-activated kinase c-Jun, as well as up-regulation of unfolding protein Bip, indicates induction of endoplasmic reticulum stress. HaCaT cells were susceptible to apoptosis by activation of caspases-3, and -8, but not caspase-9 or -12. Tumor necrosis factor-alpha (TNFalpha) in the culture medium was increased in keratinocytes with mutant K14 compared with wild K14, and the addition of neutralizing anti-TNFalpha antibody to the culture medium rescued keratinocytes from cell death. Thus, TNFalpha release and the subsequent activation of the TNFalpha receptor by an autocrine/paracrine pathway links protein aggregates to cell death in this keratinocyte EBS cellular model. Furthermore, mutation in K14 reduced its affinity to TNFalpha receptor-associated death domain (TRADD), suggesting that the susceptibility of keratinocytes to caspase-8-mediated apoptosis is increased in mutated K14 because of impairment of the cytoprotective mechanism mediated by K14-TRADD interaction.	Akita Univ, Sch Med, Dept Dermatol, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan; Natl Inst Neurosci, NCNP, Div Dev Differentiat, Tokyo 1878502, Japan; Aichi Canc Ctr, Res Inst, Div Biochem, Aichi 4648681, Japan; Japan Sci & Technol Corp, CREST, Akita 0108543, Japan	Akita University; Akita University; National Center for Neurology & Psychiatry - Japan; Aichi Cancer Center; Japan Science & Technology Agency (JST)	Yoneda, K (corresponding author), Akita Univ, Sch Med, Dept Dermatol, 1-1-1 Hondo, Akita 0108543, Japan.	kyoneda@doc.med.akita-u.ac.jp	Inagaki, Masaki/B-9920-2016; furukawa, tetsushi/ABD-3178-2020	Inagaki, Nobuya/0000-0001-8261-2593				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Arin MJ, 2001, TRENDS MOL MED, V7, P422, DOI 10.1016/S1471-4914(01)02095-0; Ban N, 2002, DIABETES, V51, P1409, DOI 10.2337/diabetes.51.5.1409; Barker V, 2001, NAT NEUROSCI, V4, P1194, DOI 10.1038/nn755; Beaulieu JM, 2003, J NEUROCHEM, V85, P248, DOI 10.1046/j.1471-4159.2003.01653.x; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; CEICHANOVER A, 1994, CELL, V79, P13; Chan YM, 1996, J INVEST DERMATOL, V106, P327, DOI 10.1111/1523-1747.ep12342985; COCKAYNE EA, 1938, BRIT J DERMATOL, V55, P358; Corden L D, 1996, Exp Dermatol, V5, P297, DOI 10.1111/j.1600-0625.1996.tb00133.x; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Faucheu C, 1996, EUR J BIOCHEM, V236, P207, DOI 10.1111/j.1432-1033.1996.t01-1-00207.x; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Furukawa T, 2001, J MOL BIOL, V313, P775, DOI 10.1006/jmbi.2001.5053; Gamady A, 2003, J CELL BIOCHEM, V89, P440, DOI 10.1002/jcb.10508; Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; ISHIDAYAMAMOTO A, 1991, J INVEST DERMATOL, V97, P959, DOI 10.1111/1523-1747.ep12491885; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Koizumi H, 2001, ARCH DERMATOL RES, V293, P325, DOI 10.1007/s004030100237; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Ku NO, 2000, J CELL BIOL, V149, P547, DOI 10.1083/jcb.149.3.547; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; LIN AN, 1993, ANNU REV MED, V44, P189, DOI 10.1146/annurev.med.44.1.189; LOWTHERT LA, 1995, BIOCHEM BIOPH RES CO, V206, P370, DOI 10.1006/bbrc.1995.1051; Mattson MP, 1998, J NEUROCHEM, V70, P1; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; PETERS JM, 1998, UBIQUITIN BIOL CELL; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Vidair CA, 1996, INT J HYPERTHER, V12, P681, DOI 10.3109/02656739609027676; Walczak H, 2001, TRENDS BIOCHEM SCI, V26, P452, DOI 10.1016/S0968-0004(01)01895-3; Warne JP, 2003, J ENDOCRINOL, V177, P351, DOI 10.1677/joe.0.1770351; Yamada H, 2001, J BIOL CHEM, V276, P19052, DOI 10.1074/jbc.M100615200; Yarosh D, 2000, PHOTODERMATOL PHOTO, V16, P263, DOI 10.1034/j.1600-0781.2000.160606.x; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YONEDA K, 1990, J INVEST DERMATOL, V94, P724, DOI 10.1111/1523-1747.ep12876298; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754; Zheng YJ, 2002, J BIOL CHEM, V277, P32268, DOI 10.1074/jbc.M202105200	61	65	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7296	7303		10.1074/jbc.M307242200	http://dx.doi.org/10.1074/jbc.M307242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660619	hybrid			2022-12-27	WOS:000188969200131
J	Go, YM; Gipp, JJ; Mulcahy, RT; Jones, DP				Go, YM; Gipp, JJ; Mulcahy, RT; Jones, DP			H2O2-dependent activation of GCLC-ARE4 reporter occurs by mitogen-activated protein kinase pathways without oxidation of cellular glutathione or thioredoxin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NAPHTHOFLAVONE-INDUCED EXPRESSION; EPIDERMAL-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; HEAVY SUBUNIT GENE; HYDROGEN-PEROXIDE; C-JUN; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS	The gp91(phox) homologue Nox1 produces H2O2, which induces cell growth, transformation, and tumorigenicity. However, it has not been clear whether H2O2 effects are mediated indirectly via a generally oxidizing cellular environment or whether H2O2 more directly targets specific signaling pathways. Here, we investigated signaling by H2O2 induced by Nox1 overexpression using a luciferase reporter regulated by the antioxidant response element ARE4. Surprisingly, Nox1-derived H2O2 activated the reporter gene 15-fold with no effect on the redox state of the major thiol antioxidant substances, glutathione and thioredoxin. H2O2 signaling to ARE4 was mediated by activation of both the c-Jun N-terminal kinase and ERK1/2 pathways modulated by Ras. Thus, "redox signaling" resulting in kinase signaling pathways is distinct from "oxidative stress," and is mediated by discrete, localized redox circuitry.	Emory Univ, Rollins Res Ctr 4131, Dept Med, Sch Med,Div Cardiol, Atlanta, GA 30322 USA; Emory Univ, Ctr Clin & Mol Nutr, Atlanta, GA 30322 USA; Univ Wisconsin, Sch Med, Dept Surg, Madison, WI 53792 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53792 USA	Emory University; Emory University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jones, DP (corresponding author), Emory Univ, Rollins Res Ctr 4131, Dept Med, Sch Med,Div Cardiol, Atlanta, GA 30322 USA.	dpjones@emory.edu			NIEHS NIH HHS [ES011195] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011195] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bladier C, 1997, CELL GROWTH DIFFER, V8, P589; Cai JY, 2000, FREE RADICAL BIO MED, V29, P334, DOI 10.1016/S0891-5849(00)00312-9; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Das KC, 2001, J BIOL CHEM, V276, P4662, DOI 10.1074/jbc.M006206200; De Keulenaer GW, 2000, ARTERIOSCL THROM VAS, V20, P385, DOI 10.1161/01.ATV.20.2.385; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; Fiaschi T, 2001, J BIOL CHEM, V276, P49156, DOI 10.1074/jbc.M107538200; Griendling KK, 1997, CIRCULATION, V96, P3264; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Ramachandran A, 2002, BIOL CHEM, V383, P693, DOI 10.1515/BC.2002.071; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sekhar KR, 2002, FREE RADICAL BIO MED, V32, P650, DOI 10.1016/S0891-5849(02)00755-4; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Wallace DC, 1998, NAT GENET, V19, P105, DOI 10.1038/448; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Watson WH, 2003, J BIOL CHEM, V278, P33408, DOI 10.1074/jbc.M211107200; Watson WH, 2003, FEBS LETT, V543, P144, DOI 10.1016/S0014-5793(03)00430-7; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; Yoshizumi Masanori, 2001, Journal of Medical Investigation, V48, P11	50	76	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5837	5845		10.1074/jbc.M307547200	http://dx.doi.org/10.1074/jbc.M307547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638694	hybrid			2022-12-27	WOS:000188776500098
J	Li, ZQ; Yasuda, Y; Li, WJ; Bogyo, M; Katz, N; Gordon, RE; Fields, GB; Bromme, D				Li, ZQ; Yasuda, Y; Li, WJ; Bogyo, M; Katz, N; Gordon, RE; Fields, GB; Bromme, D			Regulation of collagenase activities of human cathepsins by glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE TYPE-I; COLLAGENOLYTIC CATHEPSIN; MATRIX METALLOPROTEINASES; FUNCTIONAL EXPRESSION; CYSTEINE PROTEINASES; MOLECULAR-CLONING; PROTEASE; CARTILAGE; INHIBITORS; ATHEROSCLEROSIS	Cathepsin K, a lysosomal papain- like cysteine protease, forms collagenolytically highly active complexes with chondroitin sulfate and represents the most potent mammalian collagenase. Here we demonstrate that complex formation with glycosaminoglycans ( GAGs) is unique for cathepsin K among human papain- like cysteine proteases and that different GAGs compete for the binding to cathepsin K. GAGs predominantly expressed in bone and cartilage, such as chondroitin and keratan sulfates, enhance the collagenolytic activity of cathepsin K, whereas dermatan, heparan sulfate, and heparin selectively inhibit this activity. Moreover, GAGs potently inhibit the collagenase activity of other cysteine proteases such as cathepsins L and S at 37 degrees C. Along this line MMP1- generated collagen fragments in the presence of GAGs are stable against further degradation at 28 degrees C by all cathepsins but cathepsin K, whereas thermal destabilization at 37 degrees C renders the fragments accessible to all cathepsins. These results suggest a novel mechanism for the regulation of matrix protein degradation by GAGs. It further implies that cathepsin K represents the only lysosomal collagenolytic activity under physiologically relevant conditions.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; Stanford Univ, Stanford, CA 94305 USA; Florida Atlantic Univ, Boca Raton, FL 33431 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Stanford University; State University System of Florida; Florida Atlantic University	Bromme, D (corresponding author), Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave & 100th St, New York, NY 10029 USA.	dieter.bromme@mssm.edu		Bogyo, Matthew/0000-0003-3753-4412	NCI NIH HHS [CA77402, CA98799] Funding Source: Medline; NIAMS NIH HHS [AR 48669, AR46182] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077402, R01CA098799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046182, R01AR048669] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Almeida PC, 2001, J BIOL CHEM, V276, P944, DOI 10.1074/jbc.M003820200; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Benjamin IJ, 2001, J INVEST MED, V49, P381, DOI 10.2310/6650.2001.33783; Bilato C, 1996, AGING CLIN EXP RES, V8, P221; Bromme D, 1996, PROTEIN SCI, V5, P789; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; BURLEIGH MC, 1974, BIOCHEM J, V137, P387, DOI 10.1042/bj1370387; Buttle DJ, 1994, IMMUNOPHARMACOLOGY J, P225; Davies JA, 2001, BIOCHEM SOC T, V29, P166, DOI 10.1042/BST0290166; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; ETHERINGTON DJ, 1977, ACTA BIOL MED GER, V36, P1555; EVANS P, 1978, EUR J BIOCHEM, V83, P87, DOI 10.1111/j.1432-1033.1978.tb12071.x; EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674; Everts V, 1996, HISTOCHEM J, V28, P229, DOI 10.1007/BF02409011; Everts V, 2003, CALCIFIED TISSUE INT, V73, P380, DOI 10.1007/s00223-002-2092-4; EVERTS V, 1985, COLLAGEN REL RES, V5, P315; Firestein GS, 1996, ARTHRITIS RHEUM, V39, P1781, DOI 10.1002/art.1780391103; FIRSCHEIN HE, 1966, ANAL BIOCHEM, V14, P296, DOI 10.1016/0003-2697(66)90140-0; Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Hou WS, 2003, BIOL CHEM, V384, P891, DOI 10.1515/BC.2003.100; Hou WS, 2002, ARTHRITIS RHEUM, V46, P663, DOI 10.1002/art.10114; Hou WS, 2001, AM J PATHOL, V159, P2167, DOI 10.1016/S0002-9440(10)63068-4; Kafienah W, 1998, BIOCHEM J, V330, P897, DOI 10.1042/bj3300897; Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; KomsaPenkova R, 1996, BBA-PROTEIN STRUCT M, V1297, P171, DOI 10.1016/S0167-4838(96)00092-1; Konttinen YT, 2002, ARTHRITIS RHEUM, V46, P953, DOI 10.1002/art.10185; Lauer-Fields JL, 2002, BIOPOLYMERS, V66, P19, DOI 10.1002/bip.10201; Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656; Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200; Li ZQ, 2000, BIOCHEMISTRY-US, V39, P529, DOI 10.1021/bi992251u; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; Ortega N, 2003, ANN NY ACAD SCI, V995, P109, DOI 10.1111/j.1749-6632.2003.tb03214.x; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Sames K, 1994, EXS, V70, P243; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Wang B, 1998, J BIOL CHEM, V273, P32000, DOI 10.1074/jbc.273.48.32000; YAMAMOTO H, 1992, RES COMMUN CHEM PATH, V76, P95; Yamashita DS, 2000, CURR PHARM DESIGN, V6, P1, DOI 10.2174/1381612003401569	50	177	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5470	5479		10.1074/jbc.M310349200	http://dx.doi.org/10.1074/jbc.M310349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645229	hybrid			2022-12-27	WOS:000188776500054
J	Tahara, T; Sun, JY; Nakanishi, K; Yamamoto, M; Mori, H; Saito, T; Fujita, H; Igarashi, K; Taketani, S				Tahara, T; Sun, JY; Nakanishi, K; Yamamoto, M; Mori, H; Saito, T; Fujita, H; Igarashi, K; Taketani, S			Heme positively regulates the expression of beta-globin at the locus control region via the transcriptional factor Bach1 in erythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEND-ERYTHROLEUKEMIA CELLS; GENE-EXPRESSION; MESSENGER-RNA; MOLECULAR CHARACTERIZATION; TRANSLATIONAL REGULATION; SMALL MAF; DIFFERENTIATION; BINDING; NF-E2; HEMOGLOBIN	The transcription factor Bach1 heterodimerizes with small Maf proteins to repress Maf recognition element ( MARE)- dependent gene expression. The repressor activity of Bach1 is inhibited by the direct binding of heme. To investigate the involvement of Bach1 in the heme- dependent regulation of the expression of the beta- globin gene, mouse erythroleukemia ( MEL) cells were cultured with succinylacetone ( SA), a specific inhibitor of heme biosynthesis, and the level of beta- globin mRNA was examined. A marked decrease of beta- globin mRNA in SA- treated cells was observed, and this decrease was reversed by the addition of hemin. An iron chelator, desferrioxamine, also lowered the level of beta- globin mRNA. The heme- dependent expression of beta- globin is a transcriptional event since the expression of the human beta- globin gene promoter- reporter gene containing the microlocus control region ( mu LCR) was inhibited when human erythroleukemia K562 cells and MEL cells were cultured with SA. Hemin treatment restored the decrease in promoter activity caused by SA. The control of the mu LCR- beta- globin promoter reporter gene by heme was dependent on DNase I- hypersensitive site 2 ( HS2), which contains MARE. The MARE binding activity of Bach1 in K562 and MEL cells increased upon SA treatment, and the increase was diminished by the treatment with hemin. Transient expression of Bach1 suppressed the mu LCR activity, and this repressor activity was cancelled by treatment with hemin. The expression of a mutated Bach1 lacking heme- binding sites led to a loss in the heme responsiveness of the mu LCR. Furthermore, chromatin immunoprecipitation experiments revealed that Bach1 bound to the MARE of HS2 increased by the treatment of MEL cells with SA, and this was cancelled by hemin. We propose that heme positively regulates the beta- globin gene expression by blocking the interaction of Bach1 with the MARE in the LCR.	Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Med Chem, Hiroshima 7348551, Japan; Hokkaido Univ, Sch Med, Dept Environm Biol, Sapporo, Hokkaido 0608638, Japan	Kyoto Institute of Technology; Hiroshima University; Hokkaido University	Taketani, S (corresponding author), Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan.	taketani@ipc.kit.ac.jp	Tahara, Tsuyoshi/E-4024-2010; Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Igarashi, Kazuhiko/0000-0002-2470-2475; Mori, Hajime/0000-0001-9219-6140				BATTISTINI A, 1991, BLOOD, V78, P2098, DOI 10.1182/blood.V78.8.2098.bloodjournal7882098; BATTISTINI A, 1991, J BIOL CHEM, V266, P528; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Blank V, 1997, GENOMICS, V44, P147, DOI 10.1006/geno.1997.4847; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; COCCIA EM, 1992, MOL CELL BIOL, V12, P3015, DOI 10.1128/MCB.12.7.3015; Courey AJ, 2001, GENE DEV, V15, P2786; Crosby JS, 2000, BLOOD, V96, P3241; Ellis J, 1997, NUCLEIC ACIDS RES, V25, P1296, DOI 10.1093/nar/25.6.1296; Ellis J, 1996, EMBO J, V15, P562, DOI 10.1002/j.1460-2075.1996.tb00388.x; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FIBACH E, 1995, BLOOD, V85, P2967, DOI 10.1182/blood.V85.10.2967.bloodjournal85102967; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FUJITA H, 1991, J BIOL CHEM, V266, P17494; FUKUDA Y, 1994, BLOOD, V83, P1662; FUKUDA Y, 1993, BRIT J HAEMATOL, V85, P670, DOI 10.1111/j.1365-2141.1993.tb03207.x; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MEGURO K, 1995, BLOOD, V86, P940; Mizutani A, 2002, J BIOL CHEM, V277, P15851, DOI 10.1074/jbc.M111431200; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Sassa S, 1996, INT J HEMATOL, V63, P167; Sawado T, 2001, P NATL ACAD SCI USA, V98, P10226, DOI 10.1073/pnas.181344198; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6417; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; STAMATOYANNOPOU.G, 1993, MOL BASIS HUMAN DIS, P106; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Suzuki T, 2000, BIOCHEM PHARMACOL, V60, P275, DOI 10.1016/S0006-2952(00)00324-5; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	40	103	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5480	5487		10.1074/jbc.M302733200	http://dx.doi.org/10.1074/jbc.M302733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660636	hybrid			2022-12-27	WOS:000188776500055
J	Chu, JL; Bresnick, EH				Chu, JL; Bresnick, EH			Evidence that C promoter-binding factor 1 binding is required for Notch-1-mediated repression of activator protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED PROTEOLYSIS; TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; NEOPLASTIC TRANSFORMATION; INTRACELLULAR DOMAIN; GENE-EXPRESSION; ANKYRIN REPEAT; NOTCH; LIGAND; SUPPRESSOR	Cell fate determination in invertebrate and vertebrate systems is regulated by the Notch signaling pathway. Four mammalian Notch genes, Notch 1-4, encode differentially expressed transmembrane receptors. The canonical Notch pathway involves proteolytic liberation of the Notch-1 intracellular domain (NIC-1), which activates CSL ((C) under bar BF1, (S) under baru(H), and (L) under bar ag-1)-mediated transactivation. We showed previously that NIC-1 also represses activator protein-1 (AP-1)-mediated transactivation. The N-terminal RAM (RBP-Jkappa associated molecule) domain of NIC-1 was required for both activation and repression. To investigate the mechanism of AP-1 repression, we tested whether distinct sequences within the RAM domain mediate activation versus repression. We analyzed the capacity of RAM domain mutants to bind endogenous CBF1, to activate CSL-mediated transactivation, and to repress AP-1. A mutant lacking 20 amino acids of the RAM domain (Delta1759-1778) resembled the RAM domain deletion mutant in being defective in all activities. Analysis of 14 deletion and alanine substitution mutants revealed a correlation between CBF1 binding, CSL-mediated transactivation, and AP-1 repression. Stably transfected K562 cells could only tolerate very low level expression of wild-type NIC-1 and NIC-1 mutants retaining activation/repression activities. By contrast, transcriptionally compromised NIC-1 mutants accumulated at high levels. These results support a model in which the binding of NIC-1 to CBF1 is required for AP-1 repression and reveal a powerful cell-sensing mechanism that suppresses the levels of transcriptionally competent NIC-1.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 383 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	ehbresni@wisc.edu						Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; Cornell M, 1999, GENETICS, V152, P567; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Fowlkes BJ, 2002, J IMMUNOL, V169, P1817, DOI 10.4049/jimmunol.169.4.1817; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Johansen LM, 2003, J VIROL, V77, P6029, DOI 10.1128/JVI.77.10.6029-6040.2003; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Krebs LT, 2000, GENE DEV, V14, P1343; Kumano K, 2003, IMMUNITY, V18, P699, DOI 10.1016/S1074-7613(03)00117-1; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lam LT, 1998, J BIOL CHEM, V273, P24223, DOI 10.1074/jbc.273.37.24223; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Mazaleyrat SL, 2003, DEV BIOL, V255, P363, DOI 10.1016/S0012-1606(02)00086-6; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Schreiber M, 2000, DEVELOPMENT, V127, P4937; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shutter JR, 2000, GENE DEV, V14, P1313; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; Wolfer A, 2002, IMMUNITY, V16, P869, DOI 10.1016/S1074-7613(02)00330-8; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	55	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12337	12345		10.1074/jbc.M311510200	http://dx.doi.org/10.1074/jbc.M311510200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14645224	hybrid			2022-12-27	WOS:000220334900041
J	Koedding, J; Howard, P; Kaufmann, L; Polzer, P; Lustig, A; Welte, W				Koedding, J; Howard, P; Kaufmann, L; Polzer, P; Lustig, A; Welte, W			Dimerization of TonB is not essential for its binding to the outer membrane siderophore receptor FhuA of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRICHROME-IRON RECEPTOR; C-TERMINAL DOMAIN; IN-VIVO EVIDENCE; CRYSTAL-STRUCTURE; EVOLUTIONARY RELATIONSHIP; NUCLEOTIDE-SEQUENCE; PERIPLASMIC DOMAIN; PROTEIN; TRANSPORT; FEPA	FhuA belongs to a family of specific siderophore transport systems located in the outer membrane of Escherichia coli. The energy required for the transport process is provided by the proton motive force of the cytoplasmic membrane and is transmitted to FhuA by the protein TonB. Although the structure of full-length TonB is not known, the structure of the last 77 residues of a fragment composed of the 86 C-terminal amino acids was recently solved and shows an intertwined dimer (Chang, C., Mooser, A., Pluckthun, A., and Wlodawer, A. (2001) J. Biol. Chem. 276, 27535-27540). We analyzed the ability of truncated C-terminal TonB fragments of different lengths ( 77, 86, 96, 106, 116, and 126 amino acid residues, respectively) to bind to the receptor FhuA. Only the shortest TonB fragment, TonB-77, could not effectively interact with FhuA. We have also observed that the fragments TonB-77 and TonB-86 form homodimers in solution, whereas the longer fragments remain monomeric. TonB fragments that bind to FhuA in vitro also inhibit ferrichrome uptake via FhuA in vivo and protect cells against attack by bacteriophage Phi80.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany; Univ Saskatchewan, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada; Biozentrum Basel, CH-4056 Basel, Switzerland	University of Konstanz; University of Saskatchewan	Welte, W (corresponding author), Univ Konstanz, Fak Biol, Univ Str 10, D-78457 Constance, Germany.	wolfram.welte@uni-konstanz.de						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bonhivers M, 2001, BIOCHEMISTRY-US, V40, P2606, DOI 10.1021/bi001725i; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; Braun M, 1999, MOL MICROBIOL, V33, P1037, DOI 10.1046/j.1365-2958.1999.01546.x; BRAUN V, 1993, MOL MICROBIOL, V8, P261, DOI 10.1111/j.1365-2958.1993.tb01570.x; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Chang CS, 2001, J BIOL CHEM, V276, P27535, DOI 10.1074/jbc.M102778200; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; Edelstein S J, 1973, Methods Enzymol, V27, P82; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; Ferguson AD, 1998, PROTEIN SCI, V7, P1636, DOI 10.1002/pro.5560070719; Ferguson AD, 2002, BBA-BIOMEMBRANES, V1565, P318, DOI 10.1016/S0005-2736(02)00578-3; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2001, STRUCTURE, V9, P707, DOI 10.1016/S0969-2126(01)00631-1; Ferguson AD, 2000, PROTEIN SCI, V9, P956, DOI 10.1110/ps.9.5.956; GUNTER K, 1990, FEBS LETT, V274, P85, DOI 10.1016/0014-5793(90)81335-L; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANTKE K, 1978, J BACTERIOL, V135, P190, DOI 10.1128/JB.135.1.190-197.1978; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; Howard SP, 2001, J BACTERIOL, V183, P5885, DOI 10.1128/JB.183.20.5885-5895.2001; INGHAM C, 1990, J BACTERIOL, V172, P3577, DOI 10.1128/jb.172.7.3577-3583.1990; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Killmann H, 2002, MICROBIOL-SGM, V148, P3497, DOI 10.1099/00221287-148-11-3497; Killmann H, 2001, J BACTERIOL, V183, P3476, DOI 10.1128/JB.183.11.3476-3487.2001; LARSEN RA, 1994, MOL MICROBIOL, V12, P857; Larsen RA, 1997, J BACTERIOL, V179, P3213, DOI 10.1128/jb.179.10.3213-3221.1997; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Larsen RA, 2001, J BIOL CHEM, V276, P8111, DOI 10.1074/jbc.M007479200; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Lubkowski J, 1999, STRUCTURE, V7, P711, DOI 10.1016/S0969-2126(99)80092-6; LUNDRIGAN MD, 1986, J BIOL CHEM, V261, P797; MOECK GS, 1994, J BACTERIOL, V176, P4250, DOI 10.1128/jb.176.14.4250-4259.1994; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; POSTLE K, 1988, J BIOL CHEM, V263, P11000; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; PRESSLER U, 1988, J BACTERIOL, V170, P2716, DOI 10.1128/jb.170.6.2716-2724.1988; Sauter A, 2003, J BACTERIOL, V185, P5747, DOI 10.1128/JB.185.19.5747-5754.2003; Scott DC, 2001, J BIOL CHEM, V276, P13025, DOI 10.1074/jbc.M011282200; Usher KC, 2001, P NATL ACAD SCI USA, V98, P10676, DOI 10.1073/pnas.181353398; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vakharia HL, 2002, J BACTERIOL, V184, P5508, DOI 10.1128/JB.184.19.5508-5512.2002; Witty M, 2002, EMBO J, V21, P4207, DOI 10.1093/emboj/cdf417	51	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9978	9986		10.1074/jbc.M311720200	http://dx.doi.org/10.1074/jbc.M311720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14665631	hybrid			2022-12-27	WOS:000220050400041
J	Wang, FS; Wang, CJ; Chen, YJ; Chang, PR; Huang, YT; Sun, YC; Huang, HC; Yang, YJ; Yang, KD				Wang, FS; Wang, CJ; Chen, YJ; Chang, PR; Huang, YT; Sun, YC; Huang, HC; Yang, YJ; Yang, KD			Ras induction of superoxide activates ERK-dependent angiogenic transcription factor HIF-1 alpha and VEGF-A expression in shock wave-stimulated osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BONE MORPHOGENETIC PROTEINS; GENE-EXPRESSION; FACTOR 1-ALPHA; IN-VITRO; PATHWAY; CELLS; HYPERPOLARIZATION; DIFFERENTIATION	Vascular endothelial growth factor (VEGF) released by osteoblasts plays an important role in angiogenesis and endochondral ossification during bone formation. In animal studies, we have reported that shock waves (SW) can promote osteogenic differentiation of mesenchymal stem cells through superoxide-mediated signal transduction (Wang, F. S., Wang, C. J., Sheen-Chen, S. M., Kuo, Y. R., Chen, R. F., and Yang, K. D. (2002) J. Biol. Chem. 277, 10931-10937) and vascularization of the bone-tendon junction. Here, we found that SW elevation of VEGF-A expression in human osteoblasts to be mediated by Ras-induced superoxide and ERK-dependent HIF-1alpha activation. SW treatment (0.16 mJ/mm(2), 1 Hz, 500 impulses) rapidly activated Ras protein (15 min) and Rac1 protein ( 30 min) and increased superoxide production in 30 min and VEGF mRNA expression in 6 h. Early scavenging of superoxide, but not nitric oxide, peroxide hydrogen, or prostaglandin E-2, reduced SW-augmented VEGF-A levels. Inhibition of superoxide production by diphenyliodonium, an NADPH oxidase inhibitor, was found to suppress VEGF-A expression. Transfection of osteoblasts with a dominant negative (S17N) Ras mutant abrogated the SW enhancement of Rac1 activation, superoxide synthesis, and VEGF expression. Further studies demonstrated that SW significantly promoted ERK activation in 1 h and HIF-1alpha phosphorylation and HIF-1alpha binding to VEGF promoter in 3 h. In support of the observation that superoxide mediated the SW-induced ERK activation and HIF-1alpha transactivation, we further demonstrated that scavenging of superoxide by superoxide dismutase and inhibition of ERK activity by PD98059 decreased HIF-1alpha activation and VEGF-A levels. Moreover, culture medium harvested from SW-treated osteoblasts increased vessel number of chick chorioallantoic membrane. Superoxide dismutase pretreatment and anti-VEGF-A antibody neutralization reduced the promoting effect of conditioned medium on angiogenesis. Thus, modulation of redox reaction by SW may have some positive effect on angiogenesis during bone regeneration.	Chang Gung Mem Hosp, Dept Med Res, Kaohsiung 833, Taiwan; Chang Gung Mem Hosp, Dept Orthoped Surg, Kaohsiung, Taiwan; Chang Gung Univ, Dept Orthoped Surg, Linkou 244, Taiwan; Fooyin Univ, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Fooyin University	Yang, KD (corresponding author), Chang Gung Mem Hosp, Dept Med Res, 123 Ta Pei Rd, Kaohsiung 833, Taiwan.	wangfs@ms33.hinet.net						ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AROSON J, 1997, J ORTHOP RES, V15, P221; Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671; Bellahcene A, 2000, CIRC RES, V86, P885, DOI 10.1161/01.RES.86.8.885; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Chua CC, 2000, BBA-MOL CELL RES, V1497, P69, DOI 10.1016/S0167-4889(00)00040-9; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667; Durot I, 2000, FREE RADICAL BIO MED, V29, P846, DOI 10.1016/S0891-5849(00)00382-8; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925-4773(99)00142-2; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Gao N, 2002, J BIOL CHEM, V277, P31963, DOI 10.1074/jbc.M200082200; Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hatton JP, 2003, J BONE MINER RES, V18, P58, DOI 10.1359/jbmr.2003.18.1.58; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; KUROKI M, 1998, J CLIN INVEST, V10, P248; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Loew M, 1999, J BONE JOINT SURG BR, V81B, P863, DOI 10.1302/0301-620X.81B5.9374; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; MAIER M, 2003, CLIN ORTHOP RELAT R, V406, P237; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Mottet D, 1994, J CELL PHYSL, V194, P30; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Rivilis I, 2002, AM J PHYSIOL-HEART C, V283, pH1430, DOI 10.1152/ajpheart.00082.2002; Rompe JD, 2001, CLIN ORTHOP RELAT R, P102, DOI 10.1097/00003086-200106000-00014; Salter DM, 2000, J BONE MINER RES, V15, P1746, DOI 10.1359/jbmr.2000.15.9.1746; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; Suhr D, 1996, ULTRASOUND MED BIOL, V22, P671, DOI 10.1016/0301-5629(96)00044-0; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266; Wang CJ, 2003, J ORTHOP RES, V21, P984, DOI 10.1016/S0736-0266(03)00104-9; WANG CJ, 2001, CLIN ORTHOP RELAT R, V387, P95; Wang FS, 2003, BONE, V32, P387, DOI 10.1016/S8756-3282(03)00029-2; Wang FS, 2002, J BIOL CHEM, V277, P10931, DOI 10.1074/jbc.M104587200; Wang FS, 2001, BIOCHEM BIOPH RES CO, V287, P648, DOI 10.1006/bbrc.2001.5654; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838	45	166	179	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10331	10337		10.1074/jbc.M308013200	http://dx.doi.org/10.1074/jbc.M308013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681237	hybrid			2022-12-27	WOS:000220050400082
J	Hytonen, VP; Nyholm, TKM; Pentikainen, OT; Vaarno, J; Porkka, EJ; Nordlund, HR; Johnson, MS; Slotte, JP; Laitinen, OH; Kulomaa, MS				Hytonen, VP; Nyholm, TKM; Pentikainen, OT; Vaarno, J; Porkka, EJ; Nordlund, HR; Johnson, MS; Slotte, JP; Laitinen, OH; Kulomaa, MS			Chicken avidin-related protein 4/5 shows superior thermal stability when compared with avidin while retaining high affinity to biotin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED THERMOSTABILITY; MONOMERIC STREPTAVIDIN; CRYSTAL-STRUCTURE; GENE FAMILY; BINDING; HEAT; SEQUENCE; PURIFICATION; GLUCOAMYLASE; COMPLEX	The protein chicken avidin is a commonly used tool in various applications. The avidin gene belongs to a gene family that also includes seven other members known as the avidin-related genes (AVR). We report here on the extremely high thermal stability and functional characteristics of avidin-related protein AVR4/5, a member of the avidin protein family. The thermal stability characteristics of AVR4/5 were examined using a differential scanning calorimeter, microparticle analysis, and a microplate assay. Its biotin-binding properties were studied using an isothermal calorimeter and IAsys optical biosensor. According to these analyses, in the absence of biotin AVR4/5 is clearly more stable (T-m = 107.4 +/- 0.3 degreesC) than avidin (T-m = 83.5 +/- 0.1 degreesC) or bacterial streptavidin (T-m = 75.5 degreesC). AVR4/5 also exhibits a high affinity for biotin (K-d approximate to 3.6 x 10(-14) M) comparable to that of avidin and streptavidin (K-d approximate to 10(-15) M). Molecular modeling and site-directed mutagenesis were used to study the molecular details behind the observed high thermostability. The results indicate that AVR4/5 and its mutants have high potential as new improved tools for applications where exceptionally high stability and tight biotin binding are needed.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40014 Jyvaskyla, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland; Arctic Diagnost Oy, FIN-20521 Turku, Finland; Univ Kuopio, Dept Mol Med, AI Virtanen Inst, FIN-70211 Kuopio, Finland	University of Jyvaskyla; Abo Akademi University; Finland National Institute for Health & Welfare; University of Eastern Finland	Kulomaa, MS (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35 YAB, FIN-40014 Jyvaskyla, Finland.	markku.kulomaa@csc.fi	Pentikäinen, Olli T/E-1980-2012; Kulomaa, Markku S/C-9063-2014; Laitinen, Olli H/A-6618-2016; Hytonen, Vesa P./E-8855-2013	Pentikäinen, Olli T/0000-0001-7188-4016; Laitinen, Olli H/0000-0002-3751-9952; Hytonen, Vesa P./0000-0002-9357-1480				Ahlroth MK, 2001, BIOCHEM BIOPH RES CO, V285, P734, DOI 10.1006/bbrc.2001.5163; Ahlroth MK, 2000, ANIM GENET, V31, P367, DOI 10.1046/j.1365-2052.2000.00681.x; Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; CHILKOTI A, 1995, BIO-TECHNOL, V13, P1198, DOI 10.1038/nbt1195-1198; DAVAIL S, 1994, J BIOL CHEM, V269, P17448; DONOVAN JW, 1973, BIOCHEMISTRY-US, V12, P512, DOI 10.1021/bi00727a024; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; Gonzalez M, 1999, BIOMOL ENG, V16, P67, DOI 10.1016/S1050-3862(99)00041-8; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; Hytonen VP, 2003, BIOCHEM J, V372, P219, DOI 10.1042/BJ20021531; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V231, P735, DOI 10.1006/jmbi.1993.1323; Karshikoff A, 2001, TRENDS BIOCHEM SCI, V26, P550, DOI 10.1016/S0968-0004(01)01918-1; KEINANEN RA, 1994, EUR J BIOCHEM, V220, P615, DOI 10.1111/j.1432-1033.1994.tb18663.x; Kumar S, 2000, PROTEIN ENG, V13, P179, DOI 10.1093/protein/13.3.179; Laitinen OH, 2003, J BIOL CHEM, V278, P4010, DOI 10.1074/jbc.M205844200; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Laitinen OH, 2002, BIOCHEM J, V363, P609, DOI 10.1042/0264-6021:3630609; Laitinen OH, 2001, J BIOL CHEM, V276, P8219, DOI 10.1074/jbc.M007930200; Liu HL, 2000, PROTEIN ENG, V13, P655, DOI 10.1093/protein/13.9.655; Liu YF, 1996, BIOCHEMISTRY-US, V35, P3059, DOI 10.1021/bi952198j; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; Nordlund HR, 2003, J BIOL CHEM, V278, P2479, DOI 10.1074/jbc.M210721200; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; Qureshi MH, 2002, PROTEIN EXPRES PURIF, V25, P409, DOI 10.1016/S1046-5928(02)00021-9; Qureshi MH, 2001, J BIOL CHEM, V276, P46422, DOI 10.1074/jbc.M107398200; Reznik GO, 1996, NAT BIOTECHNOL, V14, P1007, DOI 10.1038/nbt0896-1007; Sano T, 1997, P NATL ACAD SCI USA, V94, P6153, DOI 10.1073/pnas.94.12.6153; Shibuya H, 2000, BIOCHEM J, V349, P651, DOI 10.1042/0264-6021:3490651; Soini E, 2000, BIOCHEM SOC T, V28, P70, DOI 10.1042/bst0280070; Stewart RJ, 2001, PROTEIN ENG, V14, P245, DOI 10.1093/protein/14.4.245; SWAMY MJ, 1995, BIOCHEM MOL BIOL INT, V36, P219; Tahirov TH, 1998, J MOL BIOL, V284, P101, DOI 10.1006/jmbi.1998.2146; Thompson MJ, 1999, J MOL BIOL, V290, P595, DOI 10.1006/jmbi.1999.2889; Usher KC, 1998, PROTEIN SCI, V7, P403; Valimaa L, 2003, BIOCONJUGATE CHEM, V14, P103, DOI 10.1021/bc020058y; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704; Wilchek M, 1999, BIOMOL ENG, V16, P1; WILLIAMSON G, 1992, EUR J BIOCHEM, V207, P661, DOI 10.1111/j.1432-1033.1992.tb17093.x	43	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9337	9343		10.1074/jbc.M310989200	http://dx.doi.org/10.1074/jbc.M310989200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660583	hybrid			2022-12-27	WOS:000189265900097
J	Roh, JH; Smith, WE; Kaplan, S				Roh, JH; Smith, WE; Kaplan, S			Effects of oxygen and light intensity on transcriptome expression in Rhodobacter sphaeroides 2.4.1 - Redox active gene expression profile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; COPROPORPHYRINOGEN-III OXIDASE; HISTIDINE KINASE PRRB; PUC OPERON EXPRESSION; CAROTENOID BIOSYNTHESIS; PHOTOSYNTHETIC GROWTH; PHOTOSYSTEM FORMATION; RHODOPSEUDOMONAS-SPHAEROIDES; POSTTRANSCRIPTIONAL CONTROL; SEQUENCE-ANALYSIS	The roles of oxygen and light on the regulation of photosynthesis gene expression in Rhodobacter sphaeroides 2.4.1 have been well studied over the past 50 years. More recently, the effects of oxygen and light on gene regulation have been shown to involve the interacting redox chains present in R. sphaeroides under diverse growth conditions, and many of the redox carriers comprising these chains have been well studied. However, the expression patterns of those genes encoding these redox carriers, under aerobic and anaerobic photosynthetic growth, have been less well studied. Here, we provide a transcriptional analysis of many of the genes comprising the photosynthesis lifestyle, including genes corresponding to many of the known regulatory elements controlling the response of this organism to oxygen and light. The observed patterns of gene expression are evaluated and discussed in light of our knowledge of the physiology of R. sphaeroides under aerobic and photosynthetic growth conditions. Finally, this analysis has enabled to us go beyond the traditional patterns of gene expression associated with the photosynthesis lifestyle and to consider, for the first time, the full complement of genes responding to oxygen, and variations in light intensity when growing photosynthetically. The data provided here should be considered as a first step in enabling one to model electron flow in R. sphaeroides 2.4.1.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Kaplan, S (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, 6431 Fannin St, Houston, TX 77030 USA.	samuel.kaplan@uth.tmc.edu			NIGMS NIH HHS [GM15590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addlesee HA, 2000, J BACTERIOL, V182, P3175, DOI 10.1128/JB.182.11.3175-3182.2000; BOWYER JR, 1985, J BIOL CHEM, V260, P3295; Braatsch S, 2002, MOL MICROBIOL, V45, P827, DOI 10.1046/j.1365-2958.2002.03058.x; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BUGGY JJ, 1994, J BACTERIOL, V176, P6936, DOI 10.1128/JB.176.22.6936-6943.1994; CAO J, 1992, J BIOL CHEM, V267, P24273; CHORY J, 1983, J BACTERIOL, V153, P465, DOI 10.1128/JB.153.1.465-474.1983; Choudhary M, 2000, NUCLEIC ACIDS RES, V28, P862, DOI 10.1093/nar/28.4.862; COOMBER SA, 1992, MOL MICROBIOL, V6, P3159, DOI 10.1111/j.1365-2958.1992.tb01772.x; Daldal F, 2001, J BACTERIOL, V183, P2013, DOI 10.1128/JB.183.6.2013-2024.2001; DONOHUE TJ, 1986, J BACTERIOL, V168, P962, DOI 10.1128/jb.168.2.962-972.1986; DONOHUE TJ, 1986, J BACTERIOL, V168, P953, DOI 10.1128/jb.168.2.953-961.1986; DONOHUE TJ, 1988, BIOCHEMISTRY-US, V27, P1918, DOI 10.1021/bi00406a018; Eraso JM, 1996, J BACTERIOL, V178, P7037, DOI 10.1128/jb.178.24.7037-7046.1996; Eraso JM, 2000, BIOCHEMISTRY-US, V39, P2052, DOI 10.1021/bi9923858; ERASO JM, 1995, J BACTERIOL, V177, P2695, DOI 10.1128/jb.177.10.2695-2706.1995; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; Ermolenko DN, 2002, CELL MOL LIFE SCI, V59, P1902, DOI 10.1007/PL00012513; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; Gibson JL, 2002, J BACTERIOL, V184, P6654, DOI 10.1128/JB.184.23.6654-6664.2002; GIBSON LCD, 1992, MOL MICROBIOL, V6, P3171, DOI 10.1111/j.1365-2958.1992.tb01773.x; Gomelsky L, 2003, MICROBIOL-SGM, V149, P377, DOI 10.1099/mic.0.25972-0; GOMELSKY M, 1995, MICROBIOL-UK, V141, P1805, DOI 10.1099/13500872-141-8-1805; GOMELSKY M, 1995, J BACTERIOL, V177, P4609, DOI 10.1128/jb.177.16.4609-4618.1995; Gomelsky M, 1998, J BIOL CHEM, V273, P35319, DOI 10.1074/jbc.273.52.35319; GOMELSKY M, 1995, J BACTERIOL, V177, P1634, DOI 10.1128/jb.177.6.1634-1637.1995; Gomelsky M, 2000, J BACTERIOL, V182, P2253, DOI 10.1128/JB.182.8.2253-2261.2000; Gualerzi CO, 2003, J MOL BIOL, V331, P527, DOI 10.1016/S0022-2836(03)00732-0; HALLENBECK PL, 1990, J BACTERIOL, V172, P1749, DOI 10.1128/jb.172.4.1749-1761.1990; Horne IM, 1998, MICROBIOL-UK, V144, P2255, DOI 10.1099/00221287-144-8-2255; Hunter C N, 1982, Prog Clin Biol Res, V102 Pt B, P257; HUNTER CN, 1987, BIOCHEM J, V247, P489, DOI 10.1042/bj2470489; JENNEY FE, 1993, EMBO J, V12, P1283, DOI 10.1002/j.1460-2075.1993.tb05773.x; Joshi HM, 1996, P NATL ACAD SCI USA, V93, P14515, DOI 10.1073/pnas.93.25.14515; JOUANNEAU Y, 1986, J BACTERIOL, V165, P620, DOI 10.1128/jb.165.2.620-624.1986; KAPLAN S, 1982, PHOTOSYNTHETIC ENERG, P67; KILEY PJ, 1988, MICROBIOL REV, V52, P50, DOI 10.1128/MMBR.52.1.50-69.1988; LANG HP, 1994, J BACTERIOL, V176, P3859, DOI 10.1128/JB.176.13.3859-3869.1994; LEE JK, 1992, J BACTERIOL, V174, P1158, DOI 10.1128/jb.174.4.1158-1171.1992; LEE JK, 1989, J BIOL CHEM, V264, P19354; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; LEE JK, 1993, J BIOL CHEM, V268, P24491; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LIN ECC, 1996, REGULATION GENE EXPR; MACGREGOR BJ, 1991, J BACTERIOL, V173, P3949, DOI 10.1128/jb.173.13.3949-3957.1991; Mackenzie C, 2001, PHOTOSYNTH RES, V70, P19, DOI 10.1023/A:1013831823701; Masuda S, 2002, CELL, V110, P613, DOI 10.1016/S0092-8674(02)00876-0; MCGLYNN P, 1993, MOL GEN GENET, V236, P227, DOI 10.1007/BF00277117; Mouncey NJ, 1998, J BACTERIOL, V180, P2228, DOI 10.1128/JB.180.8.2228-2231.1998; Mouncey NJ, 2000, FEMS MICROBIOL LETT, V192, P205, DOI 10.1111/j.1574-6968.2000.tb09383.x; Myllykallio H, 1999, P NATL ACAD SCI USA, V96, P4348, DOI 10.1073/pnas.96.8.4348; NEIDLE EL, 1993, J BACTERIOL, V175, P2292, DOI 10.1128/JB.175.8.2292-2303.1993; OGara JP, 1997, J BACTERIOL, V179, P1951, DOI 10.1128/jb.179.6.1951-1961.1997; Oh JI, 1999, BIOCHEMISTRY-US, V38, P2688, DOI 10.1021/bi9825100; Oh JI, 2003, MICROBIOL-SGM, V149, P949, DOI 10.1099/mic.0.26010-0; Oh JI, 2001, J BACTERIOL, V183, P6807, DOI 10.1128/JB.183.23.6807-6814.2001; Oh JI, 2001, MOL MICROBIOL, V39, P1116, DOI 10.1046/j.1365-2958.2001.02299.x; Oh JI, 2000, J BACTERIOL, V182, P3081, DOI 10.1128/JB.182.11.3081-3087.2000; Oh JI, 2000, EMBO J, V19, P4237, DOI 10.1093/emboj/19.16.4237; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; Porter SL, 2002, MOL MICROBIOL, V46, P1081, DOI 10.1046/j.1365-2958.2002.03218.x; Roh JH, 2002, J BACTERIOL, V184, P5330, DOI 10.1128/JB.184.19.5330-5338.2002; Romagnoli S, 2002, J BACTERIOL, V184, P5590, DOI 10.1128/JB.184.20.5590-5598.2002; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Sabaty M, 1996, J BACTERIOL, V178, P35, DOI 10.1128/jb.178.1.35-45.1996; SCHILKE BA, 1992, J MOL BIOL, V226, P101, DOI 10.1016/0022-2836(92)90127-6; SHAPLEIGH JP, 1992, MOL MICROBIOL, V6, P635, DOI 10.1111/j.1365-2958.1992.tb01511.x; SHAPLEIGH JP, 1992, J BACTERIOL, V174, P2338, DOI 10.1128/JB.174.7.2338-2343.1992; Shimada H, 1996, PLANT CELL PHYSIOL, V37, P515, DOI 10.1093/oxfordjournals.pcp.a028974; TAI SP, 1985, J BACTERIOL, V164, P181, DOI 10.1128/JB.164.1.181-186.1985; Toledo-Cuevas M, 1998, BBA-BIOENERGETICS, V1365, P421, DOI 10.1016/S0005-2728(98)00095-4; WARD MJ, 1995, MOL MICROBIOL, V17, P357, DOI 10.1111/j.1365-2958.1995.mmi_17020357.x; Wartmann T, 2001, CURR GENET, V40, P172, DOI 10.1007/s002940100254; Weber Michael H. W., 2003, Science Progress, V86, P9, DOI 10.3184/003685003783238707; Yakunin AF, 2001, CAN J MICROBIOL, V47, P206, DOI 10.1139/cjm-47-3-206; Yeliseev AA, 1996, J BACTERIOL, V178, P5877, DOI 10.1128/jb.178.20.5877-5883.1996; YELISEEV AA, 1995, J BIOL CHEM, V270, P21167, DOI 10.1074/jbc.270.36.21167; Yeliseev AA, 1999, J BIOL CHEM, V274, P21234, DOI 10.1074/jbc.274.30.21234; Yeliseev AA, 2000, J BIOL CHEM, V275, P5657, DOI 10.1074/jbc.275.8.5657; YUN CH, 1990, EUR J BIOCHEM, V194, P399, DOI 10.1111/j.1432-1033.1990.tb15633.x; Zeilstra-Ryalls J, 1998, J BACTERIOL, V180, P2801, DOI 10.1128/JB.180.11.2801-2809.1998; Zeilstra-Ryalls JH, 1998, J BACTERIOL, V180, P1496, DOI 10.1128/JB.180.6.1496-1503.1998; ZEILSTRARYALLS JH, 1995, J BACTERIOL, V177, P6422, DOI 10.1128/jb.177.22.6422-6431.1995; Zeng XH, 2003, J BACTERIOL, V185, P6171, DOI 10.1128/JB.185.20.6171-6184.2003; Zeng XH, 2001, J BACTERIOL, V183, P6355, DOI 10.1128/JB.183.21.6355-6364.2001; ZHU YS, 1986, P NATL ACAD SCI USA, V83, P7613, DOI 10.1073/pnas.83.20.7613; ZHU YS, 1986, J BACTERIOL, V168, P1180, DOI 10.1128/jb.168.3.1180-1188.1986	87	62	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9146	9155		10.1074/jbc.M311608200	http://dx.doi.org/10.1074/jbc.M311608200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14662761	hybrid			2022-12-27	WOS:000189265900076
J	Basha, E; Lee, GJ; Breci, LA; Hausrath, AC; Buan, NR; Giese, KC; Vierling, E				Basha, E; Lee, GJ; Breci, LA; Hausrath, AC; Buan, NR; Giese, KC; Vierling, E			The identity of proteins associated with a small heat shock protein during heat stress in vivo indicates that these chaperones protect a wide range of cellular functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; BACTERIAL INCLUSION-BODIES; SYNECHOCYSTIS PCC 6803; ESCHERICHIA-COLI; DENATURED PROTEINS; RIBOSOMAL-PROTEIN; BINDING PROTEIN; RNA; AGGREGATION; EXPRESSION	The small heat shock proteins (sHSPs) are a ubiquitous class of ATP-independent chaperones believed to prevent irreversible protein aggregation and to facilitate subsequent protein renaturation in cooperation with ATP-dependent chaperones. Although sHSP chaperone activity has been studied extensively in vitro, understanding the mechanism of sHSP function requires identification of proteins that are sHSP substrates in vivo. We have used both immunoprecipitation and affinity chromatography to recover 42 proteins that specifically interact with Synechocystis Hsp16.6 in vivo during heat treatment. These proteins can all be released from Hsp16.6 by the ATP-dependent activity of DnaK and cochaperones and are heat-labile. Thirteen of the putative substrate proteins were identified by mass spectrometry and reveal the potential for sHSPs to protect cellular functions as diverse as transcription, translation, cell signaling, and secondary metabolism. One of the putative substrates, serine esterase, was purified and tested directly for interaction with purified Hsp16.6. Hsp16.6 effectively formed soluble complexes with serine esterase in a heat-dependent fashion, thereby preventing formation of insoluble serine esterase aggregates. These data offer critical insights into the characteristics of native sHSP substrates and extend and provide in vivo support for the chaperone model of sHSP function.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona	Vierling, E (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St, Tucson, AZ 85721 USA.	vierling@u.arizona.edu		Vierling, Elizabeth/0000-0002-0066-4881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018966, R01GM042762, F32GM016748] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM42762, F32-GM18966, F32-GM16748] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PN, 1991, CELL, V66, P141, DOI 10.1016/0092-8674(91)90146-P; Anderson P, 2002, J CELL SCI, V115, P3227; BECK SC, 1994, J BIOL CHEM, V269, P21803; Boelens WC, 2001, BBA-PROTEIN STRUCT M, V1544, P311, DOI 10.1016/S0167-4838(00)00243-0; Carrio MM, 2001, FEBS LETT, V489, P29, DOI 10.1016/S0014-5793(01)02073-7; Carrio MM, 2002, J BIOTECHNOL, V96, P3, DOI 10.1016/S0168-1656(02)00032-9; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; COLLIER NC, 1988, J CELL BIOL, V106, P1131, DOI 10.1083/jcb.106.4.1131; Cornejo J, 1998, PLANT J, V15, P99, DOI 10.1046/j.1365-313X.1998.00186.x; Cuesta R, 2000, GENE DEV, V14, P1460; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Djabali K, 1997, J CELL SCI, V110, P2759; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FEN Y, 2001, J BIOL CHEM, V276, P31651; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; Friedrich KL, 2004, J BIOL CHEM, V279, P1080, DOI 10.1074/jbc.M311104200; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Hallberg EM, 1996, CELL STRESS CHAPERON, V1, P70, DOI 10.1379/1466-1268(1996)001<0070:TTISC>2.3.CO;2; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Horvath I, 1998, P NATL ACAD SCI USA, V95, P3513, DOI 10.1073/pnas.95.7.3513; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; JINN TL, 1995, PLANT PHYSIOL, V108, P693, DOI 10.1104/pp.108.2.693; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; KAMPINGA HH, 1995, EXP CELL RES, V219, P536, DOI 10.1006/excr.1995.1262; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1998, METHOD ENZYMOL, V290, P350, DOI 10.1016/S0076-6879(98)90031-3; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lee SY, 1998, CURR MICROBIOL, V37, P403, DOI 10.1007/s002849900400; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; NEUMANN D, 1987, EUR J CELL BIOL, V43, P71; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Perng MD, 1999, J CELL SCI, V112, P2099; Persson BC, 1997, NUCLEIC ACIDS RES, V25, P4093, DOI 10.1093/nar/25.20.4093; PETERSEN NS, 1981, P NATL ACAD SCI-BIOL, V78, P1708, DOI 10.1073/pnas.78.3.1708; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; Pfennig PL, 2001, MOL GENET GENOMICS, V266, P313, DOI 10.1007/s004380100559; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soriano A, 2000, BIOCHEMISTRY-US, V39, P12435, DOI 10.1021/bi001296o; Sugita C, 2000, MOL GEN GENET, V263, P655, DOI 10.1007/s004380051214; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; Theriault JR, 1999, FEBS LETT, V452, P170, DOI 10.1016/S0014-5793(99)00634-1; Torok Z, 2001, P NATL ACAD SCI USA, V98, P3098, DOI 10.1073/pnas.051619498; Tsvetkova NM, 2002, P NATL ACAD SCI USA, V99, P13504, DOI 10.1073/pnas.192468399; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; van Thor JJ, 1998, PLANT MOL BIOL, V36, P353, DOI 10.1023/A:1005935819038; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Voss S, 1997, PROTEIN ENG, V10, P975, DOI 10.1093/protein/10.8.975; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	63	127	137	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7566	7575		10.1074/jbc.M310684200	http://dx.doi.org/10.1074/jbc.M310684200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662763	hybrid, Green Published			2022-12-27	WOS:000189103300025
J	Juszczak, LJ				Juszczak, LJ			Comparative vibrational spectroscopy of intracellular tau and extracellular collagen I reveals parallels of gelation and fibrillar structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; UV RESONANCE RAMAN; PROTEIN SECONDARY STRUCTURE; ALZHEIMERS-DISEASE; EXCITATION PROFILES; CIRCULAR-DICHROISM; N-METHYLACETAMIDE; INFRARED-SPECTRA; ULTRAVIOLET; DEPENDENCE	The N-terminal tau 2-19 peptide undergoes gelation, syneresis, and aggregation over a period of years. These changes may be approximated on a shorter time scale by agitation and partial dehydration. The anomalously enhanced (229 nm) ultraviolet resonance Raman (UVRR) imide II band reveals a common structural feature for gels of nondehydrated tau 2-19 and collagen I and insoluble paired helical filaments (PHFs) and collagen I of weak hydrogen bonding at proline carbonyls. Anomalous UVRR enhancement of amide bands at 229 nm results from gel structure, as demonstrated by increased amide absorption at the red edge for tau 2-19 gel and implies the involvement of water in gel structure. In aged, dehydrated tau 2-19 gel, proline carbonyls lose their bonds to water and tyrosine becomes deprotonated, as demonstrated by UVRR spectroscopy. The Fourier transform infrared (FTIR) amide I band shows that antiparallel beta-sheet structure increases with syneresis in the tau 2-19 hydrogel. The comparison of FTIR results for PHFs with collagen I gel and polyproline demonstrates that the secondary structure of PHFs is polyproline II. One implication of this assignment is that the fibrillation of hydrophilic tau is thermodynamically driven by the entropy gained as hydrogen-bonded water is freed, as for collagen I. The FTIR results also show that peptide domains culled from a longer protein do not necessarily fold into identical secondary structures. A pathological, sequential mechanism of gelation, syneresis, and fibrillation for tau in AD is suggested and is supported by the observation of amorphous neurofibrillary tangle development and fibrillation in vivo.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Juszczak, LJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	juzak@aecom.yu.edu						Asher SA, 2001, J AM CHEM SOC, V123, P11775, DOI 10.1021/ja0039738; ASHER SA, 1986, J AM CHEM SOC, V108, P3186, DOI 10.1021/ja00272a005; Austin J. C., 1993, BIOMOLECULAR SPECT A, P55; Bhatnagar RS, 1996, CIRCULAR DICHROISM C, P183; BORNSTEIN P, 1974, ANNU REV BIOCHEM, V43, P567, DOI 10.1146/annurev.bi.43.070174.003031; BRAAK H, 1993, EUR NEUROL, V33, P403, DOI 10.1159/000116984; Braak H, 1996, ACTA NEUROL SCAND, V93, P3; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brandt R, 2001, CELL TISSUE RES, V305, P255, DOI 10.1007/s004410000334; BUNKER C, 1990, SOL GEL SCI, P357; CAMPENOT RB, 1985, DEV BRAIN RES, V20, P149, DOI 10.1016/0165-3806(85)90099-9; CANTOR C, 1980, BIOPHYSICAL CHEM, V1, P95; Chan WC, 2000, FMOC SOLID PHASE PEP; Chi ZH, 1998, BIOCHEMISTRY-US, V37, P2854, DOI 10.1021/bi971160z; CHIRGADZE YN, 1976, BIOPOLYMERS, V15, P607, DOI 10.1002/bip.1976.360150402; Cleary E., 1996, EXTRACELLULAR MATRIX, V1, P77; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; CRICK FHC, 1950, EXP CELL RES, V1, P37, DOI 10.1016/0014-4827(50)90048-6; CROWTHER RA, 1985, EMBO J, V4, P3661, DOI 10.1002/j.1460-2075.1985.tb04132.x; Danowski BA, 1998, CELL MOTIL CYTOSKEL, V40, P1; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; DiTella MC, 1996, J CELL SCI, V109, P467; DUDIK JM, 1985, J CHEM PHYS, V82, P1732, DOI 10.1063/1.448405; Farrell HM, 2002, J PROTEIN CHEM, V21, P307, DOI 10.1023/A:1019992900455; FERRY JD, 1948, ADV PROTEIN CHEM, V4, P1, DOI 10.1016/S0065-3233(08)60004-2; Flory PJ, 1941, J AM CHEM SOC, V63, P3083, DOI 10.1021/ja01856a061; FODOR SPA, 1989, J AM CHEM SOC, V111, P5509, DOI 10.1021/ja00197a001; Forgacs G, 2003, BIOPHYS J, V84, P1272, DOI 10.1016/S0006-3495(03)74942-X; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goux WJ, 2002, BIOCHEMISTRY-US, V41, P13798, DOI 10.1021/bi016079h; GUNDERSEN RW, 1988, J NEUROSCI RES, V21, P298, DOI 10.1002/jnr.490210222; HARADA L, 1986, SPECTROSCOPY BIOL SY, P113; HILDEBRANDT PG, 1988, BIOCHEMISTRY-US, V27, P5426, DOI 10.1021/bi00415a007; Hoffmann R, 1997, J PEPT RES, V50, P132; Holtz JSW, 2000, BIOPOLYMERS, V57, P55, DOI 10.1002/(SICI)1097-0282(2000)57:2<55::AID-BIP2>3.0.CO;2-B; INGBER DE, 1993, J CELL SCI, V104, P613; Iwaura R, 2002, CHEM MATER, V14, P3047, DOI 10.1021/cm020263n; JENNESS DD, 1976, BIOPOLYMERS, V15, P513, DOI 10.1002/bip.1976.360150308; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; Juszczak LJ, 1997, BIOCHEMISTRY-US, V36, P2227, DOI 10.1021/bi9622130; Juszczak LJ, 2002, BIOCHEMISTRY-US, V41, P376, DOI 10.1021/bi011212r; Juszczak LJ, 1998, J RAMAN SPECTROSC, V29, P963, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<963::AID-JRS332>3.0.CO;2-4; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; Kiyonaka S, 2003, CHEM-EUR J, V9, P976, DOI 10.1002/chem.200390120; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; Kucharz E. J., 1992, COLLAGENS BIOCH PATH; LAMOUREUX P, 1990, J CELL BIOL, V110, P71, DOI 10.1083/jcb.110.1.71; LAMOUREUX P, 1989, NATURE, V340, P156, DOI 10.1038/340159a0; Lockwood NA, 2002, BIOMACROMOLECULES, V3, P1225, DOI 10.1021/bm025573d; LORD RC, 1977, APPL SPECTROSC, V31, P187, DOI 10.1366/000370277774463706; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Mirkin NG, 2002, J PHYS CHEM A, V106, P3391, DOI 10.1021/jp012324v; MOONEY DJ, 1995, J CELL SCI, V108, P2311; MOONEY DJ, 1994, MOL BIOL CELL, V5, P1281, DOI 10.1091/mbc.5.12.1281; Ostrovskii D, 1999, MACROMOLECULES, V32, P5552, DOI 10.1021/ma9904969; Perez M, 1996, J NEUROCHEM, V67, P1183; PORTER KR, 1984, J CELL BIOL, V99, pS3, DOI 10.1083/jcb.99.1.3s; RAMACHANDRAN GN, 1988, INT J PEPT PROT RES, V31, P1; Ramirez G, 1999, BRAZ J MED BIOL RES, V32, P611, DOI 10.1590/S0100-879X1999000500015; Sadqi M, 2002, BIOCHEMISTRY-US, V41, P7150, DOI 10.1021/bi025777e; Schneider JP, 2002, J AM CHEM SOC, V124, P15030, DOI 10.1021/ja027993g; Shi ZS, 2002, P NATL ACAD SCI USA, V99, P9190, DOI 10.1073/pnas.112193999; SIMS JR, 1992, J CELL SCI, V103, P1215; Sokolov L, 1998, J PHYS CHEM B, V102, P8314, DOI 10.1021/jp982099q; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; SU C, 1990, J RAMAN SPECTROSC, V21, P435, DOI 10.1002/jrs.1250210709; SUGAWARA Y, 1984, J MOL SPECTROSC, V108, P206, DOI 10.1016/0022-2852(84)90179-6; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1971, BIOPOLYMERS, V10, P1597, DOI 10.1002/bip.360100913; TAKEUCHI H, 1992, J AM CHEM SOC, V114, P5321, DOI 10.1021/ja00039a049; TAKEUCHI H, 1988, SPECTROCHIM ACTA A, V44, P749, DOI 10.1016/0584-8539(88)80138-7; TAKEUCHI H, 1990, J RAMAN SPECTROSC, V21, P509, DOI 10.1002/jrs.1250210807; TIFFANY ML, 1968, BIOPOLYMERS, V6, P1379, DOI 10.1002/bip.1968.360060911; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; Tseng Y, 2002, J BIOL CHEM, V277, P18143, DOI 10.1074/jbc.M110868200; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VEIS A, 1996, EXTRACELLULAR MATRIX, P41; VINCENT IJ, 1992, P NATL ACAD SCI USA, V89, P2878, DOI 10.1073/pnas.89.7.2878; Vitagliano L, 2001, BIOPOLYMERS, V58, P459, DOI 10.1002/1097-0282(20010415)58:5<459::AID-BIP1021>3.0.CO;2-V; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Wang DJ, 1998, BIOCHEMISTRY-US, V37, P9940, DOI 10.1021/bi980295h; WANG Y, 1991, J AM CHEM SOC, V113, P6368, DOI 10.1021/ja00017a003; WESTERMARK G, 1999, AMYLOID PRIONS OTHER; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884	89	30	31	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7395	7404		10.1074/jbc.M309971200	http://dx.doi.org/10.1074/jbc.M309971200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660656	hybrid			2022-12-27	WOS:000189103300005
J	Mancini, F; Gentiletti, F; D'Angelo, M; Giglio, S; Nanni, S; D'Angelo, C; Farsetti, A; Citro, G; Sacchi, A; Pontecorvi, A; Moretti, F				Mancini, F; Gentiletti, F; D'Angelo, M; Giglio, S; Nanni, S; D'Angelo, C; Farsetti, A; Citro, G; Sacchi, A; Pontecorvi, A; Moretti, F			MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH ARREST; EMBRYONIC LETHALITY; CELLULAR-RESPONSE; UV-IRRADIATION; EXPRESSION; PROTEIN; CELLS; DEGRADATION; ACTIVATION; MICE	Rescue of embryonic lethality in MDM4(-/-) mice through concomitant loss of p53 has revealed a functional partnership between the two proteins. Biochemical studies have suggested that MDM4 may act as a negative regulator of p53 levels and activity. On the other hand, MDM4 overexpression has been reported to stabilize p53 levels and to counteract MDM2-degradative activity. We have investigated the functional role of MDM4 overexpression on cell behavior. In both established and primary cells cultured under stress conditions, overexpression of MDM4 significantly increased p53-dependent cell death, in correlation with enhanced induction of the endogenous p53 protein levels. This phenomenon was associated with induced p53 transcriptional activity and increased levels of the proapoptotic protein, Bax. Further, p53 stabilization was accompanied by decreased association of the protein to its negative regulator, MDM2. These findings reveal a novel role for MDM4 by demonstrating that in non-tumor cells under stress conditions it may act as a positive regulator of p53 activity, mainly by controlling p53 levels. They also indicate a major distinction between the biological consequences of MDM4 and MDM2 overexpression.	Regina Elena Inst Canc Res, Lab Mol Oncogenesis, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Lab Expt Chemotherapy, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Anim House Serv, I-00158 Rome, Italy; Catholic Univ, Inst Med Pathol, I-00100 Rome, Italy; CNR, Neurobiol & Mol Med Inst, I-00137 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR)	Moretti, F (corresponding author), Regina Elena Inst Canc Res, Lab Mol Oncogenesis, Via Messi Oro 156, I-00158 Rome, Italy.	moretti@ifo.it	Carmen, D'Angelo/J-2639-2017; mancini, francesca/K-6062-2016; Moretti, Fabiola/I-5647-2013; Mancini, Francesca/AAZ-1672-2021; Farsetti, Antonella/I-8710-2018	mancini, francesca/0000-0002-2459-8815; Moretti, Fabiola/0000-0002-2691-1254; Mancini, Francesca/0000-0002-2459-8815; Farsetti, Antonella/0000-0002-8603-7925				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Candi E, 2002, J INVEST DERMATOL, V119, P670, DOI 10.1046/j.1523-1747.2002.01853.x; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finch RA, 2002, CANCER RES, V62, P3221; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Freedman DA, 1999, CANCER RES, V59, P1; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Lohrum MAE, 1999, CELL DEATH DIFFER, V6, P1162, DOI 10.1038/sj.cdd.4400625; LUNA RMD, 1995, NATURE, V378, P203; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; MIYASHITA T, 1995, CELL, V80, P293; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Prives C, 1999, J PATHOL, V187, P112; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sabbatini P, 2002, DNA CELL BIOL, V21, P519, DOI 10.1089/104454902320219077; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Wadhwa R, 1999, CELL RES, V9, P261, DOI 10.1038/sj.cr.7290025; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Yap DBS, 2000, J BIOL CHEM, V275, P37296, DOI 10.1074/jbc.M004359200; Zhu JH, 2001, ONCOGENE, V20, P4050, DOI 10.1038/sj.onc.1204516	68	37	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8169	8180		10.1074/jbc.M311793200	http://dx.doi.org/10.1074/jbc.M311793200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660608	hybrid			2022-12-27	WOS:000189103300098
J	Ohara-Imaizumi, M; Nishiwaki, C; Kikuta, T; Kumakura, K; Nakamichi, Y; Nagamatsu, S				Ohara-Imaizumi, M; Nishiwaki, C; Kikuta, T; Kumakura, K; Nakamichi, Y; Nagamatsu, S			Site of docking and fusion of insulin secretory granules in live MIN6 beta cells analyzed by TAT-conjugated anti-syntaxin 1 antibody and total internal reflection fluorescence microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; EVANESCENT-WAVE MICROSCOPY; LIPID RAFTS; CELLULAR UPTAKE; EXOCYTOSIS; MEMBRANE; PROTEIN; RELEASE; DELIVERY; IDENTIFICATION	To determine the site of insulin exocytosis in the pancreatic beta cell plasma membrane, we analyzed the interaction between the docking/fusion of green fluorescent protein-tagged insulin granules and syntaxin 1 labeled by TAT-conjugated Cy3-labeled antibody (Ab) using total internal reflection fluorescence microscopy (TIRFM). Monoclonal Ab against syntaxin 1 was labeled with Cy3 then conjugated with the protein transduction domain of HIV-1 TAT. TAT-conjugated Cy3-labeled anti-syntaxin 1 Ab was transduced rapidly into the subplasmalemmal region in live MIN6 beta cells, which enabled us to observe the spatial organization and distribution of endogenous syntaxin 1. TIRFM imaging revealed that syntaxin 1 is distributed in numerous separate clusters in the intact plasma membrane, where insulin secretory granules were docked preferentially to the sites of syntaxin 1 clusters, colocalizing with synaptosomal-associated protein of 25 kDa (SNAP-25) clusters. TIRFM imaging analysis of the motion of single insulin granules demonstrated that the fusion of insulin secretory granules stimulated by 50 mM KCl occurred exclusively at the sites of the syntaxin 1 clusters. Cholesterol depletion by methyl-beta-cyclodextrin treatment, in which the syntaxin 1 clusters were disintegrated, decreased the number of docked insulin granules, and, eventually the number of fusion events was significantly reduced. Our results indicate that 1) insulin exocytosis occurs at the site of syntaxin 1 clusters; 2) syntaxin 1 clusters are essential for the docking and fusion of insulin granules in MIN6 beta cells; and 3) the sites of syntaxin 1 clusters are distinct from flotillin-1 lipid rafts.	Kyorin Univ, Sch Med, Dept Biochem 2, Tokyo 1818611, Japan; Sophia Univ, Inst Life Sci, Chiyoda Ku, Tokyo 1028554, Japan	Kyorin University; Sophia University	Nagamatsu, S (corresponding author), Kyorin Univ, Sch Med, Dept Biochem 2, Shinkawa 6-20-2, Tokyo 1818611, Japan.	shinya@kyorin-u.ac.jp						Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Axelrod D, 2001, TRAFFIC, V2, P764, DOI 10.1034/j.1600-0854.2001.21104.x; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Nagamatsu S, 1999, J BIOL CHEM, V274, P8053, DOI 10.1074/jbc.274.12.8053; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P50805, DOI 10.1074/jbc.M207988200; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE145, DOI 10.1038/14097; Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Steffen W, 2001, METH MOL B, V161, P141; Stein S, 1999, FEBS LETT, V458, P383, DOI 10.1016/S0014-5793(99)01186-2; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WOLLHEIM CB, 1996, DIABETES REV, V4, P276	35	85	91	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8403	8408		10.1074/jbc.M308954200	http://dx.doi.org/10.1074/jbc.M308954200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676208	hybrid			2022-12-27	WOS:000189103300123
J	Schmidt, M; Gerlach, F; Avivi, A; Laufs, T; Wystub, S; Simpson, JC; Nevo, E; Saaler-Reinhardt, S; Reuss, S; Hankeln, T; Burmester, T				Schmidt, M; Gerlach, F; Avivi, A; Laufs, T; Wystub, S; Simpson, JC; Nevo, E; Saaler-Reinhardt, S; Reuss, S; Hankeln, T; Burmester, T			Cytoglobin is a respiratory protein in connective tissue and neurons, which is up-regulated by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STELLATE CELL ACTIVATION; PROLYL 4-HYDROXYLASE; MESSENGER-RNA; NITRIC-OXIDE; OXYGEN; NEUROGLOBIN; GLOBIN; HEMOGLOBINS; EXPRESSION; TRANSPORT	Cytoglobin is a recently discovered vertebrate globin distantly related to myoglobin, and its function is unknown. Here we present the first detailed analysis of the distribution and expression of cytoglobin. Northern and Western blotting experiments show the presence of cytoglobin mRNA and protein in a broad range of tissues. Quantitative PCR demonstrates an up-regulation of cytoglobin mRNA levels in rat heart and liver under hypoxic conditions (22 and 44 h of 9% oxygen). Immunofluorescence studies with three antibodies directed against different epitopes of the protein consistently show cytoglobin in connective tissue fibroblasts as well as in hepatic stellate cells. Cytoglobin is also present in chondroblasts and osteoblasts and shows a decreased level of expression upon differentiation to chondrocytes and osteocytes. Cytoglobin is located in the cytoplasm of these cell types. Evidence against an exclusively nuclear localization of cytoglobin, as recently proposed, is also provided by transfection assays with green fluorescent protein fusion constructs, which demonstrates the absence of an active nuclear import. The differential expression of cytoglobin argues against a general respiratory function of this molecule, but rather indicates a connective tissue-specific function. We hypothesize that cytoglobin may be involved in collagen synthesis. Cytoglobin expression was also observed in some neuronal subpopulations of the central and the peripheral nervous systems. Surprisingly, cytoglobin is localized in both the cytoplasm and nucleus of neurons, indicating a possible additional role of this protein in neuronal tissues.	Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Mol Genet, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Dept Anat, D-55099 Mainz, Germany; Univ Haifa, Inst Evolut, IL-31095 Haifa, Israel; European Mol Biol Lab, D-69117 Heidelberg, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Haifa; European Molecular Biology Laboratory (EMBL)	Burmester, T (corresponding author), Johannes Gutenberg Univ Mainz, Inst Zool, Mullerweg 6, D-55099 Mainz, Germany.	burmeste@uni-mainz.de	Burmester, Thorsten/I-7225-2013	Burmester, Thorsten/0000-0002-5772-7863; Reuss, Stefan/0000-0003-1064-5067; Simpson, Jeremy/0000-0002-7956-7805				Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Asahina K, 2002, BBA-GENE STRUCT EXPR, V1577, P471, DOI 10.1016/S0167-4781(02)00477-3; Baroni GS, 1998, HEPATOLOGY, V27, P720; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; de Sanctis D, 2003, ACTA CRYSTALLOGR D, V59, P1285, DOI 10.1107/S0907444903009867; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; Eng FJ, 2000, AM J PHYSIOL-GASTR L, V279, pG7, DOI 10.1152/ajpgi.2000.279.1.G7; FALANGA V, 1993, J CELL PHYSIOL, V157, P408, DOI 10.1002/jcp.1041570225; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; Hamdane D, 2003, J BIOL CHEM, V278, P51713, DOI 10.1074/jbc.M309396200; Hardison R, 1998, J EXP BIOL, V201, P1099; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Horino Y, 2002, LIFE SCI, V71, P3031, DOI 10.1016/S0024-3205(02)02142-2; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; Kundu S, 2003, BIOPHYS J, V84, P3931, DOI 10.1016/S0006-3495(03)75121-2; LEONE AM, 1991, J BIOL CHEM, V266, P23790; Maher JJ, 1999, ALCOHOL CLIN EXP RES, V23, P917, DOI 10.1097/00000374-199905000-00022; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Merx Marc W., 2001, FASEB Journal, V15, P1077; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; Nieto N, 2002, J BIOL CHEM, V277, P9853, DOI 10.1074/jbc.M110506200; OSTADAL B, 1995, PHYSIOL RES, V44, P45; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; PIHLAJANIEMI T, 1991, J HEPATOL, V13, pS2, DOI 10.1016/0168-8278(91)90002-S; Reeves HL, 2002, FRONT BIOSCI-LANDMRK, V7, pD808, DOI 10.2741/reeves; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; ROGERS AW, 1983, CELLS TISSUES INTRO; Sawai H, 2003, BIOCHEMISTRY-US, V42, P5133, DOI 10.1021/bi027067e; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Shima DT, 1999, CURR BIOL, V9, P821, DOI 10.1016/S0960-9822(99)80365-0; Spagnoli FM, 1998, J CELL BIOL, V143, P1101, DOI 10.1083/jcb.143.4.1101; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9; YEN EHK, 1979, BIOCHEM J, V178, P605, DOI 10.1042/bj1780605	41	183	204	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8063	8069		10.1074/jbc.M310540200	http://dx.doi.org/10.1074/jbc.M310540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660570	hybrid			2022-12-27	WOS:000189103300085
J	Tamura, K; Noyama, T; Ishizawa, Y; Takamatsu, N; Shiba, T; Ito, M				Tamura, K; Noyama, T; Ishizawa, Y; Takamatsu, N; Shiba, T; Ito, M			Xenopus death receptor-M1 and-M2, new members of the tumor necrosis factor receptor superfamily, trigger apoptotic signaling by differential mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; KINASE (JNK)-BINDING PROTEIN; DOMAIN-CONTAINING RECEPTOR; CELL-DEATH; MONOCLONAL-ANTIBODY; MEDIATED APOPTOSIS; TNF; ACTIVATION; JNK; FAMILY	Signaling through the tumor necrosis factor receptor (TNFR) superfamily can lead to apoptosis or promote cell survival, proliferation, and differentiation. A subset of this family, including TNFR1 and Fas, signals cell death via an intracellular death domain and therefore is termed the death receptor (DR) family. In this study, we identified new members of the DR family, designated xDR-M1 and xDR-M2, in Xenopus laevis. The two proteins, which show high homology (71.7% identity), have characteristics of the DR family, that is, three cysteine-rich domains, a transmembrane domain, and a death domain. To elucidate how members of xDR-M subfamily regulate cell death and survival, we examined the intracellular signaling mediated by these receptors in 293T and A6 cells. Overexpression of xDR-M2 induced apoptosis and activated caspase-8, c-Jun N-terminal kinase, and nuclear factor-kappaB, although its death domain to a greater extent than did that of xDR-M1 in 293T cells. A caspase-8 inhibitor potently blocked this apoptosis induced by xDR-M2. In contrast, xDR-M1 showed a greater ability to induce apoptosis through its death domain than did xDR-M2 in A6 cells. Interestingly, a general serine protease inhibitor, but not the caspase-8 inhibitor, blocked the xDR-M1-induced apoptosis. These results imply that activation of caspase-8 or serine protease(s) may be required for the xDR-M2- or xDR-M1-induced apoptosis, respectively. Although xDR-M1 and xDR-M2 are very similar to each other, the difference in their death domains may result in diverse signaling, suggesting distinct roles of xDR-M1 and xDR-M2 in cell death or survival.	Kitasato Univ, Sch Sci, Dept Biosci, Sagamihara, Kanagawa 2288555, Japan	Kitasato University	Ito, M (corresponding author), Kitasato Univ, Sch Sci, Dept Biosci, 1-15-1 Kitasato, Sagamihara, Kanagawa 2288555, Japan.	ito@jet.sci.kitasato-u.ac.jp						Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hutson LD, 2001, J NEUROBIOL, V49, P79, DOI 10.1002/neu.1067; ITO M, 1993, P NATL ACAD SCI USA, V90, P6052, DOI 10.1073/pnas.90.13.6052; Ito M, 1999, MOL CELL BIOL, V19, P7539; ITOH N, 1993, J BIOL CHEM, V268, P10932; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Koyano S, 1997, GENE, V188, P101, DOI 10.1016/S0378-1119(96)00790-1; Koyano S, 1999, FEBS LETT, V457, P385, DOI 10.1016/S0014-5793(99)01084-4; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Park IC, 2001, CYTOKINE, V15, P166, DOI 10.1006/cyto.2001.0893; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200	47	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7629	7635		10.1074/jbc.M306217200	http://dx.doi.org/10.1074/jbc.M306217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668340	hybrid			2022-12-27	WOS:000189103300033
J	Zimmer, JSD; Voelker, DR; Bernlohr, DA; Murphy, RC				Zimmer, JSD; Voelker, DR; Bernlohr, DA; Murphy, RC			Stabilization of leukotriene A(4) by epithelial fatty acid-binding protein in the rat basophilic leukemia cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-GEL DIGESTION; CRYSTAL-STRUCTURE; SEQUENCE; 5-LIPOXYGENASE; PURIFICATION; B-4; IDENTIFICATION; LOCALIZATION; METABOLISM; EXPRESSION	Leukotriene A(4) ( LTA(4)) is a chemically unstable triene epoxide product of 5-lipoxygenase metabolism of arachidonic acid. Despite this chemical reactivity and its synthesis at the perinuclear membrane, LTA(4) is enzymatically converted into the cysteinyl leukotrienes and leukotriene B-4. Furthermore, LTA(4) participates in transcellular biosynthesis and is thus transferred between cells as an intact molecule. A cytosolic fatty acid-binding protein present in the rat basophilic leukemia cells was identified using mass spectrometry. This protein was determined to be the stabilizing factor present in the cell cytosol responsible for increasing the effective chemical half-life of LTA(4). Rat epithelial fatty acid-binding protein (E-FABP) was isolated using partial protein purification and immunoprecipitation. In-gel digestion with trypsin followed by peptide fingerprint analysis using matrix-assisted laser desorption ionization mass spectrometry and sequencing the major tryptic peptide obtained from liquid chromatography/mass spectrometry/mass spectrometry analysis identified E-FABP in the active fraction. Semi-quantitative Western blot analysis indicated that E-FABP in the cytosolic fraction of RBL-1 cells was present at similar to1-3 pmol/10(6) cells. E-FABP (9 muM) was tested for its ability to stabilize LTA(4), and at 37degreesC E-FABP was able to increase the half-life of LTA(4) from the previously reported half-life less than 3 s to a half-life of similar to7 min. These results present a novel function for the well studied fatty acid-binding protein as a participant in leukotriene biosynthesis that permits LTA(4) to be available for further enzymatic processing in various cellular regions.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities	Murphy, RC (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	murphyr@njc.org			NHLBI NIH HHS [HL 25785] Funding Source: Medline; NIDDK NIH HHS [DK53189] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025785, R37HL025785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053189] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1990, METHOD ENZYMOL, DOI 10.1016/0076-6879(90)82024-v; Bennaars-Eiden A, 2002, J BIOL CHEM, V277, P50693, DOI 10.1074/jbc.M209493200; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; Dickinson JS, 2002, J AM SOC MASS SPECTR, V13, P1227, DOI 10.1016/S1044-0305(02)00456-7; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Evans JF, 2002, PROSTAG OTH LIPID M, V68-9, P587, DOI 10.1016/S0090-6980(02)00057-6; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FITZPATRICK FA, 1982, J BIOL CHEM, V257, P4680; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GOETZE AM, 1985, PROSTAGLANDINS, V29, P689, DOI 10.1016/0090-6980(85)90130-3; Gutierrez-Gonzalez LH, 2002, BIOCHEM J, V364, P725, DOI 10.1042/BJ20020039; Haeggstrom JZ, 2000, AM J RESP CRIT CARE, V161, pS25, DOI 10.1164/ajrccm.161.supplement_1.ltta-6; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hertzel AV, 2002, J LIPID RES, V43, P2105, DOI 10.1194/jlr.M200227-JLR200; Hohoff C, 1999, BIOCHEMISTRY-US, V38, P12229, DOI 10.1021/bi990305u; JAKSCHIK BA, 1983, PROSTAG OTH LIPID M, V25, P767, DOI 10.1016/0090-6980(83)90002-3; Kane CD, 1996, BIOCHEMISTRY-US, V35, P2894, DOI 10.1021/bi952476e; KRIEG P, 1993, J BIOL CHEM, V268, P17362; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PETERS P, 1996, ALL ALBUMIN, P76; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Widstrom RL, 2003, BIOCHEMISTRY-US, V42, P11762, DOI 10.1021/bi034971d; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zarini S, 2003, J BIOL CHEM, V278, P11190, DOI 10.1074/jbc.M208496200; Zimmerman AW, 2001, INT J BIOCHEM CELL B, V33, P865, DOI 10.1016/S1357-2725(01)00070-X	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7420	7426		10.1074/jbc.M311404200	http://dx.doi.org/10.1074/jbc.M311404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676186	hybrid			2022-12-27	WOS:000189103300008
J	Franz, CM; Ridley, AJ				Franz, CM; Ridley, AJ			p120 catenin associates with microtubules - Inverse relationship between microtubule binding and Rho GTPase regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; CELL-CELL ADHESION; CADHERIN CYTOPLASMIC DOMAIN; MEMBRANE-PROXIMAL REGION; EPITHELIAL-CELLS; DELTA-CATENIN; ACTIN CYTOSKELETON; FAMILY GTPASES; PROTEIN; P120(CTN)	p120 catenin (p120ctn), an armadillo protein and component of the cadherin adhesion complex, has been found recently to induce a dendritic morphology by regulating Rho family GTPases. We have identified specific serines within the Arm repeat domain that, when mutated to alanine, promote p120ctn association with interphase microtubules, leading to microtubule reorganization and stabilization. The mutant p120ctn also localized to the mitotic spindle and centrosomes. In contrast to wild-type p120ctn, the microtubule-associated p120ctn mutant did not activate Rac1 and did not induce a dendritic morphology. In addition, we show that a basic motif within the p120ctn Arm repeat domain known to be required for the inhibition of RhoA is also required for binding to microtubules. We therefore propose that binding of p120ctn to microtubules is inversely related to its ability to regulate Rho GTPases.	Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Ridley, AJ (corresponding author), Royal Free & Univ Coll Sch Med, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	anne@ludwig.ucl.ac.uk		Ridley, Anne/0000-0001-8186-5708; Franz, Clemens/0000-0003-0104-4841				Albertinazzi C, 1999, J CELL SCI, V112, P3821; Allan V, 2001, NAT CELL BIOL, V3, pE226, DOI 10.1038/ncb1001-e226; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Bauer A, 1998, J BIOL CHEM, V273, P28314, DOI 10.1074/jbc.273.43.28314; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Chauvet N, 2003, MOL CELL NEUROSCI, V22, P467, DOI 10.1016/S1044-7431(03)00030-7; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; DOWNING JR, 1991, ONCOGENE, V6, P607; FALCONER MM, 1989, CELL MOTIL CYTOSKEL, V12, P169, DOI 10.1002/cm.970120306; FERREIRA A, 1989, DEV BRAIN RES, V49, P205, DOI 10.1016/0165-3806(89)90022-9; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Grosheva I, 2001, J CELL SCI, V114, P695; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kim K, 2002, EXP CELL RES, V275, P171, DOI 10.1006/excr.2002.5503; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; LEE G, 1992, J CELL SCI, V102, P227; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; Lu Q, 2002, J NEUROSCI RES, V67, P618, DOI 10.1002/jnr.10151; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; McCartney BM, 2001, NAT CELL BIOL, V3, P933, DOI 10.1038/ncb1001-933; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 1998, J CELL BIOL, V142, P1605, DOI 10.1083/jcb.142.6.1605; Pacquelet A, 2003, J CELL BIOL, V160, P313, DOI 10.1083/jcb.200207160; Ratcliffe MJ, 1999, BIOCHEM J, V338, P471, DOI 10.1042/0264-6021:3380471; Ratcliffe MJ, 1997, J BIOL CHEM, V272, P31894, DOI 10.1074/jbc.272.50.31894; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roczniak-Ferguson A, 2003, J CELL SCI, V116, P4201, DOI 10.1242/jcs.00724; Sander EE, 1999, EUR J CANCER, V35, P1302, DOI 10.1016/S0959-8049(99)00145-8; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; Shea TB, 1999, BRAIN RES BULL, V48, P255, DOI 10.1016/S0361-9230(98)00019-7; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; Thompson AJ, 2003, ANAL CHEM, V75, P3232, DOI 10.1021/ac034134h; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; WEBSTER DR, 1989, J CELL SCI, V92, P57; WEBSTER DR, 1987, J CELL BIOL, V105, P265, DOI 10.1083/jcb.105.1.265; Winkler AA, 1998, YEAST, V14, P37, DOI 10.1002/(SICI)1097-0061(19980115)14:1<37::AID-YEA198>3.3.CO;2-U; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	58	64	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6588	6594		10.1074/jbc.M312812200	http://dx.doi.org/10.1074/jbc.M312812200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660598	hybrid			2022-12-27	WOS:000188969200047
J	Angers, A; Ramjaun, AR; McPherson, PS				Angers, A; Ramjaun, AR; McPherson, PS			The HECT domain ligase itch ubiquitinates endophilin and localizes to the trans-Golgi network and endosomal system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; RECEPTOR DOWN-REGULATION; PROTEIN LIGASE; ENDOCYTIC PATHWAY; VESICLE FORMATION; PLASMA-MEMBRANE; CUE DOMAIN; SH3 DOMAIN; BINDING; MOTIF	Endophilin A1 is an SH3 domain-containing protein functioning in membrane trafficking on the endocytic pathway. We have identified the E3 ubiquitin ligase itch/AIP4 as an endophilin A1-binding partner. Itch belongs to the Nedd4/Rsp5p family of proteins and contains an N-terminal C2 domain, four WW domains and a catalytic HECT domain. Unlike other Nedd4/Rsp5p family members, itch possesses a short proline-rich domain that mediates its binding to the SH3 domain of endophilin A1. Itch ubiquitinates endophilin A1 and the SH3/ proline-rich domain interaction facilitates this activity. Interestingly, itch co-localizes with markers of the endosomal system in a C2 domain-dependent manner and upon EGF stimulation, endophilin A1 translocates to an EGF-positive endosomal compartment where it co-localizes with itch. Moreover, EGF treatment of cells stimulates endophilin A1 ubiquitination. We have thus identified endophilin A1 as a substrate for the endo-some-localized ubiquitin ligase itch. This interaction may be involved in ubiquitin-mediated sorting mechanisms operating at the level of endosomes.	McGill Univ, Montreal Neurol Inst, Dept Neurol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Dept Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Angers, A (corresponding author), Univ Montreal, Dept Sci Biol, POB 6128,Stn Ctr Ville, Montreal, PQ H3C 3J7, Canada.	Annie.Angers@umontreal.ca	Angers, Annie/P-1217-2018	Angers, Annie/0000-0003-0131-256X				Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Chen X, 2001, GENOMICS, V73, P238, DOI 10.1006/geno.2001.6512; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Dunn R, 2001, MOL BIOL CELL, V12, P421, DOI 10.1091/mbc.12.2.421; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; FIFIORE PP, 2003, NAT REV MOL CELL BIO, V4, P491; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Galinier R, 2002, BIOCHEMISTRY-US, V41, P14299, DOI 10.1021/bi020125b; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Guichet A, 2002, EMBO J, V21, P1661, DOI 10.1093/emboj/21.7.1661; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; HICKE L, 2003, MOL BIO CELL S, V14, pA360; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Miaczynska M, 2002, EXP CELL RES, V272, P8, DOI 10.1006/excr.2001.5401; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Otte L, 2003, PROTEIN SCI, V12, P491, DOI 10.1110/ps.0233203; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Ramjaun AR, 2001, J BIOL CHEM, V276, P28913, DOI 10.1074/jbc.M103198200; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	64	94	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11471	11479		10.1074/jbc.M309934200	http://dx.doi.org/10.1074/jbc.M309934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14684745	hybrid			2022-12-27	WOS:000220157600078
J	Galang, CK; Muller, WJ; Foos, G; Oshima, RG; Hauser, CA				Galang, CK; Muller, WJ; Foos, G; Oshima, RG; Hauser, CA			Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; HUMAN BREAST-CANCER; PEA3 SUBFAMILY; MOUSE MODEL; ACTIVATE; PROTEIN; EPITHELIUM; INVASION; DOMAIN; RAS	Interfering with Ets transcription factor function reverses multiple aspects of the transformed phenotype of mouse or human tumor cells. However, the unknown number of individual Ets factors expressed in any cellular context and the similar DNA binding specificities of Ets family members complicates the identification of those that mediate transformation. By utilizing quantitative PCR assays for 25 mouse Ets factors, we analyzed the expression of essentially the entire Ets family in normal mammary tissue, mammary-related cell lines, and mammary tumors. In normal mammary tissue, 24 Ets factors were expressed. Even clonal derived cell lines expressed 14-20 Ets members. The most abundant Ets factor mRNAs measured in normal mammary tissue were Elk4, Elf1, and Ets2. Subtractive analysis of mammary tissue identified which Ets factors were predominantly expressed in the myeloid/lymphoid or epithelial cell compartments. Comparison of Ets factor expression in normal mammary tissue and mammary tumors identified significantly elevated expression of Pse/ PDEF, Ese2/Elf5, Ese3/Ehf, TEL/Etv6, and Elf2/NERF in mammary tumors and confirmed previously reported alterations in expression of Ese1/Elf3 and the PEA3 subfamily. Expression of 13 Ets target genes, implicated in various aspects of tumor progression, was also analyzed. Altered expression of particular Ets target genes was significantly correlated with particular Ets factors (e. g. maspin and Ese2), suggesting specific in vivo regulatory roles. Together, this comprehensive analysis revealed unexpectedly diverse Ets family gene expression, characterized novel Ets factor changes in mammary tumors, and implicated specific Ets factors in the regulation of multiple genes involved in mammary tumor progression.	Burnham Inst, La Jolla Canc Res Ctr, Oncodev Biol Program, La Jolla, CA 92037 USA; McGill Univ, Mol Oncol Labs, Montreal, PQ H3A 1A5, Canada	Sanford Burnham Prebys Medical Discovery Institute; McGill University	Hauser, CA (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, Oncodev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chauser@burnham.org			NCI NIH HHS [CA30199, CA63130, CA74547] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, R01CA063130, R01CA074547] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrechek ER, 2003, CANCER RES, V63, P4920; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Barrett JM, 2002, BREAST CANCER RES TR, V72, P227, DOI 10.1023/A:1014993006190; Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Boyd KE, 1999, P SOC EXP BIOL MED, V222, P9, DOI 10.1111/j.1525-1373.1999.09992.x; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen JH, 1996, ONCOGENE, V13, P1667; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Christensen RA, 2002, J CELL BIOCHEM, V85, P505, DOI 10.1002/jcb.10148; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Curry J, 2002, BIOTECHNIQUES, V32, P768, DOI 10.2144/02324st02; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Nigris F, 2001, CANCER RES, V61, P2267; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Deprez RHL, 2002, ANAL BIOCHEM, V307, P63, DOI 10.1016/S0003-2697(02)00021-0; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Eckel KL, 2003, DNA CELL BIOL, V22, P79, DOI 10.1089/104454903321515896; Feldman RJ, 2003, CANCER RES, V63, P4626; Feroze-Merzoug F, 2002, BIOTECHNIQUES, V32, P776, DOI 10.2144/02324st03; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Foos G, 2000, ONCOGENE, V19, P5507, DOI 10.1038/sj.onc.1203946; Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Graven KK, 1999, BBA-GENE STRUCT EXPR, V1447, P208, DOI 10.1016/S0167-4781(99)00118-9; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hever A, 2003, EXP CELL RES, V290, P132, DOI 10.1016/S0014-4827(03)00315-X; Hogan B, 1994, MANIPULATING MOUSE E; Kleinbaum LA, 1999, BIOCHEM BIOPH RES CO, V264, P119, DOI 10.1006/bbrc.1999.1493; LALLI E, 1992, ANAL BIOCHEM, V207, P298, DOI 10.1016/0003-2697(92)90015-Y; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lopez RG, 2003, J BIOL CHEM, V278, P41316, DOI 10.1074/jbc.M306435200; LU S, 2003, BIOCHIM BIOPHYS ACTA, V1574, P152; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; McLaughlin F, 2001, BLOOD, V98, P3332, DOI 10.1182/blood.V98.12.3332; Mitas M, 2002, BRIT J CANCER, V86, P899, DOI 10.1038/sj.bjc.6600190; Netzer S, 2002, TRANSGENIC RES, V11, P123, DOI 10.1023/A:1015248525364; Neznanov N, 1999, CANCER RES, V59, P4242; Nozawa M, 2000, CANCER RES, V60, P1348; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; Rozen S, 2000, Methods Mol Biol, V132, P365; Sapi E, 1998, CANCER RES, V58, P1027; Sarrazin S, 2000, MOL CELL BIOL, V20, P2959, DOI 10.1128/MCB.20.9.2959-2969.2000; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd T, 2001, J MAMMARY GLAND BIOL, V6, P129, DOI 10.1023/A:1009576801226; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; Singh S, 2002, CURR DRUG TARGETS, V3, P359, DOI 10.2174/1389450023347489; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Tugores A, 2001, J BIOL CHEM, V276, P20397, DOI 10.1074/jbc.M010930200; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Xuan ZY, 2002, GENOME RES, V12, P1142, DOI 10.1101/gr.220102; Young LJT, 2000, METHODS MAMMARY GLAN, P67; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815; Zhou J, 1998, ONCOGENE, V17, P2719, DOI 10.1038/sj.onc.1202198	73	107	113	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11281	11292		10.1074/jbc.M311887200	http://dx.doi.org/10.1074/jbc.M311887200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14662758	hybrid			2022-12-27	WOS:000220157600056
J	Schunemann, V; Lendzian, F; Jung, C; Contzen, J; Barra, AL; Sligar, SG; Trautwein, AX				Schunemann, V; Lendzian, F; Jung, C; Contzen, J; Barra, AL; Sligar, SG; Trautwein, AX			Tyrosine radical formation in the reaction of wild type and mutant cytochrome P450cam with peroxy acids - A multifrequency EPR study of intermediates on the millisecond time scale	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; HIGH-FIELD EPR; HORSERADISH-PEROXIDASE COMPOUND; COLI RIBONUCLEOTIDE REDUCTASE; HIGH-FREQUENCY EPR; Q-BAND ENDOR; ESCHERICHIA-COLI; SPIN-RESONANCE; PHOTOSYSTEM-II; MAGNETIC-RESONANCE	We report a multifrequency (9.6-, 94-, 190-, and 285-GHz) EPR study of a freeze-quenched intermediate obtained from reaction of substrate-free cytochrome P450cam (CYP101) and its Y96F and Y96F/Y75F mutants with peroxy acids. It is generally assumed that in such a shunt reaction an intermediate [Fe(IV) = O, porphyrin-pi-cation radical] is formed, which should be identical to the species in the natural reaction cycle. However, for the wild type as well as for the mutant proteins, a porphyrin-pi-cation radical is not detectable within 8 ms. Instead, EPR signals corresponding to tyrosine radicals are obtained for the wild type and the Y96F mutant. Replacement of both Tyr-96 and Tyr-75 by phenylalanine leads to the disappearance of the tyrosine EPR signals. EPR studies at 285 GHz on freeze-quenched wild type and Y96F samples reveal g tensor components for the radical (stretched g(x) values from 2.0078 to 2.0064, g(y) = 2.0043, and g(z) = 2.0022), which are fingerprints for tyrosine radicals in a heterogeneous polar environment. The measurements at 94 GHz using a fundamental mode microwave resonator setup confirm the 285-GHz study. From the simulation of the hyperfine structure in the 94- GHz EPR spectra the signals have been assigned to Tyr-96 in the wild type and to Tyr-75 in the Y96F mutant. We suggest that a transiently formed Fe(IV) = O porphyrin-pi-cation radical intermediate in P450cam is reduced by intramolecular electron transfer from these tyrosines within 8 ms.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Med Univ Lubeck, Inst Phys, D-23538 Lubeck, Germany; Tech Univ Berlin, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany; CNRS, Grenoble High Magnet Field Lab, F-38042 Grenoble 9, France; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Lubeck; Technical University of Berlin; Centre National de la Recherche Scientifique (CNRS); University of Illinois System; University of Illinois Urbana-Champaign	Schunemann, V (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	schuenemann@uni-Luebeck.de; lendzian@struktur.chem.tu-berlin.de; cjung@mdc-berlin.de	Schünemann, Volker/C-6603-2016					AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; [Anonymous], 1990, ELECT PARAMAGNETIC R, DOI DOI 10.1007/978-3-642-74599-7; ATKINS WM, 1988, J BIOL CHEM, V263, P18842; Ballou D P, 1978, Methods Enzymol, V54, P85; Bar G, 2001, J AM CHEM SOC, V123, P3569, DOI 10.1021/ja003108n; Barra AL, 2001, APPL MAGN RESON, V21, P619, DOI 10.1007/BF03162434; BECKER D, 1988, INT J RADIAT BIOL, V53, P767, DOI 10.1080/09553008814551121; BEINERT H, 1982, BIOCHIM BIOPHYS ACTA, V683, P245, DOI 10.1016/0304-4173(82)90003-9; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BENECKY MJ, 1993, BIOCHEMISTRY-US, V32, P11929, DOI 10.1021/bi00095a024; BIEFUSS G, 2001, BIOCHEMISTRY-US, V40, P1562; BURGHAUS O, 1993, J PHYS CHEM-US, V97, P7639, DOI 10.1021/j100131a037; CARRINGTON A, 1969, INTRO MAGNETIC RESON, P132; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P7889; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Dorlet P, 2000, BIOCHEMISTRY-US, V39, P7826, DOI 10.1021/bi000175l; Dorlet P, 2002, BIOCHEMISTRY-US, V41, P6107, DOI 10.1021/bi015871f; Egawa T, 2001, J BIOL INORG CHEM, V6, P46, DOI 10.1007/s007750000181; EGAWA T, 1991, J BIOL CHEM, V266, P10246; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; FASANELL.EL, 1969, P NATL ACAD SCI USA, V62, P299, DOI 10.1073/pnas.62.2.299; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; Graslund A, 1996, ANNU REV BIOPH BIOM, V25, P259; Green MT, 1999, J AM CHEM SOC, V121, P7939, DOI 10.1021/ja991541v; Guallar V, 2003, P NATL ACAD SCI USA, V100, P6998, DOI 10.1073/pnas.0732000100; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; Hofbauer W, 2001, P NATL ACAD SCI USA, V98, P6623, DOI 10.1073/pnas.101127598; Hoganson CW, 1996, J AM CHEM SOC, V118, P4672, DOI 10.1021/ja953979a; HUYETT JE, 1995, J AM CHEM SOC, V117, P9033, DOI 10.1021/ja00140a021; Ivancich A, 1999, J AM CHEM SOC, V121, P5743, DOI 10.1021/ja990562m; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 2001, J AM CHEM SOC, V123, P5050, DOI 10.1021/ja0036514; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Ivancich A, 1996, J AM CHEM SOC, V118, P12852, DOI 10.1021/ja9628361; Jayaraj K, 1997, INORG CHEM, V36, P4555, DOI 10.1021/ic970597s; JUNG C, 1992, BIOCHEMISTRY-US, V31, P12855, DOI 10.1021/bi00166a021; JUNG C, 1991, BIOCHIM BIOPHYS ACTA, V1076, P130, DOI 10.1016/0167-4838(91)90229-S; KALYANARAMAN B, 1983, J BIOL CHEM, V258, P3855; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; Kolberg M, 2002, ARCH BIOCHEM BIOPHYS, V397, P57, DOI 10.1006/abbi.2001.2658; Lendzian F, 1996, J AM CHEM SOC, V118, P8111, DOI 10.1021/ja960917r; LEWIS D.F.V, 1996, CYTOCHROMES P450 STR; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; MOMBOURQUETTE MJ, 1992, J MAGN RESON, V99, P37, DOI 10.1016/0022-2364(92)90153-X; NELSON DJ, 1977, J CHEM SOC PERK T 2, P2005, DOI 10.1039/p29770002005; Nimz O, 1998, APPL MAGN RESON, V14, P255, DOI 10.1007/BF03161893; Ogliaro F, 2002, J INORG BIOCHEM, V91, P554, DOI 10.1016/S0162-0134(02)00437-3; Ort D.R., 1996, ADV PHOTOSYNTH, P1; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RIEGER PH, 1982, J MAGN RESON, V50, P485, DOI 10.1016/0022-2364(82)90013-0; Rigby SEJ, 2000, BIOCHEMISTRY-US, V39, P5921, DOI 10.1021/bi992614q; RIGBY SEJ, 1994, BIOCHEMISTRY-US, V33, P1734, DOI 10.1021/bi00173a016; RUTTER R, 1983, BIOCHEMISTRY-US, V22, P4769, DOI 10.1021/bi00289a024; RUTTER R, 1982, J BIOL CHEM, V257, P7958; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; Schunemann V, 2002, J INORG BIOCHEM, V91, P586, DOI 10.1016/S0162-0134(02)00476-2; Schunemann V, 2000, FEBS LETT, V479, P149, DOI 10.1016/S0014-5793(00)01886-X; SCHUNEMANN V, 2004, IN PRESS HYPERFINE I; Sligar SG, 1977, MICROSOMES DRUG OXID, P202; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STESMANS A, 1989, REV SCI INSTRUM, V60, P2949, DOI 10.1063/1.1140633; STONE EW, 1962, J CHEM PHYS, V37, P1326, DOI 10.1063/1.1733281; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Tanaka M, 2003, BIOPHYS J, V84, P1998, DOI 10.1016/S0006-3495(03)75008-5; Un S, 1996, BIOCHEMISTRY-US, V35, P679, DOI 10.1021/bi9523769; Un S, 2001, J AM CHEM SOC, V123, P3048, DOI 10.1021/ja003650b; UNGER BP, 1986, J BIOL CHEM, V261, P1158; Urano Y, 1997, J AM CHEM SOC, V119, P12008, DOI 10.1021/ja972892h; van Dam PJ, 1998, J AM CHEM SOC, V120, P5080, DOI 10.1021/ja9737127; WAGNER GC, 1981, J BIOL CHEM, V256, P6262; WAGNER GC, 1982, BIOL CHEM IRON, P405; Weber S, 2002, P NATL ACAD SCI USA, V99, P1319, DOI 10.1073/pnas.032469399	77	83	83	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10919	10930		10.1074/jbc.M307884200	http://dx.doi.org/10.1074/jbc.M307884200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14688245	hybrid			2022-12-27	WOS:000220157600013
J	Liu, WC; Shen, XY; Yang, YZ; Yin, XL; Xie, JH; Yan, J; Jiang, JH; Liu, WJ; Wang, HZ; Sun, MY; Zheng, Y; Gu, JX				Liu, WC; Shen, XY; Yang, YZ; Yin, XL; Xie, JH; Yan, J; Jiang, JH; Liu, WJ; Wang, HZ; Sun, MY; Zheng, Y; Gu, JX			Trihydrophobin 1 is a new negative regulator of A-Raf kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; B-RAF; MAP KINASE; HEMATOPOIETIC-CELLS; INDUCED PROLIFERATION; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; DROSOPHILA-MELANOGASTER; BIOCHEMICAL-PROPERTIES	Our previous work indicated that instead of binding to B-Raf or C-Raf, trihydrophobin 1 (TH1) specifically binds to A-Raf kinase both in vitro and in vivo. In this work, we investigated its function further. Using confocal microscopy, we found that TH1 colocalizes with A-Raf, which confirms our former results. The region of TH1 responsible for the interaction with A-Raf is mapped to amino acids 1 - 372. Coimmunoprecipitation experiments demonstrate that TH1 is associated with A-Raf in both quiescent and serum-stimulated cells. Wild type A-Raf binds increasingly to TH1 when it is activated by serum and/or upstream oncogenic Ras/Src compared with that of "kinase-dead" A-Raf. The latter can still bind to TH1 under the same experimental condition. The binding pattern of A-Raf implies that this interaction is mediated in part by the A-Raf kinase activity. As indicated by Raf protein kinase assays, TH1 inhibits A-Raf kinase, whereas neither B-Raf nor C-Raf kinase activity is influenced. Furthermore, we observed that TH1 inhibited cell cycle progression in TH1 stably transfected 7721 cells compared with mock cells, and flow cell cytometry analysis suggested that the TH1 stably transfected 7721 cells were G(0)/G(1) phase-arrested. Taken together, our data provide a clue to understanding the cellular function of TH1 on Raf isoform-specific regulation.	Fudan Univ, Shanghai Med Coll, State Key Lab Genet Engn, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Coll, Ctr Gene Res, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Gu, JX (corresponding author), Fudan Univ, Shanghai Med Coll, State Key Lab Genet Engn, 138 Yixeuyuan Rd, Shanghai 200032, Peoples R China.	Jxgu@shmu.edu.cn	yang, yanzhong/AAH-6132-2019; liu, weicheng/D-4173-2013; Sun, Maoyun/I-6622-2012; Wang, Hanzhou/G-9814-2012	Wang, Hanzhou/0000-0002-0493-827X				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BANGA SS, 1995, MOL GEN GENET, V246, P148, DOI 10.1007/BF00294677; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Bonthron DT, 2000, HUM GENET, V107, P165, DOI 10.1007/s004390000344; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Chen S, 2003, J BIOL CHEM, V278, P20029, DOI 10.1074/jbc.M300818200; Cioffi CL, 1997, MOL PHARMACOL, V51, P383; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Guan KL, 2000, J BIOL CHEM, V275, P27354; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; NETZKER R, 1992, J BIOL CHEM, V267, P6421; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shinkai M, 1996, BIOCHEM BIOPH RES CO, V223, P729, DOI 10.1006/bbrc.1996.0964; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STORM SM, 1990, ONCOGENE, V5, P345; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WADEWITZ AG, 1993, ONCOGENE, V8, P1055; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; Yin XL, 2002, BBA-MOL CELL RES, V1589, P71, DOI 10.1016/S0167-4889(01)00188-4; Yin XL, 2002, MOL CELL BIOCHEM, V231, P69, DOI 10.1023/A:1014437024129; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Yuryev A, 1998, Cell Res, V8, P81; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200; Zhang SW, 2001, MOL CELL BIOCHEM, V221, P161, DOI 10.1023/A:1010932211745; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	67	16	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10167	10175		10.1074/jbc.M307994200	http://dx.doi.org/10.1074/jbc.M307994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684750	hybrid			2022-12-27	WOS:000220050400063
J	Paumann, M; Lubura, B; Regelsberger, G; Feichtinger, M; Kollensberger, G; Jakopitsch, C; Furtmuller, PG; Peschek, GA; Obinger, C				Paumann, M; Lubura, B; Regelsberger, G; Feichtinger, M; Kollensberger, G; Jakopitsch, C; Furtmuller, PG; Peschek, GA; Obinger, C			Soluble Cu-A domain of cyanobacterial cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; BLUE-GREEN-ALGAE; SP. PCC 6803; PARACOCCUS-DENITRIFICANS; SUBUNIT-II; RHODOBACTER-SPHAEROIDES; ANABAENA-VARIABILIS; ANACYSTIS-NIDULANS; FOLD RECOGNITION; SURFACE MUTANTS	The genomes of several cyanobacteria show the existence of gene clusters encoding subunits I, II, and III of aa(3)-type cytochrome c oxidase. The enzyme occurs on both plasma and thylakoid membranes of these oxygenic phototrophic prokaryotes. Here we report the expression and purification of a truncated subunit II copper A (Cu-A) domain (i.e. the electron entry and donor binding site) of cytochrome c oxidase from the cyanobacterium Synechocystis PCC 6803 in high yield. The water-soluble purple redox-active bimetallic center displays a relatively low standard reduction potential of 216 mV. Its absorption spectrum at pH 7 is similar to that of other soluble fragments from aa(3)-type oxidases, but the insensitivity of both absorbance and circular dichroism spectra to pH suggests that it is less exposed to the aqueous milieu compared with other CuA domains. Oxidation of horse heart cytochrome c by the bimetallic center follows monophasic kinetics. At pH 7 and low ionic strength the bimolecular rate constant is (2.1 +/- 0.3) x 10(4) M-1 s(-1), and the rates decrease upon the increase of ionic strength. Sequence alignment and modeling of cyanobacterial CuA domains show several peculiarities such as: (i) a large insertion located between the second transmembrane region and the putative hydrophobic cytochrome c docking site, (ii) the lack of acidic residues shown to be important in the interaction between cytochrome c and Paracoccus CuA domain, and (iii) an extended C terminus similar to Escherichia coli ubiquinol oxidase.	BOKU, Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem,Metalloprot Res Grp, A-1190 Vienna, Austria; Univ Vienna, Inst Phys Chem, Mol Bioenerget Grp, A-1090 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; University of Vienna	Obinger, C (corresponding author), BOKU, Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem,Metalloprot Res Grp, Muthgasse 18, A-1190 Vienna, Austria.	christian.obinger@boku.ac.at	Furtmüller, Paul G./Y-5819-2018; Obinger, Christian/AAV-3173-2021	Furtmüller, Paul G./0000-0002-1199-2469; Obinger, Christian/0000-0002-7133-3430; Jakopitsch, Christa/0000-0002-5855-2057; Regelsberger, Gunther/0000-0002-3233-1491				Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Abramson J, 2001, BBA-PROTEIN STRUCT M, V1544, P1, DOI 10.1016/S0167-4838(00)00241-7; ALGE D, 1993, BIOCHEM MOL BIOL INT, V29, P511; ALGE D, 1993, BIOCHEM BIOPH RES CO, V191, P9, DOI 10.1006/bbrc.1993.1177; ALGE D, 1994, GENE, V138, P127, DOI 10.1016/0378-1119(94)90794-3; BANCI L, 2001, HDB METALLOPROTEINS, V1, P33; Blankenship RE, 2001, TRENDS PLANT SCI, V6, P4, DOI 10.1016/S1360-1385(00)01831-8; BRODA E, 1979, J THEOR BIOL, V81, P201, DOI 10.1016/0022-5193(79)90160-7; Bronsted JN, 1924, J AM CHEM SOC, V46, P555, DOI 10.1021/ja01668a006; CALHOUN MW, 1994, TRENDS BIOCHEM SCI, V19, P325, DOI 10.1016/0968-0004(94)90071-X; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; Drosou V, 2002, BIOCHEMISTRY-US, V41, P10629, DOI 10.1021/bi020094k; Dutton P L, 1978, Methods Enzymol, V54, P411; Fromwald S, 1999, ARCH BIOCHEM BIOPHYS, V367, P122, DOI 10.1006/abbi.1999.1236; FRY IV, 1988, METHOD ENZYMOL, V167, P450; Gupta S, 2001, BIOCHEMISTRY-US, V40, P6180, DOI 10.1021/bi002212e; HAFELE U, 1988, BIOCHIM BIOPHYS ACTA, V934, P186, DOI 10.1016/0005-2728(88)90181-8; Hennig L, 1999, BIOTECHNIQUES, V26, P1170, DOI 10.2144/99266bc02; Howitt CA, 1998, BIOCHEMISTRY-US, V37, P17944, DOI 10.1021/bi981486n; ISO GUM, 1995, GUID EXPR UNC MEAS, Vfirst; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Jones DT, 1998, FEBS LETT, V423, P281, DOI 10.1016/S0014-5793(98)00095-7; Kaneko T, 1996, DNA Res, V3, P109; Komorowski L, 2001, J BIOENERG BIOMEMBR, V33, P27, DOI 10.1023/A:1005668522801; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LARSSON S, 1995, P NATL ACAD SCI USA, V92, P7167, DOI 10.1073/pnas.92.16.7167; Lassmann T, 2002, FEBS LETT, V529, P126, DOI 10.1016/S0014-5793(02)03189-7; LOCKAU W, 1981, ARCH MICROBIOL, V128, P336, DOI 10.1007/BF00422541; Malatesta F, 1998, FEBS LETT, V434, P322, DOI 10.1016/S0014-5793(98)01006-0; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; NICHOLLS P, 1992, BIOCHIM BIOPHYS ACTA, V1098, P184, DOI 10.1016/S0005-2728(05)80335-4; NITSCHKE W, 1991, TRENDS BIOCHEM SCI, V16, P241, DOI 10.1016/0968-0004(91)90095-D; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PESCHEK GA, 1982, ARCH MICROBIOL, V131, P261, DOI 10.1007/BF00405890; Peschek GA, 1996, BIOCHEM SOC T, V24, P729, DOI 10.1042/bst0240729; Peschek GA, 1996, BBA-BIOENERGETICS, V1275, P27, DOI 10.1016/0005-2728(96)00045-X; PESCHEK GA, 1994, BBA-BIOENERGETICS, V1187, P369, DOI 10.1016/0005-2728(94)90011-6; PESCHEK GA, 1994, FEMS MICROBIOL LETT, V124, P431, DOI 10.1111/j.1574-6968.1994.tb07320.x; PETTGREW GW, 1987, CYTOCHROMES C BIOL A; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; Romero A, 1998, J MOL BIOL, V275, P327, DOI 10.1006/jmbi.1997.1455; SANDMANN G, 1980, PLANT SCI LETT, V17, P417, DOI 10.1016/0304-4211(80)90128-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Slutter CE, 1996, BIOCHEMISTRY-US, V35, P3387, DOI 10.1021/bi9525839; SONE N, 1993, BIOCHIM BIOPHYS ACTA, V1183, P130, DOI 10.1016/0005-2728(93)90012-5; Sorlie M, 2000, ANAL BIOCHEM, V287, P118, DOI 10.1006/abio.2000.4826; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Svensson-Ek M, 2002, J MOL BIOL, V321, P329, DOI 10.1016/S0022-2836(02)00619-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang KF, 1999, J BIOL CHEM, V274, P38042, DOI 10.1074/jbc.274.53.38042; WASTYN M, 1987, BIOCHEM BIOPH RES CO, V149, P102, DOI 10.1016/0006-291X(87)91610-X; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; Wilmanns M, 1995, P NATL ACAD SCI USA, V92, P11955, DOI 10.1073/pnas.92.26.11955; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; Zhen YJ, 1999, J BIOL CHEM, V274, P38032, DOI 10.1074/jbc.274.53.38032	66	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10293	10303		10.1074/jbc.M308903200	http://dx.doi.org/10.1074/jbc.M308903200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14672950	hybrid			2022-12-27	WOS:000220050400078
J	Wang, AM; Hascall, VC				Wang, AM; Hascall, VC			Hyaluronan structures synthesized by rat mesangial cells in response to hyperglycemia induce monocyte adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SMOOTH-MUSCLE-CELLS; CARBOHYDRATE ELECTROPHORESIS FACE; EXPERIMENTAL DIABETIC-NEPHROPATHY; HIGH GLUCOSE CONDITIONS; GROWTH-FACTOR-BETA; PROSTAGLANDIN PRODUCTION; RENAL HYPERTROPHY; GLOMERULAR CELLS; EXPRESSION	Mesangial expansion, the principal glomerular lesion in diabetic nephropathy, is preceded by a phenotypic activation and transient proliferation of the glomerular mesangial cells and by a prominent glomerular infiltration of monocytes and macrophages. Because this infiltration seems to play a key role in the subsequent mesangial matrix expansion, we tested the response of cultures of rat mesangial cells (RMCs) for monocyte adhesion in response to hyperglycemia. Increasing the medium glucose concentration from 5.6 mM ( normal) to 25.6 mM ( hyperglycemic) significantly increased hyaluronan in the cell matrix, with a concurrent 3- to 4-fold increase in adhesion of U937 monocytic leukemic cells to cultures of near confluent RMCs. These responses were attributed directly to the high glucose concentration and not to increased extracellular osmolality. The monocytes primarily bind directly to hyaluronan-based structures in vitro. Abnormal deposits of hyaluronan were found in glomeruli of kidney sections from diabetic rats 1 week after streptozotocin treatment, often with closely associated monocytes/macrophages, suggesting that similar structures are relevant in vivo. The monocyte adhesion response to high glucose concentration required growth stimulation of RMCs by serum and activation of protein kinase C, and was inhibited by prior passage of the RMCs in the presence of heparin. These results suggest that the response may be cell growth state and protein kinase C-dependent. When incubated with the viral mimetic, poly I: C, in the presence of normal glucose, heparin-passaged RMCs still increased cell-associated hyaluronan and exhibited hyaluronan-mediated adhesion of monocytes, indicating that the two stimuli, high glucose and viral mimetic, induce the production of the hyaluronan structures that promote monocyte adhesion by distinctly different intracellular signaling mechanisms.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Wang, AM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave,ND20, Cleveland, OH 44195 USA.	wanga@bme.ri.ccf.org			NIDDK NIH HHS [K01 DK02847] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002847] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babazono T, 1998, DIABETES, V47, P668, DOI 10.2337/diabetes.47.4.668; BARZU T, 1994, J CELL PHYSIOL, V160, P239, DOI 10.1002/jcp.1041600205; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; Calabro A, 2000, GLYCOBIOLOGY, V10, P283, DOI 10.1093/glycob/10.3.283; Calabro A, 2001, OSTEOARTHR CARTILAGE, V9, pS16, DOI 10.1053/joca.2001.0439; CALABRO A, 2000, PROTEOGLYCANS STRUCT, P5; Craven PA, 1995, J DIABETES COMPLICAT, V9, P241, DOI 10.1016/1056-8727(95)80012-4; CRAVEN PA, 1987, METABOLISM, V36, P95, DOI 10.1016/0026-0495(87)90070-9; de la Motte CA, 2003, AM J PATHOL, V163, P121, DOI 10.1016/S0002-9440(10)63636-X; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1; DIAMOND JR, 1991, AM J PHYSIOL, V260, pF779, DOI 10.1152/ajprenal.1991.260.6.F779; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; Dunlop ME, 1996, KIDNEY INT, V50, P40, DOI 10.1038/ki.1996.284; Erikstrup C, 2001, EUR J ENDOCRINOL, V145, P193, DOI 10.1530/eje.0.1450193; FURUTA T, 1993, AM J KIDNEY DIS, V21, P480, DOI 10.1016/S0272-6386(12)80393-3; GAMBARO G, 1992, KIDNEY INT, V42, P285, DOI 10.1038/ki.1992.288; GAMBARO G, 1994, KIDNEY INT, V46, P797, DOI 10.1038/ki.1994.335; Glogowski EA, 1999, KIDNEY INT, V55, P486, DOI 10.1046/j.1523-1755.1999.00284.x; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; Hascall VC, 2000, GLYCOCONJUGATE J, V17, P607, DOI 10.1023/A:1011082728155; HEGELE RG, 1989, CLIN INVEST MED, V12, P181; Jones S, 2001, KIDNEY INT, V59, P1739, DOI 10.1046/j.1523-1755.2001.0590051739.x; KIKKAWA R, 1994, DIABETOLOGIA, V37, P838, DOI 10.1007/BF00404342; KLEIN DJ, 1986, DIABETES, V35, P1130, DOI 10.2337/diabetes.35.10.1130; MAHADEVAN P, 1995, DIABETOLOGIA, V38, P298, DOI 10.1007/s001250050285; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; MAUER SM, 1994, KIDNEY INT, V45, P612, DOI 10.1038/ki.1994.80; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; Mene P, 1996, KIDNEY INT, V50, P417, DOI 10.1038/ki.1996.331; MENE P, 1995, NEPHROL DIAL TRANSPL, V10, P481, DOI 10.1093/ndt/10.4.481; Mene P, 2001, NEPHROL DIAL TRANSPL, V16, P913, DOI 10.1093/ndt/16.5.913; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; NAKAMURA T, 1993, DIABETES, V42, P450, DOI 10.2337/diabetes.42.3.450; RADOUNIKLI A, 1995, NEPHROL DIAL TRANSPL, V10, P185; Rodriguez-Iturbe B, 2001, KIDNEY INT, V59, P1626, DOI 10.1046/j.1523-1755.2001.0590051626.x; SCHAMBELAN M, 1985, J CLIN INVEST, V75, P404, DOI 10.1172/JCI111714; SHANKLAND SJ, 1994, KIDNEY INT, V46, P430, DOI 10.1038/ki.1994.291; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; Takeda M, 2001, METABOLISM, V50, P789, DOI 10.1053/meta.2001.24207; TEMPLETON DM, 1990, J BIOL CHEM, V265, P21764; Templeton DM, 2000, CARDIOVASC RES, V45, P503, DOI 10.1016/S0008-6363(99)00357-0; TOOLE BP, 2000, PROTEOGLYCANS STRUCT, P61; Wang AM, 1996, KIDNEY INT, V49, P437, DOI 10.1038/ki.1996.63; WANG AM, 1994, J CELL PHYSIOL, V159, P295, DOI 10.1002/jcp.1041590213; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Young B., 1992, Journal of the American Society of Nephrology, V3, P770; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139	49	89	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10279	10285		10.1074/jbc.M312045200	http://dx.doi.org/10.1074/jbc.M312045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679194	hybrid			2022-12-27	WOS:000220050400076
J	Cha, MK; Kim, WC; Lim, CJ; Kim, K; Kim, IH				Cha, MK; Kim, WC; Lim, CJ; Kim, K; Kim, IH			Escherichia coli periplasmic thiol peroxidase acts as lipid hydroperoxide peroxidase and the principal antioxidative function during anaerobic growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; OXIDATION; PROTEINS; STRESS	To clarify the enzymatic property of Escherichia coli periplasmic thiol peroxidase (p20), the specific peroxidase activity toward peroxides was compared with other bacterial thiol peroxidases. p20 has the most substrate preference and peroxidase activity toward organic hydroperoxide. Furthermore, p20 exerted the most potent lipid peroxidase activity. Despite that the mutation of p20 caused the highest susceptibility toward organic hydroperoxide and heat stress, the cellular level of p20 did not respond to the exposure of oxidative stress. Expression level of p20 during anaerobic growth was sustained at the similar to50% level compared with that of the aerobic growth. Viability of aerobic p20Delta without glucose was reduced to the similar to65% level of isogenic strains, whereas viability of aerobic p20Delta with 0.5% glucose supplement was sustained. The deletion of p20 resulted in a gradual loss of the cell viability during anaerobic growth. At the stationary phase, the viability of p20Delta was down to similar to10% level of parent strains. An analysis of the protein carbonyl contents of p20Delta as a marker for cellular oxidation indicates that severe reduction of viability of anaerobic p20Delta was caused by cumulative oxidative stress. P20Delta showed hypersensitivity toward membrane-soluble organic hydroperoxides. An analysis of protein carbonyl and lipid hydroperoxide contents in the membrane of the stress-imposed p20Delta demonstrates that the severe reduction of viability was caused by cumulative oxidative stress on the membrane. Taken together, present data uncover in vivo function for p20 as a lipid hydroperoxide peroxidase and demonstrate that, as the result, p20 acts as the principal antioxidant in the anaerobic habitats.	Paichai Univ, Dept Biochem, Taejon 302735, South Korea; NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Kangwon Natl Univ, Dept Biochem, Chunchon 200701, South Korea; Chonnam Natl Univ, Dept Food & Nutr, Kwangjoo 50075, South Korea	Pai Chai University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Kangwon National University; Chonnam National University	Kim, IH (corresponding author), Paichai Univ, Dept Biochem, 439-6 Doma 2 Dong, Taejon 302735, South Korea.	ihkim@mail.paichai.ac.kr	Kim, Il-Han/W-1401-2019					Baker LMS, 2003, J BIOL CHEM, V278, P9203, DOI 10.1074/jbc.M209888200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; Choi JK, 2003, J BIOL CHEM, V278, P49478, DOI 10.1074/jbc.M309015200; CLARK DP, 1989, FEMS MICROBIOL LETT, V63, P223, DOI 10.1111/j.1574-6968.1989.tb03398.x; de Macario EC, 2000, FRONT BIOSCI-LANDMRK, V5, pD780; FERRI A, 1995, BIOCHEM MOL BIOL INT, V35, P691; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Holms H, 1996, FEMS MICROBIOL REV, V19, P85, DOI 10.1111/j.1574-6976.1996.tb00255.x; ISIKORSKI RS, 1989, GENETICS, V122, P19; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; KIM KW, 1988, J BIOL CHEM, V263, P4704; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; LYNCH AS, 1996, E COLI SALMONELLA CE, V6, P1526; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Poole LB, 2000, EUR J BIOCHEM, V267, P6126, DOI 10.1046/j.1432-1327.2000.01704.x; POOLE LB, 2003, SIGNAL TRANSDUCTION, P80; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Sambrook J., 2001, MOL CLONING LAB MANU; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Talent JM, 1998, ANAL BIOCHEM, V263, P31, DOI 10.1006/abio.1998.2752; TENHAKEN R, 1995, P NATL ACAD SCI USA, V92, P4158, DOI 10.1073/pnas.92.10.4158; Wan XY, 1997, FEBS LETT, V407, P32, DOI 10.1016/S0014-5793(97)00302-5; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8	30	53	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8769	8778		10.1074/jbc.M312388200	http://dx.doi.org/10.1074/jbc.M312388200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676195	hybrid			2022-12-27	WOS:000189265900031
J	Yanagisawa, M; Kaverina, IN; Wang, AX; Fujita, Y; Reynolds, AB; Anastasiadis, PZ				Yanagisawa, M; Kaverina, IN; Wang, AX; Fujita, Y; Reynolds, AB; Anastasiadis, PZ			A novel interaction between kinesin and p120 modulates p120 localization and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; TRANSCRIPTION FACTOR; CATENIN P120(CTN); CADHERIN FUNCTION; BINDING-PROTEIN; NUCLEAR IMPORT; CELL-ADHESION; PARTNER KAISO; P120-CATENIN; CANCER	p120-catenin exists in a membrane-associated cadherin-bound pool, a cytosolic pool that affects Rho GTPases, and a nuclear pool that is thought to associate with the methylation-relevant transcriptional repressor Kaiso. We show here that cytoplasmic p120 can also associate both directly and indirectly with the microtubule network, and that p120 traffics along microtubules toward their plus ends. The direct binding required most of the armadillo repeats and was mutually exclusive for interaction with E-cadherin. Perturbing the p120-microtubule interaction with nocodazole or taxol markedly affected both the tubulin interaction and the balance between cytoplasmic and nuclear p120. The indirect binding occurred via a novel interaction between a segment of the p120 N-terminal domain and conventional kinesin heavy chains. Selective uncoupling of the p120-kinesin interaction by overexpression of the respective p120 and kinesin-binding fragments promoted nuclear p120 accumulation. In addition, expression of full-length kinesin reduced the nuclear accumulation of p120 and blocked the branching phenotype associated with p120 overexpression. Taken together, the data suggest that kinesin affects both the targeting and activity of p120 at several cellular locations.	Mayo Clin, Ctr Canc, Jacksonville, FL 32224 USA; Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, A-5020 Salzburg, Austria; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; UCL, MRC Lab, Mol Cell Biol & Cell Biol Unit, London WC1E 6BT, England; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA	Mayo Clinic; Austrian Academy of Sciences; University of Texas System; University of Texas Medical Branch Galveston; University of London; University College London; Vanderbilt University	Anastasiadis, PZ (corresponding author), Mayo Clin, Ctr Canc, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	panos@mayo.edu	Fujita, Yasuyuki/A-4324-2012		NATIONAL CANCER INSTITUTE [R01CA055724] Funding Source: NIH RePORTER; MRC [MC_U122669938] Funding Source: UKRI; Medical Research Council [MC_U122669938] Funding Source: Medline; NCI NIH HHS [R01-CA55724] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cai YF, 2001, J BIOL CHEM, V276, P41594, DOI 10.1074/jbc.M104514200; Campbell EA, 2003, ADV DRUG DELIVER REV, V55, P761, DOI 10.1016/S0169-409X(03)00049-8; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Grosheva I, 2001, J CELL SCI, V114, P695; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; Mayerle J, 2003, GASTROENTEROLOGY, V124, P949, DOI 10.1053/gast.2003.50142; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Roczniak-Ferguson A, 2003, J CELL SCI, V116, P4201, DOI 10.1242/jcs.00724; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; Wu J, 1998, HYBRIDOMA, V17, P175, DOI 10.1089/hyb.1998.17.175; Xia XB, 2003, BIOCHEMISTRY-US, V42, P9195, DOI 10.1021/bi034597h; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008	33	103	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9512	9521		10.1074/jbc.M310895200	http://dx.doi.org/10.1074/jbc.M310895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676216	hybrid			2022-12-27	WOS:000189265900118
J	Brush, MH; Guardiola, A; Connor, JH; Yao, TP; Shenolikar, S				Brush, MH; Guardiola, A; Connor, JH; Yao, TP; Shenolikar, S			Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 PHOSPHORYLATION; IN-VIVO; MITOTIC PHOSPHORYLATION; GROWTH-INHIBITION; CATALYTIC SUBUNIT; TRICHOSTATIN-A; ACETYLATION; KINASE; MICROTUBULES; FIBROBLASTS	Affinity isolation of protein serine/threonine phosphatases on the immobilized phosphatase inhibitor microcystin-LR identified histone deacetylase 1(HDAC1), HDAC6, and HDAC10 as novel components of cellular phosphatase complexes. Other HDACs, specifically HDAC2, -3, -4, and -5, were excluded from such complexes. In vitro biochemical studies showed that recombinant HDAC6, but not HDAC4, bound directly to the protein phosphatase ( PP) 1 catalytic subunit. No association was observed between HDAC6 and PP2A, another major protein phosphatase. PP1 binding was mapped to the second catalytic domain and adjacent C-terminal sequences in HDAC6, and treatment of cells with trichostatin A (TSA) disrupted endogenous HDAC6.PP1 complexes. Consistent with the inhibition of tubulin deactylase activity of HDAC6, TSA enhanced cellular tubulin acetylation, and acetylated tubulin was present in the PP1 complexes from TSA-treated cells. Trapoxin B, a weak HDAC6 inhibitor, and calyculin A, a cell-permeable phosphatase inhibitor, had no effect on the stability of the HDAC6.PP1 complexes or on tubulin acetylation. Mutations that inactivated HDAC6 prevented its incorporation into cellular PP1 complexes and suggested that when bound together both enzymes were active. Interestingly, TSA disrupted all the cellular HDAC.phosphatase complexes analyzed. This study provided new insight into the mechanism by which HDAC inhibitors elicited coordinate changes in cellular protein phosphorylation and acetylation and suggested that changes in these protein modifications at multiple subcellular sites may contribute to the known ability of HDAC inhibitors to suppress cell growth and transformation.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Shenolikar, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, LSRC C315,Res Dr, Durham, NC 27710 USA.	sheno001@mc.duke.edu		Connor, John/0000-0002-8867-7256	NIDDK NIH HHS [R01-DK52054] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; Brinkmann H, 2001, J BIOL CHEM, V276, P22491, DOI 10.1074/jbc.M100206200; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chang TH, 2002, CLIN CANCER RES, V8, P1206; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; Edmondson DG, 2002, J BIOL CHEM, V277, P29496, DOI 10.1074/jbc.M200651200; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Fass DM, 2003, J BIOL CHEM, V278, P43014, DOI 10.1074/jbc.M305905200; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Jin QM, 2003, J BIOL CHEM, V278, P30677, DOI 10.1074/jbc.M302273200; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Yamagoe S, 2003, MOL CELL BIOL, V23, P1025, DOI 10.1128/MCB.23.3.1025-1033.2003; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	52	112	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7685	7691		10.1074/jbc.M310997200	http://dx.doi.org/10.1074/jbc.M310997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670976	hybrid			2022-12-27	WOS:000189103300040
J	Cherny, I; Gazit, E				Cherny, I; Gazit, E			The YefM antitoxin defines a family of natively unfolded proteins - Implications as a novel antibacterial target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID ADDICTION SYSTEM; NUTRITIONAL STRESS; DISORDERED PROTEIN; ESCHERICHIA-COLI; DNA-BINDING; CELL-DEATH; TOXIN; PHD; P1; PROPHAGE	Although natively unfolded proteins are being observed increasingly, their physiological role is not well understood. Here, we demonstrate that the Escherichia coli YefM protein is a natively unfolded antitoxin, lacking secondary structure even at low temperature or in the presence of a stabilizing agent. This conformation of the protein is suggested to have a key role in its physiological regulatory activity. Because of the unfolded state of the protein, a linear determinant rather than a conformational one is presumably being recognized by its toxin partner, YoeB. A peptide array technology allowed the identification and validation of such a determinant. This recognition element may provide a novel antibacterial target. Indeed, a pair-constrained bioinformatic analysis facilitated the definite determination of novel YefM-YoeB toxin-antitoxin systems in a large number of bacteria including major pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, and Mycobacterium tuberculosis. Taken together, the YefM protein defines a new family of natively unfolded proteins. The existence of a large and conserved group of proteins with a clear physiologically relevant unfolded state serves as a paradigm to understand the structural basis of this state.	Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel	Tel Aviv University	Gazit, E (corresponding author), Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, George S Wise Fac Life Sci, Green Bldg,Rm 221, IL-69978 Tel Aviv, Israel.	ehudg@post.tau.ac.il	Gazit, Ehud/M-8026-2019; Gazit, Ehud/C-3715-2011; Gazit, Ehud/AHE-9332-2022	Gazit, Ehud/0000-0001-5764-1720; Gazit, Ehud/0000-0001-5764-1720; 				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Camacho AG, 2002, BIOL CHEM, V383, P1701, DOI 10.1515/BC.2002.191; Christensen SK, 2003, MOL MICROBIOL, V48, P1389, DOI 10.1046/j.1365-2958.2003.03512.x; Christensen SK, 2001, P NATL ACAD SCI USA, V98, P14328, DOI 10.1073/pnas.251327898; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Gazit E, 2002, CURR MED CHEM, V9, P1725; Gazit E, 1999, J BIOL CHEM, V274, P2652, DOI 10.1074/jbc.274.5.2652; Gazit E, 1999, J BIOL CHEM, V274, P16813, DOI 10.1074/jbc.274.24.16813; Gerdes K, 2000, J BACTERIOL, V182, P561, DOI 10.1128/JB.182.3.561-572.2000; Grady R, 2003, MOL MICROBIOL, V47, P1419, DOI 10.1046/j.1365-2958.2003.03387.x; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; JENNESS DD, 1976, BIOPOLYMERS, V15, P513, DOI 10.1002/bip.1976.360150308; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; Oberer M, 1999, BIOL CHEM, V380, P1413, DOI 10.1515/BC.1999.181; Pedersen K, 2002, MOL MICROBIOL, V45, P501, DOI 10.1046/j.1365-2958.2002.03027.x; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Pomerantsev AP, 2001, PLASMID, V46, P210, DOI 10.1006/plas.2001.1548; RADIVOJAC P, 2003, PAC S BIOC, V8, P216; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; THI MHD, 2000, J MOL BIOL, V299, P1373; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; VIHINEN M, 1994, PROTEINS, V19, P141, DOI 10.1002/prot.340190207	32	67	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8252	8261		10.1074/jbc.M308263200	http://dx.doi.org/10.1074/jbc.M308263200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672926	hybrid			2022-12-27	WOS:000189103300107
J	Feramisco, JD; Goldstein, JL; Brown, MS				Feramisco, JD; Goldstein, JL; Brown, MS			Membrane topology of human Insig-1, a protein regulator of lipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; STEROL-SENSING DOMAIN; HMG-COA REDUCTASE; ENDOPLASMIC-RETICULUM; SREBP; SCAP; ER; PATHWAY; CELLS	Insig-1 is an intrinsic protein of the endoplasmic reticulum (ER) that regulates the proteolytic processing of membrane-bound sterol regulatory element-binding proteins (SREBPs), transcription factors that activate the synthesis of cholesterol and fatty acids in mammalian cells. When cellular levels of sterols rise, Insig-1 binds to the membranous sterol-sensing domain of SREBP cleavage-activating protein ( SCAP), retaining the SCAP/SREBP complex in the ER and preventing it from moving to the Golgi for proteolytic processing. Under conditions of sterol excess, Insig-1 also binds to the ER enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, facilitating its ubiquitination and proteasomal degradation. Here, we use protease protection, glycosylation site mapping, and cysteine derivitization to define the topology of the 277-amino acid human Insig-1. The data indicate that short segments at the N and C termini of Insig-1 face the cytosol. Most of the protein is buried within the membrane, forming six transmembrane segments separated by five short luminal and cytosolic loops that range from similar to5 to 16 amino acids. The membranous nature of Insig-1 is consistent with its sterol-dependent binding to hydrophobic sterol-sensing domains in SCAP and HMG CoA reductase.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	joe.goldstein@utsouthwestern.edu; mike.brown@utsouthwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Espenshade PJ, 2002, P NATL ACAD SCI USA, V99, P11694, DOI 10.1073/pnas.182412799; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Istvan ES, 2000, EMBO J, V19, P819, DOI 10.1093/emboj/19.5.819; KOCH GLE, 1988, J CELL SCI, V90, P485; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LISCUM L, 1985, J BIOL CHEM, V260, P522; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rutledge EA, 1998, J BIOL CHEM, V273, P12169, DOI 10.1074/jbc.273.20.12169; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Sever N, 2003, J BIOL CHEM, V278, P52479, DOI 10.1074/jbc.M310053200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2000, J BIOL CHEM, V275, P29881, DOI 10.1074/jbc.M005439200; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	30	73	78	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8487	8496		10.1074/jbc.M312623200	http://dx.doi.org/10.1074/jbc.M312623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660594	hybrid			2022-12-27	WOS:000189103300132
J	Inuzuka, T; Yun, BG; Ishikawa, H; Takahashi, S; Hori, H; Matts, RL; Ishimori, K; Morishima, I				Inuzuka, T; Yun, BG; Ishikawa, H; Takahashi, S; Hori, H; Matts, RL; Ishimori, K; Morishima, I			Identification of crucial histidines for heme binding in the N-terminal domain of the heme-regulated eIF2 alpha kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EIF-2-ALPHA KINASE; PROTEIN-SYNTHESIS; RESONANCE RAMAN; REPLACEMENT; MYOGLOBIN; CYSTEINE; LIGAND	The heme-regulated eukaryotic initiation factor-2alpha (eIF2alpha) kinase (HRI) regulates the initiation of protein synthesis in reticulocytes. The binding of NO to the N-terminal heme-binding domain (NTD) of HRI positively modulates its kinase activity. By utilizing UV-visible absorption, resonance Raman, EPR and CD spectroscopies, two histidine residues have been identified that are crucial for the binding of heme to the NTD. The UV-visible absorption and resonance Raman spectra of all the histidine to alanine mutants constructed were similar to those of the unmutated NTD. However, the change in the CD spectra of the NTD construct containing mutation of His(78) to Ala (H78A) indicated loss of the specific binding of heme. The EPR spectrum for the ferric H78A mutant was also substantially perturbed. Thus, His(78) is one of the axial ligands for the NTD of HRL Significant changes in the EPR spectrum of the H123A mutant were also observed, and heme readily dissociated from both the H123A and the H78A NTD mutants, suggesting that His(123) was also an axial heme ligand. However, the CD spectrum for the Soret region of the H123A mutant indicated that this mutant still bound heme specifically. Thus, while both His(78) and His(123) are crucial for stable heme binding, the effects of their mutations on the structure of the NTD differed. His(78) appears to play the primary role in the specific binding of heme to the NTD, acting analogously to the "proximal histidine" ligand of globins, while His(123) appears to act as the "distal" heme ligand.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan; Osaka Univ, Grad Sch Engn Sci, Dept Bioengn, Osaka 5608531, Japan	Oklahoma State University System; Oklahoma State University - Stillwater; Kyoto University; Osaka University	Matts, RL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	rmatts@biochem.okstate.edu; koichiro@scl.kyoto-u.ac.jp; morisima@mds.moleng.kyoto-u.ac.jp	Ishikawa, Haruto/B-1562-2012; Ishimori, Koichiro/S-1247-2016; Ishimori, Koichiro/AAQ-4434-2021	Ishikawa, Haruto/0000-0001-6362-5719; Ishimori, Koichiro/0000-0002-5868-0462; Ishimori, Koichiro/0000-0002-5868-0462				ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; BOISPOLTORATSKY R, 1967, EUR J BIOCHEM, V2, P361, DOI 10.1111/j.1432-1033.1967.tb00146.x; Chefalo PJ, 1998, EUR J BIOCHEM, V258, P820, DOI 10.1046/j.1432-1327.1998.2580820.x; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; Hirst J, 2001, BIOCHEMISTRY-US, V40, P1274, DOI 10.1021/bi002090q; HSU MC, 1971, J AM CHEM SOC, V93, P3515; Ihara M, 2000, BIOCHEMISTRY-US, V39, P5961, DOI 10.1021/bi9922289; Ishikawa H, 2002, J AM CHEM SOC, V124, P13696, DOI 10.1021/ja0272336; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; Rafie-Kolpin M, 2000, J BIOL CHEM, V275, P5171, DOI 10.1074/jbc.275.7.5171; RIVERA M, 1992, BIOCHEMISTRY-US, V31, P12233, DOI 10.1021/bi00163a037; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x; Uma S, 2001, J BIOL CHEM, V276, P14875, DOI 10.1074/jbc.M011476200; Yoshioka S, 2001, EUR J BIOCHEM, V268, P252, DOI 10.1046/j.1432-1033.2001.01872.x	16	20	21	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6778	6782		10.1074/jbc.C300464200	http://dx.doi.org/10.1074/jbc.C300464200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14672943	hybrid			2022-12-27	WOS:000188969200071
J	O'Sullivan, A; Chang, HC; Yu, Q; Kaplan, MH				O'Sullivan, A; Chang, HC; Yu, Q; Kaplan, MH			STAT4 is required for interleukin-12-induced chromatin remodeling of the CD25 locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHAIN GENE; ACTIVATED PROTEIN-KINASE; IFN-GAMMA PROMOTER; IL-2 RECEPTOR; TYROSINE PHOSPHORYLATION; HISTONE ACETYLATION; SIGNAL TRANSDUCER; NATURAL-KILLER; BINDING-SITES; FACTOR-I	Signal transducer and activator of transcription 4 (STAT4) is a critical mediator of interleukin-12 (IL-12)stimulated inflammatory immune responses. Despite extensive analysis of the immune responses of STAT4-deficient mice, there is still very little understood about STAT4-dependent gene induction. IL-12 stimulated increases in IL-2 receptor a chain gene (CD25) mRNA levels and surface expression require STAT4. In this report, we utilize chromatin immunoprecipitation assays to analyze IL-12-stimulated and STAT4-dependent changes in chromatin remodeling of the CD25 gene. Gene activation requires binding of STAT4 to the PRRIII upstream regulatory element, the recruitment of the CREB-binding protein (CBP), and chromatin remodeling including increased acetylation and decreased methylation of histones within the CD25 promoter. Evidence suggests that STAT4 also facilitates binding of other factors to the CD25 promoter including c-Jun. Thus, these results provide a model for STAT4-dependent gene induction and a mechanism for cytokine-induced expression of the CD25 gene.	Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Kaplan, MH (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, 950 W Walnut St,Rm 302, Indianapolis, IN 46202 USA.	mkaplan2@iupui.edu			NIAID NIH HHS [AI45515] Funding Source: Medline; NIDDK NIH HHS [T32DK007519] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045515, R56AI045515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; Barbulescu K, 1998, J IMMUNOL, V160, P3642; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Chang HC, 2003, J BIOL CHEM, V278, P32471, DOI 10.1074/jbc.M302776200; Coccia EM, 1999, J BIOL CHEM, V274, P6698, DOI 10.1074/jbc.274.10.6698; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Galon J, 1999, J IMMUNOL, V162, P7256; Gingras S, 1999, NUCLEIC ACIDS RES, V27, P2722, DOI 10.1093/nar/27.13.2722; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guler ML, 1997, J IMMUNOL, V159, P1767; Hoey T, 2003, EMBO J, V22, P4237, DOI 10.1093/emboj/cdg393; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; John S, 1999, MOL CELL BIOL, V19, P1910; JOHN S, 1995, MOL CELL BIOL, V15, P1786; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kato T, 1997, CELL IMMUNOL, V176, P50, DOI 10.1006/cimm.1996.1072; Kim HP, 2002, EMBO J, V21, P3051, DOI 10.1093/emboj/cdf321; Kim HP, 2001, IMMUNITY, V15, P159, DOI 10.1016/S1074-7613(01)00167-4; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; Lawless VA, 2000, J IMMUNOL, V165, P6803, DOI 10.4049/jimmunol.165.12.6803; Lecine P, 1996, MOL CELL BIOL, V16, P6829; LIN BB, 1990, MOL CELL BIOL, V10, P850, DOI 10.1128/MCB.10.2.850; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Morris AC, 2002, MOL CELL BIOL, V22, P4781, DOI 10.1128/MCB.22.13.4781-4791.2002; Naeger LK, 1999, J BIOL CHEM, V274, P1875, DOI 10.1074/jbc.274.4.1875; Nakahira M, 2001, J IMMUNOL, V167, P1306, DOI 10.4049/jimmunol.167.3.1306; Nakahira M, 2002, J IMMUNOL, V168, P1146, DOI 10.4049/jimmunol.168.3.1146; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; Nguyen T, 2000, EUR J IMMUNOL, V30, P1445, DOI 10.1002/(SICI)1521-4141(200005)30:5<1445::AID-IMMU1445>3.0.CO;2-M; Nishikomori R, 2002, J IMMUNOL, V169, P4388, DOI 10.4049/jimmunol.169.8.4388; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Ouyang W, 1999, P NATL ACAD SCI USA, V96, P3888, DOI 10.1073/pnas.96.7.3888; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; PIERCE JW, 1995, J IMMUNOL, V155, P1972; Saccani S, 2002, GENE DEV, V16, P2219, DOI 10.1101/gad.232502; Schuh K, 1998, J EXP MED, V188, P1369, DOI 10.1084/jem.188.7.1369; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Tsytsykova AV, 2002, MOL CELL BIOL, V22, P2620, DOI 10.1128/MCB.22.8.2620-2631.2002; Valenzuela J, 2002, J IMMUNOL, V169, P6842, DOI 10.4049/jimmunol.169.12.6842; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YANAGIDA T, 1994, J IMMUNOL, V152, P4919; Yeh JH, 2001, MOL CELL BIOL, V21, P4515, DOI 10.1128/MCB.21.14.4515-4527.2001; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang SM, 2000, J IMMUNOL, V165, P1374, DOI 10.4049/jimmunol.165.3.1374; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	58	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7339	7345		10.1074/jbc.M309979200	http://dx.doi.org/10.1074/jbc.M309979200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660657	hybrid			2022-12-27	WOS:000188969200136
J	Chen, NH; Rickey, J; Berfield, JL; Reith, MEA				Chen, NH; Rickey, J; Berfield, JL; Reith, MEA			Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOAMINE TRANSPORTERS; CROSS-LINKING; INHIBITION; EXPRESSION; CLONING; SITE; ACCESSIBILITY; CYSTEINE; ALTERS	present study elucidated the role of aspartate 345, a residue conserved in the third intracellular loop of all Na+/Cl-- dependent neurotransmitter transporters, in conformational changes of the dopamine ( DA) transporter. Asparagine substitution ( D345N) resulted in near normal transporter expression on the cell surface but caused extremely low V-max and K-m values for DA uptake, converted the inhibitory effect of Zn2+ on DA uptake to a stimulatory one, and eliminated reverse transport. The cocaine- like inhibitor 2 beta- carbomethoxy-3beta ( 4- fluorophenyl) tropane or the selective DA transporter inhibitor GBR12935 bound to D345N with a normal affinity and still inhibited DA uptake potently. However, the mutation reduced the binding capacity of the surface transporter for these two inhibitors by 90% or more. Moreover, the binding activity of D345N can be significantly improved by Zn2+ but not by Na+. These results are consistent with a defect in reorientation of the substrate- binding site to the extracellular side, leading to a loss of the outward- facing conformational state where external DA binds to initiate uptake and the inhibitors bind to initiate uptake inhibition. Alanine or glutamate substitution produced a similar phenotype, suggesting that both the negative charge and the residue volume at position 345 are vital. Furthermore, in intact cells, cocaine potentiated the reaction of the membrane- impermeant sulfhydryl reagent methanethiosulfonate ethyltrimethylammonium with the extracellularly located endogenous cysteines of D345N but not those of wild type, and this potentiation was blocked upon K+ substitution for Na+. Thus, cocaine binding to D345N likely induces a different and Na+- dependent conformational change, which may contribute to its Na+ -dependent uptake inhibitory activity.	NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA	New York University; University of Illinois System; University of Illinois Peoria	Chen, NH (corresponding author), NYU, Sch Med, Dept Psychiat, 550 1st Ave,HN 604, New York, NY 10016 USA.	nianhang.chen@med.nyu.edu	Reith, Maarten E./AAD-2303-2019	Reith, Maarten E./0000-0002-1900-842X	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008379] Funding Source: NIH RePORTER; NIDA NIH HHS [DA08379] Funding Source: Medline; PHS HHS [13261] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Bonisch H, 1998, METHOD ENZYMOL, V296, P259; BURNETTE WB, 1996, ANAL CHEM, V269, P12290; Carroll F. Ivy, 2002, P381; CHEN N, 2003, IN PRESS PFLUEGERS A; Chen NH, 2003, J NEUROCHEM, V86, P678, DOI 10.1046/j.1471-4159.2003.01889.x; Chen NH, 2002, J NEUROCHEM, V81, P1383, DOI 10.1046/j.1471-4159.2002.00941.x; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Chen NH, 2000, MOL BRAIN RES, V75, P208, DOI 10.1016/S0169-328X(99)00288-0; Chen NH, 2001, J NEUROCHEM, V77, P1116, DOI 10.1046/j.1471-4159.2001.00312.x; Chen Nian-Hang, 2002, P53; Deken Scott L., 2002, P193; Eshleman AJ, 1999, J PHARMACOL EXP THER, V289, P877; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1992, MOL PHARMACOL, V42, P383; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KRUPKA RM, 1983, INT REV CYTOL, V84, P303, DOI 10.1016/S0074-7696(08)61021-9; Kula NS, 1999, EUR J PHARMACOL, V385, P291, DOI 10.1016/S0014-2999(99)00695-0; LITTLE KY, 1995, J PHARMACOL EXP THER, V274, P1473; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Povlock SL, 1997, J NEUROCHEM, V69, P1093; REITH MEA, 1993, J NEUROCHEM, V61, P167, DOI 10.1111/j.1471-4159.1993.tb03552.x; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; RICHFIELD EK, 1991, BRAIN RES, V540, P1, DOI 10.1016/0006-8993(91)90486-F; ROSS SB, 1976, MECH NEUROANAL EXTRA, P49; Scholze P, 2002, J BIOL CHEM, V277, P21505, DOI 10.1074/jbc.M112265200; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200	36	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5508	5519		10.1074/jbc.M306294200	http://dx.doi.org/10.1074/jbc.M306294200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660644	hybrid			2022-12-27	WOS:000188776500059
J	Grimard, V; Li, CH; Ramjeesingh, M; Bear, CE; Goormaghtigh, E; Ruysschaert, JM				Grimard, V; Li, CH; Ramjeesingh, M; Bear, CE; Goormaghtigh, E; Ruysschaert, JM			Phosphorylation-induced conformational changes of cystic fibrosis transmembrane conductance regulator monitored by attenuated total reflection-fourier transform IR spectroscopy and fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN STRUCTURE; CFTR CHLORIDE CHANNEL; R-DOMAIN; INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; ESCHERICHIA-COLI; MULTIDRUG TRANSPORTER; MASS-SPECTROMETRY; ORIENTATION; EXCHANGE	Cystic fibrosis transmembrane conductance regulator ( CFTR) is a member of the ABC protein superfamily. Phosphorylation of a regulatory domain of this protein is a prerequisite for activity. We analyzed the effect of protein kinase A ( PKA) phosphorylation on the structure of purified and reconstituted CFTR protein. H-1/H-2 exchange monitored by attenuated total reflection Fourier transform IR spectroscopy demonstrates that CFTR is highly accessible to aqueous medium. Phosphorylation of the regulatory ( R) domain by PKA further increases this accessibility. More specifically, fluorescence quenching of cytosolic tryptophan residues revealed that the accessibility of the cytoplasmic part of the protein is modified by phosphorylation. Moreover, the combination of polarized IR spectroscopy with H-1/H-2 exchange suggested an increase of the accessibility of the transmembrane domains of CFTR. This suggests that CFTR phosphorylation can induce a large conformational change that could correspond either to a displacement of the R domain or to long range conformational changes transmitted from the phosphorylation sites to the nucleotide binding domains and the transmembrane segments. Such structural changes may provide better access for the solutes to the nucleotide binding domains and the ion binding site.	Free Univ Brussels, Ctr Struct Biol & Bioinformat, B-1050 Brussels, Belgium; Hosp Sick Children, Res Inst, Program Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada	Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Ruysschaert, JM (corresponding author), Free Univ Brussels, Ctr Struct Biol & Bioinformat, Campus Plaine CP206-2, B-1050 Brussels, Belgium.	jmruysss@ulb.ac.be		Goormaghtigh, Erik/0000-0002-2071-2262				ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; Baldursson O, 2001, J BIOL CHEM, V276, P1904, DOI 10.1074/jbc.M006934200; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Dahan D, 2001, PFLUG ARCH EUR J PHY, V443, pS92, DOI 10.1007/s004240100652; DEMPSEY CE, 1992, BIOCHEMISTRY-US, V31, P11973, DOI 10.1021/bi00163a003; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; EARNEST TN, 1990, BIOPHYS J, V58, P1539, DOI 10.1016/S0006-3495(90)82498-X; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fringeli U P, 1981, Mol Biol Biochem Biophys, V31, P270; Goormaghtigh E, 1996, APPL SPECTROSC, V50, P1519, DOI 10.1366/0003702963904610; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Goormaghtigh E, 1994, Subcell Biochem, V23, P363; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; Grimard V, 2001, BIOCHEMISTRY-US, V40, P11876, DOI 10.1021/bi010017+; HOWELL LD, 2003, IN PRESS BIOCH J; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; King SA, 2000, BIOCHEMISTRY-US, V39, P9868, DOI 10.1021/bi992807d; Kogan I, 2003, EMBO J, V22, P1981, DOI 10.1093/emboj/cdg194; LeCoutre J, 1997, P NATL ACAD SCI USA, V94, P10167, DOI 10.1073/pnas.94.19.10167; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Linsdell P, 1997, J GEN PHYSIOL, V110, P355, DOI 10.1085/jgp.110.4.355; Linsdell P, 1998, AM J PHYSIOL-CELL PH, V275, pC323, DOI 10.1152/ajpcell.1998.275.1.C323; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Ma JJ, 1996, J BIOL CHEM, V271, P7351, DOI 10.1074/jbc.271.13.7351; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; Manciu L, 2000, BIOCHEMISTRY-US, V39, P13026, DOI 10.1021/bi001043v; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Neville DCA, 1997, PROTEIN SCI, V6, P2436; Ostedgaard LS, 2000, P NATL ACAD SCI USA, V97, P5657, DOI 10.1073/pnas.100588797; PASTRANA B, 1991, BIOCHEMISTRY-US, V30, P10058, DOI 10.1021/bi00105a033; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Ramjeesingh M, 1997, BIOCHEM J, V327, P17, DOI 10.1042/bj3270017; Ramjeesingh M, 1999, Methods Enzymol, V294, P227; Raussens V, 2003, ANAL BIOCHEM, V319, P114, DOI 10.1016/S0003-2697(03)00285-9; Reddy MM, 2003, NATURE, V423, P756, DOI 10.1038/nature01694; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIORDAN JR, 1989, SCIENCE, V245, P1066; Townsend RR, 1996, PROTEIN SCI, V5, P1865, DOI 10.1002/pro.5560050912; Vigano C, 2002, FEBS LETT, V530, P197, DOI 10.1016/S0014-5793(02)03485-3; Wang WL, 2002, AM J PHYSIOL-CELL PH, V282, pC1170, DOI 10.1152/ajpcell.00337.2001; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514	51	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5528	5536		10.1074/jbc.M311014200	http://dx.doi.org/10.1074/jbc.M311014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660584	hybrid			2022-12-27	WOS:000188776500061
J	Baron, S; Manin, M; Beaudoin, C; Leotoing, L; Communal, Y; Veyssiere, G; Morel, L				Baron, S; Manin, M; Beaudoin, C; Leotoing, L; Communal, Y; Veyssiere, G; Morel, L			Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PROSTATE-CANCER CELLS; VAS-DEFERENS PROTEIN; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; STEROID-HORMONES; SIGNAL-TRANSDUCTION; APOPTOSIS; ALPHA	Androgens are known to modulate many cellular processes such as cell growth and survival by binding to the androgen receptor (AR) and activating the transcription of target genes. Recent data suggested that AR can also mediate non-transcriptional actions outside the nucleus in addition to its ligand-inducible transcription factor function. Here, we describe a transcription-independent activation of the phosphatidylinositol 3-OH kinase (PI3-K) signaling pathway by androgens. Using non-transformed androgen-sensitive epithelial cells, we show that androgens enhance the PI3-K activity by promoting accumulation of phosphoinositide-3-P phospholipids in vitro. This activation is found in conjunction with an increased time-dependent phosphorylation of the downstream kinase AKT/protein kinase B on both Ser(473) and Thr(308) residues. Hormone-stimulated phosphorylation of AKT requires AR since incubation with the anti-androgen bicalutamide completely abolishes the androgen-stimulated AKT phosphorylation. Accordingly, we show that androgens increase AKT phosphorylation level in prostatic carcinoma PC3 cells only once they have been transfected with AR. Downstream, androgens enhance phosphorylation of transcription factor FKHR ( Forkhead in rhabdomyosarcoma)-L1 and proapoptotic Bad protein and promote cell survival as they can counteract an apoptotic process. We also report that non-genomic effects of androgens are based on direct interaction between AR and the p85alpha regulatory subunit of class I(A) PI3-K. Together, these novel findings point out an important and physiologically relevant link between androgens and the PI3-K/AKT signaling pathway in governing cell survival.	Univ Clermont Ferrand, CNRS, UMR 6547, F-63177 Clermont Ferrand, France; Ctr Jean Perrin, Immunol Lab, F-63011 Clermont Ferrand, France	Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); UNICANCER; Centre Jean Perrin	Morel, L (corresponding author), Univ Clermont Ferrand, CNRS, UMR 6547, Campus Univ Cezeaux,24 Ave Landais, F-63177 Clermont Ferrand, France.	laurent.morel@univ-bpclermont.fr						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bagowski CP, 2001, J BIOL CHEM, V276, P37708, DOI 10.1074/jbc.M104582200; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; BRANN DW, 1995, J STEROID BIOCHEM, V52, P113, DOI 10.1016/0960-0760(94)00160-N; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Cunha GR, 1996, PROSTATE, P22; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Lo Surdo P, 1999, J BIOL CHEM, V274, P15678, DOI 10.1074/jbc.274.22.15678; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; MANIN M, 1995, BIOL REPROD, V52, P50, DOI 10.1095/biolreprod52.1.50; Manin M, 2000, J ANDROL, V21, P641; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Moss RL, 1999, STEROIDS, V64, P14, DOI 10.1016/S0039-128X(98)00092-0; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Sun M, 2001, CANCER RES, V61, P5985; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Yao R, 1996, ONCOGENE, V13, P343; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	41	129	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	2004	279	15					14579	14586		10.1074/jbc.M306143200	http://dx.doi.org/10.1074/jbc.M306143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	808UT	14668339	hybrid			2022-12-27	WOS:000220594700015
J	Hirotsu, S; Chu, GC; Unno, M; Lee, DS; Yoshida, T; Park, SY; Shiro, Y; Ikeda-Saito, M				Hirotsu, S; Chu, GC; Unno, M; Lee, DS; Yoshida, T; Park, SY; Shiro, Y; Ikeda-Saito, M			The crystal structures of the ferric and ferrous forms of the heme complex of HmuO, a heme oxygenase of Corynebacterium diphtheriae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; GRAM-NEGATIVE BACTERIA; OXIDATIVE CLEAVAGE; ACTIVE-SITE; DEGRADATION; MECHANISM; PRODUCT; SYSTEM; LIGAND; GENE	Crystal structures of the ferric and ferrous heme complexes of HmuO, a 24-kDa heme oxygenase of Corynebacterium diphtheriae, have been refined to 1.4 and 1.5 Angstrom resolution, respectively. The HmuO structures show that the heme group is closely sandwiched between the proximal and distal helices. The imidazole group of His-20 is the proximal heme ligand, which closely eclipses the beta- and delta-meso axis of the porphyrin ring. A long range hydrogen bonding network is present, connecting the iron-bound water ligand to the solvent water molecule. This enables proton transfer from the solvent to the catalytic site, where the oxygen activation occurs. In comparison to the ferric complex, the proximal and distal helices move closer to the heme plane in the ferrous complex. Together with the kinked distal helix, this movement leaves only the alpha-meso carbon atom accessible to the iron-bound dioxygen. The heme pocket architecture is responsible for stabilization of the ferric hydroperoxo-active intermediate by preventing premature heterolytic O-O bond cleavage. This allows the enzyme to oxygenate selectively at the alpha-meso carbon in HmuO catalysis.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan; RIKEN Harima inst, Inst Phys & Chem Res, Sayo, Hyogo 6795143, Japan	Tohoku University; Case Western Reserve University; Yamagata University; RIKEN	Ikeda-Saito, M (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan.	mis2@tagen.tohoku.ac.jp	Shiro, Yoshitsugu Y/J-3757-2014; Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Shiro, Yoshitsugu Y/0000-0003-0695-8327; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057272] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57272] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chu GC, 1999, J STRUCT BIOL, V126, P171, DOI 10.1006/jsbi.1999.4122; Chu GC, 1999, J BIOL CHEM, V274, P21319, DOI 10.1074/jbc.274.30.21319; Chu GC, 1999, J BIOL CHEM, V274, P24490, DOI 10.1074/jbc.274.35.24490; Chu GC, 2000, J BIOL CHEM, V275, P17494, DOI 10.1074/jbc.M000830200; Colas C, 2003, CHEM REV, V103, P2305, DOI 10.1021/cr0204303; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; Davydov RM, 1999, J AM CHEM SOC, V121, P10656, DOI 10.1021/ja992425v; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Friedman J, 2003, J BIOL CHEM, V278, P34654, DOI 10.1074/jbc.M302985200; Fujii H, 1998, J AM CHEM SOC, V120, P8251, DOI 10.1021/ja973925w; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; Genco CA, 2001, MOL MICROBIOL, V39, P1, DOI 10.1046/j.1365-2958.2001.02231.x; Gorst CM, 1998, J AM CHEM SOC, V120, P8875, DOI 10.1021/ja9815475; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lad L, 2003, J MOL BIOL, V330, P527, DOI 10.1016/S0022-2836(03)00578-3; Lad L, 2003, J BIOL CHEM, V278, P7834, DOI 10.1074/jbc.M211450200; Li YM, 2003, J BIOL CHEM, V278, P6651, DOI 10.1074/jbc.M211249200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Prabhakar NR, 1999, RESP PHYSIOL, V115, P161, DOI 10.1016/S0034-5687(99)00019-5; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; SCHEIDT WR, 1986, J AM CHEM SOC, V108, P1163, DOI 10.1021/ja00266a008; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; SMULEVICH G, 1990, BIOCHEMISTRY-US, V29, P7174, DOI 10.1021/bi00483a004; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Suematsu M, 2000, HEPATOLOGY, V31, P3, DOI 10.1002/hep.510310102; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2002, J BIOL CHEM, V277, P45086, DOI 10.1074/jbc.M207267200; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; Syvitski RT, 2002, J AM CHEM SOC, V124, P14296, DOI 10.1021/ja028108x; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; Wilks A, 2000, J BIOL CHEM, V275, P11686, DOI 10.1074/jbc.275.16.11686; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; Yasutake Y, 2001, ACTA CRYSTALLOGR D, V57, P1682, DOI 10.1107/S0907444901012823; Zhang XH, 2003, BIOCHEMISTRY-US, V42, P7418, DOI 10.1021/bi027173g; Zhou H, 2000, J AM CHEM SOC, V122, P8311, DOI 10.1021/ja0002868; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	56	90	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11937	11947		10.1074/jbc.M311631200	http://dx.doi.org/10.1074/jbc.M311631200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14645223	hybrid			2022-12-27	WOS:000220157600131
J	McCarthy, JK; Uzelac, A; Davis, DF; Eveleigh, DE				McCarthy, JK; Uzelac, A; Davis, DF; Eveleigh, DE			Improved catalytic efficiency and active site modification of 1,4-beta-D-glucan glucohydrolase A from Thermotoga neapolitana by directed evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAIZE BETA-GLUCOSIDASE; CRYSTAL-STRUCTURE; AGLYCONE SPECIFICITY; TRICHODERMA-REESEI; IN-VITRO; MECHANISM; SEQUENCE; PURIFICATION; CELLULASES; INSIGHTS	Thermotoga neapolitana 1,4-beta-D-glucan glucohydrolase A preferentially hydrolyzes cello-oligomers, such as cellotetraose, releasing single glucose moieties from the reducing end of the cello-oligosaccharide chain. Using directed evolution techniques of error-prone PCR and mutant library screening, a variant glucan glucohydrolase has been isolated that hydrolyzes the disaccharide, cellobiose, at a 31% greater rate than its wild type (WT) predecessor. The mutant library, expressed in Escherichia coli, was screened at 85degreesC for increased hydrolysis of cellobiose, a native substrate rather than a chromogenic analog, using a continuous, thermostable coupled enzyme assay. The V-max for the mutant was 108 +/- 3 units mg(-1), whereas that of the WT was 75 +/- 2 units mg(-1). The K-m for both proteins was nearly the same. The k(cat) for the new enzyme increased by 31% and its catalytic efficiency (k(cat)/K-m) for cellobiose also rose by 31% as compared with the parent. The nucleotide sequence of two positive clones and two null clones identified 11 single base shifts. The nucleotide transition in the most active clone caused an isoleucine to threonine amino acid substitution at position 170. Structural models for I170T and WT proteins were derived by sequence homology with Protein Data Bank code 1BGA from Paenibacillus polymyxa. Analysis of the WT and I170T model structures indicated that the substitution in the mutant enzyme repositioned the conserved catalytic residue Asn-163 and reconfigured entry to the active site.	Rutgers State Univ, Cook Coll, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Eveleigh, DE (corresponding author), Rutgers State Univ, Cook Coll, Dept Biochem & Microbiol, New Brunswick, NJ 08901 USA.	eveleigh@aesop.rutgers.edu	Uzelac, Aleksandra/GQI-2085-2022	Uzelac, Aleksandra/0000-0002-1424-0123				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andre G, 2003, PROTEIN ENG, V16, P125, DOI 10.1093/proeng/gzg017; Arnold F H, 1997, Adv Biochem Eng Biotechnol, V58, P1; Bok JD, 1998, APPL ENVIRON MICROB, V64, P4774; Brown NP, 1998, BIOINFORMATICS, V14, P380, DOI 10.1093/bioinformatics/14.4.380; Burmeister WP, 1997, STRUCTURE, V5, P663, DOI 10.1016/S0969-2126(97)00221-9; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cicek M, 2000, J BIOL CHEM, V275, P20002, DOI 10.1074/jbc.M001609200; CONN EE, 1992, ACS SYM SER, V533, P15; Czjzek M, 2001, BIOCHEM J, V354, P37, DOI 10.1042/0264-6021:3540037; Czjzek M, 2000, P NATL ACAD SCI USA, V97, P13555, DOI 10.1073/pnas.97.25.13555; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DESAI UJ, 1995, BIOTECHNIQUES, V19, P780; Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Hrmova M, 1997, CARBOHYD RES, V305, P209, DOI 10.1016/S0008-6215(97)00257-7; Hrmova M, 1998, J BIOL CHEM, V273, P11134, DOI 10.1074/jbc.273.18.11134; HUBER R, 1992, PROKARYOTES HDB BIOL, V4, P3809; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; Joshi MD, 2000, J MOL BIOL, V299, P255, DOI 10.1006/jmbi.2000.3722; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leung DW, 1989, TECHNIQUE, V1, P11; McCarthy JK, 2003, ANAL BIOCHEM, V318, P196, DOI 10.1016/S0003-2697(03)00243-4; MONTENECOURT BS, 1977, APPL ENVIRON MICROB, V34, P777, DOI 10.1128/AEM.34.6.777-782.1977; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Nagano N, 2001, PROTEIN ENG, V14, P845, DOI 10.1093/protein/14.11.845; NEIDLEMAN SL, 2000, ACS SYM SER, V776, P14; Nesbo CL, 2002, J BACTERIOL, V184, P4475, DOI 10.1128/JB.184.16.4475-4488.2002; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; Rignall TR, 2002, APPL BIOCHEM BIOTECH, V98, P383, DOI 10.1385/ABAB:98-100:1-9:383; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sanz-Aparicio J, 1998, J MOL BIOL, V275, P491, DOI 10.1006/jmbi.1997.1467; Shafikhani S, 1997, BIOTECHNIQUES, V23, P304, DOI 10.2144/97232rr01; Sheehan JS, 2001, AGRO FOOD IND HI TEC, V12, P54; Spiridonov NA, 2001, CURR MICROBIOL, V42, P295, DOI 10.1007/s002840010220; Srisodsuk M, 1997, J BIOTECHNOL, V57, P49, DOI 10.1016/S0168-1656(97)00088-6; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Sunna A, 1997, EXTREMOPHILES, V1, P2, DOI 10.1007/s007920050009; TOLLEY SP, 1993, J MOL BIOL, V229, P791, DOI 10.1006/jmbi.1993.1082; TULL D, 1991, J BIOL CHEM, V266, P15621; VANTILBEURGH H, 1988, METHOD ENZYMOL, V160, P45; Verdoucq L, 2003, J BIOL CHEM, V278, P25055, DOI 10.1074/jbc.M301978200; Warren RAJ, 1996, ANNU REV MICROBIOL, V50, P183, DOI 10.1146/annurev.micro.50.1.183; WOOD TM, 1988, METHOD ENZYMOL, V160, P87; Yernool DA, 2000, J BACTERIOL, V182, P5172, DOI 10.1128/JB.182.18.5172-5179.2000; Zhao HM, 2002, CURR OPIN BIOTECH, V13, P104, DOI 10.1016/S0958-1669(02)00291-4; Zou JY, 1999, STRUCTURE, V7, P1035, DOI 10.1016/S0969-2126(99)80171-3; Zverlov VV, 1997, MICROBIOL-SGM, V143, P3537, DOI 10.1099/00221287-143-11-3537	57	34	38	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11495	11502		10.1074/jbc.M305642200	http://dx.doi.org/10.1074/jbc.M305642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14660638	hybrid			2022-12-27	WOS:000220157600081
J	Zhuang, SH; Nguyen, GT; Chen, YC; Gudi, T; Eigenthaler, M; Jarchau, T; Walter, U; Boss, GR; Pilz, RB				Zhuang, SH; Nguyen, GT; Chen, YC; Gudi, T; Eigenthaler, M; Jarchau, T; Walter, U; Boss, GR; Pilz, RB			Vasodilator-stimulated phosphoprotein activation of serum-response element-dependent transcription occurs downstream of RhoA and is inhibited by cGMP-dependent protein kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REQUIRES NUCLEAR TRANSLOCATION; INTACT HUMAN PLATELETS; F-ACTIN BINDING; ENA/VASP PROTEINS; GENE-EXPRESSION; FOCAL ADHESION; FIBROBLAST MOTILITY; CELL-ADHESION; FOS PROMOTER; NITRIC-OXIDE	Vasodilator-stimulated phosphoprotein (VASP) associates with cytoskeletal structures and promotes F-actin formation. RhoA, a member of the Ras superfamily of proteins, activates serum response element (SRE)-dependent transcription through changes in actin dynamics. We now show that the F-actin binding region of VASP is required for VASP stimulation of SRE-dependent transcription, and that VASP is downstream of RhoA in stimulating SRE-dependent transcription. The isolated carboxyl-terminal coiled-coil region of VASP mediates protein tetramerization and has been used as a dominant negative form of VASP; we found that it forms complexes with endogenous VASP in vivo and inhibits in a dose-dependent fashion serum, RhoA-, and VASP-stimulatedSRE-dependent transcription. Cyclic GMP-dependent protein kinase (G-kinase) inhibits RhoA activation of SREdependent transcription (Gudi, T., Chen, J. C., Casteel, D. E., Seasholtz, T. M., Boss, G. R., and Pilz, R. B. (2002) J. Biol. Chem. 277, 37382-37393). We now show that the G-kinase inhibition that occurs downstream of RhoA can be explained, at least in part, by G-kinase phosphorylation of VASP on Ser(239) at the carboxyl-terminal end of the G-actin binding site, with some contribution by phosphorylation of Ser(157), which is proximal to the profilin binding site. A phosphorylation-deficient VASP mutant can partly prevent cGMP/G-kinase inhibition of serum- and RhoA- induced SRE-dependent transcription. These studies show that VASP, an important component of the cellular microfilament system, plays a major role in regulating SRE-dependent transcription, and that G-kinase regulates VASP activity.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Klinikum Univ Wurzburg, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Wurzburg	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	rpilz@ucsd.edu	Walter, ulrich/W-2478-2017	Walter, ulrich/0000-0001-6784-2307; Boss, Gerry/0000-0002-9758-8714	NCI NIH HHS [CA89828] Funding Source: Medline; NIGMS NIH HHS [GM55586] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA089828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Arguinzonis MIG, 2002, J BIOL CHEM, V277, P45604, DOI 10.1074/jbc.M202873200; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT E, 1994, J BIOL CHEM, V269, P14509; Castellano F, 2001, EMBO J, V20, P5603, DOI 10.1093/emboj/20.20.5603; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Geese M, 2002, MOL BIOL CELL, V13, P2383, DOI 10.1091/mbc.E02-01-0058; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Gudi T, 1999, FASEB J, V13, P2143, DOI 10.1096/fasebj.13.15.2143; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Howe AK, 2002, J BIOL CHEM, V277, P38121, DOI 10.1074/jbc.M205379200; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Krause M, 2002, J CELL SCI, V115, P4721, DOI 10.1242/jcs.00218; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Kwiatkowski AV, 2003, TRENDS CELL BIOL, V13, P386, DOI 10.1016/S0962-8924(03)00130-2; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morissette MR, 2000, AM J PHYSIOL-HEART C, V278, pH1769, DOI 10.1152/ajpheart.2000.278.6.H1769; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Walders-Harbeck B, 2002, FEBS LETT, V529, P275, DOI 10.1016/S0014-5793(02)03356-2; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Zimmermann J, 2002, BIOCHEMISTRY-US, V41, P11143, DOI 10.1021/bi020379x	50	34	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10397	10407		10.1074/jbc.M313048200	http://dx.doi.org/10.1074/jbc.M313048200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679200	hybrid			2022-12-27	WOS:000220050400090
J	Lu, X; Hansen, JC				Lu, X; Hansen, JC			Identification of specific functional subdomains within the linker histone H1(o)C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTAPEPTIDE REPEAT MOTIF; SECONDARY STRUCTURE; NUCLEOSOMAL ARRAYS; ESCHERICHIA-COLI; CHROMATIN FIBER; TERMINAL DOMAIN; C-TERMINUS; N-TERMINI; DNA; H1	Linker histone binding to nucleosomal arrays in vitro causes linker DNA to form an apposed stem motif, stabilizes extensively folded secondary chromatin structures, and promotes self-association of individual nucleosomal arrays into oligomeric tertiary chromatin structures. To determine the involvement of the linker histone C-terminal domain (CTD) in each of these functions, and to test the hypothesis that the functions of this highly basic domain are mediated by neutralization of linker DNA negative charge, four truncation mutants were created that incrementally removed stretches of 24 amino acids beginning at the extreme C terminus of the mouse H1(0) linker histone. Native and truncated H1(0) proteins were assembled onto biochemically defined nucleosomal arrays and characterized in the absence and presence of salts to probe primary, secondary, and tertiary chromatin structure. Results indicate that the ability of H1(0) to alter linker DNA conformation and stabilize condensed chromatin structures is localized to specific C-terminal subdomains, rather than being equally distributed throughout the entire CTD. We propose that the functions of the linker histone CTD in chromatin are linked to the characteristic intrinsic disorder of this domain.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Colorado State University; University of Texas System; University of Texas Health San Antonio	Hansen, JC (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Campus Delivery 1870, Ft Collins, CO 80523 USA.	Jeffrey.C.Hansen@colostate.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045916, R01GM045916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Bharath MMS, 2002, BIOCHEMISTRY-US, V41, P7617, DOI 10.1021/bi025773+; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; Carter GJ, 1998, ANAL BIOCHEM, V263, P79, DOI 10.1006/abio.1998.2775; CERF C, 1993, BIOCHEMISTRY-US, V32, P11345, DOI 10.1021/bi00093a011; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; CLARK DJ, 1988, EMBO J, V7, P69, DOI 10.1002/j.1460-2075.1988.tb02784.x; Dunker AK, 2002, ADV PROTEIN CHEM, V62, P25; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; GARCIA-RAMIREZ M, 1990, Protein Expression and Purification, V1, P40, DOI 10.1016/1046-5928(90)90043-X; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; GERCHMAN SE, 1994, PROTEIN EXPRES PURIF, V5, P242, DOI 10.1006/prep.1994.1037; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HILL CS, 1989, EMBO J, V8, P2591, DOI 10.1002/j.1460-2075.1989.tb08398.x; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Khadake JR, 1997, BIOCHEMISTRY-US, V36, P1041, DOI 10.1021/bi961617p; Khadake JR, 1997, FEBS LETT, V400, P193, DOI 10.1016/S0014-5793(96)01393-2; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; PEHRSON J, 1980, NATURE, V285, P43, DOI 10.1038/285043a0; PEHRSON JR, 1981, BIOCHEMISTRY-US, V20, P2298, DOI 10.1021/bi00511a035; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SUBIRANA JA, 1990, BIOPOLYMERS, V29, P1351, DOI 10.1002/bip.360291003; SUZUKI M, 1993, PROTEIN ENG, V6, P565, DOI 10.1093/protein/6.6.565; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; van Holde K.E., 1988, CHROMATIN; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Vila R, 2000, PROTEIN SCI, V9, P627; Vila R, 2001, J BIOL CHEM, V276, P46429, DOI 10.1074/jbc.M106952200; Vila R, 2001, J BIOL CHEM, V276, P30898, DOI 10.1074/jbc.M104189200; Wellman SE, 1997, BIOTECHNOL APPL BIOC, V26, P117; Wolffe A., 1998, CHROMATIN STRUCTURE; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	46	112	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8701	8707		10.1074/jbc.M311348200	http://dx.doi.org/10.1074/jbc.M311348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668337	hybrid			2022-12-27	WOS:000189265900022
J	Vinciguerra, M; Vivacqua, A; Fasanella, G; Gallo, A; Cuozzo, C; Morano, A; Maggiolini, M; Musti, AM				Vinciguerra, M; Vivacqua, A; Fasanella, G; Gallo, A; Cuozzo, C; Morano, A; Maggiolini, M; Musti, AM			Differential phosphorylation of c-Jun and JunD in response to the epidermal growth factor is determined by the structure of MAPK targeting sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; JNK; ANTAGONIZES; SPECIFICITY; CONTAINS; PROTEINS; ELK-1; AP-1; FORM	MAPK phosphorylation of various substrates is mediated by the presence of docking sites, including the D domain and the DEF motif. Depending on the number and sequences of these domains, substrates are phosphorylated by specific subsets of MAPKs. For example, a D domain targets JNK to c-Jun, whereas a DEF motif is required for ERK phosphorylation of c-Fos. JunD, in contrast, contains both D and DEF domains. Here we show that these motifs mediate JunD phosphorylation in response to either ERK or JNK activation. An intact D domain is required for phosphorylation and activation of JunD by both subtypes of MAPK. The DEF motif acts together with the D domain to elicit efficient phosphorylation of JunD in response to the epidermal growth factor (EGF) but has no function on JunD phosphorylation and activation by JNK signaling. Furthermore, we show that conversion of a c-Jun sequence to a canonical DEF domain, as it is present in JunD, elicits c-Jun activation in response to EGF. Our results suggest that evolution of a particular modular system of MAPK targeting sequences has determined a differential response of JunD and c-Jun to ERK activation.	Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Calabria, Dipartimento Farmacobiol, I-87036 Cosenza, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Calabria	Musti, AM (corresponding author), Univ Naples Federico II, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy.	ammusti@yahoo.it	vivacqua, adele/I-2771-2015; Morano, Annalisa/K-6955-2012; Maggiolini, Marcello/Z-4729-2019; Musti, Anna Maria/M-2520-2019	vivacqua, adele/0000-0001-5333-8396; Morano, Annalisa/0000-0002-5609-4742; MUSTI, Anna Maria/0000-0003-1443-2739; Maggiolini, Marcello/0000-0002-7485-854X				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barsyte-Lovejoy D, 2002, J BIOL CHEM, V277, P9896, DOI 10.1074/jbc.M108145200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOUGLAS A, 2001, J BIOL CHEM, V29, P27256; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Gallo A, 2002, ONCOGENE, V21, P6434, DOI 10.1038/sj.onc.1205822; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Maniatis T., 1989, MOL CLONING LAB MAN; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200	34	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9634	9641		10.1074/jbc.M308721200	http://dx.doi.org/10.1074/jbc.M308721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676207	hybrid			2022-12-27	WOS:000189265900131
J	Frank, BS; Vardar, D; Chishti, AH; McKnight, CJ				Frank, BS; Vardar, D; Chishti, AH; McKnight, CJ			The NMR structure of dematin headpiece reveals a dynamic loop that is conformationally altered upon phosphorylation at a distal site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; HUMAN ERYTHROID DEMATIN; ACTIN-BINDING-SITE; VILLIN HEADPIECE; PROTEIN-KINASE; CHEMICAL-SHIFT; N-15 NMR; SPECTROSCOPY; DOMAIN; C-13	Dematin ( band 4.9) is found in the junctional complex of the spectrin cytoskeleton that supports the erythrocyte cell membrane. Dematin is a member of the larger class of cytoskeleton-associated proteins that contain a modular "headpiece" domain at their extreme C termini. The dematin headpiece domain provides the second F-actin-binding site required for in vitro F-actin bundling. The dematin headpiece is found in two forms in the cell, one of 68 residues (DHP) and one containing a 22-amino acid insert near its N terminus ( DHP + 22). In addition, dematin contains the only headpiece domain that is phosphorylated, in vivo. The 22-amino acid insert in DHP + 22 appeared unstructured in NMR spectra; therefore, we have determined the three-dimensional structure of DHP by multidimensional NMR methods. Although the overall three-dimensional structure of DHP is similar to that of the villin headpiece, there are two novel characteristics revealed by this structure. First, unlike villin headpiece that contains a single buried salt bridge, DHP contains a buried charged cluster comprising residues Glu(39), Arg(66), Lys(70), and the C-terminal carboxylate of Phe(76). Second, N-15 relaxation experiments indicate that the longer "variable loop" region near the N terminus of DHP ( residues 20 - 29) is dynamic, undergoing significantly greater motions that the rest of the structure. Furthermore, NMR chemical shift changes indicate that the conformation of the dynamic variable loop is altered by phosphorylation of serine 74, which is far in the sequence from the variable loop region. Our results suggest that phosphorylation of the dematin headpiece acts as a conformational switch within this headpiece domain.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ Illinois, Coll Med, UIC Canc Ctr, Dept Pharmacol, Chicago, IL 60607 USA	Boston University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	McKnight, CJ (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 700 Albany st, Boston, MA 02118 USA.	cjmck@bu.edu		McKnight, Christopher/0000-0002-3237-0896; Vardar-Ulu, Didem/0000-0003-3793-0124	NHLBI NIH HHS [HL07291, HL51445] Funding Source: Medline; NIGMS NIH HHS [GM62886] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051445, R56HL051445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062886] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; AZIM AC, 1995, J BIOL CHEM, V270, P17407, DOI 10.1074/jbc.270.29.17407; Azim AC, 1996, BIOCHEMISTRY-US, V35, P3001, DOI 10.1021/bi951745y; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLUBB RT, 1992, J MAGN RESON, V97, P213, DOI 10.1016/0022-2364(92)90252-3; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P227; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FORMANKAY JD, 1990, BIOCHEMISTRY-US, V29, P1566, DOI 10.1021/bi00458a030; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; GLENNEY JR, 1981, J BIOL CHEM, V256, P8156; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; HUSAINCHISHTI A, 1989, J BIOL CHEM, V264, P8985; HUSAINCHISHTI A, 1988, NATURE, V334, P718, DOI 10.1038/334718a0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Khanna R, 2002, P NATL ACAD SCI USA, V99, P6637, DOI 10.1073/pnas.052155999; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lutchman M, 1999, CANCER GENET CYTOGEN, V115, P65, DOI 10.1016/S0165-4608(99)00081-3; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; McKnight CJ, 1996, J MOL BIOL, V260, P126; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POPE B, 1994, FEBS LETT, V338, P58, DOI 10.1016/0014-5793(94)80116-9; RANA AP, 1993, P NATL ACAD SCI USA, V90, P6651, DOI 10.1073/pnas.90.14.6651; RULLMANN JAC, 1996, AQUA; SIEGEL DL, 1985, J CELL BIOL, V100, P775, DOI 10.1083/jcb.100.3.775; TEGGE W, 1995, BIOCHEMISTRY-US, V34, P10569, DOI 10.1021/bi00033a032; Vardar D, 1999, J MOL BIOL, V294, P1299, DOI 10.1006/jmbi.1999.3321; Vardar D, 2002, CELL MOTIL CYTOSKEL, V52, P9, DOI 10.1002/cm.10027; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Zhang Y.Z., 1995, THESIS U PENNSYLVANI	43	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7909	7916		10.1074/jbc.M310524200	http://dx.doi.org/10.1074/jbc.M310524200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660664	hybrid			2022-12-27	WOS:000189103300068
J	Gomez-Merino, FC; Brearley, CA; Ornatowska, M; Abdel-Haliem, MEF; Zanor, MI; Mueller-Roeber, B				Gomez-Merino, FC; Brearley, CA; Ornatowska, M; Abdel-Haliem, MEF; Zanor, MI; Mueller-Roeber, B			AtDGK2, a novel diacylglycerol kinase from Arabidopsis thaliana, phosphorylates 1-stearoyl-2-arachidonoyl-sn-glycerol and 1,2-dioleoyl-sn-glycerol and exhibits cold-inducible gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAINS; PROTEIN-KINASE; PHORBOL ESTER; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-C; BETA-GLUCURONIDASE; MOLECULAR-CLONING; PSAF GENE; CELLS; ACTIVATION	Diacylglycerol kinase (DGK) phosphorylates diacylglycerol (DAG) to generate phosphatidic acid (PA). Both DAG and PA are implicated in signal transduction pathways. DGKs have been widely studied in animals, but their analysis in plants is fragmentary. Here, we report the cloning and biochemical characterization of AtDGK2, encoding DGK from Arabidopsis thaliana. AtDGK2 has a predicted molecular mass of 79.4 kDa and, like AtDGK1 previously reported, harbors two copies of a phorbol ester/DAG-binding domain in its N-terminal region. AtDGK2 belongs to a family of seven DGK genes in A. thaliana. AtDGK3 to AtDGK7 encode similar to55-kDa DGKs that lack a typical phorbol ester/DAG-binding domain. Phylogenetically, plant DGKs fall into three clusters. Members of all three clusters are widely expressed in vascular plants. Recombinant AtDGK2 was expressed in Escherichia coli and biochemically characterized. The enzyme phosphorylated 1,2-dioleoyl-sn-glycerol to yield PA, exhibiting Michaelis-Menten type kinetics. Estimated K-m and V-max values were 125 muM for DAG and 0.25 pmol of PA min(-1) mug(-1), respectively. The enzyme was maximally active at pH 7.2. Its activity was Mg2+-dependent and affected by the presence of detergents, salts, and the DGK inhibitor R59022, but not by Ca2+. AtDGK2 exhibited substrate preference for unsaturated DAG analogues (i.e. 1-stearoyl-2-arachidonoyl-sn-glycerol and 1,2-dioleoyl-sn-glycerol). The AtDGK2 gene is expressed in various tissues of the Arabidopsis plant, including leaves, roots, and flowers, as shown by Northern blot analysis and promoter-reporter gene fusions. We found that AtDGK2 is induced by exposure to low temperature (4degreesC), pointing to a role in cold signal transduction.	Univ Potsdam, Inst Biochem & Biol, D-14476 Golm Potsdam, Germany; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Max Planck Inst Mol Plant Physiol, Cooperat Res Grp, D-14476 Golm Potsdam, Germany	University of Potsdam; University of East Anglia; Max Planck Society	Mueller-Roeber, B (corresponding author), Univ Potsdam, Inst Biochem & Biol, Karl Liebknecht Str 24-25,Haus 20, D-14476 Golm Potsdam, Germany.	bmr@rz.uni-potsdam.de	Gómez-Merino, Fernando Carlos/D-2224-2014; Abdel-Haliem, Mahmoud/AAD-3333-2019; Mueller-Roeber, Bernd/Z-4052-2019; Mohamed, Mahmoud/B-2262-2015	Mohamed, Mahmoud/0000-0002-1518-2340; Brearley, Charles/0000-0001-6179-9109				ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAKER SS, 1994, PLANT MOL BIOL, V24, P701, DOI 10.1007/BF00029852; Baudouin E, 2002, PLANTA, V214, P400, DOI 10.1007/s004250100630; Baudouin E, 1999, PLANT SCI, V142, P67, DOI 10.1016/S0168-9452(98)00241-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREARLEY CA, 1992, BIOCHEM J, V283, P255, DOI 10.1042/bj2830255; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Chandok MR, 1996, MOL GEN GENET, V251, P599, DOI 10.1007/BF02173650; Chandok MR, 2001, MOL GEN GENET, V264, P819, DOI 10.1007/s004380000371; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Gilroy S, 2001, NAT REV MOL CELL BIO, V2, P307, DOI 10.1038/35067109; GOMEZMERINO FC, 2003, IN PRESS P 12 C GEN; HAWKINS PT, 1986, BIOCHEM J, V238, P507, DOI 10.1042/bj2380507; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; Houssa B, 1998, BIOCHEM J, V331, P677; Ishioka N., 1992, PLANT TISSUE CULT LE, V9, P86; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; KAMADA Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P72, DOI 10.1016/0167-4889(91)90140-S; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; KANOH H, 1981, ARCH BIOCHEM BIOPHYS, V209, P266, DOI 10.1016/0003-9861(81)90280-0; Katagiri T, 1996, PLANT MOL BIOL, V30, P647, DOI 10.1007/BF00049339; Kim HJ, 2002, PLANT J, V29, P693, DOI 10.1046/j.1365-313X.2002.01249.x; Lee S, 2001, PLANT J, V26, P479, DOI 10.1046/j.1365-313x.2001.01037.x; LEE Y, 1991, P NATL ACAD SCI USA, V88, P2127, DOI 10.1073/pnas.88.6.2127; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LIN CH, 1986, LIPIDS, V21, P206, DOI 10.1007/BF02534823; LUNDBERG GA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P177, DOI 10.1016/0005-2760(92)90109-9; Martelli AM, 2002, CELL MOL LIFE SCI, V59, P1129, DOI 10.1007/s00018-002-8492-9; Matowe WC, 1996, PHARMACOLOGY, V53, P376, DOI 10.1159/000139453; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Mueller-Roeber B, 2002, PLANT PHYSIOL, V130, P22, DOI 10.1104/pp.004770; Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Ruelland E, 2002, PLANT PHYSIOL, V130, P999, DOI 10.1104/pp.006080; Sakane F, 2002, J BIOL CHEM, V277, P43519, DOI 10.1074/jbc.M206895200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Shindo M, 2003, J BIOL CHEM, V278, P18448, DOI 10.1074/jbc.M300400200; Snedden WA, 2000, PLANT J, V24, P317, DOI 10.1046/j.1365-313x.2000.00877.x; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Wostemeyer A, 2003, J PLANT PHYSIOL, V160, P503, DOI 10.1078/0176-1617-00912; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	54	70	75	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8230	8241		10.1074/jbc.M312187200	http://dx.doi.org/10.1074/jbc.M312187200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665624	hybrid			2022-12-27	WOS:000189103300105
J	Krishnamurthy, PK; Johnson, GVW				Krishnamurthy, PK; Johnson, GVW			Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME-17 FRONTOTEMPORAL DEMENTIA; PROTEIN PHOSPHATASE 2A; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; NEUROBLASTOMA-CELLS; PRESENILE-DEMENTIA; FILAMENT FORMATION; GENE-EXPRESSION; P301L TAU; MUTATIONS	Frontotemporal dementia and Parkinsonism linked to chromosome 17 ( FTDP-17) is an autosomal dominant neurodegenerative disorder caused by mutations in the gene that encodes for tau, a microtubule- binding protein. Neuropathologically the disease is characterized by extensive neuronal loss in the frontal and temporal lobes and the filamentous accumulation of hyperphosphorylated tau. The R406W missense mutation was originally described in an American and a Dutch family. Although R406W tau is hyperphosphorylated in FTDP-17 cases, R406W tau expressed in cell model systems has not shown increased phosphorylation. The purpose of this study was to establish a neuronal model system in which the phosphorylation of R406W tau is increased and thus more representative of the in vivo situation. To accomplish this goal immortalized mouse cortical cells that express low levels of endogenous tau were stably transfected with human wild type or R406W tau. In this neuronal model R406W tau was more highly phosphorylated at numerous epitopes and showed decreased microtubule binding compared with wild type tau, an effect that could be reversed by dephosphorylation. In addition the expression of R406W tau in the cortical cells resulted in increased cell death as compared with wild type tau-expressing cells when the cells were exposed to an apoptotic stressor. These results indicate that in an appropriate cellular context R406W tau is hyperphosphorylated, which leads to decreased microtubule binding. Furthermore, expression of R406W tau sensitized cells to apoptotic stress, which may contribute to the neuronal cell loss that occurs in this FTDP-17 tauopathy.	Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, 1720 7th Ave,S SC 1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NINDS NIH HHS [NS35060] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035060] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen B, 2002, J NEUROSCI, V22, P9340; Arawaka S, 1999, NEUROREPORT, V10, P993, DOI 10.1097/00001756-199904060-00018; BAAS PW, 1991, J CELL BIOL, V115, P1333, DOI 10.1083/jcb.115.5.1333; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bongarzone E. R., 1996, Methods (Orlando), V10, P489, DOI 10.1006/meth.1996.0126; Bongarzone ER, 1998, J NEUROSCI RES, V54, P309, DOI 10.1002/(SICI)1097-4547(19981101)54:3<309::AID-JNR2>3.0.CO;2-5; CACERES A, 1991, J NEUROSCI, V11, P1515; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Fath T, 2002, J NEUROSCI, V22, P9733; Foster NL, 1997, ANN NEUROL, V41, P706, DOI 10.1002/ana.410410606; Furukawa K, 2000, NEUROREPORT, V11, P57, DOI 10.1097/00001756-200001170-00011; Goedert M, 2000, J NEUROCHEM, V75, P2155, DOI 10.1046/j.1471-4159.2000.0752155.x; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 1998, NEURON, V21, P955, DOI 10.1016/S0896-6273(00)80615-7; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; Gotz J, 2001, J BIOL CHEM, V276, P529, DOI 10.1074/jbc.M006531200; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Ho L, 2001, NEUROSCI LETT, V310, P1, DOI 10.1016/S0304-3940(01)02044-4; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Johnson GVW, 2002, J ALZHEIMERS DIS, V4, P375, DOI 10.3233/JAD-2002-4505; JOHNSON GV, 1996, J ALZHEIMERS DIS, V1, P329; Johnson GVW, 1997, J NEUROCHEM, V68, P430; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; Krishnamurthy PK, 2000, J NEUROSCI RES, V61, P515, DOI 10.1002/1097-4547(20000901)61:5<515::AID-JNR6>3.0.CO;2-#; LEE G, 1992, J CELL SCI, V102, P227; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Mack TGA, 2001, NEUROSCIENCE, V108, P701, DOI 10.1016/S0306-4522(01)00434-1; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Matsumura N, 1999, AM J PATHOL, V154, P1649, DOI 10.1016/S0002-9440(10)65420-X; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Perez M, 2000, J NEUROCHEM, V74, P2583, DOI 10.1046/j.1471-4159.2000.0742583.x; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Reed LA, 1997, ANN NEUROL, V42, P564, DOI 10.1002/ana.410420406; Reed LA, 2001, NEUROBIOL AGING, V22, P89, DOI 10.1016/S0197-4580(00)00202-5; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Rosso SM, 2000, ANN NY ACAD SCI, V920, P115; Sahara N, 2000, J NEUROSCI RES, V60, P380, DOI 10.1002/(SICI)1097-4547(20000501)60:3<380::AID-JNR13>3.0.CO;2-5; Saito Y, 2002, NEUROLOGY, V58, P811, DOI 10.1212/WNL.58.5.811; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1996, ACTA NEUROPATHOL, V92, P42, DOI 10.1007/s004010050487; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Stoothoff WH, 2001, J NEUROSCI RES, V65, P573, DOI 10.1002/jnr.1187; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Swieten JC, 1999, ANN NEUROL, V46, P617, DOI 10.1002/1531-8249(199910)46:4<617::AID-ANA10>3.0.CO;2-I	61	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7893	7900		10.1074/jbc.M311203200	http://dx.doi.org/10.1074/jbc.M311203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660557	hybrid			2022-12-27	WOS:000189103300066
J	Carreira, A; Menendez, M; Reguera, J; Almendral, JM; Mateu, MG				Carreira, A; Menendez, M; Reguera, J; Almendral, JM; Mateu, MG			In vitro disassembly of a parvovirus capsid and effect on capsid stability of heterologous peptide insertions in surface loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINUTE VIRUS; CANINE PARVOVIRUS; FUNCTIONAL IMPLICATIONS; PORCINE PARVOVIRUS; ANTIGENIC SITE; B-CELL; PROTEIN; PARTICLES; POLIOVIRUS; MICE	We have analyzed the in vitro disassembly of the capsid of the minute virus of mice, and the stability of capsid chimeras carrying heterologous epitope insertions. Upon heating in a physiological buffer, empty capsids formed by 60 copies of protein VP2 underwent first a reversible conformational change with a small enthalpy change detected by fluorescence. This change was associated with, but not limited to, externalization of the VP2 N terminus. Irreversible capsid dissociation as detected by changes in fluorescence, hemagglutination activity, and electrophoretic mobility occurred at much higher temperatures. Differential scanning calorimetry in the same conditions indicated that the dissociation/denaturation transition involved a high enthalpy change and proceeded through one or more intermediates. In contrast, in the presence of 1.5 m guanidinium chloride, heat-induced disassembly fitted a two-state irreversible process. Both thermally and chemically induced dissociation/denaturation yielded a form that had lost a part of the tertiary structure, but still retained the native secondary structure. Data from chemical dissociation indicates this form may correspond to a molten globule-like monomeric state of the capsid protein. All five antigenic peptide insertions attempted in exposed loops, despite being perhaps among the least disruptive, led to defects in folding/assembly of the capsid and, in most cases, to reduced capsid stability against thermal dissociation. The results with one of the simplest viral capsids reveal a complex pathway for disassembly, and a reduction in capsid assembly and stability upon insertion of peptides, even within the most exposed capsid loops.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Mateu, MG (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	mgarcia@cbm.uam.es	Vidaechea, Juan J Reguera/G-7451-2012; Reguera, Juan/A-7551-2017; Mateu, Mauricio/ABF-2146-2021; Menendez, Margarita/M-1795-2014; Almendral, Jose M/I-2510-2015	Reguera, Juan/0000-0003-4977-7948; Mateu, Mauricio/0000-0002-2915-1529; Menendez, Margarita/0000-0002-3267-4443; Almendral, Jose M/0000-0003-3457-0389; Carreira, Aura/0000-0001-5489-4343				AGBANDJE M, 1993, PROTEINS, V16, P155, DOI 10.1002/prot.340160204; Agbandje-McKenna M, 1998, STRUCT FOLD DES, V6, P1369, DOI 10.1016/S0969-2126(98)00137-3; BASAK S, 1992, VIROLOGY, V186, P368, DOI 10.1016/0042-6822(92)90002-7; BROWN CS, 1994, VIROLOGY, V198, P477, DOI 10.1006/viro.1994.1059; BURKE KL, 1988, NATURE, V332, P81, DOI 10.1038/332081a0; CARRASCOSA AL, 1994, BIOTECHNIQUES, V16, P1078; Casal JI, 1999, BIOTECHNOL APPL BIOC, V29, P141; Casal JI, 1999, METHODS, V19, P174, DOI 10.1006/meth.1999.0843; Chiu W., 1997, STRUCTURAL BIOL VIRU; Chow M., 1997, STRUCTURAL BIOL VIRU, P157; Cotmore SF, 1999, VIROLOGY, V254, P169, DOI 10.1006/viro.1998.9520; DIANA GD, 1997, STRUCTURAL BIOL VIRU, P432; Dokland T, 2000, STRUCTURE, V8, pR157, DOI 10.1016/S0969-2126(00)00181-7; Douar AM, 2003, VIROLOGY, V309, P203, DOI 10.1016/S0042-6822(03)00186-7; DUDA RL, 1995, J MOL BIOL, V247, P618, DOI 10.1016/S0022-2836(05)80143-3; GALISTEO ML, 1993, BIOPHYS J, V65, P227, DOI 10.1016/S0006-3495(93)81073-7; Greber Urs F., 1994, Trends in Microbiology, V2, P52, DOI 10.1016/0966-842X(94)90126-0; HAGIHARA Y, 1994, J MOL BIOL, V237, P336, DOI 10.1006/jmbi.1994.1234; Hernando E, 2000, VIROLOGY, V267, P299, DOI 10.1006/viro.1999.0123; Hurtado A, 1996, J VIROL, V70, P5422, DOI 10.1128/JVI.70.8.5422-5429.1996; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; Johnson J. E., 1999, ENCY VIROLOGY, P1946; Johnson JE, 1997, J MOL BIOL, V269, P665, DOI 10.1006/jmbi.1997.1068; Johnson JE, 1996, P NATL ACAD SCI USA, V93, P27, DOI 10.1073/pnas.93.1.27; JURNAK FA, 1984, BIOL MACROMOLECULES; Kruger DH, 1999, BIOL CHEM, V380, P275, DOI 10.1515/BC.1999.037; Ladurner AG, 1997, J MOL BIOL, V273, P330, DOI 10.1006/jmbi.1997.1304; LILJAS L, 1986, PROG BIOPHYS MOL BIO, V48, P1, DOI 10.1016/0079-6107(86)90008-8; Liljas Lars, 1999, Current Opinion in Structural Biology, V9, P129, DOI 10.1016/S0959-440X(99)80017-7; LlamasSaiz AL, 1997, ACTA CRYSTALLOGR D, V53, P93, DOI 10.1107/S0907444996010566; Lombardo E, 2000, J VIROL, V74, P3804, DOI 10.1128/JVI.74.8.3804-3814.2000; Lombardo E, 2002, J VIROL, V76, P7049, DOI 10.1128/JVI.76.14.7049-7059.2002; Lomonossoff GP, 1996, CURR OPIN STRUC BIOL, V6, P176, DOI 10.1016/S0959-440X(96)80072-8; Lopez-Bueno A, 2003, J VIROL, V77, P2701, DOI 10.1128/JVI.77.4.2701-2708.2003; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Mach H, 1995, Methods Mol Biol, V40, P91; Mateo R, 2003, J BIOL CHEM, V278, P41019, DOI 10.1074/jbc.M304990200; MATEU MG, 1995, VIRUS RES, V38, P1, DOI 10.1016/0168-1702(95)00048-U; MINOR PD, 1983, NATURE, V301, P674, DOI 10.1038/301674a0; MIYAMURA K, 1994, P NATL ACAD SCI USA, V91, P8507, DOI 10.1073/pnas.91.18.8507; MOYNIHAN CT, 1974, J PHYS CHEM-US, V78, P2673, DOI 10.1021/j100619a008; MURRAY MG, 1988, P NATL ACAD SCI USA, V85, P3203, DOI 10.1073/pnas.85.9.3203; MUZYCZKA N, 2001, FIELDS VIROLOGY, P2361; Prevelige PE, 1998, TRENDS BIOTECHNOL, V16, P61, DOI 10.1016/S0167-7799(97)01154-2; RAMIREZ JC, 1995, VIROLOGY, V206, P57, DOI 10.1016/S0042-6822(95)80019-0; Regan L, 1999, CURR OPIN STRUC BIOL, V9, P494, DOI 10.1016/S0959-440X(99)80070-0; Ros C, 2002, J VIROL, V76, P12634, DOI 10.1128/JVI.76.24.12634-12645.2002; ROSE CSP, 1991, TRENDS BIOTECHNOL, V9, P415, DOI 10.1016/0167-7799(91)90142-5; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1997, STRUCTURAL BIOL VIRU, P105; Rueda P, 1999, VACCINE, V18, P325, DOI 10.1016/S0264-410X(99)00202-9; Rueda P, 1999, VIROLOGY, V263, P89, DOI 10.1006/viro.1999.9911; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sedlik C, 1997, P NATL ACAD SCI USA, V94, P7503, DOI 10.1073/pnas.94.14.7503; SEDLIK C, 1995, J GEN VIROL, V76, P2361, DOI 10.1099/0022-1317-76-9-2361; Simpson AA, 2002, J MOL BIOL, V315, P1189, DOI 10.1006/jmbi.2001.5319; Smyth MS, 2002, J CLIN PATHOL-MOL PA, V55, P214, DOI 10.1136/mp.55.4.214; Steven AC, 1997, FASEB J, V11, P733, DOI 10.1096/fasebj.11.10.9271358; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; USHA R, 1993, VIROLOGY, V197, P366, DOI 10.1006/viro.1993.1598; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WU H, 1993, J MOL BIOL, V233, P231, DOI 10.1006/jmbi.1993.1502; Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635-8647.2000; Yuan W, 2001, VIROLOGY, V279, P546, DOI 10.1006/viro.2000.0734	66	56	56	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6517	6525		10.1074/jbc.M307662200	http://dx.doi.org/10.1074/jbc.M307662200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660623	hybrid			2022-12-27	WOS:000188969200038
J	Goh, CH; Jung, KH; Roberts, SK; McAinsh, MR; Hetherington, AM; Park, Y; Suh, K; An, GH; Nam, HG				Goh, CH; Jung, KH; Roberts, SK; McAinsh, MR; Hetherington, AM; Park, Y; Suh, K; An, GH; Nam, HG			Mitochondria provide the main source of cytosolic ATP for activation of outward-rectifying K+ channels in mesophyll protoplast of chlorophyll-deficient mutant rice (OsCHLH) seedlings	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUARD-CELL PROTOPLASTS; MEMBRANE H+-ATPASE; PLASMA-MEMBRANE; BLUE-LIGHT; OXIDATIVE-PHOSPHORYLATION; LEAF PROTOPLASTS; VICIA-FABA; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; ELECTRON-TRANSPORT	The role of mitochondria in providing intracellular ATP that controls the activity of plasma membrane outward-rectifying K+ channels was evaluated. The Os-CHLH rice mutant, which lacks chlorophyll in the thylakoids, was isolated by T-DNA gene trapping (Jung, K.-H., Hur, J., Ryu, C.-H., Choi, Y., Chung, Y.-Y., Miyao, A., Hirochika, H., and An, G. (2003) Plant Cell Physiol. 44, 463-472). The OsCHLH mutant is unable to fix CO2 and exhibits reduced growth. Wild type and mutant plants exhibit similar rates of respiratory O-2 uptake in the dark, whereas the rate of photosynthetic O-2 evolution by the mutant was negligible during illumination. During dark respiration the wild type and mutant exhibited similar levels of cytoplasmic ATP. In the mutant oligomycin treatment (an inhibitor of mitochondrial F1F0-ATPase) drastically reduced ATP production. The fact that this was reversed by the addition of glucose suggested that the mutant produced ATP exclusively from mitochondria but not from chloroplasts. In whole cell patch clamp experiments, the activity of outward-rectifying K+ channels of rice mesophyll cells showed ATP-dependent currents, which were 1.5-fold greater in wild type than in mutant cells. Channels in both wild type and mutant cells were deactivated by the removal of cytosolic ATP, whereas in the presence of ATP the channels remained active. We conclude that mesophyll cells in the OsCHLH rice mutant derive ATP from mitochondrial respiration, and that this is critical for the normal function of plasma membrane outward-rectifying K+ channels.	Pohang Univ Sci & Technol, Dept Life Sci, Bionanotechnol Ctr, Kyungbuk 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Kyungbuk 790784, South Korea; Univ Lancaster, Dept Biol Sci, Lancaster LA1 4YQ, England; Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea; Daegu Univ, Div Life Sci, Taegu 712714, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Lancaster University; Chungnam National University; Daegu University	Goh, CH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Bionanotechnol Ctr, Kyungbuk 790784, South Korea.	gohunse@postech.ac.kr	Jung, Ki Hong/L-5570-2019; Park, Youn-Il/S-2997-2019	Jung, Ki Hong/0000-0003-0427-5901; Park, Youn-Il/0000-0003-2912-2821; McAinsh, Martin Robert/0000-0003-4294-6470; roberts, stephen/0000-0003-1740-5330; Hetherington, Alistair/0000-0001-6060-9203	Biotechnology and Biological Sciences Research Council [P18229] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ASSMANN SM, 1985, NATURE, V318, P285, DOI 10.1038/318285a0; Bei QX, 1998, PLANT J, V13, P857, DOI 10.1046/j.1365-313X.1998.00084.x; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bricker TM, 2002, BBA-BIOENERGETICS, V1556, P92, DOI 10.1016/S0005-2728(02)00367-5; Briskin DP, 1996, PLANT PHYSIOL, V111, P1199, DOI 10.1104/pp.111.4.1199; BROWN GC, 1990, EUR J BIOCHEM, V192, P355, DOI 10.1111/j.1432-1033.1990.tb19234.x; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Choi SM, 2002, PLANTA, V216, P315, DOI 10.1007/s00425-002-0852-z; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; DAVIES JM, 1995, J MEMBRANE BIOL, V145, P75; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; Dutilleul C, 2003, PLANT CELL, V15, P1212, DOI 10.1105/tpc.009464; GARDESTROM P, 1995, J BIOENERG BIOMEMBR, V27, P415, DOI 10.1007/BF02110004; GARDESTROM P, 1987, FEBS LETT, V212, P114, DOI 10.1016/0014-5793(87)81567-3; Goh CH, 1996, PLANT PHYSIOL, V111, P433, DOI 10.1104/pp.111.2.433; Goh CH, 2002, PLANT J, V32, P623, DOI 10.1046/j.1365-313X.2002.01451.x; Goh CH, 1999, PLANT CELL ENVIRON, V22, P1057, DOI 10.1046/j.1365-3040.1999.00475.x; GOH CH, 1995, PLANT PHYSIOL, V109, P187, DOI 10.1104/pp.109.1.187; Harada A, 2002, PLANTA, V214, P863, DOI 10.1007/s00425-001-0689-x; Haupt-Herting S, 2001, PLANT PHYSIOL, V126, P388, DOI 10.1104/pp.126.1.388; Homann U, 2002, P NATL ACAD SCI USA, V99, P10215, DOI 10.1073/pnas.152324399; Jensen PE, 1996, MOL GEN GENET, V250, P383; Jeong WJ, 2002, PLANT PHYSIOL, V129, P112, DOI 10.1104/pp.000588; Jung KH, 2003, PLANT CELL PHYSIOL, V44, P463, DOI 10.1093/pcp/pcg064; Keunecke M, 2000, PLANTA, V210, P792, DOI 10.1007/s004250050681; KISHONY R, 2003, J BIOL; Knopp A, 2001, CARDIOVASC RES, V52, P236, DOI 10.1016/S0008-6363(01)00395-9; KOURIE J, 1992, PLANT PHYSIOL, V98, P1087, DOI 10.1104/pp.98.3.1087; KROMER S, 1993, PLANT PHYSIOL, V102, P947, DOI 10.1104/pp.102.3.947; KROMER S, 1995, ANNU REV PLANT PHYS, V46, P45, DOI 10.1146/annurev.pp.46.060195.000401; LAMBERS H, 1997, OXIDATION MITOCHONDR, P200; Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055; Leonhardt N, 1997, P NATL ACAD SCI USA, V94, P14156, DOI 10.1073/pnas.94.25.14156; LI WW, 1993, P NATL ACAD SCI USA, V90, P262, DOI 10.1073/pnas.90.1.262; LI WW, 1994, PLANT PHYSIOL, V106, P957, DOI 10.1104/pp.106.3.957; Maathuis FJM, 1997, PLANT PHYSIOL, V114, P1141, DOI 10.1104/pp.114.4.1141; Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3; Moran N, 1996, PLANT PHYSIOL, V111, P1281, DOI 10.1104/pp.111.4.1281; NEHER E, 1992, METHOD ENZYMOL, V207, P123; NORMA A, 1983, NATURE, V305, P147; Padmasree K, 2002, CRIT REV BIOCHEM MOL, V37, P71, DOI 10.1080/10409230290771465; PARNIK T, 1995, J EXP BOT, V46, P1439, DOI 10.1093/jxb/46.special_issue.1439; Pastore D, 1996, BIOCHEM MOL BIOL INT, V39, P149; Pineros MA, 2003, PLANT PHYSIOL, V131, P583, DOI 10.1104/pp.011932; Priebe L, 1996, J PHYSIOL-LONDON, V492, P405, DOI 10.1113/jphysiol.1996.sp021317; RAGHAVENDRA AS, 1994, PLANT SCI, V97, P1, DOI 10.1016/0168-9452(94)90101-5; REY P, 1989, PLANT PHYSIOL, V89, P762, DOI 10.1104/pp.89.3.762; Romano LA, 1998, PLANT CELL PHYSIOL, V39, P1133, DOI 10.1093/oxfordjournals.pcp.a029314; RORSMAN P, 1990, POTASSIUM CHANNELS S, P96; Rosenberg C, 1999, BIOCHEMISTRY-US, V38, P15994, DOI 10.1021/bi991326r; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; SPALDING EP, 1992, PLANT PHYSIOL, V99, P96, DOI 10.1104/pp.99.1.96; SPALDING EP, 1992, PLANTA, V188, P199, DOI 10.1007/BF00216814; Spalding EP, 2000, PLANT CELL ENVIRON, V23, P665, DOI 10.1046/j.1365-3040.2000.00594.x; SPALDING EP, 1993, PLANT CELL, V5, P477, DOI 10.2307/3869727; Stahlberg R, 1999, PLANTA, V208, P188, DOI 10.1007/s004250050549; Stahlberg R, 2000, PLANTA, V212, P1, DOI 10.1007/s004250000365; Stiles KA, 2002, J EXP BOT, V53, P1651, DOI 10.1093/jxb/erf015; STITT M, 1982, PLANT PHYSIOL, V70, P971, DOI 10.1104/pp.70.4.971; Taylor AR, 2001, PLANT PHYSIOL, V125, P329, DOI 10.1104/pp.125.1.329; Thomine S, 1995, PLANT CELL, V7, P2091, DOI 10.1105/tpc.7.12.2091; Trapp S, 1998, J GEN PHYSIOL, V112, P325, DOI 10.1085/jgp.112.3.325; VALERIO M, 1993, EUR J BIOCHEM, V216, P565, DOI 10.1111/j.1432-1033.1993.tb18175.x; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; VANSELOW KH, 1989, J MEMBRANE BIOL, V110, P175, DOI 10.1007/BF01869472; VANVOLKENBURGH E, 1990, PLANTA, V182, P72, DOI 10.1007/BF00239986; VEKSHIN NL, 1991, BIOCHEM INT, V25, P603; Walker D, 1987, USE OXYGEN ELECTRODE; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911; Xie ZX, 1999, PLANT PHYSIOL, V120, P217, DOI 10.1104/pp.120.1.217; ZIMMERMANN S, 1994, PLANT J, V6, P707, DOI 10.1046/j.1365-313X.1994.6050707.x	74	22	28	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6874	6882		10.1074/jbc.M309071200	http://dx.doi.org/10.1074/jbc.M309071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660680	hybrid			2022-12-27	WOS:000188969200082
J	Ishii, H; Sen, RJ; Pazin, MJ				Ishii, H; Sen, RJ; Pazin, MJ			Combinatorial control of DNase I-hypersensitive site formation and erasure by immunoglobulin heavy chain enhancer-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX ATTACHMENT REGIONS; HELIX-LOOP-HELIX; TISSUE-SPECIFIC TRANSCRIPTION; TRANSGENIC MICE; V(D)J RECOMBINATION; GENE ENHANCER; CHROMATIN TEMPLATES; INTRONIC ENHANCER; FACTOR PU.1; B-LINEAGE	DNase I-hypersensitive sites in cellular chromatin are usually believed to be nucleosome-free regions generated by transcription factor binding. Using a cell-free system we show that hypersensitivity does not simply correlate with the number of DNA-bound proteins. Specifically, the leucine zipper containing basic helix-loop-helix protein TFE3 was sufficient to induce a DNase I-hypersensitive site at the immunoglobulin heavy chain mu enhancer in vitro. TFE3 enhanced binding of an ETS protein PU.1 to the enhancer. However, PU.1 binding erased the DNase I-hypersensitive site without abolishing TFE3 binding. Furthermore, TFE3 binding enhanced transcription in the presence and absence of a hypersensitive site, whereas endonuclease accessibility correlated strictly with DNase I hypersensitivity. We infer that chromatin constraints for transcription and nuclease sensitivity can differ.	Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Brandeis Univ, Grad Program Biophys & Struct Biol, Waltham, MA 02454 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Harvard University; Brandeis University; Brandeis University; Brandeis University	Pazin, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.	michael.pazin@cbrc2.mgh.harvard.edu		Pazin, Michael/0000-0002-7561-3640; Ishii, Haruhiko/0000-0002-1593-096X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038925, R01GM038925, R01GM061011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000524, Z01AG000524, Z01AG000383, ZIAAG000383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38925, GM61011] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Angelin-Duclos C, 1998, MOL CELL BIOL, V18, P6253, DOI 10.1128/MCB.18.11.6253; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bulger M., 1994, METH MOL G, V5, P241; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; Fernandez LA, 2001, MOL CELL BIOL, V21, P196, DOI 10.1128/MCB.21.1.196-208.2001; FERNEX C, 1995, MOL CELL BIOL, V15, P3217; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; FORD AM, 1988, EMBO J, V7, P2393, DOI 10.1002/j.1460-2075.1988.tb03084.x; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LARSON CJ, 1992, NUCLEIC ACIDS RES, V20, P3525, DOI 10.1093/nar/20.13.3525; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; Miller JA, 2003, MOL CELL BIOL, V23, P1623, DOI 10.1128/MCB.23.5.1623-1632.2003; MILLS FC, 1983, NATURE, V306, P809, DOI 10.1038/306809a0; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NELSEN B, 1992, INT REV CYTOL, V133, P121, DOI 10.1016/S0074-7696(08)61859-8; Nikolajczyk BS, 1999, IMMUNITY, V11, P11, DOI 10.1016/S1074-7613(00)80077-1; Nikolajczyk BS, 1997, MOL CELL BIOL, V17, P3527, DOI 10.1128/MCB.17.7.3527; OKADA A, 1994, J EXP MED, V180, P261, DOI 10.1084/jem.180.1.261; OLTZ EM, 1993, MOL CELL BIOL, V13, P6223, DOI 10.1128/MCB.13.10.6223; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; Pazin MJ, 1998, CHROMATIN PRACTICAL, P173; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; REIK W, 1987, EUR J IMMUNOL, V17, P465, DOI 10.1002/eji.1830170405; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; Rieske P, 2001, J BIOL CHEM, V276, P8460, DOI 10.1074/jbc.M007482200; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sakai E, 1999, P NATL ACAD SCI USA, V96, P1526, DOI 10.1073/pnas.96.4.1526; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SERWE M, 1993, EMBO J, V12, P2321, DOI 10.1002/j.1460-2075.1993.tb05886.x; Sikes ML, 2002, P NATL ACAD SCI USA, V99, P12309, DOI 10.1073/pnas.182166699; Tian G, 1999, MOL CELL BIOL, V19, P2946; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Whitehurst CE, 2000, IMMUNITY, V13, P703, DOI 10.1016/S1074-7613(00)00069-8; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	61	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7331	7338		10.1074/jbc.M308973200	http://dx.doi.org/10.1074/jbc.M308973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660676	hybrid			2022-12-27	WOS:000188969200135
J	Pollice, A; Nasti, V; Ronca, R; Vivo, M; Lo Iacono, M; Calogero, R; Calabro, V; La Mantia, G				Pollice, A; Nasti, V; Ronca, R; Vivo, M; Lo Iacono, M; Calogero, R; Calabro, V; La Mantia, G			Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							26 S PROTEASOME; RETINOBLASTOMA PROTEIN; CELL-CYCLE; P19(ARF); P53; P14(ARF); GENE; MDM2; DEGRADATION; LOCUS	The p14(ARF) tumor suppressor is a key regulator of cellular proliferation, frequently inactivated in human cancer, whose mode of action is currently not completely understood. We report here that the so-called human immunodeficiency virus Tat-binding protein-1 (TBP-1), a component of the 19 S regulatory subunit of the proteasome 26 S, also involved in transcriptional regulation and with a supposed role in the control of cell proliferation, specifically interacts with ARF, both in yeast and mammalian cells. We present evidence that the overexpression of TBP-1 in various cell lines results in a sharp increase of both transfected and endogenous ARF protein levels. Moreover, this effect depends on the binding between the two proteins and, at least in part, is exerted at the post-translational level. We also show that the ARF increase following TBP-1 overexpression results in an increase in p53 protein levels and activity. Finally, our data underline a clear involvement of TBP-1 in the control of cell proliferation.	Univ Naples Federico II, Dept Genet Gen & Mol Biol, I-80134 Naples, Italy; S Luigi Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy	University of Naples Federico II	La Mantia, G (corresponding author), Univ Naples Federico II, Dept Genet Gen & Mol Biol, Via Mezzocannone 8, I-80134 Naples, Italy.	lamantia@unina.it	Lo Iacono, Marco/L-5453-2016; Calabro, Viola/H-6156-2013; Vivo, Maria/S-3390-2017; Calogero, Raffaele/K-9428-2019	Lo Iacono, Marco/0000-0002-3936-4472; Vivo, Maria/0000-0003-2458-4226; Calogero, Raffaele/0000-0002-2848-628X; Calabro, Viola/0000-0002-6508-8889; Ronca, Raffaele/0000-0003-2217-3378				Barak O, 2001, VIROLOGY, V283, P110, DOI 10.1006/viro.2001.0883; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Calabro V, 1999, ONCOGENE, V18, P2157, DOI 10.1038/sj.onc.1202532; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chen Y, 1997, J BIOL CHEM, V272, P24081, DOI 10.1074/jbc.272.38.24081; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; David-Pfeuty T, 2002, ONCOGENE, V21, P6779, DOI 10.1038/sj.onc.1205871; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Ghee M, 2000, J NEUROCHEM, V75, P2221, DOI 10.1046/j.1471-4159.2000.0752221.x; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Ishizuka T, 2001, MOL ENDOCRINOL, V15, P1329, DOI 10.1210/me.15.8.1329; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kashuba Elena, 2003, Mol Cancer, V2, P18, DOI 10.1186/1476-4598-2-18; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Menendez S, 2003, J BIOL CHEM, V278, P18720, DOI 10.1074/jbc.M211007200; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; Ottosen S, 2002, SCIENCE, V296, P479, DOI 10.1126/science.1071270; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Park BW, 1999, P NATL ACAD SCI USA, V96, P6434, DOI 10.1073/pnas.96.11.6434; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	43	33	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6345	6353		10.1074/jbc.M310957200	http://dx.doi.org/10.1074/jbc.M310957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665636	hybrid			2022-12-27	WOS:000188969200019
J	Weng, YP; Lin, YP; Hsu, CI; Lin, JY				Weng, YP; Lin, YP; Hsu, CI; Lin, JY			Functional domains of a pore-forming cardiotoxic protein, volvatoxin A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL-DEPENDENT CYTOLYSIN; SITE-DIRECTED MUTAGENESIS; BACILLUS-THURINGIENSIS; ALPHA-HEMOLYSIN; MEMBRANE ASSOCIATION; SECONDARY STRUCTURE; BINDING; TOXINS; HELIX; MECHANISM	Volvatoxin A2 (VVA2), a novel pore-forming cardiotoxic protein was isolated from the mushroom Volvariella volvacea. We identified an N-terminal fragment (NTF) (1-127 residues) of VVA2 as a domain for oligomerization by limited tryptic digestion. On preincubation of NTF with VVA2, NTF was found to inhibit VVA2 hemolytic activity by inducing VVA2 oligomerization in the solution in the same manner as liposomes. By site-directed mutagenesis, the amphipathic a-helix B of NTF or VVA2 was shown to be indispensable for its biological functions. Interestingly, at a molar ratio of recombinant NTF (reNTF)/VVA2 as low as 0.01, reNTF was able to inhibit VVA2 hemolytic activity and induce VVA2 oligomerization. This indicates that reNTF can trigger VVA2 oligomerization by a seeding effect. Furthermore, the recombinant C-terminal fragment (128-199 residues) was found to be a functional domain that mediates the membrane binding of VVA2. We found a fragment localized at the C-terminal half of VVA2 containing beta6, -7, and -8, which is protected from protease digestion because of its insertion of a membrane. We also identified a putative heparin binding site (HBS) located in the VVA2 C terminus (166-194 residues), which was conserved among 10 kinds of snake venom cardiotoxins. VVA2 or the reHBS fragment was shown to interact with sulfated glycoaminoglycans by affinity column chromatography. The finding of a higher number of glycoaminoglycans in the membrane of cardiac myocytes suggested that they could be the specific membrane target for VVA2. Taken together, these findings indicate that VVA2 contains two functional domains, NTF and CTF. The NTF domain is responsible for VVA2 oligomerization and the CTF domain for membrane binding and insertion. Our results support a model whereby the formation of VVA2 oligomeric pre-pore complexes precedes their membrane insertion.	Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 10081, Taiwan	National Taiwan University	Lin, JY (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, F9,1,Sect 1,Jen Ai Rd, Taipei 10081, Taiwan.	jylin@ha.mc.ntu.edu.tw	Lin, Jung-Yaw/AGW-9336-2022	Lin, Jung-Yaw/0000-0002-6341-1160				BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Cortajarena AL, 2003, J BIOL CHEM, V278, P19159, DOI 10.1074/jbc.M208552200; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Du JP, 1999, BIOCHEM J, V338, P185, DOI 10.1042/0264-6021:3380185; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; Erb EM, 2000, ANAL BIOCHEM, V280, P29, DOI 10.1006/abio.1999.4469; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FASSOLD E, 1976, J MOL CELL CARDIOL, V8, P501, DOI 10.1016/0022-2828(76)90052-3; GATINEAU E, 1990, BIOCHEMISTRY-US, V29, P6480, DOI 10.1021/bi00479a021; Gilbert RJC, 2002, CELL MOL LIFE SCI, V59, P832, DOI 10.1007/s00018-002-8471-1; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Hotze EM, 2002, J BIOL CHEM, V277, P11597, DOI 10.1074/jbc.M111039200; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Li J, 1996, J MOL BIOL, V257, P129, DOI 10.1006/jmbi.1996.0152; LIN JY, 1973, NATURE, V246, P524, DOI 10.1038/246524a0; Lin WH, 1997, J BIOL CHEM, V272, P20044, DOI 10.1074/jbc.272.32.20044; Liu CL, 2000, J BIOL CHEM, V275, P1897, DOI 10.1074/jbc.275.3.1897; Martin GA, 2001, BIOTECHNIQUES, V31, P948, DOI 10.2144/01314pf01; McInerney TL, 1998, J VIROL, V72, P1523, DOI 10.1128/JVI.72.2.1523-1533.1998; Menestrina G, 2001, TOXICON, V39, P1661, DOI 10.1016/S0041-0101(01)00153-2; Palmer M, 1996, J BIOL CHEM, V271, P26664, DOI 10.1074/jbc.271.43.26664; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Patel HV, 1997, J BIOL CHEM, V272, P1484, DOI 10.1074/jbc.272.32.20185; Promdonkoy B, 2000, BIOCHEM J, V350, P275, DOI 10.1042/0264-6021:3500275; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROWE GE, 1994, METHOD ENZYMOL, V235, P657; Sangha N, 1999, J BIOL CHEM, V274, P9193, DOI 10.1074/jbc.274.14.9193; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shimada Y, 1999, J BIOL CHEM, V274, P18536, DOI 10.1074/jbc.274.26.18536; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Vyas AA, 1997, J BIOL CHEM, V272, P9661, DOI 10.1074/jbc.272.15.9661; Wang W, 1998, J BIOL CHEM, V273, P27438, DOI 10.1074/jbc.273.42.27438; WENG YP, 2000, P TAIW SOC BIOCH MOL, P49; YAMANAKA H, 1987, J GEN MICROBIOL, V133, P2859	43	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6805	6814		10.1074/jbc.M308675200	http://dx.doi.org/10.1074/jbc.M308675200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645370	hybrid			2022-12-27	WOS:000188969200074
J	Bundgaard, JR; Birkedal, H; Rehfeld, JF				Bundgaard, JR; Birkedal, H; Rehfeld, JF			Progastrin is directed to the regulated secretory pathway by synergistically acting basic and acidic motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; CARBOXYPEPTIDASE-E; SORTING RECEPTOR; CHROMOGRANIN-A; MUTATIONAL ANALYSIS; ENDOCRINE-CELLS; CLEAVAGE SITE; GRANULES; PROTEIN; BINDING	Bioactivation of prohormones occurs in the granules of the regulated secretory pathway of endocrine cells, which release hormones in response to external stimulation. How secretory granules are formed and how the cargo is selected is still unclear, but it has been shown for several prohormones and processing enzymes that domains within the prohormone structure can act as " sorting signals" for this pathway. The domains mediate interactions with other proteins or with the membrane or facilitate aggregation of the ( pro) peptides. We have now searched for domains in progastrin that are active in sorting the prohormone into secretory granules. Truncation studies showed that the N- terminal 30 residues of progastrin are dispensable, whereas the last 49 residues are sufficient for correct biosynthesis of bioactive gastrin. Thus, further N- terminal truncation abolished gastrin expression. C- terminal truncation of 8 residues resulted in an increase in basal secretion as did point mutations in the dibasic processing sites of progastrin. These mutants, however, still responded to secretagogues, suggesting a residual sorting capacity to the regulated pathway. Amino acid substitutions in an acidic, polyglutamate motif within gastrin- 17, the main bioactive, cellular gastrin form, did not alter secretion per se, but when these residues were substituted in C-terminally truncated mutants, double mutants increased in basal secretion and did not respond to secretagogue stimulation. This implies that the mutants are constitutively secreted. Our data suggest that the dibasic processing sites constitute the most important sorting domain of progastrin, and these sites act in synergy with the acidic domain.	Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Bundgaard, JR (corresponding author), Univ Copenhagen, Rigshosp, Dept Clin Biochem, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	jrb@rh.dk						Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; Bernard N, 2003, J NEUROCHEM, V85, P1592, DOI 10.1046/j.1471-4159.2003.01823.x; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; BRAKCH N, 1994, BIOCHEM BIOPH RES CO, V205, P221, DOI 10.1006/bbrc.1994.2653; Brakch N, 2002, J NEUROCHEM, V81, P1166, DOI 10.1046/j.1471-4159.2002.00919.x; Brechler V, 1996, J BIOL CHEM, V271, P20636, DOI 10.1074/jbc.271.34.20636; Bundgaard Jens R, 2002, Methods Mol Biol, V194, P291; BUNDGAARD JR, 1995, EMBO J, V14, P3073, DOI 10.1002/j.1460-2075.1995.tb07310.x; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Bundgaard JR, 1996, DNA CELL BIOL, V15, P147, DOI 10.1089/dna.1996.15.147; Canaff L, 1996, P NATL ACAD SCI USA, V93, P9483, DOI 10.1073/pnas.93.18.9483; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Cowley DJ, 2000, J BIOL CHEM, V275, P7743, DOI 10.1074/jbc.275.11.7743; Dannies PS, 2001, MOL CELL ENDOCRINOL, V177, P87, DOI 10.1016/S0303-7207(01)00437-3; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; Dhanvantari S, 2002, BIOCHEMISTRY-US, V41, P52, DOI 10.1021/bi015698n; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; Dockray GJ, 2001, ANNU REV PHYSIOL, V63, P119, DOI 10.1146/annurev.physiol.63.1.119; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; Feliciangeli S, 2001, J BIOL CHEM, V276, P6140, DOI 10.1074/jbc.M009613200; GERDES HH, 1989, J BIOL CHEM, V264, P12009; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; Gorr SU, 2001, MOL CELL ENDOCRINOL, V172, P1, DOI 10.1016/S0303-7207(00)00342-7; GORR SU, 1989, AM J PHYSIOL, V257, P247; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KRANE IM, 1988, J BIOL CHEM, V263, P13317; Kuliawat R, 2000, MOL BIOL CELL, V11, P1959, DOI 10.1091/mbc.11.6.1959; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Pannequin J, 2002, J BIOL CHEM, V277, P48602, DOI 10.1074/jbc.M208440200; REHFELD JF, 1978, J BIOL CHEM, V253, P4016; REHFELD JF, 1994, EUR J BIOCHEM, V223, P765, DOI 10.1111/j.1432-1033.1994.tb19051.x; Rehfeld JF, 2002, FEBS LETT, V510, P89, DOI 10.1016/S0014-5793(01)03234-3; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHIELDS PP, 1990, J BIOL CHEM, V265, P10905; Taupenot L, 2002, J CELL SCI, V115, P4827, DOI 10.1242/jcs.00140; Thiele C, 1997, CURR BIOL, V7, P496; Tooze SA, 1998, BBA-MOL CELL RES, V1404, P231, DOI 10.1016/S0167-4889(98)00059-7; Yoo SH, 1998, FEBS LETT, V427, P55, DOI 10.1016/S0014-5793(98)00393-7; Zhang CF, 1999, MOL ENDOCRINOL, V13, P527, DOI 10.1210/me.13.4.527; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	44	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5488	5493		10.1074/jbc.M310547200	http://dx.doi.org/10.1074/jbc.M310547200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660571	hybrid			2022-12-27	WOS:000188776500056
J	Cartron, PF; Oliver, L; Juin, P; Meflah, K; Vallette, FM				Cartron, PF; Oliver, L; Juin, P; Meflah, K; Vallette, FM			The p18 truncated form of bax behaves like a Bcl-2 homology domain 3-only protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC CELL-DEATH; DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; BH3 DOMAIN; INTRACELLULAR-LOCALIZATION; X-L; CLEAVAGE; MITOCHONDRIA; CALPAIN; CANCER	p21(Bax) is a pro-apoptotic member of the Bcl-2 family and is converted by calpain into a truncated form called p18(Bax). This proteolysis enhanced the apoptogenic properties of Bax by a mechanism not yet elucidated. We have shown recently that the first alpha helix (Halpha1) of p21(Bax) contained a mitochondrial addressing sequence, which appeared to be necessary for p21(Bax)-induced apoptosis (Cartron, P. F., Priault, M., Oliver, L., Meflah, K., Manon, S., and Vallette, F. M. (2003) J. Biol. Chem. 278, 11633 11641). This feature is in contradiction with the high apoptogenic profile of p18(Bax), because the Halpha1 is lost during the calpain cleavage of p21(Bax). We investigated the role of p18(Bax) in apoptosis and found that its activity required the presence of p21(Bax). In addition, p18(Bax) exhibited a higher affinity for Bcl-Xl than p21(Bax) did, a property that seems to be essential for the fulfillment of its pro-apoptotic role. In conclusion, calpain proteolysis converts the multi-domain p21(Bax) into a Bcl-2 homology 3-like protein capable of overcoming the inhibition of apoptosis due to Bcl-Xl.	Inst Fed Rech 26, INSERM, U419, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Vallette, FM (corresponding author), Inst Fed Rech 26, INSERM, U419, 9 Quai Moncousu, F-44035 Nantes 01, France.	fval@nantes.inserm.fr	JUIN, Philippe P/H-3636-2014; Vallette, Francois/N-2361-2018; Vallette, Francois M/K-9047-2015; Oliver, Lisa J/L-3070-2015; Cartron, Pierre Francois/K-9802-2015; JUIN, Philippe/Q-1338-2019	JUIN, Philippe P/0000-0002-4997-3888; Vallette, Francois M/0000-0002-3296-8572; Oliver, Lisa J/0000-0002-5588-7564; JUIN, Philippe/0000-0002-4997-3888; Cartron, Pierre-Francois/0000-0002-3393-784X; Vallette, Francois/0000-0003-0802-0519				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Amundson SA, 2000, CANCER RES, V60, P6101; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Chan SL, 2003, J BIOL CHEM, V278, P20453, DOI 10.1074/jbc.C300138200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Choi WS, 2001, J NEUROCHEM, V77, P1531, DOI 10.1046/j.1471-4159.2001.00368.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Juin P, 1998, BIOCHEM BIOPH RES CO, V253, P185, DOI 10.1006/bbrc.1998.9742; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Moreau C, 2003, J BIOL CHEM, V278, P19426, DOI 10.1074/jbc.M209472200; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	40	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11503	11512		10.1074/jbc.M311922200	http://dx.doi.org/10.1074/jbc.M311922200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14681224	hybrid			2022-12-27	WOS:000220157600082
J	Guilherme, A; Soriano, NA; Bose, S; Holik, J; Bose, A; Pomerleau, DP; Furcinitti, P; Leszyk, J; Corvera, S; Czech, MP				Guilherme, A; Soriano, NA; Bose, S; Holik, J; Bose, A; Pomerleau, DP; Furcinitti, P; Leszyk, J; Corvera, S; Czech, MP			EHD2 and the novel EH domain binding protein EHBP1 couple endocytosis to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; POLARIZED EPITHELIAL-CELLS; CLATHRIN-COATED PITS; ARP2/3 COMPLEX; 3T3-L1 ADIPOCYTES; MAMMALIAN-CELLS; PLASMA-MEMBRANE; GLUT4 ENDOCYTOSIS; N-WASP; INSULIN	Here we identified two novel proteins denoted EH domain protein 2 (EHD2) and EHD2-binding protein 1 (EHBP1) that link clathrin-mediated endocytosis to the actin cytoskeleton. EHD2 contains an N-terminal P-loop and a C-terminal EH domain that interacts with NPF repeats in EHBP1. Disruption of EHD2 or EHBP1 function by small interfering RNA-mediated gene silencing inhibits endocytosis of transferrin into EEA1-positive endosomes as well as GLUT4 endocytosis into cultured adipocytes. EHD2 localizes with cortical actin filaments, whereas EHBP1 contains a putative actin-binding calponin homology domain. High expression of EHD2 or EHBP1 in intact cells mediates extensive actin reorganization. Thus EHD2 appears to connect endocytosis to the actin cytoskeleton through interactions of its N-terminal domain with membranes and its C-terminal EH domain with the novel EHBP1 protein.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	Michael.Czech@umassmed.edu			NIDDK NIH HHS [DK30898, DK60837, DK54479] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060837, R01DK030898, R37DK030898, R01DK054479] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Benmerah A, 1999, J CELL SCI, V112, P1303; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Bose A, 2001, MOL CELL BIOL, V21, P5262, DOI 10.1128/MCB.21.15.5262-5275.2001; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; Confalonieri S, 2002, FEBS LETT, V513, P24, DOI 10.1016/S0014-5793(01)03241-0; de Beer T, 2000, NAT STRUCT BIOL, V7, P1018, DOI 10.1038/80924; Duncan MC, 2001, NAT CELL BIOL, V3, P687, DOI 10.1038/35083087; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Geli MI, 1998, J CELL SCI, V111, P1031; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Grant B, 2001, NAT CELL BIOL, V3, P573, DOI 10.1038/35078549; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; JACKMAN MR, 1994, J CELL SCI, V107, P2547; Jeng RL, 2001, CURR BIOL, V11, pR691, DOI 10.1016/S0960-9822(01)00410-9; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; Lin SX, 2001, NAT CELL BIOL, V3, P567, DOI 10.1038/35078543; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Munn AL, 2001, BBA-MOL BASIS DIS, V1535, P236, DOI 10.1016/S0925-4439(01)00028-X; NATION JL, 1983, STAIN TECHNOL, V58, P347, DOI 10.3109/10520298309066811; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Pohl U, 2000, GENOMICS, V63, P255, DOI 10.1006/geno.1999.6087; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Shao YF, 2002, J CELL BIOL, V157, P679, DOI 10.1083/jcb.200201063; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Woodman PG, 2000, TRAFFIC, V1, P695, DOI 10.1034/j.1600-0854.2000.010902.x; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265	52	114	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10593	10605		10.1074/jbc.M307702200	http://dx.doi.org/10.1074/jbc.M307702200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14676205	hybrid			2022-12-27	WOS:000220050400113
J	Kunz, JB; Schwarz, H; Mayer, A				Kunz, JB; Schwarz, H; Mayer, A			Determination of four sequential stages during microautophagy in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-COMPLEX FORMATION; SACCHAROMYCES-CEREVISIAE; MEMBRANE-FUSION; CVT PATHWAY; AUTOPHAGIC VESICLES; TARGETING PATHWAY; PICHIA-PASTORIS; PROTEIN-KINASE; VACUOLE; YEAST	Microautophagy is the transfer of cytosolic components into the lysosome by direct invagination of the lysosomal membrane and subsequent budding of vesicles into the lysosomal lumen. This process is topologically equivalent to membrane invagination during multivesicular body formation and to the budding of enveloped viruses. Vacuoles are lysosomal compartments of yeasts. Vacuolar membrane invagination can be reconstituted in vitro with purified yeast vacuoles, serving as a model system for budding of vesicles into the lumen of an organelle. Using this in vitro system, we defined different reaction states. We identified inhibitors of microautophagy in vitro and used them as tools for kinetic analysis. This allowed us to characterize four biochemically distinguishable steps of the reaction. We propose that these correspond to sequential stages of vacuole invagination and vesicle scission. Formation of vacuolar invaginations was slow and temperature-dependent, whereas the final scission of the vesicle from a preformed invagination was fast and proceeded even on ice. Our observations suggest that the formation of invaginations rather than the scission of vesicles is the rate-limiting step of the overall reaction.	Max Planck Gesell, Friedrich Miescher Lab, D-72076 Tubingen, Germany; Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society; Max Planck Society	Mayer, A (corresponding author), Univ Lausanne, Dept Biochim, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	andreas.mayer@tuebingen.mpg.de	Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; BAKER D, 1989, METHOD CELL BIOL, V31, P127; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Barth H, 2001, FEBS LETT, V508, P23, DOI 10.1016/S0014-5793(01)03016-2; Barth H, 2001, GENE, V274, P151, DOI 10.1016/S0378-1119(01)00614-X; Bhuiyan MSA, 1999, BIOSCI BIOTECH BIOCH, V63, P1075, DOI 10.1271/bbb.63.1075; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; Botstein D, 1997, MOL BIOL CELL, V8, pR1, DOI 10.1091/mbc.8.1.i; CARDENAS ME, 1995, J BIOL CHEM, V270, P20997, DOI 10.1074/jbc.270.36.20997; Carminati JL, 1997, J CELL BIOL, V138, P629, DOI 10.1083/jcb.138.3.629; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; Epple UD, 2001, J BACTERIOL, V183, P5942, DOI 10.1128/JB.183.20.5942-5955.2001; FRYBERG M, 1974, ARCH BIOCHEM BIOPHYS, V160, P83, DOI 10.1016/S0003-9861(74)80011-1; GUPTA RS, 1983, CANCER RES, V43, P505; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; Hutchins MU, 2001, J BIOL CHEM, V276, P20491, DOI 10.1074/jbc.M101150200; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kato M, 2001, EMBO J, V20, P4035, DOI 10.1093/emboj/20.15.4035; Khalfan WA, 2002, CURR OPIN CELL BIOL, V14, P468, DOI 10.1016/S0955-0674(02)00343-5; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Knop M, 1993, CURR OPIN CELL BIOL, V5, P990, DOI 10.1016/0955-0674(93)90082-2; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Lang T, 2000, J BACTERIOL, V182, P2125, DOI 10.1128/JB.182.8.2125-2133.2000; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; LENTZ BR, 1987, BIOCHEMISTRY-US, V26, P5389, DOI 10.1021/bi00391a026; Meiling-Wesse K, 2002, FEBS LETT, V530, P174, DOI 10.1016/S0014-5793(02)03456-7; Meiling-Wesse K, 2002, FEBS LETT, V526, P71, DOI 10.1016/S0014-5793(02)03119-8; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mukaiyama H, 2002, GENES CELLS, V7, P75, DOI 10.1046/j.1356-9597.2001.00499.x; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; Muller O, 2001, EMBO J, V20, P5657, DOI 10.1093/emboj/20.20.5657; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; POSTE G, 1973, BIOCHIM BIOPHYS ACTA, V300, P421, DOI 10.1016/0304-4157(73)90015-4; ROSENTHAL MD, 1989, BIOCHIM BIOPHYS ACTA, V1001, P1, DOI 10.1016/0005-2760(89)90299-3; Sakai Y, 1998, J CELL BIOL, V141, P625, DOI 10.1083/jcb.141.3.625; Sattler T, 2000, J CELL BIOL, V151, P529, DOI 10.1083/jcb.151.3.529; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200; Stockwell BR, 2000, NAT REV GENET, V1, P116, DOI 10.1038/35038557; Suriapranata I, 2000, J CELL SCI, V113, P4025; SUURKUUSK J, 1976, BIOCHEMISTRY-US, V15, P1393, DOI 10.1021/bi00652a007; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TITORENKO VI, 1995, J BACTERIOL, V177, P357, DOI 10.1128/jb.177.2.357-363.1995; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wang CW, 2002, J BIOL CHEM, V277, P47917, DOI 10.1074/jbc.M208191200; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200; WILSCHUT J, 1985, BIOCHEMISTRY-US, V24, P8, DOI 10.1021/bi00322a002; Yuan WP, 1997, J CELL SCI, V110, P1935	58	104	113	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9987	9996		10.1074/jbc.M307905200	http://dx.doi.org/10.1074/jbc.M307905200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679207	hybrid			2022-12-27	WOS:000220050400042
J	Beigneux, AP; Kosinski, C; Gavino, B; Horton, JD; Skarnes, WC; Young, SG				Beigneux, AP; Kosinski, C; Gavino, B; Horton, JD; Skarnes, WC; Young, SG			ATP-citrate lyase deficiency in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COENZYME-A; INSERTIONAL MUTATIONS; SEQUENCE-ANALYSIS; SYNTHESIS INVIVO; RAT; CHOLESTEROL; ACETYLCHOLINE; LIVER; BRAIN; MICE	ATP-citrate lyase (Acly) is one of two cytosolic enzymes that synthesize acetyl-coenzyme A (CoA). Because acetyl-CoA is an essential building block for cholesterol and triglycerides, Acly has been considered a therapeutic target for hyperlipidemias and obesity. To define the phenotype of Acly-deficient mice, we created Acly knockout mice in which a beta-galactosidase marker is expressed from Acly regulatory sequences. We also sought to define the cell type-specific expression patterns of Acly to further elucidate the in vivo roles of the enzyme. Homozygous Acly knockout mice died early in development. Heterozygous mice were healthy, fertile, and normolipidemic on both chow and high fat diets, despite expressing half-normal amounts of Acly mRNA and protein. Fibroblasts and hepatocytes from heterozygous Acly mice contained half-normal amounts of Acly mRNA and protein, but this did not perturb triglyceride and cholesterol synthesis or the expression of lipid biosynthetic genes regulated by sterol regulatory element-binding proteins. The expression of acetyl-CoA synthetase 1, another cytosolic enzyme for producing acetylCoA, was not up-regulated. As judged by beta-galactosidase staining, Acly was expressed ubiquitously but was expressed particularly highly in tissues with high levels of lipogenesis, such as in the livers of mice fed a high-carbohydrate diet. beta-Galactosidase staining was intense in the developing brain, in keeping with the high levels of de novo lipogenesis of the tissue. In the adult brain, beta-galactosidase staining was in general much lower, consistent with reduced levels of lipogenesis; however, beta-galactosidase expression remained very high in cholinergic neurons, likely reflecting the importance of Acly in generating acetyl-CoA for acetylcholine synthesis. The Acly knockout allele is useful for identifying cell types with a high demand for acetyl-CoA synthesis.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94141 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California Berkeley	Beigneux, AP (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	abeigneux@gladstone.ucsf.edu		Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [U01 HL066600, U01 HL066590, R01 HL094732, R01 HL094732-01S1, U01 HL066621, HL66621, HL66600, HL66590, R01 HL094732-01, R01 HL094732-02, R01 HL094732-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066600, U01HL066621, U01HL066590, R01HL094732] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNUM TE, 1969, ENZYME HDB; Beigneux A, 2002, J BIOL CHEM, V277, P38358, DOI 10.1074/jbc.M205183200; Bergo MO, 2002, J BIOL CHEM, V277, P47701, DOI 10.1074/jbc.M207734200; Bjorkegren J, 2002, J BIOL CHEM, V277, P5476, DOI 10.1074/jbc.M108514200; BRAY GA, 1976, CLIN ENDOCRINOL META, V5, P455, DOI 10.1016/S0300-595X(76)80031-X; Carroll PT, 1997, BRAIN RES, V753, P47, DOI 10.1016/S0006-8993(96)01485-0; CHEE H, 1977, J NUTR, V107, P112, DOI 10.1093/jn/107.1.112; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; DIETSCHY JM, 1983, J LIPID RES, V24, P469; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; ENDEMANN G, 1980, J BIOL CHEM, V255, P1091; FOSTER DW, 1968, J BIOL CHEM, V243, P1926; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; GREENWOOD MRC, 1981, AM J PHYSIOL, V240, pE72, DOI 10.1152/ajpendo.1981.240.1.E72; JUREVICS H, 1995, J NEUROCHEM, V64, P895; Jurevics HA, 1997, J LIPID RES, V38, P723; KNOWLES SE, 1974, BIOCHEM J, V142, P401, DOI 10.1042/bj1420401; Leonhardt M, 2001, PHYSIOL BEHAV, V74, P191, DOI 10.1016/S0031-9384(01)00547-9; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Melnick JZ, 1996, J CLIN INVEST, V98, P2381, DOI 10.1172/JCI119051; Moon YA, 2003, J BIOL CHEM, V278, P7335, DOI 10.1074/jbc.M211684200; Pearce NJ, 1998, BIOCHEM J, V334, P113, DOI 10.1042/bj3340113; RICNY J, 1980, BIOCHEM J, V188, P683, DOI 10.1042/bj1880683; RICNY J, 1982, J NEUROCHEM, V39, P668; SAXTY BA, 1991, EUR J BIOCHEM, V202, P889, DOI 10.1111/j.1432-1033.1991.tb16448.x; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; SPADY DK, 1983, J LIPID RES, V24, P303; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; SULLIVAN AC, 1974, LIPIDS, V9, P121, DOI 10.1007/BF02532136; Szutowicz A, 1999, J NEUROSCI RES, V57, P131, DOI 10.1002/(SICI)1097-4547(19990701)57:1<131::AID-JNR14>3.0.CO;2-M; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099	35	94	98	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9557	9564		10.1074/jbc.M310512200	http://dx.doi.org/10.1074/jbc.M310512200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14662765	hybrid, Green Accepted			2022-12-27	WOS:000189265900123
J	Fang, XJ; Yu, SX; Bast, RC; Liu, SY; Xu, HJ; Hu, SX; LaPushin, R; Claret, FX; Aggarwal, BB; Lu, YL; Mills, GB				Fang, XJ; Yu, SX; Bast, RC; Liu, SY; Xu, HJ; Hu, SX; LaPushin, R; Claret, FX; Aggarwal, BB; Lu, YL; Mills, GB			Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTOR; KAPPA-B; LPA RECEPTORS; INTERLEUKIN-8 EXPRESSION; INHIBITS ANGIOGENESIS; PACLITAXEL RESISTANCE; CARCINOMA CELLS; GENE-TRANSFER; LYSOPHOSPHOLIPIDS	A potential role for lysophosphatidic acid (LPA) in human oncogenesis was first suggested by the observation that LPA is present at elevated levels in ascites of ovarian cancer patients. In the current study, we demonstrated that LPA is a potent inducer of interleukin-6 (IL-6) and interleukin-8 (IL-8) production in ovarian cancer cells. Both IL-6 and IL-8 have been implicated in ovarian cancer progression. We characterized the IL-8 gene promoter to ascertain the transcriptional mechanism underlying LPA - induced expression of these cytokines. LPA stimulated the transcriptional activity of the IL-8 gene with little effect on IL-8 mRNA stability. The optimal response of the IL-8 gene promoter to LPA relied on binding sites for NF-kappaB and AP-1, two transcription factors that were strongly activated by LPA in ovarian cancer cell lines. Positive regulators of the NF-kappaB and AP-1 pathways synergistically activated the IL-8 gene promoter. Further, the effect of LPA on IL- 6 and IL- 8 generation is mediated by the Edg LPA receptors as enforced expression of LPA receptors restored LPA-induced IL-6 and IL-8 production in non-responsive cells and enhanced the sensitivity to LPA in responsive cell lines. The LPA(2) receptor was identified to be the most efficient in linking LPA to IL-6 and IL-8 production although LPA(1) and LPA(3) were also capable of increasing the response to a certain degree. These studies elucidate the transcriptional mechanism and the Edg LPA receptors involved in LPA-induced IL-6 and IL-8 production and suggest potential strategies to restrain the expression of these cytokines in ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fang, XJ (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem, Sanger Hall 2-006,1101 E Marshall St, Richmond, VA 23298 USA.	xfang@vcu.edu	Bast, Robert C/E-6585-2011; Claret, Francois X/R-2104-2016; Aggarwal, Bharat B/G-3388-2013	Bast, Robert C/0000-0003-4621-8462; Claret, Francois X/0000-0003-4629-6495; 	NCI NIH HHS [CA82716, 5P30 CA016672, CA64602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA064602, R01CA082716] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baker DL, 2002, JAMA-J AM MED ASSOC, V287, P3081, DOI 10.1001/jama.287.23.3081; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; Duan Z, 2002, CYTOKINE, V17, P234, DOI 10.1006/cyto.2001.1008; Duan ZF, 1999, CLIN CANCER RES, V5, P3445; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Fang XJ, 1997, J BIOL CHEM, V272, P13683, DOI 10.1074/jbc.272.21.13683; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Fishman DA, 2001, CANCER RES, V61, P3194; Frankel A, 1996, CLIN CANCER RES, V2, P1307; Fritsche HA, 1998, CLIN CHEM, V44, P1379; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Goetzl EJ, 1999, ADV EXP MED BIOL, V469, P259; Goetzl EJ, 1999, CANCER RES, V59, P5370; Goppelt-Struebe M, 2000, BIOCHEM J, V345, P217, DOI 10.1042/0264-6021:3450217; Hatzi E, 2002, ONCOGENE, V21, P3552, DOI 10.1038/sj.onc.1205440; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; Hu YL, 2003, J NATL CANCER I, V95, P733, DOI 10.1093/jnci/95.10.733; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Huang S, 2000, CANCER RES, V60, P5334; Imai A, 2000, J CLIN ENDOCR METAB, V85, P3370, DOI 10.1210/jc.85.9.3370; Ivarsson K, 2000, ACTA OBSTET GYN SCAN, V79, P777, DOI 10.1034/j.1600-0412.2000.079009777.x; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Lee LF, 1996, CANCER RES, V56, P1303; MAHE Y, 1991, J BIOL CHEM, V266, P13759; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; Mayerhofer K, 2001, CANCER-AM CANCER SOC, V91, P388, DOI 10.1002/1097-0142(20010115)91:2<388::AID-CNCR1013>3.3.CO;2-2; MILLS GB, 1988, CANCER RES, V48, P1066; MILLS GB, 1989, OVARIAN CANCER BIOL, P55; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; O'Rourke JP, 2002, J VIROL, V76, P1510, DOI 10.1128/JVI.76.3.1510-1515.2002; Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roberts R, 1998, J BIOL CHEM, V273, P22059, DOI 10.1074/jbc.273.34.22059; Rosen E M, 1991, EXS, V59, P194; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Sawada K, 2002, CANCER RES, V62, P6015; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Shahrestanifar M, 1999, J BIOL CHEM, V274, P3828, DOI 10.1074/jbc.274.6.3828; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Tanyi JL, 2003, CANCER RES, V63, P1073; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; VANSNICK J, 1988, EUR J IMMUNOL, V18, P193; Vigna E, 2000, J GENE MED, V2, P308; WATSON JM, 1993, GYNECOL ONCOL, V49, P8, DOI 10.1006/gyno.1993.1077; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Xu L, 2000, CANCER RES, V60, P4610; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	72	151	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9653	9661		10.1074/jbc.M306662200	http://dx.doi.org/10.1074/jbc.M306662200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670967	hybrid			2022-12-27	WOS:000189265900133
J	Morris, JB; Pham, TM; Kenney, B; Sheppard, KE; Woodcock, EA				Morris, JB; Pham, TM; Kenney, B; Sheppard, KE; Woodcock, EA			UTP transactivates epidermal growth factor receptors and promotes cardiomyocyte hypertrophy despite inhibiting transcription of the hypertrophic marker gene, atrial natriuretic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-HYPERTROPHY; ACTIVATION; APOPTOSIS; HEART; EXPRESSION; AGONIST; PATHWAY; ATP	In neonatal rat ventricular myocytes, activation of receptors that couple to the G(q) family of heterotrimeric G proteins causes hypertrophic growth, together with expression of "hypertrophic marker" genes, such as atrial natriuretic peptide (ANP) and myosin light chain 2 (MLC2). As reported previously for other G(q)-coupled receptors, stimulation of alpha(1)-adrenergic receptors with phenylephrine ( 50 muM) caused phosphorylation of epidermal growth factor (EGF) receptors as well as activation of ERK1/2, cellular growth, and ANP transcription. These responses depended on EGF receptor activation. In marked contrast, stimulation of G(q)-coupled purinergic receptors with UTP caused EGF receptor phosphorylation, ERK1/2 activation, and cellular growth but minimal increases in ANP transcription. UTP inhibited phenylephrine-dependent transcription from ANP and MLC2 promoters but not transcription from myoglobin promoters or from AP-1 elements. Myocardin is a muscle-specific transcription enhancer that activates transcription from ANP and MLC2 promoters but not myoglobin promoters or AP-1 elements. UTP inhibited ANP and MLC2 responses to overexpressed myocardin but did not inhibit responses to c-Jun, GATA4, or serum response factor, all of which are active in nonmuscle cells. Thus, UTP inhibits transcriptional responses to phenylephrine only at cardiac-specific promoters, and this may involve the muscle-specific transcription enhancer, myocardin. These studies show that EGF receptor activation is necessary but not sufficient for ANP and MLC2 responses to activation of G(q)-coupled receptors in ventricular myocytes, because inhibitory mechanisms can oppose such stimulation. ANP is a compensatory and protective factor in cardiac hypertrophy, and mechanisms that reduce its generation need to be defined.	Baker Heart Res Inst, Cellular Biochem Lab, Melbourne, Vic 8008, Australia; Baker Heart Res Inst, Gene Transcript Lab, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute; Baker Heart and Diabetes Institute	Woodcock, EA (corresponding author), Baker Heart Res Inst, Cellular Biochem Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	liz.woodcock@baker.edu.au	Sheppard, Karen/P-5947-2019; Sheppard, Karen E/U-5360-2017	Sheppard, Karen/0000-0002-2798-4703; Sheppard, Karen E/0000-0002-2798-4703				Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Arthur JF, 2001, J BIOL CHEM, V276, P37341, DOI 10.1074/jbc.M106572200; Boluyt MO, 1997, CIRC RES, V81, P176, DOI 10.1161/01.RES.81.2.176; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Calderone A, 2003, HEART FAIL REV, V8, P55, DOI 10.1023/A:1022147005110; CannonCarlson S, 1997, ANAL BIOCHEM, V246, P146, DOI 10.1006/abio.1997.2002; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Costello-Boerrigter LC, 2003, MED CLIN N AM, V87, P475, DOI 10.1016/S0025-7125(02)00181-5; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Esposito G., 2001, CARDIOVASC RES, V50, P65; Harrison SN, 1998, CIRC RES, V83, P1232, DOI 10.1161/01.RES.83.12.1232; Holtwick R, 2003, J CLIN INVEST, V111, P1399, DOI 10.1172/JCI200317061; Homcy CJ, 1998, CIRCULATION, V97, P1890, DOI 10.1161/01.CIR.97.19.1890; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Molkentin JD, 2003, J CLIN INVEST, V111, P1275, DOI 10.1172/JCI200318389; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Omura T, 2002, HYPERTENSION, V39, P81, DOI 10.1161/hy0102.100783; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Pham TM, 2003, J MOL CELL CARDIOL, V35, P287, DOI 10.1016/S0022-2828(03)00009-9; Pu WT, 2003, CIRC RES, V92, P725, DOI 10.1161/01.RES.0000069211.82346.46; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; Sesti C, 2003, J PHARMACOL EXP THER, V306, P238, DOI 10.1124/jpet.103.049874; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; Thomas WG, 2002, CIRC RES, V90, P135, DOI 10.1161/hh0202.104109; Vassort G, 2001, PHYSIOL REV, V81, P767, DOI 10.1152/physrev.2001.81.2.767; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Woodcock EA, 2002, J BIOL CHEM, V277, P22734, DOI 10.1074/jbc.M110405200	31	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8740	8746		10.1074/jbc.M310012200	http://dx.doi.org/10.1074/jbc.M310012200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676212	hybrid			2022-12-27	WOS:000189265900027
J	Bohm, E; Sturm, GJ; Weiglhofer, I; Sandig, H; Shichijo, M; McNamee, A; Pease, JE; Kollroser, M; Peskar, BA; Heinemann, A				Bohm, E; Sturm, GJ; Weiglhofer, I; Sandig, H; Shichijo, M; McNamee, A; Pease, JE; Kollroser, M; Peskar, BA; Heinemann, A			11-dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; PROSTAGLANDIN D-2; SMOOTH-MUSCLE; MAST-CELLS; ALLERGIC RHINITIS; GUINEA-PIGS; A(2); ASTHMA; BIOSYNTHESIS; ANTAGONIST	Thromboxane (TX) A(2), a cyclooxygenase-derived mediator involved in allergic responses, is rapidly converted in vivo to a stable metabolite, 11-dehydro-TXB2, which is considered to be biologically inactive. In this study, we found that 11-dehydro-TXB2, but not the TXA(2) analogue U46,619 or TXB2, activated eosinophils and basophils, as assayed by flow cytometric shape change. 11-Dehydro-TXB2 was also chemotactic for eosinophils but did not induce, nor inhibit, platelet aggregation. Chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) is an important chemoattractant receptor expressed by eosinophils, basophils, and TH2 lymphocytes, and prostaglandin (PG) D-2 has been shown to be its principal ligand. 11-Dehydro-TXB2 induced calcium flux mainly from intracellular stores in eosinophils, and this response was desensitized after stimulation with PGD(2) but not other eosinophil chemoattractants. Shape change responses of eosinophils and basophils to 11-dehydro-TXB2 were inhibited by the thromboxane (TP)/CRTH2 receptor antagonist ramatroban, but not the selective TP antagonist SQ29,548, and were insensitive to pertussis toxin. The phospholipase C inhibitor U73,122 attenuated both 11-dehydro-TXB2- and PGD(2)-induced shape change. 11-Dehydro-TXB2 also induced the chemotaxis of BaF/3 cells transfected with hCRTH2 but not naive BaF/3 cells. At a threshold concentration, 11-dehydro-TXB2 had no antagonistic effect on CRTH2-mediated responses as induced by PGD(2). These data show that 11-dehydro-TXB2 is a full agonist of the CRTH2 receptor and hence might cause CRTH2 activation in cellular contexts where PGD-synthase is not present. Given its production in the allergic lung, antagonism of the 11-dehydro-TXB2/CRTH2axis may be of therapeutic relevance.	Med Univ Graz, Dept Expt & Clin Pharmacol, A-8010 Graz, Austria; Med Univ Graz, Dept Forens Med, A-8010 Graz, Austria; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Leukocyte Biol Sect, London SW7 2AZ, England; Bayer Yakuhin Ltd, Res Ctr Kyoto, Resp Res, Kizu, Kyoto 6190216, Japan; Dept Immunopharmacol, Stevenage SG1 2NY, Herts, England	Medical University of Graz; Medical University of Graz; Imperial College London; Bayer AG; GlaxoSmithKline	Heinemann, A (corresponding author), Med Univ Graz, Dept Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemann@uni-graz.at	Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341; Heinemann, Akos/0000-0002-8554-2372; Sturm, Eva/0000-0003-4898-884X				ARMOUR CL, 1989, EUR J PHARMACOL, V165, P215, DOI 10.1016/0014-2999(89)90715-2; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Caughey GE, 1997, J IMMUNOL, V158, P351; COLEMAN RA, 1989, BRIT J PHARMACOL, V96, P688, DOI 10.1111/j.1476-5381.1989.tb11869.x; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Cracowski JL, 2000, EUR J PHARMACOL, V397, P161, DOI 10.1016/S0014-2999(00)00217-X; Davi G, 1997, AM J RESP CRIT CARE, V156, P1794, DOI 10.1164/ajrccm.156.6.9706026; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Devillier P, 1997, FUNDAM CLIN PHARM, V11, P2, DOI 10.1111/j.1472-8206.1997.tb00163.x; DWORSKI R, 1989, AM REV RESPIR DIS, V139, P46, DOI 10.1164/ajrccm/139.1.46; Fujitani Y, 2002, J IMMUNOL, V168, P443, DOI 10.4049/jimmunol.168.1.443; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Heinemann A, 2000, J IMMUNOL, V165, P7224, DOI 10.4049/jimmunol.165.12.7224; Heinemann A, 2003, J IMMUNOL, V170, P4752, DOI 10.4049/jimmunol.170.9.4752; Heinemann A, 2003, PHARMACOLOGY, V67, P49, DOI 10.1159/000066786; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hirai H, 2002, J IMMUNOL, V168, P981, DOI 10.4049/jimmunol.168.3.981; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Inoue Y, 2002, PHARMACOLOGY, V65, P62, DOI 10.1159/000056188; Ishizuka T, 1998, CLIN EXP IMMUNOL, V112, P464; Ishizuka T, 2000, CLIN EXP IMMUNOL, V120, P71, DOI 10.1046/j.1365-2249.2000.01169.x; KEERY RJ, 1988, BRIT J PHARMACOL, V94, P745, DOI 10.1111/j.1476-5381.1988.tb11584.x; KITCHEN EA, 1978, PROSTAGLANDINS, V16, P239, DOI 10.1016/0090-6980(78)90025-4; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LOTVALL J, 1992, J APPL PHYSIOL, V72, P2415, DOI 10.1152/jappl.1992.72.6.2415; LUPINETTI MD, 1989, AM REV RESPIR DIS, V140, P932, DOI 10.1164/ajrccm/140.4.932; Martinelli R, 2001, J BIOL CHEM, V276, P42957, DOI 10.1074/jbc.M103933200; Monneret G, 2002, J IMMUNOL, V168, P3563, DOI 10.4049/jimmunol.168.7.3563; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; MORINELLI TA, 1994, J BIOL CHEM, V269, P5693; NACLERIO RM, 1988, J ALLERGY CLIN IMMUN, V82, P927; Nie DT, 2000, BIOCHEM BIOPH RES CO, V267, P245, DOI 10.1006/bbrc.1999.1840; Obase Y, 1998, CHEST, V114, P1028, DOI 10.1378/chest.114.4.1028; OGLETREE ML, 1985, J PHARMACOL EXP THER, V234, P435; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Oosaki R, 1998, CLIN EXP ALLERGY, V28, P1138; Pease James E., 2001, Current Opinion in Pharmacology, V1, P248, DOI 10.1016/S1471-4892(01)00044-3; ROBERTS LJ, 1982, ADV PROSTAG THROMB L, V10, P211; Rothenberg ME, 1999, J CLIN IMMUNOL, V19, P250, DOI 10.1023/A:1020531322556; ROTONDO S, 1995, J LEUKOCYTE BIOL, V57, P72, DOI 10.1002/jlb.57.1.72; SCHEURLEN M, 1993, BIOCHEM PHARMACOL, V46, P245, DOI 10.1016/0006-2952(93)90410-X; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Stubbs VEL, 2002, J BIOL CHEM, V277, P26012, DOI 10.1074/jbc.M201803200; Sugimoto H, 2003, J PHARMACOL EXP THER, V305, P347, DOI 10.1124/jpet.102.046748; SVENSSON J, 1977, ACTA PHYSIOL SCAND, V101, P366, DOI 10.1111/j.1748-1716.1977.tb06019.x; TAYLOR IK, 1991, AM REV RESPIR DIS, V143, P119, DOI 10.1164/ajrccm/143.1.119; TRIST DG, 1989, BRIT J PHARMACOL, V96, P301, DOI 10.1111/j.1476-5381.1989.tb11817.x; UNDERWOOD DC, 1994, J PHARMACOL EXP THER, V268, P304; WESTLUND P, 1986, PROSTAGLANDINS, V31, P929, DOI 10.1016/0090-6980(86)90025-0; WESTLUND P, 1986, PROSTAGLANDINS, V31, P413, DOI 10.1016/0090-6980(86)90106-1; Yamasaki M, 1997, J PHARMACOL EXP THER, V280, P1471	54	89	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7663	7670		10.1074/jbc.M310270200	http://dx.doi.org/10.1074/jbc.M310270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668348	hybrid			2022-12-27	WOS:000189103300037
J	Grace, ML; Chandrasekharan, MB; Hall, TC; Crowe, AJ				Grace, ML; Chandrasekharan, MB; Hall, TC; Crowe, AJ			Sequence and spacing of TATA box elements are critical for accurate initiation from the beta-phaseolin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CORE PROMOTER; BINDING-PROTEIN; HISTONE ACETYLATION; CHROMATIN-STRUCTURE; DNA-SEQUENCES; MINOR-GROOVE; START SITE; IN-VITRO; GENE	The beta-phaseolin (phas) gene, which encodes one of the major seed storage proteins of P. vulgaris, is tightly regulated at the transcription level resulting in strict tissue-specific and spatial expression during embryonic development. The phas proximal promoter contains a complex arrangement of core promoter elements including three TATA boxes as well as several putative initiator elements. To delineate the respective contributions of the core promoter elements to transcription initiation we have performed site-directed mutagenesis of the phas promoter. In vivo expression studies were performed on transgenic Arabidopsis harboring phas promoter mutants driving expression of the beta-glucuronidase (gus) reporter gene. Quantitative assessment of GUS activity in seeds bearing the promoter mutants indicated that both sequence and spacing of the TATA elements influenced the efficiency of transcription. Substitution, insertion or deletion mutations had no effect on histochemical staining patterns indicating that strict spacing requirements are not essential for correct spatial expression of phas during embryogenesis. Further evaluation of the phas promoter by in vitro transcription analysis revealed the presence of multiple TATA-dependent transcription initiation start sites. The distance between TATA elements and transcription start sites was maintained in insertion and deletion mutants through the creation of novel initiation sites, indicating that positioning of the TATA elements rather than DNA sequence was the primary determinant of start site location. We conclude that, while dispensable for proper spatial distribution, the complex architecture of the phas promoter is required to ensure high levels of accurate phas transcription initiation in the developing embryo.	Univ Washington, Dept Biol, Seattle, WA 98195 USA; Texas A&M Univ, Inst Dev & Mol Biol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	University of Washington; University of Washington Seattle; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Crowe, AJ (corresponding author), Univ Washington, Dept Biol, POB 351800, Seattle, WA 98195 USA.	acrowe@u.washington.edu	Chandrasekharan, Mahesh/AAF-4793-2020	Chandrasekharan, Mahesh/0000-0002-9956-8354				APSIT V, 1993, NUCLEIC ACIDS RES, V21, P1494, DOI 10.1093/nar/21.6.1494; Bechtold N, 1998, METH MOL B, V82, P259; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUKNER I, 1993, NUCLEIC ACIDS RES, V21, P1025, DOI 10.1093/nar/21.4.1025; Burke TW, 1998, COLD SPRING HARB SYM, V63, P75, DOI 10.1101/sqb.1998.63.75; BUSTOS MM, 1991, EMBO J, V10, P1469, DOI 10.1002/j.1460-2075.1991.tb07667.x; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Chandrasekharan MB, 2003, PLANT J, V33, P853, DOI 10.1046/j.1365-313X.2003.01678.x; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Doyle MC, 2001, MOL CELLS, V12, P197; Duan ZJ, 2002, P NATL ACAD SCI USA, V99, P5509, DOI 10.1073/pnas.072084499; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; JEFFERSON RA, 1987, EMBO J, V6, P3901; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Kadonaga JT, 2002, EXP MOL MED, V34, P259, DOI 10.1038/emm.2002.36; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Li GF, 1998, P NATL ACAD SCI USA, V95, P4772, DOI 10.1073/pnas.95.8.4772; Li GF, 2001, PLANT MOL BIOL, V46, P121, DOI 10.1023/A:1010693703421; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; MUKUMOTO F, 1993, PLANT MOL BIOL, V23, P995, DOI 10.1007/BF00021814; Nakamura M, 2002, PLANT J, V29, P1, DOI 10.1046/j.0960-7412.2001.01188.x; Nap J. P., 1993, Plant Molecular Biology Reporter, V11, P156, DOI 10.1007/BF02670473; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shen CH, 2002, MOL CELL BIOL, V22, P6406, DOI 10.1128/MCB.22.18.6406-6416.2002; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SLIGHTOM JL, 1985, NUCLEIC ACIDS RES, V13, P6483, DOI 10.1093/nar/13.18.6483; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Smale ST, 2001, GENE DEV, V15, P2503, DOI 10.1101/gad.937701; Thastrom A, 1999, J MOL BIOL, V288, P213, DOI 10.1006/jmbi.1999.2686; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WORKMAN JL, 1987, PREPARATION NUCL CYT, V2; Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593; Yamada M, 2001, BIOCHEM BIOPH RES CO, V281, P53, DOI 10.1006/bbrc.2001.4308; ZHU Q, 1995, PLANT CELL, V7, P1681, DOI 10.1105/tpc.7.10.1681	47	59	70	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8102	8110		10.1074/jbc.M309376200	http://dx.doi.org/10.1074/jbc.M309376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660650	hybrid			2022-12-27	WOS:000189103300090
J	Ng, DS; Xie, CH; Maguire, GF; Zhu, XH; Ugwu, F; Lam, E; Connelly, PW				Ng, DS; Xie, CH; Maguire, GF; Zhu, XH; Ugwu, F; Lam, E; Connelly, PW			Hypertriglyceridemia in lecithin-cholesterol acyltransferase-deficient mice is associated with hepatic overproduction of triglycerides, increased lipogenesis, and improved glucose tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; LIVER-X-RECEPTOR; PLASMA LIPOLYTIC-ACTIVITIES; FATTY-ACID-METABOLISM; APOLIPOPROTEIN-A-I; LIPOPROTEIN-LIPASE; BINDING PROTEIN-1; TRANSGENIC MICE; NUTRITIONAL REGULATION; TARGETED DISRUPTION	Lecithin-cholesterol acyltransferase deficiency is frequently associated with hypertriglyceridemia (HTG) in animal models and humans. We investigated the mechanism of HTG in the ldlr-/- x lcat-/- (double knockout (dko)) mice using the ldlr-/- x lcat-/- (knock-out (ko)) littermates as control. Mean fasting triglyceride (TG) levels in the dko mice were elevated 1.75-fold compared with their controls (p < 0.002). Both the very low density lipoprotein and the low density lipoprotein/intermediate density lipoprotein fractions separated by fast protein liquid chromatography were TG-enriched in the dko mice. In vitro lipolysis assay revealed that the dko mouse very low density lipoprotein (d < 1.019 g/ml) fraction separated by ultracentrifugation was a more efficient substrate for lipolysis by exogenous bovine lipoprotein lipase. Post-heparin lipoprotein lipase activity was reduced by 61% in the dko mice. Hepatic TG production rate, determined after intravenous Triton WR1339 injection, was increased 8-fold in the dko mice. Hepatic mRNA levels of sterol regulatory element binding protein-1 (srebp-1) and its target genes acetyl-CoA carboxylase-1 (acc-1), fatty acid synthase (fas), and stearoyl-CoA desaturase-1 (scd-1) were significantly elevated in the dko mice compared with the ko control. The hepatic mRNA levels of LXRalpha (lxralpha) and its target genes including angiopoietin-like protein 3 (angptl-3) in the dko mice were unchanged. Fasting glucose and insulin levels were reduced by 31 and 42%, respectively in the dko mice, in conjunction with a 49% reduction in hepatic pepck-1 mRNA (p = 0.014). Both the HTG and the improved fasting glucose phenotype seen in the dko mice are at least in part attributable to an up-regulation of the hepatic srebp-1c gene.	St Michaels Hosp, Dept Med, Toronto, ON M5B 1A6, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Ng, DS (corresponding author), St Michaels Hosp, Dept Med, W Annex 2-015,38 Shuter St, Toronto, ON M5B 1A6, Canada.	ngd@smh.toronto.on.ca	Connelly, Philip W/B-7583-2012	Connelly, Philip W/0000-0001-7244-6843				Alexander CM, 2003, DIABETES, V52, P1210, DOI 10.2337/diabetes.52.5.1210; APPEL B, 1992, AM J PHYSIOL, V262, pE695, DOI 10.1152/ajpendo.1992.262.5.E695; Ayyobi AF, 2003, ARTERIOSCL THROM VAS, V23, P1289, DOI 10.1161/01.ATV.0000077220.44620.9B; BLOMHOFF JP, 1978, SCAND J CLIN LAB INV, V38, P177, DOI 10.3109/00365517809104922; Brinton Eliot A, 2003, Curr Diab Rep, V3, P65, DOI 10.1007/s11892-003-0056-3; Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; Fere P, 2001, BIOCHEM SOC T, V29, P547; Field FJ, 2002, BIOCHEM J, V368, P855, DOI 10.1042/BJ20020731; Forte TM, 1999, J LIPID RES, V40, P1276; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; FROHLICH J, 1988, METABOLISM, V37, P3, DOI 10.1016/0026-0495(88)90021-2; Furbee JW, 2002, J LIPID RES, V43, P428; Ginsberg HN, 2003, AM J CARDIOL, V91, p29E, DOI 10.1016/S0002-9149(02)03386-6; GJONE E, 1974, SCAND J CLIN LAB INV, V33, P73, DOI 10.3109/00365517409100633; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Groener JEM, 1996, J LIPID RES, V37, P2271; HA YC, 1985, J CHROMATOGR, V341, P154, DOI 10.1016/S0378-4347(00)84020-7; Haffner SM, 1999, AM J CARDIOL, V83, p17F; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; Hoeg JM, 1996, J BIOL CHEM, V271, P4396; Hogan JC, 2001, BIOCHEM BIOPH RES CO, V287, P484, DOI 10.1006/bbrc.2001.5606; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ide T, 2003, MOL ENDOCRINOL, V17, P1255, DOI 10.1210/me.2002-0191; Inaba T, 2003, J BIOL CHEM, V278, P21344, DOI 10.1074/jbc.M213202200; Jong MC, 1999, ARTERIOSCL THROM VAS, V19, P472, DOI 10.1161/01.ATV.19.3.472; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Knutson VP, 2000, ENDOCRINOLOGY, V141, P693, DOI 10.1210/en.141.2.693; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; Maugeais C, 2000, J LIPID RES, V41, P1673; Mensenkamp AR, 1999, J BIOL CHEM, V274, P35711, DOI 10.1074/jbc.274.50.35711; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200; Ng DS, 2002, J BIOL CHEM, V277, P11715, DOI 10.1074/jbc.M112320200; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; NG DS, 1994, J CLIN INVEST, V93, P223, DOI 10.1172/JCI116949; Olivecrona T, 1997, P NUTR SOC, V56, P723, DOI 10.1079/PNS19970072; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Pawar A, 2003, J BIOL CHEM, V278, P40736, DOI 10.1074/jbc.M307973200; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Sakai N, 1997, J BIOL CHEM, V272, P7506, DOI 10.1074/jbc.272.11.7506; SASAKI A, 1992, J BIOL CHEM, V267, P15198; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SCHUMAKER VN, 1970, J THEOR BIOL, V26, P89, DOI 10.1016/S0022-5193(70)80034-0; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Voyiaziakis E, 1998, J LIPID RES, V39, P313; WANG CS, 1987, BIOCHIM BIOPHYS ACTA, V920, P9, DOI 10.1016/0005-2760(87)90305-5; WANG CS, 1981, CLIN CHEM, V27, P663; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Yoshikawa T, 2003, MOL ENDOCRINOL, V17, P1240, DOI 10.1210/me.2002-0190; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	59	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7636	7642		10.1074/jbc.M309439200	http://dx.doi.org/10.1074/jbc.M309439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668345	hybrid			2022-12-27	WOS:000189103300034
J	Yamniuk, AP; Vogel, HJ				Yamniuk, AP; Vogel, HJ			Structurally homologous binding of plant calmodulin Isoforms to the calmodulin-binding domain of vacuolar calcium-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; LIGHT-CHAIN KINASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ENTHALPY-ENTROPY COMPENSATION; TARGET RECOGNITION; SPECTROSCOPIC CHARACTERIZATION; TRYPTOPHAN FLUORESCENCE; PEPTIDE COMPLEX; N-TERMINUS; NMR	The discovery that plants contain multiple calmodulin (CaM) isoforms having variable sequence identity to mammalian CaM has sparked a flurry of new questions regarding the intracellular role of Ca2+ regulation in plants. To date, the majority of research in this field has focused on the differential enzymatic regulation of various mammalian CaM-dependent enzymes by the different plant CaM isoforms. However, there is comparatively little information on the structural recognition of target enzymes found exclusively in plant cells. Here we have used a variety of spectroscopic techniques, including nuclear magnetic resonance, circular dichroism, and fluorescence spectroscopy, to study the interactions of the most conserved and most divergent CaM isoforms from soybean, SCaM-1, and SCaM-4, respectively, with a synthetic peptide derived from the CaM-binding domain of cauliflower vacuolar calcium-ATPase. Despite their sequence divergence, both SCaM-1 and SCaM-4 interact with the calcium-ATPase peptide in a similar calcium-dependent, stoichiometric manner, adopting an antiparallel binding orientation with an alpha-helical peptide. The single Trp residue is bound in a solvent-inaccessible hydrophobic pocket on the C-terminal domain of either protein. Thermodynamic analysis of these interactions using isothermal titration calorimetry demonstrates that the formation of each calcium-SCaM-calcium-ATPase peptide complex is driven by favorable binding enthalpy and is very similar to the binding of mammalian CaM to the CaM-binding domains of myosin light chain kinases and calmodulin-dependent protein kinase I.	Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca						Askerlund P, 1997, PLANT PHYSIOL, V114, P999, DOI 10.1104/pp.114.3.999; Barth A, 1998, BIOPOLYMERS, V45, P493, DOI 10.1002/(SICI)1097-0282(199806)45:7<493::AID-BIP3>3.0.CO;2-J; Barth A, 1998, J BIOL CHEM, V273, P2174, DOI 10.1074/jbc.273.4.2174; Brokx RD, 2001, J BIOL CHEM, V276, P14083, DOI 10.1074/jbc.M011026200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; Cho MJ, 1998, BIOCHEMISTRY-US, V37, P15593, DOI 10.1021/bi981497g; Choi JY, 2002, J BIOL CHEM, V277, P21630, DOI 10.1074/jbc.M110803200; Clapperton JA, 2002, BIOCHEMISTRY-US, V41, P14669, DOI 10.1021/bi026660t; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Evans DE, 1998, BBA-REV BIOMEMBRANES, V1376, P1, DOI 10.1016/S0304-4157(97)00009-9; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; FISCHER R, 1988, J BIOL CHEM, V263, P17055; GEISLERM, 2000, BIOCH BIOPHYS ACTA, V1465, P52; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Gomes AV, 2000, ARCH BIOCHEM BIOPHYS, V379, P28, DOI 10.1006/abbi.2000.1827; GRYCZYNSKI I, 1988, BIOPHYS CHEM, V32, P173, DOI 10.1016/0301-4622(88)87005-4; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kondo R, 1999, J BIOL CHEM, V274, P36213, DOI 10.1074/jbc.274.51.36213; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; Lee SH, 1997, J BIOL CHEM, V272, P9252, DOI 10.1074/jbc.272.14.9252; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Lee SH, 2000, BIOCHEM J, V350, P299, DOI 10.1042/0264-6021:3500299; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; MAKHATADZE GI, 1995, NAT STRUCT BIOL, V2, P852, DOI 10.1038/nsb1095-852; Malmstrom S, 2000, PLANT PHYSIOL, V122, P517, DOI 10.1104/pp.122.2.517; Malmstrom S, 1997, FEBS LETT, V400, P324, DOI 10.1016/S0014-5793(96)01448-2; Martin SR, 1996, BIOCHEMISTRY-US, V35, P3508, DOI 10.1021/bi952522a; Matsubara M, 1997, J BIOL CHEM, V272, P23050, DOI 10.1074/jbc.272.37.23050; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Reddy ASN, 2001, PLANT SCI, V160, P381, DOI 10.1016/S0168-9452(00)00386-1; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; SIIVARI K, 1995, FEBS LETT, V366, P104, DOI 10.1016/0014-5793(95)00504-3; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; Van Lierop JE, 2002, J BIOL CHEM, V277, P6550, DOI 10.1074/jbc.M111404200; Vetter SW, 2003, EUR J BIOCHEM, V270, P404, DOI 10.1046/j.1432-1033.2003.03414.x; VOGEL HJ, 1995, MOL CELL BIOCHEM, V149, P3, DOI 10.1007/BF01076558; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; Weljie AM, 2000, PROTEIN ENG, V13, P59, DOI 10.1093/protein/13.1.59; Wintrode PL, 1997, J MOL BIOL, V266, P1050, DOI 10.1006/jmbi.1996.0785; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; YAMNIUK AP, 2004, IN PRESS MOL BIOTECH; Yuan T, 1999, J BIOL CHEM, V274, P8411, DOI 10.1074/jbc.274.13.8411; YUAN T, 1995, BIOCHEMISTRY-US, V34, P10690, DOI 10.1021/bi00033a045; Yuan T, 1998, BIOCHEMISTRY-US, V37, P3187, DOI 10.1021/bi9716579; Yuan T, 1999, BIOCHEMISTRY-US, V38, P1446, DOI 10.1021/bi9816453; Yuan T, 2001, BIOPOLYMERS, V58, P50, DOI 10.1002/1097-0282(200101)58:1<50::AID-BIP60>3.0.CO;2-S; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546; ZHANG MJ, 1993, PROTEIN SCI, V2, P1931, DOI 10.1002/pro.5560021114; ZHANG MJ, 1995, J BIOL CHEM, V270, P20901, DOI 10.1074/jbc.270.36.20901; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	66	21	21	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7698	7707		10.1074/jbc.M310763200	http://dx.doi.org/10.1074/jbc.M310763200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670974	hybrid			2022-12-27	WOS:000189103300042
J	Abhyankar, MM; Reddy, JM; Sharma, R; Bullesbach, E; Bastia, D				Abhyankar, MM; Reddy, JM; Sharma, R; Bullesbach, E; Bastia, D			Biochemical investigations of control of replication initiation of plasmid R6K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; COLE1 DNA-REPLICATION; ESCHERICHIA-COLI; COPY NUMBER; NEGATIVE CONTROL; IN-VITRO; BINDING-SITES; ORIGIN GAMMA; PROTEIN; REPA	The mechanistic basis of control of replication initiation of plasmid R6K was investigated by addressing the following questions. What are the biochemical attributes of mutations in the pi initiator protein that caused loss of negative control of initiation? Did the primary control involve only initiator protein-ori DNA interaction or did it also involve protein-protein interactions between pi and several host-encoded proteins? Mutations at two different regions of the pi-encoding sequence individually caused some loss of negative control as indicated by a relatively modest increase in copy number. However, combinations of the mutation P42L, which caused loss of DNA looping, with those located in the region between the residues 106 and 113 induced a robust enhancement of copy number. These mutant forms promoted higher levels of replication in vitro in a reconstituted system consisting of 22 purified proteins. The mutant forms of pi were susceptible to pronounced iteron-induced monomerization in comparison with the WT protein. As contrasted with the changes in DNA-protein interaction, we found no detectable differences in protein-protein interaction between wild type pi with DnaA, DnaB helicase, and DnaG primase on one hand and between the high copy mutant forms and the same host proteins on the other. The DnaG-pi interaction reported here is novel. Taken together, the results suggest that both loss of negative control due to iteron-induced monomerization of the initiator and enhanced iteron-initiator interaction appear to be the principal causes of enhanced copy number.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Bastia, D (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	bastia@muse.edu						Abhyankar MM, 2003, J BIOL CHEM, V278, P45476, DOI 10.1074/jbc.M308516200; ABLES AL, 1991, P NATL ACAD SCI USA, V88, P9011; CESARENI G, 1982, P NATL ACAD SCI-BIOL, V79, P6313, DOI 10.1073/pnas.79.20.6313; CHATTORAJ D, 1984, P NATL ACAD SCI-BIOL, V81, P6456, DOI 10.1073/pnas.81.20.6456; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; Diaz-Lopez T, 2003, J BIOL CHEM, V278, P18606, DOI 10.1074/jbc.M212024200; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FILUTOWICZ M, 1985, NUCLEIC ACIDS RES, V13, P103, DOI 10.1093/nar/13.1.103; FILUTOWICZ M, 1988, NUCLEIC ACIDS RES, V16, P3829, DOI 10.1093/nar/16.9.3829; Filutowicz M., 1985, PLASMIDS BACTERIA, P125; GERMINO J, 1983, CELL, V34, P125, DOI 10.1016/0092-8674(83)90142-3; GERMINO J, 1983, CELL, V32, P131, DOI 10.1016/0092-8674(83)90503-2; Ingmer H, 2001, MOL MICROBIOL, V42, P519, DOI 10.1046/j.1365-2958.2001.02661.x; INUZUKA M, 1978, P NATL ACAD SCI USA, V75, P5381, DOI 10.1073/pnas.75.11.5381; INUZUKA M, 1985, EMBO J, V4, P2301, DOI 10.1002/j.1460-2075.1985.tb03930.x; INUZUKA M, 1975, BIOCHEMISTRY-US, V17, P2567; INUZUKA N, 1980, J BIOL CHEM, V255, P1071; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Jiang Y, 2003, P NATL ACAD SCI USA, V100, P8692, DOI 10.1073/pnas.1532393100; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KELLEY W, 1985, P NATL ACAD SCI USA, V82, P2574, DOI 10.1073/pnas.82.9.2574; KELLEY WL, 1991, J BIOL CHEM, V266, P15924; KELLEY WL, 1992, NEW BIOL, V4, P569; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Kruger R, 2001, J MOL BIOL, V306, P945, DOI 10.1006/jmbi.2000.4426; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; MACALLISTER TW, 1991, J BIOL CHEM, V266, P16056; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; MCEACHERN MJ, 1989, P NATL ACAD SCI USA, V86, P7942, DOI 10.1073/pnas.86.20.7942; MESSER W, 1991, RES MICROBIOL, V142, P119, DOI 10.1016/0923-2508(91)90018-6; MIRON A, 1994, P NATL ACAD SCI USA, V91, P6438, DOI 10.1073/pnas.91.14.6438; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; Nishihara K, 2000, APPL ENVIRON MICROB, V66, P884, DOI 10.1128/AEM.66.3.884-889.2000; Park K, 2001, EMBO J, V20, P7323, DOI 10.1093/emboj/20.24.7323; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; Sharma R, 2001, EMBO J, V20, P4577, DOI 10.1093/emboj/20.16.4577; SKOWYRA D, 1993, J BIOL CHEM, V268, P25296; VOCKE C, 1985, P NATL ACAD SCI USA, V82, P2252, DOI 10.1073/pnas.82.8.2252; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; Zhong ZP, 2003, J BIOL CHEM, V278, P45305, DOI 10.1074/jbc.M306058200	49	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6711	6719		10.1074/jbc.M312052200	http://dx.doi.org/10.1074/jbc.M312052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665626	hybrid			2022-12-27	WOS:000188969200063
J	Chuang, SS; Helvig, C; Taimi, M; Ramshaw, HA; Collop, AH; Amad, M; White, JA; Petkovich, M; Jones, G; Korczak, B				Chuang, SS; Helvig, C; Taimi, M; Ramshaw, HA; Collop, AH; Amad, M; White, JA; Petkovich, M; Jones, G; Korczak, B			CYP2U1, a novel human thymus- and brain-specific cytochrome P450, catalyzes omega- and (omega-1)-hydroxylation of fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; MOLECULAR-CLONING; LINOLEIC ACIDS; METABOLITES; PATHWAYS; RECEPTOR; CYCLOOXYGENASE; IDENTIFICATION; OXYGENATION; EXPRESSION	Long chain fatty acids have recently emerged as critical signaling molecules in neuronal, cardiovascular, and renal processes, yet little is presently known about the precise mechanisms controlling their tissue distribution and bioactivation. We have identified a novel cytochrome P450, CYP2U1, which may play an important role in modulating the arachidonic acid signaling pathway. Northern blot and real-time PCR analysis demonstrated that CYP2U1 transcripts were most abundant in the thymus and the brain (cerebellum), indicating a specific physiological role for CYP2U1 in these tissues. Recombinant human CYP2U1 protein, expressed in baculovirus-infected So insect cells, was found to metabolize arachidonic acid exclusively to two region-specific products as determined by liquid chromatography-mass spectrometry. These metabolites were identified as 19- and 20-hydroxy-modified arachidonic acids by liquid chromatography-tandem mass spectrometry analysis. In addition to omega/omega-1 hydroxylation of arachidonic acid, CYP2U1 protein also catalyzed the hydroxylation of structurally related long chain fatty acid (docosahexaenoic acid) but not fatty acids such as lauric acid or linoleic acid. This is the first report of the cloning and functional expression of a new human member of P450 family 2, CYP2U1, which metabolizes long chain fatty acids. Based on the ability of CYP2U1 to generate bioactive eicosanoid derivatives, we postulate that CYP2U1 plays an important physiological role in fatty acid signaling processes in both cerebellum and thymus.	Cytochroma Inc, Markham, ON L3R 8E4, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Korczak, B (corresponding author), Cytochroma Inc, 330 Cochrane Dr, Markham, ON L3R 8E4, Canada.	bozena@cytochroma.com						AOYAMA T, 1990, J LIPID RES, V31, P1477; Bazan NG, 2002, PROG BRAIN RES, V135, P175; Benveniste I, 1998, BIOCHEM BIOPH RES CO, V243, P688, DOI 10.1006/bbrc.1998.8156; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; Bylund J, 1998, ANAL BIOCHEM, V265, P55, DOI 10.1006/abio.1998.2897; Bylund J, 1998, J PHARMACOL EXP THER, V284, P51; Capdevila JH, 2001, BIOCHEM BIOPH RES CO, V285, P571, DOI 10.1006/bbrc.2001.5167; Capdevila JH, 2002, CELL MOL LIFE SCI, V59, P780, DOI 10.1007/s00018-002-8466-y; Capdevila JH, 2000, J LIPID RES, V41, P163; Cheng JB, 2003, J BIOL CHEM, V278, P38084, DOI 10.1074/jbc.M307028200; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; ESCALANTE B, 1990, J CARDIOVASC PHARM, V16, P438, DOI 10.1097/00005344-199009000-00013; Fang X, 1999, HYPERTENSION, V34, P1242, DOI 10.1161/01.HYP.34.6.1242; Fang X, 2001, J BIOL CHEM, V276, P14867, DOI 10.1074/jbc.M011761200; Fleming I, 2001, CIRC RES, V89, P753, DOI 10.1161/hh2101.099268; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Glenn HL, 2003, CELL MOTIL CYTOSKEL, V55, P265, DOI 10.1002/cm.10128; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Imig JD, 2000, AM J PHYSIOL-RENAL, V279, pF965, DOI 10.1152/ajprenal.2000.279.6.F965; Kehl F, 2002, AM J PHYSIOL-HEART C, V282, pH1556, DOI 10.1152/ajpheart.00924.2001; Koike K, 1997, BIOCHEM BIOPH RES CO, V232, P643, DOI 10.1006/bbrc.1997.6342; Kroetz DL, 2002, CURR OPIN LIPIDOL, V13, P273, DOI 10.1097/00041433-200206000-00007; McMurray DN, 2000, J INFECT DIS, V182, pS103, DOI 10.1086/315909; Moreno C, 2001, AM J HYPERTENS, V14, p90S, DOI 10.1016/S0895-7061(01)02075-1; Nie DT, 2001, CANCER METAST REV, V20, P195, DOI 10.1023/A:1015579209850; Oleksiak MF, 2000, J BIOL CHEM, V275, P2312, DOI 10.1074/jbc.275.4.2312; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; Parnes Steven M, 2002, Expert Opin Pharmacother, V3, P33, DOI 10.1517/14656566.3.1.33; Planaguma A, 2002, FASEB J, V16, P1937, DOI 10.1096/fj.02-0224fje; Qu W, 2001, J BIOL CHEM, V276, P25467, DOI 10.1074/jbc.M100545200; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; Roman RJ, 2000, CLIN EXP PHARMACOL P, V27, P855, DOI 10.1046/j.1440-1681.2000.03349.x; SAWAMURA A, 1993, BIOCHIM BIOPHYS ACTA, V1168, P30; Seeds MC, 1999, CLIN REV ALLERG IMMU, V17, P5, DOI 10.1007/BF02737594; Stockton RA, 2001, MOL BIOL CELL, V12, P1937, DOI 10.1091/mbc.12.7.1937; Werck-Reichhart D, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-6-REVIEWS3003; Wu S, 1996, J BIOL CHEM, V271, P3460; Yamane M, 1995, NEUROSCI LETT, V200, P203, DOI 10.1016/0304-3940(95)12132-N; YAQOOB P, 1994, IMMUNOLOGY, V82, P603; Zeldin DC, 2001, J BIOL CHEM, V276, P36059, DOI 10.1074/jbc.R100030200; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zheng YM, 1998, BIOCHEMISTRY-US, V37, P12847, DOI 10.1021/bi981280m; Ziboh VA, 2002, ARCH PHARM RES, V25, P747, DOI 10.1007/BF02976988	43	127	129	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6305	6314		10.1074/jbc.M311830200	http://dx.doi.org/10.1074/jbc.M311830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660610	hybrid			2022-12-27	WOS:000188969200015
J	Lin, PJ; Straight, DL; Stafford, DW				Lin, PJ; Straight, DL; Stafford, DW			Binding of the factor IX gamma-carboxyglutamic acid domain to the vitamin K-dependent gamma-glutamyl carboxylase active site induces an allosteric effect that may ensure processive carboxylation and regulate the release of carboxylated product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPEPTIDE REGION; ENZYME-ACTIVITY; FACTOR-X; PROTEINS; OSTEOCALCIN; PROTHROMBIN; MECHANISM; COAGULATION; RECOGNITION; ACTIVATION	Propeptides of the vitamin K-dependent proteins bind to an exosite on gamma-glutamyl carboxylase; while they are bound, multiple glutamic acids in the gamma-carboxyglutamic acid (Gla) domain are carboxylated. The role of the propeptides has been studied extensively; however, the role of the Gla domain in substrate binding is less well understood. We used kinetic and fluorescence techniques to investigate the interactions of the carboxylase with a substrate containing the propeptide and Gla domain of factor IX (FIXproGla41). In addition, we characterized the effect of the Gla domain and carboxylation on propeptide and substrate binding. For the propeptide of factor IX (proFIX18), FIXproGla41, and carboxylated FIXproGla41, the K-d values were 50, 2.5, and 19.7 nm and the k(off) values were 273 X 10(-5), 9 x 10(-5), and 37 x 10(-5) s(-1), respectively. The k(off) of proFIX18 is reduced 3-fold by FLEEL and 9-fold by the Gla domain (residues 1-46) of FIX. The pre-steady state rate constants for carboxylation of FIXproGla41 was 0.02 s-1 in enzyme excess and 0.016 s(-1) in substrate excess. The steady state rate in substrate excess is 4.5 x 10(-4) s(-1). These results demonstrate the following. 1) The pre-steady state carboxylation rate constant of FIXproGla41 is significantly slower than that of FLEEL. 2) The Gla domain plays an allosteric role in substrate-enzyme interactions. 3) Carboxylation reduces the allosteric effect. 4) The similarity between the steady state carboxylation rate constant and product dissociation rate constant suggests that product release is rate-limiting. 5) The increased dissociation rate after carboxylation contributes to the release of product.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Stafford, DW (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	dws@email.unc.edu			NHLBI NIH HHS [HL06350, HL48318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Binkley NC, 2000, AM J CLIN NUTR, V72, P1523; Binkley NC, 2002, AM J CLIN NUTR, V76, P1055, DOI 10.1093/ajcn/76.5.1055; Bovill E G, 1987, Adv Exp Med Biol, V214, P17; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; Chu K, 1996, J CLIN INVEST, V98, P1619, DOI 10.1172/JCI118956; ESMON CT, 1975, J BIOL CHEM, V250, P4744; Furie BC, 1997, J BIOL CHEM, V272, P28258, DOI 10.1074/jbc.272.45.28258; Gillis S, 1997, PROTEIN SCI, V6, P185; Hallgren KW, 2002, BIOCHEMISTRY-US, V41, P15045, DOI 10.1021/bi026016e; Houben RJTJ, 2002, BIOCHEM J, V364, P323, DOI 10.1042/bj3640323; Houben RJTJ, 1999, BIOCHEM J, V341, P265, DOI 10.1042/0264-6021:3410265; KATAYAMA K, 1979, P NATL ACAD SCI USA, V76, P4990, DOI 10.1073/pnas.76.10.4990; Kelleher RL, 1999, ANAL CHEM, V71, P4250, DOI 10.1021/ac990684x; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; Lin PJ, 2002, J BIOL CHEM, V277, P28584, DOI 10.1074/jbc.M202292200; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MALHOTRA OP, 1985, J BIOL CHEM, V260, P279; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; Oldenburg J, 1997, BRIT J HAEMATOL, V98, P240, DOI 10.1046/j.1365-2141.1997.2213036.x; Presnell SR, 2002, THROMB HAEMOSTASIS, V87, P937, DOI 10.1055/s-0037-1613115; Presnell SR, 2001, BIOCHEMISTRY-US, V40, P11723, DOI 10.1021/bi010332w; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; Stanley TB, 1998, BIOCHEMISTRY-US, V37, P13262, DOI 10.1021/bi981031y; Stanley TB, 1999, J BIOL CHEM, V274, P16940, DOI 10.1074/jbc.274.24.16940; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; Stenina O, 2001, BIOCHEMISTRY-US, V40, P10301, DOI 10.1021/bi0107039; SUTTIE JW, 1980, CRC CR REV BIOCH MOL, V8, P191, DOI 10.3109/10409238009105469; ZHANG L, 1991, BIOCHEMISTRY-US, V30, P6696, DOI 10.1021/bi00241a009; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	32	14	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6560	6566		10.1074/jbc.M312239200	http://dx.doi.org/10.1074/jbc.M312239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660587	hybrid, Green Published			2022-12-27	WOS:000188969200044
J	Miedlich, SU; Gama, L; Seuwen, K; Wolf, RM; Breitwieser, GE				Miedlich, SU; Gama, L; Seuwen, K; Wolf, RM; Breitwieser, GE			Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; PROTEIN-COUPLED RECEPTORS; CALCIMIMETIC COMPOUND; CRYSTAL-STRUCTURE; ACTIVATION; ANTAGONISTS; RHODOPSIN; COOPERATIVITY; RECOGNITION; PREDICTION	A homology model for the human calcium sensing receptor (hCaR) transmembrane domain utilizing bovine rhodopsin (bRho) structural information was derived and tested by docking the allosteric antagonist, NPS 2143, followed by mutagenesis of predicted contact sites. Mutation of residues Phe-668 (helix II), Arg-680, or Phe-684 (helix III) to Ala (or Val or Leu) and Glu-837 (helix VII) to Ile (or Gln) reduced the inhibitory effects of NPS 2143 on [Ca2+](i) responses. The calcimimetic NPS R-568 increases the potency of Ca2+ in functional assays of Call. Mutations at Phe-668, Phe-684, or Glu-837 attenuated the effects of this compound, but mutations at Arg-680 had no effect. In all cases, mutant Calls responded normally to Ca2+ or phenylalanine, which act at distinct site(s). Discrimination by the Arg-680 mutant is consistent with the structural differences between NPS 2143, which contains an alkyl bridge hydroxyl group, and NPS R-568, which does not. The homology model of the Call transmembrane domain robustly accounts for binding of both an allosteric antagonist and agonist, which share a common site, and provides a basis for the development of more specific and/or potent allosteric modulators of Call. These studies suggest that the bRho backbone can be used as a starting point for homology modeling of even distantly related G protein-coupled receptors and provide a rational framework for investigation of the contributions of the transmembrane domain to Call function.	Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA; Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Syracuse University; Novartis	Breitwieser, GE (corresponding author), Syracuse Univ, Dept Biol, 122 Lyman Hall,108 Coll Pl, Syracuse, NY 13244 USA.	gebreitw@syr.edu		Gama, Lucio/0000-0001-9511-012X; Breitwieser, Gerda/0000-0001-9081-0362	NIGMS NIH HHS [GM58578] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058578] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 2001, Curr Opin Drug Discov Devel, V4, P561; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bikker JA, 1998, J MED CHEM, V41, P2911, DOI 10.1021/jm970767a; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Breitwieser GE, 2001, AM J PHYSIOL-CELL PH, V280, pC1412, DOI 10.1152/ajpcell.2001.280.6.C1412; BROWN EM, 1991, J BONE MINER RES, V6, P1217; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Burley SK, 2002, ANNU REV GENOM HUM G, V3, P243, DOI 10.1146/annurev.genom.3.022502.103227; Cohen A, 2002, CURR OPIN PHARMACOL, V2, P734, DOI 10.1016/S1471-4892(02)00210-2; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Doggrell SA, 2002, DRUG FUTURE, V27, P140, DOI 10.1358/dof.2002.027.02.656406; Dunbrack RL, 1999, PROTEINS, P81; Flower DR, 1999, BBA-REV BIOMEMBRANES, V1422, P207, DOI 10.1016/S0304-4157(99)00006-4; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; Gasparini F, 2002, CURR OPIN PHARMACOL, V2, P43, DOI 10.1016/S1471-4892(01)00119-9; Gershengorn MC, 2001, ENDOCRINOLOGY, V142, P2, DOI 10.1210/en.142.1.2; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; HAUGLAND RP, 2002, HDB FLUORESCENT PROB, P775; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; Hu JX, 2002, J BIOL CHEM, V277, P46622, DOI 10.1074/jbc.M207100200; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Litschig S, 1999, MOL PHARMACOL, V55, P453; Mailland M, 1997, ENDOCRINOLOGY, V138, P3601, DOI 10.1210/en.138.9.3601; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Miedlich S, 2002, J BIOL CHEM, V277, P49691, DOI 10.1074/jbc.M205578200; Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Spooren WPJM, 2001, TRENDS PHARMACOL SCI, V22, P331, DOI 10.1016/S0165-6147(00)01694-1; Stenkamp RE, 2002, BBA-BIOMEMBRANES, V1565, P168, DOI 10.1016/S0005-2736(02)00567-9; Urwyler S, 2001, MOL PHARMACOL, V60, P963, DOI 10.1124/mol.60.5.963; Vaidehi N, 2002, P NATL ACAD SCI USA, V99, P12622, DOI 10.1073/pnas.122357199; Young SH, 2002, AM J PHYSIOL-CELL PH, V282, pC1414, DOI 10.1152/ajpcell.00432.2001; Zhang ZX, 2002, J BIOL CHEM, V277, P33727, DOI 10.1074/jbc.M200976200; Zhang ZX, 2002, J BIOL CHEM, V277, P33736, DOI 10.1074/jbc.M200978200	47	136	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7254	7263		10.1074/jbc.M307191200	http://dx.doi.org/10.1074/jbc.M307191200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660633	hybrid			2022-12-27	WOS:000188969200127
J	Audero, E; Cascone, I; Maniero, F; Napione, L; Arese, M; Lanfrancone, L; Bussolino, F				Audero, E; Cascone, I; Maniero, F; Napione, L; Arese, M; Lanfrancone, L; Bussolino, F			Adaptor ShcA protein binds tyrosine kinase Tie2 receptor and regulates migration and sprouting but not survival of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE T-ANTIGEN; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; COLORIMETRIC ASSAY; DOCKING PROTEIN; SH2 DOMAIN; ANGIOPOIETIN-1; ACTIVATION; PHOSPHORYLATION	Angiopoietin-1 can promote migration, sprouting, and survival of endothelial cells through activation of different signaling pathways triggered by the Tie2 tyrosine kinase receptor. ShcA adapter proteins are targets of activated tyrosine kinases and are implicated in the transmission of activation signals to the Ras/mitogen-activated protein kinase pathway. Here we report the identification of an interaction between the adapter protein ShcA and the cytoplasmic domain of Tie2 through in vitro co-immunoprecipitation analysis. Stimulation of endogenous Tie2 in endothelial cells with its ligand angiopoietin-1 increased its association with ShcA and phosphorylation of the adapter protein. The interaction requires the SH2 domain of ShcA and the tyrosine phosphorylation of Tie2 as shown by pull-down experiments. Furthermore, Tyr-1101 of Tie2 was identified as the primary binding site for the SH2 domain of ShcA. Overexpression of a dominant-negative form of ShcA affects angiopoietin-1-induced chemotaxis and sprouting, although it has no effect on survival of endothelial cells. Furthermore, this mutant partially reduces the tyrosine phosphorylation of the regulatory p85 subunit of phosphatidylinositol 3-kinase. Together, our results identified a novel interaction between Tie2 with the adapter molecule ShcA and suggested that this interaction may play a role in the regulation of migration and three-dimensional organization of endothelial cells induced by angiopoietin-1.	Univ Turin, Sch Med, Inst Canc Res & Treatment, Div Mol Angiogeneis, I-10060 Candiolo, Italy; Univ Turin, Dept Oncol Sci, I-10060 Candiolo, Italy; European Inst Oncol, I-20141 Milan, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin; IRCCS European Institute of Oncology (IEO)	Bussolino, F (corresponding author), Inst Canc Res & Treatment, Div Mol Angiogenesis, Sp 142,Km 3-95, I-10060 Turin, Italy.	federico.bussolino@ircc.it	Bussolino, Federico/AES-3951-2022; Cascone, Ilaria/Q-7844-2018; Napione, Lucia/K-3927-2016; arese, marco/J-6119-2013; Lanfrancone, Luisa/AAC-8671-2019; Bussolino, Federico/K-2500-2016	Cascone, Ilaria/0000-0003-4903-8926; Napione, Lucia/0000-0003-2648-1466; arese, marco/0000-0002-7384-9406; Lanfrancone, Luisa/0000-0002-4523-3815; Bussolino, Federico/0000-0002-5348-1341; Audero, Enrica/0000-0002-6138-244X				Audero E, 2001, ARTERIOSCL THROM VAS, V21, P536, DOI 10.1161/01.ATV.21.4.536; BALDARI CT, 1995, ONCOGENE, V10, P1141; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Bussolino F, 2001, EMBO REP, V2, P763, DOI 10.1093/embo-reports/kve181; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CARMICHAEL J, 1987, CANCER RES, V47, P936; Cascone I, 2003, BLOOD, V102, P2482, DOI 10.1182/blood-2003-03-0670; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Collins LR, 1999, J CELL BIOL, V147, P1561, DOI 10.1083/jcb.147.7.1561; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Faisal A, 2002, J BIOL CHEM, V277, P30144, DOI 10.1074/jbc.M203229200; Fournier E, 1996, J BIOL CHEM, V271, P12956, DOI 10.1074/jbc.271.22.12956; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Gotoh N, 1995, ONCOGENE, V11, P2525; Grignani F, 1998, CANCER RES, V58, P14; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HUANG LW, 1995, ONCOGENE, V11, P2097; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2002, FASEB J, V16, P1126, DOI 10.1096/fj.01-0805fje; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317; Lai KMV, 2000, GENE DEV, V14, P1132; LANFRANCONE L, 1995, ONCOGENE, V10, P907; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; OKKENHAUG K, 2001, SCI STKE; Ong SH, 2001, EMBO J, V20, P6327, DOI 10.1093/emboj/20.22.6327; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Primo L, 2000, ONCOGENE, V19, P3632, DOI 10.1038/sj.onc.1203708; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Roca C, 2003, CANCER RES, V63, P1500; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; Sato A, 1998, INT IMMUNOL, V10, P1217, DOI 10.1093/intimm/10.8.1217; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Stupack D. G., 2002, SCI STKE, ppe7; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TRUB T, 1995, J BIOL CHEM, V270, P18205; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	79	42	47	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					13224	13233		10.1074/jbc.M307456200	http://dx.doi.org/10.1074/jbc.M307456200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14665640	hybrid			2022-12-27	WOS:000220334900144
J	Picossi, S; Valladares, A; Flores, E; Herrero, A				Picossi, S; Valladares, A; Flores, E; Herrero, A			Nitrogen-regulated genes for the metabolism of cyanophycin, a bacterial nitrogen reserve polymer - Expression and mutational analysis of two cyanophycin synthetase and cyanophycinase gene clusters in the heterocyst-forming cyanobacterium Anabaena sp PCC 7120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP-STRAIN PCC-7120; CLONING; ENZYME; SEQUENCES; GROWTH; NTCA; DIFFERENTIATION; TRANSCRIPTION; BIOSYNTHESIS; PROTEINS	Two gene clusters each encoding the cyanophycin-metabolism enzymes cyanophycin synthetase and cyanophycinase are found in the heterocyst-forming cyanobacterium Anabaena sp. PCC 7120. In cluster cph1, the genes cphB1 and cphA1 were expressed in media containing ammonium, nitrate, or N-2 as nitrogen sources, but expression was higher in the absence of combined nitrogen taking place both in vegetative cells and heterocysts. Both genes were cotranscribed from three putative promoters located upstream of cphB1, and, additionally, the cphA1 gene was expressed monocistronically from at least two promoters located in the intergenic cphB1-cphA1 region. Both constitutive promoters and promoters dependent on the global nitrogen control transcriptional regulator NtcA were identified. In cluster cph2, the cphB2 and cphA2 genes, which are found in opposite orientations, were expressed as monocistronic messages in media containing ammonium, nitrate, or N-2, but expression was higher in the absence of ammonium. Expression of the cph2 genes was lower than that of cph1 genes. Analysis of cph gene insertional mutants indicated that cluster cph1 genes contributed more than cluster cph2 genes to cyanophycin accumulation in the whole filament as well as in heterocysts. Diazotrophic growth was more severely impaired in cyanophycinase than in cyanophycin synthetase mutants, indicating that cyanophycin, although normally synthesized in the heterocysts, is not required for heterocyst function and that the inability to degrade this polymer is detrimental for the diazotrophic growth of the cyanobacterium.	Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, E-41092 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Herrero, A (corresponding author), Ctr Invest Cient Isla de la Cartuja, Inst Bioquim Vegetal & Fotosintesis, C Amer Vespucio S-N, E-41092 Seville, Spain.	herrero@cica.es	Herrero, Antonia/B-7246-2015; Valladares, Ana/B-7611-2015; Picossi, Silvia/I-5623-2012; Flores, Enrique/M-8407-2019; Flores, Enrique/L-2007-2014	Herrero, Antonia/0000-0003-1071-6590; Valladares, Ana/0000-0002-6683-1355; Picossi, Silvia/0000-0003-1175-6228; Flores, Enrique/0000-0001-7605-7343; Flores, Enrique/0000-0001-7605-7343				ALLEN MM, 1984, ANNU REV MICROBIOL, V38, P1, DOI 10.1146/annurev.mi.38.100184.000245; Ausubel FM, 2003, CURRENT PROTOCOLS MO; BLACK TA, 1993, MOL MICROBIOL, V9, P77, DOI 10.1111/j.1365-2958.1993.tb01670.x; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; ElhaI J, 1997, J BACTERIOL, V179, P1998, DOI 10.1128/jb.179.6.1998-2005.1997; ELHAI J, 1988, METHOD ENZYMOL, V167, P747; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; ELHAI J, 1994, J BACTERIOL, V176, P5059, DOI 10.1128/jb.176.16.5059-5067.1994; Flores E., 1994, MOL BIOL CYANOBACTER, VVol 1, P487; FRIAS JE, 1994, MOL MICROBIOL, V14, P823, DOI 10.1111/j.1365-2958.1994.tb01318.x; GOLDEN JW, 1991, J BACTERIOL, V173, P7098, DOI 10.1128/jb.173.22.7098-7105.1991; GUPTA M, 1981, J GEN MICROBIOL, V125, P17; Hejazi M, 2002, BIOCHEM J, V364, P129, DOI 10.1042/bj3640129; Herrero A, 2001, J BACTERIOL, V183, P411, DOI 10.1128/JB.183.2.411-425.2001; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Krehenbrink M, 2002, ARCH MICROBIOL, V177, P371, DOI 10.1007/s00203-001-0396-9; LAWRY NH, 1982, J PHYCOL, V18, P391; LUQUE I, 1994, EMBO J, V13, P2862, DOI 10.1002/j.1460-2075.1994.tb06580.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAZODIER P, 1985, NUCLEIC ACIDS RES, V13, P195, DOI 10.1093/nar/13.1.195; MESSINEO L, 1966, ARCH BIOCHEM BIOPHYS, V117, P534, DOI 10.1016/0003-9861(66)90094-4; MONTESINOS ML, 1995, J BACTERIOL, V177, P3150, DOI 10.1128/jb.177.11.3150-3157.1995; Muro-Pastor AM, 1999, J BACTERIOL, V181, P6664, DOI 10.1128/JB.181.21.6664-6669.1999; Muro-Pastor AM, 2002, MOL MICROBIOL, V44, P1377, DOI 10.1046/j.1365-2958.2002.02970.x; Obst M, 2002, J BIOL CHEM, V277, P25096, DOI 10.1074/jbc.M112267200; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Richter R, 1999, EUR J BIOCHEM, V263, P163, DOI 10.1046/j.1432-1327.1999.00479.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sherman DM, 2000, J PHYCOL, V36, P932, DOI 10.1046/j.1529-8817.2000.99132.x; Sherman LA, 1998, PHOTOSYNTH RES, V58, P25, DOI 10.1023/A:1006137605802; Simon R.D., 1987, CYANOBACTERIA, P199; SIMON RD, 1976, BIOCHIM BIOPHYS ACTA, V422, P407, DOI 10.1016/0005-2744(76)90151-0; TUMER NE, 1983, NATURE, V306, P337, DOI 10.1038/306337a0; Vioque A, 1997, NUCLEIC ACIDS RES, V25, P3471, DOI 10.1093/nar/25.17.3471; Wolk C.P., 1994, MOL BIOL CYANOBACTER, P769, DOI DOI 10.1007/978-94-011-0227-8_27; Ziegler K, 2001, FEMS MICROBIOL LETT, V196, P13, DOI 10.1111/j.1574-6968.2001.tb10533.x; Ziegler K, 2002, Z NATURFORSCH C, V57, P522; Ziegler K, 1998, EUR J BIOCHEM, V254, P154, DOI 10.1046/j.1432-1327.1998.2540154.x	40	46	52	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11582	11592		10.1074/jbc.M311518200	http://dx.doi.org/10.1074/jbc.M311518200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14679189	hybrid			2022-12-27	WOS:000220157600091
J	Yang, LJ; Li, N; Wang, CM; Yu, YZ; Yuan, L; Zhang, MH; Cao, XT				Yang, LJ; Li, N; Wang, CM; Yu, YZ; Yuan, L; Zhang, MH; Cao, XT			Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells (Publication with Expression of Concern. See vol. 295, pg. 8875, 2020) (Withdrawn Publication. See vol. 296, 2021) (Withdrawn Publication. See vol. 296, 2021)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Withdrawn Publication							PROTEIN-KINASE; TERMINAL DOMAIN; IN-VITRO; PHOSPHORYLATION; IDENTIFICATION; TRANSCRIPTION; ACTIVATION; GLUTAMATE; GROWTH; LINES	We report the cloning and functional characterization of human cyclin L2, a novel member of the cyclin family. Human cyclin L2 shares significant homology to cyclin L1, K, T1, T2, and C, which are involved in transcriptional regulation via phosphorylation of the C-terminal domain of RNA polymerase II. The cyclin L2 protein contains an N-terminal "cyclin box" and C-terminal dipeptide repeats of alternating arginines and serines, a hallmark of the SR family of splicing factors. A new isoform and the mouse homologue of human cyclin L2 have also been cloned in this study. Human cyclin L2 is expressed ubiquitously in normal human tissues and tumor cells. We show here that cyclin L2 co-localizes with splicing factors SC-35 and 9G8 within nuclear speckles and that it associates with hyperphosphorylated, but not hypophosphorylated, RNA polymerase II and CDK p110 PITSLRE kinase via its N-terminal cyclin domains. It can also associate with the SC-35 and 9G8 through its RS repeat region. Recombinant cyclin L2 protein can stimulate in vitro mRNA splicing. Overexpression of human cyclin L2 suppresses the growth of human hepatocellular carcinoma SMMC 7721 cells both in vitro and in vivo, inducing cellular apoptosis. This process involves up-regulation of p53 and Bax and decreased expression of Bcl-2. The data suggest that cyclin L2 represents a new member of the cyclin family, which might regulate the transcription and RNA processing of certain apoptosis-related factors, resulting in tumor cell growth inhibition and apoptosis.	Second Mil Med Univ, Inst Immunol, Shanghai 200433, Peoples R China	Naval Medical University	Cao, XT (corresponding author), Second Mil Med Univ, Inst Immunol, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.	caoxt@public3.sta.net.cn	yu, yizhi/ADP-7854-2022					ALLEY MC, 1988, CANCER RES, V48, P589; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Ariza ME, 1999, J BIOL CHEM, V274, P28505, DOI 10.1074/jbc.274.40.28505; Baba M, 2001, GENE THER, V8, P1149, DOI 10.1038/sj.gt.3301504; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Bates S, 1996, ONCOGENE, V13, P1103; Berke JD, 2001, NEURON, V32, P277, DOI 10.1016/S0896-6273(01)00465-2; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Bregman DB, 2000, FRONT BIOSCI, V5, pD244, DOI 10.2741/Bregman; Chen XB, 2002, DEV CELL, V2, P518, DOI 10.1016/S1534-5807(02)00182-X; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; de Graaf K, 2004, J BIOL CHEM, V279, P4612, DOI 10.1074/jbc.M310794200; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Hirose Y, 2000, GENE DEV, V14, P1415; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Li S, 2002, GENE THER, V9, P390, DOI 10.1038/sj.gt.3301645; Lin X, 2002, J BIOL CHEM, V277, P16873, DOI 10.1074/jbc.M200117200; Liu ZJ, 1998, MOL CELL BIOL, V18, P3445, DOI 10.1128/MCB.18.6.3445; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Miller ME, 2001, J CELL SCI, V114, P1811; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; Murray AW, 2001, NATURE, V409, P844, DOI 10.1038/35057033; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Redon R, 2002, CANCER RES, V62, P6211; Reichert V, 2000, NUCLEIC ACIDS RES, V28, P416, DOI 10.1093/nar/28.2.416; Ruegsegger U, 1998, MOL CELL, V1, P243, DOI 10.1016/S1097-2765(00)80025-8; Sanford JR, 2001, P NATL ACAD SCI USA, V98, P10184, DOI 10.1073/pnas.181340498; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Sun HY, 2003, BIOCHEM BIOPH RES CO, V301, P176, DOI 10.1016/S0006-291X(02)02985-6; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Tian HH, 2001, J BIOL CHEM, V276, P33833, DOI 10.1074/jbc.M102957200; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Yu Y, 2002, J CANCER RES CLIN, V128, P283, DOI 10.1007/s00432-002-0325-6; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200; Zhao L, 2003, MOL CANCER RES, V1, P195	45	74	84	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11639	11648		10.1074/jbc.M312895200	http://dx.doi.org/10.1074/jbc.M312895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14684736	hybrid			2022-12-27	WOS:000220157600098
J	Shang, J; Lehrman, MA				Shang, J; Lehrman, MA			Metformin-stimulated mannose transport in dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CONGENITAL DISORDERS; N-GLYCOSYLATION; LINKED OLIGOSACCHARIDES; GLUCOSE-TRANSPORT; CORRECTS; SUPPLEMENTATION; DEFICIENCY; DEFECT	The biguanide drug metformin stimulates AMP-activated protein kinase, a master regulator of cellular energy metabolism, and has antihyperglycemic activity due to attenuation of gluconeogenesis in hepatocytes and 2-fold stimulation of glucose transport by skeletal muscle. Here we identify a metformin-stimulated D-mannose transport (MSMT) activity in dermal fibroblasts. MSMT increased mannose uptake 1.8-fold and had greater affinity for mannose than basal mannose transport activity. It was attributed to robust stimulation of a transporter expressed weakly in untreated cells. MSMT was not explained by greater glucose transporter activity because metformin unexpectedly decreased transport of 2-deoxy-D-glucose and 3-O-methyl-D-glucose by fibroblasts. Effective inhibitors of MSMT retained specificity for the 3-, 4-, and 6-OH groups of the mannose ring but not the 2-OH group. Thus, MSMT could be strongly inhibited by glucose and 2-deoxy-D-glucose even though the latter was not a good transport substrate. MSMT was significant because in the presence of 2.5 muM mannose, metformin corrected experimentally induced deficiencies in the synthesis of glucose(3)mannose(9)GlcNAc(2)-P-P-dolichol and N-linked glycosylation. MSMT was also identified in congenital disorder of glycosylation types Ia and Ib fibroblasts, and metformin acted synergistically with 100 muM mannose to correct lipid-linked oligosaccharide synthesis and N-glycosylation in the Ia cells. In conclusion, metformin activates a novel fibroblast mannose-selective transport system. This suggests that AMP-activated protein kinase may be a regulator of mannose metabolism and implies a therapy for congenital disorders of glycosylation-Ia.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mark.lehrman@utsouthwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038545, GM38545] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alton G, 1998, GLYCOBIOLOGY, V8, P285, DOI 10.1093/glycob/8.3.285; Babovic-Vuksanovic D, 1999, J PEDIATR-US, V135, P775, DOI 10.1016/S0022-3476(99)70103-4; Davis S., 2001, GOODMAN GILMANS T PH, P1679; Doerrler WT, 1999, P NATL ACAD SCI USA, V96, P13050, DOI 10.1073/pnas.96.23.13050; Dupre T, 2000, GLYCOBIOLOGY, V10, P1277, DOI 10.1093/glycob/10.12.1277; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Gao NG, 2002, GLYCOBIOLOGY, V12, P353, DOI 10.1093/glycob/12.5.353; Harms HK, 2002, ACTA PAEDIATR, V91, P1065, DOI 10.1080/080352502760311566; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Korner C, 1998, GLYCOBIOLOGY, V8, P165, DOI 10.1093/glycob/8.2.165; Korner C, 1998, GLYCOCONJUGATE J, V15, P499, DOI 10.1023/A:1006939104442; KOSOWER NS, 1969, BIOCHEM BIOPH RES CO, V37, P593, DOI 10.1016/0006-291X(69)90850-X; Marquardt T, 2001, BIOL CHEM, V382, P161, DOI 10.1515/BC.2001.024; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; Panneerselvam K, 1996, J BIOL CHEM, V271, P9417, DOI 10.1074/jbc.271.16.9417; Panneerselvam K, 1997, J BIOL CHEM, V272, P23123, DOI 10.1074/jbc.272.37.23123; REBRIN K, 1992, J BIOMED ENG, V14, P33, DOI 10.1016/0141-5425(92)90033-H; Rush JS, 2000, GLYCOBIOLOGY, V10, P829, DOI 10.1093/glycob/10.8.829; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Witters LA, 2001, J CLIN INVEST, V108, P1105, DOI 10.1172/JCI200114178; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	28	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9703	9712		10.1074/jbc.M310837200	http://dx.doi.org/10.1074/jbc.M310837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681228	hybrid			2022-12-27	WOS:000220050400008
J	Jayachandran, R; Shaila, MS; Karande, AA				Jayachandran, R; Shaila, MS; Karande, AA			Analysis of the role of oligosaccharides in the apoptotic activity of glycodelin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL PROTEIN-14; HUMAN ERYTHROPOIETIN; N-GLYCOSYLATION; SIALIC-ACID; CELLS; EXPRESSION; GLYCOPROTEIN; REPRODUCTION; GAMMA; SITES	Glycodelin A, also known as placental protein-14, is a multifunctional glycosylated protein secreted by the uterine endometrium during the early phases of pregnancy. It is a known suppressor of T cell proliferation, inducer of T cell apoptosis, and inhibitor of sperm zona binding. Unlike in contraceptive activity, where the glycans on the molecule have been shown to play a crucial role, mutagenesis of the asparagines at sites of N-linked glycosylation (Asn(28) and Asn(63)) to glutamine shows that the apoptogenic activity of glycodelin A is executed by the protein backbone. Glycosylation at Asn(28) appears to play a role in the extracellular secretion of the molecule, as mutation of Asn(28) resulted in a significant decrease in the amount of secreted protein, and loss of both glycosylation sites reduced the secretion drastically. Our results also suggest that the loss of glycosylation does not affect the dimerization status of the molecule.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Karande, AA (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	anjali@biochem.iisc.ernet.in	Karande, Anjali/C-4880-2009					BOLTON AE, 1987, LANCET, V1, P593; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; CANTELL K, 1992, J INTERFERON RES, V12, P177, DOI 10.1089/jir.1992.12.177; Chotigeat W, 2000, J BIOTECHNOL, V81, P55, DOI 10.1016/S0168-1656(00)00268-6; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; GOLDWASSER E, 1974, J BIOL CHEM, V249, P4202; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; Hooker AD, 1999, BIOTECHNOL BIOENG, V63, P559, DOI 10.1002/(SICI)1097-0290(19990605)63:5<559::AID-BIT6>3.0.CO;2-L; IMAI N, 1990, EUR J BIOCHEM, V194, P457, DOI 10.1111/j.1432-1033.1990.tb15639.x; JENKINS N, 1994, ENZYME MICROB TECH, V16, P354, DOI 10.1016/0141-0229(94)90149-X; JULKUNEN M, 1986, ENDOCRINOLOGY, V118, P1782, DOI 10.1210/endo-118-5-1782; Julkunen M, 1984, Arch Androl, V12 Suppl, P59; Karri T, 2000, HISTOCHEM J, V32, P711, DOI 10.1023/A:1004144909714; Koistinen H, 1996, MOL HUM REPROD, V2, P759, DOI 10.1093/molehr/2.10.759; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Morais VA, 2001, BIOCHEM J, V353, P719, DOI 10.1042/0264-6021:3530719; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; Mukhopadhyay D, 2004, J BIOL CHEM, V279, P8577, DOI 10.1074/jbc.M306673200; Mukhopadhyay D, 2001, J BIOL CHEM, V276, P28268, DOI 10.1074/jbc.M010487200; RECNY MA, 1992, J BIOL CHEM, V267, P22428; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; Seppala M, 1997, CLIN ENDOCRINOL, V46, P381, DOI 10.1046/j.1365-2265.1997.1510943.x; SEPPO A, 1998, CELLS LAB MANUAL, V1; Wester L, 2000, GLYCOBIOLOGY, V10, P891, DOI 10.1093/glycob/10.9.891; WITTWER AJ, 1990, BIOCHEMISTRY-US, V29, P4175, DOI 10.1021/bi00469a021; YAMAGUCHI K, 1991, J BIOL CHEM, V266, P20434	26	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8585	8591		10.1074/jbc.M310480200	http://dx.doi.org/10.1074/jbc.M310480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679202	hybrid			2022-12-27	WOS:000189265900009
J	Jenkins, J; Shevchik, VE; Hugouvieux-Cotte-Pattat, N; Pickersgill, RW				Jenkins, J; Shevchik, VE; Hugouvieux-Cotte-Pattat, N; Pickersgill, RW			The crystal structure of pectate lyase Pel9A from Erwinia chrysanthemi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; PROTON ABSTRACTION; CARBON ACIDS; ENZYMES; ARCHITECTURE; PECTIN; FAMILY; MECHANISM; MOLSCRIPT; COMPLEX	The "family 9 polysaccharide lyase" pectate lyase L (Pel9A) from Erwinia chrysanthemi comprises a 10-coil parallel beta-helix domain with distinct structural features including an asparagine ladder and aromatic stack at novel positions within the superhelical structure. Pel9A has a single high affinity calcium-binding site strikingly similar to the "primary" calcium-binding site described previously for the family Pel1A pectate lyases, and there is strong evidence for a common second calcium ion that binds between enzyme and substrate in the "Michaelis" complex. Although the primary calcium ion binds substrate in subsite -1, it is the second calcium ion, whose binding site is formed by the coming together of enzyme and substrate, that facilitates abstraction of the C5 proton from the sacharride in subsite +1. The role of the second calcium is to withdraw electrons from the C6 carboxylate of the substrate, thereby acidifying the C5 proton facilitating its abstraction and resulting in an E1cb-like anti-beta-elimination mechanism. The active site geometries and mechanism of Pel1A and Pel9A are closely similar, but the catalytic base is a lysine in the Pel9A enzymes as opposed to an arginine in the Pel1A enzymes.	Univ London, Queen Mary, Sch Biol Sci, London E1 4NS, England; Univ Lyon 1, CNRS, UMR 5122, Unite Microbiol & Genet, F-69622 Villeurbanne, France; Inst Food Res, Norwich NR4 7UA, Norfolk, England	University of London; Queen Mary University London; Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Pickersgill, RW (corresponding author), Univ London, Queen Mary, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	r.w.pickersgill@qmul.ac.uk		COTTE-PATTAT, Nicole/0000-0002-4322-160X; Shevchik, Vladimir/0000-0002-8031-8638	Biotechnology and Biological Sciences Research Council [BBS/B/07896] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Akita M, 2001, ACTA CRYSTALLOGR D, V57, P1786, DOI 10.1107/S0907444901014482; Anderson VE, 1998, COMPREHENSIVE BIOL C, V2, P115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P12067, DOI 10.1073/pnas.182431199; Coutinho PM, 1999, ROY SOC CH, P3; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GERLT JA, 1992, J AM CHEM SOC, V114, P5928, DOI 10.1021/ja00041a004; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Herron SR, 2000, P NATL ACAD SCI USA, V97, P8762, DOI 10.1073/pnas.97.16.8762; Herron SR, 2003, J BIOL CHEM, V278, P12271, DOI 10.1074/jbc.M209306200; Huang WJ, 1999, J MOL BIOL, V294, P1257, DOI 10.1006/jmbi.1999.3292; JENCKS WP, 1980, ACCOUNTS CHEM RES, V13, P161, DOI 10.1021/ar50150a001; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; Jenkins J, 2001, J MOL BIOL, V305, P951, DOI 10.1006/jmbi.2000.4324; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lietzke SE, 1996, PLANT PHYSIOL, V111, P73, DOI 10.1104/pp.111.1.73; LOJKOWSKA E, 1995, MOL MICROBIOL, V16, P1183, DOI 10.1111/j.1365-2958.1995.tb02341.x; Mayans O, 1997, STRUCTURE, V5, P677, DOI 10.1016/S0969-2126(97)00222-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murzin AG, 2001, PROTEINS, P76; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; OFERRALL RA, 1970, J CHEM SOC B, P274, DOI 10.1039/j29700000274; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1991, DARESBURY STUDY WEEK, P80; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Petersen TN, 1997, STRUCTURE, V5, P533, DOI 10.1016/S0969-2126(97)00209-8; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; Rigden DJ, 2002, FEBS LETT, V530, P225, DOI 10.1016/S0014-5793(02)03490-7; Roy C, 1999, J BACTERIOL, V181, P3705, DOI 10.1128/JB.181.12.3705-3709.1999; Scavetta RD, 1999, PLANT CELL, V11, P1081, DOI 10.1105/tpc.11.6.1081; Shevchik V, 1998, ACTA CRYSTALLOGR D, V54, P419, DOI 10.1107/S0907444997012043; Shevchik VE, 1999, J BACTERIOL, V181, P3912, DOI 10.1128/JB.181.13.3912-3919.1999; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	40	64	65	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9139	9145		10.1074/jbc.M311390200	http://dx.doi.org/10.1074/jbc.M311390200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670977	hybrid			2022-12-27	WOS:000189265900075
J	Magnusson, U; Salopek-Sondi, B; Luck, LA; Mowbray, SL				Magnusson, U; Salopek-Sondi, B; Luck, LA; Mowbray, SL			X-ray structures of the leucine-binding protein illustrate conformational changes and the basis of ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI; TRANSPORT-SYSTEMS; D-ALLOSE; PROGRAM; RECEPTOR; PRODUCE; MODELS; MOTION	The periplasmic leucine-binding protein is the primary receptor for the leucine transport system in Escherichia coli. We report here the structure of an open ligand-free form solved by molecular replacement and refined at 1.5-Angstrom resolution. In addition, two closed ligand-bound structures of the same protein are presented, a phenylalanine-bound form at 1.8 Angstrom and a leucine-bound structure at a nominal resolution of 2.4 Angstrom. These structures show the basis of this protein's ligand specificity, as well as illustrating the conformational changes that are associated with ligand binding. Comparison with earlier structures provides further information about solution conformations, as well as the different specificity of the closely related leucine/isoleucine/valine-binding protein.	Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biosci, Div Struct Biol, S-75124 Uppsala, Sweden; Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden; Clarkson Univ, Dept Chem, Potsdam, NY 13699 USA	Swedish University of Agricultural Sciences; Uppsala University; Clarkson University	Mowbray, SL (corresponding author), Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biosci, Div Struct Biol, Box 590, S-75124 Uppsala, Sweden.	mowbray@xray.bmc.uu.se	Sondi, Branka Salopek/AAG-1614-2019; Mowbray, Sherry L/D-2141-2013	Sondi, Branka Salopek/0000-0001-8202-8960; 	NATIONAL CANCER INSTITUTE [R03CA089705] Funding Source: NIH RePORTER; NCI NIH HHS [R03-CA 89705] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1991, J BIOL CHEM, V266, P6209; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOHL E, 1995, J THEOR BIOL, V172, P83, DOI 10.1006/jtbi.1995.0006; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaudhuri BN, 1999, J MOL BIOL, V286, P1519, DOI 10.1006/jmbi.1999.2571; *COLL COMP PROJ, 1984, ACTA CRYSTALLOGR D, V50, P760; GERSTEIN M, 1993, J MOL BIOL, V234, P357, DOI 10.1006/jmbi.1993.1592; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDICK R, 1985, J BIOL CHEM, V260, P8257; Luck LA, 2000, PROTEIN SCI, V9, P2573, DOI 10.1110/ps.9.12.2573; Magnusson U, 2002, J BIOL CHEM, V277, P14077, DOI 10.1074/jbc.M200514200; McPherson A, 1982, PREPARATION ANAL PRO; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; OLAH GA, 1993, J BIOL CHEM, V268, P16241; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAHMANIAN M, 1973, J BACTERIOL, V116, P1258, DOI 10.1128/JB.116.3.1258-1266.1973; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SACK JS, 1989, J MOL BIOL, V206, P193, DOI 10.1016/0022-2836(89)90532-9; Salopek-Sondi B, 2002, PROTEIN ENG, V15, P855, DOI 10.1093/protein/15.11.855; Salopek-Sondi B, 2002, J BIOMOL STRUCT DYN, V20, P381, DOI 10.1080/07391102.2002.10506856; SHILTON BH, 1995, PROTEIN SCI, V4, P1346, DOI 10.1002/pro.5560040710; Shilton BH, 1996, J MOL BIOL, V264, P364, DOI 10.1006/jmbi.1996.0646; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	40	60	60	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8747	8752		10.1074/jbc.M311890200	http://dx.doi.org/10.1074/jbc.M311890200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672931	hybrid			2022-12-27	WOS:000189265900028
J	Pell, G; Taylor, EJ; Gloster, TM; Turkenburg, JP; Fontes, CMGA; Ferreira, LMA; Nagy, T; Clark, SJ; Davies, GJ; Gilbert, HJ				Pell, G; Taylor, EJ; Gloster, TM; Turkenburg, JP; Fontes, CMGA; Ferreira, LMA; Nagy, T; Clark, SJ; Davies, GJ; Gilbert, HJ			The mechanisms by which family 10 glycoside hydrolases bind decorated substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GLUCURONIDASE; PSEUDOMONAS-FLUORESCENS; CELLULOSA XYLANASE; ACTIVE-SITE; XYLOOLIGOSACCHARIDES; INTERMEDIATE; SPECIFICITY; MOLSCRIPT; FAMILIES; SEQUENCE	Endo-beta-1,4-xylanases (xylanases), which cleave beta-1,4 glycosidic bonds in the xylan backbone, are important components of the repertoire of enzymes that catalyze plant cell wall degradation. The mechanism by which these enzymes are able to hydrolyze a range of decorated xylans remains unclear. Here we reveal the three-dimensional structure, determined by x-ray crystallography, and the catalytic properties of the Cellvibrio mixtus enzyme Xyn10B (CmXyn10B), the most active GH10 xylanase described to date. The crystal structure of the enzyme in complex with xylopentaose reveals that at the +1 subsite the xylose moiety is sandwiched between hydrophobic residues, which is likely to mediate tighter binding than in other GH10 xylanases. The crystal structure of the xylanase in complex with a range of decorated xylooligosaccharides reveals how this enzyme is able to hydrolyze substituted xylan. Solvent exposure of the O-2 groups of xylose at the +4, +3, +1, and -3 subsites may allow accommodation of the alpha-1,2-linked 4-O-methyl-D-glucuronic acid side chain in glucuronoxylan at these locations. Furthermore, the uronic acid makes hydrogen bonds and hydrophobic interactions with the enzyme at the +1 subsite, indicating that the sugar decorations in glucuronoxylan are targeted to this proximal aglycone binding site. Accommodation of 3'-linked L-arabinofuranoside decorations is observed in the -2 subsite and could, most likely, be tolerated when bound to xylosides in -3 and +4. A notable feature of the binding mode of decorated substrates is the way in which the subsite specificities are tailored both to prevent the formation of "dead-end" reaction products and to facilitate synergy with the xylan degradation-accessory enzymes such as alpha-glucuronidase. The data described in this report and in the accompanying paper ( Fujimoto, Z., Kaneko, S., Kuno, A., Kobayashi, H., Kusakabe, I., and Mizuno, H. ( 2004) J. Biol. Chem. 279, 9606 - 9614) indicate that the complementarity in the binding of decorated substrates between the glycone and aglycone regions appears to be a conserved feature of GH10 xylanases.	Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Tecn Lisboa, CIISA Fac Med Vet, P-1300477 Lisbon, Portugal	Newcastle University - UK; University of York - UK; Universidade de Lisboa	Gilbert, HJ (corresponding author), Newcastle Univ, Sch Cell & Mol Biosci, Agr Bldg, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Fontes, Carlos/0000-0002-1219-9753; Ferreira, Luis/0000-0002-3543-9166; Taylor, Edward/0000-0003-4024-0976; Turkenburg, Johan/0000-0001-6992-6838				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; ATKINS EDT, 1992, PROGR BIOTECHNOL, V7, P39; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beylot MH, 2001, BIOCHEM J, V358, P607, DOI 10.1042/0264-6021:3580607; Biely P, 1997, J BIOTECHNOL, V57, P151, DOI 10.1016/S0168-1656(97)00096-5; BIELY P, 1981, EUR J BIOCHEM, V119, P559, DOI 10.1111/j.1432-1033.1981.tb05644.x; BRETT CT, 1996, TOPICS PLANT FUNCTIO, V1; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Ducros V, 2000, J BIOL CHEM, V275, P23020, DOI 10.1074/jbc.275.30.23020; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fontes CMGA, 2000, MICROBIOL-SGM, V146, P1959, DOI 10.1099/00221287-146-8-1959; Fujimoto Z, 2004, J BIOL CHEM, V279, P9606, DOI 10.1074/jbc.M312293200; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Leggio L, 1999, PROTEINS, V36, P295; Lo Leggio L, 2000, PROTEINS, V41, P362, DOI 10.1002/1097-0134(20001115)41:3<362::AID-PROT80>3.0.CO;2-N; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; Nagy T, 2003, J BIOL CHEM, V278, P20286, DOI 10.1074/jbc.M302205200; Nagy T, 2002, J BACTERIOL, V184, P4925, DOI 10.1128/JB.184.17.4925-4929.2002; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Nurizzo D, 2002, STRUCTURE, V10, P547, DOI 10.1016/S0969-2126(02)00742-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z	35	143	146	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9597	9605		10.1074/jbc.M312278200	http://dx.doi.org/10.1074/jbc.M312278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668328	hybrid			2022-12-27	WOS:000189265900127
J	Yang, C; Boucher, F; Tremblay, A; Michaud, JL				Yang, C; Boucher, F; Tremblay, A; Michaud, JL			Regulatory interaction between arylhydrocarbon receptor and SIM1, two basic helix-loop-helix PAS proteins involved in the control of food intake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; TRANSCRIPTION FACTOR FAMILY; DIOXIN-RESPONSIVE ENHANCER; TISSUE-SPECIFIC EXPRESSION; CENTRAL-NERVOUS-SYSTEM; LIGANDED AH RECEPTOR; NUCLEAR TRANSLOCATOR; MESSENGER-RNA; CDNA CLONING; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD	The basic helix-loop-helix PAS (bHLH-PAS) transcription factors SIM1 and arylhydrocarbon receptor (AHR) are involved in the control of feeding behavior. Sim1 haploinsufficiency causes hyperphagia in mice and humans, most likely by perturbing the hypothalamus function. The administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin ( TCDD), a ligand of AHR, causes severe anorexia, which also appears to be of central origin. Both SIM1 and AHR require heterodimerization either with ARNT or ARNT2 to function. Here, we characterize the promoter for Sim1 and show that a consensus AHR-ARNT/2 binding site positively regulates its activity in the context of transfection experiments in Neuro-2A cells. A gel shift assay indicated that AHR-ARNT/2 can bind its putative site in the Sim1 promoter. Overexpression of Arnt, Arnt2, or Ahr increased the activity of a reporter construct containing the Sim1 promoter by 1.8-, 1.5-, and 2.2-fold, respectively, but failed to do so when the AHRARNT/2 binding site was mutated. Similarly, TCDD increased the activity of the reporter construct by 1.8- fold but not that of its mutated version. Finally, we found that TCDD increased Sim1 expression in Neuro-2A cells and in mouse kidney and hypothalamus by 4-, 3-, and 2-fold, respectively. We conclude that Sim1 expression is regulated by AHR-ARNT/2. This result raises the possibility that Sim1 mediates the effect of TCDD on feeding and points to a complex network of regulatory interactions between bHLH-PAS proteins.	Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada	Universite de Montreal	Michaud, JL (corresponding author), Hop St Justine, Ctr Rech, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	jmichaud@justine.umontreal.ca						Abbott BD, 1999, TOXICOL SCI, V47, P76, DOI 10.1093/toxsci/47.1.76; Adachi J, 2001, J BIOL CHEM, V276, P31475, DOI 10.1074/jbc.C100238200; Buckhaults P, 2001, CANCER RES, V61, P6996; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Cheng SB, 2002, BRAIN RES, V931, P176, DOI 10.1016/S0006-8993(02)02257-6; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Falahatpisheh MH, 2003, ONCOGENE, V22, P2160, DOI 10.1038/sj.onc.1206238; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heath-Pagliuso S, 1998, BIOCHEMISTRY-US, V37, P11508, DOI 10.1021/bi980087p; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Holder JL, 2000, HUM MOL GENET, V9, P101; Hosoya T, 2001, GENES CELLS, V6, P361, DOI 10.1046/j.1365-2443.2001.00421.x; Huang P, 2000, TOXICOL APPL PHARM, V169, P159, DOI 10.1006/taap.2000.9064; Ikeda M, 2000, BIOCHEM BIOPH RES CO, V275, P493, DOI 10.1006/bbrc.2000.3248; Ikeda M, 1997, BIOCHEM BIOPH RES CO, V233, P258, DOI 10.1006/bbrc.1997.6371; Jeon MS, 2000, J IMMUNOL, V165, P6975, DOI 10.4049/jimmunol.165.12.6975; Keith B, 2001, P NATL ACAD SCI USA, V98, P6692, DOI 10.1073/pnas.121494298; KELLING CK, 1985, FUND APPL TOXICOL, V5, P700, DOI 10.1016/0272-0590(85)90194-0; Laiosa MD, 2002, TOXICOL SCI, V69, P117, DOI 10.1093/toxsci/69.1.117; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Maemura K, 2000, J BIOL CHEM, V275, P36847, DOI 10.1074/jbc.C000629200; Michaud JL, 2000, MECH DEVELOP, V90, P253, DOI 10.1016/S0925-4773(99)00328-7; Michaud JL, 1998, GENE DEV, V12, P3264, DOI 10.1101/gad.12.20.3264; Michaud JL, 2001, HUM MOL GENET, V10, P1465, DOI 10.1093/hmg/10.14.1465; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Moriguchi T, 2003, P NATL ACAD SCI USA, V100, P5652, DOI 10.1073/pnas.1037886100; Okano T, 2001, NEUROSCI LETT, V300, P111, DOI 10.1016/S0304-3940(01)01581-6; Petersen SL, 2000, J COMP NEUROL, V427, P428, DOI 10.1002/1096-9861(20001120)427:3<428::AID-CNE9>3.0.CO;2-P; POHJANVIRTA R, 1989, TOXICOLOGY, V58, P167, DOI 10.1016/0300-483X(89)90006-1; POHJANVIRTA R, 1994, PHARMACOL BIOCHEM BE, V47, P273, DOI 10.1016/0091-3057(94)90010-8; POHJANVIRTA R, 1994, PHARMACOL REV, V46, P483; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SHEN ES, 1992, J BIOL CHEM, V267, P6815; Shridhar S, 2001, TOXICOL SCI, V63, P181, DOI 10.1093/toxsci/63.2.181; Song JS, 2002, P NATL ACAD SCI USA, V99, P14694, DOI 10.1073/pnas.232562899; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; UNKILA M, 1995, INT J BIOCHEM CELL B, V27, P443, DOI 10.1016/1357-2725(95)00023-I; Wang F, 2001, MOL CELL ENDOCRINOL, V172, P91, DOI 10.1016/S0303-7207(00)00379-8; Wei YD, 2000, ARCH BIOCHEM BIOPHYS, V383, P99, DOI 10.1006/abbi.2000.2037; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Wolting CD, 1998, MAMM GENOME, V9, P463, DOI 10.1007/s003359900797; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200	53	16	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9306	9312		10.1074/jbc.M307927200	http://dx.doi.org/10.1074/jbc.M307927200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660629	hybrid			2022-12-27	WOS:000189265900093
J	Bergt, C; Fu, XY; Huq, NP; Kao, J; Heinecke, JW				Bergt, C; Fu, XY; Huq, NP; Kao, J; Heinecke, JW			Lysine residues direct the chlorination of tyrosines in YXXK motifs of apolipoprotein A-I when hypochlorous acid oxidizes high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE-CHLORIDE; HUMAN ATHEROSCLEROTIC LESIONS; HUMAN NEUTROPHILS EMPLOY; AMINO-ACIDS; GENERATED HYPOCHLORITE; MYELOPEROXIDASE SYSTEM; MODIFIED PROTEINS; TYROSYL RESIDUES; HUMAN PHAGOCYTES; LIPID-FREE	Oxidized lipoproteins may play an important role in the pathogenesis of atherosclerosis. Elevated levels of 3-chlorotyrosine, a specific end product of the reaction between hypochlorous acid (HOCl) and tyrosine residues of proteins, have been detected in atherosclerotic tissue. Thus, HOCl generated by the phagocyte enzyme myeloperoxidase represents one pathway for protein oxidation in humans. One important target of the myeloperoxidase pathway may be high density lipoprotein (HDL), which mobilizes cholesterol from artery wall cells. To determine whether activated phagocytes preferentially chlorinate specific sites in HDL, we used tandem mass spectrometry (MS/MS) to analyze apolipoprotein A-I that had been oxidized by HOCl. The major site of chlorination was a single tyrosine residue located in one of the protein's YXXK motifs ( where X represents a nonreactive amino acid). To investigate the mechanism of chlorination, we exposed synthetic peptides to HOCl. The peptides encompassed the amino acid sequences YKXXY, YXXKY, or YXXXY. MS/MS analysis demonstrated that chlorination of tyrosine in the peptides that contained lysine was regioselective and occurred in high yield if the substrate was KXXY or YXXK. NMR and MS analyses revealed that the N-epsilon amino group of lysine was initially chlorinated, which suggests that chloramine formation is the first step in tyrosine chlorination. Molecular modeling of the YXXK motif in apolipoprotein A-I demonstrated that these tyrosine and lysine residues are adjacent on the same face of an amphipathic alpha-helix. Our observations suggest that HOCl selectively targets tyrosine residues that are suitably juxtaposed to primary amino groups in proteins. This mechanism might enable phagocytes to efficiently damage proteins when they destroy microbial proteins during infection or damage host tissue during inflammation.	Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA; Washington Univ, Dept Chem, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; Washington University (WUSTL)	Heinecke, JW (corresponding author), Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu		Huq Saifee, Nabiha/0000-0003-1646-9201	NHLBI NIH HHS [HL64344] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIEHS NIH HHS [P30 ES07033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; Aratani Y, 1999, INFECT IMMUN, V67, P1828; Bergt C, 2000, BIOCHEM J, V346, P345, DOI 10.1042/0264-6021:3460345; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Carr AC, 2000, BIOCHEM J, V346, P491, DOI 10.1042/0264-6021:3460491; Chapman ALP, 2000, ARCH BIOCHEM BIOPHYS, V377, P95, DOI 10.1006/abbi.2000.1744; Chapman ALP, 2002, J BIOL CHEM, V277, P9757, DOI 10.1074/jbc.M106134200; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; Frank PG, 2000, J LIPID RES, V41, P853; Fu XY, 2002, BIOCHEMISTRY-US, V41, P1293, DOI 10.1021/bi015777z; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hawkins CL, 1999, BIOCHEM J, V340, P539, DOI 10.1042/0264-6021:3400539; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; Kang DK, 2003, J BIOL CHEM, V278, P14857, DOI 10.1074/jbc.M300616200; Kettle AJ, 1996, FEBS LETT, V379, P103, DOI 10.1016/0014-5793(95)01494-2; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Nightingale ZD, 2000, FREE RADICAL BIO MED, V29, P425, DOI 10.1016/S0891-5849(00)00262-8; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; Panzenboeck U, 1997, J BIOL CHEM, V272, P29711, DOI 10.1074/jbc.272.47.29711; Pattison DI, 2001, CHEM RES TOXICOL, V14, P1453, DOI 10.1021/tx0155451; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; Pullar JM, 2001, J BIOL CHEM, V276, P22120, DOI 10.1074/jbc.M102088200; Raftery MJ, 2001, J BIOL CHEM, V276, P33393, DOI 10.1074/jbc.M101566200; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rosen H, 2002, J BIOL CHEM, V277, P30463, DOI 10.1074/jbc.M202331200; Schoneich C, 2002, CHEM RES TOXICOL, V15, P717, DOI 10.1021/tx025504k; SCOTT JW, 1974, J AM OIL CHEM SOC, V51, P200, DOI 10.1007/BF02632894; SEGREST JP, 1992, J LIPID RES, V33, P141; SELVARAJ RJ, 1974, INFECT IMMUN, V9, P255, DOI 10.1128/IAI.9.2.255-260.1974; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; Van Lenten BJ, 2001, TRENDS CARDIOVAS MED, V11, P155, DOI 10.1016/S1050-1738(01)00095-0; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; WILEY WC, 1955, REV SCI INSTRUM, V26, P1150, DOI 10.1063/1.1715212; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; Yang CY, 2001, J LIPID RES, V42, P1891; ZGLICZYNSKI JM, 1968, EUR J BIOCHEM, V4, P540, DOI 10.1111/j.1432-1033.1968.tb00246.x	65	110	120	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7856	7866		10.1074/jbc.M309046200	http://dx.doi.org/10.1074/jbc.M309046200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660678	hybrid			2022-12-27	WOS:000189103300062
J	Cheng, X; Kinosaki, M; Takami, M; Choi, Y; Zhang, HT; Murali, R				Cheng, X; Kinosaki, M; Takami, M; Choi, Y; Zhang, HT; Murali, R			Disabling of receptor activator of nuclear factor-kappa B (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; N-TERMINAL KINASE; TNF-RECEPTOR; CRYSTAL-STRUCTURE; T-CELLS; FAMILY-MEMBER; LIGAND RANKL; POSTMENOPAUSAL WOMEN; MULTIPLE-MYELOMA	The tumor necrosis factor family ligand, tumor necrosis factor-related activation-induced cytokine ( TRANCE), and its receptors, receptor activator of nuclear factor-kappaB ( RANK) and osteoprotegerin (OPG), are known to be regulators of development and activation of osteoclasts in bone remodeling. Sustained osteoclast activation that occurs through TRANCE-RANK causes osteopenic disorders such as osteoporosis and contributes to osteolytic metastases. Here, we report a rationally designed small molecule mimic of osteoprotegerin to inhibit osteoclast formation in vitro and limit bone loss in an animal model of osteoporosis. One of the mimetics, OP3-4, significantly inhibited osteoclast formation in vitro (IC50 = 10 muM) and effectively inhibited total bone loss in ovariectomized mice at a dosage of 2 mg/kg/day. Unlike soluble OPG receptors, which preclude TRANCE binding to RANK, OP3-4 shows the ability to modulate RANK-TRANCE signaling pathways and alters the biological functions of the RANK-TRANCE receptor complex by facilitating a defective receptor complex. These features suggest that OPG-derived small molecules can be used as a probe to understand complex biological functions of RANK-TRANCE-OPG receptors and also can be used as a platform to develop more useful therapeutic agents for inflammation and bone disease.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst Canc Res, Philadelphia, PA 19104 USA	University of Pennsylvania	Murali, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst Canc Res, 252 John Morgan Bldg, Philadelphia, PA 19104 USA.	murali@xray.med.upenn.edu		Zhang, Hongtao/0000-0001-9173-0049; Murali, Ramachandran/0000-0002-8384-2793; Takami, Masamichi/0000-0002-4506-3975				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Andersson N, 2001, J ENDOCRINOL, V170, P529, DOI 10.1677/joe.0.1700529; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Atkins GJ, 2001, BONE, V28, P370, DOI 10.1016/S8756-3282(01)00404-5; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bekker PJ, 2001, J BONE MINER RES, V16, P348, DOI 10.1359/jbmr.2001.16.2.348; Bell Norman H., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P93, DOI 10.2174/1568008013341622; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Body JJ, 2003, CANCER-AM CANCER SOC, V97, P887, DOI 10.1002/cncr.11138; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Cha SS, 2000, J BIOL CHEM, V275, P31171, DOI 10.1074/jbc.M004414200; Choi Y, 2001, EUR J IMMUNOL, V31, P2179, DOI 10.1002/1521-4141(200107)31:7<2179::AID-IMMU2179>3.0.CO;2-X; Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Eghbali-Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Green EA, 2002, IMMUNITY, V16, P183, DOI 10.1016/S1074-7613(02)00279-0; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Holen I, 2002, CANCER RES, V62, P1619; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200; Jimi E, 1999, J IMMUNOL, V163, P434; Jones DH, 2002, ANN RHEUM DIS, V61, P32, DOI 10.1136/ard.61.suppl_2.ii32; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lee YJ, 2001, J IMMUNOL, V167, P82, DOI 10.4049/jimmunol.167.1.82; Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Martin TJ, 2001, TRENDS ENDOCRIN MET, V12, P2, DOI 10.1016/S1043-2760(00)00351-9; Michigami T, 2001, CANCER RES, V61, P1637; Min H, 2000, J EXP MED, V192, P463, DOI 10.1084/jem.192.4.463; Mori H, 2002, HISTOCHEM CELL BIOL, V117, P283, DOI 10.1007/s00418-001-0376-9; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Murali R, 1998, IMMUNOL RES, V17, P163, DOI 10.1007/BF02786441; MURALI R, 2000, CYTOKINE INHIBITORS, P133; Naismith JH, 1998, TRENDS BIOCHEM SCI, V23, P74, DOI 10.1016/S0968-0004(97)01164-X; Naismith JH, 1996, J INFLAMM, V47, P1; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002-9440(10)63016-7; RAMACHANDRAN GN, 1968, BIOPOLYMERS, V6, P1255, DOI 10.1002/bip.1968.360060903; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; Sato M, 1997, ENDOCRINOLOGY, V138, P4330, DOI 10.1210/en.138.10.4330; Schoppet M, 2002, ARTERIOSCL THROM VAS, V22, P549, DOI 10.1161/01.ATV.0000012303.37971.DA; Shiotani A, 2002, ANAT REC, V268, P137, DOI 10.1002/ar.10121; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516; Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197-1266; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359-6101(03)00027-3; Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P; Weitzmann MN, 2001, J BONE MINER RES, V16, P328, DOI 10.1359/jbmr.2001.16.2.328; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715; ZHANG KYJ, 1994, PROTEIN SCI, V3, P687	73	72	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8269	8277		10.1074/jbc.M309690200	http://dx.doi.org/10.1074/jbc.M309690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14679212	hybrid			2022-12-27	WOS:000189103300109
J	Di Leva, F; Ferrante, MI; Demarchi, F; Caravelli, A; Matarazzo, MR; Giacca, M; D'Urso, M; D'Esposito, M; Franze, A				Di Leva, F; Ferrante, MI; Demarchi, F; Caravelli, A; Matarazzo, MR; Giacca, M; D'Urso, M; D'Esposito, M; Franze, A			Human synaptobrevin-like 1 gene basal transcription is regulated through the interaction of selenocysteine tRNA gene transcription activating factor-zinc finger 143 factors with evolutionary conserved cis-elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMALDEHYDE CROSS-LINKING; MOLECULAR-CLONING; MEMBRANE-PROTEIN; POLYMERASE-III; STAF; PROMOTER; METHYLATION; REGION; ZNF76; SYBL1	The synaptobrevin-like 1 (SYBL1) gene is ubiquitously expressed and codes for an unusual member of the v-SNAREs molecules implicated in cellular exocytosis. This X-linked gene has the peculiarity of also being present on the Y chromosome in a transcriptional inactive status. Moreover, although ubiquitous, the function of SYBL1 is prominent in specific tissues, such as brain. As a first insight into the molecular mechanisms controlling SYBL1 expression, in this report we describe the extent and role of SYBL1 upstream regions and characterize the binding of trans-acting factors. In vivo foot-printing experiments identify three protected regions. Band shift and transient reporter gene assays indicate a strong role of two of these evolutionary conserved regions in regulating SYBL1 transcription. Because one site is the classical CAAT box, we characterized the binding to the other site of the mammalian homologues of the selenocysteine tRNA gene transcription activating factor (Staf) family, zinc-finger transcription factors, and their role in regulating SYBL1 expression. The results reported here clarify that a Staf-zinc finger family factor, together with the CAAT factor, is the major nuclear protein bound to the SYBL1 promoter region and is responsible for its regulation in HeLa cells, thus identifying the basic control of SYBL1 transcription. In vivo binding of Staf proteins to the SYBL1 promoter is confirmed by chromatin immunoprecipitation assays. Our results identify a fourth mRNA promoter stimulated by a member of the Staf-zinc finger family, the function of which on mRNA polymerase II promoters is still very poorly understood.	CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy; Univ Naples Federico II, Dept Neurosci & Behav Sci, Inst Audiol, I-80131 Naples, Italy; Int Ctr Genet Engn & Biotechnol, I-30142 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Naples Federico II; International Center for Genetic Engineering & Biotechnology (ICGEB)	Franze, A (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, Via P Castellino 111, I-80131 Naples, Italy.	franze@iigb.na.cnr.it	Giacca, Mauro/J-9287-2016; Franzè, Annamaria/V-3837-2019; D'Esposito, Maurizio/AAY-6376-2020; Franze', Annamaria/H-2539-2012	Giacca, Mauro/0000-0003-2927-7225; Franzè, Annamaria/0000-0002-4392-9739; Demarchi, Francesca/0000-0003-1565-3162; Ferrante, Maria Immacolata/0000-0002-8102-8018; DI LEVA, Francesca/0000-0002-6167-0679	Telethon [GGP02308] Funding Source: Medline	Telethon(Fondazione Telethon)		Adachi K, 1998, J BIOL CHEM, V273, P8598, DOI 10.1074/jbc.273.15.8598; DEsposito M, 1996, NAT GENET, V13, P227, DOI 10.1038/ng0696-227; Filippini F, 2001, TRENDS BIOCHEM SCI, V26, P407, DOI 10.1016/S0968-0004(01)01861-8; Fournier C, 2002, EMBO J, V21, P6560, DOI 10.1093/emboj/cdf655; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Hansen RS, 2000, HUM MOL GENET, V9, P2575, DOI 10.1093/hmg/9.18.2575; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Kubota H, 2000, J BIOL CHEM, V275, P28641, DOI 10.1074/jbc.M005009200; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Mach CM, 2002, J BIOL CHEM, V277, P4853, DOI 10.1074/jbc.M108308200; MAJELLO B, 1995, ONCOGENE, V10, P1841; Martinez-Arca S, 2000, J CELL BIOL, V149, P889, DOI 10.1083/jcb.149.4.889; Martinez-Arca S, 2003, P NATL ACAD SCI USA, V100, P9011, DOI 10.1073/pnas.1431910100; Matarazzo MR, 1999, GENE, V240, P233, DOI 10.1016/S0378-1119(99)00375-3; Matarazzo MR, 2002, HUM MOL GENET, V11, P3191, DOI 10.1093/hmg/11.25.3191; MUELLER PR, 1992, CURRENT PROTOCOLS MO; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; RAGOUSSIS J, 1992, GENOMICS, V14, P673, DOI 10.1016/S0888-7543(05)80167-3; Rincon JC, 1998, NUCLEIC ACIDS RES, V26, P4846, DOI 10.1093/nar/26.21.4846; Saur D, 2002, J BIOL CHEM, V277, P25798, DOI 10.1074/jbc.M109802200; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Schuster C, 1998, MOL CELL BIOL, V18, P2650, DOI 10.1128/MCB.18.5.2650; SCHUSTER C, 1995, EMBO J, V14, P3777, DOI 10.1002/j.1460-2075.1995.tb00047.x; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5	28	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7734	7739		10.1074/jbc.M308140200	http://dx.doi.org/10.1074/jbc.M308140200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672948	hybrid			2022-12-27	WOS:000189103300046
J	Olzmann, JA; Brown, K; Wilkinson, KD; Rees, HD; Huai, Q; Ke, HM; Levey, AI; Li, L; Chin, LS				Olzmann, JA; Brown, K; Wilkinson, KD; Rees, HD; Huai, Q; Ke, HM; Levey, AI; Li, L; Chin, LS			Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; INTRACELLULAR PROTEASE; PYROCOCCUS-FURIOSUS; ANDROGEN RECEPTOR; 2 PARTS; GENE; UBIQUITIN; DEGRADATION; FERTILITY	Mutations in DJ-1, a protein of unknown function, were recently identified as the cause for an autosomal recessive, early onset form of familial Parkinson's disease. Here we report that DJ-1 is a dimeric protein that exhibits protease activity but no chaperone activity. The protease activity was abolished by mutation of Cys-106 to Ala, suggesting that DJ-1 functions as a cysteine protease. Our studies revealed that the Parkinson's disease-linked L166P mutation impaired the intrinsic folding propensity of DJ-1 protein, resulting in a spontaneously unfolded structure that was incapable of forming a homodimer with itself or a heterodimer with wild-type DJ-1. Correlating with the disruption of DJ-1 structure, the L166P mutation abolished the catalytic function of DJ-1. Furthermore, as a result of protein misfolding, the L166P mutant DJ-1 was selectively polyubiquitinated and rapidly degraded by the proteasome. Together these findings provide insights into the molecular mechanism by which loss-of-function mutations in DJ-1 lead to Parkinson's disease.	Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Emory University; Emory University; Emory University; University of North Carolina; University of North Carolina Chapel Hill	Li, L (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Ctr Neurodegenerat Dis, 1510 Clifton Rd, Atlanta, GA 30322 USA.	lianli@pharm.emory.edu	Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Chin, Lih-Shen/0000-0002-0817-0368; Olzmann, James/0000-0001-7751-8316; Li, Lian/0000-0003-4700-1134	NIA NIH HHS [AG021489] Funding Source: Medline; NIEHS NIH HHS [ES012068] Funding Source: Medline; NINDS NIH HHS [F31 NS054597-01, F31 NS054597, F31 NS054597-02, NS047199] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U54ES012068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047199, F31NS054597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021489] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Batra R, 2001, NAT STRUCT BIOL, V8, P810, DOI 10.1038/nsb0901-810; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Chin LS, 2002, J BIOL CHEM, V277, P35071, DOI 10.1074/jbc.M203300200; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; DARKE PL, 1994, J BIOL CHEM, V269, P18708; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gwinn-Hardy K, 2002, MOVEMENT DISORD, V17, P645, DOI 10.1002/mds.10173; Hague S, 2003, ANN NEUROL, V54, P271, DOI 10.1002/ana.10663; Halio SB, 1996, J BACTERIOL, V178, P2605, DOI 10.1128/jb.178.9.2605-2612.1996; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jones LJ, 1997, ANAL BIOCHEM, V251, P144, DOI 10.1006/abio.1997.2259; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klinefelter GR, 2002, J ANDROL, V23, P48, DOI 10.1002/jand.2002.23.1.48; Klinefelter GR, 1997, J ANDROL, V18, P139; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; LI L, 1990, BIOCHEMISTRY-US, V29, P5428, DOI 10.1021/bi00475a003; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; McGrath WJ, 2001, BIOCHEMISTRY-US, V40, P13237, DOI 10.1021/bi0111653; McNaught KS, 2003, ANN NEUROL, V53, pS73, DOI 10.1002/ana.10512; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Mizote T, 1999, MICROBIOL-UK, V145, P495, DOI 10.1099/13500872-145-2-495; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Niki T, 2003, MOL CANCER RES, V1, P247; Sastry MSR, 2002, J BIOL CHEM, V277, P46026, DOI 10.1074/jbc.M205800200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Welch JE, 1998, J ANDROL, V19, P385; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100	53	218	225	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8506	8515		10.1074/jbc.M311017200	http://dx.doi.org/10.1074/jbc.M311017200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665635	Green Published, hybrid			2022-12-27	WOS:000189103300134
J	Sekiguchi, T; Todaka, Y; Wang, YG; Hirose, E; Nakashima, N; Nishimoto, T				Sekiguchi, T; Todaka, Y; Wang, YG; Hirose, E; Nakashima, N; Nishimoto, T			A novel human nucleolar protein, Nop132, binds to the G proteins, RRAG A/C/D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; RAN; RCC1; GTPASE; EXCHANGE; GTR1P; PROGRESSION; MECHANISMS; INHIBITOR	RRAG A (Rag A)/Gtr1p is a member of the Ras-like small G protein family that genetically interacts with RCC1, a guanine nucleotide exchange factor for RanGTPase. RRAG A/Gtr1p forms a heterodimer with other G proteins, RRAG C and RRAG D/Gtr2p, in a nucleotide-independent manner. To further elucidate the function of RRAG A/Gtr1p, we isolated a protein that interacts with RRAG A. This protein is a novel nucleolar protein, Nop132. Nop132 is associated with the GTP form, but not the GDP form, of RRAG A, suggesting that RRAG A might regulate Nop132 function. Nop132 is also associated with RRAG C and RRAG D. The Nop132 amino acid sequence is similar to the Saccharomyces cerevisiae nucleolar Nop8p, which is associated with Gtr1p, Gtr2p, and Nip7p. Nop132 also interacts with human Nip7 and is colocalized with RRAG A, RRAG C, and Nip7. RNA interference knockdown of Nop132 inhibited cell growth of HeLa cells.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Sekiguchi, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	sekigu@molbiol.med.kyushu-u.ac.jp	Nakashima, Nobutaka/G-3777-2016	Nakashima, Nobutaka/0000-0002-5836-9148				Azuma Y, 2000, CURR OPIN CELL BIOL, V12, P302, DOI 10.1016/S0955-0674(00)00093-4; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BUN YM, 1992, MOL CELL BIOL, V12, P2958; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Exton JH, 1998, J BIOL CHEM, V273, P19923, DOI 10.1074/jbc.273.32.19923; Heald R, 2000, TRENDS CELL BIOL, V10, P1, DOI 10.1016/S0962-8924(99)01691-8; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Hirose E, 1998, J CELL SCI, V111, P11; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Isaac C, 2001, J CELL SCI, V114, P4253; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Li HN, 2003, J CELL BIOL, V160, P635, DOI 10.1083/jcb.200211004; Li YG, 1997, J VIROL, V71, P1576, DOI 10.1128/JVI.71.2.1576-1582.1997; Lukashok SA, 2000, J VIROL, V74, P4705, DOI 10.1128/JVI.74.10.4705-4709.2000; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Nakashima N, 1999, GENETICS, V152, P853; Nakashima N, 1996, J CELL SCI, V109, P2311; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Nishimoto T, 2000, BIOL CHEM, V381, P397, DOI 10.1515/BC.2000.052; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; Sazer S, 2000, J CELL SCI, V113, P1111; SCHURMANN A, 1995, J BIOL CHEM, V270, P28982, DOI 10.1074/jbc.270.48.28982; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; Sekiguchi T, 1999, ONCOGENE, V18, P1797, DOI 10.1038/sj.onc.1202508; Sekiguchi T, 2001, J BIOL CHEM, V276, P7246, DOI 10.1074/jbc.M004389200; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Zanchin NIT, 1999, MOL CELL BIOL, V19, P1518	34	25	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8343	8350		10.1074/jbc.M305935200	http://dx.doi.org/10.1074/jbc.M305935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660641	hybrid			2022-12-27	WOS:000189103300116
J	Stasyk, OV; Stasyk, OG; Komduur, J; Veenhuis, M; Cregg, JM; Sibirny, AA				Stasyk, OV; Stasyk, OG; Komduur, J; Veenhuis, M; Cregg, JM; Sibirny, AA			A hexose transporter homologue controls glucose repression in the methylotrophic yeast Hansenula polymorpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; SACCHAROMYCES-CEREVISIAE; ALCOHOL OXIDASE; PEROXISOME BIOGENESIS; METHANOL UTILIZATION; REGULATORY MUTANT; GENE ENCODES; PROTEIN; DEGRADATION; CELLS	Peroxisome biogenesis and synthesis of peroxisomal enzymes in the methylotrophic yeast Hansenula polymorpha are under the strict control of glucose repression. We identified an H. polymorpha glucose catabolite repression gene (HpGCR1) that encodes a hexose transporter homologue. Deficiency in GCR1 leads to a pleiotropic phenotype that includes the constitutive presence of peroxisomes and peroxisomal enzymes in glucose-grown cells. Glucose transport and repression defects in a UV-induced gcr1-2 mutant were found to result from a missense point mutation that substitutes a serine residue (Ser(85)) with a phenylalanine in the second predicted transmembrane segment of the Gcr1 protein. In addition to glucose, mannose and trehalose fail to repress the peroxisomal enzyme, alcohol oxidase in gcr1-2 cells. A mutant deleted for the GCR1 gene was additionally deficient in fructose repression. Ethanol, sucrose, and maltose continue to repress peroxisomes and peroxisomal enzymes normally and therefore, appear to have GCR1-independent repression mechanisms in H. polymorpha. Among proteins of the hexose transporter family of baker's yeast, Saccharomyces cerevisiae, the amino acid sequence of the H. polymorpha Gcr1 protein shares the highest similarity with a core region of Snf3p, a putative high affinity glucose sensor. Certain features of the phenotype exhibited by gcr1 mutants suggest a regulatory role for Gcr1p in a repression pathway, along with involvement in hexose transport.	Natl Acad Sci Ukraine, Inst Cell Biol, UA-79005 Lvov, Ukraine; Univ Groningen, Ctr Biol, NL-9750 AA Haren, Netherlands; Keck Grad Inst Appl Life Sci, Claremont, CA 91711 USA; Rzeszow Univ, PL-35310 Rzeszow, Poland	National Academy of Sciences Ukraine; Institute of Cell Biology of NASU; University of Groningen; Claremont Colleges; Keck Graduate Institute; Keck Graduate Institute of Applied Life Sciences; University of Rzeszow	Sibirny, AA (corresponding author), Natl Acad Sci Ukraine, Inst Cell Biol, Drahomanov St 14-16, UA-79005 Lvov, Ukraine.	sibirny@biochem.lviv.ua	Stasyk, Olena/K-9254-2017; Stasyk, Oleh/E-9496-2019	Stasyk, Olena/0000-0002-0253-2372; Stasyk, Oleh/0000-0001-8135-6102; Sibirny, Andriy/0000-0001-8579-1566				Betina S, 2001, GENETICS, V158, P541; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FABER KN, 1994, CURR GENET, V25, P305, DOI 10.1007/BF00351482; GAMO FJ, 1994, J BACTERIOL, V176, P7423, DOI 10.1128/JB.176.24.7423-7429.1994; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GLEESON MA, 1988, YEAST, V4, P293, DOI 10.1002/yea.320040407; Gonchar MV, 1998, BIOSENS BIOELECTRON, V13, P945, DOI 10.1016/S0956-5663(98)00034-7; Gonchar MV, 2001, FOOD TECHNOL BIOTECH, V39, P37; Johnson MA, 1999, GENETICS, V151, P1379; Karp H, 1998, FEMS MICROBIOL LETT, V166, P267, DOI 10.1016/S0378-1097(98)00342-5; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klein CJL, 1998, MICROBIOL-SGM, V144, P13, DOI 10.1099/00221287-144-1-13; Kramarenko T, 2000, FOLIA MICROBIOL, V45, P521, DOI 10.1007/BF02818721; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Madi L, 1997, GENETICS, V146, P499; MAGASANIK B, 1961, COLD SPRING HARB SYM, V26, P249, DOI 10.1101/SQB.1961.026.01.031; MARSHALLCARLSON L, 1990, MOL CELL BIOL, V10, P1105, DOI 10.1128/MCB.10.3.1105; Moroz OM, 2000, BIOTECHNOL BIOENG, V68, P44, DOI [10.1002/(SICI)1097-0290(20000405)68:1&lt;44::AID-BIT5&gt;3.0.CO;2-8, 10.1002/(SICI)1097-0290(20000405)68:1<44::AID-BIT5>3.0.CO;2-8]; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Parpinello G, 1998, J BACTERIOL, V180, P2958, DOI 10.1128/JB.180.11.2958-2967.1998; Reifenberger E, 1997, EUR J BIOCHEM, V245, P324, DOI 10.1111/j.1432-1033.1997.00324.x; ROGGENKAMP R, 1984, MOL GEN GENET, V194, P489, DOI 10.1007/BF00425563; ROGGENKAMP R, 1988, MOL GEN GENET, V213, P535, DOI 10.1007/BF00339627; SAKAI Y, 1987, APPL ENVIRON MICROB, V53, P1812, DOI 10.1128/AEM.53.8.1812-1818.1987; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIBIRNY AA, 1986, UKR BIOKHIM ZH+, V58, P65; SIBIRNY AA, 1987, YEAST, V3, P233, DOI 10.1002/yea.320030404; SIBIRNY AA, 1988, J BASIC MICROB, V28, P293, DOI 10.1002/jobm.3620280503; Stasyk O. V., 1997, Mikrobiologiya, V66, P755; STASYK OV, 1994, FOLIA MICROBIOL, V39, P545, DOI 10.1007/BF02814101; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TITORENKO VI, 1995, J BACTERIOL, V177, P357, DOI 10.1128/jb.177.2.357-363.1995; van Dijk R, 2000, ENZYME MICROB TECH, V26, P793, DOI 10.1016/S0141-0229(00)00173-3; VANDERKLEI IJ, 1990, METHOD ENZYMOL, V188, P420; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757; Veenhuis M, 2000, MICROSC RES TECHNIQ, V51, P584, DOI 10.1002/1097-0029(20001215)51:6<584::AID-JEMT8>3.0.CO;2-W; Walsh MC, 1996, J BACTERIOL, V178, P2593, DOI 10.1128/jb.178.9.2593-2597.1996; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; Ye L, 1999, J BACTERIOL, V181, P4673, DOI 10.1128/JB.181.15.4673-4675.1999	47	42	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8116	8125		10.1074/jbc.M310960200	http://dx.doi.org/10.1074/jbc.M310960200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660581	hybrid, Green Published			2022-12-27	WOS:000189103300092
J	Goel, R; Phillips-Mason, PJ; Gardner, A; Raben, DM; Baldassare, JJ				Goel, R; Phillips-Mason, PJ; Gardner, A; Raben, DM; Baldassare, JJ			alpha-thrombin-mediated phosphatidylinositol 3-kinase activation through release of G beta gamma dimers from G alpha q and G alpha(i2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 1321N1 ASTROCYTOMA-CELLS; PERTUSSIS-TOXIN; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; PHOSPHOLIPASE-C; GENE-EXPRESSION; DNA-SYNTHESIS; LIPID RAFTS; SUBUNITS	Chinese hamster embryonic fibroblasts (IIC9 cells) express the Galpha subunits Galpha(s), Galpha(i2), Galpha(i3), Galpha(o), Galpha(q/11), and Galpha(13). Consistent with reports in other cell types, alpha-thrombin stimulates a subset of the expressed G proteins in IIC9 cells, namely G(i2), G(i3), and G(q) as measured by an in vitro membrane [S-35]guanosine 5'-O-(3-thio)triphosphate binding assay. Using specific Ga peptides, which block coupling of G-protein receptors to selective G proteins, as well as dominant negative xanthine nucleotide-binding Ga mutants, we show that activation of the phosphatidylinositol 3-kinase/Akt pathway is dependent on G(q) and G(i2). To examine the role of the two G proteins, we examined the events upstream of PI 3-kinase. The activation of the PI 3-kinase/Akt pathway by alpha-thrombin in IIC9 cells is blocked by the expression of dominant negative Ras and beta-arrestin1 (Phillips-Mason, P. J., Raben, D. M., and Baldassare, J. J. (2000) J. BioL Chem. 275, 18046-18053, and Goel, R., Phillips-Mason, P. J., Raben, D. M., and Baldassare, J. J. (2002) J. BioL Chem. 277, 18640-18648), indicating a role for Ras and beta-arrestin1. Interestingly, inhibition of G(i2) and G(q) activation blocks Ras activation and beta-arrestin1 membrane translocation, respectively. Furthermore, expression of the Gbetagamma sequestrant, alpha-transducin, inhibits both Ras activation and membrane translocation of beta-arrestin1, suggesting that Gbetagamma dimers from Galpha(i2) and Galpha(q) activate different effectors to coordinately regulate the PI 3-kinase/Akt pathway.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Saint Louis University; Johns Hopkins University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	baldasjj@slu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059251] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BAFFY G, 1994, J BIOL CHEM, V269, P8483; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; Cheng J, 1997, J BIOL CHEM, V272, P17312, DOI 10.1074/jbc.272.28.17312; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Dhanasekaran N, 1998, BIOL SIGNAL RECEPT, V7, P109; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Gardner A, 2002, CELL SIGNAL, V14, P499, DOI 10.1016/S0898-6568(01)00279-0; GARDNER AJ, 1998, THESIS ST LOUIS U ST; Gilchrist A, 1999, J BIOL CHEM, V274, P6610, DOI 10.1074/jbc.274.10.6610; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Goel R, 2002, ANN NY ACAD SCI, V973, P138, DOI 10.1111/j.1749-6632.2002.tb04622.x; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Kanthou C, 1996, CELL SIGNAL, V8, P59, DOI 10.1016/0898-6568(95)02018-7; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Ogino Y, 1996, EUR J PHARMACOL, V316, P105, DOI 10.1016/S0014-2999(96)00653-X; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Scott JK, 2001, EMBO J, V20, P767, DOI 10.1093/emboj/20.4.767; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; Weber JD, 1997, J BIOL CHEM, V272, P17320, DOI 10.1074/jbc.272.28.17320; Windh RT, 2002, METHOD ENZYMOL, V344, P3; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Yu B, 2000, J BIOL CHEM, V275, P71, DOI 10.1074/jbc.275.1.71; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	46	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6701	6710		10.1074/jbc.M308753200	http://dx.doi.org/10.1074/jbc.M308753200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14668344	hybrid			2022-12-27	WOS:000188969200062
J	Ho, RH; Leake, BF; Robertson, RL; Lee, W; Kim, RB				Ho, RH; Leake, BF; Robertson, RL; Lee, W; Kim, RB			Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; ANION UPTAKE SYSTEMS; SALT EXPORT PUMP; EXPRESSION CLONING; RAT HEPATOCYTES; FUNCTIONAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; HUMAN LIVER; SODIUM; TRANSPORTER	The key transporter responsible for hepatic uptake of bile acids from portal circulation is Na+-taurocholate cotransporting polypeptide (NTCP, SLC10A1). This transporter is thought to be critical for the maintenance of enterohepatic recirculation of bile acids and hepatocyte function. Therefore, functionally relevant polymorphisms in this transporter would be predicted to have an important impact on bile acid homeostasis/liver function. However, little is known regarding genetic heterogeneity in NTCP. In this study, we demonstrate the presence of multiple single nucleotide polymorphisms in NTCP in populations of European, African, Chinese, and Hispanic Americans. Specifically four nonsynonymous single nucleotide polymorphisms associated with a significant loss of transport function were identified. Cell surface biotinylation experiments indicated that the altered transport activity of T668C (Ile(223) --> Thr), a variant seen only in African Americans, was due at least in part to decreased plasma membrane expression. Similar expression patterns were observed when the variant alleles were expressed in HepG2 cells, and plasma membrane expression was assessed using immunofluorescence confocal microscopy. Interestingly the C800T (Ser(267) --> Phe) variant, seen only in Chinese Americans, exhibited a near complete loss of function for bile acid uptake yet fully normal transport function for the nonbile acid substrate estrone sulfate, suggesting this position may be part of a region in the transporter critical and specific for bile acid substrate recognition. Accordingly, our study indicates functionally important polymorphisms in NTCP exist and that the likelihood of being carriers of such polymorphisms is dependent on ethnicity.	Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Div Pediat Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Master Sci Clin Invest Program, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Kim, RB (corresponding author), Vanderbilt Univ, Med Ctr, Div Clin Pharmacol, Dept Med, 572 Robinson Res Bldg,23rd Ave & Pierce Ave, Nashville, TN 37232 USA.	richard.kim@vanderbilt.edu	Lee, Wooin/K-7789-2012; Kim, Richard/D-6971-2011	Lee, Wooin/0000-0001-7805-869X; Kim, Richard/0000-0001-8148-1632	NATIONAL CANCER INSTITUTE [K12CA090625, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL065962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304, U01GM061374, R01GM054724, R55GM054724] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, K12-CA90625] Funding Source: Medline; NHLBI NIH HHS [U01 HL65962] Funding Source: Medline; NIDDK NIH HHS [DK20593, DK58404] Funding Source: Medline; NIGMS NIH HHS [GM54724, U01GM61374, GM31304] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Cattori V, 1999, BBA-GENE STRUCT EXPR, V1445, P154, DOI 10.1016/S0167-4781(99)00029-9; CONNOLLY CS, 1995, J AM ACAD DERMATOL, V33, P801, DOI 10.1016/0190-9622(95)91818-3; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; Dawson Paul A., 1995, Current Opinion in Lipidology, V6, P109, DOI 10.1097/00041433-199504000-00009; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Hagenbuch B, 1996, BIOCHEM J, V316, P901, DOI 10.1042/bj3160901; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; Hallen S, 1999, BIOCHEMISTRY-US, V38, P11379, DOI 10.1021/bi990554i; Hofmann A.F., 1998, GASTROINTESTINAL LIV, P937; Jansen PLM, 1999, GASTROENTEROLOGY, V117, P1370, DOI 10.1016/S0016-5085(99)70287-8; Karpen SJ, 1996, J BIOL CHEM, V271, P15211, DOI 10.1074/jbc.271.25.15211; Kim RB, 1999, J PHARMACOL EXP THER, V291, P1204; Koop I, 1996, GUT, V39, P661, DOI 10.1136/gut.39.5.661; Kouzuki H, 1998, J PHARMACOL EXP THER, V286, P1043; Kramer W, 1999, J LIPID RES, V40, P1604; Meier PJ, 1997, HEPATOLOGY, V26, P1667, DOI 10.1002/hep.510260641; Muller M, 1998, J HEPATOL, V28, P344, DOI 10.1016/0168-8278(88)80024-2; Oelkers P, 1997, J CLIN INVEST, V99, P1880, DOI 10.1172/JCI119355; Riepl R L, 1996, Eur J Med Res, V1, P499; Saito S, 2002, J HUM GENET, V47, P576, DOI 10.1007/s100380200088; SCHARSCHMIDT BF, 1981, P NATL ACAD SCI-BIOL, V78, P986, DOI 10.1073/pnas.78.2.986; Shneider BL, 1997, HEPATOLOGY, V25, P1176, DOI 10.1002/hep.510250521; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; St-Pierre MV, 2001, J EXP BIOL, V204, P1673; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Tirona RG, 2001, J BIOL CHEM, V276, P35669, DOI 10.1074/jbc.M103792200; Trauner M, 2003, PHYSIOL REV, V83, P633, DOI 10.1152/physrev.00027.2002; Weinman SA, 1997, YALE J BIOL MED, V70, P331; WONG MH, 1994, J BIOL CHEM, V269, P1340; YAMAZAKI M, 1993, AM J PHYSIOL, V264, pG693, DOI 10.1152/ajpgi.1993.264.4.G693	34	141	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7213	7222		10.1074/jbc.M305782200	http://dx.doi.org/10.1074/jbc.M305782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660639	hybrid			2022-12-27	WOS:000188969200121
J	Sauer, U; Canonaco, F; Heri, S; Perrenoud, A; Fischer, E				Sauer, U; Canonaco, F; Heri, S; Perrenoud, A; Fischer, E			The soluble and membrane-bound transhydrogenases UdhA and PntAB have divergent functions in NADPH metabolism of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDINE-NUCLEOTIDE TRANSHYDROGENASE; CENTRAL CARBON METABOLISM; SACCHAROMYCES-CEREVISIAE; FLUX ANALYSIS; CORYNEBACTERIUM-GLUTAMICUM; NETWORK ANALYSIS; GLUCOSE; GROWTH; MODEL; RESPONSES	Pentose phosphate pathway and isocitrate dehydrogenase are generally considered to be the major sources of the anabolic reductant NADPH. As one of very few microbes, Escherichia coli contains two transhydrogenase isoforms with unknown physiological function that could potentially transfer electrons directly from NADH to NADP(+) and vice versa. Using defined mutants and metabolic flux analysis, we identified the proton-translocating transhydrogenase PntAB as a major source of NADPH in E. coli. During standard aerobic batch growth on glucose, 35-45% of the NADPH that is required for biosynthesis was produced via PntAB, whereas pentose phosphate pathway and isocitrate dehydrogenase contributed 35-45% and 20-25%, respectively. The energy-independent transhydrogenase UdhA, in contrast, was essential for growth under metabolic conditions with excess NADPH formation, i.e. growth on acetate or in a phosphoglucose isomerase mutant that catabolized glucose through the pentose phosphate pathway. Thus, both isoforms have divergent physiological functions: energy-dependent reduction of NADP(+) with NADH by PntAB and reoxidation of NADPH by UdhA. Expression appeared to be modulated by the redox state of cellular metabolism, because genetic and environmental manipulations that increased or decreased NADPH formation down-regulated pntA or udhA transcription, respectively. The two transhydrogenase isoforms provide E. coli primary metabolism with an extraordinary flexibility to cope with varying catabolic and anabolic demands, which raises two general questions: why do only a few bacteria contain both isoforms, and how do other organisms manage NADPH metabolism?	ETH, Inst Biotechnol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Sauer, U (corresponding author), ETH, Inst Biotechnol, CH-8093 Zurich, Switzerland.	sauer@biotech.biol.ethz.ch	Sauer, Uwe/Y-3556-2019; Fischer, Eliane/M-2590-2013	Fischer, Eliane/0000-0002-3399-3737				Bizouarn T, 2002, BBA-BIOENERGETICS, V1555, P122, DOI 10.1016/S0005-2728(02)00266-9; BOLES E, 1993, EUR J BIOCHEM, V217, P469, DOI 10.1111/j.1432-1033.1993.tb18266.x; Boonstra B, 1999, J BACTERIOL, V181, P1030, DOI 10.1128/JB.181.3.1030-1034.1999; Canonaco F, 2001, FEMS MICROBIOL LETT, V204, P247, DOI 10.1111/j.1574-6968.2001.tb10892.x; Chassagnole C, 2002, BIOTECHNOL BIOENG, V79, P53, DOI 10.1002/bit.10288; Christiansen T, 2002, METAB ENG, V4, P159, DOI 10.1006/mben.2001.0219; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; CSONKA LN, 1977, J BIOL CHEM, V252, P3382; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Dauner M, 2001, BIOTECHNOL BIOENG, V76, P144, DOI 10.1002/bit.1154; Edwards JS, 2000, P NATL ACAD SCI USA, V97, P5528, DOI 10.1073/pnas.97.10.5528; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; Emmerling M, 1999, METAB ENG, V1, P117, DOI 10.1006/mben.1998.0109; Fiaux J, 2003, EUKARYOT CELL, V2, P170, DOI 10.1128/EC.2.1.170-180.2003; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Fischer E, 2004, ANAL BIOCHEM, V325, P308, DOI 10.1016/j.ab.2003.10.036; Fischer E, 2003, J BIOL CHEM, V278, P46446, DOI 10.1074/jbc.M307968200; Flores S, 2002, METAB ENG, V4, P124, DOI 10.1006/mben.2001.0209; Forster J, 2003, GENOME RES, V13, P244, DOI 10.1101/gr.234503; FRAENKEL DG, 1968, J BIOL CHEM, V243, P6451; FRAENKEL DG, 1967, J BACTERIOL, V93, P1571, DOI 10.1128/JB.93.5.1571-1578.1967; FRAENKEL DG, 1996, ESCHERICHIA COLI SAL, P189; GEROLIMATOS B, 1978, J BACTERIOL, V134, P394, DOI 10.1128/JB.134.2.394-400.1978; Gottschalk G., 1986, BACTERIAL METABOLISM; HANSON RL, 1980, J BACTERIOL, V141, P401, DOI 10.1128/JB.141.1.401-404.1980; Harold F. M., 1986, VITAL FORCE STUDY BI; HOEK JB, 1988, BIOCHEM J, V254, P1; Holden C, 2002, SCIENCE, V297, P1459; Jackson JB, 1998, BBA-BIOENERGETICS, V1365, P79; LIANG A, 1980, FEBS LETT, V109, P185, DOI 10.1016/0014-5793(80)81082-9; Marx A, 2003, J BIOTECHNOL, V104, P185, DOI 10.1016/S0168-1656(03)00153-6; Marx A, 1999, METAB ENG, V1, P35, DOI 10.1006/mben.1998.0106; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; Nissen TL, 2001, YEAST, V18, P19, DOI 10.1002/1097-0061(200101)18:1<19::AID-YEA650>3.3.CO;2-X; Ouzounis CA, 2000, GENOME RES, V10, P568, DOI 10.1101/gr.10.4.568; Papin JA, 2003, TRENDS BIOCHEM SCI, V28, P250, DOI 10.1016/S0968-0004(03)00064-1; Park SM, 1997, BIOTECHNOL BIOENG, V55, P864, DOI 10.1002/(SICI)1097-0290(19970920)55:6<864::AID-BIT5>3.0.CO;2-E; Pramanik J, 1997, BIOTECHNOL BIOENG, V56, P398, DOI 10.1002/(SICI)1097-0290(19971120)56:4<398::AID-BIT6>3.0.CO;2-J; RUSSELL JB, 1995, MICROBIOL REV, V59, P48, DOI 10.1128/MMBR.59.1.48-62.1995; Sambrook J., 2001, MOL CLONING LAB MANU; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Sauer U, 1997, NAT BIOTECHNOL, V15, P448, DOI 10.1038/nbt0597-448; Schmidt K, 1998, BIOTECHNOL BIOENG, V58, P254, DOI 10.1002/(SICI)1097-0290(19980420)58:2/3<254::AID-BIT19>3.0.CO;2-C; Schmidt K, 1999, J BIOTECHNOL, V71, P175, DOI 10.1016/S0168-1656(99)00021-8; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Stelling J, 2002, NATURE, V420, P190, DOI 10.1038/nature01166; SZYPERSKI T, 1995, EUR J BIOCHEM, V232, P433, DOI 10.1111/j.1432-1033.1995.433zz.x; VOORDOUW G, 1983, EUR J BIOCHEM, V131, P527, DOI 10.1111/j.1432-1033.1983.tb07293.x; WIDMER F, 1977, BIOCHEM BIOPH RES CO, V76, P1287, DOI 10.1016/0006-291X(77)90995-0; Wiechert W, 2001, METAB ENG, V3, P195, DOI 10.1006/mben.2001.0187; Wittmann C, 2002, APPL ENVIRON MICROB, V68, P5843, DOI 10.1128/AEM.68.12.5843-5859.2002; Yang C, 2003, BIOTECHNOL BIOENG, V84, P129, DOI 10.1002/bit.10692; Zamboni N, 2003, FEMS MICROBIOL LETT, V226, P121, DOI 10.1016/S0378-1097(03)00614-1; Zhao J, 2003, J BIOTECHNOL, V101, P101, DOI 10.1016/S0168-1656(02)00316-4	54	399	452	3	96	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6613	6619		10.1074/jbc.M311657200	http://dx.doi.org/10.1074/jbc.M311657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660605	hybrid			2022-12-27	WOS:000188969200050
J	Tsygankova, OM; Feshchenko, E; Klein, PS; Meinkoth, JL				Tsygankova, OM; Feshchenko, E; Klein, PS; Meinkoth, JL			Thyroid-stimulating hormone/cAMP and glycogen synthase kinase 3 beta elicit opposing effects on Rap1GAP stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SCLEROSIS GENE-2 PRODUCT; P70 S6 KINASE; CYCLIC-AMP; BETA-CATENIN; CELL-CYCLE; PROTEASOME INHIBITORS; 3-KINASE/AKT PATHWAY; SIGNALING PATHWAYS; DEPENDENT KINASE	Beyond regulating Rap activity, little is known regarding the regulation and function of the Rap GTPase-activating protein Rap1GAP. Tuberin and E6TP1 protein levels are tightly regulated through ubiquitin-mediated proteolysis. A role for these RapGAPs, along with SPA- 1, as tumor suppressors has been demonstrated. Whether Rap1GAP performs a similar role was investigated. We now report that Rap1GAP protein levels are dynamically regulated in thyroid- stimulating hormone ( TSH)- dependent thyroid cells. Upon TSH withdrawal, Rap1GAP undergoes a net increase in phosphorylation followed by proteasome- mediated degradation. Sequence analysis identified two putative destruction boxes in the Rap1GAP C- terminal domain. Glycogen synthase kinase 3 beta ( GSK3beta) phosphorylated Rap1GAP immunoprecipitated from thyroid cells, and GSK3beta inhibitors prevented phosphorylation and degradation of endogenous Rap1GAP. Co- expression of GSK3beta and Rap1GAP in human embryonic kidney 293 cells stimulated proteasome- dependent Rap1GAP turnover. Mutational analysis established a role for serine 525 in the regulation of Rap1GAP stability. Overexpression of Rap1GAP in thyroid cells impaired TSH/ cAMP-stimulated p70S6 kinase activity and cell proliferation. These data are the first to show that Rap1GAP protein levels are tightly regulated and are the first to support a role for Rap1GAP as a tumor suppressor.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Hematol Oncol, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 164 John Morgan,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	meinkoth@pharm.med.upenn.edu	Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [DK45696] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045696] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Gao QS, 1999, MOL CELL BIOL, V19, P733; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; Hengstschlager M, 2001, MUTAT RES-REV MUTAT, V488, P233, DOI 10.1016/S1383-5742(01)00058-8; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; JANOUEIXLEROSEY I, 1994, BIOCHEM BIOPH RES CO, V202, P967, DOI 10.1006/bbrc.1994.2024; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Leost M, 2000, EUR J BIOCHEM, V267, P5983, DOI 10.1046/j.1432-1327.2000.01673.x; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; Meng JW, 2002, J BIOL CHEM, V277, P43417, DOI 10.1074/jbc.M204074200; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NICE EC, 1992, J BIOL CHEM, V267, P1546; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; PIERCE SB, 1995, DEVELOPMENT, V121, P755; POLAKIS P, 1992, J BIOL CHEM, V267, P10780; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Riedel C, 2001, J BIOL CHEM, V276, P21458, DOI 10.1074/jbc.M100561200; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7	59	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5501	5507		10.1074/jbc.M305824200	http://dx.doi.org/10.1074/jbc.M305824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660640	hybrid			2022-12-27	WOS:000188776500058
J	Wong, SK; Li, WH; Moore, MJ; Choe, H; Farzan, M				Wong, SK; Li, WH; Moore, MJ; Choe, H; Farzan, M			A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE RESPIRATORY SYNDROME; SPIKE GLYCOPROTEIN; RECEPTOR; VIRUS; IDENTIFICATION; EXPRESSION; DOMAIN; ENTRY; SITE	The coronavirus spike (S) protein mediates infection of receptor-expressing host cells and is a critical target for antiviral neutralizing antibodies. Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for the coronavirus (severe acute respiratory syndrome (SARS)-CoV) that causes SARS. Here we demonstrate that a 193-amino acid fragment of the S protein (residues 318-510) bound ACE2 more efficiently than did the full S1 domain (residues 12-672). Smaller S protein fragments, expressing residues 327-510 or 318-490, did not detectably bind ACE2. A point mutation at aspartic acid 454 abolished association of the full S1 domain and of the 193-residue fragment with ACE2. The 193-residue fragment blocked S protein-mediated infection with an IC50 of less than 10 nM, whereas the IC50 of the S1 domain was similar to50 nM. These data identify an independently folded receptor-binding domain of the SARS-CoV S protein.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Partners AIDS Res Ctr, Dept Med Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Pulm Div,Perlmutter Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Farzan, M (corresponding author), Partners AIDS Res Ctr, 65 Landsdowne St, Cambridge, MA 02139 USA.	farzan@mbcrr.harvard.edu		Farzan, Michael/0000-0002-2990-5319; Li, Wenhui/0000-0003-1305-7404				Bannert N, 2000, J VIROL, V74, P10984, DOI 10.1128/JVI.74.23.10984-10993.2000; Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003; Breslin JJ, 2003, J VIROL, V77, P4435, DOI 10.1128/JVI.77.7.4435-4438.2003; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; DVEKSLER GS, 1993, J VIROL, V67, P1; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Jackwood MW, 2001, AVIAN DIS, V45, P366, DOI 10.2307/1592976; KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Sturman L S, 1984, Adv Exp Med Biol, V173, P25; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0	18	513	576	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3197	3201		10.1074/jbc.C300520200	http://dx.doi.org/10.1074/jbc.C300520200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14670965	Green Published, hybrid			2022-12-27	WOS:000188379600009
J	Crack, J; Green, J; Thomson, AJ				Crack, J; Green, J; Thomson, AJ			Mechanism of oxygen sensing by the bacterial transcription factor fumarate-nitrate reduction (FNR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; IRON-SULFUR CENTER; ESCHERICHIA-COLI; AZOTOBACTER-VINELANDII; CRYSTAL-STRUCTURE; REGULATOR FNR; PROTEIN; CLUSTER; DNA; 4FE-4S	The facultative anaerobe Escherichia coli adopts different metabolic modes in response to the availability of oxygen. The global transcriptional regulator FNR (fumarate-nitrate reduction) monitors the availability of oxygen in the environment. Binding as a homodimer to palindromic sequences of DNA, FNR carries a sensory domain, remote from the DNA binding helix-turn-helix motif, which responds to oxygen. The sensing mechanism involves the transformation of a [4Fe-4S](2+) cluster into a [2Fe-2S] form in vitro on reaction with oxygen. Evidence is presented to show that this process proceeds by at least two steps, the first, an oxidative one, being the formation, on reaction with O-2, of a [3Fe-4S](1+) cluster as an intermediate accompanied by the production of hydrogen peroxide. This is followed by a slower, non-redox, pseudo-first order step in which the [3Fe-4S](1+) form converts to a [2Fe-2S](2+) cluster. This must be accompanied by a substantial protein conformational change since the four cysteine ligands that bind the two forms of the FeS clusters have different spatial disposition. Hydrogen peroxide is also an oxidant of the [4Fe-4S](2+), causing a similar cluster transformation to a [2Fe-2S] form. Either the hydrogen peroxide formed on reaction with oxygen can be recycled by intracellular catalase or it can be used to oxidize further Fe-S clusters. In both cases, the efficacy of oxygen sensing by FNR will be increased.	Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of East Anglia; University of Sheffield	Thomson, AJ (corresponding author), Univ E Anglia, Sch Chem Sci & Pharm, Norwich NR4 7TJ, Norfolk, England.	a.thomson@uea.ac.uk		Crack, Jason C./0000-0002-4979-1910				AEBI H, 1984, METHOD ENZYMOL, V105, P121; AGARWAL A, 1995, P NATL ACAD SCI USA, V92, P9440, DOI 10.1073/pnas.92.21.9440; Becker S, 1996, J BACTERIOL, V178, P4515, DOI 10.1128/jb.178.15.4515-4521.1996; Beinert H, 1996, FEBS LETT, V382, P218, DOI 10.1016/0014-5793(96)00140-8; Bes MT, 1999, STRUCT FOLD DES, V7, P1201, DOI 10.1016/S0969-2126(00)80054-4; Busby Stephen, 1996, P255; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Green J, 2001, ADV MICROB PHYSIOL, V44, P1, DOI 10.1016/S0065-2911(01)44010-0; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Green J, 1996, MOL MICROBIOL, V19, P125, DOI 10.1046/j.1365-2958.1996.353884.x; GREEN J, 1991, P ROY SOC B-BIOL SCI, V244, P137, DOI 10.1098/rspb.1991.0062; Guest JR, 1995, PHILOS T R SOC B, V350, P189, DOI 10.1098/rstb.1995.0152; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; MELVILLE SB, 1990, J BIOL CHEM, V265, P18733; Miller J. H., 1972, EXPT MOL GENETICS, P431; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Popescu CV, 1998, P NATL ACAD SCI USA, V95, P13431, DOI 10.1073/pnas.95.23.13431; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHARROCKS AD, 1990, FEBS LETT, V270, P119, DOI 10.1016/0014-5793(90)81248-M; SHAW DJ, 1983, J MOL BIOL, V166, P241, DOI 10.1016/S0022-2836(83)80011-4; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; Tilley GJ, 2001, BIOCHEM J, V360, P717, DOI 10.1042/0264-6021:3600717; Unden G, 1997, MOL MICROBIOL, V25, P205, DOI 10.1046/j.1365-2958.1997.4731841.x; Vogel A. I., 1989, VOGELS TXB PRACTICAL, P395; Wu GH, 2000, J BIOL CHEM, V275, P4679, DOI 10.1074/jbc.275.7.4679; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	37	104	104	2	22	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9278	9286		10.1074/jbc.M309878200	http://dx.doi.org/10.1074/jbc.M309878200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14645253	hybrid			2022-12-27	WOS:000189265900090
J	Kitzing, K; Auweter, S; Amrhein, N; Macheroux, P				Kitzing, K; Auweter, S; Amrhein, N; Macheroux, P			Mechanism of chorismate synthase - Role of the two invariant histidine residues in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANALOGS PROVIDE EVIDENCE; NEUROSPORA-CRASSA; FLAVIN; SUBSTRATE; BINDING; INTERMEDIATE; PHOSPHATE; FMN	Chorismate synthase catalyzes the last step in the common shikimate pathway leading to aromatic compounds such as the aromatic amino acids. The reaction consists of the 1,4-anti-elimination of the 3-phosphate group and the C-(6proR) hydrogen from 5-enolpyruvylshikimate 3-phosphate to yield chorismate. Although this reaction does not involve a net redox change, the enzyme has an absolute requirement for reduced flavin mononucleotide, which is not consumed during the reaction. Two invariant histidine residues are found in the active site of the enzyme: His(17) and His(106). Using site-directed mutagenesis, both histidines were replaced by alanine, reducing the activity 10- and 20-fold in the H106A and H17A mutant protein, respectively. Based on the characterization of the two single mutant proteins, it is proposed that His106 serves to protonate the monoanionic reduced FMN, whereas His(17) protonates the leaving phosphate group of the substrate. An enzymatic reaction mechanism in keeping with the experimental results is presented.	Swiss Fed Inst Technol, Inst Plant Sci, Dept Agr & Food Sci, CH-8092 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Plant Sci, Dept Biol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Macheroux, P (corresponding author), Graz Tech Univ, Inst Biochem, Petersgasse 12-II, A-8010 Graz, Austria.	peter.macheroux@tugraz.at	Macheroux, Peter/AAB-5157-2019	Macheroux, Peter/0000-0002-0242-454X				Bornemann S, 1996, BIOCHEMISTRY-US, V35, P9907, DOI 10.1021/bi952958q; Bornemann S, 2000, BIOORG CHEM, V28, P191, DOI 10.1006/bioo.2000.1174; Bornemann S, 1996, BIOCHEM SOC T, V24, P84, DOI 10.1042/bst0240084; Dmitrenko O, 2001, ORG LETT, V3, P4137, DOI 10.1021/ol0167964; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; DUDLEY KH, 1964, HELV CHIM ACTA, V47, P1354, DOI 10.1002/hlca.19640470531; Fitzpatrick TB, 2001, J BIOL CHEM, V276, P18052, DOI 10.1074/jbc.M100867200; FLOSS HG, 1972, J BIOL CHEM, V247, P736; HALL LH, 1987, INT J QUANTUM CHEM, V31, P217, DOI 10.1002/qua.560310204; HENSTRAND JM, 1995, J BIOL CHEM, V270, P20447, DOI 10.1074/jbc.270.35.20447; Kitzing K, 2001, J BIOL CHEM, V276, P42658, DOI 10.1074/jbc.M107249200; Knaggs AR, 2001, NAT PROD REP, V18, P334, DOI 10.1039/b001717p; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Macheroux P, 1996, BIOCHEMISTRY-US, V35, P1643, DOI 10.1021/bi951705u; Macheroux P, 1999, PLANTA, V207, P325, DOI 10.1007/s004250050489; Macheroux P, 1998, BIOCHEM J, V335, P319, DOI 10.1042/bj3350319; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; MACHEROUX P, 1997, FLAVINS FLAVOPROTEIN, P113; Maclean J, 2003, STRUCTURE, V11, P1499, DOI 10.1016/j.str.2003.11.005; Maniatis T., 1982, MOL CLONING; Massey V., 1991, FLAVINS FLAVOPROTEIN, P581; Miles E W, 1977, Methods Enzymol, V47, P431; MORELL H, 1967, J BIOL CHEM, V242, P82; Osborne A, 2000, J BIOL CHEM, V275, P35825, DOI 10.1074/jbc.M005796200; RAMJEE MN, 1991, J AM CHEM SOC, V113, P8566, DOI 10.1021/ja00022a078; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8	26	26	29	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9451	9461		10.1074/jbc.M312471200	http://dx.doi.org/10.1074/jbc.M312471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668332	hybrid			2022-12-27	WOS:000189265900111
J	Xin, HW; Yoon, HG; Singh, PB; Wong, JM; Qin, J				Xin, HW; Yoon, HG; Singh, PB; Wong, JM; Qin, J			Components of a pathway maintaining histone modification and heterochromatin protein 1 binding at the pericentric heterochromatin in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CANCER-CELLS; DNA METHYLATION; H3 METHYLTRANSFERASE; LYSINE-9 METHYLATION; NEUROSPORA-CRASSA; COMPLEX; HP1; DNMT1; HYPOMETHYLATION; ARABIDOPSIS	Heterochromatin is a higher order chromatin structure that is important for transcriptional silencing, chromosome segregation, and genome stability. The establishment and maintenance of heterochromatin is regulated not only by genetic elements but also by epigenetic elements that include histone tail modification ( e. g. acetylation and methylation) and DNA methylation. Here we show that the p33ING1-Sin3-HDAC complex as well as DNA methyltransferase 1 (DNMT1) and DNMT1-associated protein 1 (DMAP1) are components of a pathway required for maintaining proper histone modification and heterochromatin protein 1 binding at the pericentric heterochromatin. p33ING1 and DMAP1 interact physically and co-localize to heterochromatin in the late S phase, and both are required for heterochromatin protein 1 binding to heterochromatin. Although the p33ING1-Sin3-HDAC and DMAP1-DNMT1 complexes are recruited independently to pericentric heterochromatin regions, they are both required for deacetylation of histones and methylation of histone H3 at lysine 9. These data support a cooperative model for histone deacetylation, methylation, and DNA methylation in maintaining pericentric heterochromatin structure throughout cell divisions.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Roslin Inst Edinburgh, Div Gene Express & Dev, Nucl Reprogramming Lab, Roslin EH25 9PS, Midlothian, Scotland	Baylor College of Medicine; Baylor College of Medicine; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Qin, J (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA.	jqin@bcm.tmc.edu	Singh, Prim/G-1088-2014	Singh, Prim/0000-0002-9571-0974; Xin, Huawei/0000-0003-4017-6572; Wong, Jiemin/0000-0002-5311-842X				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gendrel AV, 2002, SCIENCE, V297, P1871, DOI 10.1126/science.1074950; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Soppe WJJ, 2002, EMBO J, V21, P6549, DOI 10.1093/emboj/cdf657; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Wang Y, 2000, GENE DEV, V14, P927; WAYE JS, 1985, NUCLEIC ACIDS RES, V13, P2731, DOI 10.1093/nar/13.8.2731	26	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9539	9546		10.1074/jbc.M311587200	http://dx.doi.org/10.1074/jbc.M311587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14665632	hybrid			2022-12-27	WOS:000189265900121
J	Zhao, HR; Bernardo, MM; Osenkowski, P; Sohail, A; Pei, DQ; Nagase, H; Kashiwagi, M; Soloway, PD; DeClerck, YA; Fridman, R				Zhao, HR; Bernardo, MM; Osenkowski, P; Sohail, A; Pei, DQ; Nagase, H; Kashiwagi, M; Soloway, PD; DeClerck, YA; Fridman, R			Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-MATRIX METALLOPROTEINASE; HIGH-AFFINITY BINDING; C-TERMINAL DOMAIN; GELATINASE-A; CELL-SURFACE; PROGELATINASE-A; 1-MATRIX METALLOPROTEINASE; PERICELLULAR PROTEOLYSIS; EFFICIENT ACTIVATION; EXPRESSION SYSTEM	The membrane type (MT)-matrix metalloproteinases (MMPs) constitute a subgroup of membrane-anchored MMPs that are major mediators of pericellular proteolysis and physiological activators of pro-MMP-2. The MT-MMPs also exhibit differential inhibition by members of the tissue inhibitor of metalloproteinase ( TIMP) family. Here we investigated the processing, catalytic activity, and TIMP inhibition of MT3-MMP (MMP-16). Inhibitor profile and mutant enzyme studies indicated that MT3-MMP is regulated on the cell surface by autocatalytic processing and ectodomain shedding. Inhibition kinetic studies showed that TIMP-3 is a high affinity inhibitor of MT3-MMP when compared with MT1-MMP (K-i = 0.008 nM for MT3-MMP versus K-i = 0.16 nM for MT1-MMP). In contrast, TIMP-2 is a better inhibitor of MT1-MMP. MT3-MMP requires TIMP-2 to accomplish full pro-MMP-2 activation and this process is enhanced in marimastat-pretreated cells, consistent with regulation of active enzyme turnover by synthetic MMP inhibitors. TIMP-3 also enhances the activation of pro-MMP-2 by MT3-MMP but not by MT1-MMP. TIMP-4, in contrast, cannot support pro-MMP-2 activation with either enzyme. Affinity chromatography experiments demonstrated that pro-MMP-2 can assemble trimolecular complexes with a catalytic domain of MT3-MMP and TIMP-2 or TIMP-3 suggesting that pro-MMP-2 activation by MT3-MMP involves ternary complex formation on the cell surface. These results demonstrate that TIMP-3 is a major regulator of MT3-MMP activity and further underscores the unique interactions of TIMPs with MT-MMPs in the control of pericellular proteolysis.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Univ So Calif, Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Childrens Hosp Los Angeles, Dept Pediat, Los Angeles, CA 90027 USA	Wayne State University; University of Minnesota System; University of Minnesota Twin Cities; Imperial College London; University of Oxford; Cornell University; Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California	Fridman, R (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	rfridman@med.wayne.edu	Soloway, Paul/T-8243-2019	DeClerck, Yves/0000-0002-3688-0113; Sohail, Anjum/0000-0001-5567-9645; Soloway, Paul/0000-0003-1967-0437	NATIONAL CANCER INSTITUTE [R01CA100475, R01CA061986] Funding Source: NIH RePORTER; NCI NIH HHS [CA100475, CA61986] Funding Source: Medline; NIAMS NIH HHS [AR39198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Aznavoorian S, 2001, CANCER RES, V61, P6264; Bernardo MM, 2003, BIOCHEM J, V374, P739, DOI 10.1042/BJ20030557; Bernardo MM, 2002, J BIOL CHEM, V277, P11201, DOI 10.1074/jbc.M111021200; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bigg HF, 2001, CANCER RES, V61, P3610; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P10846, DOI 10.1074/jbc.274.16.10846; Daja MM, 2003, PROSTATE CANCER P D, V6, P15, DOI 10.1038/sj.pcan.4500609; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Fridman R, 2003, CURR TOP DEV BIOL, V54, P75, DOI 10.1016/S0070-2153(03)54005-4; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hernandez-Barrantes S, 2001, BIOCHEM BIOPH RES CO, V281, P126, DOI 10.1006/bbrc.2001.4323; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Jung JC, 2002, DEV DYNAM, V223, P402, DOI 10.1002/dvdy.10069; Kai HST, 2002, J BIOL CHEM, V277, P48696, DOI 10.1074/jbc.M209177200; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2002, CANCER RES, V62, P675; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Kitagawa Y, 1999, J UROLOGY, V162, P905, DOI 10.1097/00005392-199909010-00088; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P18; Ko YC, 1997, BIOCHEM BIOPH RES CO, V236, P100, DOI 10.1006/bbrc.1997.6859; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Murphy G, 2003, BIOCHEM SOC SYMP, V70, P65, DOI 10.1042/bss0700065; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nuttall RK, 2003, MOL CANCER RES, V1, P333; Ohnishi Y, 2001, EUR J DERMATOL, V11, P420; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shofuda K, 1997, J BIOL CHEM, V272, P9749; Shofuda K, 2001, FASEB J, V15, P2010, DOI 10.1096/fj.00-0871fje; Shofuda KI, 2001, ANN NY ACAD SCI, V947, P337; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Toth M, 2003, BIOCHEM BIOPH RES CO, V308, P386, DOI 10.1016/S0006-291X(03)01405-0; Toth M, 1997, CANCER RES, V57, P3159; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; URIA JA, 1994, CANCER RES, V54, P2091; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Worley JR, 2003, BIOCHEM J, V372, P799, DOI 10.1042/BJ20021573; Yoshiyama Y, 1998, ACTA NEUROPATHOL, V96, P347, DOI 10.1007/s004010050904; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	77	119	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8592	8601		10.1074/jbc.M308708200	http://dx.doi.org/10.1074/jbc.M308708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681236	hybrid			2022-12-27	WOS:000189265900010
J	Boukaba, A; Georgieva, EI; Myers, FA; Thorne, AW; Lopez-Rodas, G; Crane-Robinson, C; Franco, L				Boukaba, A; Georgieva, EI; Myers, FA; Thorne, AW; Lopez-Rodas, G; Crane-Robinson, C; Franco, L			A short-range gradient of histone H3 acetylation and Tup1p redistribution at the promoter of the Saccharomyces cerevisiae SUC2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNF1 PROTEIN-KINASE; DNASE-I SENSITIVITY; CHROMATIN-STRUCTURE; GLUCOSE REPRESSION; SWI-SNF; NUCLEOSOME ACETYLATION; INVERTASE SYNTHESIS; YEAST; COMPLEX; TRANSCRIPTION	Chromatin immunoprecipitation assays are used to map H3 and H4 acetylation over the promoter nucleosomes and the coding region of the Saccharomyces cerevisiae SUC2 gene, under repressed and derepressed conditions, using wild type and mutant strains. In wild type cells, a high level of H3 acetylation at the distal end of the promoter drops sharply toward the proximal nucleosome that covers the TATA box, a gradient that become even steeper on derepression. In contrast, substantial H4 acetylation shows no such gradient and extends into the coding region. Overall levels of both H3 and H4 acetylation rise on derepression. Mutation of GCN5 or SNF2 lead to substantially reduced SUC2 expression; in gnc5 there is no reduction in basal H3 acetylation, but large reductions occur on derepression. SNF2 mutation has little effect on H3 acetylation, so SAGA and SWI/SNF recruitment seem to be independent events. H4 acetylation is little affected by either GCN5 or SNF2 mutation. In a double snf2/gcn5 mutant (very low SUC2 expression), H3 acetylation is at the minimal level, but H4 acetylation remains largely unaffected. Transcription is thus linked to H3 but not H4 acetylation. Chromatin immunoprecipitation assays show that Tup1p is evenly distributed over the four promoter nucleosomes in repressed wild type cells but redistributes upstream on derepression, a movement probably linked to its conversion from a repressor to an activator.	Univ Valencia, Dept Biochem & Mol Biol, E-46100 Burjassot, Valencia, Spain; Bulgarian Acad Sci, Inst Genet, BU-1113 Sofia, Bulgaria; Univ Portsmouth, Fac Sci, Inst Biomed & Biomol Sci, Biophys Labs, Portsmouth PO1 2DT, Hants, England	University of Valencia; Bulgarian Academy of Sciences; University of Portsmouth	Franco, L (corresponding author), Univ Valencia, Dept Biochem & Mol Biol, Dr Moliner 50, E-46100 Burjassot, Valencia, Spain.	luis.franco@uv.es	Georgieva, Elena/O-1674-2019; , thorne/AAC-4984-2020; LOPEZ-RODAS, GERARDO/I-1349-2015	, thorne/0000-0002-8670-2358; Myers, Fiona/0000-0001-5568-1817; Franco, Luis/0000-0001-9610-6448; LOPEZ-RODAS, GERARDO/0000-0001-8367-653X				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Bone JR, 2001, J BIOL CHEM, V276, P1808, DOI 10.1074/jbc.M008668200; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Bu Y, 1998, NUCLEIC ACIDS RES, V26, P1002, DOI 10.1093/nar/26.4.1002; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; CARLSON M, 1984, GENETICS, V107, P19; CARLSON M, 1981, GENETICS, V98, P25; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Gavin IM, 1997, EMBO J, V16, P6263, DOI 10.1093/emboj/16.20.6263; Goldstein A, 1975, Methods Enzymol, V42, P504; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IGUAL JC, 1992, MOL MICROBIOL, V6, P1867, DOI 10.1111/j.1365-2958.1992.tb01359.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; Jiang R, 1997, MOL CELL BIOL, V17, P2099, DOI 10.1128/MCB.17.4.2099; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lutfiyya LL, 1998, GENETICS, V150, P1377; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; NEHLIN JO, 1992, NUCLEIC ACIDS RES, V20, P5271, DOI 10.1093/nar/20.20.5271; NEIGEBORN L, 1984, GENETICS, V108, P845; NEIGEBORN L, 1987, GENETICS, V115, P247; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; PEREZORTIN JE, 1986, MOL GEN GENET, V205, P422, DOI 10.1007/BF00338077; PEREZORTIN JE, 1987, NUCLEIC ACIDS RES, V15, P6937; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Recht J, 1999, EMBO J, V18, P229, DOI 10.1093/emboj/18.1.229; Redd MJ, 1997, J BIOL CHEM, V272, P11193; Roberts SM, 1997, GENETICS, V147, P451; Salgado APC, 2002, FEBS LETT, V532, P324, DOI 10.1016/S0014-5793(02)03695-5; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Torres L, 2000, FASEB J, V14, P95, DOI 10.1096/fasebj.14.1.95; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Wu L, 1997, NUCLEIC ACIDS RES, V25, P4230, DOI 10.1093/nar/25.21.4230	55	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7678	7684		10.1074/jbc.M310849200	http://dx.doi.org/10.1074/jbc.M310849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670975	hybrid			2022-12-27	WOS:000189103300039
J	Dairou, J; Atmane, N; Rodrigues-Lima, F; Dupret, JM				Dairou, J; Atmane, N; Rodrigues-Lima, F; Dupret, JM			Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells - A cellular and mechanistic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLTRANSFERASE; NITRIC-OXIDE; ACTIVE-SITE; REVERSIBLE INACTIVATION; COLORECTAL-CARCINOMA; CATALYTIC MECHANISM; MOLECULAR-GENETICS; CREATINE-KINASE; INHIBITION; NITRATION	Arylamine N-acetyltransferases (NATs) play an important role in the detoxification and metabolic activation of a variety of aromatic xenobiotics, including numerous carcinogens. Both of the human isoforms, NAT1 and NAT2, display interindividual variations, and associations between NAT genotypes and cancer risk have been established. Contrary to NAT2, NAT1 has a ubiquitous tissue distribution and has been shown to be expressed in cancer cells. Given that the activity of NAT1 depends on a reactive cysteine that can be a target for oxidants, we studied whether peroxynitrite, a highly reactive nitrogen species involved in human carcinogenesis, could inhibit the activity of endogenous NAT1 in MCF7 breast cancer cells. We show here that exposure of MCF7 cells to physiological concentrations of peroxynitrite and to a peroxynitrite generator (3-morpholinosydnonimine N-ethylcarbamide, or SIN1) leads to the irreversible inactivation of NAT1 in cells. Further kinetic and mechanistic analyses using recombinant NAT1 showed that the enzyme is rapidly (k(inact) = 5 x 10(4) M-1.s(-1)) and irreversibly inactivated by peroxynitrite. This inactivation is due to oxidative modification of the catalytic cysteine. We conclude that the reducing cellular environment of MCF7 cells does not sufficiently protect NAT1 from peroxynitrite-dependent inactivation and that only high concentrations of reduced glutathione could significantly protect NAT1. Thus, cellular generation of peroxynitrite may contribute to carcinogenesis and tumor progression by weakening key cellular defense enzymes such as NAT1.	Univ Paris 06, CNRS, Unite Mixte Rech 7000, F-75013 Paris, France; Univ Paris 07, Unite Format & Rech Biochim, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Rodrigues-Lima, F (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7000, F-75013 Paris, France.	rlima@ext.jussieu.fr; jmdupret@infobiogen.fr						Adam PJ, 2003, MOL CANCER RES, V1, P826; ANDRES HH, 1988, J BIOL CHEM, V263, P7521; Atmane N, 2003, J BIOL CHEM, V278, P35086, DOI 10.1074/jbc.M303813200; BADAWI AF, 1995, CANCER RES, V55, P5230; BLUM M, 1990, DNA CELL BIOL, V9, P193, DOI 10.1089/dna.1990.9.193; Boelsterli, 2003, MECH TOXICOLOGY MOL; Butcher N. J., 2002, Pharmacogenomics Journal, V2, P30, DOI 10.1038/sj.tpj.6500053; Butcher NJ, 2000, MOL PHARMACOL, V57, P468, DOI 10.1124/mol.57.3.468; Butcher NJ, 2000, BIOCHEM PHARMACOL, V60, P1829, DOI 10.1016/S0006-2952(00)00501-3; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Dairou J, 2003, BIOCHEM BIOPH RES CO, V307, P1059, DOI 10.1016/S0006-291X(03)01311-1; DEGUCHI T, 1992, J BIOL CHEM, V267, P18140; Delgoda R, 2003, BBA-GEN SUBJECTS, V1620, P8, DOI 10.1016/S0304-4165(02)00500-7; DUPRET JM, 1992, J BIOL CHEM, V267, P7381; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Giles NM, 2003, BIOCHEM BIOPH RES CO, V300, P1, DOI 10.1016/S0006-291X(02)02770-5; GRANT DM, 1991, MOL PHARMACOL, V39, P184; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; Hein DW, 2002, MUTAT RES-FUND MOL M, V506, P65, DOI 10.1016/S0027-5107(02)00153-7; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Hein DW, 2000, DRUG METAB DISPOS, V28, P1425; Hosker BS, 2001, DIABETOLOGIA, V44, pA144; Ignarro LJ, 1999, BIOSCIENCE REP, V19, P51, DOI 10.1023/A:1020150124721; ILETT KF, 1994, BIOCHEM PHARMACOL, V47, P914, DOI 10.1016/0006-2952(94)90493-6; Josephs M, 2002, FEBS LETT, V531, P329, DOI 10.1016/S0014-5793(02)03551-2; Kondo S, 2002, CANCER LETT, V179, P87, DOI 10.1016/S0304-3835(01)00859-X; Konorev EA, 1998, FEBS LETT, V427, P171, DOI 10.1016/S0014-5793(98)00413-X; Kuhn DM, 1999, J BIOL CHEM, V274, P29726, DOI 10.1074/jbc.274.42.29726; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lin HL, 2003, CHEM RES TOXICOL, V16, P129, DOI 10.1021/tx020040b; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; Maeda H, 1998, BIOCHEMISTRY-MOSCOW+, V63, P854; Matas N, 1997, CYTOGENET CELL GENET, V77, P290, DOI 10.1159/000134601; Meisel P, 2002, PHARMACOGENOMICS, V3, P349, DOI 10.1517/14622416.3.3.349; Mihm MJ, 2002, BIOCHIMIE, V84, P1013, DOI 10.1016/S0300-9084(02)00005-6; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Mushtaq A, 2002, J BIOL CHEM, V277, P12175, DOI 10.1074/jbc.M104365200; Payne CM, 1999, ANTIOXID REDOX SIGN, V1, P449, DOI 10.1089/ars.1999.1.4-449; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; Pompeo F, 2002, PHARMACOGENOMICS, V3, P19, DOI 10.1517/14622416.3.1.19; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Rodrigues-Lima F, 2003, J HISTOCHEM CYTOCHEM, V51, P789, DOI 10.1177/002215540305100610; Rodrigues-Lima F., 2002, Pharmacogenomics Journal, V2, P152, DOI 10.1038/sj.tpj.6500114; Rodrigues-Lima F, 2002, BIOCHEM BIOPH RES CO, V291, P116, DOI 10.1006/bbrc.2002.6414; Rodrigues-Lima F, 2001, BIOCHEM J, V356, P327, DOI 10.1042/0264-6021:3560327; Samoszuk M, 2002, BREAST CANCER RES TR, V74, P271, DOI 10.1023/A:1016328526866; Sandy J, 2002, J MOL BIOL, V318, P1071, DOI 10.1016/S0022-2836(02)00141-9; Sim E, 2000, HUM MOL GENET, V9, P2435, DOI 10.1093/hmg/9.16.2435; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Sinclair JC, 1998, PROTEIN EXPRES PURIF, V12, P371, DOI 10.1006/prep.1997.0856; Singh RJ, 1999, ARCH BIOCHEM BIOPHYS, V361, P331, DOI 10.1006/abbi.1998.1007; Slaviero KA, 2003, LANCET ONCOL, V4, P224, DOI 10.1016/S1470-2045(03)01034-9; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Szaleczky E, 2000, J CLIN GASTROENTEROL, V30, P47, DOI 10.1097/00004836-200001000-00008; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Wong PSY, 2001, ARCH BIOCHEM BIOPHYS, V394, P216, DOI 10.1006/abbi.2001.2532; Wu YL, 1998, FEBS LETT, V440, P111, DOI 10.1016/S0014-5793(98)01415-X	61	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7708	7714		10.1074/jbc.M311469200	http://dx.doi.org/10.1074/jbc.M311469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672957	hybrid			2022-12-27	WOS:000189103300043
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; DRUG-BINDING SITE; CYSTEINE-SCANNING MUTAGENESIS; MULTIDRUG-RESISTANCE; ESCHERICHIA-COLI; FUNCTIONAL CONSEQUENCES; COVALENT MODIFICATION; MUTATIONAL ANALYSIS; PERIPLASMIC LOOPS; LACTOSE PERMEASE	Human P-glycoprotein (P-gp) transports a wide variety of structurally diverse compounds out of the cell. Knowledge about the packing of the transmembrane (TM) segments is essential for understanding the mechanism of drug recognition and transport. We used cysteine-scanning mutagenesis and disulfide cross-linking analysis to determine which TM segment in the COOH half of P-gp was close to TMs 5 and 6 since these segments in the NH2 half are important for drug binding. An active Cys-less P-gp mutant cDNA was used to generate 240 double cysteine mutants that contained 1 cysteine in TMs 5 or 6 and another in TMs 7 or 8. The mutants were subjected to oxidative cross-linking analysis. No disulfide cross-linking was observed in the 140 TM6/TM7 or TM6/TM8 mutants. By contrast, cross-linking was detected in several P-gp TM5/TM8 mutants. At 4degreesC, when thermal motion is low, P-gp mutants N296C(TM5)/G774C(TM8), I299C(TM5)/F770C(TM8), I299C(TM5)/G774C(TM8), and G300C(TM5)/F770C(TM8) showed extensive cross-linking with oxidant. These mutants retained drug-stimulated ATPase activity, but their activities were inhibited after treatment with oxidant. Similarly, disulfide cross-linking was inhibited by vanadate trapping of nucleotide. These results indicate that significant conformational changes must occur between TMs 5 and 8 during ATP hydrolysis. We revised the rotational symmetry model for TM packing based on our results and by comparison to the crystal structure of MsbA (Chang, G. (2003) J. Mol. Biol. 330, 419-430) such that TM5 is adjacent to TM8, TM2 is adjacent to TM11, and TMs 1 and 7 are next to TMs 6 and 12, respectively.	Univ Toronto, Dept Med, Canadian Inst Hlth Res, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	Institute for Work & Health; University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res, Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	david.clarke@utoronto.ca	Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KATZ BA, 1986, J BIOL CHEM, V261, P5480; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P39706, DOI 10.1074/jbc.M308559200; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, BIOCHEM CELL BIOL, V77, P11, DOI 10.1139/bcb-77-1-11; Loo TW, 2003, J BIOL CHEM, V278, P50136, DOI 10.1074/jbc.M310448200; Loo TW, 2003, J BIOL CHEM, V278, P20449, DOI 10.1074/jbc.C300154200; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P27585, DOI 10.1074/jbc.C200330200; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Loo TW, 1998, METHOD ENZYMOL, V292, P480; Omote H, 2002, J BIOL CHEM, V277, P45688, DOI 10.1074/jbc.M206479200; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sun JZ, 1999, BIOCHEMISTRY-US, V38, P3100, DOI 10.1021/bi982360t; Sun JZ, 1998, BIOCHEMISTRY-US, V37, P8020, DOI 10.1021/bi973192s; Thomas Hilary, 2003, Cancer Control, V10, P159; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	62	71	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7692	7697		10.1074/jbc.M311825200	http://dx.doi.org/10.1074/jbc.M311825200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670948	hybrid			2022-12-27	WOS:000189103300041
J	Mattera, R; Ritter, B; Sidhu, SS; McPherson, PS; Bonifacino, JS				Mattera, R; Ritter, B; Sidhu, SS; McPherson, PS; Bonifacino, JS			Definition of the consensus motif recognized by gamma-adaptin ear domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN RECRUITMENT; STRUCTURAL EXPLANATION; APPENDAGE DOMAIN; PHAGE DISPLAY; BINDING; INTERACTS; IDENTIFICATION; SPECIFICITY; EXPRESSION; COMPLEX	The heterotetrameric adaptor complex 1 (AP-1) and the monomeric Golgi-localized, gamma ear-containing, Arf-binding (GGA) proteins are components of clathrin coats associated with the trans-Golgi network and endosomes. The carboxyl-terminal ear domains (or gamma-adaptin ear (GAE) domains) of two gamma-adaptin subunit isoforms of AP-1 and of the GGAs are structurally similar and bind to a common set of accessory proteins. In this study, we have systematically defined a core tetrapeptide motif PsiG(P/D/E)(Psi/L/M) (where Psi is an aromatic residue), which is responsible for the interactions of accessory proteins with GAE domains. The definition of this motif has allowed us to identify novel GAE-binding partners named NECAP and aftiphilin, which also contain clathrin-binding motifs. These findings shed light on the mechanism of accessory protein recruitment to trans-Golgi network and endosomal clathrin coats.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); McGill University; Roche Holding; Genentech	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Ritter, Brigitte/0000-0002-0094-0460; Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aguilar RC, 2001, J BIOL CHEM, V276, P13145, DOI 10.1074/jbc.M010591200; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Collins BM, 2003, NAT STRUCT BIOL, V10, P607, DOI 10.1038/nsb955; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Deshayes K, 2002, CHEM BIOL, V9, P495, DOI 10.1016/S1074-5521(02)00129-1; Duncan MC, 2003, TRENDS CELL BIOL, V13, P211, DOI 10.1016/S0962-8924(03)00076-X; Duncan MC, 2003, NAT CELL BIOL, V5, P77, DOI 10.1038/ncb901; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Kalthoff C, 2002, MOL BIOL CELL, V13, P4060, DOI 10.1091/mbc.E02-03-0171; Kent HM, 2002, STRUCTURE, V10, P1139, DOI 10.1016/S0969-2126(02)00801-8; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Lewin DA, 1998, FEBS LETT, V435, P263, DOI 10.1016/S0014-5793(98)01083-7; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Miller GJ, 2003, NAT STRUCT BIOL, V10, P599, DOI 10.1038/nsb953; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Nogi T, 2002, NAT STRUCT BIOL, V9, P527, DOI 10.1038/nsb808; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Owen DJ, 2001, TRAFFIC, V2, P105, DOI 10.1034/j.1600-0854.2001.020205.x; Page LJ, 1999, J CELL BIOL, V146, P993, DOI 10.1083/jcb.146.5.993; Ritter B, 2003, EMBO REP, V4, P1089, DOI 10.1038/sj.embor.7400004; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	36	51	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8018	8028		10.1074/jbc.M311873200	http://dx.doi.org/10.1074/jbc.M311873200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665628	hybrid			2022-12-27	WOS:000189103300080
J	Baek, SJ; Kim, JS; Nixon, JB; DiAugustine, RP; Eling, TE				Baek, SJ; Kim, JS; Nixon, JB; DiAugustine, RP; Eling, TE			Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE-CELLS; VASCULAR ENDOTHELIAL-CELLS; BREAST-CANCER CELLS; PPAR-GAMMA; TRANSCRIPTION FACTOR; INDUCE APOPTOSIS; CYCLE ARREST; SIGNALING PATHWAY; CARCINOMA CELLS	Troglitazone (TGZ) and 15-deoxy-Delta(12,14) -prostaglandin J(2) (PGJ(2)) are peroxisome proliferator-activated receptor-gamma (PPARgamma) ligands that have been shown to possess pro-apoptotic activity in human colon cancer. Although these compounds bind to PPARgamma transcription factors as agonists, emerging evidence suggests that TGZ acts independently of PPARgamma in many functions, including apoptosis. We previously reported that TGZ induces an early growth response transcription factor (EGR-1) by the ERK phosphorylation pathway rather than by the PPARgamma pathway (Baek, S. J., Wilson, L. C., Hsi, L. C., and Eling, T. E. (2003) J. Biol. Chem. 278, 5845-5853). In this report, we show that the expression of the antitumorigenic and/or pro-apoptotic gene NAG-1 (nonsteroidal anti-inflammatory drug-Activated gene-1) is induced by TGZ and correlates with EGR-1 induction. In cotransfection and gel shift assays, we show that EGR-1-binding sites are located within region -73 to -51 of the NAG-1 promoter and have an important role in the transactivation of TGZ-induced NAG-1 expression. In contrast, PGJ(2) induced NAG-1 protein expression, but PJG(2) may not affect the same region that TGZ does in the NAG-1 promoter. The effect of PGJ(2) is probably PPARgamma-dependent because a PPARgamma antagonist inhibited the PGJ(2)-induced expression of NAG-1. TGZ-induced NAG-1 expression was not inhibited by the PPARgamma antagonist. The fact that TGZ-induced NAG-1 expression was accompanied by the biosynthesis of EGR-1 also suggests that EGR-1 plays a pivotal role in TGZ-induced NAG-1 expression. Our results suggest that EGR-1 induction is a unique property of TGZ, but is independent of PPARgamma activation. The up-regulation of NAG-1 may provide a novel explanation for the antitumorigenic property of TGZ.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Tennessee, Coll Vet Med, Dept Pathobiol, Knoxville, TN 37996 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Eling, TE (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	Eling@niehs.nih.gov		Baek, Seung/0000-0001-7866-7778	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010016, ZIAES010016, Z01ES048005] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andrew SD, 2002, GENE, V298, P9, DOI 10.1016/S0378-1119(02)00919-8; Bae MA, 2003, TOXICOL LETT, V139, P67, DOI 10.1016/S0378-4274(02)00468-X; Baek SJ, 2003, J BIOL CHEM, V278, P5845, DOI 10.1074/jbc.M208394200; Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Calogero A, 2001, CLIN CANCER RES, V7, P2788; Chang TH, 2000, CANCER RES, V60, P1129; Chung SH, 2002, JPN J CANCER RES, V93, P1358, DOI 10.1111/j.1349-7006.2002.tb01245.x; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Davis W, 2003, NUCLEIC ACIDS RES, V31, P1097, DOI 10.1093/nar/gkg192; Eligini S, 2002, THROMB HAEMOSTASIS, V88, P524; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Hattori Y, 1999, HYPERTENSION, V33, P943, DOI 10.1161/01.HYP.33.4.943; Heaney AP, 2002, NAT MED, V8, P1281, DOI 10.1038/nm784; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; Huang RP, 1998, CELL DEATH DIFFER, V5, P96, DOI 10.1038/sj.cdd.4400322; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kim KS, 2002, GASTROENTEROLOGY, V122, P1388, DOI 10.1053/gast.2002.32972; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kubota T, 1998, CANCER RES, V58, P3344; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu T, 2003, CANCER RES, V63, P5034; Masamune A, 2002, PANCREAS, V24, P130, DOI 10.1097/00006676-200203000-00003; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; Muthukkumar S, 1997, J BIOL CHEM, V272, P27987, DOI 10.1074/jbc.272.44.27987; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; Nencioni A, 2002, EXP HEMATOL, V30, P1020, DOI 10.1016/S0301-472X(02)00877-9; Newman D, 2003, MOL PHARMACOL, V63, P557, DOI 10.1124/mol.63.3.557; Nikitakis NG, 2002, BRIT J CANCER, V87, P1396, DOI 10.1038/sj.bjc.6600618; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Okura T, 2000, EUR J PHARMACOL, V407, P227, DOI 10.1016/S0014-2999(00)00758-5; Raychowdhury R, 2002, MOL ENDOCRINOL, V16, P2802, DOI 10.1210/me.2001-0292; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Swirnoff AH, 1998, MOL CELL BIOL, V18, P512, DOI 10.1128/MCB.18.1.512; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; Wang MH, 1999, DIABETES, V48, P254, DOI 10.2337/diabetes.48.2.254; Wilson LC, 2003, INT J CANCER, V105, P747, DOI 10.1002/ijc.11173; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yoshizawa K, 2002, CANCER-AM CANCER SOC, V95, P2243, DOI 10.1002/cncr.10906; Zhang JF, 2002, BIOCHEM BIOPH RES CO, V298, P128, DOI 10.1016/S0006-291X(02)02401-4; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF1216, DOI 10.1152/ajprenal.00426.2002	61	121	126	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6883	6892		10.1074/jbc.M305295200	http://dx.doi.org/10.1074/jbc.M305295200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662774	hybrid			2022-12-27	WOS:000188969200083
J	Heath, C; Cross, NCP				Heath, C; Cross, NCP			Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-1; MYELOPROLIFERATIVE DISORDER FUSES; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; FUSION PROTEINS; CELLS; GENE; APOPTOSIS; LEUKEMIA; FGFR1	The 8p11 myeloproliferative syndrome is an aggressive disorder caused by FGFR1 fusion proteins resulting from a subset of acquired translocations that target chromosome band 8p11. These chimeric proteins have constitutive FGFR1 tyrosine kinase activity and are believed to deregulate hemopoietic development in a manner analogous to BCR-ABL in chronic myeloid leukemia. Here we have studied the role of STAT proteins in transformation mediated by the most common of these fusions, ZNF198-FGFR1. We found that STATs 1, 3, and 5 were activated constitutively in ZNF198-FGFR1-transformed Ba/F3 cells and that STATs 2, 4, and 6 were also tyrosine-phosphorylated. Induction of dominant negative STAT mutants showed that activation of STAT5, but not STATs 1 or 3, was essential for the anti-apoptotic effect of ZNF198-FGFR1 and that STAT5 activation is essential for the elevated levels of BclXL in transformed cells. STAT5 activation was also shown to be required for continued cell cycle progression of BaF3/ZNF198-FGFR1 cells in conditions of cytokine deprivation and for up-regulation of the DNA repair protein Rad51. These findings suggest a critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.	Hammersmith Hosp, Imperial Coll, Fac Med, Dept Haematol, London W12 ONN, England; Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England; Univ Southampton, Sch Med, Div Human Genet, Southampton SO16 6YD, Hants, England	Imperial College London; University of Southampton	Cross, NCP (corresponding author), Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury SP2 8BJ, Wilts, England.	ncpc@soton.ac.uk	Cross, Nicholas/B-4817-2009	Cross, Nicholas/0000-0001-5481-2555				Baumann H, 2003, J BIOL CHEM, V278, P16198, DOI 10.1074/jbc.M300018200; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Demiroglu A, 2001, BLOOD, V98, P3778, DOI 10.1182/blood.V98.13.3778; Fioretos T, 2001, GENE CHROMOSOME CANC, V32, P302, DOI 10.1002/gcc.1195; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; INHORN RC, 1995, BLOOD, V85, P1881, DOI 10.1182/blood.V85.7.1881.bloodjournal8571881; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Macdonald D, 2002, ACTA HAEMATOL-BASEL, V107, P101, DOI 10.1159/000046639; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shuai K, 1996, ONCOGENE, V13, P247; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; Smedley Damian, 1999, Neoplasia (New York), V1, P349, DOI 10.1038/sj.neo.7900035; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84	35	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6666	6673		10.1074/jbc.M308743200	http://dx.doi.org/10.1074/jbc.M308743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660670	hybrid			2022-12-27	WOS:000188969200057
J	Hiromasa, Y; Fujisawa, T; Aso, Y; Roche, TE				Hiromasa, Y; Fujisawa, T; Aso, Y; Roche, TE			Organization of the cores of the mammalian pyruvate dehydrogenase complex formed by E2 and E2 plus the E3-binding protein and their capacities to bind the E1 and E3 components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL TRANSACETYLASE COMPONENT; ACETYLTRANSFERASE COMPONENT; CRYOELECTRON MICROSCOPY; NUCLEOTIDE-SEQUENCE; RECONSTITUTION; EXPRESSION; DOMAINS; KINASE; ACETYLATION; CLEAVAGE	The subunits of the dihydrolipoyl acetyltransferase (E2) component of mammalian pyruvate dehydrogenase complex can form a 60-mer via association of the C-terminal I domain of E2 at the vertices of a dodecahedron. Exterior to this inner core structure, E2 has a pyruvate dehydrogenase component (El)-binding domain followed by two lipoyl domains, all connected by mobile linker regions. The assembled core structure of mammalian pyruvate dehydrogenase complex also includes the dihydrolipoyl dehydrogenase (E3)-binding protein (E3BP) that binds the I domain of E2 by its C-terminal I' domain. E3BP similarly has linker regions connecting an E3-binding domain and a lipoyl domain. The composition of E2.E3BP was thought to be 60 E2 plus similar to12 E3BP. We have prepared homogenous human components. E2 and E2.E3BP have s(20,w) values of 36 S and 31.8 S, respectively. Equilibrium sedimentation and small angle x-ray scattering studies indicate that E2.E3BP has lower total mass than E2, and small angle x-ray scattering showed that E3 binds to E2.E3BP outside the central dodecahedron. In the presence of saturating levels of E1, E2 bound similar to60 E1 and maximally sedimented 64.4 +/- 1.5 S faster than E2, whereas E1-saturated E2.E3BP maximally sedimented 49.5 +/- 1.4 S faster than E2.E3BP. Based on the impact on sedimentation rates by bound E1, we estimate fewer E1 (similar to12) were bound by E2.E3BP than by E2. The findings of a smaller E2.E3BP mass and a lower capacity to bind El support the smaller E3BP substituting for E2 subunits rather than adding to the 60-mer. We describe a substitution model in which 12 I' domains of E3BP replace 12 1 domains of E2 by forming 6 dimer edges that are symmetrically located in the dodecahedron structure. Twelve E3 dimers were bound per E2(48).E3BP(12) mass, which is consistent with this model.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; RIKEN, Harima Inst, Lab Struct Biochem, Hyogo 3410198, Japan; Kyushu Univ, Lab Prot Chem & Engn, Fukuoka 8128581, Japan	Kansas State University; RIKEN; Kyushu University	Roche, TE (corresponding author), Kansas State Univ, Dept Biochem, Willard Hall, Manhattan, KS 66506 USA.	bchter@ksu.edu	Fujisawa, Tetsuro/AAA-5202-2019		NIDDK NIH HHS [DK18320] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK018320, R01DK018320] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS ET, 1962, ULTRACENTRIFUGAL ANA, P119; AMEMIYA Y, 1995, REV SCI INSTRUM, V66, P2290, DOI 10.1063/1.1145667; BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BEHAL RH, 1994, J BIOL CHEM, V269, P31372; BEHAL RH, 1989, P NATL ACAD SCI USA, V86, P8732, DOI 10.1073/pnas.86.22.8732; BLEILE DM, 1981, J BIOL CHEM, V256, P514; CHATELIER RC, 1987, BIOPOLYMERS, V26, P507, DOI 10.1002/bip.360260405; COLE N, 1992, BIOCHIM BIOPHYS ACTA, V1121, P23, DOI 10.1016/0167-4838(92)90332-8; Correia JJ, 2000, METHOD ENZYMOL, V321, P81; DEMARCUCCI O, 1985, EUR J BIOCHEM, V149, P641, DOI 10.1111/j.1432-1033.1985.tb08972.x; Fujisawa T, 1999, J SYNCHROTRON RADIAT, V6, P1106, DOI 10.1107/S0909049599010250; GOPALAKRISHNAN S, 1989, BIOCHEM BIOPH RES CO, V160, P715, DOI 10.1016/0006-291X(89)92492-3; GRAY RA, 1995, A1815A BECKM APPL IN, P1; Guinier A., 1955, SMALL ANGLE SCATTERI; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Hiromasa Y, 2003, J BIOL CHEM, V278, P33681, DOI 10.1074/jbc.M212733200; HODGSON JA, 1986, EUR J BIOCHEM, V158, P595, DOI 10.1111/j.1432-1033.1986.tb09796.x; Izard T, 1999, P NATL ACAD SCI USA, V96, P1240, DOI 10.1073/pnas.96.4.1240; JILKA JM, 1986, J BIOL CHEM, V261, P1858; KIM HJ, 1991, J BIOL CHEM, V266, P9367; Kong YF, 2003, J MOL BIOL, V330, P129, DOI 10.1016/S0022-2836(03)00555-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUE TM, 1996, A1821A BECKM APPL IN, P1; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P11249, DOI 10.1021/bi00111a009; LI L, 1992, ARCH BIOCHEM BIOPHYS, V296, P497, DOI 10.1016/0003-9861(92)90603-T; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MATTEVI A, 1993, BIOCHEMISTRY-US, V32, P3887, DOI 10.1021/bi00066a007; McCartney RG, 1997, BIOCHEMISTRY-US, V36, P6819, DOI 10.1021/bi9630016; MINTON AP, 1995, BIOPHYS CHEM, V57, P65, DOI 10.1016/0301-4622(95)00046-Z; NEAGLE J, 1989, FEBS LETT, V253, P11, DOI 10.1016/0014-5793(89)80919-6; OLIVER RM, 1982, ELECTRON MICROS, V2, P1; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; RAHMATULLAH M, 1987, J BIOL CHEM, V262, P10265; REED LJ, 1990, J BIOL CHEM, V265, P8971; Roche T. E., 1996, CHANNELING INTERMEDI, P115; ROCHE TE, 1993, BIOCHEMISTRY-US, V32, P5629, DOI 10.1021/bi00072a019; Roche TE, 2003, EUR J BIOCHEM, V270, P1050, DOI 10.1046/j.1432-1033.2003.03468.x; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Sanderson SJ, 1996, BIOCHEM J, V319, P109, DOI 10.1042/bj3190109; Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x; SCHACHMAN HK, 1992, ANAL ULTRACENTRIFUGA, P3; Stafford WF, 2000, METHOD ENZYMOL, V323, P302; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; Stoops JK, 1997, J BIOL CHEM, V272, P5757, DOI 10.1074/jbc.272.9.5757; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; TECUNG L, 1995, J BIOL CHEM, V270, P15545; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; Yang DQ, 1997, J BIOL CHEM, V272, P6361, DOI 10.1074/jbc.272.10.6361; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698; Zhou ZH, 2001, J BIOL CHEM, V276, P21704, DOI 10.1074/jbc.M101765200	60	79	91	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6921	6933		10.1074/jbc.M308172200	http://dx.doi.org/10.1074/jbc.M308172200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638692	hybrid			2022-12-27	WOS:000188969200087
J	Whittington, DA; Grubb, JH; Waheed, A; Shah, GN; Sly, WS; Christianson, DW				Whittington, DA; Grubb, JH; Waheed, A; Shah, GN; Sly, WS; Christianson, DW			Expression, assay, and structure of the extracellular domain of murine carbonic anhydrase XIV - Implications for selective inhibition of membrane-associated isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CDNA CLONING; GXXXG MOTIF; PH SHIFTS; WILD-TYPE; MN/CA IX; IV; PURIFICATION; MECHANISM; SUBSTRATE	Carbonic anhydrase (CA) XIV is the most recently identified mammalian carbonic anhydrase isozyme, and its presence has been demonstrated in a number of tissues. Full-length CA XIV is a transmembrane protein composed of an extracellular catalytic domain, a single transmembrane helix, and a short intracellular polypeptide segment. The amino acid sequence identity of human CA XIV relative to the other membrane-associated isozymes (CA IV, CA IX, and CA XII) is 34-46%. We report here the expression and purification of both the full-length enzyme and a truncated, secretory form of murine CA XIV. Both forms of this isozyme are highly active, and both show an abrogation of activity in the presence of 0.2% SDS, in contrast to the behavior of murine CA IV. We also report the crystal structure of the extracellular domain of murine CA XIV at 2.8 Angstrom resolution and of an enzyme-acetazolamide complex at 2.9 Angstrom resolution. The structure shows a monomeric glycoprotein with a topology similar to that of other mammalian CA isozymes. Based on the x-ray crystallographic results, we compare and contrast known structures of membrane-associated CA isozymes to rationalize the structural elements responsible for the SDS resistance of CA IV and to discuss prospects for the design of selective inhibitors of membrane-associated CA isozymes.	St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA	Saint Louis University; University of Pennsylvania	Sly, WS (corresponding author), St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.	slyws@slu.edu; chris@xtal.chem.upenn.edu	Wahhed, Abdul/AAA-3099-2020		NIDDK NIH HHS [DK40163] Funding Source: Medline; NIGMS NIH HHS [GM45614] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045614, R01GM045614] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN JCT, 1992, P NATL ACAD SCI USA, V89, P7786, DOI 10.1073/pnas.89.16.7786; COLEMAN JE, 1967, J BIOL CHEM, V242, P5212; Fokine A, 2002, ACTA CRYSTALLOGR D, V58, P1387, DOI 10.1107/S0907444902010284; Fujikawa-Adachi K, 1999, GENOMICS, V61, P74, DOI 10.1006/geno.1999.5938; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HAKANSSON K, 1994, ACTA CRYSTALLOGR D, V50, P101, DOI 10.1107/S0907444993009667; Hewett-Emmett D, 2000, EXS, V90, P29; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; JEWELL DA, 1991, BIOCHEMISTRY-US, V30, P1484, DOI 10.1021/bi00220a006; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karhumaa P, 2000, MOL HUM REPROD, V6, P68, DOI 10.1093/molehr/6.1.68; Kaunisto K, 2002, KIDNEY INT, V61, P2111, DOI 10.1046/j.1523-1755.2002.00371.x; Kim CY, 2002, J MED CHEM, V45, P888, DOI 10.1021/jm010163d; Kivela A, 2000, AM J PATHOL, V156, P577, DOI 10.1016/S0002-9440(10)64762-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MAREN TH, 1960, J PHARMACOL EXP THER, V130, P26; McKiernan JM, 1997, CANCER RES, V57, P2362; MERZ KM, 1990, J MOL BIOL, V214, P799, DOI 10.1016/0022-2836(90)90333-H; Mori K, 1999, J BIOL CHEM, V274, P15701, DOI 10.1074/jbc.274.22.15701; NAIR SK, 1991, J AM CHEM SOC, V113, P9455, DOI 10.1021/ja00025a005; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 2000, EXS, V90, P79; Parkkila S, 2001, P NATL ACAD SCI USA, V98, P1918, DOI 10.1073/pnas.98.4.1918; Parkkila Seppo, 2002, BMC Gastroenterol, V2, P13, DOI 10.1186/1471-230X-2-13; Pastorekova S, 1997, GASTROENTEROLOGY, V112, P398, DOI 10.1053/gast.1997.v112.pm9024293; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Ponstingl H, 2000, PROTEINS, V41, P47; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Saarnio J, 1998, AM J PATHOL, V153, P279, DOI 10.1016/S0002-9440(10)65569-1; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; Stams T, 1996, P NATL ACAD SCI USA, V93, P13589, DOI 10.1073/pnas.93.24.13589; Stams T, 1998, PROTEIN SCI, V7, P556, DOI 10.1002/pro.5560070303; Sugrue MF, 2000, PROG RETIN EYE RES, V19, P87, DOI 10.1016/S1350-9462(99)00006-3; SUNDARAM V, 1986, AM J HUM GENET, V38, P125; Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025; Tamai S, 1996, P NATL ACAD SCI USA, V93, P13647, DOI 10.1073/pnas.93.24.13647; Tashian RE, 2000, EXS, V90, P105; Tong CK, 2000, GLIA, V31, P125, DOI 10.1002/1098-1136(200008)31:2<125::AID-GLIA40>3.0.CO;2-7; Torcynski R. M., 1996, US Pat., Patent No. 5589579; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Ulmasov B, 2000, P NATL ACAD SCI USA, V97, P14212, DOI 10.1073/pnas.97.26.14212; WALZ W, 1989, CAN J PHYSIOL PHARM, V67, P577, DOI 10.1139/y89-092; Whittington DA, 2001, P NATL ACAD SCI USA, V98, P9545, DOI 10.1073/pnas.161301298; XUE YF, 1993, PROTEINS, V17, P93, DOI 10.1002/prot.340170112; XUE YF, 1993, PROTEINS, V15, P80, DOI 10.1002/prot.340150110; ZHU XL, 1990, J BIOL CHEM, V265, P8795	51	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7223	7228		10.1074/jbc.M310809200	http://dx.doi.org/10.1074/jbc.M310809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660577	hybrid			2022-12-27	WOS:000188969200122
J	Yamada, T; Sato, K; Komachi, M; Malchinkhuu, E; Tobo, M; Kimura, T; Kuwabara, A; Yanagita, Y; Ikeya, T; Tanahashi, Y; Ogawa, T; Ohwada, S; Morishita, Y; Ohta, H; Im, DS; Tamoto, K; Tomura, H; Okajima, F				Yamada, T; Sato, K; Komachi, M; Malchinkhuu, E; Tobo, M; Kimura, T; Kuwabara, A; Yanagita, Y; Ikeya, T; Tanahashi, Y; Ogawa, T; Ohwada, S; Morishita, Y; Ohta, H; Im, DS; Tamoto, K; Tomura, H; Okajima, F			Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTOR; LOW-DENSITY-LIPOPROTEIN; OVARIAN-CANCER; SPHINGOSINE 1-PHOSPHATE; QUANTITATIVE-ANALYSIS; LYSOPHOSPHOLIPASE-D; SIGNALING PATHWAYS; ACTIVATION; INVASION	Cytokines and growth factors in malignant ascites are thought to modulate a variety of cellular activities of cancer cells and normal host cells. The motility of cancer cells is an especially important activity for invasion and metastasis. Here, we examined the components in ascites, which are responsible for cell motility, from patients and cancer cell-injected mice. Ascites remarkably stimulated the migration of pancreatic cancer cells. This response was inhibited or abolished by pertussis toxin, monoglyceride lipase, an enzyme hydrolyzing lysophosphatidic acid (LPA), and Ki16425 and VPC12249, antagonists for LPA receptors (LPA(1) and LPA(3)), but not by an LPA(3)-selective antagonist. These agents also inhibited the response to LPA but not to the epidermal growth factor. In malignant ascites, LPA is present at a high level, which can explain the migration activity, and the fractionation study of ascites by lipid extraction and subsequent thin-layer chromatography indicated LPA as an active component. A significant level of LPA(1) receptor mRNA is expressed in pancreatic cancer cells with high migration activity to ascites but not in cells with low migration activity. Small interfering RNA against LPA(1) receptors specifically inhibited the receptor mRNA expression and abolished the migration response to ascites. These results suggest that LPA is a critical component of ascites for the motility of pancreatic cancer cells and LPA(1), receptors may mediate this activity. LPA receptor antagonists including Ki16425 are potential therapeutic drugs against the migration and invasion of cancer cells.	Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan; Gunma Univ, Grad Sch Med, Dept Lab Med, Maebashi, Gumma 3718511, Japan; Gunma Univ, Grad Sch Med, Dept Surg 2, Maebashi, Gumma 3718511, Japan; Maebashi Red Cross Hosp, Maebashi, Gumma 3710014, Japan; Kirin Brewery Co Ltd, Res Lab, Takasaki, Gumma 3701295, Japan; Pusan Natl Univ, Coll Pharm, Pharmacol Lab, Pusan 609735, South Korea; Hlth Sci Univ Hokkaido, Dept Microbiol, Ishikari, Hokkaido 06102, Japan	Gunma University; Gunma University; Gunma University; Maebashi Red Cross Hospital; Kirin Brewery Company Limited; Pusan National University; Health Sciences University of Hokkaido	Okajima, F (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Lab Signal Transduct, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.	fokajima@showa.gunma-u.ac.jp	Malchinkhuu, Enkhzol/AAH-4600-2019	IM, DONG-SOON/0000-0001-8054-8946; Sato, Koichi/0000-0001-7694-4014; Malchinkhuu, Enkhzol/0000-0003-0744-079X				Aihara Y, 2001, STROKE, V32, P212, DOI 10.1161/01.STR.32.1.212; Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Fishman DA, 2001, CANCER RES, V61, P3194; Goetzl EJ, 1999, CANCER RES, V59, P5370; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heise CE, 2001, MOL PHARMACOL, V60, P1173, DOI 10.1124/mol.60.6.1173; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; KAYAHARA M, 1992, CANCER, V70, P2061, DOI 10.1002/1097-0142(19921015)70:8<2061::AID-CNCR2820700808>3.0.CO;2-V; Keleg S, 2003, MOL CANCER, V2, P1; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Liu CD, 2002, J SURG RES, V102, P31, DOI 10.1006/jsre.2001.6307; Maschberger P, 2000, J BIOL CHEM, V275, P19159, DOI 10.1074/jbc.M910257199; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; NIEDERHUBER JE, 1995, CANCER, V76, P1671, DOI 10.1002/1097-0142(19951101)76:9<1671::AID-CNCR2820760926>3.0.CO;2-R; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; PLANTE M, 1994, CANCER, V73, P1882, DOI 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R; Sato K, 2000, MOL BRAIN RES, V85, P151, DOI 10.1016/S0169-328X(00)00262-X; Sawada K, 2002, CANCER RES, V62, P6015; Shida D, 2003, CANCER RES, V63, P1706; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; Tanyi JL, 2003, CANCER RES, V63, P1073; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 2001, J SOC GYNECOL INVEST, V8, P1, DOI 10.1016/S1071-5576(00)00092-7; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yamada T, 1998, INT J CANCER, V76, P141, DOI 10.1002/(SICI)1097-0215(19980330)76:1<141::AID-IJC22>3.0.CO;2-E; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Zebrowski BK, 1999, CLIN CANCER RES, V5, P3364; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317	46	152	181	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6595	6605		10.1074/jbc.M308133200	http://dx.doi.org/10.1074/jbc.M308133200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660630	hybrid			2022-12-27	WOS:000188969200048
J	Kostyukova, AS; Hitchcock-DeGregori, SE				Kostyukova, AS; Hitchcock-DeGregori, SE			Effect of the structure of the N terminus of tropomyosin on tropomodulin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; ALPHA-TROPOMYOSIN; COILED-COIL; SKELETAL-MUSCLE; POINTED-END; ADP-ACTIN; BINDING; FILAMENTS; DYNAMICS; PROTEIN	Tropomodulins (Tmod) bind to the N terminus of tropomyosin and cap the pointed end of actin filaments. Tropomyosin alone also inhibits the rate of actin depolymerization at the pointed end of filaments. Here we have defined 1) the structural requirements of the N terminus of tropomyosin important for regulating the pointed end alone and with erythrocyte Tmod (Tmod1), and 2) the Tmod1 subdomains required for binding to tropomyosin and for regulating the pointed end. Changes in pyrene-actin fluorescence during polymerization and depolymerization were measured with actin filaments blocked at the barbed end with gelsolin. Three tropomyosin isoforms differently influence pointed end dynamics. Recombinant TM5a, a short non-muscle alpha-tropomyosin, inhibited depolymerization. Recombinant (unacetylated) TM2 and N-acetylated striated muscle TM (stTM), long alpha-tropomyosin isoforms with the same N-terminal sequence, different from TM5a, also inhibited depolymerization but were less effective than TM5a. All blocked the pointed end with Tmod1 in the order of effectiveness TM5a > stTM > TM2, showing the importance of the N-terminal sequence and modification. Tmod1-(1-344), lacking the C-terminal 15 residues, did not nucleate polymerization but blocked the pointed end with all three tropomyosin isoforms as does a shorter fragment, Tmod1-(1-92), lacking the C-terminal "capping" domain though higher concentrations were required. An even shorter fragment, Tmod1-(1-48), bound tropomyosin but did not influence actin filament elongation. Tropomyosin-Tmod may function to locally regulate cytoskeletal dynamics in cells by stabilizing actin filaments.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Kostyukova, AS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA.	kostyuas@umdnj.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063257] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63257] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrianantoandro E, 2001, J MOL BIOL, V312, P721, DOI 10.1006/jmbi.2001.5005; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; BERNSTEIN BW, 1982, CELL MOTIL CYTOSKEL, V2, P1, DOI 10.1002/cm.970020102; Blanchoin L, 2001, CURR BIOL, V11, P1300, DOI 10.1016/S0960-9822(01)00395-5; BROSCHAT KO, 1990, J BIOL CHEM, V265, P21323; BROSCHAT KO, 1989, BIOCHEMISTRY-US, V28, P8501, DOI 10.1021/bi00447a035; Brown JH, 2001, P NATL ACAD SCI USA, V98, P8496, DOI 10.1073/pnas.131219198; Cooper JA, 2002, CURR BIOL, V12, pR523, DOI 10.1016/S0960-9822(02)01028-X; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DesMarais V, 2002, J CELL SCI, V115, P4649, DOI 10.1242/jcs.00147; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FASMAN GD, 1989, PRACTICAL HDB BIOCH, P84; FATTOUM A, 1983, BIOCHEMISTRY-US, V22, P1187, DOI 10.1021/bi00274a031; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; Fowler VM, 1997, SOC GEN PHY, V52, P79; FOWLER VM, 2003, J BIOL CHEM, V14, P14; FUJIME S, 1971, J MOL BIOL, V62, P251, DOI 10.1016/0022-2836(71)90144-6; Geeves Michael A, 2002, Results Probl Cell Differ, V36, P111; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Greenfield NJ, 1998, BIOCHEMISTRY-US, V37, P7834, DOI 10.1021/bi973167m; Greenfield NJ, 2002, BIOPHYS J, V82, P2580, DOI 10.1016/S0006-3495(02)75600-2; Greenfield NJ, 2001, J MOL BIOL, V312, P833, DOI 10.1006/jmbi.2001.4982; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; HITCHCOCKDEGREGORI SE, 1985, BIOCHEMISTRY-US, V24, P3305, DOI 10.1021/bi00334a035; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; Kostyukova A, 2000, EUR J BIOCHEM, V267, P6470, DOI 10.1046/j.1432-1327.2000.01738.x; Kostyukova AS, 2001, BIOPHYS J, V81, P345, DOI 10.1016/S0006-3495(01)75704-9; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Krieger I, 2002, BIOPHYS J, V83, P2716, DOI 10.1016/S0006-3495(02)75281-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer Sherwin S, 2002, Results Probl Cell Differ, V36, P107; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Moraczewska J, 1999, BIOCHEMISTRY-US, V38, P15885, DOI 10.1021/bi991816j; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P6624, DOI 10.1021/bi00344a049; Nyakern-Meazza M, 2002, J BIOL CHEM, V277, P28774, DOI 10.1074/jbc.M203360200; OHTSUKI I, 1982, ADV BIOPHYS, V15, P93, DOI 10.1016/0065-227X(82)90006-5; Ono S, 2002, J CELL BIOL, V156, P1065, DOI 10.1083/jcb.200110013; Percival JM, 2000, CELL MOTIL CYTOSKEL, V47, P189, DOI 10.1002/1097-0169(200011)47:3<189::AID-CM3>3.0.CO;2-C; Perry SV, 2001, J MUSCLE RES CELL M, V22, P5, DOI 10.1023/A:1010303732441; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1986, J CELL BIOCHEM, V31, P87, DOI 10.1002/jcb.240310202; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUNG LA, 1994, BIOCHEM BIOPH RES CO, V201, P627, DOI 10.1006/bbrc.1994.1747; SUSSMAN MA, 1992, EUR J BIOCHEM, V205, P355, DOI 10.1111/j.1432-1033.1992.tb16787.x; Vera C, 2000, ARCH BIOCHEM BIOPHYS, V378, P16, DOI 10.1006/abbi.2000.1802; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; YAMASHIROMATSUMURA S, 1988, J CELL BIOL, V106, P1973, DOI 10.1083/jcb.106.6.1973	60	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5066	5071		10.1074/jbc.M311186200	http://dx.doi.org/10.1074/jbc.M311186200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660556	hybrid			2022-12-27	WOS:000188776500005
J	Miyazaki, K; Fujita, T; Ozaki, T; Kato, C; Kurose, Y; Sakamoto, M; Kato, S; Goto, T; Itoyama, Y; Aoki, M; Nakagawara, A				Miyazaki, K; Fujita, T; Ozaki, T; Kato, C; Kurose, Y; Sakamoto, M; Kato, S; Goto, T; Itoyama, Y; Aoki, M; Nakagawara, A			NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; INTRACYTOPLASMIC HYALINE INCLUSIONS; POSTERIOR COLUMN INVOLVEMENT; SOD1 GENE-MUTATIONS; ENDOPLASMIC-RETICULUM; UNFOLDED PROTEIN; GOLGI-APPARATUS; SPINAL-CORD; DISEASE; ALS	Approximately 20% of familial amyotrophic lateral sclerosis (FALS) arises from germ-line mutations in the superoxide dismutase-1 (SOD1) gene. However, the molecular mechanisms underlying the process have been elusive. Here, we show that a neuronal homologous to E6AP carboxyl terminus (HECT)-type ubiquitin-protein isopeptide ligase (NEDL1) physically binds translocon-associated protein-delta and also binds and ubiquitinates mutant (but not wild-type) SOD1 proportionately to the disease severity caused by that particular mutant. Immunohistochemically, NEDL1 is present in the central region of the Lewy body-like hyaline inclusions in the spinal cord ventral horn motor neurons of both FALS patients and mutant SOD1 transgenic mice. Two-hybrid screening for the physiological targets of NEDL1 has identified Dishevelled-1, one of the key transducers in the Wnt signaling pathway. Mutant SOD1 also interacted with Dishevelled-1 in the presence of NEDL1 and caused its dysfunction. Thus, our results suggest that an adverse interaction among misfolded SOD1, NEDL1, translocon-associated protein-delta, and Dishevelled-1 forms a ubiquitinated protein complex that is included in potentially cytotoxic protein aggregates and that mutually affects their functions, leading to motor neuron death in FALS.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Tottori Univ, Fac Med, Inst Neurol Sci, Div Neuropathol, Yonago, Tottori 6838504, Japan; Hisamitsu Pharmaceut Co Inc, Tokyo 100622, Japan; Tohoku Univ, Sch Med, Dept Neurol, Sendai, Miyagi 9808574, Japan	Chiba Cancer Center; Tottori University; Hisamitsu Pharmaceutical Co Ltd; Tohoku University	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-ccri.chuo.chiba.jp						Andersen PM, 1996, BRAIN, V119, P1153, DOI 10.1093/brain/119.4.1153; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BROCHELT DR, 1994, P NATL ACAD SCI USA, V16, P8292; Brown RH, 2001, SEMIN NEUROL, V21, P131; Cleveland DW, 2000, NAT MED, V6, P1320, DOI 10.1038/82122; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; De Ferrari GV, 2000, BRAIN RES REV, V33, P1, DOI 10.1016/S0165-0173(00)00021-7; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Fujita Y, 2000, J NEUROL SCI, V174, P137, DOI 10.1016/S0022-510X(00)00265-3; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Julien JP, 2000, J NEUROL SCI, V180, P7, DOI 10.1016/S0022-510X(00)00422-6; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kato M, 2001, NEUROSCI LETT, V312, P165, DOI 10.1016/S0304-3940(01)02212-1; Kato S, 1996, J NEUROPATH EXP NEUR, V55, P1089, DOI 10.1097/00005072-199655100-00009; Kato S, 1997, AM J PATHOL, V151, P611; Kato S, 2000, AMYOTROPH LATERAL SC, V1, P163, DOI 10.1080/14660820050515160; Kaytor MD, 2002, CURR OPIN NEUROBIOL, V12, P275, DOI 10.1016/S0959-4388(02)00320-3; Keller JN, 2000, NEUROSCIENCE, V98, P149, DOI 10.1016/S0306-4522(00)00067-1; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kunst CB, 1997, NAT GENET, V15, P91, DOI 10.1038/ng0197-91; Luo ZG, 2002, NEURON, V35, P489, DOI 10.1016/S0896-6273(02)00783-3; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nagai M, 2001, J NEUROSCI, V21, P9246, DOI 10.1523/JNEUROSCI.21-23-09246.2001; Nakagawara A, 1998, MED PEDIATR ONCOL, V31, P113, DOI 10.1002/(SICI)1096-911X(199808)31:2<113::AID-MPO14>3.0.CO;2-O; Niwa J, 2002, J BIOL CHEM, V277, P36793, DOI 10.1074/jbc.M206559200; OGASAWARA M, 1993, NAT GENET, V5, P323, DOI 10.1038/ng1293-323; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Orrell RW, 2001, NEUROLOGY, V57, P9, DOI 10.1212/WNL.57.1.9; Orrell RW, 2000, NEUROMUSCULAR DISORD, V10, P63, DOI 10.1016/S0960-8966(99)00071-1; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tsang M, 1996, DEV DYNAM, V207, P253, DOI 10.1002/(SICI)1097-0177(199611)207:3<253::AID-AJA2>3.0.CO;2-G; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	46	133	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11327	11335		10.1074/jbc.M312389200	http://dx.doi.org/10.1074/jbc.M312389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14684739	hybrid			2022-12-27	WOS:000220157600061
J	Yuasa, K; Fukumoto, S; Kamasaki, Y; Yamada, A; Fukumoto, E; Kanaoka, K; Saito, K; Harada, H; Arikawa-Hirasawa, E; Miyagoe-Suzuki, Y; Takeda, S; Okamoto, K; Kato, Y; Fujiwara, T				Yuasa, K; Fukumoto, S; Kamasaki, Y; Yamada, A; Fukumoto, E; Kanaoka, K; Saito, K; Harada, H; Arikawa-Hirasawa, E; Miyagoe-Suzuki, Y; Takeda, S; Okamoto, K; Kato, Y; Fujiwara, T			Laminin alpha 2 is essential for odontoblast differentiation regulating dentin sialoprotein expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; LINKED AMELOGENESIS IMPERFECTA; TOOTH DEVELOPMENT; TARGETED DISRUPTION; MUTANT MICE; IN-VIVO; GENE; MEROSIN; MOUSE; BINDING	Laminin alpha2 is subunit of laminin-2 (alpha2beta1gamma1), which is a major component of the muscle basement membrane. Although the laminin alpha2 chain is expressed in the early stage of dental mesenchyme development and localized in the tooth germ basement membrane, its expression pattern in the late stage of tooth germ development and molecular roles are not clearly understood. We analyzed the role of laminin alpha2 in tooth development by using targeted mice with a disrupted lama2 gene. Laminin alpha2 is expressed in dental mesenchymal cells, especially in odontoblasts and during the maturation stage of ameloblasts, but not in the pre-secretory or secretory stages of ameloblasts. Lama2 mutant mice have thin dentin and a widely opened dentinal tube, as compared with wildtype and heterozygote mice, which is similar to the phenotype of dentinogenesis imperfecta. During dentin formation, the expression of dentin sialoprotein, a marker of odontoblast differentiation, was found to be decreased in odontoblasts from mutant mice. Furthermore, in primary cultures of dental mesenchymal cells, dentin matrix protein, and dentin sialophosphoprotein, mRNA expression was increased in laminin-2 coated dishes but not in those coated with other matrices, fibronectin, or type I collagen. Our results suggest that laminin alpha2 is essential for odontoblast differentiation and regulates the expression of dentin matrix proteins.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Pediat Dent, Nagasaki 8528588, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Publ Hlth, Div Oral Hlth Serv Res, Nagasaki 8528588, Japan; Osaka Univ, Grad Sch Dent, Dept Oral Anat & Dev Biol, Suita, Osaka 5650871, Japan; Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Therapy, Tokyo 1878502, Japan	Nagasaki University; Nagasaki University; Osaka University; Juntendo University; National Center for Neurology & Psychiatry - Japan	Fukumoto, S (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Dev & Reconstruct Med, Div Pediat Dent, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	satoshi@dh.nagasaki-u.ac.jp	Saito, Kan/AAG-3507-2020; Saito, Kan/AFS-5564-2022	Saito, Kan/0000-0002-2151-6204; Saito, Kan/0000-0002-2151-6204; Fukumoto, Satoshi/0000-0002-5046-6891				Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; Boskey AL, 1997, CALCIFIED TISSUE INT, V61, P298, DOI 10.1007/s002239900339; BROWN JC, 1994, J CELL SCI, V107, P329; Cerny R, 1996, J BONE MINER RES, V11, P883; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; Deutsch, 1998, CONNECT TISSUE RES, V39, P141; Diekwisch TGH, 1997, J HISTOCHEM CYTOCHEM, V45, P859, DOI 10.1177/002215549704500610; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Fong C D, 1996, Adv Dent Res, V10, P195; Fukumoto E, 2003, J DENT RES, V82, P17, DOI 10.1177/154405910308200105; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Hoshi K, 1999, J BONE MINER RES, V14, P273, DOI 10.1359/jbmr.1999.14.2.273; Kawano S, 2002, CONNECT TISSUE RES, V43, P409, DOI 10.1080/03008200290000637; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; KUKITA A, 1992, CALCIFIED TISSUE INT, V51, P393, DOI 10.1007/BF00316886; LAGERSTROM M, 1991, GENOMICS, V10, P971, DOI 10.1016/0888-7543(91)90187-J; Lee SK, 1996, INT J DEV BIOL, V40, P1141; LENCH NJ, 1995, HUM MUTAT, V5, P251, DOI 10.1002/humu.1380050310; LESOT H, 1981, DEV BIOL, V82, P371, DOI 10.1016/0012-1606(81)90460-7; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1997, GENOMICS, V41, P115, DOI 10.1006/geno.1997.4643; Miyagoe Y, 1997, FEBS LETT, V415, P33, DOI 10.1016/S0014-5793(97)01007-7; Miyagoe-Suzuki Y, 2000, MICROSC RES TECHNIQ, V48, P181, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<181::AID-JEMT6>3.0.CO;2-Q; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Pall EA, 1996, J BIOL CHEM, V271, P3817; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Ruch J V, 1987, Revis Biol Celular, V14, P1; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Salmivirta K, 1998, ANN NY ACAD SCI, V857, P279, DOI 10.1111/j.1749-6632.1998.tb10132.x; Salmivirta K, 1997, DEV DYNAM, V210, P206, DOI 10.1002/(SICI)1097-0177(199711)210:3<206::AID-AJA2>3.3.CO;2-S; SCHULER F, 1995, J CELL SCI, V108, P3795; Sewry CA, 1998, NEUROPATH APPL NEURO, V24, P66; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; Smith CE, 1998, CONNECT TISSUE RES, V39, P75, DOI 10.3109/03008209809023914; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; THESLEFF I, 1981, DEV BIOL, V81, P182, DOI 10.1016/0012-1606(81)90361-4; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	52	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10286	10292		10.1074/jbc.M310013200	http://dx.doi.org/10.1074/jbc.M310013200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681233	hybrid			2022-12-27	WOS:000220050400077
J	Brdlik, CM; Crews, CM				Brdlik, CM; Crews, CM			A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS INHIBITOR TNP-470; ESCHERICHIA-COLI; PHASE-I; FUMAGILLIN; YEAST; GENE; EXPRESSION; AGM-1470; ANALOGS	TNP-470, the first anti-angiogenic small molecule to enter clinical trials, targets methionine aminopeptidase-2 (MetAP-2), a metalloprotease that cleaves the N-terminal methionine of proteins. Previously, biochemical binding, in vivo yeast studies, and structural studies of human methionine aminopeptidase-2 bound to TNP-470 and its analogs fumagillin and ovalicin revealed that these compounds exhibit specificity for MetAP-2 over its family member MetAP-1. To further elucidate the nature of this specificity, we developed a yeast-based screen for human MetAP-2 mutations that confer ovalicin resistance. Of the three resistant alleles, A362T appeared in the majority of clones and was found to be the most resistant to the ovalicin class of inhibitors. Alignment of human MetAP-2 with human MetAP-1, which is naturally ovalicin-resistant, revealed that the analogous residue in MetAP-1 is also a threonine. Mutation of this residue to alanine resulted in an ovalicin-sensitive MetAP-1 allele, demonstrating that an alanine at this position is critical for inhibition by ovalicin. These results provide a molecular explanation for the specificity exhibited by this class of anti-angiogenic agents for MetAP-2 over MetAP-1 and may prove useful in the development of additional MetAP-2-specific therapeutic agents.	Yale Univ, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Crews, CM (corresponding author), 219 Prospect St, New Haven, CT 06520 USA.	craig.crews@yale.edu	Crews, Craig M./ABH-9346-2020	Crews, Craig M./0000-0002-8456-2005	NATIONAL CANCER INSTITUTE [R01CA083049] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83049, R01 CA083049-05S1, R01 CA083049] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; Baldwin JE, 2002, TETRAHEDRON, V58, P5441, DOI 10.1016/S0040-4020(02)00514-8; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; CHANG SYP, 1989, J BACTERIOL, V171, P4071, DOI 10.1128/jb.171.7.4071-4072.1989; CHANG YH, 1992, J BIOL CHEM, V267, P8007; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; Dezube BJ, 1998, J CLIN ONCOL, V16, P1444, DOI 10.1200/JCO.1998.16.4.1444; Dummitt B, 2002, PROTEIN PEPTIDE LETT, V9, P295, DOI 10.2174/0929866023408607; FINK G, 1991, METHODS ENZYMOL GUID, V194, P322; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Griffith EC, 1997, CHEM BIOL, V4, P461, DOI 10.1016/S1074-5521(97)90198-8; Han CK, 2000, BIOORG MED CHEM LETT, V10, P39, DOI 10.1016/S0960-894X(99)00577-6; HIETER P, 1985, CELL, V42, P913, DOI 10.1016/0092-8674(85)90287-9; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Kruger EA, 2000, EXPERT OPIN INV DRUG, V9, P1383, DOI 10.1517/13543784.9.6.1383; Kudelka AP, 1997, CLIN CANCER RES, V3, P1501; KUSAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P1070, DOI 10.1016/0006-291X(91)91529-L; Kwon JY, 2000, J ANTIBIOT, V53, P799, DOI 10.7164/antibiotics.53.799; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Lowther WT, 1998, P NATL ACAD SCI USA, V95, P12153, DOI 10.1073/pnas.95.21.12153; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; OREILLY MS, 1995, J PEDIATR SURG, V30, P325, DOI 10.1016/0022-3468(95)90583-9; PEACOCK DJ, 1995, CELL IMMUNOL, V160, P178, DOI 10.1016/0008-8749(95)80025-E; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shusterman S, 2001, CLIN CANCER RES, V7, P977; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Son KH, 2002, BIOORGAN MED CHEM, V10, P185, DOI 10.1016/S0968-0896(01)00268-1; Stadler WM, 1999, J CLIN ONCOL, V17, P2541, DOI 10.1200/JCO.1999.17.8.2541; Wang JY, 2003, BIOCHEMISTRY-US, V42, P5035, DOI 10.1021/bi020670c; Weisman R, 2001, J BIOL CHEM, V276, P24736, DOI 10.1074/jbc.M102090200	37	19	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9475	9480		10.1074/jbc.M307246200	http://dx.doi.org/10.1074/jbc.M307246200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676204	Green Accepted, hybrid			2022-12-27	WOS:000189265900113
J	Mawji, IA; Robb, GB; Tai, SC; Marsden, PA				Mawji, IA; Robb, GB; Tai, SC; Marsden, PA			Role of the 3 '-untranslated region of human endothelin-1 in vascular endothelial cells - Contribution to transcript lability and the cellular heat shock response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; GATA-BINDING PROTEIN; AU-RICH ELEMENTS; GENE-EXPRESSION; SELECTIVE DEGRADATION; INDUCTION; SEQUENCE; APOPTOSIS; TURNOVER	Endothelin-1 (ET-1) is a potent vasoconstrictor peptide expressed in the vascular endothelium. Stringent control over ET-1 expression is achieved through a highly regulated promoter and rapid mRNA turnover. Since little is known about mechanisms governing ET-1 post-transcriptional regulation, and changes in ET-1 mRNA stability are implicated in disease processes, we characterized these pathways using a variety of functional approaches. We expressed human ET-1 and luciferase transcripts with or without a wild type ET-1 3'-untranslated region (3'-UTR) and found that the 3'-UTR had potent mRNA destabilizing activity. Deletion analysis localized this activity to two domains of the 3'-UTR we have termed destabilizing elements 1 and 2 (DE1 and DE2). Mutational studies revealed that DE1 functions as an AU-rich element (ARE) dependent on a 100-nucleotide region. This activity was further localized to a 10-nucleotide region at position 978 - 987 of the 3'-UTR. Depletion of AUF1 by RNA interference up-regulated ET-1 in endothelial cells suggesting AUF1-dependent regulation. Since AUF1 functions through the ubiquitin-proteasome pathway, we disrupted this pathway with heat shock and proteasome inhibitor in endothelial cells and observed stabilization of endogenous ET-1 mRNA. Chimeric transcripts bearing wild type ET-1 3'-UTRs were also stabilized in response to proteasome inhibition whereas DE1 mutants failed to respond. Taken together, these findings suggest a complex model of ARE-mediated mRNA turnover dependent on two 3'-UTR domains, DE1 and DE2. Furthermore, DE1 functions as an ARE directing mRNA half-life through the proteasome. Finally, this data provides evidence for a novel pathway of ET-1 mRNA stabilization by heat shock.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; St Michaels Hosp, Div Renal, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Marsden, PA (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Med Sci Bldg,Rm 7358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	p.marsden@utoronto.ca	Marsden, Philip A/B-1441-2012	Robb, Gregory Brett/0000-0002-2382-2256				BERBERIAN PA, 1990, AM J PATHOL, V136, P71; Bitzan MM, 1998, J CLIN INVEST, V101, P372, DOI 10.1172/JCI522; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; Douthwaite JA, 2003, BIOCHEM PHARMACOL, V66, P589, DOI 10.1016/S0006-2952(03)00336-8; Gan LM, 2000, CARDIOVASC RES, V48, P168, DOI 10.1016/S0008-6363(00)00174-7; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; HORIE M, 1991, J CARDIOVASC PHARM, V17, pS222, DOI 10.1097/00005344-199100177-00064; INOUE A, 1989, J BIOL CHEM, V264, P14954; IWASAKI S, 1995, J BIOL CHEM, V270, P6997, DOI 10.1074/jbc.270.12.6997; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Jarrousse AS, 1999, J BIOL CHEM, V274, P5925, DOI 10.1074/jbc.274.9.5925; JORNOT L, 1991, AM J RESP CELL MOL, V5, P265, DOI 10.1165/ajrcmb/5.3.265; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; KETIS NV, 1988, CANCER RES, V48, P2101; Knapp M, 1998, FEBS LETT, V434, P108, DOI 10.1016/S0014-5793(98)00961-2; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Laroia G, 2002, P NATL ACAD SCI USA, V99, P1842, DOI 10.1073/pnas.042575699; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; LEE ME, 1991, J BIOL CHEM, V266, P16188; Lee SD, 2000, PULM PHARMACOL THER, V13, P257, DOI 10.1006/pupt.2000.0252; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1992, AM J PHYSIOL, V262, pC854, DOI 10.1152/ajpcell.1992.262.4.C854; Mawji IA, 2003, MICROSC RES TECHNIQ, V60, P46, DOI 10.1002/jemt.10242; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Moffat GJ, 1997, BIOCHEM J, V324, P91, DOI 10.1042/bj3240091; Moraes KCM, 2003, BIOL CHEM, V384, P25, DOI 10.1515/BC.2003.004; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Ochoa TJ, 2003, CURR OPIN INFECT DIS, V16, P259, DOI 10.1097/00001432-200306000-00013; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Prokipcak RD, 1999, BIOCHEM BIOPH RES CO, V261, P627, DOI 10.1006/bbrc.1999.1101; RAJAGOPALAN LE, 1995, BLOOD, V86, P2551; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Santoro MG, 2000, BIOCHEM PHARMACOL, V59, P55, DOI 10.1016/S0006-2952(99)00299-3; Sarkar B, 2003, MOL CELL BIOL, V23, P6685, DOI 10.1128/MCB.23.18.6685-6693.2003; SCHEPER W, 1995, MOL CELL BIOL, V15, P235, DOI 10.1128/MCB.15.1.235; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; Sonna LA, 2002, J APPL PHYSIOL, V92, P1725, DOI 10.1152/japplphysiol.01143.2001; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilson GM, 2003, J BIOL CHEM, V278, P33039, DOI 10.1074/jbc.M305775200; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wong HR, 1996, AM J RESP CELL MOL, V15, P745, DOI 10.1165/ajrcmb.15.6.8969269; Wu-Wong JR, 1997, BIOCHEM J, V328, P733, DOI 10.1042/bj3280733; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZUMI M, 1990, BIOCHEM BIOPH RES CO, V166, P324, DOI 10.1016/0006-291X(90)91948-R; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhu WM, 1996, ARTERIOSCL THROM VAS, V16, P1104, DOI 10.1161/01.ATV.16.9.1104	71	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8655	8667		10.1074/jbc.M312190200	http://dx.doi.org/10.1074/jbc.M312190200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660616	hybrid			2022-12-27	WOS:000189265900018
J	Tan, BCM; Lee, SC				Tan, BCM; Lee, SC			Nek9, a novel FACT-associated protein, modulates interphase progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION-FACTORS; DNA-POLYMERASE ALPHA; KINASE AURORA-A; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; POB3; COMPLEX; SPT16; INTERACTS; SSRP1	The heterodimeric Spt16-Pob3/DUF/FACT complex is a class of chromatin structure modulators with important roles in replication and transcription. Although regarded as a transcription elongator for chromatin template, little is known about the mode of action and involvement in other molecular processes of the mammalian FACT. Here we report the identification of a novel interacting and functional partner of FACT, Nek9. Nek9 forms a stable, similar to600-kDa complex with FACT in the interphase nuclei. Its active form is characterized by phosphorylation-dependent electrophoretic mobility shift and phosphorylation at a conserved residue within the activation loop (Thr(210)). When complexed with FACT, Nek9 exhibits markedly elevated phosphorylation on Thr(210). Cell cycle analysis on the Nek9(dsRNAi) cells directly implicated Nek9 in maintaining proper G(1) and S progression, a role temporally correlated to the formation of a phospho-Nek9-FACT complex. Collectively, these observations provide evidence that Nek9, potentially as an active enzymatic partner of FACT, mediates certain FACT-associated cellular processes, which are ultimately essential for interphase progression.	Natl Taiwan Univ, Coll Med, Sch Med, Inst Mol Med, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Inst Clin Med, Taipei 10018, Taiwan; Acad Sinica, Inst Biol Chem, Taipei, Taiwan	National Taiwan University; National Taiwan University; Academia Sinica - Taiwan	Lee, SC (corresponding author), Natl Taiwan Univ, Coll Med, Sch Med, Inst Mol Med, 7 Chung Shan S Rd, Taipei 10018, Taiwan.	slee@ccms.ntu.edu.tw		Tan, Bertrand/0000-0002-2218-7115				Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; Evans DRH, 1998, GENETICS, V150, P1393; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Formosa T, 2002, GENETICS, V162, P1557; Holland PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/jbc.M108662200; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; John S, 2000, GENE DEV, V14, P1196; Kang SW, 2000, GENES CELLS, V5, P251, DOI 10.1046/j.1365-2443.2000.00323.x; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; Schlesinger MB, 2000, GENETICS, V155, P1593; Seo H, 2003, BIOCHEM BIOPH RES CO, V303, P8, DOI 10.1016/S0006-291X(03)00307-3; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Tsay YG, 2000, ANAL BIOCHEM, V287, P55, DOI 10.1006/abio.2000.4837; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553	26	40	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9321	9330		10.1074/jbc.M311477200	http://dx.doi.org/10.1074/jbc.M311477200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660563	hybrid			2022-12-27	WOS:000189265900095
J	Botos, I; Melnikov, EE; Cherry, S; Tropea, JE; Khalatova, AG; Rasulova, F; Dauter, Z; Maurizi, MR; Rotanova, TV; Wlodawer, A; Gustchina, A				Botos, I; Melnikov, EE; Cherry, S; Tropea, JE; Khalatova, AG; Rasulova, F; Dauter, Z; Maurizi, MR; Rotanova, TV; Wlodawer, A; Gustchina, A			The catalytic domain of Escherichia coli Lon protease has a unique fold and a Ser-Lys dyad in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; BACTERIAL SIGNAL PEPTIDASE; CRYSTAL-STRUCTURE; PROTEOLYTIC DOMAIN; MITOCHONDRIAL LON; QUALITY-CONTROL; EGLIN-C; COMPLEX; MUTAGENESIS; PROTEINASE	ATP-dependent Lon protease degrades specific short-lived regulatory proteins as well as defective and abnormal proteins in the cell. The crystal structure of the proteolytic domain (P domain) of the Escherichia coli Lon has been solved by single-wavelength anomalous dispersion and refined at 1.75-Angstrom resolution. The P domain was obtained by chymotrypsin digestion of the full-length, proteolytically inactive Lon mutant (S679A) or by expression of a recombinant construct encoding only this domain. The P domain has a unique fold and assembles into hexameric rings that likely mimic the oligomerization state of the holoenzyme. The hexamer is dome-shaped, with the six N termini oriented toward the narrower ring surface, which is thus identified as the interface with the ATPase domain in full-length Lon. The catalytic sites lie in a shallow concavity on the wider distal surface of the hexameric ring and are connected to the proximal surface by a narrow axial channel with a diameter of similar to18 Angstrom. Within the active site, the proximity of Lys(722) to the side chain of the mutated Ala(679) and the absence of other potential catalytic side chains establish that Lon employs a Ser(679)-Lys(722) dyad for catalysis. Alignment of the P domain catalytic pocket with those of several Ser-Lys dyad peptide hydrolases provides a model of substrate binding, suggesting that polypeptides are oriented in the Lon active site to allow nucleophilic attack by the serine hydroxyl on the si-face of the peptide bond.	NCI, Macromol Crystallog Lab, Frederick, MD 21702 USA; Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; NCI, Cell Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gustchina, A (corresponding author), NCI, Macromol Crystallog Lab, Bldg 539,Rm 143, Frederick, MD 21702 USA.	alla@ncifcrf.gov	Ротанова, Татьяна В/J-7156-2018	Rotanova, Tatyana/0000-0001-6981-6284; Botos, Istvan/0000-0002-7702-6749	NATIONAL CANCER INSTITUTE [ZIABC010348, Z01BC010378, Z01BC010348, ZIABC005597, ZIABC010378, Z01BC005597] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMERIK AY, 1990, BIOORG KHIM+, V16, P869; AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bell CE, 2000, CELL, V101, P801, DOI 10.1016/S0092-8674(00)80891-0; Birghan C, 2000, EMBO J, V19, P114, DOI 10.1093/emboj/19.1.114; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Frank EG, 1996, P NATL ACAD SCI USA, V93, P10291, DOI 10.1073/pnas.93.19.10291; FRIGERIO F, 1992, J MOL BIOL, V225, P107, DOI 10.1016/0022-2836(92)91029-O; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1981, METHOD ENZYMOL, V80, P680; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1995, COLD SPRING HARB SYM, V60, P533, DOI 10.1101/SQB.1995.060.01.057; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Klenotic PA, 2000, J BIOL CHEM, V275, P6490, DOI 10.1074/jbc.275.9.6490; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Krzywda S, 2002, STRUCTURE, V10, P1073, DOI 10.1016/S0969-2126(02)00806-7; Kwon AR, 2003, J MOL BIOL, V330, P185, DOI 10.1016/S0022-2836(03)00580-1; Luo Y, 2001, CELL, V106, P585, DOI 10.1016/S0092-8674(01)00479-2; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Maurizi Michael R., 2001, EMBO Reports, V2, P980, DOI 10.1093/embo-reports/kve229; McPherson A, 1982, PREPARATION ANAL PRO; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Neuwald AF, 1999, GENOME RES, V9, P27; Nicholls A., 1992, GRASP GRAPHICAL REPR; Niwa H, 2002, STRUCTURE, V10, P1415, DOI 10.1016/S0969-2126(02)00855-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paetzel M, 2002, J BIOL CHEM, V277, P9512, DOI 10.1074/jbc.M110983200; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; Ramachandran R, 2002, P NATL ACAD SCI USA, V99, P7396, DOI 10.1073/pnas.102188799; Rasulova FS, 1998, FEBS LETT, V432, P179, DOI 10.1016/S0014-5793(98)00859-X; Rotanova T. V., 2003, Bioorganicheskaya Khimiya, V29, P97; Rotanova TV, 1999, BIOORG KHIM+, V25, P883; ROTANOVA TV, 1994, BIOORG KHIM+, V20, P114; Roudiak SG, 1998, BIOCHEMISTRY-US, V37, P11255, DOI 10.1021/bi980945h; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Stahlberg H, 1999, P NATL ACAD SCI USA, V96, P6787, DOI 10.1073/pnas.96.12.6787; Starkova NN, 1998, FEBS LETT, V422, P218, DOI 10.1016/S0014-5793(98)00012-X; SWAMY KHS, 1981, NATURE, V292, P652, DOI 10.1038/292652a0; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1763, DOI 10.1107/S0907444901013749; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; Vasilyeva OV, 2002, FEBS LETT, V526, P66, DOI 10.1016/S0014-5793(02)03117-4; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81; Wlodawer A, 2001, NAT STRUCT BIOL, V8, P442, DOI 10.1038/87610; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Yoo SJ, 1997, FEBS LETT, V412, P57, DOI 10.1016/S0014-5793(97)00742-4; Zwickl P, 2000, CURR OPIN STRUC BIOL, V10, P242, DOI 10.1016/S0959-440X(00)00075-0; [No title captured]; [No title captured]; [No title captured]; [No title captured]	70	146	155	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8140	8148		10.1074/jbc.M312243200	http://dx.doi.org/10.1074/jbc.M312243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665623	hybrid			2022-12-27	WOS:000189103300095
J	Cok, SJ; Acton, SJ; Sexton, AE; Morrison, AR				Cok, SJ; Acton, SJ; Sexton, AE; Morrison, AR			Identification of RNA-binding proteins in RAW 264.7 cells that recognize a lipopolysaccharide-responsive element in the 3-untranslated region of the murine cyclooxygenase-2 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH-ELEMENT; TNF-ALPHA; TYROSINE PHOSPHORYLATION; 3'-UNTRANSLATED REGION; GENOMIC ORGANIZATION; STABILITY; EXPRESSION; HUR; TRISTETRAPROLIN; MACROPHAGES	RAW 264.7 cells rapidly induce cyclooxygenase-2 (COX-2) in response to lipopolysaccharide treatment. Part of the increased COX-2 expression occurred through post-transcriptional mechanisms mediated through specific regions of the 3'-untranslated region (UTR) of the message. The proximal region of the 3'-UTR of COX-2 contains a highly conserved AU-rich element that was able to confer lipopolysaccharide regulation of a chimeric reporter-gene. Electrophoretic mobility shift assays demonstrated that the RNA-binding proteins TIAR, AUF1, HuR, and TIA-1 all form an RNA-protein complex with the first 60 nucleotides of the 3'-UTR of COX-2. Biotinylated RNA probes were used to isolate additional proteins that bind the 3'-UTR of COX-2. We identified several RNA-binding proteins including TIAR, AUF1, CBF-A, RBM3, heterogeneous nuclear ribonucleoprotein (hnRNP) A3, and hnRNP A2/B1. We identified four alternatively spliced isoforms of AUF1 which migrated at multiple isoelectric points. Likewise, we identified alternatively spliced isoforms of CBF-A, hnRNP A3, and hnRNP A2/B1. Western analysis of two-dimensional gels identified multiple isoforms of TIA-1, TIAR, and AUF1 at pI values that spanned nearly 3 pH units. Thus, through a combination of alternative splicing and post-translational modification cells are able to increase greatly the repertoire of protein species expressed at a given time or in response to extracellular stimuli.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Morrison, AR (corresponding author), Washington Univ, Sch Med, Dept Med, 4940 Parkview Pl,Wohl Clin,Rm 8843, St Louis, MO 63110 USA.	Morrison@pcg.wustl.edu			NIDDK NIH HHS [DK 59932] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059932] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baghdoyan S, 2000, BLOOD, V95, P3750; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Barrios-Rodiles M, 1999, J IMMUNOL, V163, P963; Beck ARP, 1996, NUCLEIC ACIDS RES, V24, P3829, DOI 10.1093/nar/24.19.3829; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Danno S, 1997, BIOCHEM BIOPH RES CO, V236, P804, DOI 10.1006/bbrc.1997.7059; Danno S, 2000, AM J PATHOL, V156, P1685, DOI 10.1016/S0002-9440(10)65039-0; Dean JLE, 2002, BIOCHEM J, V366, P709, DOI 10.1042/BJ20020402; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Grzybowska EA, 2001, BIOCHEM BIOPH RES CO, V288, P291, DOI 10.1006/bbrc.2001.5738; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Ma ASW, 2002, J BIOL CHEM, V277, P18010, DOI 10.1074/jbc.M200050200; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; PYPE S, 1994, J BIOL CHEM, V269, P31457; Rousseau S, 2002, EMBO J, V21, P6505, DOI 10.1093/emboj/cdf639; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Tebo J, 2003, J BIOL CHEM, V278, P12085, DOI 10.1074/jbc.M212992200; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilson GM, 2003, J BIOL CHEM, V278, P33039, DOI 10.1074/jbc.M305775200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	38	90	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8196	8205		10.1074/jbc.M308475200	http://dx.doi.org/10.1074/jbc.M308475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662769	hybrid			2022-12-27	WOS:000189103300101
J	Kumar, AP; Piedrafita, FJ; Reynolds, WF				Kumar, AP; Piedrafita, FJ; Reynolds, WF			Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN ATHEROSCLEROTIC LESIONS; ASSOCIATION IMPLICATES MYELOPEROXIDASE; HYPOCHLORITE-MODIFIED PROTEINS; MONOCYTE-DERIVED MACROPHAGES; ACUTE CORONARY SYNDROMES; LOW-DENSITY-LIPOPROTEIN; ACID RESPONSE ELEMENT; ALZHEIMERS-DISEASE; PPAR-GAMMA	A functional myeloperoxidase (MPO) promoter polymorphism, - 463GA, has been associated with incidence or severity of inflammatory diseases, including atherosclerosis and Alzheimer's disease, and some cancers. The polymorphism is within an Alu element encoding four hexamer repeats recognized by nuclear receptors (AluRRE). Here we show that peroxisome proliferator-activated receptor gamma (PPARgamma) agonists strongly regulate MPO gene expression through the AluRRE. Opposite effects were observed in granulocyte/macrophage colony-stimulating factor ( GMCSF)- versus macrophage colony-stimulating factor (MCSF)-derived macrophages (Mphi): Expression was markedly up-regulated ( mean 26-fold) in MCSF-Mphi and down-regulated (34-fold) in GMCSF-Mphi. This was observed with rosiglitazone and three other PPARgamma ligands of the thiazolidinedione class, as well as the natural prostaglandin metabolite 15-deoxy-Delta(12,14) prostaglandin J(2). The selective PPARgamma antagonist, GW9662, blocked both the positive and negative effects on MPO expression. Gel retardation assays showed PPARgamma bound hexamers 3/4, and estrogen receptor-alpha bound hexamers 1/2, with -463A in hexamer 1 enhancing binding. Estrogen blocked PPARgamma effects on MPO expression, especially for the A allele. Charcoal filtration of fetal calf serum eliminated the block of PPARgamma, whereas replenishing the medium with 17beta-estradiol reinstated the block. These findings suggest a model in which estrogen receptor binds the AluRRE, preventing PPARgamma binding to the adjacent site. The positive and negative regulation by PPARgamma ligands, and the block by estrogen, was also observed in transgenic mice expressing the G and A alleles. The mouse MPO gene, which lacks the primate-specific AluRRE, was unresponsive to PPARgamma ligands, suggesting the human MPO transgenes will enhance the utility of mouse models for diseases involving MPO, such as atherosclerosis and Alzheimer's.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA		Reynolds, WF (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	wreynolds@skcc.org			NIA NIH HHS [R01 AG17879] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG017879] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akagawa KS, 2002, INT J HEMATOL, V76, P27, DOI 10.1007/BF02982715; AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; Baldus S, 2003, CIRCULATION, V108, P1440, DOI 10.1161/01.CIR.0000090690.67322.51; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Brennan ML, 2001, J NEUROIMMUNOL, V112, P97, DOI 10.1016/S0165-5728(00)00392-1; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chumakov AM, 2000, INT J ONCOL, V16, P401; CLINTON SK, 1992, AM J PATHOL, V140, P301; Crawford FC, 2001, EXP NEUROL, V167, P456, DOI 10.1006/exnr.2000.7560; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Ediger TR, 2002, MOL ENDOCRINOL, V16, P1828, DOI 10.1210/me.2001-0290; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Fontaine C, 2003, J BIOL CHEM, V278, P37672, DOI 10.1074/jbc.M304664200; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Heinecke JW, 2002, TOXICOLOGY, V177, P11, DOI 10.1016/S0300-483X(02)00192-0; Hoy A, 2001, EUR J HUM GENET, V9, P780, DOI 10.1038/sj.ejhg.5200702; Keler T, 2000, J IMMUNOL, V164, P5746, DOI 10.4049/jimmunol.164.11.5746; Klebanoff SJ, 1999, P ASSOC AM PHYSICIAN, V111, P383, DOI 10.1111/paa.1999.111.5.383; KLEBANOFF SJ, 1970, SCIENCE, V169, P1095, DOI 10.1126/science.169.3950.1095; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Komuro I, 2001, J BIOL CHEM, V276, P24360, DOI 10.1074/jbc.M102081200; Kutter D, 2000, ACTA HAEMATOL-BASEL, V104, P10, DOI 10.1159/000041062; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leininger-Muller B, 2003, NEUROSCI LETT, V349, P95, DOI 10.1016/S0304-3940(03)00795-X; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; London SJ, 1997, CANCER RES, V57, P5001; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Makela R, 2003, J CLIN ENDOCR METAB, V88, P3823, DOI 10.1210/jc.2002-021771; Makela R, 2003, LAB INVEST, V83, P919, DOI 10.1097/01.LAB.0000077981.49367.46; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Meisel P, 2002, GENES IMMUN, V3, P102, DOI 10.1038/sj.gene.6363840; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Nagra RM, 1997, J NEUROIMMUNOL, V78, P97, DOI 10.1016/S0165-5728(97)00089-1; NAUSEEF WM, 1988, EUR J HAEMATOL, V40, P97; Nauseef WM, 2001, J CLIN INVEST, V107, P401, DOI 10.1172/JCI11713; Nauseef WM, 2001, INT J HEMATOL, V74, P125, DOI 10.1007/BF02981994; Nikpoor B, 2001, AM HEART J, V142, P336, DOI 10.1067/mhj.2001.116769; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Pecoits R, 2003, KIDNEY INT, V63, pS172, DOI 10.1046/j.1523-1755.63.s84.32.x; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; Plenz G, 1999, ATHEROSCLEROSIS, V144, P25, DOI 10.1016/S0021-9150(99)00035-0; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Reynolds W, 2002, GENES IMMUN, V3, P345, DOI 10.1038/sj.gene.6363880; Reynolds WF, 2000, NEUROLOGY, V55, P1284, DOI 10.1212/WNL.55.9.1284; Reynolds WF, 1999, EXP NEUROL, V155, P31, DOI 10.1006/exnr.1998.6977; Reynolds WF, 1997, BLOOD, V90, P2730, DOI 10.1182/blood.V90.7.2730.2730_2730_2737; Reynolds WF, 2002, CLIN IMMUNOL, V103, P154, DOI 10.1006/clim.2002.5206; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Schabath MB, 2002, LUNG CANCER-J IASLC, V37, P35, DOI 10.1016/S0169-5002(02)00034-X; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Spiegelman B M, 1997, Eur J Med Res, V2, P457; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Tarkowski E, 2001, ACTA NEUROL SCAND, V103, P166, DOI 10.1034/j.1600-0404.2001.103003166.x; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; YOUNG DA, 1990, J IMMUNOL, V145, P607; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	71	84	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8300	8315		10.1074/jbc.M311625200	http://dx.doi.org/10.1074/jbc.M311625200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668325	hybrid			2022-12-27	WOS:000189103300112
J	Nogami, K; Suzuki, H; Habuchi, H; Ishiguro, N; Iwata, H; Kimata, K				Nogami, K; Suzuki, H; Habuchi, H; Ishiguro, N; Iwata, H; Kimata, K			Distinctive expression patterns of heparan sulfate O-sulfotransferases and regional differences in heparan sulfate structure in chick limb buds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; APICAL ECTODERMAL RIDGE; CONTROLS CELLULAR-RESPONSES; CRYSTAL-STRUCTURE; TOUT-VELU; HEPARIN/HEPARAN SULFATE; POLARIZING ACTIVITY; MOLECULAR-CLONING; CDNA CLONING; IN-VIVO	The skeletal tissue development and patterning in chick limb buds are known to be under the spacio-temporal control of various heparin-binding cell growth factors such as fibroblast growth factors and bone morphogenetic proteins. Different structural regions on heparan sulfate (HS) chains of proteoglycans could be implicated in regional differences in the binding capacities of these cell growth factors, by which they could selectively interact with targeted cells and regulate their signaling in those processes. In this study we first demonstrated by cDNA cloning that one heparan sulfate 2-O-sulfotransferase (HS2ST) and two isoforms of heparan sulfate 6-O-sulfotransferase (HS6ST-1 and -2) occurred in chick embryos and had different substrate specificities each other. We next showed by whole mount in situ hybridization that the HS6ST-1 and HS6ST-2 transcripts were preferentially localized to the anterior proximal region and at the posterior proximal region of the limb bud, respectively, whereas the HS2ST transcript was distributed rather uniformly throughout the bud. Analyses of the structures of HS from different regions of the wing buds have shown variation in that 6-O-sulfated residues are more abundant in the proximal than distal region, whereas iduronosyl 6-O-sulfated residues are abundant in the anterior proximal region and glucuronosyl 6-O-sulfated residues in the posterior proximal region. These results suggest that HS with different sulfation patterns created with multiple sulfotransferase activities provides an appropriate extracellular environment for morphogenetic signal transduction.	Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Nagoya Univ, Sch Med, Dept Orthopaed Surg, Showa Ku, Nagoya, Aichi 4668550, Japan	Aichi Medical University; Nagoya University	Kimata, K (corresponding author), Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan.	kimata@amugw.aichi-med-u.ac.jp	Ishiguro, Naoki/I-1563-2012					Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Crawford BE, 2001, J BIOL CHEM, V276, P21538, DOI 10.1074/jbc.M100880200; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Dealy CN, 1997, DEV BIOL, V184, P343, DOI 10.1006/dbio.1997.8525; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Friedl A, 1997, AM J PATHOL, V150, P1443; Grisaru S, 2001, DEV BIOL, V231, P31, DOI 10.1006/dbio.2000.0127; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Habuchi H, 2003, BIOCHEM J, V371, P131, DOI 10.1042/BJ20021259; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Irie A, 2002, DEVELOPMENT, V129, P61; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kubota Y, 2000, DEV DYNAM, V217, P170, DOI 10.1002/(SICI)1097-0177(200002)217:2<170::AID-DVDY4>3.0.CO;2-9; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lizarraga G, 1999, DEV GENET, V25, P331, DOI 10.1002/(SICI)1520-6408(1999)25:4<331::AID-DVG7>3.0.CO;2-U; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; Mariani FV, 2003, NATURE, V423, P319, DOI 10.1038/nature01655; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; Morita H, 1995, VIRCHOWS ARCH, V427, P395; Nakato H, 2002, BBA-GEN SUBJECTS, V1573, P312, DOI 10.1016/S0304-4165(02)00398-7; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pizette S, 1999, DEVELOPMENT, V126, P883; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; ROWE DA, 1982, DEV BIOL, V93, P83, DOI 10.1016/0012-1606(82)90241-X; RUBIN L, 1972, DEV BIOL, V28, P94, DOI 10.1016/0012-1606(72)90129-7; SAKSELA O, 1990, J CELL BIOL, V110, P767, DOI 10.1083/jcb.110.3.767; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; Schaller SA, 2001, DEV BIOL, V240, P443, DOI 10.1006/dbio.2001.0500; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Sen J, 2000, DEVELOPMENT, V127, P5541; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Tickle C, 2001, CURR OPIN GENET DEV, V11, P476, DOI 10.1016/S0959-437X(00)00220-3; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VOGEL A, 1993, DEVELOPMENT, V119, P199; Vogt TF, 1999, CELL, V99, P563, DOI 10.1016/S0092-8674(00)81545-7; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Xu XL, 1998, DEVELOPMENT, V125, P753; Zako M, 2002, J BIOL CHEM, V277, P25592, DOI 10.1074/jbc.M201279200	74	45	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8219	8229		10.1074/jbc.M307304200	http://dx.doi.org/10.1074/jbc.M307304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660620	hybrid			2022-12-27	WOS:000189103300104
J	Novi, F; Scarselli, M; Corsini, GU; Maggio, R				Novi, F; Scarselli, M; Corsini, GU; Maggio, R			The paired activation of the two components of the muscarinic M-3 receptor dimer is required for induction of ERK1/2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ARRESTIN; DOPAMINE; OLIGOMERIZATION; IDENTIFICATION	Muscarinic M-3 receptors stimulate ERK1/2, the mitogen-activated protein kinase pathway. A mutant of the muscarinic M-3 receptor in which most of the third intracellular (i3) loop had been deleted (M-3-short) completely lost the ability to stimulate the ERK1/2 phosphorylation in COS-7 cells. This loss was evident despite the fact that the receptor was able to couple efficiently to the phospholipase C second messenger pathway. In co-transfected cells, M-3-short greatly reduced the ability of M-3 to activate ERK1/2. In another set of experiments we tested the ability of a mutant M-3/M-2(16aa) receptor, in which the first 16 amino acids of the i3 loop of the M-3 receptor were replaced with the corresponding segment of the muscarinic M-2 receptor to stimulate ERK1/2 phosphorylation. This mutant is not coupled to Galpha(q), but it is weakly coupled to Galpha(i). Despite its coupling modification this receptor was able to stimulate ERK1/2 phosphorylation. Again, M-3-short greatly reduced the ability of M-3/M-2(16aa) to activate ERK1/2 in co-transfected cells. Similar results were obtained in stable-transfected Chinese hamster ovary (CHO) cells lines. In CHO M-3 cells carbachol induced a biphasic increase of ERK1/2 phosphorylation; a first increase at doses as low as 0.1 muM and a second increase starting from 10 muM. In CHO M-3-short and in double-transfected CHO M-3/M-3-short cells we observed only the lower doses increase of ERK1/2 phosphorylation; no further increase was observed up to 1 mM carbachol. This suggests that in double-transfected CHO cells M-3-short prevents the effect of the higher doses of carbachol on the M-3 receptor. In a final experiment we tested the ability of co-transfected chimeric alpha(2)/M-3 and M-3/alpha(2) receptors to activate the ERK1/2 pathway. When given alone, carbachol and, to a lesser extent, clonidine, stimulated the coupling of the co-transfected chimeric receptors to the phospholipase C second messenger pathway, but they were unable to stimulate ERK1/2 phosphorylation. On the contrary, a strong stimulation of ERK1/2 phosphorylation was observed when the two agonists were given together despite the fact that the overall increase in phosphatidylinositol hydrolysis was not dissimilar from that observed in cells treated with carbachol alone. Our data suggest that the activation of the ERK1/2 pathway requires the coincident activation of the two components of a receptor dimer.	Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy	University of Pisa	Maggio, R (corresponding author), Univ Pisa, Dept Neurosci, Via Roma 55, I-56100 Pisa, Italy.	r.maggio@drugs.med.unipi.it	maggio, Roberto/Q-2032-2015	Scarselli, Marco/0000-0001-5087-3182; Maggio, Roberto/0000-0003-4436-2356				AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Budd DC, 2001, J BIOL CHEM, V276, P4581, DOI 10.1074/jbc.M008827200; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Hillion J, 2002, J BIOL CHEM, V277, P18091, DOI 10.1074/jbc.M107731200; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maggio R, 1996, J BIOL CHEM, V271, P31055, DOI 10.1074/jbc.271.49.31055; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; Shiina T, 2001, LIFE SCI, V68, P2251, DOI 10.1016/S0024-3205(01)01013-X; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; WESS J, 1990, MOL PHARMACOL, V38, P517; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	29	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7476	7486		10.1074/jbc.M306818200	http://dx.doi.org/10.1074/jbc.M306818200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660647	hybrid			2022-12-27	WOS:000189103300015
J	Boue-Grabot, E; Emerit, MB; Toulme, E; Seguela, P; Garret, M				Boue-Grabot, E; Emerit, MB; Toulme, E; Seguela, P; Garret, M			Cross-talk and co-trafficking between rho 1/GABA receptors and ATP-gated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; GABA(C) RECEPTOR; RHO-SUBUNITS; IMMUNOCYTOCHEMICAL LOCALIZATION; P2X RECEPTORS; ION CHANNELS; RAT; NEURONS; EXPRESSION; SYNAPSES	gamma-Aminobutyric-acid (GABA) and ATP ionotropic receptors represent two structurally and functionally different classes of neurotransmitter-gated channels involved in fast synaptic transmission. We demonstrate here that, when the inhibitory rho1/GABA and the excitatory P2X(2) receptor channels are co-expressed in Xenopus oocytes, activation of one channel reduces the currents mediated by the other one. This reciprocal inhibitory cross-talk is a receptor-mediated phenomenon independent of agonist cross-modulation, membrane potential, direction of ionic flux, or channel densities. Functional interaction is disrupted when the cytoplasmic C-terminal domain of P2X(2) is deleted or in competition experiments with minigenes coding for the C-terminal domain of P2X(2) or the main intracellular loop of rho1 subunits. We also show a physical interaction between P2X(2) and rho1 receptors expressed in oocytes and the co-clustering of these receptors in transfected hippocampal neurons. Co-expression with P2X(2) induces retargeting and recruitment of mainly intracellular rho1/ GABA receptors to surface clusters. Therefore, molecular and functional cross-talk between inhibitory and excitatory ligand-gated channels may regulate synaptic strength both by activity-dependent current occlusion and synaptic receptors co-trafficking.	Univ Bordeaux 2, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France; Hop La Pitie Salpetriere, INSERM, U288, F-75013 Paris, France; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; McGill University	Boue-Grabot, E (corresponding author), Univ Bordeaux 2, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France.	eric.boue-grabot@umr5543.u-bordeaux2.fr	Boué-Grabot, Eric/AAQ-2061-2020	Boué-Grabot, Eric/0000-0003-2187-9037				Barajas-Lopez C, 1998, J PHYSIOL-LONDON, V513, P671, DOI 10.1111/j.1469-7793.1998.671ba.x; Barnard EA, 1996, TRENDS PHARMACOL SCI, V17, P305, DOI 10.1016/0165-6147(96)10041-9; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Bormann J, 2000, TRENDS PHARMACOL SCI, V21, P16, DOI 10.1016/S0165-6147(99)01413-3; Boue-Grabot E, 2000, ENDOCRINOLOGY, V141, P1627, DOI 10.1210/en.141.5.1627; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Boue-Grabot E, 2003, J NEUROSCI, V23, P1246, DOI 10.1523/JNEUROSCI.23-04-01246.2003; Boue-Grabot E, 1998, J NEUROCHEM, V70, P899; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Brandle U, 1998, MOL BRAIN RES, V59, P269, DOI 10.1016/S0169-328X(98)00159-4; Cheng Q, 2001, J NEUROPHYSIOL, V86, P2605, DOI 10.1152/jn.2001.86.5.2605; Dutton JL, 2000, NEUROPHARMACOLOGY, V39, P2054, DOI 10.1016/S0028-3908(00)00058-7; Enz R, 1996, J NEUROSCI, V16, P4479; Gendreau S, 2003, J CHROMATOGR B, V786, P311, DOI 10.1016/S1570-0232(02)00743-2; Giustetto M, 1998, J COMP NEUROL, V395, P231, DOI 10.1002/(SICI)1096-9861(19980601)395:2<231::AID-CNE7>3.0.CO;2-3; Goslin K., 1998, CULTURING NERVE CELL, P339; Hanley JG, 1999, NATURE, V397, P66, DOI 10.1038/16258; Jo YH, 2002, J NEUROSCI, V22, P4794, DOI 10.1523/JNEUROSCI.22-12-04794.2002; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Kanjhan R, 1999, J COMP NEUROL, V407, P11; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Knuesel I, 1999, EUR J NEUROSCI, V11, P4457, DOI 10.1046/j.1460-9568.1999.00887.x; Koulen P, 1997, J COMP NEUROL, V380, P520, DOI 10.1002/(SICI)1096-9861(19970421)380:4<520::AID-CNE8>3.0.CO;2-3; Koulen P, 1998, EUR J NEUROSCI, V10, P115, DOI 10.1046/j.1460-9568.1998.00005.x; Le KT, 1999, J BIOL CHEM, V274, P15415, DOI 10.1074/jbc.274.22.15415; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Li GH, 2000, J BIOL CHEM, V275, P29107, DOI 10.1074/jbc.M910277199; Li Y, 2003, J BIOL CHEM, V278, P38637, DOI 10.1074/jbc.M303735200; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pan ZH, 2000, EUR J NEUROSCI, V12, P3137, DOI 10.1046/j.1460-9568.2000.00198.x; Qian HH, 1999, P ROY SOC B-BIOL SCI, V266, P2419, DOI 10.1098/rspb.1999.0941; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Searl TJ, 1998, J PHYSIOL-LONDON, V510, P783, DOI 10.1111/j.1469-7793.1998.783bj.x; Sokolova E, 2001, J NEUROSCI, V21, P4958, DOI 10.1523/JNEUROSCI.21-14-04958.2001; Stojilkovic SS, 2000, BIOCHEM CELL BIOL, V78, P393, DOI 10.1139/bcb-78-3-393; Vulchanova L, 1997, NEUROPHARMACOLOGY, V36, P1229, DOI 10.1016/S0028-3908(97)00126-3; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wegelius K, 1998, EUR J NEUROSCI, V10, P350, DOI 10.1046/j.1460-9568.1998.00023.x; WHEELERSCHILLIN.TH, 2002, BRAIN RES MOL BRAIN, V76, P415; Wotring VE, 1999, J PHYSIOL-LONDON, V521, P327, DOI 10.1111/j.1469-7793.1999.00327.x; Zheng W, 2003, J BIOL CHEM, V278, P48321, DOI 10.1074/jbc.M307930200; Zhou XP, 1998, J PHYSIOL-LONDON, V513, P685, DOI 10.1111/j.1469-7793.1998.685ba.x	48	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6967	6975		10.1074/jbc.M307772200	http://dx.doi.org/10.1074/jbc.M307772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660627	hybrid			2022-12-27	WOS:000188969200092
J	Brunson, LE; Dixon, C; Kozubowski, L; Mathias, N				Brunson, LE; Dixon, C; Kozubowski, L; Mathias, N			The amino-terminal portion of the F-box protein Met30p mediates its nuclear import and assimilation into an SCF complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIGASE COMPLEX; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; YEAST; DEGRADATION; PROTEOLYSIS; CDC4P; MET4; DESTRUCTION; INHIBITOR	SCF complexes are a conserved family of ubiquitin ligases composed of a common core of components and a variable component called an F-box protein that defines substrate specificity. The F-box motif links the F-box protein to the core components via its interaction with Skp1p. In yeast, the SCFMet30p complex contains the Met30p F-box protein and regulates Met4p, a transcription factor that mediates sulfur fixation and methionine biosynthesis. Although a nuclear protein, Met30p lacks a definable nuclear localization sequence. Here we show that the entire amino-terminal half of Met30p is required for its proper nuclear localization. Mutations in the F-box, but not mutations in Skp1p, affect Met30p nuclear localization, indicating that the F-box motif plays an important role in Met30p trafficking independent of its interaction with Skp1p binding. Met30p mutants that poorly localize to the nucleus display increased nuclear to cytoplasmic exchange, indicating that the amino terminus mediates nuclear retention in addition to nuclear import. The Met30p F-box motif, residues 180-225, is necessary and sufficient to bind Skp1p; however, mutations upstream of the Met30p F-box inhibit Skp1p binding. We propose that additional factors bind the amino-terminal region of Met30p and mediate its nuclear localization and assimilation into an SCF complex.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Mathias, N (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	pmathi@lsuhsc.edu						Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dixon C, 2003, EUKARYOT CELL, V2, P123, DOI 10.1128/EC.2.1.123-133.2003; Elbe R, 1992, BIOTECHNIQUES, V13, P18; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; James P, 1996, GENETICS, V144, P1425; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rose MD., 1990, METHODS YEAST GENETI; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	32	7	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6674	6682		10.1074/jbc.M308875200	http://dx.doi.org/10.1074/jbc.M308875200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660673	hybrid			2022-12-27	WOS:000188969200058
J	Meng, XB; Yuan, Y; Maestas, A; Shen, ZY				Meng, XB; Yuan, Y; Maestas, A; Shen, ZY			Recovery from DNA damage-induced G(2) arrest requires actin-binding protein filamin-A/actin-binding protein 280	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHECKPOINT KINASE CHK1; CELL-CYCLE ARREST; MITOTIC CATASTROPHE; MORPHOGENESIS CHECKPOINT; TUMOR-CELLS; ATAXIA-TELANGIECTASIA; ANDROGEN RECEPTOR; FISSION YEAST; PHOSPHORYLATION; APOPTOSIS	Filamin-A (filamin-1) is an actin-binding protein involved in the organization of actin networks. Our previous study shows that filamin-A interacts with BRCA2, and lack of filamin-A expression results in increased cellular sensitivity to several DNA damaging agents in melanoma cells (Yuan, Y., and Shen, Z. (2001) J. Biol. Chem. 276, 48318-48324), suggesting a role of filamin-A in DNA damage response. In this report, we demonstrated that deficiency of filamin-A results in an 8-h delay in the recovery from G(2) arrest in response to ionizing radiation. However, filamin-A deficiency does not affect the initial activation of the G(2)/M checkpoint. We also found that filamin-A deficiency results in sustained activation of Chk1 and Chk2 after irradiation. This in turn causes a delay in the dephosphorylation of phospho-Cdc2, which is inhibitory to the G(2)/M transition. In addition, filamin-A-deficient M2 cells undergo mitotic catastrophe-related nuclear fragmentation after they are released from the G(2) arrest. Together, these data suggest a functional role of filamin-A in the recovery from G(2) arrest and subsequent mitotic cell death after DNA damage.	1 Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of New Mexico	Shen, ZY (corresponding author), 1 Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, MSC08 4660, Albuquerque, NM 87131 USA.	zshen@salud.unm.edu		meng, xiangbing/0000-0002-9612-6438; Shen, Zhiyuan/0000-0003-2834-0309	NIEHS NIH HHS [R01 ES08353] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008353] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATES PR, 1989, MUTAT RES, V218, P165, DOI 10.1016/0921-8777(89)90023-2; Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Berry L D, 1996, Prog Cell Cycle Res, V2, P99; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Busby EC, 2000, CANCER RES, V60, P2108; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Harrison JC, 2001, NAT CELL BIOL, V3, P417, DOI 10.1038/35070104; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; HONG JH, 1994, RADIAT RES, V140, P17, DOI 10.2307/3578563; Ianzini F, 1997, INT J RADIAT BIOL, V72, P409, DOI 10.1080/095530097143185; Ianzini F, 1999, INT J RADIAT BIOL, V75, P717, DOI 10.1080/095530099140050; Jackson JR, 2000, CANCER RES, V60, P566; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Liu F, 1999, MOL CELL BIOL, V19, P5113; Liu JH, 2000, J CELL SCI, V113, P1223; Liu QH, 2000, GENE DEV, V14, P1448; Lock RB, 1996, CANCER RES, V56, P4006; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; McMillan JN, 1999, MOL CELL BIOL, V19, P6929; McMillan JN, 1998, J CELL BIOL, V142, P1487, DOI 10.1083/jcb.142.6.1487; Nakahata K, 2002, INT J HYPERTHER, V18, P332, DOI 10.1080/02656730210129736; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OConnor PM, 1997, CANCER SURV, V29, P151; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Rhind N, 1998, CURR OPIN CELL BIOL, V10, P749, DOI 10.1016/S0955-0674(98)80118-X; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ross GM, 1999, ENDOCR-RELAT CANCER, V6, P41, DOI 10.1677/erc.0.0060041; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wang X, 2003, J BIOL CHEM, V278, P30869, DOI 10.1074/jbc.M301876200; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Yu Q, 2002, CANCER RES, V62, P5743; Yuan Y, 2001, J BIOL CHEM, V276, P48318, DOI 10.1074/jbc.M102557200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	57	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6098	6105		10.1074/jbc.M306794200	http://dx.doi.org/10.1074/jbc.M306794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660646	hybrid			2022-12-27	WOS:000188776500125
J	Roher, AE; Kokjohn, TA; Esh, C; Weiss, N; Childress, J; Kalback, W; Luehrs, DC; Lopez, J; Brune, D; Kuo, YM; Farlow, M; Murrell, J; Vidal, R; Ghetti, B				Roher, AE; Kokjohn, TA; Esh, C; Weiss, N; Childress, J; Kalback, W; Luehrs, DC; Lopez, J; Brune, D; Kuo, YM; Farlow, M; Murrell, J; Vidal, R; Ghetti, B			The human amyloid-beta precursor protein(770) mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; TRANSGENIC MICE; CHEMICAL-CHARACTERIZATION; CLEAVAGE; DEPOSITION; PATHOLOGY; DISTINCT	One of the familial forms of Alzheimer's disease (AD) encodes the amyloid-beta precursor protein (AbetaPP) substitution mutation V717F. This mutation is relevant to AD research, since it has been utilized to generate transgenic mice models to study AD pathology and therapeutic interventions. Amyloid beta (Abeta) peptides were obtained from the cerebral tissue of three familial AD subjects carrying the AbetaPP V717F mutation. A combination of ultracentrifugation, size-exclusion, and reverse-phase high performance liquid chromatography, tryptic and cyanogen bromide hydrolysis, amino acid analysis, and matrix-assisted laser desorption ionization and surface-enhanced laser desorption ionization mass spectrometry was used to characterize the familial AD mutant Abeta peptides. The AbetaPP V717F mutation, located 4-6 residues beyond the wild-type AbetaPP gamma-secretase cleavage site, yielded longer Abeta peptides with C termini between residues 43 and 54. In the cerebral cortex these peptides aggregated into thin water- and SDS-insoluble amyloid bundles that condensed into flocculent spherical plaques. In the leptomeningeal arteries the amyloid was deposited in moderate amounts and was primarily composed of the shorter and more soluble Abeta species ending at residues 40, 42, and 44. The single V717F mutation in AbetaPP results in distinctive and drastic changes in the length and tertiary structure of Abeta peptides, which appear to be responsible for the earlier clinical manifestations of dementia and death of these patients.	Sun Hlth Res Inst, Longtine Ctr Mol Biol & Genet, Sun City, AZ 85351 USA; Midwestern Univ, Dept Microbiol, Glendale, AZ 85308 USA; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Natl Cheng Kung Univ, Dept Cell Biol & Anat, Tainan 701, Taiwan; Indiana Alzheimer Dis Ctr, Indianapolis, IN 46202 USA	Banner Research; Banner Health; Banner Sun Health Research Institute; Midwestern University; Arizona State University; Arizona State University-Tempe; National Cheng Kung University	Roher, AE (corresponding author), Sun Hlth Res Inst, Longtine Ctr Mol Biol & Genet, 10515 W Santa Fe Dr, Sun City, AZ 85351 USA.	alex.roher@sunhealth.org	Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482	NIA NIH HHS [AG-10133, AG-17490, AG-19795, U24 AG021886] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010133, U24AG021886, P01AG017490, R01AG019795] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; Chaney MO, 1998, PROTEIN ENG, V11, P761, DOI 10.1093/protein/11.9.761; FARLOW M, 1994, NEUROLOGY, V44, P105, DOI 10.1212/WNL.44.1.105; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GHETTI B, 1992, BRAIN RES, V571, P133, DOI 10.1016/0006-8993(92)90519-F; GOWING E, 1994, J BIOL CHEM, V269, P10987; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Higaki J, 1996, J BIOL CHEM, V271, P31885, DOI 10.1074/jbc.271.50.31885; Kalback W, 2002, BIOCHEMISTRY-US, V41, P922, DOI 10.1021/bi015685+; Kuo YM, 1997, BIOCHEM BIOPH RES CO, V237, P188, DOI 10.1006/bbrc.1997.7083; Kuo YM, 2000, AM J PATHOL, V156, P797, DOI 10.1016/S0002-9440(10)64947-4; Kuo YM, 2001, MOL MED, V7, P609, DOI 10.1007/BF03401867; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; Masliah E, 1996, J NEUROSCI, V16, P5795; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Mirra S. S., 2002, GREENFIELDS NEUROPAT, V2, P195; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Shimizu T, 2000, ARCH BIOCHEM BIOPHYS, V381, P225, DOI 10.1006/abbi.2000.1955; Sinha S, 1999, P NATL ACAD SCI USA, V96, P11049, DOI 10.1073/pnas.96.20.11049; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Weller RO, 1998, AM J PATHOL, V153, P725, DOI 10.1016/S0002-9440(10)65616-7	31	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5829	5836		10.1074/jbc.M311380200	http://dx.doi.org/10.1074/jbc.M311380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645225	hybrid			2022-12-27	WOS:000188776500097
J	Dawson, TR; Sansam, CL; Emeson, RB				Dawson, TR; Sansam, CL; Emeson, RB			Structure and sequence determinants required for the RNA editing of ADAR2 substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; ADENOSINE DEAMINASES; GLUR-B; UNWINDING ACTIVITY; PREFRONTAL CORTEX; IN-VITRO; RECEPTOR; BINDING; SITE; PURIFICATION	ADAR2 is a double-stranded RNA-specific adenosine deaminase involved in the editing of mammalian RNAs by the site-specific conversion of adenosine to inosine. We have demonstrated previously that ADAR2 can modify its own pre-mRNA, leading to the creation of a proximal 3'-splice junction containing a non-canonical adenosine-inosine (A-I) dinucleotide. Alternative splicing to this proximal acceptor shifts the reading frame of the mature mRNA transcript, resulting in the loss of functional ADAR2 expression. Both evolutionary sequence conservation and mutational analysis support the existence of an extended RNA duplex within the ADAR2 pre-mRNA formed by base-pairing interactions between regions similar to1.3-kilobases apart in intron 4 and exon 5. Characterization of ADAR2 pre-mRNA transcripts isolated from adult rat brain identified 16 editing sites within this duplex region, and sites preferentially modified by ADAR1 and ADAR2 have been defined using both tissue culture and in vitro editing systems. Statistical analysis of nucleotide sequences surrounding edited and non-edited adenosine residues have identified a nucleotide sequence bias correlating with ADAR2 site preference and editing efficiency. Among a mixed population of ADAR substrates, ADAR2 preferentially favors its own transcript, yet mutation of a poor substrate to conform to the defined nucleotide bias increases the ability of that substrate to be modified by ADAR2. These data suggest that both sequence and structural elements are required to define adenosine moieties targeted for specific ADAR2-mediated deamination.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Emeson, RB (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 465 21st Ave S,8160 Med Res Bldg 3, Nashville, TN 37232 USA.	ron.emeson@vanderbilt.edu	Dawson, Toni/P-8599-2016	Sansam, Christopher/0000-0002-0545-2693; Emeson, Ronald/0000-0002-4585-1648	NINDS NIH HHS [NS33323] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033323] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKBARIAN S, 1995, BRAIN RES, V699, P297, DOI 10.1016/0006-8993(95)00922-D; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Bass BL, 1997, TRENDS BIOCHEM SCI, V22, P157, DOI 10.1016/S0968-0004(97)01035-9; Bass BL, 1997, RNA, V3, P947; Beghini A, 2000, HUM MOL GENET, V9, P2297, DOI 10.1093/oxfordjournals.hmg.a018921; Bratt E, 2003, RNA, V9, P309, DOI 10.1261/rna.2750803; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Cho DSC, 2003, J BIOL CHEM, V278, P17093, DOI 10.1074/jbc.M213127200; Eckmann CR, 1997, J CELL BIOL, V138, P239, DOI 10.1083/jcb.138.2.239; EMESON RB, 2000, RNA EDITING, P109; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gott JM, 2000, ANNU REV GENET, V34, P499, DOI 10.1146/annurev.genet.34.1.499; Gurevich I, 2002, NEURON, V34, P349, DOI 10.1016/S0896-6273(02)00660-8; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Holz B, 1999, J BIOL CHEM, V274, P15066, DOI 10.1074/jbc.274.21.15066; Hoopengardner B, 2003, SCIENCE, V301, P832, DOI 10.1126/science.1086763; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Hough RF, 1997, RNA, V3, P356; Kallman AM, 2003, NUCLEIC ACIDS RES, V31, P4874, DOI 10.1093/nar/gkg681; Klaue Y, 2003, RNA, V9, P839, DOI 10.1261/rna.2167603; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lehmann KA, 2000, BIOCHEMISTRY-US, V39, P12875, DOI 10.1021/bi001383g; Lehmann KA, 1999, J MOL BIOL, V291, P1, DOI 10.1006/jmbi.1999.2914; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Morse DP, 1999, P NATL ACAD SCI USA, V96, P6048, DOI 10.1073/pnas.96.11.6048; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; Niswender CM, 2001, NEUROPSYCHOPHARMACOL, V24, P478, DOI 10.1016/S0893-133X(00)00223-2; O'Connell MA, 1998, METHODS, V15, P51, DOI 10.1006/meth.1998.0605; OConnell MA, 1997, J BIOL CHEM, V272, P473; Palladino MJ, 2000, RNA, V6, P1004, DOI 10.1017/S1355838200000248; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; Reenan RA, 2000, NEURON, V25, P139, DOI 10.1016/S0896-6273(00)80878-8; Rueter S.M., 1998, MODIFICATION EDITING, P343; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Schaub M, 2002, BIOCHIMIE, V84, P791, DOI 10.1016/S0300-9084(02)01446-3; Slavov D, 2002, GENE, V299, P83, DOI 10.1016/S0378-1119(02)01016-8; Sodhi MS, 2001, MOL PSYCHIATR, V6, P373, DOI 10.1038/sj.mp.4000920; Stephens OM, 2000, BIOCHEMISTRY-US, V39, P12243, DOI 10.1021/bi0011577; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; Wong SK, 2001, RNA, V7, P846, DOI 10.1017/S135583820101007X; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; Yang JH, 1997, P NATL ACAD SCI USA, V94, P4354, DOI 10.1073/pnas.94.9.4354; Yi-Brunozzi HY, 2001, J BIOL CHEM, V276, P37827; Yi-Brunozzi HY, 1999, NUCLEIC ACIDS RES, V27, P2912, DOI 10.1093/nar/27.14.2912; Zuker M, 1994, Methods Mol Biol, V25, P267; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	63	82	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4941	4951		10.1074/jbc.M310068200	http://dx.doi.org/10.1074/jbc.M310068200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14660658	hybrid, Green Submitted			2022-12-27	WOS:000188554300120
J	Roisin-Bouffay, C; Luciani, MF; Klein, G; Levraud, JP; Adam, M; Golstein, P				Roisin-Bouffay, C; Luciani, MF; Klein, G; Levraud, JP; Adam, M; Golstein, P			Developmental cell death in Dictyostelium does not require paracaspase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; DIFFERENTIATION; FAMILIES; ORIGIN	Apoptotic cell death often requires caspases. Caspases are part of a family of related molecules including also paracaspases and metacaspases. Are molecules of this family generally involved in cell death? More specifically, do non-apoptotic caspase-independent types of cell death require paracaspases or metacaspases? Dictyostelium discoideum lends itself well to answering these questions because 1) it undergoes non-apoptotic developmental cell death of a vacuolar autophagic type and 2) it bears neither caspase nor metacaspase genes and apparently only one paracaspase gene. This only paracaspase gene can be inactivated by homologous recombination. Paracaspase-null clones were thus obtained in each of four distinct Dictyostelium strains. These clones were tested in two systems, developmental stalk cell death in vivo and vacuolar autophagic cell death in a monolayer system mimicking developmental cell death. Compared with parent cells, all of the paracaspase-null cells showed unaltered cell death in both test systems. In addition, paracaspase inactivation led to no alteration in development or interaction with a range of bacteria. Thus, in Dictyostelium, vacuolar programmed cell death in development and in a monolayer model in vitro would seem not to require paracaspase. To our knowledge, this is the first instance of developmental programmed cell death shown to be independent of any caspase, paracaspase or metacaspase. These results have implications as to the relationship in evolution between cell death and the caspase family.	Univ Mediterranie, Ctr Immunol Marseille Luminy, CNRS, INSERM, F-13288 Marseille 9, France; Comm Energie Atom Grenobel, Lab Biochim & Biophys Syst Integres, F-38054 Grenoble 9, France; Inst Pasteur, Unite Postulante Macrophages & Dev Immun, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; CEA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Golstein, P (corresponding author), Univ Mediterranie, Ctr Immunol Marseille Luminy, CNRS, INSERM, Parc Sci Liminy,Case 906, F-13288 Marseille 9, France.	golstein@ciml.univ-mrs.fr	Golstein, Pierre/A-4954-2014	Golstein, Pierre/0000-0003-1750-3483				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Aravind L, 2002, PROTEINS, V46, P355, DOI 10.1002/prot.10060; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; CORNILLON S, 1994, J CELL SCI, V107, P2691; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; Eichinger L, 2003, EMBO J, V22, P1941, DOI 10.1093/emboj/cdg214; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FONG D, 1978, J BACTERIOL, V134, P521, DOI 10.1128/JB.134.2.521-527.1978; Golstein P, 2003, NAT REV MOL CELL BIO, V4, P798, DOI 10.1038/nrm1224; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAY RR, 1987, METHOD CELL BIOL, V28, P433; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Levraud JP, 2003, J CELL BIOL, V160, P1105, DOI 10.1083/jcb.200212104; Levraud JP, 2001, METHOD CELL BIOL, V66, P469; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Olie RA, 1998, CURR BIOL, V8, P955, DOI 10.1016/S0960-9822(98)70395-1; Puta F, 1998, FOLIA BIOL-PRAGUE, V44, P185; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITTINGHAM WF, 1960, P NATL ACAD SCI USA, V46, P642, DOI 10.1073/pnas.46.5.642; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9	28	62	65	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11489	11494		10.1074/jbc.M312741200	http://dx.doi.org/10.1074/jbc.M312741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14681218	hybrid			2022-12-27	WOS:000220157600080
J	Stockel, J; Oelmuller, R				Stockel, J; Oelmuller, R			A novel protein for photosystem I biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM SYNECHOCYSTIS SP; LUPINUS-LUTEUS COTYLEDONS; SYNECHOCOCCUS SP PCC-7002; SP PCC 6803; ARABIDOPSIS-THALIANA; CHLAMYDOMONAS-REINHARDTII; ESCHERICHIA-COLI; SUBCELLULAR-LOCALIZATION; PHOTOAUTOTROPHIC GROWTH; STRUCTURAL ORGANIZATION	Hcf101-1 is a high-chlorophyll-fluorescence (hcf) Arabidopsis mutant that lacks photosystem I ( 1). Photosystem I subunits are synthesized in the mutant but do not assemble into a stable complex. hcf101 was isolated by map-based cloning and encodes an MRP-like protein with a nucleotide-binding domain. The protein is localized in the chloroplast stroma. In green tissue, the Hcf101 level is stimulated by light, and the protein is not detectable in roots. Two independent knock-out lines, hcf101-2 and hcf101-3, are also impaired in Hcf101 accumulation, although to different extents. Like hcf101-1, hcf101-2 and hcf01-3 are hcf mutants with impaired photosystem I. Our results indicate that Hcf101 is a novel component required for photosystem I biosynthesis.	Univ Jena, Inst Allgemeine Bot & Pflanzenphysiol, D-07747 Jena, Germany	Friedrich Schiller University of Jena	Oelmuller, R (corresponding author), Univ Jena, Inst Allgemeine Bot & Pflanzenphysiol, Dornburger Str 159, D-07747 Jena, Germany.	b7oera@uni-jena.de						Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Ausubel FM, 1988, MOL REPROD DEV; Barth C, 2002, PLANTA, V216, P273, DOI 10.1007/s00425-002-0843-0; Bartsevich VV, 1997, J BIOL CHEM, V272, P6382, DOI 10.1074/jbc.272.10.6382; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Boudreau E, 1997, EMBO J, V16, P6095, DOI 10.1093/emboj/16.20.6095; CHITNIS PR, 2001, ANNU REV PLANT PHYS, V52, P627; Colletti KS, 2000, CURR BIOL, V10, P507, DOI 10.1016/S0960-9822(00)00466-8; Cordell SC, 2001, FEBS LETT, V492, P160, DOI 10.1016/S0014-5793(01)02216-5; DARDEL F, 1990, MOL GEN GENET, V223, P121, DOI 10.1007/BF00315804; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; Diener A, 2000, TRENDS PLANT SCI, V5, P10, DOI 10.1016/S1360-1385(99)01512-5; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Emanuelsson O, 1999, PROTEIN SCI, V8, P978, DOI 10.1110/ps.8.5.978; Fischer N, 1999, BIOCHEMISTRY-US, V38, P5546, DOI 10.1021/bi982821a; Fischer N, 1996, MOL GEN GENET, V251, P373, DOI 10.1007/s004380050179; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Haldrup A, 2000, J BIOL CHEM, V275, P31211, DOI 10.1074/jbc.M002933200; Hihara Y, 1998, PLANT PHYSIOL, V117, P1205, DOI 10.1104/pp.117.4.1205; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; Hu ZL, 2003, J BACTERIOL, V185, P196, DOI 10.1128/JB.185.1.196-203.2003; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; KERFELD CA, 1995, J MOL BIOL, V250, P627, DOI 10.1006/jmbi.1995.0404; Klukas O, 1999, J BIOL CHEM, V274, P7351, DOI 10.1074/jbc.274.11.7351; Knoetzel H, 2002, FEBS LETT, V510, P145, DOI 10.1016/S0014-5793(01)03253-7; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; Kroll D, 2001, P NATL ACAD SCI USA, V98, P4238, DOI 10.1073/pnas.061500998; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Kusnetsov V, 1998, MOL GEN GENET, V259, P21, DOI 10.1007/PL00008626; KUSNETSOV VV, 1994, PLANTA, V194, P318, DOI 10.1007/BF00197531; LI N, 1991, BIOCHIM BIOPHYS ACTA, V1059, P215, DOI 10.1016/S0005-2728(05)80206-3; Lutkenhaus J, 2003, MOL MICROBIOL, V48, P295, DOI 10.1046/j.1365-2958.2003.03427.x; MACHOLD O, 1979, CARLSBERG RES COMMUN, V44, P235, DOI 10.1007/BF02906158; MAIER RM, 1995, J MOL BIOL, V251, P614, DOI 10.1006/jmbi.1995.0460; Mann NH, 2000, FEBS LETT, V479, P72, DOI 10.1016/S0014-5793(00)01871-8; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; Meurer J, 1996, PLANTA, V198, P385, DOI 10.1007/BF00620055; Meurer J, 2002, PLANT CELL, V14, P3255, DOI 10.1105/tpc.006809; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; Moseley J, 2000, EMBO J, V19, P2139, DOI 10.1093/emboj/19.10.2139; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Naver H, 2001, PLANT CELL, V13, P2731, DOI 10.1105/tpc.010253; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Olivera ER, 1998, P NATL ACAD SCI USA, V95, P6419, DOI 10.1073/pnas.95.11.6419; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; PALOMARES R, 1993, EUR J BIOCHEM, V217, P345, DOI 10.1111/j.1432-1033.1993.tb18252.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Reardon EM, 1995, PLANT MOL BIOL REP, V13, P320, DOI 10.1007/BF02669185; Redding K, 1998, EMBO J, V17, P50, DOI 10.1093/emboj/17.1.50; Ruf S, 1997, J CELL BIOL, V139, P95, DOI 10.1083/jcb.139.1.95; Schaffner AR, 1996, PLANT MOL BIOL REP, V14, P11, DOI 10.1007/BF02671897; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schlessman JL, 1998, J MOL BIOL, V280, P669, DOI 10.1006/jmbi.1998.1898; Schneider A, 1998, J BIOL CHEM, V273, P21608, DOI 10.1074/jbc.273.34.21608; Schwabe TME, 2000, INDIAN J BIOCHEM BIO, V37, P351; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; Shen GZ, 2002, J BIOL CHEM, V277, P20343, DOI 10.1074/jbc.M201103200; SMART LB, 1993, P NATL ACAD SCI USA, V90, P1132, DOI 10.1073/pnas.90.3.1132; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; Theodoulou FL, 2000, BBA-BIOMEMBRANES, V1465, P79, DOI 10.1199/tab.0153; Vassiliev IR, 1999, J BIOL CHEM, V274, P9993, DOI 10.1074/jbc.274.15.9993; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wilde A, 2001, BIOCHEM J, V357, P211, DOI 10.1042/0264-6021:3570211; WILDE A, 1995, PLANT CELL, V7, P649, DOI 10.1105/tpc.7.5.649; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; Zak E, 1999, EUR J BIOCHEM, V261, P311, DOI 10.1046/j.1432-1327.1999.00281.x; Zak E, 2000, PLANT PHYSIOL, V123, P215, DOI 10.1104/pp.123.1.215; Zhou TQ, 2001, J BIOL CHEM, V276, P30414, DOI 10.1074/jbc.M103671200	74	65	74	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10243	10251		10.1074/jbc.M309246200	http://dx.doi.org/10.1074/jbc.M309246200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14645254	hybrid			2022-12-27	WOS:000220050400072
J	Hershko, T; Ginsberg, D				Hershko, T; Ginsberg, D			Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; FAMILY-MEMBER; E2F-1-INDUCED APOPTOSIS; NEURONAL APOPTOSIS; GENE-EXPRESSION; RELATIVE BIM; CANCER-CELLS; CPG ISLAND; S PHASE; P53	The E2F1 transcription factor is a critical downstream target of the tumor suppressor pRB. The retinoblastoma (RB) pathway is often inactivated in human tumors, resulting in deregulated E2F activity that can induce both proliferation and apoptosis. Bcl-2 homology 3 (BH3)-only proteins are pro-apoptotic members of the Bcl-2 protein family that trigger apoptosis in response to diverse stimuli. We show here that E2F1 up-regulates the expression of the pro-apoptotic BH3-only proteins PUMA, Noxa, Bim, and Hrk/DP5 through a direct transcriptional mechanism. Expression of the E7 protein of HPV16, which disrupts RB/E2F complexes, also up-regulates the expression of these four BH3-only proteins, implicating endogenous E2F in this phenomenon. Indeed, endogenous E2F1 binds the promoters of these four genes. Furthermore, inhibition of E2F1-induced expression of either Noxa or PUMA results in a significant reduction in E2F1-induced apoptosis, indicating that increased Noxa and PUMA levels mediate this E2F1-induced apoptosis. Importantly, inhibition of E2F activity abolishes DNA damage-induced elevation of PUMA levels, implicating E2F in the physiological regulation of PUMA expression. These data provide a novel direct link between E2F and the apoptotic machinery and may explain the increased sensitivity of cells with a defective RB/E2F pathway to chemotherapy.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	doron.ginsberg@weizmann.ac.il		ginsberg, doron/0000-0002-1257-4920				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Berkovich E, 2003, CELL CYCLE, V2, P127, DOI 10.4161/cc.2.2.293; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dong YB, 1999, CANCER, V86, P2021, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Yang HL, 2000, CLIN CANCER RES, V6, P1579; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	38	266	280	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8627	8634		10.1074/jbc.M312866200	http://dx.doi.org/10.1074/jbc.M312866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684737	hybrid			2022-12-27	WOS:000189265900014
J	Schoch, GA; Yano, JK; Wester, MR; Griffin, KJ; Stout, CD; Johnson, EF				Schoch, GA; Yano, JK; Wester, MR; Griffin, KJ; Stout, CD; Johnson, EF			Structure of human microsomal cytochrome P4502C8 - Evidence for a peripheral fatty acid binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; METABOLISM; EXPRESSION; PURIFICATION; REDUCTASE; PROGRAM; ENZYMES; CYP2C8	A 2.7-Angstrom molecular structure of human microsomal cytochrome P450 2C8 (CYP2C8) was determined by x-ray crystallography. The membrane protein was modified for crystallization by replacement of the hydrophobic N-terminal transmembrane domain with a short hydrophilic sequence before residue 28. The structure of the native sequence is complete from residue 28 to the beginning of a C-terminal histidine tag used for purification. CYP2C8 is one of the principal hepatic drug-metabolizing enzymes that oxidizes therapeutic drugs such as taxol and cerivastatin and endobiotics such as retinoic acid and arachidonic acid. Consistent with the relatively large size of its preferred substrates, the active site volume is twice that observed for the structure of CYP2C5. The extended active site cavity is bounded by the beta1 sheet and helix F' that have not previously been implicated in substrate recognition by mammalian P450s. CYP2C8 crystallized as a symmetric dimer formed by the interaction of helices F, F', G', and G. Two molecules of palmitic acid are bound in the dimer interface. The dimer is observed in solution, and mass spectrometry confirmed the association of palmitic acid with the enzyme. This novel finding identifies a peripheral binding site in P450s that may contribute to drug-drug interactions in P450 metabolism.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Stout, CD (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd,MB8, La Jolla, CA 92037 USA.	dave@scripps.edu; johnson@scripps.edu		Yano, Jason/0000-0002-9774-2611	NCRR NIH HHS [M01 RR00883] Funding Source: Medline; NIGMS NIH HHS [GM31001, GM59229] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001, R01GM059229] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSTON K, 1991, J BIOL CHEM, V266, P735; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin SJ, 1999, BRIT J CLIN PHARMACO, V48, P424; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; Cresteil T, 2002, DRUG METAB DISPOS, V30, P438, DOI 10.1124/dmd.30.4.438; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Klose TS, 1999, J BIOCHEM MOL TOXIC, V13, P289, DOI 10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee DS, 2003, J BIOL CHEM, V278, P9761, DOI 10.1074/jbc.M211575200; LESLIE AGW, 1996, DATA COLLECTION STRA; Li XQ, 2002, J PHARMACOL EXP THER, V300, P399, DOI 10.1124/jpet.300.2.399; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; MATSUURA S, 1978, J CELL BIOL, V78, P503, DOI 10.1083/jcb.78.2.503; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369; OHTA Y, 1994, J BIOL CHEM, V269, P15597; Ohyama K, 2000, DRUG METAB DISPOS, V28, P1303; OMURA T, 1964, J BIOL CHEM, V239, P2379; Prueksaritanont T, 2002, DRUG METAB DISPOS, V30, P1280, DOI 10.1124/dmd.30.11.1280; RAHMAN A, 1994, CANCER RES, V54, P5543; RICHARDSON TH, 1995, ARCH BIOCHEM BIOPHYS, V323, P87, DOI 10.1006/abbi.1995.0013; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Szczesna-Skorupa E, 2003, J BIOL CHEM, V278, P31269, DOI 10.1074/jbc.M301489200; Tracy TS, 1999, BRIT J CLIN PHARMACO, V47, P545, DOI 10.1046/j.1365-2125.1999.00923.x; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; Wang JS, 2002, DRUG METAB DISPOS, V30, P1352, DOI 10.1124/dmd.30.12.1352; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Wester MR, 2002, METHOD ENZYMOL, V357, P73; Williams D, 2002, CLIN PHARMACOKINET, V41, P343, DOI 10.2165/00003088-200241050-00003; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P10113, DOI 10.1021/bi00032a003; Yamazaki H, 1999, DRUG METAB DISPOS, V27, P1260; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zhao X, 2003, CURR DRUG METAB, V4, P73, DOI 10.2174/1389200033336892	43	341	351	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9497	9503		10.1074/jbc.M312516200	http://dx.doi.org/10.1074/jbc.M312516200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676196	hybrid			2022-12-27	WOS:000189265900116
J	Tanaka, Y; Kobayashi, H; Suzuki, M; Kanayama, N; Terao, T				Tanaka, Y; Kobayashi, H; Suzuki, M; Kanayama, N; Terao, T			Transforming growth factor-beta 1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PLASMINOGEN-ACTIVATOR; FACTOR-I; PHOSPHATIDYLINOSITOL-3 KINASE; PHOSPHOINOSITIDE 3-KINASE; RECEPTOR EXPRESSION; PROTEASE INHIBITOR; TGF-BETA; BIKUNIN; AKT	Urokinase-type plasminogen activator (uPA) has been implicated in tumor cell invasion and metastasis. We reported previously that transforming growth factor (TGF)-beta1 induces a dose- and time-dependent up-regulation of uPA mRNA and protein in highly invasive human ovarian cancer cell line HRA, leading to invasion. To further elucidate the mechanism of the invasive effect of TGF-beta1, we investigated which signaling pathway transduced by TGF-beta1 is responsible for this effect. Here, we show that 1) nontoxic concentrations of TGF-beta1 activated Src kinase; 2) TGF-beta1 rapidly phosphorylates ERK1/2 and Akt, but not p38; 3) pharmacological Src inhibitor PP2 or antisense ( AS) c-Src oligodeoxynucleotide (ODN) treatment reduced TGF-beta1-induced phosphorylation of ERK1/2 and Akt by 85 - 90% compared with controls; 4) pharmacological inhibition of MAPK by PD98059 abrogated TGF-beta1-mediated Akt stimulation, whereas TGF-beta1-induced ERK1/2 stimulation was not inhibited by PI3K inhibitor LY294002 or AS-PI3K ODN transfection; 5) up-regulation of uPA mRNA in response to TGF-beta1 was almost totally blocked by PP2 and PD98059 and partially (similar to55%) by LY294002; 6) TGF-beta1-induced uPA mRNA up-regulation was inhibited by treatment with AS ODNs to c-Src or PI3K by 90 or 60%, respectively, compared with control ODN treatment; and 7) blockade of the release of the transcription factor NF-kappaB by pyrrolidinedithiocarbamate reduced the TGF-beta1-induced activation of the uPA gene by similar to 65%. In addition, curcumin, a blocker of the transcriptional factor AP-1, partially (35%) canceled this effect. Taken together, these data support a role for TGF-beta1 activation of two distinct pathways ( Src-MAPK- PI3K-NF-kappaB-dependent and Src-MAPK-AP-1-dependent) for TGF-beta1-dependent uPA up-regulation and promotion of invasion.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handayama 1-20-1, Shizuoka 4313192, Japan.	hirokoba@hama-med.ac.jp						BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEL PL, 1997, SCIENCE, V278, P687; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dunn SE, 2001, CANCER RES, V61, P1367; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Fukuda K, 1998, ONCOGENE, V16, P3349, DOI 10.1038/sj.onc.1201896; Han SH, 1998, J PHARMACOL EXP THER, V287, P1105; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200; Iglesias M, 2000, ONCOGENE, V19, P4134, DOI 10.1038/sj.onc.1203764; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Kobayashi H, 1998, EUR J BIOCHEM, V253, P817, DOI 10.1046/j.1432-1327.1998.2530817.x; Kobayashi H, 2003, J BIOL CHEM, V278, P7790, DOI 10.1074/jbc.M210407200; Kobayashi H, 2002, EUR J BIOCHEM, V269, P3945, DOI 10.1046/j.1432-1033.2002.03068.x; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Liu Q, 1998, J IMMUNOL, V160, P1393; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Mehra A, 2002, BIOCHEM CELL BIOL, V80, P605, DOI 10.1139/O02-161; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Mori T, 2000, J NEURO-ONCOL, V46, P115, DOI 10.1023/A:1006339717748; Muehlenweg B, 2001, EXPERT OPIN BIOL TH, V1, P683; Ozes ON, 1999, NATURE, V401, P82; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shimamura H, 2003, J AM SOC NEPHROL, V14, P1427, DOI 10.1097/01.ASN.0000066140.99610.32; Shin EY, 2002, J CANCER RES CLIN, V128, P596, DOI 10.1007/s00432-002-0388-4; Suzuki M, 2003, INT J CANCER, V104, P289, DOI 10.1002/ijc.10950; Suzuki M, 2003, J BIOL CHEM, V278, P14640, DOI 10.1074/jbc.M300239200; Suzuki M, 2002, J BIOL CHEM, V277, P8022, DOI 10.1074/jbc.M108545200; Tanno S, 2001, CANCER RES, V61, P589; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	46	64	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8567	8576		10.1074/jbc.M309131200	http://dx.doi.org/10.1074/jbc.M309131200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676209	hybrid			2022-12-27	WOS:000189265900007
J	Znaidi, S; Pelletier, B; Mukai, Y; Labbe, S				Znaidi, S; Pelletier, B; Mukai, Y; Labbe, S			The Schizosaccharomyces pombe corepressor Tup11 interacts with the iron-responsive transcription factor Fep1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSPORTER GENE-EXPRESSION; NEURAL SPECIFICITY GENE; FISSION YEAST; DNA-BINDING; SIDEROPHORE BIOSYNTHESIS; USTILAGO-MAYDIS; NEUROSPORA-CRASSA; GATA FACTOR; CAENORHABDITIS-ELEGANS	The Schizosaccharomyces pombe fep1(+) gene encodes a GATA transcription factor that represses the expression of iron transport genes in response to elevated iron concentrations. This transcriptional response is altered only in strains harboring a combined deletion of both tup11(+) and tup12(+) genes. This suggests that Tup11 is capable of negatively regulating iron transport gene expression in the absence of Tup12 and vice versa. The tup11(+)- and tup12(+)-encoded proteins resemble the Saccharomyces cerevisiae Tup1 corepressor. Using yeast two-hybrid analysis we show that Tup11 and Fep1 physically interact with each other. The C-terminal region from amino acids 242 to 564 of Fep1 is required for interaction with Tup11. Within this region, a minimal domain encompassing amino acids 405 - 541 was sufficient for Tup11-Fep1 association. Deletion mapping analysis revealed that the WD40-repeat sequence motifs of Tup11 are necessary for its interaction with Fep1. Analysis of Tup11 mutants with single amino acid substitutions in the WD40 repeats suggested that the Fep1 transcription factor interacts with a putative flat upper surface on the predicted beta-propeller structure of this motif. Further analysis by in vivo coimmunoprecipitation showed that Tup11 and Fep1 are physically associated. In vitro pull-down experiments further verified a direct interaction between the Fep1 C terminus and the Tup11 C-terminal WD40 repeat domain. Taken together, these results describe the first example of a physical interaction between a corepressor and an iron-sensing factor controlling the expression of iron uptake genes.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada; Osaka Univ, Dept Biotechnol, Suita, Osaka 5650871, Japan	University of Sherbrooke; Osaka University	Labbe, S (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12E Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Simon.Labbe@USherbrooke.ca	Znaidi, Sadri/W-6952-2019	Znaidi, Sadri/0000-0001-9238-2218; Mukai, Yukio/0000-0003-1265-0839; Labbe, Simon/0000-0002-4947-523X				ALFA C, 1993, EXPT FISSION YEASTS; An ZQ, 1997, P NATL ACAD SCI USA, V94, P5882, DOI 10.1073/pnas.94.11.5882; An ZQ, 1997, EMBO J, V16, P1742, DOI 10.1093/emboj/16.7.1742; Askwith C, 1997, J BIOL CHEM, V272, P401; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; Beaudoin J, 2003, J BIOL CHEM, V278, P14565, DOI 10.1074/jbc.M300861200; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Boukhalfa H, 2002, BIOMETALS, V15, P325, DOI 10.1023/A:1020218608266; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Fashena SJ, 2000, METHOD ENZYMOL, V328, P14, DOI 10.1016/S0076-6879(00)28387-0; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Greenall A, 2002, MOL BIOL CELL, V13, P2977, DOI 10.1091/mbc.01-12-0568; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haas H, 1997, GENE, V184, P33, DOI 10.1016/S0378-1119(96)00570-7; Haas H, 1999, J BIOL CHEM, V274, P4613, DOI 10.1074/jbc.274.8.4613; Haas H, 2003, APPL MICROBIOL BIOT, V62, P316, DOI 10.1007/s00253-003-1335-2; Harrison KA, 2002, BIOCHEMISTRY-US, V41, P15288, DOI 10.1021/bi0204995; Henikoff S, 2003, NATURE, V423, P814, DOI 10.1038/423814a; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Janoo RTK, 2001, GENETICS, V157, P1205; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; Kaplan J, 2002, CELL, V111, P603, DOI 10.1016/S0092-8674(02)01164-9; Kaplan J, 2002, SEMIN HEMATOL, V39, P219, DOI 10.1053/shem.2002.35631; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; Knight SAB, 2002, MICROBIOL-SGM, V148, P29, DOI 10.1099/00221287-148-1-29; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; Kowalski K, 2002, J BIOL CHEM, V277, P35720, DOI 10.1074/jbc.M204663200; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Lesuisse E, 2001, MICROBIOL-UK, V147, P289, DOI 10.1099/00221287-147-2-289; Lesuisse E, 2002, YEAST, V19, P329, DOI 10.1002/yea.840; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; MILLER DM, 1993, GENETICS, V135, P741; Miller J. H, 1972, EXPT MOL GENETICS; Mukai Y, 1999, MOL CELL BIOL, V19, P8461; Mukai Y, 2003, J BIOL CHEM, V278, P18895, DOI 10.1074/jbc.M302155200; Oberegger H, 2002, BIOCHEM SOC T, V30, P781, DOI 10.1042/bst0300781; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Ostling J, 1996, MOL CELL BIOL, V16, P753; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Pelletier B, 2003, NUCLEIC ACIDS RES, V31, P4332, DOI 10.1093/nar/gkg647; Pelletier B, 2002, J BIOL CHEM, V277, P22950, DOI 10.1074/jbc.M202682200; Pflugrad A, 1997, DEVELOPMENT, V124, P1699; Philpott CC, 2002, BIOCHEM SOC T, V30, P698, DOI 10.1042/bst0300698; Pickles LM, 2002, STRUCTURE, V10, P751, DOI 10.1016/S0969-2126(02)00768-2; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Rutherford JC, 2003, J BIOL CHEM, V278, P27636, DOI 10.1074/jbc.M300076200; Scazzocchio C, 2000, CURR OPIN MICROBIOL, V3, P126, DOI 10.1016/S1369-5274(00)00063-1; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Touati D, 2000, ARCH BIOCHEM BIOPHYS, V373, P1, DOI 10.1006/abbi.1999.1518; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; VOISARD C, 1993, MOL CELL BIOL, V13, P7091, DOI 10.1128/MCB.13.11.7091; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOJTEK AB, 1997, YEAST 2 HYBRID SYSTE, P29; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; Winnier AR, 1999, GENE DEV, V13, P2774, DOI 10.1101/gad.13.21.2774; Zhou LW, 1999, BIOCHEMISTRY-US, V38, P4335, DOI 10.1021/bi982543f; Zhou LW, 1998, MOL GEN GENET, V259, P532, DOI 10.1007/s004380050845	83	43	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9462	9474		10.1074/jbc.M312787200	http://dx.doi.org/10.1074/jbc.M312787200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668334	hybrid			2022-12-27	WOS:000189265900112
J	Broderick, KE; Kean, L; Dow, JAT; Pyne, NJ; Davies, SA				Broderick, KE; Kean, L; Dow, JAT; Pyne, NJ; Davies, SA			Ectopic expression of bovine type 5 phosphodiesterase confers a renal phenotype in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; HUMAN CGMP-BINDING; NITRIC-OXIDE; MALPIGHIAN TUBULES; EPITHELIAL FUNCTION; SIGNALING PATHWAY; FLUID SECRETION; MELANOGASTER; PDE5; GENE	cGMP signaling regulates epithelial fluid transport by Drosophila Malpighian (renal) tubules. In order to directly evaluate the importance of cGMP-degrading phosphodiesterases (PDEs) in epithelial transport, bovine PDE5 (a bona fide cGMP-PDE), was ectopically expressed in vivo. Transgenic UAS-PDE5 Drosophila were generated, and PDE5 expression was driven in specified tubule cells in vivo by cell-specific GAL4 drivers. Targeted expression was verified by PCR and Western blotting. Immunolocalization of PDE5 in tubule confirmed specificity of expression and demonstrated localization to the apical plasma membrane. GAL4/UAS-PDE5 tubules exhibit increased cG-PDE activity and reduced basal cGMP levels compared with control lines. We show that wild-type and control tubules are sensitive to the PDE5-specific inhibitor sildenafil and that GAL4/UAS-PDE5 tubules display enhanced sensitivity to sildenafil, compared with controls. cGMP content in GAL4/UAS-PDE5 tubules is restored to control levels by treatment with sildenafil. Thus bovine PDE5 retains cGMP-degrading activity and inhibitor sensitivity when expressed in Drosophila. Expression of PDE5 in tubule principal cells results in an epithelial phenotype, reducing rates of basal and cGMP-/Cardioaccelatory peptide(2b)(CAP(2b))-stimulated fluid transport. Furthermore, inhibition of PDE5 activity by sildenafil restores basal and cGMP-stimulated fluid transport rates to control levels. However, corticotrophin releasing factor-like-stimulated transport, which is activated by cAMP signaling, was unaffected, confirming that only cGMP-stimulated signaling events in tubule are compromised by overexpression of PDE5. Successful ectopic expression of a vertebrate cG-PDE in Drosophila has shown that cG-PDE has a critical role in tubule function in vivo and that cG-PDE function is conserved across evolution. The transgene also provides a generic tool for the analysis of cGMP signaling in Drosophila.	Univ Glasgow, Inst Biomed & Life Sci, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland; Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland	University of Glasgow; University of Strathclyde	Davies, SA (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland.	s.a.davies@bio.gla.ac.uk	Dow, Julian/M-2371-2019	Dow, Julian/0000-0002-9595-5146; Pyne, Nigel/0000-0002-5657-4578				Bouley R, 2000, J CLIN INVEST, V106, P1115, DOI 10.1172/JCI9594; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broderick KE, 2003, AM J PHYSIOL-CELL PH, V285, pC1207, DOI 10.1152/ajpcell.00123.2003; Cabrero P, 2002, J EXP BIOL, V205, P3799; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; Corbin JD, 2002, INT J CLIN PRACT, V56, P453; Davies SA, 1995, AM J PHYSIOL-REG I, V269, pR1321, DOI 10.1152/ajpregu.1995.269.6.R1321; Davies SA, 1997, AM J PHYSIOL-REG I, V273, pR823, DOI 10.1152/ajpregu.1997.273.2.R823; Davies SA, 2000, INSECT BIOCHEM MOLEC, V30, P1123, DOI 10.1016/S0965-1748(00)00118-1; Dousa TP, 1999, KIDNEY INT, V55, P29, DOI 10.1046/j.1523-1755.1999.00233.x; Dow JAT, 2003, PHYSIOL REV, V83, P687, DOI 10.1152/physrev.00035.2002; Dow JAT, 1999, J BIOENERG BIOMEMBR, V31, P75, DOI 10.1023/A:1005400731289; Dow JAT, 2001, ADV INSECT PHYSIOL, V28, P1, DOI 10.1016/S0065-2806(01)28008-4; DOW JAT, 1994, AM J PHYSIOL, V266, pR1716, DOI 10.1152/ajpregu.1994.266.5.R1716; DOW JAT, 1994, J EXP BIOL, V197, P421; Kean L, 2002, AM J PHYSIOL-REG I, V282, pR1297, DOI 10.1152/ajpregu.00584.2001; KERR M, 2000, COMP BIOCH PHYSL, V126, P77; Kurjak M, 2001, J PHYSIOL-LONDON, V534, P827, DOI 10.1111/j.1469-7793.2001.00827.x; Lee EYW, 1996, AM J PHYSIOL-RENAL, V271, pF3, DOI 10.1152/ajprenal.1996.271.1.F3; Loughney K, 1998, GENE, V216, P139, DOI 10.1016/S0378-1119(98)00303-5; MacPherson MR, 2001, AM J PHYSIOL-CELL PH, V280, pC394, DOI 10.1152/ajpcell.2001.280.2.C394; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Murthy KS, 2001, BIOCHEM J, V360, P199, DOI 10.1042/0264-6021:3600199; Pollock VP, 2003, J EXP BIOL, V206, P901, DOI 10.1242/jeb.00189; PYNE NJ, 1993, AGENT ACTION SUPPL, V43, P35; Radford JC, 2002, J BIOL CHEM, V277, P38810, DOI 10.1074/jbc.M203694200; Riegel JA, 1998, J EXP BIOL, V201, P3411; Rosay P, 1997, J CELL SCI, V110, P1683; Sokolowski MB, 2002, NATURE, V419, P893, DOI 10.1038/419893a; SOZEN HA, 1997, P NATL ACAD SCI USA, V94, P5207; Stacey P, 1998, BIOCHEM BIOPH RES CO, V247, P249, DOI 10.1006/bbrc.1998.8769; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; Terhzaz S, 1999, J EXP BIOL, V202, P3667; Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124; Turko IV, 1998, BIOCHEM J, V329, P505; Vaandrager AB, 1996, MOL CELL BIOCHEM, V157, P23, DOI 10.1007/BF00227877; Welch WJ, 2002, CURR OPIN NEPHROL HY, V11, P109, DOI 10.1097/00041552-200201000-00016	38	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8159	8168		10.1074/jbc.M304679200	http://dx.doi.org/10.1074/jbc.M304679200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662775	hybrid			2022-12-27	WOS:000189103300097
J	Kim, W; Kook, S; Kim, DJ; Teodorof, C; Song, WK				Kim, W; Kook, S; Kim, DJ; Teodorof, C; Song, WK			The 31-kDa caspase-generated cleavage product of p130(cas) functions as a transcriptional repressor of E2A in apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; LOOP-HELIX PROTEINS; DNA-BINDING; EXTRACELLULAR-MATRIX; DOCKING PROTEIN; GROWTH ARREST; ID PROTEINS; DEPENDENT CLEAVAGE; ENDOTHELIAL-CELLS; CARCINOMA CELLS	In response to integrin receptor binding to the extracellular matrix, the multidomain docking protein p130(cas) (Crk-associated substrate) activates various signaling cascades modulating such cellular processes as proliferation, migration, and apoptosis. During apoptosis, caspase-mediated cleavage of p130(cas) generated a C-terminal 31-kDa fragment (31-kDa) and promoted morphological changes characteristic of apoptosis, including loss of focal adhesions, cell rounding, and nuclear condensation and fragmentation. By contrast, a p130(cas) D748E mutant, which was unable to produce 31-kDa, attenuated the disassembly of focal adhesions at the bottom of the cell. 31-kDa contains a helix-loop-helix (HLH) domain that shows greater sequence homology with Id proteins than with basic HLH proteins, which enabled heterodimerization with E2A. Once coupled to E2A, 31-kDa was translocated to the cell nucleus, where it inhibited E2A-mediated p21(Waf1/Cip1) transcription. Moreover, overexpression of 31-kDa led to cell death that could be inhibited by treatment with the caspase inhibitor ZVAD-fluoromethyl ketone or by ectopic expression of E2A or p21(Waf1/Cip1). These data suggest that during etoposide-induced apoptosis, 31-kDa promotes caspase-mediated cell death by inhibiting E2A-mediated activation of p21(Waf1/Cip1) transcription.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Gwangju Institute of Science & Technology (GIST); Vanderbilt University	Song, WK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	wksong@kjist.ac.kr						Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Glaser T, 2001, ONCOGENE, V20, P4757, DOI 10.1038/sj.onc.1204498; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Harte MT, 2000, BBA-MOL CELL RES, V1499, P34, DOI 10.1016/S0167-4889(00)00104-X; Herblot S, 2002, MOL CELL BIOL, V22, P886, DOI 10.1128/MCB.22.3.886-900.2002; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; Kee BL, 2002, EMBO J, V21, P103, DOI 10.1093/emboj/21.1.103; Kim DH, 2003, BIOCHEM BIOPH RES CO, V300, P141, DOI 10.1016/S0006-291X(02)02786-9; Kook S, 2000, MOL BIOL CELL, V11, P929, DOI 10.1091/mbc.11.3.929; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Law SF, 1999, EXP CELL RES, V252, P224, DOI 10.1006/excr.1999.4609; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Shim SR, 2001, BIOCHEM BIOPH RES CO, V286, P601, DOI 10.1006/bbrc.2001.5441; Sigvardsson M, 2000, MOL CELL BIOL, V20, P3640, DOI 10.1128/MCB.20.10.3640-3654.2000; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Tian H, 2000, CANCER RES, V60, P679; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Wei L, 2002, J CELL BIOCHEM, V87, P439, DOI 10.1002/jcb.10322; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	56	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8333	8342		10.1074/jbc.M312026200	http://dx.doi.org/10.1074/jbc.M312026200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660614	hybrid			2022-12-27	WOS:000189103300115
J	Xu, BE; Stippec, S; Lenertz, L; Lee, BH; Zhang, W; Lee, YK; Cobb, MH				Xu, BE; Stippec, S; Lenertz, L; Lee, BH; Zhang, W; Lee, YK; Cobb, MH			WNK1 activates ERK5 by an MEKK2/3-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; TYROSINE KINASES; IDENTIFICATION; PATHWAYS; GENE; MEK5; PHOSPHORYLATION; NEUROTROPHINS	WNK1 belongs to a unique protein kinase family that lacks the catalytic lysine in its normal position. Mutations in human WNK1 and WNK4 have been implicated in causing a familial form of hypertension. Here we report that overexpression of WNK1 led to increased activity of cotransfected ERK5 in HEK293 cells. ERK5 activation was blocked by the MEK5 inhibitor U0126 and expression of a dominant negative MEK5 mutant. Expression of dominant negative mutants of MEKK2 and MEKK3 also blocked activation of ERK5 by WNK1. Moreover, both MEKK2 and MEKK3 coimmunoprecipitated with endogenous WNK1 from cell lysates. WNK1 phosphorylated both MEKK2 and - 3 in vitro, and MEKK3 was activated by WNK1 in 293 cells. Finally, ERK5 activation by epidermal growth factor was attenuated by suppression of WNK1 expression using small interfering RNA. Taken together, these results place WNK1 in the ERK5 MAP kinase pathway upstream of MEKK2/3.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mcobb@mednet.swmed.edu		Cobb, Melanie/0000-0003-0833-5473; Lee, Byung-Hoon/0000-0002-7101-0471	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Cameron SJ, 2004, J BIOL CHEM, V279, P1506, DOI 10.1074/jbc.M308755200; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chen Z, 2003, J BIOL CHEM, V278, P22278, DOI 10.1074/jbc.M301173200; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Dong F, 2001, J BIOL CHEM, V276, P10811, DOI 10.1074/jbc.M008748200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kostich M, 2002, GENOME BIOL, V3; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Murakami-Kojima M, 2002, PLANT CELL PHYSIOL, V43, P675, DOI 10.1093/pcp/pcf084; Nakamichi N, 2002, BIOSCI BIOTECH BIOCH, V66, P2429, DOI 10.1271/bbb.66.2429; Pearson GW, 2002, J BIOL CHEM, V277, P48094, DOI 10.1074/jbc.M208535200; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; Xu BE, 2002, J BIOL CHEM, V277, P48456, DOI 10.1074/jbc.M207917200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443; Zambrowicz BP, 2003, P NATL ACAD SCI USA, V100, P14109, DOI 10.1073/pnas.2336103100; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	36	118	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7826	7831		10.1074/jbc.M313465200	http://dx.doi.org/10.1074/jbc.M313465200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681216	hybrid			2022-12-27	WOS:000189103300058
J	Baroli, I; Gutman, BL; Ledford, HK; Shin, JW; Chin, BL; Havaux, M; Niyogi, KK				Baroli, I; Gutman, BL; Ledford, HK; Shin, JW; Chin, BL; Havaux, M; Niyogi, KK			Photo-oxidative stress in a xanthophyll-deficient mutant of Chlamydomonas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLET OXYGEN; PHOTOPROTECTION; GENE; ACCUMULATION; CAROTENOIDS; REINHARDTII; PLANTS	When there is an imbalance between the light energy absorbed by a photosynthetic organism and that which can be utilized in photosynthesis, photo-oxidative stress can damage pigments, proteins, lipids, and nucleic acids. In this work we compared the wild type and a xanthophyll-deficient mutant of Chlamydomonas reinhardtii in their response to high amounts of light. Wildtype Chlamydomonas cells were able to acclimate to high amounts of light following transfer from low light conditions. In contrast, the npq1 lor1 double mutant, which lacks protective xanthophylls (zeaxanthin and lutein) in the chloroplast, progressively lost viability and photosynthetic capacity along with destruction of thylakoid membrane protein-pigment complexes and accumulation of reactive oxygen species and membrane lipid peroxides. Loss of viability was partially rescued by lowered oxygen tension, suggesting that the high sensitivity of the mutant to light stress is caused by the production of reactive oxygen species in the chloroplast. Cell death was not prevented by the addition of an organic carbon source to the growth medium, demonstrating that the photo-oxidative damage can target other essential chloroplast processes besides photosynthesis. From the differential sensitivity of the mutant to exogenously added pro-oxidants, we infer that the reactive oxygen species produced during light stress in npq1 lor1 may be singlet oxygen and/or superoxide but not hydrogen peroxide. The bleaching phenotype of npq1 lor1 was not due to enhanced photodamage to photosystem II but rather to a less localized phenomenon of accumulation of photo-oxidation products in chloroplast membranes.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Mediterranee, CEA 1000,CEA 163, CNRS,Lab Ecophysiol Photosynth,UMR, Dept Ecophysiol Vegetale & Microbiol,Cdarache, F-13108 St Paul Les Durance, France	University of California System; University of California Berkeley; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Niyogi, KK (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	niyogi@nature.berkeley.edu		Baroli, Irene/0000-0001-9014-0821	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007127, R01GM058799] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07127, GM58799] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baroli I, 2003, PLANT CELL, V15, P992, DOI 10.1105/tpc.010405; Baroli I, 2000, PHILOS T R SOC B, V355, P1385, DOI 10.1098/rstb.2000.0700; CADENAS E, 1984, PHOTOCHEM PHOTOBIOL, V40, P823, DOI 10.1111/j.1751-1097.1984.tb04657.x; CHUNAEV AS, 1991, PHOTOSYNTHETICA, V25, P291; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; Ducruet JM, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P4353; Elrad D, 2002, PLANT CELL, V14, P1801, DOI 10.1105/tpc.002154; Frank H. A., 1993, CAROTENOIDS PHOTOSYN, P252, DOI [10.1007/978-94-011-2124-8_8, DOI 10.1007/978-94-011-2124-8_8]; Gruszecki WI, 1999, ADV PHOTOSYNTH, V8, P363; Harris E., 1989, CHLAMYDOMONAS SOURCE, P575; Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762; Havaux M, 2003, TRENDS PLANT SCI, V8, P409, DOI 10.1016/S1360-1385(03)00185-7; Havaux M, 1998, TRENDS PLANT SCI, V3, P147, DOI 10.1016/S1360-1385(98)01200-X; Hideg E, 1998, BIOCHEMISTRY-US, V37, P11405, DOI 10.1021/bi972890+; Leisinger U, 2001, PLANT MOL BIOL, V46, P395, DOI 10.1023/A:1010601424452; MACPHERSON AN, 1993, BIOCHIM BIOPHYS ACTA, V1143, P301, DOI 10.1016/0005-2728(93)90201-P; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; Muller-Moule P, 2003, PLANT PHYSIOL, V133, P748, DOI 10.1104/pp.103.026252; Niyogi KK, 1997, P NATL ACAD SCI USA, V94, P14162, DOI 10.1073/pnas.94.25.14162; Niyogi KK, 2001, PHOTOSYNTH RES, V67, P139, DOI 10.1023/A:1010661102365; Niyogi KK, 1997, PLANT CELL, V9, P1369, DOI 10.2307/3870388; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; Pogson BJ, 1998, P NATL ACAD SCI USA, V95, P13324, DOI 10.1073/pnas.95.22.13324; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Ryter SW, 1998, FREE RADICAL BIO MED, V24, P1520, DOI 10.1016/S0891-5849(97)00461-9; SCHMIDT GW, 1977, P NATL ACAD SCI USA, V74, P610, DOI 10.1073/pnas.74.2.610; TELFER A, 1994, J BIOL CHEM, V269, P13244; Vavilin DV, 1998, PHOTOCHEM PHOTOBIOL, V68, P191, DOI 10.1111/j.1751-1097.1998.tb02488.x; WEBB MR, 1995, PLANT PHYSIOL, V107, P885, DOI 10.1104/pp.107.3.885	29	96	96	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6337	6344		10.1074/jbc.M312919200	http://dx.doi.org/10.1074/jbc.M312919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665619	hybrid			2022-12-27	WOS:000188969200018
J	Kappler, U; Aguey-Zinsou, KF; Hanson, GR; Bernhardt, PV; McEwan, AG				Kappler, U; Aguey-Zinsou, KF; Hanson, GR; Bernhardt, PV; McEwan, AG			Cytochrome c(551) from Starkeya novella - Characterization, spectroscopic properties, and phylogeny of a diheme protein of the SoxAX family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INORGANIC SULFUR-COMPOUNDS; PARACOCCUS-PANTOTROPHUS; THIOSULFATE OXIDATION; THIOBACILLUS-NOVELLUS; SULFITE DEHYDROGENASE; OXIDIZING SYSTEM; STRUCTURAL BASIS; SIGNAL PEPTIDES; GENE-CLUSTER; IDENTIFICATION	Cytochromes from the SoxAX family have a major role in thiosulfate oxidation via the thiosulfate-oxidizing multi-enzyme system (TOMES). Previously characterized SoxAX proteins from Rhodovulum sulficlophilum and Paracoccus pantotrophus contain three heme c groups, two of which are located on the SoxA subunit. In contrast, the SoxAX protein purified from Starkeya novella was found to contain only two heme groups. Mass spectrometry showed that a disulfide bond replaced the second heme group found in the diheme SoxA subunits. Apparent molecular masses of 27,229 +/- 10.3 Da and 20,258.6 +/- 1 Da were determined for SoxA and SoxX with an overall mass of 49.7 kDa, indicating a heterodimeric structure. Optical redox potentiometry found that the two heme cofactors are reduced at similar potentials (versus NHE) that are as follows: + 133 mV (pH 6.0); + 104 mV (pH 7.0); +49 (pH 7.9) and +10 mV (pH 8.7). EPR spectroscopy revealed that both ferric heme groups are in the low spin state, and the spectra were consistent with one heme having a His/Cys axial ligation and the other having a His/Met axial ligation. The His/Cys ligated heme is present in different conformational states and gives rise to three distinct signals. Amino acid sequencing was used to unambiguously assign the protein to the encoding genes, soxAX, which are part of a complete sox gene cluster found in S. novella. Phylogenetic analysis of soxA- and soxX-related gene sequences indicates a parallel development of SoxA and SoxY, with the diheme and monoheme SoxA sequences located on clearly separated branches of a phylogenetic tree.	Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Dept Chem, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Magnet Resonance, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Kappler, U (corresponding author), Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia.	u.kappler@uq.edu.au	Bernhardt, Paul V/J-8008-2013; Kappler, Ulrike/A-9483-2013; Aguey-Zinsou, Kondo-Francois/D-7162-2012; /C-3940-2008	Bernhardt, Paul V/0000-0001-6839-1763; Kappler, Ulrike/0000-0002-2642-1319; /0000-0003-0306-4360; McEwan, Alastair/0000-0002-2419-1003				Aguey-Zinsou KF, 2003, J AM CHEM SOC, V125, P530, DOI 10.1021/ja028293e; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Appia-Ayme C, 2002, BIOCHEM BIOPH RES CO, V296, P737, DOI 10.1016/S0006-291X(02)00936-1; Appia-Ayme C, 2001, J BACTERIOL, V183, P6107, DOI 10.1128/JB.183.20.6107-6118.2001; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bamford VA, 2002, EMBO J, V21, P5599, DOI 10.1093/emboj/cdf566; Bardischewsky F, 2001, FEMS MICROBIOL LETT, V202, P215, DOI 10.1016/S0378-1097(01)00318-4; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BOHAN TL, 1977, J MAGN RESON, V26, P109, DOI 10.1016/0022-2364(77)90240-2; Cheesman MR, 2001, BIOCHEMISTRY-US, V40, P10562, DOI 10.1021/bi0100081; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dutton P L, 1978, Methods Enzymol, V54, P411; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Friedrich CG, 1998, ADV MICROB PHYSIOL, V39, P235; Friedrich CG, 2001, APPL ENVIRON MICROB, V67, P2873, DOI 10.1128/AEM.67.7.2873-2882.2001; Friedrich CG, 2000, J BACTERIOL, V182, P4677, DOI 10.1128/JB.182.17.4677-4687.2000; Griffin M., 1999, Molecular Physics Reports, V26, P60; Hanson GR, 2003, PROG T CHEM, V10, P197; Kappler U, 2000, J BIOL CHEM, V275, P13202, DOI 10.1074/jbc.275.18.13202; Kappler U, 2001, ARCH MICROBIOL, V175, P102, DOI 10.1007/s002030000241; Kelly DP, 1997, ANTON LEEUW INT J G, V71, P95, DOI 10.1023/A:1000135707181; Kelly DP, 2000, INT J SYST EVOL MICR, V50, P1797, DOI 10.1099/00207713-50-5-1797; Klarskov K, 1998, BIOCHEMISTRY-US, V37, P10555, DOI 10.1021/bi9806706; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITCH FA, 1984, BIOCHEMISTRY-US, V23, P1831, DOI 10.1021/bi00303a039; McEwan AG, 2002, FEBS LETT, V518, P10, DOI 10.1016/S0014-5793(02)02532-2; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; OH JK, 1977, J GEN MICROBIOL, V99, P413, DOI 10.1099/00221287-99-2-413; OH JK, 1977, J GEN MICROBIOL, V99, P397, DOI 10.1099/00221287-99-2-397; Petri R, 2001, FEMS MICROBIOL LETT, V197, P171, DOI 10.1111/j.1574-6968.2001.tb10600.x; Pettigrew, 1990, CYTOCHROME C EVOLUTI; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Quentmeier A, 2001, FEBS LETT, V503, P168, DOI 10.1016/S0014-5793(01)02727-2; Quentmeier A, 2000, ARCH MICROBIOL, V173, P117, DOI 10.1007/s002039900118; Rother D, 2002, BBA-PROTEINS PROTEOM, V1598, P65, DOI 10.1016/S0167-4838(02)00332-1; Rother D, 2001, J BACTERIOL, V183, P4499, DOI 10.1128/JB.183.15.4499-4508.2001; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Stanley NR, 2002, MOL MICROBIOL, V43, P1005, DOI 10.1046/j.1365-2958.2002.02797.x; Starkey RL, 1935, SOIL SCI, V39, P197, DOI 10.1097/00010694-193503000-00004; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Verte F, 2002, BIOCHEMISTRY-US, V41, P2932, DOI 10.1021/bi011404m; Westermeier R, 2002, PROTEOMICS PRACTICE; Wilkins MR, 1997, J THEOR BIOL, V186, P7, DOI 10.1006/jtbi.1996.0346; Wodara C, 1997, J BACTERIOL, V179, P5014, DOI 10.1128/jb.179.16.5014-5023.1997; WODARA C, 1994, J BACTERIOL, V176, P6188, DOI 10.1128/jb.176.20.6188-6191.1994	54	30	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6252	6260		10.1074/jbc.M310644200	http://dx.doi.org/10.1074/jbc.M310644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645228	hybrid			2022-12-27	WOS:000188969200009
J	Lee, G; Tanaka, M; Park, K; Lee, SS; Kim, YM; Junn, E; Lee, SH; Mouradian, MM				Lee, G; Tanaka, M; Park, K; Lee, SS; Kim, YM; Junn, E; Lee, SH; Mouradian, MM			Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; ABNORMAL PHOSPHORYLATION; LEWY BODIES; PROTEIN; SYNPHILIN-1; TAU; AGGREGATION; MUTATION; BRAIN	alpha-Synuclein is a phosphoprotein that accumulates as a major component of Lewy bodies in the brains of patients with Parkinson disease. Synphilin-1, which is also present in Lewy bodies, binds with alpha-synuclein and forms cytoplasmic inclusions in transfected cells. Yet the molecular determinants of this protein-protein interaction are unknown. Here we report that casein kinase II (CKII) phosphorylates synphilin-1 and that the beta subunit of this enzyme complex binds to synphilin-1. Additionally, both CKII alpha and beta subunits are present within cytoplasmic inclusions in cells that overexpress synphilin-1. Notably, the interaction between synphilin-1 and alpha-synuclein is markedly dependent on phosphorylation. Inhibition of CKII activity by 5,6-dichlorol-beta-D-ribofuranosylbenzimidazole blocks the binding between these two proteins and significantly reduces the percentage of cells that contain eosinophilic cytoplasmic inclusions. Mutation of the major CKII phosphorylation site in alpha-synuclein (S129A) has no significant impact on the binding between alpha-synuclein and synphilin-1 or on the formation of synphilin-1/alpha-synuclein-positive inclusions. These data suggest that the CKII-mediated phosphorylation of synphilin-1 rather than that of alpha-synuclein is critical in modulating their tendency to aggregate into inclusions. These observations collectively indicate that a ubiquitous post-translational modification such as phosphorylation can regulate inclusion body formation in the context of alpha-synuclein and synphilin-1 interaction.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, Piscataway, NJ 08854 USA; NINDS, Genet Pharmacol Unit, NIH, Bethesda, MD 20824 USA; Ajou Univ, Sch Med, Med Genet Lab, Suwon 442721, South Korea	Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Ajou University	Mouradian, MM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, 683 Hoes Lane,Rm 180, Piscataway, NJ 08854 USA.	mouradian@umdnj.edu		Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002826] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Baba M, 1998, AM J PATHOL, V152, P879; BAUM L, 1992, BRAIN RES, V573, P126, DOI 10.1016/0006-8993(92)90121-O; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; GIRAULT JA, 1990, J NEUROCHEM, V55, P1772, DOI 10.1111/j.1471-4159.1990.tb04968.x; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; IIMOTO DS, 1990, BRAIN RES, V507, P273, DOI 10.1016/0006-8993(90)90282-G; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee G, 2002, J NEUROCHEM, V83, P346, DOI 10.1046/j.1471-4159.2002.01136.x; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; MARTIN ME, 1990, INT J DEV NEUROSCI, V8, P47; MASLIAH E, 1992, AM J PATHOL, V140, P263; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; NAKAJO S, 1986, BIOCHEM INT, V13, P701; Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi M, 2003, NEUROSCI LETT, V336, P155, DOI 10.1016/S0304-3940(02)01258-2; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Wakabayashi K, 2002, ACTA NEUROPATHOL, V103, P209, DOI 10.1007/s004010100451	41	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6834	6839		10.1074/jbc.M312760200	http://dx.doi.org/10.1074/jbc.M312760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645218	hybrid			2022-12-27	WOS:000188969200077
J	Vainauskas, S; Menon, AK				Vainauskas, S; Menon, AK			A conserved proline in the last transmembrane segment of Gaa1 is required for glycosylphosphatidylinositol (GPI) recognition by GPI transamidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; ANCHOR ATTACHMENT; MEMBRANE-PROTEINS; PIG-T; COMPLEX; BIOSYNTHESIS; MECHANISM; SUBUNITS; HELICES; FORM	Glycosylphosphatidylinositol (GPI)-anchored proteins are synthesized as precursor proteins that are processed in the endoplasmic reticulum by GPI transamidase (GPIT). Human GPIT is a multisubunit membrane-bound protein complex consisting of Gaa1, Gpi8, phosphatidylinositol glycan (PIG)-S, PIG-T, and PIG-U. The enzyme recognizes a C-terminal signal sequence in the proprotein and replaces it with a preformed GPI lipid. The nature of the functional interaction of the GPIT subunits with each other and with the proprotein and GPI substrates is largely unknown. We recently analyzed the GPIT subunit Gaa1, a polytopic protein with seven transmembrane (TM) spans, to identify sequence determinants in the protein that are required for its interaction with other subunits and for function (Vainauskas, S., Maeda, Y., Kurniawan, H., Kinoshita, T., and Menon, A. K. (2002) J. Biol Chem. 277, 30535-30542). We showed that elimination of the C-terminal TM segment of Gaa1 allows the protein to interact with Gpi8, PIG-S, and PIG-T but renders the resulting GPIT complex nonfunctional. We now show that GPIT complexes containing C-terminally truncated Gaa1 possess a full complement of subunits and are able to interact with a proprotein substrate but cannot co-immunoprecipitate GPI. We go on to show that mutation of a conserved proline residue centrally located within the C-terminal TM span of Gaa1 is sufficient to abrogate the ability of the resulting GPIT complex to co-immunoprecipitate GPI. We suggest that the putative dynamic hinge created by the proline residue provides a structural basis for the interaction of GPI with GPIT.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Vainauskas, S (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	saulius@biochem.wisc.edu		Menon, Anant Kumar/0000-0001-6924-2698	NIGMS NIH HHS [GM55427] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Chen R, 2003, J CELL BIOCHEM, V88, P1025, DOI 10.1002/jcb.10439; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Hiroi Y, 1998, FEBS LETT, V421, P252, DOI 10.1016/S0014-5793(97)01576-7; Hong YJ, 2003, MOL BIOL CELL, V14, P1780, DOI 10.1091/mbc.E02-12-0794; Karaoglu D, 2001, BIOCHEMISTRY-US, V40, P12193, DOI 10.1021/bi0111911; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KODUKULA K, 1992, P NATL ACAD SCI USA, V89, P4982, DOI 10.1073/pnas.89.11.4982; MAXWELL SE, 1995, J BIOL CHEM, V270, P19576, DOI 10.1074/jbc.270.33.19576; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Nagamune K, 2003, P NATL ACAD SCI USA, V100, P10682, DOI 10.1073/pnas.1833260100; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 2003, J BIOL CHEM, V278, P13959, DOI 10.1074/jbc.M300586200; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; Reiersen H, 2001, TRENDS BIOCHEM SCI, V26, P679, DOI 10.1016/S0968-0004(01)01957-0; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Spurway TD, 2001, J BIOL CHEM, V276, P15975, DOI 10.1074/jbc.M010128200; Tieleman DP, 2001, PROTEINS, V44, P63, DOI 10.1002/prot.1073; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vainauskas S, 2002, J BIOL CHEM, V277, P30535, DOI 10.1074/jbc.M205402200; VIDUGIRIENE J, 1995, METHOD ENZYMOL, V250, P513; Vidugiriene J, 2001, EUR J BIOCHEM, V268, P2290, DOI 10.1046/j.1432-1327.2001.02106.x; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	28	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6540	6545		10.1074/jbc.M312191200	http://dx.doi.org/10.1074/jbc.M312191200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660601	hybrid			2022-12-27	WOS:000188969200041
J	Gagnon, E; Bergeron, MJ; Brunet, GM; Daigle, ND; Simard, CF; Isenring, P				Gagnon, E; Bergeron, MJ; Brunet, GM; Daigle, ND; Simard, CF; Isenring, P			Molecular mechanisms of Cl- transport by the renal Na+-K+-Cl- cotransporter - Identification of an intracellular locus that may form part of a high affinity Cl--binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-2CL(-) COTRANSPORTER; BUMETANIDE BINDING; CHLORIDE COTRANSPORTER; FUNCTIONAL EXPRESSION; ION-TRANSPORT; CLONING; RABBIT; KIDNEY; FAMILY; NKCC1	The 2(nd) transmembrane domain ( tm) of the secretory Na+-K+-Cl- cotransporter ( NKCC1) and of the kidney-specific isoform ( NKCC2) has been shown to play an important role in cation transport. For NKCC2, by way of illustration, alternative splicing of exon 4, a 96- bp sequence from which tm2 is derived, leads to the formation of the NKCC2A and F variants that both exhibit unique affinities for cations. Of interest, the NKCC2 variants also exhibit substantial differences in Cl- affinity as well as in the residue composition of the first intracellular connecting segment ( cs1a), which immediately follows tm2 and which too is derived from exon 4. In this study, we have prepared chimeras of the shark NKCC2A and F ( saA and saF) to determine whether cs1a could play a role in Cl (-) transport; here, tm2 or cs1a in saF was replaced by the corresponding domain from saA ( generating saA/ F or saF/ A, respectively). Functional analyses of these chimeras have shown that cs1a- specific residues account for most of the A- F difference in Cl (-) affinity. For example, Km(Cl-) s were similar to 8 mM for saF/ A and saA, and similar to 70 mM for saA/ F and saF. Intriguingly, variant residues in cs1a also affected cation transport; here, Km(Na+) s for the chimeras and for saA were all similar to 20 mM, and Km(Rb+) all similar to 2 mM. Regarding tm2, our studies have confirmed its importance in cation transport and have also identified novel properties for this domain. Taken together, our results demonstrate for the first time that an intracellular loop in NKCC contributes to the transport process perhaps by forming a flexible structure that positions itself between membrane spanning domains.	Univ Laval, Fac Med, Dept Med, Nephrol Res Grp, Quebec City, PQ G1R 2J6, Canada	Laval University	Isenring, P (corresponding author), Hotel Dieu Quebec Res Ctr, 10 Rue McMahon Rm 3852, Quebec City, PQ G1R 2J6, Canada.	paul.isenring@crhdq.ulaval.ca						Benjamin BA, 1997, AM J PHYSIOL-RENAL, V273, pF473, DOI 10.1152/ajprenal.1997.273.3.F473; Bergeron MJ, 2003, AM J PHYSIOL-RENAL, V285, pF68, DOI 10.1152/ajprenal.00032.2003; BROWN CDA, 1985, J MEMBRANE BIOL, V87, P131, DOI 10.1007/BF01870659; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; FORBUSH B, 1995, INT SOC NEPHR AM PHY; Gagnon E, 2003, AM J PHYSIOL-CELL PH, V284, pC365, DOI 10.1152/ajpcell.00262.2002; Gagnon E, 2002, AM J PHYSIOL-RENAL, V283, pF1046, DOI 10.1152/ajprenal.00107.2002; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gimenez I, 2002, J BIOL CHEM, V277, P8767, DOI 10.1074/jbc.C200021200; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HAAS M, 1987, KIDNEY INT, V32, pS134; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Isenring P, 2001, COMP BIOCHEM PHYS A, V130, P487, DOI 10.1016/S1095-6433(01)00420-2; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Kaplan MR, 1996, KIDNEY INT, V49, P40, DOI 10.1038/ki.1996.6; Labro AJ, 2003, J BIOL CHEM, V278, P50724, DOI 10.1074/jbc.M306097200; Lytle C, 1998, AM J PHYSIOL-CELL PH, V274, pC299, DOI 10.1152/ajpcell.1998.274.2.C299; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; MIYAMOTO H, 1986, J MEMBRANE BIOL, V92, P135, DOI 10.1007/BF01870703; MOORE ML, 1995, BIOCHEM J, V309, P637, DOI 10.1042/bj3090637; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Mount DB, 1998, J EXP BIOL, V201, P2091; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Plata C, 2002, J BIOL CHEM, V277, P11004, DOI 10.1074/jbc.M110442200; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; Yang TX, 1996, AM J PHYSIOL-RENAL, V271, pF931, DOI 10.1152/ajprenal.1996.271.4.F931	40	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5648	5654		10.1074/jbc.M311218200	http://dx.doi.org/10.1074/jbc.M311218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645215	hybrid			2022-12-27	WOS:000188776500075
J	Rydziel, S; Delany, AM; Canalis, E				Rydziel, S; Delany, AM; Canalis, E			AU-rich elements in the collagenase 3 mRNA mediate stabilization of the transcript by cortisol in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; FAR UPSTREAM ELEMENT; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; URIDINE BINDING-FACTOR; 3'-UNTRANSLATED REGION; PARATHYROID-HORMONE; C-MYC; INTERSTITIAL COLLAGENASE; POSTTRANSCRIPTIONAL MECHANISMS; MOLECULAR-CLONING	Collagenase 3 degrades collagen fibrils and is necessary for bone resorption. Cortisol increases collagenase 3 mRNA in osteoblasts by stabilizing collagenase 3 transcripts. To understand mechanisms involved, we used RNA electrophoretic mobility shift assay and RNA turnover studies. Cortisol increased the binding of Ob cell cytosolic extracts to AU-rich sequences in the collagenase 3 3'-untranslated region (UTR). No cortisol-dependent protein complexes were formed with the coding region or the 5'-UTR. Functional assays, using transient transfections of CMV-driven c-fos collagenase 3'-UTR chimeric constructs, demonstrated that the 3'-UTR of collagenase 3 stabilizes c-fos mRNA in transcriptionally arrested Ob cells, cortisol prolongs the transcript half-life, and mutations of AU-rich sequences destabilize c-fos transcripts precluding the cortisol effect. Purification of osteoblast cytosolic extracts by ultracentrifugation, ion exchange, and RNA affinity chromatography, and polyacrylamide gel electrophoresis followed by mass spectroscopy identified specific proteins. RNA gel mobility supershift assays demonstrated that vinculin and far upstream element (FUSE)-binding protein 2 interacted with collagenase 3 3'-UTR sequences, and RNA interference demonstrated these proteins altered collagenase mRNA stability. In conclusion, AU-rich sequences of the 3'-UTR of collagenase 3 and vinculin and FUSE-binding protein 2 regulate collagenase mRNA stability in osteoblasts.	St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Farmington, CT 06030 USA	Saint Francis Hospital & Medical Center; University of Connecticut	Canalis, E (corresponding author), St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.	ecanalis@stfranciscare.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045227] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45227] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441; Carbonare LD, 2001, J BONE MINER RES, V16, P97, DOI 10.1359/jbmr.2001.16.1.97; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; CURRAN T, 1987, ONCOGENE, V2, P79; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314; DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945-053X(00)00051-2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GILLIS P, 1991, J BIOL CHEM, V266, P3172; Gramolini AO, 2001, J CELL BIOL, V154, P1173, DOI 10.1083/jcb.200101108; He LS, 2000, EMBO J, V19, P1034, DOI 10.1093/emboj/19.5.1034; Heise T, 1997, J BIOL CHEM, V272, P20222, DOI 10.1074/jbc.272.32.20222; Hel Z, 1996, MOL CELL BIOL, V16, P5579; HESKETH J, 1994, BIOCHEM J, V298, P143, DOI 10.1042/bj2980143; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382; Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053; Horton R. M., 1993, PCR PROTOCOLS, P251; HUANG LY, 1993, J BIOL CHEM, V268, P25769; Irwin N, 1997, NUCLEIC ACIDS RES, V25, P1281, DOI 10.1093/nar/25.6.1281; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; LEEDMAN PJ, 1995, MOL ENDOCRINOL, V9, P375, DOI 10.1210/me.9.3.375; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756-3282(02)00687-7; Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756-3282(01)00422-7; Poon M, 1999, MOL CELL BIOL, V19, P6471; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; RIFAS L, 1994, ENDOCRINOLOGY, V134, P213, DOI 10.1210/en.134.1.213; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006; RUBY SW, 1990, METHOD ENZYMOL, V181, P97; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Sokal R. R, 1981, BIOMETRY; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; Wang XJ, 1998, NEUROSCI LETT, V252, P191, DOI 10.1016/S0304-3940(98)00598-9; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Winchester SK, 2000, J BIOL CHEM, V275, P23310, DOI 10.1074/jbc.M003004200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158	63	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5397	5404		10.1074/jbc.M311984200	http://dx.doi.org/10.1074/jbc.M311984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645243	hybrid			2022-12-27	WOS:000188776500045
J	Boesen, T; Mohammad, SS; Pavitt, GD; Andersen, GR				Boesen, T; Mohammad, SS; Pavitt, GD; Andersen, GR			Structure of the catalytic fragment of translation initiation factor 2B and identification of a critically important catalytic residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; FACTOR 5 EIF5; CRYSTAL-STRUCTURE; EPSILON-SUBUNIT; BETA-SUBUNIT; ACTIVATION; GTPASE; COMPLEX; BINDING; RAS	Eukaryotic initiation factor (eIF) 2B catalyzes the nucleotide activation of eIF2 to its active GTP-bound state. The exchange activity has been mapped to the C terminus of the eIF2Bepsilon subunit. We have determined the crystal structure of residues 544 - 704 from yeast eIF2Bepsilon at 2.3-Angstrom resolution, and this fragment is an all-helical protein built around the conserved aromatic acidic ( AA) boxes also found in eIF4G and eIF5. The eight helices are organized in a manner similar to HEAT repeats. The molecule is highly asymmetric with respect to surface charge and conservation. One area in the N terminus is proposed to be directly involved in catalysis. In agreement with this hypothesis, mutation of glutamate 569 is shown to be lethal. An acidic belt and a second area in the C terminus containing residues from the AA boxes are important for binding to eIF2. Two mutations causing the fatal human genetic disease leukoencephalopathy with vanishing white matter are buried and appear to disrupt the structural integrity of the catalytic domain rather than interfering directly with catalysis or binding of eIF2.	Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ Manchester, Inst Sci & Technol, Manchester M60 1QD, Lancs, England	Aarhus University; University of Manchester	Andersen, GR (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	grand@imsb.au.dk	Pavitt, Graham D/A-1363-2010	Pavitt, Graham D/0000-0002-8593-2418; Boesen, Thomas/0000-0002-5633-6844; Andersen, Gregers Rom/0000-0001-6292-3319	NIGMS NIH HHS [GM62789-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062789] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; Das S, 2001, J BIOL CHEM, V276, P6720, DOI 10.1074/jbc.M008863200; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Erickson FL, 2001, GENETICS, V158, P123; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; LESLIE AGW, 1992, NEWSLETTER PROTEIN C, V26; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Mazza C, 2001, MOL CELL, V8, P383, DOI 10.1016/S1097-2765(01)00299-4; Paulin FEM, 2001, CURR BIOL, V11, P55, DOI 10.1016/S0960-9822(00)00025-7; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; van der Knaap MS, 2002, ANN NEUROL, V51, P264, DOI 10.1002/ana.10112; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Williams DD, 2001, J BIOL CHEM, V276, P3733, DOI 10.1074/jbc.M008041200; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yang WM, 1996, MOL CELL BIOL, V16, P6603	43	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10584	10592		10.1074/jbc.M311055200	http://dx.doi.org/10.1074/jbc.M311055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681227	hybrid			2022-12-27	WOS:000220050400112
J	Brown, CO; Chi, X; Garcia-Gras, E; Shirai, M; Feng, XH; Schwartz, RJ				Brown, CO; Chi, X; Garcia-Gras, E; Shirai, M; Feng, XH; Schwartz, RJ			The cardiac determination factor, Nkx2-5, is activated by mutual cofactors GATA-4 and Smad1/4 via a novel upstream enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; TUMOR-SUPPRESSOR SMAD4/DPC4; DNA-BINDING TARGETS; GROWTH-FACTOR-BETA; TGF-BETA; CARDIOMYOCYTE DIFFERENTIATION; TRANSCRIPTION FACTORS; GENE-EXPRESSION; MESODERM INDUCTION; MOUSE EMBRYO	The mammalian homologue of Drosophila tinman, Nkx2-5, plays an early role in regulating cardiac genes and morphogenesis. Bone morphogenetic proteins (BMPs), members of the transforming growth factor (TGF)-beta family of signaling molecules, are involved in numerous developmental processes. BMP signaling is crucial in the regulation of Nkx2-5 expression and specification of the cardiac lineage. Constitutively active BMP type I receptor or the downstream pathway components and DNA-binding transcription factors, Smad1/4 directly activated Nkx2-5 gene transcription. We identified and characterized a novel upstream Nkx2-5 enhancer, composed of clustered repeats of Smad and GATA DNA binding sites. This composite Nkx2-5 enhancer was a direct target of BMP signaling via cooperative interactions between the downstream transducers Smad1/4 and GATA-4. In mammalian two hybrid assays, Smad factors recruited the hybrid gene GATA4-VP16 to strongly drive transcription of a reporter gene containing multimerized Smad binding sites These cofactors interacted through the second zinc finger and adjacent basic domain of GATA-4 and the N-terminal domain of Smads. Smad4 and GATA4 were also found to bind in vivo with the Nkx2-5 composite enhancer, as revealed by chromatin immunoprecipitation analysis of differentiated P19 cells. Finally, transgenic mice containing the Smad/GATA composite enhancer recapitulated early murine Nkx2-5 cardiac expression and deletion of this enhancer within a 10-kb transgene pBS-Nkx2-5 LacZ significantly reduced expression in the cardiac crescent. Thus, integration of GATA transcription factors with BMP signaling, through co-association with Smads factors, may initiate early Nkx2-5 expression; suggesting a vital role for the combination of these factors in the specification of cardiac progenitors.	Baylor Coll Med, Dept Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Schwartz, RJ (corresponding author), 1 Baylor Plaza, Houston, TX 77030 USA.	schwartz@bcm.tmc.edu		Garcia Gras, Eduardo/0000-0002-6930-0111	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blokzijl A, 2002, CURR BIOL, V12, P35, DOI 10.1016/S0960-9822(01)00623-6; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Chang H, 1999, DEVELOPMENT, V126, P1631; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1996, MOL CELL BIOL, V16, P6372; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Ehrman LA, 1999, DEV BIOL, V207, P163, DOI 10.1006/dbio.1998.9167; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jamali M, 2001, FEBS LETT, V509, P126, DOI 10.1016/S0014-5793(01)03151-9; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Ladd AN, 1998, DEV BIOL, V204, P407, DOI 10.1006/dbio.1998.9094; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liberatore CM, 2002, DEV BIOL, V244, P243, DOI 10.1006/dbio.2002.0604; Lien CL, 1999, DEVELOPMENT, V126, P75; Lien CL, 2002, DEV BIOL, V244, P257, DOI 10.1006/dbio.2002.0603; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Ramchandran R, 2000, AM J HEMATOL, V65, P14, DOI 10.1002/1096-8652(200009)65:1<14::AID-AJH3>3.0.CO;2-F; Reecy JM, 1999, DEVELOPMENT, V126, P839; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; Schneider MD, 2003, CYTOKINE GROWTH F R, V14, P1, DOI 10.1016/S1359-6101(02)00053-9; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Schwartz RJ, 1999, DEVELOPMENT, V126, P4187; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Walters MJ, 2001, MECH DEVELOP, V100, P263, DOI 10.1016/S0925-4773(00)00535-9; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yatskievych TA, 1997, DEVELOPMENT, V124, P2561; Zhang HB, 1996, DEVELOPMENT, V122, P2977	50	124	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10659	10669		10.1074/jbc.M301648200	http://dx.doi.org/10.1074/jbc.M301648200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14662776	hybrid			2022-12-27	WOS:000220050400120
J	Luo, BH; Takagi, J; Springer, TA				Luo, BH; Takagi, J; Springer, TA			Locking the beta(3) integrin I-like domain into high and low affinity conformations with disulfides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; A-DOMAIN; EXTRACELLULAR SEGMENT; SUBUNIT; PROTEIN; LIGAND; ACTIVATION; COMPLEX; ALPHA(5)BETA(1); ALPHA-L-BETA-2	Although integrin alpha subunit I domains exist in multiple conformations, it is controversial whether integrin beta subunit I-like domains undergo structurally analogous movements of the alpha7-helix that are linked to affinity for ligand. Disulfide bonds were introduced into the beta(3) integrin I-like domain to lock its beta6-alpha7 loop and alpha7-helix in two distinct conformations. Soluble ligand binding, ligand mimetic mAb binding and cell adhesion studies showed that disulfide-bonded receptor alpha(IIbbeta3)(T329C/A347C) was locked in a low affinity state, and dithiothreitol treatment restored the capability of being activated to high affinity binding; by contrast, disulfide-bonded alpha(IIb)beta3(V332C/M335C) was locked in a high affinity state. The results suggest that activation of the beta subunit I-like domain is analogous to that of the alpha subunit I domain, i.e. that axial movement in the C-terminal direction of the alpha7-helix is linked to rearrangement of the I-like domain metal ion-dependent adhesion site into a high affinity conformation.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu			NHLBI NIH HHS [HL48675] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; EIRIN MT, 1986, BIOCHEM J, V240, P147, DOI 10.1042/bj2400147; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KALOMIRIS EL, 1985, BIOCHEMISTRY-US, V24, P5430, DOI 10.1021/bi00341a022; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Mould AP, 2003, J BIOL CHEM, V278, P51622, DOI 10.1074/jbc.M306655200; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2002, P NATL ACAD SCI USA, V99, P16737, DOI 10.1073/pnas.252633099; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200	29	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10215	10221		10.1074/jbc.M312732200	http://dx.doi.org/10.1074/jbc.M312732200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14681220	hybrid, Green Published			2022-12-27	WOS:000220050400068
J	Prasad, S; Cantwell, AM; Bush, LA; Shih, P; Xu, H; Di Cera, E				Prasad, S; Cantwell, AM; Bush, LA; Shih, P; Xu, H; Di Cera, E			Residue Asp-189 controls both substrate binding and the monovalent cation specificity of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; CONVERTING TRYPSIN; CHYMOTRYPSIN; ACTIVATION; SITE; HIRUDIN; ENZYME; RECOGNITION; EVOLUTION; LYASE	Residue Asp-189 plays an important dual role in thrombin: it defines the primary specificity for Arg side chains and participates indirectly in the coordination of Na+. The former role is shared by other proteases with trypsin-like specificity, whereas the latter is unique to Na+-activated proteases in blood coagulation and the complement system. Replacement of Asp-189 with Ala, Asn, Glu, and Ser drastically reduces the specificity toward substrates carrying Arg or Lys at P1, whereas it has little or no effect toward the hydrolysis of substrates carrying Phe at P1. These findings confirm the important role of Asp-189 in substrate recognition by trypsin-like proteases. The substitutions also affect significantly and unexpectedly the monovalent cation specificity of the enzyme. The Ala and Asn mutations abrogate monovalent cation binding, whereas the Ser and Glu mutations change the monovalent cation preference from Na+ to the smaller cation Li+ or to the larger cation Rb+, respectively. The observation that a single amino acid substitution can alter the monovalent cation specificity of thrombin from Na+ (Asp-189) to Li+ (Ser-189) or Rb+ (Glu-189) is unprecedented in the realm of monovalent cation-activated enzymes.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	enrico@biochem.wustl.edu			NHLBI NIH HHS [HL73813, HL58141, HL49413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL073813, R01HL049413, R01HL058141] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; Di Cera E, 2003, CHEST, V124, p11S, DOI 10.1378/chest.124.3_suppl.11S; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; GRAF L, 1988, P NATL ACAD SCI USA, V85, P4961, DOI 10.1073/pnas.85.14.4961; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; HEDSTROM L, 1994, BIOCHEMISTRY-US, V33, P8764, DOI 10.1021/bi00195a018; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Hedstrom L, 2002, CHEM REV, V102, P4501, DOI 10.1021/cr000033x; Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; Phillips RS, 1998, EUR J BIOCHEM, V255, P508, DOI 10.1046/j.1432-1327.1998.2550508.x; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Sundararaju B, 2000, BIOCHEMISTRY-US, V39, P8546, DOI 10.1021/bi000063u; Szabo E, 2003, J MOL BIOL, V331, P1121, DOI 10.1016/S0022-2836(03)00849-0; Szabo E, 1999, EUR J BIOCHEM, V263, P20, DOI 10.1046/j.1432-1327.1999.00452.x; Venekei I, 1996, FEBS LETT, V379, P143, DOI 10.1016/0014-5793(95)01484-5; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008	32	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10103	10108		10.1074/jbc.M312614200	http://dx.doi.org/10.1074/jbc.M312614200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679197	hybrid			2022-12-27	WOS:000220050400055
J	Rosnet, O; Blanco-Betancourt, C; Grivel, K; Richter, K; Schiff, C				Rosnet, O; Blanco-Betancourt, C; Grivel, K; Richter, K; Schiff, C			Binding of free immunoglobulin light chains to VpreB3 inhibits their maturation and secretion in chicken B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; FREE KAPPA-LIGHT; ENDOPLASMIC-RETICULUM; PRE-B; QUALITY-CONTROL; CEREBROSPINAL-FLUID; MULTIPLE-MYELOMA; GENE CONVERSION; BONE-MARROW; MAST-CELLS	The VpreB3 gene product was first characterized as an immunoglobulin (Ig) mu heavy chain-binding protein in mouse precursor B (pre-B) cells. Although its function is unknown, it has been proposed to participate in the assembly and transport of the pre-B cell receptor. We have identified a VpreB3 orthologous gene in chicken that is located close to the immunoglobulin light chain (LC) gene cluster and specifically expressed in the bursa of Fabricius. By overexpressing VpreB3 in the DT40 IgM(+) immature chicken B cell line, we have characterized VpreB3 as an endoplasmic reticulum-resident glycoprotein that binds preferentially to free IgLC. However, binding to IgHC is observed in IgLC-deficient DT40 cells. Interaction of VpreB3 with free IgLC is partly covalent and induces retention of free IgLC in the endoplasmic reticulum, preventing their secretion without affecting IgM surface expression. Our results demonstrate that this evolutionarily conserved molecule may play a role in the regulation of the maturation and secretion of free IgLC in B cells. We discuss possible implications in the regulation of the immune response.	Univ Mediterranee, INSERM, CNRS, Ctr Immunol Marseille Luminy, F-13288 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Rosnet, O (corresponding author), Univ Mediterranee, INSERM, CNRS, Ctr Immunol Marseille Luminy, Campus Luminy,Case 906, F-13288 Marseille 09, France.	rosnet@ciml.univ-mrs.fr; schiff@ciml.univ-mrs.fr	Rosnet, Olivier/G-3536-2013	Rosnet, Olivier/0000-0002-3020-910X				Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Brouns GS, 1996, J BIOL CHEM, V271, P19272, DOI 10.1074/jbc.271.32.19272; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Cariappa A, 2002, CURR OPIN IMMUNOL, V14, P241, DOI 10.1016/S0952-7915(02)00328-X; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FAGNART OC, 1988, J NEUROIMMUNOL, V19, P119, DOI 10.1016/0165-5728(88)90041-0; Fang T, 2001, J IMMUNOL, V167, P3846, DOI 10.4049/jimmunol.167.7.3846; Gauthier L, 2002, P NATL ACAD SCI USA, V99, P13014, DOI 10.1073/pnas.202323999; Hardy RR, 2000, IMMUNOL REV, V175, P23, DOI 10.1111/j.1600-065X.2000.imr017517.x; Hayakawa K, 1999, SCIENCE, V285, P113, DOI 10.1126/science.285.5424.113; Hertz M, 1998, CURR OPIN IMMUNOL, V10, P208, DOI 10.1016/S0952-7915(98)80250-1; Hoffmann R, 2002, GENOME RES, V12, P98, DOI 10.1101/gr.201501; KALOFF CR, 1995, IMMUNITY, V2, P629, DOI 10.1016/1074-7613(95)90007-1; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LAMERS KJB, 1995, J NEUROIMMUNOL, V62, P19, DOI 10.1016/0165-5728(95)00086-H; Lassoued K, 1996, J EXP MED, V183, P421, DOI 10.1084/jem.183.2.421; Leitzgen K, 1997, J BIOL CHEM, V272, P3117, DOI 10.1074/jbc.272.5.3117; LENNY N, 1991, J BIOL CHEM, V266, P20532; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; Martensson IL, 2002, SEMIN IMMUNOL, V14, P335, DOI 10.1016/S1044-5323(02)00066-0; Masteller E L, 1997, Int Rev Immunol, V15, P185, DOI 10.3109/08830189709068176; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; Meffre E, 2002, P NATL ACAD SCI USA, V99, P11334, DOI 10.1073/pnas.172369999; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; OHNISHI K, 1994, J BIOL CHEM, V269, P28347; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; Redegeld FA, 2003, TRENDS IMMUNOL, V24, P181, DOI 10.1016/S1471-4906(03)00059-0; Redegeld FA, 2002, NAT MED, V8, P694, DOI 10.1038/nm722; REYNAUD CA, 1994, ADV IMMUNOL, V57, P353, DOI 10.1016/S0065-2776(08)60676-8; Rolink AG, 2000, J EXP MED, V191, P23, DOI 10.1084/jem.191.1.23; Rosnet O, 1999, CYTOGENET CELL GENET, V87, P205, DOI 10.1159/000015468; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; SHIRASAWA T, 1993, EMBO J, V12, P1827, DOI 10.1002/j.1460-2075.1993.tb05831.x; SINCLAIR D, 1986, BRIT J HAEMATOL, V62, P689, DOI 10.1111/j.1365-2141.1986.tb04092.x; Skowronek MH, 1998, P NATL ACAD SCI USA, V95, P1574, DOI 10.1073/pnas.95.4.1574; SOLLING K, 1982, SCAND J HAEMATOL, V28, P309; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7	47	22	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10228	10236		10.1074/jbc.M312169-A200	http://dx.doi.org/10.1074/jbc.M312169-A200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14670953	hybrid			2022-12-27	WOS:000220050400070
J	Viegas, LR; Vicent, GP; Baranao, JL; Beato, M; Pecci, A				Viegas, LR; Vicent, GP; Baranao, JL; Beato, M; Pecci, A			Steroid hormones induce bcl-X gene expression through direct activation of distal promoter P4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; GLUCOCORTICOID RECEPTOR; IN-VIVO; APOPTOSIS; BINDING; PROTEINS; LINE; RNA; DEXAMETHASONE; EXTRACTION	Bcl-X exists in at least five different isoforms with complex effects on programmed cell death. Glucocorticoids and progestins control bcl-X expression and influence the ratio between bcl-X-L ( antiapoptotic isoform) and bcl-X-S (proapoptotic isoform) in different tissues. The 5'-UTR region of the mouse bcl-X gene contains at least five different promoters, which exhibit a tissue-specific pattern of promoter usage. Several mRNAs with different 5'-leading exons can be generated upon promoter activation. Here we explore the potential of the various bcl-X gene promoters to be regulated by glucocorticoids or progestins. We found that the region located immediately upstream of promoter 4 (P4) contains two hormone response element (HRE)-like sequences at positions - 3040 ( HRE I) and - 3001 ( HRE II) relative to the translation initiation codon. These HRE-like sequences confer hormone responsiveness to a core promoter and bind glucocorticoid or progesterone receptors in vitro. Point mutations of both HREs that prevent steroid receptor binding also eliminate hormonal inducibility. In cells treated with glucocorticoids, the hormone receptor is recruited to the P4 region containing the HREs. Analysis of the products of the endogenous bcl-X in epithelial mammary cells showed that only transcripts originating from P4 increased upon hormone treatment. This observation correlates with the induction of the bcl-X-L mRNA, suggesting that P4 is one of the bcl-X promoters responsible for the generation of this antiapoptotic isoform.	Ctr Regulacio Genom, E-08003 Barcelona, Spain; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1428 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1428 Buenos Aires, DF, Argentina	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Beato, M (corresponding author), Ctr Regulacio Genom, Passeig Maritim 37-49, E-08003 Barcelona, Spain.	miguel.beato@crg.es	Beato, Miguel/B-5564-2015; Vicent, Guillermo P./K-5432-2015	Beato, Miguel/0000-0002-2878-2222; Vicent, Guillermo P./0000-0002-0554-2226				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bottenstein J, 1979, Methods Enzymol, V58, P94; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; FANG W, 1994, J IMMUNOL, V153, P4388; Gascoyne DM, 2003, J BIOL CHEM, V278, P18022, DOI 10.1074/jbc.M301812200; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; Pecci A, 1997, J BIOL CHEM, V272, P11791, DOI 10.1074/jbc.272.18.11791; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; Schorr K, 2000, CANCER RES, V60, P5950; Shiraiwa N, 1996, J BIOL CHEM, V271, P13258, DOI 10.1074/jbc.271.22.13258; Strutt H, 1999, METH MOL B, V119, P455; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Vicent GP, 2002, EXP CELL RES, V276, P142, DOI 10.1006/excr.2002.5532; Walton KD, 2001, MECH DEVELOP, V109, P281, DOI 10.1016/S0925-4773(01)00549-4; Yamamoto M, 1998, HEPATOLOGY, V27, P959, DOI 10.1002/hep.510270410; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	30	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9831	9839		10.1074/jbc.M312402200	http://dx.doi.org/10.1074/jbc.M312402200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679196	hybrid			2022-12-27	WOS:000220050400022
J	Gustafson, WC; Ray, S; Jamieson, L; Thompson, EA; Brasier, AR; Fields, AP				Gustafson, WC; Ray, S; Jamieson, L; Thompson, EA; Brasier, AR; Fields, AP			Bcr-Abl regulates protein kinase C iota (PKC iota) transcription via an Elk1 site in the PKC iota promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; COLON CARCINOGENESIS; BETA-II; PHILADELPHIA-CHROMOSOME; K562 CELLS; MEDIATED TRANSFORMATION; INDUCE APOPTOSIS; ACTIVATION; BCR/ABL; RAS	The protein kinase C (PKC) family of serine/threonine kinases plays an important role in numerous cancer signaling pathways, including those downstream of the bcr-abl oncogene. We demonstrated previously that atypical PKCiota is required for Bcr-Abl-mediated resistance of human K562 chronic myelogenous leukemia (CML) cells to Taxol-induced apoptosis. Here, we report that the pattern of PKC isozyme expression characteristic of CML cells is regulated by Bcr-Abl. When Bcr-Abl was expressed in Bcr-Abl-negative HL-60 promyelocytic leukemia cells, expression of the PKCbetaI, PKCbetaII, and PKCiota genes was induced, whereas expression of the PKCdelta gene was reduced to levels similar to those found in CML cells. Given the importance of PKCiota in Bcr-Abl-mediated transformation, we characterized the mechanism by which Bcr-Abl regulates PKCiota expression. A 1200-bp PKC iota promoter construct isolated from genomic DNA was highly active in Bcr-Abl-positive K562 cells and was activated when Bcr-Abl-negative cells were transfected with Bcr-Abl. Bcr-Abl-mediated induction of the PKCiota promoter was dependent upon MEK1/2 activity, but not phosphatidylinositol 3-kinase or p38 MAPK activity. Mutational analysis of the PKCiota promoter revealed a region between 97 and 114 bp upstream of the transcriptional start site that is responsible for Bcr-Abl-mediated regulation. Mutation of a consensus Elk1-binding site within this region abolished Bcr-Abl-mediated regulation. We conclude that Bcr-Abl regulates PKCiota expression through the MEK-dependent activation of an Elk1 element within the proximal PKCiota promoter. Our results indicate that Bcr-Abl-mediated transformation involves transcriptional activation of the PKCiota gene, which in turn is required for Bcr-Abl-mediated chemoresistance.	Mayo Clin, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston	Fields, AP (corresponding author), Mayo Clin, Ctr Comprehens Canc, Griffin Canc Res Bldg,Rm 312,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu	Ray, Sutapa/D-3272-2012	Ray, Sutapa/0000-0003-4234-2124; Brasier, Allan/0000-0002-5012-4090				Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Che W, 2001, CIRCULATION, V104, P1399, DOI 10.1161/hc3701.095581; Clark JH, 2002, BIOCHEMISTRY-US, V41, P11847, DOI 10.1021/bi025600k; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Desai DS, 1999, BIOCHEM BIOPH RES CO, V263, P28, DOI 10.1006/bbrc.1999.1307; Druker BJ, 2003, MOL CANCER THER, V2, P225; Fields Alan P, 2003, Methods Mol Biol, V233, P519; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; GOSS VL, 1994, J BIOL CHEM, V269, P19074; GOTOH A, 1994, LEUKEMIA, V8, P115; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Kirchner D, 2003, EXP HEMATOL, V31, P504, DOI 10.1016/S0301-472X(03)00069-9; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Murray NR, 2002, J CELL BIOL, V157, P915, DOI 10.1083/jcb.200201127; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; OBEID LM, 1992, J BIOL CHEM, V267, P20804; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Perrotti D, 2000, MOL CELL BIOL, V20, P6159, DOI 10.1128/MCB.20.16.6159-6169.2000; Quan TH, 1999, J BIOL CHEM, V274, P28566, DOI 10.1074/jbc.274.40.28566; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAKAI N, 1994, EXP CELL RES, V215, P131, DOI 10.1006/excr.1994.1324; Shuai K, 1996, ONCOGENE, V13, P247; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; TAKANAGA H, 1995, FEBS LETT, V368, P276, DOI 10.1016/0014-5793(95)00665-V; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Yu CR, 2002, CANCER RES, V62, P188; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200	47	38	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9400	9408		10.1074/jbc.M312840200	http://dx.doi.org/10.1074/jbc.M312840200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670960	hybrid			2022-12-27	WOS:000189265900105
J	Ishino, T; Pasut, G; Scibek, J; Chaiken, I				Ishino, T; Pasut, G; Scibek, J; Chaiken, I			Kinetic interaction analysis of human interleukin 5 receptor alpha mutants reveals a unique binding topology and charge distribution for cytokine recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; GM-CSF; CHAIN; IDENTIFICATION; MUTAGENESIS; AFFINITY; IL-5; EXPRESSION; RESIDUES; DYNAMICS	Human interleukin 5 receptor alpha (IL5Ralpha) comprises three fibronectin type III domains (D1, D2, and D3) in the extracellular region. Previous results have indicated that residues in the D1D2 domains are crucial for high affinity interaction with human interleukin 5 (IL5). Yet, it is the D2D3 domains that have sequence homology with the classic cytokine recognition motif that is generally assumed to be the minimum cytokine-recognizing unit. In the present study, we used kinetic interaction analysis of alanine-scanning mutational variants of IL5Ralpha to define the residues involved in IL5 recognition. Soluble forms of IL5Ralpha variants were expressed in S2 cells, selectively captured via their C-terminal V5 tag by anti-V5 tag antibody immobilized onto the sensor chip and examined for IL5 interaction by using a sandwich surface plasmon resonance biosensor method. Marked effects on the interaction kinetics were observed not only in D1 (Asp(55), Asp(56), and Glu(58)) and D2 (Lys(186) and Arg(188)) domains, but also in the D3 (Arg(297)) domain. Modeling of the tertiary structure of IL5Ralpha indicated that these binding residues fell into two clusters. The first cluster consists of D1 domain residues that form a negatively charged patch, whereas the second cluster consists of residues that form a positively charged patch at the interface of D2 and D3 domains. These results suggest that the IL5 . IL5Ralpha system adopts a unique binding topology, in which the cytokine is recognized by a D2D3 tandem domain combined with a D1 domain, to form an extended cytokine recognition interface.	Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19102 USA; Drexel Univ, Coll Med, Aj Drexel Inst Basic & Appl Prot Sci, Philadelphia, PA 19102 USA; Univ Padua, Dept Pharmaceut Sci, I-35121 Padua, Italy	Drexel University; Drexel University; University of Padua	Chaiken, I (corresponding author), Drexel Univ, Coll Med, Dept Biochem, 11102 New Coll Bldg,MS 497,245 N 15th St, Philadelphia, PA 19102 USA.	imc23@drexel.edu	Pasut, Gianfranco/I-5944-2012	Pasut, Gianfranco/0000-0002-8754-0899	NIAID NIH HHS [AI40462] Funding Source: Medline; NIGMS NIH HHS [GM55648] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055648] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHAIKEN MI, 1999, INTERLEUKIN 5 MOL DR, P167; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; Czabotar PE, 2000, CYTOKINE, V12, P867, DOI 10.1006/cyto.1999.0663; De Crescenzo G, 2003, J MOL BIOL, V328, P1173, DOI 10.1016/S0022-2836(03)00360-7; DEVOS R, 1994, EUR J BIOCHEM, V225, P635, DOI 10.1111/j.1432-1033.1994.00635.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; Dowd CS, 2002, BIOCHEMISTRY-US, V41, P7038, DOI 10.1021/bi012168i; Elkins PA, 2000, NAT STRUCT BIOL, V7, P808, DOI 10.1038/79047; Foster PS, 2002, TRENDS MOL MED, V8, P162, DOI 10.1016/S1471-4914(02)02302-X; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; Karlen S, 1998, Int Rev Immunol, V16, P227, DOI 10.3109/08830189809042996; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 1996, J BIOL CHEM, V271, P1817, DOI 10.1074/jbc.271.4.1817; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MCKINNON M, 1999, INTERLEUKIN 5 MOL DR, P299; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; Plugariu CG, 2000, BIOCHEMISTRY-US, V39, P14939, DOI 10.1021/bi001467p; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Scibek JJ, 2002, ANAL BIOCHEM, V307, P258, DOI 10.1016/S0003-2697(02)00043-X; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Tello Diana, 1994, Journal of Molecular Recognition, V7, P57, DOI 10.1002/jmr.300070108; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walter MR, 2002, BIOTECHNIQUES, P46; Wu SJ, 1999, J BIOL CHEM, V274, P20479, DOI 10.1074/jbc.274.29.20479	43	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9547	9556		10.1074/jbc.M309327200	http://dx.doi.org/10.1074/jbc.M309327200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14662768	hybrid			2022-12-27	WOS:000189265900122
J	Silvie, O; Franetich, JF; Charrin, S; Mueller, MS; Siau, A; Bodescot, M; Rubinstein, E; Hannoun, L; Charoenvit, Y; Kocken, CH; Thomas, AW; van Gemert, GJ; Sauerwein, RW; Blackman, MJ; Anders, RF; Pluschke, G; Mazier, D				Silvie, O; Franetich, JF; Charrin, S; Mueller, MS; Siau, A; Bodescot, M; Rubinstein, E; Hannoun, L; Charoenvit, Y; Kocken, CH; Thomas, AW; van Gemert, GJ; Sauerwein, RW; Blackman, MJ; Anders, RF; Pluschke, G; Mazier, D			A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL EPITOPES; APICOMPLEXAN PARASITES; GLIDING MOTILITY; CIRCUMSPOROZOITE PROTEIN; MONOCLONAL-ANTIBODIES; ERYTHROCYTE INVASION; MICRONEMAL PROTEINS; ANONYMOUS PROTEIN; HOST-CELLS; SURFACE	Plasmodium sporozoites are transmitted through the bite of infected mosquitoes and invade hepatocytes as a first and obligatory step of the parasite life cycle in man. Hepatocyte invasion involves proteins secreted from parasite vesicles called micronemes, the most characterized being the thrombospondin-related adhesive protein ( TRAP). Here we investigated the expression and function of another microneme protein recently identified in Plasmodium falciparum sporozoites, apical membrane antigen 1 (AMA-1). P. falciparum AMA-1 is expressed in sporozoites and is lost after invasion of hepatocytes, and anti-AMA-1 antibodies inhibit sporozoite invasion, suggesting that the protein is involved during invasion of hepatocytes. As observed with TRAP, AMA-1 is initially mostly sequestered within the sporozoite. Upon microneme exocytosis, AMA-1 and TRAP relocate to the sporozoite surface, where they are proteolytically cleaved, resulting in the shedding of soluble fragments. A subset of serine protease inhibitors blocks the processing and shedding of both AMA-1 and TRAP and inhibits sporozoite infectivity, suggesting that interfering with sporozoite proteolytic processing may constitute a valuable strategy to prevent hepatocyte infection.	Univ Paris 06, CHU Pitie Salpetriere, INSERM, U511, F-75013 Paris, France; Univ Paris 11, Hop Paul Brousse, Inst Andre Lwoff, INSERM,U268, F-94807 Villejuif, France; Swiss Trop Inst, CH-4002 Basel, Switzerland; Hop La Pitie Salpetriere, Serv chirurg Digest Hepatobiliopancreat & Transpl, F-75013 Paris, France; USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA; Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands; Univ Med Ctr St Radboud, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia; La Trobe Univ, Cooperat Res Ctr Vaccine Technol, Bundoora, Vic 3086, Australia	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Basel; Swiss Tropical & Public Health Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; United States Department of Defense; United States Navy; Radboud University Nijmegen; MRC National Institute for Medical Research; La Trobe University; La Trobe University	Silvie, O (corresponding author), Univ Paris 06, INSERM, U511, 91 Blvd Hop, F-75013 Paris, France.	silvie@ext.jussieu.fr	CHARRIN, Stephanie/B-2892-2019; Franetich, Jean-François/GZA-9674-2022; Sauerwein, Robert/C-8519-2013; Rubinstein, Eric/B-4650-2019; Silvie, Olivier/AAF-5437-2021; Silvie, Olivier/K-7290-2017	Rubinstein, Eric/0000-0001-7623-9665; Silvie, Olivier/0000-0002-0525-6940; Silvie, Olivier/0000-0002-0525-6940; Charrin, Stephanie/0000-0002-4942-3990; Anders, Robin/0000-0002-0693-4547; Kocken, Clemens/0000-0002-4784-1734				Bannister LH, 2003, J CELL SCI, V116, P3825, DOI 10.1242/jcs.00665; Bergman LW, 2003, J CELL SCI, V116, P39, DOI 10.1242/jcs.00194; Bhanot P, 2003, MOL BIOCHEM PARASIT, V126, P263, DOI 10.1016/S0166-6851(02)00295-5; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Charoenvit Y, 1997, INFECT IMMUN, V65, P3430, DOI 10.1128/IAI.65.8.3430-3437.1997; Coley AM, 2001, PROTEIN ENG, V14, P691, DOI 10.1093/protein/14.9.691; CREWTHER PE, 1990, EXP PARASITOL, V70, P193, DOI 10.1016/0014-4894(90)90100-Q; DRUILHE P, 1986, INFECT IMMUN, V53, P393, DOI 10.1128/IAI.53.2.393-397.1986; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; GUGUENGUILLOUZO C, 1982, CELL BIOL INT REP, V6, P625, DOI 10.1016/0309-1651(82)90187-4; Healer J, 2002, INFECT IMMUN, V70, P5751, DOI 10.1128/IAI.70.10.5751-5758.2002; Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001; Howell SA, 2003, J BIOL CHEM, V278, P23890, DOI 10.1074/jbc.M302160200; Howell SA, 2001, J BIOL CHEM, V276, P31311, DOI 10.1074/jbc.M103076200; ISOM HC, 1985, P NATL ACAD SCI USA, V82, P3252, DOI 10.1073/pnas.82.10.3252; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Kappe SHI, 2003, TRENDS PARASITOL, V19, P135, DOI 10.1016/S1471-4922(03)00007-2; Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; MAZIER D, 1985, SCIENCE, V227, P440, DOI 10.1126/science.3880923; MEIS JFGM, 1985, CELL BIOL INT REP, V9, P976, DOI 10.1016/0309-1651(85)90062-1; Menard R, 2001, CELL MICROBIOL, V3, P63, DOI 10.1046/j.1462-5822.2001.00097.x; Menard R, 2000, MICROBES INFECT, V2, P633, DOI 10.1016/S1286-4579(00)00362-2; Mota MM, 2002, NAT MED, V8, P1318, DOI 10.1038/nm785; Mueller MS, 2003, INFECT IMMUN, V71, P4749, DOI 10.1128/IAI.71.8.4749-4758.2003; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; Opitz C, 2002, EMBO J, V21, P1577, DOI 10.1093/emboj/21.7.1577; PONNUDURAI T, 1982, T ROY SOC TROP MED H, V76, P242, DOI 10.1016/0035-9203(82)90289-9; STEWART MJ, 1991, J PROTOZOOL, V38, P411, DOI 10.1111/j.1550-7408.1991.tb01379.x; STUBER D, 1990, EUR J IMMUNOL, V20, P819, DOI 10.1002/eji.1830200416; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x	34	239	249	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9490	9496		10.1074/jbc.M311331200	http://dx.doi.org/10.1074/jbc.M311331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676185	Green Published, hybrid			2022-12-27	WOS:000189265900115
J	Grundstrom, S; Anderson, P; Scheipers, P; Sundstedt, A				Grundstrom, S; Anderson, P; Scheipers, P; Sundstedt, A			Bcl-3 and NF kappa B p50-p50 homodimers act as transcriptional repressors in tolerant CD4(+) T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE PROTOONCOGENE BCL-3; STAPHYLOCOCCAL ENTEROTOXIN-A; NECROSIS-FACTOR-ALPHA; IN-VIVO; P50 HOMODIMERS; NUCLEAR TRANSLOCATION; ONCOPROTEIN BCL-3; GENE-EXPRESSION; LYMPHOCYTE-PROLIFERATION; NF-KAPPA-B1 P50	The transcriptional events that control T cell tolerance are still poorly understood. To investigate why tolerant T cells fail to produce interleukin (IL)-2, we analyzed the regulation of NFkappaB-mediated transcription in CD4(+) T cells after tolerance induction in vivo. We demonstrate that a predominance of p50-p50 homodimers binding to the IL-2 promoter kappaB site in tolerant T cells correlated with repression of NFkappaB-driven transcription. Impaired translocation of the p65 subunit in tolerant T cells was a result from reduced activation of IkappaB kinase and poor phosphorylation and degradation of cytosolic IkappaBs. Moreover, tolerant T cells expressed high amounts of the p50 protein. However, the increased expression of p50 could not be explained by activation-induced de novo synthesis of the precursor p105, which was constitutively expressed in tolerant T cells. We also demonstrate the exclusive induction of the IkappaB protein B cell lymphoma 3 (Bcl-3) in tolerant T cells as well as its specific binding to the NFkappaB site. These results suggest that the cellular ratio of NFkappaB dimers, and thus the repression of NFkappaB activity and IL-2 production, are regulated at several levels in tolerant CD4(+) T cells in vivo.	Act Biotech Res Ctr, S-22363 Lund, Sweden; Lund Univ, Dept Cell & Mol Biol, Biomed Ctr I12, Sect Tumor Immunol, S-22184 Lund, Sweden; Lund Univ, Biomed Ctr I13, Immunol Sect, S-22184 Lund, Sweden	Lund University; Lund University	Grundstrom, S (corresponding author), Huddinge Univ Hosp, Ctr Infect Dis, F59, SE-14186 Stockholm, Sweden.	susanna.grundstrom@medhs.ki.se	Brighenti, Susanna/AAA-2255-2022	Brighenti, Susanna/0000-0001-8540-153X; Anderson, Per/0000-0002-0958-7990				BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; DOHLSTEN M, 1993, IMMUNOLOGY, V79, P520; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grundstrom S, 2000, J IMMUNOL, V164, P1175, DOI 10.4049/jimmunol.164.3.1175; Han YQ, 1997, J BIOL CHEM, V272, P9825; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; HEDLUND G, 1991, J IMMUNOL, V147, P4082; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Hour TC, 2000, EUR J CELL BIOL, V79, P121, DOI 10.1078/S0171-9335(04)70014-X; Kalli K, 1998, MOL CELL BIOL, V18, P3140, DOI 10.1128/MCB.18.6.3140; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lechler R, 2001, IMMUNOLOGY, V103, P262, DOI 10.1046/j.1365-2567.2001.01250.x; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Miller C, 1999, J EXP MED, V190, P53, DOI 10.1084/jem.190.1.53; Mondino A, 1996, J IMMUNOL, V157, P2048; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Noel C, 2001, INT IMMUNOL, V13, P431, DOI 10.1093/intimm/13.4.431; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Pape KA, 1998, CIBA F SYMP, V215, P103; PIMENTELMUINOS FX, 1995, EUR J IMMUNOL, V25, P179, DOI 10.1002/eji.1830250130; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; Rothenberg EV, 1996, P NATL ACAD SCI USA, V93, P9358, DOI 10.1073/pnas.93.18.9358; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUNDSTEDT A, 1994, IMMUNOLOGY, V82, P117; Sundstedt A, 1996, P NATL ACAD SCI USA, V93, P979, DOI 10.1073/pnas.93.3.979; Sundstedt A, 1998, J IMMUNOL, V161, P5930; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Wedel A, 1999, BIOL CHEM, V380, P1193, DOI 10.1515/BC.1999.151; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	56	73	78	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8460	8468		10.1074/jbc.M312398200	http://dx.doi.org/10.1074/jbc.M312398200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668329	hybrid			2022-12-27	WOS:000189103300129
J	Leulliot, N; Quevillon-Cheruel, S; Sorel, I; de La Sierra-Gallay, IL; Collinet, B; Graille, M; Blondeau, K; Bettache, N; Poupon, A; Janin, JL; van Tilbeurgh, H				Leulliot, N; Quevillon-Cheruel, S; Sorel, I; de La Sierra-Gallay, IL; Collinet, B; Graille, M; Blondeau, K; Bettache, N; Poupon, A; Janin, JL; van Tilbeurgh, H			Structure of protein phosphatase methyltransferase 1 (PPM1), a leucine carboxyl methyltransferase involved in the regulation of protein phosphatase 2A activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PP2A CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; METHYLATION; BINDING; ASSOCIATION; FAMILY; MAD	The important role of the serine/threonine protein phosphatase 2A (PP2A) in various cellular processes requires a precise and dynamic regulation of PP2A activity, localization, and substrate specificity. The regulation of the function of PP2A involves the reversible methylation of the COOH group of the C-terminal leucine of the catalytic subunit, which, in turn, controls the enzyme's heteromultimeric composition and confers different protein recognition and substrate specificity. We have determined the structure of PPM1, the yeast methyltransferase responsible for methylation of PP2A. The structure of PPM1 reveals a common S-adenosyl-L-methionine- dependent methyltransferase fold, with several insertions conferring the specific function and substrate recognition. The complexes with the S-adenosyl-L-methionine methyl donor and the S-adenosyl-L-homocysteine product and inhibitor unambiguously revealed the co-substrate binding site and provided a convincing hypothesis for the PP2A C-terminal peptide binding site. The structure of PPM1 in a second crystal form provides clues to the dynamic nature of the PPM1/PP2A interaction.	Univ Paris 11, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91405 Orsay, France; CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Paris 11, CNRS, UMR 8621, Inst Genet & Microbiol, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	van Tilbeurgh, H (corresponding author), Univ Paris 11, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, Bat 430, F-91405 Orsay, France.	herman@lebs.cnrs-gif.fr	Janin, Joel/I-2958-2012; GRAILLE, Marc/D-3242-2014; Leulliot, Nicolas/AAA-7160-2019	GRAILLE, Marc/0000-0002-7853-5852; Leulliot, Nicolas/0000-0003-0283-4298; Poupon, Anne/0000-0003-0617-0935; Li de la Sierra-Gallay, Ines/0000-0003-2770-7439				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kahn K, 2000, J AM CHEM SOC, V122, P46, DOI 10.1021/ja993084o; Kalhor HR, 2001, ARCH BIOCHEM BIOPHYS, V395, P239, DOI 10.1006/abbi.2001.2558; Kuhn B, 2000, J AM CHEM SOC, V122, P2586, DOI 10.1021/ja992218v; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; MUMBY M, 2001, SCI STKE; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; RAY MVL, 1993, BIO-TECHNOL, V11, P64, DOI 10.1038/nbt0193-64; Ryttersgaard C, 2002, J BIOL CHEM, V277, P10642, DOI 10.1074/jbc.M200229200; Schluckebier G, 1997, J MOL BIOL, V265, P56, DOI 10.1006/jmbi.1996.0711; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Vafai SB, 2002, FEBS LETT, V518, P1, DOI 10.1016/S0014-5793(02)02702-3; Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wei HJ, 2001, J BIOL CHEM, V276, P1570, DOI 10.1074/jbc.M008694200; Westhead DR, 1999, PROTEIN SCI, V8, P897; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; Zolnierowicz S, 2000, BIOCHEM PHARMACOL, V60, P1225, DOI 10.1016/S0006-2952(00)00424-X	32	67	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8351	8358		10.1074/jbc.M311484200	http://dx.doi.org/10.1074/jbc.M311484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660564	Green Published, hybrid			2022-12-27	WOS:000189103300117
J	Veljkovic, E; Stasiuk, S; Skelly, PJ; Shoemaker, CB; Verrey, F				Veljkovic, E; Stasiuk, S; Skelly, PJ; Shoemaker, CB; Verrey, F			Functional characterization of Caenorhabditis elegans heteromeric amino acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4F2 HEAVY-CHAIN; SUBSTRATE SELECTIVITY; GENE-EXPRESSION; SYSTEM L; IDENTIFICATION; CLONING; EXCHANGERS; CYSTINURIA; KIDNEY	Mammalian heteromeric amino acid transporters (HATs) are composed of a multi-transmembrane spanning catalytic protein covalently associated with a type II glycoprotein (e.g. 4F2hc, rBAT) through a disulfide bond. Caenorhabditis elegans has nine genes encoding close homologues of the HAT catalytic proteins. Three of these genes (designated AAT-1 to AAT-3) have a much higher degree of similarity to the mammalian homologues than the other six, including the presence of a cysteine residue at the position known to form a disulfide bridge to the glycoprotein partner in mammalian HATs. C. elegans also has two genes encoding homologues of the heteromeric amino acid transporter type II glycoprotein subunits (designated ATG-1 and ATG-2). Both ATG, and/or AAT-1, -2, -3 proteins were expressed in Xenopus oocytes and tested for amino acid transport function. This screen revealed that AAT-1 and AAT-3 facilitate amino acid transport when expressed together with ATG-2 but not with ATG-1 or the mammalian type II glycoproteins 4F2hc and rBAT. AAT-1 and AAT-3 covalently bind to both C. elegans ATG glycoproteins, but only the pairs with ATG-2 traffic to the oocyte surface. Both of these functional, surface-expressed C. elegans HATs transport most neutral amino acids and display the highest transport rate for L-Ala and L-Ser (apparent Km 100 muM range). Similar to their mammalian counterparts, the C. elegans HATs function as (near) obligatory amino acid exchangers. Taken together, this study demonstrates that the heteromeric structure and the amino acid exchange function of HATs have been conserved throughout the evolution of nematodes to mammals.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; AgRes, Anim Hlth, Upper Hutt, New Zealand; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	University of Zurich; AgResearch - New Zealand; Harvard University; Harvard T.H. Chan School of Public Health	Verrey, F (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	verrey@access.unizh.ch		Verrey, Francois/0000-0003-3250-9824				Bauch C, 2002, AM J PHYSIOL-RENAL, V283, pF181, DOI 10.1152/ajprenal.00212.2001; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; Harlow E., 1988, ANTIBODIES LAB MANUA; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Puoti A, 1997, P NATL ACAD SCI USA, V94, P5949, DOI 10.1073/pnas.94.11.5949; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Verrey F, 2003, PFLUG ARCH EUR J PHY, V445, P529, DOI 10.1007/S00424-002-0973-Z; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	22	21	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7655	7662		10.1074/jbc.M309528200	http://dx.doi.org/10.1074/jbc.M309528200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668347	hybrid			2022-12-27	WOS:000189103300036
J	Bohm, M; Raghunath, M; Sunderkotter, C; Schiller, M; Stander, S; Brzoska, T; Cauvet, T; Schioth, HB; Schwarz, T; Luger, TA				Bohm, M; Raghunath, M; Sunderkotter, C; Schiller, M; Stander, S; Brzoska, T; Cauvet, T; Schioth, HB; Schwarz, T; Luger, TA			Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN DERMAL FIBROBLASTS; NF-KAPPA-B; MELANOCORTIN-1 RECEPTOR; HUMAN SKIN; IN-VITRO; FIBROSIS; EXPRESSION; CELLS; SCLERODERMA	Suppression of collagen synthesis is a major therapeutic goal in the treatment of fibrotic disorders. We show here that alpha-melanocyte-stimulating hormone (alpha-MSH), a neuropeptide well known for its pigment-inducing capacity, modulates collagen synthesis and deposition. alpha-MSH in vitro suppresses the synthesis of collagen types I, III, and V and down-regulates the secretion of procollagen type I C-terminal peptide (PICP) in human dermal fibroblasts treated with the fibrogenic cytokine transforming growth factor-beta(1), (TGF-beta(1)). alpha-MSH did not interfere with TGF-beta(1) signaling, because TGF-beta(1)-induced expression of collagen mRNA was not affected, implying a posttranscriptional mechanism. Human dermal fibroblasts in vitro express a high affinity binding site for MSH, which was identified by reverse transcription PCR and immunofluoreseence analysis as the melanocortin-1 receptor (MC-1R). Immunohistochemical studies on normal adult human skin confirmed MC-1R expression in distinct dermal fibroblastic cells. The MC-1R on fibroblasts appears to be functionally relevant because a-MSH increased the amount of intracellular cAMP, and coincubation with a synthetic peptide corresponding to the human Agouti signaling protein abrogated the inhibition of TGF-beta(1)-induced PICP secretion by a-MSH. To assess the in vivo relevance of these findings, a mouse model was used in which dermal fibrosis was induced by repetitive intracutaneous injections with TGF-beta(1). The inductive activity of TGF-beta(1) on collagen deposition and the number of dermal cells immunoreactive for vimentin and a-smooth muscle actin was significantly suppressed by injection of a-MSH. Melanocortins such as alpha-MSH may therefore represent a novel class of modulators with potential usefulness for the treatment of fibrotic disorders.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany; Univ Munster, Dept Expt Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Haematol & Med Oncol, D-48149 Munster, Germany; Uppsala Univ, Dept Neurosci, S-75124 Uppsala, Sweden	University of Munster; University of Munster; University of Munster; University of Munster; Uppsala University	Bohm, M (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.	bohmm@uni-muenster.de	Schioth, Helgi/AAQ-7239-2020; Raghunath, Michael/E-6483-2010; Raghunath, Michael/M-2727-2019	Raghunath, Michael/0000-0002-2138-6614; Stander, Sonja/0000-0003-3612-7786; Sunderkotter, Cord/0000-0002-2929-145X				Badid C, 2000, HISTOL HISTOPATHOL, V15, P269, DOI 10.14670/HH-15.269; BATEMAN JF, 1990, BIOCHEM J, V267, P573, DOI 10.1042/bj2670573; Berk JL, 2000, J APPL PHYSIOL, V89, P1425, DOI 10.1152/jappl.2000.89.4.1425; Bhardwaj R, 1997, J IMMUNOL, V158, P3378; Bohm M, 2002, J INVEST DERMATOL, V118, P533, DOI 10.1046/j.0022-202x.2001.01704.x; Bohm M, 2000, HORM RES, V54, P287, DOI 10.1159/000053273; Bohm M, 1999, ANN NY ACAD SCI, V885, P277; Bohm M, 1999, EXP DERMATOL, V8, P453, DOI 10.1111/j.1600-0625.1999.tb00303.x; Bohm M, 1999, ANN NY ACAD SCI, V885, P372; CANNON JG, 1986, J IMMUNOL, V137, P2232; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; GLINSKI W, 1994, BRIT J DERMATOL, V131, P260; Hartmeyer M, 1997, J IMMUNOL, V159, P1930; HaskellLuevano C, 1997, J MED CHEM, V40, P2133, DOI 10.1021/jm960840h; Hill C, 2001, J ENDOCRINOL, V170, P647, DOI 10.1677/joe.0.1700647; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; KHALIL N, 1991, CIBA F SYMP, V157, P194; KISS M, 1995, BIOL CHEM H-S, V376, P425, DOI 10.1515/bchm3.1995.376.7.425; LERNER AB, 1961, NATURE, V189, P176, DOI 10.1038/189176a0; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Manna SK, 1998, J IMMUNOL, V161, P2873; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; McCormick LL, 1999, J IMMUNOL, V163, P5693; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Ng YY, 1998, KIDNEY INT, V54, P864, DOI 10.1046/j.1523-1755.1998.00076.x; Pedagogos E, 1997, AM J KIDNEY DIS, V29, P912, DOI 10.1016/S0272-6386(97)90466-2; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RAGHUNATH M, 1994, PEDIATR RES, V36, P441, DOI 10.1203/00006450-199410000-00005; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Schiller M, 2001, J INVEST DERMATOL, V117, P227, DOI 10.1046/j.0022-202x.2001.01412.x; SCHIOTH HB, 1995, EUR J PHARM-MOLEC PH, V288, P311, DOI 10.1016/0922-4106(95)90043-8; Shihab FS, 1996, SEMIN NEPHROL, V16, P536; Shinozaki M, 1997, BIOCHEM BIOPH RES CO, V237, P292, DOI 10.1006/bbrc.1997.7134; SLOMINSKI A, 1993, J LAB CLIN MED, V122, P658; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; THODY AJ, 1983, PEPTIDES, V4, P813, DOI 10.1016/0196-9781(83)90072-4; Tuan TL, 1998, MOL MED TODAY, V4, P19, DOI 10.1016/S1357-4310(97)80541-2; VARGA JM, 1976, P NATL ACAD SCI USA, V73, P559, DOI 10.1073/pnas.73.2.559; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; Yamamoto T, 1999, CLIN IMMUNOL, V92, P6, DOI 10.1006/clim.1999.4720; Yokozeki M, 1997, EXP CELL RES, V231, P328, DOI 10.1006/excr.1997.3473	49	85	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6959	6966		10.1074/jbc.M312549200	http://dx.doi.org/10.1074/jbc.M312549200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645373	hybrid			2022-12-27	WOS:000188969200091
J	Doering, CB; Healey, JF; Parker, ET; Barrow, RT; Lollar, P				Doering, CB; Healey, JF; Parker, ET; Barrow, RT; Lollar, P			Identification of porcine coaglulation factor VIII domains responsible for high level expression via enhanced secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VIII; CLOTTING FACTOR-VIII; FACTOR-V; MAMMALIAN-CELLS; SCANNING MUTAGENESIS; INHIBITORY EPITOPE; MAJOR DETERMINANT; CODING REGION; HEMOPHILIA-A; PROTEIN	Blood coagulation factor VIII has a domain structure designated A1-A2-B-ap-A3-C1-C2. Human factor VIII is present at low concentration in normal plasma and, comparably, is produced at low levels in vitro and in vivo using transgenic expression techniques. Heterologous expression of B domain-deleted porcine factor VIII in mammalian cell culture is significantly greater than B domain-deleted human or murine factor VIII. Novel hybrid human/porcine factor VIII molecules were constructed to identify porcine factor VIII domains that confer high level expression. Hybrid human/porcine factor VIII constructs containing the porcine factor VIII A1 and ap-A3 domains expressed at levels comparable with recombinant porcine factor VIII. A hybrid construct containing only the porcine A1 domain expressed at intermediate levels between human and porcine factor VIII, whereas a hybrid construct containing the porcine ap-A3 domain expressed at levels comparable with human factor VIII. Additionally, hybrid murine/porcine factor VIII constructs containing the porcine factor VIII A1 and ap-A3 domain sequences expressed at levels significantly higher than recombinant murine factor VIII. Therefore, the porcine Al and ap-A3 domains are necessary and sufficient for the high level expression associated with porcine factor VIII. Metabolic radiolabeling experiments demonstrated that high level expression was attributable to enhanced secretory efficiency.	Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University	Lollar, P (corresponding author), Emory Univ, Winship Canc Inst, 1639 Pierce Dr,Rm 1003 Woodruff Mem Bldg, Atlanta, GA 30322 USA.	jlollar@emory.edu	Doering, Christopher/W-2064-2019		PHS HHS [R01-L40921] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barrow RT, 2001, BLOOD, V97, P169, DOI 10.1182/blood.V97.1.169; Barrow RT, 2000, BLOOD, V95, P564, DOI 10.1182/blood.V95.2.564; Bohn RL, 1998, THROMB HAEMOSTASIS, V79, P932; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; Doering CB, 2002, J BIOL CHEM, V277, P38345, DOI 10.1074/jbc.M206959200; Doering CB, 2002, THROMB HAEMOSTASIS, V88, P450; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; Fang XD, 2001, THROMB RES, V102, P177, DOI 10.1016/S0049-3848(01)00229-8; Garber K, 2000, NAT BIOTECHNOL, V18, P1133, DOI 10.1038/81098; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; Healey JF, 1996, BLOOD, V88, P4209; HOEBEN RC, 1995, BLOOD, V85, P2447, DOI 10.1182/blood.V85.9.2447.bloodjournal8592447; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KAUFMAN RJ, 1997, BLOOD COAGUL FIBRIN, V8, P3; KOEBERL DD, 1995, HUM GENE THER, V6, P469, DOI 10.1089/hum.1995.6.4-469; LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; Lubin IM, 1997, J BIOL CHEM, V272, P30191, DOI 10.1074/jbc.272.48.30191; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; MARQUETTE KA, 1995, J BIOL CHEM, V270, P10297, DOI 10.1074/jbc.270.17.10297; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; Qian JJ, 1999, THROMB HAEMOSTASIS, V81, P240, DOI 10.1055/s-0037-1614450; Roth DA, 2001, NEW ENGL J MED, V344, P1735, DOI 10.1056/NEJM200106073442301; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Swaroop M, 1997, J BIOL CHEM, V272, P24121, DOI 10.1074/jbc.272.39.24121; Tagliavacca L, 1997, J BIOL CHEM, V272, P27428, DOI 10.1074/jbc.272.43.27428; Tagliavacca L, 2000, BIOCHEMISTRY-US, V39, P1973, DOI 10.1021/bi991896r; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	41	50	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6546	6552		10.1074/jbc.M312451200	http://dx.doi.org/10.1074/jbc.M312451200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660593	hybrid			2022-12-27	WOS:000188969200042
J	Sekiya, T; Adachi, S; Kohu, K; Yamada, T; Higuchi, O; Furukawa, Y; Nakamura, Y; Nakamura, T; Tashiro, K; Kuhara, S; Ohwada, S; Akiyama, T				Sekiya, T; Adachi, S; Kohu, K; Yamada, T; Higuchi, O; Furukawa, Y; Nakamura, Y; Nakamura, T; Tashiro, K; Kuhara, S; Ohwada, S; Akiyama, T			Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS-POLYPOSIS-COLI; APC GENE-PRODUCT; SUPPRESSOR PROTEIN; HEPATOCELLULAR CARCINOMAS; IN-VIVO; CANCER; AXIN; EXPRESSION; ICAT; ASSOCIATION	The Wnt signaling pathway is activated in most human colorectal tumors. Mutational inactivation in the tumor suppressor adenomatous polyposis coli (APC), as well as activation of beta-catenin, causes the accumulation of beta-catenin, which in turn associates with the T cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors and activates transcription of their target genes. Here we show that beta-catenin activates transcription of the BMP and activin membrane-bound inhibitor (BAMBI)/NMA gene. The expression level of BAMBI was found to be aberrantly elevated in most colorectal and hepatocellular carcinomas relative to the corresponding non-cancerous tissues. Expression of BAMBI in colorectal tumor cell lines was repressed by a dominant-negative mutant of TCF-4 or by an inhibitor of beta-catenin-TCF interaction, suggesting that beta-catenin is responsible for the aberrant expression of BAMBI in colorectal tumor cells. Furthermore, overexpression of BAMBI inhibited the response of tumor cells to transforming growth factor-beta signaling. These results suggest that beta-catenin interferes with transforming growth factor-beta-mediated growth arrest by inducing the expression of BAMBI, and this may contribute to colorectal and hepatocellular tumorigenesis.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan; Gunma Univ, Sch Med, Dept Surg 2, Maebashi, Gumma 371, Japan; Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Lab Mol Gene Tech,Higashi Ku, Fukuoka 8128581, Japan	University of Tokyo; University of Tokyo; Gunma University; Kyushu University	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp	Adachi, Shungo/L-6348-2018	Adachi, Shungo/0000-0001-5232-411X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Daniels DL, 2002, MOL CELL, V10, P573, DOI 10.1016/S1097-2765(02)00631-7; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NAKAMURA Y, 1995, J CANCER RES CLIN, V121, P529, DOI 10.1007/BF01197765; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sekiya T, 2002, CANCER RES, V62, P3322; Shtutman Michael, 2002, Cancer Research, V62, P5947; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; Suzuki Y, 2002, NUCLEIC ACIDS RES, V30, P328, DOI 10.1093/nar/30.1.328; Tago K, 2000, GENE DEV, V14, P1741; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; Tsang M, 2000, GENESIS, V28, P47, DOI 10.1002/1526-968X(200010)28:2<47::AID-GENE20>3.0.CO;2-S; Xu LF, 2000, GENE DEV, V14, P585; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498	54	121	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6840	6846		10.1074/jbc.M310876200	http://dx.doi.org/10.1074/jbc.M310876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660579	hybrid			2022-12-27	WOS:000188969200078
J	Yu, KF; Huang, FT; Lieber, AR				Yu, KF; Huang, FT; Lieber, AR			DNA substrate length and surrounding sequence affect the activation-induced deaminase activity at cytidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; SOMATIC HYPERMUTATION; AID; TRANSCRIPTION; EXCISION; REGIONS; GENES; MECHANISM	Activation-induced deaminase (AID) is required for both immunoglobulin class switch recombination and somatic hypermutation. AID is known to deaminate cytidines in single-stranded DNA, but the relationship of this step to the class switch or somatic hypermutation processes is not entirely clear. We have studied the activity of a recombinant form of the mouse AID protein that was purified from a baculovirus expression system. We find that the length of the single-stranded DNA target is critical to the action of AID at the Cs positioned anywhere along the length of the DNA. The DNA sequence surrounding a given C influences AID deamination efficiency. AID preferentially deaminates Cs in the WRC motif, and additionally has a small but consistent preference for purine at the position after the WRC, thereby favoring WRCr (the lowercase r corresponds to the smaller impact on activity).	Univ So Calif, Norris Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Norris Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA; Univ So Calif, Norris Comprehens Canc Ctr, Dept Biol Sci, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Lieber, AR (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA.	lieber@usc.edu	Hsiao, Wei-Hung/B-9931-2013	Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056984] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056984] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abner CW, 2001, J BIOL CHEM, V276, P13379, DOI 10.1074/jbc.M010641200; Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Doi T, 2003, P NATL ACAD SCI USA, V100, P2634, DOI 10.1073/pnas.0437710100; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; Fugmann SD, 2003, NAT IMMUNOL, V4, P429, DOI 10.1038/ni0503-429; Kitao H, 2000, INT IMMUNOL, V12, P959, DOI 10.1093/intimm/12.7.959; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Michael N, 2002, IMMUNITY, V16, P123, DOI 10.1016/S1074-7613(02)00261-3; Milstein C, 1998, P NATL ACAD SCI USA, V95, P8791, DOI 10.1073/pnas.95.15.8791; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; REABAN ME, 1994, J BIOL CHEM, V269, P21850; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Shapiro GS, 2002, J IMMUNOL, V168, P2302, DOI 10.4049/jimmunol.168.5.2302; Shinkura R, 2003, NAT IMMUNOL, V4, P435, DOI 10.1038/ni918; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; TA VT, 2003, NAT IMMUNOL, V4, P945; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919	32	148	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6496	6500		10.1074/jbc.M311616200	http://dx.doi.org/10.1074/jbc.M311616200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645244	hybrid			2022-12-27	WOS:000188969200035
J	Tantin, D; Tussie-Luna, MI; Roy, AL; Sharp, PA				Tantin, D; Tussie-Luna, MI; Roy, AL; Sharp, PA			Regulation of immunoglobulin promoter activity by TFII-I class transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC COACTIVATOR; RNA-POLYMERASE-II; BINDING PROTEIN; SEQUENCE ELEMENTS; ENHANCER-BINDING; IMMUNE-RESPONSE; MICE LACKING; DNA-BINDING; GENE; IDENTIFICATION	The restriction of immunoglobulin variable region promoter activity to B lymphocytes is a well known paradigm of promoter specificity. Recently, a cis- element, located downstream of the transcription initiation site of murine heavy chain variable promoters, was shown to be critical for B cell activity and specificity. Here we show that mutation of this element, termed DICE ( Downstream Immunoglobulin Control Element), reduces in vivo activity in B cells. Gel mobility shift assays show that DICE forms B cell- specific complexes that were also sensitive to DICE mutation. DICE mutation strongly reduces the ability of a distal immunoglobulin heavy chain intronic enhancer to stimulate transcription. We also identify a DICE- interacting factor: a TFII- I- related protein known as BEN ( also termed Mus-TRD1 and WBSCR11). Dominant- negative and RNA(i)- mediated knockdown experiments indicate that BEN can both positively and negatively regulate IgH promoter activity, depending on the cell line.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; McGovern Inst, Cambridge, MA 02139 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Tufts University	Sharp, PA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,Rm E17-529, Cambridge, MA 02139 USA.	sharppa@mit.edu		Tussie-Luna, Maria Isabel/0000-0002-5033-408X	NCI NIH HHS [P30-CA14051, P01-CA42063] Funding Source: Medline; NIAID NIH HHS [AI 45150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045150, R56AI045150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLARD DW, 1986, P NATL ACAD SCI USA, V83, P9626, DOI 10.1073/pnas.83.24.9626; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; Bayarsaihan D, 2002, GENOMICS, V79, P137, DOI 10.1006/geno.2001.6674; Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Casellas R, 2002, CELL, V110, P575, DOI 10.1016/S0092-8674(02)00911-X; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; GARCIA JV, 1986, NATURE, V322, P383, DOI 10.1038/322383a0; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUNDERSON SI, 1988, J BIOL CHEM, V263, P17603; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; Handa H, 1999, PRACT APPROACH SER, V204, P283; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Henderson AJ, 1995, CRIT REV EUKAR GENE, V5, P255, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.30; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MERCOLA M, 1983, SCIENCE, V221, P663, DOI 10.1126/science.6306772; MURPHY JT, 1982, CELL, V29, P265, DOI 10.1016/0092-8674(82)90111-8; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Novina CD, 1999, MOL CELL BIOL, V19, P5014; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; Osborne LR, 1999, GENOMICS, V57, P279, DOI 10.1006/geno.1999.5784; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PARVIN JD, 1991, J BIOL CHEM, V266, P22878; Pelletier MR, 1997, NUCLEIC ACIDS RES, V25, P3995, DOI 10.1093/nar/25.20.3995; Polly P, 2003, J BIOL CHEM, V278, P36603, DOI 10.1074/jbc.M212814200; Ring C, 2002, GENE DEV, V16, P820, DOI 10.1101/gad.963802; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Tantin D, 2002, MOL CELL BIOL, V22, P1460, DOI 10.1128/MCB.22.5.1460-1473.2002; Tay ESE, 2003, BIOCHEM J, V374, P359, DOI 10.1042/BJ20030189; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tussie-Luna MI, 2002, J BIOL CHEM, V277, P43185, DOI 10.1074/jbc.M207635200; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Tussie-Luna MI, 2001, P NATL ACAD SCI USA, V98, P7789, DOI 10.1073/pnas.141222298; Vullhorst D, 2003, J BIOL CHEM, V278, P8370, DOI 10.1074/jbc.M209361200; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604	67	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5460	5469		10.1074/jbc.M311177200	http://dx.doi.org/10.1074/jbc.M311177200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645227	hybrid			2022-12-27	WOS:000188776500053
J	Wittmann, T; Bokoch, GM; Waterman-Storer, CM				Wittmann, T; Bokoch, GM; Waterman-Storer, CM			Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; EPIDERMAL GROWTH-FACTOR; ONCOPROTEIN 18; IN-VIVO; P21-ACTIVATED KINASES; DYNAMIC INSTABILITY; CELL MOTILITY; RHO-GTPASES; SERINE 16; PHOSPHORYLATION	In the leading edge of migrating cells, a subset of microtubules exhibits net growth in a Rac1- and p21-activated kinase-dependent manner. Here, we explore the possibility of whether phosphorylation and inactivation of the microtubule-destabilizing protein Op18/stathmin could be a mechanism regulating microtubule dynamics downstream of Rac1 and p21-activated kinases. We find that, in vitro, Pak1 phosphorylates Op18/stathmin specifically at serine 16 and inactivates its catastrophe promoting activity in biochemical and time lapse microscopy microtubule assembly assays. Furthermore, phosphorylation of either serine 16 or 63 is sufficient to inhibit Op18/stathmin in vitro. In cells, the microtubule-destabilizing effect of an excess of Op18/stathmin can be partially overcome by expression of constitutively active Rac1(Q61L), which is dependent on Pak activity, suggesting that the microtubule cytoskeleton can be regulated through inactivation of Op18/stathmin downstream of Rac1 and Pak in vivo. However, in vivo, Pak1 activity alone is not sufficient to phosphorylate Op18, indicating that additional pathways downstream of Rac1 are required for Op18 regulation.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wittmann, T (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	twittman@scripps.edu; waterman@scripps.edu	Wittmann, Torsten/F-9833-2013	Wittmann, Torsten/0000-0001-9134-691X; Waterman, Clare/0000-0001-6142-6775	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39434, GM68104] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 2002, BIOESSAYS, V24, P305, DOI 10.1002/bies.10084; BELL CW, 1982, METHOD CELL BIOL, V24, P373; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; BRATTSAND G, 1993, LEUKEMIA, V7, P569; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Gavet O, 1998, J CELL SCI, V111, P3333; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Gupton SL, 2002, CURR BIOL, V12, P1891, DOI 10.1016/S0960-9822(02)01276-9; HOELSCHER SR, 1994, ENDOCRINOLOGY, V135, P662, DOI 10.1210/en.135.2.662; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, J CELL SCI, V112, P3713; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; JI H, 1993, J BIOL CHEM, V268, P13396; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Kinoshita K, 2002, TRENDS CELL BIOL, V12, P267, DOI 10.1016/S0962-8924(02)02295-X; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Komarova YA, 2002, J CELL BIOL, V159, P589, DOI 10.1083/jcb.200208058; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; le Gouvello S, 1998, J IMMUNOL, V161, P1113; MELANDER HG, 1998, J CELL BIOL, V140, P131; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Palazzo AF, 2001, CURR BIOL, V11, P1536, DOI 10.1016/S0960-9822(01)00475-4; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Segerman B, 2003, J CELL SCI, V116, P197, DOI 10.1242/jcs.00205; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wittmann T, 2001, J CELL SCI, V114, P3795; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHAI Y, 1994, J CELL SCI, V107, P881; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	54	187	195	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6196	6203		10.1074/jbc.M307261200	http://dx.doi.org/10.1074/jbc.M307261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645234	hybrid			2022-12-27	WOS:000188776500136
J	Dong, L; Xu, CW				Dong, L; Xu, CW			Carbohydrates induce mono-ubiquitination of H2B in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H2B; SACCHAROMYCES-CEREVISIAE; METHYLATION; RAD6; H3; MONOUBIQUITINATION; EXPRESSION; COMPONENT; SEQUENCE; COMPASS	Histone modifications have emerged to be a major regulatory mechanism for gene expression ( 1 - 4). However, it is not clear how histone modifications are physiologically regulated. Here, we show that mono-ubiquitinated H2B at lysine 123 (uH2B) in the yeast ( Saccharomyces cerevisiae) is present in exponential phase and absent in stationary phase. A wide array of carbohydrates or sugars, including glucose, fructose, mannose, and sucrose, are capable of inducing uH2B in stationary phase yeast. In contrast, non-metabolic glucose analogs are defective in inducing uH2B. Furthermore, uH2B induction is inhibited by iodoacetate, an inhibitor of glyceraldehyde-3- phosphate dehydrogenase in glycolysis. Moreover, uH2B induction is markedly impaired in yeast mutants, in which glycolytic genes are deleted. These data indicate that glycolysis is required for the carbohydrate-induced mono-ubiquitination of H2B at lysine 123. Therefore, our study reveals a novel paradigm of metabolic regulation of histone modifications.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Xu, CW (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.	xuc@mskcc.org						Alberts B., 2008, MOL BIOL CEL, V5th ed.; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Carlson M, 1998, CURR OPIN GENET DEV, V8, P560, DOI 10.1016/S0959-437X(98)80011-7; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; GUELMAN R, 2002, BONE, V30, P23; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; HUNT LT, 1977, BIOCHEM BIOPH RES CO, V74, P650, DOI 10.1016/0006-291X(77)90352-7; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Klein CJL, 1998, MICROBIOL-SGM, V144, P13, DOI 10.1099/00221287-144-1-13; Michal G, 1999, BIOCH PATHWAYS ATLAS; Ng HH, 2003, J BIOL CHEM, V278, P33625, DOI 10.1074/jbc.C300270200; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; OLSON MOJ, 1976, J BIOL CHEM, V251, P5901; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; van Holde KE., 1989, SPRINGER SERIES MOL; WEBB J, 1966, ENZYME METABOLIC INH, V3; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	31	23	26	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1577	1580		10.1074/jbc.C300505200	http://dx.doi.org/10.1074/jbc.C300505200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14660635	hybrid			2022-12-27	WOS:000188005700002
J	Cluzel, C; Lethias, C; Garrone, R; Exposito, JY				Cluzel, C; Lethias, C; Garrone, R; Exposito, JY			Distinct maturations of N-propeptide domains in fibrillar procollagen molecules involved in the formation of heterotypic fibrils in adult sea urchin collagenous tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; STRONGYLOCENTROTUS-PURPURATUS; ASTHENOSOMA-IJIMAI; I PROCOLLAGEN; 2-ALPHA CHAIN; XIV COLLAGEN; V COLLAGEN; PROTEINASE; EXPRESSION; IDENTIFICATION	We have characterized the primary structure of a new sea urchin fibrillar collagen, the 5alpha chain, including nine repeats of the sea urchin fibrillar module in its N-propeptide. By Western blot and immunofluorescence analyses, we have shown that 5alpha is co-localized in adult collagenous ligaments with the 2alpha fibrillar collagen chain and fibrosurfin, two other extracellular matrix proteins possessing sea urchin fibrillar modules. At the ultrastructural level, the 5alpha N-propeptide is detected at the surface of fibrils, suggesting the retention of this domain in mature collagen molecules. Biochemical characterization of pepsinized collagen molecules extracted from the test tissue ( the endoskeleton) together with a matrix-assisted laser desorption ionization time-of-flight analysis allowed us to determine that 5alpha is a quantitatively minor fibrillar collagen chain in comparison with the 1alpha and 2alpha chains. Moreover, 5alpha forms heterotrimeric molecules with two 1alpha chains. Hence, as in vertebrates, sea urchin collagen fibrils are made up of quantitatively major and minor fibrillar molecules undergoing distinct maturation of their N-propeptide regions and participating in the formation of heterotypic fibrils.	Univ Lyon 1, Inst Federatif Rech Biosci Lyon Gerland 128, CNRS,Unite Mixte Rech 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Exposito, JY (corresponding author), Univ Lyon 1, Inst Federatif Rech Biosci Lyon Gerland 128, CNRS,Unite Mixte Rech 5086, Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.	jy.exposito@ibcp.fr		Cluzel, Caroline/0000-0001-8946-3439; Exposito, Jean-Yves/0000-0002-4926-4942				BERGER J, 1985, BIOCHEMISTRY-US, V24, P600, DOI 10.1021/bi00324a009; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; BURKE RD, 1989, COMP BIOCHEM PHYS B, V94, P41, DOI 10.1016/0305-0491(89)90007-2; Cluzel C, 2000, MATRIX BIOL, V19, P545, DOI 10.1016/S0945-053X(00)00109-8; Cluzel C, 2001, J BIOL CHEM, V276, P18108, DOI 10.1074/jbc.M009597200; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; CORTAY JC, 1994, J BIOL CHEM, V269, P14885; DALESSIO M, 1989, P NATL ACAD SCI USA, V86, P9303, DOI 10.1073/pnas.86.23.9303; DALESSIO M, 1990, J BIOL CHEM, V265, P7050; Ellers O, 1996, P ROY SOC B-BIOL SCI, V263, P39, DOI 10.1098/rspb.1996.0007; EXPOSITO JY, 1992, J BIOL CHEM, V267, P17404; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; EXPOSITO JY, 1995, EUR J BIOCHEM, V234, P59, DOI 10.1111/j.1432-1033.1995.059_c.x; Exposito JY, 2002, ANAT RECORD, V268, P302, DOI 10.1002/ar.10162; HOJIMA Y, 1994, J BIOL CHEM, V269, P11381; Johnson AS, 2002, P ROY SOC B-BIOL SCI, V269, P215, DOI 10.1098/rspb.2001.1881; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; LEAHY PS, 1986, METHOD CELL BIOL, V27, P1, DOI 10.1016/S0091-679X(08)60339-8; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Lethias C, 1997, EUR J BIOCHEM, V245, P434, DOI 10.1111/j.1432-1033.1997.t01-2-00434.x; LETHIAS C, 1993, J INVEST DERMATOL, V101, P92, DOI 10.1111/1523-1747.ep12360433; Miller EJ, 1984, EXTRACELLULAR MATRIX, P41; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; Omura Y, 1996, COMP BIOCHEM PHYS B, V115, P63, DOI 10.1016/0305-0491(96)00085-5; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; PUCCIMINAFRA I, 1978, J SUBMICR CYTOL PATH, V10, P53; SHIMIZU K, 1990, BIOCHIM BIOPHYS ACTA, V1038, P39, DOI 10.1016/0167-4838(90)90007-3; TOMITA M, 1994, BBA-GENE STRUCT EXPR, V1217, P131, DOI 10.1016/0167-4781(94)90026-4; TROTTER JA, 1994, COMP BIOCHEM PHYS B, V107, P125, DOI 10.1016/0305-0491(94)90234-8; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Wilkie IC, 2002, J EXP BIOL, V205, P159; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314	37	14	14	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9811	9817		10.1074/jbc.M311803200	http://dx.doi.org/10.1074/jbc.M311803200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14665629	hybrid			2022-12-27	WOS:000220050400020
J	Kim, JY; Han, WS; Namkung, W; Lee, JH; Kim, KH; Shin, HW; Kim, E; Lee, MG				Kim, JY; Han, WS; Namkung, W; Lee, JH; Kim, KH; Shin, HW; Kim, E; Lee, MG			Inhibitory regulation of cystic fibrosis transmembrane conductance regulator anion-transporting activities by Shank2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEINS; DEPENDENT HCO3-TRANSPORT; CFTR CHLORIDE CHANNELS; MOLECULAR-MECHANISM; CL-/HCO3-EXCHANGE; PANCREATIC DUCT; FAMILY; CELLS; PDZ; ASSOCIATION	Accumulating evidence suggests that protein-protein interactions play an important role in transepithelial ion transport. In the present study, we report on the biochemical and functional association between cystic fibrosis transmembrane conductance regulator (CFTR) and a PDZ domain-containing protein Shank2. Exploratory reverse transcription-PCR screening revealed mRNAs for several members of PDZ domain-containing proteins in epithelial cells. Shank2, one of these scaffolding proteins, showed a strong interaction with CFTR by yeast two-hybrid assays. Shank2-CFTR interaction was verified by co-immunoprecipitation experiments in mammalian cells. Notably, this interaction was abolished by mutations in the PDZ domain of Shank2. Protein phosphorylation, HCO3- transport and Cl- current by CFTR were measured in NIH 3T3 cells with heterologous expression of Shank2. Of interest, expression of Shank2 suppressed cAMP-induced phosphorylation and activation of CFTR. Importantly, loss of Shank2 by stable transfection of antisense-hShank2 plasmid strongly increased CFTR currents in colonic T84 cells, in which CFTR and Shank2 were natively expressed. Our results indicate that Shank2 negatively regulates CFTR and that this may play a significant role in maintaining epithelial homeostasis under normal and diseased conditions such as those presented by secretory diarrhea.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Korea Adv Inst Sci & Technol, Creat Res Ctr Synaptogenesis, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Lee, MG (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, 134 Sinchon Dong, Seoul 120752, South Korea.	mlee@yumc.yonsei.ac.kr	Kim, Eunjoon/C-1566-2011; Lee, Min Goo/D-5635-2012; Lee, Min Goo/AAS-4636-2020; Kim, Joo Young/X-7562-2019	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X; Kim, Joo Young/0000-0003-2623-1491				Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Cormet-Boyaka E, 2002, P NATL ACAD SCI USA, V99, P12477, DOI 10.1073/pnas.192203899; Dahan D, 2001, PFLUG ARCH EUR J PHY, V443, pS92, DOI 10.1007/s004240100652; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Kunzelmann K, 2001, NEWS PHYSIOL SCI, V16, P167; Lee M G, 2001, JOP, V2, P203; Lee MG, 1999, J BIOL CHEM, V274, P3414, DOI 10.1074/jbc.274.6.3414; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; Mok H, 2002, J NEUROSCI, V22, P5253; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Namkung W, 2003, J BIOL CHEM, V278, P200, DOI 10.1074/jbc.M207199200; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Park E, 2003, J BIOL CHEM, V278, P19220, DOI 10.1074/jbc.M301052200; Park M, 2002, J BIOL CHEM, V277, P50503, DOI 10.1074/jbc.M201862200; Quinton PM, 2001, NAT MED, V7, P292, DOI 10.1038/85429; QUINTON PM, 1999, PHYSIOL REV, V79, P3; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9	32	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10389	10396		10.1074/jbc.M312871200	http://dx.doi.org/10.1074/jbc.M312871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679199	hybrid, Green Published			2022-12-27	WOS:000220050400089
J	Tzeng, TY; Liu, HC; Yang, CH				Tzeng, TY; Liu, HC; Yang, CH			The C-terminal sequence of LMADS1 is essential for the formation of homodimers for B function proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MADS-BOX GENES; FLORAL ORGAN IDENTITY; HOMEOTIC GENE; FLOWER DEVELOPMENT; MOLECULAR EVOLUTION; MULTIGENE FAMILY; ARABIDOPSIS; APETALA3; EXPRESSION; PISTILLATA	LMADS1, a lily ( Lilium longiflorum) AP3 orthologue, contains the complete consensus sequence of the paleoAP3 ( YGSHDLRLA) and PI-derived (YEFRVQPSQPNLH) motifs in the C-terminal region of the protein. Interestingly, through yeast two-hybrid analysis, LMADS1 was found to be capable of forming homodimers. These results indicated that LMADS1 represents an ancestral form of the B function protein, which retains the ability to form homodimers in regulating petal and stamen development in lily. To explore the involvement of the conserved motifs in the C-terminal region of LMADS1 in forming homodimers, truncated forms of LMADS1 were generated, and their ability to form homodimers was analyzed using yeast two-hybrid and electrophoretic mobility shift assay. The ability of LMADS1 to form homodimers decreased once the C-terminal paleoAP3 motif was deleted. When both paleoAP3 and PI-derived motifs were deleted, the ability of LMADS1 to form homodimers was completely abolished. This result indicated that although the paleoAP3 motif promotes the formation of LMADS1 homodimers, the PI-derived motif is essential. Deletion analysis indicated that two amino acids, RV, of the 5 final amino acids, YEFRV, in the PI-derived motif are essential for the formation of homodimers. Further, point mutation analysis indicated that amino acid Val was absolutely necessary, whereas residue Arg played a less important role in the formation of homodimers. Furthermore, Arabidopsis AP3 was able to form homodimers once its C-terminal region was replaced by that of LMADS1. This result indicated that the C-terminal region of LMADS1 is responsible and essential for homodimer formation of the ancestral form of the B function protein.	Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan	National Chung Hsing University	Yang, CH (corresponding author), Natl Chung Hsing Univ, Grad Inst Biotechnol, Taichung 40227, Taiwan.	chyang@dragon.nchu.edu.tw		Tzeng, Tsai-Yu/0000-0001-7334-6270				ANGENENT GC, 1992, PLANT CELL, V4, P983, DOI 10.1105/tpc.4.8.983; ANGENENT GC, 1995, PLANT CELL, V7, P505; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; CHUNG YY, 1995, PLANT SCI, V109, P45, DOI 10.1016/0168-9452(95)04153-L; DOYLE JJ, 1994, SYST BIOL, V43, P307; Egea-Cortines M, 1999, EMBO J, V18, P5370, DOI 10.1093/emboj/18.19.5370; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; Hill TA, 1998, DEVELOPMENT, V125, P1711; Hsu HF, 2002, PLANT CELL PHYSIOL, V43, P1198, DOI 10.1093/pcp/pcf143; HUANG H, 1993, NUCLEIC ACIDS RES, V21, P4769, DOI 10.1093/nar/21.20.4769; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; Kramer EM, 1998, GENETICS, V149, P765; Kyozuka J, 2000, PLANT CELL PHYSIOL, V41, P710, DOI 10.1093/pcp/41.6.710; McGonigle B, 1996, GENE DEV, V10, P1812, DOI 10.1101/gad.10.14.1812; Miller J.H., 1992, SHORT COURSE BACTERI, P74; Moon YH, 1999, PLANT MOL BIOL, V40, P167, DOI 10.1023/A:1026429922616; Mouradov A, 1999, DEV GENET, V25, P245, DOI 10.1002/(SICI)1520-6408(1999)25:3&lt;245::AID-DVG7&gt;3.0.CO;2-N; Munster T, 2001, GENE, V262, P1, DOI 10.1016/S0378-1119(00)00556-4; Purugganan MD, 1997, J MOL EVOL, V45, P392, DOI 10.1007/PL00006244; PURUGGANAN MD, 1995, GENETICS, V140, P345; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; Riechmann JL, 1997, BIOL CHEM, V378, P1079; ROUNSLEY SD, 1995, PLANT CELL, V7, P1259, DOI 10.1105/tpc.7.8.1259; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; Sheppard LA, 2000, PLANT PHYSIOL, V124, P627, DOI 10.1104/pp.124.2.627; SHIRAISHI H, 1993, PLANT J, V4, P385, DOI 10.1046/j.1365-313X.1993.04020385.x; Sundstrom J, 1999, DEV GENET, V25, P253, DOI 10.1002/(SICI)1520-6408(1999)25:3&lt;253::AID-DVG8&gt;3.0.CO;2-P; Theissen G, 2000, PLANT MOL BIOL, V42, P115, DOI 10.1023/A:1006332105728; THEISSEN G, 1995, CURR OPIN GENET DEV, V5, P628, DOI 10.1016/0959-437X(95)80032-8; Theissen G, 1996, J MOL EVOL, V43, P484, DOI 10.1007/BF02337521; Tilly JJ, 1998, DEVELOPMENT, V125, P1647; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; Tzeng TY, 2001, PLANT CELL PHYSIOL, V42, P1156, DOI 10.1093/pcp/pce151; Vandenbussche M, 2003, NUCLEIC ACIDS RES, V31, P4401, DOI 10.1093/nar/gkg642; VANDERKROL AR, 1993, GENE DEV, V7, P1214, DOI 10.1101/gad.7.7a.1214; Winter KU, 1999, P NATL ACAD SCI USA, V96, P7342, DOI 10.1073/pnas.96.13.7342; Winter KU, 2002, MOL BIOL EVOL, V19, P587, DOI 10.1093/oxfordjournals.molbev.a004118; Yu DY, 1999, PLANT J, V17, P51, DOI 10.1046/j.1365-313X.1999.00351.x	40	40	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10747	10755		10.1074/jbc.M311646200	http://dx.doi.org/10.1074/jbc.M311646200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14676188	hybrid			2022-12-27	WOS:000220050400130
J	Hosfield, DJ; Zhang, YM; Dougan, DR; Broun, A; Tari, LW; Swanson, RV; Finn, J				Hosfield, DJ; Zhang, YM; Dougan, DR; Broun, A; Tari, LW; Swanson, RV; Finn, J			Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL DIPHOSPHATE SYNTHASE; NITROGEN-CONTAINING BISPHOSPHONATES; PYROPHOSPHATE SYNTHASE; ESCHERICHIA-COLI; IN-VITRO; OSTEOPOROSIS; PURIFICATION; ALENDRONATE; SYNTHETASE; PROTEINS	Farnesyl pyrophosphate synthetase (FPPS) synthesizes farnesyl pyrophosphate through successive condensations of isopentyl pyrophosphate with dimethylallyl pyrophosphate and geranyl pyrophosphate. Nitrogen-containing bisphosphonate drugs used to treat osteoclast-mediated bone resorption and tumor-induced hypercalcemia are potent inhibitors of the enzyme. Here we present crystal structures of substrate and bisphosphonate complexes of FPPS. The structures reveal how enzyme conformational changes organize conserved active site residues to exploit metal-induced ionization and substrate positioning for catalysis. The structures further demonstrate how nitrogen-containing bisphosphonates mimic a carbocation intermediate to inhibit the enzyme. Together, these FPPS complexes provide a structural template for the design of novel inhibitors that may prove useful for the treatment of osteoporosis and other clinical indications including cancer.	Syrrx Inc, Dept Struct Chem, San Diego, CA 92121 USA; Tril Pharmaceut, San Diego, CA 92121 USA		Hosfield, DJ (corresponding author), Syrrx Inc, Dept Struct Chem, 10410 Sci Ctr Dr, San Diego, CA 92121 USA.			Swanson, Ronald/0000-0002-6486-2676				Bartl R, 2002, DEUT MED WOCHENSCHR, V127, P638; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; CORNFORTH JW, 1966, J BIOL CHEM, V241, P3970; DING VDH, 1991, BIOCHEM J, V275, P61, DOI 10.1042/bj2750061; Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Holstein SA, 2003, BIOCHEMISTRY-US, V42, P4384, DOI 10.1021/bi027227m; Hosfield D, 2003, J STRUCT BIOL, V142, P207, DOI 10.1016/S1047-8477(03)00051-0; Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Leyes AE, 1999, ORG LETT, V1, P1071, DOI 10.1021/ol990876e; Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Montalvetti A, 2003, J BIOL CHEM, V278, P17075, DOI 10.1074/jbc.M210467200; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NISHINO T, 1972, J AM CHEM SOC, V94, P6849, DOI 10.1021/ja00774a045; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phan RM, 2000, ORG LETT, V2, P2287, DOI 10.1021/ol006055n; POULTER CD, 1978, J BIOL CHEM, V253, P7227; Riccardi A, 2003, TUMORI J, V89, P223, DOI 10.1177/030089160308900301; Rodan GA, 2003, J BONE JOINT SURG AM, V85A, P8, DOI 10.2106/00004623-200300003-00003; Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640; Spurgeon SL, 1981, BIOSYNTHESIS ISOPREN, P1; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224; Vicent D, 2000, MOL CELL BIOL, V20, P2158, DOI 10.1128/MCB.20.6.2158-2166.2000; Waldman A, 2003, DRUGS, V63, P139, DOI 10.2165/00003495-200363020-00002; Watts NB, 2003, CLIN GERIATR MED, V19, P395, DOI 10.1016/S0749-0690(02)00069-1; Werbovetz Karl A, 2002, Expert Opin Ther Targets, V6, P407, DOI 10.1517/14728222.6.4.407	32	226	234	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8526	8529		10.1074/jbc.C300511200	http://dx.doi.org/10.1074/jbc.C300511200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672944	hybrid			2022-12-27	WOS:000189265900002
J	Maclean, KN; Kraus, E; Kraus, JP				Maclean, KN; Kraus, E; Kraus, JP			The dominant role of Sp1 in regulating the cystathionine beta-synthase-1a and -1b promoters facilitates potential tissue-specific regulation by Kruppel-like factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SYNTHASE GENE; THYMIDINE KINASE PROMOTER; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTORS; SACCHAROMYCES-CEREVISIAE; CELL-PROLIFERATION; ALZHEIMERS-DISEASE; NF-Y; EXPRESSION; ACTIVATION	Cystathionine beta-synthase (CBS) catalyzes the condensation of serine with homocysteine to form cystathionine and occupies a crucial regulatory position between the methionine cycle and transsulfuration. The human cystathionine beta-synthase gene promoters - 1a and - 1b are expressed in a limited number of tissues and are coordinately regulated with proliferation through a redox-sensitive mechanism. Site-directed mutagenesis, DNase I footprinting and deletion analysis of 5276 bp of 5' proximal - 1b flanking sequence revealed that this region does not confer tissue-specific expression and that 210 bp of proximal sequence is sufficient for maximal promoter activity. As little as 32 bp of the - 1b proximal promoter region is capable of driving transcription in HepG2 cells, and this activity is entirely dependent upon the presence of a single overlapping Sp1/Egr1 binding site. Co-transfection studies in Drosophila SL2 cells indicated that both promoters are transactivated by Sp1 and Sp3 but only the - 1b promoter is subject to a site-specific synergistic regulatory interaction between Sp1 and Sp3. Sp1-deficient fibroblasts expressing both Sp3 and NF-Y were negative for CBS activity. Transfection of these cells with a mammalian Sp1 expression construct induced high levels of CBS activity indicating that Sp1 has a critical and indispensable role in the regulation of cystathionine beta-synthase. Sp1 binding to both CBS promoters is sensitive to proliferation status and is negatively regulated by Kruppel-like factors in co-transfection experiments suggesting a possible mechanism for the tissue specific regulation of cystathionine beta-synthase.	Univ Colorado, Sch Med, Dept Pediat, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maclean, KN (corresponding author), Univ Colorado, Sch Med, Dept Pediat, C-233, Denver, CO 80262 USA.	ken.maclean@uchsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065217] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65217] Funding Source: Medline; NICHD NIH HHS [P01 HD0805] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bao LM, 1998, ARCH BIOCHEM BIOPHYS, V350, P95, DOI 10.1006/abbi.1997.0486; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIDOVICHKEIL JL, 1993, CELL GROWTH DIFFER, V4, P679; FRIDOVICHKEIL JL, 1991, CELL GROWTH DIFFER, V2, P67; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Ge YB, 2003, BLOOD, V101, P1551, DOI 10.1182/blood-2002-07-2337; Ge YB, 2001, BIOCHEM J, V357, P97, DOI 10.1042/0264-6021:3570097; Ge YB, 2001, J BIOL CHEM, V276, P43570, DOI 10.1074/jbc.M104930200; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GOLDSTEIN JL, 1972, J CLIN INVEST, V51, P1034, DOI 10.1172/JCI106863; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hromas R, 1996, LEUKEMIA, V10, P1049; IKEDA K, 1993, GENE, V136, P341; Janosik M, 2001, AM J HUM GENET, V68, P1506, DOI 10.1086/320597; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Karsunky H, 2002, NAT GENET, V30, P295, DOI 10.1038/ng831; KRAUS JP, 1987, METHOD ENZYMOL, V143, P388; Kraus JP, 1998, GENOMICS, V52, P312, DOI 10.1006/geno.1998.5437; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Kumar AP, 1998, BIOCHEM BIOPH RES CO, V252, P517, DOI 10.1006/bbrc.1998.9676; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Maclean KN, 2002, J CELL PHYSIOL, V192, P81, DOI 10.1002/jcp.10118; Maclean KN, 2000, J INORG BIOCHEM, V81, P161, DOI 10.1016/S0162-0134(00)00100-8; Maclean KN, 2002, HUM MUTAT, V19, P641, DOI 10.1002/humu.10089; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Mudd S., 2001, METABOLIC MOL BASES, P2007; MUDD SH, 1965, J BIOL CHEM, V240, P4382; Nagavarapu U, 2001, J BIOL CHEM, V276, P16749, DOI 10.1074/jbc.M009712200; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; O'Leary KA, 2000, ARCH BIOCHEM BIOPHYS, V379, P97, DOI 10.1006/abbi.2000.1862; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Quere I, 1999, BIOCHEM BIOPH RES CO, V254, P127, DOI 10.1006/bbrc.1998.9079; Schafer D, 1996, FEBS LETT, V391, P35, DOI 10.1016/0014-5793(96)00701-6; Selhub J, 1997, HAEMATOLOGICA, V82, P129; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SKOVBY F, 1984, HUM GENET, V65, P291, DOI 10.1007/BF00286520; SMITH GJ, 1984, PATHOLOGY, V16, P401, DOI 10.3109/00313028409084730; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Terraz C, 2001, J BIOL CHEM, V276, P37011, DOI 10.1074/jbc.M104185200; WADE DP, 1994, J BIOL CHEM, V269, P19757; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; WU SE, 1983, BIOCHEMISTRY-US, V22, P2828, DOI 10.1021/bi00281a009; Yoon JH, 1999, BIOCHEM J, V344, P367, DOI 10.1042/0264-6021:3440367; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	55	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8558	8566		10.1074/jbc.M310211200	http://dx.doi.org/10.1074/jbc.M310211200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670973	hybrid			2022-12-27	WOS:000189265900006
J	Vogel, CFA; Sciullo, E; Park, S; Liedtke, C; Trautwein, C; Matsumura, F				Vogel, CFA; Sciullo, E; Park, S; Liedtke, C; Trautwein, C; Matsumura, F			Dioxin increases C/EBP beta transcription by activating cAMP/protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-BETA; KAPPA-B INTERACTIONS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ADIPOCYTE DIFFERENTIATION; HYDROCARBON RECEPTOR; STRESS-RESPONSE; C-JUN; GENE; EXPRESSION; PROMOTER	The environmental pollutant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD = dioxin) has been shown to increase the expression of C/EBPbeta. The modulated expression of C/EBPbeta has been suggested to be associated with toxic responses of TCDD such as wasting syndrome, diabetes, and inhibition of adipocyte differentiation. This study focused on the regulatory mechanism of TCDD-mediated transcriptional activation of C/EBPbeta. Elevated C/EBPbeta mRNA and protein levels in mouse embryonic fibroblasts (C(3)H(10)T1/2) and in mouse hepatoma cells (Hepa1c1c7) were correlated with increased binding affinity of the C/EBPbeta protein. Transfection studies with different deletion constructs of the CCAAT/enhancer-binding protein promoter indicated that a small region located 60-120 bp upstream of the start site of transcription is required for activation of the C/EBPbeta gene by TCDD in both cell lines tested. Further analysis using mutation constructs of the C/EBPbeta promoter demonstrated that activation of the C/EBPbeta promoter is mediated through incomplete cAMP-response element-binding protein (CREB) sites located close to the TATA box of the C/EBPbeta gene. The protein kinase A (PKA) inhibitor H89 completely blocks the TCDD-dependent effect on C/EBPbeta promoter activity, indicating that TCDD activates CREB binding via a cAMP/PKA pathway, which is supported by the increased cAMP level and PKA activity observed after TCDD treatment. Gel shift analyses demonstrated that CREB itself binds to the putative CREB motif that mediates the TCDD-dependent effect on C/EBPbeta gene transcription. Cotransfection experiments with CREB and PKA expression plasmids further supported our conclusions that the TCDD-dependent effect on C/EBPbeta transcription is mediated via PKA-dependent CREB activation.	Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA; Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Lower Saxony, Germany	University of California System; University of California Davis; Hannover Medical School	Matsumura, F (corresponding author), Univ Calif Davis, Dept Environm Toxicol, 1 Shields Ave, Davis, CA 95616 USA.	fmatsumura@ucdavis.edu	Liedtke, Christian/DTV-1874-2022	Liedtke, Christian/0000-0003-4681-7887	NIEHS NIH HHS [P0-1-ES5707, R0-ES05233] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bolger GB, 2003, J BIOL CHEM, V278, P33351, DOI 10.1074/jbc.M303269200; BOMBICK DW, 1988, P NATL ACAD SCI USA, V85, P4128, DOI 10.1073/pnas.85.12.4128; Carver LA, 1997, J BIOL CHEM, V272, P11452; CHANG CJ, 1995, DNA CELL BIOL, V14, P529, DOI 10.1089/dna.1995.14.529; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dunlap DY, 2002, TOXICOLOGY, V172, P125, DOI 10.1016/S0300-483X(02)00006-9; Enan E, 1996, REPROD TOXICOL, V10, P191, DOI 10.1016/0890-6238(96)00021-4; Foka P, 2001, BIOCHEM BIOPH RES CO, V285, P430, DOI 10.1006/bbrc.2001.5203; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Jaspers I, 1997, AM J PHYSIOL-LUNG C, V272, pL504, DOI 10.1152/ajplung.1997.272.3.L504; Jurado LA, 2002, J BIOL CHEM, V277, P27606, DOI 10.1074/jbc.M201429200; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lenny N, 1997, MOL BIOL REP, V24, P157, DOI 10.1023/A:1006859700409; Lin WC, 2002, DNA CELL BIOL, V21, P551, DOI 10.1089/104454902320308924; Liu PCC, 2002, J BIOCHEM MOL TOXIC, V16, P70, DOI 10.1002/jbt.10020; Liu PCC, 1996, MOL PHARMACOL, V49, P989; LIU PCC, 1998, BIOCHEM PHARMACOL, V23, P123; Ma Q, 1997, J BIOL CHEM, V272, P8878; Matsumura F, 2003, BIOCHEM PHARMACOL, V66, P527, DOI 10.1016/S0006-2952(03)00157-6; MATSUMURA F, 1984, ARCH ENVIRON CON TOX, V13, P509, DOI 10.1007/BF01056330; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; PARK EA, 1993, J BIOL CHEM, V268, P613; PHILLIPS M, 1995, J CELL SCI, V108, P395; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Savouret JF, 2001, J BIOL CHEM, V276, P3054, DOI 10.1074/jbc.M005988200; Simeonova PP, 1997, J IMMUNOL, V159, P3921; STAHL BU, 1993, TOXICOLOGY, V79, P81, DOI 10.1016/0300-483X(93)90207-9; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tian YN, 2002, CHEM-BIOL INTERACT, V141, P97, DOI 10.1016/S0009-2797(02)00068-6; Vogel C, 2000, CARCINOGENESIS, V21, P2267, DOI 10.1093/carcin/21.12.2267; Vogel CFA, 2003, BIOCHEM PHARMACOL, V66, P1231, DOI 10.1016/S0006-2952(03)00404-0; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Yan SF, 1997, J BIOL CHEM, V272, P4287, DOI 10.1074/jbc.272.7.4287; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yang YM, 2002, BBA-GENE STRUCT EXPR, V1577, P102, DOI 10.1016/S0167-4781(02)00401-3; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	50	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8886	8894		10.1074/jbc.M310190200	http://dx.doi.org/10.1074/jbc.M310190200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684744	hybrid			2022-12-27	WOS:000189265900046
J	Conant, K; St Hillaire, C; Nagase, H; Visse, R; Gary, D; Haughey, N; Anderson, C; Turchan, J; Nath, A				Conant, K; St Hillaire, C; Nagase, H; Visse, R; Gary, D; Haughey, N; Anderson, C; Turchan, J; Nath, A			Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; MATRIX METALLOPROTEINASES; CELL-ADHESION; SIGNALING PATHWAY; GELATINASE-A; INDUCTION; ACID; LOCALIZATION; ACTIVATION; RECEPTORS	Several studies have demonstrated that matrix metalloproteinases (MMPs) are cytotoxic. The responsible mechanisms, however, are not well understood. MMPs may promote cytotoxicity through their ability to disrupt or degrade matrix proteins that support cell survival, and MMPs may also cleave substrates to generate molecules that stimulate cell death. In addition, MMPs may themselves act on cell surface receptors that affect cell survival. Among such receptors is the alpha(2)beta(1) integrin, a complex that has previously been linked to leukocyte death. In the present study we show that human neurons express alpha(2)beta(1) and that pro-MMP-1 interacts with this integrin complex. We also show that stimulation of neuronal cultures with MMP-1 is associated with a rapid reduction in the phosphorylation of Akt, a kinase that can influence caspase activity and cell survival. Moreover, MMP-1-associated dephosphorylation of Akt is inhibited by a blocking antibody to the alpha(2) integrin, but not by batimastat, an inhibitor of MMP-1 enzymatic activity. Such dephosphorylation is also stimulated by a catalytic mutant of pro-MMP-1. Additional studies show that MMP-1 causes neuronal death, which is significantly diminished by both a general caspase inhibitor and anti-(2) but not by batimastat. Together, these results suggest that MMP-1 can stimulate dephosphorylation of Akt and neuronal death through a non-proteolytic mechanism that involves changes in integrin signaling.	Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neuropathol, Baltimore, MD 21287 USA; Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, Dept Matrix Biol, London W6 8LH, England	Johns Hopkins University; Johns Hopkins University; Imperial College London; University of Oxford	Conant, K (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Pathol Bldg,Rm 625,600 N Wolfe St, Baltimore, MD 21287 USA.	kconant@mail.jhmi.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063722] Funding Source: NIH RePORTER; NIMH NIH HHS [MH63722] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arencibia I, 2002, EUR J IMMUNOL, V32, P1129, DOI 10.1002/1521-4141(200204)32:4<1129::AID-IMMU1129>3.0.CO;2-G; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chen HJ, 2003, AM J PHYSIOL-HEART C, V284, pH1612, DOI 10.1152/ajpheart.00992.2002; Chen ZL, 2003, MOL BIOL CELL, V14, P2665, DOI 10.1091/mbc.E02-12-0832; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Conant K, 2002, J NEUROCHEM, V82, P885, DOI 10.1046/j.1471-4159.2002.01038.x; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Fernandez-Patron C, 1999, CIRC RES, V85, P906; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Huang XC, 1996, ADV EXP MED BIOL, V396, P209; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Johnston JB, 2001, ANN NEUROL, V49, P230, DOI 10.1002/1531-8249(20010201)49:2<230::AID-ANA43>3.0.CO;2-O; Kim HE, 2000, J CLIN INVEST, V106, P857, DOI 10.1172/JCI8040; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; Manna PP, 2003, J IMMUNOL, V170, P3544, DOI 10.4049/jimmunol.170.7.3544; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McFarlane S, 2003, NEURON, V37, P559, DOI 10.1016/S0896-6273(03)00089-8; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nath D, 2000, J CELL SCI, V113, P2319; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Schonbeck U, 1998, J IMMUNOL, V161, P3340; SPURLINO JC, 1994, PROTEINS, V19, P98, DOI 10.1002/prot.340190203; Stepanova VV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P109, DOI 10.1023/A:1013912500373; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Stricker TP, 2001, J BIOL CHEM, V276, P29375, DOI 10.1074/jbc.M102217200; Takada T, 2002, J BIOL CHEM, V277, P34359, DOI 10.1074/jbc.M206541200; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Vos CMP, 2000, EXP NEUROL, V163, P324, DOI 10.1006/exnr.2000.7388; Woessner J.F., 2000, PROTEIN PROFILE SER; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zigrino P, 2002, J BIOL CHEM, V277, P40528, DOI 10.1074/jbc.M202049200	50	52	56	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8056	8062		10.1074/jbc.M307051200	http://dx.doi.org/10.1074/jbc.M307051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14679206	hybrid			2022-12-27	WOS:000189103300084
J	Lee, DK; Lanca, AJ; Cheng, R; Nguyen, T; Ji, XD; Gobeil, F; Chemtob, S; George, SR; O'Dowd, BF				Lee, DK; Lanca, AJ; Cheng, R; Nguyen, T; Ji, XD; Gobeil, F; Chemtob, S; George, SR; O'Dowd, BF			Agonist-independent nuclear localization of the apelin, angiotensin AT(1), and bradykinin B-2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROSTAGLANDIN E-2 RECEPTORS; PROTEIN-COUPLED RECEPTOR; ENDOGENOUS LIGAND APELIN; HUMAN APJ RECEPTOR; ORPHAN RECEPTOR; MESSENGER-RNA; TISSUE DISTRIBUTION; RAT-BRAIN; TRANSLOCATION	Signaling of the apelin, angiotensin, and bradykinin peptides is mediated by G protein-coupled receptors related through structure and similarities of physiological function. We report nuclear expression as a characteristic of these receptors, including a nuclear localization for the apelin receptor in brain and cerebellum-derived D283 Med cells and the AT(1) and bradykinin B-2 receptors in HEK-293T cells. Immunocytochemical analyses revealed the apelin receptor with localization in neuronal nuclei in cerebellum and hypothalamus, exhibiting expression in neuronal cytoplasm or in both nuclei and cytoplasm. Confocal microscopy of HEK-293T cells revealed the majority of transfected cells displayed constitutive nuclear localization of AT(1) and B-2 receptors, whereas apelin receptors did not show nuclear localization in these cells. The majority of apelin receptor-transfected cerebellum D283 Med cells showed receptor nuclear expression. Immunoblot analyses of subcellular-fractionated D283 Med cells demonstrated endogenous apelin receptor species in nuclear fractions. In addition, an identified nuclear localization signal motif in the third intracellular loop of the apelin receptor was disrupted by a substituted glutamine in place of lysine. This apelin receptor (K242Q) did not exhibit nuclear localization in D283 Med cells. These results demonstrate the following: (i) the apelin receptor exhibits nuclear localization in human brain; (ii) distinct cell-dependent mechanisms for the nuclear transport of apelin, AT(1), and B-2 receptors; and (iii) the disruption of a nuclear localization signal sequence disrupts the nuclear translocation of the apelin receptor. This discovery of apelin, AT(1), and B-2 receptors with agonist-independent nuclear translocation suggests major unanticipated roles for these receptors in cell signaling and function.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Menatl Hlth, Toronto, ON M5S 2S1, Canada; Hop St Justine, Dept Pediat Ophthalmol & Pharmacol, Montreal, PQ M3T 1C5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Universite de Montreal; McGill University	O'Dowd, BF (corresponding author), Univ Toronto, Dept Pharmacol, Med Sci Bldg,Rm 4352,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	brian.odowd@utoronto.ca	George, Susan R/P-9669-2018; George, Susan/W-7494-2019					AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Bachvarov DR, 2001, J PHARMACOL EXP THER, V297, P19; Bhattacharya M, 1998, P NATL ACAD SCI USA, V95, P15792, DOI 10.1073/pnas.95.26.15792; Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719; Boivin B, 2003, J BIOL CHEM, V278, P29153, DOI 10.1074/jbc.M301738200; Brailoiu GC, 2002, NEUROSCI LETT, V327, P193, DOI 10.1016/S0304-3940(02)00411-1; Chen R, 2000, AM J PHYSIOL-RENAL, V279, pF440, DOI 10.1152/ajprenal.2000.279.3.F440; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choe W, 2000, J NEUROVIROL, V6, pS61; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; De Falco M, 2002, IN VIVO, V16, P333; De Mota N, 2000, NEUROENDOCRINOLOGY, V72, P400, DOI 10.1159/000054609; Edinger AL, 1998, J VIROL, V72, P7934, DOI 10.1128/JVI.72.10.7934-7940.1998; EGGENA P, 1993, HYPERTENSION, V22, P496, DOI 10.1161/01.HYP.22.4.496; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Fatima S, 2003, J CELL SCI, V116, P353, DOI 10.1242/jcs.00242; Gobeil F, 2002, CIRC RES, V90, P682, DOI 10.1161/01.RES.0000013303.17964.7A; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346; Hosoya M, 2000, J BIOL CHEM, V275, P21061, DOI 10.1074/jbc.M908417199; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; Katugampola SD, 2001, BRIT J PHARMACOL, V132, P1255, DOI 10.1038/sj.bjp.0703939; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lamb ME, 2001, BIOCHEM J, V355, P741, DOI 10.1042/bj3550741; Lanca AJ, 1999, NEUROSCIENCE, V91, P1331, DOI 10.1016/S0306-4522(98)00709-X; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/en.139.1.365; Miserey-Lenkei S, 2001, MOL ENDOCRINOL, V15, P294, DOI 10.1210/me.15.2.294; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; O'Carroll AM, 2000, BBA-GENE STRUCT EXPR, V1492, P72, DOI 10.1016/S0167-4781(00)00072-5; O'Malley KL, 2003, J BIOL CHEM, V278, P28210, DOI 10.1074/jbc.M300792200; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Puffer BA, 2000, VIROLOGY, V276, P435, DOI 10.1006/viro.2000.0557; Reaux A, 2001, J NEUROCHEM, V77, P1085, DOI 10.1046/j.1471-4159.2001.00320.x; Reaux A, 2002, NEUROSCIENCE, V113, P653, DOI 10.1016/S0306-4522(02)00192-6; ROTH BL, 1981, J BIOL CHEM, V256, P117; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Szokodi I, 2002, CIRC RES, V91, P434, DOI 10.1161/01.RES.0000033522.37861.69; Taheri S, 2002, BIOCHEM BIOPH RES CO, V291, P1208, DOI 10.1006/bbrc.2002.6575; Tatemoto K, 2001, REGUL PEPTIDES, V99, P87, DOI 10.1016/S0167-0115(01)00236-1; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200; Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756-3282(99)00264-1; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Wells A, 2002, NAT REV MOL CELL BIO, V3, P697, DOI 10.1038/nrm905; Willard FS, 2000, IMMUNOL CELL BIOL, V78, P387, DOI 10.1046/j.1440-1711.2000.00927.x; Yamamoto S, 1998, MICROSC RES TECHNIQ, V40, P479, DOI 10.1002/(SICI)1097-0029(19980301)40:6<479::AID-JEMT8>3.0.CO;2-K	52	160	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7901	7908		10.1074/jbc.M306377200	http://dx.doi.org/10.1074/jbc.M306377200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14645236	hybrid			2022-12-27	WOS:000189103300067
J	Mouillet, JF; Sonnenberg-Hirche, C; Yan, XM; Sadovsky, Y				Mouillet, JF; Sonnenberg-Hirche, C; Yan, XM; Sadovsky, Y			p300 regulates the synergy of steroidogenic factor-1 and early growth response-1 in activating luteinizing hormone-beta subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN-RELEASING-HORMONE; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; TRANSGENIC MICE; NGFI-A; HISTONE ACETYLTRANSFERASE; MOLECULAR-CLONING; DISCRETE STAGES; BINDING-SITES; GNRH RECEPTOR	Tight regulation of luteinizing hormone-beta subunit (LHbeta) expression is critical for differentiation and maturation of mammalian sexual organs and reproductive function. Two transcription factors, steroidogenic factor-1 (SF-1) and early growth response-1 (Egr-1), play a central role in activating LHbeta promoter, and the synergy between these two factors is essential in mediating gonadotropin-releasing hormone stimulation of LHbeta promoter. Here we demonstrate that the transcriptional co-activator p300 regulates this synergy. Overexpression of p300 results in strong stimulation of LHbeta promoter but only in the presence of both SF-1 and Egr-1, and not in the presence of other Egr proteins. Mutation of the binding sites for either SF-1 or Egr-1 completely abolishes the synergy between these two factors, as well as the influence of p300. Importantly, LHbeta promoter is precipitated using p300 antibodies in a chromatin immunoprecipitation assay with LbetaT2 gonadotropes, and this effect is enhanced by gonadotropin-releasing hormone. The influence of p300 on LHbeta promoter is potentiated by steroid receptor co-activator, as well as by E1A proteins, and attenuated by Smad nuclear interacting protein 1. Taken together, these results suggest that p300 is recruited to LHbeta promoter where it coordinates the functional synergy between SF-1 and Egr-1.	Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Sadovsky, Y (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, 4566 Scott Ave,Campus Box 8064, St Louis, MO 63110 USA.	sadovskyy@wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037571] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD37571] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alarid ET, 1996, DEVELOPMENT, V122, P3319; Alarid ET, 1998, MOL CELL ENDOCRINOL, V140, P25; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOLKERS GE, 1995, MOL CELL BIOL, V15, P5868; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Goodman RH, 2000, GENE DEV, V14, P1553; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; Halvorson LM, 1998, J BIOL CHEM, V273, P14712, DOI 10.1074/jbc.273.24.14712; Hammer GD, 1999, FRONT NEUROENDOCRIN, V20, P199, DOI 10.1006/frne.1999.0182; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200; Kim RH, 2000, GENE DEV, V14, P1605; Kraus S, 2001, ARCH MED RES, V32, P499, DOI 10.1016/S0188-4409(01)00331-9; Lee KC, 2003, MOL ENDOCRINOL, V17, P908, DOI 10.1210/me.2002-0308; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; Meijer OC, 2000, ENDOCRINOLOGY, V141, P2192, DOI 10.1210/en.141.6.2192; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; Ou QL, 2001, MOL ENDOCRINOL, V15, P69, DOI 10.1210/me.15.1.69; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Quirk CC, 2001, MOL ENDOCRINOL, V15, P734, DOI 10.1210/me.15.5.734; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SVENSSON C, 1984, EMBO J, V3, P789, DOI 10.1002/j.1460-2075.1984.tb01886.x; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Thomas P, 1996, ENDOCRINOLOGY, V137, P2979, DOI 10.1210/en.137.7.2979; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay JJ, 1999, EMBO J, V18, P3431, DOI 10.1093/emboj/18.12.3431; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wahlstrom GM, 1999, MOL ENDOCRINOL, V13, P1119, DOI 10.1210/me.13.7.1119; Weck J, 2000, MOL ENDOCRINOL, V14, P472, DOI 10.1210/me.14.4.472; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wolfe MW, 1999, MOL ENDOCRINOL, V13, P752, DOI 10.1210/me.13.5.752; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhao LP, 2001, DEVELOPMENT, V128, P147	79	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7832	7839		10.1074/jbc.M312574200	http://dx.doi.org/10.1074/jbc.M312574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681221	hybrid			2022-12-27	WOS:000189103300059
J	Park, HS; Yu, JW; Cho, JH; Kim, MS; Huh, SH; Ryoo, K; Choi, EJ				Park, HS; Yu, JW; Cho, JH; Kim, MS; Huh, SH; Ryoo, K; Choi, EJ			Inhibition of apoptosis signal-regulating kinase 1 by nitric oxide through a thiol redox mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; S-NITROSYLATION; PC12 CELLS; INTERFERON-GAMMA; 1 ASK1; SYNTHASE; CALCIUM; DIFFERENTIATION; SURVIVAL	Nitric oxide is an endogenous thiol-reactive molecule that modulates the functions of many regulatory proteins by a thiol-redox mechanism. NO has now been shown to inhibit the activation of apoptosis signal-regulating kinase 1 (ASK1) in murine fibrosarcoma L929 cells through such a mechanism. Exposure of L929 cells to interferon-gamma resulted in the endogenous production of NO and in inhibition of the activation of ASK1 by hydrogen peroxide. The interferon-gamma-induced inhibition of ASK1 activity was blocked by N-G-nitro-L-arginine, an inhibitor of NO synthase. Furthermore, the NO donor S-nitro-N-acetyl-DL-penicillamine (SNAP) inhibited ASK1 activity in vitro, and this inhibition was reversed by thiol-reducing agents such as dithiothreitol and beta-mercaptoethanol. SNAP did not inhibit the kinase activities of MKK3, MKK6, or p38 in vitro. The inhibition of ASK1 by interferon-gamma was not changed by 1H-(1,2,4) oxadiazolo[4,3-alpha] quinoxalin-1-one, an inhibitor of guanylyl cyclase nor was it mimicked by 8-bromo-cyclic GMP. Site-directed mutagenesis revealed that replacement of cysteine 869 of ASK1 by serine rendered this protein resistant to the inhibitory effects both of interferon-gamma in intact cells and of SNAP in vitro. Coimmunoprecipitation data showed that NO production inhibited a binding of ASK1, but not ASK1(C869S), to MKK3 or MKK6. Moreover, interferon-gamma induced the S-nitrosylation of endogenous ASK1 in L929 cells. Together, these results suggest that NO mediates the interferon-gamma-induced inhibition of ASK1 in L929 cells through a thiol-redox mechanism.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Korea Univ, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea	Korea University; Korea University	Choi, EJ (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	ejchoi@korea.ac.kr	Cho, Jun-Ho/AAF-2210-2019	Cho, Jun-Ho/0000-0002-8756-8824; Yu, Je-Wook/0000-0001-5943-4071				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FEINSTEIN DL, 1994, ANN NY ACAD SCI, V738, P325; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kim H, 1997, BIOCHEMISTRY-US, V36, P13677, DOI 10.1021/bi970837f; Ko YG, 2001, J BIOL CHEM, V276, P6030, DOI 10.1074/jbc.M006189200; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; PHELPS DC, 1981, BIOCHEMISTRY-US, V20, P453, DOI 10.1021/bi00506a001; POPESCU LM, 1985, EUR J PHARMACOL, V107, P393, DOI 10.1016/0014-2999(85)90269-9; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Teng KK, 1999, J BIOL CHEM, V274, P37315, DOI 10.1074/jbc.274.52.37315; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	46	87	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7584	7590		10.1074/jbc.M304183200	http://dx.doi.org/10.1074/jbc.M304183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668338	hybrid			2022-12-27	WOS:000189103300027
J	Rescalli, E; Saini, S; Bartocci, C; Rychlewski, L; de Lorenzo, V; Bertoni, G				Rescalli, E; Saini, S; Bartocci, C; Rychlewski, L; de Lorenzo, V; Bertoni, G			Novel physiological modulation of the Pu promoter of TOL plasmid - Negative regulatory role of the TurA protein of Pseudomonas putida in the response to suboptimal growth temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR; H-NS; EFFECTOR CONTROL; RNA-POLYMERASE; B-LINKER; INTEGRATION; SIGMA(54); DNA; GENE; BINDING	From crude protein extracts of Pseudomonas putida KT2440, we identified a small protein, TurA, able to bind to DNA fragments bearing the entire Pu promoter sequence of the TOL plasmid. The knock-out inactivation of the turA gene resulted in enhanced transcription initiation from the Pu promoter, initially suggesting a negative regulatory role of TurA on Pu expression. Ectopic expression of TurA both in P. putida and in Escherichia coli reporter strains and transcription in vitro of the Pu promoter in the presence of purified TurA confirmed the TurA repressor role on Pu activity. turA gene inactivation did not significantly alter two well characterized physiological regulations of the Pu expression in routine conditions of cultivation, exponential silencing, and carbon-mediated repression, respectively. However, the growth at suboptimal temperatures resulted in a TurA-dependent increase of Pu repression. These results strongly suggest that a physiological significance of the negative role of TurA on Pu activity could be limitation of the expression of the toluene-degrading enzymes at suboptimal growth temperatures. Therefore, the identification of TurA as Pu-binding protein revealed a novel physiological modulation of Pu promoter that is different from those strictly nutritional described previously.	Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; BioInfoBank Inst, PL-60744 Poznan, Poland; CSIC, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, E-28049 Madrid, Spain	University of Milan; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bertoni, G (corresponding author), Univ Milan, Dipartimento Sci Biomol & Biotecnol, Via Celoria 26, I-20133 Milan, Italy.	giovanni.bertoni@unimi.it	BERTONI, GIOVANNI/J-3437-2012	BERTONI, GIOVANNI/0000-0001-5761-9494; de Lorenzo, Victor/0000-0002-6041-2731				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Atlung T, 1997, MOL MICROBIOL, V24, P7, DOI 10.1046/j.1365-2958.1997.3151679.x; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bertin P, 2001, BIOCHIMIE, V83, P235, DOI 10.1016/S0300-9084(01)01247-0; Bertoni G, 1998, EMBO J, V17, P5120, DOI 10.1093/emboj/17.17.5120; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Carmona M, 1999, J BIOL CHEM, V274, P33790, DOI 10.1074/jbc.274.47.33790; Cases I, 1998, CURR OPIN MICROBIOL, V1, P303, DOI 10.1016/S1369-5274(98)80034-9; Cases I, 1999, J BIOL CHEM, V274, P15562, DOI 10.1074/jbc.274.22.15562; Cases I, 1996, MOL MICROBIOL, V19, P7, DOI 10.1046/j.1365-2958.1996.345873.x; Cases I, 2000, J BACTERIOL, V182, P956, DOI 10.1128/JB.182.4.956-960.2000; Cases I, 2001, EMBO J, V20, P1, DOI 10.1093/emboj/20.1.1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Diggle SP, 2002, J BACTERIOL, V184, P2576, DOI 10.1128/JB.184.10.2576-2586.2002; Falconi M, 1998, EMBO J, V17, P7033, DOI 10.1093/emboj/17.23.7033; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; Garmendia J, 2000, MOL MICROBIOL, V38, P401, DOI 10.1046/j.1365-2958.2000.02139.x; GARMENDIA J, 2001, THESIS U AUTONOMA MA; Geiselmann J, 1997, BIOL CHEM, V378, P599; Ginalski K, 2003, NUCLEIC ACIDS RES, V31, P3804, DOI 10.1093/nar/gkg504; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HOLTEL A, 1994, J BACTERIOL, V176, P1773, DOI 10.1128/jb.176.6.1773-1776.1994; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; KANIGA K, 1991, GENE, V109, P137, DOI 10.1016/0378-1119(91)90599-7; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Macchi R, 2003, J BIOL CHEM, V278, P27695, DOI 10.1074/jbc.M303031200; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; O'Neill E, 1999, J BIOL CHEM, V274, P32425, DOI 10.1074/jbc.274.45.32425; O'Neill E, 1998, MOL MICROBIOL, V28, P131, DOI 10.1046/j.1365-2958.1998.00780.x; O'Neill E, 2001, EMBO J, V20, P819, DOI 10.1093/emboj/20.4.819; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; PerezMartin J, 1996, CELL, V86, P331, DOI 10.1016/S0092-8674(00)80104-X; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P7277, DOI 10.1073/pnas.92.16.7277; Peterson JD, 2001, NUCLEIC ACIDS RES, V29, P123, DOI 10.1093/nar/29.1.123; Ramos JL, 1997, ANNU REV MICROBIOL, V51, P341, DOI 10.1146/annurev.micro.51.1.341; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Rosenthal RS, 1998, PROTEIN SCI, V7, P178, DOI 10.1002/pro.5560070118; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPURIO R, 1992, MOL GEN GENET, V231, P201, DOI 10.1007/BF00279792; Studholme DJ, 2003, J BACTERIOL, V185, P1757, DOI 10.1128/JB.185.6.1757-1767.2003; Sze CC, 2002, J BACTERIOL, V184, P760, DOI 10.1128/JB.184.3.760-770.2002; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Valls M, 2002, J BIOL CHEM, V277, P2169, DOI 10.1074/jbc.M108162200; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; Wikstrom P, 2001, J MOL BIOL, V314, P971, DOI 10.1006/jmbi.2000.5212; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	57	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7777	7784		10.1074/jbc.M310580200	http://dx.doi.org/10.1074/jbc.M310580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672954	hybrid			2022-12-27	WOS:000189103300051
J	Lara-Pezzi, E; Pezzi, N; Prieto, I; Barthelemy, I; Carreiro, C; Martinez, A; Maldonado-Rodriguez, A; Lopez-Cabrera, M; Barbero, JL				Lara-Pezzi, E; Pezzi, N; Prieto, I; Barthelemy, I; Carreiro, C; Martinez, A; Maldonado-Rodriguez, A; Lopez-Cabrera, M; Barbero, JL			Evidence of a transcriptional co-activator function of cohesin STAG/SA/Scc3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; NUCLEAR RECEPTOR; SUBUNIT SCC1; COMPLEX; EXPRESSION; SEPARATION; RAD21; HETEROCHROMATIN; CHROMOSOMES	Cohesins hold sister chromatids together from DNA replication until they are segregated. Although cohesins Smc1, Smc3, and Scc1/Rad21 are involved in chromatid cohesion and other cellular processes, little is known about the other mitotic cohesin subunit, Scc3/STAG. Here we describe STAG/Scc3, which may act as a transcriptional co-activator. STAG2 is able to enhance the activity of the tumor necrosis factor alpha, the CD69, and the human immunodeficiency virus long terminal repeat promoters in a NF-kappaB-dependent manner. In addition, STAG2 interacts with the viral transactivator Tat and enhances the Tat-mediated activation of the human immunodeficiency virus long terminal repeat promoter. Moreover, STAG2 co-activates a multimeric NF-kappaB reporter construct and enhances the activity of the transactivation domain of p65/RelA in a Gal4 system. This function is dependent on one of the LXXLL co-activation motives present in this cohesin and is substantiated by the interaction of STAG2 with the p65 subunit of NF-kappaB. These results describe a novel activity for cohesins, suggesting a role for STAG/ Scc3 in transcriptional regulation.	Ctr Nacl Biotecnol, Dept Inmunol & Oncol, Madrid 28049, Spain; Hosp Princesa, Unidad Biol Mol, Madrid 28006, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Hospital de La Princesa	Barbero, JL (corresponding author), Ctr Nacl Biotecnol, Dept Inmunol & Oncol, Campus Cantoblanco, Madrid 28049, Spain.	jlbarbero@cnb.uam.es	Lara-Pezzi, Enrique/E-2350-2015; Barbero, Jose Luis/J-9833-2014; Cabrera, Manuel López/AAA-5463-2019	Lara-Pezzi, Enrique/0000-0002-2743-1033; Lopez Cabrera, Manuel/0000-0002-0976-9719; BARBERO, JOSE LUIS/0000-0002-1226-0323				Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Carretero M, 2002, VIROLOGY, V299, P288, DOI 10.1006/viro.2002.1526; Castellanos MD, 2002, EUR J IMMUNOL, V32, P3108; Chen F, 2002, J BIOL CHEM, V277, P16775, DOI 10.1074/jbc.M201322200; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Ghiselli G, 2000, J BIOL CHEM, V275, P20235, DOI 10.1074/jbc.C000213200; Glass CK, 2000, GENE DEV, V14, P121; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Hagstrom KA, 2003, NAT REV GENET, V4, P520, DOI 10.1038/nrg1110; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horak CE, 2002, GENE DEV, V16, P3017, DOI 10.1101/gad.1039602; Ivanov D, 2002, CURR BIOL, V12, P323, DOI 10.1016/S0960-9822(02)00681-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kino T, 2002, J BIOL CHEM, V277, P2396, DOI 10.1074/jbc.M106312200; LOPEZCABRERA M, 1995, J BIOL CHEM, V270, P21545, DOI 10.1074/jbc.270.37.21545; Mallardo M, 1996, J BIOL CHEM, V271, P20820, DOI 10.1074/jbc.271.34.20820; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Pati D, 2002, MOL CELL BIOL, V22, P8267, DOI 10.1128/MCB.22.23.8267-8277.2002; Piacentini L, 2003, J CELL BIOL, V161, P707, DOI 10.1083/jcb.200303012; Prieto I, 2002, EMBO REP, V3, P543, DOI 10.1093/embo-reports/kvf108; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Vass S, 2003, CURR BIOL, V13, P208, DOI 10.1016/S0960-9822(03)00047-2; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702	34	40	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6553	6559		10.1074/jbc.M307663200	http://dx.doi.org/10.1074/jbc.M307663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660624	hybrid			2022-12-27	WOS:000188969200043
J	Zhang, YC; Berger, SA				Zhang, YC; Berger, SA			Increased calcium influx and ribosomal content correlate with resistance to endoplasmic reticulum stress-induced cell death in mutant leukemia cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELLS; CA2+ STORES; ENTRY; ACTIVATION; APOPTOSIS; DEPLETION; GRP78; INHIBITION; MECHANISM; ECONAZOLE	Cell clones were derived by treatment of HL-60 cells with stepwise increasing concentrations of econazole (EC), an imidazole antifungal that blocks Ca2+ influx and induces endoplasmic reticulum (ER) stress-related cell death in multiple mammalian cell types. Clones exhibit 20- to more than 300-fold greater resistance to Ec. Unexpectedly, they also display stable cross-resistance to tunicamycin, thapsigargin, dithiothreitol, and cycloheximide but not doxorubicin, etoposide, or Fas ligand. Phenotypic analysis indicates that the cells display increased store-operated calcium influx and resistance to ER Ca2+ store depletion by Ec. E2R2, the most resistant clone, was observed to maintain protein synthesis levels after treatment with Ec or thapsigargin. Expression of GRP78, an ER-based chaperone, was induced by these ER stress treatments but to equal degrees in HL-60 and E2R2 cells. By using microarray analysis, at least 15 ribosomal protein genes were found to be overexpressed in E2R2 compared with HL-60 cells. We also found that ribosomal protein content was increased by 30% in E2R2 as well as other clones. The resistance phenotype was partially reversed by the ribosome-inactivating protein saporin. Therefore, increased store-operated calcium influx, resistance to ER Ca2+ store depletion, and overexpression of ribosomal proteins define a novel phenotype of ER stress-associated multidrug resistance.	Univ Hlth Network, Arthrit & Immune Disorder Res Ctr, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Berger, SA (corresponding author), Univ Hlth Network, Arthrit & Immune Disorder Res Ctr, 620 Univ Ave,Ste 700, Toronto, ON M5G 2M9, Canada.	Berger@uhnres.utoronto.ca						Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Beheshti B, 2003, NEOPLASIA, V5, P53, DOI 10.1016/S1476-5586(03)80017-9; Bergamaschi G, 1996, BRIT J HAEMATOL, V93, P789, DOI 10.1046/j.1365-2141.1996.d01-1730.x; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; BUCKLEY NE, 1995, BBA-LIPID LIPID MET, V1256, P275, DOI 10.1016/0005-2760(95)00030-G; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; ESTACION M, 1993, CELL CALCIUM, V14, P439, DOI 10.1016/0143-4160(93)90003-O; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gamberucci A, 1998, BIOCHEM BIOPH RES CO, V248, P75, DOI 10.1006/bbrc.1998.8810; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Gommerman JL, 1998, BLOOD, V91, P1891, DOI 10.1182/blood.V91.6.1891.1891_1891_1900; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jan CR, 1999, BBA-MOL CELL RES, V1448, P533, DOI 10.1016/S0167-4889(98)00159-1; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KOHN EC, 1992, CANCER RES, V52, P3208; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; MADJAR JJ, 1977, MOL BIOL REP, V3, P289, DOI 10.1007/BF00368299; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Miyake H, 2000, J CELL BIOCHEM, V77, P396, DOI 10.1002/(SICI)1097-4644(20000601)77:3<396::AID-JCB5>3.0.CO;2-5; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Soboloff J, 2002, J BIOL CHEM, V277, P13812, DOI 10.1074/jbc.M112129200; Soboloff J, 2002, EXP HEMATOL, V30, P1219, DOI 10.1016/S0301-472X(02)00893-7; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Zhang YC, 2002, BREAST CANCER RES TR, V72, P265, DOI 10.1023/A:1014965726663; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	36	21	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6507	6516		10.1074/jbc.M306117200	http://dx.doi.org/10.1074/jbc.M306117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660643	hybrid			2022-12-27	WOS:000188969200037
J	Fanelli, M; Fantozzi, A; De Luca, P; Caprodossi, S; Matsuzawa, S; Lazar, MA; Pelicci, PG; Minucci, S				Fanelli, M; Fantozzi, A; De Luca, P; Caprodossi, S; Matsuzawa, S; Lazar, MA; Pelicci, PG; Minucci, S			The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIAH UBIQUITIN LIGASE; ALPHA FUSION PROTEIN; PML-RAR-ALPHA; RETINOIC ACID; PML/RAR-ALPHA; TRANSCRIPTIONAL REPRESSION; PREMATURE SENESCENCE; HISTONE DEACETYLASE; ONCOGENIC RAS; PATHWAY	Mammalian homologues of Drosophila Seven in Absentia (SIAHs) target for proteasome-mediated degradation several factors involved in cell growth and tumorigenesis. Here we show that SIAH-1/2 binds and targets for proteasome-mediated degradation the putative tumor suppressor and tripartite motif (TRIM) family member PML, leading to the loss of its transcriptional co-activating properties and a reduction in the number of endogenous PML nuclear bodies. Association with PML requires the substrate-binding domain (SBD) of SIAH-1/2 through an interacting surface apparently distinct from those predicted by the structural studies, or shown experimentally to mediate binding to SIAH-associated factors. Within PML, the coiled-coil domain is required for Siah- and proteasome-mediated degradation, and deletions of regions critical for the integrity of this region impair the ability of Siah to trigger PML-RAR degradation. Fusion of the coiled-coil domain to heterologous proteins resulted in the capacity of mSiah-2 to target their degradation. All of the TRIM proteins tested were degraded upon mSiah-2 overexpression. Finally, we show that the fusion protein PML-RAR (that retains the coiled-coil domain), which causes acute promyelocytic leukemias, is also a potential substrate of mSiah-2. As a result of mSiah-2 overexpression and subsequent degradation of the fusion protein, the arrest in hematopoietic differentiation because of expression of PML-RAR is partially rescued. These results identify PML and other TRIMs as new factors post-translationally regulated by SIAH and involve the coiled-coil region of PML and of other SIAH substrates as a novel structural determinant for targeted degradation.	Univ Urbino Carlo Bo, Ctr Biotecnol, Fac Sci, MM FF NN, I-61032 Fano, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Milan, Dept Biomol Sci & Biotechnol, Fac Biol Sci, I-20132 Milan, Italy; Burnham Inst, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Dept Med Genet & Biochem, Philadelphia, PA 19104 USA	University of Urbino; IRCCS European Institute of Oncology (IEO); University of Milan; Sanford Burnham Prebys Medical Discovery Institute; University of Pennsylvania	Fanelli, M (corresponding author), Univ Urbino Carlo Bo, Ctr Biotecnol, Fac Sci, MM FF NN, Via Campanella 1, I-61032 Fano, Italy.	mirco.fanelli@uniurb.it	Fanelli, Mirco/F-2665-2011; Lazar, Mitchell A/AAF-3738-2019; Minucci, Saverio/J-9669-2012; De Luca, Pasquale/AAL-5673-2021; Pelicci, Pier Giuseppe/AAL-6572-2020	Fanelli, Mirco/0000-0002-9649-8661; De Luca, Pasquale/0000-0003-4289-6784; 				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Antolini F, 2003, PROTEIN EXPRES PURIF, V29, P94, DOI 10.1016/S1046-5928(03)00004-4; Chomienne C, 1996, FASEB J, V10, P1025, DOI 10.1096/fasebj.10.9.8801163; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Ferbeyre G, 2000, GENE DEV, V14, P2015; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Frew IJ, 2002, MOL CELL BIOL, V22, P8155, DOI 10.1128/MCB.22.23.8155-8164.2002; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Grignani F, 1999, ONCOGENE, V18, P6313, DOI 10.1038/sj.onc.1203029; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1998, CANCER RES, V58, P14; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Li SH, 2002, MOL CELL BIOL, V22, P6854, DOI 10.1128/MCB.22.19.6854-6865.2002; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nervi C, 1998, BLOOD, V92, P2244; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yoshida H, 1996, CANCER RES, V56, P2945; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	46	50	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5374	5379		10.1074/jbc.M306407200	http://dx.doi.org/10.1074/jbc.M306407200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645235	hybrid			2022-12-27	WOS:000188776500042
J	Jin, XS; Foley, KM; Geiger, JH				Jin, XS; Foley, KM; Geiger, JH			The structure of the 1L-myo-inositol-1-phosphate synthase-NAD(+)-2deoxy-D-glucitol 6-(E)-vinylhomophosphonate complex demands a revision of the enzyme mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL 1-PHOSPHATE SYNTHASE; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; L-MYO-INOSITOL-1-PHOSPHATE SYNTHASE; INOSITOL-1-PHOSPHATE SYNTHASE; DEHYDROQUINATE SYNTHASE; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; BOVINE TESTIS; INOSITOL; GLUCOSE	1L-myo-inositol 1-phosphate (MIP) synthase catalyzes the conversion of D-glucose 6-phosphate to 1L-myo-inositol 1-phosphate, the first and rate-limiting step in the biosynthesis of all inositol-containing compounds. It involves an oxidation, enolization, intramolecular aldol cyclization, and reduction. Here we present the structure of MIP synthase in complex with NAD(+) and a high-affinity inhibitor, 2-deoxy-D-glucitol 6-(E)-vinylhomophosphonate. This structure reveals interactions between the enzyme active site residues and the inhibitor that are significantly different from that proposed for 2-deoxy-D-glucitol 6- phosphate in the previously published structure of MIP synthase-NAD(+)-2-deoxy-D-glucitol 6- phosphate. There are several other conformational changes in NAD(+) and the enzyme active site as well. Based on the new structural data, we propose a new and completely different mechanism for MIP synthase.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA	Michigan State University	Geiger, JH (corresponding author), Michigan State Univ, Dept Chem, 320 Chem, E Lansing, MI 48824 USA.		ID, IMCACAT/D-5867-2014	Jin, Xiangshu/0000-0002-6551-8850; Geiger, James/0000-0002-9443-4488				ABUABIED M, 1994, PLANT PHYSIOL, V106, P1689, DOI 10.1104/pp.106.4.1689; ADHIKARI J, 1983, FEBS LETT, V163, P46, DOI 10.1016/0014-5793(83)81159-4; ADHIKARI J, 1988, INDIAN J BIOCHEM BIO, V25, P408; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ARGANOFF BW, 1991, INOSITOL PHOSPHATES, P20; BARNETT J E G, 1973, Biochemical Society Transactions, V1, P1267; BARNETT JEG, 1968, BIOCHEM J, V108, P125, DOI 10.1042/bj1080125; BELMAKER RG, 1995, DEPRESSION MANIA NEU; Belmaker RH, 1996, ANNU REV MED, V47, P47; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7560, DOI 10.1021/bi00445a010; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carpenter EP, 1998, NATURE, V394, P299, DOI 10.1038/28431; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; EXTON JH, 1986, ADV CYCLIC NUCL PROT, V20, P211; FREY PA, 1987, PYRIDINE NUCLEOTID B, P461; HASEGAWA R, 1981, P NATL ACAD SCI-BIOL, V78, P4863, DOI 10.1073/pnas.78.8.4863; Ishitani M, 1996, PLANT J, V9, P537, DOI 10.1046/j.1365-313X.1996.09040537.x; Jin XS, 2003, ACTA CRYSTALLOGR D, V59, P1154, DOI 10.1107/S0907444903008205; JOHNSON MD, 1995, PLANT PHYSIOL, V107, P613, DOI 10.1104/pp.107.2.613; JOHNSON MD, 1994, PLANT PHYSIOL, V105, P1023, DOI 10.1104/pp.105.3.1023; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOEWUS FA, 1962, BIOCHEM BIOPH RES CO, V7, P204, DOI 10.1016/0006-291X(62)90175-4; LOEWUS MW, 1977, J BIOL CHEM, V252, P7221; LOEWUS MW, 1980, J BIOL CHEM, V255, P1710; LOEWUS MW, 1980, CARBOHYD RES, V82, P333, DOI 10.1016/S0008-6215(00)85707-9; Lohia A, 1999, MOL BIOCHEM PARASIT, V98, P67, DOI 10.1016/S0166-6851(98)00147-9; Majumder AL, 1997, BBA-LIPID LIPID MET, V1348, P245, DOI 10.1016/S0005-2760(97)00122-7; MAUCK LA, 1980, BIOCHEMISTRY-US, V19, P3623, DOI 10.1021/bi00556a031; MIGAUD ME, 1995, J AM CHEM SOC, V117, P5154, DOI 10.1021/ja00123a019; Norman RA, 2002, STRUCTURE, V10, P393, DOI 10.1016/S0969-2126(02)00718-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park D, 2000, BBA-GENE STRUCT EXPR, V1494, P277, DOI 10.1016/S0167-4781(00)00085-3; POTTER BVL, 1995, ANGEW CHEM INT EDIT, V34, P1933, DOI 10.1002/anie.199519331; SHERMAN WR, 1969, J BIOL CHEM, V244, P5703; SMART CC, 1993, PLANT J, V4, P279, DOI 10.1046/j.1365-313X.1993.04020279.x; Stein AJ, 2002, J BIOL CHEM, V277, P9484, DOI 10.1074/jbc.M109371200; Stein AJ, 2000, ACTA CRYSTALLOGR D, V56, P348, DOI 10.1107/S0907444999016777; Tian F, 1999, J AM CHEM SOC, V121, P5795, DOI 10.1021/ja9900196; Vaden DL, 2001, J BIOL CHEM, V276, P15466, DOI 10.1074/jbc.M004179200; WANG X, 1995, PLANT PHYSIOL, V110, P336; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; WONG YHH, 1982, METHOD ENZYMOL, V90, P309	45	22	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13889	13895		10.1074/jbc.M308986200	http://dx.doi.org/10.1074/jbc.M308986200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14684747	hybrid			2022-12-27	WOS:000220478500075
J	Balbis, A; Baquiran, G; Dumas, V; Posner, BI				Balbis, A; Baquiran, G; Dumas, V; Posner, BI			Effect of inhibiting vacuolar acidification on insulin signaling in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; DEPENDENT DIABETES-MELLITUS; PROTEIN-KINASE-B; RECEPTOR KINASE; RAT HEPATOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; INTERNALIZED INSULIN; GLYCOGEN-SYNTHASE; TRANSDUCTION PATHWAYS; ENDOSOMAL PROTEOLYSIS	Previous studies have shown that the endosomal apparatus plays an important role in insulin signaling. Inhibition of endosomal acidification leads to a decrease in insulin-insulin receptor kinase (IRK) dissociation and insulin degradation. Thus, vacuolar pH could function as a modulator of insulin signaling in endosomes. In the present study we show that in primary hepatocytes pretreated with bafilomycin, there is an inhibition of vacuolar acidification. Incubation of these cells with insulin was followed by an augmentation of IRK activity but an inhibition of phosphatidylinositol 3-kinase/Akt activity and a decrease in insulin-induced DNA and glycogen synthesis. Bafilomycin treatment inhibited IRK recycling to the plasma membrane without affecting IRK internalization. Impaired IRK recycling correlated with a decrease in insulin signaling. We suggest that inhibiting vacuolar acidification sequesters activated IRKs in an intracellular compartment(s) where signaling is inhibited. This implies that endosomal receptor trafficking plays a role in regulating signal transduction.	McGill Univ, Fac Med, Polypeptide Hormone Lab, Montreal, PQ H3A 2B2, Canada	McGill University	Posner, BI (corresponding author), McGill Univ, Fac Med, Polypeptide Hormone Lab, 3640 Univ St,Ste W315, Montreal, PQ H3A 2B2, Canada.	barry.posner@staff.mcgill.ca	Posner, Barry/B-6733-2008					Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; AUTHIER F, 1994, J BIOL CHEM, V269, P3010; Authier F, 2002, J BIOL CHEM, V277, P9437, DOI 10.1074/jbc.M110188200; Band CJ, 1999, ENDOCRINOLOGY, V140, P5626, DOI 10.1210/en.140.12.5626; Band CJ, 1997, J BIOL CHEM, V272, P138; Bevan AP, 1997, J BIOL CHEM, V272, P26833, DOI 10.1074/jbc.272.43.26833; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Contreres JO, 1998, J BIOL CHEM, V273, P22007, DOI 10.1074/jbc.273.34.22007; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DESBUQUOIS B, 1992, DIABETES METAB, V18, P104; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; Drake PG, 1998, MOL CELL BIOCHEM, V182, P79, DOI 10.1023/A:1006808100755; Drose S, 1997, J EXP BIOL, V200, P1; DUNN WA, 1986, J CELL BIOL, V102, P24, DOI 10.1083/jcb.102.1.24; FAURE R, 1992, J BIOL CHEM, V267, P11215; HAMEL FG, 1988, J BIOL CHEM, V263, P6703; Hribal ML, 2001, MOL PHARMACOL, V59, P322, DOI 10.1124/mol.59.2.322; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KHAN MN, 1989, J BIOL CHEM, V264, P12931; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; LEVY JR, 1987, ENDOCRINOLOGY, V121, P2075, DOI 10.1210/endo-121-6-2075; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; MANABE T, 1993, J CELL PHYSIOL, V157, P445, DOI 10.1002/jcp.1041570303; MARSHALL S, 1985, J BIOL CHEM, V260, P4136; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mounier C, 2001, MOL CELL ENDOCRINOL, V173, P15, DOI 10.1016/S0303-7207(00)00439-1; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Posner Barry I, 2003, Curr Opin Investig Drugs, V4, P430; POSNER BI, 1982, J BIOL CHEM, V257, P5789; POWRIE JK, 1993, METABOLISM, V42, P415, DOI 10.1016/0026-0495(93)90096-7; POWRIE JK, 1991, AM J PHYSIOL, V260, pE897, DOI 10.1152/ajpendo.1991.260.6.E897; ROMANEK R, 1993, BIOCHEM J, V296, P321, DOI 10.1042/bj2960321; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Saurin AJ, 1996, BIOCHEM J, V313, P65, DOI 10.1042/bj3130065; Sesti G, 1996, DIABETOLOGIA, V39, P289; SMITH GD, 1987, BRIT MED J, V294, P465, DOI 10.1136/bmj.294.6570.465; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; UEDA M, 1985, J BIOL CHEM, V260, P3941; Urso B, 1999, J BIOL CHEM, V274, P30864, DOI 10.1074/jbc.274.43.30864; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002	47	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12777	12785		10.1074/jbc.M311493200	http://dx.doi.org/10.1074/jbc.M311493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14688247	hybrid			2022-12-27	WOS:000220334900092
J	Bao, XY; Chen, YY; Reuss, L; Altenberg, GA				Bao, XY; Chen, YY; Reuss, L; Altenberg, GA			Functional expression in Xenopus Oocytes of gap-junctional hemichannels formed by a cysteine-less connexin 43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INTRACELLULAR CALCIUM; CHANNELS; MEMBRANE; CELLS; PHOSPHORYLATION; IDENTIFICATION; ASTROCYTES; PORE	Gap-junctional channels are formed by two connexons or gap-junctional hemichannels in series, with each connexon conformed by six connexin molecules. As with other membrane proteins, structural information on connexons can potentially be obtained with techniques that take advantage of the highly specific thiol chemistry by positioning Cys residues at locations of interest, ideally in an otherwise Cys-less protein. It has been shown that conserved Cys residues located in the extracellular loops of connexins are essential for the docking of connexons from adjacent cells, preventing the formation of functional gap-junctional channels. Here we engineered a Cys-less version of connexin 43 (Cx43) and assessed its function using a Xenopus oocyte expression system. The Cys-less protein was expressed at the plasma membrane and did not form gap-junctional channels but formed hemichannels that behave similarly to those formed by Cx43 in terms of permeation to carboxyfluorescein. The carboxyfluorescein permeability of Cys-less hemichannels was increased by protein kinase C inhibition, like the wild-type Cx43 hemichannels. We generated a protein with a single Cys in a position ( residue 34) thought to face the channel pore and show that thiol modification of the Cys abolishes the carboxyfluorescein permeability. We conclude that Cys-less Cx43 forms regulated functional hemichannels, and therefore Cys-less Cx43 is a useful tool for future structural studies.	Univ Texas, Med Branch, Sealy Ctr Struct Biol, Membrane Prot Lab, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Altenberg, GA (corresponding author), Univ Texas, Med Branch, Sealy Ctr Struct Biol, Membrane Prot Lab, Galveston, TX 77555 USA.	galtenbe@utmb.edu		Altenberg, Guillermo/0000-0002-8932-740X				BAO X, 2004, IN PRESS AM J PHYSL; Becker DL, 1998, CELL BIOL INT, V22, P527, DOI 10.1006/cbir.1998.0295; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Bukauskas FF, 2001, BIOPHYS J, V81, P137, DOI 10.1016/S0006-3495(01)75687-1; Button B, 2001, J GEN PHYSIOL, V117, P457, DOI 10.1085/jgp.117.5.457; DAHL G, 1992, BIOPHYS J, V62, P172, DOI 10.1016/S0006-3495(92)81803-9; DAHL G, 1991, EUR J BIOCHEM, V197, P141, DOI 10.1111/j.1432-1033.1991.tb15892.x; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DUPONT E, 1989, J MEMBRANE BIOL, V108, P247, DOI 10.1007/BF01871739; Ebihara L, 1996, BIOPHYS J, V71, P742, DOI 10.1016/S0006-3495(96)79273-1; Foote CI, 1998, J CELL BIOL, V140, P1187, DOI 10.1083/jcb.140.5.1187; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; GOODENOUGH DA, 1975, AM J CLIN PATHOL, V63, P636; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; JOHN SA, 1991, BIOCHEM BIOPH RES CO, V178, P1312, DOI 10.1016/0006-291X(91)91037-D; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; LITTLE TL, 1995, AM J PHYSIOL-HEART C, V268, pH729, DOI 10.1152/ajpheart.1995.268.2.H729; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; Moreno AP, 2002, CIRC RES, V90, P450, DOI 10.1161/hh0402.105667; PEPPER MS, 1992, AM J PHYSIOL, V262, pC1246, DOI 10.1152/ajpcell.1992.262.5.C1246; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; RAHMAN S, 1991, J CELL SCI, V100, P567; Revilla A, 1999, BIOPHYS J, V77, P1374, DOI 10.1016/S0006-3495(99)76986-9; SAINIO K, 1992, DEVELOPMENT, V115, P827; Skerrett IM, 2001, CELL COMMUN ADHES, V8, P179, DOI 10.3109/15419060109080720; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; Unger VM, 1997, NAT STRUCT BIOL, V4, P39, DOI 10.1038/nsb0197-39; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; Vanoye CG, 1999, AM J PHYSIOL-CELL PH, V276, pC279, DOI 10.1152/ajpcell.1999.276.1.C279; Venance L, 1998, J PHYSIOL-LONDON, V510, P429, DOI 10.1111/j.1469-7793.1998.429bk.x; Vergara L, 2003, J MEMBRANE BIOL, V196, P173, DOI 10.1007/s00232-003-0636-9; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4	40	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9689	9692		10.1074/jbc.M311438200	http://dx.doi.org/10.1074/jbc.M311438200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14676187	hybrid			2022-12-27	WOS:000220050400005
J	Morgan, GW; Goulding, D; Field, MC				Morgan, GW; Goulding, D; Field, MC			The single dynamin-like protein of Trypanosoma brucei regulates mitochondrial division and is not required for endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; DEVELOPMENTAL REGULATION; PATHOGENIC TRYPANOSOMES; ENDOPLASMIC-RETICULUM; CHLOROPLAST DIVISION; MOLECULAR-CLONING; CELL-CYCLE; GTPASE; MORPHOLOGY; MEMBRANE	Members of the evolutionarily conserved dynamin-related GTPase family mediate numerous cellular membrane remodeling events. Dynamin family functions include the scission of clathrin-coated pits from the plasma membrane, mitochondrial fission, and chloroplast division. Here we report that the divergent eukaryote Trypanosoma brucei possesses a single dynamin family gene, which we have designated TbDLP. Furthermore, a single dynamin family gene is also found in the Leishmania major and Trypanosoma vivax genomes, indicating that this is a conserved feature among the kinetoplastida. TbDLP is most homologous to the DMN/DRP family of dynamin-like proteins. Indirect immunofluorescence microscopy reveals that TbDLP is distributed in punctate structures within the cell that partially co-localize with the mitochondrion when labeled with MitoTracker. To define TbDLP function, we have used RNA interference to silence the TbDLP gene. Reduction of TbDLP protein levels causes a profound alteration in mitochondrial morphology without affecting the structure of other membrane-bound compartments, including the endocytic and exocytic apparatus. The mitochondrial profiles present in wild type trypanosomes fuse and collapse in the mutant cells, and by electron microscopy the mitochondria are found to contain an accumulation of constriction sites. These findings demonstrate TbDLP functions in division of the mitochondrial membrane. Most significantly, as TbDLP is the sole member of the dynamin family in this organism, scission of clathrin-coated pits involved in protein trafficking through the highly active endocytic system in trypanosomes must function in the absence of dynamin. The evolutionary implications of these findings are discussed.	Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Labs Mol Parasitol, London SW7 2AY, England	Imperial College London	Field, MC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Labs Mol Parasitol, Exhibit Rd, London SW7 2AY, England.	mfield@ic.ac.uk	Field, Mark/AAD-6455-2021	Field, Mark/0000-0002-4866-2885				Allen CL, 2003, EMBO J, V22, P4991, DOI 10.1093/emboj/cdg481; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANGS JD, 1993, J CELL SCI, V105, P1101; Beech PL, 2000, SCIENCE, V287, P1276, DOI 10.1126/science.287.5456.1276; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; BRICKMAN MJ, 1995, J CELL SCI, V108, P3611; CHEN JH, 1995, CELL, V80, P61, DOI 10.1016/0092-8674(95)90451-4; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Erickson HP, 2000, J CELL BIOL, V148, P1103, DOI 10.1083/jcb.148.6.1103; Field H, 1997, J BIOL CHEM, V272, P10498, DOI 10.1074/jbc.272.16.10498; Field H, 2000, MOL BIOCHEM PARASIT, V106, P21, DOI 10.1016/S0166-6851(99)00192-9; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Grunfelder CG, 2003, MOL BIOL CELL, V14, P2029, DOI 10.1091/mbc.E02-10-0640; Harlow E., 1988, ANTIBODIES LAB MANUA; HECKER H, 1980, PATHOL RES PRACT, V166, P203; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351; Legesse-Miller A, 2003, MOL BIOL CELL, V14, P1953, DOI 10.1091/mbc.E02-10-0657; Matthews KR, 1999, PARASITOL TODAY, V15, P76, DOI 10.1016/S0169-4758(98)01381-7; MICHELS PAM, 1986, EMBO J, V5, P1049, DOI 10.1002/j.1460-2075.1986.tb04321.x; Miyagishima S, 2003, PLANT CELL, V15, P655, DOI 10.1105/tpc.009373; Morgan GW, 2002, TRENDS PARASITOL, V18, P540, DOI 10.1016/S1471-4922(02)02392-9; Morgan GW, 2001, J CELL SCI, V114, P2605; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nishida K, 2003, P NATL ACAD SCI USA, V100, P2146, DOI 10.1073/pnas.0436886100; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Ogbadoyi EO, 2003, MOL BIOL CELL, V14, P1769, DOI 10.1091/mbc.E02-08-0525; Osteryoung KW, 1998, PLANT CELL, V10, P1991, DOI 10.1105/tpc.10.12.1991; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; PRIEST JW, 1994, J BIOENERG BIOMEMBR, V26, P179, DOI 10.1007/BF00763067; Redmond S, 2003, MOL BIOCHEM PARASIT, V128, P115, DOI 10.1016/S0166-6851(03)00045-8; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Sogin ML, 1998, INT J PARASITOL, V28, P11, DOI 10.1016/S0020-7519(97)00181-1; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Swofford D., 1998, PAUP VERSION 4 0; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VICKERMAN K, 1965, NATURE, V208, P762, DOI 10.1038/208762a0; VICKERMAN K, 1985, BRIT MED BULL, V41, P105, DOI 10.1093/oxfordjournals.bmb.a072036; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wienke DC, 1999, MOL BIOL CELL, V10, P225, DOI 10.1091/mbc.10.1.225; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341	55	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10692	10701		10.1074/jbc.M312178200	http://dx.doi.org/10.1074/jbc.M312178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14670954	hybrid			2022-12-27	WOS:000220050400124
J	Housden, NG; Harrison, S; Housden, HR; Thomas, KA; Beckingham, JA; Roberts, SE; Bottomley, SP; Graille, M; Stura, E; Gore, MG				Housden, NG; Harrison, S; Housden, HR; Thomas, KA; Beckingham, JA; Roberts, SE; Bottomley, SP; Graille, M; Stura, E; Gore, MG			Observation and characterization of the interaction between a single immunoglobulin binding domain of protein L and two equivalents of human kappa light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTOSTREPTOCOCCUS-MAGNUS; SITE; IGG	Detailed stopped-flow studies in combination with site-directed mutagenesis, isothermal titration calorimetry data and x-ray crystallographic knowledge have revealed that the biphasic pre-equilibrium fluorescence changes reported for a single Ig-binding domain of protein L from Peptostreptococcus magnus binding to kappa light chain are due to the binding of the kappa light chain at two separate sites on the protein L molecule. Elimination of binding site 2 through the mutation A66W has allowed the K-d for kappa light chain binding at site 1 to be measured by stopped-flow fluorescence and isothermal titration calorimetry techniques, giving values of 48.0 +/- 8.0 nM and 37.5 +/- 7.3 nM respectively. Conversely, a double mutation Y53F/L57H eliminates binding at site 1 and has allowed the Kd for binding at site 2 to be determined. Stopped-flow fluorimetry suggests this to be 3.4 +/- 0.8 muM in good agreement with the value of 4.6 +/- 0.8 muM determined by isothermal titration calorimetry. The mutation Y53F reduces the affinity of site 1 to approximately that of site 2.	Univ Southampton, Sch Biol Sci, Dept Biochem, Div Biochem & Mol Biol, Southampton SO16 7PX, Hants, England; Ctr Etud Saclay, DIEP, CEA, F-91191 Gif Sur Yvette, France	University of Southampton; CEA; UDICE-French Research Universities; Universite Paris Saclay	Gore, MG (corresponding author), Univ Southampton, Sch Biol Sci, Dept Biochem, Div Biochem & Mol Biol, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	M.G.Gore@soton.ac.uk	Stura, Enrico A./A-2793-2010; GRAILLE, Marc/D-3242-2014	Stura, Enrico A./0000-0001-6718-2118; GRAILLE, Marc/0000-0002-7853-5852; Housden, Nicholas/0000-0002-4706-8278				Beckingham JA, 2001, BIOCHEM J, V353, P395, DOI 10.1042/0264-6021:3530395; Beckingham JA, 1999, BIOCHEM J, V340, P193, DOI 10.1042/0264-6021:3400193; Bottomley SP, 1995, BIOSEPARATION, V5, P359; Enokizono J, 1997, J MOL BIOL, V270, P8, DOI 10.1006/jmbi.1997.1090; Gore M. G., 2000, SPECTROPHOTOMETRY SP; Graille M, 2002, J BIOL CHEM, V277, P47500, DOI 10.1074/jbc.M206105200; Graille M, 2001, STRUCTURE, V9, P679, DOI 10.1016/S0969-2126(01)00630-X; Hiromi K., 1979, KINETICS FAST ENZYME; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; MCPHERSON SG, 2000, PCR; PATELLA V, 1990, J IMMUNOL, V145, P3054; Stura EA, 2002, ACTA CRYSTALLOGR D, V58, P1744, DOI 10.1107/S0907444902012805; WIKSTROM M, 1994, BIOCHEMISTRY-US, V33, P14011, DOI 10.1021/bi00251a008; Wikstrom M, 1996, EUR J BIOCHEM, V235, P543, DOI 10.1111/j.1432-1033.1996.00543.x; WIKSTROM M, 1995, J MOL BIOL, V250, P128, DOI 10.1006/jmbi.1995.0364; WILSON MT, 2000, SPECTROPHOTOMETRY SP	18	17	22	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9370	9378		10.1074/jbc.M312938200	http://dx.doi.org/10.1074/jbc.M312938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668335	hybrid, Green Published, Green Accepted			2022-12-27	WOS:000189265900101
J	Carlson, BA; Novoselov, SV; Kumaraswamy, E; Lee, BJ; Anver, MR; Gladyshev, VN; Hatfield, DL				Carlson, BA; Novoselov, SV; Kumaraswamy, E; Lee, BJ; Anver, MR; Gladyshev, VN; Hatfield, DL			Specific excision of the selenocysteine tRNA([Ser]Sec) (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; TRANSFER-RNA; SELENIUM; MICE; DISRUPTION; PATTERNS; PROTEIN; PLASMA	Selenium is essential in mammalian embryonic development. However, in adults, selenoprotein levels in several organs including liver can be substantially reduced by selenium deficiency without any apparent change in phenotype. To address the role of selenoproteins in liver function, mice homozygous for a floxed allele encoding the selenocysteine (Sec) tRNA([Ser]Sec) gene were crossed with transgenic mice carrying the Cre recombinase under the control of the albumin promoter that expresses the recombinase specifically in liver. Recombination was nearly complete in mice 3 weeks of age, whereas liver selenoprotein synthesis was virtually absent, which correlated with the loss of Sec tRNA([Ser] Sec) and activities of major selenoproteins. Total liver selenium was dramatically decreased, whereas levels of low molecular weight selenocompounds were little affected. Plasma selenoprotein P levels were reduced by about 75%, suggesting that selenoprotein P is primarily exported from the liver. Glutathione S-transferase levels were elevated in the selenoprotein-deficient liver, suggesting a compensatory activation of this detoxification program. Mice appeared normal until about 24 h before death. Most animals died between 1 and 3 months of age. Death appeared to be due to severe hepatocellular degeneration and necrosis with concomitant necrosis of peritoneal and retroperitoneal fat. These studies revealed an essential role of selenoproteins in liver function.	NCI, Sect Mol Biol Selenium, Basic Res Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Seoul Natl Univ, Sch Biol Sci, Mol Genet Lab, Seoul 151742, South Korea; NCI, Pathol Histotechnol Lab, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System; University of Nebraska Lincoln; Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Hatfield, DL (corresponding author), NCI, Sect Mol Biol Selenium, Basic Res Lab, Ctr Canc Res,NIH, Bldg 37,Rm 6016,9000 Rockville Pike, Bethesda, MD 20892 USA.	hatfield@dc37a.nci.nih.gov	Gladyshev, Vadim N/A-9894-2013; Gladyshev, Vadim N/J-6187-2013	Novoselov, Sergey/0000-0003-0104-6492; Gladyshev, Vadim/0000-0002-0372-7016	NATIONAL CANCER INSTITUTE [Z01BC005317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM065204, R01GM065204, R01GM061603] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NIGMS NIH HHS [GM065204, GM061603] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; BOUWENS L, 1992, ENZYME, V46, P155, DOI 10.1159/000468782; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; Burk RF, 2001, BIOFACTORS, V14, P107, DOI 10.1002/biof.5520140115; Cheng WH, 1997, J NUTR, V127, P1445, DOI 10.1093/jn/127.8.1445; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Esworthy RS, 2001, AM J PHYSIOL-GASTR L, V281, pG848, DOI 10.1152/ajpgi.2001.281.3.G848; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; Gladyshev VN, 1999, P NATL ACAD SCI USA, V96, P835, DOI 10.1073/pnas.96.3.835; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; HAMES BD, 1995, PRACTICAL APPROACH S; HATFIELD D, 1979, BIOCHIM BIOPHYS ACTA, V564, P414, DOI 10.1016/0005-2787(79)90032-7; Hatfield D. L., 2001, SELENIUM ITS MOL BIO; Hatfield DL, 2002, MOL CELL BIOL, V22, P3565, DOI 10.1128/MCB.22.11.3565-3576.2002; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; KATO T, 1992, AM J PHYSIOL, V262, pG854, DOI 10.1152/ajpgi.1992.262.5.G854; KELMERS AD, 1971, ANAL BIOCHEM, V44, P486, DOI 10.1016/0003-2697(71)90236-3; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Kumaraswamy E, 2003, MOL CELL BIOL, V23, P1477, DOI 10.1128/MCB.23.5.1477-1488.2003; LEI XG, 1995, J NUTR, V125, P1438; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Moustafa ME, 2001, MOL CELL BIOL, V21, P3840, DOI 10.1128/MCB.21.11.3840-3852.2001; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; SAIJOH K, 1995, MOL BRAIN RES, V30, P301, DOI 10.1016/0169-328X(94)00007-2; Schneider MJ, 2001, MOL ENDOCRINOL, V15, P2137, DOI 10.1210/me.15.12.2137; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Watanabe Y, 2003, J CELL BIOCHEM, V89, P244, DOI 10.1002/jcb.10501; Yang XG, 2000, BBA-GEN SUBJECTS, V1474, P390, DOI 10.1016/S0304-4165(00)00035-0; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6	30	142	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8011	8017		10.1074/jbc.M310470200	http://dx.doi.org/10.1074/jbc.M310470200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660662	hybrid, Green Submitted			2022-12-27	WOS:000189103300079
J	Johansson, C; Lillig, CH; Holmgren, A				Johansson, C; Lillig, CH; Holmgren, A			Human mitochondrial glutaredoxin reduces S-glutathionylated proteins with high affinity accepting electrons from either glutathione or thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; SITE-DIRECTED MUTAGENESIS; NMR SOLUTION STRUCTURE; AMINO-ACID-SEQUENCE; RED-BLOOD-CELLS; THIOLTRANSFERASE GLUTAREDOXIN; DISULFIDE-ISOMERASE; ACTIVE-SITE; SACCHAROMYCES-CEREVISIAE; MIXED DISULFIDE	Glutaredoxins catalyze glutathione-dependent thiol disulfide oxidoreductions via a GSH-binding site and active cysteines. Recently a second human glutaredoxin (Grx2), which is targeted to either mitochondria or the nucleus, was cloned. Grx2 contains the active site sequence CSYC, which is different from the conserved CPYC motif present in the cytosolic Grx1. Here we have compared the activity of Grx2 and Grx1 using glutathionylated substrates and active site mutants. The kinetic studies showed that Grx2 catalyzes the reduction of glutathionylated substrates with a lower rate but higher affinity compared with Grx1, resulting in almost identical catalytic efficiencies (k(cat)/K-m). Permutation of the active site motifs of Grx1 and Grx2 revealed that the CSYC sequence of Grx2 is a prerequisite for its high affinity toward glutathionylated proteins, which comes at the price of lower k(cat). Furthermore Grx2 was a substrate for NADPH and thioredoxin reductase, which efficiently reduced both the active site disulfide and the GSH-glutaredoxin intermediate formed in the reduction of glutathionylated substrates. Using this novel electron donor pathway, Grx2 reduced low molecular weight disulfides such as CoA but with particular high efficiency glutathionylated substrates including GSSG. These results suggest an important role for Grx2 in protection and recovery from oxidative stress.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.	Arne.Holmgren@mbb.ki.se	Lillig, Christopher Horst/AAD-7098-2019	Lillig, Christopher Horst/0000-0003-2509-5117				Agorio A, 2003, J BIOL CHEM, V278, P12920, DOI 10.1074/jbc.M209266200; Alger HM, 2002, MOL BIOCHEM PARASIT, V121, P129, DOI 10.1016/S0166-6851(02)00031-2; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BERGLUND O, 1975, J BIOL CHEM, V250, P2778; Borges CR, 2002, J BIOL CHEM, V277, P48295, DOI 10.1074/jbc.M209042200; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Cotgreave IA, 2002, METHOD ENZYMOL, V348, P175, DOI 10.1016/S0076-6879(02)48636-3; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Foloppe N, 2001, J MOL BIOL, V310, P449, DOI 10.1006/jmbi.2001.4767; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Furuno T, 2001, BIOCHEM PHARMACOL, V62, P1037, DOI 10.1016/S0006-2952(01)00745-6; GAN ZR, 1986, J BIOL CHEM, V261, P996; Ghezzi P, 2002, MOL IMMUNOL, V38, P773, DOI 10.1016/S0161-5890(01)00114-6; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; INGELMAN M, 1995, FEBS LETT, V370, P209, DOI 10.1016/0014-5793(95)00806-K; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; KATTI SK, 1995, PROTEIN SCI, V4, P1998, DOI 10.1002/pro.5560041005; Kenchappa RS, 2003, FASEB J, V17, P717, DOI 10.1096/fj.02-0771fje; Klatt P, 2002, METHOD ENZYMOL, V348, P157, DOI 10.1016/S0076-6879(02)48635-1; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; Lundstrom-Ljung J, 1999, FEBS LETT, V443, P85, DOI 10.1016/S0014-5793(98)01698-6; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; LUTHMAN M, 1979, P NATL ACAD SCI USA, V76, P2158, DOI 10.1073/pnas.76.5.2158; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Mossner E, 1998, PROTEIN SCI, V7, P1233; Mossner E, 2000, FEBS LETT, V477, P21, DOI 10.1016/S0014-5793(00)01738-5; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; Nordstrand K, 1999, FEBS LETT, V449, P196, DOI 10.1016/S0014-5793(99)00401-9; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; ONDARZA RN, 1965, BIOCHIM BIOPHYS ACTA, V107, P112, DOI 10.1016/0304-4165(65)90393-4; Padilla CA, 1996, FEBS LETT, V378, P69; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Qiao FY, 2001, INVEST OPHTH VIS SCI, V42, P743; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; SIESS EA, 1978, H-S Z PHYSIOL CHEM, V359, P785, DOI 10.1515/bchm2.1978.359.2.785; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; Sun CH, 1997, PROTEIN SCI, V6, P383; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Takashima Y, 1999, IMMUNOL LETT, V68, P397, DOI 10.1016/S0165-2478(99)00087-5; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Wang J, 2003, P NATL ACAD SCI USA, V100, P5103, DOI 10.1073/pnas.0931345100; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Washburn MP, 1999, BIOCHEMISTRY-US, V38, P268, DOI 10.1021/bi980480v; Watabe S, 1999, EUR J BIOCHEM, V264, P74, DOI 10.1046/j.1432-1327.1999.00578.x; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WELLS WW, 1990, J BIOL CHEM, V265, P15361; YANG YF, 1991, J BIOL CHEM, V266, P12766; YANG YF, 1991, J BIOL CHEM, V266, P12759; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	81	232	244	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7537	7543		10.1074/jbc.M312719200	http://dx.doi.org/10.1074/jbc.M312719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676218	hybrid			2022-12-27	WOS:000189103300022
J	Chen, LY; Zuraw, BL; Ye, RD; Pan, ZXK				Chen, LY; Zuraw, BL; Ye, RD; Pan, ZXK			A Rho exchange factor mediates fMet-Leu-Phe-induced NF-kappa B activation in human peripheral blood monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BINDING PROTEIN-RHO; DBL ONCOGENE PRODUCT; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; INTERLEUKIN-8 EXPRESSION; FAMILY GTPASES; CELLS; HOMOLOGY	We reported previously that fMLP stimulates NF-kappaB activation, and this function of fMLP requires small GTPase RhoA in human peripheral blood monocytes (Huang, S., Chen, L.-Y., Zuraw, B. L., Ye, R. D., and Pan, Z. K. (2001) J. Biol. Chem. 276, 40977-40981). Here we present evidence that RhoA associates specifically with the guanine nucleotide exchange factor Lbc in human peripheral blood monocytes stimulated with fMLP and that Lbc specifically catalyzes the guanine nucleotide exchange activity of RhoA in human peripheral blood monocytes. Cotransfection of the monocytic THP1 cells with Ibc with a kappaB promoter reporter plasmid results in a marked increase in NF-kappaB-mediated reporter gene expression. Finally, Lbc-enhanced NF-kappaB activation is inhibited by a RhoA inhibitor, C3 transferase from Clostridium botulinum. A dominant-negative form of RhoA (T19N) also inhibited Lbc-enhanced reporter gene expression in a kappaB-dependent manner. These results indicate that guanine nucleotide exchange factor Lbc is a novel signal transducer for RhoA-mediated NF-kappaB activation in human peripheral blood monocytes stimulated with bacterial products.	Med Coll Ohio, Dept Microbiol & Immunol, Toledo, OH 43614 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	Scripps Research Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pan, ZXK (corresponding author), Med Coll Ohio, Dept Microbiol & Immunol, 3035 Arlington Ave, Toledo, OH 43614 USA.	zkpan@mco.edu	Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Zuraw, Bruce/0000-0003-0640-6768	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI043524, T32AI007469, R01AI043524] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [AI43524, T32 AI 07469] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JM, 1992, ONCOGENE, V7, P611; Arbour N, 1996, CYTOKINE, V8, P468, DOI 10.1006/cyto.1996.0063; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Cochrane CG, 1990, CELLULAR MOL MECHANI, P83; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hippenstiel S, 2000, BLOOD, V95, P3044; Huang S, 2001, J BIOL CHEM, V276, P40977, DOI 10.1074/jbc.M105242200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; Liu R, 2000, ARTHRITIS RHEUM, V43, P1145, DOI 10.1002/1529-0131(200005)43:5<1145::AID-ANR25>3.0.CO;2-T; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MARI B, 1994, J BIOL CHEM, V269, P8517; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; NAKAJIMA T, 1994, BIOCHEM BIOPH RES CO, V204, P950, DOI 10.1006/bbrc.1994.2552; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; PAN ZX, 1995, J BIOL CHEM, V270, P7787, DOI 10.1074/jbc.270.14.7787; Pan ZXK, 2000, J IMMUNOL, V164, P404, DOI 10.4049/jimmunol.164.1.404; Pan ZXK, 1998, BBA-GENE STRUCT EXPR, V1443, P90, DOI 10.1016/S0167-4781(98)00198-5; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKSOZ D, 1994, ONCOGENE, V9, P621; VAN AL, 1997, GENE DEV, V11, P2295; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	36	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7208	7212		10.1074/jbc.M309542200	http://dx.doi.org/10.1074/jbc.M309542200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660653	hybrid			2022-12-27	WOS:000188969200120
J	Kolfschoten, MV; Dirven, RJ; Vos, HL; Tans, G; Rosing, J; Bertina, RM				Kolfschoten, MV; Dirven, RJ; Vos, HL; Tans, G; Rosing, J; Bertina, RM			Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; PEPTIDE-BOND CLEAVAGES; BLOOD-COAGULATION; FACTOR-XA; THROMBOTIC DISEASE; FACTOR VA(R506Q); HONG-KONG; MUTATION; RESISTANCE; CAMBRIDGE	Activated protein C (APC) exerts its anticoagulant activity via proteolytic degradation of the heavy chains of activated factor VIII (FVIIIa) and activated factor V (FVa). So far, three APC cleavage sites have been identified in the heavy chain of FVa: Arg-306, Arg-506, and Arg-679. To obtain more insight in the structural and functional implications of each individual cleavage, recombinant factor V (rFV) mutants were constructed in which two or three of the APC cleavage sites were mutated. After expression in COS-1 cells, rFV mutants were purified, activated with thrombin, and inactivated by APC. During this study we observed that activated rFV-GQA (rFVa-GQA), in which the arginines at positions 306, 506, and 679 were replaced by glycine, glutamine, and alanine, respectively, was still inactivated by APC. Further analysis showed that the inactivation of rFVa-GQA by APC was phospholipid-dependent and sensitive to an inhibitory monoclonal antibody against protein C. Inactivation proceeded via a rapid phase (k(x1) = 5.4 x 10(4) M-1 s(-1)) and a slow phase (k(x2) = 3.2 x 10(3) M-1 s(-1)). Analysis of the inactivation curves showed that the rapid phase yielded a reaction intermediate that retained similar to 80% of the original FVa activity, whereas the slow cleavage resulted in formation of a completely inactive reaction product. Inactivation of rFVa-GQA was accelerated by protein S, most likely via stimulation of the slow phase. Immunoblot analysis using a monoclonal antibody recognizing an epitope between Arg-306 and Arg-506 indicated that during the rapid phase of inactivation a fragment of 80 kDa was generated that resulted from cleavage at a residue very close to Arg-506. The slow phase was associated with the formation of fragments resulting from cleavage at a residue 1.5-2 kDa carboxyl-terminal to Arg-306. Our observations may explain the unexpectedly mild APC resistance associated with mutations at Arg-306 (FV HongKong and FV Cambridge) in the heavy chain of FV.	Leiden Univ, Med Ctr, Dept Hematol, Ctr Hemostasis & Thrombosis Res, NL-2300 RC Leiden, Netherlands; Univ maastricht, Cardiovasc Res Inst Maastricht, Dept Biochem, NL-6200 MD Maastricht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Maastricht University	Kolfschoten, MV (corresponding author), Leiden Univ, Med Ctr, Dept Hematol, Ctr Hemostasis & Thrombosis Res, C2-R,POB 9600, NL-2300 RC Leiden, Netherlands.	mneut@lumc.nl	Bertina, Rogier/AGQ-5246-2022	Dirven, Richard/0000-0001-9626-9925				BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Chan WP, 1998, BLOOD, V91, P1135, DOI 10.1182/blood.V91.4.1135; Chen F, 1999, THROMB HAEMOSTASIS, P105; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; Esmon CT, 2001, THROMB HAEMOSTASIS, V86, P51; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Franco RF, 1998, BRIT J HAEMATOL, V103, P888; Franco RF, 1999, THROMB HAEMOSTASIS, V81, P312; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; Guasch JF, 1998, BRIT J HAEMATOL, V101, P32, DOI 10.1046/j.1365-2141.1998.00664.x; Heeb MJ, 1999, EUR J BIOCHEM, V260, P64, DOI 10.1046/j.1432-1327.1999.00137.x; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; Hockin MF, 1997, ARTERIOSCL THROM VAS, V17, P2765, DOI 10.1161/01.ATV.17.11.2765; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kolfschoten MV, 2002, BLOOD COAGUL FIBRIN, V13, P207, DOI 10.1097/00001721-200204000-00006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Norstrom E, 2002, BLOOD, V100, P524, DOI 10.1182/blood-2002-02-0343; Norstrom EA, 2003, J BIOL CHEM, V278, P24904, DOI 10.1074/jbc.M303829200; OWREN PA, 1947, LANCET, V252, P446; Pellequer JL, 2000, THROMB HAEMOSTASIS, V84, P849, DOI 10.1055/s-0037-1614127; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; ROSING J, 1980, J BIOL CHEM, V255, P274; SALA N, 1984, BLOOD, V63, P671; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; van der Neut Kolfschoten M, 2003, THROMB HAEMOSTASIS, V89, P429; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; Williamson D, 1998, BLOOD, V91, P1140, DOI 10.1182/blood.V91.4.1140	43	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6567	6575		10.1074/jbc.M308574200	http://dx.doi.org/10.1074/jbc.M308574200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660667	hybrid			2022-12-27	WOS:000188969200045
J	Schafer, T; Zentgraf, H; Zehe, C; Brugger, B; Bernhagen, J; Nickel, W				Schafer, T; Zentgraf, H; Zehe, C; Brugger, B; Bernhagen, J; Nickel, W			Unconventional secretion of fibroblast growth factor 2 is mediated by direct translocation across the plasma membrane of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIGRATION INHIBITORY FACTOR; BINDING CASSETTE TRANSPORTER; RETICULUM-GOLGI-COMPLEX; COPI-COATED VESICLES; ENDOPLASMIC-RETICULUM; EXTRACELLULAR-MATRIX; SIGNAL SEQUENCE; INTERCELLULAR TRAFFICKING; STRUCTURAL PROTEIN; INNER MEMBRANES	Fibroblast growth factor 2 (FGF-2) is a pro-angiogenic mediator that is secreted by both normal and neoplastic cells. Intriguingly, FGF-2 has been shown to be exported by an endoplasmic reticulum/Golgi-independent pathway; however, the molecular machinery mediating this process has remained elusive. Here we introduce a novel in vitro system that functionally reconstitutes FGF-2 secretion. Based on affinity-purified plasma membrane inside-out vesicles, we demonstrate post-translational membrane translocation of FGF-2 as shown by protease protection experiments. This process is blocked at low temperature but apparently does not appear to be driven by ATP hydrolysis. FGF-2 membrane translocation occurs in a unidirectional fashion requiring both integral and peripheral membrane proteins. These findings provide direct evidence that FGF-2 secretion is based on its direct translocation across the plasma membrane of mammalian cells. When galectin-1 and macrophage migration inhibitory factor, other proteins exported by unconventional means, were analyzed for translocation into plasma membrane inside-out vesicles, galectin-1 was found to be transported as efficiently as FGF-2. By contrast, migration inhibitory factor failed to traverse the membrane of inside-out vesicles. These findings establish the existence of multiple distinct secretory routes that are operational in the absence of a functional endoplasmic reticulum/Golgi system.	Univ Heidelberg, Biochem Ctr, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Hosp RWTH Aachen, Inst Biochem, Unit Biochem & Mol Cell Biol, D-52074 Aachen, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); RWTH Aachen University; RWTH Aachen University Hospital	Nickel, W (corresponding author), Univ Heidelberg, Biochem Ctr, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	walter.nickel@urz.uni-heidelberg.de						Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; AURON PE, 1987, J IMMUNOL, V138, P1447; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Bernhagen J, 1998, J MOL MED-JMM, V76, P151, DOI 10.1007/s001090050204; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Cleves AE, 1997, CURR BIOL, V7, pR318, DOI 10.1016/S0960-9822(06)00148-5; Cleves AE, 1996, J CELL BIOL, V133, P1017, DOI 10.1083/jcb.133.5.1017; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; Dahl JP, 2000, BIOCHEMISTRY-US, V39, P14877, DOI 10.1021/bi001073y; Denny PW, 2000, J BIOL CHEM, V275, P11017, DOI 10.1074/jbc.275.15.11017; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Engling A, 2002, J CELL SCI, V115, P3619, DOI 10.1242/jcs.00036; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Jenne N, 2002, J BIOL CHEM, V277, P46504, DOI 10.1074/jbc.M206989200; Keppler D, 1998, METHOD ENZYMOL, V292, P607; KETTLUN AM, 1994, INT J BIOCHEM, V26, P437, DOI 10.1016/0020-711X(94)90065-5; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Lecellier CH, 2002, J VIROL, V76, P3388, DOI 10.1128/JVI.76.7.3388-3394.2002; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; Lutomski D, 1997, GLYCOBIOLOGY, V7, P1193, DOI 10.1093/glycob/7.8.1193; Mandinova A, 2003, J CELL SCI, V116, P2687, DOI 10.1242/jcs.00471; McKean PG, 2001, CELL MICROBIOL, V3, P511, DOI 10.1046/j.1462-5822.2001.00135.x; Mehul B, 1997, J CELL SCI, V110, P1169; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; Mischke R, 1997, FEBS LETT, V414, P226, DOI 10.1016/S0014-5793(97)01039-9; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nickel W, 2002, J CELL SCI, V115, P3235; Nickel W, 1998, J CELL SCI, V111, P3081; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Pencer J, 2001, BIOPHYS J, V81, P2716, DOI 10.1016/S0006-3495(01)75914-0; Prudovsky I, 2002, J CELL BIOL, V158, P201, DOI 10.1083/jcb.200203084; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; Seelenmeyer C, 2003, J CELL SCI, V116, P1305, DOI 10.1242/jcs.00312; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; Swope MD, 1999, REV PHYSIOL BIOCH P, V139, P1, DOI 10.1007/BFb0033647; Trotman LC, 2003, TRAFFIC, V4, P390, DOI 10.1034/j.1600-0854.2003.00094.x; Trudel C, 2000, J CELL PHYSIOL, V185, P260, DOI 10.1002/1097-4652(200011)185:2<260::AID-JCP11>3.0.CO;2-X; van Meer G, 1998, TRENDS CELL BIOL, V8, P29, DOI 10.1016/S0962-8924(97)01196-3; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; Zhou XQ, 2002, BIOCHEM BIOPH RES CO, V291, P598, DOI 10.1006/bbrc.2002.6473	64	105	106	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6244	6251		10.1074/jbc.M310500200	http://dx.doi.org/10.1074/jbc.M310500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645213	hybrid			2022-12-27	WOS:000188969200008
J	Viviano, BL; Paine-Saunders, S; Gasiunas, N; Gallagher, J; Saunders, S				Viviano, BL; Paine-Saunders, S; Gasiunas, N; Gallagher, J; Saunders, S			Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist noggin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS CELLULAR-RESPONSES; STRUCTURAL FEATURES; MITOGENIC ACTIVITY; SPEMANN ORGANIZER; XENOPUS EMBRYOS; SONIC HEDGEHOG; PROTEOGLYCANS; SURFACE; WNT; OLIGOSACCHARIDES	We have reported previously that Noggin is a heparin-binding protein and associates with the cell surface through heparan sulfate proteoglycans, where it remains functional for the binding of bone morphogenetic proteins ( BMPs). Here we report that the binding of Noggin to the cell surface is highly selective for heparan sulfate and that specific structural features are required for the interaction. Noggin binds most efficiently to heparin sequences composed of 10 or more monosaccharides; N-, 6- O-, and 2- O- sulfates contribute to this interaction. In addition, we have shown that the developmentally regulated endosulfatase Qsulf1 selectively removes sulfate groups from the 6- O position of sugars within the most highly sulfated S domains of heparan sulfate, whereas 6- O- sulfates in the NA/ NS domains are not substrates for the enzyme. The activity of Qsulf1 in cells in culture results in the release of Noggin from the cell surface and a restoration of BMP responsiveness to the cells. This shows that Noggin binds to the S domains of heparan sulfate and provides evidence that, in addition to modulating Wnt signaling in vivo by the release of heparan sulfate bound Wnt, Qsulf1 also modulates BMP signaling by the release of surface- bound Noggin.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Paterson Inst Canc Res, Dept Med Oncol, Manchester M20 4BX, Lancs, England	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Paterson Institute for Cancer Research	Saunders, S (corresponding author), Washington Univ, Sch Med, Dept Pediat, 660 S Euclid Ave,Campus Box 8208, St Louis, MO 63110 USA.	saunders_s@kids.wustl.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD039952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056063] Funding Source: NIH RePORTER; NICHD NIH HHS [HD39952] Funding Source: Medline; NIDDK NIH HHS [DK56063] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blackhall FH, 2003, BIOCHEM J, V375, P131, DOI 10.1042/BJ20030730; Dale L, 1999, SEMIN CELL DEV BIOL, V10, P319, DOI 10.1006/scdb.1999.0308; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Dosch R, 1997, DEVELOPMENT, V124, P2325; Friedl A, 1997, AM J PATHOL, V150, P1443; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Hirsinger E, 1997, DEVELOPMENT, V124, P4605; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006-291X(03)01500-6; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Jayson GC, 1998, J BIOL CHEM, V273, P51, DOI 10.1074/jbc.273.1.51; Lyon M, 2000, J BIOL CHEM, V275, P4599, DOI 10.1074/jbc.275.7.4599; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Paine-Saunders S, 2000, DEV BIOL, V225, P179, DOI 10.1006/dbio.2000.9831; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rubin JB, 2002, DEVELOPMENT, V129, P2223; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Takada T, 2003, J BIOL CHEM, V278, P43229, DOI 10.1074/jbc.M300937200; Tonegawa A, 1998, DEV BIOL, V202, P172, DOI 10.1006/dbio.1998.8895; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	32	158	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5604	5611		10.1074/jbc.M310691200	http://dx.doi.org/10.1074/jbc.M310691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645250	hybrid			2022-12-27	WOS:000188776500070
J	Nishikawa, H; Ooka, S; Sato, K; Arima, K; Okamoto, J; Klevit, RE; Fukuda, M; Ohta, T				Nishikawa, H; Ooka, S; Sato, K; Arima, K; Okamoto, J; Klevit, RE; Fukuda, M; Ohta, T			Mass spectrometric and mutational analyses reveal lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN CHAIN; DNA-REPAIR; BRCA1/BARD1 HETERODIMER; REGULATORY COMPLEX; 26S PROTEASOMES; RING DOMAIN; BRCA1; PROTEIN; CANCER; DEGRADATION	The breast and ovarian cancer suppressor BRCA1 acquires significant ubiquitin ligase activity when bound to BARD1 as a RING heterodimer. Although the activity may well be important for the role of BRCA1 as a tumor suppressor, the biochemical consequence of the activity is not yet known. Here we report that BRCA1-BARD1 catalyzes Lys-6-linked polyubiquitin chain formation. K6R mutation of ubiquitin dramatically reduces the polyubiquitin products mediated by BRCA1-BARD1 in vitro. BRCA1-BARD1 preferentially utilizes ubiquitin with a single Lys residue at Lys-6 or Lys-29 to mediate autoubiquitination of BRCA1 in vivo. Furthermore, mass spectrometry analysis identified the Lys-6-linked branched ubiquitin fragment from the polyubiquitin chain produced by BRCA1-BARD1 using wild type ubiquitin. The BRCA1-BARD1-mediated Lys-6-linked polyubiquitin chains are deubiquitinated by 26 S proteasome in vitro, whereas autoubiquitinated CUL1 through Lys-48-linked polyubiquitin chains is degraded. Proteasome inhibitors do not alter the steady state level of the autoubiquitinated BRCA1 in vivo. Hence, the results indicate that BRCA1-BARD1 mediates novel polyubiquitin chains that may be distinctly edited by 26 S proteasome from conventional Lys-48-linked polyubiquitin chains.	St Marianna Univ, Sch Med, Inst Med Sci, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan; St Marianna Univ, Sch Med, Inst Med Sci, Div Immunoregulat, Kawasaki, Kanagawa 2168511, Japan; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Saint Marianna University; Saint Marianna University; University of Washington; University of Washington Seattle	Ohta, T (corresponding author), St Marianna Univ, Sch Med, Inst Med Sci, Div Breast & Endocrine Surg, Kawasaki, Kanagawa 2168511, Japan.	to@marianna-u.ac.jp	Klevit, Rachel/AAI-7038-2021	Klevit, Rachel/0000-0002-3476-969X; Ohta, Tomohiko/0000-0002-9700-7342				Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	35	180	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					3916	3924		10.1074/jbc.M308540200	http://dx.doi.org/10.1074/jbc.M308540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14638690	hybrid			2022-12-27	WOS:000188554300004
J	Yoshida, K; Furuya, S; Osuka, S; Mitoma, J; Shinoda, Y; Watanabe, M; Azuma, N; Tanaka, H; Hashikawa, T; Itohara, S; Hirabayashi, Y				Yoshida, K; Furuya, S; Osuka, S; Mitoma, J; Shinoda, Y; Watanabe, M; Azuma, N; Tanaka, H; Hashikawa, T; Itohara, S; Hirabayashi, Y			Targeted disruption of the mouse 3-phosphoglycerate dehydrogenase gene causes severe neurodevelopmental defects and results in embryonic lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SERINE; HIPPOCAMPAL-NEURONS; METABOLISM; CELLS; BIOSYNTHESIS; EXPRESSION; TISSUES; LINEAGE; MUTANTS; GLIA	D-3-Phosphoglycerate dehydrogenase (Phgdh; EC 1.1.1.95) is the first committed enzyme of L-serine biosynthesis in the phosphorylated pathway. To determine the physiological importance of Phgdh-dependent L-serine biosynthesis in vivo, we generated Phgdh-deficient mice using targeted gene disruption in embryonic stem cells. The absence of Phgdh led to a drastic reduction of L-serine metabolites such as phosphatidyl-L-serine and sphingolipids. Phgdh null embryos have small bodies with abnormalities in selected tissues and died after days post-coitum 13.5. Striking abnormalities were evident in the central nervous system in which the Phgdh null mutation culminated in hypoplasia of the telencephalon, diencephalon, and mesencephalon; in particular, the olfactory bulbs, ganglionic eminence, and cerebellum appeared as indistinct structures. These observations demonstrate that the Phgdh-dependent phosphorylated pathway is essential for normal embryonic development, especially for brain morphogenesis.	RIKEN, Brain Sci Inst, Neuronal Circuit Mech Res Grp, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Behab Genet, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Neural Architecture, Wako, Saitama 3510198, Japan; Burnham Inst, Glycobiol Program, La Jolla, CA 92037 USA; Hokkaido Univ, Sch Med, Dept Anat, Sapporo, Hokkaido 0608638, Japan; Utsunomiya Univ, Fac Agr, Dept Appl Biochem, Utsunomiya, Tochigi 3218505, Japan; Tokyo Univ Agr & Technol, United Grad Sch Agr Sci, Fuchu, Tokyo 1838509, Japan	RIKEN; RIKEN; RIKEN; Sanford Burnham Prebys Medical Discovery Institute; Hokkaido University; Utsunomiya University; Tokyo University of Agriculture & Technology	Furuya, S (corresponding author), RIKEN, Brain Sci Inst, Neuronal Circuit Mech Res Grp, Wako, Saitama 3510198, Japan.	furuyash@postman.riken.go.jp; hirabaya@postman.riken.go.jp	Watanabe, Masahiko/S-3614-2019; WATANABE, Masahiko/A-4055-2012; Itohara, Shigeyoshi/I-8769-2012	Watanabe, Masahiko/0000-0001-5037-7138; WATANABE, Masahiko/0000-0001-5037-7138; Itohara, Shigeyoshi/0000-0002-2410-9989; Hirabayashi, Yoshio/0000-0002-5774-7354; Furuya, Shigeki/0000-0001-9020-3597				Achouri Y, 1997, BIOCHEM J, V323, P365, DOI 10.1042/bj3230365; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chen YP, 1998, J EXP ZOOL, V282, P691; De Koning TJ, 2003, BIOCHEM J, V371, P653, DOI 10.1042/BJ20021785; Furuya S, 2000, P NATL ACAD SCI USA, V97, P11528, DOI 10.1073/pnas.200364497; Furuya S, 2003, ARCH HISTOL CYTOL, V66, P109, DOI 10.1679/aohc.66.109; FURUYA S, 1994, J BIOL CHEM, V269, P32418; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; Holzenberger M, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e92; ICHIHARA A, 1957, J BIOL CHEM, V224, P331; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; Mitoma J, 1998, J BIOL CHEM, V273, P19363, DOI 10.1074/jbc.273.31.19363; Mitoma J, 1998, NEUROSCI RES, V30, P195, DOI 10.1016/S0168-0102(97)00113-2; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Narkewicz MR, 1996, PEDIATR RES, V39, P1085, DOI 10.1203/00006450-199606000-00025; Nishijima M, 1997, TRENDS CELL BIOL, V7, P324, DOI 10.1016/S0962-8924(97)01084-2; ROWSELL EV, 1969, BIOCHEM J, V115, P1071, DOI 10.1042/bj1151071; Shibata T, 1997, J NEUROSCI, V17, P9212; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; SNELL K, 1987, BIOCHEM J, V245, P609, DOI 10.1042/bj2450609; WALSH DA, 1966, J BIOL CHEM, V241, P4068; WHITE FV, 1986, J NEUROCHEM, V46, P1200, DOI 10.1111/j.1471-4159.1986.tb00638.x; Yamasaki M, 2001, J NEUROSCI, V21, P7691, DOI 10.1523/JNEUROSCI.21-19-07691.2001; Yanagawa Y, 1999, TRANSGENIC RES, V8, P215, DOI 10.1023/A:1008914020843	25	102	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3573	3577		10.1074/jbc.C300507200	http://dx.doi.org/10.1074/jbc.C300507200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14645240	hybrid			2022-12-27	WOS:000188379600054
J	Gutierrez-Cirlos, EB; Merbitz-Zahradnik, T; Trumpower, BL				Gutierrez-Cirlos, EB; Merbitz-Zahradnik, T; Trumpower, BL			Inhibition of the yeast cytochrome bc(1) complex by ilicicolin H, a novel inhibitor that acts at the Qn site of the bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; UBIQUINOL OXIDATION; ELECTRON-TRANSFER; C OXIDOREDUCTASE; MECHANISM; ANTIMYCIN; MITOCHONDRIA; ANALOGS; Q(O)	Ilicicolin H is an antibiotic isolated from the "imperfect" fungus Cylindrocladium iliciola strain MFC-870. Ilicicolin inhibits mitochondrial respiration by inhibiting the cytochrome bc(1) complex. In order to identify the site of ilicicolin action within the bc(1) complex we have characterized the effects of ilicicolin on the cytochrome bc(1) complex of Saccharomyces cerevisiae. Ilicicolin inhibits ubiquinol-cytochrome c reductase activity of the yeast bc(1) complex with an IC50 of 3-5 nM, while 200 - 250 nM ilicicolin was required to obtain comparable inhibition of the bovine bc(1) complex. Ilicicolin blocks oxidation-reduction of cytochrome b through center N of the bc(1) complex and promotes oxidant-induced reduction of cytochrome b but has no effect on oxidation of ubiquinol through center P. These results indicate that ilicicolin binds to the Qn site of the bc(1) complex. Ilicicolin induces a blue shift in the absorption spectrum of ferro-cytochrome b, and titration of the spectral shift indicates binding of one inhibitor molecule per Qn site. The effects of ilicicolin on electron transfer reactions in the bc(1) complex are similar to those of antimycin, another inhibitor that binds to the Qn site of the bc(1) complex. However, because the two inhibitors have different effects on the absorption spectrum of cytochrome b, they differ in their mode of binding to the Qn site.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.	Trumpower@Dartmouth.edu	Gutierrez Cirlos, Emma Berta/D-4463-2011; Gutiérrez, Emma/AAG-5191-2021	Gutierrez Cirlos, Emma Berta/0000-0002-6672-1711	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERDEN JA, 1972, BIOCHIM BIOPHYS ACTA, V256, P199, DOI 10.1016/0005-2728(72)90053-9; BOWYER JR, 1980, FEBS LETT, V115, P171, DOI 10.1016/0014-5793(80)81160-4; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; CAVAZZONI M, 1993, ARCH BIOCHEM BIOPHYS, V303, P246, DOI 10.1006/abbi.1993.1279; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; HAYAKAWA S, 1971, J ANTIBIOT, V24, P653, DOI 10.7164/antibiotics.24.653; HOWELL N, 1993, BIOCHEMISTRY-US, V32, P11162, DOI 10.1021/bi00092a028; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KAMENSKY Y, 1985, FEBS LETT, V181, P95, DOI 10.1016/0014-5793(85)81120-0; Kim H, 1999, J AM CHEM SOC, V121, P4902, DOI 10.1021/ja990190h; KUBOTA T, 1992, J BIOCHEM-TOKYO, V111, P91, DOI 10.1093/oxfordjournals.jbchem.a123725; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; Margoliash E, 1967, METHOD ENZYMOL, V10, P339; MATSUMOTO M, 1976, TETRAHEDRON LETT, P3827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Palsdottir H, 2003, J BIOL CHEM, V278, P31303, DOI 10.1074/jbc.M302195200; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; Snyder C, 1998, BBA-BIOENERGETICS, V1365, P125, DOI 10.1016/S0005-2728(98)00052-8; Snyder CH, 1999, J BIOL CHEM, V274, P31209, DOI 10.1074/jbc.274.44.31209; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; TANABE M, 1983, TETRAHEDRON, V39, P3569, DOI 10.1016/S0040-4020(01)88667-1; TOKUTAKE N, 1993, BIOCHIM BIOPHYS ACTA, V1142, P262, DOI 10.1016/0005-2728(93)90154-8; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	26	48	50	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8708	8714		10.1074/jbc.M311805200	http://dx.doi.org/10.1074/jbc.M311805200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670947	hybrid			2022-12-27	WOS:000189265900023
J	Javelle, A; Severi, E; Thornton, J; Merrick, M				Javelle, A; Severi, E; Thornton, J; Merrick, M			Ammonium sensing in Escherichia coli - Role of the ammonium transporter AmtB and AmtB-GlnK complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PROTEIN; GLUTAMINE-SYNTHETASE; MOLECULAR CHARACTERIZATION; GENE-EXPRESSION; REVEALS; PII; VECTORS; HOMOLOG; OPERON; FAMILY	The Amt proteins are high affinity ammonium transporters that are conserved in all domains of life. In bacteria and archaea the Amt structural genes ( amtB) are invariably linked to glnK, which encodes a member of the P-II signal transduction protein family, proteins that regulate many facets of nitrogen metabolism. We have now shown that Escherichia coli AmtB is inactivated by formation of a membrane-bound complex with GlnK. Complex formation is reversible and occurs within seconds in response to micromolar changes in the extracellular ammonium concentration. Regulation is mediated by the uridylylation/deuridylylation of GlnK in direct response to fluctuations in the intracellular glutamine pool. Furthermore under physiological conditions AmtB activity is required for GlnK deuridylylation. Hence the transporter is an integral part of the signal transduction cascade, and AmtB can be formally considered to act as an ammonium sensor. This system provides an exquisitely sensitive mechanism to control ammonium flux into the cell, and the conservation of glnK linkage to amtB suggests that this regulatory mechanism may occur throughout prokaryotes.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Merrick, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.	mike.merrick@bbsrc.ac.uk						Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Atkinson MR, 1998, MOL MICROBIOL, V29, P431, DOI 10.1046/j.1365-2958.1998.00932.x; Atkinson MR, 1999, MOL MICROBIOL, V32, P301, DOI 10.1046/j.1365-2958.1999.01349.x; Atkinson MR, 2002, J BACTERIOL, V184, P5364, DOI 10.1128/JB.184.19.5364-5375.2002; Avent ND, 1996, J BIOL CHEM, V271, P14233, DOI 10.1074/jbc.271.24.14233; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; Blauwkamp TA, 2003, MOL MICROBIOL, V48, P1017, DOI 10.1046/j.1365-2958.2003.03479.x; Blauwkamp TA, 2002, MOL MICROBIOL, V46, P203, DOI 10.1046/j.1365-2958.2002.03153.x; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Forchhammer K, 1999, MOL MICROBIOL, V33, P338, DOI 10.1046/j.1365-2958.1999.01477.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Ikeda TP, 1996, J MOL BIOL, V259, P589, DOI 10.1006/jmbi.1996.0342; Jack R, 1999, J BACTERIOL, V181, P1156, DOI 10.1128/JB.181.4.1156-1162.1999; Javelle A, 2003, TRENDS MICROBIOL, V11, P53, DOI 10.1016/S0966-842X(02)00012-4; Javelle A, 2003, MOL MICROBIOL, V47, P411, DOI 10.1046/j.1365-2958.2003.03303.x; Javelle A, 2001, FEBS LETT, V505, P393, DOI 10.1016/S0014-5793(01)02802-2; JAYAKUMAR A, 1986, J BACTERIOL, V166, P281, DOI 10.1128/jb.166.1.281-284.1986; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12782, DOI 10.1021/bi980667m; KLEINER D, 1985, FEMS MICROBIOL LETT, V32, P87, DOI 10.1016/0378-1097(85)90059-X; LIAW SH, 1995, PROTEIN SCI, V4, P2358, DOI 10.1002/pro.5560041114; Little R, 2002, J BIOL CHEM, V277, P15472, DOI 10.1074/jbc.M112262200; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; Ludewig U, 2003, J BIOL CHEM, V278, P45603, DOI 10.1074/jbc.M307424200; Maharjan RP, 2003, ANAL BIOCHEM, V313, P145; Maheswaran M, 2003, MICROBIOL-SGM, V149, P2163, DOI 10.1099/mic.0.26449-0; Marini AM, 2000, MOL MICROBIOL, V38, P552, DOI 10.1046/j.1365-2958.2000.02151.x; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Monahan BJ, 2002, FUNGAL GENET BIOL, V36, P35, DOI 10.1016/S1087-1845(02)00004-X; Plumbridge J, 2002, CURR OPIN MICROBIOL, V5, P187, DOI 10.1016/S1369-5274(02)00296-5; Reyes-Ramirez F, 2001, J BACTERIOL, V183, P3076, DOI 10.1128/JB.183.10.3076-3082.2001; SCHUTT H, 1972, EUR J BIOCHEM, V26, P68, DOI 10.1111/j.1432-1033.1972.tb01740.x; Smith DG, 2003, MOL MICROBIOL, V50, P259, DOI 10.1046/j.1365-2958.2003.03680.x; Thomas G, 2000, TRENDS GENET, V16, P11, DOI 10.1016/S0168-9525(99)01887-9; Thomas GH, 2000, MOL MICROBIOL, V37, P331, DOI 10.1046/j.1365-2958.2000.01994.x; VANDOMMELEN A, 2001, AUST J PLANT PHYSL, V28, P959; vanHeeswijk WC, 1996, MOL MICROBIOL, V21, P133, DOI 10.1046/j.1365-2958.1996.6281349.x; WANG MY, 1993, PLANT PHYSIOL, V103, P1259, DOI 10.1104/pp.103.4.1463; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; Yakunin AF, 2002, J BACTERIOL, V184, P4081, DOI 10.1128/JB.184.15.4081-4088.2002; Zhang YP, 2001, J BACTERIOL, V183, P6159, DOI 10.1128/JB.183.21.6159-6168.2001	43	171	178	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8530	8538		10.1074/jbc.M312399200	http://dx.doi.org/10.1074/jbc.M312399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668330	hybrid			2022-12-27	WOS:000189265900003
J	Lee, JS; Hmama, Z; Mui, A; Reiner, NE				Lee, JS; Hmama, Z; Mui, A; Reiner, NE			Stable gene silencing in human monocytic cell lines using lentiviral-delivered small interference RNA - Silencing of the p110 alpha isoform of phosphoinositide 3-kinase reveals differential regulation of adherence induced by 1 alpha,25-dihydroxycholecalciferol and bacterial lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; KINASE-C-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN-CELLS; ADENOASSOCIATED VIRUS; PROTEIN-KINASE; THP-1 CELLS; IN-VIVO; B-CELL; EMBRYONIC LETHALITY	Studying mononuclear phagocyte cell biology through genetic manipulation by non-viral transfection methods has been challenging due to the dual problems of low transfection efficiency and the difficulty in obtaining stable transfection. To overcome this problem, we developed a system for mediating RNA interference in monocytic cells. The p110alpha isoform of phosphoinositide 3-kinases (PI3Ks) was silenced using a lentiviral vector expressing short hairpin RNA (shRNA). This resulted in the generation of stable THP-1 and U-937 monocytic cell lines deficient in p110alpha. Notably, p110alpha was silenced without affecting levels of either the other class I-A PI3K catalytic subunits p110beta and p110delta, or the p85alpha regulatory subunit. The role of p110alpha in mediating cell adherence was examined. Monocyte adherence induced in response to either lipopolysaccharide (LPS) or 1alpha, 25-dihydroxycholecalciferol (D-3) was blocked by the PI3K inhibitor LY294002. However, although adherence induced in response to D3 was sensitive to silencing of p110alpha, LPS-induced adherence was not. Expression of the monocyte differentiation marker CD11b was also induced by D-3 in a PI3K-dependent manner and gene silencing using shRNA showed that p110alpha was also required for this effect. Taken together, these findings demonstrate that LPS and D-3 use distinct isoforms of class IA PI3K to induce functional responses and that lentiviral-mediated delivery of shRNA is a powerful approach to study monocyte biology.	Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Med, Dept Surg, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Med, Dept Microbiol & Immunol, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Fac Sci, Vancouver, BC V5Z 3J5, Canada; Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 3J5, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Reiner, NE (corresponding author), Univ British Columbia, Fac Med, Dept Med, Div Infect Dis, Rm 452D,2733 Heather St, Vancouver, BC V5Z 3J5, Canada.	ethan@interchange.ubc.ca						Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bambacioni F, 2001, HAEMATOLOGICA, V86, P1095; Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; Blomer U, 1997, J VIROL, V71, P6641; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buchschacher GL, 2000, BLOOD, V95, P2499; Burke B, 2002, J LEUKOCYTE BIOL, V72, P417; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Dey BR, 1998, GENE, V209, P175, DOI 10.1016/S0378-1119(98)00045-6; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Ehlers MRW, 2000, MICROBES INFECT, V2, P289, DOI 10.1016/S1286-4579(00)00299-9; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Far RKK, 2003, NUCLEIC ACIDS RES, V31, P4417, DOI 10.1093/nar/gkg649; Farach-Carson MC, 2003, CURR DRUG TARGETS, V4, P67, DOI 10.2174/1389450033347118; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Follenzi Antonia, 2002, Methods Mol Med, V69, P259; Foukas LC, 2003, ARCH BIOCHEM BIOPHYS, V414, P13, DOI 10.1016/S0003-9861(03)00177-2; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Funaki M, 1999, J BIOL CHEM, V274, P22019, DOI 10.1074/jbc.274.31.22019; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P107; Hamada K, 1998, BIOCHEM BIOPH RES CO, V244, P745, DOI 10.1006/bbrc.1998.8328; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Hewison M, 2001, Rev Endocr Metab Disord, V2, P217, DOI 10.1023/A:1010015013211; HICKSTEIN DD, 1987, J BIOL CHEM, V262, P5576; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Hmama Z, 1999, J EXP MED, V190, P1583, DOI 10.1084/jem.190.11.1583; Hohjoh H, 2002, FEBS LETT, V521, P195, DOI 10.1016/S0014-5793(02)02860-0; Introna M, 1998, BRIT J HAEMATOL, V103, P449, DOI 10.1046/j.1365-2141.1998.01020.x; Itou T, 1998, INT J HEMATOL, V67, P27; Janssen JWG, 1998, ONCOGENE, V16, P1767, DOI 10.1038/sj.onc.1201695; Jimenez C, 2002, J BIOL CHEM, V277, P41556, DOI 10.1074/jbc.M205893200; JOCKUSCH BM, 1991, J CELL SCI, P41; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Kusumawati A, 1999, ANAL BIOCHEM, V269, P219, DOI 10.1006/abio.1999.4024; LEIBBRANDT MEI, 1994, CELL GROWTH DIFFER, V5, P17; Liao HS, 1997, J LIPID RES, V38, P1433; Liu Y, 2000, J INTERF CYTOK RES, V20, P21, DOI 10.1089/107999000312702; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; McGilvray ID, 1998, J SURG RES, V80, P272, DOI 10.1006/jsre.1998.5319; MILLER LJ, 1986, J IMMUNOL, V137, P2891; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Monick MM, 2000, J IMMUNOL, V165, P4632, DOI 10.4049/jimmunol.165.8.4632; Mountain A, 2000, TRENDS BIOTECHNOL, V18, P119, DOI 10.1016/S0167-7799(99)01416-X; MURAO S, 1983, CANCER RES, V43, P4989; Nakajima H, 1996, LEUKEMIA RES, V20, P665, DOI 10.1016/0145-2126(96)00020-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Norman AW, 2002, MOL CELL ENDOCRINOL, V197, P1, DOI 10.1016/S0303-7207(02)00273-3; Norman AW, 2002, STEROIDS, V67, P457, DOI 10.1016/S0039-128X(01)00167-2; Okkenhaug K, 2002, SCIENCE, V297, P1031; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pinette KV, 2003, MINI-REV MED CHEM, V3, P193, DOI 10.2174/1389557033488204; POHLMAN TH, 1986, J IMMUNOL, V136, P4548; POLLA BS, 1986, J CLIN INVEST, V77, P1332, DOI 10.1172/JCI112438; Ponnazhagan S, 2001, J VIROL, V75, P9493, DOI 10.1128/JVI.75.19.9493-9501.2001; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; SHATTOCK RJ, 1993, J VIROL, V67, P3569, DOI 10.1128/JVI.67.6.3569-3575.1993; Shepherd PR, 1997, J BIOL CHEM, V272, P19000, DOI 10.1074/jbc.272.30.19000; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; SMEDLY LA, 1986, J CLIN INVEST, V77, P1233, DOI 10.1172/JCI112426; Stripecke R, 2000, BLOOD, V96, P1317, DOI 10.1182/blood.V96.4.1317; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wagner RS, 1996, SHOCK, V5, P41, DOI 10.1097/00024382-199601000-00009; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	85	36	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9379	9388		10.1074/jbc.M310638200	http://dx.doi.org/10.1074/jbc.M310638200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672955	hybrid			2022-12-27	WOS:000189265900102
J	Morais, MC; Zhang, GF; Zhang, WH; Olsen, DB; Dunaway-Mariano, D; Allen, KN				Morais, MC; Zhang, GF; Zhang, WH; Olsen, DB; Dunaway-Mariano, D; Allen, KN			X-ray crystallographic and site-directed mutagenesis analysis of the mechanism of Schiff-base formation in phosphonoacetaldehyde hydrolase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-PHOSPHORUS BOND; ACTIVE-SITE; ACETOACETATE DECARBOXYLASE; MOLECULAR REPLACEMENT; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE; CLEAVING ENZYME; CLEAVAGE; SUBSTRATE; MODELS	Phosphonoacetaldehyde hydrolase ( phosphonatase) catalyzes the hydrolytic P-C bond cleavage of phosphonoacetaldehyde (Pald) to form orthophosphate and acetaldehyde. The reaction proceeds via a Schiff-base intermediate formed between Lys-53 and the Pald carbonyl. The x-ray crystal structures of the wild-type phosphonatase complexed with Mg(II) alone or with Mg( II) plus vinylsulfonate ( a phosphonoethylenamine analog) were determined to 2.8 and 2.4 Angstrom, respectively. These structures were used to determine the identity and positions of active site residues surrounding the Lys-53 ammonium group and the Pald carbonyl. These include Cys-22, His-56, Tyr-128, and Met-49. Site-directed mutagenesis was then employed to determine whether or not these groups participate in catalysis. Based on rate contributions, Tyr-128 and Cys-22 were eliminated as potential catalytic groups. The Lys-53 epsilon-amino group, positioned for reaction with the Pald carbonyl, forms a hydrogen bond with water 120. Water 120 is also within hydrogen bond distance of an imidazole nitrogen of His-56 and the sulfur atom of Met-49. Kinetic constants for mutants indicated that His-56 (1000-fold reduction in k(cat)/K-m upon Ala substitution) and Met-49 (17,000-fold reduction in k(cat)/K-m upon Leu substitution) function in catalysis of Schiff-base formation. Based on these results, it is proposed that a network of hydrogen bonds among Lys-53, water 120, His-56, and Met-49 facilitate proton transfer from Lys-53 to the carbinolamine intermediate. Comparison of the vinylsulfonate complex versus unliganded structures indicated that association of the cap and core domains is essential for the positioning of the Lys-53 for attack at the Pald carbonyl and that substrate binding at the core domain stabilizes cap domain binding.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	University of New Mexico; Boston University	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.	dd39@unm.edu; allen@med-xtal.bu.edu	Allen, Karen N./J-7045-2019	Allen, Karen N./0000-0001-7296-0551; olsen, david/0000-0001-5521-0206	NIGMS NIH HHS [GM61099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard J, 2001, P NATL ACAD SCI USA, V98, P3679, DOI 10.1073/pnas.071380898; ALLEN KN, 1998, COMPREHENSIVE BIOL C, P135; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker AS, 1998, BIOCHEMISTRY-US, V37, P9305, DOI 10.1021/bi972677d; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Choi KH, 1999, BIOCHEMISTRY-US, V38, P12655, DOI 10.1021/bi9828371; Choi KH, 2001, BIOCHEMISTRY-US, V40, P13868, DOI 10.1021/bi0114877; GUTHRIE JP, 1967, FED PROC, V26, P562; GUTHRIE JP, 1972, J AM CHEM SOC, V94, P7024, DOI 10.1021/ja00775a027; Heine A, 2001, SCIENCE, V294, P369, DOI 10.1126/science.1063601; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; ISBELL AF, 1969, J ORG CHEM, V34, P755, DOI 10.1021/jo01255a067; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P121; Jia J, 1997, PROTEIN SCI, V6, P119; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; Kononova SV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P184, DOI 10.1023/A:1014409929875; LANAUZE JM, 1970, BIOCHIM BIOPHYS ACTA, V212, P332, DOI 10.1016/0005-2744(70)90214-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTHEWS BW, 1985, METHOD ENZYMOL, V114, P176; Maurady A, 2002, J BIOL CHEM, V277, P9474, DOI 10.1074/jbc.M107600200; MCMULLAN G, 1994, J BACTERIOL, V176, P320, DOI 10.1128/JB.176.2.320-324.1994; Morais MC, 2000, ACTA CRYSTALLOGR D, V56, P206, DOI 10.1107/S0907444999015899; Morais MC, 2000, BIOCHEMISTRY-US, V39, P10385, DOI 10.1021/bi001171j; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; OLEARY MH, 1972, J AM CHEM SOC, V94, P626, DOI 10.1021/ja00757a051; OLSEN DB, 1992, ARCH BIOCHEM BIOPHYS, V296, P144, DOI 10.1016/0003-9861(92)90556-C; OLSEN DB, 1988, BIOCHEMISTRY-US, V27, P2229, DOI 10.1021/bi00406a063; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROSSMANN MG, 1990, ACTA CRYSTALLOGR A, V46, P73, DOI 10.1107/S0108767389009815; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; Ternan NG, 1998, BIOCHEM BIOPH RES CO, V248, P378, DOI 10.1006/bbrc.1998.8962; VOET D, 1990, BIOCHEMISTRY-US, P62; WACKETT LP, 1987, J BACTERIOL, V169, P710, DOI 10.1128/jb.169.2.710-717.1987; Zhang GF, 2002, BIOCHEMISTRY-US, V41, P13370, DOI 10.1021/bi026388n	37	28	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9353	9361		10.1074/jbc.M312345200	http://dx.doi.org/10.1074/jbc.M312345200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670958	hybrid			2022-12-27	WOS:000189265900099
J	Gao, GH; Prutzman, KC; King, ML; Scheswohl, DM; DeRose, EF; London, RE; Schaller, MD; Campbell, SL				Gao, GH; Prutzman, KC; King, ML; Scheswohl, DM; DeRose, EF; London, RE; Schaller, MD; Campbell, SL			NMR solution structure of the focal adhesion targeting domain of focal adhesion kinase in complex with a paxillin LD peptide - Evidence for a two-site binding model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; DIFFERENTIAL REGULATION; BIOLOGICAL RESPONSES; DIPOLAR COUPLINGS; HIGH-SENSITIVITY; TERMINAL DOMAIN; C-13	Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is regulated by integrins. Upon activation, FAK generates signals that modulate crucial cell functions, including cell proliferation, migration, and survival. The C-terminal focal adhesion targeting ( FAT) sequence mediates localization of FAK to discrete regions in the cell called focal adhesions. Several binding partners for the FAT domain of FAK have been identified, including paxillin. We have determined the solution structure of the avian FAT domain in complex with a peptide mimicking the LD2 motif of paxillin by NMR spectroscopy. The FAT domain retains a similar fold to that found in the unliganded form when complexed to the paxillin-derived LD2 peptide, an antiparallel four-helix bundle. However, noticeable conformational changes were observed upon the LD2 peptide binding, especially the position of helix 4. Multiple lines of evidence, including the results obtained from isothermal titration calorimetry, intermolecular nuclear Overhauser effects, mutagenesis, and protection from paramagnetic line broadening, support the existence of two distinct paxillin-binding sites on the opposite faces of the FAT domain. The structure of the FAT domain-LD2 complex was modeled using the program HADDOCK based on our solution structure of the LD2-bound FAT domain and mutagenesis data. Our model of the FAT domain-LD2 complex provides insight into the molecular basis of FAK-paxillin binding interactions, which will aid in understanding the role of paxillin in FAK targeting and signaling.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Comprehens Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Campbell, SL (corresponding author), Univ N Carolina, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.	campbesl@med.unc.edu	London, Robert E/F-7990-2019	London, Robert E/0000-0001-9108-8463; campbell, sharon/0000-0003-0311-409X	NATIONAL CANCER INSTITUTE [R01CA090901] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050110, ZIAES050111, Z01ES050111, Z01ES050110] Funding Source: NIH RePORTER; NCI NIH HHS [CA90901] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIDCR NIH HHS [DE13079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Arumugam S, 1998, BIOCHEMISTRY-US, V37, P9650, DOI 10.1021/bi980128h; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Boetzel R, 2000, PROTEIN SCI, V9, P1709, DOI 10.1110/ps.9.9.1709; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CANCE WG, 1995, BREAST CANCER RES TR, V35, P105, DOI 10.1007/BF00694751; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hauck CR, 2001, CANCER RES, V61, P7079; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Hecker TP, 2003, FRONT BIOSCI-LANDMRK, V8, pS705, DOI 10.2741/1115; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Hubbard SJ, 1993, NACCESS COMPUTER PRO; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones G, 2001, CANCER RES, V61, P4978; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Leyton J, 2001, CANCER LETT, V162, P87, DOI 10.1016/S0304-3835(00)00639-X; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li XW, 2001, J CELL SCI, V114, P2665; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Liu GH, 2002, MOL CELL BIOL, V22, P2751, DOI 10.1128/MCB.22.8.2751-2760.2002; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; LYONS BA, 1993, BIOCHEMISTRY-US, V32, P7839, DOI 10.1021/bi00082a001; Matsuo H, 1996, J MAGN RESON SER B, V113, P91, DOI 10.1006/jmrb.1996.0161; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; McLean GW, 2003, EXPERT OPIN PHARMACO, V4, P227, DOI 10.1517/eoph.4.2.227.21093; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; NILGES M, 1997, FOLD DES, V2, P53; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rose DM, 2003, J IMMUNOL, V170, P5912, DOI 10.4049/jimmunol.170.12.5912; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schneider GB, 2002, CANCER, V95, P2508, DOI 10.1002/cncr.10992; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Tumbarello DA, 2002, FEBS LETT, V513, P114, DOI 10.1016/S0014-5793(01)03244-6; TURNER CE, 1994, J CELL SCI, V107, P1583; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; Yang DW, 1999, J BIOMOL NMR, V14, P333, DOI 10.1023/A:1008314803561; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	77	62	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8441	8451		10.1074/jbc.M309808200	http://dx.doi.org/10.1074/jbc.M309808200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662767	hybrid			2022-12-27	WOS:000189103300127
J	Horstman, AL; Bauman, SJ; Kuehn, MJ				Horstman, AL; Bauman, SJ; Kuehn, MJ			Lipopolysaccharide 3-deoxy-D-manno-octulosonic acid (Kdo) core determines bacterial association of secreted toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS LEUKOTOXIN; ESCHERICHIA-COLI; CHOLERA-TOXIN; OUTER-MEMBRANE; HAEMOPHILUS-INFLUENZAE; BORDETELLA-PERTUSSIS; EPITHELIAL-CELLS; RECEPTOR-BINDING; KINASE	In contrast to cholera toxin (CT), which is secreted solubly by Vibrio cholerae across the outer membrane, heat-labile enterotoxin (LT) is retained on the surface of enterotoxigenic Escherichia coli (ETEC) via an interaction with lipopolysaccharide (LPS). We examined the nature of the association between LT and LPS. Soluble LT binds to the surface of LPS deep-rough biosynthesis mutants but not to lipid A, indicating that only the Kdo (3-deoxy-D-manno-octulosonic acid) core is required for binding. Although capable of binding truncated LPS and Kdo, LT has a higher affinity for longer, more complete LPS species. A putative LPS binding pocket is proposed based on the crystal structure of the toxin. The ability to bind LPS and remain associated with the bacterial surface is not unique to LT, as CT also binds to E. coli LPS. However, neither LT nor CT is capable of binding to the surface of Vibrio. The core structures of Vibrio and E. coli LPS differ in that Vibrio contains a phosphorylated single Kdo-lipid A, and E. coli LPS contains unphosphorylated Kdo2-lipid A. We determined that the phosphate group on the Kdo core of Vibrio LPS prevents CT from binding, resulting in the secretion of soluble toxin. Because LT binds E. coli LPS, it remains associated with the extracellular bacterial surface and is released in association with outer membrane vesicles. We propose that difference in the extracellular fates of LT and CT contribute to the differences in disease caused by ETEC and Vibrio cholerae.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Kuehn, MJ (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	meta.kuehn@duke.edu	Kuehn, Meta/AAL-2950-2021	Kuehn, Meta/0000-0003-0519-3019	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI054606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066140] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angstrom J, 2000, J BIOL CHEM, V275, P3231, DOI 10.1074/jbc.275.5.3231; BACON KB, 1990, BIOCHEM BIOPH RES CO, V169, P1099, DOI 10.1016/0006-291X(90)92008-N; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; BOOTH BA, 1983, INFECT IMMUN, V42, P639, DOI 10.1128/IAI.42.2.639-644.1983; Bowman CC, 2001, INFECT IMMUN, V69, P1528, DOI 10.1128/IAI.69.3.1528-1535.2001; Brabetz W, 2000, J BIOL CHEM, V275, P34954, DOI 10.1074/jbc.M005204200; Cox AD, 1996, CARBOHYD RES, V290, P43, DOI 10.1016/0008-6215(96)00135-8; DALLAS WS, 1980, NATURE, V288, P499, DOI 10.1038/288499a0; DIRIENZO JM, 1978, ANNU REV BIOCHEM, V47, P481, DOI 10.1146/annurev.bi.47.070178.002405; FISHMAN PH, 1993, ADV LIPID RES, V25, P165; Francetic O, 2000, EMBO J, V19, P6697, DOI 10.1093/emboj/19.24.6697; FUKUTA S, 1988, INFECT IMMUN, V56, P1748, DOI 10.1128/IAI.56.7.1748-1753.1988; Garcia-Cuellar C, 2000, CAN J VET RES, V64, P88; GILL DM, 1979, J SUPRAMOL STR CELL, V10, P151, DOI 10.1002/jss.400100205; Giron JA, 1997, GENE, V192, P39, DOI 10.1016/S0378-1119(97)00039-5; HAVEKES L, 1977, J BACTERIOL, V129, P1; HIRST TR, 1984, P NATL ACAD SCI-BIOL, V81, P7752, DOI 10.1073/pnas.81.24.7752; HOLMGREN J, 1982, INFECT IMMUN, V38, P424, DOI 10.1128/IAI.38.2.424-433.1982; Horstman AL, 2000, J BIOL CHEM, V275, P12489, DOI 10.1074/jbc.275.17.12489; Horstman AL, 2002, J BIOL CHEM, V277, P32538, DOI 10.1074/jbc.M203740200; Isobe T, 1999, J BACTERIOL, V181, P2648, DOI 10.1128/JB.181.8.2648-2651.1999; Jobling MG, 1997, PLASMID, V38, P158, DOI 10.1006/plas.1997.1309; Kato S, 2002, MICROB PATHOGENESIS, V32, P1, DOI 10.1006/mpat.2001.0474; Keenan J, 2000, FEMS MICROBIOL LETT, V182, P259, DOI 10.1111/j.1574-6968.2000.tb08905.x; Kolling GL, 1999, APPL ENVIRON MICROB, V65, P1843; KUNKEL SL, 1979, INFECT IMMUN, V25, P586, DOI 10.1128/IAI.25.2.586-596.1979; LALLY ET, 1989, J BIOL CHEM, V264, P15451; LealBerumen I, 1996, J IMMUNOL, V156, P316; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Lencer WI, 1997, J BIOL CHEM, V272, P15562, DOI 10.1074/jbc.272.24.15562; Levine M M, 1983, Scand J Gastroenterol Suppl, V84, P121; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; Merritt EA, 1997, PROTEIN SCI, V6, P1516, DOI 10.1002/pro.5560060716; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MERRITT EA, 1994, FEBS LETT, V337, P88, DOI 10.1016/0014-5793(94)80635-7; MERRITT EA, 1994, MOL MICROBIOL, V13, P745, DOI 10.1111/j.1365-2958.1994.tb00467.x; MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9; Nashar TO, 1996, P NATL ACAD SCI USA, V93, P226, DOI 10.1073/pnas.93.1.226; OHTA H, 1993, INFECT IMMUN, V61, P4878, DOI 10.1128/IAI.61.11.4878-4884.1993; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Rodighiero C, 1999, J BIOL CHEM, V274, P3962, DOI 10.1074/jbc.274.7.3962; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sandkvist M, 1997, J BACTERIOL, V179, P6994, DOI 10.1128/jb.179.22.6994-7003.1997; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; Tauschek M, 2002, P NATL ACAD SCI USA, V99, P7066, DOI 10.1073/pnas.092152899; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; VERLINDE CLMJ, 1994, PROTEIN SCI, V3, P1670, DOI 10.1002/pro.5560031006; WAI SN, 1995, MICROBIOL IMMUNOL, V39, P451, DOI 10.1111/j.1348-0421.1995.tb02228.x; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; White KA, 1999, J BIOL CHEM, V274, P31391, DOI 10.1074/jbc.274.44.31391; YAMAMOTO T, 1987, J BACTERIOL, V169, P1352, DOI 10.1128/jb.169.3.1352-1357.1987; Zaretzky FR, 2002, MOL MICROBIOL, V45, P1589, DOI 10.1046/j.1365-2958.2002.03107.x	58	47	48	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8070	8075		10.1074/jbc.M308633200	http://dx.doi.org/10.1074/jbc.M308633200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660669	hybrid, Green Accepted			2022-12-27	WOS:000189103300086
J	Kim, H; Kwak, NJ; Lee, JY; Choi, BH; Lim, Y; Ko, YJ; Kim, YH; Huh, PW; Lee, KH; Rha, HK; Wang, YP				Kim, H; Kwak, NJ; Lee, JY; Choi, BH; Lim, Y; Ko, YJ; Kim, YH; Huh, PW; Lee, KH; Rha, HK; Wang, YP			Merlin neutralizes the inhibitory effect of Mdm2 on p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; CELL-GROWTH; C-ABL; ONCOPROTEIN MDM2; FEEDBACK LOOP; EXPRESSION; PROMOTES; MUTATION	The stability of p53 tumor suppressor is regulated by Mdm2 via the ubiquitination and proteasome-mediated proteolysis pathway. The c-Abl and PTEN tumor suppressors are known to stabilize p53 by blocking the Mdm2-mediated p53 degradation. This study investigated the correlation between p53 and merlin, a neurofibromatosis 2 ( NF2)-related tumor suppressor, in association with the Mdm2 function. The results showed that merlin increased the p53 stability by inhibiting the Mdm2-mediated degradation of p53, which accompanied the increase in the p53-dependent transcriptional activity. The stabilization of p53 by merlin appeared to be accomplished through Mdm2 degradation, and the N-terminal region of merlin was responsible for this novel activity. This study also showed that overexpression of merlin-induced apoptosis of cells depending preferentially on p53 in response to the serum starvation or a chemotherapeutic agent. These results suggest that merlin could be a positive regulator of p53 in terms of tumor suppressor activity, and provide the promising therapeutic means for treating tumors with non-functional merlin or Mdm2 overexpression.	Catholic Univ Korea, Neurosci Genome Res Ctr, Seoul 137701, South Korea; Catholic Univ Korea, Dept Occupat & Environm Med, Seoul 137701, South Korea; Catholic Univ Korea, Dept Pharmacol, Seoul 137701, South Korea; Catholic Univ Korea, Dept Thorac & Cardiovasc Surg, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Lee, KH (corresponding author), Catholic Univ Korea, Neurosci Genome Res Ctr, 505 Banpo Dong, Seoul 137701, South Korea.	Lkh@catholic.ac.kr	Lee, Joo-Yong/AAE-3388-2019	Lee, Joo-Yong/0000-0003-1049-6006				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Giovannini M, 2000, GENE DEV, V14, P1617; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Han JS, 2000, BIOCHEM BIOPH RES CO, V272, P525, DOI 10.1006/bbrc.2000.2801; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ikeda K, 1999, J NEUROSURG, V91, P85, DOI 10.3171/jns.1999.91.1.0085; Kim H, 2002, MOL CELLS, V14, P108; Kim JY, 2002, BIOCHEM BIOPH RES CO, V296, P1295, DOI 10.1016/S0006-291X(02)02077-6; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee H, 1998, J BIOL CHEM, V273, P19786, DOI 10.1074/jbc.273.31.19786; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHORT MP, 1994, NEUROFIBROMATOSES PA, P414; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VAN MEIR EG, 1994, CANCER RES, V54, P649; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	39	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7812	7818		10.1074/jbc.M305526200	http://dx.doi.org/10.1074/jbc.M305526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14679203	Green Published, hybrid			2022-12-27	WOS:000189103300056
J	McCarron, JG; MacMillan, D; Bradley, KN; Chalmers, S; Muir, TC				McCarron, JG; MacMillan, D; Bradley, KN; Chalmers, S; Muir, TC			Origin and mechanisms of Ca2+ waves in smooth muscle as revealed by localized photolysis of caged inositol 1,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; LUMINAL CA2+; RYANODINE RECEPTORS; SIGNAL-TRANSDUCTION; CALCIUM-RELEASE; GATED CHANNELS; CYTOSOLIC CA2+; TRISPHOSPHATE; INHIBITION; OSCILLATIONS	The cytosolic Ca2+ concentration ([Ca2+](c)) controls diverse cellular events via various Ca2+ signaling patterns; the latter are influenced by the method of cell activation. Here, in single-voltage clamped smooth muscle cells, sarcolemma depolarization generated uniform increases in [Ca2+](c) throughout the cell entirely by Ca2+ influx. On the other hand, the Ca2+ signal produced by InsP(3)-generating agonists was a propagated wave. Using localized uncaged InsP(3), the forward movement of the Ca2+ wave arose from Ca2+-induced Ca2+ release at the InsP(3) receptor (InsP(3)R) without ryanodine receptor involvement. The decline in [Ca2+](c) ( the back of the wave) occurred from a functional compartmentalization of the store, which rendered the site of InsP(3)-mediated Ca2+ release, and only this site, refractory to the phosphoinositide. The functional compartmentalization arose by a localized feedback deactivation of InsP(3) receptors produced by an increased [Ca2+](c) rather than a reduced luminal [Ca2+] or an increased cytoplasmic [InsP(3)]. The deactivation of the InsP(3) receptor was delayed in onset, compared with the time of the rise in [Ca2+](c), persisted (>30 s) even when [Ca2+](c) had regained resting levels, and was not prevented by kinase or phosphatase inhibitors. Thus different forms of cell activation generate distinct Ca2+ signaling patterns in smooth muscle. Sarcolemma Ca2+ entry increases [Ca2+](c) uniformly; agonists activate InsP(3)R and produce Ca2+ waves. Waves progress by Ca2+-induced Ca2+ release at InsP(3)R, and persistent Ca2+-dependent inhibition of InsP(3)R accounts for the decline in [Ca2+](c) at the back of the wave.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	McCarron, JG (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.	J.McCarron@bio.gla.ac.uk	Chalmers, Susan/C-1392-2009	Chalmers, Susan/0000-0002-8073-7576				Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; Ashby MC, 2002, J CELL BIOL, V158, P283, DOI 10.1083/jcb.200112025; BENHAM CD, 1986, J PHYSIOL-LONDON, V381, P385, DOI 10.1113/jphysiol.1986.sp016333; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; Boittin FX, 1999, AM J PHYSIOL-CELL PH, V277, pC139, DOI 10.1152/ajpcell.1999.277.1.C139; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; Bradley KN, 2002, J PHYSIOL-LONDON, V538, P465, DOI 10.1113/jphysiol.2001.013039; CHEEK TR, 1994, BIOCHEM J, V301, P879, DOI 10.1042/bj3010879; Cheng H, 1996, AM J PHYSIOL-CELL PH, V270, pC148; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Dreja K, 2001, BRIT J PHARMACOL, V132, P1957, DOI 10.1038/sj.bjp.0703986; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; Flynn ERM, 2001, J BIOL CHEM, V276, P36411, DOI 10.1074/jbc.M104308200; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Gordienko DV, 2002, J PHYSIOL-LONDON, V542, P743, DOI 10.1113/jphysiol.2001.015966; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; Heppner TJ, 2002, AM J PHYSIOL-HEART C, V283, pH2169, DOI 10.1152/ajpheart.00603.2002; IINO M, 1994, MOL CELL ENDOCRINOL, V98, P141, DOI 10.1016/0303-7207(94)90132-5; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IINO M, 1994, EMBO J, V13, P5026, DOI 10.1002/j.1460-2075.1994.tb06831.x; ILYIN V, 1994, J PHYSIOL-LONDON, V477, P503, DOI 10.1113/jphysiol.1994.sp020211; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; Lansley AB, 1999, BIOPHYS J, V77, P629, DOI 10.1016/S0006-3495(99)76919-5; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; Lukyanenko V, 1999, J PHYSIOL-LONDON, V518, P173, DOI 10.1111/j.1469-7793.1999.0173r.x; Mackenzie L, 2002, J PHYSIOL-LONDON, V541, P395, DOI 10.1113/jphysiol.2001.013411; Marchant JS, 1998, BIOCHEMISTRY-US, V37, P11524, DOI 10.1021/bi980808k; McCarron JG, 2002, J CELL SCI, V115, P2207; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; MCCARRON JG, 1992, NATURE, V357, P74, DOI 10.1038/357074a0; McCarron JG, 2000, J PHYSIOL-LONDON, V525, P113, DOI 10.1111/j.1469-7793.2000.00113.x; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; NUNN DL, 1992, MOL PHARMACOL, V41, P115; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; Parker I, 1996, J PHYSIOL-LONDON, V491, P663, DOI 10.1113/jphysiol.1996.sp021247; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Sanders KM, 2001, J APPL PHYSIOL, V91, P1438, DOI 10.1152/jappl.2001.91.3.1438; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; TAKEI K, 1992, J NEUROSCI, V12, P489; TOESCU EC, 1995, AM J PHYSIOL-GASTR L, V269, pG173, DOI 10.1152/ajpgi.1995.269.2.G173; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; Wier WG, 2004, REV PHYSIOL BIOCH P, V150, P91, DOI 10.1007/s10254-003-0019-8; ZHOLOS AV, 1994, J PHYSIOL-LONDON, V481, P97, DOI 10.1113/jphysiol.1994.sp020421	58	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8417	8427		10.1074/jbc.M311797200	http://dx.doi.org/10.1074/jbc.M311797200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660609	hybrid			2022-12-27	WOS:000189103300125
J	Nebohacova, M; Maslov, DA; Falick, AM; Simpson, L				Nebohacova, M; Maslov, DA; Falick, AM; Simpson, L			The effect of RNA interference down-regulation of RNA editing 3 '-terminal uridylyl transferase (TUTase) 1 on mitochondrial de novo protein synthesis and stability of respiratory complexes in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; LEISHMANIA-TARENTOLAE; MESSENGER-RNA; KINETOPLASTID MITOCHONDRIA; TRANSLATION PRODUCTS; ALTERNATIVE OXIDASE; GUIDE RNAS; YEAST; IDENTIFICATION; COMPONENTS	Inhibition of RNA editing by down-regulation of expression of the mitochondrial RNA editing TUTase 1 by RNA interference had profound effects on kinetoplast biogenesis in Trypanosoma brucei procyclic cells. De novo synthesis of the apocytochrome b and cytochrome oxidase subunit I proteins was no longer detectable after 3 days of RNAi. The effect on protein synthesis correlated with a decline in the levels of the assembled mitochondrial respiratory complexes III and IV, and also cyanide-sensitive oxygen uptake. The steady-state levels of nuclear-encoded subunits of complexes III and IV were also significantly decreased. Because the levels of the corresponding mRNAs were not affected, the observed effect was likely due to an increased turnover of these imported mitochondrial proteins. This induced protein degradation was selective for components of complexes III and IV, because little effect was observed on components of the F-1 . F-0-ATPase complex and on several other mitochondrial proteins.	Univ Calif Los Angeles, Howard Hughes Med Inst, MacDonald Res Labs 6780, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Mass Spectrometry Lab, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Riverside; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Simpson, L (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, MacDonald Res Labs 6780, 675 Charles Young Dr S, Los Angeles, CA 90095 USA.	simpson@kdna.ucla.edu	Nebohacova, Martina/I-3937-2014		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009102, R37AI009102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; Aphasizhev R, 2003, P NATL ACAD SCI USA, V100, P10617, DOI 10.1073/pnas.1833120100; Aphasizhev R, 2003, RNA, V9, P62, DOI 10.1261/rna.2134303; Aphasizhev R, 2003, EMBO J, V22, P913, DOI 10.1093/emboj/cdg083; Aphasizhev R, 2002, CELL, V108, P637, DOI 10.1016/S0092-8674(02)00647-5; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1983, NUCLEIC ACIDS RES, V11, P6925, DOI 10.1093/nar/11.20.6925; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; Bienvenut WV, 2002, PROTEOMICS, V2, P868, DOI 10.1002/1615-9861(200207)2:7<868::AID-PROT868>3.0.CO;2-D; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Bringaud F, 1995, MOL BIOCHEM PARASIT, V74, P119, DOI 10.1016/0166-6851(95)02486-7; BRINGAUD F, 1995, MOL BIOCHEM PARASIT, V71, P65, DOI 10.1016/0166-6851(95)00023-T; Brown BSV, 2001, MOL BIOCHEM PARASIT, V113, P289, DOI 10.1016/S0166-6851(01)00233-X; BRUN R, 1979, ACTA TROP, V36, P289; Chaudhuri M, 1998, MOL BIOCHEM PARASIT, V95, P53, DOI 10.1016/S0166-6851(98)00091-7; Chaudhuri M, 1996, MOL BIOCHEM PARASIT, V83, P125, DOI 10.1016/S0166-6851(96)02754-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Jong L, 2000, FEBS LETT, V483, P62, DOI 10.1016/S0014-5793(00)02086-X; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; Estevez AM, 1999, MOL BIOCHEM PARASIT, V103, P251, DOI 10.1016/S0166-6851(99)00139-5; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1997, FEBS LETT, V412, P410, DOI 10.1016/S0014-5793(97)00799-0; Grivell LA, 1999, FEBS LETT, V452, P57, DOI 10.1016/S0014-5793(99)00532-3; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; Horvath A, 2000, J BIOL CHEM, V275, P17160, DOI 10.1074/jbc.M907246199; Horvath A, 2000, SCIENCE, V287, P1639, DOI 10.1126/science.287.5458.1639; Horvath A, 2002, J BIOL CHEM, V277, P7222, DOI 10.1074/jbc.M109715200; Horvath A, 2000, EXP PARASITOL, V96, P160, DOI 10.1006/expr.2000.4564; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; Kable ML, 1997, TRENDS BIOCHEM SCI, V22, P162, DOI 10.1016/S0968-0004(97)01041-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARRES CAM, 1977, BIOCHIM BIOPHYS ACTA, V462, P531, DOI 10.1016/0005-2728(77)90099-8; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; Maslov DA, 2002, MOL BIOCHEM PARASIT, V125, P113, DOI 10.1016/S0166-6851(02)00235-9; Panigrahi AK, 2003, J AM SOC MASS SPECTR, V14, P728, DOI 10.1016/S1044-0305(03)00126-0; Panigrahi AK, 2003, RNA, V9, P484, DOI 10.1261/rna.2194603; PRIEST JW, 1993, BIOCHIM BIOPHYS ACTA, V1144, P229, DOI 10.1016/0005-2728(93)90178-I; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schnaufer A, 2003, MOL CELL, V12, P307, DOI 10.1016/S1097-2765(03)00286-7; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Simpson L, 1998, NUCLEIC ACIDS RES, V26, P170, DOI 10.1093/nar/26.1.170; Stuart K, 2002, MOL MICROBIOL, V45, P591, DOI 10.1046/j.1365-2958.2002.03028.x; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; Tielens AGM, 1998, PARASITOL TODAY, V14, P265, DOI 10.1016/S0169-4758(98)01263-0	49	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7819	7825		10.1074/jbc.M311360200	http://dx.doi.org/10.1074/jbc.M311360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681226	hybrid			2022-12-27	WOS:000189103300057
J	Arimura, T; Hayashi, T; Terada, H; Lee, SY; Zhou, Q; Takahashi, M; Ueda, K; Nouchi, T; Hohda, S; Shibutani, M; Hirose, M; Chen, J; Park, JE; Yasunami, M; Hayashi, H; Kimura, A				Arimura, T; Hayashi, T; Terada, H; Lee, SY; Zhou, Q; Takahashi, M; Ueda, K; Nouchi, T; Hohda, S; Shibutani, M; Hirose, M; Chen, J; Park, JE; Yasunami, M; Hayashi, H; Kimura, A			A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-DOMAIN; HEART-FAILURE; GENE; PDZ; TRANSLOCATION; EPSILON; MUSCLE; IDENTIFICATION; PHOSPHOLAMBAN; LOCALIZATION	Dilated cardiomyopathy is characterized by ventricular dilation with systolic dysfunction of cardiac muscle. Recent genetic studies have revealed that mutations in genes for cytoskeleton proteins distributed in the Z-disc and/or intercalated discs of the cardiac muscle are major predictors of cardiomyopathy. However, as mutations in these genes can account for only a part of the patient population, there should be another disease-causing gene(s) for cardiomyopathy. Cypher/ZASP appears to be an ideal candidate for the cardiomyopathy causative gene, because Cypher/ZASP encodes a Z-disc associated protein, and recent studies have demonstrated that Cypher/ZASP knock-out mice develop cardiomyopathy. In this study, we searched for sequence variations in Cypher/ZASP in 96 unrelated Japanese patients with dilated cardiomyopathy. A D626N mutation located within the third LIM domain was identified in a familial case but not found in the unrelated controls. A family study of the patient showed that all affected siblings tested had the same mutation. Clinical information of the affected family members suggested that the mutation was associated with late onset cardiomyopathy. To reveal the biochemical changes due to the mutation, we performed a yeast two-hybrid assay and a pull-down assay. It was demonstrated by both assays that the D626N mutation of Cypher/ZASP increased the affinity of the LIM domain for protein kinase C, suggesting a novel biochemical mechanism of the pathogenesis of dilated cardiomyopathy.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pathogenesis, Chiyoda Ku, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Lab Genome Divers, Sch Biomed Sci, Tokyo 1010062, Japan; Natl Inst Hlth Sci, Div Pathol, Tokyo 1588501, Japan; Hamamatsu Univ Sch Med, Dept Internal Med 3, Hamamatsu, Shizuoka 4313192, Japan; Samsung Med Ctr, Div Cardiol, Seoul 135230, South Korea; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); National Institute of Health Sciences - Japan; Hamamatsu University School of Medicine; Sungkyunkwan University (SKKU); Samsung Medical Center; University of California System; University of California San Diego; University of California System; University of California San Diego	Kimura, A (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pathogenesis, Chiyoda Ku, 2-3-10 Kandasurugadai, Tokyo 1010062, Japan.	akitis@mri.tmd.ac.jp	Shibutani, Makoto/AGK-2801-2022; Chen, Ju/E-5579-2011; Arimura, Takuro/AAA-2745-2022; Shibutani, Makoto/C-2510-2013; Kimura, Akinori/I-5989-2018	Shibutani, Makoto/0000-0003-3417-9697; Arimura, Takuro/0000-0002-0929-3140; Kimura, Akinori/0000-0002-4933-2132	NHLBI NIH HHS [R01 HL066100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Gerull B, 2002, NAT GENET, V30, P201, DOI 10.1038/ng815; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Haghighi K, 2003, J CLIN INVEST, V111, P869, DOI 10.1172/JCI200317892; Huang CQ, 2003, J BIOL CHEM, V278, P7360, DOI 10.1074/jbc.M211875200; Itoh-Satoh M, 2002, BIOCHEM BIOPH RES CO, V291, P385, DOI 10.1006/bbrc.2002.6448; Jalili T, 1999, AM J PHYSIOL-HEART C, V277, pH2298, DOI 10.1152/ajpheart.1999.277.6.H2298; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/S0092-8674(02)01226-6; Kurokawa M, 1998, NAT PROD LETT, V12, P35, DOI 10.1080/10575639808048868; Li DX, 1999, CIRCULATION, V100, P461, DOI 10.1161/01.CIR.100.5.461; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Olson TM, 2001, J MOL CELL CARDIOL, V33, P723, DOI 10.1006/jmcc.2000.1339; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Olson TM, 2002, CIRCULATION, V105, P431, DOI 10.1161/hc0402.102930; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; Passier R, 2000, MECH DEVELOP, V92, P277, DOI 10.1016/S0925-4773(99)00330-5; Robia SL, 2001, BIOPHYS J, V80, P2140, DOI 10.1016/S0006-3495(01)76187-5; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; STEINBERG SF, 1995, J MOL CELL CARDIOL, V27, P141, DOI 10.1016/S0022-2828(08)80014-4; Towbin J A, 2000, Curr Cardiol Rep, V2, P475, DOI 10.1007/s11886-000-0063-9; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; WU RY, 1994, J BIOL CHEM, V269, P25085; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092	37	113	120	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6746	6752		10.1074/jbc.M311849200	http://dx.doi.org/10.1074/jbc.M311849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660611	hybrid			2022-12-27	WOS:000188969200067
J	Dou, SX; Wang, PY; Xu, HQ; Xi, XG				Dou, SX; Wang, PY; Xu, HQ; Xi, XG			The DNA binding properties of the Escherichia coli RecQ helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; WERNER-SYNDROME PROTEIN; SYNDROME GENE-PRODUCT; NUCLEIC-ACID INTERACTIONS; TOPOISOMERASE-III-ALPHA; FLUORESCENCE ANISOTROPY; EQUILIBRIUM BINDING; REP HELICASE; ILLEGITIMATE RECOMBINATION; REPLICATION CHECKPOINT	The RecQ helicase family is highly conserved from bacteria to men and plays a conserved role in the preservation of genome integrity. Its deficiency in human cells leads to a marked genomic instability that is associated with premature aging and cancer. To determine the thermodynamic parameters for the interaction of Escherichia coli RecQ helicase with DNA, equilibrium binding studies have been performed using the thermodynamic rigorous fluorescence titration technique. Steady-state fluorescence anisotropy measurements of fluorescein-labeled oligonucleotides revealed that RecQ helicase bound to DNA with an apparent binding stoichiometry of 1 protein monomer/10 nucleotides. This stoichiometry was not altered in the presence of AMPPNP (adenosine 5'-(beta,gamma-imido) triphosphate) or ADP. Analyses of RecQ helicase interactions with oligonucleotides of different lengths over a wide range of pH, NaCl, and nucleic acid concentrations indicate that the RecQ helicase has a single strong DNA binding site with an association constant at 25 degreesC of K = 6.7 +/- 0.95 x 10(6) M-1 and a cooperativity parameter of omega = 25.5 +/- 1.2. Both single-stranded DNA and double-stranded DNA bind competitively to the same site. The intrinsic affinities are salt-dependent, and the formation of DNA-helicase complex is accompanied by a net release of 3-4 ions. Allosteric effects of nucleotide cofactors on RecQ binding to DNA were observed only for single-stranded DNA in the presence of 1.5 mm AMPPNP, whereas both AMPPNP and ADP had no detectable effect on double-stranded DNA binding over a large range of nucleotide cofactor concentrations.	Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, F-94235 Cachan, France; Chinese Acad Sci, Inst Phys, Lab Soft Matter Phys, Beijing 100080, Peoples R China	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Chinese Academy of Sciences; Institute of Physics, CAS	Xi, XG (corresponding author), Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, 61 Ave President Wilson, F-94235 Cachan, France.	xi@lbpa.ens-cachan.fr	王, 鹏业/A-9811-2012; Xi, Xu Guang/AAK-4511-2020; Dou, Shi Xue/D-5179-2012	Dou, Shi Xue/0000-0003-3824-7693; Wang, Peng-Ye/0000-0002-9765-0610; Dou, Shuo-Xing/0000-0002-7201-2081				Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Bujalowski W, 2000, BIOCHEMISTRY-US, V39, P2106, DOI 10.1021/bi992413m; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; BUJALOWSKI W, 1987, J MOL BIOL, V195, P897, DOI 10.1016/0022-2836(87)90493-1; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN MA, 1978, PROG EXP TUMOR RES, V21, P72; Frei C, 2000, J CELL SCI, V113, P2641; Frei C, 2000, GENE DEV, V14, P81; Freire R, 2001, NUCLEIC ACIDS RES, V29, P3172, DOI 10.1093/nar/29.15.3172; Gourves AS, 2000, J BIOL CHEM, V275, P10864, DOI 10.1074/jbc.275.15.10864; Hanada K, 2000, P NATL ACAD SCI USA, V97, P5989, DOI 10.1073/pnas.100101297; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Jezewska MJ, 1996, J BIOL CHEM, V271, P4261; Jezewska MJ, 2000, BIOCHEMISTRY-US, V39, P10454, DOI 10.1021/bi001113y; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KOPELMAN M, 1976, BIOCHIM BIOPHYS ACTA, V439, P449, DOI 10.1016/0005-2795(76)90082-9; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAHUE EE, 1990, J BACTERIOL, V172, P1385, DOI 10.1128/jb.172.3.1385-1391.1990; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOHMAN TM, 1991, METHOD ENZYMOL, V208, P258; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; Morris PD, 2001, J BIOL CHEM, V276, P19691, DOI 10.1074/jbc.M010928200; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; Ozers MS, 1997, J BIOL CHEM, V272, P30405, DOI 10.1074/jbc.272.48.30405; PERRINO FW, 1990, MUTAT RES, V236, P289, DOI 10.1016/0921-8777(90)90012-T; Preugschat F, 2000, BIOCHEMISTRY-US, V39, P5174, DOI 10.1021/bi9923860; Sevenich FW, 1998, NUCLEIC ACIDS RES, V26, P1373, DOI 10.1093/nar/26.6.1373; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; Wu L, 2002, NUCLEIC ACIDS RES, V30, P4823, DOI 10.1093/nar/gkf611; Wu X, 2001, NUCLEIC ACIDS RES, V29, P1765, DOI 10.1093/nar/29.8.1765; Xu H, 2001, BIOCHEMISTRY-US, V40, P7651, DOI 10.1021/bi010116n; Xu HQ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng070; Xu HQ, 2003, J BIOL CHEM, V278, P34925, DOI 10.1074/jbc.M303581200; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	52	50	65	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6354	6363		10.1074/jbc.M311272200	http://dx.doi.org/10.1074/jbc.M311272200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665634	hybrid			2022-12-27	WOS:000188969200020
J	Lannon, CL; Martin, MJ; Tognon, CE; Jin, W; Kim, SJ; Sorensen, PHB				Lannon, CL; Martin, MJ; Tognon, CE; Jin, W; Kim, SJ; Sorensen, PHB			A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1 - An essential interaction for transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; GENE FUSION; CONGENITAL FIBROSARCOMA; PROSTATE-CANCER; NEUROTROPHIN RECEPTORS; IRS-1 PHOSPHORYLATION; MESOBLASTIC NEPHROMA; MYELOGENOUS LEUKEMIA	Receptor tyrosine kinases are integral components of cellular signaling pathways and are frequently deregulated in malignancies. The NTRK family of neurotrophin receptors mediate neuronal cell survival and differentiation, but altered NTRK signaling has also been implicated in oncogenesis. The ETV6-NTRK3 (EN) gene fusion occurs in human pediatric spindle cell sarcomas and secretory breast carcinoma, and encodes the oligomerization domain of the ETV6 transcription factor fused to the protein-tyrosine kinase domain of NTRK3. The EN protein functions as a constitutively active protein-tyrosine kinase with potent transforming activity in multiple cell lineages, and EN constitutively activates both the Ras-MAPK and phosphatidylinositol 3-kinase-Akt pathways. EN transformation is associated with constitutive tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1). Further, IRS-1 functions as the adaptor protein linking EN to downstream signaling pathways. However, the exact nature of the EN-IRS-1 interaction remains unknown. We now demonstrate that EN specifically binds the phosphotyrosine binding domain of IRS-1 via an interaction at the C terminus of EN. An EN mutant lacking the C-terminal 19 amino acids does not bind IRS-1 and lacks transforming ability. Moreover, expression of an IRS-1 polypeptide containing the phosphotyrosine binding domain acts in a dominant negative manner to inhibit EN transformation, and overexpression of IRS-1 potentiates EN transforming activity. These findings indicate that EN-IRS-1 complex formation through the NTRK3 C terminus is essential for EN transformation.	British Columbia Res Inst Childrens & Womens Hlth, Dept Pathol, Vancouver, BC V5Z 4H4, Canada; British Columbia Res Inst Childrens & Womens Hlth, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	University of British Columbia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sorensen, PHB (corresponding author), British Columbia Res Inst Childrens & Womens Hlth, Dept Pathol, Rm 3082,950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	psor@interchange.ubc.ca		, Matthew/0000-0002-8948-961X	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Chang Q, 2002, CANCER RES, V62, P6035; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GUITON M, 1995, J BIOL CHEM, V270, P20384, DOI 10.1074/jbc.270.35.20384; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; Hisaoka M, 2002, J PATHOL, V197, P661, DOI 10.1002/path.1138; Ito T, 1996, MOL CELL BIOL, V16, P943; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Meshinchi S, 2003, BLOOD, V102, P1474, DOI 10.1182/blood-2003-01-0137; Miknyoczki SJ, 1999, INT J CANCER, V81, P417, DOI 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6; Miranda C, 2001, J CELL PHYSIOL, V186, P35; Morrison KB, 2002, ONCOGENE, V21, P5684, DOI 10.1038/sj.onc.1205669; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; NALDINI L, 1986, MOL CELL BIOL, V6, P1803, DOI 10.1128/MCB.6.5.1803; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Pahlman S, 1996, MOL MED TODAY, V2, P432, DOI 10.1016/1357-4310(96)84847-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Tanaka S, 1996, CANCER RES, V56, P3391; Tognon C, 2001, CANCER RES, V61, P8909; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Traina F, 2003, FEBS LETT, V535, P17, DOI 10.1016/S0014-5793(02)03845-0; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Walch ET, 1999, CLIN EXP METASTAS, V17, P307, DOI 10.1023/A:1006652605568; Weeraratna AT, 2000, PROSTATE, V45, P140, DOI 10.1002/1097-0045(20001001)45:2<140::AID-PROS8>3.0.CO;2-#; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300	52	52	53	5	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6225	6234		10.1074/jbc.M307388200	http://dx.doi.org/10.1074/jbc.M307388200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14668342	hybrid			2022-12-27	WOS:000188969200006
J	Cook, JG; Chasse, DAD; Nevins, JR				Cook, JG; Chasse, DAD; Nevins, JR			The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; EUKARYOTIC DNA-REPLICATION; NUCLEOTIDE-BINDING SITE; LICENSING FACTOR CDT1; S-PHASE; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; FISSION YEAST; BUDDING YEAST; MCM-PROTEINS	Chromosomal DNA replication requires the recruitment of the six-subunit minichromosome maintenance (Mcm) complex to chromatin through the action of Cdc6 and Cdt1. Although considerable work has described the functions of Cdc6 and Cdt1 in yeast and biochemical systems, evidence that their mammalian counterparts are subject to distinct regulation suggests the need to further explore the molecular relationships involving Cdc6 and Cdt1. Here we demonstrate that Cdc6 and Cdt1 are mutually dependent on one another for loading Mcm complexes onto chromatin in mammalian cells. The association of Cdt1 with Mcm2 is regulated by cell growth. Mcm2 prepared from quiescent cells associates very weakly with Cdt1, whereas Mcm2 from serum-stimulated cells associates with Cdt1 much more efficiently. Cdc6, which normally accumulates as cells progress from quiescence into G(1), is capable of inducing the binding of Mcm2 to Cdt1 when ectopically expressed in quiescent cells. We further show that Cdc6 physically associates with Cdt1 via its N-terminal noncatalytic domain, a region we had previously shown to be essential for Cdc6 function. Cdt1 activity is inhibited by the geminin protein, and we provide evidence that the mechanism of this inhibition involves blocking the binding of Cdt1 to both Mcm2 and Cdc6. These results identify novel molecular functions for both Cdc6 and geminin in controlling the association of Cdt1 with other components of the replication apparatus and indicate that the association of Cdt1 with the Mcm complex is controlled as cells exit and reenter the cell cycle.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Mol Genet & Microbiol, Box 3054, Durham, NC 27710 USA.	jnevins@duke.edu		Cook, Jeanette/0000-0003-0849-7405	NCI NIH HHS [1 K01 CA094907-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA094907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Berger C, 1999, CYTOGENET CELL GENET, V86, P307, DOI 10.1159/000015324; Blow JJ, 2001, EMBO J, V20, P3293, DOI 10.1093/emboj/20.13.3293; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DELMOLINO LM, 2001, J BIOL CHEM, V9, P9; Devault A, 2002, CURR BIOL, V12, P689, DOI 10.1016/S0960-9822(02)00768-6; Diffley JFX, 2002, J CELL SCI, V115, P869; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gopalakrishnan V, 2001, P NATL ACAD SCI USA, V98, P13114, DOI 10.1073/pnas.221467598; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Li CJ, 2002, MOL CELL BIOL, V22, P105, DOI 10.1128/MCB.22.1.105-116.2002; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Luo KQ, 2003, BIOCHEM BIOPH RES CO, V306, P851, DOI 10.1016/S0006-291X(03)01082-9; Madine MA, 2000, J STRUCT BIOL, V129, P198, DOI 10.1006/jsbi.2000.4218; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Pelizon C, 2003, TRENDS CELL BIOL, V13, P110, DOI 10.1016/S0962-8924(03)00024-2; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Rialland M, 2002, J CELL SCI, V115, P1435; Ritzi M, 2000, GENE, V245, P13, DOI 10.1016/S0378-1119(00)00020-2; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SCHULTE D, 1995, J CELL SCI, V108, P1381; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takisawa H, 2000, CURR OPIN CELL BIOL, V12, P690, DOI 10.1016/S0955-0674(00)00153-8; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tatsumi Y, 2003, J BIOL CHEM, V278, P41528, DOI 10.1074/jbc.M307534200; TODOROV IT, 1994, J CELL SCI, V107, P253; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wang B, 1999, J BIOL CHEM, V274, P8291, DOI 10.1074/jbc.274.12.8291; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Whittaker AJ, 2000, GENE DEV, V14, P1765; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648	66	83	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9625	9633		10.1074/jbc.M311933200	http://dx.doi.org/10.1074/jbc.M311933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672932	hybrid			2022-12-27	WOS:000189265900130
J	Fujimoto, Z; Kaneko, S; Kuno, A; Kobayashi, H; Kusakabe, I; Mizuno, H				Fujimoto, Z; Kaneko, S; Kuno, A; Kobayashi, H; Kusakabe, I; Mizuno, H			Crystal structures of decorated xylooligosaccharides bound to a family 10 xylanase from Streptomyces olivaceoviridis E-86	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F/10 XYLANASE; BINDING DOMAIN; BETA-XYLANASE; MODULE; CEX; SPECIFICITY; SEQUENCE; CLASSIFICATION; ASSOCIATION; MECHANISMS	The family 10 xylanase from Streptomyces olivaceoviridis E-86 (SoXyn10A) consists of a GH10 catalytic domain, which is joined by a Gly/Pro-rich linker to a family 13 carbohydrate-binding module (CBM13) that interacts with xylan. To understand how GH10 xylanases and CBM13 recognize decorated xylans, the crystal structure of SoXyn10A was determined in complex with alpha-L-arabinofuranosyl- and 4-O-methyl-alpha-D-glucuronosyl-xylooligosaccharides. The bound sugars were observed in the subsites of the catalytic cleft and also in subdomains alpha and gamma of CBM13. The data reveal that the binding mode of the oligosaccharides in the active site of the catalytic domain is entirely consistent with the substrate specificity and, in conjunction with the accompanying paper (Pell, G., Taylor, E. J., Gloster, T. M., Turkenburg, J. P., Fontes, C. M. G. A., Ferreira, L. M. A., Nagy, T., Clark, S. J., Davies, G. J., and Gilbert, H. J. ( 2004) J. Biol. Chem. 279, 9597 - 9605), demonstrate that the accommodation of the side chains in decorated xylans is conserved in GH10 xylanases of SoXyn10A against arabinoglucuronoxylan. CBM13 was shown to bind xylose or xylooligosaccharides reversibly by using nonsymmetric sugars as the ligands. The independent multiple sites in CBM13 may increase the probability of substrate binding.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; Natl Food Res Inst, Biol Funct Div, Tsukuba, Ibaraki 3058642, Japan; Yamagata Univ, Dept Mat & Biol Chem, Yamagata 9908560, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	National Institute of Agrobiological Sciences - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; Yamagata University; University of Tsukuba	Fujimoto, Z (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, 2-1-2 Kannondai, Tsukuba, Ibaraki 3058602, Japan.	zui@affrc.go.jp	Kuno, Atsushi/M-2151-2018	Kuno, Atsushi/0000-0002-6147-6171; Fujimoto, Zui/0000-0002-3551-6854				Birsan C, 1998, BIOCHEM SOC T, V26, P156, DOI 10.1042/bst0260156; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2000, BIOCHEM J, V350, P933, DOI 10.1042/0264-6021:3500933; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fujimoto Z, 1997, J BIOCHEM-TOKYO, V121, P826; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; Gilbert HJ, 2002, ROY SOC CH, P89, DOI 10.1039/9781847550323-00089; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Kaneko S, 1999, FEBS LETT, V460, P61, DOI 10.1016/S0014-5793(99)01318-6; Kaneko S, 2000, PROTEIN ENG, V13, P873, DOI 10.1093/protein/13.12.873; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuno A, 2000, FEBS LETT, V482, P231, DOI 10.1016/S0014-5793(00)02067-6; Kuno A, 1999, FEBS LETT, V450, P299, DOI 10.1016/S0014-5793(99)00498-6; Kuno A, 1998, J FERMENT BIOENG, V86, P434, DOI 10.1016/S0922-338X(98)80147-5; KUSAKABE I, 1983, AGR BIOL CHEM TOKYO, V47, P2713, DOI 10.1080/00021369.1983.10866038; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Notenboom V, 2002, BIOCHEMISTRY-US, V41, P4246, DOI 10.1021/bi015865j; Notenboom V, 1998, NAT STRUCT BIOL, V5, P812, DOI 10.1038/1852; Pell G, 2004, J BIOL CHEM, V279, P9597, DOI 10.1074/jbc.M312278200; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; Scharpf M, 2002, BIOCHEMISTRY-US, V41, P4255, DOI 10.1021/bi015866b; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; Yoshida S, 1998, J WOOD SCI, V44, P457, DOI 10.1007/BF00833410; YOSHIDA S, 1994, BIOSCI BIOTECH BIOCH, V58, P2068, DOI 10.1271/bbb.58.2068; YOSHIDA S, 1990, AGR BIOL CHEM TOKYO, V54, P449, DOI 10.1080/00021369.1990.10869948	38	67	68	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9606	9614		10.1074/jbc.M312293200	http://dx.doi.org/10.1074/jbc.M312293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670957	hybrid			2022-12-27	WOS:000189265900128
J	Milakovic, T; Tucholski, J; McCoy, E; Johnson, GVW				Milakovic, T; Tucholski, J; McCoy, E; Johnson, GVW			Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; RETINOBLASTOMA PROTEIN; NUCLEAR-LOCALIZATION; IN-SITU; APOPTOSIS; CYCLE; CALCIUM; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION	Tissue transglutaminase (tTG) is a unique member of the transglutaminase family as it is both a transamidating enzyme and a GTPase. In the cell tTG is mostly cytosolic, however it is also found in the nucleus and associated with the plasma membrane. tTG can be proapoptotic, however anti-apoptotic activities of the enzyme have also been reported. To determine how the intracellular localization and transamidating activity of tTG modulates its effects on apoptosis, HEK293 cells were transiently transfected with tTG or [C277S] tTG ( which lacks transamidating activity) constructs that were targeted to different intracellular compartments. Apoptosis was induced by thapsigargin treatment, which results in increased intracellular calcium concentrations. Cytosolic tTG was pro-apoptotic, while nuclear localization of [C277S] tTG attenuated apoptosis. Membrane-targeted tTG had neither pro- nor anti-apoptotic functions. This finding indicates for the first time that intracellular localization is an important determinant of the effect of tTG on apoptosis. Previous studies have suggested that tTG may modulate retinoblastoma (Rb) protein, an important suppressor of apoptosis. tTG interacted with Rb and after induction of apoptosis, the interaction of nuclear-targeted [ C277S] tTG with Rb was increased significantly concomitant with an attenuation of apoptosis. In contrast, the interaction of nuclear-targeted tTG with Rb was significantly decreased and apoptosis was not attenuated. These data suggest that tTG protects cells against apoptosis in response to stimuli that do not result in increased transamidating activity by translocating to the nucleus, and that complexing with Rb may be an important aspect of the protective effects of tTG.	Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama Birmingham, Dept Psychiat, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NATIONAL INSTITUTE ON AGING [R01AG012396] Funding Source: NIH RePORTER; NIA NIH HHS [AG12396] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; An B, 1996, CANCER RES, V56, P438; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Claudio P, 2002, GENOME BIOL, V3; DASCALU A, 1995, J PHYSIOL-LONDON, V486, P97, DOI 10.1113/jphysiol.1995.sp020793; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FISCHERFANTUZZI L, 1988, MOL CELL BIOL, V8, P5495, DOI 10.1128/MCB.8.12.5495; FURUYA Y, 1994, CANCER RES, V54, P6167; GREENBERG CS, 1987, BLOOD, V70, P702; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Hettasch JM, 1996, LAB INVEST, V75, P637; IWAKI T, 1994, AM J PATHOL, V145, P776; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; JONES KT, 1994, EXP CELL RES, V210, P71, DOI 10.1006/excr.1994.1011; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kim JH, 2001, ANN NY ACAD SCI, V928, P65; Lesort M, 1999, J NEUROCHEM, V73, P2018; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; MACCIONI RB, 1986, MOL CELL BIOCHEM, V69, P161; Marchenko SM, 2000, EXP PHYSIOL, V85, P151, DOI 10.1017/S0958067000019436; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nath R, 1997, BIOCHEM MOL BIOL INT, V43, P197; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Peng XJ, 1999, FEBS LETT, V446, P35, DOI 10.1016/S0014-5793(99)00018-6; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLIFE CW, 1985, ARCH BIOCHEM BIOPHYS, V241, P329, DOI 10.1016/0003-9861(85)90554-5; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; TAKEUCHI Y, 1992, FEBS LETT, V307, P177, DOI 10.1016/0014-5793(92)80762-6; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; Tong JF, 1999, BIOCHEM J, V343, P39, DOI 10.1042/0264-6021:3430039; Tucholski J, 1999, J NEUROCHEM, V73, P1871; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; YEE AS, 1998, FRONT BIOSCI, V3, P532; Yen A, 1997, EUR J CELL BIOL, V72, P159; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222	63	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8715	8722		10.1074/jbc.M308479200	http://dx.doi.org/10.1074/jbc.M308479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670969	hybrid			2022-12-27	WOS:000189265900024
J	Reilly, KB; Srinivasan, S; Hatley, ME; Patricia, MK; Lannigan, J; Bolick, DT; Vandenhoff, G; Pei, H; Natarajan, R; Nadler, JL; Hedrick, CC				Reilly, KB; Srinivasan, S; Hatley, ME; Patricia, MK; Lannigan, J; Bolick, DT; Vandenhoff, G; Pei, H; Natarajan, R; Nadler, JL; Hedrick, CC			12/15-lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE ADHESION; GENE DISRUPTION; INBRED STRAINS; MESSENGER-RNA; 15-LIPOXYGENASE; EXPRESSION; OXIDATION; ACID; LDL	We have shown that the 12/15-lipoxygenase (12/15-LO) product 12S-hydroxyeicosatetraenoic acid increases monocyte adhesion to human endothelial cells (EC) in vitro. Recent studies have implicated 12/15-LO in mediating atherosclerosis in mice. We generated transgenic mice on a C57BL/6J (B6) background that modestly overexpressed the murine 12/15-LO gene ( designated LOTG). LOTG mice had 2.5-fold elevations in levels of 12S-hydroxyeicosatetraenoic acid and a 2-fold increase in expression of 12/15-LO protein in vivo. These mice developed spontaneous aortic fatty streak lesions on a chow diet. Thus, we examined effects of 12/15-LO expression on early events leading to atherosclerosis in these mice. We found that, under basal unstimulated conditions, LOTG EC bound more monocytes than B6 control EC ( 18 +/- 2 versus 7 +/- 1 monocytes/field, respectively; p < 0.0001). Inhibition of 12/15-LO activity in LOTG EC using a 12/15-LO ribozyme completely blocked monocyte adhesion in LOTG mice. Thus, 12/15-LO activity is required for monocyte/EC adhesion in the vessel wall. Expression of ICAM-1 in aortic endothelia of LOTG mice was increased severalfold. VCAM-1 expression was not changed. In a series of blocking studies, antibodies to alpha(4) and beta(2) integrins in WEHI monocytes blocked monocyte adhesion to both LOTG and B6 control EC. Inhibition of ICAM-1, VCAM-1, and connecting segment-1 fibronectin in EC significantly reduced adhesion of WEHI monocytes to LOTG EC. In summary, these data indicate that EC from LOTG mice are "pre-activated" to bind monocytes. Monocyte adhesion in LOTG mice is mediated through beta(2) integrin and ICAM-1 interactions as well as through VLA-4 and connecting segment-1 fibronectin/ VCAM-1 interactions. Thus, 12/15-LO mediates monocyte/ EC interactions in the vessel wall in atherogenesis at least in part through molecular regulation of expression of endothelial adhesion molecules.	Univ Virginia, Cardiovasc Res Ctr, Div Endocrinol & Metab, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; City Hope Natl Med Ctr, Beckman Res Inst, Dept Diabet, Duarte, CA 91010 USA	University of Virginia; University of Virginia; City of Hope; Beckman Research Institute of City of Hope	Hedrick, CC (corresponding author), Univ Virginia, Cardiovasc Res Ctr, Div Endocrinol & Metab, MR5 Rm G123,POB 801394,415 Lane Rd, Charlottesville, VA 22908 USA.	cch6n@virginia.edu	Hedrick, Catherine/D-1106-2012; Bolick, David/A-3467-2017	Lannigan, Joanne/0000-0002-3981-8681	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798, R01HL071141] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039721] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071141-01, P01 HL55798-08] Funding Source: Medline; NIDDK NIH HHS [DK39721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; Bleich D, 1999, J CLIN INVEST, V103, P1431, DOI 10.1172/JCI5241; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Chavis C, 1999, ANAL BIOCHEM, V271, P105, DOI 10.1006/abio.1999.4113; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHO H, 1991, J MED CHEM, V34, P1503, DOI 10.1021/jm00108a039; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; Daugherty Alan, 2003, Methods Mol Biol, V209, P293; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; Funk CD, 2002, PROSTAG OTH LIPID M, V68-9, P303, DOI 10.1016/S0090-6980(02)00036-9; Funk CD, 2001, TRENDS CARDIOVAS MED, V11, P116; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; George J, 2001, CIRCULATION, V104, P1646, DOI 10.1161/hc3901.095772; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; Harats D, 2000, ARTERIOSCL THROM VAS, V20, P2100, DOI 10.1161/01.ATV.20.9.2100; Hatley ME, 2003, J BIOL CHEM, V278, P25369, DOI 10.1074/jbc.M301175200; Hedrick CC, 2001, J LIPID RES, V42, P563; Honda HM, 1999, ARTERIOSCL THROM VAS, V19, P680, DOI 10.1161/01.ATV.19.3.680; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI12877; Huo YQ, 2000, CIRC RES, V87, P153, DOI 10.1161/01.RES.87.2.153; ISHIDA BY, 1989, ATHEROSCLEROSIS MOUS, P189; Johnson EN, 1999, ADV EXP MED BIOL, V447, P63; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maier KG, 2000, AM J PHYSIOL-HEART C, V279, pH863, DOI 10.1152/ajpheart.2000.279.2.H863; McEvoy LM, 1997, J EXP MED, V185, P2069, DOI 10.1084/jem.185.12.2069; MCNALLY AK, 1990, J IMMUNOL, V145, P254; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; Patricia MK, 2001, CIRC RES, V88, P659, DOI 10.1161/hh0701.088838; Patricia MK, 1999, ARTERIOSCL THROM VAS, V19, P2615, DOI 10.1161/01.ATV.19.11.2615; Sigari F, 1997, ARTERIOSCL THROM VAS, V17, P3639, DOI 10.1161/01.ATV.17.12.3639; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; Srinivasan S, 2003, CIRC RES, V92, P371, DOI 10.1161/01.RES.0000061714.74668.5C; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TSAO PS, 1994, CIRCULATION, V89, P2176, DOI 10.1161/01.CIR.89.5.2176; WALENGA RW, 1988, PEDIATR RES, V24, P563, DOI 10.1203/00006450-198811000-00005; WALENGA RW, 1987, PROSTAGLANDINS, V34, P733, DOI 10.1016/0090-6980(87)90296-6; WANG LX, 1990, J LIPID RES, V31, P2265; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971; Yoshimoto T, 2002, PROSTAG OTH LIPID M, V68-9, P245, DOI 10.1016/S0163-7827(97)00002-7; Zhao L, 2002, J BIOL CHEM, V277, P35350, DOI 10.1074/jbc.M205738200; Zink MH, 2001, AM J PHYSIOL-HEART C, V280, pH693, DOI 10.1152/ajpheart.2001.280.2.H693	47	113	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9440	9450		10.1074/jbc.M303857200	http://dx.doi.org/10.1074/jbc.M303857200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676201	hybrid			2022-12-27	WOS:000189265900110
J	Outten, CE; Culotta, VC				Outten, CE; Culotta, VC			Alternative start sites in the Saccharomyces cerevisiae GLR1 gene are responsible for mitochondrial and cytosolic isoforms of glutathione reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE TRANSLATION PRODUCT; AUG INITIATOR CODON; OXIDATIVE STRESS; SUBCELLULAR-LOCALIZATION; OXIDIZED GLUTATHIONE; EUKARYOTIC RIBOSOMES; INTERMEMBRANE SPACE; YEAST; GLUTAREDOXIN; THIOREDOXIN	To combat oxidative damage, eukaryotic cells have evolved with numerous anti-oxidant factors that are often distributed between cytosolic and mitochondrial pools. Glutathione reductase, which regenerates the reduced form of glutathione, represents one such antioxidant factor, yet nothing is known regarding the partitioning of this enzyme within the cell. Using the bakers' yeast Saccharomyces cerevisiae as a model, we provide evidence that a single gene, namely GLR1, encodes both the mitochondrial and cytosolic forms of glutathione reductase. A deletion in GLR1 drastically increases levels of oxidized glutathione in these two subcellular compartments. The GLR1 gene has two in-frame start codons that are both used as translation initiation sites. Translation from the first codon generates the mitochondrial form that includes a mitochondrial targeting signal, whereas translation from the second codon produces the cytosolic form that lacks this sequence. Our results indicate that the sequence context of the two AUG codons influences the efficiency of translation initiation at each site, which in turn affects the relative levels of cytosolic and mitochondrial Glr1p. This method of subcellular distribution of glutathione reductase may be conserved in mammalian cells as well.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Culotta, VC (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.	vculotta@jhsph.edu	Outten, Caryn E./I-9433-2019	Outten, Caryn E./0000-0003-0335-6531	NIGMS NIH HHS [F32 GM066594, R01 GM050016, GM 50016, R37 GM050016] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM066594, R37GM050016, R01GM050016] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Chen ZF, 1998, J PHARMACOL EXP THER, V285, P608; CIGAN AM, 1987, GENE, V59, P1; COLLINSON LP, 1995, GENE, V156, P123, DOI 10.1016/0378-1119(95)00026-3; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; DAUM G, 1982, J BIOL CHEM, V257, P3028; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; GREEN RC, 1970, BIOCHIM BIOPHYS ACTA, V197, P31, DOI 10.1016/0005-2728(70)90005-8; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Hobbs AEA, 2001, J CELL BIOL, V152, P401, DOI 10.1083/jcb.152.2.401; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Juhnke H, 1996, MOL GEN GENET, V252, P456, DOI 10.1007/BF02173011; Kelner MJ, 2000, BIOCHEM BIOPH RES CO, V269, P366, DOI 10.1006/bbrc.2000.2267; Knox C, 1998, J BIOL CHEM, V273, P25587, DOI 10.1074/jbc.273.40.25587; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lenton KJ, 1999, ANAL BIOCHEM, V274, P125, DOI 10.1006/abio.1999.4258; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MBEMBA F, 1985, BIOCHIM BIOPHYS ACTA, V838, P211, DOI 10.1016/0304-4165(85)90081-9; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; OLAFSDOTTIR K, 1988, BIOCHIM BIOPHYS ACTA, V964, P377, DOI 10.1016/0304-4165(88)90038-4; Outten CE, 2003, EMBO J, V22, P2015, DOI 10.1093/emboj/cdg211; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Pedrajas JR, 2002, BIOCHEM J, V364, P617, DOI 10.1042/BJ20020570; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; Rodriguez-Manzaneque MT, 2002, MOL BIOL CELL, V13, P1109, DOI 10.1091/mbc.01-10-0517; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; SCHATZ G, 1983, CELL, V32, P316, DOI 10.1016/0092-8674(83)90450-6; Sherman F., 1978, METHODS YEAST GENETI; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; STEVENS BJ, 1977, BIOL CELLULAIRE, V28, P37; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; Tamura T, 1997, BIOCHEM BIOPH RES CO, V237, P419, DOI 10.1006/bbrc.1997.7153; Trotter EW, 2003, EMBO REP, V4, P184, DOI 10.1038/sj.embor.embor729	44	96	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7785	7791		10.1074/jbc.M312421200	http://dx.doi.org/10.1074/jbc.M312421200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672937	Green Accepted, hybrid			2022-12-27	WOS:000189103300052
J	Velasco-Loyden, G; Arribas, J; Lopez-Casillas, F				Velasco-Loyden, G; Arribas, J; Lopez-Casillas, F			The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; AMYLOID PRECURSOR PROTEIN; RECOMBINANT SOLUBLE BETAGLYCAN; TGF-BETA; CONVERTING-ENZYME; LIGAND-BINDING; III RECEPTOR; TYROSINE PHOSPHORYLATION; ENDOTHELIAL-CELLS	Betaglycan is a membrane-anchored proteoglycan that binds transforming growth factor-beta (TGF-beta) via its core protein. A soluble form of betaglycan can be released by proteolytic cleavage ( also known as shedding) of the membrane-bound form, yielding soluble betaglycan. The mechanism leading to the generation of soluble betaglycan is poorly understood. Because the membrane and soluble forms of betaglycan have opposite effects regulating the availability of TGF-beta, it is important to characterize the shedding of betaglycan further. Here we present evidence showing that in certain cell types, pervanadate, a general tyrosine phosphatase inhibitor, induces the release of the previously described fragment that encompasses almost the entire extracellular domain of betaglycan (sBG-120). In addition, treatment with pervanadate unveils the existence of a novel 90-kDa fragment (sBG-90). Noticeably, the cleavage that generates sBG-90 is mediated by a tissue inhibitor of metalloprotease-2-sensitive protease. Overexpression of all membrane type matrix metalloproteases (MT-MMPs) described to date indicates that MT1-MMP and MT3-MMP are endowed with ability to generate sBG-90. Furthermore, the patterns of expression of different MT-MMPs in the cell lines used in this study suggest that MT1-MMP is the protease involved in the shedding of sBG-90. Overexpression of MT1-MMP in COS-1 cells, which do not express detectable levels of this metalloprotease, confirms the feasibility of this hypothesis. Unexpectedly, during the course of these experiments, we observed that MT2-MMP decreases the levels of MT1-MMP and betaglycan. Finally, binding competition experiments indicate that, similar to the wild type membrane betaglycan, sBG-90 binds the TGF-beta2 isoform with greater affinity than TGF-beta1, suggesting that once released, it could affect the cellular availability of TGF-beta.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico; Hosp Univ Vall Hebron, Med Oncol Serv, Lab Rec Oncol, Barcelona 08035, Spain	Universidad Nacional Autonoma de Mexico; Hospital Universitari Vall d'Hebron	Lopez-Casillas, F (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Apartado Postal 70-246, Mexico City 04510, DF, Mexico.	fcasilla@ifc.unam.mx	Arribas, Joaquin/M-4482-2014	Arribas, Joaquin/0000-0002-0504-0664				Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bandyopadhyay A, 2002, CANCER RES, V62, P4690; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bjorn SF, 2000, PLACENTA, V21, P170, DOI 10.1053/plac.1999.0447; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Chapman SC, 2002, MOL CELL ENDOCRINOL, V196, P79, DOI 10.1016/S0303-7207(02)00227-7; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Codony-Servat J, 1999, CANCER RES, V59, P1196; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gray PC, 2002, MOL CELL ENDOCRINOL, V188, P253, DOI 10.1016/S0303-7207(02)00037-0; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; Llano E, 1999, CANCER RES, V59, P2570; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Pepin MC, 1995, FEBS LETT, V377, P368, DOI 10.1016/0014-5793(95)01378-4; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Shofuda K, 1997, J BIOL CHEM, V272, P9749; SLACK BE, 1995, J BIOL CHEM, V270, P8337, DOI 10.1074/jbc.270.14.8337; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Urena JM, 1999, J CELL SCI, V112, P773; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Velasco G, 2000, CANCER RES, V60, P877; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	72	95	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7721	7733		10.1074/jbc.M306499200	http://dx.doi.org/10.1074/jbc.M306499200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672946	hybrid			2022-12-27	WOS:000189103300045
J	Yep, A; Ballicora, MA; Sivak, MN; Preiss, J				Yep, A; Ballicora, MA; Sivak, MN; Preiss, J			Identification and characterization of a critical region in the glycogen synthase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MAIZE STARCH SYNTHASE; GLY-GLY SEQUENCE; ACTIVE-SITE; MALTODEXTRIN PHOSPHORYLASE; ADP-GLUCOSE; PROTEIN-STRUCTURE; CRYSTAL-STRUCTURE; RESIDUES; BACTERIAL	The cysteine-specific reagent 5,5'-dithiobis(2-nitrobenzoic acid) inactivates the Escherichia coli glycogen synthase ( Holmes, E., and Preiss, J. ( 1982) Arch. Biochem. Biophys. 216, 736 - 740). To find the responsible residue, all cysteines, Cys(7), Cys(379), and Cys(408), were substituted combinatorially by Ser. 5,5'-Dithiobis(2-nitrobenzoic acid) modified and inactivated the enzyme if and only if Cys(379) was present and it was prevented by the substrate ADP-glucose (ADP-Glc). Mutations C379S and C379A increased the S-0.5 for ADP-Glc 40- and 77-fold, whereas the specific activity was decreased 5.8- and 4.3-fold, respectively. Studies of inhibition by glucose 1-phosphate and AMP indicated that Cys(379) was involved in the interaction of the enzyme with the phosphoglucose moiety of ADP-Glc. Other mutations, C379T, C379D, and C379L, indicated that this site is intolerant for bulkier side chains. Because Cys(379) is in a conserved region, other residues were scanned by mutagenesis. Replacement of Glu(377) by Ala and Gln decreased V-max more than 10,000-fold without affecting the apparent affinity for ADP-Glc and glycogen binding. Mutation of Glu(377) by Asp decreased V-max only 57-fold indicating that the negative charge of Glu(377) is essential for catalysis. The activity of the mutation E377C, on an enzyme form without other Cys, was chemically restored by carboxymethylation. Other conserved residues in the region, Ser(374) and Gln(383), were analyzed by mutagenesis but found not essential. Comparison with the crystal structure of other glycosyltransferases suggests that this conserved region is a loop that is part of the active site. The results of this work indicate that this region is critical for catalysis and substrate binding.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Preiss, J (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	preiss@msu.edu		Ballicora, Miguel/0000-0002-5324-0724				Abdian PL, 2000, J BIOL CHEM, V275, P40568, DOI 10.1074/jbc.M007496200; Axe DD, 1998, BIOCHEMISTRY-US, V37, P7157, DOI 10.1021/bi9804028; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; CHEN Z, 1990, BIOCHEMISTRY-US, V29, P1112, DOI 10.1021/bi00457a003; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; Cid E, 2002, FEBS LETT, V528, P5, DOI 10.1016/S0014-5793(02)03313-6; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Dick S, 2002, BBA-PROTEIN STRUCT M, V1594, P219, DOI 10.1016/S0167-4838(01)00305-3; FOX J, 1976, BIOCHEMISTRY-US, V15, P849, DOI 10.1021/bi00649a019; FRANCONE OL, 1991, P NATL ACAD SCI USA, V88, P1716, DOI 10.1073/pnas.88.5.1716; Frueauf JB, 2001, J BIOL CHEM, V276, P46319, DOI 10.1074/jbc.M107408200; FURUKAWA K, 1993, J BIOL CHEM, V268, P23837; FURUKAWA K, 1990, J BIOL CHEM, V265, P2086; FURUKAWA K, 1994, J BIOL CHEM, V269, P868; GAO GJ, 1994, J BIOL CHEM, V269, P8234; Garcia GA, 1997, J PROTEIN CHEM, V16, P11, DOI 10.1023/A:1026334726357; Geremia S, 2002, J MOL BIOL, V322, P413, DOI 10.1016/S0022-2836(02)00771-4; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; GREENBERG E, 1964, J BIOL CHEM, V239, pC4315; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; HOLMES E, 1982, J BACTERIOL, V151, P1444, DOI 10.1128/JB.151.3.1444-1453.1982; HOLMES E, 1982, ARCH BIOCHEM BIOPHYS, V216, P736, DOI 10.1016/0003-9861(82)90264-8; HOLMES E, 1979, ARCH BIOCHEM BIOPHYS, V196, P436, DOI 10.1016/0003-9861(79)90295-9; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Imparl-Radosevich JM, 1999, FEBS LETT, V457, P357, DOI 10.1016/S0014-5793(99)01066-2; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu J, 2003, PROTEIN SCI, V12, P1418, DOI 10.1110/ps.0302103; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MacGregor EA, 2002, J PROTEIN CHEM, V21, P297, DOI 10.1023/A:1019701621256; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Nichols DJ, 2000, BIOCHEMISTRY-US, V39, P7820, DOI 10.1021/bi000407g; Orho M, 1998, J CLIN INVEST, V102, P507, DOI 10.1172/JCI2890; PREISS J, 1973, METHOD ENZYMOL, V28, P279; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; Rost B, 1996, METHOD ENZYMOL, V266, P525; Salleh HM, 1996, BIOCHEMISTRY-US, V35, P8942, DOI 10.1021/bi952373w; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; SCHINZEL R, 1990, BIOCHEMISTRY-US, V29, P9956, DOI 10.1021/bi00494a028; SCHINZEL R, 1991, FEBS LETT, V286, P125, DOI 10.1016/0014-5793(91)80956-4; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Segel IH, 1975, ENZYME KINETICS BEHA; SOLLING H, 1979, EUR J BIOCHEM, V94, P231, DOI 10.1111/j.1432-1033.1979.tb12890.x; THORBURN AW, 1991, J CLIN INVEST, V87, P489, DOI 10.1172/JCI115022; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang JY, 2002, J BIOL CHEM, V277, P2377, DOI 10.1074/jbc.C100686200; Watson KA, 1999, EMBO J, V18, P4619, DOI 10.1093/emboj/18.17.4619; Watson KA, 1997, EMBO J, V16, P1, DOI 10.1093/emboj/16.1.1; Wrabl JO, 2001, J MOL BIOL, V314, P365, DOI 10.1006/jmbi.2001.5151	52	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8359	8367		10.1074/jbc.M312686200	http://dx.doi.org/10.1074/jbc.M312686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665620	hybrid			2022-12-27	WOS:000189103300118
J	Ahvazi, B; Boeshans, KM; Idler, W; Baxa, U; Steinert, PM; Rastinejad, F				Ahvazi, B; Boeshans, KM; Idler, W; Baxa, U; Steinert, PM; Rastinejad, F			Structural basis for the coordinated regulation of transglutaminase 3 by guanine nucleotides and calcium/magnesium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; PROTRANSGLUTAMINASE-E; CORNIFIED ENVELOPE; PHOSPHOLIPASE-C; BINDING PROTEIN; CALCIUM-IONS; GTP-BINDING; ACTIVATION; RECONSTITUTION; PURIFICATION	Transglutaminase 3 (TGase 3) is a member of a family of Ca2+-dependent enzymes that catalyze covalent cross-linking reactions between proteins or peptides. TGase 3 isoform is widely expressed and is important for effective epithelial barrier formation in the assembly of the cell envelope. Among the nine TGase enzyme isoforms known in the human genome, only TGase 2 is known to bind and hydrolyze GTP to GDP; binding GTP inhibits its transamidation activity but allows it to function in signal transduction. Here we present biochemical and crystallographic evidence for the direct binding of GTP/GDP to the active TGase 3 enzyme, and we show that the TGase 3 enzyme undergoes a GTPase cycle. The crystal structures of active TGase 3 with guanosine 5% O-(thiotriphosphate) (GTPgammaS) and GDP were determined to 2.1 and 1.9 Angstrom resolution, respectively. These studies reveal for the first time the reciprocal actions of Ca2+ and GTP with respect to TGase 3 activity. GTPgammaS binding is coordinated with the replacement of a bound Ca2+ with Mg2+ and conformational rearrangements that together close a central channel to the active site. Hydrolysis of GTP to GDP results in two stable conformations, resembling both the GTP state and the nonnucleotide bound state, the latter of which allows substrate access to the active site.	NIAMS, Xray Crystallog Facil, NIH, Bethesda, MD 20892 USA; NIAMS, Off Sci & Technol, NIH, Bethesda, MD 20892 USA; NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Res Lab, NIH, Bethesda, MD 20892 USA; Univ Virginia Hlth Syst, Dept Pharmacol & Biochem & Mol Genet, Charlottesville, VA 22908 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Virginia	Ahvazi, B (corresponding author), NIAMS, Xray Crystallog Facil, NIH, Bldg 50,Rm 1345,50 South Dr, Bethesda, MD 20892 USA.	ahvazib@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041142, Z01AR041087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHYUTHAN KE, 1989, MOL CELL BIOCHEM, V85, P57; Aeschlimann Daniel, 1996, Seminars in Thrombosis and Hemostasis, V22, P437; Ahvazi B, 2003, EXP MOL MED, V35, P228, DOI 10.1038/emm.2003.31; Ahvazi B, 2003, J BIOL CHEM, V278, P23834, DOI 10.1074/jbc.M301162200; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRESE NE, 1991, ACTA CRYSTALLOGR B, V47, P192, DOI 10.1107/S0108768190011041; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAS T, 1993, J BIOL CHEM, V268, P27398; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; FOLK JE, 1966, BIOCHIM BIOPHYS ACTA, V122, P244, DOI 10.1016/0926-6593(66)90066-X; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HO KC, 1992, J BIOL CHEM, V267, P12660; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; Iismaa SE, 2000, J BIOL CHEM, V275, P18259, DOI 10.1074/jbc.M000583200; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1992, J BIOL CHEM, V267, P8887; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HC, 2001, J STRUCT BIOL, V135, P73, DOI 10.1006/jsbi.2001.4384; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM IG, 1993, J BIOL CHEM, V268, P12682; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Melino G, 1998, Results Probl Cell Differ, V24, P175; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Nemes Z, 2000, J BIOL CHEM, V275, P2636, DOI 10.1074/jbc.275.4.2636; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PISANO JJ, 1968, SCIENCE, V160, P892, DOI 10.1126/science.160.3830.892; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702	47	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7180	7192		10.1074/jbc.M312310200	http://dx.doi.org/10.1074/jbc.M312310200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645372	hybrid			2022-12-27	WOS:000188969200117
J	Elm, C; Braathen, R; Bergmann, S; Frank, R; Vaerman, JP; Kaetzel, CS; Chhatwal, GS; Johansen, FE; Hammerschmidt, S				Elm, C; Braathen, R; Bergmann, S; Frank, R; Vaerman, JP; Kaetzel, CS; Chhatwal, GS; Johansen, FE; Hammerschmidt, S			Ectodomains 3 and 4 of human polymeric immunoglobulin receptor (hpIgR) mediate invasion of Streptococcus pneumoniae into the epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARR-VIRUS INFECTION; SECRETORY COMPONENT; IG RECEPTOR; MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDE; INFLUENZA-VIRUS; CELLS; PROTEIN; TRANSPORT; BINDING	Streptococcus pneumoniae binds to the ectodomain of the human polymeric Ig receptor (plgR), also known as secretory component (SC), via a hexapeptide motif in the choline-binding protein SpsA. The SpsA-pIgR interaction mediates adherence and internalization of the human pathogen into epithelial cells. In this study the results of SpsA binding to human, mouse, and chimeric SC strongly supported the human specificity of this unique interaction and suggested that binding sites in the third and fourth Ig-like domain of human SC (D3 and D4, respectively) are involved in SpsA-pIgR complex formation. Binding of SpsA to SC-derived synthetic peptides indicated surface-located potential binding motifs in D3 and D4. Adherence and uptake of pneumococci or SpsA-coated latex beads depended on the SpsA hexapeptide motif as well as SpsA-binding sites in D3 and D4 of human pIgR. The involvement of D3 and D4 in adherence and invasion was demonstrated by the lack of binding of SpsA-coated latex beads to transfected epithelial cells expressing mutated pIgR. Finally, blocking experiments with chimeric human-mouse SC as well as synthetic peptides indicated the participation of D3 and a key role of D4 in pneumococcal invasion.	Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; GBF, German Res Ctr Biotechnol, D-38124 Braunschweig, Germany; Univ Oslo, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway; Catholic Univ Louvain, ICP, Expt Med Unit, B-1200 Brussels, Belgium; Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY 40536 USA	University of Wurzburg; Helmholtz Association; Helmholtz-Center for Infection Research; University of Oslo; Universite Catholique Louvain; University of Kentucky	Hammerschmidt, S (corresponding author), Univ Wurzburg, Res Ctr Infect Dis, Rontgenring 11, D-97070 Wurzburg, Germany.	s.hammerschmidt@mail.uni-wuerzburg.de	Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681; Kaetzel, Charlotte/0000-0001-7546-0085				BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; Bergmann S, 2001, MOL MICROBIOL, V40, P1273, DOI 10.1046/j.1365-2958.2001.02448.x; Blanch VJ, 1999, J IMMUNOL, V162, P1232; Brandtzaeg P, 1999, IMMUNOL REV, V171, P45, DOI 10.1111/j.1600-065X.1999.tb01342.x; Brock SC, 2002, INFECT IMMUN, V70, P5091, DOI 10.1128/IAI.70.9.5091-5095.2002; Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533; Dallas SD, 1998, J MED MICROBIOL, V47, P879, DOI 10.1099/00222615-47-10-879; de Oliveira IR, 2001, FEMS MICROBIOL LETT, V203, P29, DOI 10.1016/S0378-1097(01)00332-9; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; Enriquez FJ, 1998, INFECT IMMUN, V66, P4469; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; FUBARA ES, 1973, J IMMUNOL, V111, P395; Gan YJ, 1997, J VIROL, V71, P519, DOI 10.1128/JVI.71.1.519-526.1997; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Godding V, 1998, EUR RESPIR J, V11, P1043, DOI 10.1183/09031936.98.11051043; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hammerschmidt S, 2000, MOL MICROBIOL, V36, P726, DOI 10.1046/j.1365-2958.2000.01897.x; Heremans J F, 1974, Adv Exp Med Biol, V45, P3; Iannelli F, 2002, GENE, V284, P63, DOI 10.1016/S0378-1119(01)00896-4; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; Johansen FE, 1999, EUR J IMMUNOL, V29, P1701, DOI 10.1002/(SICI)1521-4141(199905)29:05<1701::AID-IMMU1701>3.0.CO;2-Z; Johansen FE, 1999, J EXP MED, V190, P915, DOI 10.1084/jem.190.7.915; Kaetzel CS, 2001, CURR BIOL, V11, pR35, DOI 10.1016/S0960-9822(00)00041-5; KRAMER DR, 1995, J IMMUNOL, V154, P2051; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Lin CT, 1997, AM J PATHOL, V150, P1745; Lin CT, 2000, LAB INVEST, V80, P1149, DOI 10.1038/labinvest.3780123; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Luton F, 1999, MOL BIOL CELL, V10, P1409, DOI 10.1091/mbc.10.5.1409; MAZANEC MB, 1993, IMMUNOL TODAY, V14, P430, DOI 10.1016/0167-5699(93)90245-G; MIZOGUCHI A, 1982, J BIOL CHEM, V257, P9612; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; Nice EC, 1996, MOL IMMUNOL, V33, P659, DOI 10.1016/0161-5890(96)00016-8; OUTLAW MC, 1990, J GEN VIROL, V71, P69, DOI 10.1099/0022-1317-71-1-69; Phalipon A, 2003, TRENDS IMMUNOL, V24, P55, DOI 10.1016/S1471-4906(02)00031-5; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; PISKURICH JF, 1995, J IMMUNOL, V154, P1735; PISKURICH JF, 1993, MOL IMMUNOL, V30, P413, DOI 10.1016/0161-5890(93)90071-I; Rojas R, 2002, NAT REV MOL CELL BIO, V3, P944, DOI 10.1038/nrm972; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; Shimada S, 1999, J IMMUNOL, V163, P5367; SIXBEY JW, 1992, SCIENCE, V255, P1578, DOI 10.1126/science.1312750; SOLLID LM, 1987, J IMMUNOL, V138, P4303; TAMER CM, 1995, J IMMUNOL, V155, P707; TUOMANEN EI, 1995, NEW ENGL J MED, V332, P1280, DOI 10.1056/NEJM199505113321907; UNDERDOWN BJ, 1986, ANNU REV IMMUNOL, V4, P389, DOI 10.1146/annurev.iy.04.040186.002133; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; WILLIAMS RC, 1972, SCIENCE, V177, P697, DOI 10.1126/science.177.4050.697; YOUNGMAN KR, 1994, J IMMUNOL, V153, P675; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	53	82	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6296	6304		10.1074/jbc.M310528200	http://dx.doi.org/10.1074/jbc.M310528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660617	hybrid			2022-12-27	WOS:000188969200014
J	Mamidipudi, V; Lin, CR; Seibenhener, ML; Wooten, MW				Mamidipudi, V; Lin, CR; Seibenhener, ML; Wooten, MW			Regulation of interleukin receptor-associated kinase (IRAK) phosphorylation and signaling by iota protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATION; PKC; ZETA; IDENTIFICATION; FAMILY; CELLS	We have previously shown that the activity of the interleukin-1 (IL-1) receptor-associated kinase (IRAK) is required for nerve growth factor (NGF)-induced activation of NF-kappaB and cell survival ((2002) J. Biol. Chem. 277, 28010-28018). Herein we demonstrate that NGF induces co-association of IRAK with atypical protein kinase C iota (PKC) and that the iota PKC.IRAK complex is recruited to the p75 neurotrophin receptor. Recruitment of IRAK to the receptor was dependent upon the activity of the iota PKC. Moreover, transfection of kinase-dead iota PKC blocked both NGF- and IL-1-induced IRAK activation and the activity of NF-kappaB. Hence, iota PKC lies upstream of IRAK in the kappaB pathway. Examining the primary structure of IRAK, we identified three putative PKC phosphorylation sites; iota PKC selectively phosphorylated peptide 1 (R (T) under bar AS) within the death domain domain at Thr(66), which is highly conserved among all IRAK family members. Mutation of Thr(66) to Ala impaired the autokinase activity of IRAK and reduced its association with iota PKC but not TRAM resulting in impaired NGF- as well as IL-1-induced NF-kappaB activation. These findings provide insight into the underlying mechanism whereby IRAK regulates the kappaB pathway and reveal that IRAK is a substrate of iota PKC.	Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA	Auburn University System; Auburn University; Stanford University	Wooten, MW (corresponding author), Auburn Univ, Dept Biol Sci, Program Cell & Mol Biosci, 331 Funchess Hall, Auburn, AL 36849 USA.	wootemw@auburn.edu			NINDS NIH HHS [NS-33661] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033661] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Hu J, 2002, J IMMUNOL, V168, P3910, DOI 10.4049/jimmunol.168.8.3910; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Ross K, 2002, J BIOL CHEM, V277, P37414, DOI 10.1074/jbc.M205160200; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Wooten MW, 1999, CELL DEATH DIFFER, V6, P753, DOI 10.1038/sj.cdd.4400548	16	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4161	4165		10.1074/jbc.C300431200	http://dx.doi.org/10.1074/jbc.C300431200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14684752	hybrid			2022-12-27	WOS:000188554300031
J	Stedman, C; Robertson, G; Coulter, S; Liddle, C				Stedman, C; Robertson, G; Coulter, S; Liddle, C			Feed-forward regulation of bile acid detoxification by CYP3A4 - Studies in humanized transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; CONSTITUTIVE-ANDROSTANE RECEPTOR; ORPHAN NUCLEAR RECEPTOR; HUMAN LIVER-MICROSOMES; LITHOCHOLIC ACID; BILIARY OBSTRUCTION; DUCT LIGATION; RAT-LIVER; METABOLISM; CHOLESTASIS	Bile acids are potentially toxic end products of cholesterol metabolism and their concentrations must be tightly regulated. Homeostasis is maintained by both feed-forward regulation and feedback regulation. We used humanized transgenic mice incorporating 13 kb of the 5' regulatory flanking sequence of CYP3A4 linked to a lacZ reporter gene to explore the in vivo relationship between bile acids and physiological adaptive CYP3A gene regulation in acute cholestasis after bile duct ligation (BDL). Male transgenic mice were subjected to BDL or sham surgery prior to sacrifice on days 3, 6, and 10, and others were injected with intraperitoneal lithocholic acid (LCA) or vehicle alone. BDL resulted in marked hepatic activation of the CYP3A4/lacZ transgene in pericentral hepatocytes, with an 80-fold increase in transgene activation by day 10. Individual bile acids were quantified by liquid chromatography/mass spectrometry. Serum 6beta-hydroxylated bile acids were increased following BDL, confirming the physiological relevance of endogenous Cyp3a induction to bile acid detoxification. Although concentrations of conjugated primary bile acids increased after BDL, there was no increase in LCA, a putative PXR ligand, indicating that this cannot be the only endogenous bile acid mediating this protective response. Moreover, in LCA-treated animals, 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside staining showed hepatic activation of the CYP3A4 transgene only on the liver capsular surface, and minimal parenchymal induction, despite significant liver injury. This study demonstrates that CYP3A up-regulation is a significant in vivo adaptive response to cholestasis. However, this up-regulation is not dependent on increases in circulating LCA and the role of other bile acids as regulatory molecules requires further exploration.	Univ Sydney, Dept Clin Pharmacol, Mol Pharmacol Lab, Westmead, NSW 2145, Australia; Univ Sydney, Dept Med, Mol Pharmacol Lab, Westmead, NSW 2145, Australia; Westmead Hosp, Westmead Millennium Inst, Storr Liver Unit, Westmead, NSW 2145, Australia; Westmead Hosp, Inst Clin Pathol & Med Res, Westmead, NSW 2145, Australia	University of Sydney; University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of Sydney	Liddle, C (corresponding author), Westmead Hosp, Dept Clin Pharmacol, Darcy Rd, Westmead, NSW 2145, Australia.	chris_liddle@wmi.usyd.edu.au						Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; BORNHEIM LM, 1990, MOL PHARMACOL, V38, P319; BREMMELGAARD A, 1980, SCAND J GASTROENTERO, V15, P593, DOI 10.3109/00365528009182221; CHANG TKH, 1993, BIOCHEM J, V291, P429, DOI 10.1042/bj2910429; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; DANIELSS.H, 1968, BIOCHEMISTRY-US, V7, P346, DOI 10.1021/bi00841a044; DANIELSSON H, 1973, STEROIDS, V22, P567, DOI 10.1016/0039-128X(73)90013-5; DUELAND S, 1991, BIOCHEM J, V280, P373, DOI 10.1042/bj2800373; Eyssen HJ, 1999, APPL ENVIRON MICROB, V65, P3158; FOSTER R, 1988, J BIOL CHEM, V263, P11528; Furster C, 1999, BBA-MOL CELL BIOL L, V1437, P46, DOI 10.1016/S0005-2760(98)00175-1; Gascon-Barre M, 2003, HEPATOLOGY, V37, P1034, DOI 10.1053/jhep.2003.50176; GEORGE J, 1995, HEPATOLOGY, V21, P120, DOI 10.1002/hep.1840210121; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; GUSTAFSSON J, 1978, J LIPID RES, V19, P237; Hofmann Alan F., 1994, P677; Honda A, 2001, J BIOL CHEM, V276, P34579, DOI 10.1074/jbc.M103025200; KINUGASA T, 1981, J LIPID RES, V22, P201; Kitada H, 2003, J BIOL CHEM, V278, P17838, DOI 10.1074/jbc.M210634200; LAMBIOTTE M, 1988, EUR J BIOCHEM, V175, P595, DOI 10.1111/j.1432-1033.1988.tb14233.x; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Naito T, 1996, J SURG RES, V65, P70, DOI 10.1006/jsre.1996.0345; Ourlin JC, 2003, MOL ENDOCRINOL, V17, P1693, DOI 10.1210/me.2002-0383; PALMER RH, 1972, ARCH INTERN MED, V130, P606, DOI 10.1001/archinte.130.4.606; Paolini M, 2000, J INVEST MED, V48, P49; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Purucker E, 2001, BBA-GEN SUBJECTS, V1526, P44, DOI 10.1016/S0304-4165(01)00096-4; RADOMINSKA A, 1993, SEMIN LIVER DIS, V13, P219, DOI 10.1055/s-2007-1007351; Robertson GR, 2003, MOL PHARMACOL, V64, P42, DOI 10.1124/mol.64.1.42; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schuetz EG, 1998, MOL PHARMACOL, V54, P1113, DOI 10.1124/mol.54.6.1113; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; SETCHELL KDR, 1995, BIOCHEMISTRY-US, V34, P4169, DOI 10.1021/bi00013a004; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; SUMMERFIELD JA, 1976, BIOCHEM J, V154, P507, DOI 10.1042/bj1540507; TAKITA M, 1988, J BIOCHEM-TOKYO, V103, P778, DOI 10.1093/oxfordjournals.jbchem.a122346; TEIXEIRA J, 1991, J BIOL CHEM, V266, P21030; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	45	75	78	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11336	11343		10.1074/jbc.M310258200	http://dx.doi.org/10.1074/jbc.M310258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14681232	hybrid			2022-12-27	WOS:000220157600062
J	Aoki, N; Ueno, S; Mano, H; Yamasaki, S; Shiota, M; Miyazaki, H; Yamaguchi-Aoki, Y; Matsuda, T; Ullrich, A				Aoki, N; Ueno, S; Mano, H; Yamasaki, S; Shiota, M; Miyazaki, H; Yamaguchi-Aoki, Y; Matsuda, T; Ullrich, A			RETRACTED: Mutual regulation of protein-tyrosine phosphatase 20 and protein-tyrosine kinase Tec activities by tyrosine phosphorylation and dephosphorylation (Retracted Article. See vol 285, pg 32678, 2010)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							X-LINKED AGAMMAGLOBULINEMIA; COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; HEMATOPOIETIC-CELLS; POSITIVE REGULATOR; SIGNALING PATHWAY; ACTIVATION; FAMILY; EXPRESSION	PTP20, also known as HSCF/protein-tyrosine phosphatase K1/fetal liver phosphatase 1/brain-derived phosphatase 1, is a cytosolic protein-tyrosine phosphatase with currently unknown biological relevance. We have identified that the nonreceptor protein-tyrosine kinase Tec-phosphorylated PTP20 on tyrosines and coimmunoprecipitated with the phosphatase in a phosphotyrosine-dependent manner. The interaction between the two proteins involved the Tec SH2 domain and the C-terminal tyrosine residues Tyr-281, Tyr-303, Tyr-354, and Tyr-381 of PTP20, which were also necessary for tyrosine phosphorylation/dephosphorylation. Association between endogenous PTP20 and Tec was also tyrosine phosphorylation-dependent in the immature B cell line Ramos. Finally, the Tyr-281 residue of PTP20 was shown to be critical for deactivating Tec in Ramos cells upon B cell receptor ligation as well as dephosphorylation and deactivation of Tec and PTP20 itself in transfected COS7 cells. Taken together, PTP20 appears to play a negative role in Tec-mediated signaling, and Tec-PTP20 interaction might represent a negative feedback mechanism.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Jichi Med Sch, Div Funct Genom, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Div Cardiol, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Div Hematol, Minami Kawachi, Tochigi 3290498, Japan; Chiba Univ, Grad Sch Med, Chiba 2608670, Japan; Univ Tsukuba, Ctr Gene Res, Tsukuba, Ibaraki 3058572, Japan; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Nagoya University; Jichi Medical University; Jichi Medical University; Jichi Medical University; Chiba University; University of Tsukuba; Max Planck Society	Aoki, N (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	naoki@agr.nagoya-u.ac.jp						Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; Dosil M, 1996, BLOOD, V88, P4510, DOI 10.1182/blood.V88.12.4510.bloodjournal88124510; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Gadina M, 1998, J IMMUNOL, V160, P4657; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; HAIRE RN, 1995, MAMM GENOME, V6, P476, DOI 10.1007/BF00360659; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; Huang K, 1996, ONCOGENE, V13, P1567; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; Kim YW, 1996, ONCOGENE, V13, P2275; Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1993, ONCOGENE, V8, P417; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Shiota M, 2003, MOL ENDOCRINOL, V17, P534, DOI 10.1210/me.2002-0187; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; Tao JC, 2001, J BIOL CHEM, V276, P29520, DOI 10.1074/jbc.M103721200; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang B, 2001, MOL CELL BIOL, V21, P1077, DOI 10.1128/MCB.21.4.1077-1088.2001; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Wu Y, 1998, J BIOL CHEM, V273, P30487, DOI 10.1074/jbc.273.46.30487; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; Yamashita Y, 1997, EXP HEMATOL, V25, P211; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199	51	18	20	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10765	10775		10.1074/jbc.M310401200	http://dx.doi.org/10.1074/jbc.M310401200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679216	hybrid			2022-12-27	WOS:000220050400132
J	Scheijen, B; Bronk, M; van der Meer, T; De Jong, D; Bernards, R				Scheijen, B; Bronk, M; van der Meer, T; De Jong, D; Bernards, R			High incidence of thymic epithelial tumors in E2F2 transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE ENTRY; CELLULAR PROLIFERATION; TRANSCRIPTION FACTORS; IN-VIVO; DEREGULATED EXPRESSION; NEGATIVE SELECTION; DNA-REPLICATION; MOUSE MODEL; APOPTOSIS; CELLS	In virtually all human tumors, genetic and epigenetic alterations have been found which affect the INK4/-CYCLIN D/RB pathway, which regulates cell cycle entry and exit in normal cells. E2F transcription factors are important downstream components of this pathway, which act by controlling the expression of genes involved in DNA replication and cell cycle progression. To determine whether E2F2 deregulation promotes proliferation and tumorigenesis in vivo, we generated E2F2 transgenic mice, in which the Emu and murine pim1 promoter ( pp) direct high expression of E2F2 in thymic epithelial cells. Emu-pp-E2F2 mice start to develop cytokeratin- and ER-TR4-positive cortical thymomas from the age of 20 weeks, and within 1 year, nearly all mice succumb to gross thymic epithelial tumors. General thymic morphology is largely maintained, but T cell development is perturbed in thymomas, with proportionately less CD4(+) CD8(+) double-positive thymocytes. In the first 3 months, E2F2 transgenic thymi exhibit only mild epithelial hyperplasia, and thereafter thymomas arise stochastically, probably following additional mutations. Interestingly, Emu-pp-E2F1 mice do not display cortical thymomas. These data argue that E2F2 promotes unscheduled cell division and oncogenic transformation of thymic epithelial cells.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	R.Bernards@nki.nl	Scheijen, Blanca/E-3523-2016	Scheijen, Blanca/0000-0001-8029-9230; Bernards, Rene/0000-0001-8677-3423				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Bargou RC, 1996, J EXP MED, V183, P1205, DOI 10.1084/jem.183.3.1205; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bennett AR, 2002, IMMUNITY, V16, P803, DOI 10.1016/S1074-7613(02)00321-7; BOYD RL, 1993, IMMUNOL TODAY, V14, P445, DOI 10.1016/0167-5699(93)90248-J; Carraresi L, 2001, ONCOGENE, V20, P8148, DOI 10.1038/sj.onc.1205007; Chen Q, 2000, INVEST OPHTH VIS SCI, V41, P4223; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; delaLuna S, 1996, J CELL SCI, V109, P2443; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dong YB, 2002, CANCER RES, V62, P1776; Elliott MJ, 2002, TUMOR BIOL, V23, P76, DOI 10.1159/000059708; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Gill J, 2002, NAT IMMUNOL, V3, P635, DOI 10.1038/ni812; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Humbert PO, 2000, GENE DEV, V14, P690; Hunt KK, 1997, CANCER RES, V57, P4722; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; IZON DJ, 1994, INT IMMUNOL, V6, P31, DOI 10.1093/intimm/6.1.31; Klug DB, 1998, P NATL ACAD SCI USA, V95, P11822, DOI 10.1073/pnas.95.20.11822; Lee SS, 1998, VIRCHOWS ARCH, V432, P33, DOI 10.1007/s004280050131; Li FX, 2003, MOL CELL BIOL, V23, P3607, DOI 10.1128/MCB.23.10.3607-3622.2003; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Rampalli AM, 1998, ONCOGENE, V16, P399, DOI 10.1038/sj.onc.1201546; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 2000, AM J PATHOL, V157, P1039, DOI 10.1016/S0002-9440(10)64616-0; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Rounbehler RJ, 2002, CANCER RES, V62, P3276; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; Scheijen B, 2003, MOL CELL BIOL, V23, P3656, DOI 10.1128/MCB.23.10.3656-3668.2003; Slack JMW, 2000, SCIENCE, V287, P1431, DOI 10.1126/science.287.5457.1431; Smith DS, 2000, CELL GROWTH DIFFER, V11, P625; SPANOPOULOU E, 1989, NATURE, V342, P185, DOI 10.1038/342185a0; VANVLIET E, 1984, EUR J IMMUNOL, V14, P524, DOI 10.1002/eji.1830140608; Wikonkal NM, 2003, NAT CELL BIOL, V5, P655, DOI 10.1038/ncb1001; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001	61	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10476	10483		10.1074/jbc.M313682200	http://dx.doi.org/10.1074/jbc.M313682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684733	Green Published, hybrid			2022-12-27	WOS:000220050400099
J	Anderson, HDI; Wang, F; Gardner, DG				Anderson, HDI; Wang, F; Gardner, DG			Role of the epidermal growth factor receptor in signaling strain-dependent activation of the brain natriuretic peptide gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; CANCER CELL-LINES; EGF-RECEPTOR; NAD(P)H OXIDASE; ANGIOTENSIN-II; MECHANICAL STRETCH; PROTEIN-KINASE; VENTRICULAR MYOCYTES; REGULATED KINASE; HEART-FAILURE	The epidermal growth factor receptor ( EGFR) and ectoshedding of heparin-binding epidermal growth factor (HBEGF), an EGFR ligand, have been linked to the development of cardiac myocyte hypertrophy. However, the precise role that the liganded EGFR plays in the transcriptional activation of the gene program that accompanies hypertrophy remains undefined. Utilizing the human (h) BNP gene as a model of hypertrophy-dependent gene activation, we show that activation of the EGFR plays an important role in mediating mechanical strain-dependent stimulation of the hBNP promoter. Strain promotes endothelin ( ET) generation through NAD(P) H oxidase-dependent production of reactive oxygen species. ET in turn induces metalloproteinase-mediated cleavage of pro-HBEGF and ectoshedding of HBEGF, which activates the EGFR and stimulates hBNP promoter activity. HBEGF also stimulates other phenotypic markers of hypertrophy including protein synthesis and sarcomeric assembly. The antioxidant N-acetylcysteine or the NAD( P) H oxidase inhibitor, apocynin, inhibited strain-dependent activation of the ET-1 promoter, HBEGF shedding, and hBNP promoter activation. The metalloproteinase inhibitor, GM-6001, prevented the induction of HBEGF ectoshedding and the hBNP promoter response to strain, suggesting a critical role for the metalloproteinase-dependent cleavage event in signaling the strain response. These findings suggest that metalloproteinase activity as an essential step in this pathway may prove to be a relevant therapeutic target in the management of cardiac hypertrophy.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gardner, DG (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	gardner@itsa.ucsf.edu		Anderson, Hope/0000-0001-6570-6678	NHLBI NIH HHS [HL35753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BENES AJ, 1985, J CELL SCI, V75, P35; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Cordero JB, 2002, J BIOL CHEM, V277, P38965, DOI 10.1074/jbc.M203736200; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Fahmi H, 2002, OSTEOARTHR CARTILAGE, V10, P100, DOI 10.1053/joca.2001.0485; Fahmi H, 2001, ARTHRITIS RHEUM, V44, P595, DOI 10.1002/1529-0131(200103)44:3<595::AID-ANR108>3.3.CO;2-#; FALETTE N, 1989, MOL CELL ENDOCRINOL, V63, P189, DOI 10.1016/0303-7207(89)90095-6; Fink C, 2000, FASEB J, V14, P669, DOI 10.1096/fasebj.14.5.669; Fujino T, 1998, CARDIOVASC RES, V38, P365, DOI 10.1016/S0008-6363(98)00010-8; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Gonzalez EA, 2002, KIDNEY INT, V61, P1627, DOI 10.1046/j.1523-1755.2002.00327.x; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; Grote K, 2003, CIRC RES, V92, pE80, DOI 10.1161/01.RES.0000077044.60138.7C; Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23; Hamilton CA, 2002, HYPERTENSION, V40, P755, DOI 10.1161/01.HYP.0000037063.90643.0B; HASEGAWA K, 1993, CIRCULATION, V88, P372, DOI 10.1161/01.CIR.88.2.372; Hashimoto K, 2002, J GASTROINTEST CANC, V32, P7, DOI 10.1385/IJGC:32:1:7; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Kagiyama S, 2003, HYPERTENSION, V41, P824, DOI 10.1161/01.HYP.0000047104.42047.9B; Kent RL, 1996, CIRC RES, V78, P829, DOI 10.1161/01.RES.78.5.829; Kitamura S, 2001, INT J CANCER, V94, P335, DOI 10.1002/ijc.1470; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Kudoh S, 1998, J BIOL CHEM, V273, P24037, DOI 10.1074/jbc.273.37.24037; LaPointe MC, 1996, HYPERTENSION, V27, P715, DOI 10.1161/01.HYP.27.3.715; Lee EA, 2001, BIOCHEM BIOPH RES CO, V284, P419, DOI 10.1006/bbrc.2001.4943; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Liang FQ, 2000, HYPERTENSION, V35, P188, DOI 10.1161/01.HYP.35.1.188; Liang FQ, 1998, J BIOL CHEM, V273, P14612, DOI 10.1074/jbc.273.23.14612; Liang FQ, 2003, ENDOCRINOLOGY, V144, P4187, DOI 10.1210/en.2002-0217; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Liang PQ, 1997, J BIOL CHEM, V272, P28050, DOI 10.1074/jbc.272.44.28050; Liao JK, 2002, NAT MED, V8, P20, DOI 10.1038/nm0102-20; Marx N, 2003, ARTERIOSCL THROM VAS, V23, P283, DOI 10.1161/01.ATV.0000054195.35121.5E; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; Miyata S, 1996, EUR J PHARMACOL, V307, P81, DOI 10.1016/0014-2999(96)00152-5; Morrison LK, 2002, J AM COLL CARDIOL, V39, P202, DOI 10.1016/S0735-1097(01)01744-2; Nakagami H, 2003, J MOL CELL CARDIOL, V35, P851, DOI 10.1016/S0022-2828(03)00145-7; NAKAGAWA O, 1995, J CLIN INVEST, V96, P1280, DOI 10.1172/JCI118162; Oeckler RA, 2003, CIRC RES, V92, P23, DOI 10.1161/01.RES.0000051860.84509.CE; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PAUL M, 1995, HYPERTENSION, V25, P683, DOI 10.1161/01.HYP.25.4.683; PERRELLA MA, 1994, J BIOL CHEM, V269, P27045; Pimentel DR, 2001, CIRC RES, V89, P453, DOI 10.1161/hh1701.096615; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Sabatini M, 2002, OSTEOARTHR CARTILAGE, V10, P673, DOI 10.1053/joca.2002.0827; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Shiomi T, 2002, CIRCULATION, V106, P3126, DOI 10.1161/01.CIR.0000039346.31538.2C; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Song JI, 2001, CANCER RES, V61, P5919; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Sunami E, 2002, SURG TODAY, V32, P343, DOI 10.1007/s005950200049; Takano H, 2000, CIRC RES, V87, P596, DOI 10.1161/01.RES.87.7.596; Tong WM, 1998, EUR J CANCER, V34, P2119, DOI 10.1016/S0959-8049(98)00267-6; Troughton RW, 2000, LANCET, V355, P1126, DOI 10.1016/S0140-6736(00)02060-2; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582; WU JP, 1989, J BIOL CHEM, V264, P6472; Xiao L, 2002, AM J PHYSIOL-CELL PH, V282, pC926, DOI 10.1152/ajpcell.00254.2001	68	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9287	9297		10.1074/jbc.M309227200	http://dx.doi.org/10.1074/jbc.M309227200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14645255	hybrid			2022-12-27	WOS:000189265900091
J	Gate, L; Majumdar, RS; Lunk, A; Tew, KD				Gate, L; Majumdar, RS; Lunk, A; Tew, KD			Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and janus kinase/STAT pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; TYROSINE-PHOSPHATASE SHP-1; RAS-DEPENDENT ACTIVATION; C-JUN; CONSTITUTIVE ACTIVATION; CELL-LINES; P53 PHOSPHORYLATION; JAK/STAT PATHWAY; PROLIFERATION	It has been shown that glutathione S-transferase pi (GSTpi) interacts with and suppresses the activity of c-Jun NH2-terminal kinase (JNK). GST-deficient mice (GSTpi(-/-)) have higher levels of circulating white blood cells, with similar proportions of lymphocytes, monocytes, and granulocytes. Interestingly, a selective expansion of splenic B lymphocytes was observed in GSTpi(-/-) animals but no change in T lymphocytes or natural killer cells. A peptidomimetic inhibitor of GSTpi that disrupts the interaction between GSTpi and JNK mimics in wild type mice the increased myeloproliferation observed in GSTpi(-/-) animals. Until now, the molecular basis for this effect has not been defined. In an in vitro hematopoiesis assay, interleukin-3, granulocyte colony-stimulating factor, and granulocyte/ macrophage colony-stimulating factor were more effective at stimulating proliferation of hematopoietic cells in GSTpi(-/-) mice than in wild type. The JNK inhibitor SP600125 which caused little inhibition of cytokine-induced myeloproliferation in wild type mice, decreased the number of colonies in GSTpi(-/-) animals. A more sustained phosphorylation of the STAT family of proteins was also observed in GSTpi(-/-) bone marrow-derived mast cells exposed to interleukin-3. This was associated with an increased proliferation and a down-regulation of expression of negative regulators of the Janus kinase-STAT pathway SHP, Src homology 2 domain-containing tyrosine phosphatase-1 and -2. The increased activation of JNK and STATs in GSTpi-deficient mice provides a viable mechanism for the increased myeloproliferation in these animals. These data also confirm the important role that GSTpi plays in the regulation of cell signaling pathways in a myeloproliferative setting.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Tew, KD (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	KD_Tew@fccc.edu			NATIONAL CANCER INSTITUTE [P30CA006927, R01CA085660] Funding Source: NIH RePORTER; NCI NIH HHS [CA85660, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Baumann MA, 2001, AM J HEMATOL, V68, P99, DOI 10.1002/ajh.1160; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Chai SK, 1997, J IMMUNOL, V159, P4720; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Dong Zigang, 2003, Mol Interv, V3, P306, DOI 10.1124/mi.3.6.306; Foltz IN, 1997, BLOOD, V89, P3092, DOI 10.1182/blood.V89.9.3092; Gamero AM, 2001, J BIOL CHEM, V276, P13547, DOI 10.1074/jbc.M007948200; Gate Laurent, 2001, Expert Opin Ther Targets, V5, P477; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kauvar LM, 1998, CHEM-BIOL INTERACT, V112, P225, DOI 10.1016/S0009-2797(97)00163-4; Keller G, 1999, EXP HEMATOL, V27, P777, DOI 10.1016/S0301-472X(99)00024-7; Kirito K, 2002, INT J HEMATOL, V75, P51, DOI 10.1007/BF02981979; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Kita A, 2003, BIOCHEM BIOPH RES CO, V302, P805, DOI 10.1016/S0006-291X(03)00264-X; Kwon YW, 2002, J BIOL CHEM, V277, P1837, DOI 10.1074/jbc.M105033200; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Miranda MB, 2002, LEUKEMIA, V16, P683, DOI 10.1038/sj.leu.2402400; Morgan AS, 1996, CANCER CHEMOTH PHARM, V37, P363, DOI 10.1007/s002800050398; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Paling NRD, 2002, BIOCHEM J, V368, P885, DOI 10.1042/BJ20021054; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Ruscoe JE, 2001, J PHARMACOL EXP THER, V298, P339; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shuai K, 1996, ONCOGENE, V13, P247; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Srinivasa SP, 2002, LEUKEMIA, V16, P244, DOI 10.1038/sj.leu.2402367; Su YR, 2002, J LIPID RES, V43, P2180, DOI 10.1194/jlr.D200020-JLR200; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TEW KD, 1994, CANCER RES, V54, P4313; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Townsend Danyelle, 2003, Am J Pharmacogenomics, V3, P157, DOI 10.2165/00129785-200303030-00002; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Ward AC, 2000, BLOOD, V95, P19; WeberNordt RM, 1996, BLOOD, V88, P809; Wheadon H, 2002, CELL SIGNAL, V14, P219, DOI 10.1016/S0898-6568(01)00241-8; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yin ZM, 2000, CANCER RES, V60, P4053; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599	48	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8608	8616		10.1074/jbc.M308613200	http://dx.doi.org/10.1074/jbc.M308613200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684749	hybrid			2022-12-27	WOS:000189265900012
J	Gauthier, NC; Ricci, V; Gounon, P; Doye, A; Tauc, M; Poujeol, P; Boquet, P				Gauthier, NC; Ricci, V; Gounon, P; Doye, A; Tauc, M; Poujeol, P; Boquet, P			Glycosylphosphatidylinositol-anchored proteins and actin cytoskeleton modulate chloride transport by channels formed by the Helicobacter pylori vacuolating cytotoxin VacA in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-SELECTIVE CHANNELS; TOXIN VACA; PLASMA-MEMBRANE; LIPID-BILAYERS; RAFTS; INTERNALIZATION; ACCUMULATION; ENDOCYTOSIS; INHIBITION; ENDOSOMES	The vacuolating cytotoxin VacA is an important virulence factor of Helicobacter pylori. Removing glycosylphosphatidylinositol-anchored proteins (GPI-Ps) from the cell surface by phosphatidylinositol-phospholipase C or disrupting the cell actin cytoskeleton by cytochalasin D reduced VacA-induced vacuolation of cells (Ricci V., Galmiche, A., Doye, A., Necchi, V., Solcia, E., and Boquet, P. ( 2000) Mol. Biol. Cell 11, 3897 - 3909). Using the fluorescent dye 6-methoxy-N-ethylquinolinium chloride, an indicator for cytosolic chloride, we have investigated the role of either GPI-Ps or actin cytoskeleton in the activity of the selective anionic channel formed by VacA at the plasma membrane level. Removal of GPI-Ps from HeLa cell surfaces did not impair VacA localization into lipid rafts but strongly reduced VacA channel-mediated cell influx and efflux of chloride. Disruption of the actin cytoskeleton of HeLa cells by cytochalasin D did not affect VacA localization in lipid rafts but blocked VacA cell internalization and inhibited cell vacuolation while increasing the overall chloride transport by the toxin channel at the cell surface. Specific enlargement of Rab7-positive compartments induced by VacA could be mimicked by the weak base chloroquine alone, and the vacuolating activities of either chloroquine alone or VacA were blocked with the same potency by the anion channel blocker 5-nitro-2-(3-phenylpropylamino)- benzoic acid shown to inhibit VacA channel activity ( Tombola, F., Oregna, F., Brutsche, S., Szabo`, I., Del Giudice, G., Rappuoli, R., Montecucco, C., Papini, E., and Zoratti, M. ( 1999) FEBS Lett. 460, 221 - 225). We suggest that formation of functional VacA channels at the cell surface required GPI-Ps and that endocytosis of these channels by an actin-dependent process increases the chloride content of late endosomes that accumulate weak bases, provoking their enlargement by osmotic swelling.	Fac Med, INSERM, U452, F-06107 Nice, France; Univ Pavia, Dept Expt Med, Human Physiol Sect, I-27100 Pavia, Italy; Univ Nice, Ctr Commun Microscopie Appl, F-06108 Nice, France; Fac Sci, CNRS, UMR 6548, F-06108 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Pavia; UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS)	Boquet, P (corresponding author), Fac Med, INSERM, U452, IFR 50,28 Ave Valombrose, F-06107 Nice, France.	boquet@unice.fr	Tauc, Michel/F-1530-2013	Tauc, Michel/0000-0002-8383-9818				Adrian M, 2002, J MOL BIOL, V318, P121, DOI 10.1016/S0022-2836(02)00047-5; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; BIWERSI J, 1991, BIOCHEMISTRY-US, V30, P7879, DOI 10.1021/bi00246a001; Boquet P, 2003, TRENDS MICROBIOL, V11, P410, DOI 10.1016/S0966-842X(03)00211-7; Cover TL, 1996, MOL MICROBIOL, V20, P241, DOI 10.1111/j.1365-2958.1996.tb02612.x; COVER TL, 1992, J BIOL CHEM, V267, P10570; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DEBERNARD M, 1995, J BIOL CHEM, V270, P23937, DOI 10.1074/jbc.270.41.23937; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Fivaz M, 2001, CURR TOP MICROBIOL, V257, P35; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; GOGELEIN H, 1989, PFLUG ARCH EUR J PHY, V413, P287, DOI 10.1007/BF00583543; Hotchin NA, 2000, J BIOL CHEM, V275, P14009, DOI 10.1074/jbc.C000153200; Iwamoto H, 1999, FEBS LETT, V450, P101, DOI 10.1016/S0014-5793(99)00474-3; Kuo CH, 2003, BIOCHEM BIOPH RES CO, V303, P640, DOI 10.1016/S0006-291X(03)00380-2; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Morbiato L, 2001, FEBS LETT, V508, P479, DOI 10.1016/S0014-5793(01)03133-7; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; Patel HK, 2002, INFECT IMMUN, V70, P4112, DOI 10.1128/IAI.70.8.4112-4123.2002; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Ricci V, 2000, MOL BIOL CELL, V11, P3897, DOI 10.1091/mbc.11.11.3897; Ricci V, 1997, J PATHOL, V183, P453; Salama NR, 2001, INFECT IMMUN, V69, P730, DOI 10.1128/IAI.69.2.730-736.2001; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sonawane ND, 2003, J CELL BIOL, V160, P1129, DOI 10.1083/jcb.200211098; Sonawane ND, 2002, J BIOL CHEM, V277, P5506, DOI 10.1074/jbc.M110818200; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; Tombola F, 1999, FEBS LETT, V460, P221, DOI 10.1016/S0014-5793(99)01348-4; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vinion-Dubiel AD, 1999, J BIOL CHEM, V274, P37736, DOI 10.1074/jbc.274.53.37736; Willhite DC, 2002, INFECT IMMUN, V70, P3824, DOI 10.1128/IAI.70.7.3824-3832.2002; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	44	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9481	9489		10.1074/jbc.M312040200	http://dx.doi.org/10.1074/jbc.M312040200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676190	hybrid			2022-12-27	WOS:000189265900114
J	Mitri, C; Parmentier, ML; Pin, JP; Bockaert, J; Grau, Y				Mitri, C; Parmentier, ML; Pin, JP; Bockaert, J; Grau, Y			Divergent evolution in metabotropic glutamate receptors - A new receptor activated by an endogenous ligand different from glutamate in insects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AGONIST-BINDING; FUNCTIONAL EXPRESSION; DOMAIN; IDENTIFICATION; SPECIFICITY; RECOGNITION; DATABASE; SUBUNIT; SITE	The metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors involved in the regulation of glutamatergic synapses. Surprisingly, the evolutionarily distant Drosophila mGluR shares a very similar pharmacological profile with its mammalian orthologues (mGlu2R and mGlu3R). Such a conservation in ligand recognition indicates a strong selective pressure during evolution to maintain the ligand recognition selectivity of mGluRs and suggests that structural constraints within the ligand binding pocket (LBP) would hinder divergent evolution. Here we report the identification of a new receptor homologous to mGluRs found in Anopheles gambiae, Apis mellifera, and Drosophila melanogaster genomes and called AmXR, HBmXR, and DmXR, respectively ( the mXRs group). Sequence comparison associated with three-dimensional modeling of the LBP revealed that the residues contacting the amino acid moiety of glutamate (the alpha-COO- and NH3+ groups) were conserved in mXRs, whereas the residues interacting with the gamma-carboxylic group were not. This suggested that the mXRs evolved to recognize an amino acid different from glutamate. The Drosophila cDNA encoding DmXR was isolated and found to be insensitive to glutamate or any other standard amino acid. However, a chimeric receptor with the heptahelical and intracellular domains of DmXR coupled to G-protein. We found that the DmX receptor was activated by a ligand containing an amino group, which was extracted from Drosophila head and from other insects ( Anopheles and Schistocerca). No orthologue of mXR could be detected in Caenorhabditis elegans or human genomes. These data indicate that the LBP of the mGluRs has diverged in insects to recognize a new ligand.	Lab Genom Fonct, CNRS, UPR2580, F-34094 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS)	Grau, Y (corresponding author), Lab Genom Fonct, CNRS, UPR2580, 141 Rue Cardonille, F-34094 Montpellier 05, France.	Yves.Grau@ccipe.cnrs.fr	Parmentier, Marie-Laure/N-9915-2017; Pin, Jean-Philippe/Y-6668-2019	Parmentier, Marie-Laure/0000-0001-6133-3413; Pin, Jean-Philippe/0000-0002-1423-345X; Mitri, Christian/0000-0003-3882-2029				Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Aurelio L, 2002, ORG LETT, V4, P3767, DOI 10.1021/ol026799w; Bessis AS, 2002, P NATL ACAD SCI USA, V99, P11097, DOI 10.1073/pnas.162138699; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Broeck JV, 2001, ARCH INSECT BIOCHEM, V48, P1, DOI 10.1002/arch.1054; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; Gelbart WM, 2002, NUCLEIC ACIDS RES, V30, P106; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Jensen AA, 2000, EUR J PHARMACOL, V397, P247, DOI 10.1016/S0014-2999(00)00283-1; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Malherbe P, 2001, MOL PHARMACOL, V60, P944, DOI 10.1124/mol.60.5.944; MIKS B, 1975, FOL HISTOCH CYTOCHEM, V13, P77; Mouillac B, 1995, ADV EXP MED BIOL, V395, P301; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Parmentier ML, 1996, J NEUROSCI, V16, P6687; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; Pin JP, 2002, CNS NEUROL DISORD-DR, V1, P297, DOI 10.2174/1568007023339328; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; ROSELLIREHFUSS L, 1992, MOL GEN GENET, V235, P213, DOI 10.1007/BF00279363; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sato T, 2003, J BIOL CHEM, V278, P4314, DOI 10.1074/jbc.M210278200; Schoepp DD, 2001, J PHARMACOL EXP THER, V299, P12; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	32	36	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9313	9320		10.1074/jbc.M310878200	http://dx.doi.org/10.1074/jbc.M310878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660580	Green Published, hybrid			2022-12-27	WOS:000189265900094
J	Wang, X; Ma, DW; Keski-Oja, J; Pei, DQ				Wang, X; Ma, DW; Keski-Oja, J; Pei, DQ			Co-recycling of MT1-MMP and MT3-MMP through the trans-Golgi network - Identification of DKV582 as a recycling signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 MATRIX-METALLOPROTEINASE; CELL-SURFACE; MDCK CELLS; MT-MMPS; ACTIVATION; PROGELATINASE; MEMBRANE-TYPE-1; LOCALIZATION; PROTEOLYSIS; CARCINOMAS	Members of the membrane-type matrix metalloproteinases (MT-MMPs) have been implicated in a wide range of physiological and pathological processes from normal development to tumor growth. Tethered on plasma membrane, these enzymes are potentially regulated by the trafficking machinery of the cells. Here we demonstrate that both MT1-MMP and MT3-MMP are internalized, transported to the trans-Golgi network through early endosomes, and recycled back to cell surface in 60 min in a manner distinct from the one employed by transferrin receptor. Interestingly, co-expressed MT1-MMP and MT3-MMP are localized and routed in the same vesicles throughout the trafficking process. We further demonstrated that the carboxyl-terminal sequence DKV582 of MT1-MMP is required for its recycling, thus defining a novel recycling motif. These results suggest that MT-MMPs may coordinate their proteolytic activities through the cellular trafficking machinery.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Chinese Acad Sci, Shanghai Inst Organ Chem, Shanghai 200032, Peoples R China; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki Hosp, FIN-00014 Helsinki, Finland	University of Minnesota System; University of Minnesota Twin Cities; Chinese Academy of Sciences; Shanghai Institute of Organic Chemistry, CAS; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Pei, DQ (corresponding author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	peixx003@umn.edu	Wang, Xing/G-2917-2015		NCI NIH HHS [CA76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076308, R01CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; Jiang AX, 2003, J BIOL CHEM, V278, P38765, DOI 10.1074/jbc.M306618200; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jou TS, 2000, MOL BIOL CELL, V11, P287, DOI 10.1091/mbc.11.1.287; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2002, CANCER RES, V62, P675; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Llano E, 1999, CANCER RES, V59, P2570; Muller L, 2003, J BIOL CHEM, V278, P545, DOI 10.1074/jbc.M208949200; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Ueno H, 1997, CANCER RES, V57, P2055; Urena JM, 1999, J CELL SCI, V112, P773; Velasco G, 2000, CANCER RES, V60, P877; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WU W, 2004, IN PRESS BIOORG MED; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	34	85	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9331	9336		10.1074/jbc.M312369200	http://dx.doi.org/10.1074/jbc.M312369200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14665622	hybrid			2022-12-27	WOS:000189265900096
J	Wu, XY; Suetsugu, S; Cooper, LA; Takenawa, T; Guan, JL				Wu, XY; Suetsugu, S; Cooper, LA; Takenawa, T; Guan, JL			Focal adhesion kinase regulation of N-WASP subcellular localization and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; GTPASE-ACTIVATING PROTEIN; PROMOTED CELL-MIGRATION; SRC FAMILY KINASES; TYROSINE PHOSPHORYLATION; ARP2/3 COMPLEX; STRESS FIBERS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN-FILAMENTS; GROWTH-FACTOR	N-WASP is a member of the WASP family of proteins that regulate actin cytoskeleton remodeling. FAK is a cytoplasmic tyrosine kinase implicated in integrin signaling during cell migration. Here we identify a direct interaction between N-WASP and FAK and show that N-WASP is phosphorylated by FAK at a conserved tyrosine residue, Tyr(256). We found that phosphorylation of Tyr(256) affected N-WASP nuclear localization, suggesting that phosphorylation of N-WASP by FAK may regulate its activity in vivo by altering its subcellular localization. We also showed that the nuclear localization of N-WASP is dependent on its being in the open conformation either after its activation by Cdc42 or the truncation of the C-terminal VCA domain. Phosphorylation of Tyr(256) of N-WASP could reduce its interaction with nuclear importin NPI-1, which might be responsible for its decreased nuclear localization. Lastly, we show that phosphorylation of Tyr(256) plays an important role in promoting cell migration. Together, these results suggest a novel regulatory mechanism of N-WASP by tyrosine phosphorylation and subcellular localization and its potential role in the regulation of cell migration.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Univ Tokyo, Dept Biochem, Tokyo 1088639, Japan	Cornell University; University of Tokyo	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	jg19@cornell.edu	Suetsugu, Shiro/ABB-6033-2020; Suetsugu, Shiro/B-3300-2010; Suetsugu, Shiro/AAF-4427-2019	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628				Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Christopher RA, 2000, INT J MOL MED, V5, P575; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; DeMali KA, 2002, J CELL BIOL, V159, P881, DOI 10.1083/jcb.200206043; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sturge J, 2002, J CELL SCI, V115, P699; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Takenawa T, 2001, J CELL SCI, V114, P1801; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; Vetterkind S, 2002, J BIOL CHEM, V277, P87, DOI 10.1074/jbc.M104555200; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Withers BE, 1996, PROTEIN EXPRES PURIF, V7, P12, DOI 10.1006/prep.1996.0002; Yamaguchi H, 2002, CANCER RES, V62, P2503; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5	54	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9565	9576		10.1074/jbc.M310739200	http://dx.doi.org/10.1074/jbc.M310739200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676198	hybrid			2022-12-27	WOS:000189265900124
J	Brugger, B; Graham, C; Leibrecht, I; Mombelli, E; Jen, A; Wieland, F; Morris, R				Brugger, B; Graham, C; Leibrecht, I; Mombelli, E; Jen, A; Wieland, F; Morris, R			The membrane domains occupied by glycosylphosphatidylinositol-anchored prion protein and Thy-1 differ in lipid composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; LOW PICOMOLE LEVEL; FC-EPSILON-RI; PHASE-EQUILIBRIA; CELL-MEMBRANES; QUANTITATIVE-ANALYSIS; BIOLOGICAL-MEMBRANES; NEUROBLASTOMA-CELLS; NEURONAL SURFACE; MODEL MEMBRANES	Glycosylphosphatidylinositol-anchored prion protein and Thy-1, found in adjacent microdomains or "rafts" on the neuronal surface, traffic very differently and show distinctive differences in their resistance to detergent solubilization. Monovalent immunogold labeling showed that the two proteins were largely clustered in separate domains on the neuronal surface: 86% of prion protein was clustered in domains containing no Thy-1, although 40% of Thy-1 had a few molecules of prion protein associated with it. Only 1% of all clusters contained appreciable levels of both proteins (>3 immunogold label for both). In keeping with this distribution, immunoaffinity isolation of detergent-resistant membranes (DRMs) using the non-ionic detergent Brij 96 yielded prion protein DRMs with little Thy-1, whereas Thy-1 DRMs contained similar to20% of prion protein. The lipid content of prion protein and Thy-1 DRMs was measured by quantitative nano-electrospray ionization tandem mass spectrometry. In four independent preparations, the lipid content was highly reproducible, with Thy-1 and prion protein DRMs differing markedly from each other and from the total DRM pool from which they were immunoprecipitated. Prion protein DRMs contained significantly more unsaturated, longer chain lipids than Thy-1 DRMs and had 5-fold higher levels of hexosylceramide. The different lipid compositions are in keeping with the different trafficking dynamics and solubility of the two proteins and show that, under the conditions used, DRMs can isolate individual membrane microenvironments. These results further identify unsaturation and glycosylation of lipids as major sources of diversity of raft structure.	Kings Coll London, MRC, Ctr Dev Neurobiol, Mol Neurobiol Grp, London SE1 1UL, England; Univ Heidelberg, BZH, D-69120 Heidelberg, Germany	University of London; King's College London; Ruprecht Karls University Heidelberg	Morris, R (corresponding author), Kings Coll London, MRC, Ctr Dev Neurobiol, Mol Neurobiol Grp, Guys Campus, London SE1 1UL, England.	roger.morris@kcl.ac.uk	Morris, Roger/C-4615-2008; Mombelli, Enrico/R-5306-2018	Hay, Catriona/0000-0002-9667-0812; Mombelli, Enrico/0000-0001-7006-0680				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Baird B, 1999, BIOPHYS CHEM, V82, P109, DOI 10.1016/S0301-4622(99)00110-6; BARCLAY AN, 1975, BIOCHEM J, V151, P699, DOI 10.1042/bj1510699; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brown RE, 1998, J CELL SCI, V111, P1; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; DERRY DM, 1967, SCIENCE, V158, P1450, DOI 10.1126/science.158.3807.1450; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Ford MJ, 2002, NEUROSCIENCE, V113, P177, DOI 10.1016/S0306-4522(02)00155-0; Ford MJ, 2002, NEUROSCIENCE, V111, P533, DOI 10.1016/S0306-4522(01)00603-0; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Gurr MI, 2002, LIPID BIOCH, P127; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Hueber AO, 1997, CURR BIOL, V7, P705, DOI 10.1016/S0960-9822(06)00300-9; IPSEN JH, 1987, BIOCHIM BIOPHYS ACTA, V905, P162; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; LEMANSKY P, 1990, J CELL BIOL, V110, P1525, DOI 10.1083/jcb.110.5.1525; Leventis R, 2001, BIOPHYS J, V81, P2257, DOI 10.1016/S0006-3495(01)75873-0; Li XM, 2001, BIOCHEMISTRY-US, V40, P5954, DOI 10.1021/bi002791n; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MASON DW, 1980, BIOCHEM J, V187, P1; MATEO CR, 1995, BIOPHYS J, V68, P978, DOI 10.1016/S0006-3495(95)80273-0; Miao L, 2002, BIOPHYS J, V82, P1429, DOI 10.1016/S0006-3495(02)75497-0; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Mombelli E, 2003, BIOPHYS J, V84, P1507, DOI 10.1016/S0006-3495(03)74963-7; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; MORRIS R, 1992, BIOESSAYS, V14, P715, DOI 10.1002/bies.950141014; MORRIS RJ, 2004, IN PRESS MEMBRANE DY; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; Parizek P, 2001, J BIOL CHEM, V276, P44627, DOI 10.1074/jbc.M107458200; Parkin ET, 2001, BIOCHEM J, V358, P209, DOI 10.1042/0264-6021:3580209; PERKINS SJ, 1988, TRENDS BIOCHEM SCI, V13, P302, DOI 10.1016/0968-0004(88)90124-7; RECKTENWALD DJ, 1981, BIOCHEMISTRY-US, V20, P4505, DOI 10.1021/bi00518a042; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Rog T, 2001, FEBS LETT, V502, P68, DOI 10.1016/S0014-5793(01)02668-0; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Sandhoff R, 1999, J LIPID RES, V40, P126; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; THEWALT JL, 1992, BIOPHYS J, V63, P1176, DOI 10.1016/S0006-3495(92)81681-8; VIST MR, 1990, BIOCHEMISTRY-US, V29, P451, DOI 10.1021/bi00454a021; Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311; Watanabe R, 2002, J BIOL CHEM, V277, P49538, DOI 10.1074/jbc.M206209200; Wilson BS, 2001, J CELL BIOL, V154, P645, DOI 10.1083/jcb.200104049; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200	63	137	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7530	7536		10.1074/jbc.M310207200	http://dx.doi.org/10.1074/jbc.M310207200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660659	hybrid			2022-12-27	WOS:000189103300021
J	Nymalm, Y; Puranen, JS; Nyholm, TKM; Kapyla, J; Kidron, H; Pentikainen, OT; Airenne, TT; Heino, J; Slotte, JP; Johnson, MS; Salminen, TA				Nymalm, Y; Puranen, JS; Nyholm, TKM; Kapyla, J; Kidron, H; Pentikainen, OT; Airenne, TT; Heino, J; Slotte, JP; Johnson, MS; Salminen, TA			Jararhagin-derived RKKH peptides induce structural changes in alpha I-1 domain of human integrin alpha(1)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM METALLOPROTEINASE; INTEGRIN I-DOMAIN; PARTICLE MESH EWALD; CRYSTAL-STRUCTURE; CELL-ADHESION; EXTRACELLULAR SEGMENT; MOLECULAR-DYNAMICS; COLLAGEN-BINDING; LIGAND-BINDING; PROTEIN	Integrin alpha(1)beta(1) is one of four collagen-binding integrins in humans. Collagens bind to the alphaI domain and in the case of alpha(2)I collagen binding is competitively inhibited by peptides containing the RKKH sequence and derived from the metalloproteinase jararhagin of snake venom from Bothrops jararaca. In alpha(2)I, these peptides bind near the metal ion-dependent adhesion site (MIDAS), where a collagen ( I)-like peptide is known to bind; magnesium is required for binding. Published structures of the ligand-bound "open" conformation of alpha(2)I differs significantly from the "closed" conformation seen in the structure of apo-alpha(2)I near MIDAS. Here we show that two peptides, CTRKKHDC and CARKKHDC, derived from jararhagin also bind to alpha(1)I and competitively inhibit collagen I binding. Furthermore, calorimetric and fluorimetric measurements show that the structure of the complex of alpha(1)I with Mg2+ and CTRKKHDC differs from structure in the absence of peptide. A comparison of the x-ray structure of apo-alpha(1)I ("closed" conformation) and a model structure of the alpha(1)I ("open" conformation) based on the closely related structure of alpha(2)I reveals that the binding site is partially blocked to ligands by Glu(255) and Tyr(285) in the "closed" structure, whereas in the "open" structure helix C is unwound and these residues are shifted, and the "RKKH" peptides fit well when docked. The "open" conformation of alpha(2)I resulting from binding a collagen ( I)-like peptide leads to exposure of hydrophobic surface, also seen in the model of alpha(1)I and shown experimentally for alpha(1)I using a fluorescent hydrophobic probe.	Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland; Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland	Abo Akademi University; University of Jyvaskyla; University of Turku	Salminen, TA (corresponding author), Abo Akad Univ, Dept Biochem & Pharm, POB 66, FIN-20521 Turku, Finland.	tiina.salminen@abo.fi	Kidron, Heidi/A-5826-2015; Salminen, Tiina A./AAM-5443-2021; Pentikäinen, Olli T/E-1980-2012; Salminen, Tiina A/G-7492-2019	Kidron, Heidi/0000-0001-6427-8042; Salminen, Tiina A./0000-0002-4135-8020; Pentikäinen, Olli T/0000-0001-7188-4016; Salminen, Tiina A/0000-0002-4135-8020; Kapyla, Jarmo/0000-0003-3036-713X				Aquilina A, 2002, EUR J BIOCHEM, V269, P1136, DOI 10.1046/j.0014-2956.2001.02740.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin ET, 1998, STRUCTURE, V6, P923, DOI 10.1016/S0969-2126(98)00093-8; Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658, DOI 10.1007/978-94-015-7658]; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FREIRE E, 1995, ANNU REV BIOPH BIOM, V24, P141, DOI 10.1146/annurev.bb.24.060195.001041; Ghose AK, 1998, J PHYS CHEM A, V102, P3762, DOI 10.1021/jp980230o; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; Gong WM, 1998, J MOL BIOL, V283, P657, DOI 10.1006/jmbi.1998.2110; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Gullberg D, 2003, MOL B INT U, P67; HEIDEN W, 1993, J COMPUT AID MOL DES, V7, P503, DOI 10.1007/BF00124359; Heino J, 2003, MOL B INT U, P143; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; HOCKNEY RW, 1974, J COMPUT PHYS, V14, P148, DOI 10.1016/0021-9991(74)90010-2; Humphries MJ, 2002, ARTHRITIS RES THER, V4, pS69, DOI 10.1186/ar563; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jia LG, 1997, J BIOL CHEM, V272, P13094, DOI 10.1074/jbc.272.20.13094; Johnson MS, 2003, MOL B INT U, P1; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Kamiguti AS, 2003, FEBS LETT, V549, P129, DOI 10.1016/S0014-5793(03)00799-3; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; Karpusas M, 2003, J MOL BIOL, V327, P1031, DOI 10.1016/S0022-2836(03)00203-1; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARJAVA H, 1990, J CELL BIOL, V110, P803, DOI 10.1083/jcb.110.3.803; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mendelson JK, 2000, J CUTAN PATHOL, V27, P61, DOI 10.1034/j.1600-0560.2000.027002061.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Pentikainen O, 1999, J BIOL CHEM, V274, P31493, DOI 10.1074/jbc.274.44.31493; PIGOTT R, 1993, ADHESION MOL FACTS; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Salminen TA, 1999, ACTA CRYSTALLOGR D, V55, P1365, DOI 10.1107/S0907444999006009; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEITZMAN JB, 1995, J CELL SCI, V108, P3635; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200; Zigrino P, 2002, J BIOL CHEM, V277, P40528, DOI 10.1074/jbc.M202049200	70	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7962	7970		10.1074/jbc.M312912200	http://dx.doi.org/10.1074/jbc.M312912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660600	hybrid			2022-12-27	WOS:000189103300074
J	Reyes-Moreno, C; Girouard, J; Lapointe, R; Darveau, A; Mourad, W				Reyes-Moreno, C; Girouard, J; Lapointe, R; Darveau, A; Mourad, W			CD40/CD40 homodimers are required for CD40-induced phosphatidylinositol 3-kinase-dependent expression of B7.2 by human B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHRITIDIS-DERIVED MITOGEN; GERMINAL CENTER FORMATION; NF-KAPPA-B; CD40 LIGAND; CYTOKINE SECRETION; CELL DEVELOPMENT; PROTEIN-KINASE; FACTORS TRAFS; ACTIVATION; RECEPTOR	Preformed CD40/CD40 homodimers were initially observed on human Burkitt lymphoma cell lines, normal B cells, and transitional bladder carcinoma cell lines. However, the nature and the biological relevance of these homodimers have not yet been investigated. In the present study, we demonstrated that Epstein-Barr virus-transformed B cells and CD40-transfected HEK 293 cells constitutively expressed disulfide-linked CD40/ CD40 homodimers at low levels. Oligomerization of CD40 leads to a rapid and significant increase in the disulfide-linked CD40/ CD40 homodimer formation, a response that could be prevented using a thiol-alkylating agent. Formation of CD40/ CD40 homodimers was found to be absolutely required for CD40-mediated activation of phosphatidylinositol 3-kinase, which, in turn regulated B7.2 expression. In contrast, CD40 monomers provided the minimal signal emerging from CD40, activating p38 MAP kinase and inducing homotypic B cell adhesion. CD40/ CD40 homodimer formation was totally independent of TRAF1/2/3/5 associations with the threonine at position 254 in the cytoplasmic tail of the CD40 molecules. This finding may be vital to better understanding the molecular mechanisms that govern cell signaling triggered by CD40/ CD154 interactions.	CHU Laval, CRRI, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Biochem & Microbiol, Quebec City, PQ G1V 4G2, Canada; Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ H2W 1T8, Canada	Laval University; Laval University; Universite de Montreal	Mourad, W (corresponding author), CHU Laval, CRRI, 2705 Blvd Laurier,T-121, Quebec City, PQ G1V 4G2, Canada.	walid.mourad@crchul.ulaval.ca		Mourad, Walid/0000-0002-1859-9387				ALDACCAK R, 1995, EUR J IMMUNOL, V25, P2539, DOI 10.1002/eji.1830250920; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S; Baker MP, 1998, BLOOD, V92, P2830, DOI 10.1182/blood.V92.8.2830.420k10_2830_2843; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Dallman C, 2003, APOPTOSIS, V8, P45, DOI 10.1023/A:1021696902187; Ding JY, 2000, J BIOL CHEM, V275, P30873, DOI 10.1074/jbc.M004813200; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Etongue-Mayer P, 2002, EUR J IMMUNOL, V32, P50, DOI 10.1002/1521-4141(200201)32:1<50::AID-IMMU50>3.0.CO;2-A; Evans DE, 2000, J IMMUNOL, V164, P688, DOI 10.4049/jimmunol.164.2.688; Fanslow W C, 1994, Semin Immunol, V6, P267, DOI 10.1006/smim.1994.1035; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Grammer A C, 2000, Adv Immunol, V76, P61; Grammer AC, 1998, J IMMUNOL, V161, P1183; GRAZIOLI L, 1994, J BIOL CHEM, V269, P22304; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Haswell LE, 2001, EUR J IMMUNOL, V31, P3094, DOI 10.1002/1521-4141(2001010)31:10<3094::AID-IMMU3094>3.0.CO;2-F; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Langlois MA, 2000, EUR J IMMUNOL, V30, P1748, DOI 10.1002/1521-4141(200006)30:6<1748::AID-IMMU1748>3.0.CO;2-J; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LEVINE BL, 1995, INT IMMUNOL, V7, P891, DOI 10.1093/intimm/7.6.891; Li YY, 1996, J IMMUNOL, V157, P1440; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Mauri C, 2000, NAT MED, V6, P673, DOI 10.1038/76251; Morris AE, 1999, J BIOL CHEM, V274, P418, DOI 10.1074/jbc.274.1.418; Pound JD, 1999, INT IMMUNOL, V11, P11, DOI 10.1093/intimm/11.1.11; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Tamada K, 2002, J CLIN INVEST, V109, P549, DOI 10.1172/JCI200213604; Town T, 2001, NEUROCHEM INT, V39, P371, DOI 10.1016/S0197-0186(01)00044-4; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	48	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7799	7806		10.1074/jbc.M313168200	http://dx.doi.org/10.1074/jbc.M313168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676197	hybrid			2022-12-27	WOS:000189103300054
J	Sozio, MS; Mathis, MA; Young, JA; Walchli, S; Pitcher, LA; Wrage, PC; Bartok, B; Campbell, A; Watts, JD; Aebersold, R; van Huijsduijnen, RH; van Oers, NSC				Sozio, MS; Mathis, MA; Young, JA; Walchli, S; Pitcher, LA; Wrage, PC; Bartok, B; Campbell, A; Watts, JD; Aebersold, R; van Huijsduijnen, RH; van Oers, NSC			PTPH1 is a predominant protein-tyrosine phosphatase capable of interacting with and dephosphorylating the T cell receptor zeta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; TCR-ZETA; SIGNAL-TRANSDUCTION; STRUCTURAL BASIS; MOLECULAR-BASIS; MOTH-EATEN; KINASE; CD45; SUBSTRATE; COMPLEX	Protein-tyrosine phosphatases (PTPases) play key roles in regulating tyrosine phosphorylation levels in cells, yet the identity of their substrates remains limited. We report here on the identification of PTPases capable of dephosphorylating the phosphorylated immune tyrosine-based activation motifs present in the T cell receptor zeta subunit. To characterize these PTPases, we purified enzyme activities directed against the phosphorylated T cell receptor zeta subunit by a combination of anion and cation chromatography procedures. A novel ELISA-based PTPase assay was developed to rapidly screen protein fractions for enzyme activity following the various chromatography steps. We present data that SHP-1 and PTPH1 are present in highly enriched protein fractions that exhibit PTPase activities toward a tyrosine-phosphorylated TCR zeta substrate (specific activity ranging from 0.23 to 40 pmol/min/mug). We also used a protein-tyrosine phosphatase substrate-trapping library comprising the catalytic domains of 47 distinct protein-tyrosine phosphatases, representing almost all the tyrosine phosphatases identified in the human genome. PTPH1 was the predominant phosphatase capable of complexing phospho-zeta. Subsequent transfection assays indicated that SHP-1 and PTPH1 are the two principal PTPases capable of regulating the phosphorylation state of the TCR zeta ITAMs, with PTPH1 directly dephosphorylating zeta. This is the first reported demonstration that PTPH1 is a candidate PTPase capable of interacting with and dephosphorylating TCR zeta.	Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Inst Syst Biol, Seattle, WA 98103 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Institute for Systems Biology (ISB)	van Oers, NSC (corresponding author), NA7-201,6000 Harry Hines Blvd, Dallas, TX 75390 USA.	nicolai.vanoers@utsouthwestern.edu	Van+Oers, Nicolai/ABA-2437-2021; Hooft van Huijsduijnen, Rob/B-3653-2009	Walchli, Sebastien/0000-0001-5869-1746; Hooft van Huijsduijnen, Rob/0000-0002-2261-9424; van Oers, Nicolai/0000-0002-6545-8405	NIAID NIH HHS [AI42953] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042953] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFFOLTER M, 1994, ANAL BIOCHEM, V223, P74, DOI 10.1006/abio.1994.1549; Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; Brockdorff J, 1999, EUR J IMMUNOL, V29, P2539, DOI 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Guntermann C, 2002, J IMMUNOL, V168, P4420, DOI 10.4049/jimmunol.168.9.4420; Han SL, 2000, EUR J IMMUNOL, V30, P1318, DOI 10.1002/(SICI)1521-4141(200005)30:5<1318::AID-IMMU1318>3.0.CO;2-G; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Huyer G, 1999, CURR BIOL, V9, pR129, DOI 10.1016/S0960-9822(99)80080-3; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Pitcher LA, 2003, IMMUNOL REV, V191, P47, DOI 10.1034/j.1600-065X.2003.00003.x; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Stone JD, 1997, J IMMUNOL, V158, P5773; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; van Oers NSC, 2000, NAT IMMUNOL, V1, P322, DOI 10.1038/79774; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; Veillette A, 2002, ANNU REV IMMUNOL, V20, P669, DOI 10.1146/annurev.immunol.20.081501.130710; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; WATTS JD, 1992, J BIOL CHEM, V267, P901; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weissenhorn W, 1996, EUR J BIOCHEM, V238, P440, DOI 10.1111/j.1432-1033.1996.0440z.x; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067	52	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7760	7769		10.1074/jbc.M309994200	http://dx.doi.org/10.1074/jbc.M309994200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672952	hybrid			2022-12-27	WOS:000189103300049
J	Tang, CR; Vaughan, AM; Oram, JF				Tang, CR; Vaughan, AM; Oram, JF			Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASSETTE TRANSPORTER A1; HIGH-DENSITY-LIPOPROTEIN; APOA-I; SIGNALING PATHWAYS; PEST SEQUENCE; EFFLUX; BINDING; PHOSPHORYLATION; DEGRADATION; MACROPHAGES	ATP-binding cassette transporter A1 (ABCA1) mediates transport of cellular cholesterol and phospholipids to high density lipoprotein (HDL) apolipoproteins, such as apoA-I. ABCA1 mutations can cause a severe HDL deficiency and atherosclerosis. Here we show that the protein-tyrosine kinase (TK) Janus kinase 2 (JAK2) modulates the apolipoprotein interactions with ABCA1 required for removing cellular lipids. The protein kinase A (PKA) inhibitor H89, the TK inhibitor genistein, and the JAK2 inhibitor AG490 suppressed apoA-I-mediated cholesterol and phospholipid efflux from ABCA1-expressing cells without altering the membrane ABCA1 content. Whereas PKA inhibition had no effect on apoA-I binding to cells or to ABCA1, TK and JAK2 inhibition greatly reduced these activities. Conversely, PKA but not JAK2 inhibition significantly reduced the intrinsic cholesterol translocase activity of ABCA1. Mutant cells lacking JAK2 had a severely impaired apoA-I-mediated cholesterol and phospholipid efflux and apoA-I binding despite normal ABCA1 protein levels and near normal cholesterol translocase activity. Thus, although PKA modulates ABCA1 lipid transport activity, JAK2 appears to selectively modulate apolipoprotein interactions with ABCA1. TK-mediated phosphorylation of ABCA1 was undetectable, implicating the involvement of another JAK2-targeted protein. Acute incubation of ABCA1-expressing cells with apoA-I had no effect on ABCA1 phosphorylation but stimulated JAK2 autophosphorylation. These results suggest that the interaction of apolipoproteins with ABCA1-expressing cells activates JAK2, which in turn activates a process that enhances apolipoprotein interactions with ABCA1 and lipid removal from cells.	Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Oram, JF (corresponding author), Univ Washington, Dept Med, Box 356424, Seattle, WA 98195 USA.	joram@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055362] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL186, HL55362] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiello RJ, 2003, ARTERIOSCL THROM VAS, V23, P972, DOI 10.1161/01.ATV.0000054661.21499.FB; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Burfoot MS, 1997, J BIOL CHEM, V272, P24183, DOI 10.1074/jbc.272.39.24183; Carvalheira JBC, 2003, BIOL CHEM, V384, P151, DOI 10.1515/BC.2003.016; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Garver WS, 1997, ARTERIOSCL THROM VAS, V17, P2698, DOI 10.1161/01.ATV.17.11.2698; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; Joyce C, 2003, ARTERIOSCL THROM VAS, V23, P965, DOI 10.1161/01.ATV.0000055194.85073.FF; Kerr IM, 2003, FEBS LETT, V546, P1, DOI 10.1016/S0014-5793(03)00411-3; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Saad MJA, 1996, J BIOL CHEM, V271, P22100, DOI 10.1074/jbc.271.36.22100; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Singaraja RR, 2003, ARTERIOSCL THROM VAS, V23, P1322, DOI 10.1161/01.ATV.0000078520.89539.77; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Wang YT, 2002, J BIOL CHEM, V277, P5692, DOI 10.1074/jbc.M109977200; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Wellington CL, 2003, J LIPID RES, V44, P1470, DOI 10.1194/jlr.M300110-JLR200; Yamauchi Y, 2003, J BIOL CHEM, V278, P47890, DOI 10.1074/jbc.M306258200	33	96	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7622	7628		10.1074/jbc.M312571200	http://dx.doi.org/10.1074/jbc.M312571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668333	hybrid			2022-12-27	WOS:000189103300032
J	Zhao, XB; Girotto, S; Yu, SW; Magliozzo, RS				Zhao, XB; Girotto, S; Yu, SW; Magliozzo, RS			Evidence for radical formation at Tyr-353 in Mycobacterium tuberculosis catalase-peroxidase (KatG)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H SYNTHASE-1 AND-2; NITRIC-OXIDE; ISONIAZID ACTIVATION; TYROSYL RADICALS; PHOTOSYSTEM-II; RIBONUCLEOTIDE REDUCTASE; DRUG-RESISTANCE; PURIFICATION; IDENTIFICATION; CATALYSIS	Mycobacterium tuberculosis KatG is a heme-containing catalase-peroxidase responsible for activation, through its peroxidase cycle, of the front line antituberculosis antibiotic isoniazid (isonicotinic acid hydrazide). Formation of Compound I (oxyferryl heme-porphyrin pi-cation radical), the classical peroxidase intermediate generated when the resting enzyme turns over with alkyl peroxides, is rapidly followed by production of a protein-centered tyrosyl radical in this enzyme. In our efforts to identify the residue at which this radical is formed, nitric oxide was used as a radical scavenging reagent. Quenching of the tyrosyl radical generated in the presence of NO was shown using electron paramagnetic resonance spectroscopy, and formation of nitrotyrosine was confirmed by proteolytic digestion followed by high performance liquid chromatography analysis of the NO-treated enzyme. These results are consistent with formation of nitrosyltyrosine by addition of NO to tyrosyl radical and oxidation of this intermediate to nitrotyrosine. Two predominant nitrotyrosine-containing peptides were identified that were purified and sequenced by Edman degradation. Both peptides were derived from the same M. tuberculosis KatG sequence spanning residues 346-356 with the amino acid sequence SPAGAWQYTAK, and both peptides contained nitrotyrosine at residue 353. Some modification of Trp-351 most probably into nitrosotryptophan was also found in one of the two peptides. Control experiments using denatured KatG or carried out in the absence of peroxide did not produce nitrotyrosine. In the mutant enzyme KatG(Y353F), which was constructed using site-directed mutagenesis, a tyrosyl radical was also formed upon turnover with peroxide but in poor yield compared with wild-type KatG. Residue Tyr-353 is unique to M. tuberculosis KatG and may play a special role in the function of this enzyme.	CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA; CUNY, Grad Ctr, Dept Chem, New York, NY 10016 USA; CUNY, Grad Ctr, Dept Biochem, New York, NY 10016 USA	City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) System	Magliozzo, RS (corresponding author), CUNY Brooklyn Coll, Dept Chem, 2900 Bedford Ave, Brooklyn, NY 11210 USA.	rmaglioz@brooklyn.cuny.edu	Girotto, Stefania/F-5997-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-43582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARRY BA, 1990, J BIOL CHEM, V265, P20139; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; DUNFORD HB, 1999, HEME PEROXIDASES, P141; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Gunther MR, 2000, FREE RADICAL BIO MED, V28, P709, DOI 10.1016/S0891-5849(00)00164-7; Herold S, 2002, BIOCHEMISTRY-US, V41, P13460, DOI 10.1021/bi026046h; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; Kirsch M, 2003, J BIOL CHEM, V278, P11931, DOI 10.1074/jbc.M300237200; Langella E, 2002, J AM CHEM SOC, V124, P11531, DOI 10.1021/ja020465k; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; LOEWEN PC, 1990, BIOCHEM CELL BIOL, V68, P1037, DOI 10.1139/o90-153; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; PACKER L, 1996, METHOD ENZYMOL, V269, P185; PETROULEAS V, 1990, BIOCHIM BIOPHYS ACTA, V1015, P131, DOI 10.1016/0005-2728(90)90224-R; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Szalai VA, 1996, BIOCHEMISTRY-US, V35, P15080, DOI 10.1021/bi961117w; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; Wei CJ, 2003, ANTIMICROB AGENTS CH, V47, P670, DOI 10.1128/AAC.47.2.670-675.2003; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; Yu SW, 2003, J BIOL CHEM, V278, P44121, DOI 10.1074/jbc.M304757200; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1994, J ANTIMICROB CHEMOTH, V34, P313, DOI 10.1093/jac/34.3.313	34	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7606	7612		10.1074/jbc.M311884200	http://dx.doi.org/10.1074/jbc.M311884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665627	hybrid			2022-12-27	WOS:000189103300030
J	Barzilay, E; Ben-Califa, N; Supino-Rosin, L; Kashman, Y; Hirschberg, K; Elazar, Z; Neumann, D				Barzilay, E; Ben-Califa, N; Supino-Rosin, L; Kashman, Y; Hirschberg, K; Elazar, Z; Neumann, D			Geldanamycin-associated inhibition of intracellular trafficking is attributed to a co-purified activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; BENZOQUINONE ANSAMYCINS; SIGNAL-TRANSDUCTION; IN-VIVO; DEGRADATION; HSP90; COMPLEX; ERYTHROPOIETIN; BINDS	Geldanamycin, an ansamycin antibiotic that specifically inhibits heat-shock protein-90 (HSP90) and its endoplasmic reticulum homologue, glucose-regulated protein-94 (GRP94), accelerates the degradation of selected cellular proteins. We showed previously that geldanamycin inhibits maturation and transport of the epidermal growth factor receptor in addition to accelerating its degradation (Supino-Rosin, L., Yoshimura, A., Yarden, Y., Elazar, Z., and Neumann, D. (2000) J. Biol. Chem. 275, 21850-21855). Here we demonstrate that the additional activities of geldanamycin on intracellular transport and protein maturation are related to its supply source. By combining chemical separation of Streptomyces hygroscopicus var. geldanus extracts and biological screens, we show that the geldanamycin-associated effects on intracellular transport and protein maturation are not mediated by geldanamycin itself but are due to the presence of an additional component(s). Chromatography of S. hygroscopicus var. geldanus extracts on a silica-gel column allowed separation between the inhibition of intracellular trafficking and geldanamycin-mediated degradation. One fraction that was devoid of geldanamycin blocked secretion of a soluble form of the erythropoietin receptor, retarded maturation of the epidermal growth factor receptor without enhancing its degradation, and blocked anterograde transport of a temperature-sensitive mutant of the vesicular stomatitis virus G protein (VSVGtsO45) from the early Golgi cisternae. This fraction was enriched (> 95%) in 17-demethylgeldanamycin. However, as synthetically derived 17-demethylgeldanamycin did not inhibit intracellular trafficking, we concluded that 17-demethylgeldanamycin is not the active component. We thus propose that a compound(s) that co-purifies with benzoquinone ansamycins inhibits intracellular transport. Taken together, our data demonstrate that the inhibitory effects on protein maturation and intracellular trafficking, previously attributed to geldanamycin, are mediated by another distinct moiety.	Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Ramat Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Pathol, IL-69978 Ramat Aviv, Israel; Tel Aviv Univ, Sch Chem, IL-69978 Ramat Aviv, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Weizmann Institute of Science	Neumann, D (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Cell & Dev Biol, IL-69978 Ramat Aviv, Israel.	Histo6@post.tau.ac.il	Hirschberg, Koret/AAF-4566-2019	Barzilay, Eran/0000-0001-5496-4866; Neumann, Drorit/0000-0002-4805-7511				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Chavany C, 1996, J BIOL CHEM, V271, P4974; Cohen J, 1997, BIOCHEM J, V327, P391, DOI 10.1042/bj3270391; DEBOER C, 1970, J ANTIBIOT, V23, P442, DOI 10.7164/antibiotics.23.442; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; MILLER P, 1994, CANCER RES, V54, P2724; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Neumann D, 1996, BIOCHEM J, V313, P391, DOI 10.1042/bj3130391; NEUMANN D, 1993, J BIOL CHEM, V268, P13639; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Sakagami M, 1999, CELL STRESS CHAPERON, V4, P19, DOI 10.1054/csac.1998.0115; SCHNUR RC, 1995, J MED CHEM, V38, P3806, DOI 10.1021/jm00019a010; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200	27	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6847	6852		10.1074/jbc.M312799200	http://dx.doi.org/10.1074/jbc.M312799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660597	hybrid			2022-12-27	WOS:000188969200079
J	Nishita, M; Wang, Y; Tomizawa, C; Suzuki, A; Niwa, R; Uemura, T; Mizuno, K				Nishita, M; Wang, Y; Tomizawa, C; Suzuki, A; Niwa, R; Uemura, T; Mizuno, K			Phosphoinositide 3-kinase-mediated activation of cofilin phosphatase slingshot and its role for insulin-induced membrane protrusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ACTIN REORGANIZATION; TUMOR-SUPPRESSOR; PROTEIN-KINASE; CELL POLARITY; LIM-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NEUTROPHIL CHEMOTAXIS; SIGNALING PATHWAYS; PHOSPHORYLATION; ADF/COFILIN	Cofilin plays an essential role in actin filament dynamics and membrane protrusion in motile cells. Cofilin is inactivated by phosphorylation at Ser-3 by LIM kinase and reactivated by dephosphorylation by cofilin-phosphatase Slingshot (SSH). Although cofilin is dephosphorylated in response to various extracellular stimuli, signaling pathways regulating SSH activation and cofilin dephosphorylation have remained to be elucidated. Here we show that insulin stimulates the phosphatase activity of Slingshot-1L (SSH1L) and cofilin dephosphorylation in cultured cells, in a manner dependent on phosphoinositide 3-kinase (PI3K) activity. Consistent with this, the level of Ser-3-phosphorylated cofilin is increased in PTEN (phosphatase and tensin homolog deleted in chromosome 10)-overexpressing cells and decreased in PTEN-deficient cells. Insulin induced the accumulation of SSH1L and active Akt (a downstream effector of PI3K), together with a PI3K product phosphatidylinositol 3,4,5-trisphosphate, onto membrane protrusions. Cofilin, but not Ser-3-phosphorylated cofilin, accumulated in membrane protrusions in insulin-stimulated cells, indicating that cofilin is dephosphorylated in these areas. Finally, suppression of SSH1L expression by RNA interference abolished insulin-induced cofilin dephosphorylation and the membrane protrusion. These findings suggest that SSH1L is activated downstream of PI3K and plays a critical role in insulin-induced membrane protrusion by dephosphorylating and activating cofilin.	Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan; Akita Univ, Sch Med, Dept Mol Biol, Akita 0108543, Japan; Kyoto Univ, Inst Virus Res, Dept Mol Genet, Kyoto 6068507, Japan; Japan Sci & Technol Corp, CREST, Kyoto 6068507, Japan	Tohoku University; Akita University; Kyoto University; Japan Science & Technology Agency (JST)	Mizuno, K (corresponding author), Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan.	kmizuno@biology.tohoku.ac.jp	Mizuno, Kensaku/G-8631-2015; Suzuki, Akira/GYD-6697-2022	Suzuki, Akira/0000-0002-5950-8808; UEMURA, Tadashi/0000-0001-7204-3606				Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bailly M, 2003, CURR BIOL, V13, pR128, DOI 10.1016/S0960-9822(03)00072-1; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Dawe HR, 2003, CURR BIOL, V13, P252, DOI 10.1016/S0960-9822(03)00040-X; Endo M, 2003, J NEUROSCI, V23, P2527; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Kaji N, 2003, J BIOL CHEM, V278, P33450, DOI 10.1074/jbc.M305802200; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ohta Y, 2003, GENES CELLS, V8, P811, DOI 10.1046/j.1365-2443.2003.00678.x; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosenblatt J, 1998, NATURE, V393, P739, DOI 10.1038/31597; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tobe K, 2003, GENES CELLS, V8, P29, DOI 10.1046/j.1365-2443.2003.00611.x; Toshima J, 2001, MOL BIOL CELL, V12, P1131, DOI 10.1091/mbc.12.4.1131; Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zebda N, 2000, J CELL BIOL, V151, P1119, DOI 10.1083/jcb.151.5.1119	34	89	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7193	7198		10.1074/jbc.M312591200	http://dx.doi.org/10.1074/jbc.M312591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645219	hybrid			2022-12-27	WOS:000188969200118
J	Tan, W; Zheng, L; Lee, WH; Boyer, TG				Tan, W; Zheng, L; Lee, WH; Boyer, TG			Functional dissection of transcription factor ZBRK1 reveals zinc fingers with dual roles in DNA-binding and BRCA1-dependent transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE RESPONSE; BREAST-CANCER; CELL-CYCLE; ATAXIA-TELANGIECTASIA; GENETIC INSTABILITY; CRYSTAL-STRUCTURE; OVARIAN-CANCER; FACTOR-IIIA; BRCA1; KRAB	The breast- and ovarian-specific tumor suppressor BRCA1 has been implicated in both activation and repression of gene transcription by virtue of its direct interaction with sequence-specific DNA-binding transcription factors. However, the mechanistic basis by which BRCA1 mediates the transcriptional activity of these regulatory proteins remains largely unknown. To clarify this issue, we have examined the functional interaction between BRCA1 and ZBRK1, a BRCAl-dependent KRAB eight zinc finger transcriptional repressor. We report here the identification and molecular characterization of a portable BRCAl-dependent transcriptional repression domain within ZBRK1 composed of zinc fingers 5-8 along with sequences in the unique ZBRK1 C terminus. This C-terminal repression domain functions in a BRCAl-, histone deacetylase-, and promoter-specific manner and is thus functionally distinguishable from the N-terminal KRAB repression domain in ZBRK1, which exhibits no BRCA1 dependence and broad promoter specificity. Significantly, we also find that the BRCAl-dependent transcriptional repression domain on ZBRK1 includes elements that modulate its sequence-specific DNA binding activity. These findings thus reveal the presence within ZBRK1 of functionally bipartite zinc fingers with dual roles in sequence-specific DNA-binding and BRCAl-dependent transcriptional repression. We discuss the implications of these findings for the role of BRCA1 as ZBRK1 co-repressor.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Irvine	Boyer, TG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	boyer@uthscsa.edu			NCI NIH HHS [CA098301-01, CA81020, CA94170] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098301, R01CA094170, P01CA081020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DELRIO S, 1993, P NATL ACAD SCI USA, V90, P168, DOI 10.1073/pnas.90.1.168; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Jasin M, 2002, ONCOGENE, V21, P8981, DOI 10.1038/sj.onc.1206176; Jheon AH, 2001, J BIOL CHEM, V276, P18282, DOI 10.1074/jbc.M010885200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyake T, 2000, J BIOL CHEM, V275, P40169, DOI 10.1074/jbc.M007138200; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Park JJ, 2000, CANCER RES, V60, P5946; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Peng HZ, 2002, CANCER RES, V62, P3773; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Tirkkonen M, 1997, CANCER RES, V57, P1222; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wagner S, 2000, J BIOL CHEM, V275, P15685, DOI 10.1074/jbc.M910152199; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	64	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6576	6587		10.1074/jbc.M312270200	http://dx.doi.org/10.1074/jbc.M312270200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660588	hybrid			2022-12-27	WOS:000188969200046
J	Batonnet, S; Leibovitch, MP; Tintignac, L; Leibovitch, SA				Batonnet, S; Leibovitch, MP; Tintignac, L; Leibovitch, SA			Critical role for lysine 133 in the nuclear ubiquitin-mediated degradation of MyoD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; SKELETAL-MUSCLE; MYOBLASTS; PROTEIN; PHOSPHORYLATION; EXPRESSION; ACTIVATION; BINDING; SYSTEM; ACETYLATION	The ubiquitin-proteasome system is responsible for the regulation and turnover of the nuclear transcription factor MyoD. The degradation of MyoD can occur via an NH2 terminus-dependent pathway or a lysine-dependent pathway, suggesting that MyoD ubiquitination may be driven by different mechanisms. To understand this process, deletion analysis was used to identify the region of MyoD that is required for rapid proteolysis in the lysine-dependent pathway. Here we report that the basic helix-loop-helix domain is required for ubiquitination and lysine-dependent degradation of MyoD in the nucleus. Site-directed mutagenesis in MyoD revealed that lysine 133 is the major internal lysine of ubiquitination. The half-life of the MyoD K133R mutant protein was longer than that of wild type MyoD, substantiating the implication of lysine 133 in the turnover of MyoD in myoblasts. In addition, the MyoD K133R mutant displayed activity 2-3-fold higher than the wild type in transactivation muscle-specific gene and myogenic conversion of 10T1/2 cells. Taken together, our data demonstrate that lysine 133 is targeted for ubiquitination and rapid degradation of MyoD in the lysine-dependent pathway and plays an integral role in compromising MyoD activity in the nucleus.	CNRS, UMR 8125, Lab Genet Oncol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Leibovitch, SA (corresponding author), CNRS, UMR 8125, Lab Genet Oncol, F-94805 Villejuif, France.	leibovit@igr.fr		Tintignac, Lionel/0000-0001-5902-1138				Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; Benayoun B, 1998, FEBS LETT, V437, P39, DOI 10.1016/S0014-5793(98)01192-2; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huijbregts J, 2001, ACTA HISTOCHEM, V103, P379, DOI 10.1078/0065-1281-00607; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Megeney LA, 1995, BIOCHEM CELL BIOL, V73, P723, DOI 10.1139/o95-080; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tintignac LA, 2000, EXP CELL RES, V259, P300, DOI 10.1006/excr.2000.4973; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	30	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5413	5420		10.1074/jbc.M310315200	http://dx.doi.org/10.1074/jbc.M310315200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660660	hybrid			2022-12-27	WOS:000188776500047
J	Baudouin-Cornu, P; Schuerer, K; Marliere, P; Thomas, D				Baudouin-Cornu, P; Schuerer, K; Marliere, P; Thomas, D			Intimate evolution of proteins - Proteome atomic content correlates with genome base composition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-COMPOSITION; BACTERIAL EVOLUTION; GENETIC-CODE; DNA; USAGE; YEAST; BIAS	Discerning the significant relations that exist within and among genome sequences is a major step toward the modeling of biopolymer evolution. Here we report the systematic analysis of the atomic composition of proteins encoded by organisms representative of each kingdoms. Protein atomic contents are shown to vary largely among species, the larger variations being observed for the main architectural component of proteins, the carbon atom. These variations apply to the bulk proteins as well as to subsets of ortholog proteins. A pronounced correlation between proteome carbon content and genome base composition is further evidenced, with high G + C genome content being related to low protein carbon content. The generation of random proteomes and the examination of the canonical genetic code provide arguments for the hypothesis that natural selection might have driven genome base composition.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Inst Pasteur, F-75015 Paris, France; Evolg SA, F-91000 Evry, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Thomas, D (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.	thomas@cgm.cnrs-gif.fr		Baudouin-Cornu, Peggy/0000-0001-7296-099X				Akashi H, 2002, P NATL ACAD SCI USA, V99, P3695, DOI 10.1073/pnas.062526999; Baudouin-Cornu P, 2001, SCIENCE, V293, P297, DOI 10.1126/science.1061052; BERNARDI G, 1985, J MOL EVOL, V22, P363, DOI 10.1007/BF02115693; BROCK D, 1991, BIOL MICROORGANISMS, P634; Fauchon M, 2002, MOL CELL, V9, P713, DOI 10.1016/S1097-2765(02)00500-2; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; HAIG D, 1991, J MOL EVOL, V33, P412, DOI 10.1007/BF02103132; KARLIN S, 1992, PROTEIN ENG, V5, P729, DOI 10.1093/protein/5.8.729; KARLIN S, 1992, SCIENCE, V257, P39, DOI 10.1126/science.1621093; Kimura M., 1983, NEUTRAL THEORY MOL E; Koonin EV, 2000, CELL, V101, P573, DOI 10.1016/S0092-8674(00)80867-3; Lobry JR, 1997, GENE, V205, P309, DOI 10.1016/S0378-1119(97)00403-4; MAZEL D, 1989, NATURE, V341, P245, DOI 10.1038/341245a0; MUTO A, 1987, P NATL ACAD SCI USA, V84, P166, DOI 10.1073/pnas.84.1.166; Nei M., 1987, MOL EVOLUTIONARY GEN; NEIDHARDT FC, 1996, ESCHERICHIA COLI SAL, P13; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Rocha EPC, 2002, TRENDS GENET, V18, P291, DOI 10.1016/S0168-9525(02)02690-2; Singer GAC, 2000, MOL BIOL EVOL, V17, P1581, DOI 10.1093/oxfordjournals.molbev.a026257; SUEKOA N, 1961, COLD SPRING HARB SYM, V26, P35; SUEOKA N, 1962, P NATL ACAD SCI USA, V48, P582, DOI 10.1073/pnas.48.4.582; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Thorne JL, 2000, CURR OPIN GENET DEV, V10, P602, DOI 10.1016/S0959-437X(00)00142-8; Tourasse NJ, 2000, MOL BIOL EVOL, V17, P656, DOI 10.1093/oxfordjournals.molbev.a026344; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1965, P NATL ACAD SCI USA, V54, P71, DOI 10.1073/pnas.54.1.71	26	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5421	5428		10.1074/jbc.M306415200	http://dx.doi.org/10.1074/jbc.M306415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645368	hybrid			2022-12-27	WOS:000188776500048
J	Bharti, AC; Takada, Y; Shishodia, S; Aggarwal, BB				Bharti, AC; Takada, Y; Shishodia, S; Aggarwal, BB			Evidence that receptor activator of nuclear factor (NF)-kappa B ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappa B-independent and TRAF6-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; LYMPH-NODE ORGANOGENESIS; TNF FAMILY-MEMBER; TERMINAL KINASE; FAS LIGAND; OSTEOPROTEGERIN-LIGAND; MEDIATED APOPTOSIS; T-CELLS; C-MYC	The receptor activator of NF-kappaB ligand (RANKL), a recently identified member of the tumor necrosis factor (TNF) superfamily, has been shown to induce osteoclastogenesis and dendritic cell survival. Most members of the TNF superfamily suppress cell proliferation and induce apoptosis, but whether RANKL does so is not known. We demonstrate that treatment of monocyte RAW 264.7 cells with RANKL induces dose-dependent growth inhibition (IC50 = 10 ng/ml) as determined by dye uptake and [H-3]thymidine incorporation methods. Suppression of RANKL-induced NF-kappaB activation by dominant-negative IkappaBalpha or by the NEMO-peptide had no effect on RANKL-induced cell growth inhibition. Inhibition of RANKL-induced JNK activation, however, abolished the RANKL-induced apoptosis. Suppression of interaction of RANK with TRAF6 by TRAF6-binding peptide abrogated the anti-proliferative effects of RANKL, suggesting the critical role of TRAF6. Flow cytometric analysis of cells treated with RANKL showed accumulation of cells in G(0)/G(1) phase of the cell cycle, and this accumulation correlated with a decline in the levels of cyclin D1, cyclin D3, and cyclin E and an increase in cyclin-dependent kinase inhibitor p27 (Kip). Flow cytometric analysis showed the presence of annexin V-positive cells in cultures treated with RANKL. RANKL-induced apoptosis was further confirmed using calcein AM/ethidium homodimer-1 dye and cleavage of poly(ADP-ribose) polymerase (PARP), procaspase 3, and procaspase 9; benzyloxycarbonyl-VAD, the pancaspase inhibitor, suppressed the PARP cleavage. Thus, overall, our studies indicate that RANKL can inhibit cell proliferation and induce apoptosis through a TRAF-6-dependent but NF-kappaB-independent mechanism.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Sect, Dept Bioimmunol,Unit 143, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cytokine Res Sect, Dept Bioimmunol,Unit 143, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Bharti, Prof. AC/AGL-5994-2022; Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [P01 CA91844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bergman MC, 1996, J IMMUNOL, V156, P3118; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756-3282(99)00105-2; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Dormond O, 2002, ANTICANCER RES, V22, P3159; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Dunger A, 1996, J AUTOIMMUN, V9, P309, DOI 10.1006/jaut.1996.0042; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fiumara P, 2001, BLOOD, V98, P2784, DOI 10.1182/blood.V98.9.2784; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; Haridas V, 1999, ONCOGENE, V18, P6496, DOI 10.1038/sj.onc.1203059; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Josien R, 1999, J IMMUNOL, V162, P2562; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Koo MS, 2002, MOL CELLS, V13, P194; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lecoeur H, 2002, EXP CELL RES, V277, P1, DOI 10.1006/excr.2002.5537; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lomaga MA, 2000, J NEUROSCI, V20, P7384; Lunemann JD, 2002, J IMMUNOL, V168, P4881, DOI 10.4049/jimmunol.168.10.4881; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Matsui K, 1998, J IMMUNOL, V161, P3469; Muller I, 2003, CANCER RES, V63, P1772; N'cho M, 2001, HUM IMMUNOL, V62, P310, DOI 10.1016/S0198-8859(01)00214-2; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; NORIMATSU M, 1995, INFECT IMMUN, V63, P1122, DOI 10.1128/IAI.63.3.1122-1126.1995; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Okahashi N, 2001, J CELL BIOCHEM, V80, P339, DOI 10.1002/1097-4644(20010301)80:3<339::AID-JCB60>3.0.CO;2-#; Olashaw Nancy, 2002, Sci STKE, V2002, pre7; PeguetNavarro J, 1997, J IMMUNOL, V158, P144; Qin ZH, 1999, J NEUROSCI, V19, P4023; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	76	91	94	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6065	6076		10.1074/jbc.M308062200	http://dx.doi.org/10.1074/jbc.M308062200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645259	hybrid			2022-12-27	WOS:000188776500122
J	Liang, XH; Ochaion, A; Xu, YX; Liu, Q; Michaeli, S				Liang, XH; Ochaion, A; Xu, YX; Liu, Q; Michaeli, S			Small nucleolar RNA clusters in trypanosomatid Leptomonas collosoma - Genome organization, expression studies, and the potential role of sequences present upstream from the first repeated cluster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER-ASSOCIATED RNA; SNORNA GENE CLUSTERS; PRE-MESSENGER-RNA; RIBOSOMAL-RNA; PSEUDOURIDINE FORMATION; PRERIBOSOMAL RNA; BINDING-PROTEIN; SMALL NUCLEAR; SL RNA; BRUCEI	Trypanosomatid small nucleolar RNA (snoRNA) genes are clustered in the genome. snoRNAs are transcribed polycistronically and processed into mature RNAs. In this study, we characterized four snoRNA clusters in Leptomonas collosoma. All of the clusters analyzed carry both C/D and H/ACA RNAs. The H/ACA RNAs are composed of a single hairpin, a structure typical to trypanosome and archaea guide RNAs. Using deletion and mutational analysis of a tagged C/D snoRNA situated within the snoRNA cluster, we identified 10-nucleotide flanking sequences that are essential for processing snoRNA from its precursor. Chromosome walk was performed on a snoRNA cluster, and a sequence of 700 bp was identified between the first repeat and the upstream open reading frame. Cloning of this sequence in an episome vector enhanced the expression of a tagged snoRNA gene in an orientation-dependent manner. However, continuous transcript spanning of this region was detected in steady-state RNA, suggesting that snoRNA transcription also originates from an upstream-long polycistronic transcriptional unit. The 700-bp fragment may therefore represent an example of many more elements to be discovered that enhance transcription along the chromosome, especially when transcription from the upstream gene is reduced or when enhanced transcription is needed.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	michaes@mail.biu.ac.il	Michaeli, Shulamit/AAC-8255-2022; Xu, Yu-Xin/G-4041-2010	Xu, Yu-Xin/0000-0002-0200-4633				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; BELLOFATTO V, 1991, P NATL ACAD SCI USA, V88, P6711, DOI 10.1073/pnas.88.15.6711; Brown JWS, 2003, TRENDS PLANT SCI, V8, P42, DOI 10.1016/S1360-1385(02)00007-9; Brown JWS, 2001, RNA, V7, P1817; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; Campbell DA, 2000, PARASITOL TODAY, V16, P78, DOI 10.1016/S0169-4758(99)01545-8; Cavaille J, 1996, BIOCHIMIE, V78, P443, DOI 10.1016/0300-9084(96)84751-1; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; Downey N, 1999, MOL BIOCHEM PARASIT, V104, P25, DOI 10.1016/S0166-6851(99)00135-8; Dunbar DA, 2000, NUCLEIC ACIDS RES, V28, P2855, DOI 10.1093/nar/28.15.2855; Dunbar DA, 2000, J BIOL CHEM, V275, P14767, DOI 10.1074/jbc.M001180200; Estevez AM, 2001, EMBO J, V20, P3831, DOI 10.1093/emboj/20.14.3831; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; Goldring A, 1996, EXP PARASITOL, V84, P28, DOI 10.1006/expr.1996.0087; GOLDRING A, 1995, GENE, V156, P139, DOI 10.1016/0378-1119(95)00048-B; HUANG J, 1991, MOL CELL BIOL, V11, P3180, DOI 10.1128/MCB.11.6.3180; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Lee MGS, 1997, ANNU REV MICROBIOL, V51, P463, DOI 10.1146/annurev.micro.51.1.463; Levitan A, 1998, NUCLEIC ACIDS RES, V26, P1775, DOI 10.1093/nar/26.7.1775; Liang D, 2002, NUCLEIC ACIDS RES, V30, P3262, DOI 10.1093/nar/gkf426; Liang XH, 2003, P NATL ACAD SCI USA, V100, P7521, DOI 10.1073/pnas.1332001100; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; Liang XH, 2001, J BIOL CHEM, V276, P40313, DOI 10.1074/jbc.M104488200; McAndrew M, 1998, EXP PARASITOL, V90, P65, DOI 10.1006/expr.1998.4317; Myler PJ, 2000, BIOCHEM SOC T, V28, P527, DOI 10.1042/bst0280527; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; Roberts TG, 1996, MOL BIOCHEM PARASIT, V83, P163, DOI 10.1016/S0166-6851(96)02762-4; Robinson KA, 2003, MOL BIOCHEM PARASIT, V128, P217, DOI 10.1016/S0166-6851(03)00079-3; Rozhdestvensky TS, 2003, NUCLEIC ACIDS RES, V31, P869, DOI 10.1093/nar/gkg175; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Terns MP, 2002, GENE EXPRESSION, V10, P17; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VALCARCEL J, 1997, CURR BIOL, V7, P705; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473; Xu YX, 2001, J BIOL CHEM, V276, P14289, DOI 10.1074/jbc.M007007200	49	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5100	5109		10.1074/jbc.M308264200	http://dx.doi.org/10.1074/jbc.M308264200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645367	hybrid			2022-12-27	WOS:000188776500009
J	Lorenz, M; Wessler, S; Follmann, E; Michaelis, W; Dusterhoft, T; Baumann, G; Stangl, K; Stangl, V				Lorenz, M; Wessler, S; Follmann, E; Michaelis, W; Dusterhoft, T; Baumann, G; Stangl, K; Stangl, V			A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT THORACIC AORTA; HEART-DISEASE; PHOSPHORYLATION; CONSUMPTION; FLAVONOIDS; CATECHINS; HEALTH; MECHANISMS; MORTALITY; DRINKING	Epidemiological studies suggest that tea catechins may reduce the risk of cardiovascular disease, but the mechanisms of benefit have not been determined. The objective of the present study was to investigate the effects of epigallocatechin-3-gallate (EGCG), the major constituent of green tea, on vasorelaxation and on eNOS expression and activity in endothelial cells. EGCG (1-50 muM) induced dose-dependent vasodilation in rat aortic rings. Vasodilation was abolished by pretreatment with N-G-nitro L-arginine methyl ester. In bovine aortic endothelial cells, EGCG increased endothelial nitric oxide (eNOS) activity dose-dependently after 15 min. Treatment with EGCG induced a sustained activation of Akt, ERK1/2, and eNOS Ser(1179) phosphorylation. Inhibition of extracellular signal-regulated kinase (ERK)1/2 had no influence on eNOS activity or Ser(1179) phosphorylation. Simultaneous treatment of cells with selective inhibitors for cAMP-dependent protein kinase (PKA) and Akt completely prevented the increase in eNOS activity by EGCG after 15 min, indicating that both kinases act in concert. Specific phosphatidylinositol-3-OH-kinase inhibitors yielded identical results. Akt inhibition prevented eNOS Ser(1179) phosphorylation, whereas inhibition of PKA did not influence Akt and eNOS Ser(1179) phosphorylation. Pretreatment of endothelial cells with EGCG for 4 h markedly enhanced the increase in eNOS activity stimulated by Ca-ionomycin, suggesting that Akt accounts for prolonged eNOS activation. Treatment of cells for 72 h with EGCG did not change eNOS protein levels. Our results indicate that EGCG-induced endothelium-dependent vasodilation is primarily based on rapid activation of eNOS by a phosphatidylinositol 3-kinase-, PKA-, and Akt-dependent increase in eNOS activity, independently of an altered eNOS protein content.	Humboldt Univ, Charite, Med Klin Schwerpunkt Kardiol Angiol Pneumol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stangl, V (corresponding author), Humboldt Univ, Charite, Med Klin Schwerpunkt Kardiol Angiol Pneumol, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	verena.stangl@charite.de	Wessler, Silja/C-6309-2015	Wessler, Silja/0000-0001-7011-6162; Lorenz, Mario/0000-0001-5267-4101				Andriambeloson E, 1998, J NUTR, V128, P2324, DOI 10.1093/jn/128.12.2324; Arts ICW, 2001, AM J CLIN NUTR, V74, P227; Balentine DA, 1997, CRIT REV FOOD SCI, V37, P693, DOI 10.1080/10408399709527797; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Duffy SJ, 2001, CIRCULATION, V104, P151, DOI 10.1161/01.CIR.104.2.151; Geleijnse JM, 1999, ARCH INTERN MED, V159, P2170, DOI 10.1001/archinte.159.18.2170; Hong J, 2002, CANCER RES, V62, P7241; Huang Y, 1999, BBA-GEN SUBJECTS, V1427, P322, DOI 10.1016/S0304-4165(99)00034-3; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Kris-Etherton PM, 2002, CURR OPIN LIPIDOL, V13, P41, DOI 10.1097/00041433-200202000-00007; Landsverk HB, 2001, J CELL SCI, V114, P3255; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Mukamal KJ, 2002, CIRCULATION, V105, P2476, DOI 10.1161/01.CIR.0000017201.88994.F7; Nakachi K, 2000, BIOFACTORS, V13, P49, DOI 10.1002/biof.5520130109; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Rimm EB, 1996, ANN INTERN MED, V125, P384, DOI 10.7326/0003-4819-125-5-199609010-00005; Sanae F, 2002, LIFE SCI, V71, P2553, DOI 10.1016/S0024-3205(02)02080-5; Shen JZ, 2003, CLIN EXP PHARMACOL P, V30, P88, DOI 10.1046/j.1440-1681.2003.03796.x; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Umegaki K, 2001, J NUTR SCI VITAMINOL, V47, P402, DOI 10.3177/jnsv.47.402; Vinson JA, 1998, FEBS LETT, V433, P44, DOI 10.1016/S0014-5793(98)00880-1; Woodward M, 1999, J EPIDEMIOL COMMUN H, V53, P481, DOI 10.1136/jech.53.8.481; Yang CS, 1998, CANCER EPIDEM BIOMAR, V7, P351	25	273	295	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6190	6195		10.1074/jbc.M309114200	http://dx.doi.org/10.1074/jbc.M309114200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645258	hybrid			2022-12-27	WOS:000188776500135
J	Daniel, JA; Torok, MS; Sun, ZW; Schieltz, D; Allis, CD; Yates, JR; Grant, PA				Daniel, JA; Torok, MS; Sun, ZW; Schieltz, D; Allis, CD; Yates, JR; Grant, PA			Deubiquitination of histone H2B by a yeast acetyltransferase complex regulates transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; SACCHAROMYCES-CEREVISIAE; SAGA COMPLEX; FUNCTIONAL-ORGANIZATION; NUCLEOSOME ACETYLATION; BINDING PROTEIN; COMPONENTS; UBIQUITINATION; IDENTIFICATION; COACTIVATOR	Post-translational modifications of the histone protein components of eukaryotic chromatin play an important role in the regulation of chromatin structure and gene expression ( 1). Given the requirement of Rad6/Bre1-dependent ubiquitination of histone H2B for H3 dimethylation (at lysines 4 and 79) and gene silencing (2 - 7), removal of ubiquitin from H2B may have a significant regulatory effect on transcription. Here we show that a putative deubiquitinating enzyme, Ubp8, is a structurally nonessential component of both the Spt-Ada-Gcn5-acetyltransferase ( SAGA) and SAGA-like (SLIK) histone acetyltransferase ( HAT) complexes in yeast. Disruption of this gene dramatically increases the cellular level of ubiquitinated-H2B, and SAGA and SLIK are shown to have H2B deubiquitinase activity. These findings demonstrate, for the first time, how the ubiquitin moiety can be removed from histone H2B in a regulated fashion. Ubp8 is required for full expression of the SAGA- and SLIK-dependent gene GAL10 and is recruited to the upstream activation sequence (UAS) of this gene under activating conditions, while Rad6 dissociates. Furthermore, trimethylation of H3 at lysine 4 within the UAS increases significantly under activating conditions, and remarkably, Ubp8 is shown to have a role in regulating the methylation status of this residue. Collectively, these data suggest that the SAGA and SLIK HAT complexes can regulate an integrated set of multiple histone modifications, counteracting repressive effects that alter chromatin and regulate gene expression.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Diversa Corp, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Virginia; Scripps Research Institute	Grant, PA (corresponding author), Univ Virginia Hlth Syst, Box 800733, Charlottesville, VA 22908 USA.	pag9n@virginia.edu	Daniel, Jeremy/S-4729-2016	Daniel, Jeremy/0000-0002-1981-5571	NCRR NIH HHS [RR 11823-03] Funding Source: Medline; NIDDK NIH HHS [DK 58646] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058646] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grant PA, 2001, GENOME BIOL, V2; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Kao CF, 2003, METHODS, V31, P59, DOI 10.1016/S1046-2023(03)00088-4; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Saleh A, 1998, J MOL BIOL, V282, P933, DOI 10.1006/jmbi.1998.2036; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002	33	220	227	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2004	279	3					1867	1871		10.1074/jbc.C300494200	http://dx.doi.org/10.1074/jbc.C300494200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	762WT	14660634	hybrid			2022-12-27	WOS:000188005700038
J	Sengupta, TK; Bandyopadhyay, S; Fernandes, DJ; Spicer, EK				Sengupta, TK; Bandyopadhyay, S; Fernandes, DJ; Spicer, EK			Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HELA CYTOPLASMIC EXTRACTS; HUMAN CANCER-CELLS; OKADAIC ACID; RIBOSOMAL-RNA; 3'-UNTRANSLATED REGION; DOWN-REGULATION; LEUKEMIA-CELLS; APOPTOSIS; DESTABILIZATION	bcl-2 mRNA contains an AU-rich element (ARE) that functions in regulating bcl-2 stability. Our earlier studies indicated that taxol- or okadaic acid-induced bcl-2 mRNA destabilization in HL-60 cells is associated with decreased binding of trans-acting factors to the ARE. To identify factors that play a role in the regulation of bcl-2 mRNA stability, bcl-2 ARE-binding proteins were purified from HL-60 cells. Three polypeptides of 100, 70, and 32 kDa were isolated from a bcl-2 ARE affinity matrix. Matrix-assisted laser desorption ionization mass spectroscopy analysis identified these proteins as full-length nucleolin and proteolytic fragments of nucleolin. RNA gel shifts assays indicated that recombinant nucleolin ( residues 284-707) binds specifically to bcl-2 ARE RNA. In addition, recombinant nucleolin decreases the rate of decay of mRNA in HL-60 cell extracts in an ARE-dependent manner. Taxol or okadaic acid treatment of HL-60 cells results in proteolysis of nucleolin in a similar time frame as drug-induced bcl-2 mRNA down-regulation. These findings suggest that nucleolin functions as a bcl-2-stabilizing factor and that taxol and okadaic acid treatment induces apoptosis in HL-60 cells through a process that involves down-regulation of nucleolin and destabilization of bcl-2 mRNA.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Spicer, EK (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, POB 250509, Charleston, SC 29425 USA.	spicer@musc.edu	Sengupta, Tapas K/P-7126-2014		NATIONAL CANCER INSTITUTE [R01CA087553] Funding Source: NIH RePORTER; NCI NIH HHS [CA 87553] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bandyopadhyay S, 2003, BIOCHEM PHARMACOL, V66, P1151, DOI 10.1016/S0006-2952(03)00453-2; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1987, J BIOL CHEM, V262, P10922; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Ceman S, 1999, MOL CELL BIOL, V19, P7925; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 2000, GENE DEV, V14, P1236; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; DERENZINI M, 1995, LAB INVEST, V73, P497; Donnini M, 2001, BIOCHEM BIOPH RES CO, V287, P1063, DOI 10.1006/bbrc.2001.5700; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, METHODS, V17, P21, DOI 10.1006/meth.1998.0703; Gao G, 2000, MOL PHARMACOL, V58, P1001, DOI 10.1124/mol.58.5.1001; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GLUICK TC, 1994, J MOL BIOL, V241, P246, DOI 10.1006/jmbi.1994.1493; GORDON G, 1987, NATURE, V329, P489; GUY GR, 1992, J BIOL CHEM, V267, P1846; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Harris N L, 2001, Hematology Am Soc Hematol Educ Program, P194, DOI 10.1182/asheducation-2001.1.194; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Liu Y., 1996, Cellular Pharmacology, V3, P405; Malter JS, 2001, J NEUROSCI RES, V66, P311, DOI 10.1002/jnr.10021; Mi YC, 2003, J BIOL CHEM, V278, P8572, DOI 10.1074/jbc.M207637200; Morimoto H, 2002, J HISTOCHEM CYTOCHEM, V50, P1187, DOI 10.1177/002215540205000905; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Riordan FA, 1998, FEBS LETT, V435, P195, DOI 10.1016/S0014-5793(98)01070-9; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SCHNEIDER HR, 1989, EUR J BIOCHEM, V180, P449, DOI 10.1111/j.1432-1033.1989.tb14667.x; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Skalweit A, 2003, CIRC RES, V92, P419, DOI 10.1161/01.RES.0000059300.67152.4E; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; STEUBE KG, 1995, LEUKEMIA, V9, P1841; Tholanikunnel BG, 1999, BIOCHEMISTRY-US, V38, P15564, DOI 10.1021/bi9913348; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Yang C, 2002, NUCLEIC ACIDS RES, V30, P2251, DOI 10.1093/nar/30.10.2251; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	55	136	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10855	10863		10.1074/jbc.M309111200	http://dx.doi.org/10.1074/jbc.M309111200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14679209	hybrid			2022-12-27	WOS:000220157600006
J	Uchiki, T; Dice, LT; Hettich, RL; Dealwis, C				Uchiki, T; Dice, LT; Hettich, RL; Dealwis, C			Identification of phosphorylation sites on the yeast ribonucleotide reductase inhibitor Sml1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; PROTEIN-PHOSPHORYLATION; CHECKPOINT PATHWAYS; GLYCOGEN-SYNTHASE; CDK INHIBITOR; BUDDING YEAST; CELL-CYCLE; KINASE	Sml1 is a small protein in Saccharomyces cerevisiae which inhibits the activity of ribonucleotide reductase (RNR). RNR catalyzes the rate-limiting step of de novo dNTP synthesis. Sml1 is a downstream effector of the Mec1/Rad53 cell cycle checkpoint pathway. The phosphorylation by Dun1 kinase during S phase or in response to DNA damage leads to diminished levels of Sml1. Removal of Sml1 increases the population of active RNR, which raises cellular dNTP levels. In this study using mass spectrometry and site-directed mutagenesis, we have identified the region of Sml1 phosphorylation to be between residues 52 and 64 containing the sequence GSSAS-ASASSLEM. This is the first identification of a phosphorylation sequence of a Dun1 biological substrate. This sequence is quite different from the consensus Dun1 phosphorylation sequence reported previously from peptide library studies. The specific phosphoserines were identified to be Ser(56), Ser(58), and Ser(60) by chemical modification of these residues to S-ethylcysteines followed by collision activated dissociation. To investigate further Sml1 phosphorylation, we constructed the single mutants S56A, S58A, S60A, and the triple mutant S56A/S58A/S60A and compared their degrees of phosphorylation with that of wild type Sml1. We observed a 90% decrease in the relative phosphorylation of S60A compared with that of wild type, a 25% decrease in S58A, and little or no decrease in the S56A mutant. There was no observed phosphate incorporation in the triple mutant, suggesting that Ser(56), Ser(58), and Ser(60) in Sml1 are the sites of phosphorylation. Further mutagenesis studies reveal that Dun1 kinase requires an acidic residue at the +3 position, and there is cooperativity between the phosphorylation sites. These results show that Dun1 has a unique phosphorylation motif.	Oak Ridge Natl Lab, Div Chem Sci, Organ & Biol Mass Spectrometry Grp, Oak Ridge, TN 37831 USA; Univ Tennessee, Genome Sci & Technol Grad Sch, Knoxville, TN 37996 USA; Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville	Hettich, RL (corresponding author), Oak Ridge Natl Lab, Div Chem Sci, Organ & Biol Mass Spectrometry Grp, POB 2008, Oak Ridge, TN 37831 USA.	hettichrl@ornl.gov	Hettich, Robert L/N-1458-2016	Hettich, Robert L/0000-0001-7708-786X	NCI NIH HHS [1R01CA100827-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamczyk M, 2001, RAPID COMMUN MASS SP, V15, P1481, DOI 10.1002/rcm.394; Bashkirov VI, 2003, MOL CELL BIOL, V23, P1441, DOI 10.1128/MCB.23.4.1441-1452.2003; Bashkirov VI, 2000, MOL CELL BIOL, V20, P4393, DOI 10.1128/MCB.20.12.4393-4404.2000; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; Cleverley KE, 1998, BIOCHEMISTRY-US, V37, P3917, DOI 10.1021/bi9724523; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; GAUTHIER JW, 1991, ANAL CHIM ACTA, V246, P211, DOI 10.1016/S0003-2670(00)80678-9; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Horn DM, 2000, J AM SOC MASS SPECTR, V11, P320, DOI 10.1016/S1044-0305(99)00157-9; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Lapko VN, 1997, BIOCHEMISTRY-US, V36, P10595, DOI 10.1021/bi970708z; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Pati D, 1997, MOL CELL BIOL, V17, P3037, DOI 10.1128/MCB.17.6.3037; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; Resing KA, 1997, METHOD ENZYMOL, V283, P29; Sanchez Y, 1997, METHOD ENZYMOL, V283, P398; Stensballe A, 2000, RAPID COMMUN MASS SP, V14, P1793, DOI 10.1002/1097-0231(20001015)14:19<1793::AID-RCM95>3.0.CO;2-Q; THOMAS BJ, 1989, GENETICS, V123, P725; Uchiki T, 2002, ANAL BIOCHEM, V301, P35, DOI 10.1006/abio.2001.5492; UCHIKI T, 2002, 50 ASMS C MASS SPECT; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299; Zhao XL, 2000, MOL CELL BIOL, V20, P9076, DOI 10.1128/MCB.20.23.9076-9083.2000; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	38	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11293	11303		10.1074/jbc.M309751200	http://dx.doi.org/10.1074/jbc.M309751200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14684746	hybrid			2022-12-27	WOS:000220157600057
J	Reinehr, R; Gorg, B; Hongen, A; Haussinger, D				Reinehr, R; Gorg, B; Hongen, A; Haussinger, D			CD95-tyrosine nitration inhibits hyperosmotic and CD95 ligand-induced CD95 activation in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SUPPRESSES; TYROSINE PHOSPHORYLATION; INDUCED APOPTOSIS; S-NITROSYLATION; MITOCHONDRIAL RESPIRATION; PROTEIN-KINASE; IN-VIVO; PEROXYNITRITE; CELLS; DEATH	Epidermal growth factor receptor-dependent CD95-tyrosine phosphorylation was recently identified as an early step in apoptosis induction via the CD95 system (Reinehr, R., Schliess, F., and Haussinger, D. (2003) FASEB J. 17, 731-733). The effect of peroxynitrite (ONOO-) on modulation of the hyperosmotic and CD95 ligand (CD95L)-induced CD95 activation process was studied. Pretreatment of hepatocytes with ONOO- inhibited CD95L- and hyperosmolarity-induced CD95 membrane trafficking and formation of the death-inducing signaling complex, but not epidermal growth factor receptor activation and its association with CD95. Under these conditions, however, no tyrosine phosphorylation of CD95 occurred; instead, CD95 was tyrosine-nitrated. When ONOO- was added after induction of CD95-tyrosine phosphorylation by CD95L or hyperosmolarity, tyrosine nitration of CD95 was largely prevented and death-inducing signaling complex formation occurred. CD95-tyrosine nitration abolished the hyperosmotic sensitization of hepatocytes toward CD95L- induced apoptosis. Additionally, in CD95-yellow fluorescent protein-transfected Huh7-hepatoma cells, ONOO- induced CD95 Tyr nitration and prevented CD95L- induced Tyr phosphorylation and apoptosis. Tyrosine-nitrated CD95 was also found in rat livers derived from an in vivo model of endotoxinemia. The data suggest that CD95-tyrosine nitration prevents CD95 activation by inhibiting CD95-tyrosine phosphorylation. Apparently, CD95-tyrosine phosphorylation and nitration are mutually exclusive. The data identify critical tyrosine residues of CD95 as another target of the anti-apoptotic action of NO.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Klinikum Dusseldorf, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Reinehr, Roland/G-6118-2016	Gorg, Boris/0000-0002-4630-9420				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BOLANOS JP, 1994, J NEUROCHEM, V63, P910; Brito C, 1999, J IMMUNOL, V162, P3356; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Castaneda F, 2001, J CANCER RES CLIN, V127, P418, DOI 10.1007/s004320000227; Crow JP, 1997, J NEUROCHEM, V69, P1945; Faubion WA, 1999, HEPATOLOGY, V29, P1, DOI 10.1002/hep.510290101; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Fu YX, 2001, J BIOL CHEM, V276, P43004, DOI 10.1074/jbc.M106946200; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Gorg B, 2003, HEPATOLOGY, V37, P334, DOI 10.1053/jhep.2003.50061; GRANGER DL, 1980, J CLIN INVEST, V65, P357, DOI 10.1172/JCI109679; Hurst JK, 2002, J CLIN INVEST, V109, P1287, DOI 10.1172/JCI200215816; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kiroycheva M, 2000, J AM SOC NEPHROL, V11, P1026, DOI 10.1681/ASN.V1161026; Klotz LO, 2002, FREE RADICAL BIO MED, V33, P737, DOI 10.1016/S0891-5849(02)00892-4; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LIU SF, 1993, BIOCHEM BIOPH RES CO, V196, P1208, DOI 10.1006/bbrc.1993.2380; Mallozzi C, 2001, FEBS LETT, V503, P189, DOI 10.1016/S0014-5793(01)02726-0; Miyoshi H, 1999, GASTROENTEROLOGY, V117, P669, DOI 10.1016/S0016-5085(99)70461-0; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Ramezanian MS, 1996, METHOD ENZYMOL, V269, P195; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Saeki M, 1999, NEUROSCI RES, V33, P325, DOI 10.1016/S0168-0102(99)00019-X; Schliess F, 2002, FASEB J, V16, P739, DOI 10.1096/fj.01-0862fje; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; Seki Shuichi, 1999, Medical Electron Microscopy, V32, P199; Tzeng E, 1997, SURGERY, V122, P255, DOI 10.1016/S0039-6060(97)90016-7; Wang YN, 2002, ANN NY ACAD SCI, V962, P415, DOI 10.1111/j.1749-6632.2002.tb04085.x; Yoon JH, 2002, J HEPATOL, V37, P400, DOI 10.1016/S0168-8278(02)00209-X; Zamora R, 2001, J BIOL CHEM, V276, P46887, DOI 10.1074/jbc.M101865200; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	49	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10364	10373		10.1074/jbc.M311997200	http://dx.doi.org/10.1074/jbc.M311997200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679192	hybrid			2022-12-27	WOS:000220050400086
J	Sawada, H; Kohno, R; Kihara, T; Izumi, Y; Sakka, N; Ibi, M; Nakanishi, M; Nakamizo, T; Yamakawa, K; Shibasaki, H; Yamamoto, N; Akaike, A; Inden, M; Kitamura, Y; Taniguchi, T; Shimohama, S				Sawada, H; Kohno, R; Kihara, T; Izumi, Y; Sakka, N; Ibi, M; Nakanishi, M; Nakamizo, T; Yamakawa, K; Shibasaki, H; Yamamoto, N; Akaike, A; Inden, M; Kitamura, Y; Taniguchi, T; Shimohama, S			Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COMPLEX-I; PARKINSONS-DISEASE; LEWY BODIES; CELL-DEATH; SIGNALING PATHWAY; SUBSTANTIA-NIGRA; PROTEIN; DEGRADATION; APOPTOSIS; KINASE	Parkinson's disease is characterized by dopaminergic neuronal death and the presence of Lewy bodies. alpha-Synuclein is a major component of Lewy bodies, but the process of its accumulation and its relationship to dopaminergic neuronal death has not been resolved. Although the pathogenesis has not been clarified, mitochondrial complex I is suppressed, and caspase-3 is activated in the affected midbrain. Here we report that a combination of 1-methyl-4-phenylpyridinium ion (MPP+) or rotenone and proteasome inhibition causes the appearance of alpha-synuclein-positive inclusion bodies. Unexpectedly, however, proteasome inhibition blocked MPP+- or rotenone-induced dopaminergic neuronal death. MPP+ elevated proteasome activity, dephosphorylated mitogen-activating protein kinase ( MAPK), and activated caspase-3. Proteasome inhibition reversed the MAPK dephosphorylation and blocked caspase-3 activation; the neuroprotection was blocked by a p42 and p44 MAPK kinase inhibitor. Thus, the proteasome plays an important role in both inclusion body formation and dopaminergic neuronal death but these processes form opposite sides on the proteasome regulation in this model.	Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Pharmaceut Univ, Dept Neurobiol, Yamashina Ku, Kyoto 6078412, Japan	Kyoto University; Kyoto Pharmaceutical University	Shimohama, S (corresponding author), Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	i53367@sakura.kudpc.kyoto-u.ac.jp	Nakamizo, Tomoki/AAM-8615-2021	Nakamizo, Tomoki/0000-0002-8377-1235; Inden, Masatoshi/0000-0002-7480-4920; Sawada, Hideyuki/0000-0002-5909-3366; Ibi, Masakazu/0000-0003-1414-100X				Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; Drexler HCA, 2000, FASEB J, V14, P65, DOI 10.1096/fasebj.14.1.65; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015; Furukawa Y, 2002, ANN NEUROL, V51, P779, DOI 10.1002/ana.10207; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hashimoto K, 2000, J NEUROCHEM, V74, P92, DOI 10.1046/j.1471-4159.2000.0740092.x; HATTORI N, 1991, ANN NEUROL, V30, P563, DOI 10.1002/ana.410300409; Hoglinger GU, 2003, J NEUROCHEM, V86, P1297, DOI 10.1046/j.1471-4159.2003.01952.x; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Manenti S, 2002, BIOCHEM BIOPH RES CO, V294, P976, DOI 10.1016/S0006-291X(02)00594-6; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; MIZUNO Y, 1987, J NEUROCHEM, V48, P1787, DOI 10.1111/j.1471-4159.1987.tb05737.x; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Naoi M, 1997, J NEURAL TRANSM-SUPP, P89; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Przedborski S, 2001, CLIN NEUROSCI RES, V1, P407, DOI 10.1016/S1566-2772(01)00019-6; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V134, P743, DOI 10.1016/S0006-291X(86)80483-1; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Sawada H, 2000, FASEB J, V14, P1202, DOI 10.1096/fasebj.14.9.1202; Sawada H, 1996, J NEUROSCI RES, V43, P503, DOI 10.1002/(SICI)1097-4547(19960215)43:4<503::AID-JNR12>3.0.CO;2-2; Schapira AHV, 1998, ANN NEUROL, V44, pS89, DOI 10.1002/ana.410440714; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stadheim TA, 2001, CANCER RES, V61, P1533; Takeda A, 1998, AM J PATHOL, V152, P367; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Tortosa A, 1997, NEUROSCI LETT, V238, P78, DOI 10.1016/S0304-3940(97)00837-9; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; van de Warrenburg BPC, 2001, NEUROLOGY, V56, P555, DOI 10.1212/WNL.56.4.555; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	52	97	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10710	10719		10.1074/jbc.M308434200	http://dx.doi.org/10.1074/jbc.M308434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14672949	hybrid			2022-12-27	WOS:000220050400126
J	Ai, WD; Liu, Y; Langlois, M; Wang, TC				Ai, WD; Liu, Y; Langlois, M; Wang, TC			Kruppel-like factor 4 (KLF4) represses histidine decarboxylase gene expression through an upstream Sp1 site and downstream gastrin responsive elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; PHORBOL 12-MYRISTATE 13-ACETATE; ZINC-FINGER PROTEIN; HUMAN KERATIN 4; PROMOTER ACTIVITY; TRANSCRIPTION FACTORS; CANCER CELLS; EPITHELIAL-CELLS; CPG METHYLATION; GUT	Histidine decarboxylase (HDC) is the enzyme that catalyzes the conversion of histidine to histamine, a bioamine that plays an important role in allergic responses, inflammation, neurotransmission, and gastric acid secretion. Previously, we demonstrated that gastrin activates HDC promoter activity in a gastric cancer (AGS-E) cell line through three overlapping downstream promoter elements. In the current study, we used the yeast one-hybrid strategy to identify nuclear factors that bind to these three elements. Among eight positives from the one-hybrid screen, we identified Kruppel-like factor 4 (KLF4) (previously known as gut-enriched Kruppel-like factor ( GKLF)) as one factor that binds to the gastrin responsive elements in the HDC promoter. Electrophoretic mobility shift assays confirmed that KLF4 is able to bind all three gastrin responsive elements. In addition, transient cotransfection experiments showed that overexpression of KLF4 dose dependently and specifically inhibited HDC promoter activity. Regulation of HDC transcription by KLF4 was confirmed by changes in the endogenous HDC messenger RNA by KLF4 small interfering RNA and KLF4 overexpression. We further showed that KLF4 inhibits HDC promoter activity by competing with Sp1 at the upstream GC box and also independently by binding the three downstream gastrin responsive elements. Taken together, these results indicate that KLF4 can act to repress HDC gene expression by Sp1-dependent and - independent mechanisms.	Univ Massachusetts, Sch Med, Div Gastroenterol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Wang, TC (corresponding author), Univ Massachusetts, Sch Med, Div Gastroenterol, Lazare Res Bldg,Rm 208,364 Plantat St, Worcester, MA 01605 USA.	timothy.wang@umassmed.edu	Li, Yapeng/N-1042-2017	Li, Yapeng/0000-0002-5042-6881	NIDDK NIH HHS [R01 DK-48077] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048077] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; Barocelli E, 2003, PHARMACOL RES, V47, P299, DOI 10.1016/S1043-6618(03)00009-4; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fleming JV, 2003, J BIOL CHEM, V278, P686, DOI 10.1074/jbc.M210718200; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Gelfaned EW, 2002, AM J MED, V113, p2S; Gerhard M, 2001, ENDOCRINOLOGY, V142, P3663, DOI 10.1210/en.142.8.3663; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GIGLIONI B, 1989, BIOCHEM BIOPH RES CO, V164, P149, DOI 10.1016/0006-291X(89)91695-1; Higaki Y, 2002, NUCLEIC ACIDS RES, V30, P2270, DOI 10.1093/nar/30.11.2270; Hirasawa N, 2001, EUR J PHARMACOL, V418, P23, DOI 10.1016/S0014-2999(01)00931-1; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; Hocker M, 1998, J BIOL CHEM, V273, P23046, DOI 10.1074/jbc.273.36.23046; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; Hocker M, 1996, YALE J BIOL MED, V69, P21; Hocker M, 1998, J BIOL CHEM, V273, P34000, DOI 10.1074/jbc.273.51.34000; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Katz JP, 2002, DEVELOPMENT, V129, P2619; KATZ JP, 2003, ABSTR DIGESTIVE DIS, pA147; Krikun G, 2000, MOL ENDOCRINOL, V14, P393, DOI 10.1210/me.14.3.393; Kuramasu A, 1998, J BIOL CHEM, V273, P31607, DOI 10.1074/jbc.273.47.31607; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MCLAUGHLIN JT, 2004, AM J PHYSIOL, V268, pG51; Medina MA, 1999, BIOCHEM PHARMACOL, V57, P1341, DOI 10.1016/S0006-2952(99)00005-2; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; OHGOH M, 1993, BIOCHEM BIOPH RES CO, V196, P1113, DOI 10.1006/bbrc.1993.2366; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Pacilio M, 2001, BIOCHEM BIOPH RES CO, V285, P1095, DOI 10.1006/bbrc.2001.5296; RANGACHARI PK, 1992, AM J PHYSIOL, V262, pG1, DOI 10.1152/ajpgi.1992.262.1.G1; Raychowdhury R, 1999, J BIOL CHEM, V274, P20961, DOI 10.1074/jbc.274.30.20961; Raychowdhury R, 2002, BIOCHEM BIOPH RES CO, V297, P1089, DOI 10.1016/S0006-291X(02)02345-8; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SINCLAIR NF, 2004, IN PRESS AM J PHYSL; Suzuki H, 1996, J BIOL CHEM, V271, P18981, DOI 10.1074/jbc.271.31.18981; Suzuki-Ishigaki S, 2000, NUCLEIC ACIDS RES, V28, P2627, DOI 10.1093/nar/28.14.2627; Wessler S, 2002, FASEB J, V16, P417, DOI 10.1096/fj.01-0766fje; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	54	55	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8684	8693		10.1074/jbc.M308278200	http://dx.doi.org/10.1074/jbc.M308278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670968	hybrid			2022-12-27	WOS:000189265900020
J	Antoniou, AN; Ford, S; Taurog, JD; Butcher, GW; Powis, SJ				Antoniou, AN; Ford, S; Taurog, JD; Butcher, GW; Powis, SJ			Formation of HLA-B27 homodimers and their relationship to assembly kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; UNFOLDED PROTEIN RESPONSE; CD4(+) T-LYMPHOCYTES; ANKYLOSING-SPONDYLITIS; ENDOPLASMIC-RETICULUM; CELL-SURFACE; INFLAMMATORY DISEASE; MONOCLONAL-ANTIBODY; HEAVY-CHAINS; ANTIGEN PRESENTATION	The human HLA-B27 class I molecule exhibits a strong association with the inflammatory arthritic disorder ankylosing spondylitis and other related arthropathies. Major histocompatibility complex class I heavy chains normally associate with beta(2)-microglobulin and peptide in the endoplasmic reticulum before transit to the cell surface. However, an unusual characteristic of HLA-B27 is its ability to form heavy chain homodimers through an unpaired cysteine at position 67 in the peptide groove. Homodimers have previously been detected within the ER and at the cell surface, but their mechanism of formation and role in disease remain undefined. Here we demonstrate, in the rat C58 thymoma cell line and in human HeLa cells transfected with HLA-B27, that homodimer formation involves not only cysteine at position 67 but also the conserved structural cysteine at position 164. We also show that homodimer formation can be induced in the non-disease- associated HLA class I allele HLA-A2 by slowing its assembly rate by incubation of cells at 26degreesC, suggesting that homodimer formation in the endoplasmic reticulum may occur as a result of the slower folding kinetics of HLA-B27. Finally, we report an association between unfolded HLA-B27 molecules and immunoglobulin-binding protein at the cell surface.	Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland; Univ Texas, SW Med Ctr, Harold C Simmons Arthrit Res Ctr, Dallas, TX 75390 USA; Babraham Inst, Mol Immunol Programme, Cambridge CB2 4AT, England	University of Dundee; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Powis, SJ (corresponding author), Univ Dundee, Sch Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.	s.j.powis@dundee.ac.uk		Powis, Simon/0000-0003-4218-2984; Antoniou, Antony/0000-0002-6536-7781				Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Allen RL, 1999, J IMMUNOL, V162, P5045; Alvarez I, 2001, J BIOL CHEM, V276, P48740, DOI 10.1074/jbc.M108882200; Antoniou AN, 2003, ANTIOXID REDOX SIGN, V5, P375, DOI 10.1089/152308603768295104; Antoniou AN, 2003, CURR OPIN IMMUNOL, V15, P75, DOI 10.1016/S0952-7915(02)00010-9; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Bird LA, 2003, EUR J IMMUNOL, V33, P748, DOI 10.1002/eji.200323678; Bowness P, 2002, RHEUMATOLOGY, V41, P857, DOI 10.1093/rheumatology/41.8.857; Boyle LH, 2003, RHEUMATOLOGY, V42, P404, DOI 10.1093/rheumatology/keg097; Boyle LH, 2001, J IMMUNOL, V167, P2619, DOI 10.4049/jimmunol.167.5.2619; Boyson JE, 2002, P NATL ACAD SCI USA, V99, P16180, DOI 10.1073/pnas.212643199; BREWERTON DA, 1973, LANCET, V1, P904; Cauli A, 2002, RHEUMATOLOGY, V41, P1375, DOI 10.1093/rheumatology/41.12.1375; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; Dangoria NS, 2002, J BIOL CHEM, V277, P23459, DOI 10.1074/jbc.M110336200; de Castro JAL, 1998, CURR OPIN IMMUNOL, V10, P59, DOI 10.1016/S0952-7915(98)80033-2; Dick TP, 2002, METHOD ENZYMOL, V348, P49, DOI 10.1016/S0076-6879(02)48625-9; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; Duftner C, 2003, ARTHRITIS RES THER, V5, pR292, DOI 10.1186/ar793; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; ELZAATARI FAK, 1990, J IMMUNOL, V144, P1512; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gu J, 2002, J RHEUMATOL, V29, P2159; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hellman R, 1999, J CELL BIOL, V144, P21, DOI 10.1083/jcb.144.1.21; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; Kingsbury DJ, 2000, ARTHRITIS RHEUM, V43, P2290, DOI 10.1002/1529-0131(200010)43:10<2290::AID-ANR17>3.0.CO;2-6; Kollnberger S, 2002, ARTHRITIS RHEUM, V46, P2972, DOI 10.1002/art.10605; Kostyu DD, 1997, HUM IMMUNOL, V57, P1, DOI 10.1016/S0198-8859(97)00175-4; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Malik P, 2002, J IMMUNOL, V169, P4379, DOI 10.4049/jimmunol.169.8.4379; Mear JP, 1999, J IMMUNOL, V163, P6665; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; PARHAM P, 1981, HUM IMMUNOL, V3, P277, DOI 10.1016/0198-8859(81)90065-3; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; Powis SJ, 1997, EUR J IMMUNOL, V27, P2744, DOI 10.1002/eji.1830271040; Ramos M, 2002, TISSUE ANTIGENS, V60, P191, DOI 10.1034/j.1399-0039.2002.600301.x; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; STAM NJ, 1986, J IMMUNOL, V137, P2299; TAUROG JD, 1993, J IMMUNOL, V150, P4168; Taurog JD, 1999, IMMUNOL REV, V169, P209; Uchanska-Ziegler B, 2003, TRENDS IMMUNOL, V24, P73, DOI 10.1016/S1471-4906(02)00028-5; WEINREICH S, 1995, HUM IMMUNOL, V42, P103, DOI 10.1016/0198-8859(94)00034-N; WHELAN MA, 1993, EUR J IMMUNOL, V23, P3278, DOI 10.1002/eji.1830231233; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; YAMAGUCHI A, 1995, ARTHRITIS RHEUM-US, V38, P1672, DOI 10.1002/art.1780381120; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang Q, 1998, J IMMUNOL, V160, P831; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	68	82	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8895	8902		10.1074/jbc.M311757200	http://dx.doi.org/10.1074/jbc.M311757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684742	hybrid			2022-12-27	WOS:000189265900047
J	Jewett, TJ; Sibley, LD				Jewett, TJ; Sibley, LD			The toxoplasma proteins MIC2 and M2AP form a hexameric complex necessary for intracellular survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; HOST-CELLS; APICOMPLEXAN PARASITES; MICRONEME PROTEINS; MOLECULAR CHARACTERIZATION; GONDII; INVASION; SECRETION; CLEAVAGE; THROMBOSPONDIN	Toxoplasma gondii parasites gain entry into host cells through a process that depends on apically stored adhesins that are strategically released during invasion. One of these adhesins, microneme protein 2 (MIC2), is a type one transmembrane protein that binds to an accessory protein known as MIC2-associated protein (M2AP). Together the MIC2 . M2AP complex participates in host cell attachment and invasion. The short cytoplasmic C-domain of MIC2 is implicated in protein trafficking and mediating an association with the parasite cytoskeleton. To define the role of the cytoplasmic domain of MIC2, proteins lacking the C-domain were expressed in transgenic T. gondii. Surprisingly, protein trafficking and secretion were not affected. We hypothesized that mutant mic2 lacking the C-domain might be escorted to the micronemes by association with endogenous wild-type MIC2 possessing functional transmembrane and cytoplasmic domains. To investigate this interaction, native blue gels and gel filtration were employed to identify a stable macromolecular MIC2 . M2AP complex of similar to 450 kDa. Our findings reveal that MIC2 and M2AP proteins form stable hexamers consisting of three alphabeta dimers. Resolution of this complex has implications for how MIC2 . M2AP associates with host cell receptors and the cytoskeleton to facilitate parasite motility and invasion.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Sibley, LD (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	sibley@borcim.wustl.edu	Sibley, L. David/C-4616-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034036] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI034036, AI34036] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brossier F, 2003, J BIOL CHEM, V278, P6229, DOI 10.1074/jbc.M209837200; Brydges SD, 2000, MOL BIOCHEM PARASIT, V111, P51, DOI 10.1016/S0166-6851(00)00296-6; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 1999, BIOCHEM J, V342, P379, DOI 10.1042/0264-6021:3420379; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Carruthers VB, 2000, INFECT IMMUN, V68, P4005, DOI 10.1128/IAI.68.7.4005-4011.2000; Cerede O, 2002, EMBO J, V21, P2526, DOI 10.1093/emboj/21.11.2526; Di Cristina M, 2000, MOL CELL BIOL, V20, P7332, DOI 10.1128/MCB.20.19.7332-7341.2000; Donald RGK, 1998, MOL BIOCHEM PARASIT, V91, P295, DOI 10.1016/S0166-6851(97)00210-7; HARPER JM, 2004, IN PRESS MOL BIOCH P; Huynh MH, 2003, EMBO J, V22, P2082, DOI 10.1093/emboj/cdg217; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Meissner M, 2002, J CELL SCI, V115, P563; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Opitz C, 2002, EMBO J, V21, P1577, DOI 10.1093/emboj/21.7.1577; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; Reiss M, 2001, J CELL BIOL, V152, P563, DOI 10.1083/jcb.152.3.563; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Soldati D, 2001, INT J PARASITOL, V31, P1293, DOI 10.1016/S0020-7519(01)00257-0; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; Wan KL, 1997, MOL BIOCHEM PARASIT, V84, P203, DOI 10.1016/S0166-6851(96)02796-X	28	41	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9362	9369		10.1074/jbc.M312590200	http://dx.doi.org/10.1074/jbc.M312590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670959	hybrid			2022-12-27	WOS:000189265900100
J	Lozupone, F; Lugini, L; Matarrese, P; Luciani, F; Federici, C; Iessi, E; Margutti, P; Stassi, G; Malorni, W; Fais, S				Lozupone, F; Lugini, L; Matarrese, P; Luciani, F; Federici, C; Iessi, E; Margutti, P; Stassi, G; Malorni, W; Fais, S			Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FERM DOMAIN; PLASMA-MEMBRANE; ACTIN-BINDING; TYROSINE PHOSPHORYLATION; T-LYMPHOCYTES; ERM PROTEINS; EPITHELIAL-CELLS; MOESIN; CYTOSKELETON	The CD95 (Fas/APO-1) linkage to the actin cytoskeleton through ezrin is an essential requirement for susceptibility to the CD95-mediated apoptosis in CD4+ T cells. We have previously shown that moesin was not involved in the binding to CD95. Here we further support the specificity of the ezrin/CD95 binding, showing that radixin did not bind CD95. The ezrin region specifically and directly involved in the binding to CD95 was located in the middle lobe of the ezrin FERM domain, between amino acids 149 and 168. In this region, ezrin, radixin, and moesin show 60-65% identity, as compared with the 86% identity in the whole FERM domain. Transfection of two different human cell lines with a green fluorescent protein-tagged ezrin mutated in the CD95-binding epitope, induced a marked inhibition of CD95-mediated apoptosis. In these cells, the mutated ezrin did not co-localize or co-immunoprecipitate with CD95. Further analysis showed that the mutated ezrin, while unable to bind CD95, was fully able to bind actin, thus preventing the actin linkage to CD95. Altogether, our results support the specificity of ezrin in the association to CD95 and the importance of the ezrin-to-CD95 linkage in CD95-mediated apoptosis. Moreover, this study suggests that a major role of ezrin is to connect CD95 to actin, thus allowing the CD95 polarization on the cells and the occurrence of the following multiple cascades of the CD95 pathway.	Ist Super Sanita, Immunol Lab, Tumor Immunol Sect, I-00161 Rome, Italy; Ist Super Sanita, Lab Ultrastruct, I-00161 Rome, Italy; Univ Palermo, Dept Surg & Oncol Sci, Lab Cellular & Mol Pathophysiol, I-90127 Palermo, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); University of Palermo	Fais, S (corresponding author), Ist Super Sanita, Immunol Lab, Tumor Immunol Sect, Viale Regina Elena 299, I-00161 Rome, Italy.	fais@iss.it	Lugini, Luana/J-8672-2016; Malorni, Walter/G-5874-2016; Federici, Cristina/O-4676-2016; Iessi, Elisabetta/O-2460-2017; Fais, Stefano/J-8638-2016; Stassi, Giorgio/AAC-1175-2022; Lozupone, Francesco/H-2998-2016; Matarrese, Paola/A-4369-2014	Lugini, Luana/0000-0002-8778-2601; Federici, Cristina/0000-0001-6366-0231; Iessi, Elisabetta/0000-0001-7221-9173; Fais, Stefano/0000-0001-9060-2766; Lozupone, Francesco/0000-0002-4959-9400; Luciani, Francesca/0000-0002-1362-2808; malorni, walter/0000-0002-1223-7000				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ausbel FM, 1994, CURRENT PROTOCOLS MO; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 1997, J CELL SCI, V110, P3011; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; del Pozo MA, 1998, CELL ADHES COMMUN, V6, P125, DOI 10.3109/15419069809004468; Edwards SD, 2001, BIOCHEMISTRY-US, V40, P7061, DOI 10.1021/bi010419h; Fais S, 2000, HISTOL HISTOPATHOL, V15, P539, DOI 10.14670/HH-15.539; Fais S, 2003, J LEUKOCYTE BIOL, V73, P556, DOI 10.1189/jlb.1102568; FRANCK Z, 1993, J CELL SCI, V105, P219; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Jiang WG, 1995, BIOCHEM BIOPH RES CO, V217, P1062, DOI 10.1006/bbrc.1995.2877; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Kulms D, 2002, CELL DEATH DIFFER, V9, P598, DOI 10.1038/sj.cdd.4401002; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Luciani F, 2002, BLOOD, V99, P641, DOI 10.1182/blood.V99.2.641; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Perez OD, 2002, IMMUNITY, V16, P51, DOI 10.1016/S1074-7613(02)00266-2; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Ramoni C, 2002, EUR J IMMUNOL, V32, P3059, DOI 10.1002/1521-4141(200211)32:11<3059::AID-IMMU3059>3.0.CO;2-3; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Smith WJ, 2003, J BIOL CHEM, V278, P4949, DOI 10.1074/jbc.M210601200; Smith WJ, 2002, ACTA CRYSTALLOGR D, V58, P1359, DOI [10.1107/S0907444902010004, 10.1107/S0907444902009162]; TAKEUCHI K, 1994, J CELL SCI, V107, P1921; THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Turunen O, 1998, BBA-PROTEIN STRUCT M, V1387, P1, DOI 10.1016/S0167-4838(98)00103-4; Vicente-Manzanares M, 2000, Dev Immunol, V7, P51, DOI 10.1155/2000/70801; Wang GQ, 2001, J BIOL CHEM, V276, P3610, DOI 10.1074/jbc.M006222200; Yao XB, 1996, J BIOL CHEM, V271, P7224, DOI 10.1074/jbc.271.12.7224; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	49	56	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9199	9207		10.1074/jbc.M305561200	http://dx.doi.org/10.1074/jbc.M305561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676203	hybrid			2022-12-27	WOS:000189265900081
J	Ng, CP; Lee, HC; Ho, CW; Arooz, T; Siu, WY; Lau, A; Poon, RYC				Ng, CP; Lee, HC; Ho, CW; Arooz, T; Siu, WY; Lau, A; Poon, RYC			Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE; PROTEIN-KINASE; TUMOR-SUPPRESSOR; PHOSPHORYLATION; ATR; ACTIVATION; CLASPIN; PATHWAY; BINDING	CHK1 and CHK2 are key mediators that link the machineries that monitor DNA integrity to components of the cell cycle engine. Despite the similarity and potential redundancy in their functions, CHK1 and CHK2 are unrelated protein kinases, each having a distinctive regulatory domain. Here we compare how the regulatory domains of human CHK1 and CHK2 modulate the respective kinase activities. Recombinant CHK1 has only low basal activity when expressed in cultured cells. Surprisingly, disruption of the C-terminal regulatory domain activates CHK1 even in the absence of stress. Unlike the full-length protein, C-terminally truncated CHK1 displays autophosphorylation, phosphorylates CDC25C on Ser(216), and delays cell cycle progression. Intriguingly, enzymatic activity decreases when the entire regulatory domain is removed, suggesting that the regulatory domain contains both inhibitory and stimulatory elements. Conversely, the kinase domain suppresses Ser(345) phosphorylation, a major ATM/ATR phosphorylation site in the regulatory domain. In marked contrast, CHK2 expressed in either mammalian cells or in bacteria is already active as a kinase against itself and CDC25C and can delay cell cycle progression. Unlike CHK1, disruption of the regulatory domain of CHK2 abolishes its kinase activity. Moreover, the regulatory domain of CHK2, but not that of CHK1, can oligomerize. Finally, CHK1 but not CHK2 is phosphorylated during the spindle assembly checkpoint, which correlates with the inhibition of the kinase. The mitotic phosphorylation of CHK1 requires the regulatory domain, does not involve Ser(345), and is independent on ATM. Collectively, these data reveal the very different mode of regulation between CHK1 and CHK2.	Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China.	bcrandy@ust.hk		Poon, Randy/0000-0001-5571-6231				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Jiang W, 1998, BIOTECHNIQUES, V24, P349; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Millband DN, 2002, TRENDS CELL BIOL, V12, P205, DOI 10.1016/S0962-8924(02)02276-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Takai H, 2000, GENE DEV, V14, P1439; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; Wang X, 2003, J BIOL CHEM, V278, P30869, DOI 10.1074/jbc.M301876200; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	58	48	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8808	8819		10.1074/jbc.M312215200	http://dx.doi.org/10.1074/jbc.M312215200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681223	hybrid			2022-12-27	WOS:000189265900036
J	Rodriguez, M; Li, SSC; Harper, JW; Zhou, SY				Rodriguez, M; Li, SSC; Harper, JW; Zhou, SY			An oriented peptide array library (OPAL) strategy to study protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOEPITOPE ANTIBODY; COMBINATORIAL LIBRARIES; SUBSTRATE-SPECIFICITY; MONOCLONAL-ANTIBODIES; IDENTIFYING LIGANDS; RECEPTOR LIGANDS; MITOTIC CELLS; DOMAINS; BINDING; KINASE	One of the major questions in signal transduction is how the specificities of protein-protein interactions determine the assembly of distinct signaling complexes in response to stimuli. Several peptide library methods have been developed and widely used to study protein-protein interactions. These approaches primarily rely on peptide or DNA sequencing to identify the peptide or consensus motif for binding and may prove too costly or difficult to accommodate high throughput applications. We report here an oriented peptide array library (OPAL) approach that should facilitate high throughput proteomic analysis of protein-protein interactions. OPAL integrates the principles of both the oriented peptide libraries and array technologies. Hundreds of pools of oriented peptide libraries are synthesized as amino acid scan arrays. We demonstrate that these arrays can be used to map the specificities of a variety of interactions, including antibodies, protein domains such Src homology 2 domains, and protein kinases.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Western Ontario, Fac Med & Dent, Dept Biochem, London, ON N6A 5C1, Canada	Baylor College of Medicine; Western University (University of Western Ontario)	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	songyang@bcm.tmc.edu		Harper, Jeffrey/0000-0002-6944-7236	NCI NIH HHS [CA84208] Funding Source: Medline; NIA NIH HHS [R01 AG011085, AG11085] Funding Source: Medline; NIGMS NIH HHS [GM569209] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CABILLY S, 1998, METHODS MOL BIOL COM, V87, P87; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; Daum JR, 1998, J BIOL CHEM, V273, P30622, DOI 10.1074/jbc.273.46.30622; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; MAEJI NJ, 1990, J IMMUNOL METHODS, V134, P23; Mah AS, 2001, P NATL ACAD SCI USA, V98, P7325, DOI 10.1073/pnas.141098998; MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nollau P, 2001, P NATL ACAD SCI USA, V98, P13531, DOI 10.1073/pnas.241215998; OOI J, 1995, ONCOGENE, V10, P1621; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Tegge WJ, 1998, METH MOL B, V87, P99; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhou SY, 1999, PROG BIOPHYS MOL BIO, V71, P359, DOI 10.1016/S0079-6107(98)00045-5	37	74	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8802	8807		10.1074/jbc.M311886200	http://dx.doi.org/10.1074/jbc.M311886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679191	hybrid			2022-12-27	WOS:000189265900035
J	Wintjens, R; Noel, C; May, ACW; Gerbod, D; Dufernez, F; Capron, M; Viscogliosi, E; Rooman, M				Wintjens, R; Noel, C; May, ACW; Gerbod, D; Dufernez, F; Capron, M; Viscogliosi, E; Rooman, M			Specificity and phenetic relationships of iron- and manganese-containing superoxide dismutases on the basis of structure and sequence comparisons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-SPECIFIC ACTIVITY; THERMUS-THERMOPHILUS HB8; ALPHA-TURN MOTIFS; ESCHERICHIA-COLI; PORPHYROMONAS-GINGIVALIS; ACTIVE-SITE; PROTEIN; RESOLUTION; STABILITY; MUTATION	The iron- and manganese-containing superoxide dismutases (Fe/Mn-SOD) share the same chemical function and spatial structure but can be distinguished according to their modes of oligomerization and their metal ion specificity. They appear as homodimers or homotetramers and usually require a specific metal for activity. On the basis of 261 aligned SOD sequences and 12 superimposed x-ray structures, two phenetic trees were constructed, one sequence-based and the other structure-based. Their comparison reveals the imperfect correlation of sequence and structural changes; hyperthermophilicity requires the largest sequence alterations, whereas dimer/tetramer and manganese/iron specificities are induced by the most sizable structural differences within the monomers. A systematic investigation of sequence and structure characteristics conserved in all aligned SOD sequences or in subsets sharing common oligomeric and/or metal specificities was performed. Several residues were identified as guaranteeing the common function and dimeric conformation, others as determining the tetramer formation, and yet others as potentially responsible for metal specificity. Some form cation-pi interactions between an aromatic ring and a fully or partially positively charged group, suggesting that these interactions play a significant role in the structure and function of SOD enzymes. Dimer/tetramer- and iron/manganese-specific fingerprints were derived from the set of conserved residues; they can be used to propose selected residue substitutions in view of the experimental validation of our in silico derived hypotheses.	Free Univ Brussels, Inst Pharm, B-1050 Brussels, Belgium; Inst Pasteur, INSERM, U547, F-59019 Lille, France; Inst Pathol Cellulaire Christian de Duve ICP TROP, B-1200 Brussels, Belgium; Natl Inst Med Res, Div Math Biol, London NW7 1AA, England	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; MRC National Institute for Medical Research	Rooman, M (corresponding author), Free Univ Brussels, Inst Pharm, CP 165-61,50 Ave Roosevelt, B-1050 Brussels, Belgium.	chrn@nhm.ac.uk; mrooman@ulb.ac.be	Capron, monique/Z-2207-2019	Capron, monique/0000-0001-5625-5158; Viscogliosi, Eric/0000-0002-5805-7179				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; BEYER WF, 1991, J BIOL CHEM, V266, P303; BOUTONNET NS, 1995, PROTEIN ENG, V8, P647, DOI 10.1093/protein/8.7.647; BROCK CJ, 1977, BIOCHEM SOC T, V5, P1533; BULL C, 1991, J AM CHEM SOC, V113, P4069, DOI 10.1021/ja00011a003; BULL C, 1985, J AM CHEM SOC, V107, P3295, DOI 10.1021/ja00297a040; Cabelli DE, 1999, BIOCHEMISTRY-US, V38, P11686, DOI 10.1021/bi9909142; Chen HY, 2002, ARCH BIOCHEM BIOPHYS, V404, P218, DOI 10.1016/S0003-9861(02)00299-0; Edward RA, 1998, J AM CHEM SOC, V120, P9684, DOI 10.1021/ja981072h; Edwards RA, 2001, BIOCHEMISTRY-US, V40, P15, DOI 10.1021/bi0018943; Edwards RA, 2001, BIOCHEMISTRY-US, V40, P4622, DOI 10.1021/bi002403h; ELSENSTEIN J, 1995, PHYLIP PHYLOGENY INF; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; Hiraoka BY, 2000, BIOCHEM J, V345, P345, DOI 10.1042/0264-6021:3450345; HUBBARD SJ, 1992, NACCESS PROGRAM; Hunter T, 1997, BIOCHEMISTRY-US, V36, P4925, DOI 10.1021/bi9629541; Hunter T, 2002, EUR J BIOCHEM, V269, P5137, DOI 10.1046/j.1432-1033.2002.03200.x; Jackson SMJ, 1998, BIOMETALS, V11, P159, DOI 10.1023/A:1009238214394; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kardinahl S, 1996, FEMS MICROBIOL LETT, V138, P65; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; LANYON SM, 1985, SYST ZOOL, V34, P397, DOI 10.2307/2413204; Leveque VJP, 2000, BIOCHEMISTRY-US, V39, P7131, DOI 10.1021/bi9929958; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MARTIN ME, 1986, J BIOL CHEM, V261, P9361; May ACW, 1999, PROTEINS, V37, P20; May ACW, 1999, STRUCT FOLD DES, V7, pR213, DOI 10.1016/S0969-2126(99)80168-3; MCADAM ME, 1977, BIOCHEM J, V165, P71, DOI 10.1042/bj1650071; MCCORD JM, 1988, FREE RADICAL BIO MED, V5, P363, DOI 10.1016/0891-5849(88)90109-8; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; OSE DE, 1979, ARCH BIOCHEM BIOPHYS, V194, P360, DOI 10.1016/0003-9861(79)90628-3; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PARKER MW, 1987, PROTEIN ENG, V1, P393, DOI 10.1093/protein/1.5.393; PARKER MW, 1988, FEBS LETT, V229, P377, DOI 10.1016/0014-5793(88)81160-8; Ridley M., 1996, EVOLUTION; Romesburg H. C., 1984, CLUSTER ANAL RES; Santos R, 1999, J BACTERIOL, V181, P4509, DOI 10.1128/JB.181.15.4509-4516.1999; SATO S, 1978, J BIOCHEM-TOKYO, V83, P1165, DOI 10.1093/oxfordjournals.jbchem.a132007; SATO S, 1977, EUR J BIOCHEM, V73, P373, DOI 10.1111/j.1432-1033.1977.tb11328.x; SINES J, 1990, J PHYS CHEM-US, V94, P959, DOI 10.1021/j100365a084; STALLINGS WC, 1981, J BIOL CHEM, V256, P5857; STALLINGS WC, 1985, J BIOL CHEM, V260, P6424; STALLINGS WC, 1991, FREE RADICAL RES COM, V12-3, P259, DOI 10.3109/10715769109145794; STALLINGS WC, 1984, J BIOL CHEM, V259, P1095; Tabares LC, 2003, J BACTERIOL, V185, P3223, DOI 10.1128/JB.185.10.3223-3227.2003; Vance CK, 2001, BIOCHEMISTRY-US, V40, P13079, DOI 10.1021/bi0113317; Vance CK, 1998, J AM CHEM SOC, V120, P461, DOI 10.1021/ja972060j; Whittaker MM, 1997, BIOCHEMISTRY-US, V36, P8923, DOI 10.1021/bi9704212; Whittaker MM, 1998, J BIOL CHEM, V273, P22188, DOI 10.1074/jbc.273.35.22188; Whittaker MM, 1999, J BIOL CHEM, V274, P34751, DOI 10.1074/jbc.274.49.34751; Wintjens R, 2000, J MOL BIOL, V302, P395, DOI 10.1006/jmbi.2000.4040; Wintjens R, 1998, PROTEIN ENG, V11, P505, DOI 10.1093/protein/11.7.505; Wintjens RT, 1996, J MOL BIOL, V255, P235, DOI 10.1006/jmbi.1996.0020; Yamakura F, 2003, BIOCHEMISTRY-US, V42, P10790, DOI 10.1021/bi0349625; YAMAKURA F, 1995, EUR J BIOCHEM, V227, P700, DOI 10.1111/j.1432-1033.1995.tb20191.x; Yamakura F, 1995, BIOCHEM MOL BIOL INT, V36, P233	61	66	68	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9248	9254		10.1074/jbc.M312329200	http://dx.doi.org/10.1074/jbc.M312329200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672935	hybrid			2022-12-27	WOS:000189265900086
J	Denis, M; Haidar, B; Marcil, M; Bouvier, M; Krimbou, L; Genest, J				Denis, M; Haidar, B; Marcil, M; Bouvier, M; Krimbou, L; Genest, J			Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE MICROSOLUBILIZATION; REVERSE CHOLESTEROL TRANSPORT; FAMILIAL HDL DEFICIENCY; PRE-BETA; APOA-I; FUNCTIONAL-PROPERTIES; TANGIER-DISEASE; EFFLUX; PARTICLES	The dynamics of ABCA1-mediated apoA-I lipidation were investigated in intact human fibroblasts induced with 22(R)-hydroxycholesterol and 9-cis-retinoic acid (stimulated cells). Specific binding parameters of I-125-apoA-I to ABCA1 at 37degreesC were determined: K-d=0.65 mug/ml, B-max=0.10 ng/mug cell protein. Lipid-free apoA-I inhibited the binding of I-125-apoA-I to ABCA1 more efficiently than pre-beta(1)-LpA-I, reconstituted HDL particles r(LpA-I), or HDL3 (IC50=0.35+/-1.14, apoA-I; 1.69+/-1.07, pre-beta(1)-LpA-I; 17.91+/-1.39, r(LpA-I); and 48.15+/-1.72 mug/ml, HDL3). Treatment of intact cells with either phosphatidylcholine-specific phospholipase C or sphingomyelinase affected neither I-125-apoA-I binding nor I-125-apoA-I/ABCA1 cross-linking. We next investigated the dynamics of apoA-I lipidation by monitoring the kinetic of apoA-I dissociation from ABCA1. The dissociation of I-125-apoA-I from normal cells at 37degreesC was rapid (t(1/2)=1.4+/-0.66 h; n=3) but almost completely inhibited at either 15 or 4degreesC. A time course analysis of apoA-I-containing particles released during the dissociation period showed nascent apoA-I-phospholipid complexes that exhibited alpha-electrophoretic mobility with a particle size ranging from 9 to 20 nm (designated alpha-LpA-I-like particles), whereas lipid-free apoA-I incubated with ABCA1 mutant (Q597R) cells was unable to form such particles. These results demonstrate that: 1) the physical interaction of apoA-I with ABCA1 does not depend on membrane phosphatidylcholine or sphingomyelin; 2) the association of apoA-I with lipids reduces its ability to interact with ABCA1; and 3) the lipid translocase activity of ABCA1 generates alpha-LpA-I-like particles. This process plays in vivo a key role in HDL biogenesis.	McGill Univ, Ctr Hlth, Royal Victoria Hosp, Cardiol Div,Cardiovasc Genet Lab, Montreal, PQ H3A 1A1, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	McGill University; Royal Victoria Hospital; Universite de Montreal	Genest, J (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp, Cardiol Div,Cardiovasc Genet Lab, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	jacques.genest@muhc.mcgill.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				Asztalos B, 1997, ARTERIOSCL THROM VAS, V17, P1630, DOI 10.1161/01.ATV.17.9.1630; ASZTALOS BF, 1995, ARTERIOSCL THROM VAS, V15, P1419, DOI 10.1161/01.ATV.15.9.1419; BARRANS A, 1994, J BIOL CHEM, V269, P11572; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Batal R, 1998, ARTERIOSCL THROM VAS, V18, P655, DOI 10.1161/01.ATV.18.4.655; BEDOSSA P, 1989, ARCH PATHOL LAB MED, V113, P777; BIELICKI JK, 1992, J LIPID RES, V33, P1699; Brewer HB, 2003, AM J CARDIOL, V91, p3E, DOI 10.1016/S0002-9149(02)03382-9; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brownawell AM, 1996, BIOCHEMISTRY-US, V35, P6839, DOI 10.1021/bi952585t; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; DAVIDSON WS, 1994, J BIOL CHEM, V269, P8959; DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206; Fidge NH, 1999, J LIPID RES, V40, P187; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FORTE TM, 1993, J LIPID RES, V34, P317; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Gillotte KL, 1998, J LIPID RES, V39, P1918; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; HARA H, 1991, J BIOL CHEM, V266, P3080; JONAS A, 1993, J BIOL CHEM, V268, P1596; Kee P, 2002, ARTERIOSCL THROM VAS, V22, P1912, DOI 10.1161/01.ATV.0000038485.94020.7F; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krimbou L, 1998, J LIPID RES, V39, P861; Krimbou L, 2003, J LIPID RES, V44, P884, DOI 10.1194/jlr.M200273-JLR200; Krimbou L, 1998, J LIPID RES, V39, P2373; Krimbou L, 2001, J BIOL CHEM, V276, P33241, DOI 10.1074/jbc.M100326200; KUNITAKE ST, 1990, ARTERIOSCLEROSIS, V10, P25, DOI 10.1161/01.ATV.10.1.25; Lambert G, 1999, J LIPID RES, V40, P1294; Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Marcil M, 2003, CIRCULATION, V107, P1366, DOI 10.1161/01.CIR.0000056764.53152.F9; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; Martinez LO, 2003, J BIOL CHEM, V278, P37368, DOI 10.1074/jbc.M307161200; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Paradis V, 1996, CELL MOL BIOL, V42, P525; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200	47	83	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7384	7394		10.1074/jbc.M306963200	http://dx.doi.org/10.1074/jbc.M306963200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660648	hybrid			2022-12-27	WOS:000189103300004
J	Kessler, N; Schuhmann, H; Morneweg, S; Linne, U; Marahiel, MA				Kessler, N; Schuhmann, H; Morneweg, S; Linne, U; Marahiel, MA			The linear pentadecapeptide gramicidin is assembled by four multimodular nonribosomal peptide synthetases that comprise 16 modules with 56 catalytic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATION DOMAINS; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; EPIMERIZATION DOMAIN; BIOSYNTHESIS OPERON; ENZYME; CONDENSATION; PROTEIN; ACID; PHENYLALANINE	Linear gramicidin is a membrane channel forming pentadecapeptide that is produced via the nonribosomal pathway. It consists of 15 hydrophobic amino acids with alternating L- and D-configuration forming a beta-helix-like structure. It has an N-formylated valine and a C-terminal ethanolamine. Here we report cloning and sequencing of the entire biosynthetic gene cluster as well as initial biochemical analysis of a new reductase domain. The biosynthetic gene cluster was identified on two nonoverlapping fosmids and a 13-kilobase pair (kbp) interbridge fragment covering a region of 74 kbp. Four very large open reading frames, lgrA, lgrB, lgrC, and lgrD with 6.8, 15.5, 23.3, and 15.3 kbp, were identified and shown to encode nonribosomal peptide synthetases with two, four, six, and four modules, respectively. Within the 16 modules identified, seven epimerization domains in alternating positions were detected as well as a putative formylation domain fused to the first module LgrA and a putative reductase domain attached to the C-terminal module of LgrD. Analysis of the substrate specificity by phylogenetic studies using the residues of the substrate-binding pockets of all 16 adenylation domains revealed a good agreement of the substrate amino acids predicted with the sequence of linear gramicidin. Additional biochemical analysis of the three adenylation domains of modules 1, 2, and 3 confirmed the colinearity of this nonribosomal peptide synthetase assembly line. Module 16 was predicted to activate glycine, which would then, being the C-terminal residue of the peptide chain, be reduced by the adjacent reductase domain to give ethanolamine, thereby releasing the final product N-formyl-pentadecapeptide-ethanolamine. However, initial biochemical analysis of this reductase showed only a one-step reduction yielding the corresponding aldehyde in vitro.	Univ Marburg, FB Chem, D-35032 Marburg, Germany	Philipps University Marburg	Marahiel, MA (corresponding author), Univ Marburg, FB Chem, Hans Meerwein Str, D-35032 Marburg, Germany.	marahiel@chemie.uni-marburg.de						AKASHI K, 1977, J BIOCHEM-TOKYO, V81, P269, DOI 10.1093/oxfordjournals.jbchem.a131446; AKERS HA, 1977, BIOCHEMISTRY-US, V16, P5722, DOI 10.1021/bi00645a012; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; Clugston SL, 2003, BIOCHEMISTRY-US, V42, P12095, DOI 10.1021/bi035090+; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; Doekel S, 2000, CHEM BIOL, V7, P373, DOI 10.1016/S1074-5521(00)00118-6; Gaitatzis N, 2001, P NATL ACAD SCI USA, V98, P11136, DOI 10.1073/pnas.201167098; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; Hotchkiss RD, 1940, J BIOL CHEM, V132, P791; Keating TA, 2002, NAT STRUCT BIOL, V9, P522, DOI 10.1038/nsb810; Konz D, 1997, CHEM BIOL, V4, P927, DOI 10.1016/S1074-5521(97)90301-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linne U, 2003, BIOCHEMISTRY-US, V42, P5114, DOI 10.1021/bi034223o; Linne U, 2001, BIOCHEMISTRY-US, V40, P15824, DOI 10.1021/bi011595t; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Mootz HD, 2000, P NATL ACAD SCI USA, V97, P5848, DOI 10.1073/pnas.100075897; Mootz HD, 2002, CHEMBIOCHEM, V3, P490, DOI 10.1002/1439-7633(20020603)3:6<490::AID-CBIC490>3.0.CO;2-N; Pospiech A, 1996, MICROBIOL-UK, V142, P741, DOI 10.1099/00221287-142-4-741; Rouhiainen L, 2000, MOL MICROBIOL, V37, P156, DOI 10.1046/j.1365-2958.2000.01982.x; SAGISAKA S, 1959, NATURE, V184, P1709, DOI 10.1038/1841709b0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGES R, 1965, J AM CHEM SOC, V87, P2011, DOI 10.1021/ja01087a027; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; Schwarzer D, 2002, P NATL ACAD SCI USA, V99, P14083, DOI 10.1073/pnas.212382199; Sieber SA, 2003, J AM CHEM SOC, V125, P10862, DOI 10.1021/ja0361852; Silakowski B, 2000, EUR J BIOCHEM, V267, P6476, DOI 10.1046/j.1432-1327.2000.01740.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Stachelhaus T, 2000, BIOCHEMISTRY-US, V39, P5775, DOI 10.1021/bi9929002; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1111/j.1574-6968.1995.tb07328.x; STEIN T, 1995, BIOCHEMISTRY-US, V34, P4633, DOI 10.1021/bi00014a017; Wallace BA, 1998, J STRUCT BIOL, V121, P123, DOI 10.1006/jsbi.1997.3948; Weber T, 2001, STRUCTURE, V9, pR3, DOI 10.1016/S0969-2126(00)00560-8; WEINSTEIN S, 1980, J MOL BIOL, V143, P1, DOI 10.1016/0022-2836(80)90121-7	39	76	86	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7413	7419		10.1074/jbc.M309658200	http://dx.doi.org/10.1074/jbc.M309658200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670971	hybrid			2022-12-27	WOS:000189103300007
J	Ko, JE; Kim, CW; Kim, DR				Ko, JE; Kim, CW; Kim, DR			Amino acid residues in RAG1 responsible for the interaction with RAG2 during the V(D)J recombination process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SYNAPTIC COMPLEX; ACTIVE-SITE; IN-VITRO; CLEAVAGE; GENES; DNA; INITIATION; DEFINITION; BINDING	The V(D) J recombinase, a complex of RAG1 and RAG2, carries out a gene rearrangement process that is required for the achievement of diverse antigen receptor repertoires during the early developmental stage of lymphocytes. It recognizes a specific site spanning the coding DNA region of antigen receptor genes and produces double-stranded DNA breaks at the board between coding and signal sequences. Two broken DNA ends are joined by a double-stranded break repair system. Both RAG (recombination activation gene) 1 and RAG2 proteins are absolutely required for this process although the catalytic residues of V(D) J recombinase are exclusively located at RAG1 according to recent mutational analyses. In this study we identified some acidic amino acid residues in RAG1 responsible for the interaction with RAG2. Mutation on these residues caused a decrease of cleavage activity in vitro and failure of RAG-RSS DNA synaptic complex formation. This result is complementary to previous reports in which positively charged amino acids in RAG2 play an important role in RAG1 binding.	Gyeongsang Natl Univ, Dept Biochem, Jinju 660751, South Korea; Gyeongsang Natl Univ, Coll Med, RINS, Jinju 660751, South Korea; Gyeongsang Natl Univ, Gyeongsang Inst Hlth Sci, Jinju 660751, South Korea	Gyeongsang National University; Gyeongsang National University; Gyeongsang National University	Kim, DR (corresponding author), Gyeongsang Natl Univ, Dept Biochem, 92 Chilam Dong, Jinju 660751, South Korea.	drkim@gsnu.ac.kr						Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Aidinis V, 2000, J IMMUNOL, V164, P5826, DOI 10.4049/jimmunol.164.11.5826; Akamatsu Y, 1998, MOL CELL BIOL, V18, P4670, DOI 10.1128/MCB.18.8.4670; Bailin T, 1999, MOL CELL BIOL, V19, P4664; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; EPPLEN JT, 1987, HUM GENET, V75, P300, DOI 10.1007/BF00284099; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; FUMANN S, 2001, MOL CELL, V8, P889; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; Kim DD, 2000, MOL CELLS, V10, P367; Kim DR, 1998, MOL CELL BIOL, V18, P4679, DOI 10.1128/MCB.18.8.4679; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; McMahan CJ, 1997, J IMMUNOL, V158, P2202; Mo XM, 1999, J BIOL CHEM, V274, P7025, DOI 10.1074/jbc.274.11.7025; Mundy CL, 2002, MOL CELL BIOL, V22, P69, DOI 10.1128/MCB.22.1.69-77.2002; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; QUI J, 2001, MOL CELL, V7, P77; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Swanson PC, 1999, MOL CELL BIOL, V19, P3674; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8	33	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7715	7720		10.1074/jbc.M311471200	http://dx.doi.org/10.1074/jbc.M311471200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670978	hybrid			2022-12-27	WOS:000189103300044
J	Liu, J; Liao, ZJ; Camden, J; Griffin, KD; Garrad, RC; Santiago-Perez, LI; Gonzalez, FA; Seye, CI; Weisman, GA; Erb, L				Liu, J; Liao, ZJ; Camden, J; Griffin, KD; Garrad, RC; Santiago-Perez, LI; Gonzalez, FA; Seye, CI; Weisman, GA; Erb, L			Src homology 3 binding sites in the P2Y(2) nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; EGF RECEPTOR; C-SRC; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ACTIVATION; EXTRACELLULAR ATP; BETA; ADHESION; INTEGRIN; PYK2	Many G protein-coupled receptors activate growth factor receptors, although the mechanisms controlling this transactivation are unclear. We have identified two pro-line-rich, SH3 binding sites (PXXP) in the carboxyl-terminal tail of the human P2Y(2) nucleotide receptor that directly associate with the tyrosine kinase Src in protein binding assays. Furthermore, Src co-precipitated with the P2Y(2) receptor in 1321N1 astrocytoma cells stimulated with the P2Y(2) receptor agonist UTP. A mutant P2Y(2) receptor lacking the PXXP motifs was found to stimulate calcium mobilization and serine/threonine phosphorylation of the Erk1/2 mitogen-activated protein kinases, like the wild-type receptor, but was defective in its ability to stimulate tyrosine phosphorylation of Src and Src-dependent tyrosine phosphorylation of the proline-rich tyrosine kinase 2, epidermal growth factor receptor (EGFR), and platelet-derived growth factor receptor. Dual immunofluorescence labeling of the P2Y(2) receptor and the EGFR indicated that UTP caused an increase in the co-localization of these receptors in the plasma membrane that was prevented by the Src inhibitor PP2. Together, these data suggest that agonist-induced binding of Src to the SH3 binding sites in the P2Y(2) receptor facilitates Src activation, which recruits the EGFR into a protein complex with the P2Y(2) receptor and allows Src to efficiently phosphorylate the EGFR.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA; SW Missouri State Univ, Dept Biomed Sci, Springfield, MO 65804 USA; Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA	University of Missouri System; University of Missouri Columbia; Missouri State University; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Erb, L (corresponding author), Univ Missouri, Dept Biochem, M743 Med Sci Bldg, Columbia, MO 65212 USA.	erbl@missouri.edu		Erb, Laurie/0000-0001-6372-3378	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG018357] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15565] Funding Source: Medline; NIA NIH HHS [AG18357] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn JS, 2000, AM J PHYSIOL-CELL PH, V279, pC286, DOI 10.1152/ajpcell.2000.279.2.C286; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Du QS, 2001, J CELL SCI, V114, P2977; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; LUSTIG KD, 1992, BIOCHIM BIOPHYS ACTA, V1134, P61, DOI 10.1016/0167-4889(92)90028-A; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2002, TRENDS CARDIOVAS MED, V12, P46, DOI 10.1016/S1050-1738(01)00138-4; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Oldenhof J, 1998, BIOCHEMISTRY-US, V37, P15726, DOI 10.1021/bi981634+; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Satterwhite CM, 1999, AM J PHYSIOL-HEART C, V276, pH1091, DOI 10.1152/ajpheart.1999.276.3.H1091; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Seye CI, 2002, CIRCULATION, V106, P2720, DOI 10.1161/01.CIR.0000038111.00518.35; Shah BH, 2002, MOL PHARMACOL, V61, P343, DOI 10.1124/mol.61.2.343; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889	35	129	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8212	8218		10.1074/jbc.M312230200	http://dx.doi.org/10.1074/jbc.M312230200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670955	hybrid			2022-12-27	WOS:000189103300103
J	Park, SY; Chang, I; Kim, JY; Kang, SW; Park, SH; Singh, K; Lee, MS				Park, SY; Chang, I; Kim, JY; Kang, SW; Park, SH; Singh, K; Lee, MS			Resistance of mitochondrial DNA-depleted cells against cell death - Role of mitochondrial superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; COMPLEX-I DEFICIENCY; INDUCED APOPTOSIS; CYTOCHROME-C; OXIDATIVE STRESS; GENE-EXPRESSION; P53-DEPENDENT APOPTOSIS; MEDIATED APOPTOSIS	We have shown that mitochondrial DNA-depleted (rho(0)) SK-Hep1 hepatoma cells are resistant to apoptosis, contrary to previous papers reporting normal apoptotic susceptibility of rho(0) cells. We studied the changes of gene expression in SK-Hep1 rho(0) cells. DNA chip analysis showed that MnSOD expression was profoundly increased in rho(0) cells. O-2(radical anion). contents increased during rho(0) cell derivation but became normalized after establishment of rho(0) phenotypes, suggesting that MnSOD induction is an adaptive process to increased O-2(radical anion). rho(0) cells were resistant to menadione, paraquat, or doxorubicin, and O-2(radical anion) contents after treatment with them were lower in rho(0) cells compared with parental cells because of MnSOD overexpression. Expression levels and activity of glutathione peroxidases were also increased in rho(0) cells, rendering them resistant to exogenous H2O2. rho(0) cells were resistant to p53, and intracellular ROS contents after p53 expression were lower compared with parental cells. Other types of rho(0) cells also showed increased MnSOD expression and resistance against ROS. Heme oxygenase-1 expression was increased in rho(0) cells, and a heme oxygenase-1 inhibitor decreased the induction of MnSOD in rho(0) cells and their resistance against ROS donors. These results indicate that rho(0) cells are resistant to cell death contrary to previous reports and suggest that an adaptive increase in the expression of antioxidant enzymes renders cancer cells or aged cells with frequent mitochondrial DNA mutations to resist against oxidative stress, host anti-cancer surveillance, or chemotherapeutic agents, conferring survival advantage on them.	Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea; Korea Univ, Grad Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Sungkyunkwan University (SKKU); Samsung Medical Center; Korea University; Ewha Womans University; Ewha Womans University; Roswell Park Cancer Institute	Lee, MS (corresponding author), Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Dept Med, 50 Irwon Dong Kangnam Ku, Seoul 135710, South Korea.	mslee@smc.samsung.co.kr	Lee, Myung Shik/C-9606-2011	Lee, Myung-Shik/0000-0003-3292-1720	PHS HHS [R01-097714] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APPLEGATE LA, 1991, CANCER RES, V51, P974; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Delsite R, 2002, MOL CANCER, V1, P1; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Frankel D, 2000, J CELL PHYSIOL, V185, P80, DOI 10.1002/1097-4652(200010)185:1<80::AID-JCP7>3.0.CO;2-W; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Higuchi M, 1998, ONCOGENE, V17, P2753, DOI 10.1038/sj.onc.1202211; Hollensworth SB, 2000, FREE RADICAL BIO MED, V28, P1161, DOI 10.1016/S0891-5849(00)00214-8; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; Hwang ES, 1998, INT J GYNECOL CANCER, V8, P27; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; Izutani R, 1998, J GASTROENTEROL, V33, P816, DOI 10.1007/s005350050181; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Janssen AML, 1998, BRIT J CANCER, V78, P1051, DOI 10.1038/bjc.1998.626; JI LL, 1990, AM J PHYSIOL, V258, P918; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KADIISKA MB, 1993, TOXICOL APPL PHARM, V123, P187, DOI 10.1006/taap.1993.1236; Kim JY, 2002, ONCOGENE, V21, P3139, DOI 10.1038/sj.onc.1205406; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Li SJ, 2000, CANCER RES, V60, P3927; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo XP, 1997, J CLIN INVEST, V99, P2877, DOI 10.1172/JCI119481; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; MANGANARO F, 1995, FREE RADICAL BIO MED, V19, P823, DOI 10.1016/0891-5849(95)02008-X; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marchetti P, 1996, CANCER RES, V56, P2033; MATHAI JC, 1994, J BIOL CHEM, V269, P17784; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; MIMNAUGH EG, 1981, BIOCHEM PHARMACOL, V30, P2797, DOI 10.1016/0006-2952(81)90417-2; Morgan WA, 1998, TOXICOL LETT, V94, P209, DOI 10.1016/S0378-4274(98)00024-1; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBERLEY LW, 1979, CANCER RES, V39, P1141; Pansarasa O, 1999, FREE RADICAL BIO MED, V27, P617, DOI 10.1016/S0891-5849(99)00108-2; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Suh Y, 2002, NAT MED, V8, P3, DOI 10.1038/nm0102-3; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; THOR H, 1982, J BIOL CHEM, V257, P2419; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wei YH, 2001, ANN NY ACAD SCI, V928, P97; Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x; YAGI N, 1995, DIABETES, V44, P744, DOI 10.2337/diabetes.44.7.744	58	155	161	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7512	7520		10.1074/jbc.M307677200	http://dx.doi.org/10.1074/jbc.M307677200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660625	hybrid			2022-12-27	WOS:000189103300019
J	Rousseau, F; Schymkowitz, JWH; Wilkinson, HR; Itzhaki, LS				Rousseau, F; Schymkowitz, JWH; Wilkinson, HR; Itzhaki, LS			Intermediates control domain swapping during folding of p13(suc1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-REGULATORY PROTEIN; CRYSTAL-STRUCTURE; TRANSITION-STATE; CONTACT ORDER; P13SUC1; STABILITY; MECHANISM; PATHWAY; RATES	The 13-kDa protein p13(suc1) has two folded states, a monomer and a structurally similar domain-swapped dimer formed by exchange of a beta-strand. The refolding reaction of p13(suc1) is multiphasic, and in this paper we analyze the kinetics as a function of denaturant and protein concentration and compare the behavior of wild type and a set of mutants previously designed with dimerization propensities that span 9 orders of magnitude. We show that the folding reactions of wild type and all mutants produce the monomer predominantly despite their very different equilibrium behavior. However, the addition of low concentrations of denaturant in the refolding buffer leads to thermodynamic control of the folding reaction with products that correspond to the wild type and mutant equilibrium dimerization propensities. We present evidence that the kinetic control in the absence of urea arises because of the population of the folding intermediates. Intermediates are usually considered to be detrimental to folding because they slow down the reaction; however, our work shows that intermediates buffer the monomeric folding pathway against the effect of mutations that favor the nonfunctional, dimeric state at equilibrium.	Univ Cambridge, Chem Lab, MRC, Ctr Prot Engn, Cambridge CB2 1EW, England; Free Univ Brussels VIB, SWITCH Lab, B-1050 Brussels, Belgium	University of Cambridge; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Itzhaki, LS (corresponding author), Univ Cambridge, Chem Lab, MRC, Ctr Prot Engn, Lensfield Rd, Cambridge CB2 1EW, England.	isi10@cam.ac.uk	Rousseau, Frederic/J-9044-2016; Schymkowitz, Joost/AAV-3680-2021; Schymkowitz, Joost/K-7764-2016	Rousseau, Frederic/0000-0002-9189-7399; Schymkowitz, Joost/0000-0003-2020-0168				Alonso DOV, 2000, STRUCTURE, V8, P101, DOI 10.1016/S0969-2126(00)00083-6; Baker D, 2000, NATURE, V405, P39, DOI 10.1038/35011000; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BOURNE Y, 1995, P NATL ACAD SCI USA, V92, P10232, DOI 10.1073/pnas.92.22.10232; Ellis RJ, 2001, CURR OPIN STRUC BIOL, V11, P114, DOI 10.1016/S0959-440X(00)00172-X; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; Fersht AR, 2000, P NATL ACAD SCI USA, V97, P1525, DOI 10.1073/pnas.97.4.1525; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; GRAY TE, 1993, EMBO J, V12, P4145, DOI 10.1002/j.1460-2075.1993.tb06098.x; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; Khazanovich N, 1996, STRUCTURE, V4, P299, DOI 10.1016/S0969-2126(96)00034-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Newcomer ME, 2002, CURR OPIN STRUC BIOL, V12, P48, DOI 10.1016/S0959-440X(02)00288-9; O'Neill JW, 2001, STRUCTURE, V9, P1017, DOI 10.1016/S0969-2126(01)00667-0; Oliveberg M, 2001, CURR OPIN STRUC BIOL, V11, P94, DOI 10.1016/S0959-440X(00)00171-8; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Rousseau F, 2002, STRUCTURE, V10, P649, DOI 10.1016/S0969-2126(02)00762-1; Rousseau F, 1998, J MOL BIOL, V284, P503, DOI 10.1006/jmbi.1998.2173; Rousseau F, 2001, P NATL ACAD SCI USA, V98, P5596, DOI 10.1073/pnas.101542098; Schymkowitz JWH, 2001, NAT STRUCT BIOL, V8, P888, DOI 10.1038/nsb1001-888; Schymkowitz JWH, 2000, J MOL BIOL, V301, P199, DOI 10.1006/jmbi.2000.3958; Schymkowitz JWH, 2000, STRUCTURE, V8, P89, DOI 10.1016/S0969-2126(00)00084-8; Silow M, 1999, BIOCHEMISTRY-US, V38, P13006, DOI 10.1021/bi9909997; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p	28	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8368	8377		10.1074/jbc.M310640200	http://dx.doi.org/10.1074/jbc.M310640200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662764	hybrid			2022-12-27	WOS:000189103300119
J	Samanta, AK; Huang, HJ; Bast, RC; Liao, WSL				Samanta, AK; Huang, HJ; Bast, RC; Liao, WSL			Overexpression of MEKK3 confers resistance to apoptosis through activation of NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; MAP KINASE; PROSTATE-CANCER; UP-REGULATION; PROTEIN; CELLS; TARGET; ERK; EXPRESSION; RECEPTOR	Many cancers have constitutively activated NFkappaB, the elevation of which contributes to cancer cell resistance to chemotherapeutic agent-induced apoptosis. Although mitogen-activated protein kinase/extracellular-regulated kinase kinase kinase-3 (MEKK3) has been shown to participate in the activation of NFkappaB, its relations to apoptosis and cancer are unclear. In this study, we established cell model systems to examine whether stable expression of MEKK3 could lead to increased NFkappaB activity and confer resistance to apoptosis. In addition, we investigated in breast and ovarian cancers whether MEKK3 expression may be altered and correlated with aberrant NFkappaB activity. We show that stable cell lines overexpressing MEKK3 not only had elevated levels of NFkappaB binding activity but also were more responsive to cytokine stimulation. These stable cells showed 2-4-fold higher basal expression of Bcl-2 and xIAP than the parental cells. Consistent with this increased expression of cell survival genes, MEKK3 stable cells showed reduced activation of caspases 3 and 8 and poly(ADPribose) polymerase cleavage and dramatically increased resistance to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand, doxorubicin, daunorubicin, camptothecin, and paclitaxel. Intriguingly, analysis of human breast and ovarian cancers showed that a significant fraction of these samples have elevated MEKK3 protein levels with corresponding increases in NFkappaB binding activities. Thus, our results established that elevated expression of MEKK3 appears to be a frequent occurrence in breast and ovarian cancers and that overexpression of MEKK3 in cells leads to increased NFkappaB activity and increased expression of cell survival factors and ultimately contributes to their resistance to apoptosis. As such, MEKK3 may serve as a therapeutic target to control cancer cell resistance to cytokine- or drug-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev,Unit 117, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liao, WSL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Program Genes & Dev,Unit 117, 1515 Holcombe Blvd, Houston, TX 77030 USA.	wsliao@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462				Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Boone DL, 2002, INFLAMM BOWEL DIS, V8, P201, DOI 10.1097/00054725-200205000-00008; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dugourd C, 2003, HYPERTENSION, V41, P882, DOI 10.1161/01.HYP.0000060821.62417.35; Engedal N, 2003, J BIOL CHEM, V278, P10934, DOI 10.1074/jbc.M211556200; Fidler IJ, 2000, NAT MED, V6, P500, DOI 10.1038/74969; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Huang S, 2000, CANCER RES, V60, P5334; Huang S, 2000, CLIN CANCER RES, V6, P2573; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Li XH, 2000, AIDS RES HUM RETROV, V16, P1583, DOI 10.1089/08892220050192994; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Manna SK, 1998, J IMMUNOL, V161, P2863; Manna SK, 1998, J BIOL CHEM, V273, P33333, DOI 10.1074/jbc.273.50.33333; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mukhopadhyay A, 2002, J BIOL CHEM, V277, P30622, DOI 10.1074/jbc.M204748200; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Rabbani SA, 2000, INT J CANCER, V87, P276, DOI 10.1002/1097-0215(20000715)87:2<276::AID-IJC20>3.0.CO;2-L; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Reed RC, 2003, J BIOL CHEM, V278, P31853, DOI 10.1074/jbc.M305480200; Schlegel J, 2002, ANTICANCER RES, V22, P2837; Scovassi AI, 1998, EUR J HISTOCHEM, V42, P251; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Shibata A, 2002, BREAST CANCER RES TR, V73, P237, DOI 10.1023/A:1015872531675; Sun ZW, 2002, SHOCK, V18, P99, DOI 10.1097/00024382-200208000-00001; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Tsai PW, 2003, J BIOL CHEM, V278, P5750, DOI 10.1074/jbc.M204863200; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	48	70	77	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7576	7583		10.1074/jbc.M311659200	http://dx.doi.org/10.1074/jbc.M311659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662759				2022-12-27	WOS:000189103300026
J	Bertelsen, LS; Barrett, KE; Keely, SJ				Bertelsen, LS; Barrett, KE; Keely, SJ			G(s) protein-coupled receptor agonists induce transactivation of the epidermal growth factor receptor in T-84 cells - Implications for epithelial secretory responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; DEPENDENT CHLORIDE SECRETION; SIGNAL-REGULATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ARACHIDONIC-ACID; EGF-RECEPTOR; MAP KINASE; CFTR TRAFFICKING; K+ CHANNELS; T84 CELLS	We have previously shown that G(q) protein-coupled receptor (G(q)PCR) agonists stimulate epidermal growth factor receptor (EGFr) transactivation and activation of mitogen-activated protein kinases (MAPK) in colonic epithelial cells. This constitutes a mechanism by which Cl- secretory responses to G(q)PCR agonists are limited. In the present study we examined a possible role for the EGFr in regulating Cl- secretion stimulated by agonists that act through G(s)PCRs. All experiments were performed using monolayers of T-84 colonic epithelial cells grown on permeable supports. Protein phosphorylation and protein-protein interactions were analyzed by immunoprecipitation and Western blotting. Cl- secretion was measured as changes in short-circuit current (DeltaI(sc)) across voltage-clamped T-84 cells. The G(s)PCR agonist, vasoactive intestinal polypeptide (VIP; 100 nm), rapidly stimulated EGFr phosphorylation in T-84 cells. This effect was mimicked by a cell-permeant analog of cAMP, Bt(2)cAMP/AM (3 muM), and was attenuated by the protein kinase A (PKA) inhibitor, H-89 (20 muM). The EGFr inhibitor, tyrphostin AG1478 (1 muM), inhibited both Bt(2)cAMP/ AM-stimulated EGFr phosphorylation and I., responses. VIP and Bt(2)cAMP/AM both stimulated ERK MAPK phosphorylation and recruitment of the p85 subunit of phosphatidylinositol 3-kinase (PI3K) to the EGFr in a tyrphostin AG1478-sensitive manner. The PI3K inhibitor, wortmannin (50 nm), but not the ERK inhibitor, PD 98059 (20 muM), attenuated Bt(2)cAMP/AM-stimulated secretory responses. We conclude that G(s)PCR agonists rapidly transactivate the EGFr in T-84 cells by a signaling pathway involving cAMP and PKA. Through a mechanism that likely involves PI3K, transactivation of the EGFr is required for the full expression of cAMP-dependent Cl- secretory responses.	Univ Calif San Diego, Med Ctr, Div Gastroenterol, Dept Med, San Diego, CA 92103 USA	University of California System; University of California San Diego	Keely, SJ (corresponding author), Univ Calif San Diego, Med Ctr, Div Gastroenterol, Dept Med, 200 W Arbor Dr, San Diego, CA 92103 USA.	skeely@ucsd.edu		Keely, Stephen/0000-0002-6315-3587	NIDDK NIH HHS [DK28305] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028305] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alleaume C, 2003, NEUROPEPTIDES, V37, P98, DOI 10.1016/S0143-4179(03)00020-9; Ameen NA, 2000, HISTOCHEM CELL BIOL, V114, P219; Ameen NA, 2003, AM J PHYSIOL-CELL PH, V284, pC429, DOI 10.1152/ajpcell.00261.2002; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; Bertelsen LS, 2002, GASTROENTEROLOGY, V122, pA88; Bertrand CA, 2003, AM J PHYSIOL-CELL PH, V285, pC1, DOI 10.1152/ajpcell.00554.2002; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Chang N, 2001, AM J PHYSIOL-GASTR L, V281, pG129, DOI 10.1152/ajpgi.2001.281.1.G129; Charney AN, 2002, GASTROENTEROLOGY, V122, P318, DOI 10.1053/gast.2002.31101; Chow JYC, 2000, J BIOL CHEM, V275, P21169, DOI 10.1074/jbc.M002160200; Cussac D, 2002, J BIOL CHEM, V277, P19882, DOI 10.1074/jbc.M110142200; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC149, DOI 10.1152/ajpcell.1998.274.1.C149; Devor DC, 1998, AM J PHYSIOL-CELL PH, V274, pC138, DOI 10.1152/ajpcell.1998.274.1.C138; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; Dickson JL, 2000, AM J PHYSIOL-CELL PH, V278, pC865, DOI 10.1152/ajpcell.2000.278.5.C865; Djordjevic S, 2002, TRENDS BIOCHEM SCI, V27, P426, DOI 10.1016/S0968-0004(02)02136-9; Ecay TW, 2000, BBA-BIOMEMBRANES, V1467, P54, DOI 10.1016/S0005-2736(00)00204-2; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gallet C, 2003, BIOCHEM J, V371, P733, DOI 10.1042/BJ20021030; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; Gekle M, 2002, STEROIDS, V67, P499, DOI 10.1016/S0039-128X(01)00183-0; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; HARVEY J, 2000, J PHYSL, V15, P95; Hayama M, 2002, AM J PHYSIOL-RENAL, V282, pF485, DOI 10.1152/ajprenal.00210.2001; He H, 2001, J BIOL CHEM, V276, P26741, DOI 10.1074/jbc.C100229200; Hsu AL, 2000, J BIOL CHEM, V275, P16242, DOI 10.1074/jbc.M002077200; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2003, AM J PHYSIOL-CELL PH, V284, pC339, DOI 10.1152/ajpcell.00144.2002; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Keely SJ, 1999, J BIOL CHEM, V274, P33449, DOI 10.1074/jbc.274.47.33449; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Kjeken R, 2001, BIOCHEM J, V357, P497, DOI 10.1042/0264-6021:3570497; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; Lee JY, 2001, ARCH PHARM, V334, P357, DOI 10.1002/1521-4184(200112)334:11<357::AID-ARDP357>3.0.CO;2-Q; Lee-Kwon W, 2001, J BIOL CHEM, V276, P31296, DOI 10.1074/jbc.M103900200; Lehrich RW, 1998, J CLIN INVEST, V101, P737, DOI 10.1172/JCI803; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Piiper A, 2003, BIOCHEM BIOPH RES CO, V301, P848, DOI 10.1016/S0006-291X(03)00055-X; Piiper A, 2002, J BIOL CHEM, V277, P43623, DOI 10.1074/jbc.M203926200; POWELL DW, 1999, TXB GASTROENTEROLOGY, P858; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SCHULTZ C, 1994, MOL PHARMACOL, V46, P702; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Shiraha H, 1999, J CELL BIOL, V146, P243; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; Xing MZ, 1997, AM J PHYSIOL-CELL PH, V272, pC1380, DOI 10.1152/ajpcell.1997.272.4.C1380; Xu JF, 2002, J NEUROCHEM, V83, P259, DOI 10.1046/j.1471-4159.2002.01145.x; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yoon JH, 2002, GASTROENTEROLOGY, V122, P985, DOI 10.1053/gast.2002.32410	61	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6271	6279		10.1074/jbc.M311612200	http://dx.doi.org/10.1074/jbc.M311612200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660604	hybrid			2022-12-27	WOS:000188969200011
J	Dvorsky, R; Blumenstein, L; Vetter, IR; Ahmadian, MR				Dvorsky, R; Blumenstein, L; Vetter, IR; Ahmadian, MR			Structural insights into the interaction of ROCKI with the switch regions of RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-BINDING DOMAIN; SMALL G-PROTEIN; NUCLEOTIDE EXCHANGE FACTORS; KINASE ROK-ALPHA; CRYSTAL-STRUCTURE; COILED-COIL; IN-VIVO; ACTIVATION; FAMILY; PHOSPHORYLATION	The Rho-ROCK pathway modulates the phosphorylation level of a variety of important signaling proteins and is thereby involved in miscellaneous cellular processes including cell migration, neurite outgrowth, and smooth muscle contraction. The observation of the involvement of the Rho-ROCK pathway in tumor invasion and in diseases such as hypertension and bronchial asthma makes it an interesting target for drug development. We herein present the crystal structure of the complex between active RhoA and the Rho-binding domain of ROCKI. The Rho-binding domain structure forms a parallel a-helical coiled-coil dimer and, in contrast to the published Rho-protein kinase N structure, binds exclusively to the switch I and II regions of the guanosine 5'-(beta,gamma-imido)triphosphate-bound RhoA. The switch regions of two different RhoA molecules form a predominantly hydrophobic patch, which is complementarily bound by two identical short helices of 13 residues (amino acids 9981010). The identified ROCK-binding site of RhoA strikingly supports the assumption of a common consensus-binding site for effector recognition.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany	Max Planck Society	Ahmadian, MR (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	reza.ahmadian@mpi-dortmund.mpg.de	Dvorsky, Radovan/ABE-3042-2020					Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chen XQ, 2002, J BIOL CHEM, V277, P12680, DOI 10.1074/jbc.M109839200; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Fiegen D, 2002, FEBS LETT, V525, P100, DOI 10.1016/S0014-5793(02)03094-6; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Garavini H, 2002, BIOCHEMISTRY-US, V41, P6303, DOI 10.1021/bi025651h; Gruber M, 2003, TRENDS BIOCHEM SCI, V28, P679, DOI 10.1016/j.tibs.2003.10.008; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leung T, 1996, MOL CELL BIOL, V16, P5313; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Nakajima M, 2003, EUR J PHARMACOL, V459, P113, DOI 10.1016/S0014-2999(02)02869-8; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Naud N, 2003, BIOCHEM J, V372, P105, DOI 10.1042/BJ20021652; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owen D, 2003, J BIOL CHEM, V278, P50578, DOI 10.1074/jbc.M304313200; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Ridley AJ, 1997, INT J BIOCHEM CELL B, V29, P1225, DOI 10.1016/S1357-2725(97)00052-6; Riento K, 2003, MOL CELL BIOL, V23, P4219, DOI 10.1128/MCB.23.12.4219-4229.2003; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Shimizu T, 2003, J BIOL CHEM, V278, P46046, DOI 10.1074/jbc.M306458200; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	63	103	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7098	7104		10.1074/jbc.M311911200	http://dx.doi.org/10.1074/jbc.M311911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660612	Green Published, hybrid			2022-12-27	WOS:000188969200108
J	Fu, XY; Kao, JLF; Bergt, C; Kassim, SY; Huq, NP; d'Avignon, A; Parks, WC; Mecham, RP; Heinecke, JW				Fu, XY; Kao, JLF; Bergt, C; Kassim, SY; Huq, NP; d'Avignon, A; Parks, WC; Mecham, RP; Heinecke, JW			Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity - Specific structural motifs control protein oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HYPOCHLOROUS ACID; MYELOPEROXIDASE; ACTIVATION; COLLAGENASE; MECHANISM; CYSTEINE; PATHWAY	Matrix metalloproteinases (MMPs) function in homeostatic and repair processes, but unregulated catalysis by these extracellular proteinases leads to the pathological destruction of tissue proteins. An important mechanism for controlling enzyme activity might involve hypochlorous acid (HOCl), a potent oxidant produced by the myeloperoxidase system of phagocytes. We have shown that inactivation of MMP-7 (matrilysin) by HOCl coincides with the formation of a novel oxidation product, WG-4, through modification of adjacent tryptophan and glycine residues and loss of 4 atomic mass units. Here, we use mass spectrometry, UV/visible spectroscopy, hydrogen-deuterium exchange, and NMR spectroscopy to investigate the formation and structure of WG-4. For the initial step, HOCl chlorinates the indole ring of tryptophan. The resulting 3-chloroindolenine generates a previously unknown cyclic indole-amide species, in which tryptophan cross-links to the main chain nitrogen of the adjacent glycine residue to form an aromatic six-membered ring. WG-4 kinks and stiffens the peptide backbone, which may hinder the interaction of substrate with the catalytic pocket of MMP-7. Our observations indicate that specific structural motifs are important for controlling protein modification by oxidants and suggest that pericellular oxidant production by phagocytes might limit MMP activity during inflammation.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Washington Univ, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Heinecke, JW (corresponding author), Univ Washington, Dept Med, Box 356426, Seattle, WA 98195 USA.	heineeke@u.washington.edu	Parks, William C./AAH-6786-2021	Huq Saifee, Nabiha/0000-0003-1646-9201	NHLBI NIH HHS [HL64344] Funding Source: Medline; NIA NIH HHS [AG021191] Funding Source: Medline; NIDDK NIH HHS [P30 DK35816] Funding Source: Medline; NIEHS NIH HHS [P30 ES07033] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Carr AC, 2000, BIOCHEM J, V346, P491, DOI 10.1042/0264-6021:3460491; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; DEROSA M, 1978, J ORG CHEM, V43, P2639, DOI 10.1021/jo00407a017; Fu XY, 2003, J BIOL CHEM, V278, P28403, DOI 10.1074/jbc.M304739200; Fu XY, 2002, BIOCHEMISTRY-US, V41, P1293, DOI 10.1021/bi015777z; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Kang DK, 2003, J BIOL CHEM, V278, P14857, DOI 10.1074/jbc.M300616200; KATRITZKY AR, 1984, COMPREHENSIVE HETERO, V4, P214; Kettle AJ, 2000, REDOX REP, V5, P179, DOI 10.1179/135100000101535726; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTIONA; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; MICHAELIS J, 1992, ARCH BIOCHEM BIOPHYS, V292, P555, DOI 10.1016/0003-9861(92)90030-Z; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Razmiafshari M, 2001, TOXICOL APPL PHARM, V172, P1, DOI 10.1006/taap.2001.9132; Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680; SANDERS JKM, 1993, MODERN NMR SPECTROSC; Shapiro SD, 2002, BIOCHEM SOC T, V30, P98, DOI 10.1042/BST0300098; van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; Winterbourn CC, 2000, CURR OPIN HEMATOL, V7, P53, DOI 10.1097/00062752-200001000-00010; Woessner J.F., 2000, PROTEIN PROFILE SER; Zhang H, 2003, J BIOL CHEM, V278, P24078, DOI 10.1074/jbc.M302051200	29	80	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6209	6212		10.1074/jbc.C300506200	http://dx.doi.org/10.1074/jbc.C300506200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14670964	hybrid			2022-12-27	WOS:000188969200002
J	Kim, SM; Kwon, MS; Park, CS; Choi, KR; Chun, JS; Ahn, J; Song, WK				Kim, SM; Kwon, MS; Park, CS; Choi, KR; Chun, JS; Ahn, J; Song, WK			Modulation of Thr phosphorylation of integrin beta(1) during muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; BETA-1-INTEGRIN CYTOPLASMIC DOMAIN; FOCAL ADHESION KINASE; CELL-ADHESION; SIGNAL-TRANSDUCTION; BETA-SUBUNIT; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; EXTRACELLULAR-MATRIX; MUTATIONAL ANALYSIS	By using transient elevations of cytosolic free calcium levels triggered by integrin antibody or laminin (Kwon, M. S., Park, C. S., Choi, K., Park, C.-S., Ahnn, J., Kim, J. I., Eom, S. H., Kaufman, S. J., and Song, W. K. (2000) Mol. Biol. Cell 11, 1433-1443), we have demonstrated that protein phosphatase 2A (PP2A) is implicated in the regulation of reversible phosphorylation of integrin. In E63 skeletal myoblasts, the treatment of PP2A inhibitors such as okadaic acid and endothall induces an increase of phosphorylation of integrin beta(1A) and thereby inhibits integrin-induced elevation of cytosolic calcium level and formation of focal adhesions. None of these effects were in differentiated myotubes expressing the alternate beta(1D) isoform. In the presence of okadaic acid, PP2A in association with integrin beta(1A) was reduced on myoblasts, whereas beta(1D) on myotubes remained bound with PP2A. Both coimmunoprecipitation and in vitro phosphatase assays revealed that dephosphorylation of residues Thr(788)-Thr(789) in the integrin beta(1A) cytoplasmic domain is dependent upon PP2A activity. Mutational analysis of the cytoplasmic domain and confocal microscopy experiments indicated that substitution of Thr(788)- Thr(789) with Asn(788)-Asn(789) is of critical importance for regulating the function of integrin beta(1),. These results suggest that PP2A may be a primary regulator of threonine phosphorylation of integrin beta(1A) and subsequent activation of downstream signaling molecules. Taken together, we propose that dephosphorylation of residues Thr(788)-Thr(789) in the cytoplasmic domain of integrin beta(1A) may contribute to the linkage of integrins to focal adhesion sites and induce the association with cytoskeleton proteins. The switch of integrin beta(1A) to beta(1D) isoform in myotubes therefore may be a mechanism to escape from phospho-regulation by PP2A and promotes a more stable association of the cytoskeleton with the extracellular matrix.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST)	Song, WK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	wksong@kjist.ac.kr		Park, Chun Shik/0000-0002-4329-3953				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Barreuther MF, 1996, EXP CELL RES, V222, P10, DOI 10.1006/excr.1996.0002; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Baudoin C, 1998, GENE DEV, V12, P1202, DOI 10.1101/gad.12.8.1202; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bouvard D, 1998, J CELL SCI, V111, P657; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Green LJ, 1998, INT J BIOCHEM CELL B, V30, P179, DOI 10.1016/S1357-2725(97)00107-6; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HELMER ME, 1990, ANNU REV IMMUNOL, V8, P365; Hendey B, 1996, BLOOD, V87, P2038; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; Hiraga A, 2000, BIOCHEM J, V346, P433, DOI 10.1042/0264-6021:3460433; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KAUFMAN SJ, 1977, P NATL ACAD SCI USA, V74, P3888, DOI 10.1073/pnas.74.9.3888; Kim YY, 1999, CELL ADHES COMMUN, V7, P85, DOI 10.3109/15419069909034393; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Lerea KM, 1999, J BIOL CHEM, V274, P1914, DOI 10.1074/jbc.274.4.1914; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Liu SC, 2000, J CELL SCI, V113, P3563; Meredith JE, 1999, J BIOL CHEM, V274, P8111, DOI 10.1074/jbc.274.12.8111; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; POMIES P, 1995, BIOCHEMISTRY-US, V34, P5104, DOI 10.1021/bi00015a022; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Retta SF, 1998, MOL BIOL CELL, V9, P715, DOI 10.1091/mbc.9.4.715; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sakai T, 2001, P NATL ACAD SCI USA, V98, P3808, DOI 10.1073/pnas.240456398; SONG WK, 1993, J CELL SCI, V106, P1139; Wennerberg K, 1998, J CELL SCI, V111, P1117; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; Wrenn RW, 1996, BIOCHEM BIOPH RES CO, V226, P876, DOI 10.1006/bbrc.1996.1443; Wu CY, 1999, J CELL SCI, V112, P4485	60	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7082	7090		10.1074/jbc.M311581200	http://dx.doi.org/10.1074/jbc.M311581200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660602	hybrid			2022-12-27	WOS:000188969200106
J	Pellegrino, M; Furmaniak-Kazmierczak, E; LeBlanc, JC; Cho, TW; Cao, K; Marcovina, SM; Boffa, MB; Cote, GP; Koschinsky, ML				Pellegrino, M; Furmaniak-Kazmierczak, E; LeBlanc, JC; Cho, TW; Cao, K; Marcovina, SM; Boffa, MB; Cote, GP; Koschinsky, ML			The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; KINASE RHO-KINASE; MYOSIN PHOSPHATASE; FOCAL ADHESIONS; SMOOTH-MUSCLE; GAP FORMATION; PHOSPHORYLATION; PERMEABILITY; PLASMINOGEN; EXPRESSION	Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a risk factor for a variety of atherosclerotic disorders including coronary heart disease. In the current study, we report that incubation of cultured human umbilical vein or coronary artery endothelial cells with Lp(a) elicits a dramatic rearrangement of the actin cytoskeleton characterized by increased central stress fiber formation and redistribution of focal adhesions. These effects are mediated by the apolipoprotein(a) (apo(a)) component of Lp(a) since incubation of apo(a) with the cells evoked similar cytoskeletal rearrangements, while incubation with low density lipoprotein had no effect. Apo(a) also produced a time-dependent increase in transendothelial permeability. The cytoskeletal rearrangements evoked by apo(a) were abolished by C3 transferase, which inhibits Rho, and by Y-27632, an inhibitor of Rho kinase. In addition to actin cytoskeleton remodeling, apo(a) was found to cause VE-cadherin disruption and focal adhesion molecule reorganization in a Rho- and Rho kinase-dependent manner. Cell-cell contacts were found to be regulated by Rho and Rae but not Cdc42. Apo(a) caused a transient increase in the extent of myosin light chain phosphorylation. Finally apo(a) did not evoke increases in intracellular calcium levels, although the effects of apo(a) on the cytoskeleton were found to be calcium-dependent. We conclude that the apo(a) component of Lp(a) activates aRho/Rho kinase-dependent intracellular signaling cascade that results in increased myosin light chain phosphorylation with attendant rearrangements of the actin cytoskeleton. We propose that the resultant increase in endothelial permeability caused by Lp(a) may help explain the atherosclerotic risk posed by elevated concentrations of this lipoprotein.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Univ Washington, NW Lipid Res Labs, Seattle, WA 98103 USA	Queens University - Canada; University of Washington; University of Washington Seattle	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Rm A208 Botterell Hall, Kingston, ON K7L 3N6, Canada.	mk11@post.queensu.ca	Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288				Allen S, 1998, FASEB J, V12, P1765, DOI 10.1096/fasebj.12.15.1765; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Edelstein C, 2001, ANAL BIOCHEM, V288, P201, DOI 10.1006/abio.2000.4904; Essler M, 1999, J BIOL CHEM, V274, P30361, DOI 10.1074/jbc.274.43.30361; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Gabel BR, 1998, ARTERIOSCL THROM VAS, V18, P1738, DOI 10.1161/01.ATV.18.11.1738; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; GOTLIEB AI, 1991, LAB INVEST, V65, P123; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; Hajjar KA, 1999, TRENDS CARDIOVAS MED, V9, P128, DOI 10.1016/S1050-1738(99)00020-1; Haque NS, 2000, CIRCULATION, V102, P786, DOI 10.1161/01.CIR.102.7.786; Hippenstiel S, 2002, AM J PHYSIOL-LUNG C, V283, pL830, DOI 10.1152/ajplung.00467.2001; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LUM H, 1992, AM J PHYSIOL, V263, pL219, DOI 10.1152/ajplung.1992.263.2.L219; LUM H, 1994, AM J PHYSIOL, V267, P223; Marcovina S M, 1999, Curr Cardiol Rep, V1, P105, DOI 10.1007/s11886-999-0067-z; Marcovina Santica M, 2002, Semin Vasc Med, V2, P335, DOI 10.1055/s-2002-35404; Marcovina SM, 1996, J LIPID RES, V37, P2569; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1995, THROMB HAEMOSTASIS, V73, P458; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Norwood N, 2000, AM J PHYSIOL-LUNG C, V279, pL815, DOI 10.1152/ajplung.2000.279.5.L815; Poredos P, 2001, CLIN APPL THROMB-HEM, V7, P276, DOI 10.1177/107602960100700404; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sangrar W, 1997, BIOCHEMISTRY-US, V36, P10353, DOI 10.1021/bi962433d; Scanu Angelo M, 2003, Curr Atheroscler Rep, V5, P106, DOI 10.1007/s11883-003-0081-3; Schachinger V, 1997, J AM COLL CARDIOL, V30, P927, DOI 10.1016/S0735-1097(97)00237-4; SHASBY DM, 1982, CIRC RES, V51, P657, DOI 10.1161/01.RES.51.5.657; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; Takami S, 1998, CIRCULATION, V97, P721, DOI 10.1161/01.CIR.97.8.721; TSURUMI Y, 1995, J AM COLL CARDIOL, V26, P1242, DOI 10.1016/0735-1097(95)00321-5; Verin AD, 1998, AM J RESP CELL MOL, V19, P758, DOI 10.1165/ajrcmb.19.5.3125; VERIN AD, 1995, AM J PHYSIOL-LUNG C, V269, pL99, DOI 10.1152/ajplung.1995.269.1.L99; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B	48	37	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6526	6533		10.1074/jbc.M309705200	http://dx.doi.org/10.1074/jbc.M309705200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660654	hybrid			2022-12-27	WOS:000188969200039
J	Shiba, Y; Katoh, Y; Shiba, T; Yoshino, K; Takatsu, H; Kobayashi, H; Shin, HW; Wakatsuki, S; Nakayama, K				Shiba, Y; Katoh, Y; Shiba, T; Yoshino, K; Takatsu, H; Kobayashi, H; Shin, HW; Wakatsuki, S; Nakayama, K			GAT (GGA and Tom1) domain responsible for ubiquitin binding and ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUE DOMAIN; PROTEINS; GOLGI; COMPLEX; MOTIF; RECRUITMENT; RECEPTORS; TRANSPORT; ARF; TRAFFICKING	GGAs (Golgi-localizing, gamma-adaptin ear domain homology, ADP-ribosylation factor (ARF)-binding proteins) are a family of monomeric adaptor proteins involved in membrane trafficking from the trans-Golgi network to endosomes. The GAT (GGA and Tom1) domains of GGAs have previously been shown to interact with GTP-bound ARF and to be crucial for membrane recruitment of GGAs. Here we show that the C-terminal subdomain of the GAT domain, which is distinct from the N-terminal GAT subdomain responsible for ARF binding, can bind ubiquitin. The binding is mediated by interactions between residues on one side of the alpha3 helix of the GAT domain and those on the so-called Ile-44 surface patch of ubiquitin. The binding of the GAT domain to ubiquitin can be enhanced by the presence of a GTP-bound form of ARF. Furthermore, GGA itself is ubiquitinated in a manner dependent on the GAT-ubiquitin interaction. These results delineate the molecular basis for the interaction between ubiquitin and GAT and suggest that GGA-mediated trafficking is regulated by the ubiquitin system as endosomal trafficking mediated by other ubiquitin-binding proteins.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Kanazawa, Ishikawa 9200934, Japan; KEK, High Energy Accelerator Res Org, Inst Mat Struct Sci, Tsukuba, Ibaraki 3050801, Japan; RIKEN, Res Ctr Allergy & Immunol, Kanagawa 2300045, Japan	University of Tsukuba; Kanazawa University; Kanazawa University; High Energy Accelerator Research Organization (KEK); RIKEN	Nakayama, K (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.	kazunaka@pharm.kyoto-u.ac.jp	Nakayama, Kazuhisa/ABF-2924-2020; Shin, Hye-Won/P-5398-2018; Katoh, Yohei/AAA-3378-2020; Shiba, Yoko/AAX-3885-2020	Shin, Hye-Won/0000-0002-9138-9554; Shiba, Yoko/0000-0001-8229-541X; Nakayama, Kazuhisa/0000-0001-7701-7183; Wakatsuki, Soichi/0000-0001-5896-7968; Katoh, Yohei/0000-0003-1649-4917				Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Boman AL, 2001, J CELL SCI, V114, P3413; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Collins BM, 2003, DEV CELL, V4, P321, DOI 10.1016/S1534-5807(03)00037-6; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hinners I, 2003, J CELL SCI, V116, P763, DOI 10.1242/jcs.00270; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Nogi T, 2002, NAT STRUCT BIOL, V9, P527, DOI 10.1038/nsb808; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Shiba T, 2003, NAT STRUCT BIOL, V10, P386, DOI 10.1038/nsb920; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Shin HW, 1997, J BIOCHEM-TOKYO, V122, P525; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Suer S, 2003, P NATL ACAD SCI USA, V100, P4451, DOI 10.1073/pnas.0831133100; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; TAKADA K, 1995, EUR J BIOCHEM, V233, P42, DOI 10.1111/j.1432-1033.1995.042_1.x; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; TAKATSU H, 2000, BIOCHEM BIOPH RES CO, V271, P917; TRELER M, 1994, CELL, V78, P787; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Zhu GY, 2003, BIOCHEMISTRY-US, V42, P6392, DOI 10.1021/bi034334n; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	44	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7105	7111		10.1074/jbc.M311702200	http://dx.doi.org/10.1074/jbc.M311702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660606	hybrid			2022-12-27	WOS:000188969200109
J	Grimsley, CM; Kinchen, JM; Tosello-Trampont, AC; Brugnera, E; Haney, LB; Lu, MJ; Chen, Q; Klingele, D; Hengartner, MO; Ravichandran, KS				Grimsley, CM; Kinchen, JM; Tosello-Trampont, AC; Brugnera, E; Haney, LB; Lu, MJ; Chen, Q; Klingele, D; Hengartner, MO; Ravichandran, KS			Dock180 and ELMO1 proteins cooperate to promote evolutionarily conserved Rac-dependent cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO FAMILY GTPASES; C-ELEGANS; CAENORHABDITIS-ELEGANS; MYOBLAST CITY; CRKII/DOCK180/RAC PATHWAY; SIGNALING PATHWAY; MOLECULAR SWITCH; BINDING PROTEIN; APOPTOTIC CELLS; LIVING CELLS	Cell migration is essential throughout embryonic and adult life. In numerous cell systems, the small GTPase Rac is required for lamellipodia formation at the leading edge and movement ability. However, the molecular mechanisms leading to Rac activation during migration are still unclear. Recently, a mammalian superfamily of proteins related to the prototype member Dock180 has been identified with homologues in Drosophila and Caenorhabditis elegans. Here, we addressed the role of Dock180 and ELMO1 proteins, which function as a complex to mediate Rac activation, in mammalian cell migration. Using mutants of Dock180 and ELMO1 in a Transwell assay as well as transgenic rescue of a C. elegans mutant lacking CED-5 (Dock180 homologue), we identified specific regions of Dock180 and ELMO1 required for migration in vitro and in a whole animal model. In both systems, the Dock180.ELMO1 complex formation and the ability to activate Rac were required. We also found that ELMO1 regulated multiple Dock180 superfamily members to promote migration. Interestingly, deletion mutants of ELMO1 missing their first 531 or first 330 amino acids that can still bind and cooperate with Dock180 in Rac activation failed to promote migration, which correlated with the inability to localize to lamellipodia. This finding suggests that Rac activation by the ELMO.Dock180 complex at discrete intracellular locations mediated by the N-terminal 330 amino acids of ELMO1 rather than generalized Rac activation plays a role in cell migration.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11743 USA; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Salk Inst Biol Studies, Cellular Neurobiol Lab, La Jolla, CA 92037 USA	University of Virginia; University of Virginia; University of Virginia; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Zurich; Salk Institute	Ravichandran, KS (corresponding author), Univ Virginia, Beirne Carter Ctr Immunol Res, MR4,Rm 4072D,Box 801386,Lane Rd, Charlottesville, VA 22908 USA.	Ravi@virginia.edu	Hengartner, Michael O/E-6235-2011; Kinchen, Jason/ABC-5663-2021; Lu, Mingjian/AAO-6179-2021; Hengartner, Michael O/A-7058-2008; Lu, Mingjian/AGK-0751-2022	Lu, Mingjian/0000-0001-9328-4935; Kinchen, Jason/0000-0001-8430-2265; Hengartner, Michael/0000-0002-7584-596X				Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; BRENNER S, 1974, GENETICS, V77, P71; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Chen Q, 2002, J CELL BIOL, V158, P79, DOI 10.1083/jcb.200110151; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Hubbard EJA, 2000, DEV DYNAM, V218, P2, DOI 10.1002/(SICI)1097-0177(200005)218:1<2::AID-DVDY2>3.0.CO;2-W; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Lundquist EA, 2001, DEVELOPMENT, V128, P4475; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nishihara H, 1999, BBA-MOL CELL RES, V1452, P179, DOI 10.1016/S0167-4889(99)00133-0; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Reif K, 2002, TRENDS CELL BIOL, V12, P368, DOI 10.1016/S0962-8924(02)02330-9; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, J CELL SCI, V114, P2713; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wittmann T, 2001, J CELL SCI, V114, P3795; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wu YC, 2001, DEV CELL, V1, P491, DOI 10.1016/S1534-5807(01)00056-9; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	53	172	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					6087	6097		10.1074/jbc.M307087200	http://dx.doi.org/10.1074/jbc.M307087200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638695	Green Accepted, hybrid			2022-12-27	WOS:000188776500124
J	Ryan, C; Stokes, DL; Chen, MG; Zhang, ZM; Hardwicke, PMD				Ryan, C; Stokes, DL; Chen, MG; Zhang, ZM; Hardwicke, PMD			Effect of orthophosphate, nucleotide analogues, ADP, and phosphorylation on the cytoplasmic domains of Ca2+-ATPase from scallop sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-FREE CA-ATPASE; PROTEIN-KINASE-A; CALCIUM-PUMP; ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; STRUCTURAL-CHANGES; TRYPTIC CLEAVAGE; SKELETAL-MUSCLE; CONFORMATIONAL TRANSITIONS; PHOSPHOENZYME INTERMEDIATE	The effects of orthophosphate, nucleotide analogues, ADP, and covalent phosphorylation on the tryptic fragmentation patterns of the E-1 and E-2 forms of scallop Ca-ATPase were examined. Sites preferentially cleaved by trypsin in the E1 form of the Ca-ATPase were detected in the nucleotide (N) and phosphorylation (P) domains, as well as the actuator (A) domain. These sites were occluded in the E-2 (Ca2+-free) form of the enzyme, consistent with mutual protection of the A, N, and P domains through their association into a clustered structure. Similar protection of cytoplasmic Ca2+-dependent tryptic cleavage sites was observed when the catalytic binding site for substrate on the E1 form of scallop Ca-ATPase was occupied by P-i, AMP-PNP, AMP-PCP, or ADP despite the presence of saturating levels of Ca2+. These results suggest that occupation of the catalytic site on E-1 can induce condensation of the cytoplasmic domains to yield a unique structural intermediate that may be related to the form of the enzyme in which the active site is prepared for phosphoryl transfer. The effect of P-i on the E-2 form of the scallop Ca-ATPase was also investigated, when it was found that formation of E-2-P led to extreme resistance toward secondary cleavage by trypsin and stabilization of enzymatic activity for long periods of time.	So Illinois Univ, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University	Hardwicke, PMD (corresponding author), So Illinois Univ, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA.	phardwicke@siumed.edu			NIGMS NIH HHS [R01 GM56960] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056960] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; ANDERSEN JP, 1986, J MEMBRANE BIOL, V93, P85, DOI 10.1007/BF01871021; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANDERSEN JP, 1985, P NATL ACAD SCI USA, V82, P4573, DOI 10.1073/pnas.82.14.4573; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CASTELLANI L, 1983, J CELL BIOL, V97, P557, DOI 10.1083/jcb.97.2.557; CASTELLANI L, 1989, J CELL BIOL, V108, P511, DOI 10.1083/jcb.108.2.511; Chen MG, 2000, J BIOL CHEM, V275, P22961, DOI 10.1074/jbc.M001743200; CUENDA A, 1994, BBA-BIOMEMBRANES, V1194, P35, DOI 10.1016/0005-2736(94)90200-3; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1973, J BIOL CHEM, V248, P3696; DEMEIS L, 1981, SARCOPLASMIC RETICUL, P69; Dode L, 2001, J BIOL CHEM, V276, P3911, DOI 10.1074/jbc.M007719200; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; Farley RA, 2001, BIOCHEMISTRY-US, V40, P6361, DOI 10.1021/bi010270+; FROUD RJ, 1986, BIOCHEM J, V237, P207, DOI 10.1042/bj2370207; Hardwicke PMD, 1999, BBA-BIOMEMBRANES, V1417, P1, DOI 10.1016/S0005-2736(98)00241-7; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P245, DOI 10.1007/BF01739814; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P229, DOI 10.1007/BF01739813; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; Hua SM, 2000, J BIOL CHEM, V275, P30546, DOI 10.1074/jbc.M003218200; INESI G, 1967, J BIOL CHEM, V242, P4637; Jorgensen PL, 2001, J BIOENERG BIOMEMBR, V33, P367, DOI 10.1023/A:1010611322024; KALABOKIS V, 1988, J BIOL CHEM, V263, P15184; KALABOKIS VN, 1993, BIOCHEMISTRY-US, V32, P4389, DOI 10.1021/bi00067a031; KALABOKIS VN, 1993, BIOCHIM BIOPHYS ACTA, V1147, P35, DOI 10.1016/0005-2736(93)90313-O; KALABOKIS VN, 1991, J BIOL CHEM, V266, P22044; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; MacLennan DH, 2000, NATURE, V405, P633, DOI 10.1038/35015206; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; McIntosh DB, 2000, NAT STRUCT BIOL, V7, P532, DOI 10.1038/76735; Mignaco JA, 1996, BIOCHEMISTRY-US, V35, P3886, DOI 10.1021/bi9518353; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NEET KE, 1977, ARCH BIOCHEM BIOPHYS, V178, P588, DOI 10.1016/0003-9861(77)90230-2; PICKART CM, 1984, J BIOL CHEM, V259, P1629; ROSS DC, 1987, J BIOL CHEM, V262, P12977; ROSS DC, 1991, J BIOL CHEM, V266, P4613; Saino T, 1997, J BIOL CHEM, V272, P21142, DOI 10.1074/jbc.272.34.21142; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwarz FP, 1997, BIOPHYS J, V73, P2179, DOI 10.1016/S0006-3495(97)78249-3; Shi X, 1998, COMP BIOCHEM PHYS B, V120, P359, DOI 10.1016/S0305-0491(98)10025-1; SHIGEKAWA M, 1985, J BIOL CHEM, V260, P1679; Shin JM, 2001, J BIOL CHEM, V276, P48440, DOI 10.1074/jbc.M106864200; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; Stokes DL, 2003, ANNU REV BIOPH BIOM, V32, P445, DOI 10.1146/annurev.biophys.32.110601.142433; TAYLOR JS, 1981, J BIOL CHEM, V256, P9793; TAYLOR JS, 1979, J BIOL CHEM, V254, P4402; THE R, 1972, EUR J BIOCHEM, V28, P357, DOI 10.1111/j.1432-1033.1972.tb01921.x; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; von Germar F, 2000, BIOPHYS J, V78, P1531, DOI 10.1016/S0006-3495(00)76705-1; WU C, 2002, J MOL BIOL, V316, P201	62	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5380	5386		10.1074/jbc.M310085200	http://dx.doi.org/10.1074/jbc.M310085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645252	hybrid			2022-12-27	WOS:000188776500043
J	Taverna, E; Saba, E; Rowe, J; Francolini, M; Clementi, F; Rosa, P				Taverna, E; Saba, E; Rowe, J; Francolini, M; Clementi, F; Rosa, P			Role of lipid microdomains in P/Q-type calcium channel (Ca(v)2.1) clustering and function in presynaptic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; PLASMA-MEMBRANE; SNARE PROTEINS; RAFTS; CELLS; IDENTIFICATION; LOCALIZATION; ASSOCIATION; DOMAINS; COMPLEX	Lipid microdomains can selectively include or exclude proteins and may be important in a variety of functions such as protein sorting, cell signaling, and synaptic transmission. The present study demonstrates that two different voltage-gated calcium channels, which both interact with soluble N-ethyl-maleimide-sensitive fusion protein attachment protein receptor (SNARE) proteins but have distinct subcellular distributions and roles in synaptic transmission, are differently distributed in lipid microdomains; presynaptic P/Q (Ca(v)2.1) but not Lc (Ca(v)1.2) calcium channel subtypes are mainly accumulated in detergent-insoluble complexes. The immunoisolation of multiprotein complexes from detergent-insoluble or detergent-soluble fractions shows that the alpha1A subunits of Ca(v)2.1 colocalize and interact with SNARE complexes in lipid microdomains. The altered organization of these microdomains caused by saponin and methyl-beta-cyclodextrin treatment largely impairs the buoyancy and distribution of Ca(v)2.1 channels and SNAREs in flotation gradients. On the other hand, cholesterol reloading partially reverses the drug effects. Methyl-beta-cyclodextrin treatment alters the colocalization of Ca(v)2.1 with the proteins of the exocytic machinery and also impairs calcium influx in nerve terminals. These results show that lipid microdomains in presynaptic terminals are important in organizing membrane sites specialized for synaptic vesicle exocytosis. The cholesterol-enriched microdomains contribute to optimizing the compartmentalization of exocytic machinery and the calcium influx that triggers synaptic vesicle exocytosis.	Univ Milan, Ctr Excellence Neurodegenerat Dis, Inst Neurosci Cellular & Mol Pharmacol, CNR,Dept Med Pharmacol, I-20129 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan	Rosa, P (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Inst Neurosci Cellular & Mol Pharmacol, CNR,Dept Med Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	p.rosa@in.cnr.it	Saba, Elena/ABH-9313-2020; Taverna, Elena/AFW-4935-2022; taverna, elena/O-8180-2014	Saba, Elena/0000-0002-8217-5968; taverna, elena/0000-0002-2430-4725; FRANCOLINI, MAURA/0000-0002-3126-1575; Rosa, Patrizia/0000-0002-2590-6955				Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Christian AE, 1997, J LIPID RES, V38, P2264; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Faivre-Sarrailh C, 2000, J CELL BIOL, V149, P491, DOI 10.1083/jcb.149.2.491; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hering H, 2003, J NEUROSCI, V23, P3262; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; Missler M, 2003, NATURE, V423, P939, DOI 10.1038/nature01755; Mochida S, 2003, P NATL ACAD SCI USA, V100, P2819, DOI 10.1073/pnas.262787699; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; Passafaro M, 1996, J BIOL CHEM, V271, P30096, DOI 10.1074/jbc.271.47.30096; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Rowe J, 2001, J CELL SCI, V114, P3323; SAKURAI T, 1995, J BIOL CHEM, V270, P21234, DOI 10.1074/jbc.270.36.21234; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Spafford JD, 2003, CURR OPIN NEUROBIOL, V13, P308, DOI 10.1016/S0959-4388(03)00061-8; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Taverna E, 2002, J CELL SCI, V115, P3909, DOI 10.1242/jcs.00072; Tsui-Pierchala BA, 2002, TRENDS NEUROSCI, V25, P412, DOI 10.1016/S0166-2236(02)02215-4; Valiyaveetil FI, 2002, BIOCHEMISTRY-US, V41, P10771, DOI 10.1021/bi026215y; Weiss JL, 2001, J BIOL CHEM, V276, P44804, DOI 10.1074/jbc.M103262200	43	102	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5127	5134		10.1074/jbc.M308798200	http://dx.doi.org/10.1074/jbc.M308798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660672	hybrid			2022-12-27	WOS:000188776500012
J	Okada, M; Hatakeyama, T; Itoh, H; Tokuta, N; Tokumitsu, H; Kobayashi, R				Okada, M; Hatakeyama, T; Itoh, H; Tokuta, N; Tokumitsu, H; Kobayashi, R			S100A1 is a novel molecular chaperone and a member of the Hsp70/Hsp90 multichaperone complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CALCIUM-BINDING PROTEINS; CITRATE SYNTHASE; NONNATIVE PROTEIN; ESCHERICHIA-COLI; TARGET PROTEIN; IN-VITRO; HSP90; CALMODULIN; HSP70	Although calmodulin is known to be a component of the Hsp70/Hsp90 multichaperone complex, the functional role of the protein remains uncertain. In this study, we have identified S100A1, but not calmodulin or other S100 proteins, as a potent molecular chaperone and a new member of the multichaperone complex. Glutathione S-transferase pull-down assays and co-immunoprecipitation experiments indicated the formation of stable complexes between S100A1 and Hsp90, Hsp70, FKBP52, and CyP40 both in vitro and in mammalian cells. S100A1 potently protected citrate synthase, aldolase, glyceraldehyde-3-phosphate dehydrogenase, and rhodanese from heat-induced aggregation and suppressed the aggregation of chemically denatured rhodanese and citrate synthase during the refolding pathway. In addition, S100A1 suppressed the heat-induced inactivation of citrate synthase activity, similar to that for Hsp90 and p23. The chaperone activity of S100A1 was antagonized by calmodulin antagonists, such as fluphenazine and prenylamine, that is, indeed an intrinsic function of the protein. The overexpression of S100A1 in COS-7 cells protected transiently expressed firefly luciferase and Escherichia coli beta-galactosidase from inactivation during heat shock. The results demonstrate a novel physiological function for S100A1 and bring us closer to a comprehensive understanding of the molecular mechanisms of the Hsp70/Hsp90 multichaperone complex.	Kagawa Univ, Fac Med, Dept Signal Transduct Sci, Miki, Kagawa 7610793, Japan; Akita Univ, Fac Engn & Resource Sci, Dept Mat Proc Engn & Appl Chem Environm, Akita 0108502, Japan	Kagawa University; Akita University	Kobayashi, R (corresponding author), Kagawa Univ, Fac Med, Dept Signal Transduct Sci, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	ryoji@kms.ac.jp	; Tokumitsu, Hiroshi/M-3978-2015	Takashi, Hatakeyama/0000-0001-6325-0814; Tokumitsu, Hiroshi/0000-0002-2193-6794				Bennett MK, 1997, CURR OPIN NEUROBIOL, V7, P316, DOI 10.1016/S0959-4388(97)80058-X; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csermely P, 1997, LIFE SCI, V61, P411, DOI 10.1016/S0024-3205(97)00398-6; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FILIPEK A, 1995, INT J BIOCHEM CELL B, V27, P1123, DOI 10.1016/1357-2725(95)00096-8; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Graumann K, 2000, BIOCHEM J, V345, P627, DOI 10.1042/0264-6021:3450627; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; ITOH H, 1990, ARCH BIOCHEM BIOPHYS, V282, P290, DOI 10.1016/0003-9861(90)90119-J; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Landar A, 1996, CELL CALCIUM, V20, P279, DOI 10.1016/S0143-4160(96)90033-0; Landar A, 1998, BIOCHEMISTRY-US, V37, P17429, DOI 10.1021/bi9817921; MARSHAK DR, 1985, BIOCHEMISTRY-US, V24, P144, DOI 10.1021/bi00322a020; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; Okada M, 2002, BIOCHEM BIOPH RES CO, V292, P1023, DOI 10.1006/bbrc.2002.6761; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RATAJCZAK T, 1995, BIOCHEM BIOPH RES CO, V209, P117, DOI 10.1006/bbrc.1995.1478; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Tsvetkov PO, 1999, J BIOL CHEM, V274, P18161, DOI 10.1074/jbc.274.26.18161; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Yamashita K, 1999, PROTEIN EXPRES PURIF, V16, P47, DOI 10.1006/prep.1998.1026; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; ZIMMER DB, 1993, CELL CALCIUM, V14, P323, DOI 10.1016/0143-4160(93)90053-9; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424; ZIMMER M, 1987, EUR J BIOCHEM, V164, P411, DOI 10.1111/j.1432-1033.1987.tb11073.x	50	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4221	4233		10.1074/jbc.M309014200	http://dx.doi.org/10.1074/jbc.M309014200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14638689	hybrid			2022-12-27	WOS:000188554300039
J	Kelicen, P; Tindberg, N				Kelicen, P; Tindberg, N			Lipopolysaccharide induces CYP2E1 in astrocytes through MAP kinase kinase-3 and C/EBP beta and -delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; CCAAT/ENHANCER-BINDING-PROTEIN; INDUCIBLE CYTOCHROME-P-450 IIE1; DOWN-REGULATION; INFLAMMATORY CYTOKINES; GENE-EXPRESSION; RAT-LIVER; IN-VIVO; C-JUN; ETHANOL	Cytochrome P450 2E1 (CYP2E1) is highly inducible in a subset of astrocytes in vivo following ischemic or mechanical injury and in vitro by lipopolysaccharide (LPS) or interleukin-1beta. We have studied the mechanism of induction, and found that transcriptional activation of CYP2E1 occurred within 3 h, and CYP2E1 dependent catalytic activity was induced more than 4-fold within 5 h. The induction was sensitive to several tyrosine kinase inhibitors, and was further modulated by inhibitors of p38 MAP kinase. MAP kinase kinase-3 (MKK3) was phosphorylated in response to LPS, and expression of constitutively active MKK3, but not the MAP kinase kinases MEKK1 or MKK1, activated CYP2E1. Transcriptional activation was mediated through a C/EBPbeta and -delta binding element situated at -486/-474, and appeared to involve activation of prebound factors as well as recruitment of newly synthesized C/EBPbeta and -delta. It is thus suggested that LPS induces MKK3 activation in astrocytes, which in turn stimulates a C/EBPbeta and -delta binding element to mediate transcriptional activation of CYP2E1.	Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-17177 Stockholm, Sweden	Karolinska Institutet	Tindberg, N (corresponding author), Karolinska Inst, Inst Environm Med, Div Mol Toxicol, S-17177 Stockholm, Sweden.	nictin@ki.se						ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; Bae MA, 2001, MOL PHARMACOL, V60, P847; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bondoc FY, 1999, BIOCHEM PHARMACOL, V58, P461, DOI 10.1016/S0006-2952(99)00111-2; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I; CASAZZA JP, 1984, J BIOL CHEM, V259, P231; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Cuenda A, 2000, INT J BIOCHEM CELL B, V32, P581, DOI 10.1016/S1357-2725(00)00003-0; Cui X, 2003, BBA-GEN SUBJECTS, V1619, P325, DOI 10.1016/S0304-4165(02)00491-9; Davis MA, 1999, TOXICOL APPL PHARM, V161, P59, DOI 10.1006/taap.1999.8765; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; Hakkola J, 2003, J PHARMACOL EXP THER, V304, P1048, DOI 10.1124/jpet.102.041582; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1993, J BIOL CHEM, V268, P25009; HANSSON T, 1990, NEUROSCIENCE, V34, P451, DOI 10.1016/0306-4522(90)90154-V; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Hu Y, 1999, BIOCHEM BIOPH RES CO, V263, P286, DOI 10.1006/bbrc.1999.1362; JOHANSSON I, 1986, FEBS LETT, V196, P59, DOI 10.1016/0014-5793(86)80214-9; Jover R, 2002, FASEB J, V16, P1799, DOI 10.1096/fj.02-0195fje; Keesler GA, 1998, PROTEIN EXPRES PURIF, V14, P221, DOI 10.1006/prep.1998.0947; Kietzmann T, 2003, J BIOL CHEM, V278, P17927, DOI 10.1074/jbc.M203929200; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MONTOLIU C, 1995, J NEUROCHEM, V65, P2561; MORGAN ET, 1994, BBA-GENE STRUCT EXPR, V1219, P475, DOI 10.1016/0167-4781(94)90074-4; MORGAN ET, 1993, BIOCHEM PHARMACOL, V45, P415, DOI 10.1016/0006-2952(93)90078-B; Nord M, 1998, DNA CELL BIOL, V17, P481, DOI 10.1089/dna.1998.17.481; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; Sewer MB, 1996, DRUG METAB DISPOS, V24, P401; Simi A, 2000, J CEREBR BLOOD F MET, V20, P1077, DOI 10.1097/00004647-200007000-00007; Simi A, 2002, J NEUROCHEM, V83, P727, DOI 10.1046/j.1471-4159.2002.01178.x; Tindberg N, 1996, MOL PHARMACOL, V50, P1065; TINDBERG N, 1989, BIOCHEMISTRY-US, V28, P4499, DOI 10.1021/bi00436a056; Tindberg N, 2003, J NEUROCHEM, V86, P888, DOI 10.1046/j.1471-4159.2003.01897.x; Tindberg N, 1996, J NEUROCHEM, V67, P2066, DOI 10.1046/j.1471-4159.1996.67052066.x; Tindberg N, 2000, NEUROCHEM RES, V25, P527, DOI 10.1023/A:1007520311457; UMENO M, 1988, J BIOL CHEM, V263, P4956; Wang H, 2001, BRIT J PHARMACOL, V133, P713, DOI 10.1038/sj.bjp.0704102; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WARNER M, 1994, P NATL ACAD SCI USA, V91, P1019, DOI 10.1073/pnas.91.3.1019; Yano S, 1996, J BIOL CHEM, V271, P23520, DOI 10.1074/jbc.271.38.23520	53	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					15734	15742		10.1074/jbc.M311850200	http://dx.doi.org/10.1074/jbc.M311850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14670949	hybrid			2022-12-27	WOS:000220747900007
J	Cox, KH; Kulkarni, A; Tate, JJ; Cooper, TG				Cox, KH; Kulkarni, A; Tate, JJ; Cooper, TG			Gln3 phosphorylation and intracellular localization in nutrient limitation and starvation differ from those generated by rapamycin inhibition of tor1/2 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; RETROGRADE GENE-EXPRESSION; NUCLEAR-LOCALIZATION; SIGNALING PATHWAYS; PROTEINS; TARGET; TAP42	The ability of the cell to sense environmental conditions and alter gene expression in response to them is critical to its survival. In Saccharomyces cerevisiae, the Tor1/2 serine/threonine kinases are global regulators situated at the top of a signal cascade reported to receive and transmit nutritional signals associated with the nitrogen supply of the cell. At the other end of that cascade is Gln3, one of two transcriptional activators responsible for most nitrogen catabolic gene expression. When nitrogen is in excess, Tor1/2 are active, and Gln3 is phosphorylated and localizes to the cytoplasm. If Tor1/2 are inhibited by rapamycin or mutation, Gln3 becomes dephosphorylated, accumulates in the nucleus, and mediates nitrogen catabolite repression (NCR)-sensitive transcription. The observations that Gln3 also accumulates in the nuclei of cells provided with poor nitrogen sources or during nitrogen starvation has led to the conclusion that Tor1/2 control intracellular Gln3 localization and NCR-sensitive transcription by regulating Gln3 phosphorylation/dephosphorylation. To test this model, we compared Gln3 phosphorylation states and intracellular localizations under a variety of physiological conditions known to elicit different levels of NCR-sensitive transcription. Our data indicate that: (i) observable Gln3 phosphorylation levels do not correlate in a consistent way with the quality or quantity of the nitrogen source provided, the intracellular localization of Gln3, or the capacity to support NCR-sensitive transcription. (ii) Gln3-Myc(13) is hyperphosphorylated during nitrogen and carbon starvation, but this uniform response does not correlate with Gln3 intracellular localization. (iii) Gln3-Myc(13) dephosphorylation and nuclear localization correlate with one another at early but not late times after rapamycin treatment. These data suggest that rapamycin treatment and growth with poor nitrogen sources bring about nuclear accumulation of Gln3 but likely do so by different mechanisms or by a common mechanism involving molecules other than Gln3 and/or other than the levels of Gln3-Myc(13) phosphorylation thus far detected by others and ourselves.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, 858 Madison Ave,Rm 501, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1991, CURRENT PROTOCOLS MO; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carvalho J, 2001, J BIOL CHEM, V276, P25359, DOI 10.1074/jbc.M103050200; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Cooper TG, 1996, MYCOTA, V3, P139; COOPER TG, 2004, IN PRESS CURR GEN; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Tate JJ, 2003, J BIOL CHEM, V278, P36924, DOI 10.1074/jbc.M301829200	26	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10270	10278		10.1074/jbc.M312023200	http://dx.doi.org/10.1074/jbc.M312023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679193	Green Accepted, hybrid			2022-12-27	WOS:000220050400075
J	Day, RM; Thiel, G; Lum, J; Chevere, RD; Yang, YZ; Stevens, J; Sibert, L; Fanburg, BL				Day, RM; Thiel, G; Lum, J; Chevere, RD; Yang, YZ; Stevens, J; Sibert, L; Fanburg, BL			Hepatocyte growth factor regulates angiotensin converting enzyme expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; MESSENGER-RNA EXPRESSION; ACTIVATED PROTEIN-KINASE; FACTOR SCATTER FACTOR; GENE-EXPRESSION; ENHANCED EXPRESSION; LIVER-REGENERATION; ENDOTHELIAL-CELLS; LAVAGE FLUID; LUNG INJURY	Hepatocyte growth factor (HGF) is a mitogen, morphogen, and motogen that functions in tissue healing and acts as an anti-fibrotic factor. The mechanism for this is not well understood. Recent studies implicate somatic angiotensin-converting enzyme (ACE) in fibrosis. We examined the effects of HGF on ACE expression in bovine pulmonary artery endothelial cells (BPAEC). Short term treatment of BPAEC with HGF transiently increased both ACE mRNA (3 h) and activity (24 h), as determined by ACE protease assays and reverse transcription-PCR. Incubation of BPAEC with HGF for longer periods suppressed ACE mRNA (6 h) and activity (72 h). In contrast, phorbol ester (PMA) treatment produced sustained increase in ACE mRNA and activity. We examined the short term molecular effects of HGF on ACE using PMA for comparison. HGF and PMA increased transcription from a luciferase reporter with the core ACE promoter, which contains a composite binding site for SP1/3 and Egr-1. Immunocytochemistry and electrophoretic mobility shift assay showed that both HGF and PMA increased Egr-1 binding. HGF also increased SP3 binding, as measured by EMSA. However, HGF and PMA increased the cellular activity of only Egr-1, not SP3, as measured by luciferase reporter assays. Deletion of the Egr-1 site in the reporter construct completely abrogated HGF-induced transcription but only similar to50% of PMA-induced activity. Expression of dominant negative Egr-1 and SP3 blocked up-regulation of the ACE promoter by HGF but only reduced up-regulation by PMA. These results show that HGF transiently increases gene transcription of ACE via activation of Egr-1, whereas PMA regulation involves Egr-1 and additional factor(s).	Tufts Univ New England Med Ctr, Tupper Res Inst, Div Pulm & Crit Care, Boston, MA 02111 USA; Univ Saarland, Med Ctr, Dept Med Biochem & Mol Biol, D-6642 Homburg, Germany	Tufts Medical Center; Saarland University	Day, RM (corresponding author), Georgetown Univ, Sch Med, Dept Pharmacol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	reginamday@hotmail.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073929, R01HL042376, R01HL014456] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-42376, R01 HL073929-01A1, R01 HL073929, R01 HL-14456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamson IYR, 1999, AM J PATHOL, V155, P949, DOI 10.1016/S0002-9440(10)65194-2; Ali SM, 1998, PHARMACOLOGY, V57, P20, DOI 10.1159/000028222; ASCHOFF JM, 1994, ANAL BIOCHEM, V219, P218, DOI 10.1006/abio.1994.1260; BARRETOCHAVES M, 2001, AM J PHYSIOL-REG I, V280, P25; Border WA, 1998, HYPERTENSION, V31, P181, DOI 10.1161/01.HYP.31.1.181; CALDWELL PRB, 1976, SCIENCE, V191, P1050, DOI 10.1126/science.175444; Campbell SE, 1997, J MOL CELL CARDIOL, V29, P1947, DOI 10.1006/jmcc.1997.0435; Cibelli G, 1996, EUR J BIOCHEM, V237, P311, DOI 10.1111/j.1432-1033.1996.0311n.x; CORVOL P, 1995, J HYPERTENS, V13, pS3, DOI 10.1097/00004872-199509003-00002; Cui MZ, 1999, J BIOL CHEM, V274, P32795, DOI 10.1074/jbc.274.46.32795; DASARATHY Y, 1992, AM J PHYSIOL, V263, pL645, DOI 10.1152/ajplung.1992.263.6.L645; Day RM, 2001, AM J RESP CELL MOL, V25, P613, DOI 10.1165/ajrcmb.25.5.4521; DELVECCHIO PJ, 1981, J CELL PHYSIOL, V108, P337, DOI 10.1002/jcp.1041080307; Dohi M, 2000, AM J RESP CRIT CARE, V162, P2302, DOI 10.1164/ajrccm.162.6.9908097; FISHEL RS, 1995, J CLIN INVEST, V95, P377, DOI 10.1172/JCI117666; FRIEDLAND J, 1976, AM J CLIN PATHOL, V66, P416; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HAMANOUE M, 1992, HEPATOLOGY, V16, P1485, DOI 10.1002/hep.1840160626; HIRSCH AT, 1991, CIRC RES, V69, P475, DOI 10.1161/01.RES.69.2.475; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; IGAWA T, 1993, AM J PHYSIOL, V265, pF61, DOI 10.1152/ajprenal.1993.265.1.F61; KATO H, 1991, J HYPERTENS, V9, P17; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kitta K, 2001, FREE RADICAL BIO MED, V31, P902, DOI 10.1016/S0891-5849(01)00663-3; LANZILLO JJ, 1994, PCR METH APPL, V4, P167; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA J, 1995, AM J RESP CRIT CARE, V152, P1587, DOI 10.1164/ajrccm.152.5.7582299; Marshall RP, 2000, AM J RESP CRIT CARE, V161, P1999, DOI 10.1164/ajrccm.161.6.9907004; MATSUDA Y, 1995, J BIOCHEM-TOKYO, V118, P643, DOI 10.1093/oxfordjournals.jbchem.a124958; Matsuda Y, 1997, HEPATOLOGY, V26, P81; Matsumoto K, 1993, EXS, V65, P225; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; OKABE T, 1987, BIOCHEM BIOPH RES CO, V145, P1211, DOI 10.1016/0006-291X(87)91566-X; Okada K, 1998, AM J RESP CRIT CARE, V158, P939, DOI 10.1164/ajrccm.158.3.9710007; Ono K, 1997, CIRCULATION, V95, P2552, DOI 10.1161/01.CIR.95.11.2552; ROSEN EM, 1985, J CELL PHYSIOL, V122, P30, DOI 10.1002/jcp.1041220106; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sacco G, 2001, EUR J PHARMACOL, V414, P71, DOI 10.1016/S0014-2999(01)00782-8; Saijonmaa O, 2001, AM J PHYSIOL-HEART C, V280, pH885, DOI 10.1152/ajpheart.2001.280.2.H885; Schaper W, 1997, CIRCULATION, V95, P2471, DOI 10.1161/01.CIR.95.11.2471; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Sun YO, 1998, J MOL CELL CARDIOL, V30, P1559, DOI 10.1006/jmcc.1998.0721; Tahara M, 1999, J CLIN INVEST, V103, P313, DOI 10.1172/JCI4433; Taipale J, 1996, J BIOL CHEM, V271, P4342; TESTUT P, 1993, BIOCHEM J, V293, P843, DOI 10.1042/bj2930843; Thiel G, 2000, BBA-GENE STRUCT EXPR, V1493, P289, DOI 10.1016/S0167-4781(00)00207-4; Tsuzuki N, 2001, NEUROL RES, V23, P417, DOI 10.1179/016164101101198659; Uehara Y, 2000, GENESIS, V27, P99, DOI 10.1002/1526-968X(200007)27:3<99::AID-GENE20>3.0.CO;2-Y; Ueno S, 1996, CANCER CHEMOTH PHARM, V38, P233, DOI 10.1007/s002800050476; Uhal BD, 1998, AM J PHYSIOL-LUNG C, V275, pL1013, DOI 10.1152/ajplung.1998.275.5.L1013; Venkatesan N, 1997, LIFE SCI, V61, pPL51; Verghese GM, 1998, AM J RESP CRIT CARE, V158, P386, DOI 10.1164/ajrccm.158.2.9711111; Villard E, 1998, J BIOL CHEM, V273, P25191, DOI 10.1074/jbc.273.39.25191; Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143, DOI 10.1152/ajplung.2000.279.1.L143; Wang RQ, 1999, AM J PHYSIOL-LUNG C, V277, pL1245, DOI 10.1152/ajplung.1999.277.6.L1245; Wung BS, 1999, CIRC RES, V84, P804; Yaekashiwa M, 1997, AM J RESP CRIT CARE, V156, P1937, DOI 10.1164/ajrccm.156.6.9611057; Yamada T, 2000, AM J RESP CRIT CARE, V162, P707, DOI 10.1164/ajrccm.162.2.9908064; Yamazaki H, 1997, EUR RESPIR J, V10, P2539, DOI 10.1183/09031936.97.10112539; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; Yasuda H, 1996, HEPATOLOGY, V24, P636, DOI 10.1002/hep.510240328; Yasuda S, 1999, HYPERTENSION, V33, P1374, DOI 10.1161/01.HYP.33.6.1374; Zhang F, 2003, J BIOL CHEM, V278, P44246, DOI 10.1074/jbc.M305564200; Zhuo JL, 1998, J HYPERTENS, V16, P2027, DOI 10.1097/00004872-199816121-00026; Zulueta JJ, 2002, AM J RESP CELL MOL, V26, P22, DOI 10.1165/ajrcmb.26.1.4510	72	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8792	8801		10.1074/jbc.M311140200	http://dx.doi.org/10.1074/jbc.M311140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679188	hybrid, Green Accepted			2022-12-27	WOS:000189265900034
J	Oyedotun, KS; Lemire, BD				Oyedotun, KS; Lemire, BD			The quaternary structure of the Saccharomyces cerevisiae succinate dehydrogenase - Homology modeling, cofactor docking, and molecular dynamics simulation studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI FUMARATE REDUCTASE; QUINONE-BINDING-SITES; PARTICLE MESH EWALD; ESCHERICHIA-COLI; UBIQUINONE OXIDOREDUCTASE; AUTOMATED DOCKING; COMPLEX-II; RESPIRATORY COMPLEX; ELECTRON-TRANSFER; FLEXIBLE LIGANDS	Succinate dehydrogenases and fumarate reductases are complex mitochondrial or bacterial respiratory chain proteins with remarkably similar structures and functions. Succinate dehydrogenase oxidizes succinate and reduces ubiquinone using a flavin adenine dinucleotide cofactor and iron-sulfur clusters to transport electrons. A model of the quaternary structure of the tetrameric Saccharomyces cerevisiae succinate dehydrogenase was constructed based on the crystal structures of the Escherichia coli succinate dehydrogenase, the E. coli fumarate reductase, and the Wolinella succinogenes fumarate reductase. One FAD and three iron-sulfur clusters were docked into the Sdh1p and Sdh2p catalytic dimer. One b-type heme and two ubiquinone or inhibitor analog molecules were docked into the Sdh3p and Sdh4p membrane dimer. The model is consistent with numerous experimental observations. The calculated free energies of inhibitor binding are in excellent agreement with the experimentally determined inhibitory constants. Functionally important residues identified by mutagenesis of the SDH3 and SDH4 genes are located near the two proposed quinone-binding sites, which are separated by the heme. The proximal quinone-binding site, located nearest the catalytic dimer, has a considerably more polar environment than the distal site. Alternative low energy conformations of the membrane subunits were explored in a molecular dynamics simulation of the dimer embedded in a phospholipid bilayer. The simulation offers insight into why Sdh4p Cys-78 may be serving as the second axial ligand for the heme instead of a histidine residue. We discuss the possible roles of heme and of the two quinone-binding sites in electron transport.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada.	bernard.lemire@ualberta.ca						Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Bamford VA, 2002, EMBO J, V21, P5599, DOI 10.1093/emboj/cdf566; Barak A, 1998, FUTURE GENER COMP SY, V13, P361, DOI 10.1016/S0167-739X(97)00037-X; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fiser A, 2000, PROTEIN SCI, V9, P1753, DOI 10.1110/ps.9.9.1753; Gasteiger J., 1990, TETRAHEDRON COMPUT M, V3, P537, DOI DOI 10.1016/0898-5529(90)90156-3; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo J, 2003, J BIOL CHEM, V278, P47629, DOI 10.1074/jbc.M306312200; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iverson TM, 2000, CURR OPIN STRUC BIOL, V10, P448, DOI 10.1016/S0959-440X(00)00113-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemire BD, 2002, BBA-BIOENERGETICS, V1553, P102, DOI 10.1016/S0005-2728(01)00229-8; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Melo F, 1997, J MOL BIOL, V267, P207, DOI 10.1006/jmbi.1996.0868; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Oyedotun KS, 1999, BBA-BIOENERGETICS, V1411, P170, DOI 10.1016/S0005-2728(99)00040-7; Oyedotun KS, 2001, J BIOL CHEM, V276, P16936, DOI 10.1074/jbc.M100184200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tieleman DP, 1996, J CHEM PHYS, V105, P4871, DOI 10.1063/1.472323; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020	56	164	180	4	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9424	9431		10.1074/jbc.M311876200	http://dx.doi.org/10.1074/jbc.M311876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672929	hybrid			2022-12-27	WOS:000189265900108
J	Sato, Y; Sagami, I; Shimizu, T				Sato, Y; Sagami, I; Shimizu, T			Identification of caveolin-1-interacting sites in neuronal nitric-oxide synthase - Molecular mechanism for inhibition of NO formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; SCAFFOLDING DOMAIN; SKELETAL-MUSCLE; CALMODULIN; CAVEOLIN; BINDING; FLAVIN; ACTIVATION; ROLES; EXPRESSION	Caveolin is known to down-regulate both neuronal (nNOS) and endothelial nitric-oxide synthase (eNOS). In the present study, direct interactions of recombinant caveolin-1 with both the oxygenase and reductase domains of nNOS were demonstrated using in vitro binding assays. To elucidate the mechanism of nNOS regulation by caveolin, we examined the effects of a caveolin-1 scaffolding domain peptide (CaV1p1; residues (82-101)) on the catalytic activities of wild-type and mutant nNOSs. CaV1p1 inhibited NO formation activity and NADPH oxidation of wild-type nNOS in a dose-dependent manner with an IC50 value of 1.8 muM. Mutations of Phe(584) and Trp(587) within a caveolin binding consensus motif of the oxygenase domain did not result in the loss of CaV1p1 inhibition, indicating that an alternate region of nNOS mediates inhibition by caveolin. The addition of CaV1p1 also inhibited more than 90% of the cytochrome c reductase activity in the isolated reductase domain with or without the calmodulin (CaM) binding site, whereas CaV1p1 inhibited ferricyanide reductase activity by only 50%. These results suggest that there are significant differences in the mechanism of inhibition by caveolin for nNOS as compared with those previously reported for eNOS. Further analysis of the interaction through the use of several reductase domain deletion mutants revealed that the FMN domain was essential for successful interaction between caveolin-1 and nNOS reductase. We also examined the effects of CaV1p1 on an autoinhibitory domain deletion mutant (Delta40) and a C-terminal truncation mutant (DeltaC33), both of which are able to form NO in the absence of CaM, unlike the wild-type enzyme. Interestingly, CaV1p1 inhibited CaM-dependent, but not CaM-independent, NO formation activities of both Delta40 and DeltaC33, suggesting that CaV1p1 inhibits interdomain electron transfer induced by CaM from the reductase domain to the oxygenase domain.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Sagami, I (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	ikuko@tagen.tohoku.ac.jp		Shimizu, Toru/0000-0002-3950-5554				Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 1998, BIOCHEMISTRY-US, V37, P193, DOI 10.1021/bi972307p; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; Ludwig ML, 1999, STRUCTURE, V7, pR73, DOI 10.1016/S0969-2126(99)80047-1; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; Mayer B, 2000, NITRIC OXIDE; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nedvetsky PI, 2002, P NATL ACAD SCI USA, V99, P16510, DOI 10.1073/pnas.262701999; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Repetto S, 1999, BIOCHEM BIOPH RES CO, V261, P547, DOI 10.1006/bbrc.1999.1055; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Rozhkova EA, 2002, J BIOL CHEM, V277, P16888, DOI 10.1074/jbc.M200642200; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SESSA WC, 1992, J BIOL CHEM, V267, P15274; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; Sunada Y, 2001, HUM MOL GENET, V10, P173, DOI 10.1093/hmg/10.3.173; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187	46	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8827	8836		10.1074/jbc.M310327200	http://dx.doi.org/10.1074/jbc.M310327200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681230	hybrid			2022-12-27	WOS:000189265900038
J	Chen, SH; Bubb, MR; Yarmola, EG; Zuo, J; Jiang, J; Lee, BS; Lu, M; Gluck, SL; Hurst, IR; Holliday, LS				Chen, SH; Bubb, MR; Yarmola, EG; Zuo, J; Jiang, J; Lee, BS; Lu, M; Gluck, SL; Hurst, IR; Holliday, LS			Vacuolar H+-ATPase binding to microfilaments - Regulation in response to phosphatidylinositol 3-kinase activity and detailed characterization of the actin-binding site in subunit B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW CULTURES; CELL POLARITY; INTERSTITIAL COLLAGENASE; PROFILIN INTERACTS; INTERCALATED CELLS; LIPID PRODUCTS; V-ATPASE; F-ACTIN; OSTEOCLASTS; ASSOCIATION	Vacuolar H+-ATPase (V-ATPase) binds microfilaments, and that interaction may be mediated by an actin binding domain in subunit B of the enzyme. To test for possible physiologic functions of the actin binding activity of V-ATPase, early responses of resorbing osteoclasts to inhibition of phosphatidylinositol 3-kinase activity by wortmannin and LY294002 were examined. Rapid co-localization between V-ATPase and F-actin was demonstrated by immunocytochemistry, and corresponding association between V-ATPase and F-actin in immunoprecipitations and pelleting assays was detected. This response was reversed as osteoclasts recovered resorptive activity after inhibitors were removed. By expressing and characterizing fusion proteins containing segments of the actin-binding amino-terminal regions of the B subunits of V-ATPase, we mapped the actin-binding site to a 44-amino acid domain. An 11-amino acid segment with a sequence similar to the actin-binding site of human profilin I was detected within this region. 13-Mers containing these profilin-like segments bound actin in fluorescent anisotropy studies and competed with profilin for binding to actin. Using site-directed mutagenesis, the 11-amino acid profilin-like actin-binding motifs ( amino acids 49 - 59 of B1 and 55 - 65 of B2) were replaced with an 11-amino acid spacer with a sequence based on the homologous sequence from subunit B of Pyrococcus horikoshii, an organism that lacks an actin cytoskeleton. These substitutions eliminated the actin-binding activity of the B subunit fusion proteins. In summary, binding between V-ATPase and F-actin in osteoclasts occurs in response to blocking phosphatidylinositol 3-kinase activity. This response was fully reversible. The actin binding activities of the B subunits of V-ATPase required 11-amino acid actin-binding motifs that are similar in sequence to the actin-binding site of mammalian profilin I.	Univ Florida, Coll Dent, Dept Orthodont, J Hillis Miller Hlth Ctr, Gainesville, FL 32610 USA; Univ Florida, Coll Dent, Dept Endodont, Gainesville, FL 32610 USA; Malcolm Randall Vet Affairs Med Ctr, Gainesville, FL 32608 USA; Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University System of Ohio; Ohio State University	Holliday, LS (corresponding author), Univ Florida, Coll Dent, Dept Orthodont, J Hillis Miller Hlth Ctr, D7-18,Campus Box 100444, Gainesville, FL 32610 USA.	sholliday@dental.ufl.edu	Holliday, Lexie/GYQ-4972-2022; Lee, Beth S/E-9578-2010	Lee, Beth S/0000-0002-1468-6387; Holliday, Lexie/0000-0002-0844-1965	NIAMS NIH HHS [R01 AR047959, R01 AR47959] Funding Source: Medline; NIDDK NIH HHS [R01 DK38848] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038848] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbuAmer Y, 1997, J CELL BIOL, V137, P247, DOI 10.1083/jcb.137.1.247; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; BUBB MR, 1994, J BIOL CHEM, V269, P14869; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200; Chung CY, 2001, TRENDS BIOCHEM SCI, V26, P557, DOI 10.1016/S0968-0004(01)01934-X; Chung CY, 2001, MOL CELL, V7, P937, DOI 10.1016/S1097-2765(01)00247-7; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRATA T, 2003, J BIOL CHEM; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053; Holliday LS, 2003, CALCIFIED TISSUE INT, V72, P206, DOI 10.1007/s00223-002-1008-7; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127; Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071; Lelievre SA, 1998, J CELL BIOCHEM, P250; Machen T E, 2001, JOP, V2, P229; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; Nakamura I, 1997, J CELL PHYSIOL, V172, P230, DOI 10.1002/(SICI)1097-4652(199708)172:2<230::AID-JCP10>3.0.CO;2-D; Nakamura I, 1997, FEBS LETT, V401, P207, DOI 10.1016/S0014-5793(96)01454-8; NAKAMURA I, 1995, FEBS LETT, V361, P79, DOI 10.1016/0014-5793(95)00153-Z; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Pilkington MF, 2001, J BONE MINER RES, V16, P1237, DOI 10.1359/jbmr.2001.16.7.1237; Pilkington MF, 1998, J BONE MINER RES, V13, P688, DOI 10.1359/jbmr.1998.13.4.688; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; Schluter K, 1998, J CELL SCI, V111, P3261; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Skinner MA, 1999, J HISTOCHEM CYTOCHEM, V47, P1247, DOI 10.1177/002215549904701004; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Vitavska O, 2003, J BIOL CHEM, V278, P18499, DOI 10.1074/jbc.M212844200; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wax MB, 1997, P NATL ACAD SCI USA, V94, P6752, DOI 10.1073/pnas.94.13.6752; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Xu T, 2001, J BIOL CHEM, V276, P24855, DOI 10.1074/jbc.M100637200; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; YOKOYAMA K, 2003, J BIOL CHEM	58	95	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7988	7998		10.1074/jbc.M305351200	http://dx.doi.org/10.1074/jbc.M305351200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662773	hybrid			2022-12-27	WOS:000189103300077
J	Cayouette, S; Lussier, MP; Mathieu, EL; Bousquet, SM; Boulay, G				Cayouette, S; Lussier, MP; Mathieu, EL; Bousquet, SM; Boulay, G			Exocytotic insertion of TRPC6 channel into the plasma membrane upon G(q) protein-coupled receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CAPACITATIVE CALCIUM-ENTRY; CA2+-PERMEABLE CATION CHANNEL; INTRACELLULAR CA2+ STORES; OPERATED HTRP3 CHANNELS; GTP-BINDING PROTEINS; TRANSIENT RECEPTOR; SIGNAL-TRANSDUCTION; MAST-CELLS; FUNCTIONAL EXPRESSION	TRPC proteins are the mammalian homologues of the Drosophila transient receptor potential channel and are involved in calcium entry after agonist stimulation of non-excitable cells. Seven mammalian TRPCs have been cloned, and their mechanisms of activation and regulation are still the subject of intense research. TRPC proteins interact with the inositol 1,4,5-trisphosphate receptor, and the conformational coupling plays a critical role in the activation of calcium entry. Some evidence also supports an exocytotic mechanism as part of the activation of calcium entry. To investigate the possible involvement of exocytosis in TRPC6 activation, we evaluated the location of TRPC6 at the plasma membrane by biotinylation labeling of cell surface proteins and by indirect immunofluorescence marking of TRPC6 in stably transfected HEK 293 cells. We showed that when the muscarinic receptor was stimulated or the thapsigargin-induced intracellular calcium pool was depleted the level of TRPC6 at the plasma membrane increased. The carbachol concentration at which TRPC6 externalization occurred was lower than the concentration required to activate TRPC6. Externalization occurred within the first 30 s of stimulation, and TRPC6 remained at the plasma membrane as long as the stimulus was present. These results indicate that an exocytotic mechanism is involved in the activation of TRPC6.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Boulay, G (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, 3001,12 Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Guylain.Boulay@USherbrooke.ca	Boulay, Guylain/D-9773-2010	Lussier, Marc/0000-0001-5568-0072				Alderton JM, 2000, CELL CALCIUM, V28, P161, DOI 10.1054/ceca.2000.0144; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Basora N, 2003, J BIOL CHEM, V278, P31709, DOI 10.1074/jbc.M304437200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Fierro L, 1999, J PHYSIOL-LONDON, V520, P407, DOI 10.1111/j.1469-7793.1999.00407.x; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich T, 2001, J BIOL CHEM, V276, P42401, DOI 10.1074/jbc.M106956200; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Mehta D, 2003, J BIOL CHEM, V278, P33492, DOI 10.1074/jbc.M302401200; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; SUI AL, 1994, NEUROCHEM RES, V19, P753, DOI 10.1007/BF00967716; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Torihashi S, 2002, J BIOL CHEM, V277, P19191, DOI 10.1074/jbc.M201728200; Trevino CL, 2001, FEBS LETT, V509, P119, DOI 10.1016/S0014-5793(01)03134-9; Trost C, 2001, BIOCHEM J, V355, P663, DOI 10.1042/bj3550663; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vogler O, 1999, J PHARMACOL EXP THER, V288, P36; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; WenzelSeifert K, 1996, BIOCHEM J, V314, P679, DOI 10.1042/bj3140679; Xu XZS, 2003, CELL, V114, P285, DOI 10.1016/S0092-8674(03)00565-8; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	61	147	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7241	7246		10.1074/jbc.M312042200	http://dx.doi.org/10.1074/jbc.M312042200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662757	hybrid			2022-12-27	WOS:000188969200125
J	Varadan, R; Assfalg, M; Haririnia, A; Raasi, S; Pickart, C; Fushman, D				Varadan, R; Assfalg, M; Haririnia, A; Raasi, S; Pickart, C; Fushman, D			Solution conformation of Lys(63)-linked di-ubiquitin chain provides clues to functional diversity of polyubiquitin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; MULTIUBIQUITIN CHAIN; MEMBRANE-PROTEIN; BINDING; DOMAIN; PROTEOLYSIS; INHIBITION; VALIDATION; PROTEASOME; RELAXATION	Diverse cellular events are regulated by post-translational modification of substrate proteins via covalent attachment of one or a chain of ubiquitin molecules. The outcome of (poly)ubiquitination depends upon the specific lysine residues involved in the formation of polyubiquitin chains. Lys(48)-linked chains act as a universal signal for proteasomal degradation, whereas Lys(63)-linked chains act as a specific signal in several nondegradative processes. Although it has been anticipated that functional diversity between alternatively linked polyubiquitin chains relies on linkage-dependent differences in chain conformation/topology, direct structural evidence in support of this model has been lacking. Here we use NMR methods to determine the structure of a Lys(63)-linked di-ubiquitin chain. The structure is characterized by an extended conformation, with no direct contact between the hydrophobic residues Leu(8), Ile(44), and Val(70) on the ubiquitin units. This structure contrasts with the closed conformation observed for Lys(48)- linked di-ubiquitin wherein these residues form the interdomain interface (Cook, W. J., Jeffrey, L. C., Carson, M., Zhijian, C., and Pickart, C. M. (1992) J. Biol. Chem. 267, 16467-16471; Varadan, R., Walker, O., Pickart, C., and Fushman, D. (2002) J. Mol. Biol. 324, 637-647). Consistent with the open conformation of the Lys(63)-linked di-ubiquitin, our binding studies show that both ubiquitin domains in this chain can bind a ubiquitin-associated domain from HHR23A independently and in a mode similar to that for mono-ubiquitin. In contrast, Lys(48)- linked di-ubiquitin binds in a different, higher affinity mode that has yet to be determined. This is the first experimental evidence that alternatively linked polyubiquitin chains adopt distinct conformations.	Univ Maryland, Dept Chem & Biochem, Ctr Biomol Struct & Org, College Pk, MD 20742 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	University System of Maryland; University of Maryland College Park; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Fushman, D (corresponding author), Univ Maryland, Dept Chem & Biochem, Ctr Biomol Struct & Org, 1115 Agr Life Sci Surge Bldg, College Pk, MD 20742 USA.	fushman@wam.umd.edu		Assfalg, Michael/0000-0001-9331-3169	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065334, R01GM060372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60372, GM65334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P850; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHOSE R, 2001, J MAGN RESON, V149, P214; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; COOK WJ, 1992, J BIOL CHEM, V267, P16467; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fushman D, 1999, BIOCHEMISTRY-US, V38, P10225, DOI 10.1021/bi990897g; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hall JB, 2003, J BIOMOL NMR, V27, P261, DOI 10.1023/A:1025467918856; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	39	264	271	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7055	7063		10.1074/jbc.M309184200	http://dx.doi.org/10.1074/jbc.M309184200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645257	hybrid			2022-12-27	WOS:000188969200103
J	Biasio, W; Chang, T; McIntosh, CJ; McDonald, FJ				Biasio, W; Chang, T; McIntosh, CJ; McDonald, FJ			Identification of Murr1 as a regulator of the human delta epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; LIDDLES-SYNDROME; COPPER TOXICOSIS; BETA-SUBUNIT; GAMMA-SUBUNIT; SYNTAXIN 1A; HYPERTENSION; PROTEIN; GENE; EXPRESSION	The human delta epithelial sodium channel (deltaENaC) subunit is related to the alpha-, beta-, and gammaENaC subunits that control salt homeostasis. deltaENaC forms an amiloride-sensitive Na+ channel with the beta and gamma subunits. However, the in vivo function of deltaENaC is not known. To gain insight into the function of deltaENaC, a yeast two-hybrid screen of a human brain cDNA library was carried out using the C- and N-terminal domains of deltaENaC. A novel deltaENaC-interacting protein called Murr1 (mouse U2af1-rs1 region) was isolated in the C- terminal domain screen. Murr1 is a 21-kDa protein mutated in Bedlington terriers suffering from copper toxicosis. The interaction of Murr1 and deltaENaC was confirmed by glutathione S-transferase pulldown assay and coimmunoprecipitation. To test the functional significance of the interaction, Murr1 was coexpressed with deltabetagammaENaC in Xenopus oocytes. Murr1 inhibited amiloride-sensitive sodium current in a dose-dependent manner. In addition, deletion of the last 59 amino acids of deltaENaC abolished the inhibition. Murr1 also bound to the beta- and gammaENaC subunits and inhibited alphabetagammaENaC sodium current. Therefore, these results suggest that Murr1 is a novel regulator of ENaC.	Univ Otago, Dept Physiol, Dunedin 9001, New Zealand; Univ Victoria, Sch Biol Sci, Wellington 6004, New Zealand	University of Otago; Victoria University Wellington	McDonald, FJ (corresponding author), Univ Otago, Dept Physiol, POB 913, Dunedin 9001, New Zealand.	fiona.mcdonald@stonebow.otago.ac.nz						Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; Brockway LM, 2002, AM J PHYSIOL-CELL PH, V283, pC126, DOI 10.1152/ajpcell.00457.2001; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Condliffe SB, 2003, J BIOL CHEM, V278, P12796, DOI 10.1074/jbc.M210772200; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Handy RD, 2002, BBA-BIOMEMBRANES, V1566, P104, DOI 10.1016/S0005-2736(02)00590-4; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; JOHNSON GF, 1981, HEPATOLOGY, V1, P243, DOI 10.1002/hep.1840010309; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Muller T, 2003, J HEPATOL, V38, P164, DOI 10.1016/S0168-8278(02)00356-2; Nabetani A, 1997, MOL CELL BIOL, V17, P789, DOI 10.1128/MCB.17.2.789; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tao TY, 2003, J BIOL CHEM, V278, P41593, DOI 10.1074/jbc.C300391200; van de Sluis B, 2002, HUM MOL GENET, V11, P165, DOI 10.1093/hmg/11.2.165; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	32	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5429	5434		10.1074/jbc.M311155200	http://dx.doi.org/10.1074/jbc.M311155200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645214	hybrid			2022-12-27	WOS:000188776500049
J	Ward, CW; Feng, W; Tu, JC; Pessah, IN; Worley, PK; Schneider, MF				Ward, CW; Feng, W; Tu, JC; Pessah, IN; Worley, PK; Schneider, MF			Homer protein increases activation of Ca2+ sparks in permeabilized skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CALCIUM-RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; IP3 RECEPTORS; COMPLEX; MODULATION; CALMODULIN; BINDING; FROG	Members of the Homer family of proteins are known to form multimeric complexes capable of cross-linking plasma membrane channels (e.g. metabotropic glutamate receptor) and intracellular Ca2+ release channels (e.g. inositol trisphosphate receptor) in neurons, which potentiates Ca2+ release. Recent work has demonstrated direct interaction of Homer proteins with type 1 and type 2 ryanodine receptor (RyR) isoforms. Moreover, Homer proteins have been shown to modulate RyR-dependent Ca2+ release in isolated channels as well as in whole cell preparations. We now show that long and short forms of Homer H1 (H1c and H1-EVH1) are potent activators of Ca2+ release via RyR in skeletal muscle fibers (e.g. Ca-2_ sparks) and potent modulators of ryanodine binding to membranes enriched with RyR, with H1c being significantly more potent than H1-EVH1. Homer did not significantly alter the spatio-temporal properties of the sparks, demonstrating that Homer increases the rate of opening of RyRs, with no change in the overall RyR channel open time and amount of Ca2+ released during a spark. No changes in Ca2+ spark frequency or properties were observed using a full-length H1c with mutation in the EVH1 binding domain (H1c-G89N). One novel finding with each Homer agonist (H1c and H1-EVH1) was that in combination their actions on [3H]ryanodine binding was additive, an effect also observed for these Homer agonists in the Ca2+ spark studies. Finally, in Ca2+ spark studies, excess H1c-G89N prevented the effects of H1c in a dominant negative manner. Taken together our results suggest that the EVH1 domain is critical for the agonist behavior on Ca2+ sparks and ryanodine binding, and that the coiled-coil domain, present in long but not short form Homer, confers an increase in agonist potential apparently through the multimeric association of Homer ligand.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Sch Nursing, Dept Syst & Adult Hlth, Baltimore, MD 21201 USA; Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of California System; University of California Davis; Johns Hopkins University	Schneider, MF (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St Rm 229, Baltimore, MD 21201 USA.	mschneid@umaryland.edu	Pessah, Isaac N/K-7985-2017	Pessah, Isaac N/0000-0002-8149-588X				Beneken J, 2000, NEURON, V26, P143, DOI 10.1016/S0896-6273(00)81145-9; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Hwang SY, 2003, CELL CALCIUM, V34, P177, DOI 10.1016/S0143-4160(03)00082-4; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kammermeier PJ, 2000, J NEUROSCI, V20, P7238; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, BIOCHEM BIOPH RES CO, V139, P235, DOI 10.1016/S0006-291X(86)80104-8; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sandona D, 2000, BIOCHEM BIOPH RES CO, V279, P348, DOI 10.1006/bbrc.2000.3948; Schneider MF, 1999, J GEN PHYSIOL, V113, P365, DOI 10.1085/jgp.113.3.365; Schneider MF, 2002, FRONT BIOSCI-LANDMRK, V7, pD1212, DOI 10.2741/schneide; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; Shtifman A, 2000, BIOPHYS J, V79, P814, DOI 10.1016/S0006-3495(00)76338-7; Shtifman A, 2002, J GEN PHYSIOL, V119, P15, DOI 10.1085/jgp.119.1.15; Soloviev MM, 2000, EUR J BIOCHEM, V267, P634, DOI 10.1046/j.1432-1327.2000.01078.x; Tang W, 2002, FRONT BIOSCI, V7, pD1583, DOI 10.2741/tang; Thomas U, 2002, J NEUROCHEM, V81, P407, DOI 10.1046/j.1471-4159.2002.00869.x; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TSUCHIYA T, 1988, BIOPHYS J, V53, P415, DOI 10.1016/S0006-3495(88)83118-7; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Wagenknecht T, 2002, FRONT BIOSCI, V7, pD1464, DOI 10.2741/wagen; Ward CW, 2003, FASEB J, V17, P1517, DOI 10.1096/fj.02-1083fje; Westhoff JH, 2003, CELL CALCIUM, V34, P261, DOI 10.1016/S0143-4160(03)00112-X; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	38	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5781	5787		10.1074/jbc.M311422200	http://dx.doi.org/10.1074/jbc.M311422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660561	hybrid			2022-12-27	WOS:000188776500092
J	Liu, LP; Hachey, DL; Valadez, G; Williams, KM; Guengerich, FP; Loktionova, NA; Kanugula, S; Pegg, AE				Liu, LP; Hachey, DL; Valadez, G; Williams, KM; Guengerich, FP; Loktionova, NA; Kanugula, S; Pegg, AE			Characterization of a mutagenic DNA adduct formed from 1,2-dibromoethane by O-6-alkylguanine-DNA alkyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN O(6)-ALKYLGUANINE-DNA ALKYLTRANSFERASE; MAMMALIAN GLUTATHIONE TRANSFERASES; ESCHERICHIA-COLI; ETHYLENE DIBROMIDE; ALKYLATING-AGENTS; EXCISION-REPAIR; CONJUGATION; BINDING; DIBROMOALKANES; BACTERIAL	It has been proposed that the DNA repair protein O-6-alkylguanine-DNA alkyltransferase increases the mutagenicity of 1,2-dibromoethane by reacting with it at its cysteine acceptor site to form a highly reactive half-mustard, which can then react with DNA (Liu, L., Pegg, A. E., Williams, K. M., and Guengerich, F. P. (2002) J. Biol. Chem. 277, 37920-37928). Incubation of Escherichia coli-expressed human alkyltransferase with 1,2-dibromoethane and single-stranded oligodeoxyribonucleotides led to the formation of covalent transferaseoligo complexes. The order of reaction determined was Gua>Thy>Cyt>Ade. Mass spectrometry analysis of the tryptic digest of the reaction product indicated that some of the adducts led to depurination with the release of the Gly(136)-Arg(147) peptide cross-linked to a Gua at the N-7 position, with the site of reaction being the active site Cys(145) as established by chromatographic retention time and the fragmentation pattern determined by tandem mass spectrometry of a synthetic peptide adduct. The alkyltransferase-mediated mutations produced by 1,2-dibromoethane were predominantly Gua to Ade transitions but, in the spectrum of such rifampicin-resistant mutations in the RpoB gene, 20% were Gua to Thy transversions. The latter are likely to have arisen from the apurinic site generated from the Gua-N-7 adduct. Support exists for an additional adduct/mutagenic pathway because evidence was obtained for DNA adducts other than at the Gua N-7 atom and for mutations other than those attributable to depurination. Thus, chemical and biological evidence supports the existence of at least two alkyltransferase-dependent pathways for 1,2-dibromoethane-induced mutagenicity, one involving Gua N-7-alkylation by alkyltransferase-S-CH2CH2Br and depurination, plus another as yet uncharacterized system(s).	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Vanderbilt University; Vanderbilt University	Pegg, AE (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.	apegg@psu.edu	Williams, Kevin/C-3804-2011	Williams, Kevin/0000-0003-4019-8528	NCI NIH HHS [R01 CA18137] Funding Source: Medline; NIEHS NIH HHS [R01 ES10546, T32 ES07028, P30 ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007028, R01ES010546, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abril N, 1997, CARCINOGENESIS, V18, P1883, DOI 10.1093/carcin/18.10.1883; Abril N, 2001, MUTAT RES-GEN TOX EN, V497, P111, DOI 10.1016/S1383-5718(01)00235-2; ABRIL N, 1995, MOL CARCINOGEN, V12, P110, DOI 10.1002/mc.2940120208; Abril N, 1999, CARCINOGENESIS, V20, P2089, DOI 10.1093/carcin/20.11.2089; Abril N, 1999, CHEM RES TOXICOL, V12, P544, DOI 10.1021/tx980250h; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; Bridges BA, 1999, CURR BIOL, V9, pR475, DOI 10.1016/S0960-9822(99)80299-1; CMARIK JL, 1992, J BIOL CHEM, V267, P6672; Crone TM, 1996, MUTAT RES-DNA REPAIR, V363, P15, DOI 10.1016/0921-8777(95)00058-5; Daniels DS, 2000, EMBO J, V19, P1719, DOI 10.1093/emboj/19.7.1719; FOSTER PL, 1988, MUTAT RES, V194, P171, DOI 10.1016/0167-8817(88)90019-3; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Garibyan L, 2003, DNA REPAIR, V2, P593, DOI 10.1016/S1568-7864(03)00024-7; Goodtzova K, 1998, BIOCHEMISTRY-US, V37, P12489, DOI 10.1021/bi9811718; GORDON AJE, 1990, MUTAT RES, V233, P95, DOI 10.1016/0027-5107(90)90154-V; Guengerich FP, 2003, BIOCHEMISTRY-US, V42, P10965, DOI 10.1021/bi034937z; HUMPHREYS WG, 1990, BIOCHEMISTRY-US, V29, P10342, DOI 10.1021/bi00497a008; Kim MS, 1998, CHEM RES TOXICOL, V11, P311, DOI 10.1021/tx970206m; KOGA N, 1986, BIOCHEMISTRY-US, V25, P2192, DOI 10.1021/bi00356a051; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LETZ GA, 1984, JAMA-J AM MED ASSOC, V252, P2428, DOI 10.1001/jama.252.17.2428; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Liu H, 2000, MUTAT RES-FUND MOL M, V452, P1, DOI 10.1016/S0027-5107(00)00062-2; Liu LP, 2002, CANCER RES, V62, P3037; Liu LP, 2002, J BIOL CHEM, V277, P37920, DOI 10.1074/jbc.M205548200; MANIATIS T, 1982, MOL CLONING LABORATO, P440; MATTES WB, 1986, NUCLEIC ACIDS RES, V14, P2971, DOI 10.1093/nar/14.7.2971; Mortelmans K, 2000, MUTAT RES-FUND MOL M, V455, P29, DOI 10.1016/S0027-5107(00)00064-6; OLSON WA, 1973, JNCI-J NATL CANCER I, V51, P1993, DOI 10.1093/jnci/51.6.1993; OZAWA N, 1983, P NATL ACAD SCI-BIOL, V80, P5266, DOI 10.1073/pnas.80.17.5266; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; PETERSON LA, 1988, J AM CHEM SOC, V110, P3284, DOI 10.1021/ja00218a045; Pieper RO, 1997, PHARMACOL THERAPEUT, V74, P285, DOI 10.1016/S0163-7258(97)00003-X; RANNUG U, 1980, MUTAT RES, V76, P269, DOI 10.1016/0165-1110(80)90020-2; Rasimas JJ, 2003, J BIOL CHEM, V278, P7973, DOI 10.1074/jbc.M211854200; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; Samson L, 1997, CARCINOGENESIS, V18, P919, DOI 10.1093/carcin/18.5.919; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; Spratt TE, 1999, BIOCHEMISTRY-US, V38, P6801, DOI 10.1021/bi982908w; VANBLADEREN PJ, 1980, BIOCHEM PHARMACOL, V29, P2975, DOI 10.1016/0006-2952(80)90047-7; VANBLADEREN PJ, 1980, MUTAT RES, V74, P341, DOI 10.1016/0165-1161(80)90192-2; VANBLADEREN PJ, 1981, CARCINOGENESIS, V2, P499; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Wheeler JB, 2001, CHEM RES TOXICOL, V14, P1107, DOI 10.1021/tx0100183; Wheeler JB, 2001, CHEM RES TOXICOL, V14, P1118, DOI 10.1021/tx010019v; Wibley JEA, 2000, NUCLEIC ACIDS RES, V28, P393, DOI 10.1093/nar/28.2.393; Xu-Welliver M, 1998, CANCER RES, V58, P1936; YAMADA M, 1995, J BACTERIOL, V177, P1511, DOI 10.1128/jb.177.6.1511-1519.1995	48	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4250	4259		10.1074/jbc.M311105200	http://dx.doi.org/10.1074/jbc.M311105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645247	hybrid			2022-12-27	WOS:000188554300042
J	Ruefli-Brasse, AA; Lee, WP; Hurst, S; Dixit, VM				Ruefli-Brasse, AA; Lee, WP; Hurst, S; Dixit, VM			Rip2 participates in Bcl10 signaling and T-cell receptor-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; IMMUNE-RESPONSES; LYMPHOCYTE-ACTIVATION; MALT LYMPHOMA; CARMA1; KINASE; REGULATOR; CARD11; PHOSPHORYLATION; IDENTIFICATION	Engagement of the T-cell receptor (TCR) initiates a signaling cascade that ultimately results in activation of the transcription factor NF-kappaB, which regulates many T-cell functions including proliferation, differentiation and cytokine production. Herein we demonstrate that Rip2, a caspase recruitment domain (CARD)-containing serine/threonine kinase, plays an important role in this cascade and is required for optimal TCR signaling and NF-kappaB activation. Following TCR engagement, Rip2 associated with Bcl10, a CARD-containing signaling component of the TCR-induced NF-kappaB pathway, and induced its phosphorylation. Rip2-deficient mice were defective in TCR-induced NF-kappaB activation, interleukin-2 production, and proliferation in vitro and exhibited defective T-cell-dependent responses in vivo. The defect in Rip2(-/-) T-cells correlated with a lack of TCR-induced Bcl10 phosphorylation. Furthermore, deficiency in Bcl10-dependent NF-kappaB activation could be rescued in Rip2(-/-) embryonic fibroblasts by exogenous wild-type Rip2 but not a kinase-dead mutant. Together these data define an important role for Rip2 in TCR-induced NF-kappaB activation and T-cell function and highlight the significance of post-translational modification of Bcl10 by Rip2 in T-cell signaling.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,Mail Stop 40, San Francisco, CA 94080 USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Mak TW, 2002, NATURE, V418, P835, DOI 10.1038/418835a; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thome M, 2001, J CELL BIOL, V152, P1115, DOI 10.1083/jcb.152.5.1115; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287	24	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	2004	279	2					1570	1574		10.1074/jbc.C300460200	http://dx.doi.org/10.1074/jbc.C300460200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	759DJ	14638696	hybrid			2022-12-27	WOS:000187722800090
J	Mehta, A; Shaha, C				Mehta, A; Shaha, C			Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition - Complex II inhibition results in increased pentamidine cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ROTENONE-INDUCED APOPTOSIS; PARASITE LEISHMANIA; ELECTRON-TRANSPORT; OXIDATIVE STRESS; SH-SY5Y CELLS; HL-60 CELLS; ANTIMYCIN-A; MITOCHONDRIA; ACTIVATION	The biochemical changes consequent to respiratory chain inhibition and their relationship to cell death in Leishmania spp. remain elusive. Inhibitors of respiratory chain complexes I, II, and III were able to induce apoptotic death of the bloodstream form of Leishmania donovani. Complex I inhibition resulted in mitochondrial hyperpolarization that was preceded by increased superoxide production. Limitation of electron transport by thenoyltrifluoroacetone and antimycin A, inhibitors of complexes II and III, respectively, resulted in dissipation of mitochondrial membrane potential that was sensitive to cyclosporin A, a blocker of mitochondrial permeability transition pore. Further studies conducted with thenoyltrifluoroacetone showed maximal generation of hydrogen peroxide with a moderate elevation of superoxide levels. Complex III inhibition provoked superoxide generation only. Interference with complex II but not complexes I and III increased intracellular Ca2+. A tight link between Ca2+ and reactive oxygen species was demonstrated by antioxidant-induced diminution of the Ca2+ increase. However, chelation of extracellular Ca2+ could not abrogate the early increase of reactive oxygen species, providing evidence that Ca2+ elevation was downstream to reactive oxygen species generation. Ca2+ influx occurred through nonselective cation and L-type channels and Na+/Ca2+ exchanger-like pathways. Antioxidants such as glutathione and Ca2+ channel blockers reduced apoptotic death. This study provides a new possibility that concurrent inhibition of respiratory chain complex II with pentamidine administration increases cytotoxicity of the drug. This increased cytotoxicity was connected to a 4-fold elevation in intracellular Ca2+ that was pooled only from intracellular sources. Therefore, inhibition of complexes I, II, and III leads to apoptosis and complex II inhibition in parallel with pentamidine administration-enhanced drug efficacy.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Shaha, C (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	cshaha@nii.res.in	Mehta, Ashish/A-5537-2011	Mehta, Ashish/0000-0002-0187-4477				Armstrong JS, 2001, BIOCHEM BIOPH RES CO, V289, P973, DOI 10.1006/bbrc.2001.6054; Arnoult D, 2002, CELL DEATH DIFFER, V9, P65, DOI 10.1038/sj.cdd.4400951; Barbu A, 2002, MOL CELL ENDOCRINOL, V190, P75, DOI 10.1016/S0303-7207(02)00009-6; Basselin M, 1997, PARASITOL RES, V83, P413, DOI 10.1007/s004360050274; Bermudez R, 1997, MOL BIOCHEM PARASIT, V90, P43, DOI 10.1016/S0166-6851(97)00131-X; Bray PG, 2003, TRENDS PARASITOL, V19, P232, DOI 10.1016/S1471-4922(03)00069-2; Brill LB, 2003, EXP NEUROL, V181, P25, DOI 10.1016/S0014-4886(02)00045-6; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Chinopoulos C, 2000, J NEUROSCI, V20, P2094; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROFT SL, 1982, ANN TROP MED PARASIT, V76, P37, DOI 10.1080/00034983.1982.11687502; Das M, 2001, J CELL SCI, V114, P2461; Datta G, 2000, INDIAN J MED RES, V112, P15; de Graaf AO, 2002, BBA-BIOENERGETICS, V1554, P57, DOI 10.1016/S0005-2728(02)00213-X; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Dvorakova K, 2001, BLOOD, V97, P3544, DOI 10.1182/blood.V97.11.3544; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kalbacova M, 2003, CYTOM PART A, V52A, P110, DOI 10.1002/cyto.a.10031; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x; King MA, 2002, CYTOMETRY, V49, P106, DOI 10.1002/cyto.10156; Kitamura Y, 2002, NEUROSCI LETT, V333, P25, DOI 10.1016/S0304-3940(02)00964-3; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lee N, 2002, CELL DEATH DIFFER, V9, P53, DOI 10.1038/sj.cdd.4400952; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; Matsunaga T, 1996, LEUKEMIA LYMPHOMA, V20, P487, DOI 10.3109/10428199609052434; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Mukherjee SB, 2002, J BIOL CHEM, V277, P24717, DOI 10.1074/jbc.M201961200; MUTURINJOGU R, 1980, MOL BIOCHEM PARASIT, V1, P13, DOI 10.1016/0166-6851(80)90038-9; Opuni K, 2000, J BIOL CHEM, V275, P21549, DOI 10.1074/jbc.M003158200; Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6; Pei W, 2003, FASEB J, V17, P520, DOI 10.1096/fj.02-0653fje; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P2064, DOI 10.1128/AAC.45.7.2064-2069.2001; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; Sudhandiran G, 2003, J BIOL CHEM, V278, P25120, DOI 10.1074/jbc.M301975200; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; Yuhki K, 2001, J CARDIOVASC PHARM, V38, P850, DOI 10.1097/00005344-200112000-00006; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zangger H, 2002, CELL DEATH DIFFER, V9, P1126, DOI 10.1038/sj.cdd.4401071	52	157	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11798	11813		10.1074/jbc.M309341200	http://dx.doi.org/10.1074/jbc.M309341200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14679210	hybrid			2022-12-27	WOS:000220157600117
J	Qin, HJ; Percival-Smith, A; Li, CJ; Jia, CYH; Gloor, G; Li, SSC				Qin, HJ; Percival-Smith, A; Li, CJ; Jia, CYH; Gloor, G; Li, SSC			A novel transmembrane protein recruits numb to the plasma membrane during asymmetric cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; FATE DETERMINANT NUMB; DROSOPHILA-MELANOGASTER; NOTCH RECEPTOR; DAUGHTER CELL; PTB DOMAIN; LOCALIZATION; POLARITY; COMPLEX; PROSPERO	Numb, an evolutionarily conserved cell fate-determining factor, plays a pivotal role in the development of Drosophila and vertebrate nervous systems. Despite lacking a transmembrane segment, Numb is associated with the cell membrane during the asymmetric cell division of Drosophila neural precursor cells and is selectively partitioned to one of the two progeny cells from a binary cell division. Numb contains an N-terminal phosphotyrosine-binding (PTB) domain that is essential for both the asymmetric localization and the fate specification function of Numb. We report here the isolation and characterization of a novel PTB domain-binding protein, NIP (Numb-interacting protein). NIP is a multipass transmembrane protein that contains two PTB domain-binding, NXXF motifs required for the interaction with Numb. In dividing Drosophila neuroblasts, NIP is colocalized to the cell membrane with Numb in a basal cortical crescent. Expression of NIP in Cos-7 cells recruited Numb from the cytosol to the plasma membrane. This recruitment of Numb to membrane by NIP was dependent on the presence of at least one NXXF site. In Drosophila Schneider 2 cells, NIP and Numb were colocalized at the plasma membrane. Inhibition of NIP expression by RNA interference released Numb to the cytosol. These results suggest that a direct protein-protein interaction between NIP and Numb is necessary and sufficient for the recruitment of Numb to the plasma membrane. Recruitment of Numb to a basal cortical crescent in a dividing neuroblast is essential for Numb to function as an intrinsic cell fate determinant.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Li, SSC (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sli@uwo.ca	Gloor, Greg B/D-1671-2013	Gloor, Gregory/0000-0001-5803-3380				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Frank R, 2002, J IMMUNOL METHODS, V267, P13, DOI 10.1016/S0022-1759(02)00137-0; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; Kilpartick GJ, 1999, TRENDS PHARMACOL SCI, V20, P294, DOI 10.1016/S0165-6147(99)01355-3; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Knoblich JA, 1997, P NATL ACAD SCI USA, V94, P13005, DOI 10.1073/pnas.94.24.13005; KNOBLICH JA, 1994, CELL, V76, P477; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Li CJ, 2003, J BIOL CHEM, V278, P3852, DOI 10.1074/jbc.M206649200; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qin HJ, 2001, J PATHOL, V195, P604, DOI 10.1002/path.994; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Schaefer M, 2001, EXP CELL RES, V271, P66, DOI 10.1006/excr.2001.5371; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3489; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Wakamatsu Y, 2000, DEVELOPMENT, V127, P2811; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; Wodarz A, 2000, J CELL BIOL, V150, P1361, DOI 10.1083/jcb.150.6.1361; Yaich L, 1998, J BIOL CHEM, V273, P10381, DOI 10.1074/jbc.273.17.10381; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zwahlen C, 2000, EMBO J, V19, P1505, DOI 10.1093/emboj/19.7.1505	58	29	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11304	11312		10.1074/jbc.M311733200	http://dx.doi.org/10.1074/jbc.M311733200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14670962	hybrid			2022-12-27	WOS:000220157600058
J	Stone, SJ; Myers, HM; Watkins, SM; Brown, BE; Feingold, KR; Elias, PM; Farese, RV				Stone, SJ; Myers, HM; Watkins, SM; Brown, BE; Feingold, KR; Elias, PM; Farese, RV			Lipopenia and skin barrier abnormalities in DGAT2-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-DIACYLGLYCEROL ACYLTRANSFERASE-1; FATTY-ACID DEFICIENCY; WHITE ADIPOSE-TISSUE; MONOACYLGLYCEROL ACYLTRANSFERASE; PERMEABILITY BARRIER; EMBRYONIC LETHALITY; LEPTIN SENSITIVITY; OBESITY RESISTANCE; APOLIPOPROTEIN-B; STRATUM-CORNEUM	synthesis of triglycerides is catalyzed by two known acyl-CoA:diacylglycerol acyltransferase (DGAT) enzymes. Although they catalyze the same biochemical reaction, these enzymes share no sequence homology, and their relative functions are poorly understood. Gene knockout studies in mice have revealed that DGAT1 contributes to triglyceride synthesis in tissues and plays an important role in regulating energy metabolism but is not essential for life. Here we show that DGAT2 plays a fundamental role in mammalian triglyceride synthesis and is required for survival. DGAT2-deficient (Dgat2(-/-)) mice are lipopenic and die soon after birth, apparently from profound reductions in substrates for energy metabolism and from impaired permeability barrier function in the skin. DGAT1 was unable to compensate for the absence of DGAT2, supporting the hypothesis that the two enzymes play fundamentally different roles in mammalian triglyceride metabolism.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94121 USA; Lip Technol, W Sacramento, CA 95691 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA.	bfarese@gladstone.ucsf.edu			NIDDK NIH HHS [DK56084, R01 DK056084] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056084, R56DK056084] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Burr GO, 1929, J BIOL CHEM, V82, P345; Cao JS, 2003, J BIOL CHEM, V278, P25657, DOI 10.1074/jbc.M302835200; Cao JS, 2003, J BIOL CHEM, V278, P13860, DOI 10.1074/jbc.M300139200; Cartlidge P, 2000, Semin Neonatol, V5, P273, DOI 10.1053/siny.2000.0013; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2003, J CLIN INVEST, V111, P1715, DOI [10.1172/JCI15859, 10.1172/JCI200315859]; Chen HC, 2002, DIABETES, V51, P3189, DOI 10.2337/diabetes.51.11.3189; Chen HC, 2002, J CLIN INVEST, V109, P175, DOI 10.1172/JCI0213880; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Chen HC, 2002, ENDOCRINOLOGY, V143, P2893, DOI 10.1210/en.143.8.2893; Cheng D, 2003, J BIOL CHEM, V278, P13611, DOI 10.1074/jbc.C300042200; ELIAS PM, 1980, J INVEST DERMATOL, V74, P230, DOI 10.1111/1523-1747.ep12541775; ELIAS PM, 1978, LAB INVEST, V39, P574; Farese RV, 1996, J LIPID RES, V37, P347; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRUBAUER G, 1989, J LIPID RES, V30, P323; GUNSTONE FD, 1994, LIPID HDB, P646; HOLLERAN WM, 1991, J CLIN INVEST, V88, P1338, DOI 10.1172/JCI115439; Holt RIG, 2002, TRENDS ENDOCRIN MET, V13, P392, DOI 10.1016/S1043-2760(02)00697-5; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI200213563; Lockwood JF, 2003, AM J PHYSIOL-ENDOC M, V285, pE927, DOI 10.1152/ajpendo.00179.2003; MADISON KC, 1987, J INVEST DERMATOL, V88, P714, DOI 10.1111/1523-1747.ep12470386; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Oelkers P, 2002, J BIOL CHEM, V277, P8877, DOI 10.1074/jbc.M111646200; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Unger RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6; Wakimoto K, 2003, BIOCHEM BIOPH RES CO, V310, P296, DOI 10.1016/j.bbrc.2003.09.015; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Watkins SM, 2001, LIPIDS, V36, P247, DOI 10.1007/s11745-001-0714-8; WERTZ PW, 1990, J LIPID RES, V31, P1839; Yen CLE, 2003, J BIOL CHEM, V278, P18532, DOI 10.1074/jbc.M301633200; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; Zhang Q, 2003, J BIOL CHEM, V278, P47145, DOI 10.1074/jbc.M306998200	46	442	486	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11767	11776		10.1074/jbc.M311000200	http://dx.doi.org/10.1074/jbc.M311000200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14668353	hybrid			2022-12-27	WOS:000220157600114
J	Cui, DY; Brown, CR; Chiang, HL				Cui, DY; Brown, CR; Chiang, HL			The type 1 phosphatase Reg1p-Glc7p is required for the glucoseinduced degradation of fructose-1,6-bisphosphatase in the vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CARBON CATABOLITE REPRESSION; CELL-CYCLE PROGRESSION; SNF1 PROTEIN-KINASE; MEMBRANE-FUSION; GENETIC INTERACTIONS; REGULATORY SUBUNITS; DEFICIENT MUTANTS; PEPTIDE SEQUENCES; CATALYTIC SUBUNIT	Protein phosphatases play an important role in vesicular trafficking and membrane fusion processes. The type 1 phosphatase Glc7p and its regulatory subunit Reg1p were identified as required components in the glucose-induced targeting of the key gluconeogenic enzyme fructose-1,6-bisphosphatase (FBPase) to the vacuole for degradation. The interaction of Reg1p with Glc7p was important for the transport of FBPase from intermediate vacuole import and degradation (Vid) vesicles to vacuoles. The glc7-T152K mutant strain exhibited a reduced Reg1p binding along with defects in FBPase degradation and Vid vesicle trafficking to the vacuole. In this mutant, Vid vesicles were the most defective components, whereas the vacuole was also defective. Shp1p and Glc8p regulate Glc7p phosphatase activity and are required for FBPase degradation. In the Deltashp1 and Deltaglc8 strains, Reg1p-Glc7p interaction was not affected, suggesting that phosphatase activity is also necessary for FBPase degradation. Similar to those seen in the glc7-T152K mutant, the Deltashp1 and Deltaglc8 mutants exhibited severely defective Vid vesicles, but partially defective vacuoles. Taken together, our results suggest that Reg1p-Glc7p interaction and Glc7p phosphatase activity play a required role in the Vid vesicle to vacuole-trafficking step along the FBPase degradation pathway.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Brown, CR (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.	crb13@psu.edu			NIGMS NIH HHS [R01GM59480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059480] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarraberes FA, 2001, BBA-BIOMEMBRANES, V1513, P1, DOI 10.1016/S0304-4157(01)00005-3; Baker SH, 1997, GENETICS, V145, P615; Brown CR, 2001, J BIOL CHEM, V276, P48017, DOI 10.1074/jbc.M109222200; Brown CR, 2003, J BIOL CHEM, V278, P25688, DOI 10.1074/jbc.M210549200; Brown CR, 2002, J CELL SCI, V115, P655; Brown CR, 2000, J CELL BIOL, V150, P65, DOI 10.1083/jcb.150.1.65; CANNON JF, 1994, GENETICS, V136, P485; Cheng C, 1997, YEAST, V13, P1; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; Chiang MC, 1998, J CELL BIOL, V140, P1347, DOI 10.1083/jcb.140.6.1347; Cullen PJ, 2002, EUKARYOT CELL, V1, P884, DOI 10.1128/EC.1.6.884-894.2002; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; ENTIAN KD, 1980, MOL GEN GENET, V177, P345, DOI 10.1007/BF00267449; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Frederick DL, 1996, MOL CELL BIOL, V16, P2922; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; Gurunathan S, 2002, MOL BIOL CELL, V13, P1594, DOI 10.1091/mbc.01-11-0541; Hammerle M, 1998, J BIOL CHEM, V273, P25000, DOI 10.1074/jbc.273.39.25000; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hoffman M, 1996, GENETICS, V143, P1555; HOLZER H, 1989, RBC-CELL BIOL REV, V21, P305; Horak J, 2002, J BIOL CHEM, V277, P8248, DOI 10.1074/jbc.M107255200; Huang DQ, 1996, GENETICS, V143, P119; Huang PH, 1997, J CELL BIOL, V136, P803, DOI 10.1083/jcb.136.4.803; Jiang H, 2000, MOL GEN GENET, V263, P411, DOI 10.1007/s004380051185; Jiang Y, 1998, EMBO J, V17, P6942, DOI 10.1093/emboj/17.23.6942; Kholodenko BN, 2002, TRENDS CELL BIOL, V12, P173, DOI 10.1016/S0962-8924(02)02251-1; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kozubowski L, 2003, MOL BIOL CELL, V14, P26, DOI 10.1091/mbc.E02-06-0373; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MATSUMOTO K, 1983, J BACTERIOL, V153, P1405, DOI 10.1128/JB.153.3.1405-1414.1983; NEIGEBORN L, 1987, GENETICS, V115, P247; Nigavekar SS, 2002, ARCH BIOCHEM BIOPHYS, V404, P71, DOI 10.1016/S0003-9861(02)00231-X; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; Shieh HL, 1998, J BIOL CHEM, V273, P3381, DOI 10.1074/jbc.273.6.3381; Shieh HL, 2001, J BIOL CHEM, V276, P10398, DOI 10.1074/jbc.M001767200; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; Suzuki K, 2002, DEV CELL, V3, P815, DOI 10.1016/S1534-5807(02)00359-3; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TU JL, 1994, MOL CELL BIOL, V14, P6789, DOI 10.1128/MCB.14.10.6789; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037	58	18	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9713	9724		10.1074/jbc.M310793200	http://dx.doi.org/10.1074/jbc.M310793200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684743	hybrid			2022-12-27	WOS:000220050400009
J	Oyedotun, KS; Yau, PF; Lemire, BD				Oyedotun, KS; Yau, PF; Lemire, BD			Identification of the heme axial ligands in the cytochrome b(562) of the Saccharomyces cerevisiae succinate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS SUCCINATE; COMPLEX-II SUCCINATE; MEMBRANE-INTEGRAL DOMAIN; QUINONE-BINDING-SITES; FUMARATE REDUCTASE; UBIQUINONE OXIDOREDUCTASE; WOLINELLA-SUCCINOGENES; ESCHERICHIA-COLI; PROTON; BIOENERGETICS	Succinate dehydrogenase (SDH) plays a key role in energy generation by coupling the oxidation of succinate to the reduction of ubiquinone in the mitochondrial electron transport chain. The Saccharomyces cerevisiae SDH is composed of a catalytic dimer of the Sdh1p and Sdh2p subunits containing flavin adenine dinucleotide (FAD) and iron-sulfur clusters and a heme b-containing membrane-anchoring domain comprised of the Sdh3p and Sdh4p subunits. We systematically mutated all the histidine and cysteine residues in Sdh3p and Sdh4p to identify the residues involved in axial heme ligation. The mutants were characterized for growth on a non-fermentable carbon source, for enzyme assembly, for succinate-dependent quinone reduction, for heme b content, and for heme spectral properties. Mutation of Sdh3p His-46 or His-113 leads to a marked reduction in the catalytic efficiency of the enzyme for quinone reduction, suggesting that these residues form part of a quinone-binding site. We identified Sdh3p His-106 and Sdh4p Cys-78 as the most probable axial ligands for cytochrome b(562). Replacement of His-106 or Cys-78 with an alanine residue leads to a marked reduction in cytochrome b(562) content and to altered heme spectral characteristics that are consistent with a direct perturbation of heme b environment. This is the first identification of a cysteine residue serving as an axial ligand for heme b in the SDH family of enzymes. Loss of cytochrome b(562) has no effect on enzyme assembly and quinone reduction; the role of the heme in enzyme structure and function is discussed.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Membrane Prot Res, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Membrane Prot Res, Edmonton, AB T6G 2H7, Canada.	bernard.lemire@ualberta.ca						Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Baysal BE, 2001, J MOL MED, V79, P495, DOI 10.1007/s001090100267; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cecchini G, 2003, FEBS LETT, V545, P31, DOI 10.1016/S0014-5793(03)00390-9; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; CROUSE BR, 1995, FEBS LETT, V367, P1, DOI 10.1016/0014-5793(95)00522-B; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; FRIDEN H, 1990, BIOCHIM BIOPHYS ACTA, V1041, P207, DOI 10.1016/0167-4838(90)90067-P; HAGERHALL C, 1995, BIOCHEMISTRY-US, V34, P11080; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; Hederstedt L, 1998, BIOCHEM SOC T, V26, P408, DOI 10.1042/bst0260408; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; Hederstedt L, 2002, BBA-BIOENERGETICS, V1553, P74, DOI 10.1016/S0005-2728(01)00231-6; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; KITA K, 1989, J BIOL CHEM, V264, P2672; Kroger A, 2002, BBA-BIOENERGETICS, V1553, P23, DOI 10.1016/S0005-2728(01)00234-1; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2002, BBA-BIOMEMBRANES, V1565, P215, DOI 10.1016/S0005-2736(02)00571-0; Lemire BD, 2002, BBA-BIOENERGETICS, V1553, P102, DOI 10.1016/S0005-2728(01)00229-8; Maklashina E, 2001, J BIOL CHEM, V276, P18968, DOI 10.1074/jbc.M011270200; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Ohnishi T, 2000, STRUCTURE, V8, pR23, DOI 10.1016/S0969-2126(00)00098-8; Oyedotun KS, 2004, J BIOL CHEM, V279, P9424, DOI 10.1074/jbc.M311876200; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Oyedotun KS, 2001, J BIOL CHEM, V276, P16936, DOI 10.1074/jbc.M100184200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; Rich P, 1999, BIOCHEM SOC T, V27, P561, DOI 10.1042/bst0270561; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schnorpfeil M, 2001, EUR J BIOCHEM, V268, P3069, DOI 10.1046/j.1432-1327.2001.02202.x; Vibat CRT, 1998, BIOCHEMISTRY-US, V37, P4148, DOI 10.1021/bi9716635; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; YU L, 1987, J BIOL CHEM, V262, P1137	44	21	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9432	9439		10.1074/jbc.M311877200	http://dx.doi.org/10.1074/jbc.M311877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672930	hybrid			2022-12-27	WOS:000189265900109
J	Perron, K; Caille, O; Rossier, C; van Delden, C; Dumas, JL; Kohler, T				Perron, K; Caille, O; Rossier, C; van Delden, C; Dumas, JL; Kohler, T			CzcR-CzcS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-EUTROPHUS CH34; MULTIPLE ANTIBIOTIC-RESISTANCE; MULTIDRUG EFFLUX SYSTEM; GRAM-NEGATIVE BACTERIA; BASIC-AMINO-ACIDS; MEXE-MEXF-OPRN; OUTER-MEMBRANE; HISTIDINE KINASE; ESCHERICHIA-COLI; ZINC	Pseudomonas aeruginosa is an environmental bacterium involved in mineralization of organic matter. It is also an opportunistic pathogen able to cause serious infections in immunocompromised hosts. As such, it is exposed to xenobiotics including solvents, heavy metals, and antimicrobials. We studied the response of P. aeruginosa upon exposure to heavy metals or antibiotics to investigate whether common regulatory mechanisms govern resistance to both types of compounds. We showed that sublethal zinc concentrations induced resistance to zinc, cadmium, and cobalt, while lethal zinc concentrations selected mutants constitutively resistant to these heavy metals. Both zinc-induced and stable zinc-resistant strains were also resistant to the carbapenem antibiotic imipenem. On the other hand, only 20% of clones selected on imipenem were also resistant to zinc. Heavy metal resistance in the mutants could be correlated by quantitative real time PCR with increased expression of the heavy metal efflux pump CzcCBA and its cognate two-component regulator genes czcR-czcS. Western blot analysis revealed reduced expression of the basic amino acid and carbapenem-specific OprD porin in all imipenem-resistant mutants. Sequencing of the czcR-czcS DNA region in eight independent zinc- and imipenem-resistant mutants revealed the presence of the same V194L mutation in the CzcS sensor protein. Overexpression in a susceptible wild type strain of the mutated CzsS protein, but not of the wild type form, resulted in decreased oprD and increased czcC expression. We further show that zinc is released from latex urinary catheters into urine in amounts sufficient to induce carbapenem resistance in P. aeruginosa, possibly compromising treatment of urinary tract infections by this class of antibiotics.	Univ Geneva, Ctr Med Univ, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Ctr Med Univ, Dept Bot & Plant Biol Sci 3, Lab Bacteriol & Microbial Ecol, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva	Kohler, T (corresponding author), Univ Geneva, Ctr Med Univ, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland.	Thilo.Kohler@medecine.unige.ch	Perron, Karl/AAC-3128-2022; Köhler, Thilo/AAN-9498-2021	Perron, Karl/0000-0002-3259-4638				ANDERSEN J, 1990, BIOCHEMISTRY-US, V29, P9249, DOI 10.1021/bi00491a020; Baxter IA, 1997, J ANTIMICROB CHEMOTH, V39, P838, DOI 10.1093/jac/39.6.838; Conejo MC, 2003, ANTIMICROB AGENTS CH, V47, P2313, DOI 10.1128/AAC.47.7.2313-2315.2003; COOPER GL, 1993, J CLIN MICROBIOL, V31, P2366, DOI 10.1128/JCM.31.9.2366-2370.1993; Daly JS, 1997, J CLIN MICROBIOL, V35, P1027, DOI 10.1128/JCM.35.4.1027-1029.1997; DEHAAN KEC, 1990, BURNS, V16, P393, DOI 10.1016/0305-4179(90)90016-P; Delihas N, 2001, J MOL BIOL, V313, P1, DOI 10.1006/jmbi.2001.5029; DEVICENTE A, 1990, J APPL BACTERIOL, V68, P625, DOI 10.1111/j.1365-2672.1990.tb05228.x; Dutta R, 2000, J BIOL CHEM, V275, P38645, DOI 10.1074/jbc.M005872200; Epp SF, 2001, ANTIMICROB AGENTS CH, V45, P1780, DOI 10.1128/AAC.45.6.1780-1787.2001; ESTERLING L, 1994, MOL MICROBIOL, V12, P639, DOI 10.1111/j.1365-2958.1994.tb01051.x; Filali BK, 2000, CURR MICROBIOL, V41, P151, DOI 10.1007/s0028400; FUKUDA H, 1990, ANTIMICROB AGENTS CH, V34, P1757, DOI 10.1128/AAC.34.9.1757; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; HANSON RS, 1981, MANUAL METHODS GENER, P328; Hassan MET, 1999, GENE, V238, P417, DOI 10.1016/S0378-1119(99)00349-2; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; Kohler T, 1999, J BACTERIOL, V181, P6300; Kohler T, 1997, MOL MICROBIOL, V23, P345, DOI 10.1046/j.1365-2958.1997.2281594.x; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; LIESEGANG H, 1993, J BACTERIOL, V175, P767, DOI 10.1128/JB.175.3.767-778.1993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUES AM, 1979, J APPL BACTERIOL, V47, P347, DOI 10.1111/j.1365-2672.1979.tb01765.x; Martinez-Martinez L, 1999, ANTIMICROB AGENTS CH, V43, P397, DOI 10.1128/AAC.43.2.397; Maseda H, 2000, FEMS MICROBIOL LETT, V192, P107, DOI 10.1016/S0378-1097(00)00419-5; MASUDA N, 1992, ANTIMICROB AGENTS CH, V36, P1847, DOI 10.1128/AAC.36.9.1847; Mergeay M, 2003, FEMS MICROBIOL REV, V27, P385, DOI 10.1016/S0168-6445(03)00045-7; MERGEAY M, 1978, CR SOC BIOL, V172, P575; MERGEAY M, 1985, J BACTERIOL, V162, P328, DOI 10.1128/JB.162.1.328-334.1985; NIES D, 1987, J BACTERIOL, V169, P4865, DOI 10.1128/jb.169.10.4865-4868.1987; NIES DH, 1992, J BACTERIOL, V174, P8102, DOI 10.1128/JB.174.24.8102-8110.1992; NIES DH, 1989, J BACTERIOL, V171, P896, DOI 10.1128/jb.171.2.896-900.1989; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ochs MM, 1999, ANTIMICROB AGENTS CH, V43, P1085, DOI 10.1128/AAC.43.5.1085; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; RAMOSAIRES J, 1999, ANTIMICROB AGENTS CH, V43, P2624; Rensing C, 1997, J BACTERIOL, V179, P6871, DOI 10.1128/jb.179.22.6871-6879.1997; Rosenfeld M, 2003, CURR OPIN PULM MED, V9, P492, DOI 10.1097/00063198-200311000-00008; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI DOI 10.1111/J.1365-2958.1994.TB00362.X; Sambrook J., 2001, MOL CLONING LAB MANU; SCHMIDT T, 1994, J BACTERIOL, V176, P7045, DOI 10.1128/JB.176.22.7045-7054.1994; SMITH AW, 1989, NUCLEIC ACIDS RES, V17, P10509, DOI 10.1093/nar/17.24.10509; TALJA M, 1993, ANN CHIR GYNAECOL FE, V82, P74; Tanaka T, 1997, MICROBIOL IMMUNOL, V41, P697, DOI 10.1111/j.1348-0421.1997.tb01913.x; TRIAS J, 1990, J BIOL CHEM, V265, P15680; TRIAS J, 1990, ANTIMICROB AGENTS CH, V34, P52, DOI 10.1128/AAC.34.1.52; Wang CL, 1997, APPL ENVIRON MICROB, V63, P4075, DOI 10.1128/AEM.63.10.4075-4078.1997; YONEYAMA H, 1993, ANTIMICROB AGENTS CH, V37, P2385, DOI 10.1128/AAC.37.11.2385; Yoshida T, 2002, MOL MICROBIOL, V46, P1283, DOI 10.1046/j.1365-2958.2002.03240.x; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808; Zhu Y, 2003, J BIOL CHEM, V278, P22812, DOI 10.1074/jbc.M300916200; Ziha-Zarifi I, 1999, ANTIMICROB AGENTS CH, V43, P287, DOI 10.1128/AAC.43.2.287	57	197	220	7	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8761	8768		10.1074/jbc.M312080200	http://dx.doi.org/10.1074/jbc.M312080200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679195	hybrid			2022-12-27	WOS:000189265900030
J	Caplan, JF; Filipenko, NR; Fitzpatrick, SL; Waisman, DM				Caplan, JF; Filipenko, NR; Fitzpatrick, SL; Waisman, DM			Regulation of annexin A2 by reversible glutathionylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II TETRAMER; PHOSPHOLIPID-BINDING; MEMBRANE INTERACTIONS; S-GLUTATHIOLATION; QUICK-FREEZE; PROTEINS; ACTIN; IDENTIFICATION; AGGREGATION; CELL	The annexin A2-S100A10 heterotetramer (AIIt) is a multifunctional Ca2+-dependent, phospholipid-binding, and F-actin-binding phosphoprotein composed of two annexin A2 subunits and two S100A10 subunits. It was reported previously that oxidative stress from exogenous hydrogen peroxide or generated in response to tumor necrosis factor-alpha results in the glutathionylation of Cys(8) of annexin A2. In this study, we demonstrate that AIIt is an oxidatively labile protein whose level of activity is regulated by the redox status of its sulfhydryl groups. Oxidation of AIIt by diamide resulted in a time- and concentration-dependent loss of the ability of AIIt to interact with phospholipid liposomes and F-actin. The inhibitory effect of diamide on the activity of AIIt was partially reversed by dithiothreitol. In addition, incubation of AIIt with diamide and GSH resulted in the glutathionylation of AIIt in vitro. Mass spectrometry established the incorporation of 2 mol of GSH/mol of annexin A2 subunit at Cys(8) and Cys(132). Glutathionylation potentiated the inhibitory effects of diamide on the activity of AIIt. Furthermore, AIIt could be deglutathionylated by glutaredoxin (thiol transferase). Thus, we show for the first time that AIIt can undergo functional reactivation by glutaredoxin, therefore establishing that AIIt is regulated by reversible glutathionylation.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@ucalgary.ca		Waisman, David/0000-0002-5097-9662				BABIZHAYEV MA, 1990, MECH AGEING DEV, V56, P199, DOI 10.1016/0047-6374(90)90082-Q; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; Choi KS, 2003, MOL B INT U, P218; Choi KS, 2001, J BIOL CHEM, V276, P25212, DOI 10.1074/jbc.M101426200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; Donato R., 1999, Cell Calcium, V26, P85, DOI 10.1054/ceca.1999.0079; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; Filipenko NR, 2003, MOL B INT U, P127; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; Hajjar KA, 1998, J INVEST MED, V46, P364; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; HUBAISHY I, 1995, BIOCHEMISTRY-US, V34, P14527, DOI 10.1021/bi00044a031; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KOSOWER EM, 1972, BIOCHIM BIOPHYS ACTA, V264, P39, DOI 10.1016/0304-4165(72)90114-6; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Kwon M, 2002, J BIOL CHEM, V277, P10903, DOI 10.1074/jbc.M111219200; LIU L, 1995, BBA-LIPID LIPID MET, V1259, P166, DOI 10.1016/0005-2760(95)00159-A; Liu L, 2002, EUR J BIOCHEM, V269, P4277, DOI 10.1046/j.1432-1033.2002.03118.x; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Palmieri SJ, 2000, CELL MOTIL CYTOSKEL, V46, P285, DOI 10.1002/1097-0169(200008)46:4<285::AID-CM6>3.0.CO;2-N; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rowan WH, 2002, BIOCHEMISTRY-US, V41, P1409, DOI 10.1021/bi0119767; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Seaton BA, 1998, BIOMETALS, V11, P399, DOI 10.1023/A:1009205925714; SENDA T, 1994, CELL TISSUE RES, V277, P51; Seres T, 1996, J IMMUNOL, V156, P1973; Singh TK, 2000, ARCH BIOCHEM BIOPHYS, V381, P235, DOI 10.1006/abbi.2000.1994; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Yin HL, 1999, J BIOL CHEM, V274, P32529, DOI 10.1074/jbc.274.46.32529; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	52	73	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7740	7750		10.1074/jbc.M313049200	http://dx.doi.org/10.1074/jbc.M313049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668336	hybrid			2022-12-27	WOS:000189103300047
J	Foukas, LC; Panayotou, G; Shepherd, PR				Foukas, LC; Panayotou, G; Shepherd, PR			Direct interaction of major histocompatibility complex class II-derived peptides with class Ia phosphoinositide 3-kinase results in dose-dependent stimulatory effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; SH2 DOMAINS; REGULATORY SUBUNIT; PI 3-KINASE; INHIBITION; ACTIVATION; KINASE; SITE; RAPAMYCIN; ANTIGENS	Peptides corresponding to residues 65-79 of human lymphocyte antigen class II sequence (DQA*03011) are cell-permeable and at high concentrations block activation of protein kinase B/Akt and p70-S6 kinase in T-cells, effects attributed to inhibition of phosphoinositide (PI) 3-kinase activity. To understand the molecular basis of this, we analyzed the effect this peptide had on activity of class I PI 3-kinases. Although there was no effect on the activity of class Ib PI 3-kinase or on the protein kinase activity of class I PI 3-kinases, there was a biphasic effect on lipid kinase activity of the class Ia enzymes. There was an inhibition of activity at higher peptide concentrations because of a formation of insoluble complexes between peptide and enzyme. Conversely, at lower peptide concentrations there was a profound activation of PI 3-kinase activity of class Ia PI 3-kinases. Studies of peptide variants revealed that all active peptides conform to heptad repeat motifs characteristic of coiled-coil helices. Surface plasmon resonance studies confirmed direct sequence-specific binding of active peptide to the p85alpha adapter subunit of class Ia PI 3-kinase. Active peptides also activated protein kinase B and extracellular signal-regulated kinase (ERK) in vivo in a wortmannin-sensitive manner while reducing recoverable cellular p85 levels. These results indicate that the human lymphocyte antigen class II-derived peptides regulate PI 3-kinase by direct interaction, probably via the coiled-coil domain. These peptides define a novel mechanism of regulating PI 3-kinase and will provide a useful tool for specifically dissecting the function of class Ia PI 3-kinase in cells and for probing structure-function relationships in the class Ia PI 3-kinase heterodimers.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Biomed Sci Res Ctr Alexander Fleming, Vari 16672, Greece	University of London; University College London; Alexander Fleming Biomedical Sciences Research Center	Shepherd, PR (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	p.shepherd@ucl.ac.uk						BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Beeton C A, 1999, Mol Cell Biol Res Commun, V1, P153, DOI 10.1006/mcbr.1999.0124; Boytim ML, 2000, J CLIN INVEST, V105, P1447, DOI 10.1172/JCI8139; Boytim ML, 1998, J IMMUNOL, V160, P2215; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CLAUS R, 1990, IMMUNOL LETT, V26, P203, DOI 10.1016/0165-2478(90)90147-I; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Fu Z, 2003, P NATL ACAD SCI USA, V100, P3275, DOI 10.1073/pnas.0535975100; Heesom KJ, 1998, BIOCHEM J, V336, P39, DOI 10.1042/bj3360039; KRANGEL MS, 1986, J EXP MED, V163, P1173, DOI 10.1084/jem.163.5.1173; Layton MJ, 1998, J BIOL CHEM, V273, P33379, DOI 10.1074/jbc.273.50.33379; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PUPPO F, 1995, IMMUNOL TODAY, V16, P124, DOI 10.1016/0167-5699(95)80127-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	25	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7505	7511		10.1074/jbc.M303999200	http://dx.doi.org/10.1074/jbc.M303999200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660637	hybrid			2022-12-27	WOS:000189103300018
J	Liang, XQ; Lu, Y; Wilkes, M; Neubert, TA; Resh, MD				Liang, XQ; Lu, Y; Wilkes, M; Neubert, TA; Resh, MD			The N-terminal SH4 region of the Src family kinase Fyn is modified by methylation and heterogeneous fatty acylation - Role in membrane targeting, cell adhesion, and spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3 METHYLATION; ARGININE METHYLATION; LYSINE 9; IN-VIVO; METHYLTRANSFERASE; BINDING; PROTEINS; P59(FYN); ASSOCIATION; HP1	The N-terminal SH4 domain of Src family kinases is responsible for promoting membrane binding and plasma membrane targeting. Most Src family kinases contain an N-terminal Met-Gly-Cys consensus sequence that undergoes dual acylation with myristate and palmitate after removal of methionine. Previous studies of Src family kinase fatty acylation have relied on radiolabeling of cells with radioactive fatty acids. Although this method is useful for verifying that a given fatty acid is attached to a protein, it does not reveal whether other fatty acids or other modifying groups are attached to the protein. Here we use matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry to identify fatty acylated species of the Src family kinase Fyn. Our results reveal that Fyn is efficiently myristoylated and that some of the myristoylated proteins are also heterogeneously S-acylated with palmitate, palmitoleate, stearate, or oleate. Furthermore, we show for the first time that Fyn is trimethylated at lysine residues 7 and/or 9 within its N-terminal region. Both myristoylation and palmitoylation were required for methylation of Fyn. However, a general methylation inhibitor had no inhibitory effect on myristoylation and palmitoylation of Fyn, suggesting that methylation occurs after myristoylation and palmitoylation. Lysine mutants of Fyn that could not be methylated failed to promote cell adhesion and spreading, suggesting that methylation is important for Fyn function.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Columbia Univ, New York, NY 10027 USA	Memorial Sloan Kettering Cancer Center; New York University; New York University; Columbia University	Resh, MD (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.	m-resh@ski.mskcc.org	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Resh, Marilyn/0000-0001-6118-9466	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014662] Funding Source: NIH RePORTER; NCRR NIH HHS [S10 RR14662-01] Funding Source: Medline; NIGMS NIH HHS [GM 57966] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; DURBAN E, 1978, J BIOL CHEM, V253, P1427; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KLEIN RR, 1995, PLANT MOL BIOL, V27, P249, DOI 10.1007/BF00020181; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Liang XQ, 2002, J BIOL CHEM, V277, P33032, DOI 10.1074/jbc.M204607200; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MAHER PA, 1993, J BIOL CHEM, V268, P4244; Maurer-Stroh S, 2002, J MOL BIOL, V317, P523, DOI 10.1006/jmbi.2002.5425; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; ROWE PM, 1986, J BIOL CHEM, V261, P7060; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159	26	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8133	8139		10.1074/jbc.M311180200	http://dx.doi.org/10.1074/jbc.M311180200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660555	hybrid			2022-12-27	WOS:000189103300094
J	Nguyen, TM; Lieberherr, M; Fritsch, J; Guillozo, H; Alvarez, ML; Fitouri, Z; Jehan, F; Garabedian, M				Nguyen, TM; Lieberherr, M; Fritsch, J; Guillozo, H; Alvarez, ML; Fitouri, Z; Jehan, F; Garabedian, M			The rapid effects of 1,25-dihydroxyvitamin D-3 require the vitamin D receptor and influence 24-hydroxylase activity - Studies in human skin fibroblasts bearing vitamin D receptor mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; D-RESISTANT RICKETS; BINDING DOMAIN; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; MOUSE OSTEOBLASTS; MEMBRANE-RECEPTOR; HORMONE RECEPTOR; CYP24 PROMOTER; CALCIUM; CELLS	If both rapid and genomic pathways may co-exist in the same cell, the involvement of the nuclear vitamin D receptor (VDR) in the rapid effects of 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) remains unclear. We therefore studied rapid and long term effects of 1,25-(OH)(2)D-3 in cultured skin fibroblasts from three patients with severe vitamin D-resistant rickets and one age-matched control. Patients bear homozygous missense VDR mutations that abolished either VDR binding to DNA (patient 1, mutation K45E) or its stable ligand binding (patients 2 and 3, mutation W286R). In patient 1 cells, 1,25-(OH)(2)D-3 (1 pM-10 nM) had no effect on either intracellular calcium or 24-hydroxylase (enzyme activity and mRNA expression). In contrast, cells bearing the W286R mutation had calcium responses to 1,25-(OH)(2)D-3 (profile and magnitude) and 24-hydroxylase responses to low (1 pM-100 pM) 1,25-(OH)(2)D-3 concentrations (activity, CYP24, and ferredoxin mRNAs) similar to those of controls. The blocker of Ca2+ channels, verapamil, impeded both rapid (calcium) and long term (24-hydroxylase activity, CYP24, and ferredoxin mRNAs) responses in patient and control fibroblasts. The MEK 1/2 kinase inhibitor PD98059 also blocked the CYP24 mRNA response. Taken together, these results suggest that 1,25-(OH)(2)D-3 rapid effects require the presence of VDR and control, in part, the first step of 1,25-(OH)(2)D-3 catabolism via increased mRNA expression of the CYP24 and ferredoxin genes in the 24-hydroxylase complex.	Hop St Vincent de Paul, CNRS, UPR 1524, UMR 8104, F-75014 Paris, France; INRA, Lab Nutr & Secur Alimentaire, F-78352 Jouy En Josas, France; Hop Enfants, Serv Pediat, Tunis 1007, Tunisia	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Universite de Tunis-El-Manar; Hopital d'Enfants	Nguyen, TM (corresponding author), Hop St Vincent de Paul, CNRS, UPR 1524, UMR 8104, 82 Ave Denfert Rechereau, F-75014 Paris, France.	cnrs.svp@wanadoo.fr	Jehan, Frederic/P-1568-2014	Jehan, Frederic/0000-0003-1271-6594				BARAN DT, 1994, P SOC EXP BIOL MED, V207, P175, DOI 10.3181/00379727-207-43803; Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO;2-Q; Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; BARSONY J, 1992, J BIOL CHEM, V267, P457; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; BOURDEAU A, 1990, ENDOCRINOLOGY, V127, P2739; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; DEBOLAND AR, 1990, BIOCHEM BIOPH RES CO, V166, P217, DOI 10.1016/0006-291X(90)91933-J; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Farach-Carson MC, 2003, CURR DRUG TARGETS, V4, P67, DOI 10.2174/1389450033347118; Gniadecki R, 1996, J INVEST DERMATOL, V106, P1212, DOI 10.1111/1523-1747.ep12348498; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Henry HL, 2001, STEROIDS, V66, P391, DOI 10.1016/S0039-128X(00)00158-6; HEWISON M, 1993, CLIN ENDOCRINOL, V39, P663, DOI 10.1111/j.1365-2265.1993.tb02424.x; Kerry DM, 1996, J BIOL CHEM, V271, P29715, DOI 10.1074/jbc.271.47.29715; Kim YS, 1996, ENDOCRINOLOGY, V137, P3649, DOI 10.1210/en.137.9.3649; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Le Mellay V, 1999, J CELL BIOCHEM, V75, P138, DOI 10.1002/(SICI)1097-4644(19991001)75:1<138::AID-JCB14>3.0.CO;2-I; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; Mailhot G, 2000, ENDOCRINOLOGY, V141, P891, DOI 10.1210/en.141.3.891; Malloy PJ, 1999, ENDOCR REV, V20, P156, DOI 10.1210/er.20.2.156; MASSHEIMER V, 1994, CELL SIGNAL, V6, P299, DOI 10.1016/0898-6568(94)90034-5; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; NEMERE I, 1984, ENDOCRINOLOGY, V115, P1476, DOI 10.1210/endo-115-4-1476; Nguyen TM, 2002, J BONE MINER RES, V17, P1728, DOI 10.1359/jbmr.2002.17.9.1728; NISHIMURA A, 1994, ENDOCRINOLOGY, V134, P1794, DOI 10.1210/en.134.4.1794; Norman AW, 2002, MOL CELL ENDOCRINOL, V197, P1, DOI 10.1016/S0303-7207(02)00273-3; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; OHYAMA Y, 1993, BIOCHEMISTRY-US, V32, P76, DOI 10.1021/bi00052a011; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; RASMUSSEN H, 1982, FED PROC, V41, P72; RUT AR, 1994, CLIN ENDOCRINOL, V41, P581, DOI 10.1111/j.1365-2265.1994.tb01822.x; Schwartz Z, 2001, CALCIFIED TISSUE INT, V69, P365, DOI 10.1007/s00223-001-1009-y; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Song XD, 1998, ENDOCRINOLOGY, V139, P457, DOI 10.1210/en.139.2.457; Wali R, 2001, J BONE MINER RES, V16, pS229; WHEELER DG, 1995, NUCLEIC ACIDS RES, V23, P3268, DOI 10.1093/nar/23.16.3268	48	46	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7591	7597		10.1074/jbc.M309517200	http://dx.doi.org/10.1074/jbc.M309517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665637	hybrid			2022-12-27	WOS:000189103300028
J	Wu, YI; Munshi, HG; Sen, R; Snipas, SJ; Salvesen, GS; Fridman, R; Stack, MS				Wu, YI; Munshi, HG; Sen, R; Snipas, SJ; Salvesen, GS; Fridman, R; Stack, MS			Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; TISSUE INHIBITOR; I COLLAGEN; MEDIATED ENDOCYTOSIS; CATALYTIC DOMAIN; PROGELATINASE-A; CARCINOMA-CELLS; TUMOR INVASION; ACTIVE ENZYME; GROWTH-FACTOR	Membrane type 1 matrix metalloproteinase (MT1-MMP) is a collagenolytic enzyme that has been implicated in normal development and in pathological processes such as cancer metastasis. The activity of MT1-MMP is regulated extensively at the post-translational level, and the current data support the hypothesis that MT1-MMP activity is modulated by glycosylation. Enzymatic deglycosylation, site-directed mutagenesis, and lectin precipitation assays were used to demonstrate that MT1-MMP contains O-linked complex carbohydrates on the Thr(291), Thr(299), Thr(300), and/or Ser(301) residues in the proline-rich linker region. MT1-MMP glycoforms were detected in human cancer cell lines, suggesting that MT1-MMP activity may be regulated by differential glycosylation in vivo. Although the autolytic processing and interstitial collagenase activity of MT1-MMP were not impaired in glycosylation-deficient mutants, cell surface MT1-MMP-catalyzed activation of pro-matrix metalloproteinase-2 ( proMMP-2) required proper glycosylation of MT1-MMP. The inability of carbohydrate-free MT1-MMP to activate proMMP-2 was not a result of defective MT1-MMP zymogen activation, aberrant protein stability, or inability of the mature enzyme to oligomerize. Rather, our data support a mechanism whereby glycosylation affects the recruitment of tissue inhibitor of metalloproteinases-2 (TIMP-2) to the cell surface, resulting in defective formation of the MT1-MMP/ TIMP-2/proMMP-2 trimeric activation complex. These data provide evidence for an additional mechanism for post-translational control of MT1-MMP activity and suggest that glycosylation of MT1-MMP may regulate its substrate targeting.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA	Northwestern University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Sanford Burnham Prebys Medical Discovery Institute; Wayne State University	Stack, MS (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu	yi, wu/GLR-2824-2022		NCI NIH HHS [K08CA94877, R01CA85870] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085870, K08CA094877] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; English WR, 2001, J BIOL CHEM, V276, P42018, DOI 10.1074/jbc.M107783200; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Hansen JE, 1997, NUCLEIC ACIDS RES, V25, P278, DOI 10.1093/nar/25.1.278; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; HUET G, 1995, J CELL SCI, V108, P1275; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Ihrke G, 2001, EMBO J, V20, P6256, DOI 10.1093/emboj/20.22.6256; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Koo HM, 2002, MOL CELLS, V13, P118; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Munshi HG, 2002, J BIOL CHEM, V277, P41480, DOI 10.1074/jbc.M207695200; Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091-679X(02)69013-2; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Noe V, 2001, J CELL SCI, V114, P111; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Tsukada H, 2002, J BIOL CHEM, V277, P27378, DOI 10.1074/jbc.M201367200; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Van den Steen PE, 2001, BBA-GEN SUBJECTS, V1528, P61, DOI 10.1016/S0304-4165(01)00190-8; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yu Q, 2000, GENE DEV, V14, P163; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	68	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8278	8289		10.1074/jbc.M311870200	http://dx.doi.org/10.1074/jbc.M311870200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670950	hybrid			2022-12-27	WOS:000189103300110
J	Yu, YD; Liu, YQ; Shen, N; Xu, X; Xu, F; Jia, J; Jin, YX; Arnold, E; Ding, JP				Yu, YD; Liu, YQ; Shen, N; Xu, X; Xu, F; Jia, J; Jin, YX; Arnold, E; Ding, JP			Crystal structure of human tryptophanyl-tRNA synthetase catalytic fragment - Insights into substrate recognition, tRNA binding, and angiogenesis activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATTERN-RECOGNITION; SEQUENCE HOMOLOGY; TRANSITION-STATE; RECEPTOR-BINDING; CYTOKINE; PEPTIDE; SITE; AMINOACYLATION; MUTAGENESIS; MECHANISMS	Human tryptophanyl-tRNA synthetase (hTrpRS) produces a full-length and three N terminus-truncated forms through alternative splicing and proteolysis. The shortest fragment that contains the aminoacylation catalytic fragment (T2-hTrpRS) exhibits the most potent angiostatic activity. We report here the crystal structure of T2-hTrpRS at 2.5 Angstrom resolution, which was solved using the multi-wavelength anomalous diffraction method. T2-hTrpRS shares a very low sequence homology of 22% with Bacillus stearothermophilus TrpRS (bTrpRS); however, their overall structures are strikingly similar. Structural comparison of T2-hTrpRS with bTrpRS reveals substantial structural differences in the substrate-binding pocket and at the entrance to the pocket that play important roles in substrate binding and tRNA binding. T2-hTrpRS has a wide opening to the active site and adopts a compact conformation similar to the closed conformation of bTrpRS. These results suggest that mammalian and bacterial TrpRSs might use different mechanisms to recognize the substrate. Modeling studies indicate that tRNA binds with the dimeric enzyme and interacts primarily with the connective polypeptide 1 of hTrpRS via its acceptor arm and the alpha-helical domain of hTrpRS via its anticodon loop. Our results also suggest that the angiostatic activity is likely located at the alpha-helical domain, which resembles the short chain cytokines.	Chinese Acad Sci, Key Lab Proteom, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; CABM, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA	Chinese Academy of Sciences; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Rutgers State University New Brunswick	Ding, JP (corresponding author), Chinese Acad Sci, Key Lab Proteom, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jpding@sibs.ac.cn	Xu, Xiang/G-5528-2012	ding, jian ping/0000-0001-7029-7346; Jia, Jie/0000-0002-9583-1055	NIAID NIH HHS [AI 27690] Funding Source: Medline; NIGMS NIH HHS [GM 66671] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027690, R37AI027690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM066671] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; DOUBLIE S, 1995, STRUCTURE, V3, P17, DOI 10.1016/S0969-2126(01)00132-0; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grotzinger J, 2002, BBA-MOL CELL RES, V1592, P215, DOI 10.1016/S0167-4889(02)00316-6; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HIMENO H, 1991, NUCLEIC ACIDS RES, V19, P6379, DOI 10.1093/nar/19.23.6379; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HOUNTONDJI C, 1986, BIOCHIMIE, V68, P1071, DOI 10.1016/S0300-9084(86)80181-X; Ilyin VA, 2000, PROTEIN SCI, V9, P218; Jia J, 2002, BIOCHEM J, V365, P749, DOI 10.1042/BJ20020141; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Mueller TD, 2002, BBA-MOL CELL RES, V1592, P237, DOI 10.1016/S0167-4889(02)00318-X; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; NAGEL GM, 1995, J MOL EVOL, V40, P487; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otani A, 2002, P NATL ACAD SCI USA, V99, P178, DOI 10.1073/pnas.012601899; Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1998, ACTA CRYSTALLOGR D, V54, P1285, DOI 10.1107/S0907444998004119; Praetorius-Ibba M, 2000, BIOCHEMISTRY-US, V39, P13136; Retailleau P, 2003, J MOL BIOL, V325, P39, DOI 10.1016/S0022-2836(02)01156-7; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; Shiba K, 2002, J MOL EVOL, V55, P727, DOI 10.1007/s00239-002-2368-3; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOLSTRUP AB, 1995, J BIOL CHEM, V270, P397, DOI 10.1074/jbc.270.1.397; Turpaev KT, 1996, EUR J BIOCHEM, V240, P732, DOI 10.1111/j.1432-1033.1996.0732h.x; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; Wakasugi K, 2002, J BIOL CHEM, V277, P20124, DOI 10.1074/jbc.C200126200; Wakasugi K, 2002, P NATL ACAD SCI USA, V99, P173, DOI 10.1073/pnas.012602099; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; Xu F, 2001, PROTEIN EXPRES PURIF, V23, P296, DOI 10.1006/prep.2001.1500; Xu F, 2001, NUCLEIC ACIDS RES, V29, P4125, DOI 10.1093/nar/29.20.4125; Yang XL, 2003, HELV CHIM ACTA, V86, P1246, DOI 10.1002/hlca.200390107; Yang XL, 2002, P NATL ACAD SCI USA, V99, P15369, DOI 10.1073/pnas.242611799; Yaremchuk A, 2002, EMBO J, V21, P3829, DOI 10.1093/emboj/cdf373; Zuniga R, 2002, FEBS LETT, V532, P387, DOI 10.1016/S0014-5793(02)03720-1	53	32	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8378	8388		10.1074/jbc.M311284200	http://dx.doi.org/10.1074/jbc.M311284200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660560	hybrid			2022-12-27	WOS:000189103300120
J	Omori, K; Naruishi, K; Nishimura, F; Yamada-Naruishi, H; Takashiba, S				Omori, K; Naruishi, K; Nishimura, F; Yamada-Naruishi, H; Takashiba, S			High glucose enhances interleukin-6-induced vascular endothelial growth factor 165 expression via activation of Gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in gingival fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GENE-EXPRESSION; DIABETIC COMPLICATIONS; 3T3-L1 PREADIPOCYTES; VEGF; RECEPTOR; ADIPOGENESIS; ANGIOGENESIS; MIGRATION; MELLITUS	Diabetic patients are susceptible to severe inflammatory periodontitis manifesting as swollen gingiva with bleeding, but the underlying mechanism is not well understood. Our purpose was to determine the effect of a high glucose (HG) condition on the interleukin-6/soluble interleukin-6 receptor (IL-6/sIL-6R)-induced activation of signaling and vascular endothelial growth factor (VEGF) expression in human gingival fibroblasts (HGFs). In this study, HGFs were cultured for at least two passages under a normal glucose (NG; 5.5 mm) condition or high glucose (25 mm) condition. Importantly, the HG condition significantly induced expression of gp130 mRNA in HGFs compared with levels in control cells. Consistent with the expression of its mRNA, the HG condition also increased the expression of gp130 protein, and phosphorylation of the tyrosine residue by gp130 was enhanced significantly by IL-6/sIL-6R stimulation. Furthermore, the HG condition enhanced the IL-6/sIL-6R-induced phosphorylation of p44/42 MAPK and led to subsequent activation of CCAAT/enhancer binding protein in nuclei. In contrast, there was no significant difference in phosphorylation of JNK between the HG and NG condition. Interestingly, HGFs increased IL-6/sIL-6R,induced VEGF165 mRNA expression and VEGF165 secretion under the HG condition compared with levels under the NG condition. In contrast, the induction of VEGF165 secretion was partially inhibited by PD98059 (selective p44/42 MAPK inhibitor) under the HG condition. In addition, the VEGF165 secretion was completely inhibited by the combination of PD98059 and SP600125 (JNK inhibitor). Our findings suggest that the HG condition indirectly increases VEGF expression via activation of gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in HGFs. Thus, elevated VEGF secretion in HGFs under the HG condition may play a role in the development of the severe periodontitis observed in diabetic patients.	Okayama Univ, Grad Sch Med & Dent, Dept Pathophysiol Periodontal Sci, Okayama 7008525, Japan	Okayama University	Takashiba, S (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Pathophysiol Periodontal Sci, 2-5-1 Shikata Cho, Okayama 7008525, Japan.	stakashi@cc.okayama-u.ae.jp	Omori, Kazuhiro/AAX-5268-2020; Takashiba, Shogo/C-9830-2010	Takashiba, Shogo/0000-0002-4712-6829				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Benjamin LE, 2001, AM J PATHOL, V158, P1181, DOI 10.1016/S0002-9440(10)64066-7; Bickel M, 2001, J CLIN PERIODONTOL, V28, P840, DOI 10.1034/j.1600-051x.2001.028009840.x; Cameron NE, 2001, DIABETOLOGIA, V44, P1973, DOI 10.1007/s001250100001; Cho YH, 2003, MOL PHARMACOL, V63, P512, DOI 10.1124/mol.63.3.512; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Funatsu H, 2001, RETINA-J RET VIT DIS, V21, P469, DOI 10.1097/00006982-200110000-00009; GHOSH D, 1991, TRENDS BIOCHEM SCI, V16, P445, DOI 10.1016/0968-0004(91)90173-S; GUILLOT JL, 1995, J PERIODONTOL, V66, P667, DOI 10.1902/jop.1995.66.8.667; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hoshi S, 2002, BIOCHEM BIOPH RES CO, V290, P177, DOI 10.1006/bbrc.2001.6138; Iacopino A M, 2001, Ann Periodontol, V6, P125, DOI 10.1902/annals.2001.6.1.125; Isner JM, 2001, CIRC RES, V89, P389, DOI 10.1161/hh1701.096259; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; LOPESVIRELLA MF, 1996, DIABETES S3, V45, P40; Mandl-Weber S, 2002, KIDNEY INT, V61, P570, DOI 10.1046/j.1523-1755.2002.00143.x; Naruishi K, 2003, TRANSPLANTATION, V76, P1380, DOI 10.1097/01.TP.0000085661.52980.95; Naruishi K, 1999, J PERIODONTAL RES, V34, P296, DOI 10.1111/j.1600-0765.1999.tb02257.x; Naruishi K, 2001, J DENT RES, V80, P1421, DOI 10.1177/00220345010800050701; Natarajan R, 1997, AM J PHYSIOL-HEART C, V273, pH2224, DOI 10.1152/ajpheart.1997.273.5.H2224; Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026; Persson RE, 2003, J CLIN PERIODONTOL, V30, P207, DOI 10.1034/j.1600-051X.2003.00237.x; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Ritz E, 1999, NEW ENGL J MED, V341, P1127, DOI 10.1056/NEJM199910073411506; Rogus JJ, 2002, DIABETES, V51, P1655, DOI 10.2337/diabetes.51.6.1655; Soskolne W A, 2001, Ann Periodontol, V6, P91, DOI 10.1902/annals.2001.6.1.91; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; Unlu F, 2003, J PERIODONTOL, V74, P181, DOI 10.1902/jop.2003.74.2.181; Wei D, 2002, INT IMMUNOPHARMACOL, V2, P1163, DOI 10.1016/S1567-5769(02)00082-6; Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200	35	35	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6643	6649		10.1074/jbc.M311688200	http://dx.doi.org/10.1074/jbc.M311688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14676217	Green Submitted, hybrid			2022-12-27	WOS:000188969200054
J	Saito, S; Liu, XF; Kamijo, K; Raziuddin, R; Tatsumoto, T; Okamoto, I; Chen, XY; Lee, CC; Lorenzi, MV; Ohara, N; Miki, T				Saito, S; Liu, XF; Kamijo, K; Raziuddin, R; Tatsumoto, T; Okamoto, I; Chen, XY; Lee, CC; Lorenzi, MV; Ohara, N; Miki, T			Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the Rho signaling pathways leading to malignant transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CDNA CLONING; EXCHANGE FACTOR ECT2; FISSION YEAST; DBL FAMILY; GTPASES; RAC; ONCOGENE; REPLICATION; PROTEINS; DAMAGE	The human ECT2 protooncogene encodes a guanine nucleotide exchange factor for the Rho GTPases and regulates cytokinesis. Although the oncogenic form of ECT2 contains an N-terminal truncation, it is not clear how the structural abnormality of ECT2 causes malignant transformation. Here we show that both the removal of the negative regulatory domain and alteration of subcellular localization are required to induce the oncogenic activity of ECT2. The transforming activity of oncogenic ECT2 was strongly inhibited by dominant negative Rho GTPases, suggesting the involvement of Rho GTPases in ECT2 transformation. Although deletion of the N-terminal cell cycle regulator-related domain (N) of ECT2 did not activate its transforming activity, removal of the small central domain (S), which contains two nuclear localization signals (NLSs), significantly induced the activity. The ECT2 N domain interacted with the catalytic domain and significantly inhibited the focus formation by oncogenic ECT2. Interestingly, the introduction of the NLS mutations in the S domain of N-terminally truncated ECT2 dramatically induced the transforming activity of this otherwise nononcogenic derivative. Among the known Rho GTPases expressed in NIH 3T3 cells, RhoA was predominantly activated by oncogenic ECT2 in vivo. Therefore, the mislocalization of structurally altered ECT2 might cause the untimely activation of cytoplasmic Rho GTPases leading to the malignant transformation.	NCI, Mol Tumor Biol Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miki, T (corresponding author), NCI, Mol Tumor Biol Sect, Basic Res Lab, NIH, 37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	toru@helix.nih.gov	OHARA, Naoya/B-2481-2011		NATIONAL CANCER INSTITUTE [Z01BC005548] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan AML, 1996, ONCOGENE, V12, P1259; CHAN AML, 1994, ONCOGENE, V9, P1057; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Lorenzi MV, 1999, ONCOGENE, V18, P4742, DOI 10.1038/sj.onc.1202851; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Sakata H, 2000, HEPATOLOGY, V32, P193, DOI 10.1053/jhep.2000.8271; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739	31	97	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7169	7179		10.1074/jbc.M306725200	http://dx.doi.org/10.1074/jbc.M306725200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645260	hybrid			2022-12-27	WOS:000188969200116
J	Tripp, BC; Bell, CB; Cruz, F; Krebs, C; Ferry, JG				Tripp, BC; Bell, CB; Cruz, F; Krebs, C; Ferry, JG			A role for iron in an ancient carbonic anhydrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEINS	Since 1933, carbonic anhydrase research has focused on enzymes from mammals (alpha class) and plants (beta class); however, two additional classes (gamma and delta) were discovered recently. Cam, from the procaryote Methanosarcina thermophila, is the prototype of the gamma class and the first carbonic anhydrase to be characterized from either an anaerobic organism or the Archaea domain. All of the enzymes characterized from the four classes have been purified aerobically and are reported to contain a catalytic zinc. Herein, we report the anaerobic reconstitution of apo-Cam with Fe2+, which yielded Cam with an effective k(cat) that exceeded that for the Zn2+-reconstituted enzyme. Mossbauer spectroscopy showed that the Fe2+-reconstituted enzyme contained high spin Fe2+ that, when oxidized to Fe3+, inactivated the enzyme. Reconstitution with Fe3+ was unsuccessful. Reconstitution with Cu2+, Mn2+, Ni2+, or Cd2+ yielded enzymes with effective k(cat), values that were 10% or less than the value for the Zn2+-reconstituted Cam. Cam produced in Escherichia coli and purified anaerobically contained iron with effective k(cat) and k(cat)/K-m values exceeding the values for Zn2+-reconstituted Cam. The results identify a previously unrecognized biological function for iron.	Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Western Michigan Univ, Dept Biol Sci, Kalamazoo, MI 49008 USA; Western Michigan Univ, Dept Chem, Kalamazoo, MI 49008 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Western Michigan University; Western Michigan University	Ferry, JG (corresponding author), Penn State Univ, Eberly Coll Sci, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	jgf3@psu.edu	Krebs, Carsten/D-4773-2009	Krebs, Carsten/0000-0002-3302-7053	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044661] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44661] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alber BE, 1999, BIOCHEMISTRY-US, V38, P13119, DOI 10.1021/bi9828876; ALBER BE, 1994, P NATL ACAD SCI USA, V91, P6909, DOI 10.1073/pnas.91.15.6909; Alber BE, 1996, J BACTERIOL, V178, P3270, DOI 10.1128/jb.178.11.3270-3274.1996; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; D'souza VM, 1999, BIOCHEMISTRY-US, V38, P11079, DOI 10.1021/bi990872h; Da Silva J. F., 2001, BIOL CHEM ELEMENTS I; DAILEY HA, 1977, J BACTERIOL, V129, P815, DOI 10.1128/JB.129.2.815-820.1977; Ferry JG, 1999, FEMS MICROBIOL REV, V23, P13, DOI 10.1016/S0168-6445(98)00029-1; Hewett-Emmett D, 2000, EXS, V90, P29; Hunt JA, 1999, BIOCHEMISTRY-US, V38, P9054, DOI 10.1021/bi9900166; Iverson TM, 2000, BIOCHEMISTRY-US, V39, P9222, DOI 10.1021/bi000204s; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; Lane TW, 2000, P NATL ACAD SCI USA, V97, P4627, DOI 10.1073/pnas.090091397; LINDSKOG S, 1966, BIOCHEMISTRY-US, V5, P2641, DOI 10.1021/bi00872a023; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; MELDRUM N. IT., 1933, JOUR PHYSIOL, V80, P113; Milligan AJ, 2002, SCIENCE, V297, P1848, DOI 10.1126/science.1074958; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Potter CPS, 2003, BRIT J CANCER, V89, P2, DOI 10.1038/sj.bjc.6600936; Rajagopalan PTR, 1997, J AM CHEM SOC, V119, P12418, DOI 10.1021/ja9734096; Rajagopalan PTR, 1998, J BIOL CHEM, V273, P22305, DOI 10.1074/jbc.273.35.22305; ROWLETT RS, 1994, BIOCHEMISTRY-US, V33, P13967, DOI 10.1021/bi00251a003; SCHERER P, 1983, BIOL TRACE ELEM RES, V5, P149, DOI 10.1007/BF02916619; SIGEL H, 1970, ACCOUNTS CHEM RES, V3, P201, DOI 10.1021/ar50030a004; Smith KS, 1999, P NATL ACAD SCI USA, V96, P15184, DOI 10.1073/pnas.96.26.15184; Smith KS, 2000, FEMS MICROBIOL REV, V24, P335, DOI 10.1016/S0168-6445(00)00030-9; Strop P, 2001, J BIOL CHEM, V276, P10299, DOI 10.1074/jbc.M009182200; Tripp BC, 2000, BIOCHEMISTRY-US, V39, P9232, DOI 10.1021/bi0001877; Tripp BC, 2002, BIOCHEMISTRY-US, V41, P669, DOI 10.1021/bi010768b; Tripp BC, 2001, J BIOL CHEM, V276, P48615, DOI 10.1074/jbc.R100045200; WACHTERSHAUSER G, 1990, ORIGINS LIFE EVOL B, V20, P173, DOI 10.1007/BF01808279	32	112	120	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6683	6687		10.1074/jbc.M311648200	http://dx.doi.org/10.1074/jbc.M311648200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662760	hybrid			2022-12-27	WOS:000188969200059
J	Fang, XD; Han, HM; Stamatoyannopoulos, G; Li, QL				Fang, XD; Han, HM; Stamatoyannopoulos, G; Li, QL			Developmentally specific role of the CCAAT box in regulation of human gamma-globin gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN FACTORS; NF-Y; PROMOTER ELEMENTS; IN-VIVO; HEREDITARY PERSISTENCE; FETAL HEMOGLOBIN; BINDING; TRANSCRIPTION; REGION; RECRUITMENT	The CCAAT box is a widespread motif in eukaryotic promoters. In this study we demonstrate that the effects of the CCAAT box on gamma-globin gene activation are developmentally distinct. Although this promoter element is essential for high level gamma gene expression in adult erythropoiesis, it plays little role in embryonic erythroid cells. The CCAAT mutation in the human gamma-globin gene promoter impairs recruitment of TATA-binding protein (TBP), TFIIB, and RNA polymerase II in adult splenic erythroblasts but not in embryonic erythroid cells. We also show that the efficiency of gamma gene transcription is correlated with recruitment of TBP on the TATA box but that the level of TBP recruitment is not nuclear factor Y (NF-Y)-dependent. Our data also suggest that it is unlikely that transcriptional stimulation by the CCAAT box is exerted through direct protein-protein interaction between NF-Y and TBP.	Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Li, QL (corresponding author), Univ Washington, Sch Med, Dept Med, Div Med Genet, I-164 Hlth Sci Bldg,Box 357720, Seattle, WA 98195 USA.	li111640@u.washington.edu			NHLBI NIH HHS [HL73439, R01 HL073439] Funding Source: Medline; NIDDK NIH HHS [DK61805, R56 DK045365, R01 DK045365-06S1, R01 DK045365, DK45365, R37 DK045365-07S1, R37 DK045365, R01 DK061805] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045365, R56DK045365, R37DK045365, R01DK061805] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANAGNOU NP, 1986, EMBO J, V5, P121, DOI 10.1002/j.1460-2075.1986.tb04185.x; ANTONIOU M, 1995, NUCLEIC ACIDS RES, V23, P3473, DOI 10.1093/nar/23.17.3473; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CATALA F, 1989, NUCLEIC ACIDS RES, V17, P3811, DOI 10.1093/nar/17.10.3811; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; Duan ZJ, 2002, P NATL ACAD SCI USA, V99, P5509, DOI 10.1073/pnas.072084499; Duan ZJ, 2001, MOL CELL BIOL, V21, P3083, DOI 10.1128/MCB.21.9.3083-3095.2001; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; Filipe A, 1999, EMBO J, V18, P687, DOI 10.1093/emboj/18.3.687; Frontini M, 2002, J BIOL CHEM, V277, P5841, DOI 10.1074/jbc.M103651200; GUMUCIO DL, 1994, J BIOL CHEM, V269, P15371; HARA H, 1976, AM J HEMATOL, V1, P453, DOI 10.1002/ajh.2830010410; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Langdon SD, 1998, BLOOD, V91, P309, DOI 10.1182/blood.V91.1.309.309_309_318; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LI QL, 1994, MOL CELL BIOL, V14, P6087, DOI 10.1128/MCB.14.9.6087; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MANTOVANI R, 1989, NUCLEIC ACIDS RES, V17, P6681, DOI 10.1093/nar/17.16.6681; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Ottolenghi S, 1989, Prog Clin Biol Res, V316A, P229; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; Salsi V, 2003, J BIOL CHEM, V278, P6642, DOI 10.1074/jbc.M210065200; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; Stamatoyannopoulos G., 2001, MOL BASIS BLOOD DIS, Vthird, P135; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; ULRICH MJ, 1990, BLOOD, V75, P990	35	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5444	5449		10.1074/jbc.M306241200	http://dx.doi.org/10.1074/jbc.M306241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645237	Green Accepted, hybrid			2022-12-27	WOS:000188776500051
J	Sampaio, MM; Chevance, F; Dippel, R; Eppler, T; Schlegel, A; Boos, W; Lu, YJ; Rock, CO				Sampaio, MM; Chevance, F; Dippel, R; Eppler, T; Schlegel, A; Boos, W; Lu, YJ; Rock, CO			Phosphotransferase-mediated transport of the osmolyte 2-O-alpha-mannosyl-D-glycerate in Escherichia coli occurs by the product of the mngA (hrsA) gene and is regulated by the mngR (farR) gene product acting as repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; TREHALOSE SYNTHESIS; MANNOSYLGLYCERATE; MUTAGENESIS; POLYMERASE; EXPRESSION; PROTEINS; SEQUENCE; SOLUTES; ENZYMES	2-O-alpha- Mannosyl- D- glycerate ( MGs) has been recognized as an osmolyte in hyperthermophilic but not mesophilic prokaryotes. We report that MG is taken up and utilized as sole carbon source by Escherichia coli K12, strainMC4100. Uptake is mediated by the P- enolpyruvate-dependent phosphotransferase system with the MG-inducible HrsA ( now called MngA) protein as its specific EIIABC complex. The apparent K-m of MG uptake in induced cells was 10 muM, and the V-max was 0.65 nmol/ min/ 10(9) cells. Inverted membrane vesicles harboring plasmid-encoded MngA phosphorylated MG in a P- enolpyruvate-dependent manner. A deletion mutant in mngA was devoid of MG transport but is complemented by a plasmid harboring mngA. Uptake of MG in MC4100 also caused induction of a regulon specifying the uptake and the metabolism of galactarate and glucarate controlled by the CdaR activator. The ybgG gene ( now called mngB) the gene immediately downstream of mngA encodes a protein with alpha- mannosidase activity. farR, the gene upstream of mngA ( now called mngR) had previously been characterized as a fatty acyl- responsive regulator; however, deletion of mngR resulted in the up- regulation of only two genes, mngA and mngB. The mngR deletion caused constitutive MG transport that became MG- inducible after transformation with plasmid expressed mngR. Thus, MngR is the regulator ( repressor) of the MG transport/ metabolism system. Thus, the mngR mngA mngB gene cluster encodes an MG utilizing system.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Stab Vida, P-2781601 Oeiras, Portugal; St Jude Childrens Res Hosp, Dept Infect Dis, Div Prot Sci, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Biosci, Memphis, TN 38163 USA	University of Konstanz; Universidade Nova de Lisboa; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Boos, W (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	Winfried.Boos@Uni-Konstanz.de		Sampaio, Maria Manuel/0000-0003-3019-3694	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Borges N, 2002, EXTREMOPHILES, V6, P209, DOI 10.1007/s007920100236; BOUVENG H, 1955, ACTA CHEM SCAND, V9, P807, DOI 10.3891/acta.chem.scand.09-0807; BURSTEIN C, 1965, BIOCHIM BIOPHYS ACTA, V95, P634, DOI 10.1016/0005-2787(65)90517-4; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COZZAREL.NR, 1965, J BACTERIOL, V90, P1325, DOI 10.1128/JB.90.5.1325-1329.1965; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Empadinhas N, 2001, J BIOL CHEM, V276, P43580, DOI 10.1074/jbc.M108054200; ERNI B, 1987, J BIOL CHEM, V262, P5238; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HENGGEARONIS R, 1991, J BACTERIOL, V173, P7918, DOI 10.1128/jb.173.24.7918-7924.1991; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; LI YT, 1967, J BIOL CHEM, V242, P5474; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; Miller JH, 1972, EXPT MOL GENETICS, P354; Monterrubio R, 2000, J BACTERIOL, V182, P2672, DOI 10.1128/JB.182.9.2672-2674.2000; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; OCHMAN H, 1988, GENETICS, V120, P621; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; QUAIL MA, 1994, FEBS LETT, V356, P183, DOI 10.1016/0014-5793(94)01264-4; Ramos A, 1997, APPL ENVIRON MICROB, V63, P4020, DOI 10.1128/AEM.63.10.4020-4025.1997; SAMPAIO MM, 2003, J BACTERIOL, V69, P233; Santos H, 2001, METHOD ENZYMOL, V334, P302; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TCHIEU JH, 2002, JMMB SYMP S, V5, P9; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; Utsumi R, 1996, BIOSCI BIOTECH BIOCH, V60, P309, DOI 10.1271/bbb.60.309; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; YARMOLINSKY MB, 1959, P NATL ACAD SCI USA, V45, P1786, DOI 10.1073/pnas.45.12.1786; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zhang YM, 2002, J BIOL CHEM, V277, P15558, DOI 10.1074/jbc.M201399200	35	32	36	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5537	5548		10.1074/jbc.M310980200	http://dx.doi.org/10.1074/jbc.M310980200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645248	hybrid			2022-12-27	WOS:000188776500062
J	Uno, T; Ryu, D; Tsutsumi, H; Tomisugi, Y; Ishikawa, Y; Wilkinson, AJ; Sato, H; Hayashi, T				Uno, T; Ryu, D; Tsutsumi, H; Tomisugi, Y; Ishikawa, Y; Wilkinson, AJ; Sato, H; Hayashi, T			Residues in the distal heme pocket of neuroglobin - Implications for the multiple ligand binding steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION-ASSOCIATED PROTEIN; SPERM WHALE MYOGLOBIN; RESONANCE RAMAN; HEXACOORDINATE HEMOGLOBIN; AXIAL COORDINATION; GENE SYNTHESIS; NITRIC-OXIDE; GLOBIN; EXPRESSION; HISTIDINE	Amino acid residues in the ligand binding pocket of human neuroglobin have been identified by site-directed mutagenesis and their properties investigated by resonance Raman and flash photolysis methods. Wildtype neuroglobin has been shown to have six-coordinate heme in both ferric and ferrous states. Substitution of His(96) by alanine leads to complete loss of heme, indicating that His(96) is the proximal ligand. The resonance Raman spectra of M69L and K67T mutants were similar to those of wild-type (WT) neuroglobin in both ferric and ferrous states. By contrast, H64V was six-coordinate high-spin and five-coordinate high-spin in the ferric and ferrous states, respectively, at acidic pH. The spectra were pH-dependent and six-coordinate with the low-spin component dominating at alkaline pH. In a double mutant H64V/K67T, the high-spin component alone was detected in the both ferric and the ferrous states. This implies that His(64) is the endogenous ligand and that Lys(67) is situated nearby in the distal pocket. In the ferrous H64V and H64V/K67T mutants, the v(Fe-His) stretching frequency appears at 221 cm(-1), which is similar to that of deoxymyoglobin. In the ferrous CO-bound state, the v(Fe-CO) stretching frequency was detected at 521 and 494 cm(-1) in WT, M69L, and K67T, while only the 494 cm(-1) component was detected in the H64V and H64V/K67T mutants. Thus, the 521 cm(-1) component is attributed to the presence of polar His(64). The CO binding kinetics were biphasic for WT, H64V, and K67T and monophasic for H64V/K67T. Thus, His(64) and Lys(67) comprise a unique distal heme pocket in neuroglobin.	Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan; Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England; Kyushu Univ, Grad Sch Engn, Dept Chem & Biochem, Fukuoka 8128581, Japan	Kumamoto University; University of York - UK; Kyushu University	Uno, T (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan.	unot@gpo.kumamoto-u.ac.jp	Uno, Tadayuki/E-1622-2013	Uno, Tadayuki/0000-0003-2056-5781; Hayashi, Takashi/0000-0002-2215-935X; Wilkinson, Anthony/0000-0003-4577-9479				Asahina K, 2002, BBA-GENE STRUCT EXPR, V1577, P471, DOI 10.1016/S0167-4781(02)00477-3; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; CASIMIRO DR, 1995, BIOCHEMISTRY-US, V34, P6640, DOI 10.1021/bi00020a009; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; DOU Y, 1995, J BIOL CHEM, V270, P15993, DOI 10.1074/jbc.270.27.15993; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; HANSON JC, 1981, J MOL BIOL, V153, P117, DOI 10.1016/0022-2836(81)90530-1; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Iizuka T, 1970, Adv Biophys, V1, P157; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kincaid J.R., 2000, PORPHYRIN HDB, V7, P227; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; LAI HH, 1995, PROTEINS, V22, P322, DOI 10.1002/prot.340220404; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Merx Marc W., 2001, FASEB Journal, V15, P1077; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; Nistor SV, 2002, CHEM PHYS LETT, V361, P355, DOI 10.1016/S0009-2614(02)00961-2; OLDFIELD E, 1991, J AM CHEM SOC, V113, P7537, DOI 10.1021/ja00020a014; OLDFIELD TJ, 1992, BIOCHEMISTRY-US, V31, P8732, DOI 10.1021/bi00152a008; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2002, J BIOL CHEM, V277, P19538, DOI 10.1074/jbc.M201934200; Uno T, 2003, BIOCHEMISTRY-US, V42, P10191, DOI 10.1021/bi034569z; UNO T, 1987, J BIOL CHEM, V262, P4549; Vandergon TL, 1998, J BIOL CHEM, V273, P16998, DOI 10.1074/jbc.273.27.16998; Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200; YU NT, 1983, BIOCHEMISTRY-US, V22, P4534, DOI 10.1021/bi00288a028; Zhang CG, 2002, BIOCHEM BIOPH RES CO, V290, P1411, DOI 10.1006/bbrc.2002.6360	48	64	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5886	5893		10.1074/jbc.M311748200	http://dx.doi.org/10.1074/jbc.M311748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645216	hybrid			2022-12-27	WOS:000188776500104
J	Pasyk, EA; Kang, YH; Huang, XH; Cui, NR; Sheu, L; Gaisano, HY				Pasyk, EA; Kang, YH; Huang, XH; Cui, NR; Sheu, L; Gaisano, HY			Syntaxin-1A binds the nucleotide-binding folds of sulphonylurea receptor 1 to regulate the K-ATP channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; GK RAT; 1A; PROTEINS; SNAP-25; CA2+; EXPRESSION; INTERACTS; CLEAVES; MGADP	ATP-sensitive potassium (K-ATP) channels in neuron and neuroendocrine cells consist of a pore-forming Kir6.2 and regulatory sulfonylurea receptor (SUR1) subunits, which are regulated by ATP and ADP. SNARE protein syntaxin 1A (Syn-1A) is known to mediate exocytic fusion, and more recently, to also bind and modulate membrane-repolarizing voltage-gated K+ channels. Here we show that Syn-1A acts as an endogenous regulator of K-ATP channels capable of closing these channels when cytosolic ATP concentrations were lowered. Botulinum neurotoxin C1 cleavage of endogenous Syn-1A in insulinoma HIT-T15 cells resulted in the increase in K-ATP currents, which could be subsequently inhibited by recombinant Syn-1A. Whereas Syn-1A binds both nucleotide-binding folds (NBF-1 and NBF-2) of SUR1, the functional inhibition of K-ATP channels in rat islet beta-cells by Syn-1A seems to be mediated primarily by its interactions with NBF-1. These inhibitory actions of Syn-1A can be reversed by physiologic concentrations of ADP and by diazoxide. Syn-1A therefore acts to fine-tune the regulation of K-ATP channels during dynamic changes in cytosolic ATP and ADP concentrations. These actions of Syn-1A on K-ATP channels contribute to the role of Syn-1A in coordinating the sequence of ionic and exocytic events leading to secretion.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Hlth Network, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada.	gaisano@utoronto.ca			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK055160] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55160] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1992, INSULIN MOL BIOL PAT; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Fili O, 2001, J NEUROSCI, V21, P1964, DOI 10.1523/JNEUROSCI.21-06-01964.2001; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; Gaisano HY, 2002, ENDOCRINOLOGY, V143, P4218, DOI 10.1210/en.2002-220237; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Hernandez-Sanchez C, 1999, J BIOL CHEM, V274, P18261, DOI 10.1074/jbc.274.26.18261; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Honer WG, 2002, CEREB CORTEX, V12, P349, DOI 10.1093/cercor/12.4.349; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; MATSUO M, 1999, J BIOL CHEM, V274, P41184; Nagamatsu S, 1999, DIABETES, V48, P2367, DOI 10.2337/diabetes.48.12.2367; Nakayama T, 1998, CYTOGENET CELL GENET, V82, P49, DOI 10.1159/000015063; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TSUURA Y, 1993, DIABETES, V42, P1446, DOI 10.2337/diabetes.42.10.1446; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Vanoye CG, 2002, J BIOL CHEM, V277, P23260, DOI 10.1074/jbc.M112004200; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yang SN, 1999, P NATL ACAD SCI USA, V96, P10164, DOI 10.1073/pnas.96.18.10164	33	57	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4234	4240		10.1074/jbc.M309667200	http://dx.doi.org/10.1074/jbc.M309667200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645230	hybrid			2022-12-27	WOS:000188554300040
J	Xu, QJ; Yan, B; Li, SH; Duan, CM				Xu, QJ; Yan, B; Li, SH; Duan, CM			Fibronectin binds insulin-like growth factor-binding protein 5 and abolishes its ligand-dependent action on cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-5; IGF-I; EXTRACELLULAR-MATRIX; AMINO-ACIDS; HUMAN FIBROBLASTS; TERMINAL DOMAINS; HEPARIN-BINDING; IGFBP-5; SURVIVAL; SUBSTITUTIONS	Insulin-like growth factor-binding protein 5 (IGFBP-5) is a secreted protein that binds to insulin-like growth factors (IGFs) and modulates IGF actions on cell proliferation, differentiation, survival, and motility. IGFBP-5 also regulates these cellular events through IGF-independent mechanisms. To elucidate the molecular mechanisms governing these diverse actions of IGFBP-5, we screened a human cDNA library by a yeast two-hybrid system using IGFBP-5 as bait and identified fibronectin (FN) as a potential IGFBP-5-interacting partner. The complex formation of IGFBP-5 and FN was established by glutathione S-transferase pull-down, solution, and solid phase binding assays using glutathione S-transferase-IGFBP-5 and native IGFBP-5 in vitro and by co-immunoprecipitation in vivo. Binding assay using deletion mutants indicated that the IGFBP-5 C domain binds to the 10(th) and 11(th) type I repeats of FN. IGFBP-5 potentiated IGF-I-induced cell migration in FN-null, but not in wildtype, mouse embryonic cells. When FN was reintroduced either as an adhesive substrate or in solution to the FN-null cells, the potentiating effect of IGFBP-5 on IGF-I-induced cell migration was abolished. Binding of IGFBP-5 to FN had no effect on the ability of IGFBP-5 to bind IGF-I, but it increased the proteolytic degradation of IGFBP-5. Inhibition of IGFBP-5 proteolysis restored the potentiating effect of IGFBP-5. These results suggest that FN and IGFBP-5 bind to each other, and this binding negatively regulates the ligand-dependent action of IGFBP-5 by triggering IGFBP-5 proteolysis.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	cduan@umich.edu	Xu, Qijin/B-2680-2009	Xu, Qijin/0000-0003-0521-9039	NHLBI NIH HHS [R01HL60679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060679] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrass CK, 1997, AM J PHYSIOL-RENAL, V273, pF899, DOI 10.1152/ajprenal.1997.273.6.F899; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; Berfield AK, 2000, KIDNEY INT, V57, P1991, DOI 10.1046/j.1523-1755.2000.00049.x; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; Busby WH, 2000, J BIOL CHEM, V275, P37638, DOI 10.1074/jbc.M006107200; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; Campbell PG, 1997, AM J PHYSIOL-ENDOC M, V273, pE996, DOI 10.1152/ajpendo.1997.273.5.E996; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; Duan CM, 1996, J BIOL CHEM, V271, P4280; Duan CM, 1998, J BIOL CHEM, V273, P16836, DOI 10.1074/jbc.273.27.16836; Duan Cunming, 2003, Acta Zoologica Sinica, V49, P421; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Globus RK, 1998, J CELL SCI, V111, P1385; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Hsieh T, 2003, J BIOL CHEM, V278, P42886, DOI 10.1074/jbc.M303835200; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Martin JA, 2002, OSTEOARTHR CARTILAGE, V10, P556, DOI 10.1053/joca.2002.0791; McCaig C, 2002, J CELL SCI, V115, P4293, DOI 10.1242/jcs.00097; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nam T, 2002, ENDOCRINOLOGY, V143, P30, DOI 10.1210/en.143.1.30; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; Richman C, 1999, ENDOCRINOLOGY, V140, P4699, DOI 10.1210/en.140.10.4699; Rozen F, 1997, J NATL CANCER I, V89, P652, DOI 10.1093/jnci/89.9.652; Scott G, 1997, J INVEST DERMATOL, V108, P147, DOI 10.1111/1523-1747.ep12332650; Shand JH, 2003, J BIOL CHEM, V278, P17859, DOI 10.1074/jbc.M300526200; Sottile J, 1998, J CELL SCI, V111, P2933; Sottile J, 2000, J CELL SCI, V113, P4287; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994	43	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4269	4277		10.1074/jbc.M311586200	http://dx.doi.org/10.1074/jbc.M311586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645245	hybrid			2022-12-27	WOS:000188554300044
J	Xiong, HB; Zhu, C; Li, FL; Hegazi, R; He, KL; Babyatsky, M; Bauer, AJ; Plevy, SE				Xiong, HB; Zhu, C; Li, FL; Hegazi, R; He, KL; Babyatsky, M; Bauer, AJ; Plevy, SE			Inhibition of interleukin-12 p40 transcription and NF-kappa B activation by nitric oxide in murine macrophages and dendritic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; BLOOD MONONUCLEAR-CELLS; IFN-GAMMA PRODUCTION; MOUSE BONE-MARROW; MICE LACKING; T-CELLS; IL-12; GENE; EXPRESSION; MECHANISMS	Nitric oxide ( NO), an important effector molecule of the innate immune system, can also regulate adaptive immunity. In this study, the molecular effects of NO on the toll-like receptor signaling pathway were determined using interleukin-12 (IL-12) as an immunologically relevant target gene. The principal conclusion of these experiments is that NO inhibits IL-1 receptor-associated kinase ( IRAK) activity and attenuates the molecular interaction between tumor necrosis factor receptor-associated factor-6 and IRAK. As a consequence, the NO donor S-nitroso-N-acetylpenicillamine ( SNAP) inhibits lipopolysaccharide (LPS)-induced IL-12 p40 mRNA expression, protein production, and promoter activity in murine macrophages, dendritic cells, and the murine macrophage cell line RAW 264.7. Splenocytes from inducible nitric-oxide synthase-deficient mice demonstrate markedly increased IL-12 p40 protein and mRNA expression compared with wild type splenocytes. The inhibitory action of NO on IL-12 p40 is independent of the cytokine IL-10. The effects of NO can be directly attributed to inhibition of NF-kappaB activation through IRAK-dependent pathways. Accordingly, SNAP strongly reduces LPS-induced NF-kappaB DNA binding to the p40 promoter and inhibits LPS-induced IkappaB phosphorylation. Similarly, NO attenuates IL-1beta-induced NF-kappaB activation. These experiments provide another example of how an innate immune molecule may have a profound effect on adaptive immunity.	Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15261 USA; Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; Mt Sinai Sch Med, Div Gastroenterol, New York, NY 10029 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Plevy, SE (corresponding author), Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Scaife Hall,Rm S566,3550 Terrace St, Pittsburgh, PA 15261 USA.	sep1@pitt.edu	Hegazi, Refaat A./AAR-4026-2021; Hegazi, Refaat/ABG-4179-2020					Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; Bogdan C, 1998, J EXP MED, V187, P1361, DOI 10.1084/jem.187.9.1361; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; Fenyk-Melody JE, 1998, J IMMUNOL, V160, P2940; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO;2-K; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kwak HJ, 2001, MOL CELLS, V12, P178; La EH, 2001, J IMMUNOL, V166, P6149, DOI 10.4049/jimmunol.166.10.6149; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANDER HM, 1993, J IMMUNOL, V150, P1509; Liu JJ, 2003, J IMMUNOL, V170, P4489, DOI 10.4049/jimmunol.170.9.4489; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; MacLean A, 1998, J GEN VIROL, V79, P825, DOI 10.1099/0022-1317-79-4-825; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; Niedbala W, 2002, P NATL ACAD SCI USA, V99, P16186, DOI 10.1073/pnas.252464599; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; Seder RA, 1996, J IMMUNOL, V157, P2745; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; WOLF SF, 1991, J IMMUNOL, V146, P3074; Xiong HB, 1996, CELL IMMUNOL, V172, P118, DOI 10.1006/cimm.1996.0222; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	36	86	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10776	10783		10.1074/jbc.M313416200	http://dx.doi.org/10.1074/jbc.M313416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679201	hybrid			2022-12-27	WOS:000220050400133
J	Corazza, A; Pettirossi, F; Viglino, P; Verdone, G; Garcia, J; Dumy, P; Giorgetti, S; Mangione, P; Raimondi, S; Stoppini, M; Bellotti, V; Esposito, G				Corazza, A; Pettirossi, F; Viglino, P; Verdone, G; Garcia, J; Dumy, P; Giorgetti, S; Mangione, P; Raimondi, S; Stoppini, M; Bellotti, V; Esposito, G			Properties of some variants of human beta(2)-microglobulin and amyloidogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-MICROGLOBULIN REVEALS; AMYLOID FIBRIL FORMATION; DISULFIDE BOND; PH; SPECTROSCOPY; MECHANISMS; EXCITATION; ENERGY; COPPER; STATES	Three variants of human beta(2)-microglobulin (beta(2)-m) were compared with wild-type protein. For two variants, namely the mutant R3Abeta(2)-m and the form devoid of the N-terminal tripeptide (DeltaN3beta(2)-m), a reduced unfolding free energy was measured compared with wild-type beta(2)-m, whereas an increased stability was observed for the mutant H31Ybeta(2)-m. The solution structure could be determined by H-1 NMR spectroscopy and restrained modeling only for R3Abeta(2)-m that showed the same conformation as the parent species, except for deviations at the interstrand loops. Analogous conclusions were reached for H31Ybeta(2)-m and DeltaN3beta(2)-m. Precipitation and unfolding were observed over time periods shorter than 4 - 6 weeks with all the variants and, sometimes, with wild-type protein. The rate of structured protein loss from solution as a result of precipitation and unfolding always showed pseudo-zeroth order kinetics. This and the failure to observe an unfolded species without precipitation suggest that a nucleated conformational conversion scheme should apply for beta(2)-m fibrillogenesis. The mechanism is consistent with the previous and present results on beta(2)-m amyloid transition, provided a nucleated oligomeric species be considered the stable intermediate of fibrillogenesis, the monomeric intermediate being the necessary transition step along the pathway from the native protein to the nucleated oligomer.	Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Univ Udine, Micrograv Aging Training & Immobil Ctr Excellence, I-33100 Udine, Italy; Univ Grenoble 1, Etud Dynam & Struct Select Lab, F-38041 Grenoble 9, France; Univ Pavia, Dipartimento Biochim, I-27100 Pavia, Italy; Policlin San Matteo, Ist Recovero & Cura Carattere Sci, Lab Biotecnol, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Udine; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Pavia; IRCCS Fondazione San Matteo	Esposito, G (corresponding author), Univ Udine, Dipartimento Sci & Tecnol Biomed, Piazzale Kolbe 4, I-33100 Udine, Italy.	gesposito@mail.dstb.uniud.it	Corazza, Alessandra/AGB-1457-2022; dumy, pascal/C-4863-2008; Giorgetti, Sofia/AAD-4341-2019; Bellotti, Vittorio/A-6201-2014	Corazza, Alessandra/0000-0003-2272-1928; dumy, pascal/0000-0002-7660-763X; Giorgetti, Sofia/0000-0001-9438-6511; Bellotti, Vittorio/0000-0001-8678-662X; Mangione, Palma/0000-0003-0260-1400				ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bellotti V, 1998, EUR J BIOCHEM, V258, P61, DOI 10.1046/j.1432-1327.1998.2580061.x; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; De Lorenzi E, 2002, ELECTROPHORESIS, V23, P918, DOI 10.1002/1522-2683(200203)23:6<918::AID-ELPS918>3.0.CO;2-F; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Eakin CM, 2002, BIOCHEMISTRY-US, V41, P10646, DOI 10.1021/bi025944a; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Fogolari F, 2000, PROTEINS, V39, P317, DOI 10.1002/(SICI)1097-0134(20000601)39:4<317::AID-PROT50>3.0.CO;2-W; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jones S, 2003, J MOL BIOL, V330, P935, DOI 10.1016/S0022-2836(03)00688-0; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KEELER J, 1994, METHOD ENZYMOL, V239, P145; Kelly JW, 2000, NAT STRUCT BIOL, V7, P824, DOI 10.1038/82815; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; MADURA JD, 1995, COMPUT PHYS COMMUN, V91, P57, DOI 10.1016/0010-4655(95)00043-F; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; McParland VJ, 2002, NAT STRUCT BIOL, V9, P326, DOI 10.1038/nsb791; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Merlini G, 2003, NEW ENGL J MED, V349, P583, DOI 10.1056/NEJMra023144; Monti M, 2002, PROTEIN SCI, V11, P2362, DOI 10.1110/ps.0206902; Morgan CJ, 2001, J MOL BIOL, V309, P339, DOI 10.1006/jmbi.2001.4661; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; Ohhashi Y, 2002, J BIOCHEM, V131, P45, DOI 10.1093/oxfordjournals.jbchem.a003076; OKON M, 1992, BIOCHEMISTRY-US, V31, P8906, DOI 10.1021/bi00152a030; Pace C N, 1986, Methods Enzymol, V131, P266; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rosano C, 2004, J MOL BIOL, V335, P1051, DOI 10.1016/j.jmb.2003.11.040; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Smith DP, 2003, J MOL BIOL, V330, P943, DOI 10.1016/S0022-2836(03)00687-9; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Trinh CH, 2002, P NATL ACAD SCI USA, V99, P9771, DOI 10.1073/pnas.152337399; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P6044, DOI 10.1021/bi00393a015; Uchanska-Ziegler B, 2003, TRENDS IMMUNOL, V24, P73, DOI 10.1016/S1471-4906(02)00028-5; Verdone G, 2002, PROTEIN SCI, V11, P487, DOI 10.1110/ps.29002; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WUTHRICH K, 1986, NMR SPECTROSCOPY PRO; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288	53	61	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9176	9189		10.1074/jbc.M310779200	http://dx.doi.org/10.1074/jbc.M310779200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660575	hybrid			2022-12-27	WOS:000189265900079
J	Filipenko, NR; MacLeod, TJ; Yoon, CS; Waisman, DM				Filipenko, NR; MacLeod, TJ; Yoon, CS; Waisman, DM			Annexin A2 is a novel RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT EXOCYTOSIS; ROUS-SARCOMA-VIRUS; C-MYC ONCOGENE; CALPACTIN-I; HEAVY-CHAIN; LIGHT-CHAIN; PHOSPHOLIPID-BINDING; ENHANCED EXPRESSION; CELLULAR SUBSTRATE; KINASE SUBSTRATE	Annexin A2 (ANXA2) is a Ca2+-binding protein that is up-regulated in virally transformed cell lines and in human tumors. Here, we show that ANXA2 binds directly to both ribonucleotide homopolymers and human c-myc RNA. ANXA2 was shown to bind specifically to poly( G) with high affinity (K-d = 60 nM) and not to poly( A), poly( C), or poly( U). The binding of ANXA2 to poly( G) required Ca2+ (A(50%) = 10 muM). The presence of RNA in the immunoprecipitates of ANXA2 isolated from HeLa cells established that ANXA2 formed a ribonucleoprotein complex in vivo. Sucrose gradient analysis showed that ANXA2 associates with ribonucleoprotein complexes and not with polyribosomes. Reverse transcriptase-PCR identified c-myc mRNA as a component of the ribonucleoprotein complex formed by ANXA2 in vivo, and binding studies confirmed a direct interaction between ANXA2 and c-myc mRNA. Transfection of LNCaP cells with the ANXA2 gene resulted in the up-regulation of c-Myc protein. These findings identify ANXA2 as a Ca2+-dependent RNA-binding protein that interacts with the mRNA of the nuclear oncogene, c-myc.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@ucalgary.ca		Waisman, David/0000-0002-5097-9662	NCI NIH HHS [R01CA 78639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ALI SM, 1990, CELL SIGNAL, V2, P265, DOI 10.1016/0898-6568(90)90054-E; ARANY I, 1994, SURG ONCOL, V3, P153, DOI 10.1016/0960-7404(94)90044-2; ARRIGO AP, 1983, EMBO J, V2, P309, DOI 10.1002/j.1460-2075.1983.tb01424.x; Ayala-Sanmartin J, 2000, BIOCHEMISTRY-US, V39, P15190, DOI 10.1021/bi000764r; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Babiychuk EB, 2002, FASEB J, V16, DOI 10.1096/fj.02-0070com; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; BOYKO V, 1994, FEBS LETT, V345, P139, DOI 10.1016/0014-5793(94)00419-6; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; Chetcuti A, 2001, CANCER RES, V61, P6331; CHU E, 1995, MOL CELL BIOL, V15, P179, DOI 10.1128/MCB.15.1.179; COURTNEIDGE S, 1983, MOL CELL BIOL, V3, P340, DOI 10.1128/MCB.3.3.340; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Eberhard DA, 2001, J CELL SCI, V114, P3155; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Emoto K, 2001, ANTICANCER RES, V21, P1339; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; ERIKSON E, 1984, MOL CELL BIOL, V4, P77, DOI 10.1128/MCB.4.1.77; Filipenko NR, 2003, MOL B INT U, P127; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; Herms JW, 1999, SURG NEUROL, V51, P536, DOI 10.1016/S0090-3019(98)00028-7; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; KEITH G, 1983, BIOCHIMIE, V65, P367, DOI 10.1016/S0300-9084(83)80159-X; Kenmochi N, 1998, GENOME RES, V8, P509, DOI 10.1101/gr.8.5.509; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KRISHNA P, 1990, P NATL ACAD SCI USA, V87, P1292, DOI 10.1073/pnas.87.4.1292; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; LENS D, 1994, LEUKEMIA, V8, P2102; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; OZAKI T, 1993, ONCOGENE, V8, P1707; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; RADKE K, 1979, P NATL ACAD SCI USA, V76, P5212, DOI 10.1073/pnas.76.10.5212; REEVES SA, 1992, CANCER RES, V52, P6871; SALEHI Z, 1990, J IMMUNOL, V145, P276; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Vedeler A, 2000, BIOCHEM J, V348, P565, DOI 10.1042/0264-6021:3480565; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; VISHWANATHA JK, 1992, J CELL SCI, V101, P25; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WANG MY, 1992, NUCLEIC ACIDS RES, V20, P3519, DOI 10.1093/nar/20.13.3519; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; Zalfa F, 2003, CELL, V112, P317, DOI 10.1016/S0092-8674(03)00079-5; Zeuschner D, 2001, EUR J CELL BIOL, V80, P499, DOI 10.1078/0171-9335-00184; ZINN AR, 1994, MOL CELL BIOL, V14, P2485, DOI 10.1128/MCB.14.4.2485; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	60	108	121	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8723	8731		10.1074/jbc.M311951200	http://dx.doi.org/10.1074/jbc.M311951200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672933	hybrid			2022-12-27	WOS:000189265900025
J	Hegazy, UM; Mannervik, B; Stenberg, G				Hegazy, UM; Mannervik, B; Stenberg, G			Functional role of the lock and key motif at the subunit interface of glutathione transferase P1-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HELIX-COIL TRANSITION; INDUCED-FIT MECHANISM; S-TRANSFERASES; CLASS-PI; 3-DIMENSIONAL STRUCTURE; CATALYTIC MECHANISM; SULFHYDRYL-GROUP; ENTHALPY CHANGE; HUMAN PLACENTA	The glutathione transferases (GSTs) represent a superfamily of dimeric proteins. Each subunit has an active site, but there is no evidence for the existence of catalytically active monomers. The lock and key motif is responsible for a highly conserved hydrophobic interaction in the subunit interface of pi, mu, and alpha class glutathione transferases. The key residue, which is either Phe or Tyr (Tyr(50) in human GSTP1-1) in one subunit, is wedged into a hydrophobic pocket of the other subunit. To study how an essentially inactive subunit influences the activity of the neighboring subunit, we have generated the heterodimer composed of subunits from the fully active human wild-type GSTP1-1 and the nearly inactive mutant Y50A obtained by mutation of the key residue Tyr(50) to Ala. Although the key residue is located far from the catalytic center, the k(cat) value of mutant Y50A decreased about 1300-fold in comparison with the wild-type enzyme. The decrease of the kcat value of the heterodimer by about 27-fold rather than the expected 2-fold in comparison with the wild-type enzyme indicates that the two active sites of the dimeric enzyme work synergistically. Further evidence for cooperativity was found in the nonhyperbolic GSH saturation curves. A network of hydrogen-bonded water molecules, found in crystal structures of GSTP1-1, connects the two active sites and the main chain carbonyl group of Tyr50, thereby offering a mechanism for communication between the two active sites. It is concluded that a subunit becomes catalytically competent by positioning the key residue of one subunit into the lock pocket of the other subunit, thereby stabilizing the loop following the helix alpha2, which interacts directly with GSH.	Uppsala Univ, Ctr Biomed, Dept Biochem, SE-75123 Uppsala, Sweden	Uppsala University	Stenberg, G (corresponding author), Uppsala Univ, Ctr Biomed, Dept Biochem, Box 576, SE-75123 Uppsala, Sweden.	gun.stenberg@biokem.uu.se	Hegazy, Usama/E-4066-2010; Hegazy, Usama/H-3568-2019	Hegazy, Usama/0000-0002-3611-0792				Abdalla AM, 2002, PROTEIN ENG, V15, P827, DOI 10.1093/protein/15.10.827; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BOYER TD, 1989, HEPATOLOGY, V9, P486, DOI 10.1002/hep.1840090324; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; CHOU PY, 1971, BIOPOLYMERS, V10, P657, DOI 10.1002/bip.360100406; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1988, GLUTATHIONE CONJUGAT, P316; Hitchens TK, 2001, BIOCHEMISTRY-US, V40, P11660, DOI 10.1021/bi010909+; Hornby JAT, 2002, BIOCHEMISTRY-US, V41, P14238, DOI 10.1021/bi020548d; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KOLM RH, 1995, PROTEIN EXPRES PURIF, V6, P265, DOI 10.1006/prep.1995.1034; Lo Bello M, 1998, J MOL BIOL, V284, P1717; LOBELLO M, 1993, BIOCHEM BIOPH RES CO, V194, P804, DOI 10.1006/bbrc.1993.1893; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B., 1978, CONJUGATION REACTION, P101; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Oakley AJ, 1998, BIOCHEMISTRY-US, V37, P9912, DOI 10.1021/bi980323w; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Pickett C.B., 1989, ANNU REV BIOCHEM, V58, P734; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; RIALDI G, 1966, J AM CHEM SOC, V88, P5719, DOI 10.1021/ja00976a007; RICCI G, 1991, J BIOL CHEM, V266, P21409; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Sayed Y, 2000, FEBS LETT, V465, P169, DOI 10.1016/S0014-5793(99)01747-0; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; Stella L, 1999, PROTEINS, V37, P1; Stenberg G, 2000, BIOCHEM BIOPH RES CO, V271, P59, DOI 10.1006/bbrc.2000.2579; TAHIR MK, 1985, FEBS LETT, V181, P249; TAHIR MK, 1986, J BIOL CHEM, V261, P1048; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; Vargo MA, 2001, BIOCHEMISTRY-US, V40, P8624; WAXMAN DJ, 1990, CANCER RES, V50, P6449; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8	51	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9586	9596		10.1074/jbc.M312320200	http://dx.doi.org/10.1074/jbc.M312320200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676193	hybrid			2022-12-27	WOS:000189265900126
J	Padmanabhan, B; Kuzuhara, T; Adachi, N; Horikoshi, M				Padmanabhan, B; Kuzuhara, T; Adachi, N; Horikoshi, M			The crystal structure of CCG1/TAF(II)250-interacting factor B (CIB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; TRANSCRIPTION FACTOR ATF; TATA-BINDING PROTEIN; ALPHA/BETA-HYDROLASE; HUMAN TAF(II)250; DNA-BINDING; INITIATION; NUCLEOSOME; ACETYLATION; PROMOTER	The general transcription initiation factor TFIID and its interactors play critical roles in regulating the transcription from both naked and chromatin DNA. We have isolated a novel TFIID interactor that we denoted as CCG1/TAF(II)250-interacting factor B (CIB). We show here that CIB activates transcription. To further understand the function of this protein, we determined its crystal structure at 2.2-Angstrom resolution. The tertiary structure of CIB reveals an alpha/beta-hydrolase fold that resembles structures in the prokaryotic alpha/beta-hydrolase family proteins. It is not similar in structure or primary sequence to any eukaryotic transcription or chromatin factors that have been reported to date. CIB possesses a conserved catalytic triad that is found in other alpha/beta-hydrolases, and our in vitro studies confirmed that it bears hydrolase activity. However, CIB differs from other alpha/beta-hydrolases in that it lacks a binding site excursion, which facilitates the substrate selectivity of the other alpha/beta-hydrolases. Further functional characterization of CIB based on its tertiary structure and through biochemical studies may provide novel insights into the mechanisms that regulate eukaryotic transcription.	Japan Sci & Technol Corp, Exploratory Res Adv Technol, Horikoshi Gene Selector Project, Tsukuba, Ibaraki 3002635, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Dev Biol Lab, Bunkyo Ku, Tokyo 1130032, Japan	Japan Science & Technology Agency (JST); University of Tokyo	Horikoshi, M (corresponding author), Japan Sci & Technol Corp, Exploratory Res Adv Technol, Horikoshi Gene Selector Project, 5-9-6 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	horikosh@iam.u-tokyo.ac.jp		Kuzuhara, Takashi/0000-0003-0565-6060				Adachi N, 2002, J BIOL CHEM, V277, P35688, DOI 10.1074/jbc.M204640200; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bando M, 1997, J BIOCHEM-TOKYO, V121, P591; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chimura T, 2002, P NATL ACAD SCI USA, V99, P9334, DOI 10.1073/pnas.142627899; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; CYGLER M, 1994, J AM CHEM SOC, V116, P3180, DOI 10.1021/ja00087a002; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HECHT HJ, 1994, NAT STRUCT BIOL, V1, P532, DOI 10.1038/nsb0894-532; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hochheimer A, 2003, GENE DEV, V17, P1309, DOI 10.1101/gad.1099903; Hofmann B, 1998, J MOL BIOL, V279, P889, DOI 10.1006/jmbi.1998.1802; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kanaya S, 1998, BIOCHEM J, V332, P75, DOI 10.1042/bj3320075; Kim KK, 1997, STRUCTURE, V5, P1571, DOI 10.1016/S0969-2126(97)00306-7; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Marmorstein R, 2001, STRUCTURE, V9, P1127, DOI 10.1016/S0969-2126(01)00690-6; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moshkin YM, 2002, GENE DEV, V16, P2621, DOI 10.1101/gad.231202; Munakata T, 2000, GENES CELLS, V5, P221, DOI 10.1046/j.1365-2443.2000.00319.x; Nandhagopal N, 1997, P JPN ACAD B-PHYS, V73, P154, DOI 10.2183/pjab.73.154; Nardini M, 1999, J BIOL CHEM, V274, P14579, DOI 10.1074/jbc.274.21.14579; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padmanabhan B, 2000, ACTA CRYSTALLOGR D, V56, P1479, DOI 10.1107/S0907444900010957; Padmanabhan B, 2001, J CRYST GROWTH, V232, P326, DOI 10.1016/S0022-0248(01)01073-9; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Siegert JL, 1999, MOL CELL BIOL, V19, P846; Sutton A, 2003, J BIOL CHEM, V278, P16887, DOI 10.1074/jbc.M210709200; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; Tan S, 2001, NAT STRUCT BIOL, V8, P8, DOI 10.1038/83098; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Umehara T, 2003, J BIOL CHEM, V278, P35660, DOI 10.1074/jbc.M303549200; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; Veenstra GJC, 2001, TRENDS BIOCHEM SCI, V26, P665, DOI 10.1016/S0968-0004(01)01970-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yamaki M, 2001, GENES CELLS, V6, P1043, DOI 10.1046/j.1365-2443.2001.00487.x; Yamamoto T, 1998, GENES CELLS, V3, P347, DOI 10.1046/j.1365-2443.1998.00195.x; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yeates TO, 2002, CELL, V111, P5, DOI 10.1016/S0092-8674(02)01010-3; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	75	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9615	9624		10.1074/jbc.M312165200	http://dx.doi.org/10.1074/jbc.M312165200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672934	hybrid			2022-12-27	WOS:000189265900129
J	Tsukahara, F; Maru, Y				Tsukahara, F; Maru, Y			Identification of novel nuclear export and nuclear localization-related signals in human heat shock cognate protein 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BINDING DOMAIN; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; KARYOPHILIC PROTEINS; SUBSTRATE-BINDING; HUMAN HSP70; HSC70; RECEPTOR; IMPORT; ATPASE	Heat shock cognate protein 70 (Hsc70) serves nuclear transport of several proteins as a molecular chaperone. We have recently identified a novel variant of human Hsc70, heat shock cognate protein 54 (Hsc54), that lacks amino acid residues 464-616 in the protein binding and variable domains of Hsc70. In the present study, we examined nucleocytoplasmic localization of Hsc70 and Hsc54 by using green fluorescent protein (GFP) fusions. GFP-Hsc70 is localized in both the cytoplasm and the nucleus at 37degreesC and accumulated into the nucleolus/nucleus after heat shock, whereas GFP-Hsc54 always remained exclusively in the cytoplasm under these conditions. Mutation studies indicated that 20 amino acid residues of nuclear localization-related signals, which are missing in Hsc54 but are retained in Hsc70, are required for proper nuclear localization of Hsc70. We further found that Hsc54 contains a functional leucine-rich nuclear export signal (NES, (LDVTPLSL401)-L-394) which is differently situated from the previously proposed NES in Saccharomyces cerevisiae Ssb1p. The cytoplasmic localization of Hsc54 was impaired by a mutation in NES as well as by a nuclear export inhibitor, leptomycin B, suggesting that Hsc54 is actively exported from the nucleus to the cytoplasm through a CRM1-dependent mechanism. In contrast, the nucleocytoplasmic localization of Hsc70 was not affected by the same mutation of NES or leptomycin B. These results suggest that the nuclear localization-related signal could functionally mask NES leading to prolonged retention of Hsc70 in the nucleus. An additional mechanism for unmasking the NES may regulate nucleocytoplasmic trafficking of Hsc70.	Tokyo Womens Med Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, Tokyo 1628666, Japan	Tokyo Women's Medical University	Tsukahara, F (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Pharmacol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	fuji@research.twmu.ac.jp						ABE T, 1995, BIOCHEM BIOPH RES CO, V206, P548, DOI 10.1006/bbrc.1995.1078; Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Fujihara SM, 1999, EMBO J, V18, P411, DOI 10.1093/emboj/18.2.411; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hu SM, 1996, ARCH BIOCHEM BIOPHYS, V332, P163, DOI 10.1006/abbi.1996.0328; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; Lamian V, 1996, EXP CELL RES, V228, P84, DOI 10.1006/excr.1996.0302; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NUNES SL, 1995, BIOCHEM BIOPH RES CO, V213, P1, DOI 10.1006/bbrc.1995.2090; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Shulga N, 1999, J BIOL CHEM, V274, P16501, DOI 10.1074/jbc.274.23.16501; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TSAI MY, 1994, J BIOL CHEM, V269, P5958; Tsukahara F, 2000, MOL PHARMACOL, V58, P1257, DOI 10.1124/mol.58.6.1257; WANG TF, 1993, J BIOL CHEM, V268, P26049; WELCH WJ, 1988, J CELL BIOL, V106, P1117, DOI 10.1083/jcb.106.4.1117; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YANG J, 1994, MOL CELL BIOL, V14, P5088, DOI 10.1128/MCB.14.8.5088; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	38	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8867	8872		10.1074/jbc.M308848200	http://dx.doi.org/10.1074/jbc.M308848200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684748	hybrid			2022-12-27	WOS:000189265900043
J	Park, JS; Svetkauskaite, D; He, QB; Kim, JY; Strassheim, D; Ishizaka, A; Abraham, E				Park, JS; Svetkauskaite, D; He, QB; Kim, JY; Strassheim, D; Ishizaka, A; Abraham, E			Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; I-KAPPA-B; TUMOR-NECROSIS-FACTOR; NEURITE OUTGROWTH; MULTILIGAND RECEPTOR; CUTTING EDGE; MOLECULAR-MECHANISMS; CHROMATIN PROTEIN; HUMAN NEUTROPHILS; GENE-EXPRESSION	High mobility group box 1 (HMGB1) protein, originally described as a DNA-binding protein that stabilizes nucleosomes and facilitates transcription, can also be released extracellularly during acute inflammatory responses. Exposure of neutrophils, monocytes, or macrophages to HMGB1 results in increased nuclear translocation of NF-kappaB and enhanced expression of proinflammatory cytokines. Although the receptor for advanced glycation end products (RAGE) has been shown to interact with HMGB1, other putative HMGB1 receptors are known to exist but have not been characterized. In the present experiments, we explored the role of RAGE, Toll-like receptor (TLR) 2, and TLR 4, as well as associated kinases, in HMGB1-induced cellular activation. Culture of neutrophils or macrophages with HMGB1 produced activation of NF-kappaB through TLR 4-independent mechanisms. Unlike lipopolysaccharide (LPS), which primarily increased the activity of IKKbeta, HMGB1 exposure resulted in activation of both IKKalpha and IKKbeta. Kinases and scaffolding proteins downstream of TLR 2 and TLR 4, but not TLR/interleukin- 1 receptor (IL-1R)-independent kinases such as tumor necrosis factor receptor-associated factor 2, were involved in the enhancement of NF-kappaB-dependent transcription by HMGB1. Transfections with dominant negative constructs demonstrated that TLR 2 and TLR 4 were both involved in HMGB1-induced activation of NF-kappaB. In contrast, RAGE played only a minor role in macrophage activation by HMGB1. Interactions of HMGB1 with TLR 2 and TLR 4 may provide an explanation for the ability of HMGB1 to generate inflammatory responses that are similar to those initiated by LPS.	Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Keio Univ, Sch Med, Dept Med, Tokyo 160, Japan	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Keio University	Abraham, E (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Box C272,4200 E 9th Ave, Denver, CO 80262 USA.	Edward.Abraham@uchsc.edu	STRASSHEIM, DEREK/AHB-1158-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062221, P01HL068743] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62221, 1P01HL068743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham E, 2003, J IMMUNOL, V170, P5644, DOI 10.4049/jimmunol.170.11.5644; Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6; Andersson U, 2002, J LEUKOCYTE BIOL, V72, P1084; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Arcaroli J, 2002, J LEUKOCYTE BIOL, V72, P571; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Chung JY, 2002, J CELL SCI, V115, P679; Czura CJ, 2003, CRIT CARE MED, V31, pS46, DOI 10.1097/00003246-200301001-00007; Czura CJ, 2001, J ENDOTOXIN RES, V7, P315, DOI 10.1177/09680519010070041401; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dintilhac A, 2002, J BIOL CHEM, V277, P7021, DOI 10.1074/jbc.M108417200; DUNNE A, 2003, SCI STKE; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hori O, 1996, NEPHROL DIAL TRANSPL, V11, P13; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Huttunen HJ, 2002, CANCER RES, V62, P4805; Huttunen HJ, 2002, J BIOL CHEM, V277, P38635, DOI 10.1074/jbc.M202515200; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Imler J L, 2000, Rev Immunogenet, V2, P294; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nick JA, 1996, J IMMUNOL, V156, P4867; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park JS, 2003, AM J PHYSIOL-CELL PH, V284, pC870, DOI 10.1152/ajpcell.00322.2002; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Sabroe I, 2002, J IMMUNOL, V168, P4701, DOI 10.4049/jimmunol.168.9.4701; Sajithlal G, 2002, J BIOL CHEM, V277, P6888, DOI 10.1074/jbc.M107627200; SANDERS C, 1977, BIOCHEM BIOPH RES CO, V78, P1034, DOI 10.1016/0006-291X(77)90525-3; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Schmidt AM, 1996, DIABETES, V45, pS77, DOI 10.2337/diab.45.3.S77; SCHWARTZ MC, 1995, AM J RESP CELL MOL, V12, P434, DOI 10.1165/ajrcmb.12.4.7695923; Sparatore B, 2002, BIOCHEM J, V363, P529, DOI 10.1042/0264-6021:3630529; Stern D, 2002, ADV DRUG DELIVER REV, V54, P1615, DOI 10.1016/S0169-409X(02)00160-6; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yang H, 2001, SHOCK, V15, P247, DOI 10.1097/00024382-200115040-00001; Yang KY, 2003, CELL SIGNAL, V15, P225, DOI 10.1016/S0898-6568(02)00063-3; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Yoshinari D, 2001, CRIT CARE MED, V29, P628, DOI 10.1097/00003246-200103000-00029; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414	66	1252	1340	3	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7370	7377		10.1074/jbc.M306793200	http://dx.doi.org/10.1074/jbc.M306793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660645	hybrid			2022-12-27	WOS:000189103300002
J	Ren, Y; Meng, SS; Mei, L; Zhao, ZJ; Jove, R; Wu, J				Ren, Y; Meng, SS; Mei, L; Zhao, ZJ; Jove, R; Wu, J			Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-KINASE; PHOSPHATASE SHP-2; C-SRC; FACTOR RECEPTOR; EPITHELIAL MORPHOGENESIS; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAY; FAMILY KINASES; CELL MOTILITY	Epidermal growth factor (EGF) induces paxillin tyrosine dephosphorylation and Src activation, but the signaling pathways that mediate these responses were largely undefined. We found that Gab1, a docking protein for the SHP2 protein-tyrosine phosphatase in EGF-stimulated cells, was associated with paxillin. SHP2 dephosphorylated paxillin and caused dissociation of Csk, a negative regulator of Src, from paxillin but had no effect on paxillin-Src association. A lower level of Src Tyr-530 phosphorylation was detected in paxillin-associated Src in EGF-stimulated cells. Expression of an SHP2 binding defective mutant of Gab1 (Gab1FF) or a catalytically inactive mutant of SHP2 (SHP2DN) prevented paxillin tyrosine dephosphorylation and Src activation induced by EGF. Importantly, Gab1FF blocked paxillin-SHP2 complex formation, Src Tyr-530 dephosphorylation, Erk activation, and cell migration induced by EGF. Inhibition of Src tyrosine kinase activity abrogated EGF-stimulated Erk activation and cell migration. Together, these results reveal that Gab1 recruits SHP2 to dephosphorylate paxillin, leading to dissociation of Csk from the paxillin-Src complex and Src activation and that Src is an SHP2 effector involved in EGF-stimulated Erk activation and cell migration.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ Alabama, Dept Neurobiol, Civitan Int Res Ctr, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Civitan Int Res Ctr, Birmingham, AL 35294 USA; Univ Alabama, Dept Phys Med & Rehabil, Civitan Int Res Ctr, Birmingham, AL 35294 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Vanderbilt University	Wu, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC 3-E,12902 Magnolia Dr, Tampa, FL 33612 USA.	wu@moffitt.usf.edu	Wu, Jie/R-2404-2019; Mei, Lin/G-8755-2012	Wu, Jie/0000-0002-2864-1606; 	NCI NIH HHS [R01 CA077467, CA77467] Funding Source: Medline; NINDS NIH HHS [NS44521, NS45710] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA077467, R29CA077467, R01CA077467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044521, R01NS045710] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2002, J BIOL CHEM, V277, P9498, DOI 10.1074/jbc.M110547200; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Dorsey JF, 2002, BLOOD, V99, P1388, DOI 10.1182/blood.V99.4.1388; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishibe S, 2003, MOL CELL, V12, P1275, DOI 10.1016/S1097-2765(03)00406-4; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Lotz M, 2003, J SURG RES, V109, P123, DOI 10.1016/S0022-4804(02)00100-2; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Manes S, 1999, MOL CELL BIOL, V19, P3125; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; MEI L, 1994, J BIOL CHEM, V269, P12254; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ren Y, 2003, ANTICANCER RES, V23, P3231; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Turner CE, 2000, J CELL SCI, V113, P4139; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zeng Q, 1998, ANAL BIOCHEM, V259, P187, DOI 10.1006/abio.1998.2645; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	55	136	139	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8497	8505		10.1074/jbc.M312575200	http://dx.doi.org/10.1074/jbc.M312575200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665621	hybrid			2022-12-27	WOS:000189103300133
J	Shibasaki, T; Sunaga, Y; Fujimoto, K; Kashima, Y; Seino, S				Shibasaki, T; Sunaga, Y; Fujimoto, K; Kashima, Y; Seino, S			Interaction of ATP sensor, cAMP sensor, Ca2+ sensor, and voltage-dependent Ca2+ channel in insulin granule exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE ZONE; SYNAPTOTAGMIN-I; BINDING DOMAINS; RAB3 EFFECTOR; PROTEIN; COMPLEX; FAMILY; SECRETION; PICCOLO; SUBUNIT	ATP, cAMP, and Ca2+ are the major signals in the regulation of insulin granule exocytosis in pancreatic beta cells. The sensors and regulators of these signals have been characterized individually. The ATP-sensitive K+ channel, acting as the ATP sensor, couples cell metabolism to membrane potential. cAMP-GEFII, acting as a cAMP sensor, mediates cAMP-dependent, protein kinase A-independent exocytosis, which requires interaction with both Piccolo as a Ca2+ sensor and Rim2 as a Rab3 effector. L-type voltage-dependent Ca2+ channels (VDCCs) regulate Ca2+ influx. In the present study, we demonstrate interactions of these molecules. Sulfonylurea receptor 1, a subunit of ATP-sensitive K+ channels, interacts specifically with cAMP-GEFII through nucleotide-binding fold 1, and the interaction is decreased by a high concentration of cAMP. Localization of cAMP-GEFII overlaps with that of Rim2 in plasma membrane of insulin-secreting MIN6 cells. Localization of Rab3 coincides with that of Rim2. Rim2 mutant lacking the Rab3 binding region, when overexpressed in MIN6 cells, is localized exclusively in cytoplasm, and impairs cAMP-dependent exocytosis in MIN6 cells. In addition, Rim2 and Piccolo bind directly to the alpha(1) 1.2- subunit of VDCC. These results indicate that ATP sensor, cAMP sensor, Ca2+ sensor, and VDCC interact with each other, which further suggests that ATP, cAMP, and Ca2+ signals in insulin granule exocytosis are integrated in a specialized domain of pancreatic beta cells to facilitate stimulus-secretion coupling.	Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan; Chiba Univ, Grad Sch Med, Dept Cellular & Mol Med, Chiba 2608670, Japan	Kobe University; Chiba University	Seino, S (corresponding author), Kobe Univ, Grad Sch Med, Div Cellular & Mol Med, Kobe, Hyogo 6500017, Japan.	seino@med.kobe-u.ac.jp						Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brown J C, 1975, Recent Prog Horm Res, V31, P487; Calakos N, 1996, PHYSIOL REV, V76, P1; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; Coppola T, 2001, J BIOL CHEM, V276, P32756, DOI 10.1074/jbc.M100929200; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; Fujimoto K, 2002, J BIOL CHEM, V277, P50497, DOI 10.1074/jbc.M210146200; Harris BZ, 2001, J CELL SCI, V114, P3219; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; LANDIS DMD, 1988, J ELECTRON MICR TECH, V10, P129, DOI 10.1002/jemt.1060100203; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; YORIFUJI H, 1989, J ELECTRON MICR TECH, V12, P160, DOI 10.1002/jemt.1060120210; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	39	131	141	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7956	7961		10.1074/jbc.M309068200	http://dx.doi.org/10.1074/jbc.M309068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660679	hybrid			2022-12-27	WOS:000189103300073
J	Zylberman, V; Craig, PO; Klinke, S; Braden, BC; Cauerhff, A; Goldbaum, FA				Zylberman, V; Craig, PO; Klinke, S; Braden, BC; Cauerhff, A; Goldbaum, FA			High order quaternary arrangement confers increased structural stability to Brucella sp lumazine synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE ANALYSIS; HEAVY RIBOFLAVIN SYNTHASE; RAY STRUCTURE-ANALYSIS; BETA-SUBUNIT CAPSIDS; BACILLUS-SUBTILIS; ANGSTROM RESOLUTION; B-SUBUNIT; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; CYTOPLASMIC PROTEIN; LABILE ENTEROTOXIN	The penultimate step in the pathway of riboflavin biosynthesis is catalyzed by the enzyme lumazine synthase (LS). One of the most distinctive characteristics of this enzyme is the structural quaternary divergence found in different species. The protein exists as pentameric and icosahedral forms, built from practically the same structural monomeric unit. The pentameric structure is formed by five 18-kDa monomers, each extensively contacting neighboring monomers. The icosahedrical structure consists of 60 LS monomers arranged as 12 pentamers giving rise to a capsid exhibiting icosahedral 532 symmetry. In all lumazine synthases studied, the topologically equivalent active sites are located at the interfaces between adjacent subunits in the pentameric modules. The Brucella sp. lumazine synthase (BLS) sequence clearly diverges from pentameric and icosahedric enzymes. This unusual divergence prompted us to further investigate its quaternary arrangement. In the present work, we demonstrate by means of solution light scattering and x-ray structural analyses that BLS assembles as a very stable dimer of pentamers, representing a third category of quaternary assembly for lumazine synthases. We also describe by spectroscopic studies the thermodynamic stability of this oligomeric protein and postulate a mechanism for dissociation/unfolding of this macromolecular assembly. The higher molecular order of BLS increases its stability 20degreesC compared with pentameric lumazine synthases. The decameric arrangement described in this work highlights the importance of quaternary interactions in the stabilization of proteins.	Consejo Nacl Invest Cient & Tecn, Inst Leloir, Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina; Bowie State Univ, Dept Nat Sci, Bowie, MD 20715 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires; University System of Maryland; Bowie State University	Goldbaum, FA (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Leloir, Patricias Argentinas 435,C1405BWE, Buenos Aires, DF, Argentina.	fgoldbaum@leloir.org.ar	Klinke, Sebastián/N-6174-2018	Klinke, Sebastián/0000-0002-8777-0870; Goldbaum, Fernando/0000-0001-6235-3002; Cauerhff, Ana/0000-0001-9686-9883				BACHER A, 1986, METHOD ENZYMOL, V122, P192; BHAKUNI V, 1991, BIOCHEMISTRY-US, V30, P5055, DOI 10.1021/bi00234a031; Botelho MG, 2003, J BIOL CHEM, V278, P34259, DOI 10.1074/jbc.M303189200; Boudker O, 1997, J MOL BIOL, V272, P770, DOI 10.1006/jmbi.1997.1263; Braden BC, 2000, J MOL BIOL, V297, P1031, DOI 10.1006/jmbi.2000.3640; D'Alfonso L, 1999, BBA-PROTEIN STRUCT M, V1432, P194, DOI 10.1016/S0167-4838(99)00105-3; Dams T, 1999, BIOCHEMISTRY-US, V38, P9169, DOI 10.1021/bi990635e; DANIEL E, 1966, BIOCHEMISTRY-US, V5, P1893, DOI 10.1021/bi00870a016; FORNASARI MS, 2003, MOL BIOL EVOL; Gerhardt S, 2002, J MOL BIOL, V318, P1317, DOI 10.1016/S0022-2836(02)00116-X; Goldbaum FA, 1998, J STRUCT BIOL, V123, P175, DOI 10.1006/jsbi.1998.4022; Goldbaum FA, 1999, J MED MICROBIOL, V48, P833, DOI 10.1099/00222615-48-9-833; GOLDBAUM FA, 1993, J CLIN MICROBIOL, V31, P2141, DOI 10.1128/JCM.31.8.2141-2145.1993; GREENE RF, 1974, J BIOL CHEM, V249, P5388; Guidry JJ, 2000, PROTEIN SCI, V9, P2109, DOI 10.1110/ps.9.11.2109; Jaenicke R, 2000, J BIOTECHNOL, V79, P193, DOI 10.1016/S0168-1656(00)00236-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIS K, 1995, BIOCHEMISTRY-US, V34, P2883, DOI 10.1021/bi00009a019; Kohler S, 2003, TRENDS MICROBIOL, V11, P215, DOI 10.1016/S0966-842X(03)00078-7; KOHN WD, 1995, J BIOL CHEM, V270, P25495, DOI 10.1074/jbc.270.43.25495; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LADENSTEIN R, 1994, EUR J BIOCHEM, V223, P1007, DOI 10.1111/j.1432-1033.1994.tb19079.x; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Meining W, 2000, J MOL BIOL, V299, P181, DOI 10.1006/jmbi.2000.3742; Mok YK, 1996, PROTEIN SCI, V5, P310; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Panse VG, 2000, BIOCHEMISTRY-US, V39, P2362, DOI 10.1021/bi992484l; Polikarpov I, 1998, NUCL INSTRUM METH A, V405, P159, DOI 10.1016/S0168-9002(97)01202-3; Reddy GB, 1999, BIOCHEMISTRY-US, V38, P4464, DOI 10.1021/bi982828s; RITSERT K, 1995, J MOL BIOL, V253, P151, DOI 10.1006/jmbi.1995.0542; Ruddock LW, 1996, BIOCHEMISTRY-US, V35, P16069, DOI 10.1021/bi961865l; Ruddock LW, 1996, J BIOL CHEM, V271, P19118, DOI 10.1074/jbc.271.32.19118; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; Velikovsky CA, 2002, INFECT IMMUN, V70, P2507, DOI 10.1128/IAI.70.5.2507-2511.2002; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435	38	64	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8093	8101		10.1074/jbc.M312035200	http://dx.doi.org/10.1074/jbc.M312035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660615	hybrid			2022-12-27	WOS:000189103300089
J	Gelling, CL; Piper, MDW; Hong, SP; Kornfeld, GD; Dawes, IW				Gelling, CL; Piper, MDW; Hong, SP; Kornfeld, GD; Dawes, IW			Identification of a novel one-carbon metabolism regulon in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE HYDROXYMETHYLTRANSFERASE; MOLECULAR CHARACTERIZATION; PURINE BIOSYNTHESIS; TRYPTOPHAN SYNTHASE; MASTER REGULATOR; FOLATE COENZYMES; GENE-EXPRESSION; FOLIC-ACID; IN-VIVO; YEAST	Glycine specifically induces genes encoding subunits of the glycine decarboxylase complex (GCV1, GCV2, and GCV3), and this is mediated by a fall in cytoplasmic levels of 5,10-methylenetetrahydrofolate caused by inhibition of cytoplasmic serine hydroxymethyltransferase. Here it is shown that this control system extends to genes for other enzymes of one-carbon metabolism and de novo purine biosynthesis. Northern analysis of the response to glycine demonstrated that the induction of the GCV genes and the induction of other amino acid metabolism genes are temporally distinct. The genomewide response to glycine revealed that several other genes are rapidly co-induced with the GCV genes, including SHM2, which encodes cytoplasmic serine hydroxymethyltransferase. These results were refined by examining transcript levels in an shm2Delta strain (in which cytoplasmic 5,10-methylenetetrahydrofolate levels are reduced) and a met13Delta strain, which lacks the main methylenetetrahydrofolate reductase activity of yeast and is effectively blocked at consumption of 5,10-methylene tetrahydrofolate for methionine synthesis. Glycine addition also caused a substantial transient disturbance to metabolism, including a sequence of changes in induction of amino acid biosynthesis and respiratory chain genes. Analysis of the glycine response in the shm2Delta strain demonstrated that apart from the one-carbon regulon, most of these transient responses were not contingent on a disturbance to one-carbon metabolism. The one-carbon response is distinct from the Bas1p purine biosynthesis regulon and thus represents the first example of transcriptional regulation in response to activated one-carbon status.	Univ New S Wales, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia; Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of New South Wales Sydney	Dawes, IW (corresponding author), Univ New S Wales, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia.	i.dawes@unsw.edu.au	Piper, Matthew/C-1714-2008	Piper, Matthew/0000-0003-3245-7219				ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; Bailey LB, 2003, J NUTR, V133, p1961S, DOI 10.1093/jn/133.6.1961S; BARLOWE C K, 1988, Biofactors, V1, P171; BLANCHETTE M, 2001, BIOINFORMATICS, V1, P1; BOTSFORD JL, 1969, J BACTERIOL, V97, P1176, DOI 10.1128/JB.97.3.1176-1183.1969; CAPERELLI CA, 1980, J BIOL CHEM, V255, P1885; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; Dax SL, 1997, ANTIBACTERIAL CHEMOT, P38; Denis V, 1998, MOL GEN GENET, V259, P246, DOI 10.1007/s004380050810; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Halsted CH, 2002, ALCOHOL, V27, P169, DOI 10.1016/S0741-8329(02)00225-2; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Hong SP, 1999, J BIOL CHEM, V274, P10523, DOI 10.1074/jbc.274.15.10523; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; HOUBEN KF, 1989, BIOCHEMISTRY-US, V28, P4140, DOI 10.1021/bi00436a003; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; Lucock M, 2000, MOL GENET METAB, V71, P121, DOI 10.1006/mgme.2000.3027; MCKENZIE KQ, 1977, GENETICS, V86, P85; McNeil JB, 1997, GENE, V186, P13, DOI 10.1016/S0378-1119(96)00670-1; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; McNeil JB, 1996, GENETICS, V142, P371; MORGAN SL, 1995, FOLATE HLTH DIS, P405; Morris Martha Savaria, 2002, Nutr Clin Care, V5, P124, DOI 10.1046/j.1523-5408.2002.t01-1-00006.x; Nagarajan L, 1997, J BIOL CHEM, V272, P4444, DOI 10.1074/jbc.272.7.4444; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; OGUR M, 1977, J BACTERIOL, V129, P926, DOI 10.1128/JB.129.2.926-933.1977; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; PASTERNACK LB, 1992, BIOCHEMISTRY-US, V31, P8713, DOI 10.1021/bi00152a005; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; Pinson B, 2000, MOL MICROBIOL, V36, P1460, DOI 10.1046/j.1365-2958.2000.01966.x; Piper MD, 2000, J BIOL CHEM, V275, P30987, DOI 10.1074/jbc.M004248200; Raymond RK, 1999, ARCH BIOCHEM BIOPHYS, V372, P300, DOI 10.1006/abbi.1999.1498; Ro HS, 1999, J BIOL CHEM, V274, P31189, DOI 10.1074/jbc.274.44.31189; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Rodriguez-Navarro S, 2002, YEAST, V19, P1261, DOI 10.1002/yea.916; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sinclair DA, 1996, MOL MICROBIOL, V19, P611, DOI 10.1046/j.1365-2958.1996.419947.x; Sinha S, 2002, NUCLEIC ACIDS RES, V30, P5549, DOI 10.1093/nar/gkf669; STOVER P, 1990, J BIOL CHEM, V265, P14227; STOVER P, 1991, J BIOL CHEM, V266, P1543; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; Tibbetts AS, 2000, J BIOL CHEM, V275, P20920, DOI 10.1074/jbc.M909851199; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906	54	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7072	7081		10.1074/jbc.M309178200	http://dx.doi.org/10.1074/jbc.M309178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645232	hybrid			2022-12-27	WOS:000188969200105
J	Dan, HC; Sun, M; Kaneko, S; Feldman, RI; Nicosia, SV; Wang, HG; Tsang, BK; Cheng, JQ				Dan, HC; Sun, M; Kaneko, S; Feldman, RI; Nicosia, SV; Wang, HG; Tsang, BK; Cheng, JQ			Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES CELL-SURVIVAL; SERINE-THREONINE KINASE; OVARIAN-CANCER CELLS; ACTIVATION; EXPRESSION; CISPLATIN; PATHWAY; IAPS; CHEMORESISTANCE; CASPASE-9	Akt negatively regulates apoptotic pathways at a pre-mitochondrial level through phosphorylation and modulation of proteins such as Bad, Forkhead proteins, and GSK-3beta. Akt has also been shown to protect cell death at a post-mitochondrial level, although its downstream targets have not been well documented. Here, we demonstrate that Akt, including AKT1 and AKT2, interacts with and phosphorylates X-linked inhibitor of apoptosis protein ( XIAP) at residue serine-87 in vitro and in vivo. Phosphorylation of XIAP by Akt protects XIAP from ubiquitination and degradation in response to cisplatin. Moreover, autoubiquitination of XIAP is also inhibited by Akt. Consistent with this, an XIAP mutant introduced into cells which mimics the Akt-phosphorylated form (i.e. XIAP-S87D) displays reduced ubiquitination and degradation as compared with wild type XIAP. The greater stability of XIAP-S87D in cells translated to increased cell survival after cisplatin treatment. Conversely, a mutant that could not be phosphorylated by Akt (XIAP-S87A) was more rapidly degraded and showed increased cisplatin-induced apoptosis. Furthermore, suppression of XIAP by either siRNA or adenovirus of antisense of XIAP induced programmed cell death and inhibited Akt-stimulated cell survival in ovarian cancer cells. These data identify XIAP as a new downstream target of Akt and a potentially important mediator of the effect of Akt on cell survival.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA; Univ Ottawa, Dept Obstet & Gynaecol & Cellular & Mol Med, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Cheng, JQ (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC Box 11, Tampa, FL 33612 USA.	jcheng@hsc.usf.edu	高, 雨莉/HGU-8187-2022		NATIONAL CANCER INSTITUTE [R01CA089242, R01CA077935, R29CA077935] Funding Source: NIH RePORTER; NCI NIH HHS [CA77935, CA89242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Matsumiya T, 2001, ORAL ONCOL, V37, P296, DOI 10.1016/S1368-8375(00)00102-0; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Ozes ON, 1999, NATURE, V401, P82; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Sasaki H, 2000, CANCER RES, V60, P5659; Sasaki H, 2002, GYNECOL ONCOL, V85, P339, DOI 10.1006/gyno.2002.6632; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Xiao CW, 2001, ENDOCRINOLOGY, V142, P557, DOI 10.1210/en.142.2.557; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	34	358	379	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5405	5412		10.1074/jbc.M312044200	http://dx.doi.org/10.1074/jbc.M312044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645242	hybrid			2022-12-27	WOS:000188776500046
J	Hatano, N; Ohya, S; Muraki, K; Clark, RB; Giles, WR; Imaizumi, Y				Hatano, N; Ohya, S; Muraki, K; Clark, RB; Giles, WR; Imaizumi, Y			Two arginines in the cytoplasmic C-terminal domain are essential for voltage-dependent regulation of A-type K+ current in the Kv4 channel subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNEL; CLOSED-STATE INACTIVATION; ACTIVATION GATE; INTERACTING PROTEIN-2; MOLECULAR-CLONING; PYRAMIDAL NEURONS; BINDING PROTEIN; SPLICE VARIANTS; T1 DOMAIN; EXPRESSION	Contributions of the C-terminal domain of Kv4.3 to the voltage-dependent gating of A-type K+ current (I-A) were examined by (i) making mutations in this region, (ii) heterologous expression in HEK293 cells, and (iii) detailed voltage clamp analyses. Progressive deletions of the C terminus of rat Kv4.3M ( to amino acid 429 from the N terminus) did not markedly change the inactivation time course of IA but shifted the voltage dependence of steady state inactivation in the negative direction to a maximum of -17 mV. Further deletions ( to amino acid 420) shifted this parameter in the positive direction, suggesting a critical role for the domain 429-420 in the voltage-dependent regulation of IA. There are four positively charged amino acids in this domain: Lys(423), Lys(424), Arg(426), and Arg(429). The replacement of the two arginines with alanines (R2A) resulted in -23 and -13 mV shifts of inactivation and activation, respectively. Additional replacement of the two lysines with alanines did not result in further shifts. Single replacements of R426A or R429A induced -15 and -10 mV shifts of inactivation, respectively. R2A did not significantly change the inactivation rate but did markedly change the voltage dependence of recovery from inactivation. These two arginines are conserved in Kv4 subfamily, and alanine replacement of Arg(429) and Arg(432) in Kv4.2 gave essentially the same results. These effects of R2A were not modulated by co-expression of the K+ channel beta subunit, KChIPs. In conclusion, the two arginines in the cytosolic C-terminal domain of alpha-subunits of Kv4 subfamily strongly regulate the voltage dependence of channel activation, inactivation, and recovery.	Nagoya City Univ, Dept Mol & Cellular Pharmacol, Grad Sch Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Univ Calgary, Fac Med, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	Nagoya City University; University of Calgary	Imaizumi, Y (corresponding author), Nagoya City Univ, Dept Mol & Cellular Pharmacol, Grad Sch Pharmaceut Sci, Mizuho Ku, 3-1 Tanabedori, Nagoya, Aichi 4678603, Japan.	yimaizum@phar.nagoya-cu.ac.jp	Ohya, Susumu/AAB-3618-2020; Imaizumi, Yuji/AAF-6585-2020	Ohya, Susumu/0000-0002-5765-0667; 				An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bahring R, 2001, J PHYSIOL-LONDON, V535, P65, DOI 10.1111/j.1469-7793.2001.00065.x; Beck EJ, 2002, J PHYSIOL-LONDON, V538, P691, DOI 10.1113/jphysiol.2001.013127; Beck EJ, 2001, BIOPHYS J, V81, P867, DOI 10.1016/S0006-3495(01)75747-5; Castro PA, 2001, J NEUROSCI, V21, P6626, DOI 10.1523/JNEUROSCI.21-17-06626.2001; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; Cormier JW, 2002, J BIOL CHEM, V277, P9233, DOI 10.1074/jbc.M110204200; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Decher N, 2001, CARDIOVASC RES, V52, P255, DOI 10.1016/S0008-6363(01)00374-1; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Hatano N, 2002, PFLUG ARCH EUR J PHY, V444, P80, DOI 10.1007/s00424-002-0798-9; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; IMAIZUMI Y, 1990, J PHYSIOL-LONDON, V427, P301, DOI 10.1113/jphysiol.1990.sp018173; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LIPKIND GM, 1995, P NATL ACAD SCI USA, V92, P9215, DOI 10.1073/pnas.92.20.9215; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Mantegazza M, 2001, P NATL ACAD SCI USA, V98, P15348, DOI 10.1073/pnas.211563298; Martina M, 1998, J NEUROSCI, V18, P8111; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Nakamura TY, 2001, FEBS LETT, V499, P205, DOI 10.1016/S0014-5793(01)02560-1; Ohya S, 2001, LIFE SCI, V68, P1703, DOI 10.1016/S0024-3205(01)00958-4; Ohya S, 2001, BIOCHEM BIOPH RES CO, V282, P96, DOI 10.1006/bbrc.2001.4558; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; Patel SP, 2002, J PHYSIOL-LONDON, V539, P649, DOI 10.1113/jphysiol.2001.015156; Petrecca K, 2000, J NEUROSCI, V20, P8736; Rasmusson RL, 1995, J PHYSIOL-LONDON, V489, P709, DOI 10.1113/jphysiol.1995.sp021085; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Song M, 2001, J BIOL CHEM, V276, P31883, DOI 10.1074/jbc.M101058200; Takimoto K, 1997, CIRC RES, V81, P533, DOI 10.1161/01.RES.81.4.533; TSENGCRANK J, 1993, J GEN PHYSIOL, V102, P1057, DOI 10.1085/jgp.102.6.1057; Wang SM, 2002, BIOCHEM BIOPH RES CO, V295, P223, DOI 10.1016/S0006-291X(02)00658-7; Wong W, 2002, J BIOL CHEM, V277, P20423, DOI 10.1074/jbc.M109412200; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	48	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5450	5459		10.1074/jbc.M302034200	http://dx.doi.org/10.1074/jbc.M302034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645239	hybrid			2022-12-27	WOS:000188776500052
J	Moon, JJ; Rubio, ED; Martino, A; Krumm, A; Nelson, BH				Moon, JJ; Rubio, ED; Martino, A; Krumm, A; Nelson, BH			A permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; IL-2 RECEPTOR; BETA-CHAIN; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; NUCLEAR SPECKLES; BREAST-CANCER; C-MYC; STAT5; INDUCTION	The interleukin- 2 ( IL- 2) receptor promotes T cell proliferation in part by inducing the expression of D- type cyclins, which enable cells to progress from the G(1) to S phase of the cell cycle. We previously showed that the IL- 2 receptor induces expression of cyclin D2 by activating the transcription factor Stat5, which binds directly and immediately to a site upstream of the cyclin D2 promoter. We show here that subsequent transcription of the cyclin D2 gene occurs by a delayed, cycloheximide-sensitive mechanism, which implies the involvement of additional regulatory mechanisms. The transcription factor c- Myc is induced by Stat5 and is reported to bind to two E box motifs in the cyclin D2 promoter. However, in IL- 2- stimulated T cells, c- Myc does not appear to be involved in cyclin D2 induction, since we found that these two E boxes are preferentially bound by USF- 1 and USF- 2 and, moreover, are dispensable for cyclin D2 promoter activity. Instead, we found that Stat5 activates the phosphatidylinositol 3- kinase ( PI3 kinase) pathway by a delayed, cycloheximide- sensitive mechanism and that PI3 kinase activity is essential for the induction of cyclin D2 by Stat5. Chromatin immunoprecipitation experiments revealed that PI3 kinase is required for the optimal binding of RNA polymerase II to the promoters of cyclin D2 as well as other genes. Our results reveal a novel link between PI3 kinase and RNA polymerase II promoter binding activity and demonstrate discrete, coordinated roles for the PI3 kinase and Stat5 pathways in cyclin D2 transcription.	Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Radiat Oncol, Seattle, WA 98195 USA; Benaroya Res Inst Virginia Mason, Seattle, WA 98101 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Benaroya Research Institute; Virginia Mason Medical Center; Fred Hutchinson Cancer Center	Nelson, BH (corresponding author), BC Canc Agcy, 2410 Lee Ave, Victoria, BC V8R 6V5, Canada.	bnelson@bccancer.bc.ca	Nelson, Brad H/K-2622-2014	Nelson, Brad/0000-0002-4445-5539	NATIONAL CANCER INSTITUTE [T32CA009537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057931] Funding Source: NIH RePORTER; NCI NIH HHS [CA09537] Funding Source: Medline; NIGMS NIH HHS [GM57931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Friedrichsen BN, 2001, MOL ENDOCRINOL, V15, P136, DOI 10.1210/me.15.1.136; Friedrichsen BN, 2003, MOL ENDOCRINOL, V17, P945, DOI 10.1210/me.2002-0356; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lord JD, 1998, J IMMUNOL, V161, P4627; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Moon JJ, 2001, J IMMUNOL, V167, P2714, DOI 10.4049/jimmunol.167.5.2714; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nelson BH, 1996, MOL CELL BIOL, V16, P309; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; TURNER JM, 1993, INT IMMUNOL, V5, P1199, DOI 10.1093/intimm/5.10.1199; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1	53	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5520	5527		10.1074/jbc.M308998200	http://dx.doi.org/10.1074/jbc.M308998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660677	hybrid			2022-12-27	WOS:000188776500060
J	Snyder, PM; Steines, JC; Olson, DR				Snyder, PM; Steines, JC; Olson, DR			Relative contribution of Nedd4 and Nedd4-2 to ENaC regulation in epithelia determined by RNA interference	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL ENAC; LIDDLES-SYNDROME; SODIUM-CHANNEL; CELL-SURFACE; WW DOMAINS; PY MOTIF; ALDOSTERONE; EXPRESSION; INHIBITION; SGK	Epithelial Na+ transport is regulated in large part by mechanisms that control expression of the epithelial Na+ channel (ENaC) at the cell surface. Nedd4 and Nedd4-2 are candidates to control ENaC surface expression, but it is not known which of these proteins contributes to ENaC regulation in epithelia. To address this question, we used RNA interference to selectively reduce expression of Nedd4 or Nedd4-2. We found that endogenous Nedd4-2, but not Nedd4, negatively regulates ENaC in two epithelial cell lines (Fischer rat thyroid and H441); small interfering RNA (siRNA) against Nedd4-2 increased amiloride-sensitive Na+ current (compared with control siRNA), but Nedd4 siRNA did not. A mutation associated with Liddle's syndrome (beta(R566X)) abolished the effect of Nedd4-2 siRNA, suggesting that a defect in ENaC regulation by Nedd4-2 contributes to the pathogenesis of this inherited form of hypertension. Previous work found that Nedd4-2 is phosphorylated by serum and glucocorticoid-regulated kinase, a Ser/Thr kinase induced by steroid hormones. Here we found that Nedd4-2 phosphorylation contributes to ENaC regulation by steroid hormones. Consistent with this model, ENaC stimulation by dexamethasone was reduced by Nedd4-2 siRNA and by overexpression of a mutant Nedd4-2 lacking serum and glucocorticoid-regulated kinase phosphorylation sites. Thus, endogenous Nedd4-2 negatively regulates ENaC in epithelia and is a component of a signaling pathway by which steroid hormones regulate ENaC. Defects in this regulation may contribute to the pathogenesis of hypertension.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 371 Eckstein Med Res Bldg, Iowa City, IA 52242 USA.	psnyder@blue.weeg.uiowa.edu			NHLBI NIH HHS [HL03575, HL61781, HL58812, HL55006] Funding Source: Medline; NIDDK NIH HHS [DK52617] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061781, P50HL055006, R29HL058812, R01HL058812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auberson M, 2003, AM J PHYSIOL-RENAL, V285, pF459, DOI 10.1152/ajprenal.00071.2003; Benos DJ, 1997, NEWS PHYSIOL SCI, V12, P55; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Dahlmann A, 2003, AM J PHYSIOL-RENAL, V285, pF310, DOI 10.1152/ajprenal.00016.2003; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Helms MN, 2003, AM J PHYSIOL-RENAL, V284, pF480, DOI 10.1152/ajprenal.00299.2002; Henry PC, 2003, J BIOL CHEM, V278, P20019, DOI 10.1074/jbc.M211153200; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Staub O, 1997, AM J PHYSIOL-CELL PH, V272, pC1871, DOI 10.1152/ajpcell.1997.272.6.C1871; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Stokes JB, 1998, AM J PHYSIOL-CELL PH, V274, pC1699, DOI 10.1152/ajpcell.1998.274.6.C1699	33	123	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					5042	5046		10.1074/jbc.M312477200	http://dx.doi.org/10.1074/jbc.M312477200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14645220	hybrid			2022-12-27	WOS:000188554300131
J	Herold, CL; Qi, AD; Harden, TK; Nicholas, RA				Herold, CL; Qi, AD; Harden, TK; Nicholas, RA			Agonist versus antagonist action of ATP at the P2Y(4) receptor is determined by the second extracellular loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTOR; ADP RECEPTOR; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; AMINO-ACIDS; EXPRESSION; IDENTIFICATION; CLONING; RHODOPSIN	UTP is a potent full agonist at both the human P2Y(4) (hP2Y(4)) and rat P2Y(4) (rP2Y(4)) receptor. In contrast, ATP is a potent full agonist at the rP2Y(4) receptor but is a similarly potent competitive antagonist at the hP2Y(4) receptor. To delineate the structural determinants of agonism versus antagonism in these species homologues, we expressed a series of human/rat P2Y(4) receptor chimeras in 1321N1 human astrocytoma cells and assessed the capacity of ATP and UTP to mobilize intracellular Ca2+. Replacement of the NH2 terminus of the hP2Y(4) receptor with the corresponding region of the rP2Y(4) receptor resulted in a receptor that was activated weakly by ATP, whereas replacement of the second extracellular loop (EL2) of the hP2Y(4) receptor with that of the rP2Y(4) receptor yielded a chimeric receptor that was activated fully by UTP and near fully by ATP, albeit with lower potencies than those observed at the rP2Y(4) receptor. These potencies were increased, and ATP was converted to a full agonist by replacing both the NH2 terminus and EL2 in the hP2Y(4) receptor with the corresponding regions from the rP2Y(4) receptor. Mutational analysis of the five divergent amino acids in EL2 between the two receptors revealed that three amino acids, Asn-177, Ile-183, and Leu-190, contribute to the capacity of EL2 to impart ATP agonism. Taken together, these results suggest that the second extracellular loop and the NH2 terminus form a functional motif that plays a key role in determining whether ATP functions as an agonist or antagonist at mammalian P2Y(4) receptors.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Nicholas, RA (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	nicholas@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071131, HL71131] Funding Source: Medline; NIGMS NIH HHS [GM38213, R01 GM038213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1994, J BIOL CHEM, V269, P24557; Archer E, 2003, TRENDS PHARMACOL SCI, V24, P36, DOI 10.1016/S0165-6147(02)00009-3; Berthold M, 1997, NEUROCHEM RES, V22, P1023, DOI 10.1023/A:1022483027858; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Communi D, 1999, BRIT J PHARMACOL, V128, P1199, DOI 10.1038/sj.bjp.0702909; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Comstock K E, 1997, Methods Mol Biol, V62, P207; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Harden TK, 1998, DEV CARDIOVASC MED, V209, P187; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffmann C, 1999, J BIOL CHEM, V274, P14639, DOI 10.1074/jbc.274.21.14639; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jiang QL, 1997, MOL PHARMACOL, V52, P499, DOI 10.1124/mol.52.3.499; Kenakin T, 1996, PHARMACOL REV, V48, P413; Kennedy C, 2000, MOL PHARMACOL, V57, P926; King BF, 1998, TRENDS PHARMACOL SCI, V19, P506, DOI 10.1016/S0165-6147(98)01271-1; Li Q, 1998, MOL PHARMACOL, V54, P541, DOI 10.1124/mol.54.3.541; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Qi AD, 2001, MOL PHARMACOL, V60, P1375, DOI 10.1124/mol.60.6.1375; Qi AD, 2001, BRIT J PHARMACOL, V132, P318, DOI 10.1038/sj.bjp.0703788; Ralevic V, 1998, PHARMACOL REV, V50, P413; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schachter JB, 1997, BRIT J PHARMACOL, V122, P1021, DOI 10.1038/sj.bjp.0701479; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; Takasaki J, 2001, MOL PHARMACOL, V60, P432; Van Rhee A M, 1995, Drug Des Discov, V13, P133; Whistler JL, 2002, TRAFFIC, V3, P866, DOI 10.1034/j.1600-0854.2002.31203.x; Zambon AC, 2001, MOL PHARMACOL, V60, P26, DOI 10.1124/mol.60.1.26; Zhang FL, 2001, J BIOL CHEM, V276, P8608, DOI 10.1074/jbc.M009718200	41	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11456	11464		10.1074/jbc.M301734200	http://dx.doi.org/10.1074/jbc.M301734200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14670966	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000220157600076
J	MacKenzie, JA; Payne, RM				MacKenzie, JA; Payne, RM			Ribosomes specifically bind to mammalian mitochondria via protease-sensitive proteins on the outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL-RECOGNITION PARTICLE; BOUND CYTOPLASMIC POLYSOMES; YEAST MITOCHONDRIA; RAT-LIVER; IN-VIVO; MICROSOMAL-MEMBRANES; NASCENT POLYPEPTIDES; RIBONUCLEIC-ACID; TRANSIT PEPTIDE	The interaction of ribosomes with specific components of membranes is one of the central themes to the co-translational targeting and import of proteins. To examine ribosome binding to mammalian mitochondria, we used ribosome-nascent chain complexes (RNCs) to follow the in vitro binding of ribosomes that correspond to the initial targeting stage of proteins. Mitochondria were found to contain a limited number of RNC binding sites on the outer membrane. It required more than twice the amount of non-translating ribosomes to inhibit RNC binding by one-half, indicating that RNCs have a competitive binding advantage. In addition, we found that RNCs bind mainly through the ribosomal component and not the nascent chain. RNCs bind via protease-sensitive proteins on the outer membrane, as well as by protease-insensitive components suggesting that two classes of receptors exist. We also show that binding is sensitive to cation conditions. Nearly all of the binding was inhibited in 0.5 M KCl, indicating that they interact with the membrane primarily through electrostatic interactions. In addition, disruption of RNC structure by removing magnesium causes the complete inhibition of binding under normal binding conditions indicating that it is the intact ribosome that is crucial for binding and not the nascent chain. These findings support the hypothesis that the outer mitochondrial membrane contains receptors specific for ribosomes, which would support the conditions necessary for co-translational import.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Cardiol Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Mol Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Payne, RM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pediat, Cardiol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mpayne@wfubmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055765] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK55765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; ADES IZ, 1980, J BIOL CHEM, V255, P9918; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beddoe T, 2002, BBA-MOL CELL RES, V1592, P35, DOI 10.1016/S0167-4889(02)00262-8; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; CHU TW, 1987, J BIOL CHEM, V262, P12806; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; Corsi AK, 1996, J BIOL CHEM, V271, P30299, DOI 10.1074/jbc.271.48.30299; COX RA, 1976, BIOCHEM J, V160, P505, DOI 10.1042/bj1600505; Crowley KS, 1998, J BIOL CHEM, V273, P17278, DOI 10.1074/jbc.273.27.17278; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; EDELMAN IS, 1960, BIOCHIM BIOPHYS ACTA, V43, P393, DOI 10.1016/0006-3002(60)90464-9; FUJIKI M, 1991, J BIOL CHEM, V266, P6841; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; George R, 2002, FEBS LETT, V516, P213, DOI 10.1016/S0014-5793(02)02528-0; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; Hanes J, 1997, P NATL ACAD SCI USA, V94, P4937, DOI 10.1073/pnas.94.10.4937; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLEMS RE, 1972, J BIOL CHEM, V247, P8043; KELLEMS RE, 1974, J BIOL CHEM, V249, P3297; KELLEMS RE, 1975, J CELL BIOL, V65, P1, DOI 10.1083/jcb.65.1.1; KELLEMS RE, 1974, J BIOL CHEM, V249, P3304; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; MINAMI EI, 1984, ARCH BIOCHEM BIOPHYS, V235, P562, DOI 10.1016/0003-9861(84)90230-3; Morrow MW, 2001, TRAFFIC, V2, P705, DOI 10.1034/j.1600-0854.2001.21005.x; Murphy EC, 1997, J CELL BIOL, V136, P1213, DOI 10.1083/jcb.136.6.1213; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Ni L, 1999, J BIOL CHEM, V274, P12685, DOI 10.1074/jbc.274.18.12685; Nicchitta CV, 1997, J CELL BIOL, V139, P1697, DOI 10.1083/jcb.139.7.1697; Nobumoto M, 1998, J BIOCHEM, V123, P128; NOLAN RD, 1969, EUR J BIOCHEM, V10, P96; PICKETT CB, 1980, EXP CELL RES, V128, P343, DOI 10.1016/0014-4827(80)90070-1; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Stan T, 2000, EMBO J, V19, P4895, DOI 10.1093/emboj/19.18.4895; SUISSA M, 1982, J BIOL CHEM, V257, P3048; UNDERHAY E, 1956, J BIOPHYS BIOCHEM CY, V2, P635, DOI 10.1083/jcb.2.5.635; van Voorst F, 2000, BIOCHEM J, V347, P601, DOI 10.1042/bj3470601; VERNER K, 1993, TRENDS BIOCHEM SCI, V18, P366, DOI 10.1016/0968-0004(93)90090-A; WALTER P, 1983, METHOD ENZYMOL, V96, P84	53	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					9803	9810		10.1074/jbc.M307167200	http://dx.doi.org/10.1074/jbc.M307167200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14668341	hybrid			2022-12-27	WOS:000220050400019
J	Verloo, P; Kocken, CHM; Van der Wel, A; Tilly, BC; Hogema, BM; Sinaasappel, M; Thomas, AW; De Jonge, HR				Verloo, P; Kocken, CHM; Van der Wel, A; Tilly, BC; Hogema, BM; Sinaasappel, M; Thomas, AW; De Jonge, HR			Plasmodium falciparum-activated chloride channels are defective in erythrocytes from cystic fibrosis patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RED-BLOOD-CELLS; TRANSMEMBRANE CONDUCTANCE REGULATOR; MALARIA-INFECTED ERYTHROCYTES; ANION CHANNEL; PARASITE; MEMBRANE; CFTR; CAMP; ATP	An inwardly rectifying anion channel in malaria-infected red blood cells has been proposed to function as the "new permeation pathway" for parasite nutrient acquisition. As the channel shares several properties with the cystic fibrosis transmembrane conductance regulator (CFTR), we tested their interrelationship by whole-cell current measurements in Plasmodium falciparum-infected and uninfected red blood cells from control and cystic fibrosis (CF) patients. A CFTR-like linear chloride conductance as well as a malaria parasite-induced and a shrinkage-activated endogenous inwardly rectifying chloride conductance with properties identical to the malaria-induced channel were all found to be defective in CF erythrocytes. Surprisingly, the absence of the inwardly rectifying chloride conductance in CF erythrocytes had no gross effect on in vitro parasite growth or new permeation pathway activity, supporting an argument against a close association between the Plasmodium-activated chloride channel and the new permeation pathway. The functional expression of CFTR in red blood cells opens new perspectives to exploit the erythrocyte as a readily available cell type in electrophysiological, diagnostic, and therapeutic studies of CF.	Erasmus Univ, Med Ctr, Dept Biochem, NL-3000 DR Rotterdam, Netherlands; Biomed Primate Res Ctr, Dept Parasitol, NL-2280 GH Rijswijk, Netherlands; Erasmus Univ, Sophia Childrens Hosp, Med Ctr, NL-3015 GJ Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital	De Jonge, HR (corresponding author), Erasmus Univ, Med Ctr, Dept Biochem, POB 1738, NL-3000 DR Rotterdam, Netherlands.	h.dejonge@erasmusmc.nl		Verloo, Patrick/0000-0003-2077-0275; Voorberg - van der Wel, Annemarie/0000-0001-9403-0515; Kocken, Clemens/0000-0002-4784-1734				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; Baumeister S, 2003, MOL BIOCHEM PARASIT, V132, P35, DOI 10.1016/j.molbiopara.2003.08.003; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BRAUNBRETON C, 1988, NATURE, V332, P457, DOI 10.1038/332457a0; Cohn JV, 2003, MOL BIOCHEM PARASIT, V132, P27, DOI 10.1016/j.molbiopara.2003.08.001; Deng WS, 2003, BIOCHEM J, V374, P559, DOI 10.1042/BJ20030474; Deng WS, 2002, MOL MICROBIOL, V44, P1141, DOI 10.1046/j.1365-2958.2002.02948.x; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; Donald RGK, 2002, EUKARYOT CELL, V1, P317, DOI 10.1128/EC.1.3.317-328.2002; Egee S, 2002, J PHYSIOL-LONDON, V542, P795, DOI 10.1113/jphysiol.2002.022970; GINSBURG H, 1987, BIOSCIENCE REP, V7, P455, DOI 10.1007/BF01116501; Ginsburg Hagai, 1999, Novartis Foundation Symposium, V226, P99; Huber SM, 2002, EMBO J, V21, P22, DOI 10.1093/emboj/21.1.22; KIRK K, 1993, FEBS LETT, V323, P123, DOI 10.1016/0014-5793(93)81462-9; Kirk K, 1999, Novartis Found Symp, V226, P55; Kirk K, 2000, NATURE, V406, P949, DOI 10.1038/35023209; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; KUTNER S, 1982, BIOCHIM BIOPHYS ACTA, V687, P113, DOI 10.1016/0005-2736(82)90178-X; Li JL, 2000, MOL BIOCHEM PARASIT, V109, P157, DOI 10.1016/S0166-6851(00)00242-5; Ogura T, 2002, FASEB J, V16, P863, DOI 10.1096/fj.01-0845fje; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; Reddy MM, 2003, NATURE, V423, P756, DOI 10.1038/nature01694; Sprague RS, 2001, AM J PHYSIOL-CELL PH, V281, pC1158, DOI 10.1152/ajpcell.2001.281.4.C1158; Sprague RS, 1998, AM J PHYSIOL-HEART C, V275, pH1726, DOI 10.1152/ajpheart.1998.275.5.H1726; Staines HM, 2003, J PHYSIOL-LONDON, V552, P177, DOI 10.1113/jphysiol.2003.051169; Staines HM, 2001, AM J PHYSIOL-CELL PH, V280, pC1576, DOI 10.1152/ajpcell.2001.280.6.C1576; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Wagner MA, 2003, BIOPHYS J, V84, P116, DOI 10.1016/S0006-3495(03)74836-X	29	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10316	10322		10.1074/jbc.M311540200	http://dx.doi.org/10.1074/jbc.M311540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679190	hybrid			2022-12-27	WOS:000220050400080
J	Clark, JA; Black, AR; Leontieva, OV; Frey, MR; Pysz, MA; Kunneva, L; Woloszynska-Read, A; Roy, D; Black, JD				Clark, JA; Black, AR; Leontieva, OV; Frey, MR; Pysz, MA; Kunneva, L; Woloszynska-Read, A; Roy, D; Black, JD			Involvement of the ERK signaling cascade in protein kinase C-mediated cell cycle arrest in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MAP-KINASE; PHORBOL ESTER; BRYOSTATIN 1; INDUCED DIFFERENTIATION; INDUCED PROLIFERATION; SUSTAINED ACTIVATION; DOWN-REGULATION; CANCER CELLS; PC12 CELLS	We have reported previously that protein kinase C (PKC) signaling can mediate a program of cell cycle withdrawal in IEC-18 nontransformed intestinal crypt cells, involving rapid disappearance of cyclin D1, increased expression of Cip/Kip cyclin-dependent kinase inhibitors, and activation of the growth suppressor function of pocket proteins (Frey, M. R., Clark, J. A., Leontieva, O., Uronis, J. M., Black, A. R., and Black, J. D. (2000) J. Cell Biol. 151, 763 - 777). In the current study, we present evidence to support a requisite role for PKC alpha in mediating these effects. Furthermore, analysis of the signaling events linking PKC/PKC alpha activation to changes in the cell cycle regulatory machinery implicate the Ras/Raf/MEK/ERK cascade. PKC/PKC alpha activity promoted GTP loading of Ras, activation of Raf-1, and phosphorylation/activation of ERK. ERK activation was found to be required for critical downstream effects of PKC/PKC alpha activation, including cyclin D1 down-regulation, p21(Waf1/Cip1) induction, and cell cycle arrest. PKC-induced ERK activation was strong and sustained relative to that produced by proliferative signals, and the growth inhibitory effects of PKC agonists were dominant over proliferative events when these opposing stimuli were administered simultaneously. PKC signaling promoted cytoplasmic and nuclear accumulation of ERK activity, whereas growth factor-induced phospho-ERK was localized only in the cytoplasm. Comparison of the effects of PKC agonists that differ in their ability to sustain PKC alpha activation and growth arrest in IEC-18 cells, together with the use of selective kinase inhibitors, indicated that the length of PKC-mediated cell cycle exit is dictated by the magnitude/duration of input signal (i.e. PKC alpha activity) and of activation of the ERK cascade. The extent/duration of phospho-ERK nuclear localization may also be important determinants of the duration of PKC agonist-induced growth arrest in this system. Taken together, the data point to PKC alpha and the Ras/Raf/MEK/ERK cascade as key regulators of cell cycle withdrawal in intestinal epithelial cells.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Black, JD (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	jennifer.black@roswellpark.org	Frey, Mark/M-1739-2019; Frey, Mark/G-3691-2015	Frey, Mark/0000-0002-2561-5402; Frey, Mark/0000-0002-2561-5402	NCI NIH HHS [CA16056] Funding Source: Medline; NIDDK NIH HHS [DK54909, DK60632] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060632, R01DK054909, R56DK060632] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; BLUMBERG PM, 1994, PROG CLIN BIOL RES, V387, P3; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CELANO P, 1993, CELL GROWTH DIFFER, V4, P341; Chen AP, 1999, J BIOL CHEM, V274, P35505, DOI 10.1074/jbc.274.50.35505; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Frey MR, 1997, J BIOL CHEM, V272, P9424; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; HOCEVAR BA, 1992, J CELL SCI, V101, P671; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Kaiser GC, 1999, EXP CELL RES, V249, P349, DOI 10.1006/excr.1999.4488; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HW, 1997, MOL PHARMACOL, V51, P439; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Quaroni A, 1980, Methods Cell Biol, V21B, P403; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ray RM, 1999, AM J PHYSIOL-CELL PH, V276, pC684, DOI 10.1152/ajpcell.1999.276.3.C684; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Tibudan SS, 2002, J INVEST DERMATOL, V119, P1282, DOI 10.1046/j.1523-1747.2002.19625.x; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tsukada Y, 2001, J BIOL CHEM, V276, P40968, DOI 10.1074/jbc.M010890200; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708; YEE AS, 1998, FRONT BIOSCI, V3, P532; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	75	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9233	9247		10.1074/jbc.M312268200	http://dx.doi.org/10.1074/jbc.M312268200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670956	hybrid			2022-12-27	WOS:000189265900085
J	Santiago, TC; Zufferey, R; Mehra, RS; Coleman, RA; Ben Mamoun, C				Santiago, TC; Zufferey, R; Mehra, RS; Coleman, RA; Ben Mamoun, C			The Plasmodium falciparum PfGatp is an endoplasmic reticulum membrane protein important for the initial step of malarial glycerolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PFNT1 NUCLEOSIDE TRANSPORTER; PHOSPHATIDIC-ACID; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; DIHYDROXYACETONE PHOSPHATE; INFECTED ERYTHROCYTES; LIPID PARTICLES; BIOSYNTHESIS; GENE; LOCALIZATION; CHOLINE	During its 48-h asexual life cycle within human erythrocytes, Plasmodium falciparum grows to many times its own size and divides to produce 16-32 new parasites. This rapid multiplication requires active synthesis of new membranes and is fueled by phospholipid precursors and fatty acids that are scavenged from the human host. Plasmodium membrane biogenesis relies heavily on the expression of parasite enzymes that incorporate these precursors into phospholipids. However, little is known about the genes involved in membrane biogenesis or where this process takes place within the parasite. Here, we describe the analysis in P. falciparum of the first step of phospholipid biosynthesis that controls acylation of glycerol 3-phosphate (GPAT) at the sn-1 position. We show that this activity is of parasite origin and is specific for glycerol 3-phosphate substrate. We have identified the gene, PfGAT, encoding this activity in P. falciparum and reconstituted its codon composition for optimal expression in the yeast Saccharomyces cerevisiae. PfGAT complements the lethality of a yeast double mutant gat1Deltagat2Delta, lacking GPAT activity. Biochemical analysis revealed that PfGatp is a low affinity GPAT enzyme with a high specificity for C16:0 and C16:1 substrates. PfGatp is an integral membrane protein of the endoplasmic reticulum expressed throughout the intraerythrocytic life cycle of the parasite but induced mainly at the trophozoite stage. This study, which describes the first protozoan GPAT gene, reveals an important role for the endoplasmic reticulum in the initial step of Plasmodium membrane biogenesis.	Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Pathol, Farmington, CT 06030 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA	University of Connecticut; University of Connecticut; University of Connecticut; University of North Carolina; University of North Carolina Chapel Hill	Ben Mamoun, C (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, 263 Farmington Ave,MC3710, Farmington, CT 06030 USA.	choukri@up.uchc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056598] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR06192] Funding Source: Medline; NIDDK NIH HHS [DK56598] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANCELIN ML, 1986, BIOCHIM BIOPHYS ACTA, V875, P52, DOI 10.1016/0005-2760(86)90010-X; ANCELIN ML, 1986, FEBS LETT, V202, P217, DOI 10.1016/0014-5793(86)80690-1; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bozdech Z, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r9; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; CHRISTIANSEN K, 1978, BIOCHIM BIOPHYS ACTA, V530, P78, DOI 10.1016/0005-2760(78)90128-5; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; ELMENDORF HG, 1993, EMBO J, V12, P4763, DOI 10.1002/j.1460-2075.1993.tb06165.x; Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599; Foth BJ, 2003, INT REV CYTOL, V224, P57, DOI 10.1016/S0074-7696(05)24003-2; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hanada K, 2002, J EXP MED, V195, P23, DOI 10.1084/jem.20010724; HOLZ GG, 1977, B WORLD HEALTH ORGAN, V55, P237; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KUMAR N, 1991, MOL BIOCHEM PARASIT, V48, P47, DOI 10.1016/0166-6851(91)90163-Z; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Mamoun CB, 2001, MOL MICROBIOL, V39, P26, DOI 10.1046/j.1365-2958.2001.02222.x; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; Mitamura T, 2003, MICROBES INFECT, V5, P545, DOI 10.1016/S1286-4579(03)00070-4; Mitamura T, 2000, PARASITOL INT, V49, P219, DOI 10.1016/S1383-5769(00)00048-9; Prigge ST, 2003, BIOCHEMISTRY-US, V42, P1160, DOI 10.1021/bi026847k; Rager N, 2001, J BIOL CHEM, V276, P41095, DOI 10.1074/jbc.M107037200; SHERMAN IW, 1979, MICROBIOL REV, V43, P453, DOI 10.1128/MMBR.43.4.453-495.1979; Sorger D, 2003, APPL MICROBIOL BIOT, V61, P289, DOI 10.1007/s00253-002-1212-4; Sorger D, 2002, J BACTERIOL, V184, P519, DOI 10.1128/JB.184.2.519-524.2002; TILLMAN TS, 1986, J BIOL CHEM, V261, P9144; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Vial H., 1998, MALARIA PARASITE BIO, P159; VIAL HJ, 1990, BLOOD CELLS, V16, P531; VIAL HJ, 1992, MEM I OSWALDO CRUZ, V87, P251, DOI 10.1590/S0074-02761992000700042; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wengelnik K, 2002, SCIENCE, V295, P1311, DOI 10.1126/science.1067236; WHO Expert Committee on Malaria, 2000, WHO TECH REP SER, V892, P1; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200	43	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9222	9232		10.1074/jbc.M310502200	http://dx.doi.org/10.1074/jbc.M310502200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668349	hybrid			2022-12-27	WOS:000189265900084
J	Lalonde, JP; Lim, R; Ingley, E; Tilbrook, PA; Thompson, MJ; McCulloch, R; Beaumont, JG; Wicking, C; Eyre, HJ; Sutherland, GR; Howe, K; Solomon, E; Williams, JH; Klinken, SP				Lalonde, JP; Lim, R; Ingley, E; Tilbrook, PA; Thompson, MJ; McCulloch, R; Beaumont, JG; Wicking, C; Eyre, HJ; Sutherland, GR; Howe, K; Solomon, E; Williams, JH; Klinken, SP			HLS5, a novel RBCC (ring finger, B box, coiled-coil) family member isolated from a hemopoietic lineage switch, is a candidate tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; RETINOIC ACID RECEPTOR; J2E ERYTHROID-CELLS; AUG INITIATOR CODON; TRANSCRIPTION FACTOR; COLORECTAL-CANCER; RAR-ALPHA; MYELODYSPLASTIC SYNDROME; NUCLEAR RECEPTORS	Hemopoietic cells, apparently committed to one lineage, can be reprogrammed to display the phenotype of another lineage. The J2E erythroleukemic cell line has on rare occasions developed the features of monocytic cells. Subtractive hybridization was used in an attempt to identify genes that were up-regulated during this erythroid to myeloid transition. We report here on the isolation of hemopoietic lineage switch 5 (Hls5), a gene expressed by the monocytoid variant cells, but not the parental J2E cells. Hls5 is a novel member of the RBCC (Ring finger, B box, coiled-coil) family of genes, which includes Pml, Herf1, Tif-1alpha, and Rfp. Hls5 was expressed in a wide range of adult tissues; however, at different stages during embryogenesis, Hls5 was detected in the branchial arches, spinal cord, dorsal root ganglia, limb buds, and brain. The protein was present in cytoplasmic granules and punctate nuclear bodies. Isolation of the human cDNA and genomic DNA revealed that the gene was located on chromosome 8p21, a region implicated in numerous leukemias and solid tumors. Enforced expression of Hls5 in HeLa cells inhibited cell growth, clonogenicity, and tumorigenicity. It is conceivable that HLS5 is one of the tumor suppressor genes thought to reside at the 8p21 locus.	Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6000, Australia; Curtin Univ Technol, Sch Biomed Sci, Bentley, WA 6102, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Womens Hosp Med Ctr, Dept Cytogenet & Mol Genet, Ctr Med Genet, Adelaide, SA 5006, Australia; Canc Res UK, Lymphocyte Activat Lab, London WC2A 3PX, England; Guys Sch Med, Div Med & Mol Genet, London SE1 9RT, England; Kings Sch Med, Div Med & Mol Genet, London SE1 9RT, England; St Thomas Sch Med, Div Med & Mol Genet, London SE1 9RT, England	Royal Perth Hospital; University of Western Australia; University of Western Australia; Curtin University; University of Queensland; Cancer Research UK; University of London; King's College London; University of London; King's College London; University of London; King's College London	Klinken, SP (corresponding author), Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Level 6,Med Res Fdn Bldg Rear,50 Murray St, Perth, WA 6000, Australia.	pklinken@waimr.uwa.edu.au	Ingley, Evan/C-2401-2013; Sutherland, Grant Robert/D-2606-2012; Endersby, Raelene/A-2969-2013; Wicking, Carol/J-1814-2014	Ingley, Evan/0000-0002-8112-9134; Endersby, Raelene/0000-0003-3554-2769; Wicking, Carol/0000-0002-7225-3803				BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BOYD AW, 1982, NATURE, V297, P691, DOI 10.1038/297691a0; BUSFIELD SJ, 1992, BLOOD, V80, P412; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Cao TY, 1997, J CELL SCI, V110, P1563; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; ELEFANTY AG, 1992, BLOOD, V79, P1271; ElRifai W, 1996, GENE CHROMOSOME CANC, V15, P34, DOI 10.1002/(SICI)1098-2264(199601)15:1<34::AID-GCC5>3.0.CO;2-5; Farrington SM, 1996, ONCOGENE, V12, P1803; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gingras R, 1999, J BIOL CHEM, V274, P11742, DOI 10.1074/jbc.274.17.11742; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; Grimwade D, 2000, BLOOD, V96, P1297; Gustafson CE, 1996, CANCER RES, V56, P5238; Harada H, 1999, MOL CELL BIOL, V19, P3808; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KEIL U, 1995, CELL GROWTH DIFFER, V6, P439; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Kimura F, 2003, J BIOL CHEM, V278, P25046, DOI 10.1074/jbc.M303438200; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; Lim R, 2002, J BIOL CHEM, V277, P40997, DOI 10.1074/jbc.M206041200; LINDEMAN GJ, 1994, IMMUNITY, V1, P517, DOI 10.1016/1074-7613(94)90094-9; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; METCALF D, 1988, MED J AUSTRALIA, V148, P516, DOI 10.5694/j.1326-5377.1988.tb99462.x; MIURA I, 1994, CANCER GENET CYTOGEN, V72, P75, DOI 10.1016/0165-4608(94)90115-5; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mu ZM, 1997, CARCINOGENESIS, V18, P2063, DOI 10.1093/carcin/18.11.2063; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Sayer MS, 2000, J BIOL CHEM, V275, P25292, DOI 10.1074/jbc.M908695199; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SONODA Y, 1985, CANCER GENET CYTOGEN, V17, P61, DOI 10.1016/0165-4608(85)90102-5; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Vocke CD, 1996, CANCER RES, V56, P2411; Wang ZG, 1998, SCIENCE, V279, P1547; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Wright K, 1998, ONCOGENE, V17, P1185, DOI 10.1038/sj.onc.1202028; Yamada T, 2001, BLOOD, V97, P2300, DOI 10.1182/blood.V97.8.2300; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; YonedaKato N, 1996, ONCOGENE, V12, P265; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	75	27	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8181	8189		10.1074/jbc.M306751200	http://dx.doi.org/10.1074/jbc.M306751200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662771	Green Published, hybrid			2022-12-27	WOS:000189103300099
J	Nichols, RJ; Traktman, P				Nichols, RJ; Traktman, P			Characterization of three paralogous members of the mammalian vaccinia related kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; DEPENDENT PROTEIN-KINASE; ENCEPHALOMYOCARDITIS VIRUS; ENDOPLASMIC-RETICULUM; INITIATION COMPLEX; MOLECULAR-CLONING; GENE-PRODUCTS; TRANSLATION; EXPRESSION; INFECTION	Members of the novel vaccinia related kinase (VRK) protein family are characterized by notable sequence homology to the vaccinia virus-encoded B1 kinase (vvB1). vvB1 plays an essential role in viral DNA replication, and Boyle and Traktman have demonstrated that VRK1 enzymes complement the replication defect of a temperature-sensitive viral mutant defective in vvB1 ( Boyle, K., and Traktman, P. ( 2004) J. Virol. 78, 1992 - 2005). This mammalian kinase family comprises three members, VRK1, VRK2, and VRK3. We have annotated the gene structure for the members of this family and have characterized the enzyme activity and subcellular localization for the human and mouse proteins. VRK1 enzymes show robust autophosphorylation activity and will phosphorylate casein; VRK2 enzymes show modest autophosphorylation activity and will also phosphorylate casein. The VRK3 proteins have key amino acid substitutions that disrupt invariant motifs required for catalytic activity, rendering them enzymatically inert. The VRK1 and VRK2 proteins contain COOH-terminal extracatalytic sequences that mediate intracellular localization. VRK1 proteins possess a basic nuclear localization signal and are indeed nuclear; the extreme C termini of the VRK2 proteins are highly hydrophobic, and the proteins are membrane-associated and colocalize with markers of the endoplasmic reticulum. The NH2-terminal region of the VRK3s contains a bipartite nuclear localization signal, which directs these proteins to the nucleus. Our findings provide the basis for further studies of the structure and function of this newly discovered family of protein kinases.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Traktman, P (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd,BSB-273, Milwaukee, WI 53226 USA.	ptrakt@mcw.edu		Nichols, R Jeremy/0000-0002-5228-7571; Traktman, Paula/0000-0002-6517-0225	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053601] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI21758] Funding Source: Medline; NIGMS NIH HHS [R01 GM53601] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agoulnik AI, 2002, HUM MOL GENET, V11, P3047, DOI 10.1093/hmg/11.24.3047; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; BANHAM AH, 1992, VIROLOGY, V191, P803, DOI 10.1016/0042-6822(92)90256-O; Barcia R, 2002, ARCH BIOCHEM BIOPHYS, V399, P1, DOI 10.1006/abbi.2001.2746; BEATTIE E, 1995, VIROLOGY, V210, P254, DOI 10.1006/viro.1995.1342; Boyle KA, 2004, J VIROL, V78, P1992, DOI 10.1128/JVI.78.4.1992-2005.2004; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; Cuesta R, 2000, EMBO J, V19, P3465, DOI 10.1093/emboj/19.13.3465; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; Duden R, 1998, EMBO J, V17, P985, DOI 10.1093/emboj/17.4.985; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gingras AC, 1997, VIROLOGY, V237, P182, DOI 10.1006/viro.1997.8757; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hauri HP, 2000, J CELL SCI, V113, P587; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Kleijn M, 1996, VIROLOGY, V217, P486, DOI 10.1006/viro.1996.0143; Langland JO, 2002, VIROLOGY, V299, P133, DOI 10.1006/viro.2002.1479; LIN SQ, 1994, P NATL ACAD SCI USA, V91, P7653, DOI 10.1073/pnas.91.16.7653; Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MCDONALD WF, 1994, PROTEIN EXPRES PURIF, V5, P409, DOI 10.1006/prep.1994.1059; Morrison DK, 2001, J CELL SCI, V114, P1609; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; REMPEL RE, 1990, J VIROL, V64, P574, DOI 10.1128/JVI.64.2.574-583.1990; REMPEL RE, 1992, J VIROL, V66, P4413, DOI 10.1128/JVI.66.7.4413-4426.1992; SCHWAB RB, 2000, CURRENT PROTOCOLS CE; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Shors ST, 1998, J INTERF CYTOK RES, V18, P721, DOI 10.1089/jir.1998.18.721; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRAKTMAN P, 1989, J BIOL CHEM, V264, P21458; TRAKTMAN P, 1995, J VIROL, V69, P6581, DOI 10.1128/JVI.69.10.6581-6587.1995; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; Vega FM, 2003, FEBS LETT, V544, P176, DOI 10.1016/S0014-5793(03)00501-5; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WANG SP, 1995, J VIROL, V69, P6376, DOI 10.1128/JVI.69.10.6376-6388.1995; Zelko I, 1998, ARCH BIOCHEM BIOPHYS, V352, P31, DOI 10.1006/abbi.1998.0582	49	98	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7934	7946		10.1074/jbc.M310813200	http://dx.doi.org/10.1074/jbc.M310813200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14645249	hybrid			2022-12-27	WOS:000189103300071
J	Schneider, DA; Gourse, RL				Schneider, DA; Gourse, RL			Relationship between growth rate and ATP concentration in Escherichia coli - A bioassay for available cellular ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATING NUCLEOSIDE TRIPHOSPHATE; RIBOSOMAL-RNA SYNTHESIS; RATE-DEPENDENT CONTROL; GUANOSINE TETRAPHOSPHATE; SALMONELLA-TYPHIMURIUM; FIREFLY LUCIFERASE; 3'-DIPHOSPHATE; TRANSCRIPTION; POOLS; 5'-DIPHOSPHATE	Previous studies showed that adenosine triphosphate (ATP) concentrations in Escherichia coli changed during certain growth transitions and directly controlled the rate of rRNA transcription initiation at those times. The relationship between ATP concentration and rRNA transcription during steady-state growth is less clear, however. This is because two commonly employed methods for measuring ATP concentrations in bacteria, both of which rely on physical extraction followed by chromatographic separation of small molecules, resulted in dramatically different conclusions about whether ATP concentration changed with steady-state growth rate. Extraction with formic acid indicated that ATP concentration did not change with growth rate, whereas formaldehyde treatment followed by extraction with alkali indicated that ATP concentration increased proportionally to the growth rate. To resolve this discrepancy, we developed a bioassay for ATP based on the expression of a variant of the firefly luciferase enzyme in vivo and measurement of luminescence in cells growing in different conditions. We found that the available ATP concentration did not vary with growth rate, either in wildtype cells or in cells lacking guanosine 5'-diphosphate, 3'-diphosphate, providing insight into the regulation of rRNA transcription. More broadly, the luciferase bioassay described here provides a general method for evaluating the ATP concentration available for biochemical processes in E. coli and potentially in other organisms.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Gourse, RL (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.	rgourse@bact.wisc.edu		Schneider, David/0000-0003-0635-5091	NIGMS NIH HHS [R01 GM37048, R37 GM037048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037048, R37GM037048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGNARA AS, 1973, EUR J BIOCHEM, V36, P422, DOI 10.1111/j.1432-1033.1973.tb02927.x; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; BARTLETT MS, 1994, J BACTERIOL, V176, P5560, DOI 10.1128/JB.176.17.5560-5564.1994; BOWERS KC, 1992, J MOL CELL CARDIOL, V24, P213, DOI 10.1016/0022-2828(92)93159-H; Branchini BR, 1999, BIOCHEMISTRY-US, V38, P13223, DOI 10.1021/bi991181o; Dement'eva E I, 1996, Biokhimiia, V61, P1285; Di Tomaso G, 2001, ARCH MICROBIOL, V177, P11, DOI 10.1007/s00203-001-0352-8; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GRUBER MG, 1993, BIOLUMINESCENCE CHEM, P212; JENSEN KF, 1979, ANAL BIOCHEM, V98, P254, DOI 10.1016/0003-2697(79)90138-6; JENSEN KF, 1989, J GEN MICROBIOL, V135, P805; KOOP A, 1993, BIOCHEM J, V295, P165, DOI 10.1042/bj2950165; LITTLE R, 1982, ANAL BIOCHEM, V126, P381, DOI 10.1016/0003-2697(82)90531-0; LUND E, 1972, EUR J BIOCHEM, V28, P316, DOI 10.1111/j.1432-1033.1972.tb01916.x; Miller JH, 1972, EXPT MOL GENETICS, P201; Murray HD, 2003, MOL CELL, V12, P125, DOI 10.1016/S1097-2765(03)00266-1; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P445; Petersen C, 2000, J BIOL CHEM, V275, P3931, DOI 10.1074/jbc.275.6.3931; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SCHAECHTER M, 1958, J GEN MICROBIOL, V19, P592, DOI 10.1099/00221287-19-3-592; Schneider DA, 2003, J BACTERIOL, V185, P6185, DOI 10.1128/JB.185.20.6185-6191.2003; Schneider DA, 2003, J BACTERIOL, V185, P6192, DOI 10.1128/JB.185.20.6192-6194.2003; Schneider DA, 2002, P NATL ACAD SCI USA, V99, P8602, DOI 10.1073/pnas.132285199; XIAO H, 1991, J BIOL CHEM, V266, P5980	27	135	138	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8262	8268		10.1074/jbc.M311996200	http://dx.doi.org/10.1074/jbc.M311996200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670952	hybrid			2022-12-27	WOS:000189103300108
J	Nakayama, K; Okugawa, S; Yanagimoto, S; Kitazawa, T; Tsukada, K; Kawada, M; Kimura, S; Hirai, K; Takagaki, Y; Ota, Y				Nakayama, K; Okugawa, S; Yanagimoto, S; Kitazawa, T; Tsukada, K; Kawada, M; Kimura, S; Hirai, K; Takagaki, Y; Ota, Y			Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; EARLY ENDOTOXIN TOLERANCE; MONOPHOSPHORYL LIPID-A; CROSS-TOLERANCE; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; LIPOTEICHOIC ACID; DOWN-REGULATION; LIPOPOLYSACCHARIDE; CYTOKINE	The molecular mechanisms by which pathogen-associated molecular patterns recognized by TLR2, such as peptidoglycan (PGN), induce homotolerance are largely unknown. It was recently reported that IRAK-M negatively regulates TLR signaling. In this study, we elucidate the molecular mechanisms of tolerance induced by PGN, with a focus on the role of IRAK-M. We demonstrate that pretreatment of macrophage RAW264.7 cells with a high concentration (30 mug/ml) of PGN for 16 h effectively induces tolerance against following stimulation with 30 mug/ml of PGN; while pretreatment with a low concentration (1 mug/ml) of PGN does not. IRAK-M is induced in cells treated with the high concentration of PGN 4-24 h after PGN stimulation, but not in cells treated with the low concentration of PGN up to 24 h after stimulation. Phosphorylation of MAPKs and IkappaBalpha is inhibited after the second PGN stimulation in tolerant cells. Kinase activity of IRAK-1 and association between IRAK-1 and MyD88 are also suppressed in PGN-induced tolerant cells. Furthermore, down-regulation of IRAK-M expression by small interfering RNAs specific for IRAK-M reinstates the production of TNF-alpha after PGN restimulation. These results suggest that induction of IRAK-M and inhibition of kinase activity of IRAK-1 are crucial to PGN-induced tolerance in macrophages.	Univ Tokyo, Grad Sch Med, Dept Infect Dis, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Bioregulatory Funct, Tokyo 1138655, Japan; Kitasato Univ, Grad Sch Med, Dept Mol Med, Kanagawa 2288555, Japan	University of Tokyo; University of Tokyo; Kitasato University	Ota, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Infect Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	yasuota-tky@umin.ac.jp		Okugawa, Shu/0000-0003-3455-8291				Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; Bhat N, 1999, J IMMUNOL, V162, P7335; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; Ertel W, 1997, BLOOD, V89, P1612, DOI 10.1182/blood.V89.5.1612.1612_1612_1620; Gustafson G L, 1995, Prog Clin Biol Res, V392, P567; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HENRICSON BE, 1991, INFECT IMMUN, V59, P1188, DOI 10.1128/IAI.59.3.1188-1191.1991; HENRICSON BE, 1990, INFECT IMMUN, V58, P2429, DOI 10.1128/IAI.58.8.2429-2437.1990; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kraatz J, 1999, SHOCK, V11, P58, DOI 10.1097/00024382-199901000-00009; Lehner MD, 2001, J IMMUNOL, V166, P5161, DOI 10.4049/jimmunol.166.8.5161; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medvedev AE, 2001, J IMMUNOL, V167, P2257, DOI 10.4049/jimmunol.167.4.2257; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Okugawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC399, DOI 10.1152/ajpcell.00026.2003; Salkowski CA, 1998, INFECT IMMUN, V66, P3569, DOI 10.1128/IAI.66.8.3569-3578.1998; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; VANDEUREN M, 1994, J INFECT DIS, V169, P157, DOI 10.1093/infdis/169.1.157; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Zeisberger E, 1998, ANN NY ACAD SCI, V856, P116, DOI 10.1111/j.1749-6632.1998.tb08320.x; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13	37	92	97	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6629	6634		10.1074/jbc.M308620200	http://dx.doi.org/10.1074/jbc.M308620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660668	hybrid			2022-12-27	WOS:000188969200052
J	Bak-Jensen, KS; Andre, G; Gottschalk, TE; Paes, G; Tran, V; Svensson, B				Bak-Jensen, KS; Andre, G; Gottschalk, TE; Paes, G; Tran, V; Svensson, B			Tyrosine 105 and threonine 212 at outermost substrate binding subsites -6 and +4 control substrate specificity, oligosaccharide cleavage patterns, and multiple binding modes of barley alpha-amylase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-AMYLASE FAMILY; AMYLOSE CHAIN BEHAVIOR; CATALYTIC (BETA/ALPHA)(8)-BARREL DOMAIN; X-RAY-STRUCTURE; CYCLODEXTRIN-GLYCOSYLTRANSFERASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; INTERACTING CONTEXT; STARCH-BINDING	The role in activity of outer regions in the substrate binding cleft in alpha-amylases is illustrated by mutational analysis of Tyr(105) and Thr(212) localized at subsites - 6 and +4 ( substrate cleavage occurs between subsites -1 and +1) in barley alpha-amylase 1 (AMY1). Tyr(105) is conserved in plant alpha-amylases whereas Thr(212) varies in these and related enzymes. Compared with wild-type AMY1, the subsite -6 mutant Y105A has 140, 15, and < 1% activity (k(cat)/K-m) on starch, amylose DP17, and 2-chloro-4-nitrophenyl beta-D-maltoheptaoside, whereas T212Y at subsite +4 has 32, 370, and 90% activity, respectively. Thus engineering of aromatic stacking interactions at the ends of the 10-subsite long binding cleft affects activity very differently, dependent on the substrate. Y105A dominates in dual subsite -6/+4 [Y105A/T212(Y/W)] AMY1 mutants having almost retained and low activity on starch and oligosaccharides, respectively. Bond cleavage analysis of oligosaccharide degradation by wild-type and mutant AMY1 supports that Tyr105 is critical for binding at subsite -6. Substrate binding is improved by T212(Y/W) introduced at subsite +4 and the [Y105A/ T212(Y/W)] AMY1 double mutants synergistically enhanced productive binding of the substrate aglycone. The enzymatic properties of the series of AMY1 mutants suggest that longer substrates adopt several binding modes. This is in excellent agreement with computed distinct multiple docking solutions observed for maltododecaose at outer binding areas of AMY1 beyond subsites -3 and +3.	Carlsberg Lab, Dept Chem, DK-2500 Copenhagen, Denmark; INRA, Lab Physicochim Macromol, F-44316 Nantes 03, France	INRAE	Svensson, B (corresponding author), Tech Univ Denmark, Biocentrum, Biochem & Nutr Grp, DK-2800 Lyngby, Denmark.	bis@biocentrum.dtu.dk	PAES, Gabriel/F-2568-2010; Paës, Gabriel/AAT-8796-2021	PAES, Gabriel/0000-0003-0239-9716; Paës, Gabriel/0000-0003-0239-9716; Svensson, Birte/0000-0002-2993-8196				Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; AJANDOUZ EH, 1992, BIOCHIM BIOPHYS ACTA, V1159, P193, DOI 10.1016/0167-4838(92)90025-9; ANDERSEN JS, 1994, BIOL MASS SPECTROM, V23, P547, DOI 10.1002/bms.1200230904; Andre G, 1999, BIOPOLYMERS, V50, P751, DOI 10.1002/(SICI)1097-0282(199912)50:7<751::AID-BIP8>3.3.CO;2-X; Andre G, 1999, BIOPOLYMERS, V49, P107, DOI 10.1002/(SICI)1097-0282(199901)49:1<107::AID-BIP10>3.0.CO;2-S; Andre G, 1996, BIOPOLYMERS, V39, P737, DOI 10.1002/(SICI)1097-0282(199611)39:5<737::AID-BIP12>3.0.CO;2-2; Andre G, 1999, ROY SOC CH, P165; ANDRE G, 2003, RECENT ADV ENZYMES G, P9; Armand S, 2001, BIOCHEMISTRY-US, V40, P7404, DOI 10.1021/bi002704r; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERTOFT E, 1984, J I BREWING, V90, P298, DOI 10.1002/j.2050-0416.1984.tb04278.x; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; Brayer GD, 2000, BIOCHEMISTRY-US, V39, P4778, DOI 10.1021/bi9921182; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; Dauter Z, 1999, BIOCHEMISTRY-US, V38, P8385, DOI 10.1021/bi990256l; FOX JD, 1991, ANAL BIOCHEM, V195, P93, DOI 10.1016/0003-2697(91)90300-I; Frandsen TP, 1996, J MOL BIOL, V263, P79, DOI 10.1006/jmbi.1996.0557; Fujimoto Z, 1998, J MOL BIOL, V277, P393, DOI 10.1006/jmbi.1997.1599; Gottschalk TE, 2001, BIOCHEMISTRY-US, V40, P12844, DOI 10.1021/bi0108608; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; IMBERTY A, 1988, J MOL BIOL, V201, P365, DOI 10.1016/0022-2836(88)90144-1; Janecek S, 2003, EUR J BIOCHEM, V270, P635, DOI 10.1046/j.1432-1033.2003.03404.x; Janecek S, 2002, BIOLOGIA, V57, P29; Jensen MT, 2003, J CEREAL SCI, V38, P289, DOI 10.1016/S0733-5210(03)00032-8; JONES RL, 1991, INT REV CYTOL, V126, P49; Juge N, 1996, PROTEIN EXPRES PURIF, V8, P204, DOI 10.1006/prep.1996.0093; Kadziola A, 1998, J MOL BIOL, V278, P205, DOI 10.1006/jmbi.1998.1683; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; Koivula A, 1998, FEBS LETT, V429, P341, DOI 10.1016/S0014-5793(98)00596-1; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Leemhuis H, 2002, J BIOL CHEM, V277, P1113, DOI 10.1074/jbc.M106667200; MACGREGOR AW, 1992, CARBOHYD RES, V227, P301, DOI 10.1016/0008-6215(92)85080-J; MacGregor EA, 2001, BBA-PROTEIN STRUCT M, V1546, P1, DOI 10.1016/S0167-4838(00)00302-2; MACGREGOR EA, 1994, CARBOHYD RES, V257, P249, DOI 10.1016/0008-6215(94)80039-1; Machius M, 1996, J MOL BIOL, V260, P409, DOI 10.1006/jmbi.1996.0410; Machius M, 1998, STRUCTURE, V6, P281, DOI 10.1016/S0969-2126(98)00032-X; Matsui I, 1997, J BIOL CHEM, V272, P22456, DOI 10.1074/jbc.272.36.22456; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; Mori H, 2002, EUR J BIOCHEM, V269, P5377, DOI 10.1046/j.1432-1033.2002.03185.x; Mori H, 2001, EUR J BIOCHEM, V268, P6545, DOI 10.1046/j.0014-2956.2001.02609.x; Nielsen JE, 2000, BBA-PROTEIN STRUCT M, V1543, P253, DOI 10.1016/S0167-4838(00)00240-5; NITTA Y, 1971, J BIOCHEM, V69, P567; Parsiegla G, 1998, EUR J BIOCHEM, V255, P710, DOI 10.1046/j.1432-1327.1998.2550710.x; Przylas I, 2000, EUR J BIOCHEM, V267, P6903, DOI 10.1046/j.1432-1033.2000.01790.x; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; QUIOCHO FA, 1993, BIOCHEM SOC T, V21, P442, DOI 10.1042/bst0210442; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; RAPPENECKER G, 1981, CARBOHYD RES, V89, P11, DOI 10.1016/S0008-6215(00)85225-8; Robert X, 2003, STRUCTURE, V11, P973, DOI 10.1016/S0969-2126(03)00151-5; ROBYT JF, 1970, J BIOL CHEM, V245, P3917; RODENBURG KW, 1994, EUR J BIOCHEM, V221, P277, DOI 10.1111/j.1432-1033.1994.tb18739.x; Rodenburg KW, 2000, EUR J BIOCHEM, V267, P1019, DOI 10.1046/j.1432-1327.2000.01094.x; ROGERS JC, 1983, J BIOL CHEM, V258, P8169; ROGERS JC, 1985, J BIOL CHEM, V260, P3731; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sierks MR, 2000, BIOCHEMISTRY-US, V39, P8585, DOI 10.1021/bi9925219; SOGAARD M, 1990, GENE, V94, P173, DOI 10.1016/0378-1119(90)90384-4; SOGAARD M, 1993, BIO-TECHNOL, V11, P1162, DOI 10.1038/nbt1093-1162; SOGAARD M, 1993, J BIOL CHEM, V268, P22480; STONE BA, 2001, GLYCOSCIENCE CHEM CH, P1907; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; Svensson B., 1999, Journal of Applied Glycoscience, V46, P49; SVENSSON B, 1985, CARLSBERG RES COMMUN, V50, P15, DOI 10.1007/BF02910534; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Uitdehaag JCM, 2001, PROTEINS, V43, P327, DOI 10.1002/prot.1044; Uitdehaag JCM, 2000, BIOCHEMISTRY-US, V39, P7772, DOI 10.1021/bi000340x; van der Veen BA, 2001, J BIOL CHEM, V276, P44557, DOI 10.1074/jbc.M107533200; Varrot A, 1999, BIOCHEM J, V337, P297, DOI 10.1042/0264-6021:3370297; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; YAMAMOTO T, 1995, ENZYME CHEM MOL BIOL; Zou JY, 1999, STRUCTURE, V7, P1035, DOI 10.1016/S0969-2126(99)80171-3	77	34	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10093	10102		10.1074/jbc.M312825200	http://dx.doi.org/10.1074/jbc.M312825200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14660599	hybrid, Green Published			2022-12-27	WOS:000220050400054
J	Duverger, O; Paslaru, L; Morange, M				Duverger, O; Paslaru, L; Morange, M			HSP25 is involved in two steps of the differentiation of PAM212 keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; P38 MAP KINASE; CENTRAL-NERVOUS-SYSTEM; ACTIN POLYMERIZATION; HL-60 CELLS; GENE-EXPRESSION; RETINOIC ACID; CYTOCHROME-C; PHOSPHORYLATION	HSP25 is a member of the small heat shock protein family. This 25-kDa protein exhibits a highly specific distribution during mouse embryonic development. Although multiple functions have been proposed for HSP25, the role it plays during differentiation is still unknown. High levels of HSP25 can be detected in embryonic and adult skin. During epidermis differentiation, the concentration of HSP25 increases with the distance of keratinocytes from the basal layer, in parallel with the extent of keratinization. We used an ex vivo cellular system, PAM212 cells, to analyze quantitatively and qualitatively the dynamics of HSP25 production and phosphorylation during the differentiation of keratinocytes. Our observations suggest that HSP25 is involved in two steps of PAM212 keratinocyte differentiation. Shortly after the induction of differentiation, a transient hyperphosphorylation of HSP25 seems to be essential for the expression of differentiation markers. Later, the chaperone-active form of HSP25 is organized progressively into characteristic aggregates involved in the dynamics of keratin filament networks.	Ecole Normale Super, Dept Biol, Mol Genet Unit, F-75230 Paris, France; Univ Med & Pharm Carol Davila, Postgrad Dept Biochem, Fundeni Hosp, Bucharest 2, Romania	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Carol Davila University of Medicine & Pharmacy; Institutul Clinic Fundeni	Morange, M (corresponding author), Ecole Normale Super, Dept Biol, Mol Genet Unit, 46 Rue Ulm, F-75230 Paris, France.	morange@wotan.ens.fr						Armstrong CL, 2001, J COMP NEUROL, V434, P262, DOI 10.1002/cne.1176; Arrigo AP, 2002, EXP GERONTOL, V37, P1247, DOI 10.1016/S0531-5565(02)00131-6; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; Cuesta R, 2000, GENE DEV, V14, P1460; Davidson Sean M, 2002, Prog Mol Subcell Biol, V28, P103; Davidson SM, 2000, DEV BIOL, V218, P146, DOI 10.1006/dbio.1999.9596; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Ehrnsperger M, 2000, METH MOL B, V99, P421; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Favet N, 2001, CELL DEATH DIFFER, V8, P603, DOI 10.1038/sj.cdd.4400847; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; GERNOLD M, 1993, DEV GENET, V14, P103, DOI 10.1002/dvg.1020140204; GOEBEL HH, 1993, VIRCHOWS ARCH B, V64, P127, DOI 10.1007/BF02915105; Guay J, 1997, J CELL SCI, V110, P357; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; IWAKI T, 1993, AM J PATHOL, V143, P487; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Jantschitsch C, 1998, BRIT J DERMATOL, V139, P247; Jonak C, 2002, BRIT J DERMATOL, V147, P13, DOI 10.1046/j.1365-2133.2002.04667.x; KATO S, 1992, ACTA NEUROPATHOL, V84, P443; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Loones MT, 2000, CELL STRESS CHAPERON, V5, P291, DOI 10.1379/1466-1268(2000)005<0291:TDOHSP>2.0.CO;2; Loones MT, 1997, CELL MOL LIFE SCI, V53, P179, DOI 10.1007/PL00000590; LOWE J, 1992, NEUROPATH APPL NEURO, V18, P341, DOI 10.1111/j.1365-2990.1992.tb00796.x; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mehlen P, 1999, CELL DEATH DIFFER, V6, P227, DOI 10.1038/sj.cdd.4400483; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Morange M, 1998, ANN NY ACAD SCI, V851, P117, DOI 10.1111/j.1749-6632.1998.tb08984.x; MORANGE M, 1999, MOL CHAPERONES FOLDI, P163; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Perng MD, 1999, J CELL SCI, V112, P2099; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROOP DR, 1983, J INVEST DERMATOL, V81, pS144, DOI 10.1111/1523-1747.ep12540939; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Schultz H, 1997, CELL STRESS CHAPERON, V2, P41, DOI 10.1379/1466-1268(1997)002<0041:TPKISU>2.3.CO;2; SPECTOR NL, 1994, FEBS LETT, V337, P184, DOI 10.1016/0014-5793(94)80270-X; SPECTOR NL, 1993, J CELL PHYSIOL, V156, P619, DOI 10.1002/jcp.1041560322; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; YUSPA SH, 1980, CANCER RES, V40, P4694	57	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10252	10260		10.1074/jbc.M309906200	http://dx.doi.org/10.1074/jbc.M309906200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14662766	hybrid			2022-12-27	WOS:000220050400073
J	Pirneskoski, A; Klappa, P; Lobell, M; Williamson, RA; Byrne, L; Alanen, HI; Salo, KEH; Kivirikko, KI; Freedman, RB; Ruddock, LW				Pirneskoski, A; Klappa, P; Lobell, M; Williamson, RA; Byrne, L; Alanen, HI; Salo, KEH; Kivirikko, KI; Freedman, RB; Ruddock, LW			Molecular characterization of the principal substrate binding site of the ubiquitous folding catalyst protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; FUNCTIONAL-CHARACTERIZATION; DOMAIN; CHAPERONE; FAMILY	Disulfide bond formation in the endoplasmic reticulum of eukaryotes is catalyzed by the ubiquitously expressed enzyme protein disulfide isomerase (PDI). The effectiveness of PDI as a catalyst of native disulfide bond formation in folding polypeptides depends on the ability to catalyze disulfide-dithiol exchange, to bind non-native proteins, and to trigger conformational changes in the bound substrate, allowing access to buried cysteine residues. It is known that the b' domain of PDI provides the principal peptide binding site of PDI and that this domain is critical for catalysis of isomerization but not oxidation reactions in protein substrates. Here we use homology modeling to define more precisely the boundaries of the b' domain and show the existence of an intradomain linker between the b' and a' domains. We have expressed the recombinant b' domain thus defined; the stability and conformational properties of the recombinant product confirm the validity of the domain boundaries. We have modeled the tertiary structure of the b' domain and identified the primary substrate binding site within it. Mutations within this site, expressed both in the isolated domain and in full-length PDI, greatly reduce the binding affinity for small peptide substrates, with the greatest effect being I272W, a mutation that appears to have no structural effect.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Kent	Ruddock, LW (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 3000, FIN-90014 Oulu, Finland.	lloyd.ruddock@oulu.fi		Ruddock, Lloyd/0000-0002-6247-686X				Alanen HI, 2003, ANTIOXID REDOX SIGN, V5, P367, DOI 10.1089/152308603768295096; Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Blank J, 2003, ANTIOXID REDOX SIGN, V5, P359, DOI 10.1089/152308603768295087; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Freedman RB, 1998, BIOL CHEM, V379, P321, DOI 10.1515/bchm.1998.379.3.321; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; GANE PG, 1996, THESIS U KENT CANTER; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Kanai S, 1998, J MOL EVOL, V47, P200, DOI 10.1007/PL00006377; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 2000, J BIOL CHEM, V275, P13213, DOI 10.1074/jbc.275.18.13213; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Klappa P, 2001, BIOCHEM J, V354, P553, DOI 10.1042/0264-6021:3540553; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; LeMaster DM, 1997, J BIOL CHEM, V272, P29998, DOI 10.1074/jbc.272.48.29998; Lumb RA, 2002, EMBO J, V21, P6763, DOI 10.1093/emboj/cdf685; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ruddock LW, 2000, PROTEIN SCI, V9, P758; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6	34	132	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10374	10381		10.1074/jbc.M312193200	http://dx.doi.org/10.1074/jbc.M312193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684740	hybrid			2022-12-27	WOS:000220050400087
J	Tsunematsu, R; Nakayama, K; Oike, Y; Nishiyama, M; Ishida, N; Hatakeyama, S; Bessho, Y; Kageyama, R; Suda, T; Nakayama, KI				Tsunematsu, R; Nakayama, K; Oike, Y; Nishiyama, M; Ishida, N; Hatakeyama, S; Bessho, Y; Kageyama, R; Suda, T; Nakayama, KI			Mouse Fbw7/Sel-10/Cdc4 is required for Notch degradation during vascular development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; F-BOX PROTEIN; CYCLIN-E; CAENORHABDITIS-ELEGANS; NEOPLASTIC TRANSFORMATION; ENDOTHELIAL-CELLS; UBIQUITIN LIGASE; MICE; EXPRESSION; SEL-10	Mammalian Fbw7 (also known as Sel-10, hCdc4, or hAgo) is the F-box protein component of an SCF (Skp1-Cul1-F-box protein-Rbx1)-type ubiquitin ligase, and the mouse Fbw7 is expressed prominently in the endothelial cell lineage of embryos. We generated mice deficient in Fbw7 and found that the embryos died in utero at embryonic day 10.5-11.5, manifesting marked abnormalities in vascular development. Vascular remodeling was impaired in the brain and yolk sac, and the major trunk veins were not formed. In vitro para-aortic splanchnopleural explant cultures from Fbw7(-/-) embryos also manifested an impairment of vascular network formation. Notch4, which is the product of the proto-oncogene Int3 and an endothelial cell-specific mammalian isoform of Notch, accumulated in Fbw7(-/-) embryos, resulting in an increased expression of Hey1, which encodes a transcriptional repressor that acts downstream of Notch signaling and is implicated in vascular development. Expression of Notch1, -2, or -3 or of cyclin E was unaffected in Fbw7(-/-) embryos. Mammalian Fbw7 thus appears to play an indispensable role in negative regulation of the Notch4-Hey1 pathway and is required for vascular development.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Keio Univ, Sch Med, Dept Cell Differentiat, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyushu University; Kyushu University; Japan Science & Technology Agency (JST); Keio University; Kyoto University	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	Suda, Toshio/H-6761-2013; Nishiyama, Masaaki/GWU-5575-2022; Hatakeyama, Shigetsugu/C-8333-2012	Suda, Toshio/0000-0001-7540-1771; Hatakeyama, Shigetsugu/0000-0002-2150-9979				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, P61; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gessler M, 2002, CURR BIOL, V12, P1601, DOI 10.1016/S0960-9822(02)01150-8; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Krebs LT, 2000, GENE DEV, V14, P1343; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Lawson ND, 2001, DEVELOPMENT, V128, P3675; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Maruyama S, 2001, GENOMICS, V78, P214, DOI 10.1006/geno.2001.6658; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; OsumiYamashita N, 1997, DEV GROWTH DIFFER, V39, P53; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Shirayoshi Y, 1997, GENES CELLS, V2, P213, DOI 10.1046/j.1365-2443.1997.d01-310.x; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; SUNDARAM M, 1993, GENETICS, V135, P765; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Tohda S, 2001, LEUKEMIA LYMPHOMA, V42, P467, DOI 10.3109/10428190109064603; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhang XQ, 2001, BLOOD, V98, P1028, DOI 10.1182/blood.V98.4.1028; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhong TP, 2001, NATURE, V414, P216, DOI 10.1038/35102599	61	201	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9417	9423		10.1074/jbc.M312337200	http://dx.doi.org/10.1074/jbc.M312337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672936	hybrid			2022-12-27	WOS:000189265900107
J	Udagawa, T; Shimizu, Y; Ueda, T				Udagawa, T; Shimizu, Y; Ueda, T			Evidence for the translation initiation of leaderless mRNAs by the intact 70 S ribosome without its dissociation into subunits in eubacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-TERMINAL START CODONS; ESCHERICHIA-COLI; FACTORS IF2; PROTEIN S1; SELECTION; RECRUITMENT; BACTERIA	In eubacteria, the dissociation of the 70 S ribosome into the 30 S and 50 S subunits is the essential first step for the translation initiation of canonical mRNAs that possess 5'-leader sequences. However, a number of leaderless mRNAs that start with the initiation codon have been identified in some eubacteria. These have been shown to be translated efficiently in vivo. Here we investigated the process by which leaderless mRNA translation is initiated by using a highly reconstituted cell-free translation system from Escherichia coli. We found that leaderless mRNAs bind preferentially to 70 S ribosomes and that the leaderless mRNA . 70 S . fMet-tRNA complex can transit from the initiation to the elongation phase even in the absence of initiation factors ( IFs). Moreover, leaderless mRNA translation proceeds more efficiently if the intact 70 S ribosome is involved compared with the 30 S subunit. Furthermore, excess amounts of IF3 inhibit leaderless mRNA translation, probably because it promotes the disassembly of the 70 S ribosome into subunits. Finally, excess amounts of fMet-tRNA facilitate the IF-independent translation of leaderless mRNA. These observations strongly suggest that leaderless mRNA translation is initiated by the assembled 70 S ribosome and thereby bypasses the dissociation process.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan	University of Tokyo	Ueda, T (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, FSB401,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	ueda@k.u-tokyo.ac.jp	Shimizu, Yoshihiro/A-6472-2016; Ueda, Takuya/K-5217-2014	Shimizu, Yoshihiro/0000-0003-3499-1394; Ueda, Takuya/0000-0002-7760-8271				BALAKIN AG, 1992, NUCLEIC ACIDS RES, V20, P563, DOI 10.1093/nar/20.3.563; Brock S, 1998, MOL MICROBIOL, V29, P409, DOI 10.1046/j.1365-2958.1998.00893.x; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; Grill S, 2000, EMBO J, V19, P4101, DOI 10.1093/emboj/19.15.4101; Grill S, 2001, FEBS LETT, V495, P167, DOI 10.1016/S0014-5793(01)02378-X; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; JANSSEN GR, 1993, INDUSTRIAL MICROORGANISMS: BASIC AND APPLIED MOLECULAR GENETICS, P59; JONES RL, 1992, J BACTERIOL, V174, P4753, DOI 10.1128/JB.174.14.4753-4760.1992; La Teana A, 2001, RNA, V7, P1173, DOI 10.1017/S1355838201010366; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Moll I, 2002, MOL MICROBIOL, V43, P239, DOI 10.1046/j.1365-2958.2002.02739.x; Moll I, 2002, MOL MICROBIOL, V44, P1387, DOI 10.1046/j.1365-2958.2002.02971.x; Moll I, 1998, FEBS LETT, V436, P213, DOI 10.1016/S0014-5793(98)01131-4; O'Donnell SA, 2002, J BACTERIOL, V184, P6730, DOI 10.1128/JB.184.23.6730-6733.2002; Petrelli D, 2001, EMBO J, V20, P4560, DOI 10.1093/emboj/20.16.4560; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SOFFIENTINI A, 1994, PROTEIN EXPRES PURIF, V5, P118, DOI 10.1006/prep.1994.1018; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; SURYANARAYANA T, 1983, BIOCHEMISTRY-US, V22, P2715, DOI 10.1021/bi00280a020; Tedin K, 1997, MOL MICROBIOL, V25, P189, DOI 10.1046/j.1365-2958.1997.4421810.x; Tedin K, 1999, MOL MICROBIOL, V31, P67, DOI 10.1046/j.1365-2958.1999.01147.x; Van Etten WJ, 1998, MOL MICROBIOL, V27, P987, DOI 10.1046/j.1365-2958.1998.00744.x; Wu CJ, 1996, MOL MICROBIOL, V22, P339, DOI 10.1046/j.1365-2958.1996.00119.x; Wu XQ, 1996, EMBO J, V15, P4734, DOI 10.1002/j.1460-2075.1996.tb00850.x	28	88	91	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8539	8546		10.1074/jbc.M308784200	http://dx.doi.org/10.1074/jbc.M308784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670970	hybrid			2022-12-27	WOS:000189265900004
J	Ibarra, C; Estrada, M; Carrasco, L; Chiong, M; Liberona, JL; Cardenas, C; Diaz-Araya, G; Jaimovich, E; Lavandero, S				Ibarra, C; Estrada, M; Carrasco, L; Chiong, M; Liberona, JL; Cardenas, C; Diaz-Araya, G; Jaimovich, E; Lavandero, S			Insulin-like growth factor-1 induces an inositol 1,4,5-trisphosphate-dependent increase in nuclear and cytosolic calcium in cultured rat cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASE; SKELETAL-MUSCLE; G(BETA-GAMMA) SUBUNITS; VENTRICULAR MYOCYTES; SENSITIVE MECHANISM; RELEASE CHANNELS; CA2+ CHANNELS; RECEPTOR	In the heart, insulin-like growth factor-1 (IGF-1) is a pro-hypertrophic and anti-apoptotic peptide. In cultured rat cardiomyocytes, IGF-1 induced a fast and transient increase in Ca-i(2+) levels apparent both in the nucleus and cytosol, releasing this ion from intracellular stores through an inositol 1,4,5-trisphosphate (IP3)-dependent signaling pathway. Intracellular IP3 levels increased after IGF-1 stimulation in both the presence and absence of extracellular Ca2+. A different spatial distribution of IP3 receptor isoforms in cardiomyocytes was found. Ryanodine did not prevent the IGF-1-induced increase of Ca-i(2+) levels but inhibited the basal and spontaneous Ca-i(2+) oscillations observed when cardiac myocytes were incubated in Ca2+-containing resting media. Spatial analysis of fluorescence images of IGF-1-stimulated cardiomyocytes incubated in Ca2+/--containing resting media showed an early increase in Ca-i(2+), initially localized in the nucleus. Calcium imaging suggested that part of the Ca2+ released by stimulation with IGF-1 was initially contained in the perinuclear region. The IGF-1-induced increase on Ca-i(2+) levels was prevented by 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid-AM, thapsigargin, xestospongin C, 2-aminoethoxy diphenyl borate, U-73122, pertussis toxin, and betaARKct (a peptide inhibitor of Gbetagamma signaling). Pertussis toxin also prevented the IGF-1-dependent IP3 mass increase. Genistein treatment largely decreased the IGF-1-induced changes in both Ca-i(2+) and IP3. LY29402 (but not PD98059) also prevented the IGF-1-dependent Ca-i(2+) increase. Both pertussis toxin and U73122 prevented the IGF-1-dependent induction of both ERKs and protein kinase B. We conclude that IGF-1 increases Ca-i(2+) levels in cultured cardiac myocytes through a Gbetagamma subunit of a pertussis toxin-sensitive G protein-PI3K-phospholipase C signaling pathway that involves participation of IP3.	Univ Chile, Fac Med, Inst Ciencias Biomed, Santiago 6640750, Chile; Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Bioquim & Biol Mol, Santiago 6640750, Chile; Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Quim Farmacol & Toxicol, Santiago 6640750, Chile; Univ Chile, Ctr FONDAP Estudios Mol Celula, Santiago 6640750, Chile	Universidad de Chile; Universidad de Chile; Universidad de Chile; Universidad de Chile	Jaimovich, E (corresponding author), Univ Chile, Fac Med, Inst Ciencias Biomed, Independencia 1027, Santiago 6640750, Chile.	ejaimovi@machi.med.uchile.cl; slavander@uchile.cl	Estrada, Manuel/AAS-5605-2020; Chiong, Mario/I-1043-2013; Estrada, Manuel/C-1269-2014; Lavandero, Sergio/B-6001-2013; Ibarra, Cristian/D-9386-2013; Chiong, M./ABH-5784-2020; Jaimovich, Enrique/AAY-7632-2020	Estrada, Manuel/0000-0001-7877-8160; Chiong, Mario/0000-0002-5174-6545; Estrada, Manuel/0000-0001-7877-8160; Lavandero, Sergio/0000-0003-4258-1483; Chiong, M./0000-0002-5174-6545; 				Adams JW, 1998, CIRC RES, V83, P167, DOI 10.1161/01.RES.83.2.167; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Bony C, 2001, J CELL BIOL, V152, P717, DOI 10.1083/jcb.152.4.717; BORGATTA L, 1991, P NATL ACAD SCI USA, V88, P2486, DOI 10.1073/pnas.88.6.2486; BROWN J H, 1986, P245; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; CASTLEMAN KR, 1989, DIGITAL IMAGE PROCES; Chik CL, 1997, ENDOCRINOLOGY, V138, P2033, DOI 10.1210/en.138.5.2033; Cittadini A, 1996, CIRCULATION, V93, P800, DOI 10.1161/01.CIR.93.4.800; Cittadini A, 1998, CIRC RES, V83, P50, DOI 10.1161/01.RES.83.1.50; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DUERR RL, 1995, J CLIN INVEST, V95, P619, DOI 10.1172/JCI117706; Dupont J, 2001, HORM RES, V55, P22, DOI 10.1159/000063469; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; ENGELMANN GL, 1989, MOL CELL ENDOCRINOL, V63, P1, DOI 10.1016/0303-7207(89)90076-2; Estrada M, 2001, J BIOL CHEM, V276, P22868, DOI 10.1074/jbc.M100118200; Estrada M, 2000, AM J PHYSIOL-ENDOC M, V279, pE132, DOI 10.1152/ajpendo.2000.279.1.E132; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Foncea R, 2000, BIOCHEM BIOPH RES CO, V273, P736, DOI 10.1006/bbrc.2000.3008; Freestone NS, 1996, MOL CELL BIOCHEM, V164, P223, DOI 10.1007/BF00408662; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Geertz R, 1997, MOL CELL BIOCHEM, V177, P33, DOI 10.1023/A:1006836631673; Goutsouliak V, 1997, CELL SIGNAL, V9, P505, DOI 10.1016/S0898-6568(97)00008-9; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HILENSKI LL, 1991, CELL TISSUE RES, V264, P577, DOI 10.1007/BF00319047; HIRATA M, 1984, BIOCHEM J, V223, P229, DOI 10.1042/bj2230229; Hong F, 2001, BIOCHEM BIOPH RES CO, V282, P816, DOI 10.1006/bbrc.2001.4644; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; Jaconi M, 2000, MOL BIOL CELL, V11, P1845, DOI 10.1091/mbc.11.5.1845; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; KLEPPISCH T, 1992, BRAIN RES, V591, P283, DOI 10.1016/0006-8993(92)91709-N; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOJIMA I, 1992, AM J PHYSIOL, V262, pE307, DOI 10.1152/ajpendo.1992.262.3.E307; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; Lavandero S, 1998, FEBS LETT, V422, P193, DOI 10.1016/S0014-5793(98)00008-8; Lee WK, 1999, BIOCHEM BIOPH RES CO, V261, P393, DOI 10.1006/bbrc.1999.1035; Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li Q, 1997, J CLIN INVEST, V100, P1991, DOI 10.1172/JCI119730; Liberona JL, 1998, MUSCLE NERVE, V21, P902, DOI 10.1002/(SICI)1097-4598(199807)21:7<902::AID-MUS8>3.0.CO;2-A; Lipp P, 2000, CURR BIOL, V10, P939, DOI 10.1016/S0960-9822(00)00624-2; Liu JL, 2000, ENDOCRINOLOGY, V141, P4436, DOI 10.1210/en.141.12.4436; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Mackenzie L, 2002, J PHYSIOL-LONDON, V541, P395, DOI 10.1113/jphysiol.2001.013411; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; MINTA A, 1989, J BIOL CHEM, V264, P8171; Otani H, 2000, J CARDIOVASC PHARM, V35, P275, DOI 10.1097/00005344-200002000-00015; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Poiraudeau S, 1997, J CELL BIOCHEM, V64, P414; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Puceat M, 1996, BIOCHEM J, V318, P723, DOI 10.1042/bj3180723; Renganathan M, 1997, BIOCHEM BIOPH RES CO, V235, P784, DOI 10.1006/bbrc.1997.6881; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6413; SELINFREUND RH, 1994, MOL PHARMACOL, V45, P1215; Shah AS, 2001, CIRCULATION, V103, P1311; Solem ML, 1998, BIOCHEM BIOPH RES CO, V252, P151, DOI 10.1006/bbrc.1998.9626; Takahashi T, 1999, CIRC RES, V85, P884; *US NIH, 1985, NIH PUBL, V8523; Vlcek S, 2001, CELL MOL LIFE SCI, V58, P1758, DOI 10.1007/PL00000815; Ward CW, 2001, J CLIN PATHOL-MOL PA, V54, P125; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961	70	70	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7554	7565		10.1074/jbc.M311604200	http://dx.doi.org/10.1074/jbc.M311604200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660553	hybrid			2022-12-27	WOS:000189103300024
J	Thomas, M; Dadgar, N; Aphale, A; Harrell, JM; Kunkel, R; Pratt, WB; Lieberman, AP				Thomas, M; Dadgar, N; Aphale, A; Harrell, JM; Kunkel, R; Pratt, WB; Lieberman, AP			Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; HEAT-SHOCK PROTEINS; POLYGLUTAMINE; NEURODEGENERATION; DISEASE; DROSOPHILA; ATAXIN-1; MODEL; CHIP	Kennedy's disease is a degenerative disorder of motor neurons caused by the expansion of a glutamine tract near the amino terminus of the androgen receptor (AR). Ligand binding to the receptor is associated with several post-translational modifications, but it is poorly understood whether these affect the toxicity of the mutant protein. Our studies now demonstrate that mutation of lysine residues in wild-type AR that are normally acetylated in a ligand-dependent manner mimics the effects of the expanded glutamine tract on receptor trafficking, misfolding, and aggregation. Mutation of lysines 630 or 632 and 633 to alanine markedly delays ligand-dependent nuclear translocation. The K632A/K633A mutant also undergoes ligand-dependent misfolding and aggregation similar to the expanded glutamine tract AR. This acetylation site mutant exhibits ligand-dependent 1C2 immunoreactivity, forms aggregates that co-localize with Hsp40, Hsp70, and the ubiquitin-protein isopeptide ligase (E3) ubiquitin ligase carboxyl terminus of Hsc70-interacting protein (CHIP), and inhibits proteasome function. Ligand-dependent nuclear translocation of the wild-type receptor and misfolding and aggregation of the K632A/K633A mutant are blocked by radicicol, an Hsp90 inhibitor. These data identify a novel role for the acetylation site as a regulator of androgen receptor subcellular distribution and folding and indicate that ligand-dependent aggregation is dependent upon intact Hsp90 function.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Lieberman, AP (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine,4233 Med Sci 1, Ann Arbor, MI 48109 USA.	liebermn@umich.edu			NCI NIH HHS [CA28010] Funding Source: Medline; NINDS NIH HHS [NS044047] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS044047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Becker M, 2000, J CELL BIOL, V149, P255, DOI 10.1083/jcb.149.2.255; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Lieberman AP, 2002, HUM MOL GENET, V11, P1967, DOI 10.1093/hmg/11.17.1967; Lieberman AP, 2000, MUSCLE NERVE, V23, P843, DOI 10.1002/(SICI)1097-4598(200006)23:6<843::AID-MUS2>3.0.CO;2-8; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; Piccioni F, 2002, FASEB J, V16, P1418, DOI 10.1096/fj.01-1035fje; Poukka H, 2000, J CELL SCI, V113, P2991; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Taylor JP, 2003, GENE DEV, V17, P1463, DOI 10.1101/gad.1087503; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	25	93	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8389	8395		10.1074/jbc.M311761200	http://dx.doi.org/10.1074/jbc.M311761200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14670946	hybrid			2022-12-27	WOS:000189103300121
J	Das, S; Ward, SV; Markle, D; Samuel, CE				Das, S; Ward, SV; Markle, D; Samuel, CE			DNA damage-binding proteins and heterogeneous nuclear ribonucleoprotein A1 function as constitutive KCS element components of the interferon-inducible RNA-dependent protein kinase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; PKR GENE; CHROMATIN-STRUCTURE; MAMMALIAN-CELLS; REPAIR PROTEIN; MESSENGER-RNA; HELA-CELLS; V-PROTEIN; X-PROTEIN	Protein kinase regulated by RNA (PKR) plays important roles in many cellular processes including virus multiplication and cell growth, differentiation, and apoptosis. The promoter of the PKR gene possesses a novel 15-bp element designated KCS, positioned upstream of a consensus interferon (IFN)-stimulated response element, that is required for both basal and interferon-inducible transcription. Protein binding to the KCS element is not dependent upon IFN treatment and correlates with transcriptional activity of the PKR promoter. The identity of KCS-binding proteins (KBP) that selectively bind at the KCS element is largely unknown, except for the transcription factor Sp1. We now have purified KBP from HeLa cell nuclear extracts by ion-exchange and DNA-affinity chromatography steps and then identified four constituent proteins of the KBP complex by mass spectrometry and immunochemistry: KBP120 and KBP45 are the damaged DNA-binding protein subunits, p127 DDB1 and p48 DDB2, respectively; KBP100 is the transcription factor Sp1; and KBP35 is the heterogeneous nuclear ribonucleoprotein A1. The steady-state levels of these four KCS-binding proteins in human cells are not altered by IFN treatment. Components of the KBP complex bind selectively and constitutively to the KCS element in the absence of IFN treatment, both in vitro as measured by competition electrophoretic mobility shift assay (EMSA) and DNA pull-down assays and in vivo as measured by chromatin immunoprecipitation assays. Depletion of DDB2 by antisense strategy reduces KBP complex formation by EMSA. These results provide new insight into the biochemical identity and activity of proteins involved in PKR promoter function.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	samuel@lifesci.ucsb.edu			NIAID NIH HHS [AI-20611, AI-12520] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012520, R01AI020611, R01AI012520] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; ABRAMIC M, 1991, J BIOL CHEM, V266, P22439; Ayora S, 1996, J MOL BIOL, V256, P301, DOI 10.1006/jmbi.1996.0087; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta A, 2001, MUTAT RES-DNA REPAIR, V486, P89, DOI 10.1016/S0921-8777(01)00082-9; DeLuca JG, 2001, J BIOL CHEM, V276, P28014, DOI 10.1074/jbc.M102801200; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gale M, 2000, MICROBIOL MOL BIOL R, V64, P239, DOI 10.1128/MMBR.64.2.239-280.2000; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hall P, 2001, J PALLIATIVE CARE, V17, P220; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Kuhen KL, 1996, GENOMICS, V36, P197, DOI 10.1006/geno.1996.0446; Kuhen KL, 1997, VIROLOGY, V227, P119, DOI 10.1006/viro.1996.8306; Kuhen KL, 1999, VIROLOGY, V254, P182, DOI 10.1006/viro.1998.9536; Kuhen KL, 1998, J VIROL, V72, P9934, DOI 10.1128/JVI.72.12.9934-9939.1998; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lau JS, 2000, J CELL BIOCHEM, V79, P395, DOI 10.1002/1097-4644(20001201)79:3<395::AID-JCB50>3.0.CO;2-M; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Martel LS, 2002, MOL CELL BIOL, V22, P2788, DOI 10.1128/MCB.22.8.2788-2798.2002; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Otrin VR, 1997, J CELL SCI, V110, P1159; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; Poole E, 2002, VIROLOGY, V303, P33, DOI 10.1006/viro.2002.1737; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Reith W, 1999, MICROBES INFECT, V1, P839; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1993, VIROLOGY, V130, P474; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Shtrichman R, 2002, INFECT IMMUN, V70, P5579, DOI 10.1128/IAI.70.10.5579-5588.2002; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sun NK, 2002, FEBS LETT, V512, P168, DOI 10.1016/S0014-5793(02)02250-0; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; TOTH J, 2000, NUCLEIC ACIDS RES, V28, pR1; Ulane CM, 2002, VIROLOGY, V304, P160, DOI 10.1006/viro.2002.1773; van't Wout AB, 2003, J VIROL, V77, P1392, DOI 10.1128/JVI.77.2.1392-1402.2003; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Ward SV, 2003, VIROLOGY, V313, P553, DOI 10.1016/S0042-6822(03)00347-7; Ward SV, 2002, VIROLOGY, V296, P136, DOI 10.1006/viro.2002.1356; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; Wieland SF, 2003, J VIROL, V77, P1227, DOI 10.1128/JVI.77.2.1227-1236.2003; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291	58	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7313	7321		10.1074/jbc.M312585200	http://dx.doi.org/10.1074/jbc.M312585200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645369	hybrid			2022-12-27	WOS:000188969200133
J	Goo, YH; Na, SY; Zhang, H; Xu, JM; Hong, SH; Cheong, JH; Lee, SK; Lee, JW				Goo, YH; Na, SY; Zhang, H; Xu, JM; Hong, SH; Cheong, JH; Lee, SK; Lee, JW			Interactions between activating signal cointegrator-2 and the tumor suppressor retinoblastoma in androgen receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; NUCLEAR-RECEPTOR; DEPENDENT TRANSACTIVATION; HORMONE-RECEPTORS; COACTIVATOR; CANCER; MICE; TRANSCRIPTION; MOTIF; COREGULATORS	Activating signal cointegrator-2 (ASC-2), a cancer-amplified transcription coactivator of nuclear receptors and numerous other transcription factors, was previously shown to contain two LXXLL motifs, each of which interacts with a distinct set of nuclear receptors. In this work, we showed that ASC-2 has an indirect, separate binding site for androgen receptor (AR). Interestingly, this region overlapped with the direct interaction interfaces with the tumor suppressor retinoblastoma (Rb). Although ASC-2 alone stimulated AR transactivation in cotransfections of HeLa cells, ectopic expression of Rb effected ASC-2 to act as a transcription coactivator of AR in Rb-null Saos2 cells. These results, along with the previous report in which AR was shown to directly interact with Rb (Yeh, S., Miyamoto, H., Nishimura, K., Kang, H., Ludlow, J., Hsiao, P., Wang, C., Su, C., and Chang C. (1998) Biochem. Biophys. Res. Commun. 248, 361-367), suggest that the AR-ASC-2 interactions in vivo may involve Rb. Thus, ASC-2 appears to contain at least three distinct nuclear receptor interaction domains.	Baylor Coll Med, Dept Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Salk Inst Biol Studies, Gene Express Lab, San Diego, CA 92185 USA	Baylor College of Medicine; Baylor College of Medicine; Pohang University of Science & Technology (POSTECH); Harvard University; Massachusetts General Hospital; Pusan National University; Salk Institute	Lee, JW (corresponding author), Baylor Coll Med, Dept Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA.	jwlee@bcm.tmc.edu						Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kim SW, 2003, MOL CELL BIOL, V23, P3583, DOI 10.1128/MCB.23.10.3583-3592.2003; Kim SW, 2002, MOL CELL BIOL, V22, P8409, DOI 10.1128/MCB.22.24.8409-8414.2002; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Lee SK, 2001, MOL ENDOCRINOL, V15, P241, DOI 10.1210/me.15.2.241; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Na SY, 1998, J BIOL CHEM, V273, P3212, DOI 10.1074/jbc.273.6.3212; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; SAIJO M, 1995, GENOMICS, V27, P511, DOI 10.1006/geno.1995.1084; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Tanner MM, 1996, CANCER RES, V56, P3441; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Zhang H, 2003, ENDOCRINOLOGY, V144, P1435, DOI 10.1210/en.2002-0018; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2003, J BIOL CHEM, V278, P1986, DOI 10.1074/jbc.C200634200	27	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7131	7135		10.1074/jbc.M312563200	http://dx.doi.org/10.1074/jbc.M312563200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645241	hybrid			2022-12-27	WOS:000188969200112
J	Hirata, A; Adachi, M; Sekine, A; Kang, YN; Utsumi, S; Mikami, B				Hirata, A; Adachi, M; Sekine, A; Kang, YN; Utsumi, S; Mikami, B			Structural and enzymatic analysis of soybean beta-amylase mutants with increased pH optimum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS; ASPERGILLUS-AWAMORI; CRYSTAL-STRUCTURE; RAW STARCH; ANGSTROM RESOLUTION; NUCLEOTIDE-SEQUENCE; GLYCOSYL HYDROLASES; ESCHERICHIA-COLI; GLUCOAMYLASE; CLONING	Comparison of the architecture around the active site of soybean beta-amylase and Bacillus cereus beta-amylase showed that the hydrogen bond networks (Glu(380)- (Lys(295)-Met(51)) and Glu(380)-Asn(340)-Glu(178)) in soybean beta-amylase around the base catalytic residue, Glu(380), seem to contribute to the lower pH optimum of soybean beta-amylase. To convert the pH optimum of soybean beta-amylase (pH 5.4) to that of the bacterial type enzyme (pH 6.7), three mutants of soybean beta-amylase, M51T, E178Y, and N340T, were constructed such that the hydrogen bond networks were removed by site-directed mutagenesis. The kinetic analysis showed that the pH optimum of all mutants shifted dramatically to a neutral pH (range, from 5.4 to 6.0 - 6.6). The K-m values of the mutants were almost the same as that of soybean beta-amylase except in the case of M51T, while the V-max values of all mutants were low compared with that of soybean beta-amylase. The crystal structure analysis of the wild type-maltose and mutant-maltose complexes showed that the direct hydrogen bond between Glu(380) and Asn(340) was completely disrupted in the mutants M51T, E178Y, and N340T. In the case of M51T, the hydrogen bond between Glu(380) and Lys(295) was also disrupted. These results indicated that the reduced pK(a) value of Glu(380) is stabilized by the hydrogen bond network and is responsible for the lower pH optimum of soybean beta-amylase compared with that of the bacterial beta-amylase.	Kyoto Univ, Grad Sch Agr, Lab Food Qual Design & Dev, Kyoto 6110011, Japan	Kyoto University	Mikami, B (corresponding author), Kyoto Univ, Grad Sch Agr, Lab Food Qual Design & Dev, Kyoto 6110011, Japan.	mikami@kais.kyoto-u.ac.jp						Adachi M, 1998, J BIOL CHEM, V273, P19859, DOI 10.1074/jbc.273.31.19859; Becker D, 2001, BIOCHEM J, V356, P19, DOI 10.1042/0264-6021:3560019; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fang TY, 1998, PROTEIN ENG, V11, P383, DOI 10.1093/protein/11.5.383; FRANDSEN TP, 1994, BIOCHEMISTRY-US, V33, P13808, DOI 10.1021/bi00250a035; GERTLER A, 1966, BIOCHIM BIOPHYS ACTA, V118, P98, DOI 10.1016/S0926-6593(66)80148-0; HARRIS EMS, 1993, BIOCHEMISTRY-US, V32, P1618, DOI 10.1021/bi00057a028; HENRISSAT B, 1995, BIOCHEM J, V311, P350, DOI 10.1042/bj3110350; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HIGASHIHARA M, 1974, AGR BIOL CHEM TOKYO, V38, P1023, DOI 10.1080/00021369.1974.10861268; HIROMI K, 1966, J BIOCHEM, V59, P469, DOI 10.1093/oxfordjournals.jbchem.a128329; HIROMI K, 1983, MOL CELL BIOCHEM, V51, P79, DOI 10.1007/BF00215589; HOSHINO M, 1975, AGR BIOL CHEM TOKYO, V39, P2415, DOI 10.1080/00021369.1975.10861974; HYE JY, 1999, J MICROBIOL BIOTECHN, V9, P619; Joshi MD, 2000, J MOL BIOL, V299, P255, DOI 10.1006/jmbi.2000.3722; Joshi MD, 2001, BIOCHEMISTRY-US, V40, P10115, DOI 10.1021/bi0105429; KAWAZU T, 1987, J BACTERIOL, V169, P1564, DOI 10.1128/jb.169.4.1564-1570.1987; KITAMOTO N, 1988, J BACTERIOL, V170, P5848, DOI 10.1128/jb.170.12.5848-5854.1988; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREIS M, 1987, EUR J BIOCHEM, V169, P517, DOI 10.1111/j.1432-1033.1987.tb13640.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JS, 2001, APPL MICROBIOL BIOT, V56, P205, DOI 10.1007/s002530100645; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIAO SC, 1994, BIOCHEMISTRY-US, V33, P7027, DOI 10.1021/bi00189a002; Mikami B, 1999, J MOL BIOL, V285, P1235, DOI 10.1006/jmbi.1998.2379; Mikami B, 1999, BIOCHEMISTRY-US, V38, P7050, DOI 10.1021/bi9829377; MIKAMI B, 1993, BIOCHEMISTRY-US, V32, P6836, DOI 10.1021/bi00078a006; MIKAMI B, 1994, BIOCHEMISTRY-US, V33, P7779, DOI 10.1021/bi00191a005; MIKAMI B, 2000, STRUCTURE BETA AMYLA, P55; MONROE JD, 1991, PLANT PHYSIOL, V97, P1599, DOI 10.1104/pp.97.4.1599; MORITA Y, 1975, J BIOCHEM-TOKYO, V77, P343, DOI 10.1093/oxfordjournals.jbchem.a130731; NANMORI T, 1993, APPL ENVIRON MICROB, V59, P623, DOI 10.1128/AEM.59.2.623-627.1993; Nanmori T., 1988, HDB AMYLASES RELATED, P94; NITTA Y, 1979, J BIOCHEM-TOKYO, V85, P41, DOI 10.1093/oxfordjournals.jbchem.a132328; NITTA Y, 1989, J BIOCHEM-TOKYO, V100, P1175; NOMURA K, 1995, J BIOCHEM-TOKYO, V118, P1124, DOI 10.1093/oxfordjournals.jbchem.a124997; OHNISHI H, 1994, J BIOL CHEM, V269, P3503; Oyama T, 1999, J BIOCHEM-TOKYO, V125, P1120, DOI 10.1093/oxfordjournals.jbchem.a022394; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RHODES C, 1987, NUCLEIC ACIDS RES, V15, P3934, DOI 10.1093/nar/15.9.3934; RORAT T, 1991, THEOR APPL GENET, V83, P257, DOI 10.1007/BF00226260; SAHA BC, 1987, ENZYME MICROB TECH, V9, P598, DOI 10.1016/0141-0229(87)90112-8; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; SIERKS MR, 1990, PROTEIN ENG, V3, P193, DOI 10.1093/protein/3.3.193; THOMA AJ, 1965, BIOCHEMISTRY-US, V4, P714; THOMA JA, 1971, ENZYMES, V5, P115; Totsuka A, 1996, EUR J BIOCHEM, V240, P655, DOI 10.1111/j.1432-1033.1996.0655h.x; TOTSUKA A, 1993, EUR J BIOCHEM, V214, P787, DOI 10.1111/j.1432-1033.1993.tb17981.x; UEDA S, 1980, STARKE, V32, P122, DOI 10.1002/star.19800320406; YOSHIDA N, 1991, J BIOCHEM-TOKYO, V110, P196, DOI 10.1093/oxfordjournals.jbchem.a123556; ZHEREBTSOV N. A., 1968, BIOKHIMIYA, V33, P435	55	35	37	3	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7287	7295		10.1074/jbc.M309411200	http://dx.doi.org/10.1074/jbc.M309411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14638688	hybrid			2022-12-27	WOS:000188969200130
J	Just, H; Sitte, HH; Schmid, JA; Freissmuth, M; Kudlacek, O				Just, H; Sitte, HH; Schmid, JA; Freissmuth, M; Kudlacek, O			Identification of an additional interaction domain in transmembrane domains 11 and 12 that supports oligomer formation in the human serotonin transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; HUMAN DOPAMINE TRANSPORTER; RAT GABA TRANSPORTER-1; PROTEIN-KINASE-C; ESCHERICHIA-COLI; SYNTAXIN 1A; FUNCTIONAL CONSEQUENCES; TRANSFER MICROSCOPY; PLASMA-MEMBRANE; CROSS-LINKING	Na+/Cl--dependent neurotransmitter transporters form constitutive oligomers. The topological arrangement is not known, but a leucine heptad repeat in transmembrane domain (TM) 2 and a glycophorin-like motif in TM6 have been proposed to stabilize the oligomer. To determine the topology, we generated versions of the human serotonin transporter (hSERT) that carried cyan or yellow fluorescent proteins at their amino and/or carboxyl terminus. Appropriate pairs were coexpressed to measure fluorescence resonance energy transfer (FRET). Donor photobleaching FRET microscopy was employed to deduce the following arrangement: within the monomer, the amino and carboxyl termini are in close vicinity. In addition, in the oligomer, the carboxyl termini are closer to each other than the amino termini. Hence, a separate interaction domain (i.e. distinct from TM2 and TM6) must reside in the carboxyl-terminal half of hSERT. This was confirmed by expressing the amino- and carboxyl-terminal halves of hSERT. These were retained intracellularly; they also retained the coexpressed full-length transporter by forming export-deficient oligomers and, when cotransfected in all possible combinations, supported FRET. Hence, both the carboxyl and amino termini contain elements that drive oligomerization. By employing fragments comprising two neighboring TM helices, we unequivocally identified TM11/12 as a new contact site by donor photobleaching FRET and beta-lactamase protein fragment complementation assay. TM1/2 was also found to self-associate. Thus, oligomerization of hSERT involves at least two discontinuous interfaces. The currently identified interaction sites drive homophilic interactions. This is consistent with assembly of SERT oligomers in an array-like structure containing multimers of dimers.	Univ Vienna, Sch Med, Inst Pharmacol, A-1090 Vienna, Austria; Univ Vienna, Sch Med, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria	University of Vienna; University of Vienna	Freissmuth, M (corresponding author), Univ Vienna, Sch Med, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	michael.freissmuth@univie.ac.at	Sitte, Harald/N-2681-2013; Schmid, Johannes A./C-7659-2009; Sitte, Harald/O-7025-2019	Sitte, Harald/0000-0002-1339-7444; Schmid, Johannes A./0000-0002-6586-3507; Sitte, Harald/0000-0002-1339-7444; Freissmuth, Michael/0000-0001-9398-1765; Kudlacek, Oliver/0000-0002-3086-8551				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Beckman ML, 1998, J NEUROSCI, V18, P6103; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; Hastrup H, 2003, J BIOL CHEM, V278, P45045, DOI 10.1074/jbc.C300349200; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Jess U, 2002, BIOCHEM BIOPH RES CO, V294, P272, DOI 10.1016/S0006-291X(02)00460-6; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; Kocabas AM, 2003, J NEUROCHEM, V85, P1513, DOI 10.1046/j.1471-4159.2003.01793.x; Li HM, 2001, BIOCHEMISTRY-US, V40, P6636, DOI 10.1021/bi0026573; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Schmid JA, 2003, CURR OPIN ONCOL, V15, P55, DOI 10.1097/00001622-200301000-00008; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; Scholze P, 2002, J BIOL CHEM, V277, P43682, DOI 10.1074/jbc.M205602200; Scholze P, 2000, J PHARMACOL EXP THER, V293, P870; Sitte HH, 2003, EUR J PHARMACOL, V479, P229, DOI 10.1016/j.ejphar.2003.08.072; Sorkina T, 2003, J BIOL CHEM, V278, P28274, DOI 10.1074/jbc.M210652200; Sung U, 2003, J NEUROSCI, V23, P1697; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	33	85	85	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6650	6657		10.1074/jbc.M306092200	http://dx.doi.org/10.1074/jbc.M306092200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660642	hybrid			2022-12-27	WOS:000188969200055
J	Almagro, S; Riveline, D; Hirano, T; Houchmandzadeh, B; Dimitrov, S				Almagro, S; Riveline, D; Hirano, T; Houchmandzadeh, B; Dimitrov, S			The mitotic chromosome is an assembly of rigid elastic axes organized by structural maintenance of chromosomes (SMC) proteins and surrounded by a soft chromatin envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; TOPOISOMERASE-II; CONDENSATION; XENOPUS; SCAFFOLD; COMPONENT; COMPLEXES; PLAY; DNA	The structure of mitotic chromosomes is still poorly understood. Here we describe the use of a novel approach based on elasticity measurements of a single chromosome for studying the organization of these objects. The data reveal that mitotic chromosomes exhibit a non-homogenous structure consisting of rigid elastic axes surrounded by a soft chromatin envelope. The chemical continuity of DNA, but not RNA, was required for the maintenance of these axes. The axes show a modular structure, and the structural maintenance of chromosomes (SMC) proteins participate in their organization. Topoisomerase II was not involved in either the organization of the axes or the maintenance of the mitotic chromosomes. A model for the assembly and the structure of the mitotic chromosome is proposed. According this model, the chromosome axes are dynamic structures that assemble at the onset and disassemble the end of mitosis, respectively. The SMC proteins, in addition to maintaining axis elasticity, are essential for the determination of the rod-like chromosome shape. The extreme compaction of mitotic chromosomes is determined mainly by the high amount of bivalent ions bound to DNA at mitosis.	Inst Albert Bonniot, INSERM, U309, Lab Biol Mol & Cellulaire Differenciat, F-38706 La Tronche, France; Univ Grenoble 1, UMR 5588, Spectrometrie Phys Lab, F-38402 St Martin Dheres, France; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Cold Spring Harbor Laboratory	Dimitrov, S (corresponding author), Inst Albert Bonniot, INSERM, U309, Lab Biol Mol & Cellulaire Differenciat, Domaine Merci, F-38706 La Tronche, France.	stefan.dimitrov@ujf-grenoble.fr	Houchmandzadeh, Bahram/F-9199-2012; Hirano, Tatsuya/F-6008-2011; Riveline, Daniel/GXV-6609-2022; dimitrov, stefan/M-7697-2013	Houchmandzadeh, Bahram/0000-0001-8104-2576; Hirano, Tatsuya/0000-0002-4219-6473; dimitrov, stefan/0000-0002-1326-3630				ADOLPH KW, 1977, CELL, V12, P805, DOI 10.1016/0092-8674(77)90279-3; Clerc P, 2003, SEMIN CELL DEV BIOL, V14, P85, DOI 10.1016/S1084-9521(02)00140-4; de la Barre AE, 1999, METH MOL B, V119, P219; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; DUPRAW EJ, 1966, NATURE, V209, P577, DOI 10.1038/209577a0; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Houchmandzadeh B, 1999, J CELL BIOL, V145, P215, DOI 10.1083/jcb.145.2.215; HOUCHMANDZADEH B, 1997, J CELL BIOL, V138, P1; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; LAEMMLI UK, 1978, COLD SPRING HARB SYM, V42, P351; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; Poirier M, 2000, MOL BIOL CELL, V11, P269, DOI 10.1091/mbc.11.1.269; Poirier MG, 2002, P NATL ACAD SCI USA, V99, P15393, DOI 10.1073/pnas.232442599; Poirier MG, 2002, MOL BIOL CELL, V13, P2170, DOI 10.1091/mbc.01-08-0401; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SMIRNOV IV, 1988, J BIOMOL STRUCT DYN, V5, P1149, DOI 10.1080/07391102.1988.10506455; Strick R, 2001, J CELL BIOL, V155, P899, DOI 10.1083/jcb.200105026; WIDOM J, 1986, J MOL BIOL, V190, P411, DOI 10.1016/0022-2836(86)90012-4; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6	29	38	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5118	5126		10.1074/jbc.M307221200	http://dx.doi.org/10.1074/jbc.M307221200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660618	hybrid			2022-12-27	WOS:000188776500011
J	Chapman-Smith, A; Lutwyche, JK; Whitelaw, ML				Chapman-Smith, A; Lutwyche, JK; Whitelaw, ML			Contribution of the Per/Arnt/Sim (PAS) domains to DNA binding by the basic helix-loop-helix PAS transcriptional regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; DIOXIN RECEPTOR; ESCHERICHIA-COLI; AH RECEPTOR; PROTEIN; ARNT; HYPOXIA; LIGAND; RECOGNITION; DEFINITION	The basic helix-loop-helix (bHLH) PAS transcriptional regulators control critical developmental and metabolic processes, including transcriptional responses to stimuli such as hypoxia and environmental pollutants, mediated respectively by hypoxia inducible factors (HIF-alpha) and the dioxin (aryl hydrocarbon) receptor (DR). The bHLH proteins contain a basic DNA binding sequence adjacent to a helix-loop-helix dimerization domain. Dimerization among bHLH. PAS proteins is additionally regulated by the PAS region, which controls the specificity of partner choice such that HIF-alpha and DR must dimerize with the aryl hydrocarbon nuclear translocator (Arnt) to form functional DNA binding complexes. Here, we have analyzed purified bacterially expressed proteins encompassing the N-terminal bHLH and bHLH. PAS regions of Arnt, DR, and HIF-1alpha and evaluated the contribution of the PAS domains to DNA binding in vitro. Recovery of functional DNA binding proteins from bacteria was dramatically enhanced by coexpression of the bHLH. PAS regions of DR or HIF-1alpha with the corresponding region of Arnt. Formation of stable protein-DNA complexes by DR/Arnt and HIF-1alpha/Arnt heterodimers with their cognate DNA sequences required the PAS A domains and exhibited K-D values of 0.4 nM and similar to50 nM, respectively. In contrast, the presence of the PAS domains of Arnt had little effect on DNA binding by Arnt homodimers, and these bound DNA with a K-D of 45 nM. In the case of the DR, both high affinity DNA binding and dimer stability were specific to its native PAS domain, since a chimera in which the PAS A domain was substituted with the equivalent domain of Arnt generated a destabilized protein that bound DNA poorly.	Univ Adelaide, Sch Mol & Biomed Sci Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Ctr Mol Genet Dev, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Chapman-Smith, A (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci Biochem, Adelaide, SA 5005, Australia.	anne.chapmansmith@adelaide.edu.au						Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; Chapman-Smith A, 2001, PROTEIN SCI, V10, P2608, DOI 10.1110/ps.ps.22401; ChapmanSmith A, 1997, J BIOL CHEM, V272, P26017, DOI 10.1074/jbc.272.41.26017; Ciarapica R, 2003, J BIOL CHEM, V278, P12182, DOI 10.1074/jbc.M211991200; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; Ema M, 1996, MOL CELL BIOL, V16, P5865; Fieber W, 2001, J MOL BIOL, V307, P1395, DOI 10.1006/jmbi.2001.4537; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Huffman JL, 2001, J BIOL CHEM, V276, P40537, DOI 10.1074/jbc.M105675200; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; Lando D, 2003, EUR J BIOCHEM, V270, P781, DOI 10.1046/j.1432-1033.2003.03445.x; Lees MJ, 1999, MOL CELL BIOL, V19, P5811; Li C, 1997, P NATL ACAD SCI USA, V94, P2278, DOI 10.1073/pnas.94.6.2278; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Ma Y, 2000, J NEUROSCI, V20, P4596, DOI 10.1523/JNEUROSCI.20-12-04596.2000; MASON GGF, 1994, J BIOL CHEM, V269, P4438; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McGuire J, 2001, J BIOL CHEM, V276, P41841, DOI 10.1074/jbc.M105607200; Michel G, 2002, BBA-GENE STRUCT EXPR, V1578, P73, DOI 10.1016/S0167-4781(02)00484-0; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Vreede J, 2003, J BIOL CHEM, V278, P18434, DOI 10.1074/jbc.M301701200; Wendt H, 1998, J BIOL CHEM, V273, P5735, DOI 10.1074/jbc.273.10.5735; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x	42	60	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5353	5362		10.1074/jbc.M310041200	http://dx.doi.org/10.1074/jbc.M310041200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14638687	hybrid			2022-12-27	WOS:000188776500040
J	Malnou, CE; Werner, A; Borman, AM; Westhof, E; Kean, KM				Malnou, CE; Werner, A; Borman, AM; Westhof, E; Kean, KM			Effects of vaccine strain mutations in domain V of the internal ribosome entry segment compared in the wild type poliovirus type 1 context	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION-FACTOR; RNA SECONDARY STRUCTURE; TRACT-BINDING PROTEIN; HUMAN NEURO-BLASTOMA; INVITRO TRANSLATION; CLEAVAGE PRODUCTS; MESSENGER-RNAS; REGION; EIF4G; SITE	Initiation of poliovirus (PV) protein synthesis is governed by an internal ribosome entry segment structured into several domains including domain V, which is accepted to be important in PV neurovirulence because it harbors an attenuating mutation in each of the vaccine strains developed by A. Sabin. To better understand how these single point mutations exert their effects, we placed each of them into the same genomic context, that of PV type 1. Only the mutation equivalent to the Sabin type 3 strain mutation resulted in significantly reduced viral growth both in HeLa and neuroblastoma cells. This correlated with poor translation efficiency in vitro and could be explained by a structural perturbation of the domain V of the internal ribosome entry segment, as evidenced by RNA melting experiments. We demonstrated that reduced cell death observed during infection by this mutant is due to the absence of inhibition of host cell translation. We confirmed that this shut-off is correlated principally with cleavage of eIF4GII and not eIF4GI and that this cleavage is significantly impaired in the case of the defective mutant. These data support the previously reported conclusion that the 2A protease has markedly different affinities for the two eIF4G isoforms.	Inst Pasteur, CNRS URA 1966, Unite Regulat Traduct Eucaryote & Virale, F-75724 Paris 15, France; Hlth Protect Agcy, Mycol Reference Lab, Bristol BS2 8EL, Avon, England; Inst Biol Mol & Cellulaire, Lab CNRS UPR 9002, F-67084 Strasbourg, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Health Protection Agency; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Kean, KM (corresponding author), Inst Pasteur, CNRS URA 1966, Unite Regulat Traduct Eucaryote & Virale, 25 Rue Dr Roux, F-75724 Paris 15, France.	kathiemb@pasteur.fr	Borman, Andy/H-3663-2019; MALNOU, Cécile/O-9970-2019; MALNOU, Cécile E/K-1569-2014	Borman, Andy/0000-0003-0585-5721; MALNOU, Cécile/0000-0002-1223-0247; MALNOU, Cécile E/0000-0002-1223-0247				AGOL VI, 1989, J VIROL, V63, P4034, DOI 10.1128/JVI.63.9.4034-4038.1989; BELLOCQ C, 1984, VIROLOGY, V139, P403, DOI 10.1016/0042-6822(84)90386-6; Blondel B, 1998, J NEUROVIROL, V4, P1, DOI 10.3109/13550289809113478; BORMAN AM, 1994, EMBO J, V13, P3149, DOI 10.1002/j.1460-2075.1994.tb06613.x; Borman AM, 1997, RNA, V3, P186; Brion P, 1999, RNA, V5, P947, DOI 10.1017/S1355838299990477; DORNER AJ, 1984, J VIROL, V50, P507, DOI 10.1128/JVI.50.2.507-514.1984; GABARRO J, 1978, ANAL BIOCHEM, V91, P309, DOI 10.1016/0003-2697(78)90845-X; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; Gutierrez AL, 1997, J VIROL, V71, P3826; HALLER AA, 1992, J VIROL, V66, P5075, DOI 10.1128/JVI.66.8.5075-5086.1992; HELLEN CUT, 1994, J VIROL, V68, P941, DOI 10.1128/JVI.68.2.941-950.1994; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMONICA N, 1989, J VIROL, V63, P2357, DOI 10.1128/JVI.63.5.2357-2360.1989; LE SY, 1990, J MOL BIOL, V216, P729, DOI 10.1016/0022-2836(90)90395-3; Leontis NB, 2003, CURR OPIN STRUC BIOL, V13, P300, DOI 10.1016/S0959-440X(03)00076-9; MACADAM AJ, 1992, VIROLOGY, V189, P415, DOI 10.1016/0042-6822(92)90565-7; Malnou CE, 2002, J VIROL, V76, P10617, DOI 10.1128/JVI.76.21.10617-10626.2002; MALNOU CE, 2004, IN PRESS CURR TOPICS; MARC D, 1989, EMBO J, V8, P2661, DOI 10.1002/j.1460-2075.1989.tb08406.x; MARTIN A, 1991, VIROLOGY, V180, P648, DOI 10.1016/0042-6822(91)90078-P; MINOR PD, 1992, J GEN VIROL, V73, P3065, DOI 10.1099/0022-1317-73-12-3065; Minor Philip D., 1997, P555; Morley SJ, 1997, RNA, V3, P1085; Ochs K, 2003, J VIROL, V77, P115, DOI 10.1128/JVI.77.1.115-122.2003; Ochs K, 2002, J VIROL, V76, P2113, DOI 10.1128/JVI.76.5.2113-2122.2002; Perales C, 2003, FEBS LETT, V533, P89, DOI 10.1016/S0014-5793(02)03764-X; PILIPENKO EV, 1989, VIROLOGY, V168, P201, DOI 10.1016/0042-6822(89)90259-6; RACANIELLO VR, 1993, BIOLOGICALS, V21, P365, DOI 10.1006/biol.1993.1097; REED L. J., 1938, AMER JOUR HYG, V27, P493; RIVERA VM, 1988, VIROLOGY, V165, P42, DOI 10.1016/0042-6822(88)90656-3; SABIN A. B., 1973, Journal of Biology, V1, P115, DOI 10.1016/0092-1157(73)90048-6; SALK JE, 1960, LANCET, V2, P715; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SKINNER MA, 1989, J MOL BIOL, V207, P379, DOI 10.1016/0022-2836(89)90261-1; Stewart SR, 1998, NUCLEIC ACIDS RES, V26, P5318, DOI 10.1093/nar/26.23.5318; SVITKIN YV, 1985, VIROLOGY, V147, P243, DOI 10.1016/0042-6822(85)90127-8; SVITKIN YV, 1990, VIROLOGY, V175, P103, DOI 10.1016/0042-6822(90)90190-3; SVITKIN YV, 1988, VIROLOGY, V166, P394, DOI 10.1016/0042-6822(88)90510-7; TETERINA NL, 1992, J GEN VIROL, V73, P1977, DOI 10.1099/0022-1317-73-8-1977; Ventoso I, 1998, FEBS LETT, V435, P79, DOI 10.1016/S0014-5793(98)01027-8; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; ZIEGLER E, 1995, VIROLOGY, V213, P549; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	47	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10261	10269		10.1074/jbc.M307806200	http://dx.doi.org/10.1074/jbc.M307806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14672927	hybrid			2022-12-27	WOS:000220050400074
J	Mizuno, M; Tonozuka, T; Suzuki, S; Uotsu-Tomita, R; Kamitori, S; Nishikawa, A; Sakano, Y				Mizuno, M; Tonozuka, T; Suzuki, S; Uotsu-Tomita, R; Kamitori, S; Nishikawa, A; Sakano, Y			Structural insights into substrate specificity and function of glucodextranase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHROBACTER-GLOBIFORMIS I42; ACID-SEQUENCE SIMILARITIES; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; THERMOANAEROBACTERIUM-THERMOSACCHAROLYTICUM; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; GLUCOAMYLASE GENE; ESCHERICHIA-COLI; BINDING DOMAIN	A glucodextranase (iGDase) from Arthrobacter globiformis I42 hydrolyzes alpha-1,6-glucosidic linkages of dextran from the non-reducing end to produce beta-D-glucose via an inverting reaction mechanism and classified into the glycoside hydrolase family 15 (GH15). Here we cloned the iGDase gene and determined the crystal structures of iGDase of the unliganded form and the complex with acarbose at 2.42-Angstrom resolution. The structure of iGDase is composed of four domains N, A, B, and C. Domain A forms an (alpha/alpha)(6)-barrel structure and domain N consists of 17 antiparallel beta-strands, and both domains are conserved in bacterial glucoamylases (GAs) and appear to be mainly concerned with catalytic activity. The structure of iGDase complexed with acarbose revealed that the positions and orientations of the residues at subsites - 1 and + 1 are nearly identical between iGDase and GA; however, the residues corresponding to subsite 3, which form the entrance of the substrate binding pocket, and the position of the open space and constriction of iGDase are different from those of GAs. On the other hand, domains B and C are not found in the bacterial GAs. The primary structure of domain C is homologous with a surface layer homology domain of pullulanases, and the three-dimensional structure of domain C resembles the carbohydrate-binding domain of some glycohydrolases.	Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Tokyo 1838509, Japan; Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan	Tokyo University of Agriculture & Technology; Tokyo University of Agriculture & Technology	Sakano, Y (corresponding author), Tokyo Univ Agr & Technol, Dept Appl Biol Sci, 3-5-8 Saiwai Cho, Tokyo 1838509, Japan.	sakano@cc.tuat.ac.jp	Tonozuka, Takashi/D-2268-2013; Nishikawa, Atsushi/E-6766-2013	Tonozuka, Takashi/0000-0002-5422-7548; Nishikawa, Atsushi/0000-0003-4325-1160; Kamitori, Shigehiro/0000-0002-3950-3372				ALESHIN AE, 1994, J BIOL CHEM, V269, P15631; Aleshin AE, 2003, J MOL BIOL, V327, P61, DOI 10.1016/S0022-2836(03)00084-6; ASHIKARI T, 1986, AGR BIOL CHEM TOKYO, V50, P957; Brechtel E, 1999, J BACTERIOL, V181, P5017, DOI 10.1128/JB.181.16.5017-5023.1999; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COUTINHO PM, 1994, PROTEIN ENG, V7, P393, DOI 10.1093/protein/7.3.393; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Ducki A, 1998, J GEN APPL MICROBIOL, V44, P327, DOI 10.2323/jgam.44.327; Erra-Pujada M, 1999, J BACTERIOL, V181, P3284, DOI 10.1128/JB.181.10.3284-3287.1999; Ganghofner D, 1998, BIOSCI BIOTECH BIOCH, V62, P302, DOI 10.1271/bbb.62.302; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ITOH T, 1987, J BACTERIOL, V169, P4171, DOI 10.1128/jb.169.9.4171-4176.1987; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Janecek S, 1999, FEBS LETT, V456, P119, DOI 10.1016/S0014-5793(99)00919-9; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laskowski RA, 1992, PROCHECK V 2 PROGRAM; LEE SP, 1994, APPL ENVIRON MICROB, V60, P3764, DOI 10.1128/AEM.60.10.3764-3773.1994; LEE YE, 1993, APPL ENVIRON MICROB, V59, P3134, DOI 10.1128/AEM.59.9.3134-3137.1993; LUPAS A, 1994, J BACTERIOL, V176, P1224, DOI 10.1128/jb.176.5.1224-1233.1994; MATUSCHEK M, 1994, J BACTERIOL, V176, P3295, DOI 10.1128/jb.176.11.3295-3302.1994; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MESSNER P, 1992, ADV MICROB PHYSIOL, V33, P213, DOI 10.1016/S0065-2911(08)60218-0; Notenboom V, 2001, BIOCHEMISTRY-US, V40, P6248, DOI 10.1021/bi0101704; Oguma T., 1996, Journal of Applied Glycoscience, V43, P73; Oguma T, 1999, BIOSCI BIOTECH BIOCH, V63, P2174, DOI 10.1271/bbb.63.2174; OHNISHI H, 1992, EUR J BIOCHEM, V207, P413, DOI 10.1111/j.1432-1033.1992.tb17064.x; OKADA G, 1988, AGR BIOL CHEM TOKYO, V52, P2169; OKADA G, 1989, AGR BIOL CHEM TOKYO, V53, P223, DOI 10.1080/00021369.1989.10869251; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OZAKI K, 1990, J GEN MICROBIOL, V136, P1327, DOI 10.1099/00221287-136-7-1327; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAWAI T, 1974, J BIOCHEM-TOKYO, V75, P105, DOI 10.1093/oxfordjournals.jbchem.a130363; SAWAI T, 1976, AGR BIOL CHEM TOKYO, V40, P1293, DOI 10.1080/00021369.1976.10862217; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; SIERKS MR, 1989, PROTEIN ENG, V2, P621, DOI 10.1093/protein/2.8.621; Sleytr UB, 1997, FEMS MICROBIOL REV, V20, P5, DOI 10.1016/S0168-6445(97)00039-9; Uotsu-Tomita R, 2001, APPL MICROBIOL BIOT, V56, P465, DOI 10.1007/s002530100609; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; YAMAGUCH.T, 1973, AGR BIOL CHEM TOKYO, V37, P2527, DOI 10.1080/00021369.1973.10861047	50	35	37	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10575	10583		10.1074/jbc.M310771200	http://dx.doi.org/10.1074/jbc.M310771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14660574	hybrid			2022-12-27	WOS:000220050400111
J	Schulze, WX; Mann, M				Schulze, WX; Mann, M			A novel proteomic screen for peptide-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ADAPTER-PROTEIN; DIFFERENTIAL INTERACTIONS; ACCESSORY PROTEIN; INTERACTION MAPS; BINDING-SITES; CELL-CULTURE; AMINO-ACIDS; SH2 DOMAINS; RECEPTOR	Regulated interactions between short, unstructured amino acid sequences and modular protein domains are central to cell signaling. Here we use synthetic peptides in "active" (e.g. phosphorylated) and "control" (e.g. nonphosphorylated) forms as baits in affinity pull-down experiments to determine such interactions by quantitative proteomics. Stable isotope labeling by amino acids in cell culture distinguishes specific binders directly by the isotope ratios determined by mass spectrometry (Blagoev, B., Kratchmarova, I., Ong, S.-E., Nielsen, M., Foster, L. J., and Mann, M. ( 2003) Nat. Biotechnol. 21, 315 - 318). A tyrosine-phosphorylated peptide of the epidermal growth factor receptor specifically retrieved the Src homology domain (SH) 2- and SH3 domain-containing adapter protein Grb2. A proline-rich sequence of Son of Sevenless also specifically bound Grb2, demonstrating that the screen maintains specificity with low affinity interactions. The proline-rich Sos peptide retrieved only SH3 domain containing proteins as specific binding partners. Two of these, Pacsin 3 and Sorting Nexin 9, were confirmed by immunoprecipitation. Our data are consistent with a change in the role of Sos from Ras-dependent signaling to actin remodeling/endocytic signaling events by a proline-SH3 domain switch.	Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, DK-5230 Odense M, Denmark	University of Southern Denmark	Mann, M (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Ctr Expt Bioinformat, Campusvej 55, DK-5230 Odense M, Denmark.	mann@bmb.sdu.dk	Mann, Matthias/A-3454-2013; Schulze, Waltraud X/E-9800-2011	Mann, Matthias/0000-0003-1292-4799; Schulze, Waltraud X/0000-0001-9957-7245				BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Espejo A, 2002, BIOCHEM J, V367, P697, DOI 10.1042/BJ20020860; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; Ishihama Y, 2002, J CHROMATOGR A, V979, P233, DOI 10.1016/S0021-9673(02)01402-4; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kay BK, 2001, METHODS, V24, P240, DOI 10.1006/meth.2001.1185; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Legrain P, 2000, FEBS LETT, V480, P32, DOI 10.1016/S0014-5793(00)01774-9; Lundmark R, 2002, BIOCHEM J, V362, P597, DOI 10.1042/0264-6021:3620597; Mayer BJ, 2001, J CELL SCI, V114, P1253; Modregger J, 2000, J CELL SCI, V113, P4511; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; NIMNUAL A, 2002, SCI STKE; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Ong SE, 2003, J PROTEOME RES, V2, P173, DOI 10.1021/pr0255708; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sumoy L, 2001, GENE, V262, P199, DOI 10.1016/S0378-1119(00)00531-X; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vidal M, 1998, J BIOL CHEM, V273, P5343, DOI 10.1074/jbc.273.9.5343; Walhout AJM, 2001, NAT REV MOL CELL BIO, V2, P55, DOI 10.1038/35048107; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; Wasiak S, 2001, J BIOL CHEM, V276, P26622, DOI 10.1074/jbc.M100591200; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; YANG SS, 1995, J BIOL CHEM, V270, P18212, DOI 10.1074/jbc.270.31.18212; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	48	245	259	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10756	10764		10.1074/jbc.M309909200	http://dx.doi.org/10.1074/jbc.M309909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679214	hybrid			2022-12-27	WOS:000220050400131
J	Gao, RP; Brigstock, DR				Gao, RP; Brigstock, DR			Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; ENDOTHELIAL-CELLS; HUMAN LIVER; MATRICELLULAR PROTEINS; FACTOR CTGF; MYOBLAST DIFFERENTIATION; CYR61 CCN1; EXPRESSION; SURFACE; ALPHA(6)BETA(1)	Connective tissue growth factor (CCN2, also known as CTGF) is a matricellular protein that appears to play an important role in hepatic stellate cell (HSC)-mediated fibrogenesis. After signal peptide cleavage, the full-length CCN2 molecule comprises four structural modules (CCN2(1-4)) and is susceptible to proteolysis by HSC yielding isoforms comprising essentially modules 3 and 4 (CCN2(3-4)) or module 4 alone (CCN2(4)). In this study we show that rat activated HSC are capable of adhesion to all three CCN2 isoforms via the binding of module 4 to integrin alpha(v)beta(3), a process that is dependent on interactions between module 4 and cell surface heparan sulfate proteoglycans (HSPGs). These findings are based on several lines of evidence. First, integrin alpha(v)beta(3) was detected in HSC lysates by immunoprecipitation and Western blot, and CCN2(4)-mediated HSC adhesion was blocked by anti-integrin alpha(v)beta(3) antibody. Second, as assessed by immunoprecipitation and solid phase binding assay, CCN2(4) bound directly to integrin alpha(v)beta(3) in cell-free systems. Third, destruction or inhibition of synthesis of cell surface HSPGs with, respectively, heparinase or sodium chlorate abrogated HSC adhesion to CCN2(4). Fourth, prior occupancy of heparin-binding sites on CCN2(4) with soluble heparin completely blocked HSC adhesion. These findings indicate that integrin alpha(v)beta(3) functions as a co-receptor with HSPGs for CCN2(4)-mediated HSC adhesion. Furthermore, by peptide mapping and site-directed mutagenesis we demonstrated that the sequence IRTPKISKPIKFELSG within CCN2(4) is a unique binding domain for integrin alpha(v)beta(3) that is sufficient to mediate integrin alpha(v)beta(3)- and HSPG-dependent HSC adhesion. These findings offer the possibility of developing novel antifibrotic therapies that target the integrin-binding domain.	Childrens Res Inst, Ctr Cell & Vasc Biol, Columbus, OH 43205 USA; Ohio State Univ, Dept Surg, Columbus, OH 43212 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43212 USA	University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Brigstock, DR (corresponding author), Childrens Res Inst, Ctr Cell & Vasc Biol, Rm WA 2022,700 Childrens Dr, Columbus, OH 43205 USA.	brigstod@pediatrics.ohio-state.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012817] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA12817] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abou-Shady M, 2000, LIVER, V20, P296, DOI 10.1034/j.1600-0676.2000.020004296.x; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Ball DK, 2003, REPRODUCTION, V125, P271, DOI 10.1530/rep.0.1250271; Ball DK, 2003, J ENDOCRINOL, V176, pR1, DOI 10.1677/joe.0.176R001; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Bornstein P, 2000, MATRIX BIOL, V19, P555, DOI 10.1016/S0945-053X(00)00103-7; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Caldwell EEO, 1996, INT J BIOCHEM CELL B, V28, P203, DOI 10.1016/1357-2725(95)00123-9; Carey DJ, 1997, BIOCHEM J, V327, P1; Carloni V, 1996, GASTROENTEROLOGY, V110, P1127, DOI 10.1053/gast.1996.v110.pm8613002; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; Ellis PD, 2003, J VASC RES, V40, P234, DOI 10.1159/000071887; Feitsma K, 2000, J BIOL CHEM, V275, P9396, DOI 10.1074/jbc.275.13.9396; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; Gao RP, 2003, HEPATOL RES, V27, P214, DOI 10.1016/S1386-6346(03)00241-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iwamoto H, 1998, J HEPATOL, V29, P752, DOI 10.1016/S0168-8278(98)80256-0; Kerr JS, 2001, DRUG NEWS PERSPECT, V14, P143; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; MENDENDEZ JA, 2003, ENDOCR RELAT CANCER, V10, P139; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Paradis V, 2002, LAB INVEST, V82, P767, DOI 10.1097/01.LAB.0000017365.18894.D3; Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2003, J CLIN PATHOL-MOL PA, V56, P80, DOI 10.1136/mp.56.2.80; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Rachfal AW, 2003, HEPATOL RES, V26, P1, DOI 10.1016/S1386-6346(03)00115-3; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Roskams T, 1996, HEPATOLOGY, V24, P524, DOI 10.1053/jhep.1996.v24.pm0008781318; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; SCHOBER JM, 2003, J BIOL CHEM; SMITH JW, 1994, J BIOL CHEM, V269, P960; van der Pauw MTM, 2002, J PERIODONTAL RES, V37, P317, DOI 10.1034/j.1600-0765.2002.00349.x; VYAS SK, 1995, GASTROENTEROLOGY, V109, P889, DOI 10.1016/0016-5085(95)90399-2; Weiner OH, 1996, CELL TISSUE RES, V285, P11, DOI 10.1007/s004410050615; Williams EJ, 2000, J HEPATOL, V32, P754, DOI 10.1016/S0168-8278(00)80244-5	58	192	208	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8848	8855		10.1074/jbc.M313204200	http://dx.doi.org/10.1074/jbc.M313204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684735	hybrid			2022-12-27	WOS:000189265900040
J	Ji, H; Yeh, SR; Rousseau, DL				Ji, H; Yeh, SR; Rousseau, DL			Modulation of the electron redistribution in mixed valence cytochrome c oxidase by protein conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC RESONANCE SIGNAL; ESCHERICHIA-COLI; CARBON-MONOXIDE; 2.8 ANGSTROM; PHOTOLYSIS; PHOTODISSOCIATION; SPECTROSCOPY; EQUILIBRIUM; ACTIVATION; TURNOVER	The redistribution of two electrons in the four redox centers of cytochrome c oxidase following photodissociation of CO from the CO-bound mixed valence species has been examined by resonance Raman spectroscopy. To account for both the kinetic data, obtained from 5 mus to 2 ms, and the equilibrium results, a model is proposed in which the electron redistribution is modulated by a protein conformation transition from a nascent P-1 state to a relaxed P-2 state in a time window longer than 2 ms. In this model, all six possible two-electron reduced species are considered. The high population of species with a one-electron reduced binuclear center, in which the spectrum of heme a(3) is perturbed by the redox state of Cu-B, accounts for the significant residuals in the fitting of the kinetic data with four standard spectra derived from redox species with either zero or two electrons in the binuclear center. Under equilibrium conditions, the conformational change to the P-2 state destabilizes the redox states with only one electron in the binuclear center with respect to those with either zero or two electrons. As a result, the redox equilibrium is perturbed, and the electrons are redistributed. A simulation based on the new kinetics scheme, in which the electron redistribution is modulated by the protein conformation, gives reasonable agreement with both the equilibrium and the kinetic data, demonstrating the validity of this model.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.	rousseau@aecom.yu.edu		Yeh, Syun-Ru/0000-0002-9858-386X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELROTH P, 1995, BIOCHEMISTRY-US, V34, P2844; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BEINERT H, 1977, BIOCHIM BIOPHYS ACTA, V462, P121, DOI 10.1016/0005-2728(77)90194-3; BOELENS R, 1979, BIOCHIM BIOPHYS ACTA, V547, P296, DOI 10.1016/0005-2728(79)90012-4; BOELENS R, 1982, BIOCHIM BIOPHYS ACTA, V682, P264, DOI 10.1016/0005-2728(82)90107-4; Brzezinski P, 1996, BIOCHEMISTRY-US, V35, P5611, DOI 10.1021/bi960260m; BRZEZINSKI P, 1987, BIOCHIM BIOPHYS ACTA, V894, P29, DOI 10.1016/0005-2728(87)90209-X; Ching E, 2003, BIOPHYS J, V84, P2728, DOI 10.1016/S0006-3495(03)75078-4; EINARSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013, DOI 10.1021/bi00096a011; EINARSDOTTIR O, 1995, BIOCHEMISTRY-US, V34, P496, DOI 10.1021/bi00002a014; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; FINDSEN EW, 1987, J AM CHEM SOC, V109, P5367, DOI 10.1021/ja00252a011; GEORGIADIS KE, 1994, BIOCHEMISTRY-US, V33, P9245, DOI 10.1021/bi00197a028; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; JENSEN P, 1981, FEBS LETT, V125, P161, DOI 10.1016/0014-5793(81)80709-0; KARLSSON B, 1981, BIOCHIM BIOPHYS ACTA, V635, P73, DOI 10.1016/0005-2728(81)90008-6; LOU BS, 1993, J AM CHEM SOC, V115, P403, DOI 10.1021/ja00055a006; MALATESTA F, 1995, BIOPHYS CHEM, V54, P1, DOI 10.1016/0301-4622(94)00117-3; MORGAN JE, 1993, BIOCHEMISTRY-US, V32, P11413, DOI 10.1021/bi00093a019; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; Namslauer A, 2002, BIOCHEMISTRY-US, V41, P10369, DOI 10.1021/bi025976y; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; REINHAMMAR B, 1980, J BIOL CHEM, V255, P5000; Rousseau DL, 2002, METHOD ENZYMOL, V354, P351; ROUSSEAU DL, 1981, J RAMAN SPECTROSC, V10, P94, DOI 10.1002/jrs.1250100116; SHAW RW, 1978, J BIOL CHEM, V253, P6637; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VERKHOVSKY MI, 1992, BIOCHEMISTRY-US, V31, P11860, DOI 10.1021/bi00162a026; Verkhovsky MI, 2001, BBA-BIOENERGETICS, V1506, P143, DOI 10.1016/S0005-2728(01)00220-1; WITT SN, 1986, J BIOL CHEM, V261, P8104; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; Yoshikawa S, 1998, J BIOENERG BIOMEMBR, V30, P7, DOI 10.1023/A:1020595108560; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498	34	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9392	9399		10.1074/jbc.M310729200	http://dx.doi.org/10.1074/jbc.M310729200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660573	hybrid			2022-12-27	WOS:000189265900104
J	Lew, JL; Zhao, A; Yu, JH; Huang, L; de Pedro, N; Pelaez, F; Wright, SD; Cui, JS				Lew, JL; Zhao, A; Yu, JH; Huang, L; de Pedro, N; Pelaez, F; Wright, SD; Cui, JS			The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; NEGATIVE FEEDBACK-REGULATION; SALT EXPORT PUMP; BILE-ACIDS; PROTEIN GENE; LIVER; FXR; IDENTIFICATION; TRANSCRIPTION; TRANSPORTER	Farnesoid X receptor (FXR) is a nuclear receptor for bile acids. Ligand activated-FXR regulates transcription of genes to allow feedback control of bile acid synthesis and secretion. There are five major bile acids in humans. We have previously demonstrated that lithocholate acts as an FXR antagonist, and here we show that the other four bile acids, chenodeoxycholate (CDCA), deoxycholate (DCA), cholate (CA), and ursodeoxycholate (UDCA), act as selective FXR agonists in a gene-specific fashion. In an in vitro coactivator association assay, CDCA fully activated FXR, whereas CA partially activated FXR and DCA and UDCA had negligible activities. Similar results were also obtained from a glutathione S-transferase pull-down assay in which only CDCA and the synthetic FXR agonist GW4064 significantly increased the interaction of SRC-1 with FXR. In FXR transactivation assays with a bile salt export pump (BSEP) promoter-driven luciferase construct, bile acids showed distinct abilities to activate the BSEP promoter: CDCA, DCA, CA, and UDCA increased luciferase activity by 25-, 20-, 18-, and 8-fold, respectively. Consistently, CDCA increased BSEP mRNA by 750-fold in HepG2 cells, whereas DCA, CA, and UDCA induced BSEP mRNA by 250-, 75-, and 15-fold, respectively. Despite the partial induction of BSEP mRNA, CA, DCA, and UDCA effectively repressed expression of cholesterol 7alpha-hydroxylase, another FXR target. We further showed that all four bile acids significantly increased FXR protein, suggesting the existence of an auto-regulatory loop in FXR signaling pathways. In conclusion, these results suggest that the binding of each bile acid results in a different FXR conformations, which in turn differentially regulates expression of individual FXR targets.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Merck Sharp & Dohme Espana, Madrid 28027, Spain	Merck & Company; Merck & Company	Cui, JS (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, 126 E Lincoln Ave,POB 2000,RY80W-107, Rahway, NJ 07065 USA.	jisong_cui@merck.com	Pelaez, Fernando/K-1790-2014	Pelaez, Fernando/0000-0002-4861-586X				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Camp HS, 1999, FEBS LETT, V447, P186, DOI 10.1016/S0014-5793(99)00268-9; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Claudel T, 2002, J CLIN INVEST, V109, P961; Cui J, 2003, J BIOL CHEM, V278, P10214, DOI 10.1074/jbc.M209323200; Cui J, 2002, J BIOL CHEM, V277, P25963, DOI 10.1074/jbc.M200824200; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Li Y, 2002, MOL ENDOCRINOL, V16, P506, DOI 10.1210/me.16.3.506; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Takeyama K, 1996, BIOCHEM BIOPH RES CO, V222, P395, DOI 10.1006/bbrc.1996.0755; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Xu GR, 2002, J BIOL CHEM, V277, P50491, DOI 10.1074/jbc.M209176200; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	32	154	159	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8856	8861		10.1074/jbc.M306422200	http://dx.doi.org/10.1074/jbc.M306422200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684751	hybrid			2022-12-27	WOS:000189265900041
J	Martin-Puig, S; Temes, E; Olmos, G; Jones, DR; Aragones, J; Landazuri, MO				Martin-Puig, S; Temes, E; Olmos, G; Jones, DR; Aragones, J; Landazuri, MO			Role of iron (II)-2-oxoglutarate-dependent dioxygenases in the generation of hypoxia-induced phosphatidic acid through HIF-1/2 and von Hippel-Lindau-independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; STRESS FIBER FORMATION; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; MAMMALIAN TARGET; HIF-ALPHA; OXYGEN; PROLYL; ACTIVATION; PROTEIN	Hypoxia-inducible factors ( HIF-1/HIF-2) govern the expression of critical genes for cellular adaptation to low oxygen tensions. We have previously reported that the intracellular level of phosphatidic acid (PA) rises in response to hypoxia (1% O-2). In this report, we have explored whether components of the canonical HIF/von Hippel-Lindau (VHL) pathway are involved in the induction of PA. We found that hypoxia induces PA in a cell line constitutively expressing a stable version of HIF-1alpha. PA induction was also found in HIF-1alpha- and 2alpha-negative CHO Ka13 cells, as well as in HIF-beta-negative HepaC4 cells. These data indicate that HIF activity is neither sufficient nor necessary for oxygen-dependent PA accumulation. PA generation was also detected in cells deficient for the tumor suppressor VHL, indicating that the presence of VHL was not required for the induction of PA. Here we show that PA accumulation also occurs at moderate hypoxia (5% O-2), although to a lesser extent to that seen at 1% O-2, revealing that PA is induced at the same hypoxia range required to activate HIF-1. Prolyl hydroxylases (PHD) and asparaginyl hydroxylase (FIH) belong to the iron (II) and 2-oxoglutarate- dependent dioxygenase family and have been proposed as oxygen sensors involved in the regulation of HIFs. Chemical inhibition of these activities by treatment with iron chelators or 2-oxoglutarate analogs also results in a marked PA accumulation similar to that observed in hypoxia. Together these data show that PA accumulation in response to hypoxia is both HIF-1/2- and VHL-independent and indicate a role of iron (II)-2-oxoglutarate-dependent dioxygenases in the oxygen-sensing mechanisms involved in hypoxia-driven phospholipid regulation.	Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain	Autonomous University of Madrid; Hospital de La Princesa	Landazuri, MO (corresponding author), Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Diego de Leon 62, Madrid 28006, Spain.	mortiz.hlpr@salud.madrid.org		Aragones Lopez, Julian/0000-0002-0193-4679; Martin-Puig, Silvia/0000-0003-3048-6729; Olmos Centenera, Gemma/0000-0003-4835-0846				Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Ghosh S, 2003, J BIOL CHEM, V278, P45690, DOI 10.1074/jbc.M302933200; Ghosh S, 1997, FASEB J, V11, P45, DOI 10.1096/fasebj.11.1.9034165; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Gu YZ, 1998, GENE EXPRESSION, V7, P205; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung F, 2002, CIRC RES, V91, P38, DOI 10.1161/01.RES.0000024412.24491.CA; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; LIM HK, 2003, J BIOL CHEM, V12, P123; Lopez-Barneo J, 1999, RESP PHYSIOL, V115, P215, DOI 10.1016/S0034-5687(99)00016-X; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; MAJAMAA K, 1986, J BIOL CHEM, V261, P7819; Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MCCAFFREY TA, 1995, J CLIN INVEST, V95, P446, DOI 10.1172/JCI117684; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; SETA KA, 2002, SCI STKE, V146, pRE11, DOI DOI 10.1126/STKE.2002.146.RE11; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Zhu H, 2001, SCIENCE, V292, P449, DOI 10.1126/science.1060849	57	10	12	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9504	9511		10.1074/jbc.M310658200	http://dx.doi.org/10.1074/jbc.M310658200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681229	hybrid			2022-12-27	WOS:000189265900117
J	Mukhopadhyay, D; SundarRaj, S; Alok, A; Karande, AA				Mukhopadhyay, D; SundarRaj, S; Alok, A; Karande, AA			Glycodelin A, not glycodelin S, is apoptotically active - Relevance of sialic acid modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL PROTEIN-14; SEMINAL-VESICLES; T-CELLS; EXPRESSION; OLIGOSACCHARIDES; APOPTOSIS	Glycodelin, previously known as PP14 ( placental protein-14), is a kernel lipocalin secreted by the glandular epithelium of the endometrium upon progesterone stimulation and by the seminal vesicles. The isoform of the protein present in female reproductive tissue, glycodelin A (GdA), and the male counterpart, glycodelin S (GdS), have identical amino acid sequences, but strikingly different N-linked glycans. It is well documented in literature that GdA is an immunosuppressive protein, and we have shown that this activity is due to its ability to induce apoptosis in activated T cells. The precise role of GdS in seminal plasma is not known. In this study, we report that GdS is not apoptotically active. We observe that the apoptotic activity requires the presence of sialic acid residues on the complex glycans, as in the case of GdA; however, complex glycans of GdS are nonsialylated. We have expressed the wild-type protein in Pichia pastoris, which does not add sialic acid to the secreted proteins, and confirmed our observations that the protein is apoptotically inactive in the non-sialylated form. Our results indicate that differential glycosylation modulates the function of the different glycodelin isoforms.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Karande, AA (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	anjali@biochem.iisc.ernet.in	Karande, Anjali/C-4880-2009					AMR S, 1982, BIOCHEM BIOPH RES CO, V109, P146, DOI 10.1016/0006-291X(82)91577-7; Barteri M, 2000, BBA-PROTEIN STRUCT M, V1479, P255, DOI 10.1016/S0167-4838(00)00021-2; Bohn H, 1982, Placenta Suppl, V4, P67; BOLTON AE, 1987, LANCET, V1, P593; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Celis JE, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P375; Chotigeat W, 2000, J BIOTECHNOL, V81, P55, DOI 10.1016/S0168-1656(00)00268-6; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; Dutta B, 1998, PROTEIN EXPRES PURIF, V14, P327, DOI 10.1006/prep.1998.0961; FRIEDMAN ML, 1986, BIOCHEM J, V236, P149, DOI 10.1042/bj2360149; Gonzales GF, 2001, ASIAN J ANDROL, V3, P251; Haque ME, 1999, EUR J BIOCHEM, V259, P269, DOI 10.1046/j.1432-1327.1999.00062.x; Harlow E., 1988, ANTIBODIES LABORATOR, P310; Jayachandran R, 2004, J BIOL CHEM, V279, P8585, DOI 10.1074/jbc.M310480200; Jerzak M, 1998, AM J REPROD IMMUNOL, V40, P130; JULKUNEN M, 1986, ENDOCRINOLOGY, V118, P1782, DOI 10.1210/endo-118-5-1782; JULKUNEN M, 1988, P NATL ACAD SCI USA, V85, P8845, DOI 10.1073/pnas.85.23.8845; Kamarainen M, 1997, LAB INVEST, V77, P565; Karri T, 2000, HISTOCHEM J, V32, P711, DOI 10.1023/A:1004144909714; Koistinen H, 1999, FEBS LETT, V450, P158, DOI 10.1016/S0014-5793(99)00490-1; Koistinen H, 1996, MOL HUM REPROD, V2, P759, DOI 10.1093/molehr/2.10.759; Logdberg L, 2000, BBA-PROTEIN STRUCT M, V1482, P284, DOI 10.1016/S0167-4838(00)00164-3; Morris HR, 1996, J BIOL CHEM, V271, P32159, DOI 10.1074/jbc.271.50.32159; Mukhopadhyay D, 2001, J BIOL CHEM, V276, P28268, DOI 10.1074/jbc.M010487200; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; Schauer R, 1988, Adv Exp Med Biol, V228, P47; Seppala M, 1998, TUMOR BIOL, V19, P213, DOI 10.1159/000030009; SEPPALA M, 1985, ANN NY ACAD SCI, V442, P212, DOI 10.1111/j.1749-6632.1985.tb37522.x; Song MQ, 2001, P NATL ACAD SCI USA, V98, P9265, DOI 10.1073/pnas.151151198; TULPPALA M, 1995, FERTIL STERIL, V63, P792, DOI 10.1016/S0015-0282(16)57483-4	31	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8577	8584		10.1074/jbc.M306673200	http://dx.doi.org/10.1074/jbc.M306673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679205	hybrid			2022-12-27	WOS:000189265900008
J	Prasad, A; Fernandis, AZ; Rao, Y; Ganju, RK				Prasad, A; Fernandis, AZ; Rao, Y; Ganju, RK			Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ENDOTHELIAL GROWTH-FACTOR; REPULSIVE AXON GUIDANCE; OLFACTORY-BULB AXONS; TYROSINE PHOSPHATASE; MATRIX METALLOPROTEINASES; CHEMOKINE RECEPTORS; ROUNDABOUT RECEPTOR; NIH3T3 FIBROBLASTS; NEURONAL MIGRATION	Slit, which mediates its function by binding to the Roundabout ( Robo) receptor, has been shown to regulate neuronal and CXCR4-mediated leukocyte migration. Slit-2 was shown to be frequently inactivated in lung and breast cancers because of hypermethylation of its promoter region. Furthermore, the CXCR4/CXCL12 axis has been reported recently to be actively involved in breast cancer metastasis to target organs such as lymph nodes, lung, and bone. In this study, we sought to characterize the effect of Slit ( = Slit-2) on the CXCL12/ CXCR4-mediated metastatic properties of breast cancer cells. We demonstrate here that breast cancer cells and tissues derived from breast cancer patients express Robo 1 and 2 receptors. We also show that Slit treatment inhibits CXCL12/ CXCR4-induced breast cancer cell chemotaxis, chemoinvasion, and adhesion, the fundamental components that promote metastasis. Slit had no significant effect on the CXCL12-induced internalization process of CXCR4. In addition, characterization of signaling events revealed that Slit inhibits CXCL12-induced tyrosine phosphorylation of focal adhesion components such as RAFTK/Pyk2 at residues 580 and 881, focal adhesion kinase at residue 576, and paxillin. We found that Slit also inhibits CXCL12-induced phosphatidylinositol 3-kinase, p44/42 MAP kinase, and metalloproteinase 2 and 9 activities. However, it showed no effect on JNK and p38 MAP kinase activities. To our knowledge, this is the first report to analyze in detail the effect of Slit on breast cancer cell motility as well as its effect on the critical components of the cancer cell chemotactic machinery. Studies of the Slit-Robo complex may foster new anti-chemotactic approaches to block cancer cell metastasis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Washington University (WUSTL)	Ganju, RK (corresponding author), Harvard Inst Med, BIDMC, 4 Blackfan Circle,Room 343, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu	Fernandis, Aaron/C-3718-2012					Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Barrett JM, 2002, BREAST CANCER RES TR, V72, P227, DOI 10.1023/A:1014993006190; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Chen JH, 2001, J NEUROSCI, V21, P1548, DOI 10.1523/JNEUROSCI.21-05-01548.2001; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Chisholm A, 1999, CURR OPIN NEUROBIOL, V9, P603, DOI 10.1016/S0959-4388(99)00021-5; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Dallol A, 2002, CANCER RES, V62, P5874; Fernandis A. Z., 2001, SCI STKE, V2001, ppe1; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; Fernandis AZ, 2002, J BIOL CHEM, V277, P18111, DOI 10.1074/jbc.M200750200; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Ghose A, 2002, BIOESSAYS, V24, P401, DOI 10.1002/bies.10080; Gold MR, 2000, IMMUNOL REV, V176, P47; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Hyder SM, 2001, INT J CANCER, V92, P469, DOI 10.1002/ijc.1236; Itoh A, 1998, MOL BRAIN RES, V62, P175, DOI 10.1016/S0169-328X(98)00224-1; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Latil A, 2003, INT J CANCER, V103, P306, DOI 10.1002/ijc.10821; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Manes S, 1999, MOL CELL BIOL, V19, P3125; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Scotton CJ, 2002, CANCER RES, V62, P5930; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Taichman RS, 2002, CANCER RES, V62, P1832; TAYLOR P, 1990, P1; van Golen KL, 2003, BREAST CANCER RES, V5, P174, DOI 10.1186/bcr598; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Verbeek BS, 1999, EXP CELL RES, V248, P531, DOI 10.1006/excr.1999.4416; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Woods ML, 2001, J LEUKOCYTE BIOL, V69, P874; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Yuan WL, 1999, DEV BIOL, V212, P290, DOI 10.1006/dbio.1999.9371; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2	66	96	117	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9115	9124		10.1074/jbc.M308083200	http://dx.doi.org/10.1074/jbc.M308083200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14645233	hybrid			2022-12-27	WOS:000189265900073
J	Stuhlmeier, KM; Pollaschek, C				Stuhlmeier, KM; Pollaschek, C			Differential effect of transforming growth factor beta (TGF-beta) on the genes encoding hyaluronan synthases and utilization of the p38 MAPK pathway in TGF-beta-induced hyaluronan synthase 1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAYS; RHEUMATOID-ARTHRITIS; ANGIOGENIC OLIGOSACCHARIDES; SYNOVIAL-FLUID; SIGNAL-TRANSDUCTION; MURINE MACROPHAGES; DISEASE-ACTIVITY; PRIMARY ADHESION; DENDRITIC CELLS; CANCER CELLS	Unfettered hyaluronan (HA) production is a hallmark of rheumatoid arthritis. The discovery of three genes encoding hyaluronan synthases (HASs) allows for the investigation of the signaling pathways leading to the activation of these genes. Our objective is to further understanding of the regulation of these genes as well as to find ways to prevent undesired gene activation. Human fibroblast-like synoviocytes were used in these experiments. mRNA levels of HAS were monitored by reverse transcriptase-PCR. A series of specific kinase inhibitors were used to investigate intracellular pathways leading to the up-regulation of HAS1. Our experiments, testing a series of stimuli including tumor necrosis factor alpha (TNFalpha), demonstrate that TGF-beta is the most potent stimulus for HAS1 transcription. TGF-beta activates HAS1 in a dose-dependent manner with a maximum effect at a concentration of 0.5-1 ng/ml. TGF-beta-induced HAS1 mRNA can be detected within 60 min and reaches maximal levels at 6 h. Furthermore, TGF-beta treatment leads to an increase in synthase activity as determined by HA ELISA and by in vitro HA synthase assays. In contrast to the activatory effect on HAS1, TGF-beta dose-dependently suppresses HAS3 mRNA. As to the mode of action of TGF-beta-induced HAS1 mRNA activation, our experiments reveal that blocking p38 MAPK inhibited the TGF-beta effect by 90%, blocking the MEK pathway led to an inhibition by 40%, and blocking the JNK pathway had no effect. The presented data might contribute to a better understanding of the role of TGF-beta and of HA in the pathology of diseases.	Ludwig Boltzmann Inst Rheumatol & Balneol, A-1107 Vienna, Austria	Ludwig Boltzmann Institute	Stuhlmeier, KM (corresponding author), Ludwig Boltzmann Inst Rheumatol & Balneol, Kurbadstr 10,POB 78, A-1107 Vienna, Austria.	karlms@excite.com						Agren UM, 1997, FREE RADICAL BIO MED, V23, P996, DOI 10.1016/S0891-5849(97)00098-1; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Bucht A, 1996, CLIN EXP IMMUNOL, V103, P357; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Catterall JB, 1997, GLYCOCONJUGATE J, V14, P867, DOI 10.1023/A:1018598223579; Chen Wanjun, 2002, Curr Dir Autoimmun, V5, P62; CHICHIBU K, 1989, CLIN CHIM ACTA, V181, P317, DOI 10.1016/0009-8981(89)90237-4; Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; DeGrendele HC, 1997, J IMMUNOL, V159, P2549; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; ELLIS I, 1995, GROWTH FACTORS, V12, P211, DOI 10.3109/08977199509036881; Emlen W, 1996, J RHEUMATOL, V23, P974; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Estess P, 1998, J CLIN INVEST, V102, P1173, DOI 10.1172/JCI4235; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Gerdin B, 1997, J INTERN MED, V242, P49, DOI 10.1046/j.1365-2796.1997.00173.x; Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146; Goumans MJ, 2000, INT J DEV BIOL, V44, P253; HAKANSSON L, 1985, J IMMUNOL, V135, P2735; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HASCALL VC, 1974, J BIOL CHEM, V249, P4232; HAUBECK HD, 1995, ARTHRITIS RHEUM-US, V38, P669, DOI 10.1002/art.1780380515; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Horton MR, 2000, AM J PHYSIOL-LUNG C, V279, pL707, DOI 10.1152/ajplung.2000.279.4.L707; Kosaki R, 1999, CANCER RES, V59, P1141; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; LEES VC, 1995, LAB INVEST, V73, P259; Lettesjo H, 1998, SCAND J IMMUNOL, V48, P286; Louthrenoo Worawit, 2001, Journal of the Medical Association of Thailand, V84, P622; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MATUCCICERINIC M, 1990, ANN RHEUM DIS, V49, P598, DOI 10.1136/ard.49.8.598; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Meyer K, 1934, J BIOL CHEM, V107, P629; Mohamadzadeh M, 1998, J CLIN INVEST, V101, P97, DOI 10.1172/JCI1604; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; OGUCHI T, 2001, POST SESS RHEUM ARTH, pO642; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; Ropponen K, 1998, CANCER RES, V58, P342; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; Setala LP, 1999, BRIT J CANCER, V79, P1133, DOI 10.1038/sj.bjc.6690180; Slevin M, 1998, LAB INVEST, V78, P987; Spicer A P, 2001, Methods Mol Biol, V171, P373; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; UNDERHILL C, 1992, J CELL SCI, V103, P293; WAHL SM, 1990, J IMMUNOL, V145, P2514; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang JY, 2002, P NATL ACAD SCI USA, V99, P14362, DOI 10.1073/pnas.222536599; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; WEIGEL PH, 1989, CIBA F SYMP, V143, P248; WEIGEL PH, 1986, J THEOR BIOL, V119, P219, DOI 10.1016/S0022-5193(86)80076-5; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yamada H, 2000, ARCH ORTHOP TRAUM SU, V120, P521, DOI 10.1007/s004029900131; Yonekura A, 1999, ENDOCR J, V46, P545, DOI 10.1507/endocrj.46.545; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497	62	99	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8753	8760		10.1074/jbc.M303945200	http://dx.doi.org/10.1074/jbc.M303945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676202	hybrid			2022-12-27	WOS:000189265900029
J	Jiang, H; Ross, AE; Desiderio, S				Jiang, H; Ross, AE; Desiderio, S			Cell cycle-dependent accumulation in vivo of transposition-competent complexes between recombination signal ends and full-length RAG proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; TERMINAL REGION; B-CELL; DNA; REARRANGEMENT; DEGRADATION; THYMOCYTES; RESOLUTION; DELETION; PORTION	V(D) J recombination is initiated by a specialized transposase consisting of RAG-1 and RAG-2. Because full-length RAG proteins are insoluble under physiologic conditions, most previous analyses of RAG activity in vitro have used truncated core RAG-1 and RAG-2 fragments. These studies identified an intermediate in V(D) J recombination, the signal end complex (SEC), in which core RAG proteins remain associated with recombination signal sequences at the cleaved signal ends. From transfected cells expressing affinity-tagged RAG proteins, we have isolated in vivo assembled SECs containing full-length RAG proteins and cleaved recombination substrates. SEC formation in vivo did not require the repair proteins DNA-dependent protein kinase, Ku80, or XRCC4. In the presence of full-length RAG-2, SEC formation in vivo was cell cycle-regulated and restricted to the G(0)/G(1) phases. In contrast, complexes accumulated throughout cell cycle in cells expressing a RAG-2 CDK2 phosphorylation site mutant. Both core and full-length SECs supported transposition in vitro with similar efficiencies. Intracellular SECs, which are likely to persist in the absence of coding ends, represent potential donors whose transposition is not suppressed by the non-core regions of the RAG proteins.	Johns Hopkins Univ, Sch Med, Inst Cell Engn, Program Immunol,Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Desiderio, S (corresponding author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, Program Immunol,Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	sdesider@jhmi.edu			NCI NIH HHS [CA16519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P1209, DOI 10.1073/pnas.0237043100; Clatworthy AE, 2003, MOL CELL, V12, P489, DOI 10.1016/S1097-2765(03)00305-8; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; Desiderio S, 1996, CURR TOP MICROBIOL, V217, P45; Elkin SK, 2003, EMBO J, V22, P1931, DOI 10.1093/emboj/cdg184; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Jones JM, 2001, P NATL ACAD SCI USA, V98, P12926, DOI 10.1073/pnas.221471198; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kirch SA, 1998, EMBO J, V17, P4881, DOI 10.1093/emboj/17.16.4881; Lee GS, 2002, MOL CELL BIOL, V22, P2068, DOI 10.1128/MCB.22.7.2068-2077.2002; Lee J, 1999, IMMUNITY, V11, P771, DOI 10.1016/S1074-7613(00)80151-X; Li WH, 2001, MOL CELL BIOL, V21, P3935, DOI 10.1128/MCB.21.12.3935-3946.2001; Li Z, 1996, IMMUNITY, V5, P575, DOI 10.1016/S1074-7613(00)80272-1; Liang HE, 2002, IMMUNITY, V17, P639, DOI 10.1016/S1074-7613(02)00448-X; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIN WC, 1994, P NATL ACAD SCI USA, V91, P2733, DOI 10.1073/pnas.91.7.2733; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Livak F, 1996, MOL CELL BIOL, V16, P609; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMahan CJ, 1997, MOL CELL BIOL, V17, P4544, DOI 10.1128/MCB.17.8.4544; Melek M, 2000, CELL, V101, P625, DOI 10.1016/S0092-8674(00)80874-0; Messier TL, 2003, EMBO J, V22, P1381, DOI 10.1093/emboj/cdg137; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Perkins EJ, 2002, GENE DEV, V16, P159, DOI 10.1101/gad.956902; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Ross AE, 2003, MOL CELL BIOL, V23, P5308, DOI 10.1128/MCB.23.15.5308-5319.2003; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; Sekiguchi J, 2001, MOL CELL, V8, P1383, DOI 10.1016/S1097-2765(01)00423-3; Steen SB, 1999, MOL CELL BIOL, V19, P3010; Tsai CL, 2003, NUCLEIC ACIDS RES, V31, P6180, DOI 10.1093/nar/gkg819; Tsai CL, 2003, EMBO J, V22, P1922, DOI 10.1093/emboj/cdg185; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8	41	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8478	8486		10.1074/jbc.M311219200	http://dx.doi.org/10.1074/jbc.M311219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660558	hybrid			2022-12-27	WOS:000189103300131
J	Tilton, GB; Shockey, JM; Browse, J				Tilton, GB; Shockey, JM; Browse, J			Biochemical and molecular characterization of ACH2, an acyl-CoA thioesterase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A THIOESTERASE; RAT-LIVER; ESCHERICHIA-COLI; BETA-OXIDATION; PALMITOYL-COA; CLONING; IDENTIFICATION; ACID; PURIFICATION; REQUIREMENT	By using computer-based homology searches of the Arabidopsis genome, we identified the gene for ACH2, a putative acyl-CoA thioesterase. With the exception of a unique 129-amino acid N-terminal extension, the ACH2 protein is 17-36% identical to members of a family of acyl-CoA thioesterases that are found in both prokaryotes and eukaryotes. The eukaryotic homologs of ACH2 are peroxisomal acyl-CoA thioesterases that are up-regulated during times of increased fatty acid oxidation, suggesting potential roles in peroxisomal beta-oxidation. We investigated ACH2 to determine whether it has a similar role in the plant cell. Like its eukaryotic homologs, ACH2 carries a putative type 1 peroxisomal targeting sequence (-SKLCOOH), and maintains all the catalytic residues typical of this family of acyl-CoA thioesterases. Analytical ultracentrifugation of recombinant ACH2-6His shows that it associates as a 196-kDa homotetramer in vitro, a result that is significant in light of the cooperative kinetics demonstrated by ACH2-6His in vitro. The cooperative effects are most pronounced with medium chain acyl-CoAs, where the Hill coefficient is 3.8 for lauroyl-CoA, but decrease for long chain acyl-CoAs, where the Hill coefficient is only 1.9 for oleoyl-CoA. ACH2-6His hydrolyzes both medium and long chain fatty acyl-CoAs but has highest activity toward the long chain unsaturated fatty acyl-CoAs. Maximum rates were found with palmitoleoyl-CoA, which is hydrolyzed at 21 mumol/min/mg protein. Additionally, ACH2-6His is insensitive to feedback inhibition by free CoASH levels as high as 100 muM. ACH2 is most highly expressed in mature tissues such as young leaves and flowers rather than in germinating seedlings where beta-oxidation is rapidly proceeding. Taken together, these results suggest that ACH2 activity is not linked to fatty acid oxidation as has been suggested for its eukaryotic homologs, but rather has a unique role in the plant cell.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Browse, J (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	jab@wsu.edu		Shockey, Jay/0000-0002-5057-5457; Browse, John/0000-0002-2554-2821	NIGMS NIH HHS [T32 GM008336] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008336] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXSON SEH, 1993, EUR J BIOCHEM, V214, P719, DOI 10.1111/j.1432-1033.1993.tb17973.x; ANDREWS J, 1983, PLANT PHYSIOL, V72, P735, DOI 10.1104/pp.72.3.735; BERGE RK, 1981, BIOCHIM BIOPHYS ACTA, V666, P25, DOI 10.1016/0005-2760(81)90087-4; BONNER WM, 1972, J BIOL CHEM, V247, P3123; CHO HS, 1993, J BIOL CHEM, V268, P9238; Dansen TB, 2000, NAT CELL BIOL, V2, P51, DOI 10.1038/71375; Dong JZ, 1996, PLANT CELL REP, V15, P516, DOI 10.1007/BF00232985; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fulda M, 2002, PLANT J, V32, P93, DOI 10.1046/j.1365-313X.2002.01405.x; Germain V, 2001, PLANT J, V28, P1, DOI 10.1046/j.1365-313X.2001.01095.x; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0; Hunt MC, 2002, J BIOL CHEM, V277, P1128, DOI 10.1074/jbc.M106458200; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Hunt MC, 2000, J LIPID RES, V41, P814; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Jones JM, 2000, BIOCHEM BIOPH RES CO, V275, P233, DOI 10.1006/bbrc.2000.3285; Jones JM, 1999, J BIOL CHEM, V274, P9216, DOI 10.1074/jbc.274.14.9216; JOYARD J, 1980, PLANT PHYSIOL, V65, P1039, DOI 10.1104/pp.65.6.1039; LEE KY, 1979, J BIOL CHEM, V254, P4516; Leng Q, 1999, PLANT PHYSIOL, V121, P753, DOI 10.1104/pp.121.3.753; Li J, 2000, NAT STRUCT BIOL, V7, P555; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; McConn M, 1996, PLANT CELL, V8, P403, DOI 10.1105/tpc.8.3.403; Mullen RT, 1997, PLANT J, V12, P313, DOI 10.1046/j.1365-313X.1997.12020313.x; MURPHY DJ, 1984, EUR J BIOCHEM, V142, P43, DOI 10.1111/j.1432-1033.1984.tb08248.x; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Poupon V, 1999, J BIOL CHEM, V274, P19188, DOI 10.1074/jbc.274.27.19188; Richards H, 2002, PHYTOCHEMISTRY, V61, P531, DOI 10.1016/S0031-9422(02)00266-2; Robbi M, 1996, BIOCHEM J, V313, P821, DOI 10.1042/bj3130821; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; Turner JG, 2002, PLANT CELL, V14, pS153, DOI 10.1105/tpc.000679; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; Yamada J, 1997, BIOCHEM BIOPH RES CO, V232, P198, DOI 10.1006/bbrc.1997.6246; Yamada J, 1998, BIOCHEM BIOPH RES CO, V248, P608, DOI 10.1006/bbrc.1998.9048; Zeng G, 1998, BIOTECHNIQUES, V25, P206, DOI 10.2144/98252bm05; Zolman BK, 2001, J BIOL CHEM, V276, P31037, DOI 10.1074/jbc.M104679200	41	48	50	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7487	7494		10.1074/jbc.M309532200	http://dx.doi.org/10.1074/jbc.M309532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660652	hybrid			2022-12-27	WOS:000189103300016
J	Reader, JS; Metzgar, D; Schimmel, P; de Crecy-Lagard, V				Reader, JS; Metzgar, D; Schimmel, P; de Crecy-Lagard, V			Identification of four genes necessary for biosynthesis of the modified nucleoside queuosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP CYCLOHYDROLASE I; TRANSFER-RNA; QUEUINE; TRANSFORMATION; REPLACEMENT; DROSOPHILA; INSERTION; PROCEEDS; POSITION; PATHWAY	Queuosine (Q) is a hypermodified 7-deazaguanosine nucleoside located in the anticodon wobble position of four amino acid-specific tRNAs. In bacteria, Q is produced de novo from GTP via the 7-deazaguanosine precursor preQ, (7-aminoethyl 7-deazaguanine) by an uncharacterized pathway. PreQ(1) is subsequently transferred to its specific tRNA by a tRNA-guanine transglycosylase (TGT) and then further modified in situ to produce Q. Here we use comparative genomics to implicate four gene families (best exemplified by the B. subtilis operon ykvJKLM) as candidates in the preQ(1) biosynthetic pathway. Deletions were constructed in genes for each of the four orthologs in Acinetobacter. High pressure liquid chromatography analysis showed the Q nucleoside was absent from the tRNAs of each of four deletion strains. Electrospray ionization mass spectrometry confirmed the absence of Q in each mutant strain. Finally, introduction of the Bacillus subtilis ykvJKLM operon in trans complemented the Q deficiency of the two deletion mutants that were tested. Thus, the products of these four genes (named queC, -D, -E, and -F) are essential for the Q biosynthetic pathway.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC-379,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu; vcrecy@scripps.edu	de Crecy-Lagard, Valerie/AAN-8995-2020		NIGMS NIH HHS [GM23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auerbach G, 1997, BIOL CHEM, V378, P185; Bishop AC, 2002, J BIOL CHEM, V277, P25090, DOI 10.1074/jbc.M203208200; Bjork GR, 1995, TRNA STRUCTURE BIOSY, P165; Bracher A, 1999, J BIOL CHEM, V274, P16727, DOI 10.1074/jbc.274.24.16727; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; DURAND JM, 1994, J BACTERIOL, V176, P4627, DOI 10.1128/JB.176.15.4627-4634.1994; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; Garcia G.R., 1998, MODIFICATION EDITING; Graupner M, 2002, J BACTERIOL, V184, P1952, DOI 10.1128/JB.184.7.1952-1957.2002; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; JUNI E, 1969, J BACTERIOL, V98, P281, DOI 10.1128/JB.98.1.281-288.1969; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1982, SCIENCE, V216, P55; KERSTEN H, 1988, Biofactors, V1, P27; KERSTEN H, 1990, CHROMATOGRAPHY MODIF, P69; Kok RG, 1997, J BACTERIOL, V179, P4270, DOI 10.1128/jb.179.13.4270-4276.1997; KUCHINO Y, 1976, NUCLEIC ACIDS RES, V3, P393, DOI 10.1093/nar/3.2.393; Madden TL, 1996, METHOD ENZYMOL, V266, P131; Marks T, 1997, BIOCHEM BIOPH RES CO, V230, P233, DOI 10.1006/bbrc.1996.5768; Morris RC, 2001, MOL GENET METAB, V74, P147, DOI 10.1006/mgme.2001.3216; Murphy KC, 2000, GENE, V246, P321, DOI 10.1016/S0378-1119(00)00071-8; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1978, P NATL ACAD SCI USA, V75, P4247, DOI 10.1073/pnas.75.9.4247; Osterman A, 2003, CURR OPIN CHEM BIOL, V7, P238, DOI 10.1016/S1367-5931(03)00027-9; Overbeek R, 2003, NUCLEIC ACIDS RES, V31, P164, DOI 10.1093/nar/gkg148; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; OWENBY RK, 1979, MECH AGEING DEV, V11, P91, DOI 10.1016/0047-6374(79)90027-7; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146; WHITE BN, 1973, J MOL BIOL, V74, P635, DOI 10.1016/0022-2836(73)90054-5; Woo HJ, 2002, FEBS LETT, V523, P234, DOI 10.1016/S0014-5793(02)02997-6; YOKOYAMA S, 1979, NATURE, V282, P107, DOI 10.1038/282107a0; Young David M, 2002, Methods Mol Biol, V182, P103	35	107	119	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6280	6285		10.1074/jbc.M310858200	http://dx.doi.org/10.1074/jbc.M310858200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660578	hybrid			2022-12-27	WOS:000188969200012
J	Zhang, LY; Lee, JK; John, SA; Uozumi, N; Kodama, I				Zhang, LY; Lee, JK; John, SA; Uozumi, N; Kodama, I			Mechanosensitivity of GIRK channels is mediated by protein kinase C-dependent channel-phosphatidylinositol 4,5-bisphosphate interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING K+ CHANNELS; POTASSIUM CHANNELS; XENOPUS-OOCYTES; CA2+ MOBILIZATION; BETA-GAMMA; HEART; PIP2; ACTIVATION; MECHANISM; MEMBRANE	Gprotein-activated inwardly rectifying K+ channel (GIRK or Kir3) currents are inhibited by mechanical stretch of the cell membrane, but the underlying mechanisms are not understood. In Xenopus oocytes heterologously expressing GIRK channels, membrane stretch induced by 50% reduction of osmotic pressure caused a prompt reduction of GIRK1/4, GIRK1, and GIRK4 currents by 16.6-42.6%. Comparable GIRK current reduction was produced by protein kinase C (PKC) activation (phorbol 12-myristate 13-acetate). The mechanosensitivity of the GIRK4 current was abolished by pretreatment with PKC inhibitors (staurosporine or calphostin C). Neither hypo-osmotic challenge nor PKC activation affected IRK1 currents. GIRK4 chimera (GIRK4-IRK1(Lys(207)-Leu(245))) and single point mutant (GIRK4(I229L)), in which the phosphatidylinositol 4,5-bisphosphate (PIP2) binding domain or residue was replaced by the corresponding region of IRK1 to strengthen the channel-PIP2 interaction, showed no mechanosensitivity and minimal PKC sensitivity. IRK1 gained mechanosensitivity and PKC sensitivity by reverse double point mutation of the PIP2 binding domain (L222I/R213Q). Overexpression of Gbetagamma, which is known to strengthen the channel-PIP2 interaction, attenuated the mechanosensitivity of GIRK4 channels. In oocytes expressing a pleckstrin homology domain of PLC-delta tagged with green fluorescent protein, hypo-osmotic challenge or PKC activation caused a translocation of the fluorescence signal from the cell membrane to the cytosol, reflecting PIP2 hydrolysis. The translocation was prevented by pretreatment with PKC inhibitors. Involvement of PKC activation in the mechanosensitivity of muscarinic K+ channels was confirmed in native rabbit atrial myocytes. These results suggest that the mechanosensitivity of GIRK channels is mediated primarily by channel-PIP2 interaction, with PKC playing an important role in modulating the interaction probably through PIP2 hydrolysis.	Nagoya Univ, Environm Med Res Inst, Dept Circulat, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA	Nagoya University; Nagoya University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lee, JK (corresponding author), Nagoya Univ, Environm Med Res Inst, Dept Circulat, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	jlee@riem.nagoya-u.ac.jp	Uozumi, Nobuyuki/AAG-3252-2019	John, Scott/0000-0002-1232-9140; Uozumi, Nobuyuki/0000-0003-4268-1126				Arai A, 1996, AM J PHYSIOL-HEART C, V270, pH1726, DOI 10.1152/ajpheart.1996.270.5.H1726; Bolter CP, 1999, AM J PHYSIOL-REG I, V276, pR1112, DOI 10.1152/ajpregu.1999.276.4.R1112; BOON AM, 1985, BIOCHEM BIOPH RES CO, V129, P431, DOI 10.1016/0006-291X(85)90169-X; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; Ghuran AV, 2001, BRIT MED BULL, V59, P193, DOI 10.1093/bmb/59.1.193; HALENDA SP, 1984, BIOCHEM BIOPH RES CO, V124, P507, DOI 10.1016/0006-291X(84)91583-3; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Ivanina T, 2000, FEBS LETT, V466, P327, DOI 10.1016/S0014-5793(99)01738-X; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LAB MJ, 1982, CIRC RES, V50, P757, DOI 10.1161/01.RES.50.6.757; Lab MJ, 1996, CARDIOVASC RES, V32, P3, DOI 10.1016/S0008-6363(96)00088-0; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Lu ZB, 2001, CIRCULATION, V104, P951, DOI 10.1161/hc3401.093151; Mason HS, 2002, MOL PHARMACOL, V61, P285, DOI 10.1124/mol.61.2.285; Nasuhoglu C, 2002, AM J PHYSIOL-CELL PH, V283, pC223, DOI 10.1152/ajpcell.00486.2001; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Stevens EB, 1999, MOL PHARMACOL, V55, P1020, DOI 10.1124/mol.55.6.1020; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1999, ADV SEC MESS PHOSPH, V33, P179; van Tiel CM, 2000, J BIOL CHEM, V275, P21532, DOI 10.1074/jbc.M002203200; VanDenBerg MP, 1997, HEART, V77, P309, DOI 10.1136/hrt.77.4.309; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; Zeng WZ, 2003, J BIOL CHEM, V278, P16852, DOI 10.1074/jbc.M300619200; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhou W, 2001, P NATL ACAD SCI USA, V98, P6482, DOI 10.1073/pnas.111447798	37	29	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7037	7047		10.1074/jbc.M307323200	http://dx.doi.org/10.1074/jbc.M307323200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660621	hybrid			2022-12-27	WOS:000188969200101
J	Gupta, S; Natarajan, R; Payne, SG; Studer, EJ; Spiegel, S; Dent, P; Hylemon, PB				Gupta, S; Natarajan, R; Payne, SG; Studer, EJ; Spiegel, S; Dent, P; Hylemon, PB			Deoxycholic acid activates the c-Jun N-terminal kinase pathway via FAS receptor activation in primary hepatocytes - Role of acidic sphingomyelinase-mediated ceramide generation in FAS receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIGNAL-REGULATED KINASE; T-CELL-RECEPTOR; BILE-ACIDS; FEEDBACK-REGULATION; INDUCED APOPTOSIS; PROTEIN-KINASES; RAT-HEPATOCYTES; MEMBRANE RAFTS; IN-VIVO	We have shown previously that bile acids can activate the JNK pathway and down-regulate cholesterol 7alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in the neutral pathway of bile acid biosynthesis. In this study, the mechanism(s) by which deoxycholic acid (DCA) activates the JNK pathway were examined. FAS receptor (FAS-R) and acidic sphingomyelinase (ASM)-deficient hepatocytes were resistant to DCA-induced activation of the JNK pathway. Activation of the JNK pathway (2-3-fold) in response to tumor necrosis factor-alpha was similar in both wild-type and FAS-R-/- hepatocytes. In wildtype and FAS-R-/- hepatocytes, ceramide elevation was detected as early as 2 min and peaked at 10 min after DCA treatment. In contrast, ASM(-/-) hepatocytes were defective in DCA-induced ceramide generation. Treatment with DCA resulted in movement of FAS-R to the cell surface, which was blocked upon treatment with brefeldin A. However, brefeldin A failed to block DCA-mediated JNK activation in wild-type hepatocytes. DCA-induced JNK activation was independent of either the epidermal growth factor receptor activation or free radical generation. Addition of ASM to rat hepatocytes activated JNK and down-regulated CYP7A1 mRNA levels. In conclusion, these results show that DCA activates JNK and represses CYP7A1 mRNA levels in primary hepatocytes via an ASM/FAS-R-dependent mechanism that is independent of either the epidermal growth factor receptor or free radical generation.	Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Hylemon, PB (corresponding author), Virginia Commonwealth Univ, Dept Microbiol & Immunol, POB 980678, Richmond, VA 23298 USA.	hylemon@hsc.vcu.edu		Natarajan, Ramesh/0000-0002-3431-9971	NIDDK NIH HHS [F32 DK59770-01, P01-DK38030, R01-DK52825] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038030, R01DK052825, F32DK059770] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN RN, 1976, GUT, V17, P413, DOI 10.1136/gut.17.6.413; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Badorff C, 2002, J CLIN INVEST, V109, P373, DOI 10.1172/JCI200213779; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Brenner D, 1998, J GASTROEN HEPATOL, V13, pS93; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CRAWFORD JM, 1994, LAB INVEST, V71, P42; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; Fanzo JC, 2003, CANCER BIOL THER, V2, P392, DOI 10.4161/cbt.2.4.442; Faubion WA, 1999, J CLIN INVEST, V103, P137, DOI 10.1172/JCI4765; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Graf D, 2002, GASTROENTEROLOGY, V122, P1411, DOI 10.1053/gast.2002.32976; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GREIM H, 1972, GASTROENTEROLOGY, V63, P846; Guicciardi ME, 2002, DIGEST LIVER DIS, V34, P387, DOI 10.1016/S1590-8658(02)80033-0; Gulbins E, 2003, PHARMACOL RES, V47, P393, DOI 10.1016/S1043-6618(03)00052-5; Gulbins Erich, 2002, Subcell Biochem, V36, P229; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Higuchi H, 2003, AM J PHYSIOL-GASTR L, V284, pG734, DOI 10.1152/ajpgi.00491.2002; Higuchi H, 2001, J BIOL CHEM, V276, P38610, DOI 10.1074/jbc.M105300200; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Junge S, 1999, CELL SIGNAL, V11, P301, DOI 10.1016/S0898-6568(98)00068-0; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KITAMURA T, 1990, HEPATOLOGY, V12, P1358, DOI 10.1002/hep.1840120617; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Liedtke C, 2002, HEPATOLOGY, V36, P315, DOI 10.1053/jhep.2002.34615; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; OLIVERA A, 1992, GLYCOCONJUGATE J, V9, P110; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Qiao D, 2001, CARCINOGENESIS, V22, P35, DOI 10.1093/carcin/22.1.35; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Qiao L, 2001, MOL BIOL CELL, V12, P2629, DOI 10.1091/mbc.12.9.2629; Rao YP, 2002, HEPATOLOGY, V35, P307, DOI 10.1053/jhep.2002.31104; RATCLIFFE MJH, 1992, J IMMUNOL, V148, P1643; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Reinehr R, 2003, GASTROENTEROLOGY, V125, P839, DOI 10.1016/S0016-5085(03)01055-2; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Schliess F, 1997, GASTROENTEROLOGY, V113, P1306, DOI 10.1053/gast.1997.v113.pm9322526; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sodeman T, 2000, AM J PHYSIOL-GASTR L, V278, pG992, DOI 10.1152/ajpgi.2000.278.6.G992; Stravitz RT, 1996, AM J PHYSIOL-GASTR L, V271, pG293, DOI 10.1152/ajpgi.1996.271.2.G293; SUCHY FJ, 1983, AM J PHYSIOL, V245, pG681, DOI 10.1152/ajpgi.1983.245.5.G681; Takikawa Y, 2001, GASTROENTEROLOGY, V120, P1810, DOI 10.1053/gast.2001.24835; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Vlahcevic ZR, 1996, HEPATOLOGY TXB LIVER, V1, P376; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wollert KC, 2000, CIRCULATION, V101, P1172, DOI 10.1161/01.CIR.101.10.1172; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	73	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5821	5828		10.1074/jbc.M310979200	http://dx.doi.org/10.1074/jbc.M310979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14660582	hybrid			2022-12-27	WOS:000188776500096
J	Kramps, C; Strieder, V; Sapetschnig, A; Suske, G; Lutz, W				Kramps, C; Strieder, V; Sapetschnig, A; Suske, G; Lutz, W			E2F and Sp1/Sp3 synergize but are not sufficient to activate the MYCN gene in neuroblastomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-MYC; TRANSCRIPTIONAL ACTIVATION; HISTONE DEACETYLASE; C-MYC; REPRESS TRANSCRIPTION; CYTOSINE METHYLATION; ORDERED RECRUITMENT; MYC/MAX/MAD NETWORK; IN-VIVO; EXPRESSION	Amplification of the MYCN gene, resulting in overexpression of MYCN, distinguishes a subset of neuroblastomas with poor prognosis. We recently identified MYCN as a target gene of the E2F transcription factors. Here we show that Sp1 and Sp3 cooperate with E2F-1 to activate the MYCN promoter. However, in a neuroblastoma cell line that does not express MYCN, overexpression of E2F-1 was not sufficient to activate the MYCN promoter even in the presence of trichostatin A and 5-aza-cytidine. This was because of a failure of E2F-1 to bind to the MYCN promoter in these cells, although access of E2F-1 to the inactive MYCN promoter was not blocked by a nucleosome. Differences in nucleosomal organization of the MYCN promoter in different cell lines did not correlate with gene activation per se but with the switch from basal to activated transcription. Binding of E2F and Sp1/Sp3 to the MYCN promoter in vivo correlated with acetylation of histones H3 and H4 and recruitment of RNA polymerase II and the protein acetyltransferase Tip60 but not with nucleosome remodeling. Our results define distinct chromatin states of the MYCN promoter, indicate that factors in addition to E2F and Sp1/Sp3 are required to activate MYCN in neuroblastomas, and provide evidence for a novel mechanism of controlling access of E2F to selected target genes.	Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany		Lutz, W (corresponding author), Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany.	lutz@imt.uni-marburg.de		Suske, Guntram/0000-0002-4807-0513				Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Blau J, 1996, MOL CELL BIOL, V16, P2044; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Di Fiore B, 1999, NUCLEIC ACIDS RES, V27, P2852; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lutz W, 1997, ONCOGENE, V15, P303, DOI 10.1038/sj.onc.1201195; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Morrison AJ, 2002, MOL CELL BIOL, V22, P856, DOI 10.1128/MCB.22.3.856-865.2002; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; ROSS RA, 1983, J NATL CANCER I, V71, P741; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SADEE W, 1987, CANCER RES, V47, P5207; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Strieder V, 2003, J BIOL CHEM, V278, P2983, DOI 10.1074/jbc.M207596200; Strieder V, 2002, CANCER LETT, V180, P107, DOI 10.1016/S0304-3835(02)00020-4; Suske G, 2000, Methods Mol Biol, V130, P175; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Takahashi Y, 2000, GENE DEV, V14, P804; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096	56	39	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5110	5117		10.1074/jbc.M304758200	http://dx.doi.org/10.1074/jbc.M304758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645238	hybrid			2022-12-27	WOS:000188776500010
J	Brajenovic, M; Joberty, G; Kuster, B; Bouwmeester, T; Drewes, G				Brajenovic, M; Joberty, G; Kuster, B; Bouwmeester, T; Drewes, G			Comprehensive proteomic analysis of human par protein complexes reveals an interconnected protein network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY-REGULATING KINASE; C-ELEGANS EMBRYOS; CELL-POLARITY; SEQUENCE DATABASES; EPITHELIAL TIGHT; DROSOPHILA; GENE; IDENTIFICATION; LKB1; CDC42	The polarization of eukaryotic cells is controlled by the concerted activities of asymmetrically localized proteins. The PAR proteins, first identified in Caenorhabditis elegans, are common regulators of cell polarity conserved from nematode and flies to man. However, little is known about the molecular mechanisms by which these proteins and protein complexes establish cell polarity in mammals. We have mapped multiprotein complexes formed around the putative human Par orthologs MARK4 (microtubule-associated protein/microtubule affinity-regulating kinase 4) (Par-1), Par-3, LKB1 (Par-4), 14-3-3zeta and eta(Par-5), Par-6a, -b, -c, and PKClambda (PKC3). We employed a proteomic approach comprising tandem affinity purification (TAP) of protein complexes from cultured cells and protein sequencing by tandem mass spectrometry. From these data we constructed a highly interconnected protein network consisting of three core complex "modules" formed around MARK4 (Par-1), Par-3.Par-6, and LKB1 (Par-4). The network confirms most previously reported interactions. In addition we identified more than 50 novel interactors, some of which, like the 14-3-3 phospho-protein scaffolds, occur in more than one distinct complex. We demonstrate that the complex formation between LKB1.Par-4, PAPK, and Mo25 results in the translocation of LKB1 from the nucleus to the cytoplasm and to tight junctions and show that the LKB1 complex may activate MARKs, which are known to introduce 14-3-3 binding sites into several substrates. Our findings suggest co-regulation and/or signaling events between the distinct Par complexes and provide a basis for further elucidation of the molecular mechanisms that govern cell polarity.	Cellzome AG, D-69117 Heidelberg, Germany	GlaxoSmithKline; Cellzome GmbH	Bouwmeester, T (corresponding author), Cellzome AG, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Tewis.Bouwmeester@Cellzome.com; Gerard.Drewes@Cellzome.com	Kuster, Bernhard/Q-6031-2016	Kuster, Bernhard/0000-0002-9094-1677; Drewes, Gerard/0000-0003-0575-6766				Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Benton R, 2002, DEV CELL, V3, P659, DOI 10.1016/S1534-5807(02)00320-9; Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Brown AJH, 1999, MOL CELL NEUROSCI, V13, P119, DOI 10.1006/mcne.1999.0736; Clark KA, 2003, DEVELOPMENT, V130, P2611, DOI 10.1242/dev.00492; Cuenca AA, 2003, DEVELOPMENT, V130, P1255, DOI 10.1242/dev.00284; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; Drewes G, 2003, FEBS LETT, V554, P45, DOI 10.1016/S0014-5793(03)01080-9; Drewes G, 2003, CURR OPIN CELL BIOL, V15, P199, DOI 10.1016/S0955-0674(03)00005-X; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Gao L, 2002, GENE, V294, P99, DOI 10.1016/S0378-1119(02)00681-9; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Jarvik JW, 1998, ANNU REV GENET, V32, P601, DOI 10.1146/annurev.genet.32.1.601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Mollinari C, 2002, BIOL CELL, V94, P1, DOI 10.1016/S0248-4900(02)01181-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morton DG, 2002, DEV BIOL, V241, P47, DOI 10.1006/dbio.2001.0489; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nishigaki K, 2003, J BIOL CHEM, V278, P13520, DOI 10.1074/jbc.M208601200; Nozaki M, 1996, DNA CELL BIOL, V15, P505, DOI 10.1089/dna.1996.15.505; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Pellettieri J, 2002, SCIENCE, V298, P1946, DOI 10.1126/science.1072162; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schirle M, 2003, MOL CELL PROTEOMICS, V2, P1297, DOI 10.1074/mcp.M300087-MCP200; SCHNEIDER A, 2004, IN PRESS J NEUROCHEM; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Trinczek B, 2004, J BIOL CHEM, V279, P5915, DOI 10.1074/jbc.M304528200; Vaccari T, 2002, CURR BIOL, V12, P1524, DOI 10.1016/S0960-9822(02)01079-5; Watts JL, 1996, DEVELOPMENT, V122, P3133; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x	58	148	158	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12804	12811		10.1074/jbc.M312171200	http://dx.doi.org/10.1074/jbc.M312171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14676191	hybrid			2022-12-27	WOS:000220334900095
J	Kashiwagi, M; Enghild, JJ; Gendron, C; Hughes, C; Caterson, B; Itoh, Y; Nagase, H				Kashiwagi, M; Enghild, JJ; Gendron, C; Hughes, C; Caterson, B; Itoh, Y; Nagase, H			Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE DEGRADATION; INTERGLOBULAR DOMAIN; IN-VITRO; MATRIX METALLOPROTEINASES; AGGRECANASE-1 ADAM-TS4; MONOCLONAL-ANTIBODIES; ARTICULAR-CARTILAGE; ESCHERICHIA-COLI; CLEAVAGE; CATABOLISM	ADAMTS-4 ( a disintegrin and metalloprotease with thrombospondin motifs) is a multidomain metalloproteinase belonging to the reprolysin family. The enzyme cleaves aggrecan core protein at several sites. Here we report that the non-catalytic ancillary domains of the enzyme play a major role in regulating aggrecanase activity, with the C-terminal spacer domain masking the general proteolytic activity. Expressing a series of domain deletion mutants in mammalian cells and examining their aggrecan-degrading and general proteolytic activities, we found that full-length ADAMTS-4 of 70 kDa was the most effective aggrecanase, but it exhibited little activity against the Glu(373)-Ala(374) bond, the site originally characterized as a signature of aggrecanase activity. Little activity was detected against reduced and carboxymethylated transferrin (Cm-Tf), a general proteinase substrate. However, it readily cleaved the Glu(1480)-Gly(1481) bond in the chondroitin sulfate-rich region of aggrecan. Of the constructed mutants, the C-terminal spacer domain deletion mutant more effectively hydrolyzed both the Glu(373)-Ala(374) and Glu(1480)-Gly(1481) bonds. It also revealed new activities against Cm-Tf, fibromodulin, and decorin. Further deletion of the cysteine-rich domain reduced the aggrecanase activity by 80% but did not alter the activity against Cm-Tf or fibromodulin. Further removal of the thrombospondin type I domain drastically reduced all tested proteolytic activities, and very limited enzymatic activity was detected with the catalytic domain. Full-length ADAMTS-4 binds to pericellular and extracellular matrix, but deletion of the spacer domain releases the enzyme. ADAMTS-4 lacking the spacer domain has promiscuous substrate specificity considerably different from that previously reported for aggrecan core protein. Finding of ADAMTS-4 in the interleukin-1alpha-treated porcine articular cartilage primarily as a 46-kDa form suggests that it exhibits a broader substrate spectrum in the tissue than originally considered.	Univ London Imperial Coll Sci & Technol, Div Rheumatol, Kennedy Inst, London W6 8LH, England; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; Univ Cardiff, Cardiff Sch Biosci, Connect Tissue Labs, Cardiff CF1 3US, S Glam, Wales	Imperial College London; University of Oxford; Aarhus University; Cardiff University	Nagase, H (corresponding author), Univ London Imperial Coll Sci & Technol, Div Rheumatol, Kennedy Inst, 1 Aspenlea Rd, London W6 8LH, England.	h.nagase@imperial.ac.uk	Caterson, Bruce/A-8085-2010; Hughes, Clare E/A-4526-2010	Enghild, Jan Johannes/0000-0001-9292-9172; Itoh, Yoshifumi/0000-0002-2128-2823; Hughes, Clare/0000-0003-4726-5877; Caterson, Bruce/0000-0001-6016-0661	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arner EC, 2002, CURR OPIN PHARMACOL, V2, P322, DOI 10.1016/S1471-4892(02)00148-0; Bau B, 2002, ARTHRITIS RHEUM, V46, P2648, DOI 10.1002/art.10531; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CATERSON B, 1985, FED PROC, V44, P386; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Komorowicz E, 1998, BIOCHEMISTRY-US, V37, P9112, DOI 10.1021/bi980180d; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Little CB, 1999, BIOCHEM J, V344, P61, DOI 10.1042/0264-6021:3440061; Little CB, 2002, MATRIX BIOL, V21, P271, DOI 10.1016/S0945-053X(02)00004-5; Little CB, 2002, ARTHRITIS RHEUM-US, V46, P124, DOI 10.1002/1529-0131(200201)46:1<124::AID-ART10121>3.0.CO;2-X; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Miller JA, 2003, ANAL BIOCHEM, V314, P260, DOI 10.1016/S0003-2697(02)00638-3; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NAGASE H, 1995, METHOD ENZYMOL, V248, P449; Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630; NAGASE H, 1980, ANAL BIOCHEM, V107, P385, DOI 10.1016/0003-2697(80)90400-5; Pratta MA, 2003, ARTHRITIS RHEUM, V48, P119, DOI 10.1002/art.10726; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Sztrolovics R, 1999, BIOCHEM J, V339, P571, DOI 10.1042/0264-6021:3390571; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; Troeberg L, 2002, BIOCHEMISTRY-US, V41, P15025, DOI 10.1021/bi026454l; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405; Zheng XL, 2003, J BIOL CHEM, V278, P30136, DOI 10.1074/jbc.M305331200	45	174	184	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10109	10119		10.1074/jbc.M312123200	http://dx.doi.org/10.1074/jbc.M312123200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14662755	hybrid			2022-12-27	WOS:000220050400056
J	Koishi, R; Xu, HX; Ren, DJ; Navarro, B; Spiller, BW; Shi, Q; Clapham, DE				Koishi, R; Xu, HX; Ren, DJ; Navarro, B; Spiller, BW; Shi, Q; Clapham, DE			A superfamily of voltage-gated sodium channels in bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRIVEN FLAGELLAR MOTORS; ALKALOPHILIC BACILLUS; NA+-DRIVEN; SP-NOV.; STRAIN; NEURONS; VIBRIO; INACTIVATION; CURRENTS; MOTILITY	NaChBac, a six-alpha-helical transmembrane- spanning protein cloned from Bacillus halodurans, is the first functionally characterized bacterial voltage-gated Na+-selective channel (Ren, D., Navarro, B., Xu, H., Yue, L., Shi, Q., and Clapham, D. E. ( 2001) Science 294, 2372 2375). As a highly expressing ion channel protein, NaChBac is an ideal candidate for high resolution structural determination and structure-function studies. The biological role of NaChBac, however, is still unknown. In this report, another 11 structurally related bacterial proteins are described. Two of these functionally expressed as voltage-dependent Na+ channels (Na(V)PZ from Paracoccus zeaxanthinifaciens and NaVSP from Silicibacter pomeroyi). Na(V)PZ and NaVSP share similar to40% amino acid sequence identity with NaChBac. When expressed in mammalian cell lines, both Na(V)PZ and NaVSP were Na+-selective and voltage-dependent. However, their kinetics and voltage dependence differ significantly. These single six-alpha-helical transmembrane-spanning subunits constitute a widely distributed superfamily (Na(V)Bac) of channels in bacteria, implying a fundamental prokaryotic function. The degree of sequence homology (22 - 54%) is optimal for future comparisons of Na(V)Bac structure and function of similarity and dissimilarity among Na(V)Bac proteins. Thus, the Na(V)Bac superfamily is fertile ground for crystallographic, electrophysiological, and microbiological studies.	Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Dept Cardiovasc Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Clapham, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Dept Cardiovasc Res, 320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 				Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Asai Y, 2003, J MOL BIOL, V327, P453, DOI 10.1016/S0022-2836(03)00096-2; AUSUBEL FM, 1995, CURRENT PROTOCOLS MO, V1, P24; Berry A, 2003, INT J SYST EVOL MICR, V53, P231, DOI 10.1099/ijs.0.02368-0; Booth IR, 2003, BIOCHEMISTRY-US, V42, P10045, DOI 10.1021/bi034953w; Catterall MA, 2001, SCIENCE, V294, P2306, DOI 10.1126/science.1067417; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Do MTH, 2003, NEURON, V39, P109, DOI 10.1016/S0896-6273(03)00360-X; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Gonzalez JM, 2003, INT J SYST EVOL MICR, V53, P1261, DOI 10.1099/ijs.0.02491-0; Gonzalez JM, 2000, INT J SYST EVOL MICR, V50, P831, DOI 10.1099/00207713-50-2-831; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HIROTA N, 1983, J BIOL CHEM, V258, P577; IMAE Y, 1986, METHOD ENZYMOL, V125, P582; IMAE Y, 1989, J BIOENERG BIOMEMBR, V21, P705, DOI 10.1007/BF00762688; Junge K, 2003, APPL ENVIRON MICROB, V69, P4282, DOI 10.1128/AEM.69.7.4282-4284.2003; Kojima S, 1999, J BACTERIOL, V181, P1927, DOI 10.1128/JB.181.6.1927-1930.1999; Krulwich TA, 1996, BBA-BIOENERGETICS, V1275, P21, DOI 10.1016/0005-2728(96)00044-8; Krulwich TA, 2001, BBA-BIOENERGETICS, V1505, P158, DOI 10.1016/S0005-2728(00)00285-1; Liu J, 2002, J GEN PHYSIOL, V120, P723, DOI 10.1085/jgp.20028687; Lu J, 2001, FEMS MICROBIOL LETT, V205, P291, DOI 10.1111/j.1574-6968.2001.tb10963.x; McCarter LL, 2001, MICROBIOL MOL BIOL R, V65, P445, DOI 10.1128/MMBR.65.3.445-462.2001; MCCARTHY AJ, 1984, J GEN MICROBIOL, V130, P5; MELDRUM FC, 1993, P ROY SOC B-BIOL SCI, V251, P231, DOI 10.1098/rspb.1993.0034; MOORE RL, 1984, INT J SYST BACTERIOL, V34, P71, DOI 10.1099/00207713-34-1-71; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Ren DJ, 2001, SCIENCE, V294, P2372, DOI 10.1126/science.1065635; Strom MS, 2000, MICROBES INFECT, V2, P177, DOI 10.1016/S1286-4579(00)00270-7; SUGIYAMA S, 1985, FEBS LETT, V182, P265, DOI 10.1016/0014-5793(85)80312-4; Sun YM, 1997, J GEN PHYSIOL, V110, P693, DOI 10.1085/jgp.110.6.693; Taddese A, 2002, NEURON, V33, P587, DOI 10.1016/S0896-6273(02)00574-3; Takami H, 2000, EXTREMOPHILES, V4, P99, DOI 10.1007/s007920050143; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; Yamagishi T, 2001, J GEN PHYSIOL, V118, P171, DOI 10.1085/jgp.118.2.171; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yorimitsu T, 2001, BBA-BIOENERGETICS, V1505, P82, DOI 10.1016/S0005-2728(00)00279-6; Yue LX, 2002, J GEN PHYSIOL, V120, P845, DOI 10.1085/jgp.20028699	37	127	129	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9532	9538		10.1074/jbc.M313100200	http://dx.doi.org/10.1074/jbc.M313100200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14665618	hybrid			2022-12-27	WOS:000189265900120
J	Lu, M; Sautin, YY; Holliday, LS; Gluck, SL				Lu, M; Sautin, YY; Holliday, LS; Gluck, SL			The glycolytic enzyme aldolase mediates assembly, expression, and activity of vacuolar H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY FRUCTOSE INTOLERANCE; SACCHAROMYCES-CEREVISIAE; V-ATPASE; MOLECULAR-CLONING; PROTON PUMP; A-SUBUNIT; INTERACTS; ISOFORMS; MUTANTS; CELLS	Vacuolar H+-ATPases (V-ATPases) are a family of highly conserved proton pumps that couple hydrolysis of cytosolic ATP to proton transport out of the cytosol. How ATP is supplied for V-ATPase-mediated hydrolysis and for coupling of proton transport is poorly understood. We have reported that the glycolytic enzyme aldolase physically associates with V-ATPase ( Lu, M., Holliday, L. S., Zhang, L., Dunn, W. A., and Gluck, S. L. (2001) J. Biol. Chem. 276, 30407 - 30413). Here we show that aldolase interacts with three different subunits of V-ATPase ( subunits a, B, and E). The binding sites for the V-ATPase subunits on aldolase appear to be on distinct interfaces of the glycolytic enzyme. Aldolase deletion mutant cells were able to grow in medium buffered at pH 5.5 but not at pH 7.5, displaying a growth phenotype similar to that observed in V-ATPase subunit deletion mutants. Abnormalities in V-ATPase assembly and protein expression observed in aldolase deletion mutant cells could be fully rescued by aldolase complementation. The interaction between aldolase and V-ATPase increased dramatically in the presence of glucose, suggesting that aldolase may act as a glucose sensor for V-ATPase regulation. Taken together, these findings provide functional evidence that the ATP-generating glycolytic pathway is directly coupled to the ATP-hydrolyzing proton pump through physical interaction between aldolase and V-ATPase.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	University of California System; University of California San Francisco; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Lu, M (corresponding author), Univ Calif San Francisco, Dept Med, HSE 672,Box 0532,513 Parnassus Ave, San Francisco, CA 94143 USA.	minglu@medicine.ucsf.edu	Holliday, Lexie/GYQ-4972-2022	Holliday, Lexie/0000-0002-0844-1965; Sautin, Yuri/0000-0003-3618-5134	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK064977, R01DK064095] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK64095, DK64977] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI I, 1990, J BIOL CHEM, V265, P960; Alberts B, 1989, MOL BIOL CELL, P41; Ali M, 1998, J MED GENET, V35, P353, DOI 10.1136/jmg.35.5.353; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forster C, 2000, J BIOL CHEM, V275, P38245, DOI 10.1074/jbc.M006650200; FOURY F, 1990, J BIOL CHEM, V265, P18554; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HSU SC, 1991, J BIOL CHEM, V266, P21745; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; LOBO Z, 1984, J BACTERIOL, V160, P222, DOI 10.1128/JB.160.1.222-226.1984; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; MORRIS RC, 1968, J CLIN INVEST, V47, P1389, DOI 10.1172/JCI105830; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; Wu K, 1997, P NATL ACAD SCI USA, V94, P13273, DOI 10.1073/pnas.94.24.13273	29	147	149	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8732	8739		10.1074/jbc.M303871200	http://dx.doi.org/10.1074/jbc.M303871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672945	hybrid			2022-12-27	WOS:000189265900026
J	Roisin, A; Robin, JP; Dereuddre-Bosquet, N; Vitte, AL; Dormont, D; Clayette, P; Jalinot, P				Roisin, A; Robin, JP; Dereuddre-Bosquet, N; Vitte, AL; Dormont, D; Clayette, P; Jalinot, P			Inhibition of HIV-1 replication by cell-penetrating peptides binding Rev	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR EXPORT SIGNAL; NUCLEOPORIN-LIKE PROTEIN; RESPONSE RNA DECOY; TAT TRANSACTIVATOR; TYPE-1 REV; IN-VIVO; FUNCTIONAL INTERACTION; TRANSCRIPTION FACTOR; TERMINAL DOMAIN	New therapeutic agents able to block HIV-1 replication are eagerly sought after to increase the possibilities of treatment of resistant viral strains. In this report, we describe a rational strategy to identify small peptide sequences owning the dual property of penetrating within lymphocytes and of binding to a protein target. Such sequences were identified for two important HIV-1 regulatory proteins, Tat and Rev. Their association to a stabilizing domain consisting of human small ubiquitin-related modifier-1 (SUMO-1) allowed the generation of small proteins named SUMO-1 heptapeptide protein transduction domain for binding Tat (SHPT) and SUMO-1 heptapeptide protein transduction domain for binding Rev (SHPR), which are stable and efficiently penetrate within primary lymphocytes. Analysis of the antiviral activity of these proteins showed that one SHPR is active in both primary lymphocytes and macrophages, whereas one SHPT is active only in the latter cells. These proteins may represent prototypes of new therapeutic agents targeting the crucial functions exerted by both viral regulatory factors.	Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR5161, F-69364 Lyon 07, France; Univ Paris 11, EPHE, CRSSA,DRM,DSV, CEA,Serv Neurovirol,Soc Pharmacol & Immunol BIO, F-92265 Fontenay Aux Roses, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CEA; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite Paris Saclay	Jalinot, P (corresponding author), Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS, UMR5161, 46 Allee Italie, F-69364 Lyon 07, France.	pjalinot@ens-lyon.fr						Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Bohjanen PR, 1997, NUCLEIC ACIDS RES, V25, P4481, DOI 10.1093/nar/25.22.4481; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Browning CM, 1999, J VIROL, V73, P5191, DOI 10.1128/JVI.73.6.5191-5195.1999; Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; Farjot G, 1999, J BIOL CHEM, V274, P17309, DOI 10.1074/jbc.274.24.17309; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fraisier C, 1998, GENE THER, V5, P1665, DOI 10.1038/sj.gt.3300780; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Konopka K, 2000, GENE, V255, P235, DOI 10.1016/S0378-1119(00)00334-6; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P8000, DOI 10.1073/pnas.90.17.8000; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PEPINSKY RB, 1994, DNA CELL BIOL, V13, P1011, DOI 10.1089/dna.1994.13.1011; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; VENKATESH LK, 1990, VIROLOGY, V176, P39, DOI 10.1016/0042-6822(90)90228-J; Venkatesh LK, 2003, J VIROL, V77, P7236, DOI 10.1128/JVI.77.13.7236-7243.2003; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Veschambre P, 1997, J GEN VIROL, V78, P2235, DOI 10.1099/0022-1317-78-9-2235; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; Yang YD, 2003, J VIROL, V77, P6700, DOI 10.1128/JVI.77.12.6700-6708.2003; Yi R, 2002, RNA, V8, P180, DOI 10.1017/S1355838202012384; Yi R, 2002, J VIROL, V76, P2036, DOI 10.1128/JVI.76.5.2036-2042.2002; Zolotukhin AS, 1999, J VIROL, V73, P120, DOI 10.1128/JVI.73.1.120-127.1999	59	27	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9208	9214		10.1074/jbc.M311594200	http://dx.doi.org/10.1074/jbc.M311594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668323	Green Published, hybrid			2022-12-27	WOS:000189265900082
J	Wang, K; Hackett, JT; Cox, ME; van Hoek, M; Lindstrom, JM; Parsons, SJ				Wang, K; Hackett, JT; Cox, ME; van Hoek, M; Lindstrom, JM; Parsons, SJ			Regulation of the neuronal nicotinic acetylcholine receptor by Src family tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; C-SRC; CATECHOLAMINE SECRETION; NMDA RECEPTORS; SIGNALING COMPLEX; MOLECULAR-BIOLOGY; NEURAL TISSUES; GENE-PRODUCT	Src family kinases (SFKs) are abundant in chromaffin cells that reside in the adrenal medulla and respond to cholinergic stimulation by secreting catecholamines. Our previous work indicated that SFKs regulate acetyl-choline- or nicotine-induced secretion, but the site of modulatory action was unclear. Using whole cell recordings, we found that inhibition of SFK tyrosine kinase activity by PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo(3,4-d)pyrimidine) treatment or expression of a kinase-defective c-Src reduced the peak amplitude of nicotine-induced currents in chromaffin cells or in human embryonic kidney cells ectopically expressing functional neuronal alpha3beta4alpha5 acetylcholine receptors (AChRs). Conversely, the phosphotyrosine phosphatase inhibitor, sodium vanadate, or expression of mutationally activated c-Src resulted in enhanced current amplitudes. These results suggest that SFKs and putative phosphotyrosine phosphatases regulate the activity of AChRs by opposing actions. This proposed model was supported further by the findings that SFKs physically associate with the receptor and that the AChR is tyrosine-phosphorylated.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Dept Physiol, Charlottesville, VA 22908 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; George Mason Univ, Ctr Biodef, Manassas, VA 20110 USA	University of Virginia; University of Virginia; University of Virginia; University of Pennsylvania; George Mason University	Parsons, SJ (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734, Charlottesville, VA 22908 USA.	sap@virginia.edu	van Hoek, Monique/E-1629-2011	van Hoek, Monique/0000-0003-1679-4899	NCI NIH HHS [P01 CA40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; ALESSI DR, 1993, ONCOGENE, V8, P2015; Allen CM, 1996, J NEUROSCI RES, V44, P421, DOI 10.1002/(SICI)1097-4547(19960601)44:5<421::AID-JNR2>3.0.CO;2-H; Amico C, 1998, NEUROSCIENCE, V84, P529, DOI 10.1016/S0306-4522(97)00555-1; BOKSA P, 1984, J NEUROCHEM, V42, P607, DOI 10.1111/j.1471-4159.1984.tb02726.x; Brandon NJ, 2001, NEUROPHARMACOLOGY, V41, P745, DOI 10.1016/S0028-3908(01)00121-6; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CamposCaro A, 1997, J NEUROCHEM, V68, P488; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; Cheek TR, 1991, CURR OPIN CELL BIOL, V3, P199, DOI 10.1016/0955-0674(91)90139-P; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; Cox ME, 1997, J NEUROCHEM, V69, P1119; Cox ME, 1996, J NEUROCHEM, V66, P1103; CREUTZ CE, 1987, J BIOL CHEM, V262, P1860; CRIADO M, 1992, NEUROCHEM RES, V17, P281, DOI 10.1007/BF00966671; Di Angelantonio S, 2003, EUR J NEUROSCI, V17, P2313, DOI 10.1046/j.1460-9568.2003.02669.x; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FLY CM, 1994, J NEUROCHEM, V62, P923; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Free RB, 2003, BRAIN RES, V974, P60, DOI 10.1016/S0006-8993(03)02551-4; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; Gu HJ, 1996, J NEUROCHEM, V66, P1454; Haskell MD, 2001, CHEM REV, V101, P2425, DOI 10.1021/cr0002341; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1989, CRIT REV BIOCHEM MOL, V24, P183, DOI 10.3109/10409238909082553; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; Kobayashi H, 2002, ANN NY ACAD SCI, V971, P127, DOI 10.1111/j.1749-6632.2002.tb04446.x; LEE K, 1992, N-S ARCH PHARMACOL, V345, P363; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Liao GY, 2001, MOL PHARMACOL, V59, P960, DOI 10.1124/mol.59.5.960; MacFarlane SN, 2000, J NEUROSCI, V20, P5245, DOI 10.1523/JNEUROSCI.20-14-05245.2000; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; Nelson ME, 2001, J GEN PHYSIOL, V118, P563, DOI 10.1085/jgp.118.5.563; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; ODDIE KM, 1989, J NEUROSCI RES, V24, P38, DOI 10.1002/jnr.490240107; Paradiso K, 1998, J NEUROSCI, V18, P9227; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PENG ZY, 1995, ONCOGENE, V11, P1955; Picciotto MR, 2000, NEUROPSYCHOPHARMACOL, V22, P451, DOI 10.1016/S0893-133X(99)00146-3; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; Salter MW, 1998, BIOCHEM PHARMACOL, V56, P789, DOI 10.1016/S0006-2952(98)00124-5; SAPRU MK, 1994, J BIOL CHEM, V269, P27811; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SWOPE SL, 1995, ANN NY ACAD SCI, V757, P197, DOI 10.1111/j.1749-6632.1995.tb17476.x; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tiran Z, 2003, J BIOL CHEM, V278, P17509, DOI 10.1074/jbc.M212766200; VANHOEK M, 1999, RRD NEUROCHEMISTRY 1, V2, P315; vanHoek ML, 1997, BIOCHEM J, V326, P271, DOI 10.1042/bj3260271; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; Wang F, 1998, J BIOL CHEM, V273, P28721, DOI 10.1074/jbc.273.44.28721; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; WHITING P, 1986, J NEUROSCI, V6, P3061; Wijetunge S, 1995, BIOCHEM BIOPH RES CO, V217, P1039, DOI 10.1006/bbrc.1995.2874; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YAGI T, 1993, ONCOGENE, V8, P3343; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	69	52	53	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8779	8786		10.1074/jbc.M309652200	http://dx.doi.org/10.1074/jbc.M309652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679211	hybrid			2022-12-27	WOS:000189265900032
J	Bullard, B; Ferguson, C; Minajeva, A; Leake, MC; Gautel, M; Labeit, D; Ding, LL; Labeit, S; Horwitz, J; Leonard, KR; Linke, WA				Bullard, B; Ferguson, C; Minajeva, A; Leake, MC; Gautel, M; Labeit, D; Ding, LL; Labeit, S; Horwitz, J; Leonard, KR; Linke, WA			Association of the chaperone alpha B-crystallin with titin in heart muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN C; SHOCK-PROTEIN; CARDIAC MYOFIBRILS; A-CRYSTALLIN; QUATERNARY STRUCTURE; MOLECULAR CHAPERONE; PASSIVE TENSION; 2-MODE BINDING; Z-LINE; DOMAIN	alphaB-crystallin, a major component of the vertebrate lens, is a chaperone belonging to the family of small heat shock proteins. These proteins form oligomers that bind to partially unfolded substrates and prevent denaturation. alphaB-crystallin in cardiac muscle binds to myofibrils under conditions of ischemia, and previous work has shown that the protein binds to titin in the I-band of cardiac fibers (Golenhofen, N., Arbeiter, A., Koob, R., and Drenckhahn, D. ( 2002) J. Mol. Cell. Cardiol. 34, 309 319). This part of titin extends as muscles are stretched and is made up of immunoglobulin-like modules and two extensible regions (N2B and PEVK) that have no well defined secondary structure. We have followed the position of alphaB-crystallin in stretched cardiac fibers relative to a known part of the titin sequence. alphaB-crystallin bound to a discrete region of the I-band that moved away from the Z-disc as sarcomeres were extended. In the physiological range of sarcomere lengths, alphaB-crystallin bound in the position of the N2B region of titin, but not to PEVK. In overstretched myofibrils, it was also in the Ig region between N2B and the Z-disc. Binding between alphaB-crystallin and N2B was confirmed using recombinant titin fragments. The Ig domains in an eight-domain fragment were stabilized by alphaB-crystallin; atomic force microscopy showed that higher stretching forces were needed to unfold the domains in the presence of the chaperone. Reversible association with alphaB-crystallin would protect I-band titin from stress liable to cause domain unfolding until conditions are favorable for refolding to the native state.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Heidelberg Univ, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany; Univ Klinikum Mannheim, Inst Anasthesiol & Operat Intens Med, D-68135 Mannheim, Germany; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90024 USA	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of California System; University of California Los Angeles	Bullard, B (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bullard@embl.de	Minajeva, Ave/F-6977-2017; Gautel, Mathias/AAB-9860-2019; Leake, Mark/C-1245-2011; Linke, Wolfgang A/E-8662-2012	Leake, Mark/0000-0002-1715-1249; Gautel, Mathias/0000-0003-4027-9803; Linke, Wolfgang/0000-0003-0801-3773; Minajeva, Ave/0000-0003-0256-1410				Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; Barbato R, 1996, CIRC RES, V78, P821, DOI 10.1161/01.RES.78.5.821; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Freiburg A, 2000, CIRC RES, V86, P1114; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; Gautel M, 1996, J MUSCLE RES CELL M, V17, P449, DOI 10.1007/BF00123361; Golenhofen N, 1999, J MOL CELL CARDIOL, V31, P569, DOI 10.1006/jmcc.1998.0892; Golenhofen N, 2002, J MOL CELL CARDIOL, V34, P309, DOI 10.1006/jmcc.2001.1513; Granzier H, 2002, J PHYSIOL-LONDON, V541, P335, DOI 10.1113/jphysiol.2001.014381; Gregorio CC, 1999, CURR OPIN CELL BIOL, V11, P18, DOI 10.1016/S0955-0674(99)80003-9; Gruen M, 1999, FEBS LETT, V453, P254, DOI 10.1016/S0014-5793(99)00727-9; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Helmes M, 1999, CIRC RES, V84, P1339, DOI 10.1161/01.RES.84.11.1339; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kentish JC, 2001, CIRC RES, V88, P1059, DOI 10.1161/hh1001.091640; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Kulke M, 2001, CIRC RES, V89, P874, DOI 10.1161/hh2201.099453; Kunst G, 2000, CIRC RES, V86, P51, DOI 10.1161/01.RES.86.1.51; LAKEY A, 1990, EMBO J, V9, P3459, DOI 10.1002/j.1460-2075.1990.tb07554.x; Lange S, 2002, J CELL SCI, V115, P4925, DOI 10.1242/jcs.00181; Leake MC, 2003, FEBS LETT, V535, P55, DOI 10.1016/S0014-5793(02)03857-7; Li HB, 2002, NATURE, V418, P998, DOI 10.1038/nature00938; Linke WA, 2002, J MUSCLE RES CELL M, V23, P483, DOI 10.1023/A:1023462507254; Linke WA, 2002, J STRUCT BIOL, V137, P194, DOI 10.1006/jsbi.2002.4468; Linke WA, 1997, BIOPHYS J, V73, P905, DOI 10.1016/S0006-3495(97)78123-2; Linke WA, 1999, J CELL BIOL, V146, P631, DOI 10.1083/jcb.146.3.631; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Martin JL, 1997, CIRCULATION, V96, P4343; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Mornon JP, 1998, INT J BIOL MACROMOL, V22, P219, DOI 10.1016/S0141-8130(98)00019-1; Neagoe C, 2002, CIRCULATION, V106, P1333, DOI 10.1161/01.CIR.0000029803.93022.93; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; SOTERIOU A, 1993, J CELL SCI, V104, P119; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; Watanabe K, 2002, J STRUCT BIOL, V137, P248, DOI 10.1006/jsbi.2002.4458; Yamasaki R, 2002, CIRC RES, V90, P1181, DOI 10.1161/01.RES.0000021115.24712.99; Yamasaki R, 2001, BIOPHYS J, V81, P2297, DOI 10.1016/S0006-3495(01)75876-6	52	123	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7917	7924		10.1074/jbc.M307473200	http://dx.doi.org/10.1074/jbc.M307473200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676215	hybrid			2022-12-27	WOS:000189103300069
J	Ji, HL; Bishop, LTR; Anderson, SJ; Fuller, CM; Benos, DJ				Ji, HL; Bishop, LTR; Anderson, SJ; Fuller, CM; Benos, DJ			The role of pre-H2 domains of alpha- and delta-epithelial Na+ channels in ion permeation, conductance, and amiloride sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; XENOPUS OOCYTES; SELECTIVITY FILTER; CATION SELECTIVITY; PORE REGION; SUBUNIT; MUTATIONS; RESIDUES; BLOCK; NEURODEGENERATION	Epithelial Na+ channels (ENaC) regulate salt and water re-absorption across the apical membrane of absorptive epithelia such as the kidney, colon, and lung. Structure-function studies have suggested that the second transmembrane domain (M2) and the adjacent pre- and post-M2 regions are involved in channel pore formation, cation selectivity, and amiloride sensitivity. Because Na+ selectivity, unitary Na+ conductance (gamma(Na)), and amiloride sensitivity of delta-ENaC are strikingly different from those of alpha-ENaC, the hypothesis that the pre-H2 domain may contribute to these characterizations has been examined by swapping the pre-H2, H2, and both (pre-H2 + H2) domains of delta- and alpha-ENaCs. Whole-cell and single channel results showed that the permeation ratio of Li+ and Na+ (P-Li/P-Na) for the swap alpha chimeras co-expressed with betagamma-ENaC in Xenopus oocytes decreased significantly. In contrast, the ratio of P-Li/P-Na for the swap delta constructs was not significantly altered. Single channel studies confirmed that swapping of the H2 and the pre-H2 + H2 domains increased the gamma(Na) of alpha-ENaC but decreased the gamma(Na) of delta-ENaC. A significant increment in the apparent inhibitory dissociation constant for amiloride (K-i(amil)) was observed in the alpha chimeras by swapping the pre- H2, H2, and pre-H2 + H2 domains. In contrast, a striking decline of K-i(amil) was obtained in the chimeric delta constructs with substitution of the H2 and pre-H2 + H2 domains. Our results demonstrate that the pre- H2 domain, combined with the H2 domain, contributes to the P-Li/P-Na ratio, single channel Na+ conductance, and amiloride sensitivity of alpha- and delta-ENaCs.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Ji, HL (corresponding author), Univ Alabama, Dept Physiol & Biophys, UAb Stn, Birmingham, AL 35294 USA.	ji@physiology.uab.edu	Fuller, Cathy/B-4046-2011; JI, HONGLONG/N-7822-2014	JI, HONGLONG/0000-0002-3228-7144	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK056095, R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37206, DK56095] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Berdiev BK, 2001, BIOPHYS J, V80, P2176, DOI 10.1016/S0006-3495(01)76190-5; Cain SA, 2001, BIOCHEM PHARMACOL, V61, P1571, DOI 10.1016/S0006-2952(01)00608-6; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Choe H, 2000, J GEN PHYSIOL, V115, P391, DOI 10.1085/jgp.115.4.391; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Fyfe GK, 1999, J BIOL CHEM, V274, P36415, DOI 10.1074/jbc.274.51.36415; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Ji HJ, 2002, J BIOL CHEM, V277, P8395, DOI 10.1074/jbc.M109465200; Ji HL, 2001, AM J PHYSIOL-CELL PH, V281, pC64, DOI 10.1152/ajpcell.2001.281.1.C64; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Ji HL, 1999, J BIOL CHEM, V274, P37693, DOI 10.1074/jbc.274.53.37693; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, P NATL ACAD SCI USA, V96, P4170, DOI 10.1073/pnas.96.7.4170; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; Langloh ALB, 2000, AM J PHYSIOL-CELL PH, V278, pC277, DOI 10.1152/ajpcell.2000.278.2.C277; LI XJ, 1995, MOL PHARMACOL, V47, P1133; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Mense M, 2002, BIOCHEMISTRY-US, V41, P9803, DOI 10.1021/bi025819z; PALMER LG, 1985, J MEMBRANE BIOL, V87, P191, DOI 10.1007/BF01871218; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; Segal A, 2002, PFLUG ARCH EUR J PHY, V443, P882, DOI 10.1007/s00424-001-0773-x; Sheng SH, 2000, J BIOL CHEM, V275, P8572, DOI 10.1074/jbc.275.12.8572; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Sheng SH, 2001, J BIOL CHEM, V276, P1326, DOI 10.1074/jbc.M008117200; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Snyder PM, 1999, J BIOL CHEM, V274, P28484, DOI 10.1074/jbc.274.40.28484; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WARNCKE J, 1985, J MEMBRANE BIOL, V86, P255, DOI 10.1007/BF01870605; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	39	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8428	8440		10.1074/jbc.M312012200	http://dx.doi.org/10.1074/jbc.M312012200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660613	hybrid			2022-12-27	WOS:000189103300126
J	Li, DS; Yamada, T; Wang, F; Vulin, AI; Samuels, HH				Li, DS; Yamada, T; Wang, F; Vulin, AI; Samuels, HH			Novel roles of retinoid X receptor (RXR) and RXR ligand in dynamically modulating the activity of the thyroid hormone receptor/RXR heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; FUNCTIONAL EVIDENCE; ALLOSTERIC CONTROL; RESPONSE ELEMENTS; ACID RECEPTORS; BINDING DOMAIN; CO-REPRESSOR; DNA; MEDIATE; TRANSCRIPTION	Many members of the type II nuclear receptor subfamily function as heterodimers with the retinoid X receptor (RXR). A permissive heterodimer (e.g. peroxisome proliferator-activated receptor/RXR) allows for ligand binding by both partners of the receptor complex. In contrast, RXR has been thought to be incapable of ligand binding in a nonpermissive heterodimer, such as that of thyroid hormone receptor (TR)/RXR, where it has been referred to as a silent partner. However, we recently presented functional evidence suggesting that RXR in the TR/RXR heterodimer can bind its natural ligand 9-cis-RA in cells. Here we extended our study of the interrelationship of TR and RXR. We examined the potential modulatory effect of RXR and its ligand on the activity of TR, primarily using a Gal4-TR chimera. This study led to several novel and unexpected findings: 1) heterodimerization of apo-RXRalpha (in the absence of 9-cis-RA) with Gal4-TR inhibits T3-mediated transactivation; 2) the inhibition of Gal4-TR activity by RXRalpha is further enhanced by 9-cis-RA; 3) two different RXR subtypes (alpha and beta) differentially modulate the activity of Gal4-TR; 4) the N-terminal A/B domains of RXR alpha and beta are largely responsible for their differential modulation of TR activity; and 5) the RXR ligand 9-cis-RA appears to differentially affect T3-mediated transactivation from the Gal4-TR/RXRalpha (which is inhibited by 9-cis-RA) and TRE-bound TR/RXRalpha(which is further activated by 9-cis-RA) heterodimers. Taken together, these results further support our recent proposal that the RXR component in a TR/RXR heterodimer is not silent and, more importantly, reveal novel aspects of regulation of the activity of the TR/RXR heterodimer by RXR and RXR ligand.	NYU, Sch Med, Dept Pharmacol, MSB 424, New York, NY 10016 USA	New York University	Li, DS (corresponding author), NYU, Sch Med, Dept Pharmacol, MSB 424, 550 1st Ave, New York, NY 10016 USA.	lid01@med.nyu.edu; herbert.samuels@med.nyu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R01DK016636, F32DK009581, R37DK016636] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09581, DK16636] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kastner P, 1997, DEVELOPMENT, V124, P4749; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Li DS, 2002, MOL CELL BIOL, V22, P5782, DOI 10.1128/MCB.22.16.5782-5792.2002; Li DS, 1999, MOL CELL BIOL, V19, P7191; Li DS, 2001, MOL CELL BIOL, V21, P8371, DOI 10.1128/MCB.21.24.8371-8384.2001; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Mathur M, 2001, MOL CELL BIOL, V21, P2298, DOI 10.1128/MCB.21.7.2298-2311.2001; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; QI JS, 1995, MOL CELL BIOL, V15, P1817; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SAMUELS HH, 1982, RECENT PROG HORM RES, V38, P557; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wan YJY, 2000, MOL CELL BIOL, V20, P4436, DOI 10.1128/MCB.20.12.4436-4444.2000; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887	42	34	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7427	7437		10.1074/jbc.M311596200	http://dx.doi.org/10.1074/jbc.M311596200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668324	hybrid			2022-12-27	WOS:000189103300009
J	Shen, WH; Yin, YX; Broussard, SR; McCusker, RH; Freund, GG; Dantzer, R; Kelley, KW				Shen, WH; Yin, YX; Broussard, SR; McCusker, RH; Freund, GG; Dantzer, R; Kelley, KW			Tumor necrosis factor alpha inhibits cyclin A expression and retinoblastoma hyperphosphorylation triggered by insulin-like growth factor-I induction of new E2F-1 synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; UBIQUITIN-PROTEASOME PATHWAY; S-PHASE ENTRY; RECEPTOR SUBSTRATE-1; NEOPLASTIC TRANSFORMATION; TYROSINE PHOSPHORYLATION; GAMMA-INTERFERON; FAMILY PROTEINS; CARCINOMA CELLS; GENE-PRODUCT	Cyclin A is required for cell cycle S phase entry, and its overexpression contributes to tumorigenesis. Release of pre-existing E2Fs from inactive complexes of E2F and hypophosphorylated retinoblastoma (RB) is the prevailing dogma for E2F transcriptional activation of target genes such as cyclin A. Here we explored the hypothesis that new synthesis of E2F-1 is required for insulin-like growth factor-I (IGF-I) to induce cyclin A accumulation and RB hyperphosphorylation, events that are targeted by tumor necrosis factor alpha (TNFalpha) to arrest cell cycle progression. We first established that IGF-I increases expression of cyclin A, causes hyperphosphorylation of RB, and augments the mass of E2F-1 in a time-dependent manner. As expected, E2F-1 small interfering RNA blocks the ability of IGF-I to increase synthesis of E2F-1. Most important, this E2F-1 small interfering RNA also blocks the ability of IGF-I to increase cyclin A accumulation and to hyperphosphorylate RB. We next established that TNFalpha dose-dependently inhibits IGF-I-induced phosphorylation of both RB and histone H1 by cyclin A-dependent cyclin-dependent kinases. Cyclin-dependent kinase 2 (Cdk2) mediates this suppression because co-immunoprecipitation experiments revealed that TNFalpha reduces the amount of IGF-I-induced cyclin A that binds Cdk2, leading to a reduction in Cdk2 enzymatic activity. TNFalpha antagonizes the ability of IGF-I to increase mass of both E2F-1 and cyclin A but not cyclin E or D1. The cytostatic property of TNFalpha is also shown by its ability to block IGF-I-stimulated luciferase activity of a cyclin A promoter reporter. Deletion of an E2F recognition site from this reporter eliminates the regulatory effects of both IGF-I and TNFalpha on cyclin A transcription, indicating the essential role of E2F-1 in mediating their cross-talk. Collectively, these results establish that TNFalpha targets IGF-I-induced E2F-1 synthesis, leading to inhibition of the subsequent accumulation in cyclin A, formation of cyclin A-Cdk2 complexes, hyperphosphorylation of RB, and cell cycle arrest.	Univ Illinois, Dept Anim Sci, Immunophysiol Lab, Edward R Madigan Lab 207, Urbana, IL 61801 USA; Columbia Univ Coll Phys & Surg, Dept Radiat Oncol, New York, NY 10032 USA; Univ Illinois, Coll Med, Dept Pathol, Urbana, IL 61801 USA; Inst Francois Magendie Neurosci, UMR INRA Bordeaux 2, FRE CNRS, F-33077 Bordeaux, France	University of Illinois System; University of Illinois Urbana-Champaign; Columbia University; University of Illinois System; University of Illinois Urbana-Champaign; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite de Bordeaux	Kelley, KW (corresponding author), Univ Illinois, Dept Anim Sci, Immunophysiol Lab, Edward R Madigan Lab 207, 1201 W Gregory Dr, Urbana, IL 61801 USA.	kwkelley@uiuc.edu		Dantzer, Robert/0000-0001-9399-6107; Kelley, Keith W./0000-0002-6837-8793; SHEN, WEN/0000-0002-5830-6518	NIAID NIH HHS [AI50442] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Beletsky IP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P312, DOI 10.1023/A:1014884400144; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Brantl S, 2002, BBA-GENE STRUCT EXPR, V1575, P15, DOI 10.1016/S0167-4781(02)00280-4; Broussard SR, 2003, ENDOCRINOLOGY, V144, P2988, DOI 10.1210/en.2003-0087; Bukholm IRK, 2001, INT J CANCER, V93, P283, DOI 10.1002/ijc.1311; Buolamwini JK, 2000, CURR PHARM DESIGN, V6, P379, DOI 10.2174/1381612003400948; BURKE TW, 1993, IN VITRO CELL DEV-AN, V29A, P391; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chakravarthy MV, 2000, J BIOL CHEM, V275, P35942, DOI 10.1074/jbc.M005832200; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Dormond O, 2002, ANTICANCER RES, V22, P3159; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Hamelers IHL, 2002, J BIOL CHEM, V277, P47645, DOI 10.1074/jbc.M208727200; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Liu Q, 1999, MOL CELL BIOL, V19, P6229; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; Moneo V, 2003, J CELL BIOCHEM, V89, P484, DOI 10.1002/jcb.10529; Muller H, 1997, MOL CELL BIOL, V17, P5508; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; O'Connor JC, 2003, METABOLISM, V52, P666, DOI 10.1016/S0026-0495(03)00026-X; Orlovsky K, 2002, ONCOGENE, V21, P4997, DOI 10.1038/sj.onc.1205624; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; PEEPER DS, 1995, ONCOGENE, V10, P39; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; *SAS I INC, 2001, STAT AN SYST; SATOMOTO K, 1995, BIOCHEM BIOPH RES CO, V213, P1115, DOI 10.1006/bbrc.1995.2242; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shen WH, 2002, CANCER RES, V62, P4746; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Varma H, 2002, CANCER RES, V62, P3985; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Vivo C, 2001, ONCOGENE, V20, P1085, DOI 10.1038/sj.onc.1204199; Welniak LA, 2002, J LEUKOCYTE BIOL, V71, P381; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; You H, 2002, J CELL BIOCHEM, V84, P211, DOI 10.1002/jcb.10037; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	64	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7438	7446		10.1074/jbc.M310264200	http://dx.doi.org/10.1074/jbc.M310264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681231	hybrid			2022-12-27	WOS:000189103300010
J	Shimamoto, Y; Ishida, J; Yamagata, K; Saito, T; Kato, H; Matsuoka, T; Hirota, K; Daitoku, H; Nangaku, M; Yamagata, K; Fujii, H; Takeda, J; Fukamizu, A				Shimamoto, Y; Ishida, J; Yamagata, K; Saito, T; Kato, H; Matsuoka, T; Hirota, K; Daitoku, H; Nangaku, M; Yamagata, K; Fujii, H; Takeda, J; Fukamizu, A			Inhibitory effect of the small heterodimer partner on hepatocyte nuclear factor-4 mediates bile acid-induced repression of the human angiotensinogen gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION SITE; ENHANCER CORE ELEMENT; DNA-BINDING DOMAIN; DUCT LIGATION; RECEPTOR SHP; X-RECEPTOR; TRANSGENIC MICE; TATA BOX; EXPRESSION; PROMOTER	Bile acids function as transcriptional regulators for the genes important in bile acid synthesis and cholesterol homeostasis. In this study, we identified angiotensinogen (ANG), the precursor of vasoactive octapeptide angiotensin II, as a novel target gene of bile acids. In human ANG transgenic mice, administration of cholic acid resulted in the down-regulation of human ANG gene expression in the liver. ANG gene expression in HepG2 cells was also repressed by chenodeoxycholic acid. Because the expression of small heterodimer partner (SHP) mRNA was induced by chenodeoxycholic acid in HepG2 cells, we analyzed the effects of SHP on the human ANG promoter. Promoter mutation analysis demonstrated that SHP repressed human ANG promoter activity through the element, which has been previously determined as a binding site for hepatocyte nuclear factor-4 (HNF-4). SHP repressed human ANG promoter activity only when the HNF-4 expression vector was cotransfected in HeLa cells. Furthermore, we found that SHP bound to the HNF-4 N-terminal region including the DNA-binding domain and activation function-1 and that SHP prevented HNF-4 from binding to the human ANG promoter. These results suggest that bile acids negatively regulate the human ANG gene through the inhibitory effect of SHP on HNF-4.	Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tokyo, Sch Med, Div Nephrol & Endocrinol, Bunkyo Ku, Tokyo 1138655, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Osaka 5650871, Japan; Niigata Univ, Sch Med, Dept Biochem, Niigata 951, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, Mol Genet Lab, Gunma 3718512, Japan	University of Tsukuba; University of Tokyo; Osaka University; Niigata University; Gunma University	Fukamizu, A (corresponding author), Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Ten Noudai 1-1-1, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	Nangaku, Masaomi/A-5300-2010; fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; YAMAGATA, Kazuyuki/0000-0002-5804-6090				Chiang JYL, 2003, AM J PHYSIOL-GASTR L, V284, pG349, DOI 10.1152/ajpgi.00417.2002; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corvol P, 1997, ENDOCR REV, V18, P662, DOI 10.1210/er.18.5.662; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; Gines P, 1999, J AM SOC NEPHROL, V10, P1833; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Jiang GQ, 1997, MOL CELL BIOL, V17, P6546, DOI 10.1128/MCB.17.11.6546; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; KOKUBU T, 1972, BIOCHEM PHARMACOL, V21, P209; Kovacic A, 2004, MOL ENDOCRINOL, V18, P252, DOI 10.1210/me.2003-0211; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KullakUblick GA, 1996, HEPATOLOGY, V23, P1053; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; NAVEH Y, 1988, J HEPATOL, V6, P57, DOI 10.1016/S0168-8278(88)80462-8; NIBU Y, 1994, J BIOL CHEM, V269, P28598; NIBU Y, 1994, BIOCHEM BIOPH RES CO, V205, P1102, DOI 10.1006/bbrc.1994.2779; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Ourlin JC, 2003, MOL ENDOCRINOL, V17, P1693, DOI 10.1210/me.2002-0383; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; SHASHA SM, 1976, CLIN SCI MOL MED, V50, P533, DOI 10.1042/cs0500533; SHIMADA S, 1995, ENDOCRINE, V3, P543, DOI 10.1007/BF02738831; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; UBEDA M, 1994, HEPATOLOGY, V19, P1431, DOI 10.1016/0270-9139(94)90239-9; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Yanai K, 1996, J BIOL CHEM, V271, P15981, DOI 10.1074/jbc.271.27.15981; Yanai K, 1997, BIOCHEM BIOPH RES CO, V237, P158, DOI 10.1006/bbrc.1997.7000; Yanai K, 1997, FEBS LETT, V412, P285, DOI 10.1016/S0014-5793(97)00802-8; Yanai K, 1999, J BIOL CHEM, V274, P34605, DOI 10.1074/jbc.274.49.34605; Yanai K, 1997, J BIOL CHEM, V272, P30558, DOI 10.1074/jbc.272.48.30558; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zhao A, 2003, J BIOL CHEM, V278, P28765, DOI 10.1074/jbc.M304568200	41	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7770	7776		10.1074/jbc.M310577200	http://dx.doi.org/10.1074/jbc.M310577200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672953	hybrid			2022-12-27	WOS:000189103300050
J	Chiu, VK; Silletti, J; Dinsell, V; Wiener, H; Loukeris, K; Ou, GM; Philips, MR; Pillinger, MH				Chiu, VK; Silletti, J; Dinsell, V; Wiener, H; Loukeris, K; Ou, GM; Philips, MR; Pillinger, MH			Carboxyl methylation of Ras regulates membrane targeting and effector engagement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; CAAX MOTIF; K-RAS; H-RAS; PROTEIN; METHYLTRANSFERASE; ACTIVATION	Post-translational modification of Ras proteins includes prenylcysteine-directed carboxyl methylation. Because Ras participates in Erk activation by epidermal growth factor (EGF), we tested whether Ras methylation regulates Erk activation. EGF stimulation of Erk was inhibited by AFC (N-acetyl-S-farnesyl-L-cysteine), an inhibitor of methylation, but not AGC (N-acetyl-S-geranyl-L-cysteine), an inactive analog of AFC. AFC inhibited Ras methylation as well as the activation of pathway enzymes between Ras and Erk but did not inhibit EGF receptor phosphorylation, confirming action at the level of Ras. Transient transfection of human prenylcysteine-directed carboxyl methyltransferase increased EGF-stimulated Erk activation. AFC but not AGC inhibited movement of transiently transfected green fluorescent protein-Ras from the cytosol to the plasma membrane of COS-1 cells and depleted green fluorescent protein-Ras from the plasma membrane in stably transfected Madin-Darby canine kidney cells, suggesting that methylation regulates Erk by ensuring proper membrane localization of Ras. However, when COS-1 cells were transfected with Ras complexed to CD8, plasma membrane localization of Ras was unaffected by AFC, yet EGF-stimulated Erk activation was inhibited by AFC. Thus, Ras methylation appears to regulate Erk activation both through the localization of Ras as well as the propagation of Ras-dependent signals.	New York Harbor Healthcare Syst Vet Affairs, Dept Med, New York, NY 10010 USA; Hosp Joint Dis & Med Ctr, New York, NY 10003 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; New York University; New York University	Pillinger, MH (corresponding author), New York Harbor Healthcare Syst, Dept Med 630 111J, Div Rheumatol, 423 E 23rd St, New York, NY 10010 USA.	michael.pillinger@med.nyu.edu		Mark, Philips/0000-0002-1179-8156; Dinsell, Victoria/0000-0002-5067-3698	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036224, R01AI036224] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00096] Funding Source: Medline; NIAID NIH HHS [AI36224] Funding Source: Medline; NIGMS NIH HHS [GM55279] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; GanaWeisz ML, 1997, BIOCHEM BIOPH RES CO, V239, P900, DOI 10.1006/bbrc.1997.7582; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; Hart KC, 2000, EXP CELL RES, V257, P89, DOI 10.1006/excr.2000.4874; HUZOORAKBAR, 1991, J BIOL CHEM, V266, P4387; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; LACAL PM, 1988, ONCOGENE, V2, P533; MAGEE AI, 1992, BIOCHEM SOC T, V20, P497, DOI 10.1042/bst0200497; MAGEE AI, 1989, J CELL SCI, P149; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; TAN EW, 1991, J BIOL CHEM, V266, P10719; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	37	42	43	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7346	7352		10.1074/jbc.M311602200	http://dx.doi.org/10.1074/jbc.M311602200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660603	hybrid			2022-12-27	WOS:000188969200137
J	Stegman, MA; Goetz, JA; Ascano, M; Ogden, SK; Nybakken, KE; Robbins, DJ				Stegman, MA; Goetz, JA; Ascano, M; Ogden, SK; Nybakken, KE; Robbins, DJ			The kinesin-related protein Costal2 associates with membranes in a Hedgehog-sensitive, smoothened-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMA; DROSOPHILA CUBITUS INTERRUPTUS; SIGNAL-TRANSDUCTION PATHWAYS; TARGET GENE-EXPRESSION; SONIC HEDGEHOG; HUMAN HOMOLOG; PATCHED GENE; SUBCELLULAR-LOCALIZATION; MOTOR DOMAIN; TRANSCRIPTIONAL ACTIVATOR	In Drosophila, Hedgehog (Hh) signal transduction has been shown to require a multiprotein complex (Hedgehog signaling complex (HSC)), which includes the Kinesin-related protein Costal2 (Cos2), the serine/threonine protein kinase Fused (Fu), and the transcription factor Cubitus interruptus (Ci). We present evidence that a biologically relevant fraction of the HSC is found in association with cellular membranes. We demonstrate that Cos2 is capable of tethering an exogenous protein to vesicular membranes and that Cos2 association with membranes is Hh-sensitive. In addition, we demonstrate that Cos2 associates with membranes in cells that lack the transmembrane protein Smoothened (Smo) through a domain of Cos2 distinct from its recently characterized Smo binding domain. We suggest that an Hh-regulated membrane binding activity of Cos2 is part of the mechanism by which Cos2 contributes to Hh signaling. We propose a model in which there are two distinct HSCs with discrete subcellular localizations and activities: one is endosome-associated and facilitates production of a repressor form of Ci (HSC-R), and one is Smo-associated and promotes Ci activation (HSC-A). In response to Hh and through interaction with Cos2, Smo mediates both inhibition of the endosome-associated HSC-R and activation of HSC-A at the plasma membrane.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Grad Program, Cincinnati, OH 45267 USA; Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	Dartmouth College; University System of Ohio; University of Cincinnati; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Robbins, DJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen Hall, Hanover, NH 03755 USA.	david.j.robbins@dartmouth.edu	Ascano, Manuel/ABA-3586-2020; Ogden, Stacey K/N-2528-2018; Ogden, Stacey K/P-9585-2019	Ascano, Manuel/0000-0002-9370-5493; Ogden, Stacey K/0000-0001-8991-3065	NCI NIH HHS [CA82628, R01 CA082628] Funding Source: Medline; NIEHS NIH HHS [5-T32 ES07250, T32 ES007250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; Ascano M, 2002, MOL CELL BIOL, V22, P1555, DOI 10.1128/MCB.22.5.1555-1566.2002; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1999, DEVELOPMENT, V126, P3607; Chen Y, 1998, DEVELOPMENT, V125, P4943; Chidambaram A, 1996, CANCER RES, V56, P4599; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Coy DL, 1999, NAT CELL BIOL, V1, P288, DOI 10.1038/13001; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Dollar G, 2002, DEVELOPMENT, V129, P517; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FORBES AJ, 1993, DEVELOPMENT, P115; Fukumoto T, 2001, J BIOL CHEM, V276, P38441, DOI 10.1074/jbc.M105871200; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Gallet A, 2000, DEVELOPMENT, V127, P5509; Gilman A.G., 2001, GOODMAN GILMANS PHAR; Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298; GRAU Y, 1987, DEV BIOL, V122, P186, DOI 10.1016/0012-1606(87)90344-7; Hackney DD, 2000, NAT CELL BIOL, V2, P257, DOI 10.1038/35010525; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HO K, 2002, REGULATION HH TARGET; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; Hooper JE, 2003, DEVELOPMENT, V130, P3951, DOI 10.1242/dev.00594; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Lefers MA, 2001, DEV BIOL, V236, P411, DOI 10.1006/dbio.2001.0345; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MARIOL MC, 1987, MOL CELL BIOL, V7, P3244, DOI 10.1128/MCB.7.9.3244; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Methot N, 2000, DEVELOPMENT, V127, P4001; Mok H, 2002, J NEUROSCI, V22, P5253; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Monnier Veronique, 2002, BMC Dev Biol, V2, P4, DOI 10.1186/1471-213X-2-4; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; Nybakken KE, 2002, J BIOL CHEM, V277, P24638, DOI 10.1074/jbc.M110730200; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PHAM A, 1995, GENETICS, V140, P587; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Quirk J, 1997, COLD SPRING HARB SYM, V62, P217; Ramirez-Weber FA, 2000, MOL CELL, V6, P479, DOI 10.1016/S1097-2765(00)00046-0; Reifenberger J, 1998, CANCER RES, V58, P1798; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SIMPSON P, 1987, DEV BIOL, V122, P201, DOI 10.1016/0012-1606(87)90345-9; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SLUSARSKI DC, 1995, GENETICS, V139, P229; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Stegman MA, 2000, J BIOL CHEM, V275, P21809, DOI 10.1074/jbc.C000043200; Stock MF, 1999, J BIOL CHEM, V274, P14617, DOI 10.1074/jbc.274.21.14617; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Unden AB, 1996, CANCER RES, V56, P4562; Unden AB, 1997, CANCER RES, V57, P2336; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wang GL, 2000, GENE DEV, V14, P2893, DOI 10.1101/gad.843900; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828; Wang QT, 2000, DEVELOPMENT, V127, P3131; Wang QT, 1999, DEVELOPMENT, V126, P5097; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zhu AJ, 2003, GENE DEV, V17, P1240, DOI 10.1101/gad.1080803	87	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7064	7071		10.1074/jbc.M311794200	http://dx.doi.org/10.1074/jbc.M311794200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645371	Green Accepted, hybrid			2022-12-27	WOS:000188969200104
J	Vasseur, S; Folch-Puy, E; Hlouschek, V; Garcia, S; Fiedler, F; Lerch, MM; Dagorn, JC; Closa, D; Iovanna, JL				Vasseur, S; Folch-Puy, E; Hlouschek, V; Garcia, S; Fiedler, F; Lerch, MM; Dagorn, JC; Closa, D; Iovanna, JL			p8 improves pancreatic response to acute pancreatitis by enhancing the expression of the anti-inflammatory protein pancreatitis-associated protein I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HORMONE-RELEASING HORMONE; KAPPA-B ACTIVATION; PROMOTES CELLULAR GROWTH; ALPHA GENE-EXPRESSION; BREAST-CANCER CELLS; MESSENGER-RNA; ACINAR-CELLS; ACUTE-PHASE; TRYPSINOGEN ACTIVATION	p8 is a transcription cofactor whose expression is strongly and rapidly activated in pancreatic acinar cells during the acute phase of pancreatitis. A p8-deficient mouse strain was generated as a tool to investigate its function. Upon induction of acute pancreatitis, myeloperoxidase activity in pancreas and serum concentrations of amylase and lipase were much higher and pancreatic lesions more severe in p8-deficient mice than in wild-type, indicating that p8 expression decreased pancreatic sensitivity to pancreatitis induction. The protective mechanism might involve the pancreatitis-associated protein (PAP 1), whose strong induction during pancreatitis is p8-dependent, because administration of anti-PAP I antibodies to rats increased pancreatic inflammation during pancreatitis. In addition, 100 ng/ml PAP I in the culture medium of macrophages prevented their activation by tumor necrosis factor a, strongly suggesting that PAP I was an anti-inflammatory factor. Finally, PAP I was able to inhibit NFkappaB activation by tumor necrosis factor a, in macrophages and in the AR42J pancreatic acinar cell line. In conclusion, p8 improves pancreatic resistance to inducers of acute pancreatitis by a mechanism implicating the expression of the anti-inflammatory protein PAP I.	CSIC, IIBB, Dept Expt Pathol, Barcelona 08036, Spain; INSERM, Ctr Rech, F-13009 Marseille, France; Univ Munster, Med Klin B, D-48129 Munster, Germany; Hop Nord Marseille, F-13915 Marseille, France; Univ Heidelberg, Klinikum Mannheim, Inst Anasthesie, D-68167 Mannheim, Germany; Univ Greifswald, Dept Med A, Div Gastroenterol & Endocrinol, D-17487 Greifswald, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Munster; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Ruprecht Karls University Heidelberg; Ernst Moritz Arndt Universitat Greifswald	Iovanna, JL (corresponding author), CSIC, IIBB, Dept Expt Pathol, C Rossello 161,7, Barcelona 08036, Spain.	iovanna@marseille.inserm.fr	vasseur, sophie/O-9803-2017; Folch Puy, Emma/Q-3157-2017; Iovanna, Juan/M-9805-2017; Lerch, Markus M./E-2206-2016; Puy, Emma Folch/AAX-5558-2020; Closa, Daniel/Y-3848-2019	vasseur, sophie/0000-0002-2339-8854; Folch Puy, Emma/0000-0002-6277-9027; Iovanna, Juan/0000-0003-1822-2237; Lerch, Markus M./0000-0002-9643-8263; Puy, Emma Folch/0000-0002-6277-9027; Closa Autet, Daniel/0000-0003-3797-3095				Aggarwal S, 2001, J INTERF CYTOK RES, V21, P1047, DOI 10.1089/107999001317205178; Bartoli C, 1998, J CLIN ENDOCR METAB, V83, P4041, DOI 10.1210/jc.83.11.4041; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bratland A, 2000, CANCER RES, V60, P5578; Broekaert D, 2002, EUR CYTOKINE NETW, V13, P78; CHAKRABORTY C, 1995, MOL CELL ENDOCRINOL, V108, P149, DOI 10.1016/0303-7207(94)03470-E; CHAKRABORTY C, 1995, ENDOCRINOLOGY, V136, P1843, DOI 10.1210/en.136.5.1843; Christa L, 1996, AM J PHYSIOL-GASTR L, V271, pG993, DOI 10.1152/ajpgi.1996.271.6.G993; DAS DK, 1995, J MOL CELL CARDIOL, V27, P181, DOI 10.1016/S0022-2828(08)80017-X; Denham W, 1997, AM SURGEON, V63, P1045; Denham W, 1997, GASTROENTEROLOGY, V113, P1741, DOI 10.1053/gast.1997.v113.pm9352880; Deviere J, 2001, GASTROENTEROLOGY, V120, P498, DOI 10.1053/gast.2001.21172; Dieckgraefe BK, 2002, J INVEST MED, V50, P421, DOI 10.1136/jim-50-06-02; DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2; Dunn JA, 1997, AM SURGEON, V63, P1036; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; Encinar JA, 2001, J BIOL CHEM, V276, P2742, DOI 10.1074/jbc.M008594200; Ethridge RT, 2002, J AM COLL SURGEONS, V195, P497, DOI 10.1016/S1072-7515(02)01222-X; Folch E, 1998, INFLAMMATION, V22, P83, DOI 10.1023/A:1022399824880; Garcia-Montero AC, 2001, BIOCHEM J, V357, P249, DOI 10.1042/0264-6021:3570249; Goruppi S, 2002, EMBO J, V21, P5427, DOI 10.1093/emboj/cdf535; Grady T, 1996, AM J PHYSIOL-GASTR L, V271, pG20, DOI 10.1152/ajpgi.1996.271.1.G20; Grisham MB, 1999, GASTROENTEROLOGY, V116, P489, DOI 10.1016/S0016-5085(99)70148-4; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Heller A, 1999, ANESTHESIOLOGY, V91, P1408, DOI 10.1097/00000542-199911000-00034; Hoffmeister A, 2002, J BIOL CHEM, V277, P22314, DOI 10.1074/jbc.M201657200; Hughes CB, 1996, AM J SURG, V171, P274, DOI 10.1016/S0002-9610(97)89568-2; Hughes CB, 1996, AM SURGEON, V62, P8; HUTTUNEN R, 1975, SCAND J GASTROENTERO, V10, P177; Igarashi T, 2001, DEV GROWTH DIFFER, V43, P693; IOVANNA J, 1991, J BIOL CHEM, V266, P24664; IOVANNA J, 1991, AM J PHYSIOL, V261, pG418; IOVANNA JL, 1993, AM J PHYSIOL, V265, pG611, DOI 10.1152/ajpgi.1993.265.4.G611; Jaffray C, 2000, J GASTROINTEST SURG, V4, P370, DOI 10.1016/S1091-255X(00)80015-3; Jiang YF, 1999, BIOCHEM BIOPH RES CO, V260, P686, DOI 10.1006/bbrc.1999.0953; KATSUMATA N, 1995, ENDOCRINOLOGY, V136, P1332, DOI 10.1210/en.136.4.1332; KEIM V, 1991, GASTROENTEROLOGY, V100, P775, DOI 10.1016/0016-5085(91)80025-5; KOGURE K, 1993, STROKE, V24, P2121, DOI 10.1161/01.STR.24.12.2121; LASSERRE C, 1992, CANCER RES, V52, P5089; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; Malka D, 2000, GASTROENTEROLOGY, V119, P816, DOI 10.1053/gast.2000.16491; Mallo GV, 1997, J BIOL CHEM, V272, P32360, DOI 10.1074/jbc.272.51.32360; MASCIOTRA L, 1995, DIGEST DIS SCI, V40, P519, DOI 10.1007/BF02064359; Morisset J, 1997, GASTROENTEROLOGY, V112, P543, DOI 10.1053/gast.1997.v112.pm9024308; Motoo Y, 1998, INT J PANCREATOL, V23, P11; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Neoptolemos JP, 2000, LANCET, V355, P1955, DOI 10.1016/S0140-6736(00)02327-8; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Norman JG, 1996, SURGERY, V120, P515, DOI 10.1016/S0039-6060(96)80072-9; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; Quirk CC, 2003, J BIOL CHEM, V278, P1680, DOI 10.1074/jbc.M209906200; Rechreche H, 1999, INT J CANCER, V81, P688, DOI 10.1002/(SICI)1097-0215(19990531)81:5<688::AID-IJC3>3.0.CO;2-R; Ree AH, 1999, CANCER RES, V59, P4675; Rongione A J, 1997, J Gastrointest Surg, V1, P159, DOI 10.1016/S1091-255X(97)80104-7; Rongione AJ, 1997, GASTROENTEROLOGY, V112, P960, DOI 10.1053/gast.1997.v112.pm9041259; Satoh A, 1999, GUT, V44, P253, DOI 10.1136/gut.44.2.253; Sparmann G, 2001, DIGEST DIS SCI, V46, P1647, DOI 10.1023/A:1010689117772; Spielman J, 1998, J IMMUNOL, V161, P7063; STEER ML, 1987, NEW ENGL J MED, V316, P144; STEER ML, 1992, ARCH SURG-CHICAGO, V127, P1350; TACHIBANA K, 1988, MOL ENDOCRINOL, V2, P973, DOI 10.1210/mend-2-10-973; Vaccaro MI, 2000, BIOCHEM BIOPH RES CO, V268, P485, DOI 10.1006/bbrc.2000.2151; Van Laethem JL, 1998, GUT, V43, P408, DOI 10.1136/gut.43.3.408; VANLAETHEM JL, 1995, GASTROENTEROLOGY, V108, P1917, DOI 10.1016/0016-5085(95)90158-2; Vasseur S, 1999, EUR J BIOCHEM, V259, P670, DOI 10.1046/j.1432-1327.1999.00092.x; Vasseur S, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-25; Vasseur S, 2002, ONCOGENE, V21, P1685, DOI 10.1038/sj.onc.1205222; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Vasseur S, 1999, BIOCHEM J, V343, P377, DOI 10.1042/0264-6021:3430377; Waelput W, 2000, BIOCHEM J, V348, P55, DOI 10.1042/0264-6021:3480055; WILLEMER S, 1992, EUR SURG RES, V24, P29, DOI 10.1159/000129237; Yang J, 1998, SHOCK, V10, P169, DOI 10.1097/00024382-199809000-00004; Yasuda H, 1999, J INTERF CYTOK RES, V19, P637, DOI 10.1089/107999099313785; Zinke I, 2002, EMBO J, V21, P6162, DOI 10.1093/emboj/cdf600; Zou WG, 2002, J SURG RES, V103, P121, DOI 10.1006/jsre.2001.6327	78	100	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7199	7207		10.1074/jbc.M309152200	http://dx.doi.org/10.1074/jbc.M309152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660681	hybrid			2022-12-27	WOS:000188969200119
J	Niu, JG; Li, ZK; Peng, BL; Chiao, PJ				Niu, JG; Li, ZK; Peng, BL; Chiao, PJ			Identification of an autoregulatory feedback pathway involving interleukin-1 alpha in induction of constitutive NF-kappa B activation in pancreatic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; EXPRESSION; ADENOCARCINOMA; GROWTH; AP-1; PROTEINS; ENHANCER; LINE; GENE	We previously reported that NF-kappaB is constitutively activated in most human pancreatic cancer tissues and cell lines but not in normal pancreatic tissues and immortalized pancreatic ductal epithelial cells. IkappaBalphaM-mediated inhibition of constitutive NF-kappaB activity in human pancreatic cancer cells suppressed tumorigenesis and liver metastasis in an orthotopic nude mouse model, suggesting that constitutive NF-kappaB activation plays an important role in pancreatic tumor progression and metastasis. However, the underlying mechanism by which NF-kappaB is activated in pancreatic cancer remains to be elucidated. In this study, we found that an autocrine mechanism accounts for the constitutive activation of NF-kappaB in metastatic human pancreatic cancer cell lines. Further investigation showed that interleukin-1alpha was the primary cytokine secreted by these cells that activates NF-kappaB. Neutralization of interleukin-1alpha activity suppressed the constitutive activation of NF-kappaB and the expression of its downstream target gene, urokinase-type plasminogen activator, in metastatic pancreatic cancer cell lines. Our results demonstrate that regulation of interleukin-1alpha expression is primarily dependent on AP-1 activity, which is in part induced by signaling pathways that are epidermal growth factor receptor-dependent and - independent. In conclusion, our findings suggest a possible mechanism for the constitutive activation of NF-kappaB in metastatic human pancreatic cancer cells and a possible missing mechanistic link between inflammation and cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Chiao, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	pjchiao@mdanderson.org			NCI NIH HHS [CA78778-01, CA73675-01, CA097159] Funding Source: Medline; PHS HHS [R21PA-98-029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097159, R29CA073675, P01CA078778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen K, 1998, ANTICANCER RES, V18, P3299; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Apte RN, 2002, SEMIN CANCER BIOL, V12, P277, DOI 10.1016/S1044-579X(02)00014-7; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Arlt A, 2002, CANCER RES, V62, P910; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bailly S, 1996, EUR CYTOKINE NETW, V7, P125; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Breslin TM, 2001, ANN SURG ONCOL, V8, P123, DOI 10.1007/s10434-001-0123-4; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CASTELLI C, 1994, CANCER RES, V54, P4785; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DEMETRI GD, 1990, J CLIN INVEST, V86, P1261, DOI 10.1172/JCI114833; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Frazier ML, 1996, INT J PANCREATOL, V19, P31, DOI 10.1007/BF02788373; FRAZIER ML, 1990, PANCREAS, V5, P8, DOI 10.1097/00006676-199001000-00002; Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323; Fujioka S, 2003, CLIN CANCER RES, V9, P346; FURUTANI Y, 1986, NUCLEIC ACIDS RES, V14, P3167, DOI 10.1093/nar/14.8.3167; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1996, ONCOGENE, V13, P1367; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Li JX, 2003, ONCOGENE, V22, P211, DOI 10.1038/sj.onc.1206102; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; Matsuda K, 2002, CANCER RES, V62, P5611; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; Nguyen M, 1997, AM J PATHOL, V150, P1307; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Panozzo MP, 1996, INT J CLIN LAB RES, V26, P240, DOI 10.1007/BF02602956; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Sawai H, 2001, PANCREAS, V23, P399, DOI 10.1097/00006676-200111000-00011; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Sclabas GM, 2003, J GASTROINTEST SURG, V7, P37, DOI 10.1016/S1091-255X(02)00088-4; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Vale T, 2001, CANCER RES, V61, P602; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wilson J, 2002, SEMIN CANCER BIOL, V12, P113, DOI 10.1006/scbi.2001.0419; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	58	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2004	279	16					16452	16462		10.1074/jbc.M309789200	http://dx.doi.org/10.1074/jbc.M309789200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	811BR	14679213	hybrid			2022-12-27	WOS:000220747900093
J	Lee, JY; Kim, JH; Hong, SH; Lee, JY; Cherny, RA; Bush, AI; Palmiter, RD; Koh, JY				Lee, JY; Kim, JH; Hong, SH; Lee, JY; Cherny, RA; Bush, AI; Palmiter, RD; Koh, JY			Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTOCHEMICALLY-REACTIVE ZINC; ALZHEIMER A-BETA; POSTMENOPAUSAL WOMEN; PRECURSOR PROTEIN; AMYLOID PLAQUES; DISEASE; INDUCTION; BOUTONS; COPPER; MOSSY	Previous studies suggest that female sex hormones modulate synaptic zinc levels, which may influence amyloid plaque formation and Alzheimer's disease progression. We examined the effects of ovariectomy and estrogen supplement on the levels of synaptic zinc and zinc transporter protein Znt3 in the brain. Ovariectomy was performed on 5-month-old mice, and 2 weeks later, pellets containing vehicle, low (0.18 mg/pellet), or high dose (0.72 mg) 17beta-estradiol were implanted. After 4 weeks, animals were decapitated, and blood and brain were collected for analysis. Blood analysis indicated that estrogen implants altered plasma estrogen levels in a dose-dependent manner. Analysis of brain tissue showed that ovariectomy raised hippocampal synaptic vesicle zinc levels, whereas estrogen replacement lowered these zinc levels. Western blots revealed that Znt3 levels in the brain were modulated in parallel with synaptic zinc levels, whereas no change was detected in the levels of Znt3 mRNA, as determined by Northern blot and reverse transcriptase-PCR analysis. However, mRNA levels of the delta subunit of adaptor protein complex (AP)-3, which modulates the level of Znt3 levels, were altered by estrogen depletion or replacement. These data demonstrate that estrogen alters the levels of Znt3 and synaptic vesicle zinc in female mice, probably through changing AP-3 delta expression. Since synaptic zinc may play a key role in neuronal death in acute brain injury as well as in plaque formation in Alzheimer's disease, and since estrogen may be beneficial in both conditions, our results may provide new insights into the effects of estrogen on the brain.	Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study Cent Nervous Sys, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Neurol, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Obstet & Gynecol, Seoul 138736, South Korea; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Univ Melbourne, Mental Hlth Res Inst Victoria, Parkville, Vic 3052, Australia; Harvard Univ, Sch Med, Dept Psychiat, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Lab Oxidat Biol, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Univ Washington, Dept Biochem, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Ulsan; University of Ulsan; University of Ulsan; University of Melbourne; University of Melbourne; Harvard University; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Koh, JY (corresponding author), Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study Cent Nervous Sys, 388-1 Poongnapdong, Seoul 138736, South Korea.	jkko@www.amc.seoul.kr	Lee, Joo-Yong/F-4545-2014; Koh, Jae-Young/C-9014-2011; Bush, Ashley/Y-2457-2019; Bush, Ashley I/A-1186-2007	Koh, Jae-Young/0000-0002-4318-495X; Bush, Ashley/0000-0001-8259-9069; Bush, Ashley I/0000-0001-8259-9069				Amateau SK, 2002, J NEUROSCI, V22, P8586; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Danscher G, 1997, J NEUROSCI METH, V76, P53, DOI 10.1016/S0165-0270(97)00079-4; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Greenfield JP, 2002, J BIOL CHEM, V277, P12128, DOI 10.1074/jbc.M110009200; Harris-White ME, 2001, NEUROCHEM INT, V39, P435, DOI 10.1016/S0197-0186(01)00051-1; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; Kantheti P, 2003, MAMM GENOME, V14, P157, DOI 10.1007/s00335-002-2238-8; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Koh JY, 2001, MOL NEUROBIOL, V24, P99, DOI 10.1385/MN:24:1-3:099; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lee JY, 1999, J NEUROSCI, V19, DOI 10.1523/jneurosci.19-11-j0002.1999; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Li Y, 2001, J NEUROSCI, V21, P8015, DOI 10.1523/JNEUROSCI.21-20-08015.2001; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Manthey D, 2001, EUR J BIOCHEM, V268, P4285, DOI 10.1046/j.1432-1327.2001.02346.x; MARTINEZGUIJARRO FJ, 1991, J NEUROCYTOL, V20, P834, DOI 10.1007/BF01191734; MOUTON PR, 2001, SOC NEUR ABSTR, V27; Murphy DD, 1998, P NATL ACAD SCI USA, V95, P11412, DOI 10.1073/pnas.95.19.11412; Owens CT, 2002, ANN PHARMACOTHER, V36, P1273; Payami H, 1996, AM J HUM GENET, V58, P803; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; Schonknecht P, 2001, NEUROSCI LETT, V307, P122, DOI 10.1016/S0304-3940(01)01896-1; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Suh SW, 2000, BRAIN RES, V852, P274, DOI 10.1016/S0006-8993(99)02096-X; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Ueno S, 2002, J CELL BIOL, V158, P215, DOI 10.1083/jcb.200204066; Valente T, 2002, MOL CELL NEUROSCI, V21, P189, DOI 10.1006/mcne.2002.1159; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Yang DS, 2000, EUR J BIOCHEM, V267, P6692, DOI 10.1046/j.1432-1327.2000.01767.x; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745	49	118	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8602	8607		10.1074/jbc.M309730200	http://dx.doi.org/10.1074/jbc.M309730200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681234	hybrid			2022-12-27	WOS:000189265900011
J	Su, H; McClarty, G; Dong, F; Hatch, GM; Pan, ZXK; Zhong, GM				Su, H; McClarty, G; Dong, F; Hatch, GM; Pan, ZXK; Zhong, GM			Activation of Raf/MEK/ERK/cPLA2 signaling pathway is essential for chlamydial acquisition of host glycerophospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED CELLS; TRACHOMATIS INFECTION; PHOSPHOLIPASE A(2); REGULATED KINASE; GENOME SEQUENCE; PROTEIN-KINASE; HEP-2 CELLS; PNEUMONIAE; INHIBITION; IDENTIFICATION	Chlamydiae, a diverse group of obligate intracellular pathogens replicating within cytoplasmic vacuoles of eukaryotic cells, are able to acquire lipids from host cells. Here we report that activation of the host Raf-MEK-ERK-cPLA2 signaling cascade is required for the chlamydial uptake of host glycerophospholipids. Both the MAP kinase pathway (Ras/Raf/MEK/ERK) and Ca2+-dependent cytosolic phospholipase A2 (cPLA2) were activated in chlamydia-infected cells. The inhibition of cPLA2 activity resulted in the blockade of the chlamydial uptake of host glycerophospholipids and impairment in chlamydial growth. Blocking either c-Raf-1 or MEK1/2 activity prevented the chlamydial activation of ERK1/2, leading to the suppression of both chlamydial activation of the host cPLA2 and uptake of glycerophospholipids from the host cells. The chlamydia-induced phosphorylation of cPLA2 was also blocked by a dominant negative ERK2. Furthermore, activation of both ERK1/2 and cPLA2 was dependent on chlamydial growth and restricted within chlamydia-infected cells, suggesting an active manipulation of the host ERK-cPLA2 signaling pathway by chlamydiae.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, San Antonio, TX 78229 USA; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E OW3, Canada; Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB R3E OW3, Canada; Med Coll Ohio, Dept Microbiol & Immunol, Toledo, OH 43614 USA	University of Texas System; University of Texas Health San Antonio; University of Manitoba; University of Manitoba	Zhong, GM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	Zhongg@UTHSCSA.EDU			NHLBI NIH HHS [R01HL64883] Funding Source: Medline; NIAID NIH HHS [R01AI47997] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047997] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Younes HM, 2001, CELL MICROBIOL, V3, P427, DOI 10.1046/j.1462-5822.2001.00125.x; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BEATTY WL, 1994, INFECT IMMUN, V62, P3705, DOI 10.1128/IAI.62.9.3705-3711.1994; Belland RJ, 2003, P NATL ACAD SCI USA, V100, P8478, DOI 10.1073/pnas.1331135100; Belland RJ, 2001, P NATL ACAD SCI USA, V98, P13984, DOI 10.1073/pnas.241377698; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Caldwell HD, 2003, J CLIN INVEST, V111, P1757, DOI [10.1172/JCI200317993, 10.1172/JCI17993]; Carabeo RA, 2003, P NATL ACAD SCI USA, V100, P6771, DOI 10.1073/pnas.1131289100; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen LY, 2002, J IMMUNOL, V169, P3934, DOI 10.4049/jimmunol.169.7.3934; Coombes BK, 2002, CELL MICROBIOL, V4, P447, DOI 10.1046/j.1462-5822.2002.00203.x; DAWSON JM, 1984, ANAL BIOCHEM, V140, P391, DOI 10.1016/0003-2697(84)90183-0; FAN HZ, 1992, J CLIN INVEST, V90, P1803, DOI 10.1172/JCI116055; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fields KA, 2002, ANNU REV CELL DEV BI, V18, P221, DOI 10.1146/annurev.cellbio.18.012502.105845; Greene W, 2003, J INFECTION, V47, P45, DOI 10.1016/S0163-4453(03)00039-2; Hackstadt T, 1996, EMBO J, V15, P964, DOI 10.1002/j.1460-2075.1996.tb00433.x; Hatch GM, 1998, INFECT IMMUN, V66, P3727, DOI 10.1128/IAI.66.8.3727-3735.1998; HATCH GM, 1992, J BIOL CHEM, V267, P12443; Hatch GM, 1998, BIOCHEM BIOPH RES CO, V243, P356, DOI 10.1006/bbrc.1998.8101; Heuer D, 2003, CELL MICROBIOL, V5, P315, DOI 10.1046/j.1462-5822.2003.00278.x; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Hu H, 1999, J CLIN INVEST, V103, P747, DOI 10.1172/JCI4582; Iliffe-Lee ER, 2000, MOL MICROBIOL, V38, P20, DOI 10.1046/j.1365-2958.2000.02102.x; Kalayoglu MV, 2002, JAMA-J AM MED ASSOC, V288, P2724, DOI 10.1001/jama.288.21.2724; Kalman S, 1999, NAT GENET, V21, P385, DOI 10.1038/7716; Kirchner JT, 2000, POSTGRAD MED, V107, P55, DOI 10.3810/pgm.2000.01.815; Luo HL, 2002, J VIROL, V76, P3365, DOI 10.1128/JVI.76.7.3365-3373.2002; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; McClarty G, 1999, CHLAMYDIA, P69; MCCLARTY G, 1993, FEMS MICROBIOL LETT, V108, P325, DOI 10.1111/j.1574-6968.1993.tb06123.x; MORRISON RP, 1989, J EXP MED, V169, P663, DOI 10.1084/jem.169.3.663; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Ojcius DM, 1998, J BIOL CHEM, V273, P7052, DOI 10.1074/jbc.273.12.7052; Pantoja LG, 2001, INFECT IMMUN, V69, P7927, DOI 10.1128/IAI.69.12.7927-7932.2001; Papp JR, 1997, J REPROD IMMUNOL, V34, P185, DOI 10.1016/S0165-0378(97)00035-1; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136; Read TD, 2003, NUCLEIC ACIDS RES, V31, P2134, DOI 10.1093/nar/gkg321; Read TD, 2000, NUCLEIC ACIDS RES, V28, P1397, DOI 10.1093/nar/28.6.1397; SCHACHTER J, 1980, ANNU REV MICROBIOL, V34, P285, DOI 10.1146/annurev.mi.34.100180.001441; Shaw AC, 2002, CELL MICROBIOL, V4, P411, DOI 10.1046/j.1462-5822.2002.00200.x; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; Wolf K, 2001, CELL MICROBIOL, V3, P145, DOI 10.1046/j.1462-5822.2001.00098.x; Wylie JL, 1997, J BACTERIOL, V179, P7233, DOI 10.1128/jb.179.23.7233-7242.1997; Wyrick PB, 2000, CELL MICROBIOL, V2, P275, DOI 10.1046/j.1462-5822.2000.00059.x; Xia MS, 2003, J INFECT DIS, V187, P424, DOI 10.1086/367962; Xu JF, 2002, J NEUROCHEM, V83, P259, DOI 10.1046/j.1471-4159.2002.01145.x; Zhong GM, 1999, J EXP MED, V189, P1931, DOI 10.1084/jem.189.12.1931; ZHONG GM, 1988, INFECT IMMUN, V56, P283, DOI 10.1128/IAI.56.1.283-286.1988; Zhong GM, 1997, P NATL ACAD SCI USA, V94, P13856, DOI 10.1073/pnas.94.25.13856; Zhong GM, 1996, J EXP MED, V184, P2061, DOI 10.1084/jem.184.5.2061; Zhong GM, 2001, J EXP MED, V193, P935, DOI 10.1084/jem.193.8.935; Zhong GM, 2000, J EXP MED, V191, P1525, DOI 10.1084/jem.191.9.1525; Zhu XD, 2002, J LEUKOCYTE BIOL, V72, P1046	62	131	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9409	9416		10.1074/jbc.M312008200	http://dx.doi.org/10.1074/jbc.M312008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676189	hybrid			2022-12-27	WOS:000189265900106
J	Yang, EJ; Yoon, JH; Min, DS; Chung, KC				Yang, EJ; Yoon, JH; Min, DS; Chung, KC			LIM kinase 1 activates cAMP-responsive element-binding protein during the neuronal differentiation of immortalized hippocampal progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; NERVOUS-SYSTEM; CREB; GROWTH; PHOSPHORYLATION; IDENTIFICATION; FAMILY; RAS; RHO; SUFFICIENT	LIM kinase 1 (LIMK1), a novel member of a subclass of the protein-serine/threonine kinases, is known to play a role in the development and maintenance of neuronal circuits that mediate cognitive function. Genetic studies have implicated a mutation of LIMK1 as a causative factor in the impairment of visuospatial cognition in a neurodevelopmental disorder, Williams syndrome. A transcriptional factor, cAMP-responsive element-binding protein (CREB), is thought to be involved in the formation of many types of synaptic plasticity involving learning and memory. In the present study we show that the LIMK1 activity is markedly induced during the differentiation of immortalized hippocampal progenitor (H19-7) cells. We found that the addition of neurogenic growth factor to H19-7 cells induces specific binding between LIMK1 and active CREB, that LIMK1 directly phosphorylates CREB, and that this leads to the stimulation of subsequent cAMP-responsive element-mediated gene transcription during H19-7 cell neuronal differentiation. In addition, we also found that LIMK1 activation occurs through Rac/Cdc42- and p21-activated kinase-mediated signaling pathways. Moreover, when the plasmid encoding kinase-inactive LIMK1 was transfected to block the activation of endogenous LIMK1, the neuronal differentiation of H19-7 cells was significantly suppressed. These findings suggest that LIMK1 activation and subsequent CREB phosphorylation are important in the neuronal differentiation of central nervous system hippocampal progenitor cells.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Med Sci, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Catholic University of Korea	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr	Yoon, Joo-Heon/E-5781-2016	Yoon, Joo-Heon/0000-0003-2404-7156				AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bayatti N, 2001, J NEUROCHEM, V78, P972, DOI 10.1046/j.1471-4159.2001.00464.x; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BEUREN AJ, 1964, AM J CARDIOL, V13, P471, DOI 10.1016/0002-9149(64)90154-7; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; EVES EM, 1994, BRAIN RES, V656, P396, DOI 10.1016/0006-8993(94)91484-2; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; Higuchi O, 1997, ONCOGENE, V14, P1819, DOI 10.1038/sj.onc.1201020; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Meng YH, 2002, NEURON, V35, P121, DOI 10.1016/S0896-6273(02)00758-4; MIZUNO K, 1994, ONCOGENE, V9, P1605; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Mori T, 1997, MOL BRAIN RES, V45, P247, DOI 10.1016/S0169-328X(96)00257-4; Morris CA, 2000, ANNU REV GENOM HUM G, V1, P461; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Parker D, 1996, MOL CELL BIOL, V16, P694; Prigent SA, 2000, METH MOL B, V124, P251; PROSCHEL C, 1996, NAT GENET, V13, P272; Radhakrishnan I, 1998, FEBS LETT, V430, P317, DOI 10.1016/S0014-5793(98)00680-2; Sarmiere PD, 2002, NEURON, V35, P3, DOI 10.1016/S0896-6273(02)00759-6; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; Sung JY, 2001, J NEUROCHEM, V78, P1044, DOI 10.1046/j.1471-4159.2001.00491.x; TASSABEHJI M, 2002, J BIOL CHEM, V277, P22093; TRAYNOR AE, 1984, DEV BRAIN RES, V14, P205; Volterra V, 1996, CORTEX, V32, P663, DOI 10.1016/S0010-9452(96)80037-2; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; WILLIAMS JC, 1961, CIRCULATION, V24, P1311, DOI 10.1161/01.CIR.24.6.1311; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yang EJ, 2004, J BIOL CHEM, V279, P1827, DOI 10.1074/jbc.M308722200; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053	60	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8903	8910		10.1074/jbc.M311913200	http://dx.doi.org/10.1074/jbc.M311913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14684741	hybrid			2022-12-27	WOS:000189265900048
J	Zheng, QL; Yin, GY; Yan, C; Cavet, M; Berk, BC				Zheng, QL; Yin, GY; Yan, C; Cavet, M; Berk, BC			14-3-3 beta binds to big mitogen-activated protein kinase 1 (BMK1/ERK5) and regulates BMK1 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ASK1 ACTIVATION; PROTEIN-KINASE; GROWTH-FACTOR; ERK5; EXPRESSION; DISSOCIATION; ERK5/BMK1	Big mitogen-activated kinase 1 (BMK1/ ERK5) is a member of the MAPK family activated by growth factors that mediates cell growth and survival. Previous data show that BMK1 can be activated by steady laminar flow and is atheroprotective by preventing endothelial cells from undergoing apoptosis. The primary structure of BMK1 is distinct from other MAPK members by virtue of a unique long C-tail, suggesting specific mechanisms of regulation. To characterize regulatory mechanisms for BMK1 function, we identified binding proteins by yeast two-hybrid analysis. Among these proteins, the scaffolding protein 14-3-3 was identified. BMK1 bound to 14-3-3beta in vitro and in vivo as demonstrated by glutathione S-transferase (GST)-14-3-3beta fusion protein pull-down assays and coimmunoprecipitation. Phosphorylation of BMK1 was most likely required for this interaction. GST-14-3-3beta pull-down assays using truncated constructs of BMK1 and site-directed BMK1 mutants demonstrated that the interaction requires serine 486 within the C terminus of BMK1. BMK1 bound to 14-3-3beta basally, and the interaction was greatly abrogated when BMK1 was activated. The interaction of 14-3-3beta and BMK1 inhibited kinase activities stimulated by constitutively active (CA)-MEK5 and epidermal growth factor. Mutation of serine 486 (BMK1-S486A) prevented the interaction with 14-3-3beta and enhanced BMK1 activity upon epidermal growth factor stimulation. These data demonstrate an inhibitory function for 14-3-3beta binding to BMK1 and show that serine 486 phosphorylation represents a novel regulatory mechanism for BMK1.	Univ Rochester, Sch Med & Dent, Aab Inst Biomed Sci, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Aab Inst Biomed Sci, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Sch Med & Dent, Aab Inst Biomed Sci, Cardiovasc Res Ctr, 601 Elmwood Ave,Box 679, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115; Yan, Chen/0000-0002-1397-6358				Cavet ME, 2003, J BIOL CHEM, V278, P18376, DOI 10.1074/jbc.M208475200; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PI X, 2004, IN PRESS CIRC RES; Regan CP, 2002, P NATL ACAD SCI USA, V99, P9248, DOI 10.1073/pnas.142293999; Sohn SJ, 2002, J BIOL CHEM, V277, P43344, DOI 10.1074/jbc.M207573200; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	21	18	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8787	8791		10.1074/jbc.M310212200	http://dx.doi.org/10.1074/jbc.M310212200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14679215	hybrid			2022-12-27	WOS:000189265900033
J	Fukunaga, R; Fukai, S; Ishitani, R; Nureki, O; Yokoyama, S				Fukunaga, R; Fukai, S; Ishitani, R; Nureki, O; Yokoyama, S			Crystal structures of the CP1 domain from Thermus thermophilus isoleucyl-tRNA synthetase and its complex with L-valine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; DIFFRACTION DATA; AMINO-ACIDS; AMINOACYLATION; ERRORS; SIEVE; DISCRIMINATION; THREONINE; SELECTION	Isoleucyl-tRNA synthetase (IleRS) links tRNA(Ile) with not only its cognate isoleucine but also the nearly cognate valine. The CP1 domain of IleRS deacylates, or edits, the mischarged Val-tRNA(Ile). We determined the crystal structures of the Thermus thermophilus IleRS CP1 domain alone, and in its complex with valine at 1.8- and 2.0-Angstrom resolutions, respectively. In the complex structure, the Asp(328) residue, which was shown to be critical for the editing reaction against Val-tRNA(Ile) by a previous mutational analysis, recognizes the valine NH3+ group. The valine side chain binding pocket is only large enough to accommodate valine, and the placement of an isoleucine model in this location revealed that the additional methylene group of isoleucine would clash with His(319). The H319A mutant of Escherichia coli IleRS reportedly deacylates the cognate Ile-tRNA(Ile) in addition to Val-tRNA(Ile), indicating that the valine-binding mode found in this study represents that in the Val-tRNA(Ile) editing reaction. Analyses of the Val-tRNA(Ile) editing activities of T. thermophilus IleRS mutants revealed the importance of Thr(228), Thr(229), Thr(230), and Asp(328), which are coordinated with water molecules in the present structure. The structural model for the Val-adenosine moiety of Val-tRNA(Ile) bound in the IleRS editing site revealed some interesting differences in the substrate binding and recognizing mechanisms between IleRS and T. thermophilus leucyl-tRNA synthetase. For example, the carbonyl oxygens of the amino acids are located opposite to each other, relative to the adenosine ribose ring, and are differently recognized.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol, PRESTO, Kawaguchi, Saitama 3320012, Japan; RIKEN Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN Harima Inst, Cellular Signaling Lab, Mikazuki, Hyogo 6795148, Japan	University of Tokyo; Japan Science & Technology Agency (JST); RIKEN; RIKEN	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015; Fukunaga, Ryuya/AAK-8609-2020; Fukai, Shuya/X-4838-2018	Yokoyama, Shigeyuki/0000-0003-3133-7338; Fukunaga, Ryuya/0000-0002-5814-8206; Fukai, Shuya/0000-0002-1241-1443				BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Bishop AC, 2002, P NATL ACAD SCI USA, V99, P585, DOI 10.1073/pnas.012611299; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cusack S, 2000, EMBO J, V19, P2351, DOI 10.1093/emboj/19.10.2351; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FREIST W, 1988, EUR J BIOCHEM, V173, P27, DOI 10.1111/j.1432-1033.1988.tb13962.x; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; GIEGE R, 1974, EUR J BIOCHEM, V45, P351, DOI 10.1111/j.1432-1033.1974.tb03560.x; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hendrickson TL, 2000, BIOCHEMISTRY-US, V39, P8180, DOI 10.1021/bi0004798; Hendrickson TL, 2002, MOL CELL, V9, P353, DOI 10.1016/S1097-2765(02)00449-5; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P28; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Lincecum TL, 2003, MOL CELL, V11, P951, DOI 10.1016/S1097-2765(03)00098-4; Nordin BE, 2002, J BIOL CHEM, V277, P20510, DOI 10.1074/jbc.M202023200; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pauling L., 1957, FESTSCHRIFT ARTHUR S, P597; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766	26	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8396	8402		10.1074/jbc.M312830200	http://dx.doi.org/10.1074/jbc.M312830200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672940	hybrid			2022-12-27	WOS:000189103300122
J	Nishiyama, Y; Bhatia, G; Bangale, Y; Planque, S; Mitsuda, Y; Taguchi, H; Karle, S; Paul, S				Nishiyama, Y; Bhatia, G; Bangale, Y; Planque, S; Mitsuda, Y; Taguchi, H; Karle, S; Paul, S			Toward selective covalent inactivation of pathogenic antibodies - A phosphonate diester analog of vasoactive intestinal peptide that inactivates catalytic autoantibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM ALBUMIN; SERINE PROTEASES; LIGHT-CHAIN; IRREVERSIBLE INHIBITORS; REACTIVITY; CLEAVAGE; DERIVATIVES; ESTERS; MICE; ACID	We report the selective inactivation of proteolytic antibodies (Abs) to an autoantigen, the neuropeptide vasoactive intestinal peptide (VIP), by a covalently reactive analog (CRA) of VIP containing an electrophilic phosphonate diester at the Lys(20) residue. The VIP-CRA was bound irreversibly by a monoclonal Ab that catalyzes the hydrolysis of VIP. The reaction with the VIP-CRA proceeded more rapidly than with a hapten CRA devoid of the VIP sequence. The covalent binding occurred preferentially at the light chain subunit of the Ab. Covalent VIP-CRA binding was inhibited by VIP devoid of the phosphonate diester group. These results indicate the importance of noncovalent VIP recognition in guiding Ab nucleophilic attack on the phosphonate group. Consistent with the covalent binding data, the VIP-CRA inhibited catalysis by the recombinant light chain of this Ab with potency greater than the hapten-CRA. Catalytic hydrolysis of VIP by a polyclonal VIPase autoantibody preparation that cleaves multiple peptide bonds located between residues 7 and 22 essentially was inhibited completely by the VIP-CRA, suggesting that the electrophilic phosphonate at Lys(20) enjoys sufficient conformational freedom to react covalently with Abs that cleave different peptide bonds in VIP. These results suggest a novel route to antigen-specific covalent targeting of pathogenic Abs.	Univ Texas, Houston Med Sch, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Nishiyama, Y (corresponding author), Univ Texas, Houston Med Sch, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, 6431 Fannin, Houston, TX 77030 USA.	Yasuhiro.Nishiyama@uth.tmc.edu; Sudhir.Paul@uth.tmc.edu			NIAID NIH HHS [AI31268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031268, R21AI031268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALETRAS A, 1995, INT J PEPT PROT RES, V45, P488; Bangale Y, 2003, FASEB J, V17, P628, DOI 10.1096/fj.02-0475com; Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gilles JGG, 2000, SEMIN THROMB HEMOST, V26, P151, DOI 10.1055/s-2000-9817; Hatiuchi K, 2003, IMMUNOL LETT, V86, P249, DOI 10.1016/S0165-2478(03)00030-0; KAARTINEN M, 1986, EUR J IMMUNOL, V16, P98, DOI 10.1002/eji.1830160119; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; MAGGI CA, 1995, PHYSIOL REV, V75, P277, DOI 10.1152/physrev.1995.75.2.277; Marangoni A.G., 2003, ENZYME KINETICS MODE; Matsuura K, 1996, BIOL CHEM, V377, P587, DOI 10.1515/bchm3.1996.377.9.587; MEANS GE, 1979, ARCH BIOCHEM BIOPHYS, V194, P526, DOI 10.1016/0003-9861(79)90647-7; MITCHELL T J, 1990, Peptide Research, V3, P277; Nishiyama Y, 2002, ARCH BIOCHEM BIOPHYS, V402, P281, DOI 10.1016/S0003-9861(02)00087-5; OLEKSYSZYN J, 1994, J MED CHEM, V37, P226, DOI 10.1021/jm00028a004; OLEKSYSZYN J, 1994, METHOD ENZYMOL, V244, P423; OLEKSYSZYN J, 1991, BIOCHEMISTRY-US, V30, P485, DOI 10.1021/bi00216a026; PAUL S, 1991, J BIOL CHEM, V266, P16128; Paul S, 2003, J BIOL CHEM, V278, P20429, DOI 10.1074/jbc.M300870200; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; Planque S, 2003, J BIOL CHEM, V278, P20436, DOI 10.1074/jbc.M301468200; PLANQUE S, 2004, J BIOL CHEM     0115; Rekvig OP, 2003, ARTHRITIS RHEUM-US, V48, P300, DOI 10.1002/art.10739; SAMPSON NS, 1991, BIOCHEMISTRY-US, V30, P2255, DOI 10.1021/bi00222a031; SCHWARTZ M, 1982, CLIN CHIM ACTA, V124, P213, DOI 10.1016/0009-8981(82)90389-8; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; SUN M, 1994, J BIOL CHEM, V269, P734; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; Tomer Y, 1997, CLIN IMMUNOL IMMUNOP, V82, P3, DOI 10.1006/clin.1996.4243; Vincent A, 2002, NAT REV IMMUNOL, V2, P797, DOI 10.1038/nri916; Voice JK, 2002, REGUL PEPTIDES, V109, P199, DOI 10.1016/S0167-0115(02)00182-9; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; Wellings DA, 1997, METHOD ENZYMOL, V289, P44	36	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7877	7883		10.1074/jbc.M310950200	http://dx.doi.org/10.1074/jbc.M310950200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14676184	hybrid			2022-12-27	WOS:000189103300064
J	Tremeau-Bravard, A; Riedl, T; Egly, JM; Dahmus, ME				Tremeau-Bravard, A; Riedl, T; Egly, JM; Dahmus, ME			Fate of RNA polymerase II stalled at a cisplatin lesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR COUPLING FACTOR; TERMINAL DOMAIN PHOSPHATASE; NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMER; TRANSCRIBED DNA STRAND; XERODERMA-PIGMENTOSUM; ELONGATION COMPLEXES; FACTOR CSB/ERCC6; THYMINE DIMER; TEMPLATE DNA	Elongating RNA polymerase II blocked by DNA damage in the transcribed DNA strand is thought to initiate the transcription-coupled repair process. The objective of this study is to better understand the sequence of events that occurs during repair from the time RNA polymerase II first encounters the lesion. This study establishes that an immobilized DNA template containing a unique cisplatin lesion can serve as an in vitro substrate for both transcription and DNA repair. RNA polymerase II is quantitatively stalled at the cisplatin lesion during transcription and can be released from the template, along with the nascent transcript, in an ATP-dependent manner. RNA polymerase II stalled at a lesion and containing a dephosphorylated repetitive carboxyl-terminal domain (CTD) appears to be more sensitive toward release. However, a dephosphorylated CTD can become readily phosphorylated in front of the lesion by CTD kinases in the presence of ATP. The observation that RNA polymerase II and transcript release occurs in a TFIIH-deficient repair extract but not in a reconstituted repair system demonstrates that disassembly of the elongation complex can occur independently of the repair process and vice versa. Indeed, the presence of RNA polymerase II at the lesion does not prevent dual incision from occurring. Finally, we also propose that the Cockayne's syndrome B protein factor, believed to be the mammalian transcription repair coupling factor, is neither involved in transcript release nor required for dual incision in the presence of lesion-stalled RNA polymerase II in vitro. More likely, it prevents RNA polymerase from backing up when it encounters the lesion. The ability to transcribe and repair the same damaged DNA molecule fixed on beads, along with the fact that the reaction conditions can be freely altered, provides a powerful tool to study the fate of RNA polymerase II blocked on the cisplatin lesion.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	University of California System; University of California Davis; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Dahmus, ME (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, 1 Shields Ave, Davis, CA 95616 USA.	medahmus@ucdavis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33300] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Araujo SJ, 2000, GENE DEV, V14, P349; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bradsher J, 2002, MOL CELL, V10, P819, DOI 10.1016/S1097-2765(02)00678-0; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Frit P, 2002, MOL CELL, V10, P1391, DOI 10.1016/S1097-2765(02)00732-3; GERARD M, 1991, J BIOL CHEM, V266, P20940; Hara R, 1999, J BIOL CHEM, V274, P24779, DOI 10.1074/jbc.274.35.24779; JOHNSON RT, 1985, J CELL SCI, V76, P115; Kalogeraki VS, 2003, J BIOL CHEM, V278, P19558, DOI 10.1074/jbc.M301060200; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; Liu MY, 1998, J BIOL CHEM, V273, P25541, DOI 10.1074/jbc.273.40.25541; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MAY A, 1993, J BIOL CHEM, V268, P1650; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Park JS, 2002, CELL, V109, P757, DOI 10.1016/S0092-8674(02)00769-9; REINES D, 1992, J BIOL CHEM, V267, P3795; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; Shivji MKK, 1999, METH MOL B, V113, P373; Svejstrup JQ, 2003, J CELL SCI, V116, P447, DOI 10.1242/jcs.00271; Svejstrup JQ, 2002, MOL CELL, V9, P1151, DOI 10.1016/S1097-2765(02)00553-1; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; TAKAYAMA K, 1995, CANCER RES, V55, P5656; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; Tornaletti S, 2003, J BIOL CHEM, V278, P35791, DOI 10.1074/jbc.M305394200; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; van den Boom V, 2002, BIOESSAYS, V24, P780, DOI 10.1002/bies.10150; Woudstra EC, 2002, NATURE, V415, P929, DOI 10.1038/415929a; ZHEN WP, 1993, CARCINOGENESIS, V14, P919, DOI 10.1093/carcin/14.5.919; Zorio DAR, 2001, CURR BIOL, V11, pR144, DOI 10.1016/S0960-9822(01)00063-X	41	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7751	7759		10.1074/jbc.M309853200	http://dx.doi.org/10.1074/jbc.M309853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14672951	hybrid			2022-12-27	WOS:000189103300048
J	Weernink, PAO; Meletiadis, K; Hommeltenberg, S; Hinz, M; Ishihara, H; Schmidt, M; Jakobs, KH				Weernink, PAO; Meletiadis, K; Hommeltenberg, S; Hinz, M; Ishihara, H; Schmidt, M; Jakobs, KH			Activation of type I phosphatidylinositol 4-phosphate 5-kinase isoforms by the Rho GTPases, RhoA, Rac1, and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D STIMULATION; ACTIN STRESS FIBERS; LIPID KINASE FAMILY; DIFFICILE TOXIN-B; PLASMA-MEMBRANE; PHOSPHATE KINASE; 3T3 FIBROBLASTS; 4,5-BISPHOSPHATE; RECEPTOR; BINDING	Type I phosphatidylinositol 4-phosphate 5-kinase (PIP5K) catalyzes the formation of the phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2), which is implicated in many cellular processes. The Rho GTPases, RhoA and Rac1, have been shown previously to activate PIP5K and to bind PIP5K. Three type I PIP5K isoforms ( Ialpha, Ibeta, and Igamma) have been identified; however, it is unclear whether these isoforms are differentially or even sequentially regulated by Rho GTPases. Here we show that RhoA and Rac1, as well as Cdc42, but not the Ras-like GTPases, RalA and Rap1A, markedly stimulate PIP2 synthesis by all three PIP5K isoforms expressed in human embryonic kidney 293 cells, both in vitro and in vivo. RhoA-stimulated PIP2 synthesis by the PIP5K isoforms was mediated by the RhoA effector, Rho-kinase. Stimulation of PIP5K isoforms by Rac1 and Cdc42 was apparently independent of and additive with RhoA- and Rho-kinase, as shown by studies with C3 transferase and Rho-kinase mutants. RhoA, and to a lesser extent Rac1, but not Cdc42, interacted in a nucleotide-independent form with all three PIP5K isoforms. Binding of PIP5K isoforms to GTP-bound, but not GDP-bound, RhoA could be displaced by Rho-kinase, suggesting a direct and constitutive PIP5K-Rho GTPase binding, which, however, does not trigger PIP5K activation. In summary, our findings indicate that synthesis of PIP2 by the three PIP5K isoforms is controlled by RhoA, acting via Rho-kinase, as well as Rac1 and Cdc42, implicating that regulation of PIP2 synthesis has a central position in signaling by these three Rho GTPases.	Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany; Tohoku Univ, Grad Sch Med, Div Mol Metab & Diabet, Sendai, Miyagi 9808575, Japan	University of Duisburg Essen; Tohoku University	Weernink, PAO (corresponding author), Univ Klinikum Essen, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.	paschal.oudeweernink@uni-essen.de						Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Blomquist A, 2000, BIOCHEM J, V352, P319, DOI 10.1042/0264-6021:3520319; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; CHILVERS ER, 1991, BIOCHEM J, V275, P373, DOI 10.1042/bj2750373; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Doughman RL, 2003, J BIOL CHEM, V278, P23036, DOI 10.1074/jbc.M211397200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gasteier JE, 2003, J BIOL CHEM, V278, P38902, DOI 10.1074/jbc.M306229200; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Itoh T, 2000, J BIOL CHEM, V275, P19389, DOI 10.1074/jbc.M000426200; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Ma L, 1998, J CELL BIOL, V140, P1125; Malecz N, 2000, CURR BIOL, V10, P1383, DOI 10.1016/S0960-9822(00)00778-8; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Padron D, 2003, J CELL BIOL, V162, P693, DOI 10.1083/jcb.200302051; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schmidt M, 1996, EUR J BIOCHEM, V240, P707, DOI 10.1111/j.1432-1033.1996.0707h.x; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; Schmidt M, 1999, J BIOL CHEM, V274, P14648, DOI 10.1074/jbc.274.21.14648; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; van Hennik PB, 2003, J BIOL CHEM, V278, P39166, DOI 10.1074/jbc.M307001200; van Horck FPG, 2002, CURR BIOL, V12, P241, DOI 10.1016/S0960-9822(01)00660-1; Weernink PAO, 2000, EUR J BIOCHEM, V267, P5237, DOI 10.1046/j.1432-1327.2000.01599.x; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Wenk MR, 2001, NEURON, V32, P79, DOI 10.1016/S0896-6273(01)00456-1; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yamazaki M, 2002, J BIOL CHEM, V277, P17226, DOI 10.1074/jbc.M109795200; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	64	132	137	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7840	7849		10.1074/jbc.M312737200	http://dx.doi.org/10.1074/jbc.M312737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14681219	hybrid			2022-12-27	WOS:000189103300060
J	Dur n, RV; Herv s, M; De la Rosa, MA; Navarro, JA				Dur n, RV; Herv s, M; De la Rosa, MA; Navarro, JA			The efficient functioning of photosynthesis and respiration in Synechocystis sp PCC 6803 strictly requires the presence of either cytochrome c(6) or plastocyanin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLASH KINETIC-ANALYSIS; PHOTOSYSTEM-I; ELECTRON-TRANSFER; CYANOBACTERIUM; C(6); MUTAGENESIS; REDUCTION; PROTEINS; FEATURES; MEMBRANE	In cyanobacteria, cytochrome c(6) and plastocyanin are able to replace each other as redox carriers in the photosynthetic and respiratory electron transport chains with the synthesis of one or another protein being regulated by the copper concentration in the culture medium. However, the presence of a third unidentified electron carrier has been suggested. To address this point, we have constructed two deletion mutants of the cyanobacterium Synechocystis sp. PCC 6803, each variant lacking either the petE or petJ gene, which respectively codes for the copper or heme protein. The photoautotrophic and heterotrophic growth rate of the two mutants in copper-free and copper-supplemented medium as well as their photosystem I reduction kinetics in vivo were compared with those of wild-type cells. The two mutant strains grow at equivalent rates and show similar in vivo photosystem I reduction kinetics as wildtype cells when cultured in media that allow the expression of just one of the two electron donor proteins, but their ability to grow and reduce photosystem I is much lower when neither cytochrome c(6) nor plastocyanin is expressed. These findings indicate that the normal functioning of the cyanobacterial photosynthetic and respiratory chains obligatorily depends on the presence of either cytochrome c(6) or plastocyanin.	Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain; CSIC, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC)	De la Rosa, MA (corresponding author), Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Americo Vespucio S-N, Seville 41092, Spain.	marosa@us.es	Duran, Raul V./E-4764-2011; Hervas, Manuel/K-9279-2014; De la Rosa, Miguel/B-2545-2014; navarro, jose a/B-6354-2015	Duran, Raul V./0000-0002-2249-9215; Hervas, Manuel/0000-0003-4523-8891; De la Rosa, Miguel/0000-0003-1187-5737; navarro, jose a/0000-0002-0536-6074				ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Ardelean I, 2002, FEMS MICROBIOL LETT, V213, P113, DOI 10.1016/S0378-1097(02)00801-7; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Baymann F, 2001, BIOCHEMISTRY-US, V40, P10570, DOI 10.1021/bi010194a; BINDER A, 1984, BIOCHIM BIOPHYS ACTA, V765, P241, DOI 10.1016/0005-2728(84)90161-0; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; De la Cerda B, 1999, J BIOL CHEM, V274, P13292, DOI 10.1074/jbc.274.19.13292; De la Rosa MA, 2002, BIOELECTROCHEMISTRY, V55, P41, DOI 10.1016/S1567-5394(01)00136-0; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; HERVAS M, 1994, BBA-BIOENERGETICS, V1184, P235, DOI 10.1016/0005-2728(94)90228-3; Hervas M, 2003, ACCOUNTS CHEM RES, V36, P798, DOI 10.1021/ar020084b; Hervas M, 2003, J BIOL CHEM, V278, P8179, DOI 10.1074/jbc.M211913200; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; HERVAS M, 1993, FEBS LETT, V319, P257, DOI 10.1016/0014-5793(93)80558-C; Kaneko T, 1996, DNA Res, V3, P109; Malakhov MP, 1999, FEBS LETT, V444, P281, DOI 10.1016/S0014-5793(99)00074-5; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Metzger SU, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P823; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; Peschek, 1999, PHOTOTROPHIC PROKARY, P201, DOI DOI 10.1007/978-1-4615-4827-0_24; Pils D, 1997, FEMS MICROBIOL LETT, V152, P83, DOI 10.1111/j.1574-6968.1997.tb10412.x; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmetterer G, 1994, MOL BIOL CYANOBACTER, P409, DOI DOI 10.1007/0-306-48205-3_13; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; ZHANG L, 1992, J BIOL CHEM, V267, P19054; ZHANG LL, 1994, J BIOL CHEM, V269, P5036	29	58	69	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7229	7233		10.1074/jbc.M311565200	http://dx.doi.org/10.1074/jbc.M311565200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660567	hybrid, Green Published			2022-12-27	WOS:000188969200123
J	Han, DC; Lee, MY; Shin, KD; Jeon, SB; Kim, JM; Son, KH; Kim, HC; Kim, HM; Kwon, BM				Han, DC; Lee, MY; Shin, KD; Jeon, SB; Kim, JM; Son, KH; Kim, HC; Kim, HM; Kwon, BM			2 '-benzoyloxycinnamaldehyde induces apoptosis in human carcinoma via reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; OXIDATIVE STRESS; GENE-EXPRESSION; CANCER; KINASE; CINNAMALDEHYDES; INHIBITION; RADIATION; MECHANISM	2'-Hydroxycinnamaldehyde (HCA) has been shown to have inhibitory effects on farnesyl protein transferase in vitro, angiogenesis, and tumor cell growth. However, mechanism for these inhibitions remains unknown. As a derivative of HCA, BCA (2'-benzoyl-oxycinnamaldehyde) was synthesized by replacing hydroxyl group with benzoyl-oxyl group. When p53-mutated cancer cell lines (MDA-MB-231 breast cancer cell and SW620 colon cancer cell) were treated with 10 muM HCA or BCA, it induced growth arrest and apoptosis of tumor cells. Markers of apoptosis such as degradations of chromosomal DNA and poly(ADP-ribose) polymerase and activation of caspase-3 were detected after HCA or BCA treatment. BCA-induced apoptosis was blocked by pretreatment of cells with anti-oxidants, glutathione, or N-acetyl-cysteine. In addition, BCA-induced activation of caspase-3 and degradation of poly(ADP-ribose) polymerase were abolished by pretreatment of cells with the anti-oxidants. These results suggest that reactive oxygen species are major regulator of BCA-induced apoptosis. HCA or BCA-induced accumulation of reactive oxygen species was detected by using DCF-DA, an intracellular probe of oxidative stress. Furthermore, when BCA (100 mg/kg) was administrated intraperitoneally or orally into a nude mouse, it inhibited >88 or 41% of tumor growth, respectively, without any detectable weight change. These results suggest that BCA is a good drug candidate for cancer therapy.	Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kwon, BM (corresponding author), Korea Res Inst Biosci & Biotechnol, 52 Uendong Yoosunggu, Taejon 305600, South Korea.	kwonbm@kribb.re.kr		Kim, Jung Min/0000-0001-6319-0217				ARMSTRONG DK, 1994, CANCER RES, V54, P5280; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; DYPBUKT JM, 1994, J BIOL CHEM, V269, P30553; ENNIS BW, 1991, CANCER INVEST, V9, P553, DOI 10.3109/07357909109018953; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Henkels KM, 1999, CANCER RES, V59, P3077; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jeong HW, 2000, BIOORG MED CHEM LETT, V10, P1819, DOI 10.1016/S0960-894X(00)00357-7; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Koh WS, 1998, INT J IMMUNOPHARMACO, V20, P643, DOI 10.1016/S0192-0561(98)00064-2; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Kwon BM, 1996, PLANTA MED, V62, P183, DOI 10.1055/s-2006-957851; Kwon BM, 1997, BIOORG MED CHEM LETT, V7, P2473, DOI 10.1016/S0960-894X(97)10008-7; Lee CW, 1999, PLANTA MED, V65, P263, DOI 10.1055/s-2006-960772; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rao GN, 1996, ONCOGENE, V13, P713; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	38	83	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6911	6920		10.1074/jbc.M309708200	http://dx.doi.org/10.1074/jbc.M309708200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660655	hybrid			2022-12-27	WOS:000188969200086
J	Ohashi, T; Erickson, HP				Ohashi, T; Erickson, HP			The disulfide bonding pattern in ficolin multimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-D; MANNOSE-BINDING PROTEIN; HELICAL COILED-COIL; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; INNATE IMMUNITY; FIBRINOGEN-LIKE; HAKATA ANTIGEN	Ficolin is a plasma lectin, consisting of a short N-terminal multimerization domain, a middle collagen domain, and a C-terminal fibrinogen-like domain. The collagen domains assemble the subunits into trimers, and the N-terminal domain assembles four trimers into 12-mers. Two cysteine residues in the N-terminal domain are thought to mediate multimerization by disulfide bonding. We have generated three mutants of ficolin a in which the N-terminal cysteines were substituted by serines (Cys(4), Cys(24) , and Cys(4)/Cys(24)). The N-terminal cysteine mutants were produced in a mammalian cell expression system, purified by affinity chromatography, and analyzed under nondenaturing conditions to resolve the multimer structure of the native protein and under denaturing conditions to resolve the disulfide-linked structure. Glycerol gradient sedimentation and electron microscopy in nondenaturing conditions showed that plasma and recombinant wild-type protein formed 12-mers. The Cys(4) mutant also formed 12-mers, but CyS24 and CyS4/CyS24 mutants formed only trimers. This means that protein interfaces containing Cys(4) are stable as noncovalent protein-protein interactions and do not require disulfides, whereas those containing Cys(24)-Cys(24) require the disulfides for stability. Proteins were also analyzed by nonreducing SDS-PAGE to show the covalent structure under denaturing conditions. Wild-type ficolin was covalently linked into 12-mers, whereas elimination of either Cys(4) or Cys(24) gave dimers and monomers. We present a model in which symmetric Cys(24)-Cys(24) disulfide bonds between trimers are the basis for multimerization. The model may also be relevant to collectin multimers.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Erickson, HP (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	H.Erickson@cellbio.duke.edu			NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NCI NIH HHS [CA47056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUKHIL I, 1993, J BIOL CHEM, V268, P2542; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Elhalwagi BM, 1997, BIOCHEMISTRY-US, V36, P7018, DOI 10.1021/bi970100q; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Endo Y, 1996, GENOMICS, V36, P515, DOI 10.1006/geno.1996.0497; ERICKSON H P, 1974, Journal of Supramolecular Structure, V2, P393, DOI 10.1002/jss.400020228; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; Fujimori Y, 1998, BIOCHEM BIOPH RES CO, V244, P796, DOI 10.1006/bbrc.1998.8344; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; HAAS C, 1991, EUR J BIOCHEM, V197, P799; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Harumiya S, 1996, J BIOCHEM-TOKYO, V120, P745; HOLMSKOV U, 1995, BIOCHEM J, V305, P889, DOI 10.1042/bj3050889; Holmskov UL, 2000, APMIS, V108, P7; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; Kairies N, 2001, P NATL ACAD SCI USA, V98, P13519, DOI 10.1073/pnas.201523798; Kakinuma Y, 2003, IMMUNOGENETICS, V55, P29, DOI 10.1007/s00251-003-0552-2; Kenjo A, 2001, J BIOL CHEM, V276, P19959, DOI 10.1074/jbc.M011723200; KNOBEL HR, 1975, EUR J IMMUNOL, V5, P78, DOI 10.1002/eji.1830050119; Lu CL, 2000, J BACTERIOL, V182, P164, DOI 10.1128/JB.182.1.164-170.2000; Lu J, 1996, IMMUNOLOGY, V89, P289, DOI 10.1046/j.1365-2567.1996.d01-732.x; LU J, 1990, J IMMUNOL, V144, P2287; Lu JH, 1996, BIOCHEM J, V313, P473, DOI 10.1042/bj3130473; Lu JH, 2002, BBA-GEN SUBJECTS, V1572, P387, DOI 10.1016/S0304-4165(02)00320-3; LU JH, 1993, EUR J BIOCHEM, V215, P793, DOI 10.1111/j.1432-1033.1993.tb18094.x; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; Ohashi T, 1998, ARCH BIOCHEM BIOPHYS, V360, P223, DOI 10.1006/abbi.1998.0957; Olsen DR, 2001, J BIOL CHEM, V276, P24038, DOI 10.1074/jbc.M101613200; Rothmann AB, 1997, EUR J BIOCHEM, V243, P630, DOI 10.1111/j.1432-1033.1997.t01-1-00630.x; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Storgaard P, 1996, SCAND J IMMUNOL, V43, P289, DOI 10.1046/j.1365-3083.1996.d01-39.x; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; Teh C, 2000, IMMUNOLOGY, V101, P225, DOI 10.1046/j.1365-2567.2000.00099.x; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	47	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6534	6539		10.1074/jbc.M310555200	http://dx.doi.org/10.1074/jbc.M310555200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660572	hybrid			2022-12-27	WOS:000188969200040
J	Robbins, JB; Murphy, MC; White, BA; Mackie, RI; Ha, T; Cann, IKO				Robbins, JB; Murphy, MC; White, BA; Mackie, RI; Ha, T; Cann, IKO			Functional analysis of multiple single-stranded DNA-binding proteins from Methanosarcina acetivorans and their effects on DNA synthesis by DNA polymerase BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEON SULFOLOBUS-SOLFATARICUS; THERMOAUTOTROPHICUM DELTA-H; RESONANCE ENERGY-TRANSFER; REPLICATION FACTOR-C; ESCHERICHIA-COLI; PYROCOCCUS-FURIOSUS; CLAMP-LOADER; IDENTIFICATION; SSB; GENOME	Single-stranded DNA-binding proteins and their functional homologs, replication protein X are essential components of cellular DNA replication, repair and recombination. We describe here the isolation and characterization of multiple replication protein A homologs, RPA1, RPA2, and RPA3, from the archaeon Methanosarcina acetivorans. RPA1 comprises four single-stranded DNA-binding domains, while RPA2 and RPA3 are each composed of two such domains and a zinc finger domain. Gel filtration analysis suggested that RPA1 exists as homotetramers and homodimers in solution, while RPA2 and RPA3 form only homodimers. Unlike the multiple RPA proteins found in other Archaea and eukaryotes, each of the M. acetivorans RPAs can act as a distinct single-stranded DNA-binding protein. Fluorescence resonance energy transfer and fluorescence polarization anisotropy studies revealed that the M. acetivorans RPAs bind to as few as 10 single-stranded DNA bases. However, more stable binding is achieved with single-stranded DNA of 18-23 bases, and for such substrates the estimated K-d was 3.82 +/- 0.28 nm, 173.6 +/- 105.17 nm, and 5.92 +/- 0.23 nm, for RPA1, RPA2, and RPA3, respectively. The architectures of the M. acetivorans RPAs are different from those of hitherto reported homologs. Thus, these proteins may represent novel forms of replication protein A. Most importantly, our results show that the three RPAs and their combinations highly stimulate the primer extension capacity of M. acetivorans DNA polymerase BI. Although bacterial SSB and eukaryotic RPA have been shown to stimulate DNA synthesis by their cognate DNA polymerases, our findings provide the first in vitro biochemical evidence for the conservation of this property in an archaeon.	Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Cann, IKO (corresponding author), Univ Illinois, Dept Anim Sci, 1207 W Gregory Dr, Urbana, IL 61801 USA.	icann@uiuc.edu	Ha, Taekjip/B-9506-2009	Ha, Taekjip/0000-0003-2195-6258	NIGMS NIH HHS [R01 GM065367, 5T32GM08276, GM65367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008276, R01GM065367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar-Ziv R, 2001, P NATL ACAD SCI USA, V98, P9068, DOI 10.1073/pnas.151242898; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1999, GENETICS, V152, P1249; Chedin F, 1998, TRENDS BIOCHEM SCI, V23, P273, DOI 10.1016/S0968-0004(98)01243-2; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; De Felice M, 1999, J MOL BIOL, V291, P47, DOI 10.1006/jmbi.1999.2939; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; FAY PJ, 1981, J BIOL CHEM, V256, P976; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Haseltine CA, 2002, MOL MICROBIOL, V43, P1505, DOI 10.1046/j.1365-2958.2002.02807.x; Ishino Y, 1998, GENES GENET SYST, V73, P323, DOI 10.1266/ggs.73.323; Karsten R., 1997, BIF FUTURA, V12, P20; Kelly TJ, 1998, P NATL ACAD SCI USA, V95, P14634, DOI 10.1073/pnas.95.25.14634; Kelman Z, 2000, J BIOL CHEM, V275, P7327, DOI 10.1074/jbc.275.10.7327; Kelman Z, 1999, J BIOL CHEM, V274, P28751, DOI 10.1074/jbc.274.40.28751; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Komori K, 2001, J BIOL CHEM, V276, P25654, DOI 10.1074/jbc.M102423200; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P11611, DOI 10.1021/bi020361m; Krejci L, 2002, STRUCTURE, V10, P601, DOI 10.1016/S0969-2126(02)00765-7; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lilley DMJ, 2000, CURR OPIN CHEM BIOL, V4, P507, DOI 10.1016/S1367-5931(00)00124-1; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MACKIE RI, 1992, ENCY MICROBIOLOGY, V3, P97; Perler FB, 1996, ADV PROTEIN CHEM, V48, P377; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P5088; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhou ZHS, 1999, BIOCHEMISTRY-US, V38, P15915, DOI 10.1021/bi992062b	35	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6315	6326		10.1074/jbc.M304491200	http://dx.doi.org/10.1074/jbc.M304491200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14676214	hybrid			2022-12-27	WOS:000188969200016
J	Sayasith, K; Bouchard, N; Sawadogo, M; Lussier, JG; Sirois, J				Sayasith, K; Bouchard, N; Sawadogo, M; Lussier, JG; Sirois, J			Molecular characterization and role of bovine upstream stimulatory factor 1 and 2 in the regulation of the prostaglandin G/H synthase-2 promoter in granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; HUMAN CHORIONIC-GONADOTROPIN; MESSENGER-RIBONUCLEIC-ACID; ELEMENT-BINDING PROTEIN; ENDOPEROXIDE SYNTHASE-2; PREOVULATORY FOLLICLES; OVARIAN-FOLLICLES; GENE-EXPRESSION; DNA-BINDING; INDUCTION	The transcriptional activation of the prostaglandin G/H synthase-2 (PGHS-2) gene in granulosa cells is required for ovulation. To directly study the ability of upstream stimulatory factor 1 (USF1) and USF2 to trans-activate the bovine PGHS-2 promoter in granulosa cells, USF1 or USF2 expression vectors were cotransfected with the PGHS-2/luciferase (LUC) chimeric construct, -149/-2PGHS-2.LUC. Results revealed that overexpression of USF1 or USF2 caused a marked and significant increase in basal and forskolin-inducible promoter activities (p < 0.05), and these effects were dependent on the presence of a consensus E-box cis-element within the promoter fragment. Co-transfections with different N- and C-terminal truncated USF mutants led to significant reductions in promoter activation, as compared with full-length constructs (p < 0.05), thus allowing identification of putative bovine USF functional domains. Overexpression of a USF2 truncated mutant lacking the first 220 residues (U2Delta1-220) acted as a dominant negative mutant and blocked endogenous and USF-stimulated PGHS-2 promoter activation. Interestingly, transfections with U2Delta1-220 blocked the forskolin-dependent induction of PGHS-2 mRNA in granulosa cells, whereas transfections with full-length USF2 increased PGHS-2 transcript levels. Immunoblot analyses confirmed overexpression of full-length and truncated USF proteins, and electrophoretic mobility shift assays (EMSAs) and supershift EMSAs established that the observed effects were dependent on specific interactions between USF proteins and the consensus E-box cis-element. Stimulation of cells with forskolin increased, whereas treatment of extracts with phosphatase decreased USF binding activities to the E-box. Thus, this study presents for the first time direct evidence for a role of USF proteins in the regulation of the PGHS-2 promoter in preovulatory granulosa cells.	Univ Montreal, Fac Med Vet, CRRA, St Hyacinthe, PQ J2S 7C6, Canada; Univ Montreal, Fac Med Vet, Dept Biomed Vet, St Hyacinthe, PQ J2S 7C6, Canada; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Universite de Montreal; Universite de Montreal; University of Texas System; UTMD Anderson Cancer Center	Sirois, J (corresponding author), Univ Montreal, Fac Med Vet, CRRA, CP 5000, St Hyacinthe, PQ J2S 7C6, Canada.	jean.sirois@umontreal.ca						ARMSTRONG DT, 1981, J REPROD FERTIL, V62, P283; Ascoli M, 2002, ENDOCR REV, V23, P141, DOI 10.1210/er.23.2.141; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Boerboom D, 1998, ENDOCRINOLOGY, V139, P1662, DOI 10.1210/en.139.4.1662; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breen GAM, 1997, J BIOL CHEM, V272, P10538; Breen GAM, 2000, BBA-GENE STRUCT EXPR, V1517, P119, DOI 10.1016/S0167-4781(00)00269-4; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Chen WG, 2003, J NEUROSCI, V23, P2572; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; Cheung E, 1999, BIOCHEM J, V344, P145, DOI 10.1042/0264-6021:3440145; Conti M, 2002, BIOL REPROD, V67, P1653, DOI 10.1095/biolreprod.102.004952; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; ESPEY LL, 1980, BIOL REPROD, V22, P73, DOI 10.1095/biolreprod22.1.73; Filion F, 2001, J BIOL CHEM, V276, P34323, DOI 10.1074/jbc.M103709200; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Galibert MD, 1997, J IMMUNOL, V159, P6176; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; Goueli BS, 2003, ONCOGENE, V22, P8042, DOI 10.1038/sj.onc.1206847; Gourdon L, 1997, Genes Funct, V1, P87; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Han SY, 2001, FEBS LETT, V505, P57, DOI 10.1016/S0014-5793(01)02777-6; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Jiang B, 2003, MOL CELL BIOL, V23, P6117, DOI 10.1128/MCB.23.17.6117-6128.2003; Kingsley-Kallesen ML, 1999, J BIOL CHEM, V274, P34020, DOI 10.1074/jbc.274.48.34020; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; Lajoie S, 2002, J HISTOCHEM CYTOCHEM, V50, P923, DOI 10.1177/002215540205000706; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu JM, 1999, J BIOL CHEM, V274, P35037, DOI 10.1074/jbc.274.49.35037; Liu JM, 2001, BIOL REPROD, V64, P983, DOI 10.1095/biolreprod64.3.983; Liu Y, 2003, J BIOL CHEM, V278, P20603, DOI 10.1074/jbc.M212093200; Luo X, 1996, MOL CELL BIOL, V16, P1367; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; Mikuni M, 1998, BIOL REPROD, V59, P1077, DOI 10.1095/biolreprod59.5.1077; Moore ML, 2003, J BIOL CHEM, V278, P17263, DOI 10.1074/jbc.M210486200; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURDOCH WJ, 1993, PROSTAG OTH LIPID M, V46, P85, DOI 10.1016/0090-6980(93)90037-8; PRIDDY AR, 1993, PROSTAG LEUKOTR ESS, V49, P827, DOI 10.1016/0952-3278(93)90204-A; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Saito T, 2003, INT J MOL MED, V12, P161; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; SIROIS J, 1992, J BIOL CHEM, V267, P6382; Sirois J, 2000, SERONO SYMP, P208; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Szentirmay MN, 2003, J BIOL CHEM, V278, P37231, DOI 10.1074/jbc.M305791200; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Tsai SJ, 1996, ENDOCRINOLOGY, V137, P3348, DOI 10.1210/en.137.8.3348; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WONG WYL, 1989, MOL ENDOCRINOL, V3, P1714, DOI 10.1210/mend-3-11-1714; Wu YL, 2002, BIOL REPROD, V66, P1505, DOI 10.1095/biolreprod66.5.1505; Xiao QX, 2002, AM J PHYSIOL-HEART C, V283, pH213, DOI 10.1152/ajpheart.01085.2001; Yamada K, 2001, BIOL REPROD, V64, P1315, DOI 10.1095/biolreprod64.5.1315	61	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6327	6336		10.1074/jbc.M311222200	http://dx.doi.org/10.1074/jbc.M311222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660559	hybrid			2022-12-27	WOS:000188969200017
J	Jacob, R; Heine, M; Eikemeyer, J; Frerker, N; Zimmer, KP; Rescher, U; Gerke, V; Naim, HY				Jacob, R; Heine, M; Eikemeyer, J; Frerker, N; Zimmer, KP; Rescher, U; Gerke, V; Naim, HY			Annexin II is required for apical transport in polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; LACTASE-PHLORHIZIN HYDROLASE; GPI-ANCHORED PROTEINS; MDCK CELLS; INTRACELLULAR-TRANSPORT; CYTOPLASMIC DOMAIN; EARLY ENDOSOMES; SORTING SIGNAL; GOLGI NETWORK; MEMBRANE	The sorting of apical proteins comprises an initial recognition step in the trans Golgi network and a final partitioning of the apical pool of proteins into at least two different types of vesicular carriers. One criteria of these carriers is the association or non-association of the protein content with lipid rafts. We have previously characterized a population containing the raft-associated sucrase-isomaltase-carrying vesicles (SAVs) and another one, the non-raft-associated lactase-phlorizin hydrolase-carrrying vesicles (LAVs) that are targeted separately to the apical membrane. Here, we demonstrate biochemically and by employing confocal laser microscopy that the annexin II-S100A10 complex is a component of SAVs and is absent from LAVs. The unequivocal role of annexin II in the apical targeting of SI is clearly demonstrated when down-regulation of this protein by annexin II-specific small interfering RNA drastically decreases the apical delivery of SI in the epithelial cell line Madin-Darby canine kidney. The annexin II-S100A10 complex plays therefore a crucial role in routing SAVs to the apical membrane of epithelial cells.	Univ Marburg, Dept Cell Biol & Cell Pathol, D-35033 Marburg, Germany; Hannover Sch Vet Med, Dept Physiol Chem, Hannover, Germany; Univ Childrens Hosp Muenster, Munster, Germany; Univ Munster, Inst Med Biochem, Munster, Germany	Philipps University Marburg; University of Veterinary Medicine Hannover, Foundation; University of Munster; University of Munster	Jacob, R (corresponding author), Univ Marburg, Dept Cell Biol & Cell Pathol, Robert Koch Str 6, D-35033 Marburg, Germany.	jacob@staff.uni-marburg.de	Zimmer, Klaus-Peter/AAY-9351-2020; Heine, Martin/C-6285-2011; Jacob, Ralf/B-8163-2011; Zimmer, Klaus-Peter/AAY-9261-2020					BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GERKE V, 1985, J BIOL CHEM, V260, P1688; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 2003, CURR BIOL, V13, P607, DOI 10.1016/S0960-9822(03)00188-X; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; JACOB R, 1994, J BIOL CHEM, V269, P2712; Jost M, 1997, J CELL SCI, V110, P221; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; MAIURI L, 1991, GASTROENTEROLOGY, V100, P359, DOI 10.1016/0016-5085(91)90203-W; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; NEUHOFF V, 1990, ELECTROPHORESIS, V11, P101, DOI 10.1002/elps.1150110202; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Van de Graaf SFJ, 2003, EMBO J, V22, P1478, DOI 10.1093/emboj/cdg162; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596; Zobiack N, 2003, MOL BIOL CELL, V14, P4896, DOI 10.1091/mbc.E03-06-0387	39	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	2004	279	5					3680	3684		10.1074/jbc.C300503200	http://dx.doi.org/10.1074/jbc.C300503200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	766MF	14670963	hybrid			2022-12-27	WOS:000188379600067
J	Ahmad, N; Gabius, HJ; Andre, S; Kaltner, H; Sabesan, S; Roy, R; Liu, BC; Macaluso, F; Brewer, CF				Ahmad, N; Gabius, HJ; Andre, S; Kaltner, H; Sabesan, S; Roy, R; Liu, BC; Macaluso, F; Brewer, CF			Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE-BINDING PROTEIN; RECOMBINANT POLYPEPTIDE; NEGATIVE REGULATION; CELL-GROWTH; LECTIN; EXPRESSION; OLIGOSACCHARIDES; APOPTOSIS; FAMILY; IDENTIFICATION	Galectin-3 is unique among the galectin family of animal lectins in its biological activities and structure. Most members of the galectin family including galectin-1 possess apoptotic activities, whereas galectin-3 possesses anti-apoptotic activity. Galectin-3 is also the only chimera type galectin and consists of a nonlectin N-terminal domain and a C-terminal carbohydrate-binding domain. Recent sedimentation equilibrium and velocity studies show that murine galectin-3 is a monomer in the absence and presence of LacNAc, a monovalent sugar. However, quantitative precipitation studies in the present report indicate that galectin-3 precipitates as a pentamer with a series of divalent pentasaccharides with terminal LacNAc residues. Furthermore, the kinetics of precipitation are fast, on the order of seconds. This indicates that although the majority of galectin-3 in solution is a monomer, a rapid equilibrium exists between the monomer and a small percentage of pentamer. The latter, in turn, precipitates with the divalent oligosaccharides, resulting in rapid conversion of monomer to pentamer by mass action equilibria. Mixed quantitative precipitation experiments and electron microscopy suggest that galectin-3 forms heterogenous, disorganized cross-linking complexes with the multivalent carbohydrates. This contrasts with galectin-1 and many plant lectins that form homogeneous, organized cross-linked complexes. The results are discussed in terms of the biological properties of galectin-3.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol & Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Univ Munich, Inst Physiol Chem, D-80539 Munich, Germany; DuPont Co Inc, Wilmington, DE 19880 USA; Univ Ottawa, Dept Chem, Ctr Res Biopharmaceut, Ottawa, ON K1N 6N5, Canada	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Munich; DuPont; University of Ottawa	Brewer, CF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol & Microbiol & Immunol, Bronx, NY 10461 USA.	brewer@aecom.yu.edu		Kaltner, Herbert/0000-0003-4680-8411; Andre, Sabine/0000-0003-0850-0432; Gabius, Hans-Joachim/0000-0003-3467-3900	NCI NIH HHS [CA-16054, P30 CA-13330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330, R01CA016054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRWAL N, 1993, J BIOL CHEM, V268, P14932; Ahmad N, 2002, CAN J CHEM, V80, P1096, DOI 10.1139/V02-162; BAO Q, 1995, J CELL SCI, V108, P2791; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BHATTACHARYYA L, 1990, BIOCHEMISTRY-US, V29, P7523, DOI 10.1021/bi00484a022; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; Bresalier RS, 1998, GASTROENTEROLOGY, V115, P287, DOI 10.1016/S0016-5085(98)70195-7; Camby I, 2001, BRAIN PATHOL, V11, P12; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; FRIGERI LG, 1993, BIOCHEMISTRY-US, V32, P7644, DOI 10.1021/bi00081a007; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GREEN ED, 1988, J BIOL CHEM, V263, P18253; GUPTA D, 1994, BIOCHEMISTRY-US, V33, P7495, DOI 10.1021/bi00190a001; GUPTA D, 1994, BIOCHEMISTRY-US, V33, P5526, DOI 10.1021/bi00184a022; GUPTA D, 1994, CURR TOPICS PEPTIDE, V1, P177; HSU DK, 1992, J BIOL CHEM, V267, P14167; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KNIBBS RN, 1993, J BIOL CHEM, V268, P14940; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Kuklinski S, 1998, J NEUROCHEM, V70, P814; Kuwabara I, 1996, J IMMUNOL, V156, P3939; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; LAING JG, 1988, BIOCHEMISTRY-US, V27, P5329, DOI 10.1021/bi00414a057; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; Lobsanov YD, 1997, TRENDS GLYCOSCI GLYC, V9, P145, DOI 10.4052/tigg.9.145; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MEHUL B, 1994, J BIOL CHEM, V269, P18250; MORRIS S, 2004, IN PRESS GLYCOBIOLOG; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; NILSSON B, 1979, J BIOL CHEM, V254, P4545; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; Pace KE, 1999, J IMMUNOL, V163, P3801; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; Parikh I, 1974, Methods Enzymol, V34, P77; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; SABESAN S, 1992, J AM CHEM SOC, V114, P8363, DOI 10.1021/ja00048a004; SAHA SK, 1994, CARBOHYD RES, V254, P157; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; SPIRO RG, 1960, J BIOL CHEM, V235, P2860; Vespa GNR, 1999, J IMMUNOL, V162, P799; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c	52	405	415	2	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					10841	10847		10.1074/jbc.M312834200	http://dx.doi.org/10.1074/jbc.M312834200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14672941	hybrid			2022-12-27	WOS:000220157600004
J	Balakrishnan, L; Venter, H; Shilling, RA; van Veen, HW				Balakrishnan, L; Venter, H; Shilling, RA; van Veen, HW			Reversible transport by the ATP-binding cassette multidrug export pump LmrA - ATP synthesis at the expense of downhill ethidium uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; TERTIARY STRUCTURE CHANGES; REFLECTION INFRARED-SPECTROSCOPY; DISULFIDE CROSS-LINKING; NUCLEOTIDE-BINDING; CONFORMATIONAL-CHANGES; ABC TRANSPORTERS; TRANSITION-STATE; DRUG-BINDING; TRANSMEMBRANE DOMAINS	The ATP dependence of ATP-binding cassette (ABC) transporters has led to the widespread acceptance that these systems are unidirectional. Interestingly, in the presence of an inwardly directed ethidium concentration gradient in ATP-depleted cells of Lactococcus lactis, the ABC multidrug transporter LmrA mediated the reverse transport <LF>(or uptake) of ethidium with an apparent K-t of 2.0 muM. This uptake reaction was competitively inhibited by the LmrA substrate vinblastine and was significantly reduced by an E314A substitution in the membrane domain of the transporter. Similar to efflux, LmrA-mediated ethidium uptake was inhibited by the E512Q replacement in the Walker B region of the nucleotide-binding domain of the protein, which strongly reduced its drug-stimulated ATPase activity, consistent with published observations for other ABC transporters. The notion that ethidium uptake is coupled to the catalytic cycle in LmrA was further corroborated by studies in LmrA-containing cells and proteoliposomes in which reverse transport of ethidium was associated with the net synthesis of ATP. Taken together, these data demonstrate that the conformational changes required for drug transport by LmrA are (i) not too far from equilibrium under ATP-depleted conditions to be reversed by appropriate changes in ligand concentrations and (ii) not necessarily coupled to ATP hydrolysis, but associated with a reversible catalytic cycle. These findings and their thermodynamic implications shed new light on the mechanism of energy coupling in ABC transporters and have implications for the development of new modulators that could enable reverse transport-associated drug delivery in cells through their ability to uncouple ATP binding/hydrolysis from multidrug efflux.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	van Veen, HW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	hwv20@cam.ac.uk	van Veen, Hendrik W./A-4162-2008; Venter, Rietie/E-4795-2013	van Veen, Hendrik W./0000-0002-9658-8077; Venter, Rietie/0000-0001-5569-7755				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P237, DOI 10.1113/jphysiol.1967.sp008298; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Janvilisri T, 2003, J BIOL CHEM, V278, P20645, DOI 10.1074/jbc.M301358200; KO YH, 1994, J BIOL CHEM, V269, P14584; Lew V L, 1970, Nature, V225, P865, DOI 10.1038/225865a0; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1345, DOI 10.1021/bi0267745; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Sharom FJ, 1999, BBA-BIOMEMBRANES, V1461, P327, DOI 10.1016/S0005-2736(99)00166-2; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, BBA-BIOENERGETICS, V1365, P31, DOI 10.1016/S0005-2728(98)00039-5; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; van Veen HW, 2001, SEMIN CELL DEV BIOL, V12, P239, DOI 10.1006/scdb.2000.0249; van Veen HW, 2003, ABC PROTEINS BACTERI, P81; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Venter H, 2003, NATURE, V426, P866, DOI 10.1038/nature02173; Vigano C, 2000, J BIOL CHEM, V275, P10962, DOI 10.1074/jbc.275.15.10962; Wang GC, 1998, EUR J BIOCHEM, V255, P383, DOI 10.1046/j.1432-1327.1998.2550383.x	48	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11273	11280		10.1074/jbc.M308494200	http://dx.doi.org/10.1074/jbc.M308494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14660649	hybrid			2022-12-27	WOS:000220157600055
J	Liu, ZY; Shi, WB; Ji, XH; Sun, CX; Jee, WSS; Wu, YL; Mao, ZK; Nagy, TR; Li, QN; Cao, X				Liu, ZY; Shi, WB; Ji, XH; Sun, CX; Jee, WSS; Wu, YL; Mao, ZK; Nagy, TR; Li, QN; Cao, X			Molecules mimicking Smad1 interacting with hox stimulate bone formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARROW STROMAL CELLS; HOMEOBOX GENE; IN-VIVO; PROTEIN; REPRESSION; TRANSCRIPTION; DIFFERENTIATION; HOMEODOMAIN; EXPRESSION	Bone morphogenetic proteins (BMPs) induce osteoblast differentiation and bone formation. Smads, a group of functionally and structurally related intracellular effectors, mediate signaling initiated by BMPs and regulate cell definite commitment. Previously, we showed that Smad1 activates osteopontin and osteoprotegerin gene expression by dislodging Hoxc-8 from its DNA binding sites. A domain of Smad1, termed Smad1C, was characterized as interacting with Hoxc-8 and then crippling its DNA-binding ability. Ectopic expression of Smad1C is able to bypass BMP signaling in the induction of osteoblast differentiation and bone formation in vitro. To test the function of Smad1C on osteogenesis in vivo, we generated transgenic mice in which Smad1C expression was induced with doxycycline and localized in bone by using a tetracycline-inducible expression system (Tet-on) modified with a bone-specific gene promoter, type I collagen alpha1. The mice expressing Smad1C showed increased skeletal bone mineral density compared with their littermates. Bone histomorphometric analysis of mouse tibiae showed that Smad1C significantly increases trabecular bone area and length of trabecular surface covered with osteoid and up-regulates bone marker gene (OPN, Cbfa1, Col I alpha1, BSP, ALP) expression in vivo. Moreover, stromal cells isolated from mice expressing Smad1C displayed a higher potential for differentiating into osteoblasts than the other mice. These results indicate that Smad1C mimics BMPs in the induction of osteogenesis in vivo. Most important, using a high throughput screening assay based on mimicking Smad1C's displacement of Hoxc-8 binding to DNA, we identified chemical entities that exhibit bone anabolic activity in cell and bone organ cultures, suggesting the possibility that the compounds may be used as bone anabolic agents to treat bone pathologies.	Univ Alabama Birmingham, Sch Med, Dept Pathol, Birmingham, AL 35294 USA; Procter & Gamble Pharmaceut, Div Radiobiol, Mason, OH 45040 USA; Univ Utah, Salt Lake City, UT 84108 USA; Univ Alabama Birmingham, Sch Hlth Related Profess, Dept Nutr Sci, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Hlth Related Profess, Clin Nutr Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; Procter & Gamble; Utah System of Higher Education; University of Utah; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Cao, X (corresponding author), 1670 Univ Blvd VH G002, Birmingham, AL 35294 USA.	cao@path.uab.edu		Shi, Weibin/0000-0002-8267-2796; Nagy, Tim/0000-0002-2371-7114	NIAMS NIH HHS [P30AR46301] Funding Source: Medline; NIDDK NIH HHS [P30DK56336, DK57501] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056336] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEGLEY CT, 1993, BONE, V14, P661, DOI 10.1016/8756-3282(93)90089-S; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; CATRON KM, 1995, MOL CELL BIOL, V15, P861; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dirr MJ, 2000, J BONE MINER RES, V15, pS462; Emery JG, 2001, TRENDS PHARMACOL SCI, V22, P233, DOI 10.1016/S0165-6147(00)01661-8; Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kim JY, 2003, EXP CELL RES, V290, P217, DOI 10.1016/S0014-4827(03)00319-7; Kopp JB, 2002, KIDNEY INT, V61, P351, DOI 10.1046/j.1523-1755.2002.00126.x; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Ladher R, 1996, DEVELOPMENT, V122, P2385; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 1999, BONE, V25, P91, DOI 10.1016/S8756-3282(99)00113-1; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; Nagy TR, 2000, OBES RES, V8, P392, DOI 10.1038/oby.2000.47; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Schnabel CA, 1996, MOL CELL BIOL, V16, P2678; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shimamoto T, 1999, J EXP ZOOL, V283, P186; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Thickett Christopher, 2002, Gene Expression Patterns, V2, P5, DOI 10.1016/S0925-4773(02)00353-2; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; VIOLETTE SM, 1992, P NATL ACAD SCI USA, V89, P3805, DOI 10.1073/pnas.89.9.3805; Wan M, 2001, J BIOL CHEM, V276, P10119, DOI 10.1074/jbc.M006918200; Wang YJ, 2003, CELL, V114, P299, DOI 10.1016/S0092-8674(03)00603-2; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Yang X., 2001, METH MOL B, V177, P163; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Yin JL, 2001, IMMUNOL CELL BIOL, V79, P213, DOI 10.1046/j.1440-1711.2001.01002.x; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012	41	36	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11313	11319		10.1074/jbc.M312731200	http://dx.doi.org/10.1074/jbc.M312731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14672939	hybrid			2022-12-27	WOS:000220157600059
J	Zhang, F; Cheng, J; Hackett, NR; Lam, G; Shido, K; Pergolizzi, R; Jin, DK; Crystal, RG; Rafii, S				Zhang, F; Cheng, J; Hackett, NR; Lam, G; Shido, K; Pergolizzi, R; Jin, DK; Crystal, RG; Rafii, S			Adenovirus E4 gene promotes selective endothelial cell survival and angiogenesis via activation of the vascular endothelial-cadherin/Akt signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; VE-CADHERIN; GROWTH-FACTOR; BETA-CATENIN; EXPRESSION; VECTORS; AKT; TRANSDUCTION; TRANSCRIPTION; E1(-)E4(+)	The early 4 region (E4) of the adenoviral vectors (AdE4(+)) prolongs human endothelial cell (EC) survival and alters the angiogenic response, although the mechanisms for the EC-specific, AdE4(+)-mediated effects remain unknown. We hypothesized that AdE4(+) modulates EC survival through activation of the vascular endothelial (VE)-cadherin/Akt pathway. Here, we showed that AdE4(+), but not AdE4(-) vectors, selectively stimulated phosphorylation of both Akt at Ser(473) and Src kinase in ECs. The phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 and wortmannin abrogated AdE4(+) induction of both phospho-Akt expression and prolonged EC survival. Regulation of phospho-Akt was found to be under the control of various factors, namely VE-cadherin activation, Src kinase, tyrosine kinase, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK). Downstream targets of Akt signaling resulted in glycogen synthase kinase-3alpha/beta phosphorylation, beta-catenin up-regulation, and caspase-3 suppression, all of which led to AdE4(+)-mediated EC survival. Furthermore, infection with AdE4(+) vectors increased the angiogenic potential of ECs by promoting EC migration and capillary tube formation in Matrigel plugs. This selective AdE4(+)-mediated enhanced motility of ECs was also blocked by PI3K inhibitors. Taken together, these results suggest that activation of the VE-cadherin/ Akt pathway is critical for AdE4(+)-mediated survival of ECs and angiogenic potential.	Cornell Univ, Weill Med Coll, Dept Med Genet, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Div Hematol & Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Belfer Gene Therapy Core Facil, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Rafii, S (corresponding author), Cornell Univ, Weill Med Coll, Dept Med Genet, Div Hematol Oncol, 1300 York Ave,Rm D601, New York, NY 10021 USA.	srafii@med.cornell.edu	Zhang, Feng/B-6691-2012		NHLBI NIH HHS [R01 HL61849, P01 HL59312, HL67839, HL66592, HL59312] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL059312, P01HL059312, P01HL067839, R01HL061849] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Amalfitano A, 1998, J VIROL, V72, P926, DOI 10.1128/JVI.72.2.926-933.1998; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; Bach TL, 1998, J BIOL CHEM, V273, P30719, DOI 10.1074/jbc.273.46.30719; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Corada M, 2002, BLOOD, V100, P905, DOI 10.1182/blood.V100.3.905; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gorziglia MI, 1996, J VIROL, V70, P4173, DOI 10.1128/JVI.70.6.4173-4178.1996; Harris JD, 2002, HUM MOL GENET, V11, P43, DOI 10.1093/hmg/11.1.43; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HERSH J, 1995, GENE THER, V2, P124; Jornot L, 2001, ENDOTHELIUM-NEW YORK, V8, P167; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; King TD, 2001, BRAIN RES, V919, P106, DOI 10.1016/S0006-8993(01)03005-0; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Leppard KN, 1997, J GEN VIROL, V78, P2131, DOI 10.1099/0022-1317-78-9-2131; Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200; Ma H, 2002, ATHEROSCLEROSIS, V164, P79, DOI 10.1016/S0021-9150(02)00062-X; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; Rafii S, 2001, CIRC RES, V88, P903, DOI 10.1161/hh0901.089884; Ramalingam R, 1999, BLOOD, V93, P2936; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; Witzenbichler B, 1999, J CLIN INVEST, V104, P1469, DOI 10.1172/JCI7251; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zhang F, 2003, BLOOD, V102, P2115, DOI 10.1182/blood-2003-01-0049	33	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2004	279	12					11760	11766		10.1074/jbc.M312221200	http://dx.doi.org/10.1074/jbc.M312221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	802IQ	14660586	hybrid			2022-12-27	WOS:000220157600113
J	Fasshauer, D; Margittai, M				Fasshauer, D; Margittai, M			A transient N-terminal interaction of SNAP-25 and syntaxin nucleates SNARE assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; COMPLEX	The SNARE proteins syntaxin, SNAP-25, and synaptobrevin play a central role during Ca2+-dependent exocytosis at the nerve terminal. Whereas syntaxin and SNAP-25 are located in the plasma membrane, synaptobrevin resides in the membrane of synaptic vesicles. It is thought that gradual assembly of these proteins into a membrane-bridging ternary SNARE complex ultimately leads to membrane fusion. According to this model, syntaxin and SNAP-25 constitute an acceptor complex for synaptobrevin. In vitro, however, syntaxin and SNAP-25 form a stable complex that contains two syntaxin molecules, one of which is occupying and possibly obstructing the binding site of synaptobrevin. To elucidate the assembly pathway of the synaptic SNAREs, we have now applied a combination of fluorescence and CD spectroscopy. We found that SNARE assembly begins with the slow and rate-limiting interaction of syntaxin and SNAP-25. Their interaction was prevented by N-terminal but not by C-terminal truncations, suggesting that for productive assembly all three participating helices must come together simultaneously. This suggests a complicated nucleation process that might be the reason for the observed slow assembly rate. N-terminal truncations of SNAP-25 and syntaxin also prevented the formation of the ternary complex, whereas neither N- nor C-terminal shortened synaptobrevin helices lost their ability to interact. This suggests that binding of synaptobrevin occurs after the establishment of the syntaxin-SNAP-25 interaction. Moreover, binding of synaptobrevin was inhibited by an excess of syntaxin, suggesting that a 1: 1 interaction of syntaxin and SNAP-25 serves as the on-pathway SNARE assembly intermediate.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Max Planck Society	Fasshauer, D (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	dfassha@mpibpc.gwdg.de	Margittai, Martin/D-5039-2014; Fasshauer, Dirk/B-1563-2013	Margittai, Martin/0000-0003-1903-5927; Fasshauer, Dirk/0000-0002-1040-4282				Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Hazzard J, 1999, J BIOMOL NMR, V14, P203, DOI 10.1023/A:1008382027065; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kweon DH, 2003, NAT STRUCT BIOL, V10, P440, DOI 10.1038/nsb928; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174; Zhang F, 2002, J BIOL CHEM, V277, P24294, DOI 10.1074/jbc.M201200200	27	130	133	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7613	7621		10.1074/jbc.M312064200	http://dx.doi.org/10.1074/jbc.M312064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665625	Green Published, hybrid			2022-12-27	WOS:000189103300031
J	Kaeser, MD; Pebernard, S; Iggo, RD				Kaeser, MD; Pebernard, S; Iggo, RD			Regulation of p53 stability and function in HCT116 colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE ACTIVITY; APOPTOTIC RESPONSE; TUMOR-SUPPRESSOR; DNA-BINDING; PHOSPHORYLATION; MDM2; GENE; STABILIZATION; ACETYLATION; ACTIVATION	We have used a lentiviral vector to stably express p53 at a physiological level in p53 knockout HCT116 cells. Cells transduced with wild type p53 responded to genotoxic stress by stabilizing p53 and expressing p53 target genes. The reconstituted cells underwent G(1) arrest or apoptosis appropriately depending on the type of stress, albeit less efficiently than parental wild type cells. Compared with cells expressing exogenous wild type p53, the apoptotic response to 5-fluorouracil (5FU) was >50% reduced in cells expressing S15A or S20A mutant p53, and even more reduced by combined mutation of serines 6, 9, 15, 20, 33, and 37 (N6A). Among a panel of p53 target genes tested by quantitative PCR, the gene showing the largest defect in induction by 5FU was BBC3 (PUMA), which was induced 4-fold by wild type p53 and 2-fold by the N6A mutant. Mutation of N-terminal phosphorylation sites did not prevent p53 stabilization by doxorubicin or 5FU. MDM2 silencing by RNA interference activated p53 target gene expression in normal fibroblasts but not in HCT116 cells, and exogenous p53 could be stabilized in HCT116 knockout cells despite combined mutation of p53 phosphorylation sites and silencing of MDM2 expression. The MDM2 feedback loop is thus defective, and other mechanisms must exist to regulate p53 stability and function in this widely used tumor cell line.	Swiss Inst Expt Canc Res, Oncogene Grp, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Iggo, RD (corresponding author), Swiss Inst Expt Canc Res, Oncogene Grp, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	Richard.Iggo@isrec.unil.ch	Iggo, Richard/G-3546-2014; Käser-Pébernard, Stéphanie GM/C-4219-2014	Käser-Pébernard, Stéphanie GM/0000-0002-6035-6979; Kaeser, Matthias/0000-0003-0050-9408				ANDERSON CW, 2003, HDB CELL SIGNALING, V3, P237; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chao C, 2003, J BIOL CHEM, V278, P41028, DOI 10.1074/jbc.M306938200; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chene P, 2000, J MOL BIOL, V299, P245, DOI 10.1006/jmbi.2000.3738; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 2000, GENE DEV, V14, P289; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao RB, 2000, GENE DEV, V14, P981	55	91	91	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7598	7605		10.1074/jbc.M311732200	http://dx.doi.org/10.1074/jbc.M311732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14665630	hybrid			2022-12-27	WOS:000189103300029
J	Khursigara, CM; De Crescenzo, G; Pawelek, PD; Coulton, JW				Khursigara, CM; De Crescenzo, G; Pawelek, PD; Coulton, JW			Enhanced binding of TonB to a ligand-loaded outer membrane receptor - Role of the oligomeric state of TonB in formation of a functional FhuA center dot TonB complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALAMIN TRANSPORTER BTUB; FERRICHROME-IRON RECEPTOR; ESCHERICHIA-COLI K-12; IN-VIVO EVIDENCE; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGE; CYTOPLASMIC MEMBRANE; ACTIVE-TRANSPORT; PROTEIN TONB; REVEALS	The (f) under bar erric (h) under bar ydroxymate (u) under bar ptake (FhuA) receptor from Escherichia coli facilitates transport of siderophores ferricrocin and ferrichrome and siderophore-antibiotic conjugates such as albomycin and rifamycin CGP 4832. FhuA is also the receptor for phages T5, T1, Phi80, UC-1, for colicin M and for the antimicrobial peptide microcin MccJ21. Energy for transport is provided by the cytoplasmic membrane complex TonB.ExbB.ExbD, which uses the proton motive force of the cytoplasmic membrane to transduce energy to the outer membrane. To accomplish energy transfer, TonB contacts outer membrane receptors. However, the stoichiometry of TonB.receptor complexes and their sites of interaction remain uncertain. In this study, analyses of FhuA interactions with two recombinant TonB proteins by analytical ultracentrifugation revealed that TonB forms a 2:1 complex with FhuA. The presence of the FhuA-specific ligand ferricrocin enhanced the amounts of complex but is not essential for its formation. Surface plasmon resonance experiments demonstrated that FhuA.TonB interactions are multiple and have apparent affinities in the nanomolar range. TonB also possesses two distinct binding regions: one in the C terminus of the protein, for which binding to FhuA is ferricrocin-independent, and a higher affinity region outside the C terminus, for which ferricrocin enhances interactions with FhuA. Together these experiments establish that FhuA.TonB interactions are more intricate than originally predicted, that the TonB.FhuA stoichiometry is 2:1, and that ferricrocin modulates binding of FhuA to TonB at regions outside the C-terminal domain of TonB.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Sheldon Biotechnol Ctr, Prot Prot Interact Facil, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Coulton, JW (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St, Montreal, PQ H3A 2B4, Canada.	james.coulton@mcgill.ca	Pawelek, Peter/E-7950-2014	Pawelek, Peter/0000-0002-8361-6593				Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; Braun V, 1998, MET IONS BIOL SYST, V35, P67; Braun V, 2002, CURR OPIN MICROBIOL, V5, P194, DOI 10.1016/S1369-5274(02)00298-9; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Cadieux N, 2000, J BACTERIOL, V182, P5954, DOI 10.1128/JB.182.21.5954-5961.2000; Chang CS, 2001, J BIOL CHEM, V276, P27535, DOI 10.1074/jbc.M102778200; Chimento DP, 2003, J MOL BIOL, V332, P999, DOI 10.1016/j.jmb.2003.07.005; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; De Crescenzo G, 2001, J BIOL CHEM, V276, P29632, DOI 10.1074/jbc.M009765200; De Crescenzo G, 2000, BIOCHEMISTRY-US, V39, P9466, DOI 10.1021/bi992987r; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; Ferguson AD, 1998, PROTEIN SCI, V7, P1636, DOI 10.1002/pro.5560070719; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; FERGUSON AD, 2001, HDB METALLOPROTEINS, P834; GUNTER K, 1990, FEBS LETT, V274, P85, DOI 10.1016/0014-5793(90)81335-L; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Larsen RA, 2003, MOL MICROBIOL, V49, P211, DOI 10.1046/j.1365-2958.2003.03579.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Moeck GS, 1996, MOL MICROBIOL, V22, P459, DOI 10.1046/j.1365-2958.1996.00112.x; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; Sauter A, 2003, J BACTERIOL, V185, P5747, DOI 10.1128/JB.185.19.5747-5754.2003; SCHOFFLER H, 1989, MOL GEN GENET, V217, P378, DOI 10.1007/BF02464907; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SKARE JT, 1993, J BIOL CHEM, V268, P16302; ZHAO YF, 2003, BIOCHIM BIOPHYS ACTA, V1614, P201	32	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7405	7412		10.1074/jbc.M311784200	http://dx.doi.org/10.1074/jbc.M311784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668326	hybrid			2022-12-27	WOS:000189103300006
J	Koike, T; Liang, JY; Wang, XF; Ichikawa, T; Shiomi, M; Liu, G; Sun, HJ; Kitajima, S; Morimoto, M; Watanabe, T; Yamada, N; Fan, JL				Koike, T; Liang, JY; Wang, XF; Ichikawa, T; Shiomi, M; Liu, G; Sun, HJ; Kitajima, S; Morimoto, M; Watanabe, T; Yamada, N; Fan, JL			Overexpression of lipoprotein lipase in transgenic watanabe heritable hyperlipidemic rabbits improves hyperlipidemia and obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL-FED RABBITS; INSULIN-RESISTANCE; ADIPOSE-TISSUE; LDL RECEPTOR; APOLIPOPROTEIN-E; SKELETAL-MUSCLE; KNOCKOUT MICE; ATHEROSCLEROSIS; METABOLISM	Lipoprotein lipase (LPL) is the rate-limiting enzyme for the hydrolysis of the triglyceride-rich lipoproteins and plays a critical role in lipoprotein and free fatty acid metabolism. Genetic manipulation of LPL may be beneficial in the treatment of hypertriglyceridemias, but it is unknown whether increased LPL activity may be effective in lowering plasma cholesterol and improving insulin resistance in familial hypercholesterolemic patients. To test the hypothesis that stimulation of LPL expression may be used as an adjunctive therapy for treatment of homozygous familial hypercholesterolemia, we have generated transgenic (Tg) Watanabe heritable hyperlipidemic (WHHL) rabbits that overexpress the human LPL transgene and compared their plasma lipid levels, glucose metabolism, and body fat accumulation with those of non-Tg WHHL rabbits. Overexpression of LPL dramatically ameliorated hypertriglyceridemia in Tg WHHL rabbits. Furthermore, increased LPL activity in male Tg WHHL rabbits also corrected hypercholesterolemia (544+/-52 in non-Tg versus 227+/-29 mg/dl in Tg, p<0.01) and reduced body fat accumulation by 61% (323 +/- 27 in non-Tg versus 125 +/- 21 g in Tg, p<0.01), suggesting that LPL plays an important role in mediating plasma cholesterol homeostasis and adipose accumulation. In addition, overexpression of LPL significantly suppressed high fat diet-induced obesity and insulin resistance in Tg WHHL rabbits. These results imply that systemic elevation of LPL expression may be potentially useful for the treatment of hyperlipidemias, obesity, and insulin resistance.	Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Cardiovasc Dis Lab, Tsukuba, Ibaraki 3058575, Japan; Kobe Univ, Sch Med, Inst Expt Anim, Kobe, Hyogo 6500017, Japan; Peking Univ, Inst Cardiovasc Sci, Beijing 100083, Peoples R China; Dalian Med Univ, Dept Pharmacol, Dalian 116027, Peoples R China; Saga Univ, Sch Med, Saga 8498502, Japan; Univ Tsukuba, Inst Clin Med, Div Endocrinol & Metab, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; Kobe University; Peking University; Dalian Medical University; Saga University; University of Tsukuba	Fan, JL (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Cardiovasc Dis Lab, Tsukuba, Ibaraki 3058575, Japan.	j-lfan@md.tsukuba.ac.jp	Liang, Jingyan/F-6630-2014	Fan, Jianglin/0000-0002-1737-6130; Kitajima, Shuji/0000-0002-6239-2682				AVIRAM M, 1988, J BIOL CHEM, V263, P15416; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Benlian P, 1996, NEW ENGL J MED, V335, P848, DOI 10.1056/NEJM199609193351203; Brousseau ME, 1998, J LIPID RES, V39, P1558; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; Excoffon KJDA, 1997, ARTERIOSCL THROM VAS, V17, P2532, DOI 10.1161/01.ATV.17.11.2532; Fan JL, 2000, J LIPID RES, V41, P1004; Fan JL, 2001, ARTERIOSCL THROM VAS, V21, P88, DOI 10.1161/01.ATV.21.1.88; Fan JL, 2001, J BIOL CHEM, V276, P40071, DOI 10.1074/jbc.M105456200; Ferreira LDMCB, 2001, DIABETES, V50, P1064, DOI 10.2337/diabetes.50.5.1064; Ginzinger DG, 1999, EUR J CLIN INVEST, V29, P17, DOI 10.1046/j.1365-2362.1999.00435.x; Goldberg IJ, 1996, J LIPID RES, V37, P693; HAARBO J, 1991, J CLIN INVEST, V87, P1274, DOI 10.1172/JCI115129; Huang YD, 1997, J BIOL CHEM, V272, P22685, DOI 10.1074/jbc.272.36.22685; IKEDA Y, 1990, J LIPID RES, V31, P1911; IVERIUS PH, 1988, J CLIN INVEST, V82, P1106, DOI 10.1172/JCI113667; Jensen DR, 1997, AM J PHYSIOL-REG I, V273, pR683, DOI 10.1152/ajpregu.1997.273.2.R683; Kastelein JJP, 2000, CIRCULATION, V102, P1629, DOI 10.1161/01.CIR.102.14.1629; KAWAMURA M, 1994, ARTERIOSCLER THROMB, V14, P235, DOI 10.1161/01.ATV.14.2.235; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kusunoki M, 2000, DIABETOLOGIA, V43, P875, DOI 10.1007/s001250051464; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; MA PTS, 1986, P NATL ACAD SCI USA, V83, P792, DOI 10.1073/pnas.83.3.792; Mingrone G, 1999, DIABETES, V48, P1258, DOI 10.2337/diabetes.48.6.1258; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SEHAYEK E, 1991, J CLIN INVEST, V88, P553, DOI 10.1172/JCI115339; SHIMADA M, 1995, BIOCHEM BIOPH RES CO, V211, P761, DOI 10.1006/bbrc.1995.1878; Shimada M, 1996, P NATL ACAD SCI USA, V93, P7242, DOI 10.1073/pnas.93.14.7242; Shiomi M, 2003, ARTERIOSCL THROM VAS, V23, P1239, DOI 10.1161/01.ATV.0000075947.28567.50; Sugihara H, 2001, Nihon Rinsho, V59 Suppl 2, P477; TSUTSUMI K, 1993, J CLIN INVEST, V92, P411, DOI 10.1172/JCI116582; Voshol PJ, 2001, DIABETES, V50, P2585, DOI 10.2337/diabetes.50.11.2585; WATANABE Y, 1980, ATHEROSCLEROSIS, V36, P261, DOI 10.1016/0021-9150(80)90234-8; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Wittekoek ME, 1998, CIRCULATION, V97, P729, DOI 10.1161/01.CIR.97.8.729; Yagyu H, 1999, J LIPID RES, V40, P1677; Yin Weidong, 2003, Int J Exp Diabesity Res, V4, P27; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005; Zechner R, 2000, INT J OBESITY, V24, pS53, DOI 10.1038/sj.ijo.0801506; Zhang B, 2001, BRIT J BIOMED SCI, V58, P217; ZHANG B, 1991, ATHEROSCLEROSIS, V91, P277, DOI 10.1016/0021-9150(91)90175-3; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100; Zsigmond E, 1997, HUM GENE THER, V8, P1921, DOI 10.1089/hum.1997.8.16-1921	46	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7521	7529		10.1074/jbc.M311514200	http://dx.doi.org/10.1074/jbc.M311514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660566	hybrid			2022-12-27	WOS:000189103300020
J	Rodriguez, D; Quiros, LM; Salas, JA				Rodriguez, D; Quiros, LM; Salas, JA			MtmMII-mediated C-methylation during biosynthesis of the antitumor drug mithramycin is essential for biological activity and DNA-drug interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREOLIC ACID GROUP; STREPTOMYCES-ARGILLACEUS; POLYKETIDE MITHRAMYCIN; FOLD RECOGNITION; BINDING; METHYLTRANSFERASES; PURIFICATION; GENES; OLEANDOMYCIN; ANTIBIOTICUS	The antitumor drug mithramycin consists of a polyketide chromophore glycosylated with a trisaccharide and a disaccharide. Two post-polyketide methylations take place during mithramycin biosynthesis. One of these methylations has been shown to be very relevant for biological activity, that is the introduction of a methyl group at aromatic C-7. We have purified to 282-fold the MtmMII methyltransferase involved in this reaction. The protein is a monomer, and results from kinetic studies were consistent with a model for the enzyme acting via a compulsory order mechanism. The enzyme showed high substrate specificity and was unable to operate on structurally closely related molecules. Structural predictions suggest that the molecule is integrated by two domains, an essentially all alpha-amino domain and an alpha/beta-carboxyl domain displaying a variation of a Rossmann-fold containing the cofactor binding site. Although 7-demethyl-mithramycin did not show any biological activity, it was able to reach the nucleus of eukaryotic cells, with subsequent binding to DNA. Mithramycin and 7-demethylmithramycin were able to form similar complexes with Mg2+, although their respective DNA binding isotherms were very different. The dinucleotide binding model fit well the isotherms recorded for both compounds, predicting that the C-7 methyl group was essential for high affinity binding to specific GC and CG sequences. Considering previous structural studies, we propose that this effect is performed by positioning the group in the floor of the minor groove, allowing the interaction with the third sugar moiety of the trisaccharide, D-mycarose, which is involved in sequence selectivity.	Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain; Univ Oviedo, IUOPA, E-33006 Oviedo, Spain	University of Oviedo; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Salas, JA (corresponding author), Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain.	jasalas@correo.uniovi.es	Rodríguez, David/K-3872-2017; Quirós, Luis/T-3822-2017	Rodríguez, David/0000-0002-7530-2770; Quirós, Luis/0000-0003-3505-3762				AICH P, 1990, BIOCHEM BIOPH RES CO, V173, P689, DOI 10.1016/S0006-291X(05)80090-7; AICH P, 1995, BIOCHEMISTRY-US, V34, P1376, DOI 10.1021/bi00004a032; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bhattacharya SK, 1999, J BIOL CHEM, V274, P14743, DOI 10.1074/jbc.274.21.14743; Blanco G, 1996, CHEM BIOL, V3, P193, DOI 10.1016/S1074-5521(96)90262-8; Blanco G, 2000, MOL GEN GENET, V262, P991, DOI 10.1007/PL00008667; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaires JB, 2001, METHOD ENZYMOL, V340, P3; CHAIRES JB, 1982, BIOCHEMISTRY-US, V21, P3933, DOI 10.1021/bi00260a005; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DEWICK PM, 1997, MED NATURAL PRODUCTS, P85; Fernandez E, 1998, J BACTERIOL, V180, P4929; JAMES F, 1995, J BIOL CHEM, V270, P22344, DOI 10.1074/jbc.270.38.22344; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNINGER AL, 1972, BIOCHEMISTRY-US, P711; Lombo F, 1996, GENE, V172, P87, DOI 10.1016/0378-1119(96)00029-7; Lozano MJF, 2000, J BIOL CHEM, V275, P3065, DOI 10.1074/jbc.275.5.3065; Malygin EG, 2003, J BIOL CHEM, V278, P15713, DOI 10.1074/jbc.M213213200; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mendez C, 2001, TRENDS BIOTECHNOL, V19, P449, DOI 10.1016/S0167-7799(01)01765-6; Mir MA, 2001, BIOCHEM BIOPH RES CO, V280, P68, DOI 10.1006/bbrc.2000.4075; Nes WD, 2000, BBA-MOL CELL BIOL L, V1529, P63, DOI 10.1016/S1388-1981(00)00138-4; Prado L, 1999, MOL GEN GENET, V261, P216, DOI 10.1007/s004380050960; Prado L, 1999, CHEM BIOL, V6, P19, DOI 10.1016/S1074-5521(99)80017-9; PURICH DL, 1980, METHOD ENZYMOL, V64, P3; QUIROS LM, 1995, J BIOL CHEM, V270, P18234, DOI 10.1074/jbc.270.31.18234; Reither S, 2003, J MOL BIOL, V329, P675, DOI 10.1016/S0022-2836(03)00509-6; Rodriguez D, 2003, J BACTERIOL, V185, P3962, DOI 10.1128/JB.185.13.3962-3965.2003; Rohr J, 1998, CHEM COMMUN, P437, DOI 10.1039/a707446h; Rohr J, 1999, BIOORG CHEM, V27, P41, DOI 10.1006/bioo.1998.1110; ROHR J, 2002, Patent No. P200032; Rudolph F B, 1979, Methods Enzymol, V63, P138; SASTRY M, 1993, BIOCHEMISTRY-US, V32, P6588, DOI 10.1021/bi00077a012; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; VILCHES C, 1990, J GEN MICROBIOL, V136, P1447, DOI 10.1099/00221287-136-8-1447; VILTAIKIS G, 2001, J BIOL CHEM, V276, P20924; ZHOU ZS, 2001, FRONT BIOTECH PHARM, V2, P199; Zubieta C, 2001, NAT STRUCT BIOL, V8, P271, DOI 10.1038/85029	42	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8149	8158		10.1074/jbc.M312351200	http://dx.doi.org/10.1074/jbc.M312351200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660589	hybrid			2022-12-27	WOS:000189103300096
J	Hacker, S; Krebber, H				Hacker, S; Krebber, H			Differential export requirements for shuttling serine/arginine-type mRNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION ELONGATION; ARGININE METHYLATION; YEAST; COMPLEX; PHOSPHORYLATION; CYTOPLASM; TRANSPORT; DOMAIN	Messenger RNAs are transported to the cytoplasm bound to several shuttling mRNA-binding proteins. Here, we present the characterization of Hrb1, a novel component of the transported ribonucleoprotein complex in Saccharomyces cerevisiae. The protein is similar to the other two serine/arginine (SR)-type proteins in yeast, Gbp2 and Np13. Hrb1 is nuclear at steady state and its import is mediated by the karyopherin Mtr10. Hrb1 binds to poly(A)(+) RNA in vivo and its binding is significantly increased in MTR10 mutants, suggesting a role for Mtr10 in dissociating Hrb1 from the mRNAs. Interestingly, by comparing the export requirements of all three SR proteins we find similarities but also striking differences. While the export of all three proteins is dependent on the export of mRNAs in general, as no transport is observed in mutants defective in transcription (rpb1-1) or mRNA export (mex67-5), we find specific requirements for components of the THO complex, involved in transcription elongation. While both Hrb1 and Gbp2 depend on Mft1 and Hpr1 for their nuclear export, Np13 is exported independently of both proteins. These findings suggest that Hrb1 and Gbp2, but not Np13, might be loaded onto the growing mRNA via the THO complex components Mtf1 and Hrp1.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany	Philipps University Marburg	Krebber, H (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	krebber@imt.uni-marburg.de						Afonina E, 1998, J BIOL CHEM, V273, P13015, DOI 10.1074/jbc.273.21.13015; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; Barry DM, 2000, ESSAYS BIOCHEM, V36, P89, DOI 10.1042/bse0360089; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Clouse KN, 2001, NAT CELL BIOL, V3, P97, DOI 10.1038/35050625; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Estruch F, 2003, MOL BIOL CELL, V14, P1664, DOI 10.1091/mbc.E02-09-0602; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Green DM, 2003, P NATL ACAD SCI USA, V100, P1010, DOI 10.1073/pnas.0336594100; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Krebber H, 1999, GENE DEV, V13, P1994, DOI 10.1101/gad.13.15.1994; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rondon AG, 2003, J BIOL CHEM, V278, P39037, DOI 10.1074/jbc.M305718200; RUSSELL I, 1995, EUR J CELL BIOL, V66, P293; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Windgassen M, 2003, EMBO REP, V4, P278, DOI 10.1038/sj.embor.embor763; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	38	35	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5049	5052		10.1074/jbc.C300522200	http://dx.doi.org/10.1074/jbc.C300522200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14676199	hybrid			2022-12-27	WOS:000188776500001
J	Weskamp, G; Schlondorff, J; Lum, L; Becherer, JD; Kim, TW; Saftig, P; Hartmann, D; Murphy, G; Blobel, CP				Weskamp, G; Schlondorff, J; Lum, L; Becherer, JD; Kim, TW; Saftig, P; Hartmann, D; Murphy, G; Blobel, CP			Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75(NTR))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; REGULATED INTRAMEMBRANE PROTEOLYSIS; METALLOPROTEASE-DISINTEGRIN MDC9; PROTEIN-COUPLED RECEPTORS; INTRACELLULAR MATURATION; CELL-SURFACE; HB-EGF; TRANSMEMBRANE PROTEINS; JUXTAMEMBRANE STALK; SIGNALING PATHWAYS	Protein ectodomain shedding, the proteolytic release of the extracellullar domain of membrane-tethered proteins, can dramatically affect the function of cell surface receptors, growth factors, cytokines, and other proteins. In this study, we evaluated the activities involved in ectodomain shedding of p75(NTR), a neurotrophin receptor with critical roles in neuronal differentiation and survival. p75(NTR) is shed in a variety of cell types, including dorsal root ganglia cells and PC12 cells. In Chinese hamster ovary cells, inhibitors of the MEK/ERK and p38 MAP kinase pathways uncovered distinct signaling pathways required for the constitutive and stimulated shedding of p75(NTR). Stimulated p75(NTR) shedding is abrogated in M2 mutant Chinese hamster ovary cells that lack functional tumor necrosis factor-alpha converting enzyme (TALE, also referred to as ADAM17) and in cells isolated from adam17-/- mice, but not in cells from adam9/12/15-/- or adam10-/- mice. Stimulated p75(NTR) shedding is strongly reduced by deletion of 15 amino acid residues in its extracellular membrane-proximal stalk domain. However, similar to other shed proteins, point mutations and overlapping shorter deletions within this region have little or no effect on shedding. Because ectodomain shedding of p75(NTR) releases a soluble ectodomain and could also be a prerequisite for its regulated intramembrane proteolysis, these findings may have important implications for the functional regulation of p75(NTR).	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cell Biol Program, New York, NY 10021 USA; Triinst Cornell Univ Rockefeller Univ Sloan Kette, New York, NY 10021 USA; GlaxoSmithKline Inc, Dept Biochem & Analyt Pharmacol, Res Triangle Pk, NC 27709 USA; Columbia Univ, Ctr Neurobiol & Behav, Dept Pathol, New York, NY 10032 USA; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Katholieke Univ Leuven, Dept Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB4, B-3000 Louvain, Belgium; Cambridge Inst Med Res, Cambridge CB2 2XY, England	Memorial Sloan Kettering Cancer Center; GlaxoSmithKline; Columbia University; University of Kiel; KU Leuven; University of Cambridge	Blobel, CP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cell Biol Program, Box 368,1275 York Ave, New York, NY 10021 USA.	c-blobel@ski.mskcc.org	Saftig, Paul/A-7966-2010	Schlondorff, Johannes/0000-0002-9973-9731	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064750, T32GM007739] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline; NIGMS NIH HHS [5T32GM07739-17, R01 GM64750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfalah M, 2001, J BIOL CHEM, V276, P21105, DOI 10.1074/jbc.M100339200; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Codony-Servat J, 1999, CANCER RES, V59, P1196; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Galko MJ, 2000, SCIENCE, V289, P1365, DOI 10.1126/science.289.5483.1365; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; Jung KM, 2003, J BIOL CHEM, V278, P42161, DOI 10.1074/jbc.M306028200; Kanning KC, 2003, J NEUROSCI, V23, P5425, DOI 10.1523/jneurosci.23-13-05425.2003; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Mischel PS, 2001, J BIOL CHEM, V276, P11294, DOI 10.1074/jbc.M005132200; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tang P, 1996, BIOCHEMISTRY-US, V35, P8226, DOI 10.1021/bi952183l; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wen CH, 1997, DEVELOPMENT, V124, P4759; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Yamazaki S, 2003, J CELL BIOL, V163, P469, DOI 10.1083/jcb.200307035; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342	78	129	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 6	2004	279	6					4241	4249		10.1074/jbc.M307974200	http://dx.doi.org/10.1074/jbc.M307974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	768UW	14638693	hybrid			2022-12-27	WOS:000188554300041
J	Febbraio, F; Andolfo, A; Tanfani, F; Briante, R; Gentile, F; Formisano, S; Vaccaro, C; Scire, A; Bertoli, E; Pucci, P; Nucci, R				Febbraio, F; Andolfo, A; Tanfani, F; Briante, R; Gentile, F; Formisano, S; Vaccaro, C; Scire, A; Bertoli, E; Pucci, P; Nucci, R			Thermal stability and aggregation of Sulfolobus solfataricus beta-glycosidase are dependent upon the n-epsilon-methylation of specific lysyl residues - Critical role of in vivo post-translational modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; CRYSTAL-STRUCTURE; HISTONE H3; THERMOACIDOPHILIC ARCHAEBACTERIUM; SALT BRIDGES; ASPARTATE-AMINOTRANSFERASE; PROTEIN THERMOSTABILITY; ALCOHOL-DEHYDROGENASE; ESCHERICHIA-COLI; HP1 PROTEINS	Methylation in vivo is a post-translational modification observed in several organisms belonging to eucarya, bacteria, and archaea. Although important implications of this modification have been demonstrated in several eucaryotes, its biological role in hyperthermophilic archaea is far from being understood. The aim of this work is to clarify some effects of methylation on the properties of beta-glycosidase from Sulfolobus solfataricus, by a structural comparison between the native, methylated protein and its unmethylated counterpart, recombinantly expressed in Escherichia coli. Analysis by Fourier transform infrared spectroscopy indicated similar secondary structure contents for the two forms of the protein. However, the study of temperature perturbation by Fourier transform infrared spectroscopy and turbidimetry evidenced denaturation and aggregation events more pronounced in recombinant than in native beta-glycosidase. Red Nile fluorescence analysis revealed significant differences of surface hydrophobicity between the two forms of the protein. Unlike the native enzyme, which dissociated into SDS-resistant dimers upon exposure to the detergent, the recombinant enzyme partially dissociated into monomers. By electrospray mapping, the methylation sites of the native protein were identified. A computational analysis of beta-glycosidase three-dimensional structure and comparisons with other proteins from S. solfataricus revealed analogies in the localization of methylation sites in terms of secondary structural elements and overall topology. These observations suggest a role for the methylation of lysyl residues, located in selected domains, in the thermal stabilization of beta-glycosidase from S. solfataricus.	CNR, Inst Prot Biochem, I-80125 Naples, Italy; CEINGE Adv Biotechnol Scarl, I-80131 Naples, Italy; Polytech Univ Marche, Inst Biochem, I-60131 Ancona, Italy; Polytech Univ Marche, Fac Med & Surg, I-60131 Ancona, Italy; Polytech Univ Marche, Fac Sci, I-60131 Ancona, Italy; Univ Molise, Dept SAVA, I-86100 Campobasso, Italy; Univ Naples Federico II, Dept Cell & Mol Biol & Pathol, I-80131 Naples, Italy; CNR, Inst Expt Endocrinol & Oncol, I-80131 Naples, Italy; Univ Naples Federico II, Dept Organ & Biol Chem, I-80126 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); CEINGE Biotecnologie Avanzate; Marche Polytechnic University; Marche Polytechnic University; Marche Polytechnic University; University of Molise; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Febbraio, F (corresponding author), CNR, Inst Prot Biochem, Via Marconi 10, I-80125 Naples, Italy.	f.febbraio@ibp.cnr.it	Gentile, Fabrizio/K-2475-2012; Scirè, Andrea/A-2961-2010; Tanfani, Fabio/F-1441-2010; Andolfo, Annapaola/B-2532-2013; Febbraio, Ferdinando/AAX-8255-2020	Gentile, Fabrizio/0000-0002-6704-3115; Scirè, Andrea/0000-0002-8288-6989; Andolfo, Annapaola/0000-0002-0566-2391; Febbraio, Ferdinando/0000-0002-3653-9847; PUCCI, Pietro/0000-0002-5885-1495; Tanfani, Fabio/0000-0001-7685-4692				Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; AMMENDOLA S, 1992, BIOCHEMISTRY-US, V31, P12514, DOI 10.1021/bi00164a031; BANECKI B, 1992, J BIOL CHEM, V267, P25051; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; *BIOS MSI, 1995, INS US GUID; Bismuto E, 2003, PROTEINS, V51, P10, DOI 10.1002/prot.10317; CACACE MG, 1976, BIOCHEMISTRY-US, V15, P1692, DOI 10.1021/bi00653a016; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CUBELLIS MV, 1989, EUR J BIOCHEM, V186, P375, DOI 10.1111/j.1432-1033.1989.tb15219.x; CUBELLIS MV, 1990, GENE, V94, P89, DOI 10.1016/0378-1119(90)90472-4; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; DEROSA M, 1980, BIOTECHNOL LETT, V2, P29, DOI 10.1007/BF00136880; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Elcock AH, 1998, J MOL BIOL, V284, P489, DOI 10.1006/jmbi.1998.2159; Esposito L, 2002, J MOL BIOL, V318, P463, DOI 10.1016/S0022-2836(02)00088-8; FERNANDEZBALLESTER G, 1992, BIOCHEM J, V288, P421, DOI 10.1042/bj2880421; FONTANA A, 1991, LIFE EXTREME CONDITI, P89; Gentile F, 2002, J BIOL CHEM, V277, P44050, DOI 10.1074/jbc.M206761200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haseltine C, 1999, J BACTERIOL, V181, P3920, DOI 10.1128/JB.181.13.3920-3927.1999; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hughes E, 2000, J BIOL CHEM, V275, P25109, DOI 10.1074/jbc.M003554200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Katz ML, 1997, BBA-MOL BASIS DIS, V1361, P66, DOI 10.1016/S0925-4439(97)00017-3; KELLY CA, 1993, BIOCHEMISTRY-US, V32, P3913, DOI 10.1021/bi00066a010; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORNDORFER I, 1995, J MOL BIOL, V246, P511, DOI 10.1006/jmbi.1994.0103; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDO VS, 1995, BRIT J HAEMATOL, V89, P589, DOI 10.1111/j.1365-2141.1995.tb08368.x; MARAS B, 1992, EUR J BIOCHEM, V203, P81, DOI 10.1111/j.1432-1033.1992.tb19831.x; MINAMI Y, 1985, J BIOCHEM-TOKYO, V97, P745, DOI 10.1093/oxfordjournals.jbchem.a135114; MORACCI M, 1995, ENZYME MICROB TECH, V17, P992, DOI 10.1016/0141-0229(95)00012-7; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; NUCCI R, 1993, BIOTECHNOL APPL BIOC, V17, P239; OSBORNE HB, 1982, METHOD ENZYMOL, V88, P676; Paik W K, 1986, Yonsei Med J, V27, P159; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; SACKETT DL, 1987, ANAL BIOCHEM, V167, P228, DOI 10.1016/0003-2697(87)90157-6; SALOMAA P, 1964, J AM CHEM SOC, V86, P1, DOI 10.1021/ja01055a001; SkorkoGlonek J, 1997, J BIOL CHEM, V272, P8974; SPASSOV VZ, 1995, PROTEIN SCI, V4, P1516, DOI 10.1002/pro.5560040809; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TANFANI F, 1993, EUR J BIOCHEM, V218, P499, DOI 10.1111/j.1432-1033.1993.tb18402.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMSCHY A, 1994, PROTEIN ENG, V7, P1471, DOI 10.1093/protein/7.12.1471; TORCHILIN VP, 1979, BIOCHIM BIOPHYS ACTA, V567, P1, DOI 10.1016/0005-2744(79)90165-7; UMEMURA J, 1980, BIOCHIM BIOPHYS ACTA, V602, P32, DOI 10.1016/0005-2736(80)90287-4; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; WALKER JE, 1980, EUR J BIOCHEM, V108, P581, DOI 10.1111/j.1432-1033.1980.tb04753.x; Westhead DR, 1999, PROTEIN SCI, V8, P897; Williamson NA, 1997, EUR J BIOCHEM, V246, P786, DOI 10.1111/j.1432-1033.1997.00786.x; ZAPPACOSTA F, 1994, EUR J BIOCHEM, V222, P761, DOI 10.1111/j.1432-1033.1994.tb18922.x	54	35	37	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10185	10194		10.1074/jbc.M308520200	http://dx.doi.org/10.1074/jbc.M308520200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14660666	hybrid			2022-12-27	WOS:000220050400065
J	Li, YM; Syvitski, RT; Auclair, K; de Montellano, PRO; La Mar, GN				Li, YM; Syvitski, RT; Auclair, K; de Montellano, PRO; La Mar, GN			H-1 NMR investigation of the solution structure of substrate-free human heme oxygenase - Comparison to the cyanide-inhibited, substrate-bound complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; CHEMICAL-SHIFTS; ELECTRONIC-STRUCTURE; RESONANCE RAMAN; CATALYTIC SITE; RAT HEME; MECHANISM; PROTEIN; IDENTIFICATION	H-1 NMR was used to investigate the molecular structure, and dynamic properties of soluble, recombinant, substrate-free human heme oxygenase (apohHO) on a comparative basis with similar studies on the substrate complex. Limited but crucial sequence-specific assignments identify five conserved secondary structural elements, and the detection of highly characteristic dipolar or H-bond interactions among these elements together with insignificant chemical shift differences confirm a strongly conserved folding topology of helices C - H relative to that of substrate complexes in either solution or the crystal. The correction of the chemical shifts for paramagnetic and porphyrin ring current influences in the paramagnetic substrate complex reveals that the strength of all but one of the numerous relatively robust H-bonds are conserved in apohHO, and similar ordered water molecules are located near these H-bond donors as observed in the substrate complexes. The unique and significant weakening of the Tyr(58) OH hydrogen bond to the catalytically critical Asp(140) carboxylate in apohHO is suggested to arise from the removal of the axial H-bond acceptor ligand rather than the loss of substrate. The interhelical positions of the conserved strong H-bonds argue for a structural role in maintaining a conserved structure for helices C - H upon loss of substrate. While the structure and H-bond network are largely conserved upon loss of substrate, the variably increased rate of NH lability dictates a significant loss of dynamic stability in the conserved structure, particularly near the distal helix F.	Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California Davis; University of California System; University of California San Francisco	La Mar, GN (corresponding author), Univ Calif Davis, Dept Chem, Davis, CA 95616 USA.	lamar@indigo.ucdavis.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062830] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30297] Funding Source: Medline; NIGMS NIH HHS [GM62830] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asokan A, 2001, J AM CHEM SOC, V123, P4243, DOI 10.1021/ja003687w; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Beale S. I., 1994, MOL BIOL CYANOBACTER, P519; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; Caignan GA, 2002, J AM CHEM SOC, V124, P14879, DOI 10.1021/ja0274960; Clark K, 1996, J AM CHEM SOC, V118, P4654, DOI 10.1021/ja953719t; CROSS KJ, 1985, J MAGN RESON, V64, P220, DOI 10.1016/0022-2364(85)90346-4; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; de Montellano PRO, 2000, CURR OPIN CHEM BIOL, V4, P221; DEMONTELLANO PRO, 2003, PORPHRYIN HDB, P175; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; Frey PA, 2001, MAGN RESON CHEM, V39, pS190, DOI 10.1002/mrc.953; Gorst CM, 1998, J AM CHEM SOC, V120, P8875, DOI 10.1021/ja9815475; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Harris TK, 1999, PROTEINS, V35, P275, DOI 10.1002/(SICI)1097-0134(19990515)35:3<275::AID-PROT1>3.0.CO;2-V; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; Hirotsu S, 2004, J BIOL CHEM, V279, P11937, DOI 10.1074/jbc.M311631200; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jeffrey G. A., 1997, INTRO HYDROGEN BONDI, P11, DOI DOI 10.1246/CL.2012.65; JOHNSTON PD, 1979, P NATL ACAD SCI USA, V76, P3130, DOI 10.1073/pnas.76.7.3130; KUNTZ ID, 1991, J AM CHEM SOC, V113, P1406, DOI 10.1021/ja00004a050; La Mar G.N., 2000, PORPHYRIN HDB, V5, P185; La Mar GN, 2001, J BIOL CHEM, V276, P15676, DOI 10.1074/jbc.M009974200; Lad L, 2003, J BIOL CHEM, V278, P7834, DOI 10.1074/jbc.M211450200; Li YM, 2002, J BIOL CHEM, V277, P33018, DOI 10.1074/jbc.M204216200; Li YM, 2003, J AM CHEM SOC, V125, P13392, DOI 10.1021/ja036176t; Li YM, 2003, J BIOL CHEM, V278, P6651, DOI 10.1074/jbc.M211249200; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; McDermott A., 1996, ENCY NMR, P3820; Mildvan AS, 1999, METHOD ENZYMOL, V308, P219; MULLER RM, 1987, J BIOL CHEM, V262, P6795; Otting G, 1999, BIOL MAGN RESON, V17, P485; PARDI A, 1983, EUR J BIOCHEM, V137, P445, DOI 10.1111/j.1432-1033.1983.tb07848.x; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2002, J BIOL CHEM, V277, P45086, DOI 10.1074/jbc.M207267200; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; Syvitski RT, 2002, J AM CHEM SOC, V124, P14296, DOI 10.1021/ja028108x; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; WAGNER G, 1983, J AM CHEM SOC, V105, P5948, DOI 10.1021/ja00356a056; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; Yoshida T, 2000, J INORG BIOCHEM, V82, P33, DOI 10.1016/S0162-0134(00)00156-2; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042; Zhu WM, 2000, J BACTERIOL, V182, P6783, DOI 10.1128/JB.182.23.6783-6790.2000	55	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10195	10205		10.1074/jbc.M308379200	http://dx.doi.org/10.1074/jbc.M308379200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14660632	hybrid			2022-12-27	WOS:000220050400066
J	Dong, Z; Wang, JZ				Dong, Z; Wang, JZ			Hypoxia selection of death-resistant cells - A role for Bcl-X-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR; FAMILY-MEMBERS; PROTEIN FAMILY; APOPTOSIS; MITOCHONDRIA; EXPRESSION; ACTIVATION; OLIGOMERIZATION; ANGIOGENESIS; INHIBITION	Under hypoxia, some cells are irreversibly injured and die, whereas others can adapt to the stress and survive. The molecular and genetic basis underlying cellular sensitivity to hypoxic injury is unclear. Here we have selected death-resistant cells by repeated episodes of hypoxia. The selected cells are cross-resistant to apoptosis induced by staurosporine, azide, and cisplatin. These cells up-regulate Bcl-X-L, an anti-apoptotic protein. Bcl-X-L interacts with the pro-apoptotic molecule Bax and abrogates its toxicity in mitochondria, resulting in the preservation of mitochondrial integrity, cytochrome c, and cell viability. Down-regulation of Bcl-X-L by antisense oligonucleotides or the newly identified Bcl-X-L inhibitor chelerythrine restores cellular sensitivity to injury and death. Thus, Bcl-X-L is a key molecule for hypoxia selection of death resistance. These findings may have important implications for the development of solid tumors where hypoxia selects for death-resistant cells that are inert to cancer therapy.	Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	zdong@mail.mcg.edu						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Brown JM, 1999, CANCER RES, V59, P5863; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chan SL, 2003, J BIOL CHEM, V278, P20453, DOI 10.1074/jbc.C300138200; Dong Z, 2000, BIOCHEM J, V347, P669, DOI 10.1042/0264-6021:3470669; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Foreman KE, 1996, AM J PATHOL, V149, P795; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huang LE, 2003, J BIOL CHEM, V278, P19575, DOI 10.1074/jbc.R200030200; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Krajewska M, 1996, CANCER RES, V56, P2422; Maecker HL, 2000, CANCER RES, V60, P4638; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tu YP, 1998, CANCER RES, V58, P256; Wang XD, 2001, GENE DEV, V15, P2922; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200	41	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9215	9221		10.1074/jbc.M312225200	http://dx.doi.org/10.1074/jbc.M312225200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14676192	hybrid			2022-12-27	WOS:000189265900083
J	Ley, R; Ewings, KE; Hadfield, K; Howes, E; Balmanno, K; Cook, SJ				Ley, R; Ewings, KE; Hadfield, K; Howes, E; Balmanno, K; Cook, SJ			Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; CELL-CYCLE ARREST; C-JUN; PROAPOPTOTIC ACTIVITY; BIM EXPRESSION; SURVIVAL; ACTIVATION; GENE; JNK; BAX	Bim, a "BH3-only" protein, is expressed de novo following withdrawal of serum survival factors and promotes cell death. We have shown previously that activation of the ERK1/2 pathway promotes phosphorylation of Bim(EL), targeting it for degradation via the proteasome. However, the nature of the kinase responsible for Bim(EL) phosphorylation remained unclear. We now show that Bim(EL) is phosphorylated on at least three sites in response to activation of the ERK1/2 pathway. By using the peptidylprolyl isomerase, Pin1, as a probe for proline-directed phosphorylation, we show that ERK1/2-dependent phosphorylation of Bim(EL) occurs at (S/T) P motifs. ERK1/2 phosphorylates Bim(EL), but not Bim(S) or Bim(L), in vitro, and mutation of Ser(65) to alanine blocks the phosphorylation of Bim(EL) by ERK1/2 in vitro and in vivo and prevents the degradation of the protein following activation of the ERK1/2 pathway. We also find that ERK1/2, but not JNK, can physically associate with GST-Bim(EL), but not GST-Bim(L) or GST-Bim(S), in vitro. ERK1/2 also binds to full-length Bim(EL) in vivo, and we have localized a potential ERK1/2 "docking domain" lying within a 27-amino acid stretch of the Bim(EL) protein. Our findings provide new insights into the post-translational regulation of Bim(EL) and the role of the ERK1/2 pathway in cell survival signaling.	Babraham Inst, Signalling Programme, Mol Signalling Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Mol Signalling Lab, Cambridge CB2 4AT, England.	simon.cook@bbsrc.ac.uk		Balmanno, Kathryn/0000-0002-6417-3889	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C199, BBS/E/B/0000H457] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; He JQ, 2003, ONCOGENE, V22, P4524, DOI 10.1038/sj.onc.1206767; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Hsu T, 2001, NAT CELL BIOL, V3, P538, DOI 10.1038/35078508; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Seward RJ, 2003, MOL IMMUNOL, V39, P983, DOI 10.1016/S0161-5890(03)00047-6; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Tanoue T, 2002, PHARMACOL THERAPEUT, V93, P193, DOI 10.1016/S0163-7258(02)00188-2; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	43	172	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8837	8847		10.1074/jbc.M311578200	http://dx.doi.org/10.1074/jbc.M311578200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14681225	hybrid			2022-12-27	WOS:000189265900039
J	Smith, FM; Vearing, C; Lackmann, M; Treutlein, H; Himanen, J; Chen, K; Saul, A; Nikolov, D; Boyd, AW				Smith, FM; Vearing, C; Lackmann, M; Treutlein, H; Himanen, J; Chen, K; Saul, A; Nikolov, D; Boyd, AW			Dissecting the EphA3/ephrin-A5 interactions using a novel functional mutagenesis screen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; EPH RECEPTORS; LIGAND-BINDING; CRYSTAL-STRUCTURE; HEK; DIMERIZATION; ATTACHMENT; EPHRINS; DOMAIN	The EphA3 receptor tyrosine kinase preferentially binds ephrin-A5, a member of the corresponding subfamily of membrane-associated ligands. Their interaction regulates critical cell communication functions in normal development and may play a role in neoplasia. Here we describe a random mutagenesis approach, which we employed to study the molecular determinants of the EphA3/ephrin-A5 recognition. Selection and functional characterization of EphA3 point mutants with impaired ephrin-A5 binding from a yeast expression library defined three EphA3 surface areas that are essential for the EphA3/ephrin-A5 interaction. Two of these map to regions identified previously in the crystal structure of the homologous EphB2-ephrin-B2 complex as potential ligand/receptor interfaces. In addition, we identify a third EphA3/ephrin-A5 interface that falls outside the structurally characterized interaction domains. Functional analysis of EphA3 mutants reveals that all three Eph/ephrin contact areas are essential for the assembly of signaling-competent, oligomeric receptor-ligand complexes.	PO Royal Brisbane Hosp, Leukaemia Fdn Queensland Lab, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; PO Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Branch, Melbourne, Vic 3050, Australia; Cytopia, Melbourne, Vic 3004, Australia; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, Upton, NY 11973 USA; Univ Queensland, PO Royal Brisbane Hosp, Dept Med, St Lucia, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Memorial Sloan Kettering Cancer Center; University of Queensland	Lackmann, M (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.	Martin.Lackmann@med.monash.edu.au	Saul, Allan J/I-6968-2013; Boyd, Andrew/G-2083-2010; Treutlein, Herbert Rudolf/AAC-7648-2021; Saul, Allan/ABH-2091-2020	Saul, Allan J/0000-0003-0665-4091; Treutlein, Herbert Rudolf/0000-0001-5553-5553; Saul, Allan/0000-0003-0665-4091	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000727] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYD AW, 2001, SCI STKE; Coulthard MG, 2001, GROWTH FACTORS, V18, P303, DOI 10.3109/08977190109029118; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Drescher U, 2002, CURR OPIN GENET DEV, V12, P397, DOI 10.1016/S0959-437X(02)00316-7; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Himanen JP, 2003, TRENDS NEUROSCI, V26, P46, DOI 10.1016/S0166-2236(02)00005-X; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; Holmberg J, 2002, TRENDS NEUROSCI, V25, P239, DOI 10.1016/S0166-2236(02)02149-5; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; Lackmann M, 1997, J BIOL CHEM, V272, P16521, DOI 10.1074/jbc.272.26.16521; Lackmann M, 1998, J BIOL CHEM, V273, P20228, DOI 10.1074/jbc.273.32.20228; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Lemke G, 1997, MOL CELL NEUROSCI, V9, P331, DOI 10.1006/mcne.1997.0630; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Smith DK, 1998, PROTEIN SCI, V7, P886; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515	24	73	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9522	9531		10.1074/jbc.M309326200	http://dx.doi.org/10.1074/jbc.M309326200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660665	hybrid			2022-12-27	WOS:000189265900119
J	Traub, S; Kubasch, N; Morath, S; Kresse, M; Hartung, T; Schmidt, RR; Hermann, C				Traub, S; Kubasch, N; Morath, S; Kresse, M; Hartung, T; Schmidt, RR; Hermann, C			Structural requirements of synthetic muropeptides to synergize with lipopolysaccharide in cytokine induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL WALL; TUMOR-NECROSIS-FACTOR; MURAMYL-DIPEPTIDE; ANAPHYLACTOID REACTIONS; HUMAN MONOCYTES; ACID; INTERLEUKIN-1; ENDOTOXIN; ENHANCEMENT; RESPONSES	Muropeptides contribute to the recognition of bacteria by modulating immune responses: the structural requirements for adjuvant activity were described in the seventies. During the last years, our knowledge of bacterial pattern recognition has increased dramatically and the importance of the absence of contaminations in both muropeptide preparations and other bacterial stimuli has become clear. We investigated a panel of 15 synthetic Limulus-negative muropeptides, four of them synthesized for the first time, as to their potency to synergize with lipopolysaccharide (LPS) in cytokine induction in human whole blood. No muropeptide was capable of stimulating cytokine release from human blood. However, as little as 20 nM of the muropeptides N-acetyl-muramyl-L-alanyl-D-isoglutamine (muramyl dipeptide, M(ADiQ)), N-acetyl-glucosamine-muramyl dipeptide GM(ADiQ), or C18M(ADiQ), which carries a non-natural additional fatty acid, sufficed to induce an up to 3 log-order shift in tumor necrosis factor alpha-release in response to 100 pg/ml LPS. The release of interleukin-1beta, interleukin-6, and interleukin-10 was also significantly enhanced although to a lesser extent. The synergistic effect was stereoselective with M( ADiQ) being the minimal active principle. Synergy was also observed on the transcriptional level by means of real-time PCR. Smaller molecules like N-acetylmuramic acid (M), AM, carrying a naturally occurring 1,6-anhydro-bound in M or M(A), containing only the amino acid L-alanine neither synergized with LPS nor influenced the synergy of other muropeptides with LPS. In conclusion, these data show that nanomolar quantities of muropeptides dramatically potentiate LPS-induced monocyte activation. This has implications for pyrogenicity testing and endotoxemia in patients.	Univ Konstanz, Dept Biochem Pharmacol, D-78457 Constance, Germany; Univ Konstanz, Dept Chim Organ, D-78457 Constance, Germany	University of Konstanz; University of Konstanz	Hermann, C (corresponding author), Univ Konstanz, Dept Biochem Pharmacol, POB M655, D-78457 Constance, Germany.	Corinna.Hermann@uni-konstanz.de						ADAM A, 1988, ISI ATLAS-IMMUNOL, V1, P205; Alper PB, 1996, TETRAHEDRON LETT, V37, P6029, DOI 10.1016/0040-4039(96)01307-X; AZUMA I, 1992, VACCINE, V10, P1000, DOI 10.1016/0264-410X(92)90108-V; BAHR GM, 1987, CELL IMMUNOL, V107, P443, DOI 10.1016/0008-8749(87)90251-6; BERGMEYER HU, 1972, CLIN CHEM, V18, P1305; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; CZERNECKI S, 1992, TETRAHEDRON LETT, V33, P221, DOI 10.1016/0040-4039(92)88055-A; DINARELLO CA, 1986, FASEB J, V45, P2545; DOKTER WHA, 1994, J BIOL CHEM, V269, P4201; Dzierzbicka K, 2003, J MED CHEM, V46, P183, DOI 10.1021/jm020991m; ELLOUZ F, 1974, BIOCHEM BIOPH RES CO, V59, P1317, DOI 10.1016/0006-291X(74)90458-6; Flak TA, 2000, INFECT IMMUN, V68, P1235, DOI 10.1128/IAI.68.3.1235-1242.2000; Fosset S, 2003, PHYSIOL BEHAV, V79, P173, DOI 10.1016/S0031-9384(03)00065-9; Gao Y, 1998, J ORG CHEM, V63, P2133, DOI 10.1021/jo972133h; HARTUNG T, 1995, BLOOD, V85, P2482, DOI 10.1182/blood.V85.9.2482.bloodjournal8592482; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; HOLCOMB RC, 1994, TETRAHEDRON LETT, V35, P7005, DOI 10.1016/0040-4039(94)88210-X; HOLTJE JV, 1989, PROG IND M, V27, P101; HOLTJE JV, 1987, 18 WORKSH C HOECHST; Kalyuzhin OV, 2002, B EXP BIOL MED+, V134, P281, DOI 10.1023/A:1021519921125; KINZY W, 1985, LIEBIGS ANN CHEM, P1537; KINZY W, 1987, TETRAHEDRON LETT, V28, P1981, DOI 10.1016/S0040-4039(00)96025-8; KINZY W, 1987, LIEBIGS ANN CHEM, P407; KOTANI S, 1986, FASEB J, V45, P2534; Kubasch N, 2002, EUR J ORG CHEM, V2002, P2710, DOI 10.1002/1099-0690(200208)2002:16<2710::AID-EJOC2710>3.0.CO;2-8; KUSUMOTO S, 1976, B CHEM SOC JPN, V49, P533, DOI 10.1246/bcsj.49.533; Langford MP, 2002, MOL CELL BIOCHEM, V236, P63, DOI 10.1023/A:1016110429204; LECONTEL C, 1993, J IMMUNOL, V150, P4541; OREILLY T, 1992, CLIN INFECT DIS, V14, P1100, DOI 10.1093/clinids/14.5.1100; PARANT MA, 1995, INFECT IMMUN, V63, P110, DOI 10.1128/IAI.63.1.110-115.1995; PAULSEN H, 1986, LIEBIGS ANN CHEM, P664; Rossi Sergio, 2003, Dendrochronologia, V21, P33, DOI 10.1078/1125-7865-00034; Safavi KE, 2000, J ENDODONT, V26, P153, DOI 10.1097/00004770-200003000-00006; SCHMIDT U, 1984, SYNTHESIS-STUTTGART, P53, DOI 10.1055/s-1984-30730; SUZUKI K, 1994, IMMUNOPHARMACOLOGY, V28, P31, DOI 10.1016/0162-3109(94)90036-1; TAILLER D, 1992, J CHEM SOC PERK T 1, P3163, DOI 10.1039/p19920003163; TAKADA H, 1987, INFECT IMMUN, V55, P409, DOI 10.1128/IAI.55.2.409-413.1987; Takada H, 2002, J ENDOTOXIN RES, V8, P337, DOI 10.1179/096805102125000669; Takada H, 1996, INFECT IMMUN, V64, P657, DOI 10.1128/IAI.64.2.657-659.1996; TERMIN A, 1992, LIEBIGS ANN CHEM, P527; TERMIN A, 1989, LIEBIGS ANN CHEM, P789; VERMEULEN MW, 1987, J IMMUNOL, V139, P7; Wang JE, 2001, SHOCK, V16, P178, DOI 10.1097/00024382-200116030-00002; Wolfert MA, 2002, J BIOL CHEM, V277, P39179, DOI 10.1074/jbc.M204885200; Yang SH, 2001, INFECT IMMUN, V69, P2045, DOI 10.1128/IAI.69.4.2045-2053.2001; ZOLLER U, 1975, TETRAHEDRON, V31, P863, DOI 10.1016/0040-4020(75)80092-5	46	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8694	8700		10.1074/jbc.M310556200	http://dx.doi.org/10.1074/jbc.M310556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14668350	hybrid			2022-12-27	WOS:000189265900021
J	Baskakov, IV				Baskakov, IV			Autocatalytic conversion of recombinant prion proteins displays a species barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE EXPRESSING HUMAN; YEAST PRION; CONFORMATIONAL CONVERSION; SCRAPIE; PROPAGATION; STRAIN; PRP; BSE; FIBRILLIZATION; AGGREGATION	The most unorthodox feature of the prion disease is the existence of an abnormal infectious isoform of the prion protein, PrPSc. According to the "protein-only" hypothesis, PrPSc propagates its abnormal conformation in an autocatalytic manner using the normal isoform, PrPC, as a substrate. Because autocatalytic conversion is considered a key element of prion replication, in this study I tested whether in vitro conversion of recombinant PrP into abnormal isoform displays specific features of an autocatalytic process. I found that recombinant human PrP formed two distinct beta-sheet rich isoforms, the beta-oligomer and the amyloid fibrils. The kinetics of the fibrils formation measured at different pH values were consistent with a model in which the beta-oligomer was not on the kinetic pathway to the fibrillar form. As judged by electron microscopy, an acidic pH favored to the long fibrils, whereas short fibrils morphologically similar to "prion rods" were formed at neutral pH. At neutral pH the conversion to the fibrils can be seeded with small aliquots of preformed fibrils. As small as 0.001% aliquot displayed seeding activity. The conversion of human PrP was seeded with high efficacy only with the preformed fibrils of human but not mouse PrP and vice versa. These studies illustrate that in vitro conversion of recombinant PrP displays specific features of an autocatalytic process and mimics the transmission barrier of prion propagation observed in vivo. I speculate that this model can be used as a rapid assay for assessing the intrinsic propensities of prion transmission between different species.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Baskakov, IV (corresponding author), 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu						Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; GAJDUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; Kirby L, 2003, J GEN VIROL, V84, P1013, DOI 10.1099/vir.0.18903-0; Kundu B, 2003, P NATL ACAD SCI USA, V100, P12069, DOI 10.1073/pnas.2033281100; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Lu BY, 2001, BIOCHEMISTRY-US, V40, P13390, DOI 10.1021/bi011111t; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1968, RES VET SCI, V9, P408; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; RAEBER AJ, 1992, J VIROL, V66, P6155, DOI 10.1128/JVI.66.10.6155-6163.1992; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Scott MR, 1997, J VIROL, V71, P9032, DOI 10.1128/JVI.71.12.9032-9044.1997; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Vanik DL, 2002, J BIOL CHEM, V277, P49065, DOI 10.1074/jbc.M207511200; Welker E, 2002, J BIOL CHEM, V277, P33477, DOI 10.1074/jbc.M204273200; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609	37	71	74	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7671	7677		10.1074/jbc.M310594200	http://dx.doi.org/10.1074/jbc.M310594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668351	hybrid			2022-12-27	WOS:000189103300038
J	De Rosa, MF; Sillence, D; Ackerley, C; Lingwood, C				De Rosa, MF; Sillence, D; Ackerley, C; Lingwood, C			Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MDR1 P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; GLUCOSYLCERAMIDE SYNTHASE; GOLGI-APPARATUS; IMPROVED INHIBITORS; EXPRESSION CLONING; BROAD-SPECIFICITY; PLASMA-MEMBRANE; CYCLOSPORINE-A	Transfection studies have implicated the multiple drug resistance pump, MDR1, as a glucosyl ceramide translocase within the Golgi complex (Lala, P., Ito, S., and Lingwood, C. A. ( 2000) J. Biol. Chem. 275, 6246 6251). We now show that MDR1 inhibitors, cyclosporin A or ketoconazole, inhibit neutral glycosphingolipid biosynthesis in 11 of 12 cell lines tested. The exception, HeLa cells, do not express MDR1. Microsomal lactosyl ceramide and globotriaosyl ceramide synthesis from endogenous or exogenously added liposomal glucosyl ceramide was inhibited by cyclosporin A, consistent with a direct role for MDR1/glucosyl ceramide translocase activity in their synthesis. In contrast, cellular ganglioside synthesis in the same cells, was unaffected by MDR1 inhibition, suggesting neutral and acid glycosphingolipids are synthesized from distinct precursor glycosphingolipid pools. Metabolic labeling in wild type and knockout (MDR1a, 1b, MRP1) mouse fibroblasts showed the same loss of neutral glycosphingolipid ( glucosyl ceramide, lactosyl ceramide) but not ganglioside (GM3) synthesis, confirming the proposed role for MDR1 translocase activity. Cryo-immunoelectron microscopy showed MDR1 was predominantly intracellular, largely in rab6-containing Golgi vesicles and Golgi cisternae, the site of glycosphingolipid synthesis. These studies identify MDR1 as the major glucosyl ceramide flippase required for neutral glycosphingolipid anabolism and demonstrate a previously unappreciated dichotomy between neutral and acid glycosphingolipid synthesis.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L5, Canada; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Oxford	Lingwood, C (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	cling@sickkids.on.ca	Sillence, Dan J/J-9513-2019	Sillence, Dan J/0000-0003-4747-5655				ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; Allende ML, 2000, GLYCOBIOLOGY, V10, P1025, DOI 10.1093/glycob/10.10.1025; Arab S, 1999, ONCOL RES, V11, P33; Arab S, 1998, J CELL PHYSIOL, V177, P646, DOI 10.1002/(SICI)1097-4652(199812)177:4<646::AID-JCP15>3.0.CO;2-B; Arab S, 1996, GLYCOCONJUGATE J, V13, P159, DOI 10.1007/BF00731490; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Binnington B, 2002, NEUROCHEM RES, V27, P807, DOI 10.1023/A:1020261125008; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; BOULANGER J, 1990, J CLIN MICROBIOL, V28, P2830, DOI 10.1128/JCM.28.12.2830-2833.1990; BRADLEY G, 1989, CANCER RES, V49, P2790; Burger KNJ, 1996, J CELL BIOL, V133, P15, DOI 10.1083/jcb.133.1.15; Chark D., 2004, EUR J BIOCHEM, V271, P1; COHEN A, 1990, INT IMMUNOL, V2, P1, DOI 10.1093/intimm/2.1.1; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; Demeule M, 2000, FEBS LETT, V466, P219, DOI 10.1016/S0014-5793(00)01087-5; ENGELHARDT D, 1994, J STEROID BIOCHEM, V49, P261, DOI 10.1016/0960-0760(94)90267-4; FORSYTH GW, 1993, CLIN CHIM ACTA, V216, P11, DOI 10.1016/0009-8981(93)90135-Q; Fukumoto S, 1999, J BIOL CHEM, V274, P9271, DOI 10.1074/jbc.274.14.9271; Futscher BW, 1996, INT J CANCER, V66, P520, DOI 10.1002/(SICI)1097-0215(19960516)66:4<520::AID-IJC16>3.0.CO;2-B; Gariepy J, 2001, CRIT REV ONCOL HEMAT, V39, P99, DOI 10.1016/S1040-8428(01)00126-3; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; Gillard BK, 1998, GLYCOBIOLOGY, V8, P885, DOI 10.1093/glycob/8.9.885; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HEATHENGEL H, 2004, IN PRESS ANGIOGENESI; HILL BT, 1994, CANCER, V73, P2990, DOI 10.1002/1097-0142(19940615)73:12<2990::AID-CNCR2820731217>3.0.CO;2-L; HO S, 1996, CLIN IMMUNOL IMMUNOP, V80, P40; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Johnson DR, 2001, CANCER RES, V61, P1469; KIARASH A, 1994, J BIOL CHEM, V269, P11138; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; LANNERT H, 1994, FEBS LETT, V342, P91, DOI 10.1016/0014-5793(94)80591-1; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Li RX, 1997, J BIOL CHEM, V272, P1349, DOI 10.1074/jbc.272.2.1349; Lingwood CA, 1999, BIOSCIENCE REP, V19, P345, DOI 10.1023/A:1020299819637; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Lucci A, 1998, ANTICANCER RES, V18, P475; Luker GD, 1999, J BIOL CHEM, V274, P6979, DOI 10.1074/jbc.274.11.6979; Luker GD, 2001, J LIPID RES, V42, P1389; LUM BL, 1995, HEMATOL ONCOL CLIN N, V9, P319, DOI 10.1016/S0889-8588(18)30097-2; MacLeod RAF, 1999, INT J CANCER, V83, P555; Majoul I, 2002, J CELL SCI, V115, P817; Meivar-Levy I, 1999, J BIOL CHEM, V274, P4607, DOI 10.1074/jbc.274.8.4607; Nutikka Anita, 2003, Methods Mol Med, V73, P187; Nutikka Anita, 2003, Methods Mol Med, V73, P197; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; Plo I, 2002, MOL PHARMACOL, V62, P304, DOI 10.1124/mol.62.2.304; PUDYMAITIS A, 1991, ARCH BIOCHEM BIOPHYS, V286, P448, DOI 10.1016/0003-9861(91)90064-P; Raggers RJ, 2001, BIOCHEM J, V357, P859, DOI 10.1042/0264-6021:3570859; Reuter G, 2003, J BIOL CHEM, V278, P35193, DOI 10.1074/jbc.M306226200; SAEKI T, 1993, J BIOL CHEM, V268, P6077; Salhia B, 2002, NEOPLASIA, V4, P304, DOI 10.1038/sj.neo.7900243; SANDVIG K, 1987, INFECT IMMUN, V55, P298, DOI 10.1128/IAI.55.2.298-303.1987; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; Shabbits JA, 2002, MOL CANCER THER, V1, P205; Shu LM, 2000, ARCH BIOCHEM BIOPHYS, V373, P83, DOI 10.1006/abbi.1999.1553; Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232-JLR200; Smith AJ, 1998, HEPATOLOGY, V28, P530, DOI 10.1002/hep.510280234; Stern CA, 2000, GLYCOBIOLOGY, V10, P365, DOI 10.1093/glycob/10.4.365; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; Takano M, 1998, EUR J PHARMACOL, V358, P289, DOI 10.1016/S0014-2999(98)00607-4; Touhey S, 2002, EUR J CANCER, V38, P1661, DOI 10.1016/S0959-8049(02)00128-4; Tsuboi N, 2001, KIDNEY INT, V60, P1378, DOI 10.1046/j.1523-1755.2001.00967.x; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200; van Meer G, 2001, P NATL ACAD SCI USA, V98, P1321, DOI 10.1073/pnas.98.4.1321; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VELDMAN J, 2002, FASEB J, V10, P1096; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; YOGEESWARAN G, 1975, BIOCHEMISTRY-US, V14, P2151, DOI 10.1021/bi00681a017; ZACHARIAS C, 1994, J BIOL CHEM, V269, P13313; Zager RA, 2001, KIDNEY INT, V60, P944, DOI 10.1046/j.1523-1755.2001.060003944.x; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	81	81	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7867	7876		10.1074/jbc.M305645200	http://dx.doi.org/10.1074/jbc.M305645200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14662772	hybrid			2022-12-27	WOS:000189103300063
J	Kim, OJ; Gardner, BR; Williams, DB; Marinec, PS; Cabrera, DM; Peters, JD; Mak, CC; Kim, KM				Kim, OJ; Gardner, BR; Williams, DB; Marinec, PS; Cabrera, DM; Peters, JD; Mak, CC; Kim, KM			The role of phosphorylation in D-1 dopamine receptor desensitization - Evidence for a novel mechanism of arrestin association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; PROTEIN-COUPLED RECEPTORS; CYTOPLASMIC TAIL; DEPENDENT PHOSPHORYLATION; DIFFERENTIAL REGULATION; BETA-ARRESTINS; ACTIVATION; BINDING; KINASE; IDENTIFICATION	Homologous desensitization of D-1 dopamine receptors is thought to occur through their phosphorylation leading to arrestin association which interdicts G protein coupling. In order to identify the relevant domains of receptor phosphorylation, and to determine how this leads to arrestin association, we created a series of mutated D-1 receptor constructs. In one mutant, all of the serine/threonine residues within the 3rd cytoplasmic domain were altered (3rdTOT). A second construct was created in which only three of these serines (serines 256, 258, and 259) were mutated (3rd234). We also created four truncation mutants of the carboxyl terminus (T347, T369, T394, and T404). All of these constructs were comparable with the wild-type receptor with respect to expression and adenylyl cyclase activation. In contrast, both of the 3rd loop mutants exhibited attenuated agonist-induced receptor phosphorylation that was correlated with an impaired desensitization response. Sequential truncation of the carboxyl terminus of the receptor resulted in a sequential loss of agonist-induced phosphorylation. No phosphorylation was observed with the most severely truncated T347 mutant. Surprisingly, all of the truncated receptors exhibited normal desensitization. The ability of the receptor constructs to promote arrestin association was evaluated using arrestin-green fluorescent protein translocation assays and confocal fluorescence microscopy. The 3rd234 mutant receptor was impaired in its ability to induce arrrestin translocation, whereas the T347 mutant was comparable with wild type. Our data suggest a model in which arrestin directly associates with the activated 3rd cytoplasmic domain in an agonist-dependent fashion; however, under basal conditions, this is sterically prevented by the carboxyl terminus of the receptor. Receptor activation promotes the sequential phosphorylation of residues, first within the carboxyl terminus and then the 3rd cytoplasmic loop, thereby dissociating these domains and allowing arrestin to bind to the activated 3rd loop. Thus, the role of receptor phosphorylation is to allow access of arrestin to its receptor binding domain rather than to create an arrestin binding site per se.	NINDS, Mol Neuropharmacol Sect, NIH, Bethesda, MD 20892 USA; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Chonnam National University	Kim, KM (corresponding author), NINDS, Mol Neuropharmacol Sect, NIH, Bldg 10,Rm 5C108,10 Ctr Dr,MSC 1406, Bethesda, MD 20892 USA.	sibley@helix.nih.gov	Cabrera, David/I-1013-2014		Intramural NIH HHS [Z01 NS002263-31] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002263] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barak LS, 1999, METHOD ENZYMOL, V302, P153, DOI 10.1016/S0076-6879(99)02016-9; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Chaar ZY, 2001, J NEUROCHEM, V79, P1047, DOI 10.1046/j.1471-4159.2001.00648.x; Felder RA, 2002, P NATL ACAD SCI USA, V99, P3872, DOI 10.1073/pnas.062694599; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; Jackson A, 2000, FEBS LETT, V470, P183, DOI 10.1016/S0014-5793(00)01315-6; Jackson A, 2002, J NEUROCHEM, V82, P683, DOI 10.1046/j.1471-4159.2002.01001.x; Jiang D, 1999, MOL PHARMACOL, V56, P675; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kishi H, 2002, J BIOL CHEM, V277, P21939, DOI 10.1074/jbc.M110894200; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KOZELL LB, 1994, J BIOL CHEM, V269, P30299; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Lewis MM, 1998, J PHARMACOL EXP THER, V286, P345; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Mason JN, 2002, MOL PHARMACOL, V61, P806, DOI 10.1124/mol.61.4.806; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Richardson MD, 2003, J NEUROCHEM, V84, P854, DOI 10.1046/j.1471-4159.2003.01577.x; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBINSON SW, 1994, MOL PHARMACOL, V46, P352; SIBLEY DR, 1996, DOPAMINE RECEPTORS, P383; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Tumova K, 2003, J BIOL CHEM, V278, P8146, DOI 10.1074/jbc.M208059200; Ventura ALM, 2000, J PHARMACOL EXP THER, V293, P426; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	38	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7999	8010		10.1074/jbc.M308281200	http://dx.doi.org/10.1074/jbc.M308281200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660631	hybrid, Green Accepted			2022-12-27	WOS:000189103300078
J	Vanden Berghe, T; van Loo, G; Saelens, X; van Gurp, M; Brouckaert, G; Kalai, M; Declercq, W; Vandenabeele, P				Vanden Berghe, T; van Loo, G; Saelens, X; van Gurp, M; Brouckaert, G; Kalai, M; Declercq, W; Vandenabeele, P			Differential signaling to apoptotic and necrotic cell death by Fas-associated death domain protein FADD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; MAMMALIAN-CELLS; KINASE RIP; FACTOR TNF; ACTIVATION; PATHWAY; CASPASE-8; COMPLEX; MITOCHONDRIA; INHIBITION	Two general pathways for cell death have been defined, apoptosis and necrosis. Previous studies in Jurkat cells have demonstrated that the Fas-associated death domain (FADD) is required for Fas-mediated signaling to apoptosis and necrosis. Here we developed L929rTA cell lines that allow Tet-on inducible expression and FK506-binding protein ( FKBP)-mediated dimerization of FADD, FADD-death effector domain (FADD-DED), or FADD-death domain (FADD-DD). We show that expression and dimerization of FADD leads to necrosis. However, pretreatment of the cells with the Hsp90 inhibitor geldanamycin, which leads to proteasome-mediated degradation of receptor interacting protein 1 (RIP1), reverts FKBP-FADD-induced necrosis to apoptosis. Expression and dimerization of FADD-DD mediates necrotic cell death. We found that FADD-DD is able to bind RIP1, another protein necessary for Fas-mediated necrosis. Expression and dimerization of FADD-DED initiates apoptosis. Remarkably, in the presence of caspase inhibitors, FADD-DED mediates necrotic cell death. Coimmunoprecipitation studies revealed that FADD-DED in the absence procaspase-8 C/A is also capable of recruiting RIP1. However, when procaspase-8 C/A and RIP1 are expressed simultaneously, FADD-DED preferentially recruits procaspase-8 C/A.	Flanders Interuniv Inst Biotechnol VIB, Dept Mol Biomed Res, Mol Signalling & Cell Death Unit, B-9052 Zwijnaarde, Belgium; State Univ Ghent, B-9052 Zwijnaarde, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Vandenabeele, P (corresponding author), Flanders Interuniv Inst Biotechnol VIB, Dept Mol Biomed Res, Mol Signalling & Cell Death Unit, Technol Pk 927, B-9052 Zwijnaarde, Belgium.	peter.vandenabeele@dmbr.UGent.be	van Loo, Geert/C-1505-2009; Vanden Berghe, Tom/C-4916-2009; , van Loo Geert/AAD-1220-2019; Saelens, Xavier/N-5728-2015; Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009; Berghe, Tom Vanden/N-2902-2019	Vanden Berghe, Tom/0000-0002-1633-0974; , van Loo Geert/0000-0002-8427-4775; Vandenabeele, Peter/0000-0002-6669-8822; Berghe, Tom Vanden/0000-0002-1633-0974; , Xavier/0000-0002-3861-6965				Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boone E, 2000, J BIOL CHEM, V275, P37596, DOI 10.1074/jbc.M007166200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Denecker G, 2001, CELL MOL LIFE SCI, V58, P356, DOI 10.1007/PL00000863; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Freundlieb S, 1999, J GENE MED, V1, P4, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hill JM, 2004, J BIOL CHEM, V279, P1474, DOI 10.1074/jbc.M304996200; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Kalai M, 2002, CELL DEATH DIFFER, V9, P981, DOI 10.1038/sj.cdd.4401051; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; LAMKANFI M, 2003, CASPASES THEIR ROLE, P1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Schotte P, 2001, J BIOL CHEM, V276, P25939, DOI 10.1074/jbc.M104014200; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vandevoorde V, 1997, J CELL BIOL, V137, P1627, DOI 10.1083/jcb.137.7.1627; VANHOENACKER P, 1999, GENE THER MOL BIOL, V3, P301; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Wyllie A H, 1980, Int Rev Cytol, V68, P251	38	88	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7925	7933		10.1074/jbc.M307807200	http://dx.doi.org/10.1074/jbc.M307807200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668343	hybrid			2022-12-27	WOS:000189103300070
J	Wang, Y; Pennock, SD; Chen, XM; Kazlauskas, A; Wang, ZX				Wang, Y; Pennock, SD; Chen, XM; Kazlauskas, A; Wang, ZX			Platelet-derived growth factor receptor-mediated signal transduction from endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; 2 DISTINCT PHASES; PDGF RECEPTOR; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; BETA(2)-ADRENERGIC RECEPTOR; KINASE COMPLEXES; PROTEIN-KINASE; BETA-RECEPTOR; BINDING-SITE	Although accumulated evidence supports the concept of endosomal signaling of receptor tyrosine kinases, most results are generated from studies of epidermal growth factor receptor (EGFR). It is not clear whether the concept of endosomal signaling could be generally applied to the other receptor tyrosine kinases. For example, platelet-derived growth factor receptor (PDGFR) is very similar to EGFR in terms of both signaling and trafficking; however, little is known about the endosomal signaling of PDGFR. In this research, we applied the same approaches from our recent studies regarding EGFR endosomal signaling to investigate the endosomal signaling of PDGFR. We showed in this communication that we are able to establish a system that allows the specific activation of endosome-associated PDGFR without the activation of the plasma membrane-associated PDGFR and without disrupting the overall endocytosis pathway. By using this system, we showed that endosomal activation of PDGFR recruits various signaling proteins including Grb2, SHC, phospholipase C-gamma1, and the p85alpha subunit of phosphatidylinositol 3-kinase into endosomes and forms signaling complexes with PDGFR. We also showed that endosomal PDGFR signaling is sufficient to activate the major signaling pathways implicated in cell proliferation and survival. Moreover, we demonstrate that endosomal PDGFR signaling is sufficient to generate physiological output including cell proliferation and cell survival.	Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Fac Med & Dent, Signal Transduct Res Grp, Edmonton, AB T6G 2H7, Canada; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	University of Alberta; University of Alberta; Harvard University; Harvard Medical School; Schepens Eye Research Institute	Wang, ZX (corresponding author), Univ Alberta, Fac Med & Dent, Dept Cell Biol, Edmonton, AB T6G 2H7, Canada.	zwang@cellbnt.ualberta.ca						Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Clague MJ, 2001, J CELL SCI, V114, P3075; COHEN S, 1985, J BIOL CHEM, V260, P2351; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAY DG, 1986, J BIOL CHEM, V261, P8473; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS RJ, 1993, TRENDS BIOTECHNOL, V11, P439, DOI 10.1016/0167-7799(93)90075-K; KELLY JD, 1991, J BIOL CHEM, V266, P8987; Kong M, 2003, MOL ENDOCRINOL, V17, P935, DOI 10.1210/me.2002-0391; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lipson KE, 1998, J PHARMACOL EXP THER, V285, P844; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Pennock S, 2003, MOL CELL BIOL, V23, P5803, DOI 10.1128/MCB.23.16.5803-5815.2003; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WAHL MI, 1990, J BIOL CHEM, V265, P3944; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Wang Y., 2002, SCI STKE, V161, pl17; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	54	104	105	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8038	8046		10.1074/jbc.M311494200	http://dx.doi.org/10.1074/jbc.M311494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660565	hybrid			2022-12-27	WOS:000189103300082
J	Yasuno, R; von Wettstein-Knowles, P; Wada, H				Yasuno, R; von Wettstein-Knowles, P; Wada, H			Identification and molecular characterization of the beta-ketoacyl-[acyl carrier protein] synthase component of the Arabidopsis mitochondrial fatty acid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN SYNTHASE; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; LIPOIC ACID; PLANT-MITOCHONDRIA; CRYSTAL-STRUCTURE; BIOSYNTHESIS; GENE; CERULENIN	Substrate specificity of condensing enzymes is a predominant factor determining the nature of fatty acyl chains synthesized by type II fatty acid synthase (FAS) enzyme complexes composed of discrete enzymes. The gene (mtKAS) encoding the condensing enzyme, beta-ketoacyl[ acyl carrier protein] (ACP) synthase (KAS), constituent of the mitochondrial FAS was cloned from Arabidopsis thaliana, and its product was purified and characterized. The mtKAS cDNA complemented the KAS II defect in the E. coli CY244 strain mutated in both fabB and fabF encoding KAS I and KAS II, respectively, demonstrating its ability to catalyze the condensation reaction in fatty acid synthesis. In vitro assays using extracts of CY244 containing all E. coli FAS components, except that KAS I and II were replaced by mtKAS, gave C-4 - C-18 fatty acids exhibiting a bimodal distribution with peaks at C-8 and C-14 - C-16. Previously observed bimodal distributions obtained using mitochondrial extracts appear attributable to the mtKAS enzyme in the extracts. Although the mtKAS sequence is most similar to that of bacterial KAS IIs, sensitivity of mtKAS to the antibiotic cerulenin resembles that of E. coli KAS I. In the first or priming condensation reaction of de novo fatty acid synthesis, purified His-tagged mtKAS efficiently utilized malonyl-ACP, but not acetyl-CoA as primer substrate. Intracellular targeting using green fluorescent protein, Western blot, and deletion analyses identified an N-terminal signal conveying mtKAS into mitochondria. Thus, mtKAS with its broad chain length specificity accomplishes all condensation steps in mitochondrial fatty acid synthesis, whereas in plastids three KAS enzymes are required.	Univ Copenhagen, Inst Mol Biol, Dept Genet, DK-1353 Copenhagen K, Denmark; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan	University of Copenhagen; University of Tokyo	von Wettstein-Knowles, P (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Genet, Oester Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.	knowles@biobase.dk; hwada@bio.c.u-tokyo.ac.jp	Wada, Hajime/K-2186-2015; YASUNO, RIE/M-3252-2018	YASUNO, RIE/0000-0003-0108-9281				ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; BALDET P, 1993, ARCH BIOCHEM BIOPHYS, V303, P67, DOI 10.1006/abbi.1993.1256; BLOCH K, 1977, ANNU REV BIOCHEM, V46, P263, DOI 10.1146/annurev.bi.46.070177.001403; BROCK DJ, 1966, BIOCHEM BIOPH RES CO, V25, P473, DOI 10.1016/0006-291X(66)90230-0; BROCK DJH, 1966, BIOCHEM BIOPH RES CO, V23, P775, DOI 10.1016/0006-291X(66)90469-4; BRODY S, 1988, EUR J BIOCHEM, V173, P353, DOI 10.1111/j.1432-1033.1988.tb14005.x; Carlsson AS, 2002, PLANT J, V29, P761, DOI 10.1046/j.1365-313X.2002.01253.x; Chacinska A, 2002, TRENDS CELL BIOL, V12, P299, DOI 10.1016/S0962-8924(02)02310-3; CHERET G, 1993, YEAST, V9, P661, DOI 10.1002/yea.320090612; CHUMAN L, 1989, EUR J BIOCHEM, V184, P643, DOI 10.1111/j.1432-1033.1989.tb15061.x; COOPER CL, 1987, J BACTERIOL, V169, P605, DOI 10.1128/jb.169.2.605-611.1987; DAGNOLO G, 1975, J BIOL CHEM, V250, P5289; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Dehesh K, 1998, PLANT J, V15, P383, DOI 10.1046/j.1365-313X.1998.00218.x; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; ESFAHANI M, 1969, P NATL ACAD SCI USA, V64, P1057, DOI 10.1073/pnas.64.3.1057; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; HARINGTON A, 1993, MOL MICROBIOL, V9, P545, DOI 10.1111/j.1365-2958.1993.tb01715.x; Harwood JL, 1996, BBA-LIPID LIPID MET, V1301, P7, DOI 10.1016/0005-2760(95)00242-1; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JAWORSKI JG, 1989, PLANT PHYSIOL, V90, P41, DOI 10.1104/pp.90.1.41; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KOTTIG H, 1991, MOL GEN GENET, V226, P310, DOI 10.1007/BF00273618; LENNARZ WJ, 1962, P NATL ACAD SCI USA, V48, P840, DOI 10.1073/pnas.48.5.840; LUDWIG SR, 1987, P NATL ACAD SCI USA, V84, P5833, DOI 10.1073/pnas.84.16.5833; MAGNUSON K, 1995, J BACTERIOL, V177, P3593, DOI 10.1128/jb.177.12.3593-3595.1995; McGuire KA, 2001, BIOCHEMISTRY-US, V40, P9836, DOI 10.1021/bi0105577; Mekhedov S, 2000, PLANT PHYSIOL, V122, P389, DOI 10.1104/pp.122.2.389; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; MILLAR AA, 1995, PLANT PHYSIOL, V108, P1747; Miller JR, 2000, BIOCHEMISTRY-US, V39, P15166, DOI 10.1021/bi002060n; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Niwa Y, 1999, PLANT J, V18, P455, DOI 10.1046/j.1365-313X.1999.00464.x; OLIVER DJ, 1994, ANNU REV PLANT PHYS, V45, P323, DOI 10.1146/annurev.pp.45.060194.001543; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; Olsen JG, 2001, STRUCTURE, V9, P233, DOI 10.1016/S0969-2126(01)00583-4; Plesofsky N, 2000, BBA-MOL CELL RES, V1495, P223, DOI 10.1016/S0167-4889(99)00170-6; Qiu XY, 2001, J MOL BIOL, V307, P341, DOI 10.1006/jmbi.2000.4457; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RASMUSSEN AV, 2002, THESIS U COPENHAGEN; Rock C O, 1981, Methods Enzymol, V71 Pt C, P163; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Schneider R, 1997, CURR GENET, V32, P384, DOI 10.1007/s002940050292; Shanklin J, 2000, PROTEIN EXPRES PURIF, V18, P355, DOI 10.1006/prep.2000.1206; SHIMAKATA T, 1982, P NATL ACAD SCI-BIOL, V79, P5808, DOI 10.1073/pnas.79.19.5808; SHINTANI DK, 1994, PLANT PHYSIOL, V104, P1221, DOI 10.1104/pp.104.4.1221; SIGGAARDANDERSEN M, 1994, P NATL ACAD SCI USA, V91, P11027, DOI 10.1073/pnas.91.23.11027; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; ULRICH AK, 1983, J BACTERIOL, V154, P221, DOI 10.1128/JB.154.1.221-230.1983; VASSILEV AO, 1995, P NATL ACAD SCI USA, V92, P8680, DOI 10.1073/pnas.92.19.8680; von Wettstein-Knowles P, 2000, BIOCHEM SOC T, V28, P601, DOI 10.1042/BST0280601; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Yasuno R, 1998, PLANT PHYSIOL, V118, P935, DOI 10.1104/pp.118.3.935; Zhang L, 2003, J BIOL CHEM, V278, P40067, DOI 10.1074/jbc.M306121200; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200	67	61	63	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8242	8251		10.1074/jbc.M308894200	http://dx.doi.org/10.1074/jbc.M308894200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660674	hybrid			2022-12-27	WOS:000189103300106
J	di San Filippo, CA; Longo, N				di San Filippo, CA; Longo, N			Tyrosine residues affecting sodium stimulation of carnitine transport in the OCTN2 carnitine/organic cation transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION/CARNITINE TRANSPORTER; GLUCOSE COTRANSPORTER; ESCHERICHIA-COLI; DEFICIENCY; MUTATIONS; PHENOTYPE; MECHANISM; DEFECTS	Primary carnitine deficiency is a disorder of fatty acid oxidation caused by mutations in the Na+-dependent carnitine/organic cation transporter OCTN2. Studies with tyrosyl group-modifying reagents support the involvement of tyrosine residues in Na+ binding by sodium-coupled transporters. Here we report two new patients with carnitine deficiency caused by mutations affecting tyrosyl residues (Y447C and Y449D) close to a residue (Glu-452) previously shown to affect sodium stimulation of carnitine transport. Kinetic analysis indicated that the Y449D substitution, when expressed in Chinese hamster ovary cells, increased the concentration of sodium required to half-maximally stimulate carnitine transport from 14.8 +/- 1.8 to 34.9 +/- 5.8 mm (p < 0.05), whereas Y447C completely abolished carnitine transport. Substitution of these tyrosine residues with phenylalanine restored normal carnitine transport in Y449F but resulted in markedly impaired carnitine transport by Y447F. This was associated with an increase in the concentration of sodium required to half-maximally stimulate carnitine transport to 57.8 +/- 7.4 mm (p < 0.01 versus normal OCTN2). The Y447F and Y449D mutant transporters retained their ability to transport the organic cation tetraethylammonium indicating that their effect on carnitine transport was specific and likely associated with the impaired sodium stimulation of carnitine transport. By contrast, the Y447C natural mutation abolished the transport of organic cations in addition to carnitine. Confocal microscopy of OCTN2 transporters tagged with green fluorescent protein indicated that the Y447C mutant transporters failed to reach the plasma membrane, whereas Y447F, Y449D, and Y449F had normal membrane localization. These natural mutations identify tyrosine residues possibly involved in coupling the sodium electrochemical gradient to transmembrane solute transfer in the sodium-dependent co-transporter OCTN2.	Univ Utah, Dept Pediat, Div Med Genet, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Longo, N (corresponding author), Univ Utah, Dept Pediat, Div Med Genet, 2C 412 SOM,50 N Med Dr, Salt Lake City, UT 84132 USA.	Nicola.Longo@hse.utah.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053824] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53824] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; GANAPATHY V, 1989, J PHARMACOL EXP THER, V251, P9; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; KOEPSELL H, 2003, IN PRESS PFLUEGERS A; KULANTHAIVEL P, 1989, BIOCHIM BIOPHYS ACTA, V985, P139, DOI 10.1016/0005-2736(89)90358-1; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Meyer-Wentrup F, 1998, BIOCHEM BIOPH RES CO, V248, P673, DOI 10.1006/bbrc.1998.9034; Ohashi R, 2002, J PHARMACOL EXP THER, V302, P1286, DOI 10.1124/jpet.102.036004; Ohashi R, 2001, MOL PHARMACOL, V59, P358, DOI 10.1124/mol.59.2.358; PEERCE BE, 1985, J BIOL CHEM, V260, P6026; PEERCE BE, 1984, J BIOL CHEM, V259, P4105; Scaglia F, 1999, ARCH BIOCHEM BIOPHYS, V364, P99, DOI 10.1006/abbi.1999.1118; Scaglia F, 1999, SEMIN PERINATOL, V23, P152, DOI 10.1016/S0146-0005(99)80047-0; Segel, 1975, ENZYME KINETICS BEHA, P274; Seth P, 1999, J BIOL CHEM, V274, P33388, DOI 10.1074/jbc.274.47.33388; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Vockley J, 2000, MOL GENET METAB, V71, P10, DOI 10.1006/mgme.2000.3066; Wang YH, 2000, HUM MUTAT, V16, P401, DOI 10.1002/1098-1004(200011)16:5<401::AID-HUMU4>3.0.CO;2-J; Wang YH, 2000, HUM MUTAT, V15, P238, DOI 10.1002/(SICI)1098-1004(200003)15:3<238::AID-HUMU4>3.0.CO;2-3; Wang YH, 2000, J BIOL CHEM, V275, P20782, DOI 10.1074/jbc.M000194200; Wang YH, 1999, P NATL ACAD SCI USA, V96, P2356, DOI 10.1073/pnas.96.5.2356; Wang YH, 2001, GENET MED, V3, P387, DOI 10.1097/00125817-200111000-00002; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	24	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7247	7253		10.1074/jbc.M309171200	http://dx.doi.org/10.1074/jbc.M309171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14665638	hybrid			2022-12-27	WOS:000188969200126
J	Staniforth, V; Wang, SY; Shyur, LF; Yang, NS				Staniforth, V; Wang, SY; Shyur, LF; Yang, NS			Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RHEUMATOID-ARTHRITIS; TNF-ALPHA; PARTICLE BOMBARDMENT; MECHANICAL-STRESS; ANTIBODY CDP571; C-JUN; EXPRESSION; PROTEIN; DISEASE	Tumor necrosis factor alpha (TNF-alpha) contributes to the pathogenesis of both acute and chronic inflammatory diseases and has been a target for the development of new anti-inflammatory drugs. Shikonins, the naphthoquinone pigments present in the root tissues of Lithospermum erythrorhizon Sieb. et Zucc. (Boraginaceae), have been reported to exert anti-inflammatory effects both in vitro and in vivo. In this study, we evaluated the effects of shikonin and its derivatives on the transcriptional activation of human TNF-alpha promoter in a gene gun-transfected mouse skin system by using a luciferase reporter gene assay. The crude plant extract of L. erythrorhizon as well as derived individual compounds shikonin, isobutyryl shikonin, acetyl shikonin, dimethylacryl shikonin and isovaleryl shikonin showed significant dose-dependent inhibition of TNF-alpha promoter activation. Among the tested compounds, shikonin and isobutyryl shikonin exhibited the highest inhibition of TNF-alpha promoter activation and also showed significant suppression of transgenic human TNF-alpha mRNA expression and protein production. We demonstrated that shikonin-inhibitory response was retained in the core TNF-alpha promoter region containing the TATA box and a 48-bp downstream sequence relative to the transcription start site. Further our results indicated that shikonin suppressed the basal transcription and activator-regulated transcription of TNF-alpha by inhibiting the binding of transcription factor IID protein complex (TATA box-binding protein) to TATA box. These in vivo results suggest that shikonins inhibit the transcriptional activation of the human TNF-alpha promoter through interference with the basal transcription machinery. Thus, shikonins may have clinical potential as anti-inflammatory therapeutics.	Acad Sinica, Inst Bioagr Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Yang, NS (corresponding author), Acad Sinica, Inst Bioagr Sci, 128,Sec 2, Taipei 11529, Taiwan.	nsyang@gate.sinica.edu.tw						Ackermann L, 1998, ARCH DERMATOL RES, V290, P353, DOI 10.1007/s004030050317; Becker C, 1999, GENE EXPRESSION, V8, P115; BEUTLER B, 1995, J INVEST MED, V43, P227; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; Bos JD, 1997, CLIN EXP IMMUNOL, V107, P3; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Chen X, 2002, PHYTOTHER RES, V16, P199, DOI 10.1002/ptr.1100; Chen X, 2001, INT IMMUNOPHARMACOL, V1, P229, DOI 10.1016/S1567-5769(00)00033-3; CHENG L, 1993, P NATL ACAD SCI USA, V90, P4455, DOI 10.1073/pnas.90.10.4455; CHIH HW, 1995, AM J CHINESE MED, V23, P273, DOI 10.1142/S0192415X95000328; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Evans RC, 1997, ALIMENT PHARM THERAP, V11, P1031, DOI 10.1046/j.1365-2036.1997.00251.x; FELDMANN M, 1994, CIRC SHOCK, V43, P179; Haas AF, 1998, FREE RADICAL BIO MED, V25, P998, DOI 10.1016/S0891-5849(98)00135-X; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; KUO CF, 2002, GENE THERAPY PROTOCO, P137; LaDuca JR, 2001, DERMATOL CLIN, V19, P617, DOI 10.1016/S0733-8635(05)70304-1; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Palmieri EA, 2002, AM J PHYSIOL-HEART C, V282, pH926, DOI 10.1152/ajpheart.00436.2001; Papageorgiou VP, 1999, ANGEW CHEM INT EDIT, V38, P270, DOI 10.1002/(SICI)1521-3773(19990201)38:3<270::AID-ANIE270>3.0.CO;2-0; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; Pozzi L, 2003, J NEUROCHEM, V86, P451, DOI 10.1046/j.1471-4159.2003.01851.x; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.3.CO;2-M; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; RIECKMANN P, 1995, ANN NEUROL, V37, P82, DOI 10.1002/ana.410370115; SETO Y, 1992, YAKUGAKU ZASSHI, V112, P259, DOI 10.1248/yakushi1947.112.4_259; Shackelford RE, 1997, MOL PHARMACOL, V52, P421, DOI 10.1124/mol.52.3.421; SHAH A, 1995, CLIN EXP ALLERGY, V25, P1038; Stack WA, 1997, LANCET, V349, P521, DOI 10.1016/S0140-6736(97)80083-9; Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199; Subbaramaiah K, 2001, J BIOMOL SCREEN, V6, P101; TANAKA S, 1986, J NAT PROD, V49, P466, DOI 10.1021/np50045a014; THOMPSON TA, 1993, IN VITRO CELL DEV-AN, V29, P165, DOI 10.1007/BF02630949; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WANG JP, 1995, EUR J PHARMACOL, V272, P87, DOI 10.1016/0014-2999(94)00627-J; Wang JP, 1997, BIOCHEM PHARMACOL, V53, P1173, DOI 10.1016/S0006-2952(97)00098-1; Wang JP, 1997, BRIT J PHARMACOL, V121, P409, DOI 10.1038/sj.bjp.0701147; WANG QW, 1994, WARME STOFFUBERTRAG, V29, P161, DOI 10.1007/BF01548600; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Ye JP, 2001, J BIOL CHEM, V276, P5360, DOI 10.1074/jbc.M008814200; Yokoyama T, 1999, AM J PHYSIOL-HEART C, V276, pH1968, DOI 10.1152/ajpheart.1999.276.6.H1968	45	119	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5877	5885		10.1074/jbc.M309185200	http://dx.doi.org/10.1074/jbc.M309185200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645256	hybrid			2022-12-27	WOS:000188776500103
J	Horiuchi, J; Jiang, W; Zhou, H; Wu, P; Yin, JCP				Horiuchi, J; Jiang, W; Zhou, H; Wu, P; Yin, JCP			Phosphorylation of conserved casein kinase sites regulates cAMP-response element-binding protein DNA binding in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-EXPRESSION; TRANSCRIPTION FACTORS; CREB PHOSPHORYLATION; CALCIUM REGULATION; CIRCADIAN CLOCK; II INTERACTS; MULTIPLE; ACTIVATOR; MEMORY; HIPPOCAMPUS	The Drosophila homolog of cAMP-response element-binding protein (CREB), dCREB2, exists with serine 231, equivalent to mammalian serine 133, in a predominantly phosphorylated state. Thus, unlike the mammalian protein, the primary regulation of dCREB2 may occur at a different step from serine 231 phosphorylation. Although bacterially expressed dCREB2 bound cAMP-response element sites, protein from Drosophila extracts was unable to do so unless treated with phosphatase. Phosphorylation of recombinant protein by casein kinase (CK) I or II, but not calcium-calmodulin kinase II or protein kinase A, inhibited DNA binding. Up to four conserved CK sites likely to be phosphorylated in vivo were responsible for this effect, and these sites were phosphorylated by a kinase present in Drosophila cell extracts that biochemically resembles CKII. We propose that the relative importance of different signaling pathways in regulating CREB activity may differ between Drosophila and mammals. In Drosophila, the dephosphorylation of CK sites appears to be the major regulatory step, while phosphorylation of serine 231 is necessary but secondary.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Horiuchi, J (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	jcyin@wisc.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH067774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA015753] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH067774] Funding Source: Medline; NINDS NIH HHS [NS 35575] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Belvin MP, 1999, NEURON, V22, P777, DOI 10.1016/S0896-6273(00)80736-9; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BOHM S, 1993, J BIOL CHEM, V268, P3952; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; Deisseroth K, 2002, NEURON, V34, P179, DOI 10.1016/S0896-6273(02)00664-5; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Gau D, 2002, NEURON, V34, P245, DOI 10.1016/S0896-6273(02)00656-6; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Lieberman DN, 1999, NAT NEUROSCI, V2, P125, DOI 10.1038/5680; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Liu XG, 2002, ACTA PHARMACOL SIN, V23, P556; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; MARSHAK DR, 1994, CELL MOL BIOL RES, V40, P513; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Moussazadeh M, 2000, CELL MOL BIOL, V46, P1265; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Obrietan K, 1999, J BIOL CHEM, V274, P17748, DOI 10.1074/jbc.274.25.17748; Parker D, 1996, MOL CELL BIOL, V16, P694; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Saeki K, 1999, BIOCHEM J, V338, P49, DOI 10.1042/0264-6021:3380049; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Trott RL, 2001, J BIOL CHEM, V276, P2159, DOI 10.1074/jbc.M005996200; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Waddell S, 2001, TRENDS GENET, V17, P719, DOI 10.1016/S0168-9525(01)02526-4; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854; YIN JCP, 1995, MOL CELL BIOL, V15, P5123; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5	44	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12117	12125		10.1074/jbc.M212839200	http://dx.doi.org/10.1074/jbc.M212839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14676200	Green Accepted, hybrid			2022-12-27	WOS:000220334900017
J	Batten, ML; Imanishi, Y; Maeda, T; Tu, DC; Moise, AR; Bronson, D; Possin, D; Van Gelder, RN; Baehr, W; Palczewski, K				Batten, ML; Imanishi, Y; Maeda, T; Tu, DC; Moise, AR; Bronson, D; Possin, D; Van Gelder, RN; Baehr, W; Palczewski, K			Lecithin-retinol acyltransferase is essential for accumulation of all-trans-retinyl esters in the eye and in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; DIETARY VITAMIN-A; VISUAL PIGMENT; MOUSE MODEL; BINDING PROTEIN; CIS-RETINOLS; RAT-LIVER; OPSIN; GENE; REGENERATION	Lecithin-retinol acyltransferase (LRAT), an enzyme present mainly in the retinal pigmented epithelial cells and liver, converts all-trans-retinol into all-trans-retinyl esters. In the retinal pigmented epithelium, LRAT plays a key role in the retinoid cycle, a two-cell recycling system that replenishes the 11-cis-retinal chromophore of rhodopsin and cone pigments. We disrupted mouse Lrat gene expression by targeted recombination and generated a homozygous Lrat knock-out (Lrat-/-) mouse. Despite the expression of LRAT in multiple tissues, the Lrat-/- mouse develops normally. The histological analysis and electron microscopy of the retina for 6-8-week-old Lrat-/- mice revealed that the rod outer segments are similar to35% shorter than those of Lrat+/+ mice, whereas other neuronal layers appear normal. Lrat-/- mice have trace levels of all-trans-retinyl esters in the liver, lung, eye, and blood, whereas the circulating all-trans-retinol is reduced only slightly. Scotopic and photopic electroretinograms as well as pupillary constriction analyses revealed that rod and cone visual functions are severely attenuated at an early age. We conclude that Lrat-/- mice may serve as an animal model with early onset severe retinal dystrophy and severe retinyl ester deprivation.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Utah, Dept Ophthalmol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84112 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Washington University (WUSTL); Washington University (WUSTL)	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Moise, Alexander R/C-9498-2009; Van Gelder, Russell/ABB-4225-2021; Imanishi, Yoshikazu/E-8178-2010; AR, Moise/P-2474-2019; Moise, Alexander/A-7186-2008	Moise, Alexander R/0000-0003-2307-6035; Van Gelder, Russell/0000-0001-5368-3659; Imanishi, Yoshikazu/0000-0003-4696-4836; AR, Moise/0000-0003-2307-6035; 	NEI NIH HHS [EY13385, EY14988, R01 EY014988, EY09339, R01 EY009339, R01 EY013385, EYK0800403, EY08123, R01 EY008123] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013385, R01EY009339, R01EY014988, R01EY008123, K08EY000403] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ablonczy Z, 2002, J BIOL CHEM, V277, P40491, DOI 10.1074/jbc.M205507200; ADAMUS G, 1989, IN VITRO CELL DEV B, V25, P1141; ANANTHARAMAN V, 2003, GENOME BIOL; Ball SL, 2002, INVEST OPHTH VIS SCI, V43, P1595; BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659; Dawson MI, 2000, CURR PHARM DESIGN, V6, P311, DOI 10.2174/1381612003401190; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Fortuna VA, 2001, J NUTR BIOCHEM, V12, P610, DOI 10.1016/S0955-2863(01)00179-6; Gottesman ME, 2001, BIOESSAYS, V23, P409, DOI 10.1002/bies.1059; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; Hattar S, 2003, NATURE, V424, P76, DOI 10.1038/nature01761; Hetling JR, 1999, J PHYSIOL-LONDON, V516, P593, DOI 10.1111/j.1469-7793.1999.0593v.x; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Jahng WJ, 2003, BIOCHEMISTRY-US, V42, P12805, DOI 10.1021/bi035370p; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Kuksa V, 2002, J BIOL CHEM, V277, P42315, DOI 10.1074/jbc.M206014200; LI ZY, 1994, EXP EYE RES, V58, P397, DOI 10.1006/exer.1994.1032; Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; Maeda T, 2003, J NEUROCHEM, V85, P944, DOI 10.1046/j.1471-4159.2003.01741.x; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Mondal MS, 2001, FEBS LETT, V489, P14, DOI 10.1016/S0014-5793(00)02428-5; Mondal MS, 2000, BIOCHEMISTRY-US, V39, P5215, DOI 10.1021/bi9929554; NAASH MI, 1993, P NATL ACAD SCI USA, V90, P5499, DOI 10.1073/pnas.90.12.5499; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; ONG DE, 1988, J BIOL CHEM, V263, P5789; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Panda S, 2003, SCIENCE, V301, P525, DOI 10.1126/science.1086179; Perrault I, 1999, MOL GENET METAB, V68, P200, DOI 10.1006/mgme.1999.2906; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Ruiz A, 2001, INVEST OPHTH VIS SCI, V42, P31; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SAARI JC, 1993, BIOCHEM J, V291, P697, DOI 10.1042/bj2910697; SCHMITT MC, 1993, BIOL REPROD, V49, P972, DOI 10.1095/biolreprod49.5.972; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; Thompson CL, 2001, P NATL ACAD SCI USA, V98, P11708, DOI 10.1073/pnas.201301498; Thompson DA, 2001, NAT GENET, V28, P123, DOI 10.1038/88828; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Wald G, 1936, J GEN PHYSIOL, V19, P781, DOI 10.1085/jgp.19.5.781; Woodruff ML, 2003, NAT GENET, V35, P158, DOI 10.1038/ng1246; Zolfaghari R, 2002, BIOCHEM J, V368, P621, DOI 10.1042/BJ20020918; Zolfaghari R, 2002, J NUTR, V132, P1160, DOI 10.1093/jn/132.6.1160; Zolfaghari R, 2000, J LIPID RES, V41, P2024	54	269	281	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10422	10432		10.1074/jbc.M312410200	http://dx.doi.org/10.1074/jbc.M312410200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684738	Green Accepted, hybrid			2022-12-27	WOS:000220050400093
J	Kubitz, R; Saha, N; Kuhlkamp, T; Dutta, S; vom Dahl, S; Wettstein, M; Haussinger, DH				Kubitz, R; Saha, N; Kuhlkamp, T; Dutta, S; vom Dahl, S; Wettstein, M; Haussinger, DH			Ca2+-dependent protein kinase C Isoforms induce cholestasis in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN-2; CONJUGATE EXPORT PUMP; SUBSTRATE MARCKS PROTEIN; CANALICULAR MEMBRANE; SIGNAL-TRANSDUCTION; PHORBOL ESTERS; DOWN-REGULATION; BILE SECRETION; HEPG2 CELLS; CYCLIC-AMP	Bile secretion is regulated by different signaling transduction pathways including protein kinase C (PKC). However, the role of different PKC isoforms for bile formation is still controversial. This study investigates the effects of PKC isoform selective activators and inhibitors on PKC translocation, bile secretion, bile acid uptake, and subcellular transporter localization in rat liver, isolated rat hepatocytes and in HepG2 cells. In rat liver activation of Ca2+-dependent cPKCalpha and Ca2+-independent PKCepsilon by phorbol 12-myristate 13-acetate (PMA, 10 nmol/liter) is associated with their translocation to the plasma membrane. PMA also induced translocation of the cloned rat PKCepsilon fused to a yellow fluorescent protein (YFP), which was transfected into HepG2 cells. In the perfused liver, PMA induced marked cholestasis. The PKC inhibitors Go6850 (1 mumol/liter) and Go6976 (0.2 mumol/liter), a selective inhibitor of Ca2+-dependent PKC isoforms, diminished the PMA effect by 50 and 60%, respectively. Thymeleatoxin (Ttx,) a selective activator of Ca2+-dependent cPKCs, did not translocate rat PKCepsilon-YFP transfected in HepG2 cells. However, Ttx (0.5-10 nmol/liter) induced cholestasis similar to PMA and led to a retrieval of Bsep from the canalicular membrane in rat liver while taurocholate-uptake in isolated hepatocytes was not affected. Go6976 completely blocked the cholestatic effect of Ttx but had no effect on tauroursodeoxycholate-induced choleresis. The data identify Ca2+-dependent PKC isoforms as inducers of cholestasis. This is mainly due to inhibition of taurocholate excretion involving transporter retrieval from the canalicular membrane.	Univ Dusseldorf, Dept Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Kubitz, R (corresponding author), Univ Dusseldorf, Dept Gastroenterol Hepatol & Infectiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	Kubitz@med.uni-duesseldorf.de	Dahl, Stephan vom/AAF-8456-2021; Saha, Nirmalendu/J-8100-2014; Saha, Nirmalendu/AAH-7792-2021	Dahl, Stephan vom/0000-0003-0481-0601; Saha, Nirmalendu/0000-0002-9635-3024; Saha, Nirmalendu/0000-0002-9635-3024				Beuers U, 1996, GASTROENTEROLOGY, V110, P1553, DOI 10.1053/gast.1996.v110.pm8613063; Beuers U, 2001, HEPATOLOGY, V33, P1206, DOI 10.1053/jhep.2001.24034; Beuers U, 1999, HEPATOLOGY, V29, P477, DOI 10.1002/hep.510290227; Bouscarel B, 1999, GASTROENTEROLOGY, V117, P433, DOI 10.1053/gast.1999.0029900433; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CORASANTI JG, 1989, HEPATOLOGY, V10, P8, DOI 10.1002/hep.1840100103; Croquet F, 1996, BBA-MOL BASIS DIS, V1315, P163, DOI 10.1016/0925-4439(95)00124-7; DIMITRIJEVIC SM, 1995, MOL PHARMACOL, V48, P259; DIVALD A, 1994, HEPATOLOGY, V20, P159, DOI 10.1002/hep.1840200124; Dombrowski F, 2000, BIOCHEM J, V348, P183, DOI 10.1042/0264-6021:3480183; DURONIO V, 1990, J CELL PHYSIOL, V145, P381, DOI 10.1002/jcp.1041450225; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRUNE S, 1993, J BIOL CHEM, V268, P17734; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; Hansra G, 1999, BIOCHEM J, V342, P337, DOI 10.1042/0264-6021:3420337; Haussinger D, 2000, SEMIN LIVER DIS, V20, P307, DOI 10.1055/s-2000-9386; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Keppler D, 2000, SEMIN LIVER DIS, V20, P265, DOI 10.1055/s-2000-9391; KIM JY, 1994, J BIOL CHEM, V269, P28214; Kubitz R, 2001, HEPATOLOGY, V34, P340, DOI 10.1053/jhep.2001.25959; Kubitz R, 1997, GASTROENTEROLOGY, V113, P1438, DOI 10.1053/gast.1997.v113.pm9352844; Kubitz R, 1999, GASTROENTEROLOGY, V116, P401, DOI 10.1016/S0016-5085(99)70138-1; KUHN WF, 1988, AM J PHYSIOL, V254, pG732, DOI 10.1152/ajpgi.1988.254.5.G732; Kurz AK, 2001, GASTROENTEROLOGY, V121, P407, DOI 10.1053/gast.2001.26262; Llosas MD, 1996, BIOCHEM J, V315, P1049; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Mottino AD, 2002, HEPATOLOGY, V35, P1409, DOI 10.1053/jhep.2002.33327; Muller M, 2000, SEMIN LIVER DIS, V20, P323, DOI 10.1055/s-2000-9387; NATHANSON MH, 1992, AM J PHYSIOL, V262, pG1079, DOI 10.1152/ajpgi.1992.262.6.G1079; NATHANSON MH, 1992, HEPATOLOGY, V15, P107, DOI 10.1002/hep.1840150119; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Noe J, 2001, HEPATOLOGY, V33, P1223, DOI 10.1053/jhep.2001.24171; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; ORR JW, 1992, J BIOL CHEM, V267, P15263; PERLETTI GP, 1994, J BIOCHEM BIOPH METH, V28, P195, DOI 10.1016/0165-022X(94)90016-7; ROELOFSEN H, 1991, BIOCHEM J, V278, P637, DOI 10.1042/bj2780637; ROIVAINEN R, 1993, FEBS LETT, V319, P31, DOI 10.1016/0014-5793(93)80031-O; Rost D, 1999, HEPATOLOGY, V29, P814, DOI 10.1002/hep.510290319; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Schliess F, 1997, GASTROENTEROLOGY, V113, P1306, DOI 10.1053/gast.1997.v113.pm9322526; Schmitt M, 2000, BIOL CHEM, V381, P487, DOI 10.1515/BC.2000.063; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; Suzuki H, 2000, SEMIN LIVER DIS, V20, P251, DOI 10.1055/s-2000-8408; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; Trauner M, 2001, Semin Gastrointest Dis, V12, P66; Trauner M, 1998, NEW ENGL J MED, V339, P1217, DOI 10.1056/NEJM199810223391707	51	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10323	10330		10.1074/jbc.M306242200	http://dx.doi.org/10.1074/jbc.M306242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679204	hybrid			2022-12-27	WOS:000220050400081
J	Golden, JW; Bahe, JA; Lucas, WT; Nibert, ML; Schiff, LA				Golden, JW; Bahe, JA; Lucas, WT; Nibert, ML; Schiff, LA			Cathepsin S supports acid-independent infection by some reoviruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MHC CLASS-II; INTESTINAL M-CELLS; MOUSE L-CELLS; CREUTZFELDT-JAKOB-DISEASE; CAPSID PROTEIN SIGMA-3; CENTRAL-NERVOUS-SYSTEM; CYSTEINE PROTEASES; MAMMALIAN REOVIRUSES; INVARIANT CHAIN; IN-VITRO	In murine fibroblasts, efficient proteolysis of reovirus outer capsid protein sigma3 during cell entry by virions requires the acid-dependent lysosomal cysteine protease cathepsin L. The importance of cathepsin L for infection of other cell types is unknown. Here we report that the acid-independent lysosomal cysteine protease cathepsin S mediates outer capsid processing in macrophage-like P388D cells. P388D cells supported infection by virions of strain Lang, but not strain c43. Genetic studies revealed that this difference is determined by S4, the viral gene segment that encodes sigma3. c43-derived subvirion particles that lack sigma3 replicated normally in P388D cells, suggesting that the difference in infectivity of Lang and c43 virions is at the level of sigma3 processing. Infection of P388D cells with Lang virions was inhibited by the broad spectrum cysteine protease inhibitor trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane but not by NH4Cl, which raises the endocytic pH and thereby inhibits acid-dependent proteases such as cathepsins L and B. Outer capsid processing and infection of P388D cells with Lang virions were also inhibited by a cathepsin S-specific inhibitor. Furthermore, in the presence of NH4Cl, cell lines engineered to express cathepsin S supported infection by Lang, but not c43, virions. Our results thus indicate that differences in susceptibility to cathepsin S-mediated sigma3 processing are responsible for strain differences in reovirus infection of macrophage-like P388D cells and other cathepsin S-expressing cells. Additionally, our data suggest that the acid dependence of reovirus infections of most other cell types may reflect the low pH requirement for the activities of most other lysosomal proteases rather, than some other acid-dependent aspect of cell entry.	Univ Minnesota, Dept Microbiol, Mayo Mail Code 196,420 Delaware St SE, Minneapolis, MN 55455 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School	Schiff, LA (corresponding author), Univ Minnesota, Dept Microbiol, Mayo Mail Code 196,420 Delaware St SE, Minneapolis, MN 55455 USA.	schiff@lenti.med.umn.edu		Golden, Joseph/0000-0002-9709-313X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045990, R01AI046440] Funding Source: NIH RePORTER; NIAID NIH HHS [2T32 AI-0742, AI-45990, AI-46440] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMERONGEN HM, 1994, J VIROL, V68, P8428, DOI 10.1128/JVI.68.12.8428-8432.1994; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; Baer GS, 1997, J VIROL, V71, P4921, DOI 10.1128/JVI.71.7.4921-4928.1997; Baker CA, 1999, J VIROL, V73, P5089, DOI 10.1128/JVI.73.6.5089-5097.1999; Baker CA, 2002, J VIROL, V76, P10905, DOI 10.1128/JVI.76.21.10905-10913.2002; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; BASS DM, 1988, LAB INVEST, V58, P226; BASS DM, 1990, J VIROL, V64, P1830, DOI 10.1128/JVI.64.4.1830-1833.1990; BEATTIE E, 1995, J VIROL, V69, P499, DOI 10.1128/JVI.69.1.499-505.1995; Beers C, 2003, J EXP MED, V197, P169, DOI 10.1084/jem.20020978; BODKIN DK, 1989, J VIROL, V63, P4676, DOI 10.1128/JVI.63.11.4676-4681.1989; BODKIN DK, 1989, J VIROL, V63, P1188, DOI 10.1128/JVI.63.3.1188-1193.1989; BORSA J, 1973, J VIROL, V11, P1017, DOI 10.1128/JVI.11.6.1017-1019.1973; BORSA J, 1979, J GEN VIROL, V45, P161, DOI 10.1099/0022-1317-45-1-161; BORSA J, 1973, J VIROL, V11, P552, DOI 10.1128/JVI.11.4.552-564.1973; BORSA J, 1981, VIROLOGY, V111, P191, DOI 10.1016/0042-6822(81)90664-4; Broering TJ, 2000, J VIROL, V74, P5516, DOI 10.1128/JVI.74.12.5516-5524.2000; Buhling F, 2000, ADV EXP MED BIOL, V477, P241; CANNING WM, 1983, SCIENCE, V219, P987, DOI 10.1126/science.6297010; Chandran K, 1998, J VIROL, V72, P467, DOI 10.1128/JVI.72.1.467-475.1998; Chandran K, 1999, J VIROL, V73, P3941, DOI 10.1128/JVI.73.5.3941-3950.1999; CHANG CT, 1971, VIROLOGY, V46, P544, DOI 10.1016/0042-6822(71)90058-4; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Coombs KM, 1998, VIROLOGY, V243, P218, DOI 10.1006/viro.1998.9061; DANIS C, 1992, VIROLOGY, V190, P494, DOI 10.1016/0042-6822(92)91241-L; Denisova E, 1999, J VIROL, V73, P3147, DOI 10.1128/JVI.73.4.3147-3153.1999; DERMODY TS, 1990, J VIROL, V64, P5173, DOI 10.1128/JVI.64.10.5173-5176.1990; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200; Ebert DH, 2001, J VIROL, V75, P3197, DOI 10.1128/JVI.75.7.3197-3206.2001; ESTES MK, 1981, J VIROL, V39, P879, DOI 10.1128/JVI.39.3.879-888.1981; Fiebiger E, 2001, J EXP MED, V193, P881, DOI 10.1084/jem.193.8.881; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; Golden JW, 2002, J VIROL, V76, P7430, DOI 10.1128/JVI.76.15.7430-7443.2002; HAZELTON PR, 1995, VIROLOGY, V207, P46, DOI 10.1006/viro.1995.1050; Hooper JW, 1996, J VIROL, V70, P672, DOI 10.1128/JVI.70.1.672-677.1996; Hooper JW, 1996, J VIROL, V70, P459, DOI 10.1128/JVI.70.1.459-467.1996; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; Jane-Valbuena J, 2002, J VIROL, V76, P5184, DOI 10.1128/JVI.76.10.5184-5197.2002; Jane-Valbuena J, 1999, J VIROL, V73, P2963; JOKLIK WK, 1972, VIROLOGY, V49, P700, DOI 10.1016/0042-6822(72)90527-2; Kang JX, 1998, P NATL ACAD SCI USA, V95, P13687, DOI 10.1073/pnas.95.23.13687; KAUFFMAN RS, 1983, VIROLOGY, V124, P403, DOI 10.1016/0042-6822(83)90356-2; KEDL R, 1995, J VIROL, V69, P552, DOI 10.1128/JVI.69.1.552-559.1995; Kido H, 1999, MOL CELLS, V9, P235; Kido H, 1996, ADV EXP MED BIOL, V389, P233; KIRSCHKE H, 1989, BIOCHEM J, V264, P467, DOI 10.1042/bj2640467; Kirschke H, 1998, LYSOSOMAL CYSTEINE P; Kothandaraman S, 1998, VIROLOGY, V251, P264, DOI 10.1006/viro.1998.9434; Kreusch S, 2000, EUR J BIOCHEM, V267, P2965; Lazure C, 2002, CURR PHARM DESIGN, V8, P511, DOI 10.2174/1381612023395691; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEMERE CA, 1995, AM J PATHOL, V146, P848; Liuzzo JP, 1999, MOL MED, V5, P320, DOI 10.1007/BF03402068; LUCIAJANDRIS P, 1993, J VIROL, V67, P5339, DOI 10.1128/JVI.67.9.5339-5345.1993; Martinez CG, 1996, J VIROL, V70, P576; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; Montaser M, 2002, BIOL CHEM, V383, P1305, DOI 10.1515/BC.2002.147; MORGAN EM, 1974, VIROLOGY, V59, P556, DOI 10.1016/0042-6822(74)90465-6; Morin MJ, 1996, J VIROL, V70, P541, DOI 10.1128/JVI.70.1.541-548.1996; MORRISON LA, 1991, P NATL ACAD SCI USA, V88, P3852, DOI 10.1073/pnas.88.9.3852; MORTON PA, 1995, J IMMUNOL, V154, P137; MUNGER JS, 1995, BIOCHEM J, V311, P299, DOI 10.1042/bj3110299; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; NIBERT ML, 1991, J CLIN INVEST, V88, P727, DOI 10.1172/JCI115369; NIBERT ML, 1991, J VIROL, V65, P1960, DOI 10.1128/JVI.65.4.1960-1967.1991; Nibert ML, 1998, CURR TOP MICROBIOL, V233, P1; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; Nibert ML., 2001, FIELDS VIROLOGY, P1679; Olland AM, 2001, EMBO J, V20, P979, DOI 10.1093/emboj/20.5.979; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; Petanceska S, 1996, J BIOL CHEM, V271, P4403; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RAMIG RF, 1977, SCIENCE, V195, P406, DOI 10.1126/science.831284; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROSEN L, 1960, AM J HYG, V71, P242, DOI 10.1093/oxfordjournals.aje.a120107; ROSEN L, 1960, AM J HYG, V71, P258, DOI 10.1093/oxfordjournals.aje.a120109; RUBIN DH, 1985, J VIROL, V53, P391, DOI 10.1128/JVI.53.2.391-398.1985; SHARPE AH, 1978, VIROLOGY, V84, P63, DOI 10.1016/0042-6822(78)90218-0; SHATKIN AJ, 1972, J VIROL, V10, P698, DOI 10.1128/JVI.10.4.698-706.1972; SHEPARD DA, 1995, J VIROL, V69, P8180, DOI 10.1128/JVI.69.12.8180-8184.1995; SHERRY B, 1989, J VIROL, V63, P4850, DOI 10.1128/JVI.63.11.4850-4856.1989; SHERRY B, 1989, J VIROL, V63, P4840, DOI 10.1128/JVI.63.11.4840-4849.1989; SHI GP, 1992, J BIOL CHEM, V267, P7258; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; SHI GP, 1994, J BIOL CHEM, V269, P11530; Shing M, 1996, VIRUS RES, V46, P19, DOI 10.1016/S0168-1702(96)01372-X; SILVERSTEIN SC, 1972, VIROLOGY, V47, P797, DOI 10.1016/0042-6822(72)90571-5; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; TOSTESON MT, 1993, P NATL ACAD SCI USA, V90, P10549, DOI 10.1073/pnas.90.22.10549; TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X; Tyler K.L., 2001, FIELDS VIROLOGY, P1729; TYLER KL, 1985, NEUROLOGY, V35, P88, DOI 10.1212/WNL.35.1.88; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; VIRGIN HW, 1988, J VIROL, V62, P4594, DOI 10.1128/JVI.62.12.4594-4604.1988; WEINER HL, 1980, J INFECT DIS, V141, P609, DOI 10.1093/infdis/141.5.609; Wetzel JD, 1997, J VIROL, V71, P1362, DOI 10.1128/JVI.71.2.1362-1369.1997; WIENER JR, 1989, VIROLOGY, V169, P293, DOI 10.1016/0042-6822(89)90154-2; WIENER JR, 1989, VIROLOGY, V169, P194, DOI 10.1016/0042-6822(89)90055-X; WILSON GAR, 1994, J VIROL, V68, P6458, DOI 10.1128/JVI.68.10.6458-6465.1994; Wilson GJ, 2002, J VIROL, V76, P9832, DOI 10.1128/JVI.76.19.9832-9843.2002; WOLF JL, 1983, GASTROENTEROLOGY, V85, P291; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737; YOUNG JAT, 2001, FIELDS VIROLOGY, P87; Yue ZY, 1997, VIROLOGY, V234, P364, DOI 10.1006/viro.1997.8664; ZAR JH, 1984, BIOSTAT ANAL, P138	112	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8547	8557		10.1074/jbc.M309758200	http://dx.doi.org/10.1074/jbc.M309758200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14670972	hybrid, Green Published			2022-12-27	WOS:000189265900005
J	Wu, XH; Reiter, CEN; Antonetti, DA; Kimball, SR; Jefferson, LS; Gardner, TW				Wu, XH; Reiter, CEN; Antonetti, DA; Kimball, SR; Jefferson, LS; Gardner, TW			Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; GROWTH-FACTOR-I; PHOSPHOINOSITIDE 3-KINASE PATHWAY; PROTEIN-KINASE; SIGNALING PATHWAY; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSLATIONAL CONTROL; RECEPTOR SUBSTRATE-1; GENE-EXPRESSION	The purpose of this study was to examine the role of the ribosomal protein S6 protein kinase (p70S6K), a protein synthesis regulator, in promoting retinal neuronal cell survival. Differentiated R28 rat retinal neuronal cells were used as an experimental model. Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum, and during the period of experimentation were exposed either to the absence or presence of 10 nM insulin. Insulin treatment induced p70S6K, mTOR, and Akt phosphorylation, effects that were completely prevented by the PI3K inhibitor, LY294002. Insulin-induced phosphorylation of p70S6K and mTOR was prevented by the mTOR inhibitor, rapamycin. Apoptosis, induced by serum deprivation and evaluated by Hoechst staining, was inhibited by insulin treatment in R28 cells, but not in L6 muscle cells. This effect of insulin was also largely prevented by rapamycin. Inhibition of p70S6K activity by exogenous expression of a dominant negative mutant of p70S6K prevented insulin-induced cell survival, whereas, overexpression of wild type p70S6K or expression of a rapamycin resistant form of the kinase enhanced the effect of insulin on survival. Enhanced cell survival under the latter condition was accompanied by increased p70S6K activity and phosphorylation. Rapamycin did not inhibit insulin induced p70S6K phosphorylation and activity in cells transfected with the rapamycin-resistant mutant. Together, these results suggest that p70S6K plays a key role in insulin stimulated retinal neuronal cell survival.	Penn State Univ, Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA; Penn State Univ, Ulerich Ophthalmol Res Ctr, Hershey, PA 17033 USA; Penn State Univ, JDRF Diabet Retinopathy Ctr, Hershey, PA 17033 USA; Penn State Univ, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Gardner, TW (corresponding author), Penn State Univ, Coll Med, Dept Ophthalmol, 500 Univ Dr, Hershey, PA 17033 USA.	tgardner@psu.edu		Gardner, Thomas/0000-0002-5112-5810; antonetti, david/0000-0003-1130-6577	NEI NIH HHS [EY12021] Funding Source: Medline; NIDDK NIH HHS [DK13499, DK15658] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013499, R01DK013499, R01DK015658] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anthony JC, 2002, AM J PHYSIOL-ENDOC M, V282, pE1092, DOI 10.1152/ajpendo.00208.2001; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Burren CP, 1996, INVEST OPHTH VIS SCI, V37, P1459; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dardevet D, 1996, ENDOCRINOLOGY, V137, P4087, DOI 10.1210/en.137.10.4087; De Pablo F, 1996, Int J Dev Biol, VSuppl 1, p109S; DELAROSA EJ, 1994, EUR J NEUROSCI, V6, P1801; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Diaz B, 2000, DEVELOPMENT, V127, P1641; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Folli F, 1996, MOL NEUROBIOL, V13, P155, DOI 10.1007/BF02740639; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gardner T W, 2000, Diabetes Technol Ther, V2, P601; Gosbell AD, 2000, CLIN EXP OPHTHALMOL, V28, P212, DOI 10.1046/j.1442-9071.2000.00305.x; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Hosoi H, 1999, CANCER RES, V59, P886; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kawada M, 2002, J BIOL CHEM, V277, P27765, DOI 10.1074/jbc.M200318200; Kimball SR, 2002, J APPL PHYSIOL, V93, P1168, DOI 10.1152/japplphysiol.00221.2002; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Lieberthal W, 2001, AM J PHYSIOL-RENAL, V281, pF693, DOI 10.1152/ajprenal.2001.281.4.F693; MARTIN DM, 1992, MOL BRAIN RES, V12, P181, DOI 10.1016/0169-328X(92)90082-M; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Nakamura M, 2001, J BIOL CHEM, V276, P43748, DOI 10.1074/jbc.M108594200; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rehen SK, 1999, EUR J NEUROSCI, V11, P4349, DOI 10.1046/j.1460-9568.1999.00868.x; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Reiter CEN, 2003, AM J PHYSIOL-ENDOC M, V285, pE763, DOI 10.1152/ajpendo.00507.2002; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Seigel G, 2000, MOL VIS, V6, P157; SIGAL NH, 1991, TRANSPLANT P, V23, P1; Takano H, 1996, FEBS LETT, V379, P255, DOI 10.1016/0014-5793(95)01523-X; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; TERADA Y, 1994, J BIOL CHEM, V269, P31296; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Wan XL, 2002, NEOPLASIA, V4, P400, DOI 10.1038/sj.neo.7900242; Woltman AM, 2001, BLOOD, V98, P174, DOI 10.1182/blood.V98.1.174	70	71	75	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9167	9175		10.1074/jbc.M312397200	http://dx.doi.org/10.1074/jbc.M312397200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14660591	hybrid			2022-12-27	WOS:000189265900078
J	Grimminger, V; Richter, K; Imhof, A; Buchner, J; Walter, S				Grimminger, V; Richter, K; Imhof, A; Buchner, J; Walter, S			The prion curing agent guanidinium chloride specifically inhibits ATP hydrolysis by Hsp104	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST PRIONS; PROTEIN HSP104; PSI+ PRION; PROPAGATION; CHAPERONE; HYDROCHLORIDE; INHERITANCE; PSI(+); URE3	The molecular chaperone Hsp104 from Saccharomyces cerevisiae dissolves protein aggregates in the cell and is thus of crucial importance for the thermotolerance of yeast. In addition to this disaggregase activity, Hsp104 has a key function in yeast prion propagation, as Hsp104 was found to be essential for the maintenance of the associated phenotypes. In vivo data suggest that Hsp104 function is affected by guanidinium chloride. Adding small amounts of this compound to yeast medium causes curing of the prions: cells lose their prion-related phenotype. Guanidinium chloride was also found to impair heat shock resistance. Here, we present a detailed in vitro analysis showing that guanidinium chloride is an uncompetitive inhibitor of Hsp104. Micromolar concentrations of this agent reduce the ATPase activity of Hsp104 to similar to35% of its normal activity. This inhibition is not related to the denaturing properties of this compound, because Hsp104 was not affected by urea. Guanidinium ions selectively bind to the nucleotide-bound, hexameric state of the molecular chaperone. Thus, they increase the affinity of Hsp104 for adenine nucleotides and promote the nucleotide-dependent oligomerization of the chaperone. Our findings strongly suggest that guanidinium chloride causes curing of yeast prions by perturbing the ATPase of Hsp104, which is essential for both prion propagation and thermotolerance.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	Technical University of Munich; University of Munich	Walter, S (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	stefan.walter@ch.tum.de	Imhof, Axel/AAU-5313-2021; Richter, Klaus/A-2673-2010; Buchner, Johannes/A-2651-2010	Imhof, Axel/0000-0003-2993-8249; Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; Derkatch IL, 1997, GENETICS, V147, P507; Eaglestone SS, 2000, P NATL ACAD SCI USA, V97, P240, DOI 10.1073/pnas.97.1.240; Ferreira PC, 2001, MOL MICROBIOL, V40, P1357, DOI 10.1046/j.1365-2958.2001.02478.x; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Jung GM, 2002, P NATL ACAD SCI USA, V99, P9936, DOI 10.1073/pnas.152333299; Jung GM, 2001, CURR MICROBIOL, V43, P7, DOI 10.1007/s002840010251; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Narayanan S, 2003, P NATL ACAD SCI USA, V100, P9286, DOI 10.1073/pnas.1233535100; Ness F, 2002, MOL CELL BIOL, V22, P5593, DOI 10.1128/MCB.22.15.5593-5605.2002; Neuwald AF, 1999, GENOME RES, V9, P27; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Schirmer EC, 1998, METHOD ENZYMOL, V290, P430, DOI 10.1016/S0076-6879(98)90036-2; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Segel I.H., 1993, ENZYME KINETICS, P136; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Tuite MF, 1996, TRENDS GENET, V12, P467, DOI 10.1016/0168-9525(96)10045-7; TUITE MF, 1981, GENETICS, V98, P691; Wegrzyn RD, 2001, MOL CELL BIOL, V21, P4656, DOI 10.1128/MCB.21.14.4656-4669.2001; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1995, YEAST, V11, P1671, DOI 10.1002/yea.320111609	33	109	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					7378	7383		10.1074/jbc.M312403200	http://dx.doi.org/10.1074/jbc.M312403200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14668331	hybrid			2022-12-27	WOS:000189103300003
J	Sarret, P; Esdaile, MJ; McPherson, PS; Schonbrunn, A; Kreienkamp, HJ; Beaudet, A				Sarret, P; Esdaile, MJ; McPherson, PS; Schonbrunn, A; Kreienkamp, HJ; Beaudet, A			Role of amphiphysin II in somatostatin receptor trafficking in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; SYNAPTIC VESICLE ENDOCYTOSIS; SH3 DOMAIN; MEDIATED ENDOCYTOSIS; RAT-BRAIN; ADRENOCORTICOTROPIN SECRETION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA AMPHIPHYSIN; INTERACTING PROTEIN; ACTIN CYTOSKELETON	Amphiphysins are SH3 domain-containing proteins thought to function in clathrin-mediated endocytosis. To investigate the potential role of amphiphysin II in cellular trafficking of G protein-coupled somatostatin (SRIF) receptors, we generated an AtT-20 cell line stably overexpressing amphiphysin IIb, a splice variant that does not bind clathrin. Endocytosis of I-125-[D-Trp(8)]SRIF was not affected by amphiphysin IIb overexpression. However, the maximal binding capacity (B-max) of the ligand on intact cells was significantly lower in amphiphysin IIb overexpressing than in non-transfected cells. This difference was no longer apparent when the experiments were performed on crude cell homogenates, suggesting that amphiphysin IIb overexpression interferes with SRIF receptor targeting to the cell surface and not with receptor synthesis. Accordingly, immunofluorescence experiments demonstrated that, in amphiphysin overexpressing cells, sst(2A) and sst(5) receptors were segregated in a juxtanuclear compartment identified as the trans-Golgi network. Amphiphysin IIb overexpression had no effect on corticotrophin-releasing factor 41-stimulated adrenocorticotropic hormone secretion, suggesting that it is not involved in the regulated secretory pathway. Taken together, these results suggest that amphiphysin II is not necessary for SRIF receptor endocytosis but is critical for its constitutive targeting to the plasma membrane. Therefore, amphiphysin IIb may be an important component of the constitutive secretory pathway.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Texas, Sch Med, Dept Pharmacol, Houston, TX 77225 USA; Univ Hamburg, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	McGill University; University of Texas System; University of Hamburg	Beaudet, A (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.beaudet@mcgill.ca		Sarret, Philippe/0000-0002-7627-701X				Allan VJ, 2002, NAT CELL BIOL, V4, pE236, DOI 10.1038/ncb1002-e236; Balguerie A, 1999, J CELL SCI, V112, P2529; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Bensen ES, 2000, GENETICS, V154, P83; Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cervia D, 2003, BRIT J PHARMACOL, V139, P109, DOI 10.1038/sj.bjp.0705235; Collins BM, 2003, NAT STRUCT BIOL, V10, P607, DOI 10.1038/nsb955; Corda D, 2002, CELL MOL LIFE SCI, V59, P1819, DOI 10.1007/PL00012508; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dournaud P, 1996, J NEUROSCI, V16, P4468; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Floyd SR, 2001, J BIOL CHEM, V276, P8104, DOI 10.1074/jbc.M008932200; Fujimoto LM, 2000, TRAFFIC, V1, P161, DOI 10.1034/j.1600-0854.2000.010208.x; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Gu F, 2001, CELL MOL LIFE SCI, V58, P1067, DOI 10.1007/PL00000922; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; Guild SB, 2001, MOL CELL ENDOCRINOL, V184, P51, DOI 10.1016/S0303-7207(01)00645-1; Gully D, 2002, J PHARMACOL EXP THER, V301, P322, DOI 10.1124/jpet.301.1.322; HEISLER S, 1982, P NATL ACAD SCI-BIOL, V79, P6502, DOI 10.1073/pnas.79.21.6502; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Jeng RL, 2001, CURR BIOL, V11, pR691, DOI 10.1016/S0960-9822(01)00410-9; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kruse MS, 2003, PFLUG ARCH EUR J PHY, V445, P534, DOI 10.1007/s00424-002-0899-5; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Leprince C, 2003, J CELL SCI, V116, P1937, DOI 10.1242/jcs.00403; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; Leventis PA, 2001, TRAFFIC, V2, P839; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Lui WWY, 2003, MOL BIOL CELL, V14, P2385, DOI 10.1091/mbc.e02-11-0735; LUINI A, 1986, J NEUROSCI, V6, P3128; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; McPherson PS, 2002, TRENDS CELL BIOL, V12, P312, DOI 10.1016/S0962-8924(02)02309-7; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Mills IG, 2003, J CELL BIOL, V160, P213, DOI 10.1083/jcb.200208023; Modregger J, 2003, J BIOL CHEM, V278, P4160, DOI 10.1074/jbc.M208568200; Muller AJ, 2003, MOL CELL BIOL, V23, P4295, DOI 10.1128/MCB.23.12.4295-4306.2003; Mundigl O, 1998, J NEUROSCI, V18, P93; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; Onofri F, 2000, J BIOL CHEM, V275, P29857, DOI 10.1074/jbc.M006018200; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PATEL YC, 1994, J BIOL CHEM, V269, P1506; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Qualmann B, 2002, INT REV CYTOL, V220, P93; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ramjaun AR, 1999, J BIOL CHEM, V274, P19785, DOI 10.1074/jbc.274.28.19785; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Razzaq A, 2001, GENE DEV, V15, P2967, DOI 10.1101/gad.207801; REISINE T, 1988, J PHARMACOL EXP THER, V245, P225; RICHARDSON UI, 1981, ENDOCRINOLOGY, V108, P281, DOI 10.1210/endo-108-1-281; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; Routhier EL, 2003, ONCOGENE, V22, P637, DOI 10.1038/sj.onc.1206162; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sarret P, 1998, NEUROENDOCRINOLOGY, V68, P37, DOI 10.1159/000054348; Sarret P, 1999, J BIOL CHEM, V274, P19294, DOI 10.1074/jbc.274.27.19294; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Stroh T, 1999, J COMP NEUROL, V412, P69, DOI 10.1002/(SICI)1096-9861(19990913)412:1<69::AID-CNE5>3.0.CO;2-V; Strowski MZ, 2002, NEUROENDOCRINOLOGY, V75, P339, DOI 10.1159/000059430; Szaszak M, 2002, J BIOL CHEM, V277, P21650, DOI 10.1074/jbc.M200778200; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Tannenbaum GS, 1999, HDB PHYSL 7, P221; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; Vandenbulcke F, 2000, J CELL SCI, V113, P2963; Wakeham DE, 2000, TRAFFIC, V1, P393, DOI 10.1034/j.1600-0854.2000.010504.x; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wasiak S, 2001, J BIOL CHEM, V276, P26622, DOI 10.1074/jbc.M100591200; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Yang ZY, 2001, J BIOL CHEM, V276, P4251, DOI 10.1074/jbc.M006371200; Zelhof AC, 2001, DEVELOPMENT, V128, P5005; Zhang B, 2002, TRAFFIC, V3, P452, DOI 10.1034/j.1600-0854.2002.30702.x	99	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 27	2004	279	9					8029	8037		10.1074/jbc.M310792200	http://dx.doi.org/10.1074/jbc.M310792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	776EG	14660576	hybrid			2022-12-27	WOS:000189103300081
J	Tronchere, H; Laporte, J; Pendaries, C; Chaussade, C; Liaubet, L; Pirola, L; Mandel, JL; Payrastre, B				Tronchere, H; Laporte, J; Pendaries, C; Chaussade, C; Liaubet, L; Pirola, L; Mandel, JL; Payrastre, B			Production of phosphatidylinositol 5-phosphate by the phosphoinositide 3-phosphatase myotubularin in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE MYOTUBULARIN; LIPID 2ND-MESSENGER; MYOPATHY; GENE; FAMILY; IDENTIFICATION; MUTATIONS; PROTEIN; MTMR2; DEPHOSPHORYLATES	MTM1, the gene encoding myotubularin (MTM1), is mutated in the X-linked myotubular myopathy (XLMTM), a severe genetic muscular disorder. MTM1 is a phosphoinositide phosphatase hydrolyzing phosphatidylinositol 3-phosphate (PtdIns(3)P) in yeast and in vitro. Because this lipid is implicated in the regulation of vesicular trafficking, we used established cell lines from XLMTM patients to evaluate whether the lack of endogenous MTM1 expression could affect PtdIns(3)P labeling patterns. Our results showed that the vesicular trafficking related to early endosomes was not significantly affected in the XLMTM cell lines compared with control cells. However, in addition to PtdIns(3)P, we found that MTM1 can hydrolyze phosphatidylinositol 3,5-bisphosphate both in vitro and in mammalian cells. Using a mass assay, we demonstrated that the product generated is phosphatidylinositol 5-phosphate (PtdIns(5)P), a recently discovered phosphoinositide, the function of which is still unknown. In L6 myotubes overexpressing MTM1, hyperosmotic shock induced an increase in the mass level of PtdIns(5)P that was reduced by 50% upon overexpression of the MTM1 inactive mutant D278A. These data demonstrate for the first time a role for MTM1 in the production of PtdIns(5)P in mammalian cells, suggesting that the lack of transformation of phosphatidylinositol 3,5-bisphosphate into PtdIns(5)P might be an important component in the etiology of myotubular myopathy.	Hop Purpan, INSERM, U563,CPTP, Dept Oncogenese & Signalisat Cellules Hematopoiet, F-31059 Toulouse, France; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Fac Med, INSERM, U145, F-06107 Nice 2, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Tronchere, H (corresponding author), Hop Purpan, INSERM, U563, CPTP Bat C, F-31039 Toulouse, France.	helentro@toulouse.insenn.fr	Pirola, Luciano/I-5250-2018; TRONCHERE, Helene/M-5631-2014; laporte, jocelyn/O-4888-2019; Laporte, Jocelyn/H-6801-2016; laporte, jocelyn/J-7008-2012; Mandel, Jean Louis/Q-2668-2016	Mandel, Jean Louis/0000-0002-0535-6589; , Bernard/0000-0002-8693-0190; Pirola, Luciano/0000-0001-6539-5435; Liaubet, Laurence/0000-0003-0201-0264				Azzedine H, 2003, AM J HUM GENET, V72, P1141, DOI 10.1086/375034; Berger P, 2002, HUM MOL GENET, V11, P1569, DOI 10.1093/hmg/11.13.1569; Biancalana V, 2003, HUM GENET, V112, P135, DOI 10.1007/s00439-002-0869-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Bolino A, 2000, NAT GENET, V25, P17, DOI 10.1038/75542; Bolino A, 2002, GENE, V283, P17, DOI 10.1016/S0378-1119(01)00876-9; Buj-Bello A, 2002, P NATL ACAD SCI USA, V99, P15060, DOI 10.1073/pnas.212498399; Buj-Bello A, 2002, HUM MOL GENET, V11, P2297, DOI 10.1093/hmg/11.19.2297; Chaussade C, 2003, MOL ENDOCRINOL, V17, P2448, DOI 10.1210/me.2003-0261; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Firestein R, 2002, J CLIN INVEST, V109, P1165, DOI [10.1172/JCI200212589, 10.1172/JCI0212589]; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Jones DR, 1999, J BIOL CHEM, V274, P18407, DOI 10.1074/jbc.274.26.18407; Kim SA, 2003, P NATL ACAD SCI USA, V100, P4492, DOI 10.1073/pnas.0431052100; Kim SA, 2002, J BIOL CHEM, V277, P4526, DOI 10.1074/jbc.M111087200; Laporte J, 1998, HUM MOL GENET, V7, P1703, DOI 10.1093/hmg/7.11.1703; Laporte J, 2002, J CELL SCI, V115, P3105; Laporte J, 2002, BIOCHEM BIOPH RES CO, V291, P305, DOI 10.1006/bbrc.2002.6445; Laporte J, 1996, NAT GENET, V13, P175, DOI 10.1038/ng0696-175; Laporte J, 2001, ANN NEUROL, V50, P42, DOI 10.1002/ana.1033; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Meijer HJG, 2001, BIOCHEM J, V360, P491, DOI 10.1042/0264-6021:3600491; Mochizuki Y, 2003, P NATL ACAD SCI USA, V100, P9768, DOI 10.1073/pnas.1333958100; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Nandurkar HH, 2003, P NATL ACAD SCI USA, V100, P8660, DOI 10.1073/pnas.1033097100; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Senderek J, 2003, HUM MOL GENET, V12, P349, DOI 10.1093/hmg/ddg030; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Taylor GS, 2001, ANAL BIOCHEM, V295, P122, DOI 10.1006/abio.2001.5179; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Toker A, 2002, CELL MOL LIFE SCI, V59, P761, DOI 10.1007/s00018-002-8465-z; Tronchere H, 2003, CELL MOL LIFE SCI, V60, P2084, DOI 10.1007/s00018-003-3062-3; Walker DM, 2001, CURR BIOL, V11, P1600, DOI 10.1016/S0960-9822(01)00501-2; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051	40	110	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7304	7312		10.1074/jbc.M311071200	http://dx.doi.org/10.1074/jbc.M311071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660569	hybrid			2022-12-27	WOS:000188969200132
J	Zheng, XL; Gui, Y; Du, GW; Frohman, MA; Peng, DQ				Zheng, XL; Gui, Y; Du, GW; Frohman, MA; Peng, DQ			Calphostin-C induction of vascular smooth muscle cell apoptosis proceeds through phospholipase D and microtubule inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STRESS FIBER FORMATION; HUMAN NEUTROPHILS; IN-VITRO; ATHEROSCLEROSIS; ACTIVATION; STIMULATION; FIBROBLASTS; CYTOMETRY	Calphostin-C, a protein kinase C inhibitor, induces apoptosis of cultured vascular smooth muscle cells. However, the mechanisms are not completely defined. Because apoptosis of vascular smooth muscle cells is critical in several proliferating vascular diseases such as atherosclerosis and restenosis after angioplasty, we decided to investigate the mechanisms underlying the calphostin-C-induced apoptotic pathway. We show here that apoptosis is inhibited by the addition of exogenous phosphatidic acid, a metabolite of phospholipase D (PLD), and that calphostin-C inhibits completely the activities of both isoforms of PLD, PLD1 and PLD2. Overexpression of either PLD1 or PLD2 prevented the vascular smooth muscle cell apoptosis induced by serum withdrawal but not the calphostin-C-elicited apoptosis. These data suggest that PLDs have anti-apoptotic effects and that complete inhibition of PLD activity by calphostin-C induces smooth muscle cell apoptosis. We also report that calphostin-C induced microtubule disruption and that the addition of exogenous phosphatidic acid inhibits calphostin-C effects on microtubules, suggesting a role for PLD in stabilizing the microtubule network. Overexpressing PLD2 in Chinese hamster ovary cells phenocopies this result, providing strong support for the hypothesis. Finally, taxol, a microtubule stabilizer, not only inhibited the calphostin-C-induced microtubule disruption but also inhibited apoptosis. We therefore conclude that calphostin-C induces apoptosis of cultured vascular smooth muscle cells through inhibiting PLD activity and subsequent microtubule polymerization.	Univ Calgary, Hlth Sci Ctr, Fac Med,Smooth Muscle Res Grp, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zheng, XL (corresponding author), Univ Calgary, Hlth Sci Ctr, Fac Med,Smooth Muscle Res Grp, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	xlzheng@ucalgary.ca		Zheng, Xi-Long/0000-0002-0889-1827; Du, Guangwei/0000-0003-4193-6975	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064166] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK64166] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; Aoki M, 1997, HEART VESSELS, P71; Axel DI, 1997, CIRCULATION, V96, P636; Bai HZ, 1999, CIRC RES, V85, P229, DOI 10.1161/01.RES.85.3.229; Bennett MR, 1998, ATHEROSCLEROSIS, V138, P3, DOI 10.1016/S0021-9150(98)00013-6; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; CARNERO A, 1994, ONCOGENE, V9, P1387; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; deBlois D, 1997, HYPERTENSION, V29, P340, DOI 10.1161/01.HYP.29.1.340; Devlin AM, 2000, HYPERTENSION, V36, P110, DOI 10.1161/01.HYP.36.1.110; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gardiner JC, 2001, PLANT CELL, V13, P2143, DOI 10.1105/tpc.13.9.2143; Hamet P, 1995, Curr Opin Nephrol Hypertens, V4, P1, DOI 10.1097/00041552-199501000-00001; IKEMOTO H, 1995, J NEUROSURG, V83, P1008, DOI 10.3171/jns.1995.83.6.1008; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Kamentsky LA, 1997, ACTA CYTOL, V41, P123, DOI 10.1159/000332315; KAMENTSKY LA, 1991, CYTOMETRY, V12, P381, DOI 10.1002/cyto.990120502; Kim JH, 1999, IUBMB LIFE, V48, P445; Lee S, 2001, J BIOL CHEM, V276, P28252, DOI 10.1074/jbc.M008521200; LESZCZYNSKI D, 1994, AM J PATHOL, V145, P1265; Nozawa Y, 2002, BBA-MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388-1981(02)00327-X; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; Park MA, 2002, FEBS LETT, V519, P45, DOI 10.1016/S0014-5793(02)02705-9; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rossig L, 2001, BASIC RES CARDIOL, V96, P11, DOI 10.1007/s003950170073; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Sciorra VA, 2001, BIOCHEMISTRY-US, V40, P2640, DOI 10.1021/bi002528m; Spinedi A, 1998, BIOCHEM PHARMACOL, V56, P1489, DOI 10.1016/S0006-2952(98)00169-5; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; SVETLOV S, 1993, BIOCHIM BIOPHYS ACTA, V1177, P75, DOI 10.1016/0167-4889(93)90160-Q; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8; Zhu DM, 1998, CLIN CANCER RES, V4, P2967	36	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7112	7118		10.1074/jbc.M310721200	http://dx.doi.org/10.1074/jbc.M310721200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660552	hybrid			2022-12-27	WOS:000188969200110
J	Keren, Z; Diamant, E; Ostrovsky, O; Bengal, E; Melamed, D				Keren, Z; Diamant, E; Ostrovsky, O; Bengal, E; Melamed, D			Modification of ligand-independent B cell receptor tonic signals activates receptor editing in immature B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN-RECEPTOR; CLONAL SELECTION; POSITIVE SELECTION; CD19; EXPRESSION; DEFICIENT; MICE; IMMUNOGLOBULIN; PROTEIN; KINASE	Maturation of B lymphocytes strictly depends on the signaling competence of the B cell antigen receptor (BCR). Autoreactive receptors undergo negative selection and can be replaced by receptor editing. In addition, the process of maturation of non-self B cells and migration to the spleen, referred to as positive selection, is limited by the signaling competence of the BCR. Using 3-83Tg mice deficient of CD19 we have shown that signaling incompetence not only blocks positive selection but also activates receptor editing. Here we study the role of ligand-independent BCR tonic tyrosine phosphorylation signals in activation of receptor editing. We find that editing, immature 3-83Tg B cells deficient of CD19 have elevated BCR tonic signals and that lowering these tonic signals effectively suppresses receptor editing. Furthermore, we show that elevation of BCR tonic signals in non-editing, immature 3-83Tg B cells stimulates significant receptor editing. We also show that positive selection and developmental progression from the bone marrow to the spleen are limited to cells capable of establishing appropriate tonic signals, as in contrast to immature cells, splenic 3-83Tg B cells deficient of CD19 have BCR tonic signals similar to those of the control 3-83Tg cells. This developmental progression is accompanied by activation of molecules signaling for growth and survival. Hence, we suggest that ligand-independent BCR tonic signals are required for promoting positive selection and suppressing the receptor-editing mechanism in immature B cells.	Technion Israel Inst Technol, Fac Med, Dept Immunol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Melamed, D (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Immunol, IL-31096 Haifa, Israel.	melamedd@tx.technion.ac.il						Bannish G, 2001, J EXP MED, V194, P1583, DOI 10.1084/jem.194.11.1583; BILLIPS LG, 1995, J EXP MED, V182, P973, DOI 10.1084/jem.182.4.973; Brauweiler AM, 2000, IMMUNOL REV, V176, P69; Buhl AM, 1997, J EXP MED, V186, P1897, DOI 10.1084/jem.186.11.1897; Buhl AM, 2000, IMMUNOL REV, V176, P141; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Fleming HE, 2001, IMMUNITY, V15, P521, DOI 10.1016/S1074-7613(01)00216-3; Fujimoto M, 1999, IMMUNITY, V11, P191, DOI 10.1016/S1074-7613(00)80094-1; Fujimoto M, 2000, IMMUNOL RES, V22, P281, DOI 10.1385/IR:22:2-3:281; Han A, 2003, IMMUNITY, V19, P621, DOI 10.1016/S1074-7613(03)00275-9; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Kouskoff V, 2000, P NATL ACAD SCI USA, V97, P7435, DOI 10.1073/pnas.130182597; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Leider N, 2003, J IMMUNOL, V171, P2446, DOI 10.4049/jimmunol.171.5.2446; Li XL, 1998, J IMMUNOL, V161, P5901; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Martin F, 2000, IMMUNITY, V12, P39, DOI 10.1016/S1074-7613(00)80157-0; Meade J, 2002, EUR J IMMUNOL, V32, P1029, DOI 10.1002/1521-4141(200204)32:4<1029::AID-IMMU1029>3.0.CO;2-M; Meffre E, 2000, NAT IMMUNOL, V1, P379, DOI 10.1038/80816; Melamed D, 1997, J IMMUNOL, V159, P1233; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; MELAMED D, 1993, EUR J IMMUNOL, V23, P935, DOI 10.1002/eji.1830230426; Melchers F, 2000, IMMUNOL REV, V175, P33, DOI 10.1111/j.1600-065X.2000.imr017510.x; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; Nemazee D, 2000, ANNU REV IMMUNOL, V18, P19, DOI 10.1146/annurev.immunol.18.1.19; Niiro H, 2002, J EXP MED, V195, P143, DOI 10.1084/jem.20011524; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Otero DC, 2003, J IMMUNOL, V170, P73, DOI 10.4049/jimmunol.170.1.73; Otero DC, 2001, J BIOL CHEM, V276, P1474, DOI 10.1074/jbc.M003918200; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Phee H, 2001, MOL CELL BIOL, V21, P8615, DOI 10.1128/MCB.21.24.8615-8625.2001; Polic B, 2001, P NATL ACAD SCI USA, V98, P8744, DOI 10.1073/pnas.141218898; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Reichlin A, 2001, J EXP MED, V193, P13, DOI 10.1084/jem.193.1.13; Reth M, 2000, IMMUNOL REV, V176, P10; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Sato S, 1997, P NATL ACAD SCI USA, V94, P13158, DOI 10.1073/pnas.94.24.13158; Shivtiel S, 2002, EUR J IMMUNOL, V32, P2264, DOI 10.1002/1521-4141(200208)32:8<2264::AID-IMMU2264>3.0.CO;2-E; Shivtiel S, 2002, J IMMUNOL, V168, P5596, DOI 10.4049/jimmunol.168.11.5596; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Yamanashi Y, 2000, GENE DEV, V14, P11; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287	50	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2004	279	14					13418	13424		10.1074/jbc.M311970200	http://dx.doi.org/10.1074/jbc.M311970200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	807CB	14668327	hybrid			2022-12-27	WOS:000220478500019
J	Gensler, M; Buschbeck, M; Ullrich, A				Gensler, M; Buschbeck, M; Ullrich, A			Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phosphatase BDP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; EGF-RECEPTOR; NEU ONCOGENE; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; FUNCTIONAL-ANALYSIS; ACTIVATED ERBB2; LIGAND-BINDING; HUMAN-PLACENTA	Signaling by receptor tyrosine kinases (RTK) mediates a variety of complex cellular functions and in case of deregulation can contribute to pathophysiological processes. A tight and finely tuned control of RTK activity is therefore critical for the cell. We investigated the role of the PEST-type protein-tyrosine phosphatase BDP1 in the regulation of HER2, a member of the epidermal growth factor receptor (EGFR) family of RTKs. Here we demonstrate that HER2 signaling is highly sensitive to BDP1 activity. Overexpression of BDP1 inhibited ligand-induced activation of HER2 but not that of the closely related EGFR. On the other hand, suppression of endogenous BDP1 expression increased the phosphorylation state of HER2. In addition, BDP1 was able to interfere with downstream signaling events by inhibiting the phosphorylation of the adaptor protein Gab1 and reducing mitogen-activated protein kinase activation. Supported by the finding that BDP1 is coexpressed with HER2 in breast cancer cells, we suggest that BDP1 is an important regulator of HER2 activity and thus the first protein-tyrosine phosphatase shown to be involved in HER2 signal attenuation.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	ullrich@biochem.mpg.de	Buschbeck, Marcus/J-8204-2017	Buschbeck, Marcus/0000-0002-3218-4567				Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; Azios NG, 2001, ONCOGENE, V20, P5199, DOI 10.1038/sj.onc.1204555; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Baribault H, 1997, TRANSGENIC RES, V6, P359, DOI 10.1023/A:1018427215923; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; de Melker AA, 2001, J CELL SCI, V114, P2167; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Dosil M, 1996, BLOOD, V88, P4510, DOI 10.1182/blood.V88.12.4510.bloodjournal88124510; FENDLY BM, 1990, CANCER RES, V50, P1550; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Huang K, 1996, ONCOGENE, V13, P1567; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; Kim YW, 1996, ONCOGENE, V13, P2275; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; LONARDO F, 1990, New Biologist, V2, P992; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SEGATTO O, 1993, ONCOGENE, V8, P2105; Settle M, 2003, ONCOGENE, V22, P1916, DOI 10.1038/sj.onc.1206240; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOOS MA, 1992, J BIOL CHEM, V267, P12955; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284; YANG Q, 1993, J BIOL CHEM, V268, P6622; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	63	45	46	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2004	279	13					12110	12116		10.1074/jbc.M309527200	http://dx.doi.org/10.1074/jbc.M309527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	804YV	14660651	hybrid			2022-12-27	WOS:000220334900016
J	Ding, M; Lu, YJ; Bowman, L; Huang, CS; Leonard, S; Wang, LY; Vallyathan, V; Castranova, V; Shi, XL				Ding, M; Lu, YJ; Bowman, L; Huang, CS; Leonard, S; Wang, LY; Vallyathan, V; Castranova, V; Shi, XL			Inhibition of AP-1 and neoplastic transformation by fresh apple peel extract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN-1 ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; CANCER CHEMOPREVENTION; ANTIOXIDANT ACTIVITY; CRYSTALLINE SILICA; RESPONSE ELEMENT; TUMOR PROMOTION; PHORBOL ESTER; RETINOIC ACID; JB6 CELLS	Consumption of fruits and vegetables has been associated with a low incidence of cancers and other chronic diseases. Previous studies suggested that fresh apples inhibit tumor cell proliferation. Here we report that oral administration of apple peel extracts decreased the number of nonmalignant and malignant skin tumors per mouse induced by 12-O-tetradecanolyphorbol-13-acetate (TPA) in 7,12-dimethylbenz(a) anthracene-initiated mouse skin. ESR analysis indicated that apple extract strongly scavenged hydroxyl (OH) and superoxide (O-2(radical anion)) radicals. Mechanistic studies showed that pretreatment with apple peel extract inhibited AP-1 transactivation induced by ultraviolet B irradiation or TPA in JB6 cells and AP-1-luciferase reporter transgenic mice. This inhibitory effect appears to be mediated by the inhibition of ERKs and JNK activity. The results provide the first evidence that an extract from fresh apple peel extract may inhibit tumor promoter-induced carcinogenesis and associated cell signaling, and suggest that the chemopreventive effects of fresh apple may be through its antioxidant properties by blocking reactive oxygen species-mediated AP-1-MAPK activation.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); New York University	Ding, M (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA.	mid5@cdc.gov	Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096				Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; [Anonymous], 1996, CA Cancer J Clin, V46, P325; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BUSCHER M, 1988, ONCOGENE, V3, P301; Cao GH, 1998, AM J CLIN NUTR, V68, P1081, DOI 10.1093/ajcn/68.5.1081; Carlton PS, 2000, CANCER LETT, V159, P113, DOI 10.1016/S0304-3835(00)00464-X; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; Ding M, 2001, J BIOL CHEM, V276, P9108, DOI 10.1074/jbc.M007666200; Eberhardt MV, 2000, NATURE, V405, P903, DOI 10.1038/35016148; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; JANZEN EG, 1968, J AM CHEM SOC, V90, P5909, DOI 10.1021/ja01023a051; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Kresty LA, 2001, CANCER RES, V61, P6112; Krishnan K, 1998, PRIMARY CARE, V25, P361, DOI 10.1016/S0095-4543(05)70069-5; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; La Vecchia C, 1998, EUR J CANCER PREV, V7, P3, DOI 10.1097/00008469-199802001-00002; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1997, CANCER RES, V57, P3569; Lu YP, 2002, P NATL ACAD SCI USA, V99, P12455, DOI 10.1073/pnas.182429899; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Mukhtar H, 1999, TOXICOL APPL PHARM, V158, P207, DOI 10.1006/taap.1999.8721; NAITO M, 1988, CARCINOGENESIS, V9, P639, DOI 10.1093/carcin/9.4.639; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Rock CL, 1998, HEMATOL ONCOL CLIN N, V12, P975, DOI 10.1016/S0889-8588(05)70037-X; SHI XL, 1988, BIOCHEM BIOPH RES CO, V156, P137, DOI 10.1016/S0006-291X(88)80815-5; SHI XL, 1990, ARCH BIOCHEM BIOPHYS, V277, P342, DOI 10.1016/0003-9861(90)90589-Q; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wolfe K, 2003, J AGR FOOD CHEM, V51, P609, DOI 10.1021/jf020782a; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827	38	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10670	10676		10.1074/jbc.M311465200	http://dx.doi.org/10.1074/jbc.M311465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14665633	hybrid			2022-12-27	WOS:000220050400121
J	Mascarell, L; Auger, R; Alcover, A; Ojcius, DM; Jungas, T; Cadet-Daniel, V; Kanellopoulos, JM; Truffa-Bachi, P				Mascarell, L; Auger, R; Alcover, A; Ojcius, DM; Jungas, T; Cadet-Daniel, V; Kanellopoulos, JM; Truffa-Bachi, P			Characterization of a gene encoding two isoforms of a mitochondrial protein up-regulated by cyclosporin a in activated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; CALCINEURIN; CYCLOPHILIN; MEMBRANE; BINDING; IMPORT; EXPRESSION; RECEPTOR; CANCER; NFATP	Cyclosporin A (CSA) is an immunosuppressor used in organ transplantation. A recent proteomic analysis has revealed that activation of T cells in the presence of CSA induces the synthesis of hundreds of new proteins. Here we used representational difference analysis to characterize some of the corresponding induced genes. After cDNA bank screening we focused on one of these genes, which we named CSA-conditional, T cell activation-dependent (CSTAD) gene. This gene produces two mRNAs resulting from alternative splicing events. They encode two proteins of 104 and 141 amino acids, CSTADp-S and CSTADp-L, for the short and long forms, respectively. FK506 had the same effect as CSA, whereas rapamycin did not affect the level of CSTAD gene expression, demonstrating that inhibition of the calcineurin activation pathway is involved in CSTAD gene up-regulation. CSA also led to overexpression of CSTAD in mice immunized in the presence of CSA, confirming the in vitro analysis. Microscopic and cytofluorimetric analysis of cells expressing green fluorescent protein-tagged CSTADp-L and CSTADp-S showed that both proteins colocalize with mitochondrial markers and depolarize the mitochondrial transmembrane potential without causing release of cytochrome c, apoptosis, or necrosis. Both CSTADp isoforms are sensitive to proteinase K, implying that they are located in the mitochondrial outer membrane. These data reveal a new mechanism of action for CSA, which involves up-regulation of a gene whose products are sorted to mitochondria and depolarize the mitochondrial membrane.	Univ Paris 11, IBBMC, CNRS UMR 8619, Lab Activat Cellulaire & Transduct Signaux, F-91405 Orsay, France; Inst Pasteur, CNRS, Unite Biol Populat Lymphocytaires, URA 2582, F-75724 Paris 15, France; Inst Pasteur, CNRS, Unite Biol Interact Cellulaires, URA 2582, F-75724 Paris 15, France; Univ Paris 07, Inst Jacques Monod, CNRS, UMR 7592, F-75721 Paris 5, France	UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Kanellopoulos, JM (corresponding author), Univ Paris 11, IBBMC, CNRS UMR 8619, Lab Activat Cellulaire & Transduct Signaux, F-91405 Orsay, France.	Jean.Kanellopoulos@ibbmc.u-psud.fr	Ojcius, David/ABE-6557-2020	Alcover, Andres/0000-0002-9507-3450; Ojcius, David/0000-0003-1461-4495	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054624] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI054624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bemer V, 1996, EUR J IMMUNOL, V26, P1481, DOI 10.1002/eji.1830260712; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Frazer JK, 1997, J IMMUNOL METHODS, V207, P1, DOI 10.1016/S0022-1759(97)00091-4; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Johnson N, 1999, EUR J BIOCHEM, V263, P353, DOI 10.1046/j.1432-1327.1999.00490.x; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Khanna A, 1997, TRANSPLANTATION, V63, P1037, DOI 10.1097/00007890-199704150-00026; Khanna AK, 1999, TRANSPLANTATION, V67, P882, DOI 10.1097/00007890-199903270-00016; Mascarell L, 2002, IMMUNOL LETT, V84, P137, DOI 10.1016/S0165-2478(02)00157-8; Mascarell L, 2000, TRANSPLANTATION, V70, P340, DOI 10.1097/00007890-200007270-00019; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; Morton RS, 1999, J PERIODONTOL, V70, P1464, DOI 10.1902/jop.1999.70.12.1464; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Perfettini JL, 2002, METHOD ENZYMOL, V358, P334; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Rovira P, 2000, CURR MED CHEM, V7, P673, DOI 10.2174/0929867003374778; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; STEWART T, 1995, LANCET, V346, P796, DOI 10.1016/S0140-6736(95)91618-0; Teague TK, 1999, P NATL ACAD SCI USA, V96, P12691, DOI 10.1073/pnas.96.22.12691; THIEL G, 1994, TRANSPLANT P, V26, P2493; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WILLIAMSON MS, 1994, J PERIODONTOL, V65, P895, DOI 10.1902/jop.1994.65.10.895; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	39	4	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10556	10563		10.1074/jbc.M313770200	http://dx.doi.org/10.1074/jbc.M313770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14684732	Green Published, hybrid			2022-12-27	WOS:000220050400109
J	Yosef, I; Irihimovitch, V; Knopf, JA; Cohen, I; Orr-Dahan, I; Nahum, E; Keasar, C; Shapira, M				Yosef, I; Irihimovitch, V; Knopf, JA; Cohen, I; Orr-Dahan, I; Nahum, E; Keasar, C; Shapira, M			RNA binding activity of the ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit from Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; CHLOROPLAST GENE-EXPRESSION; PROTEIN DISULFIDE-ISOMERASE; PSBC MESSENGER-RNA; CRYSTAL-STRUCTURE; TRANSLATIONAL REGULATION; GREEN-ALGA; LIGHT; RUBISCO; THYLAKOIDS	Transfer of the green algae Chlamydomonas reinhardtii from low light to high light generated an oxidative stress that led to a dramatic arrest in the synthesis of the large subunit (LSU) of ribulose-1,5-bisphosphate carboxylase/ oxygenase ( Rubisco). The translational arrest correlated with transient changes in the intracellular levels of reactive oxygen species and with shifting the glutathione pool toward its oxidized form (Irihimovitch, V., and Shapira, M. ( 2000) J. Biol. Chem. 275, 16289 - 16295). Here we examined how the redox potential of glutathione affected the RNA-protein interactions with the 5'-untranslated region of rbcL. This RNA region specifically binds a group of proteins with molecular masses of 81, 62, 51, and 47 kDa in UV-cross-linking experiments under reducing conditions. Binding of these proteins was interrupted by exposure to oxidizing conditions ( GSSG), and a new protein of 55 kDa was shown to interact with the RNA. The 55-kDa protein comigrated with Rubisco LSU in one- and two-dimensional gels, and its RNA binding activity was further verified by using the purified protein in UV-cross-linking experiments under oxidizing conditions. However, the LSU of purified and oxidized Rubisco bound to RNA in a sequence-independent manner. A remarkable structural similarity was found between the amino-terminal domain of Rubisco LSU in C. reinhardtii and the RNA binding domain, a highly prevailing motif among RNA-binding proteins. It appears from the crystal structure of Rubisco that the amino terminus of LSU is buried within the holoenzyme. We propose that under oxidizing conditions it is exposed to the surface and can, therefore, bind RNA. Accordingly, a recombinant form of the polypeptide domain that corresponds to the amino terminus of LSU was found to bind RNA in vitro with or without GSSG.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Comp Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Shapira, M (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.	shapiram@bgumail.bgu.ac.il	KEASAR, CHEN/HGB-9794-2022; Cohen‬, ‪Idan/AAD-6997-2021; Keasar, Chen/J-8413-2012	Cohen‬, ‪Idan/0000-0001-6933-9385; Keasar, Chen/0000-0003-0994-1520; Shapira, Michal/0000-0002-6164-7874				Auchincloss AH, 2002, J CELL BIOL, V157, P953, DOI 10.1083/jcb.200201060; Bae WH, 2000, P NATL ACAD SCI USA, V97, P7784, DOI 10.1073/pnas.97.14.7784; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; Boudreau E, 2000, EMBO J, V19, P3366, DOI 10.1093/emboj/19.13.3366; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Choquet Y, 1998, P NATL ACAD SCI USA, V95, P4380, DOI 10.1073/pnas.95.8.4380; Cristofari G, 2002, PROG NUCLEIC ACID RE, V72, P223, DOI 10.1016/S0079-6603(02)72071-0; Danon A, 1997, PLANT PHYSIOL, V115, P1293, DOI 10.1104/pp.115.4.1293; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; FICHTNER K, 1993, PLANTA, V190, P1, DOI 10.1007/BF00195668; Foyer CH, 1997, PHYSIOL PLANTARUM, V100, P241, DOI 10.1034/j.1399-3054.1997.1000205.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GUTTERIDGE S, 1995, PLANT CELL, V7, P809, DOI 10.1105/tpc.7.7.809; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; Irihimovitch V, 2000, J BIOL CHEM, V275, P16289, DOI 10.1074/jbc.275.21.16289; Ishida H, 1999, J BIOL CHEM, V274, P5222, DOI 10.1074/jbc.274.8.5222; Karlson D, 2002, J BIOL CHEM, V277, P35248, DOI 10.1074/jbc.M205774200; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; Lopez C, 2000, VIROLOGY, V269, P462, DOI 10.1006/viro.2000.0235; Marcus Y, 2003, J BACTERIOL, V185, P1509, DOI 10.1128/JB.185.5.1509-1517.2003; MEHTA RA, 1992, J BIOL CHEM, V267, P2810; Mizohata E, 2002, J MOL BIOL, V316, P679, DOI 10.1006/jmbi.2001.5381; Mohr S, 2002, CELL, V109, P769, DOI 10.1016/S0092-8674(02)00771-7; Moreno J, 1999, J BIOL CHEM, V274, P26789, DOI 10.1074/jbc.274.38.26789; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; Noctor G, 2002, J EXP BOT, V53, P1283, DOI 10.1093/jexbot/53.372.1283; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Osmond CB, 1994, PHOTOINHIBITION PHOT, P1; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; Rodermel S, 1996, P NATL ACAD SCI USA, V93, P3881, DOI 10.1073/pnas.93.9.3881; Sambrook J., 2001, MOL CLONING LAB MANU; Severson W, 1999, J BIOL CHEM, V274, P33732, DOI 10.1074/jbc.274.47.33732; Shapira M, 1997, PLANT MOL BIOL, V33, P1001, DOI 10.1023/A:1005814800641; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; Taylor TC, 2001, J BIOL CHEM, V276, P48159, DOI 10.1074/jbc.M107765200; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; Trebitsh T, 2001, J BIOL CHEM, V276, P4564, DOI 10.1074/jbc.M005950200; Trebitsh T, 2000, MOL CELL BIOL, V20, P1116, DOI 10.1128/MCB.20.4.1116-1123.2000; Vaistij FE, 2000, P NATL ACAD SCI USA, V97, P14813, DOI 10.1073/pnas.97.26.14813; Yohn CB, 1998, P NATL ACAD SCI USA, V95, P2238, DOI 10.1073/pnas.95.5.2238; Zerges W, 1998, J CELL BIOL, V140, P101, DOI 10.1083/jcb.140.1.101; Zerges W, 1997, MOL CELL BIOL, V17, P3440, DOI 10.1128/MCB.17.6.3440; Zerges W, 2002, PLANT MOL BIOL, V50, P573, DOI 10.1023/A:1020246007858; Zerges W, 2000, BIOCHIMIE, V82, P583, DOI 10.1016/S0300-9084(00)00603-9	50	44	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 12	2004	279	11					10148	10156		10.1074/jbc.M308602200	http://dx.doi.org/10.1074/jbc.M308602200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	800TK	14679208	hybrid			2022-12-27	WOS:000220050400061
J	Eskiw, CH; Dellaire, G; Bazett-Jones, DP				Eskiw, CH; Dellaire, G; Bazett-Jones, DP			Chromatin contributes to structural integrity of promyelocytic leukemia bodies through a SUMO-1-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PML NUCLEAR-BODIES; COVALENT MODIFICATION; RAR-ALPHA; PROTEIN; INTERPHASE; DOMAINS; ND10; DAXX; DNA; CONDENSATION	Promyelocytic leukemia (PML) protein is implicated in transcriptional regulation, apoptosis, DNA repair, and tumor suppression. It is not known, however, whether PML and other components of PML bodies function within the vicinity of the bodies or elsewhere in the nucleoplasm. In this study, we demonstrate that chromatin organization around PML bodies influences their morphology, dynamics, and structural integrity by a SUMO-1-independent mechanism. Following transcriptional inhibition and during early apoptosis, chromatin retracts from the periphery of PML bodies, coinciding with the formation of new PML-containing structures through fission of supramolecular PML-containing microbodies. Both fission and fusion of microbodies with parental PML bodies indicate a loss of structural integrity of the bodies, dependent on the state of the surrounding chromatin. This is supported by the observation that treatment of live cells with DNase I could reproduce the structural instability of PML bodies. In addition, PML bodies, which are normally surrounded by chromatin and are positionally stable, become more dynamic following these treatments, presumably due to the loss of chromatin contacts. Overexpression of SUMO-1, a modification required for PML body formation, did not prevent PML body fission, indicating that chromatin-based integrity of PML body structure occurs through a SUMO-1-independent mechanism.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Bazett-Jones, DP (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	dbjones@sickkids.ca	Dellaire, Graham/L-9948-2014	Dellaire, Graham/0000-0002-3466-6316				Bazett-Jones DP, 1999, METHODS, V17, P188, DOI 10.1006/meth.1998.0729; Bazett-Jones DP, 1999, MICRON, V30, P151, DOI 10.1016/S0968-4328(99)00019-0; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Boddy MN, 1996, ONCOGENE, V13, P971; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Drouin A, 2001, EXP CELL RES, V271, P277, DOI 10.1006/excr.2001.5377; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P15404, DOI 10.1073/pnas.202608799; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Muratani M, 2002, NAT CELL BIOL, V4, P106, DOI 10.1038/ncb740; Nefkens I, 2003, J CELL SCI, V116, P513, DOI 10.1242/jcs.00253; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Plehn-Dujowich D, 2000, CHROMOSOMA, V109, P266, DOI 10.1007/s004120000073; Ren Y, 2003, J HISTOCHEM CYTOCHEM, V51, P605, DOI 10.1177/002215540305100506; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Shiels C, 2001, J CELL SCI, V114, P3705; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Sun YJ, 2003, GENOMICS, V82, P250, DOI 10.1016/S0888-7543(03)00075-2; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wiesmeijer K, 2002, J STRUCT BIOL, V140, P180, DOI 10.1016/S1047-8477(02)00529-4; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001	43	75	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					9577	9585		10.1074/jbc.M312580200	http://dx.doi.org/10.1074/jbc.M312580200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14672938	hybrid			2022-12-27	WOS:000189265900125
J	Vila, R; Kurosaki, M; Barzago, MM; Kolek, M; Bastone, A; Colombo, L; Salmona, M; Terao, M; Garattini, E				Vila, R; Kurosaki, M; Barzago, MM; Kolek, M; Bastone, A; Colombo, L; Salmona, M; Terao, M; Garattini, E			Regulation and biochemistry of mouse molybdo-flavoenzymes - The DBA/2 mouse is selectively deficient in the expression of aldehyde oxidase homologues 1 and 2 and represents a unique source for the purification and characterization of aldehyde oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID SYNTHESIS; XANTHINE-OXIDOREDUCTASE; ALCOHOL-DEHYDROGENASE; MOLECULAR-CLONING; GUINEA-PIG; TISSUE DISTRIBUTION; ESCHERICHIA-COLI; MAMMARY-GLAND; LIVER-INJURY; IN-VIVO	Mouse molybdo-flavoenzymes consist of xanthine oxidoreductase, aldehyde oxidase (AOX1), and two recently identified proteins, AOH1 and AOH2 ( aldehyde oxidase homologues 1 and 2). Here we demonstrate that CD-1, C57BL/6, 129/Sv, and other mouse strains synthesize high levels of AOH1 in the liver and AOH2 in the skin. By contrast, the DBA/2 and CBA strains are unique, having a selective deficit in the expression of the AOH1 and AOH2 genes. DBA/2 animals synthesize trace amounts of a catalytically active AOH1 protein. However, relative to CD-1 animals, an over 2 log reduction in the steady-state levels of liver AOH1 mRNA, protein, and enzymatic activity is observed in basal conditions and following administration of testosterone. The DBA/2 mouse represents a unique opportunity to purify AOX1 and compare its enzymatic characteristics to those of the AOH1 protein. The spectroscopy and biochemistry of AOX1 are very similar to those of AOH1 except for a differential sensitivity to the non-competitive inhibitory effect of norharmane. AOX1 and AOH1 oxidize an overlapping set of aldehydes and heterocycles. For most compounds, the substrate efficiency (V-max/K-m) of AOX1 is superior to that of AOH1. Alkylic alcohols and acetaldehyde, the toxic metabolite of ethanol, are poor substrates of both enzymes. Consistent with this, the levels of acetaldehyde in the livers of ethanol administered CD-1 and DBA/2 mice are similar, indicating that neither enzyme is involved in the in vivo biotransformation of acetaldehyde.	Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniele Borgomainerio, Mol Biol Lab, Dept Mol Pharmacol & Biochem, I-20157 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, E (corresponding author), Mario Negri Inst Pharmacol Res, Ctr Catullo & Daniele Borgomainerio, Mol Biol Lab, Dept Mol Pharmacol & Biochem, Via Eritrea 62, I-20157 Milan, Italy.	egarattini@marionegri.it	KUROSAKI, Mami/ABG-2224-2020; Terao, Mineko/AAA-6415-2020; terao, mineko/AAU-8089-2020; Garattini, Enrico/AAI-1998-2019; Barzago, Maria Monica/AAA-6402-2020; salmona, mario/ABI-4066-2020; colombo, laura/AAA-6716-2020; salmona, mario/AAA-7116-2020	KUROSAKI, Mami/0000-0001-8231-713X; Terao, Mineko/0000-0002-9976-9869; Barzago, Maria Monica/0000-0002-6952-0069; colombo, laura/0000-0002-3243-0270; salmona, mario/0000-0002-9098-9873; Garattini, Enrico/0000-0001-8983-886X				BADWEY JA, 1981, J BIOL CHEM, V256, P3479; Baylin SB, 1998, ADV CANCER RES, V72, P141; Calzi ML, 1995, J BIOL CHEM, V270, P31037, DOI 10.1074/jbc.270.52.31037; CARPANI G, 1990, ARCH BIOCHEM BIOPHYS, V279, P237, DOI 10.1016/0003-9861(90)90487-J; Demontis S, 1999, BBA-GENE STRUCT EXPR, V1489, P207, DOI 10.1016/S0167-4781(99)00174-8; Doehner W, 2002, CIRCULATION, V105, P2619, DOI 10.1161/01.CIR.0000017502.58595.ED; Duester G, 1999, ADV EXP MED BIOL, V463, P311; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Eriksson CJP, 2001, ALCOHOL CLIN EXP RES, V25, p15S, DOI 10.1111/j.1530-0277.2001.tb02369.x; FORTEMCROBBIE CM, 1986, J BIOL CHEM, V261, P2154; Garattini E, 2003, BIOCHEM J, V372, P15, DOI 10.1042/BJ20030121; Harrison R, 2002, FREE RADICAL BIO MED, V33, P774, DOI 10.1016/S0891-5849(02)00956-5; Holmes R S, 1980, Adv Exp Med Biol, V132, P57; HOLMES RS, 1978, COMP BIOCHEM PHYS B, V61, P339, DOI 10.1016/0305-0491(78)90134-7; HOLMES RS, 1979, BIOCHEM GENET, V17, P517, DOI 10.1007/BF00498887; HOLMES RS, 1981, ANIM BLOOD GROUPS BI, V12, P193; HUANG DY, 1994, BIOCHEM BIOPH RES CO, V205, P1278, DOI 10.1006/bbrc.1994.2803; JOHNS DG, 1967, J CLIN INVEST, V46, P1492, DOI 10.1172/JCI105641; Jordan CGM, 1999, J PHARM PHARMACOL, V51, P411, DOI 10.1211/0022357991772619; Kurosaki M, 1996, BIOCHEM J, V319, P801, DOI 10.1042/bj3190801; Kurosaki M, 1999, BIOCHEM J, V341, P71, DOI 10.1042/0264-6021:3410071; KUROSAKI M, 1995, BIOCHEM J, V306, P225, DOI 10.1042/bj3060225; Kuwabara Y, 2003, P NATL ACAD SCI USA, V100, P8170, DOI 10.1073/pnas.1431485100; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; McManaman JL, 2002, J PHYSIOL-LONDON, V545, P567, DOI 10.1113/jphysiol.2002.027185; MIRA L, 1995, ARCH BIOCHEM BIOPHYS, V318, P53, DOI 10.1006/abbi.1995.1203; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 2002, P NATL ACAD SCI USA, V99, P16111, DOI 10.1073/pnas.252626599; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Shambrook J, 1989, MOL CLONING LAB MANU; SHAW S, 1990, BIOCHEM J, V268, P579, DOI 10.1042/bj2680579; SHAW S, 1992, LIFE SCI, V50, P2045, DOI 10.1016/0024-3205(92)90570-F; STELL JGP, 1989, J CHROMATOGR, V475, P363, DOI 10.1016/S0021-9673(01)89690-4; STODDART AM, 1992, BIOCHEM PHARMACOL, V43, P2227, DOI 10.1016/0006-2952(92)90182-I; Sugihara K, 1999, BIOL PHARM BULL, V22, P1246; Terao M, 2000, J BIOL CHEM, V275, P30690, DOI 10.1074/jbc.M005355200; Terao M, 1998, BIOCHEM J, V332, P383, DOI 10.1042/bj3320383; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; Terao M, 2001, J BIOL CHEM, V276, P46347, DOI 10.1074/jbc.M105744200; TSUJITA M, 1994, BBA-PROTEIN STRUCT M, V1204, P108, DOI 10.1016/0167-4838(94)90039-6; Tuma DJ, 2002, FREE RADICAL BIO MED, V32, P303, DOI 10.1016/S0891-5849(01)00742-0; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Yoshihara S, 1997, ARCH BIOCHEM BIOPHYS, V338, P29, DOI 10.1006/abbi.1996.9774; YOSHIHARA S, 1985, ARCH BIOCHEM BIOPHYS, V242, P213, DOI 10.1016/0003-9861(85)90495-3	48	38	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2004	279	10					8668	8683		10.1074/jbc.M308137200	http://dx.doi.org/10.1074/jbc.M308137200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778XD	14665639	hybrid			2022-12-27	WOS:000189265900019
J	Branco, MR; Marinho, HS; Cyrne, L; Antunes, F				Branco, MR; Marinho, HS; Cyrne, L; Antunes, F			Decrease of H2O2 plasma membrane permeability during adaptation to H2O2 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HYDROGEN-PEROXIDE; MOLECULAR EVOLUTION; OXIDATIVE STRESS; YEAST-CELLS; MITOCHONDRIA; EXPRESSION; ERGOSTEROL; APOPTOSIS; CATALASE	Contrary to what is widely believed, recent published results show that H2O2 does not freely diffuse across biomembranes. The fast removal of H2O2 by antioxidant enzymes is able to generate a gradient if H2O2 is produced in a different compartment from that containing the enzymes (Antunes, F., and Cadenas, E. (2000) FEBS Lett. 475, 121-126). In this work, we extended these studies and tested whether an active regulation of biomembranes permeability characteristics is part of the cell response to oxidative stress. Using Saccharomyces cerevisiae as a model, we showed that: (a) H2O2 gradients across the plasma membrane are formed upon exposure to external H2O2; W there is a correlation between the magnitude of the gradients and the resistance to H2O2; (c) there is not a correlation between the intracellular capacity to remove H2O2 and the resistance to H2O2; (d) the plasma membrane permeability to H2O2 decreases by a factor of two upon acquisition of resistance to this agent by pre-exposing cells either to nonlethal doses of H2O2 or to cycloheximide, an inhibitor of protein synthesis; and (e) erg3Delta and erg6Delta mutants, which have impaired ergosterol biosynthesis pathways, show higher plasma membrane permeability to H2O2 and are more sensitive to H2O2. Altogether, the regulation of the plasma membrane permeability to H2O2 emerged as a new mechanism by which cells respond and adapt to H2O2. The consequences of the results to cellular redox compartmentalization and to the origin and evolution of the eukaryotic cell are discussed.	Univ Lisbon, Fac Ciencias, Dept Quim & Bioquim, P-1749016 Lisbon, Portugal; Univ Lisbon, Fac Ciencias, Ctr Quim & Bioquim, Grp Bioquim Oxidantes & Antioxidantes, P-1749016 Lisbon, Portugal; Inst Invest Cient Bento da Rocha Cabral, P-1250047 Lisbon, Portugal	Universidade de Lisboa; Universidade de Lisboa	Antunes, F (corresponding author), Univ Lisbon, Fac Ciencias, Dept Quim & Bioquim, P-1749016 Lisbon, Portugal.	fantunes@fc.ul.pt	Antunes, Fernando/A-1030-2009; Cyrne, Luisa/A-1358-2009; Branco, Miguel/H-9509-2019; Marinho, H. Susana/A-1357-2009	Antunes, Fernando/0000-0002-4192-2840; Cyrne, Luisa/0000-0002-0183-7713; Branco, Miguel/0000-0001-9447-1548; Marinho, H. Susana/0000-0002-4625-2516				AEBI HE, 1983, METHOD ENZYMAT AN, P273; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Antunes F, 2001, FREE RADICAL BIO MED, V30, P1008, DOI 10.1016/S0891-5849(01)00493-2; Antunes F, 1996, FREE RADICAL BIO MED, V21, P917, DOI 10.1016/S0891-5849(96)00185-2; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; Bammert GF, 2000, ANTIMICROB AGENTS CH, V44, P1255, DOI 10.1128/AAC.44.5.1255-1265.2000; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CAVALIERSMITH T, 1991, NATURE, V351, P110, DOI 10.1038/351110a0; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; COSTA SL, 2001, J BACTERIOL, V183, P7182; Cyrne L, 2003, FREE RADICAL BIO MED, V34, P385, DOI 10.1016/S0891-5849(02)01300-X; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEDUVE C, 1965, HARVEY LECT SER, V59, P48; Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9; Higgins VJ, 2002, YEAST, V19, P203, DOI 10.1002/yea.811; Izawa S, 1996, BIOCHEM J, V320, P61, DOI 10.1042/bj3200061; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; Klotz MG, 2003, MOL BIOL EVOL, V20, P1098, DOI 10.1093/molbev/msg129; Larsen AK, 2000, PHARMACOL THERAPEUT, V85, P217, DOI 10.1016/S0163-7258(99)00073-X; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; MA M, 1992, P NATL ACAD SCI USA, V89, P7924, DOI 10.1073/pnas.89.17.7924; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; MATHAI JC, 1994, J BIOL CHEM, V269, P17784; Mukhopadhyay K, 2002, ANTIMICROB AGENTS CH, V46, P3695, DOI 10.1128/AAC.46.12.3695-3705.2002; Munn AL, 1999, MOL BIOL CELL, V10, P3943, DOI 10.1091/mbc.10.11.3943; NICHOLLS P, 1965, BIOCHIM BIOPHYS ACTA, V99, P286, DOI 10.1016/S0926-6593(65)80125-4; OMKUMAR RV, 1993, BIOCHIM BIOPHYS ACTA, V1156, P267, DOI 10.1016/0304-4165(93)90041-6; Ovalle R, 1998, YEAST, V14, P1159, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1159::AID-YEA317>3.0.CO;2-3; Pani G, 2001, IUBMB LIFE, V52, P7, DOI 10.1080/15216540252774702; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Schopf J.W., 1983, P361; Smith SJ, 1996, MOL CELL BIOL, V16, P5427; Stone JR, 2002, J BIOL CHEM, V277, P15621, DOI 10.1074/jbc.M112153200; Suh JK, 1999, P NATL ACAD SCI USA, V96, P2687, DOI 10.1073/pnas.96.6.2687; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; YONETANI T, 1965, J BIOL CHEM, V240, P4503	43	122	129	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6501	6506		10.1074/jbc.M311818200	http://dx.doi.org/10.1074/jbc.M311818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14645222	hybrid			2022-12-27	WOS:000188969200036
J	Gregory, CW; Fei, XY; Ponguta, LA; He, B; Bill, HM; French, FS; Wilson, EM				Gregory, CW; Fei, XY; Ponguta, LA; He, B; Bill, HM; French, FS; Wilson, EM			Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TYROSINE KINASE INHIBITOR; LIGAND-BINDING DOMAIN; MOLECULAR-BIOLOGY; TRANSCRIPTIONAL ACTIVATION; TERMINAL INTERACTION; GENE AMPLIFICATION; PROTEIN EXPRESSION; COMPLEMENTARY-DNA; RESPONSIVE GENES; THERAPY FAILURE	Growth of normal and neoplastic prostate is mediated by the androgen receptor (AR), a ligand-dependent transcription factor activated by high affinity androgen binding. The AR is highly expressed in recurrent prostate cancer cells that proliferate despite reduced circulating androgen. In this report, we show that epidermal growth factor (EGF) increases androgen-dependent AR transactivation in the recurrent prostate cancer cell line CWR-R1 through a mechanism that involves a posttranscriptional increase in the p160 coactivator transcriptional intermediary factor 2/glucocorticoid receptor interacting protein 1 (TIF2/GRIP1). Site-specific mutagenesis and selective MAPK inhibitors linked the EGF-induced increase in AR transactivation to phosphorylation of TIF2/GRIP1. EGF signaling increased the coimmunoprecipitation of TIF2 and AR. AR transactivation and its stimulation by EGF were reduced by small interfering RNA inhibition of TIF2/GRIP1 expression. The data indicate that EGF signaling through MAPK increases TIF2/GRIP1 coactivation of AR transactivation in recurrent prostate cancer.	Univ N Carolina, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Labs Reprod Biol, CB 7500,Rm 3340C,Med Biomol Res Bldg,103 Mason Fa, Chapel Hill, NC 27599 USA.	emw@med.unc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004466, R01HD004466, R01HD016910, R37HD016910] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA077739] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA77739] Funding Source: Medline; NICHD NIH HHS [HD04466, HD16910] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Agus DB, 1999, CANCER RES, V59, P4761; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Baselga J, 2002, CANCER CELL, V2, P93, DOI 10.1016/S1535-6108(02)00098-3; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Buchanan G, 2001, CLIN CANCER RES, V7, P1273; Calegari F, 2002, P NATL ACAD SCI USA, V99, P14236, DOI 10.1073/pnas.192559699; Calvo BF, 2003, CLIN CANCER RES, V9, P1087; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chang CY, 2001, CANCER RES, V61, P8712; CHODAK GW, 1992, J UROLOGY, V147, P798, DOI 10.1016/S0022-5347(17)37389-5; Choong CS, 1996, MOL ENDOCRINOL, V10, P1527, DOI 10.1210/me.10.12.1527; CONNOLLY JM, 1990, PROSTATE, V16, P209, DOI 10.1002/pros.2990160304; Craft N, 1999, CANCER RES, V59, P5030; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Darne C, 1998, EUR J BIOCHEM, V256, P541, DOI 10.1046/j.1432-1327.1998.2560541.x; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; ELO JP, 1995, J CLIN ENDOCR METAB, V80, P3494, DOI 10.1210/jc.80.12.3494; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Graham JD, 2000, J STEROID BIOCHEM, V74, P255, DOI 10.1016/S0960-0760(00)00101-1; Gregory CW, 2001, J ANDROL, V22, P537; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P2892; Gregory CW, 2001, CANCER RES, V61, P4315; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hakimi JM, 1997, CLIN CANCER RES, V3, P1599; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2002, MOL GENET METAB, V75, P293, DOI 10.1016/S1096-7192(02)00009-4; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; ISAACS JT, 1994, VITAM HORM, V49, P433; Jia L, 2003, MOL CANCER RES, V1, P385; Jiang F, 2003, ENDOCRINOLOGY, V144, P1257, DOI 10.1210/en.2002-220718; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kim D, 2002, AM J PATHOL, V160, P219, DOI 10.1016/S0002-9440(10)64365-9; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Koivisto P, 1997, CANCER RES, V57, P314; Koivisto P, 1998, AM J PATHOL, V152, P1; Kung HJ, 2001, CONT CANC RES, P241; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lara PN, 1999, CRIT REV ONCOL HEMAT, V32, P197, DOI 10.1016/S1040-8428(99)00041-4; Leung HY, 1997, BRIT J UROL, V79, P212, DOI 10.1046/j.1464-410X.1997.30412.x; Linja MJ, 2001, CANCER RES, V61, P3550; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Marcelli M, 2000, CANCER RES, V60, P944; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; MOHLER JL, 2004, IN PRESS CLIN CANC R, V10; Morris MJ, 2002, CANCER-AM CANCER SOC, V94, P980, DOI 10.1002/cncr.10339; Murphy LC, 2000, CANCER RES, V60, P6266; Myers RB, 1999, INT J CANCER, V82, P424, DOI 10.1002/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Orio F, 2002, MOL CELL ENDOCRINOL, V198, P105, DOI 10.1016/S0303-7207(02)00374-X; Osman I, 2001, CLIN CANCER RES, V7, P2643; Palmberg C, 2000, J UROLOGY, V164, P1992, DOI 10.1016/S0022-5347(05)66935-2; Pang S, 1997, CANCER RES, V57, P495; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERHEENTUPA J, 1984, ACTA ENDOCRINOL-COP, V107, P571, DOI 10.1530/acta.0.1070571; PERHEENTUPA J, 1985, AM J PHYSIOL, V248, pE391, DOI 10.1152/ajpendo.1985.248.4.E391; PETERZIEL H, 1995, INT J CANCER, V63, P544, DOI 10.1002/ijc.2910630415; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Reese DM, 2001, AM J CLIN PATHOL, V116, P234; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Roy AK, 1999, VITAM HORM, V55, P309; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; Scher HI, 1995, CLIN CANCER RES, V1, P545; Shi XB, 2002, CANCER RES, V62, P1496; Shi Y, 2001, J UROLOGY, V166, P1514, DOI 10.1016/S0022-5347(05)65822-3; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Sirotnak FM, 2002, CLIN CANCER RES, V8, P3870; Solit DB, 2002, CLIN CANCER RES, V8, P986; STEINER MS, 1997, PROSTATE BASIC CLIN, P151; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Taplin ME, 2001, J CLIN ENDOCR METAB, V86, P3467, DOI 10.1210/jc.86.8.3467; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wen Y, 2000, CANCER RES, V60, P6841; White RD, 1997, EUR UROL, V31, P1; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yang D, 2002, P NATL ACAD SCI USA, V99, P9942, DOI 10.1073/pnas.152327299; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	116	164	183	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					7119	7130		10.1074/jbc.M307649200	http://dx.doi.org/10.1074/jbc.M307649200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14662770	hybrid, Green Published			2022-12-27	WOS:000188969200111
J	Trisciuoglio, D; Iervolino, A; Candiloro, A; Fibbi, G; Fanciulli, M; Zangemeister-Wittke, U; Zupi, G; Del Bufalo, D				Trisciuoglio, D; Iervolino, A; Candiloro, A; Fibbi, G; Fanciulli, M; Zangemeister-Wittke, U; Zupi, G; Del Bufalo, D			bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation - Involvement of ERK1/ERK2 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTION FACTOR SP1; DNA-BINDING ACTIVITY; CARCINOMA-CELLS; UP-REGULATION; PROTEIN-KINASE; TUMOR-GROWTH; HUMAN GLIOBLASTOMA; HYPOXIC INDUCTION; BREAST-CARCINOMA	We have previously demonstrated that Bcl-2 overexpression in human breast carcinoma and melanoma cells synergizes with hypoxia to increase angiogenesis through up-regulation of vascular endothelial growth factor. In this work we demonstrated, for the first time, that Bcl-2 overexpression in cancer cells exposed to hypoxia modulates urokinase plasminogen activator receptor (uPAR) expression through Sp1 transcription factor and that the extracellular signal-regulated kinase (ERK) pathway plays a role in Sp1 transcriptional activity. In particular, an increase in uPAR protein and mRNA expression was found in melanoma bcl-2 transfectants grown under hypoxia when compared with control cells, and a decrease of uPAR protein expression was induced by treatment of cells with specific bcl-2 antisense oligonucleotides. Up-regulation of uPAR expression was accompanied by increased Sp1 protein expression, stability, serine phosphorylation, and DNA binding activity. Treatment of cells with mitramycin A, an inhibitor of Sp1 activity, confirmed the role of Sp1 transcriptional activity in uPAR induction by Bcl-2. The contribution of the ERK pathway in Sp1-increased transcriptional activity was demonstrated by the use of chemical inhibition. In fact, ERK kinase activation was induced in Bcl-2-overexpressing cells exposed to hypoxia, and the ERK kinase inhibitor U0126 was able to down-regulate Sp1 phosphorylation and DNA binding activity. Using a human breast carcinoma line, we obtained data supporting our findings with melanoma cells and identified a link between the induction of Sp1 and uPAR expression as a common bcl-2-controlled phenomenon in human tumors. In conclusion, our results strongly indicate that up-regulation of uPAR expression by Bcl-2 in hypoxia is modulated by Sp1 DNA binding activity through the ERK signaling pathway.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Lab B, I-00158 Rome, Italy; Univ Florence, Dept Pathol & Oncol, I-50134 Florence, Italy; Univ Zurich Hosp, Dept Oncol, CH-8044 Zurich, Switzerland	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Florence; University of Zurich; University Zurich Hospital	Del Bufalo, D (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Oro 156, I-00158 Rome, Italy.	delbufalo@ifo.it	fanciulli, maurizio/ABH-6745-2020; trisciuoglio, Daniela/H-2131-2016; Del Bufalo, Donatella/AAC-1594-2021; Del Bufalo, Donatella/K-8673-2016; trisciuoglio, daniela/AAL-4002-2021	trisciuoglio, Daniela/0000-0002-7007-7914; Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; Fibbi, gabriella/0000-0002-0629-851X				Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Alroy I, 1999, MOL CELL BIOL, V19, P1961; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bhattacharya A, 2001, CLIN CANCER RES, V7, P267; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Del Bufalo D, 2003, ONCOGENE, V22, P8441, DOI 10.1038/sj.onc.1206999; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; DELROSSO M, 1992, EXP CELL RES, V203, P427; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; Evans CP, 1997, CANCER RES, V57, P3594; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; FOJAS DB, 2001, EMBO J, V20, P5737; FOLKMAN J, 1986, CANCER RES, V46, P467; FRODIN M, 1994, J BIOL CHEM, V269, P6207; Gualandris A, 1997, MICROVASC RES, V53, P254, DOI 10.1006/mvre.1996.1998; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HARDENBOL P, 1992, BIOCHEM BIOPH RES CO, V185, P553, DOI 10.1016/0006-291X(92)91660-I; Harmey JH, 1998, ANN SURG ONCOL, V5, P271, DOI 10.1007/BF02303785; Ibanez-Tallon I, 2002, BLOOD, V100, P3325, DOI 10.1182/blood.V100.9.3325; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KIESER A, 1994, ONCOGENE, V9, P963; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Kroon ME, 2000, BLOOD, V96, P2775; Kroon ME, 1999, AM J PATHOL, V154, P1731, DOI 10.1016/S0002-9440(10)65429-6; Maity A, 2000, EXP CELL RES, V255, P250, DOI 10.1006/excr.1999.4804; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Min HY, 1996, CANCER RES, V56, P2428; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nor JE, 2001, CANCER RES, V61, P2183; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Reisinger K, 2003, J CELL SCI, V116, P225, DOI 10.1242/jcs.00237; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sandberg T, 2001, J CLIN ENDOCR METAB, V86, P1724, DOI 10.1210/jc.86.4.1724; Schewe DM, 2003, CLIN CANCER RES, V9, P2267; SCOTLANDI K, 1994, INT J CANCER, V58, P95, DOI 10.1002/ijc.2910580116; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Simmen RCM, 2000, MOL CELL ENDOCRINOL, V159, P159, DOI 10.1016/S0303-7207(99)00191-4; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Zannetti A, 2000, CANCER RES, V60, P1546; Zhang JH, 1998, AM J RESP CELL MOL, V19, P324, DOI 10.1165/ajrcmb.19.2.3209; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030; Ziegler A, 1997, JNCI-J NATL CANCER I, V89, P1027, DOI 10.1093/jnci/89.14.1027	63	60	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 20	2004	279	8					6737	6745		10.1074/jbc.M308938200	http://dx.doi.org/10.1074/jbc.M308938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	774FM	14660675	hybrid			2022-12-27	WOS:000188969200066
J	Heske, J; Heller, U; Winklhofer, KF; Tatzelt, J				Heske, J; Heller, U; Winklhofer, KF; Tatzelt, J			The C-terminal globular domain of the prion protein is necessary and sufficient for import into the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL SEQUENCE; PROTEASOMAL DEGRADATION; TRANSMEMBRANE DOMAIN; MOLECULAR CHAPERONES; ER MEMBRANE; SCRAPIE; TRANSLOCATION; GLYCOSYLATION; TRANSPORT; RIBOSOME	The mammalian prion protein (PrP) is composed of an unstructured flexible N-terminal region and a C-terminal globular domain. We examined the import of PrP into the endoplasmic reticulum (ER) of neuronal cells and show that information present in the C-terminal globular domain is required for ER import of the N terminus. N-terminal fragments of PrP, devoid of structural domains located in the C terminus, remained in the cytosol with an uncleaved signal peptide and were rapidly degraded by the proteasome. Conversely, the separate C-terminal domain of PrP, comprising the highly ordered helix 2-loop-helix 3 motif, was entirely imported into the ER. As a consequence, two PrP mutants linked to inherited prion disease in humans, PrP-W145Stop and PrP-Q160Stop, were partially retained in the cytosol. The cytosolic fraction was characterized by an uncleaved N-terminal signal peptide and was degraded by the proteasome. Our study identified a new regulatory element in the C-terminal globular domain of PrP necessary and sufficient to promote import of PrP into the ER.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society	Tatzelt, J (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18, D-82152 Martinsried, Germany.	tatzelt@biochem.mpg.de		Winklhofer, Konstanze/0000-0002-7256-8231; Tatzelt, Jorg/0000-0001-5017-5528				Blochberger TC, 1997, PROTEIN ENG, V10, P1465, DOI 10.1093/protein/10.12.1465; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Gu YP, 2003, NEUROBIOL DIS, V12, P133, DOI 10.1016/S0969-9961(02)00014-1; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Heller U, 2003, J BIOL CHEM, V278, P36139, DOI 10.1074/jbc.M304002200; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Morgan DG, 2002, J MOL BIOL, V324, P871, DOI 10.1016/S0022-2836(02)01111-7; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Winklhofer KF, 2000, BIOL CHEM, V381, P463, DOI 10.1515/BC.2000.061; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Winklhofer KF, 2003, J BIOL CHEM, V278, P14961, DOI 10.1074/jbc.M209942200; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zimmermann R, 1998, BIOL CHEM, V379, P275	54	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 13	2004	279	7					5435	5443		10.1074/jbc.M309570200	http://dx.doi.org/10.1074/jbc.M309570200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	771GD	14645231	hybrid			2022-12-27	WOS:000188776500050
